<SEC-DOCUMENT>0001493152-23-008241.txt : 20230320
<SEC-HEADER>0001493152-23-008241.hdr.sgml : 20230320
<ACCEPTANCE-DATETIME>20230320160539
ACCESSION NUMBER:		0001493152-23-008241
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230320
DATE AS OF CHANGE:		20230320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lantern Pharma Inc.
		CENTRAL INDEX KEY:			0001763950
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				463973463
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39318
		FILM NUMBER:		23746428

	BUSINESS ADDRESS:	
		STREET 1:		1920 MCKINNEY AVENUE
		STREET 2:		7TH FLOOR
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75201
		BUSINESS PHONE:		972-277-1136

	MAIL ADDRESS:	
		STREET 1:		1920 MCKINNEY AVENUE
		STREET 2:		7TH FLOOR
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lantern Pharma
		DATE OF NAME CHANGE:	20190108
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:LTRN="http://lanternpharma.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_LTRN_lanternpharma.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001763950 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_061_GBP_0_iso4217%2D%2DGBP -->
<!-- Field: Set; Name: xdx; ID: xdx_07B_SO_form10%2Dk.xdxs -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0001763950</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0056" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0073" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0094" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0100" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0106" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0107" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0207" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0214" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0240" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0282" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0293" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0352" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0363" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LTRN:GainOnLoanForgiveness" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LTRN:ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0674" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0690" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" id="xdx2ixbrl0696" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-01-01" id="xdx2ixbrl0698" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember" id="xdx2ixbrl0937" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember" id="xdx2ixbrl0941" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2022-12-31_custom_MarketableSecuritiesMutualFundsMember" id="xdx2ixbrl0945" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2021-12-31_custom_GovernmentAgencySecuritiesMember" id="xdx2ixbrl0957" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2021-12-31_custom_CorporateBondsMember" id="xdx2ixbrl0961" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2021-12-31_custom_MarketableSecuritiesDebtMember" id="xdx2ixbrl0965" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2021-12-31_custom_MutualFundsFixedIncomeMember" id="xdx2ixbrl0969" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2021-12-31_custom_MutualFundsAlternativeInvestmentsMember" id="xdx2ixbrl0973" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2021-12-31_custom_MarketableSecuritiesMutualFundsMember" id="xdx2ixbrl0977" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2021-12-31" id="xdx2ixbrl0983" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember" id="xdx2ixbrl1008" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember" id="xdx2ixbrl1009" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember" id="xdx2ixbrl1012" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember" id="xdx2ixbrl1013" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_custom_GovernmentAgencySecuritiesMember" id="xdx2ixbrl1030" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_GovernmentAgencySecuritiesMember" id="xdx2ixbrl1032" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_custom_NAVMember_custom_GovernmentAgencySecuritiesMember" id="xdx2ixbrl1033" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateBondSecuritiesMember" id="xdx2ixbrl1036" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateBondSecuritiesMember" id="xdx2ixbrl1038" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_custom_NAVMember_us-gaap_CorporateBondSecuritiesMember" id="xdx2ixbrl1039" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsFixedIncomeMember" id="xdx2ixbrl1042" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsFixedIncomeMember" id="xdx2ixbrl1044" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_custom_NAVMember_custom_MutualFundsFixedIncomeMember" id="xdx2ixbrl1045" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsAlternativeInvestmentsMember" id="xdx2ixbrl1048" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsAlternativeInvestmentsMember" id="xdx2ixbrl1049" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsAlternativeInvestmentsMember" id="xdx2ixbrl1050" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1054" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1056" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_custom_GovernmentAgencySecuritiesMember" id="xdx2ixbrl1060" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_GovernmentAgencySecuritiesMember" id="xdx2ixbrl1062" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_custom_NAVMember_custom_GovernmentAgencySecuritiesMember" id="xdx2ixbrl1063" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateBondSecuritiesMember" id="xdx2ixbrl1066" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateBondSecuritiesMember" id="xdx2ixbrl1068" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_custom_NAVMember_us-gaap_CorporateBondSecuritiesMember" id="xdx2ixbrl1069" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsFixedIncomeMember" id="xdx2ixbrl1072" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsFixedIncomeMember" id="xdx2ixbrl1074" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_custom_NAVMember_custom_MutualFundsFixedIncomeMember" id="xdx2ixbrl1075" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsAlternativeInvestmentsMember" id="xdx2ixbrl1078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsAlternativeInvestmentsMember" id="xdx2ixbrl1079" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsAlternativeInvestmentsMember" id="xdx2ixbrl1080" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1084" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1086" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1124" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1125" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LTRN:DeferredTaxAssetsResearchAndDevelopmentAmortization" contextRef="AsOf2021-12-31" id="xdx2ixbrl1145" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1162" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1163" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ltrn-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-192021-01-20_custom_UnderwritersAgreementMember_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:UnderwritersAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-19</xbrli:startDate>
        <xbrli:endDate>2021-01-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-20_us-gaap_OverAllotmentOptionMember_custom_UnderwritersAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:UnderwritersAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-302020-05-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-30</xbrli:startDate>
        <xbrli:endDate>2020-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-122022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-12</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-122021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-12</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:LicenseStrategicAllianceAndResearchAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:LicenseStrategicAllianceAndResearchAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:LicenseStrategicAllianceAndResearchAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-01-31_custom_BioNumerikPharmaceuticalsMember_custom_AssignmentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:BioNumerikPharmaceuticalsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AssignmentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AssignmentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AssignmentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AFCLicenseAgreementMember_custom_AFChemicalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AFCLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:AFChemicalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AFCLicenseAgreementMember_custom_AFChemicalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AFCLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:AFChemicalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-212021-07-23_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:AllarityTherapeutiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-21</xbrli:startDate>
        <xbrli:endDate>2021-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:AllarityTherapeutiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:AllarityTherapeutiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CalifiaPharmaMember_custom_EvaluationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:CalifiaPharmaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:EvaluationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CalifiaPharmaMember_custom_EvaluationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:CalifiaPharmaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:EvaluationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PatheonAPIServicesMember_custom_PatheonAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:PatheonAPIServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:PatheonAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PatheonAPIServicesMember_custom_PatheonAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:PatheonAPIServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:PatheonAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SouthwestResearchInstituteMember_custom_SouthwestResearchInstituteAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:SouthwestResearchInstituteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:SouthwestResearchInstituteAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SouthwestResearchInstituteMember_custom_SouthwestResearchInstituteAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:SouthwestResearchInstituteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:SouthwestResearchInstituteAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_FoxChaseCancerCenterMember_custom_FoxChaseCancerCenterAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:FoxChaseCancerCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:FoxChaseCancerCenterAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_FoxChaseCancerCenterMember_custom_FoxChaseCancerCenterAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:FoxChaseCancerCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:FoxChaseCancerCenterAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PiramalPharmaSolutionMember_custom_PiramalPharmaAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:PiramalPharmaSolutionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:PiramalPharmaAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PiramalPharmaSolutionMember_custom_PiramalPharmaAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:PiramalPharmaSolutionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:PiramalPharmaAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VivoPharmMember_custom_VivoPharmAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:VivoPharmMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:VivoPharmAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_VivoPharmMember_custom_VivoPharmAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:VivoPharmMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:VivoPharmAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TranslationalDrugMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:TranslationalDrugMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TranslationalDrugMember_custom_TranslationalDrugAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:TranslationalDrugMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:TranslationalDrugAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_BerkshireSteruleManufacturingMember_custom_BerkshireSteruleManufacturingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:BerkshireSteruleManufacturingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:BerkshireSteruleManufacturingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_BerkshireSteruleManufacturingMember_custom_BerkshireSteruleManufacturingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:BerkshireSteruleManufacturingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:BerkshireSteruleManufacturingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ShilpaMember_custom_ShilpaAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:ShilpaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:ShilpaAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ShilpaMember_custom_ShilpaAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:ShilpaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:ShilpaAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CuriaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:CuriaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CuriaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:CuriaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LumaBridgeLLCMember_custom_LumaBridgeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:LumaBridgeLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:LumaBridgeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LumaBridgeLLCMember_custom_LumaBridgeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:LumaBridgeLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:LumaBridgeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LanternPharmaLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:LanternPharmaLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-05-31_custom_ActuateTherapeuticsMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:ActuateTherapeuticsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_custom_ActuateTherapeuticsMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:ActuateTherapeuticsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-012020-06-15_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-01</xbrli:startDate>
        <xbrli:endDate>2020-06-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-192021-01-20_us-gaap_IPOMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-19</xbrli:startDate>
        <xbrli:endDate>2021-01-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-20_us-gaap_IPOMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-192021-01-20_us-gaap_IPOMember_us-gaap_CommonStockMember_custom_UnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LTRN:UnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-19</xbrli:startDate>
        <xbrli:endDate>2021-01-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-192021-01-20_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-19</xbrli:startDate>
        <xbrli:endDate>2021-01-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-20_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30_us-gaap_CommonStockMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-01</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CashlessWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LTRN:CashlessWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CashlessWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LTRN:CashlessWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LTRN:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LTRN:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LTRN:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CorporateBondsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:CorporateBondsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MarketableSecuritiesDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MarketableSecuritiesDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MarketableSecuritiesMutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MarketableSecuritiesMutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_GovernmentAgencySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CorporateBondsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:CorporateBondsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MarketableSecuritiesDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MarketableSecuritiesDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MutualFundsFixedIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MutualFundsAlternativeInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MarketableSecuritiesMutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MarketableSecuritiesMutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_GovernmentAgencySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_custom_GovernmentAgencySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_custom_GovernmentAgencySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_GovernmentAgencySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NAVMember_custom_GovernmentAgencySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CorporateBondSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateBondSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateBondSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateBondSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NAVMember_us-gaap_CorporateBondSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MutualFundsFixedIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsFixedIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsFixedIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsFixedIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NAVMember_custom_MutualFundsFixedIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MutualFundsAlternativeInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsAlternativeInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsAlternativeInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsAlternativeInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NAVMember_custom_MutualFundsAlternativeInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NAVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_GovernmentAgencySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_custom_GovernmentAgencySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_custom_GovernmentAgencySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_GovernmentAgencySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NAVMember_custom_GovernmentAgencySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CorporateBondSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateBondSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateBondSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateBondSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NAVMember_us-gaap_CorporateBondSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MutualFundsFixedIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsFixedIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsFixedIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsFixedIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NAVMember_custom_MutualFundsFixedIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MutualFundsAlternativeInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsAlternativeInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsAlternativeInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsAlternativeInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NAVMember_custom_MutualFundsAlternativeInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NAVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-292020-05-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-29</xbrli:startDate>
        <xbrli:endDate>2020-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember16419640">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001763950</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="GBP">
      <xbrli:measure>iso4217:GBP</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000568" toRefs="Footnote000570"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1033" toRefs="Footnote001088"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1039" toRefs="Footnote001088"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1045" toRefs="Footnote001088"></ix:relationship>
  <ix:relationship fromRefs="Fact001051" toRefs="Footnote001088"></ix:relationship>
  <ix:relationship fromRefs="Fact001057" toRefs="Footnote001088"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1063" toRefs="Footnote001088"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1069" toRefs="Footnote001088"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1075" toRefs="Footnote001088"></ix:relationship>
  <ix:relationship fromRefs="Fact001081" toRefs="Footnote001088"></ix:relationship>
  <ix:relationship fromRefs="Fact001087" toRefs="Footnote001088"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90E_edei--DocumentType_c20220101__20221231_zD3otfNTJu25"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--DocumentAnnualReport_c20220101__20221231_zjsEQyCiW3y3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_903_edei--DocumentPeriodEndDate_c20220101__20221231_zNRnteACClRg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_904_edei--CurrentFiscalYearEndDate_c20220101__20221231_zf2P4BFC0lQf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90E_edei--DocumentFiscalYearFocus_c20220101__20221231_zlv6nUtkll2d"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OR</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--DocumentTransitionReport_c20220101__20221231_z3mXzRl7wiU7"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityRegistrantName_c20220101__20221231_zBLISZEubcV3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">Lantern
Pharma Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20220101__20221231_zwz973QK6Mjd"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityFileNumber_c20220101__20221231_zAnVlce9cFV7"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-39318</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20220101__20221231_z3VNgC3ZRAQ7"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">46-3973463</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or Other Jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    Incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20220101__20221231_zpuiYYSQqLF6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">1920
                                            McKinney Avenue</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20220101__20221231_zfnY8nYlxOGl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine2">7th Floor</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20220101__20221231_zZCBbync5Lgc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">Dallas</ix:nonNumeric></span>,
    <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20220101__20221231_zFNDPMWHjMX5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20220101__20221231_zlv3NdLaktf5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">75201</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of Principal Executive Offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--CityAreaCode_c20220101__20221231_zvVaO6HEP5U8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">(972)</ix:nonNumeric></span>
<span id="xdx_901_edei--LocalPhoneNumber_c20220101__20221231_zXPwU9tlb9c1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">277-1136</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<b>Registrant&#8217;s
telephone number, including area code</b>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act: Common Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20220101__20221231_znW7PO6lnwzh"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--TradingSymbol_c20220101__20221231_zzAacGe5KkGd"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:TradingSymbol">LTRN</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--SecurityExchangeName_c20220101__20221231_zPOrOAajHF29"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_90A_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_ztdMugtfwgTh"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_905_edei--EntityVoluntaryFilers_c20220101__20221231_zWCZIxys0Sgd"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_906_edei--EntityCurrentReportingStatus_c20220101__20221231_zKUGoEDuCwP2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_902_edei--EntityInteractiveDataCurrent_c20220101__20221231_zjx3y9GdpXO"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntityFilerCategory_c20220101__20221231_z1cWsMGN1Ig2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntitySmallBusiness_c20220101__20221231_zFnCGr0WQg2d"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20220101__20221231_zdy5CyBOo7sg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_907_edei--EntityExTransitionPeriod_c20220101__20221231_zOkcTWnEaHai"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_909_edei--IcfrAuditorAttestationFlag_c20220101__20221231_zIa7aIoE5Thg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_902_edei--EntityShellCompany_c20220101__20221231_zRf61xGrggs"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s
most recently completed second fiscal quarter: $<span id="xdx_909_edei--EntityPublicFloat_iI_c20220630_ziTt3J2aHzA2"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,002,262</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 6, 2023, the registrant had <span id="xdx_902_edei--EntityCommonStockSharesOutstanding_iI_c20230306_z5o4DHvqn2Me"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-03-06" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,857,040</ix:nonFraction></span> shares of common stock, $0.0001 par value per share outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DOCUMENTS
INCORPORATED BY REFERENCE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--DocumentsIncorporatedByReferenceTextBlock_c20220101__20221231_zhX4k36IBOUc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock">Portions
of the registrant&#8217;s definitive proxy statement for the registrant&#8217;s 2023 Annual Meeting of Stockholders to be filed pursuant
to Regulation 14A within 120 days of the registrant&#8217;s year ended December 31, 2022 are incorporated herein by reference into Part
III of this Annual Report on Form 10-K</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.6in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward Looking Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART IV</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit and Financial Statement Schedules.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10&#8211;K Summary.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="a_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SPECIAL
NOTE CONCERNING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. We make such forward-looking
statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act, Section 21E of the Securities
Exchange Act of 1934, as amended, and other federal securities laws. All statements, other than statements of historical fact, contained
in this Annual Report on Form 10-K, including statements regarding our strategy, future preclinical studies and clinical trials, future
financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221;
&#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221;
&#8220;seek,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
&#8220;target,&#8221; &#8220;model,&#8221; &#8220;objective,&#8221; &#8220;aim,&#8221; &#8220;upcoming,&#8221; &#8220;should,&#8221;
&#8216;will&#8221; &#8220;would,&#8221; or the negative of these words or other similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these words. Forward-looking statements reflect our current views with
respect to future events and are based on assumptions and subject to risks and uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements in this Annual Report on Form 10-K include, among other things, statements relating to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential advantages of our RADR<sup>&#174;</sup> platform in identifying drug candidates and patient populations that are likely
    to respond to a drug candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    strategic plans to advance the development of any of our drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    strategic plans to expand the number of data points that our RADR<sup>&#174;</sup> platform can access and analyze;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    research and development efforts of our internal drug discovery and development programs and antibody drug conjugate (ADC) development
    program and the utilization of our RADR<sup>&#174;</sup> platform to streamline the drug development process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, timing, progress, and results of our preclinical studies or clinical trials on any of our drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    intention to leverage artificial intelligence, machine learning and genomic data to streamline the drug development process and to
    identify patient populations that would likely respond to a drug candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves
    or in collaboration with others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our existing cash and
    cash equivalents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to secure sufficient funding and alternative source of funding to support our existing and proposed preclinical studies and
    clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding the potential market opportunity for our drug candidates we or any of our collaborators may in the future develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    anticipated growth strategies and our ability to manage the expansion of our business operations effectively;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations related to future expenses and expenditures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to keep up with rapidly changing technologies and evolving industry standards, including our ability to achieve technological
    advances;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential impact that the continuance or resurgence of the COVID-19 pandemic (or another epidemic or infectious disease outbreak)
    or its impact on the overall economy may have on our business plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to source our needs for skilled labor in the fields of artificial intelligence, genomics, biology, oncology and drug development;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of government laws and regulations on the development and commercialization of our drug candidates and ADC development program.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place
undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations
disclosed in the forward-looking statements we make. Factors that may cause actual results or events to differ materially from current
plans, intentions, and expectations include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have a limited operating history and have never generated any revenues other than from a prior research grant, which may make it
    difficult to evaluate the success of our business to date and to assess our future viability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses
    for the foreseeable future and may never achieve or maintain profitability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce
    or eliminate our drug development programs or commercialization efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    RADR<sup>&#174; </sup>platform may fail to help us discover and develop additional potential drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have limited experience in drug discovery and drug development and may not receive regulatory approval to market our drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we are successful in completing all preclinical studies and clinical trials, we may not be successful in commercializing one or
    more of our drug candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Those
    other risk factors listed under Part I, Item 1A. &#8220;Risk Factors,&#8221; Part II, Item 7. &#8220;Management&#8217;s Discussion
    and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report on Form 10-K.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors could cause actual results or events to differ materially from the forward-statements that we make. Furthermore, we operate in
a competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to
predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report on Form
10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this Annual Report on Form 10-K and the documents that we file with the Securities and Exchange Commission, or the SEC, with
the understanding that our actual future results may be materially different from what we expect. These forward-looking statements are
based on management&#8217;s current expectations. These statements are neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different
from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause actual
results or events to differ materially from current plans, intentions, and expectations include, among other things, those listed under
Part I, Item 1A. &#8220;Risk Factors,&#8221; Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations&#8221; and elsewhere in this Annual Report on Form 10-K. Given these uncertainties, you should not rely on
these forward-looking statements as predictions of future events. The forward-looking statements contained in this Annual Report on Form
10-K are made as of the date of this Annual Report on Form 10-K, and we do not assume any obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise, except as required by applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information
forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate
that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are
inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context requires otherwise, references to the &#8220;Company,&#8221; &#8220;Lantern,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and
&#8220;our&#8221; in this Annual Report on Form 10-K refer to Lantern Pharma Inc., a Delaware corporation, and, where appropriate, its
wholly-owned subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK
FACTOR SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in
this Annual Report on Form 10-K. These risks include, but are not limited to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have a limited operating history and have never generated any revenues other than from research grants, which may make it difficult
    to evaluate the success of our business to date and to assess our future viability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses
    for the foreseeable future and may never achieve or maintain profitability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce
    or eliminate our drug development programs or commercialization efforts.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have limited experience in drug discovery and drug development and may not receive regulatory approval to market our drug candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business strategy to rescue previously failed drug candidates may not be successful, and important issues relating to safety and
    efficacy remain to be resolved for all of our drug candidates. Our strategy also involves risks and uncertainties that differ from
    other biotechnology companies that focus solely on new drug candidates that do not have a history of failed clinical trials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may depend on enrollment of patients with specific genomic or biomarker signatures in our clinical trials in order for us to continue
    development of our drug candidates. If we are unable to enroll patients with specific genomic or biomarker signatures in our clinical
    trials, our research, development and commercialization efforts could be adversely affected.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delays
    in clinical testing could result in increased costs to us and delay our ability to generate revenue.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
    limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if
    any.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    RADR<sup>&#174; </sup>platform may fail to help us discover and develop additional potential drug candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    failure by us to comply with existing regulations could harm our reputation and operating results.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    inability to obtain and retain sufficient clinical trial liability insurance at an acceptable cost to protect against potential liability
    claims could prevent or inhibit our ability to conduct clinical trials for drug candidates we develop.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we are successful in completing all preclinical studies and clinical trials, we may not be successful in commercializing one or
    more of our drug candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    our drugs do not gain market acceptance, our business will suffer because we might not be able to fund future operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to obtain marketing approval in foreign jurisdictions would prevent our drug candidates from being marketed abroad.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    drug candidate that we obtain marketing approval for could be subject to post-marketing restrictions or withdrawal from the market
    and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated
    problems with our drugs, when and if any of them are approved.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we obtain regulatory approvals to commercialize LP-300, LP-184, LP-284, LP-100 or our other drug candidates, our drug candidates
    may not be accepted by physicians or the medical community in general.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
    reform measures could hinder or prevent our drug candidates&#8217; commercial success.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governments
    outside of the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully perform
    their contractual legal and regulatory duties or meet expected deadlines, we may not be able to obtain regulatory approval for or
    commercialize our drug candidates and our business could be substantially harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are substantially dependent on third parties for the manufacture of our clinical supplies of our drug candidates, and we intend to
    rely on third parties to produce commercial supplies of any approved drug candidate. Therefore, our development of our drugs could
    be stopped or delayed, and our commercialization of any future drug could be stopped or delayed or made less profitable if third
    party manufacturers fail to obtain approval of the FDA or comparable regulatory authorities or fail to provide us with drug products
    in sufficient quantities or at acceptable prices.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
    or third-party manufacturers on whom we rely, may be unable to successfully scale-up manufacturing of our drug candidates in sufficient
    quality and quantity, which would delay or prevent us from developing our drug candidates and commercializing approved drugs, if
    any.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have obtained statistical data, market data and other industry data and forecasts used throughout this report from market research,
    publicly available information and industry publications which we believe are reliable but have not been verified by any third party.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    or our licensors may become involved in lawsuits to protect or enforce our patent rights or other intellectual property rights, which
    could be expensive, time-consuming and unsuccessful.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to claims by third parties asserting that our employees, consultants, contractors or advisors have wrongfully used
    or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual
    property or claiming ownership of what we regard as our own intellectual property.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    stock price has been volatile and thinly traded, which may impair your ability to sell your shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business,
    our stock price and trading volume may decline.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be at risk of securities class action litigation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    certificate of incorporation and our by-laws, and Delaware law may have anti-takeover effects that could discourage, delay or prevent
    a change in control, which may cause our stock price to decline.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="a_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="a_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1. Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage biotechnology company, focused on leveraging artificial intelligence (&#8220;A.I.&#8221;), machine learning and
genomic data to streamline the drug development process and to identify the patients that will benefit from our targeted oncology therapies.
Our portfolio of therapies consists of small molecules that others have tried, but failed, to develop into an approved commercialized
drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach.
Our A.I. platform, known as RADR<sup>&#174;</sup>, currently includes more than 25 billion data points, and uses big data analytics (combining
molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications,
and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response,
and then identify the cancer patients that we believe may benefit most from our compounds. This data-driven, genomically-targeted and
biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and
advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer
drug development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy is to both develop new drug candidates using our RADR<sup>&#174;</sup> platform and other machine learning driven methodologies,
and to pursue the development of drug candidates that have undergone previous clinical trial testing or that may have been halted in
development or deprioritized because of insufficient clinical trial efficacy (i.e., a meaningful treatment benefit relevant for the disease
or condition under study as measured against the comparator treatment used in the relevant clinical testing) or for strategic reasons
by the owner or development team responsible for the compound. Importantly, these historical drug candidates appear to have been well-tolerated
in many instances, and often have considerable data from previous toxicity, tolerability and ADME (absorption, distribution, metabolism,
and excretion) studies that have been completed. Additionally, these drug candidates may also have a body of existing data supporting
the potential mechanism(s) by which they achieve their intended biologic effect, but often require more targeted trials in a stratified
group of patients to demonstrate statistically meaningful results. Our dual approach to both develop de-novo, biomarker-guided drug candidates
and &#8220;rescue&#8221; historical drug candidates by leveraging A.I., recent advances in genomics, computational biology and cloud
computing is emblematic of a new era in drug development that is being driven by data-intensive approaches meant to de-risk development
and accelerate the clinical trial process. In this context, we intend to create a diverse portfolio of oncology drug candidates for further
development towards regulatory and marketing approval with the objective of establishing a leading A.I.-driven, methodology for treating
the right patient with the right oncology therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key component of our strategy is to target specific cancer patient populations and treatment indications identified by leveraging our
RADR<sup>&#174;</sup> platform, a proprietary A.I. enabled engine created and owned by us. We believe the combination of our therapeutic
area expertise, our A.I. expertise, and our ability to identify and develop promising drug candidates through our collaborative relationships
with research institutions in selected areas of oncology gives us a significant competitive advantage. Our RADR<sup>&#174;</sup> platform
was developed and refined over the last five years and integrates billions of data points immediately relevant for oncology drug development
and patient response prediction using artificial intelligence and proprietary machine learning algorithms. By identifying clinical candidates,
together with relevant genomic and phenotypic data, we believe our approach will help us design more efficient preclinical studies, and
more targeted clinical trials, thereby accelerating our drug candidates&#8217; time to approval and eventually to market. Although we
have not yet applied for or received regulatory or marketing approval for any of our drug candidates, we believe our RADR<sup>&#174;</sup>
platform has the ability to reduce the cost and time to bring drug candidates to specifically targeted patient groups. We believe we
have developed a sustainable and scalable biopharma business model by combining a unique, oncology-focused big-data platform that leverages
artificial intelligence along with active clinical and preclinical programs that are being advanced in targeted cancer therapeutic areas
to address today&#8217;s treatment needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scientific
literature offers a definition for &#8220;drug rescue&#8221; as research involving abandoned small molecules and biologics that have
not been approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;). These rescued molecular compounds are often abandoned
by pharmaceutical companies in the drug discovery or preclinical testing phase, typically because they do not prove effective for the
specific use for which they were developed. Some of these compounds may be useful in treating other diseases for which they have not
been tested. <i>See, </i>Hemphill, Thomas A., &#8220;The NIH Promotes Drug Repurposing and Rescue,&#8221; Research Technology Management,
v. 5, no. 5, pp. 6-8 (2012). Our use of the term &#8220;rescue&#8221;, &#8220;drug rescue&#8221;, or &#8220;drug rescuing&#8221; refers
to, &#8220;&#8230;a system of developing new uses for chemical and biological entities that previously were investigated in clinical
studies but not further developed or submitted for regulatory approval, or had to be removed from the market for safety reasons.&#8221;,
which is a definition we believe is recognized in the drug discovery, drug development and pharmaceutical and biotechnology industries.
<i>See</i>, Naylor, S. and Schonfeld J., &#8220;Therapeutic Drug Repurposing, Repositioning and Rescue,&#8221; DDW (Drug Discovery World)
Winter 2014, and Mucke, HAM, A New Journal for the Drug Repurposing Community. Drug Repurposing, Rescue &amp; Repositioning 1, 3-4 (2014).
The use of the term &#8220;drug rescue,&#8221; &#8220;rescuing,&#8221; or words of similar meaning in this report should not be construed
to mean that our RADR<sup>&#174;</sup> platform has resolved all issues of safety and/or efficacy for any of our drug candidates. Issues
of safety and efficacy for any drug candidate may only be determined by the U.S. FDA or other applicable regulatory authorities in jurisdictions
outside the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current portfolio consists of four compounds and an Antibody Drug Conjugate (ADC) program: two drug candidates in clinical phases, two
in the pre-IND preclinical stage and our ADC program in research optimization. All of these drug candidates and our ADC program are leveraging
precision oncology, A.I. and genomic driven approaches to accelerate and direct development efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have two drug candidates in clinical development, LP-100 and LP-300, where we are leveraging data from prior preclinical studies
and clinical trials, along with insights generated from our A.I. platform, to target the types of tumors and patient groups we believe
will be most responsive to the drug. Both LP-100 and LP-300 showed promise in important patient subgroups, but failed pivotal Phase III
trials when the overall results did not meet the predefined clinical endpoints. We believe that this was due to a lack of biomarker-driven
patient stratification. LP-300 has been studied in multiple randomized, controlled, multi-center non-small cell lung cancer, or NSCLC,
trials that included administration of either paclitaxel and cisplatin and/or docetaxel and cisplatin, and we are currently conducting
a targeted phase II trial (the Harmonic&#8482; trial) for LP-300 in never smoking patients with NSCLC in combination with chemotherapy,
under an existing investigational new drug application. LP-100 was previously out-licensed by us to Allarity Therapeutics A/S. In July
2021, we entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for LP-100 from Allarity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we have two new drug candidates, LP-184 and LP-284, in pre-IND preclinical development for multiple potentially distinct indications
where we are leveraging machine learning and genomic data to streamline the drug development process and to identify the patients
and cancer subtypes that will best benefit from these drugs, if approved. Subject to regulatory clearance to move forward under
future IND applications, we are planning a Phase I clinical trial for LP-184 to begin in mid 2023 and a Phase I clinical trial for
LP-284 to begin in mid 2023. Our ADC program commenced in early 2021 is aimed at identifying targeted or therapeutic antibodies to
conjugate with selected compounds. In January 2023, we formed a wholly owned subsidiary, Starlight Therapeutics Inc.
(&#8220;Starlight&#8221;), to develop drug candidate LP-184&#8217;s central nervous system (CNS) and brain cancer indications
&#8211; including glioblastoma (GBM), brain metastases (brain mets.), and several rare pediatric CNS cancers. Following the
formation of Starlight, we will refer to the molecule LP-184, as it is developed in CNS indications, as
&#8220;STAR-001&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
development strategy is to pursue an increasing number of oncology focused, molecularly targeted therapies where artificial intelligence
and genomic data can help us provide biological insights, reduce the risk associated with development efforts and help clarify potential
patient response. We plan on strategically evaluating these on a program-by-program basis as they advance into clinical development,
either to be done entirely by us or with out-licensing partners to maximize the commercial opportunity and reduce the time it takes to
bring the right drug to the right patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of our overall growth strategy, we plan to grow our pipeline by identifying new drug candidates and pursuing potential indications
for LP-300, LP-184, LP-284, and LP-100 while leveraging our RADR<sup>&#174;</sup> platform. We are also pursuing the identification and
design of potential combination therapies in cancer for our compounds by leveraging our RADR<sup>&#174;</sup> platform to analyze synergistic
genomic networks and biological pathways with other currently approved drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an extensive multi-national portfolio of intellectual property directed to our drug candidates, and to protect the targeted use
and development of our portfolio of compounds in specific patient populations and in specific therapeutic indications. In addition, as
our RADR<sup>&#174;</sup> platform and other machine learning driven methodologies progress and mature, we will continue to evaluate additional
ways to further protect these assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 1, 2023, we own or control over 80 active patents and patent applications across over 16 patent families whose claims are directed
to our drug candidates and what we plan to do with our drug candidates. We have in-licensed or acquired patents and patent applications
from AF Chemicals, and BioNumerik that are directed to the compounds, LP-100, LP-184, LP-284 and LP-300, and methods of using the compounds.
Additionally, we have also filed patent applications to further enhance, and extend the use of these in-licensed compounds. Our 14 patent
families are directed to our drug candidates, their usage, manufacturing and other matters. These matters are essential to precision
oncology and relate to: (a) data-driven, biologically relevant biomarker signatures, (b) patient selection and stratification approaches
that rely on prediction of response derived from these signatures and, (c) the ability to develop novel, combination therapy approaches
with existing therapeutics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Drug Candidate Pipeline</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the ways we are building our drug candidate pipeline is by in-licensing clinical stage drug candidates that may have been discontinued
for development. We use our RADR<sup>&#174;</sup> platform to assist in analyzing prior clinical research conducted by others to identify
small-molecule oncology drug candidates that have (i) a well-tolerated profile evidenced by completion of phase I clinical trials, and
(ii) demonstrated at least limited antitumor or anticancer activity in clinical trials. We intend to advance the drug candidates in our
pipeline as potential precision medicine treatments for cancer. Our targeted development workflow includes preclinical studies where
drug activity and associated gene signatures are identified, in part through strategic collaborations with some of the top academic institutions
and clinical translational centers in the world. Using this collaborative approach, together with innovative observations from our RADR<sup>&#174;
</sup>platform, we intend to develop and add drug candidates to our pipeline with the objective of treating the right patient populations
with the right oncology therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current pipeline of development programs involves four small molecule drug candidates: LP-300, LP-100, LP-184, and LP-284, and an Antibody
Drug Conjugate (ADC) program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_001.jpg" alt="" style="height: 299px; width: 670px" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LP-300
                                            (Sodium 2,2&#8217;-disulfanediyldiethanesulfonate) (Tavocept<sup>&#174;</sup>): </b>We are
                                            currently advancing LP-300 in a phase II clinical trial, the Harmonic&#8482; trial, in combination
                                            with chemotherapy in never-smokers with NSCLC adenocarcinoma who relapsed while on tyrosine
                                            kinase inhibitor (TKI) therapy.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LP-100
    (6-Hydroxymethylacylfulvene: </b>LP-100 is in clinical development with a focus on treatment in combination with the class of anticancer
    agents known as PARP inhibitors (PARPi)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LP-184</b>.
    <b>( (-) hydroxyureamethylacylfulvene): </b>LP-184 is a synthetic small molecule drug with nanomolar potency that preferentially damages
    DNA in cancer cells overexpressing specific biomarkers. We are advancing LP-184 towards the launch of a phase I clinical trial targeted for
    mid 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LP-284</b>. <b>(
    (+) hydroxyureamethylacylfulvene): </b>LP-284, the stereoisomer (enantiomer) of LP-184, has shown promising <i>in-vitro</i> and <i>in
    vivo</i> anticancer activity in multiple hematological cancers, which are distinct from the indications targeted by LP-184. We are
    advancing LP-284 towards the launch of a phase I clinical trial targeted for mid 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADC
Program:</b> Based on the recognition of antibody drug conjugates as a promising therapeutic approach for cancer treatment, and one that
has growing interest due to the potential to increase targeted cancer cell death, we initiated an ADC program in early 2021.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have an existing IND in the U.S. for LP-300 that was transferred to us as part of our in-licensing and agreement with BioNumerik
to acquire the rights to the compound. There is currently no active IND in the U.S. for LP-100, LP-184 and LP-284.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Precision Cancer Therapy Development Using Our Innovative </i>RADR<sup>&#174;</sup> <i>Platform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RADR<sup>&#174;
</sup>is one of the world&#8217;s largest A.I. and machine learning (M.L.) oncology drug discovery and development platforms, consisting
of over 25+ billion oncology-focused data points. These data points consist of large-scale multi-omic data, derived from 130,000+ patient
records, 150+ drug-tumor interactions, thousands of drug classes, and covering over 135 cancer subtypes. RADR<sup>&#174;</sup> leverages
this data and over 200+ advanced ML algorithms to power its drug discovery and development modules. RADR<sup>&#174;</sup>&#8217;s data,
capabilities, and insights have powered the development of new Lantern drug candidates, advancement of new indications for existing drugs,
and identification of potential new drug combinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
cancer treatment protocols include surgery, chemotherapy and radiation therapy. Treatments have been selected based on histologic type
and disease spread, irrespective of genetic differences among patients. With the advent of precision therapies, cancer treatments increasingly
target specific genes or mechanisms of action for a more personalized approach to patient care. This trend represents a substantial advance
in cancer treatment because tumor growth is highly dependent on genetic changes and the genetic profile of the individual and the progression
of the disease is highly variable amongst patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
RADR<sup>&#174; </sup>platform is core to our drug development approach for identifying the desired candidates to in-license and develop.
According to a recent article in JAMA (<i><span style="text-decoration: underline">Estimated Research and Development Investment Needed to Bring a New Medicine to Market</span></i><span style="text-decoration: underline">,
2009-18</span>, <i>JAMA, March 3, 2020</i>) oncology drug development is costly, risky, and highly competitive with an average success rate
of 4% to 8% and average developmental costs of over $1 billion per successful drug. There is a critical need to rescue clinical research
on drugs that have failed clinical trials in order to provide additional possible therapies for patients while reducing the overall cost
of therapeutic development. Many drug failures within oncology may be attributed to the heterogeneity of the tested patient population,
even though there may be a strongly positive therapeutic impact on certain patient subgroups within that population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
data-centric and machine learning approaches begin to change the pace and scale of drug discovery and development, research and development
(&#8220;R&amp;D&#8221;) we believe efforts in large biopharma companies will begin to shift away from traditional approaches towards
new data and A.I.-centric approaches. According to Deloitte Consulting, in <i>Ten Years On | Measuring the return from pharmaceutical
innovation 2019, </i>&#8220;decades of advances in science and technology have driven improvements in health care outcomes and influenced
stakeholder expectations of the role of the biopharmaceutical industry (biopharma). However, the past decade has seen increasing pressures
undermine the productivity of biopharma R&amp;D, leading to multiple years of decline in the return on investment. At the same time,
innovative new treatments are changing the face of disease management. New treatment modalities and an increasing understanding of precision
medicine have led to the need for new R&amp;D models...&#8221; The Deloitte Consulting report further describes that R&amp;D costs will,
&#8220;shift from traditional discovery and trial execution to a process driven by large datasets, advanced computing power and cloud
storage&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analysts
estimate that this shift from traditional screening, and trial-based studies to leveraging in silico, data and A.I. methodologies has
driven a significant increase in the spending on A.I. by the biopharma and drug discovery community to approximately $4 billion in 2021,
increasing by about 40% annually from $730 million in 2019 according to PMLive and Global Market Insights. As a result of these trends
and changes in the R&amp;D model in biopharma, we believe that we, and companies that are using data-centric and A.I. centric approaches
to drug discovery and development, are in an ideal position to benefit from this industry shift that has the potential to help deliver
drugs to the right patients faster, with a higher degree of personalization and a potentially lower amount of average costs in the development
cycle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug rescue approach leverages substantial prior research and development investments in candidates that were withdrawn from development
prior to submission for FDA approval. The large volume of failed compounds, recent developments that permit increased access to validated
genomic and biomarker data, and the rapid evolution of A.I. technology creates an opportunity to efficiently capitalize on these investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
RADR<sup>&#174; </sup>platform is rapidly emerging as a robust and scalable platform for targeted cancer therapy development. Through
the use of A.I. and machine learning, RADR<sup>&#174;</sup> is designed to quickly identify and guide the development of compounds that
we can develop as potential oncology agents through either a process of drug rescue, drug repositioning or de-novo development. RADR<sup>&#174;
</sup>is being developed through an accumulation and curation of genomic and biomarker data that is directly relevant to the measurement
and classification drug-tumor interaction, and clinical datapoints related to patient response and patient stratification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Predicting
optimal drug responses in cancer patients requires the identification and validation of predictive biomarkers. Our RADR<sup>&#174; </sup>platform
seeks to identify biomarkers to assist in selecting patients who have the highest likelihood to respond to our drug candidates. For example,
the targeted indications for our drug candidate LP-184 were chosen in part because they are known to highly express the protein coding
gene PTGR1. Our planned clinical trial for LP-184 is intended to provide additional information regarding biomarkers related to LP-184&#8217;s
molecular and cellular targets. This method of using and validating targeted biomarkers during development and then using these biomarkers
during clinical trials can lead to shortening of the development timeline and compression of costs associated with oncology drug development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
we believe LP-300 targets molecular pathways that are more common in never smokers than in other groups and also targets kinases involved
in key signaling pathways involving enzymes critical for DNA synthesis and repair, such as Excision Repair Cross-Complementation Group
1 (ERCC1), Ribonucleotide Reductase 1 (RNR1), Ribonucleotide Reductase 2 (RNR2), as well as enzymes and proteins important in regulating
cell redox status, such as Thioredoxin (TRX), Peroxiredoxin (PRX), Glutaredoxin (GRX), and Protein Disulfide Isomerase (PDI).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
RADR<sup>&#174;</sup> Platform</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
human genome consists of 19,000 to 20,000 protein coding genes. One input record derived from available data bases and analyzed by our
RADR<sup>&#174; </sup>platform consists of datapoints (expression values) from approximately 20,000 genes, another input record type is
drug sensitivity data (IC20, IC50), and other sets include key clinical parameters from HIPAA compliant patient data and clinical histories.
Our RADR<sup>&#174;</sup> platform uses a data-driven gene feature selection methodology that is a combination of biology, informatics,
and statistics &#8211; computational biology. The architecture, tools and software of our platform are depicted in the figures below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><img src="form10-k_002.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
developed our platform using primarily open-source third party supervised algorithms such as Neural Networks, Support Vector Machine,
Random Forest, K-Nearest Neighbors, Logistic Regression and Penalized Multivariate Regression. Each algorithm is trained with input data
to predict drug sensitivity (regressor models) and stratify patient response as responder or non-responder (classifier models). Model
tuning and optimization is then performed using a hyperparameter search algorithm in order to produce the predicted lowest cross validation
error. The models are then evaluated using traditional performance metrics such as accuracy, area under the curve, sensitivity, specificity,
precision, root mean square error and mean absolute error calculations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
feature reduction algorithm is then used to reduce the number of genes under analysis to a biomarker gene panel of less than approximately
50 genes. This set of genes is intended to carry the highest coefficient to predict drug sensitivity and the highest variable importance
in classifying a responder from a non-responder. Genes that do not help in predicting the output variable are eliminated sequentially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_004.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
RADR<sup>&#174;</sup> Platform Workflow</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
RADR<sup>&#174; </sup>platform&#8217;s proprietary workflow involves preliminary statistical analysis on approximately 18,000 features
typically from whole transcriptomic datasets reducing the set to approximately 2,000 features. This is followed by gene filtering via
biological and statistical methodologies yielding approximately 200 significant genes. The platform currently contains 6 feature selection
methods and 13 machine learning methods to analyze the drug and omics data, in order to fine tune the model and get better and improved
prediction accuracy. Feature selection ensures that genes that do not contribute to response prediction are excluded from the output
dataset. The prediction component subsequently applies an A.I.-driven reduction algorithm to the previously filtered genes generating
a targeted set of typically less than 50 candidate biomarkers predictive of response to a particular molecule. The figure below illustrates RADR<sup>&#174;</sup>&#8217;s workflow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><img src="form10-k_005.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
distinct and unique benefit of the RADR<sup>&#174;</sup> platform is its ability to integrate biological knowledge and data-driven feature
selection to generate hypothesis-free biomarker signatures. This can then aid in identifying novel targets for predictive screening and
drug development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
RADR<sup>&#174; </sup>platform is enabled through access to, and analysis of, a number of key datasets: (i) publicly available databases
(ii) data from commercial clinical studies and trials and (iii) our proprietary data generated from <i>ex vivo</i> 3D tumor models specific
to drug-tumor interactions. We incorporate automated supervised machine learning strategies along with big data analytics, statistics
and systems biology to facilitate identification of new correlations of genetic biomarkers with drug activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of the platform architecture is derived from its validation through the analysis of over 25 billion oncology-specific clinical
and preclinical data points, more than 154 drug-cancer interactions, thousands of drug classes, data covering more than 135 cancer subtypes,
and over 130,000 patient records from 16 databases, one of which is our internal database. RADR<sup>&#174;</sup> leverages this data and
over 200+ advanced ML algorithms to power its drug discovery and development modules. Our long-term objective is to collect and analyze
over 100 billion oncology-specific clinical and preclinical data points to further enhance the prediction power of our RADR<sup>&#174;
</sup>platform. We use cancer cell line gene expression profiles and drug sensitivity data (IC50) as one of its input types. In a population
of 10 case studies our platform was able to distinguish responders from non-responders with an average historical accuracy of over 80%.
We have also used our platform to generate genetic signatures that we believe to have applicability for the majority of FDA approved
drug-tumor indications. External validation, through retrospective data analysis, of patient datasets from 10 independent clinical studies
achieved an average response prediction accuracy greater than 80%, and internal analysis of 120 drug-tumor interactions in cell lines
achieved an accuracy of greater than 85%. The figure below illustrates examples of RADR<sup>&#174;</sup>&#8217;s algorithms and how they can be used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><img src="form10-k_006.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed our platform in a cloud environment that efficiently uses parallel processing to analyze patient stratification and biomarker
selection. Best software engineering practices are followed while designing and developing our platform&#8217;s architecture. In order
to track modifications in the software, a version control system is in place. We use a software release process, including a rigorous
regression testing process, to ensure functions and programs are working as designed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
platform uses a simple user input and GUI based AI architecture that can be used in many pharmaceutical research areas such as biomarker
identification, patient stratification, drug rescue and reposition by bioinformaticians, clinicians and trained wet-lab scientists.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
late 2021, the Code Ocean Platform, a secure cloud-based computing environment manager, was integrated into RADR<sup>&#174;</sup>. The
Code Ocean environment has upgraded RADR<sup>&#174;</sup>&#8217;s data organization, synchronization, scalability and accessibility. These
architecture changes have enhanced the reproducibility of RADR<sup>&#174;</sup> aided insights and analysis and created an environment
that improves the ability to collaborate and share insights within Lantern and with Lantern&#8217;s collaborators. The figure below illustrates ways that RADR<sup>&#174;</sup>&#8217;s modules can be used to facilitate drug discovery and
development within Lantern and with our collaborators.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><img src="form10-k_007.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Actuate
Therapeutics Collaboration Utilizing RADR Platform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, we entered into a Collaboration Agreement with Actuate Therapeutics, Inc. (&#8220;Actuate&#8221;), a clinical stage private
biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading
to fibrosis. Pursuant to the agreement, as amended, we are collaborating with Actuate on utilization of our RADR&#174; platform to develop
novel biomarker derived signatures for use with one of Actuate&#8217;s product candidates. As part of the collaboration, we received
25,000 restricted shares of Actuate stock subject to meeting certain conditions of the collaboration, as well as the potential to receive
additional Actuate stock if results from the collaboration are utilized in future development efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>TTC
Oncology Collaboration to Expand the Clinical Development of Drug Candidate TTC-352</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, we entered into a Collaboration Agreement with TTC Oncology (&#8220;TTC&#8221;). The collaboration is focused on using
RADR<sup>&#174;</sup> to accelerate and sharpen the drug development of TTC&#8217;s Phase 2 ready drug candidate TTC-352. TTC-352, is
a novel, first- and best-in-class selective human estrogen receptor (ER) partial agonist (ShERPA) for the treatment of patients with
metastatic ER+ breast cancer. TTC-352 was recently evaluated in a Phase 1 accelerated dose escalation study for hormone receptor positive
metastatic breast cancer, and it showed early efficacy signals in heavily pretreated hormone refractory patients. The initial aims of
the collaboration are to 1) identify biomarker or gene signatures to power potential patient selection for an upcoming TTC-352 Phase
2 clinical trial, 2) further characterize TTC-352&#8217;s mechanism of action, and 3) discover additional treatment indications for TTC-352.
Under the terms of the collaboration, Lantern is receiving an exclusive right to license TTC-352, including any collaboration intellectual
property (&#8220;IP&#8221;), during an exclusive option period. Additionally, Lantern and TTC will each participate in upfront, milestone,
and royalty payments in the event a third-party licenses IP resulting from the collaboration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is to bring the right cancer drugs to the right patients by transforming the drug development process through the use of artificial
intelligence and data-driven development approaches. Our proprietary A.I.-enabled, and precision oncology approach, which focuses on
developing our own pipeline of compounds by rescuing drug candidates that have previously failed and developing new compounds that are
targeted to specific biological activity and genomic pathways, has the potential, we believe, to bring drugs to market faster, with lower
costs, and with reduced risk, thereby enabling a change in the cost and availability of precision cancer therapy. We work with leading
research laboratories, translational medicine and cancer centers to develop our studies and clinical trials for our portfolio, and actively
update and improve our RADR<sup>&#174;</sup> platform to incorporate additional biomarker data, patient outcome data, cancer drug efficacy
studies and computational models that relate to oncology drug development and prediction of patient response.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of our growth strategy, we plan to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursue
    existing indications for LP-300, LP-184, LP-284 and LP-100, leveraging our RADR<sup>&#174;</sup> platform to refine and optimize our
    trial design and biomarker signatures that correlate to potential patient response. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expand
    our pipeline by identifying new drug candidates that have either been abandoned or have failed in late stage clinical trials, and
    have the potential to benefit from a precision medicine approach that leverages our expertise and A.I. platform.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    and design potential combination therapy approaches to use our compounds in conjunction with currently approved drugs by leveraging
    our RADR<sup>&#174;</sup> platform to analyze and uncover synergistic mechanisms and biological pathways using genomics and machine
    learning. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    the number of data points powering our RADR<sup>&#174;</sup> A.I. platform from more than the current 25 billion to a target of
    approximately 50 billion by the end of 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance
    the algorithms, methodologies and models that underlie our computational and machine learning platform to improve the predictive
    power, and to develop additional capabilities that are focused on accelerating or de-risking oncology drug development.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursue
    collaborations and partnerships with other biotech and pharma companies where our A.I. and precision oncology expertise can be used
    to de-risk or accelerate development programs and where our stockholders can receive a significant economic benefit.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue
    to develop and patent intellectual property and advance our intellectual property portfolio associated with both fundamental patents
    and patents associated with precision, patient stratified, targeted therapies and genomic or biomarker signatures. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue
    to select and launch additional clinical development program.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LP-300</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently advancing LP-300 in a Phase II clinical trial (the &#8220;HARMONIC&#8482; Study&#8221;) of LP-300 in combination with carboplatin
and pemetrexed in never smoker patients with relapsed advanced primary adenocarcinoma of the lung after treatment with tyrosine kinase
inhibitors (TKIs).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
is a cysteine-modifying molecular entity that works to modulate multiple cellular pathways simultaneously and is a potential combination
agent for targeted indications in NSCLC. LP-300 is a small molecule (molecular weight 326.4 Da) that was in-licensed from BioNumerik
Pharmaceuticals, Inc. in May 2016, and subsequently acquired by us in 2018. We are focused on repositioning LP-300 as a potential combination
therapy for never smokers NSCLC patients with histologically defined adenocarcinoma. Prior clinical trials conducted by BioNumerik for
LP-300 did not meet their primary clinical endpoints, and at least one or more future clinical trials that meet their pre-specified primary
endpoints with statistical significance will be required before we can obtain a regulatory marketing approval, if any, to commercialize
LP-300. Safety and efficacy determinations are solely within the authority of the FDA in the U.S. or other regulatory agencies in other
jurisdictions. Currently there is no approved therapy specifically for the growing indication of never-smokers with NSCLC, and female
never smokers appear to be uniquely responsive to LP-300. With both chemosensitizing and chemoprotective activity, LP-300 has potential
as a combination agent or adjuvant in front line, second line or salvage therapy in newly diagnosed, relapsed, metastatic or advanced
NSCLC for overall survival enhancement and toxicity alleviation from primary chemotherapy or standard of care. We are currently in the
early stages of defining a specific biomarker signature that correlates with heightened sensitivity to LP-300. We believe that this signature
may help accelerate the clinical development of LP-300 and has the potential to guide patient selection for targeted clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
clinical trials conducted by BioNumerik for LP-300 did not meet their primary clinical endpoints and at least one or more future clinical
trials that meet their pre-specified primary endpoints with statistical significance will be required before we can obtain a regulatory
marketing approval, if any, to commercialize LP-300. Prior clinical trial observations are not necessarily predictive of the outcome
of any future clinical trials we may conduct.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
has been administered in multiple clinical trials to more than 1,000 subjects and has been generally well-tolerated. Retrospective analyses
of the results of a multi-country phase III lung cancer trial (study ID DMS32212R) in subgroups of adenocarcinoma patients receiving
LP-300, paclitaxel and cisplatin demonstrated substantial improvement in overall survival, particularly among female never smokers, where
a 13.6 month improvement in overall survival (p-value 0.0167, hazard ratio 0.367) in favor of LP-300 was observed, as compared to placebo
in the subgroup of paclitaxel/cisplatin-treated patients. Similar retrospective findings of increased overall survival in the subgroup
of LP-300/paclitaxel/cisplatin treated female Asian patients with adenocarcinoma of the lung were observed in a randomized, double-blind,
placebo-controlled trial in Japan. Prior historical clinical trial observations are not necessarily predictive of the outcome of future
trials. No assurances can be given that we will be successful in obtaining marketing approval for LP-300. The chemical structure of LP-300
is depicted below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
Chemical Structure</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_008.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LP-300
Phase II Clinical Trial</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are conducting a Phase II clinical trial (the &#8220;HARMONIC&#8482; Study&#8221;) of LP-300 in combination with carboplatin and pemetrexed
in never smoker patients with relapsed advanced primary adenocarcinoma of the lung after treatment with tyrosine kinase inhibitors. Our
purpose in conducting the study is to determine the potential clinical advantages for this drug combination in the study-defined patient
population. As of the date of this report, we have activated 5 clinical trial sites
in the US, across 12 locations, and we anticipate multiple additional sites in the US during the first half of 2023, with first enrolled
patients anticipated in the second quarter of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trial is designed as a multicenter, open label, Phase II trial with planned enrollment of approximately 90 patients. Patients who are
never smokers with lung adenocarcinoma and have relapsed after prior treatment with tyrosine kinase inhibitors will be eligible for enrollment.
Following a six-patient safety lead-in stage, the trial consists of randomization in a 2:1 allocation ratio to one of two arms: Arm A
(consisting of carboplatin, pemetrexed, and LP-300) or Arm B (consisting of carboplatin and pemetrexed).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objective of this study is to determine progression-free survival and overall survival in the study-defined patient population
when co-administered LP-300 with combination chemotherapy (carboplatin and pemetrexed) versus carboplatin and pemetrexed alone. The secondary
objectives of the study are to evaluate tumor response measured by objective response rate, duration of objective response, and clinical
benefit rate. We will also determine any associations between the efficacy endpoints and patient biomarkers (e.g., circulating tumor
DNA and tumor genome characteristics) as an exploratory objective. Other exploratory objectives for the study may include evaluating
quality of life in all patients and performance of patients based on the type, duration, and number of tyrosine kinase inhibitors received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Key
Findings from Prior LP-300 Clinical Trials</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized
below are some key findings from LP-300&#8217;s prior clinical trials:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LP-300
    targets molecular pathways that are more common in female non-smokers than in any other group.</b> Key mechanisms have been elucidated
    to support LP-300&#8217;s role in the observed treatment benefits for females and never smokers noted in the Phase III NSCLC adenocarcinoma
    trial. The rationale for these observations includes the following: (1) Met/ALK &amp; EGFR alterations are more common in non-smokers,
    who are most commonly female and present with advanced stage adenocarcinoma; (2) laboratory data indicate that LP-300 targets both
    EGFR WT/mut+ and Met/ALK; and (3) a high percentage of adenocarcinoma patients are either EGFR mutants or Met/ALK positive.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>There
    are several key pathways in NSCLC adenocarcinoma whose targets are often overexpressed in females, and LP-300 modulates these pathways</b>.
    LP-300 targets the following key pathways: (1) kinases involved in key signaling pathways (ALK, ROS, MET); (2) enzymes critical for
    DNA synthesis and repair (ERCC1, RNR1, RNR2); and (3) enzymes and proteins important in regulating cell redox status (TRX, PRX, GRX,
    PDI). The alterations that are targeted and modulated by LP-300 are more likely in women with lung adenocarcinoma, especially non-smokers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LP-300
    showed that females had a survival increase from 13 months to 25 months, based on a retrospective subgroup analysis of a Phase III
    NSCLC adenocarcinoma trial. </b>Results from a Phase III NSCLC adenocarcinoma trial exhibited an overall survival of 25.0 months,
    with a 2-year survival of 51.4%, in the subgroup of females with advanced adenocarcinoma of the lung receiving paclitaxel/cisplatin
    and LP-300. The observed results were statistically significant (p-value = 0.0477; HR=0.579) and were observed in a subgroup of 114
    patients in retrospective analyses. Consistent statistically significant retrospective subgroup analysis results were observed in
    female NSCLC adenocarcinoma patients receiving paclitaxel/cisplatin and LP-300 in a prior LP-300 double-blind, placebo-controlled
    phase III trial conducted in Japan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LP-300
    exhibits potential to reduce anemia and protect against chemotherapy-induced kidney toxicity, both of which are conditions that disproportionately
    affect females.</b> The LP-300 arm of the Phase III NSCLC adenocarcinoma trial also demonstrated the potential for LP-300 to protect
    against chemotherapy-induced kidney toxicity and anemia. These findings complement earlier clinical observations regarding LP-300&#8217;s
    potential to protect against neuropathy and other chemotherapy-induced toxicities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background-Scope
of Prior Phase III NSCLC Adenocarcinoma Trial (LP-300)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
was studied in a randomized, multi-center (trial locations in four US states and five European countries), double-blind and placebo-controlled
Phase III trial from 2010 to 2013 in patients with adenocarcinoma of the lung (the &#8220;Phase III NSCLC adenocarcinoma trial&#8221;).
The aim of the trial was to determine whether LP-300, combined with a standard combination of chemotherapy drugs, would increase survival
in patients with advanced NSCLC adenocarcinoma. The secondary aim of the trial was to determine if the chemoprotective properties of
LP-300 were effective in preventing or reducing common side-effects of cancer treatment, including kidney damage, anemia, nausea and
vomiting that can occur with these drug combinations. The trial enrolled NSCLC patients with newly diagnosed or recurrent advanced (stage
IIIB/IV) primary adenocarcinoma of the lung. Patients with confirmed histopathological diagnosis of inoperable and measurable advanced
primary adenocarcinoma (including bronchioalveolar cell carcinoma) of the lung, and no prior systemic treatment for NSCLC including chemotherapy,
immunotherapy, hormonal therapy, targeted therapies or investigational drugs, were included in the trial. Overall survival was the primary
outcome measure. Patients in the control arm received standard of care (cisplatin and either paclitaxel or docetaxel) plus placebo, whereas
patients in the treatment arm received standard of care (cisplatin and either paclitaxel or docetaxel) plus LP-300. The primary results
of the trial for patients receiving cisplatin and paclitaxel are outlined in the table below. While the overall results of the Phase
III NSCLC adenocarcinoma trial did not meet the specified endpoint of the trial in increasing overall survival in all patients, when
the data were retrospectively separated by gender and smoking status, the trial data demonstrated that all never smokers, especially
female never smokers, saw increased survival with LP-300 combination treatment with paclitaxel and cisplatin. Furthermore, the LP-300
group in the phase III NSCLC adenocarcinoma trial exhibited well-tolerated advantages relating to the potential to protect against chemotherapy-induced
nephrotoxicity, neuropathy and nausea along with reduced anemia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><img src="form10-k_009.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
figure below depicts the survival curves for cisplatin/paclitaxel subgroups for the Phase III NSCLC adenocarcinoma trial that ended in
2013, as summarized. The Kaplan Meier curves maintain consistent separation between treatment arms for the never smokers, females, and
female never smokers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="image_002.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rationale
Behind LP-300 Rescue and Repositioning Efforts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the results from the prior Phase III NSCL adenocarcinoma trial, we have launched the HARMONIC&#8482; LP-300 Phase II clinical trial
to target the subpopulation of never smokers with adenocarcinoma that saw strong benefit in the previous Phase III trial. Although the
incidence of never-smokers with NSCLC is rising currently there is no approved therapy specifically for the growing indication of never-smokers
with NSCLC. Preclinical observations support that LP-300 preferentially modulates ALK and EGFR, two commonly mutated genes in non-smokers
with adenocarcinoma. Based on the findings from the previous Phase III NSCL adenocarcinoma trial, it is possible that the benefits of
combining LP-300 with standard of care chemotherapy could be further improved by identifying additional molecular biomarkers in patients
who respond well to LP-300 combination treatment. We continue to seek additional opportunities for LP-300. Some of our considerations
include a never smoker population with a specific genetic signature that correlates to increased LP-300 sensitivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disease
Background and Opportunity </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lung
cancer remains one of the most common and deadly cancers worldwide. Lung cancer accounts for 12% of all new cancer diagnoses, but 21%
of all cancer deaths in the US. Lung cancer kills more people annually than cancers of the breast, prostate, colon, liver, kidney, pancreatic,
and melanoma combined. The American Cancer Society&#8217;s estimates for lung cancer in the US for 2023 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    238,340 new cases of lung cancer (117,550 in men and 120,790 in women)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    127,070 deaths from lung cancer (67,160 in men and 59,910 in women)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
most common type of lung cancer is called non-small cell lung cancer (&#8220;NSCLC&#8221;), which represents about 80% to 85% of all
lung cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lung
adenocarcinoma, a histological subtype of NSCLC that originates within the glands that line the lung, is the most common subtype of lung
cancer in the world inflicting approximately 50% to 65% of non-Asians and approximately 70% to 85% of Asians diagnosed with lung cancer.
According to LUNGevity Foundation, the National Institutes of Health and other published literature, 60% to 65% of all new lung cancer
diagnoses are among people who are former smokers or have never smoked, while 10-15% of new lung cancer cases are among never-smokers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
one-half of the patients diagnosed with NSCLC in any given year will present with inoperable advanced (stage IV) disease, for which there
is no cure. Patients with stage IV NSCLC exhibit a median overall survival time of 7 to 12 months; approximately one-third of patients
will survive for a year, and only 10% to 21% of those patients will survive for two years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lung
cancer is the most common cause of global cancer-related mortality, leading to over a million deaths each year and adenocarcinoma is
its most common histological subtype. Worldwide, lung cancer occurred in approximately 2.2 million patients in 2020 and caused an estimated
1.8 million deaths. NSCLC is described as any type of epithelial lung cancer other than small cell lung cancer (&#8220;SCLC&#8221;).
The 5-year survival rate for NSCLC is 25%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rapid
advances in understanding the molecular pathogenesis of NSCLC have demonstrated that NSCLC is a heterogeneous group of diseases. Although
the initial treatment of localized disease is the same, the molecular characterization of tumor tissue in patients with NSCLC serves
as a guide to treatment both in those who present with metastatic disease and in those who relapse after primary therapy. Molecularly
targeted therapies have dramatically improved treatment for patients whose tumors harbor somatically activated oncogenes such as mutant
EGFR1 or translocated ALK, RET, or ROS1. Smoking is the major cause of lung adenocarcinoma but, as smoking rates decrease, proportionally
more cases occur in never-smokers (defined as less than 100 cigarettes in a lifetime). KRAS mutations in lung cancer cases are nearly
exclusive to smokers. KRAS, &#8220;Kristen rat sarcoma viral oncogene homolog,&#8221; is a protein involved in regulating cell division.
KRAS mutation is a gain-of-function mutation (i.e. somatic mutation turns RAS, a benign gene &#8220;proto-oncogene&#8221; into KRAS,
an oncogenic driver of many tumors). KRAS-mutated non-small cell lung cancer represents 20% to 25% of all NSCLC. FDA granted accelerated
approval to KRAS inhibitor sotorasib and Antibody Drug Conjugate trastuzumab deruxtecan (Enhertu) for <i>KRAS G12C -</i>mutated and HER2
mutated advanced stages non-small cell lung cancer (NSCLC), respectively. In 2022, the combination of CTLA-4 inhibitor tremelimumab and
the anti-PDL1 antibody durvalumab was approved by FDA for treating metastatic NSCLC patients lacking EGFR mutation or ALK translocation.
Tumor suppressor gene abnormalities, such as those in TP53, CDKN2A8, KEAP1, and SMARCA4 are also common but are not currently clinically
actionable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
reviewing lung cancer incidence and mortality rates among never-smokers in the Journal of Clinical Oncology, Wakelee, H.A. et al. have
reported that the age-adjusted incidence rates of lung cancer among never-smokers aged 40 to 79 years from large population-based cohorts
ranged from 14.4 to 20.8 per 100,000 person-years in women and 4.8 to 13.7 per 100,000 person-years in men, supporting earlier observations
that women are more likely than men to have never smoking-associated lung cancer. The biology of lung cancer in never-smokers is apparent
in differential responses to epidermal growth factor receptor inhibitors and an increased prevalence of adenocarcinoma histology in never-smokers.
Lung cancer in never-smokers is an important public health issue needing further exploration of its incidence patterns, etiology, and
biology. Due to the fact that there are no known therapy options for this group, we believe that aggressive development of therapy options
is needed and is a high unmet clinical need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the US in 2023, there will be an estimated 12,000 diagnosed cases of NSCLC in female non-smokers, accounting for approximately 5% of
all lung cancer cases. Globally in 2020, there were an estimated 111,583 adenocarcinoma cases of NSCLC in female non-smokers. Due to
the specificity of this indication, it may be possible to classify it as a rare disease. When attempting to explain some gender susceptibility
differences, research has demonstrated that women with NSCLC tend to be:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Younger;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asian;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-3
    times more likely to be non-smokers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">more
    likely to develop adenocarcinoma and;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">more
    likely to have metastatic disease.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
high rate of adenocarcinomas in non-smoking women suggests the possible existence of other etiological factors in addition to smoking.
Some factors that have been considered include gender-specific genetic alterations and predispositions, passive smoke effects, different
nicotine metabolism in women, occupational exposure, diet, and chronic obstructive pulmonary disease. Based upon estimates published
by Global Cancer Statistics 2020 and 2023 estimates published by the American Cancer Society, below is an overview of relevant potential
patient population and market sizes that we believe LP-300 could address, if approved:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Lung cancer</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Global</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(2020)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2023)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: left">Total lung cancer estimated incidence (new cases)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">2,210,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">238,340</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NSCLC incidence (~85% of all lung cancer cases)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,878,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202,589</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NSCLC adenocarcinoma incidence (~60% of all NSCLC)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,127,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,553</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Never-smokers estimate (~15% of adenocarcinoma)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,233</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Female never-smoker estimate (~66% of never-smokers with lung cancer are female)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,034</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Potential Patient Segment in New Lung Cancer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Limitations
on Current Treatment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
of patients with advanced NSCLC in the first-line setting usually includes chemotherapy (including taxanes, vinorelbine, or gemcitabine)
in combination with a platinum doublet (cisplatin or carboplatin). According to the clinical practice guidelines published by the National
Comprehensive Cancer Network, many of these combinations have reached a plateau in terms of overall response (&#8805; 25% to 35%), time
to progression (four to six months), median survival time (eight to ten months), one-year survival rate (30% to 40%), and two-year survival
rate (10% to 15%) in patients with good performance status. Treatment remains palliative and is limited due to inherent toxicities that
may affect the quality of life resulting from treatment. Toxicities can be life-threatening or cause treatment delays, thereby limiting
the intensity of treatment delivered and affecting its efficacy. Common and serious chemotherapy-induced toxicities, such as anemia,
emesis, and peripheral neurotoxicity resulting from treatment with platinum and taxanes, and nephrotoxicity due to cisplatin can result
in treatment delays, dose modifications, and in severe cases, discontinuation of treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
identification of gene mutations in lung cancer has led to the development of molecularly targeted therapy to improve the survival of
subsets of patients with metastatic disease. In particular, genetic abnormalities in <i>EGFR</i>, <i>MAPK</i>, and <i>PI3K </i>signaling
pathways in subsets of NSCLC may define mechanisms of drug sensitivity and primary or acquired resistance to tyrosine kinase inhibitors
(TKIs). To date, approximately 21 TKIs have been approved for use in treating NSCLC with identified tyrosine kinase (TK) mutations; the
TKs targeted by these inhibitors include EGFR, ALK, ROS1, BRAF/MEK, RET, and MET. If patients are found to have specific TK mutations
to which inhibitors are known to respond, treatment with such TKIs is currently standard-of-care for this population of advanced NSCLC.
Most tumors will respond to initial treatment with TKIs, exhibiting tumor shrinking or delayed progression. Unfortunately, most patients
will eventually develop resistance to the inhibitory effects of initial used inhibitors. Therefore, second- or third-line therapy often
involves treatment with alternate inhibitors targeting the same kinase but with differing mutations. Such treatment again is often initially
successful, but further kinase mutations, or mutations arising in different kinases, often leads to relapse and the need to switch to
alternative treatment schemes. This next therapy usually involves chemotherapy (often carboplatin plus pemetrexed), sometimes used in
combination with immunotherapy, or enrollment in clinical trials testing new treatment approaches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe it is important to pursue the development of novel therapies and combinations thereof that can substantially improve patient
survival and quality of life by potentiating the antitumor activity of chemotherapy treatment while protecting against chemotherapy-induced
toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
Opportunity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
never-smoker patients with lung cancer are women, and adenocarcinoma is the most common type. Non-smoker patients with non-small-cell
lung cancer (&#8220;NSCLC&#8221;) generally have a better response to inhibitors of epidermal-growth-factor receptor (EGFR) tyrosine
kinase, including without limitation gefitinib and erlotinib, than do those with a history of tobacco smoking. Studies have identified
differences in chromosomal aberrations, genetic polymorphisms, gene mutations, and methylation status between lung cancer in non-smokers
and tobacco-associated lung cancer. These clinical and biological differences suggest that the two cancers have overlapping but unique
pathways of carcinogenesis. The EGFR mutation is one of the most important genetic change in lung cancer in people who have never smoked
because it is more common in lung cancer in never-smokers than in tobacco associated lung cancer and is associated with greater therapeutic
benefit from inhibitors of EGFR. Other alterations associated with never-smokers include mutations, fusions or amplifications in ALK,
ROS1, RET and MET genes. Based upon published articles in CA: Cancer Journal for Clinicians and Nature Review Cancer, incidence in never-smokers
is 10% to 15% of all lung cancers and globally, NSCLC in never-smokers comprises 15% to 20% of cases in men and greater than 50% in women.
In Asia, never-smokers with NSCLC are 60% to 80% women and 20% to 40% men.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focused on advancing LP-300 as a potential combination therapy for never smoking NSCLC patients with adenocarcinoma by leveraging
our A.I. platform to help uncover the genomic and biomarker networks that are associated with response in the never-smoker and non-smoker
groups. Additionally, through our early, preclinical work to define a gene signature that correlates with heightened sensitivity to LP-300,
we believe there is potential to further expand the indication to include all NSCLC patients that have this identified genetic profile
in their cancer. Currently there is no approved therapy specifically for the growing indication of never-smokers with NSCLC, and female
never smokers appear to be uniquely responsive to LP-300. If successful, LP-300 could provide improved patient benefit in terms of improved
survival, and secondarily through the concurrent prevention and mitigation of common and serious chemotherapy-induced toxicities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prior
Completed Trials of LP-300</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
I</i>. LP-300 has been evaluated in five Phase I studies (DMS10001, BioNumerik, 09/1997 through 04/2004; DMS10002, BioNumerik, 12/1997
through 08/2001; DMS12209, ASKA Pharmaceutical, 04/2000 through 12/2001; DMS10011, BioNumerik, 02/2006 through 07/2006; and DMS12307,
Baxter, 07/2002 through 07/2005) to determine the maximum tolerated dose (&#8220;MTD&#8221;), and to evaluate the safety, tolerability,
pharmacokinetics, and potential efficacy of LP-300 (alone or in combination with cisplatin, cisplatin/paclitaxel, or carboplatin/paclitaxel).
An MTD for LP-300 was not reached in any of the Phase I studies at dose levels of up to 41 g/m<sup>2</sup>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
II. </i>In a U.S. multi-center, randomized, open-label trial (n=160 patients) with advanced (Stage IIIB and IV) NSCLC treated with LP-300
or no LP-300 (DMS22210/CALGB 30303, Cancer and Leukemia Group B, 08/2004 through 03/2007), although the overall population did not meet
the pre-specified primary endpoint, an analysis of a subgroup of patients with adenocarcinoma revealed that the difference in the median
overall survival period between the 2 treatment groups was statistically significant (LP-300 = 15.6 months, no LP-300 = 8.9 months; Log-rank
p=0.0326), and the median overall survival for patients who received LP-300 was 6.7 months longer than that of those who did not receive
LP-300.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
III.</i> LP-300 has been evaluated in five Phase III studies: two in patients with metastatic breast cancer, with a primary endpoint
examining the ability to reduce platinum/taxane induced peripheral neuropathy, and three in patients with NSCLC or advanced primary lung
adenocarcinoma. (DMS32205R, ASKA Pharmaceutical, 08/2005 through 02/2008; DMS30203R, BioNumerik, 09/2001 through 10/2006; DMS30204R,
ASKA Pharmaceutical, 04/2003 through 03/2006; DMS32206R, Baxter, 10/2002 through 04/2006; and DMS32212R, BioNumerik, 04/2010 through
06/2013) Although the overall population did not meet the pre-specified primary endpoints in any of the trials, analysis of subgroups
of patients in one multi-country lung adenocarcinoma trial and one Japanese NSCLC trial revealed differences in the median overall survival
between the two treatment arms (with or without LP-300 treatment). The results from the two key lung cancer trials obtained from retrospective
analyses are described below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multi-country,
    double-blind, randomized, multi-center &amp; placebo-controlled trial (n=540 patients) with advanced primary lung adenocarcinoma
    treated with LP-300 or Placebo &amp; paclitaxel or docetaxel with cisplatin (DMS32212R). (the Phase III NSCLC adenocarcinoma trial)</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Wingdings">&#216;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
    with LP-300 nearly doubled the Overall Survival in women receiving paclitaxel/cisplatin (25.0-month median OS in LP-300 arm vs. 13.2-month
    OS in control arm) and the results in this subgroup were statistically significant (P-value = 0.0477; HR = 0.579)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Wingdings; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    never smoking women with adenocarcinoma of the lung receiving paclitaxel/cisplatin, the Overall Survival in the LP-300 arm was more
    than double the control arm (27.0 months vs. 13.4 months, respectively) also being statistically significant in favor of LP-300 (P-value
    = 0.0167; HR = 0.367) and the 2-year survival was 72.4% in the LP-300 arm vs. 32.3% in the control arm.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statistically
    significant subgroup analyses and trends from this LP-300 Phase III NSCLC adenocarcinoma trial support repositioning LP-300 for non-
    or never smokers with adenocarcinoma of the lung.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Randomized,
    double-blind, placebo-controlled and multi-center trial in patients with advanced NSCLC receiving paclitaxel &amp; cisplatin (Japan
    Trial) (DMS32205R). The Japan Trial observations support and complement observations in the multi-country Phase III NSCLC adenocarcinoma
    trial. The observations for the female adenocarcinoma patient population in the LP-300 multi-country Phase III NSCLC adenocarcinoma
    trial are consistent with observations made for the subgroup of females with adenocarcinoma of the lung receiving paclitaxel/cisplatin
    and LP-300 or placebo in the Japan Trial. Although the overall population in the Japanese trial did not meet the pre-specified primary
    endpoint, a retrospective analysis of the subgroup consisting of female patients with adenocarcinoma revealed that the difference
    in the median overall survival period between the two treatment arms in this subgroup was significant (P-value = 0.0456, HR = 0.376).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LP-300 arm of the multi-country Phase III NSCLC adenocarcinoma trial also demonstrated safety profile advantages in terms of the potential
to protect against chemotherapy-induced kidney toxicity and chemotherapy-induced anemia. These observations complemented earlier clinical
observations regarding LP-300&#8217;s potential to protect against neuropathy and other chemotherapy-induced toxicities. Results from
these trials indicate that treatment with LP-300 may, in further clinical testing, lead to improved survival in female and non- or never
smoking patients with primary adenocarcinoma of the lung receiving cisplatin/paclitaxel combination chemotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
II and III LP-300 Adverse Events Summary</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes adverse events reported from a total of 1,712 patients enrolled in five randomized multi-center phase II and phase
III studies with chemotherapy, with or without LP-300. A total of 1,712 patients were enrolled in these studies, of which 856 patients
received LP-300 with chemotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>All
    Adverse Events (AEs)</i>. The most frequently-occurring adverse events in patients receiving LP-300 with chemotherapy were generally
    similar to patients receiving placebo or chemotherapy alone. These events included blood and lymphatic system disorders (myelosuppression
    manifested as anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia; also including decreased hematocrit, hemoglobin,
    lymphocyte count, neutrophil count, red blood cell count, platelet count, and white blood cell count), with an incidence ranging
    from 12% to 83%; gastrointestinal disorders including constipation, abdominal pain, diarrhea, nausea, stomatitis, and vomiting, with
    an incidence ranging from 22% to 83%; general disorders and administrative site conditions including fatigue (ranging from 17% to
    85%); infusion/injection site pain/reactions (ranging from 12% to 18%); malaise (ranging from 16% to 28%); peripheral edema (ranging
    from 13% to 22%); pyrexia (ranging from 10% to 17%); infections and infestations disorders including nasopharyngitis (ranging from
    11% to 16%); investigations including increased liver function tests including ALT, AST, and alkaline phosphatase (ranging from approximately
    10% to 55%); increased blood lactate dehydrogenase (ranging from approximately 17% to 26%); increased blood urea or blood uric acid
    (ranging from approximately 11% to 32%); increased gamma-glutamyltransferase (ranging from approximately 23% to 33%); decreased total
    protein (ranging from approximately 12% to 21%); metabolic and nutritional disorders including weight decreased (ranging from 15%
    to 22%), anorexia (ranging from 14% to 82%), and hypomagnesemia (ranging from 22% to 30%); musculoskeletal and connective tissue
    disorders including arthralgia, back pain, and myalgia (ranging from 7% to 80%); nervous system disorders including dysgeusia (ranging
    from 12% to 22%), headache (ranging from 14% to 17%), and peripheral neuropathy (motor and sensory &#8211; ranging from 22% to 86%);
    psychiatric disorders including insomnia (ranging from 12% to 17%); respiratory, thoracic, and mediastinal disorders including dyspnea
    (ranging from 12% to 40%); skin and subcutaneous disorders including alopecia (ranging from 33% to 92%); rash (ranging from 22% to
    29%); nail disorder/discoloration (10%); and vascular disorders including angiopathy (ranging from 64% to 69%) and flushing (ranging
    from 15% to 39%).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Treatment-Related
    Adverse Events.</i> Frequently occurring treatment-related AEs experienced by patients receiving LP-300 with chemotherapy included
    gastrointestinal disorders manifesting as nausea and vomiting (ranging from 12% to 67%, and 12% to 32%, respectively); fatigue (ranging
    from 22% to 82%); infusion/injection site pain/reactions (ranging from 11% to 18%); increased ALT (alanine aminotransferase) and
    gamma-glutamyltransferase (ranging from approximately 13% to 18%, and approximately 11% to 12%, respectively); peripheral neuropathy
    (motor and sensory &#8211; ranging from 14% to 54%); and vascular disorders including angiopathy (ranging from 60% to 69%), and flushing
    (ranging from 8% to 11%). </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Serious
    Adverse Events (SAEs)</i>. 11% to 49% of patients receiving LP-300 with chemotherapy, and 7% to 42% of patients in control groups
    receiving chemotherapy alone experienced SAEs during randomized multicenter studies. Frequently-occurring SAEs in patients receiving
    LP-300 with chemotherapy included pneumonia, hypersensitivity or drug hypersensitivity, dyspnea, pyrexia and dehydration, diarrhea,
    anaphylactic shock or anaphylactic reactions, vomiting, disease progression, infection, bronchospasm, pleural effusion, pulmonary
    embolism, thrombosis, hemolysis, nausea, chills, fatigue, sudden death, neutropenic infection, sepsis, anorexia, neutropenia, febrile
    neutropenia, pneumonitis, rash, and hypotension. Multiple allergic reactions have been reported in clinical trials of LP-300, and
    some of these reactions have been severe. It is possible that patients could experience an allergic reaction that is life-threatening.
    Five reports of grade 3 or 4 hemolysis events with three fatal outcomes were reported in patients receiving LP-300 with chemotherapy
    in a study involving the weekly drug administration schedule. Two events of hemolysis were reported in a study involving drug administration
    every two weeks. No events of hemolysis were reported in studies using the three weeks schedule of administration, which is the administration
    schedule used for the multi-country Phase III NSCLC adenocarcinoma trial. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Treatment-Related
    Serious Adverse Events.</i> Approximately 7% of patients receiving LP-300 with chemotherapy experienced treatment-related SAEs during
    randomized multicenter studies. The most frequently-occurring treatment-related SAEs experienced by patients receiving LP-300 with
    chemotherapy were hypersensitivity or drug hypersensitivity (five and two patients, respectively) and neutropenia (six patients).
    Other treatment-related SAEs experienced by patients receiving LP-300 with chemotherapy included hemolysis, bronchospasm, febrile
    neutropenia, anemia, nausea, and pulmonary edema (three patients, each); chills, diarrhea, pyrexia, neutropenic infection, hyperglycemia,
    acute respiratory distress syndrome, pulmonary embolism, sudden death, infection, and rash (two patients, each); and angina pectoris,
    cardiac arrest, tachycardia, sudden hearing loss, abdominal pain, vomiting, adverse drug reaction, anaphylactic shock, <i>C. difficile
    </i>colitis, pneumonia, sepsis, chemical cystitis, thrombosis in device, dehydration, leukopenia, anorexia, atrial fibrillation,
    fatigue, weight decrease, muscle disorder, pain in extremity, dizziness, peripheral sensory neuropathy, dyspnea, hypotension, and
    thrombosis (one patient, each). </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Evidence of Toxicity Protection by LP-300 </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
data from randomized multicenter studies of LP-300 and chemotherapy demonstrates objective evidence of several instances where treatment
with LP-300 appears to provide potential benefit in terms of preventing and mitigating chemotherapy-induced toxicities, particularly
in studies of LP-300 and chemotherapy in patients with advanced NSCLC. These data support that LP-300 has the potential to protect against
chemotherapy-induced toxicities, including gastrointestinal, renal, electrolyte disturbances, and anemia; and there is data supporting
the potential for LP-300 to protect against severe forms of these toxicities. In addition, treatment with LP-300 may protect against
severe platinum-induced hearing loss and dehydration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LP-300
Mechanism of Action</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
is a water-soluble disulfide compound that lacks a free thiol or sulfate moiety. We postulate this unique structure of LP-300 may allow
it to potentiate antitumor activity of certain types of cytotoxic chemotherapy, and exert chemoprotective effects, through distinct and
interrelated mechanisms. In plasma, the lack of a free thiol prevents untoward reactivity and drug-drug interactions, and thereby may
allow chemotherapeutic agents to retain their efficacy. Once inside the tumor cell, LP-300 is metabolized and may then potentiate antitumor
activity of cytotoxic certain types of chemotherapy. A significant fraction of LP-300 is taken up by the kidneys, where LP-300&#8217;s
metabolites can interact with chemotherapy drugs, such as cisplatin, and potentially diminish the chemotherapy drug&#8217;s ability to
cause organ damage. We believe the postulated mechanisms that can enhance tumor directed chemosensitivity include restoration of apoptotic
sensitivity thereby countering drug resistance; oxidative stress enhancement; anti-angiogenesis; decreased DNA synthesis and gene expression;
and decreased glutathione and precursors (limiting glutathione tumor-mediated drug resistance). When LP-300 accumulates in the kidneys
it appears to reduce the toxicity of certain drugs, such as cisplatin, that are excreted through the renal system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
depicted in the model below, we believe LP-300 and its metabolites can modulate key components of the thioredoxin and glutaredoxin systems,
which are believed to be involved as major mechanisms of the potentially enhanced antitumor effects of LP-300 with chemotherapy. The
thioredoxin pathway is commonly upregulated in adenocarcinomas, and examination of primary lung tumors from non-smokers have shown significantly
increased gene expression of thioredoxin. Overexpression of thioredoxin in cancer cells has been postulated to lead to resistance to
apoptosis, increased cellular proliferation, increased gene expression, increased angiogenesis, increased conversion of DNA into RNA,
and resistance to oxidative stress induction. We believe the modulation of thioredoxin expression is important for the observed increases
in patient survival identified in retrospective analyses of certain subgroups of patients with primary adenocarcinoma of the lung receiving
LP-300 in conjunction with cisplatin and paclitaxel chemotherapy. Different glutaredoxin transcript variants have been found to be elevated
in transformed cells, and glutaredoxin isoforms (e.g., variants of glutaredoxin 2) have been found to be elevated in NSCLC cell lines,
lending evidence for potential roles of glutaredoxin in tumor progression.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe LP-300 and its metabolites may potentiate the antitumor activity of chemotherapy by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
shifting the redox balance and concentrations of reduced forms of thioredoxin and glutaredoxin to inactive oxidized forms of thioredoxin
and glutaredoxin, thereby restoring apoptotic sensitivity, increasing sensitivity to oxidative stress, inhibiting cell growth and angiogenesis,
RNA to DNA synthesis, and growth signaling, and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
forming thioredoxin or glutaredoxin adducts, which as inactive forms lead to thioredoxin- and glutaredoxin-mediated reduction of downstream
targets in the cell that are important for tumor resistance to chemotherapy, angiogenesis and cell growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Working
Model for LP-300 Mechanism of Action</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_011.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that LP-300 may potentiate antitumor activity of certain types of cytotoxic chemotherapy, and exert chemoprotective effects through
several distinct and interrelated mechanisms of action. LP-300 is a cysteine-modifying agent that appears to modulate multiple cellular
pathways simultaneously. Experimental data indicate that LP-300 modifies and/or modulates the following key pathways:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kinases
    involved in key signaling pathways (EGFR, ALK, ROS, MET)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enzymes
    critical for DNA synthesis and repair (ERCC1, RNR1, RNR2)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enzymes
    and proteins important in regulating cell redox status (TRX, PRX, GRX, PDI)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following key mechanisms have been observed to support our belief that LP-300 has potential to play an important role in the treatment
of females and never smokers with NSCLC adenocarcinoma. We believe these mechanisms help to explain the retrospective subgroup observations
for females and never smokers receiving LP-300 together with cisplatin and paclitaxel in the Phase III NSCLC adenocarcinoma trial:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>LP-300
    targets cysteine residues</i>. Computational and experimental data indicate that LP-300 demonstrates specificity towards cysteines.
    LP-300-mediated xenobiotic modulation of protein targets on cysteine results in distinct, (multi)target-specific effects correlated
    to the role of the cysteine residue(s) in the target.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>LP-300
    alone inhibits human ALK and stimulates the inhibitory effect of crizotinib on human ALK</i>. Alterations in ALK, along with MET,
    ROS1 &amp; PDGFRA are thought to underlie nearly 10% of NSCLC adenocarcinoma cancers. Liquid Chromatography (LC), Mass Spectrometry
    (MS) and X-ray structural data demonstrate that LP-300 covalently modifies human ALK on Cys1156 and Cys1235. Enzyme assay data demonstrates
    that LP-300 inhibits human ALK&#8217;s kinase activity and stimulates the inhibitory effect of crizotinib on human ALK&#8217;s kinase
    activity.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>LP-300
    inhibits human MET kinase activity and stimulates Staurosporine inhibition of human MET kinase activity</i>. Mesenchymal Epithelial
    Transition Factor Kinase (MET) kinase mutations and amplification are an important, specific subset of NSCLC adenocarcinoma. Enzyme
    assays demonstrate that LP-300 inhibits human MET kinase activity and stimulates the inhibitory activity of staurosporine on human
    MET kinase.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>LP-300
    inhibits EGFR kinase activity</i>. EGFR mutations are an important, specific subset of NSCLC adenocarcinoma, particularly in non-smoker
    females. Enzyme assays demonstrate that LP-300 inhibits EGFR kinase activity and potentiates the inhibitory effect of eErlotinib
    on wild type as well as mutant EGFR kinase activity.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>LP-300
    modestly inhibits retinal rod outer segment kinase (ROS1) activity</i>. ROS1 chromosomal rearrangements are a recently identified
    class of mutations in NSCLC. Estimates of frequency of ROS1 rearrangements range from 1% to 2%. Experimental data are as follows:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enzyme
    activity data demonstrates that LP-300 has an effect on Human ROS1 activity when ROS1 is preincubated with LP-300. We hypothesize
    that pre-incubation allows slower reacting cysteine residues to be modulated by LP-300.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Wingdings">&#216;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on modeling studies, the cysteines on ROS1 appeared to be in less optimal orientations compared to cysteines in ALK.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Wingdings">&#216;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
    appears not to impact ROS1 activity unless ROS1 and LP-300 are pre-incubated prior to kinase assays. Therefore, to see an effect
    <i>in vivo</i>, it may be necessary to administer LP-300 prior to LP-300&#8217;s effects on ROS1 through preincubation of ROS1 and
    LP-300, suggesting slower xenobiotic modulation reactions. However, there are several possible explanations for the LP-300 effect
    on ROS1 and in the absence of an X-ray structure this remains a hypothesis.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>LP-300
    modifies Ribonucleotide Reductase 1 and 2 (RNR1 and RNR2).</i> Selective, elevated expression of the RNR1 subunit is associated with
    gemcitabine resistance in NSCLC. RNR1/RNR2 are essential for DNA synthesis, DNA repair &amp; cell proliferation. RNR1/2 catalyzes
    the formation of deoxyribonucleotides needed for DNA synthesis, from ribonucleotides.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>LP-300
    targets proteins that may result in protection against chemotherapy-induced nephrotoxicity and neuropathy</i>. The LP-300 derivative-cisplatin/paclitaxel
    conjugate is inactive and this conjugate is not a substrate for aminopeptidase/&#947;-Glutamyl-transpeptidase (APN/GGT). These LP-300
    heteroconjugates appear to cause potent inhibition of APN/GGT leading to suppression/bypass of renal APN/GGT xenobiotic metabolism
    pathways promoting protection against chemotherapy-induced nephrotoxicity. In addition, binding of the LP-300 derivative with reactive
    cisplatin/paclitaxel species, appears to inactivate the platinum-catalyzed microtubule hyper-polymerization. This action may serve
    to protect against chemotherapy-induced peripheral neuropathy.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>LP-300
    modulates protein function in a way that may promote chemosensitization</i>. LP-300 appears to promote covalent oxidation of redox
    proteins Thioredoxin (TRX), Peroxiredoxin1 (PRX1) and Glutaredoxin (GRX). This action may keep these redox proteins in an inactive
    non-signaling state, which could enhance sensitivity to oxidative stress and apoptosis induced by concomitant chemotherapy.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Using
various <i>in vitro</i> experimental approaches, LP-300 has been observed to form adducts on cysteines of various protein targets such
as those listed below. For several of these targets, studies evaluating enzyme activity associated with the targets have demonstrated
inhibition, modulation or impairment of such activity. In addition, X-ray crystallographic studies support LP-300 derived adducts at
specific cysteines on these proteins.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Targeted
Proteins Modified by LP-300</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cellular
    Target of LP-300</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cellular
    consequence of LP-300-modification and/or modulation</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellular
    thiol/disulfide balance</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
    and LP-300-derived mesna disulfide heteroconjugates are pharmacological surrogate/modulators of physiological thiols and disulfides
    (e.g., glutathione, cysteine, and homocysteine).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gamma-Glutamyltranspeptidase
    Aminopeptidase N</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
    and LP-300-derived mesna disulfide heteroconjugates can inhibit gamma-glutamyltranspeptidase and aminopeptidase N enzyme activity.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tubulin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
    exerts direct and indirect protective interactions with tubulin.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anaplastic
    Lymphoma Kinase (ALK)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
    disrupts/blocks ATP binding site resulting in inhibition of ALK kinase activity (vide infra).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mesenchymal
    Epithelial Transition (MET) Factor Kinase</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modification
    of non-active site cysteine(s) resulting in enzyme inhibition (MET).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROS1
    kinase</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
    xenobiotically modifies ROS1 kinase in a time dependent manner.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redox
    Balance</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
    and LP-300-derived mesna disulfide heteroconjugates assist in the maintenance of cellular redox balance and support cellular defenses
    against oxidative insult.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thioredoxin
    (Trx) Glutaredoxin (Grx)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
    modifies non-catalytic cysteines important in redox protein function/structure (Grx and Trx).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thioredoxin
    (Trx) Glutaredoxin (Grx)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
    and/or LP-300-derived mesna disulfide heteroconjugates function as alternative substrates/inhibitors (Trx, Grx) resulting in impaired
    enzyme activity.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peroxiredoxin
    (Prx)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
    disrupts active site structure (Prx) resulting in impaired enzyme activity.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mechanistic
evaluation of LP-300 revealed that it has cysteine-modifying activity on select Receptor Tyrosine Kinases (RTKs) initiating proliferative
signaling such as ALK, EGFR, MET and ROS1. LP-300 may also serve as a potential chemosensitizer for certain combination chemotherapies
by inactivating proteins such as Thioredoxin (TRX), Glutaredoxin (GRX) and Peroxiredoxin (PRX) that are important in modulating cellular
redox status and in turn drug resistance. Higher levels of PRX gene expression have been shown to correlate significantly with the absence
of smoking history and with the female gender.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe well-tolerated profile advantages of LP-300 are imparted through its chemoprotective action via production of inactive LP-300-chemotherapeutic
conjugates and preventing toxic taxane/platinum metabolites in the kidney, and targeting toxicity-inducing molecules and pathways (e.g.
APN, GGT, and Tubulin).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
RADR<sup>&#174;</sup> Platform&#8217;s Approach to LP-300 Repositioning</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
RADR<sup>&#174; </sup>platform has been implemented with the objective of uncovering insights from LP-300 rescued preclinical data as
well as from lung cancer clinical trial data regarding actionable bioinformatics, biomarkers, target population demographics and smoking
history. Differential expression analyses of RNAseq data on LP-300 pre- and post-exposure in selected NSCLC cell lines has revealed gene
sets that could be upregulated and downregulated in response to LP-300 treatments involving the mapping of genes performing cellular
redox functions, kinases involved in proliferating signaling, and apoptotic markers. We are currently in the early stages of defining
a specific biomarker signature that correlates with heightened sensitivity to LP-300. We believe that this signature may help accelerate
the clinical development of LP-300 and has the potential to guide patient selection for targeted clinical trials. We are also developing
a list of approved cancer drugs that, when used in combination with LP-300, may have potential to improve the overall benefit to patients
through either potentially greater anticancer properties or improved tolerability. We believe identifying such combinations would be
attractive to established pharmaceutical and biotech companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Acquisition
of Tavocept<sup>&#174;</sup> (LP-300) Rights from BioNumerik</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2018, we entered into an Assignment Agreement (the &#8220;Assignment Agreement&#8221;) with BioNumerik Pharmaceuticals, Inc.
(&#8220;BioNumerik&#8221;), pursuant to which we acquired rights to domestic and international patents, trademarks and related technology
and data relating to LP-300 for human therapeutic treatment indications. Mr. Margrave, our Chief Financial Officer and Secretary, formerly
served as the President, Chief Administrative Officer, General Counsel and Secretary of BioNumerik and has a minority ownership interest
in BioNumerik. The Assignment Agreement replaced a License Agreement that was entered into between us and BioNumerik in May 2016. We
made upfront payments totaling $25,000 in connection with entry into the Assignment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we commercialize LP-300 internally, we will be required to pay to the BioNumerik-related payment recipients designated in the Assignment
Agreement a percentage royalty in the low double digits of cumulative net revenue up to $100 million, with incremental increases in the
percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million
and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion.
In addition, we have the right to first recover certain designated portions of patent costs and development and regulatory costs before
the payment of royalties described above. We are obligated to make royalty payments under the Assignment Agreement during the &#8220;Agreement
Term<b>&#8221; </b>that started on January 5, 2018 and continues (on a country-by-country and product-by-product basis) until the later
to occur of (i) five (5) years after the expiration of the last to expire Patent Rights, as defined in the Assignment Agreement, in an
applicable country in the Territory, as defined in the Assignment Agreement, and (ii) if no Patent Rights exist in such country, fifteen
(15) years after May 31, 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we enter into a third party transaction for LP-300, we are required to pay the BioNumerik-related payment recipients a specified percentage
of any upfront, milestone, and royalty amounts received by us from the transaction, after first recovering specified direct costs incurred
by us for the development of LP-300 that are not otherwise reimbursed from such third party transaction. In addition, the Assignment
Agreement provides that we will use commercially diligent efforts to develop LP-300 and make specified regulatory filings and pay specified
development and regulatory costs related to LP-300. The Assignment Agreement also provides that we will provide TriviumVet DAC (&#8220;TriviumVet&#8221;)
with (i) specified data and information generated by us with respect to LP-300, and (ii) an exclusive license to use specified LP-300-related
patent rights, trademark rights and related intellectual property to support LP-300 development in non-human (animal) treatment indications.
Under the Assignment Agreement, we are required to pay all patent costs on covered patents related to LP-300. These patent costs are
fully recoverable at the time of any net revenue from LP-300, with up to 50% of net revenue amounts to be applied towards repayment of
patent costs until such costs are fully recovered. In addition to the recovery of patent costs, we have the right to recover the $25,000
upfront payments made in connection with entry into the Assignment Agreement, which payments are recoverable prior to making any royalty
or third-party transaction sharing payments. We also have the right to recover all previously incurred LP-300 development and regulatory
costs, with up to a mid-single digit percentage of net revenue amounts to be applied towards repayment of development and regulatory
costs until such costs are fully recovered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LP-184</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184
(hydroxyureamethylacylfulvene) is a small molecule that preferentially damages DNA in cancer cells that overexpress certain biomarkers
or that harbor mutations in DNA repair pathways. LP-184 is converted into an active alkylating agent by the enzyme prostaglandin reductase
1 (PTGR1), which is overexpressed in many tumor types that are resistant to current standard of care treatments. The FDA has granted
LP-184 Orphan Drug Designation for the treatment of pancreatic cancer, glioblastoma and ATRT (<b>A</b>typical <b>T</b>eratoid <b>R</b>habdoid
<b>T</b>umors). We believe cancer cells are less likely to develop resistance to LP-184 because of its mode of action that is independent
of efflux pumps and oncogene/tumor suppressor mutations. We also believe that LP-184 has the potential to address a significant unmet
need in the current treatment landscape for multiple important cancer types.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184
has nanomolar potency and it is a member of a new generation of acylfulvenes, a family of naturally-derived anticancer drug candidates.
Earlier generations of acylfulvenes showed great promise in preclinical studies, but were hampered in human clinical studies because
of the inability to deliver effective therapeutic doses due to unacceptable toxicities to normal cells. In preclinical studies, LP-184
has shown significantly enhanced antitumor activity as compared to earlier generation acylfulvenes. In addition, we have used our RADR<sup>&#174;
</sup>platform, together with work of collaborators, to develop a patient-specific biomarker test we believe will be predictive of LP-184&#8217;s
anticancer activity in targeted patient populations. The chemical structure of LP-184 is depicted below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><img src="form10-k_012.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184
Chemical Structure</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Starlight
Therapeutics Inc. and STAR-001</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, we formed a wholly owned subsidiary, Starlight Therapeutics Inc. (&#8220;Starlight&#8221;), to develop drug candidate LP-184&#8217;s
central nervous system (CNS) and brain cancer indications &#8211; including glioblastoma (GBM), brain metastases (brain mets.), and several
rare pediatric CNS cancers. Following the formation of Starlight, we will refer to the molecule LP-184, as it is developed in CNS indications,
as &#8220;STAR-001&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Planned
Phase I Clinical Trial for LP-184</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are advancing LP-184 towards a Phase I clinical trial in patients with
late-stage solid tumors, including pancreatic, breast, lung, bladder, prostate, and ovarian cancers. For the dose escalation portion of
the study, in addition to the primary objective of determining the MTD (maximum tolerated dose)/MAD (maximum administered dose) and the
recommended dose range for LP-184, secondary objectives include correlation with expression of the gene PTGR1 (Prostaglandin Reductase
1) and correlations with mutations in DNA damage repair pathway genes. We expect to include up to 40 patients in the Phase 1A portion
of the study from multiple clinical sites. For the Phase 1A (dose escalation safety) portion of the study, all-comer solid tumor patients
are expected to be included.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of enrollment in Phase IA and analysis of patient safety, PK, and therapeutic data, we, together with the clinical investigators
participating in the study, will review the study data package to determine the recommended dose to be used in further clinical testing
of LP-184.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LP-184
Development Opportunities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>STAR-001
in Glioblastoma and other CNS Cancers &#8211; Starlight Therapeutics Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glioblastoma
is an aggressive type of cancer that begins in the brain and accounts for more than half of all brain cancers. Glioblastoma has an overall
five-year survival rate of 5%, meaning that only approximately 5 in 100 people survive GBM for five years and beyond. We believe that
STAR-001&#8217;s molecular features and distinct mechanism of action, anti-tumor efficacy and strong correlation with specific biomarkers
have the potential to provide a unique and powerful approach aimed at addressing high unmet needs in GBM and other aggressive CNS tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
and observations supporting the development of STAR-001 for GBM and other brain cancers include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have obtained favorable preclinical in vivo and in vitro data supporting the ability of STAR-001 to cross the blood brain barrier.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STAR-001
    treatment induced tumor regression evidenced by greater than 106% tumor growth inhibition in two subcutaneous xenograft models of
    GBM (U87 and M1123). STAR-001 also prolonged survival in mice bearing an intracranially implanted tumor model of GBM (U87), as compared
    with those that did not receive any drug substance.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intravenous
    administration of STAR-001 over two cycles reduced subcutaneous xenograft tumor volume in mice by greater than 85% within the treatment
    group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    an orthotopic GBM xenograft tumor model in mice, a single cycle of STAR-001 resulted in a statistically significant (p &lt; 0.0001)
    extension of median overall survival in the STAR-001-treated group (42 days) versus the control group (33 days).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analyses
    driven by RADR<sup>&#174;</sup> have identified, in clinical databases, GBMs with elevated PTGR1 expression and harboring defects
    in DNA damage repair components as a targeted subset of genetically defined patients who could potentially benefit from STAR-001-based
    therapy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
    data supports the observation that STAR-001 can be an effective treatment in GBM regardless of MGMT (a DNA repair enzyme) status
    of the cancer. This has significant potential to provide a much-needed alternative to the standard-of-care drug, temozolomide (TMZ),
    especially in GBMs that over-express MGMT &#8212; which can be up to 50% of GBM cancers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    August 2021, the FDA granted STAR-001 Orphan Drug Designation for the treatment of GBM and other malignant gliomas.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
standard treatment for glioblastoma includes radiation and chemotherapy with temozolomide. Based on an article in the journal Genes and
Diseases (<i>Temozolomide resistance in glioblastoma multiforme</i>, Genes Dis., 2016 May 11;3(3):198-210) and other publications, at
least fifty percent of temozolomide treated patients do not respond to this treatment, and others often form resistance to temozolomide
based regimens. We have obtained preclinical data supporting the observation that STAR-001 can be an effective treatment in GBM regardless
of the MGMT (a DNA repair enzyme) status of the cancer. This has significant potential to provide a much-needed alternative to the standard-of-care
drug, temozolomide (TMZ), especially in GBMs that over-express MGMT &#8212; which can be up to 50% of GBM cancers. Patients that have
GBMs that over-express MGMT are generally unresponsive to TMZ and need new therapy options that can exploit other molecular pathways
and mechanisms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe STAR-001&#8217;s ability to cross the blood-brain barrier, together with its anti-tumor efficacy and sensitivity correlations
with relevant biomarkers, highlight STAR-001&#8217;s potential for use as both monotherapy as well as a synergistic agent in combination
with other drugs to address the unmet needs in GBM and other aggressive central nervous system tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>STAR-001
in ATRT and Pediatric Rare Disease Designation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATRTs
(<b>A</b>typical <b>T</b>eratoid <b>R</b>habdoid <b>T</b>umors) are rare neurological tumors that primarily affect children under the
age of three. These clinically aggressive tumors are associated with a very poor prognosis, including a median survival of 6-12 months
and a 5 year survival rate of 30%. The National Cancer Institute (NCI) estimates that in the U.S. there are 600 living ATRT patients
with 60 new patients diagnosed annually. These tumors are typically pathogenetically driven by loss of function of the SMARCB1 or SMARCA4
genes. We believe that STAR-001&#8217;s molecular features and distinct mechanism of action, observed preclinical anti-tumor efficacy
and correlation with specific biomarkers have the potential to provide a unique and powerful approach aimed at addressing unmet needs
for this ultrarare pediatric cancer. We plan to pursue further preclinical studies of STAR-001 in this indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
and Observations supporting the development of STAR-001 for ATRT include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have obtained favorable preclinical in vivo and in vitro data supporting the ability of STAR-001 to cross the blood brain barrier.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STAR-001
    was observed to have a potent efficacy in ATRT cell lines CHLA-02, CHLA-05, and CHLA-06 with IC50s (nM) of 1776, 162, and 37.4, respectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    ATRT xenograft tumor models in mice, i.v. injections of STAR-001 at either 2 mg/kg or 4 mg/kg had high in vivo efficacy. At both
    concentrations xenografts showed complete tumor regression compared to the vehicle control group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
    in vivo and in vitro data supports the in-silico observation that STAR-001 can be an effective treatment for ATRT. Currently, there
    is no standard of care for treatment of children with ATRT.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STAR-001
    has been granted Orphan Drug Designation and Rare Pediatric Disease Designation to treat ATRT.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA grants rare pediatric disease designation for serious and life-threatening diseases that primarily affect children ages 18 years
or younger and fewer than 200,000 people in the United States. The Rare Pediatric Disease Priority Review Voucher Program is intended
to address the challenges that drug companies face when developing treatments for these unique patient populations. Under this program,
companies are eligible to receive a priority review voucher following approval of a product with rare pediatric disease designation if
the marketing application submitted for the product satisfies certain conditions, including approval prior to September 30, 2026 unless
changed by legislation. If issued, a sponsor may redeem a priority review voucher for priority review of a subsequent marketing application
for a different product candidate, or the priority review voucher could be sold or transferred to another sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LP-184
in Pancreatic Cancer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic
cancer is the 4th leading cause of cancer death in the U.S. Despite rigorous highly cytotoxic therapies and a few approved targeted therapies,
typical life expectancy for advanced pancreatic cancer remains below 1 year, leaving a large number of patients with no additional treatment
options. LP-184 has demonstrated significant potency in multiple preclinical studies focused on pancreatic cancer, and we are positioning
LP-184 for areas of high unmet need in genetically targeted pancreatic cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
and observations supporting the development of LP-184 for pancreatic cancer include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    believe LP-184 acts by selectively damaging DNA in tumors that express high levels of the enzyme PTGR1 &#8211; which occurs in several
    solid tumors. Analysis with our data platform, RADR<sup>&#174;</sup>, indicates that 35-40% of pancreatic tumors overexpress PTGR1.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
    studies have shown significant and targeted anti-tumor effects of LP-184, even in pancreatic cancers that are resistant to standard-of-care
    drugs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic
    tumors with DNA-damage repair deficiencies were significantly more sensitive (by two times) to LP-184 in preclinical studies. This
    and other observations support LP-184&#8217;s potential as a synthetic lethal agent in many HRD (homologous recombination deficient)
    and NERD (nucleotide excision repair deficient) cancers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184,
    demonstrated significant and rapid pancreatic tumor shrinkage, by over 90%, in <i>in-vivo</i> mouse models in 8 weeks. In comparison,
    the tumors in the untreated mice grew by over eleven-fold in volume during the same 8 week period.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    positive preclinical data on the efficacy and potency of LP-184 was gathered from 6 pancreatic cancer cell lines, and an additional
    5 patient-derived xenograft (PDX) <i>ex-vivo</i> tumor models. Significant reduction of cancer cells and cancer cell growth was observed
    across all pancreatic cancer cell lines and PDX models that were tested in the study with IC50 values in the nanomolar range (45-270
    nM).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    A.I. based identification of the key gene in the drug mechanism-of-action for LP-184 was validated by leveraging gene-editing (CRISPR)
    technology to validate PTGR1 as a fundamental driver of tumor sensitivity and cancer cell death.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184
    treatment of 2 PDX models for HR deficient pancreatic cancer in preclinical studies resulted in 110-140% tumor growth inhibition.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    August 2021, the FDA granted LP-184 Orphan Drug Designation for the treatment of pancreatic cancer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Additional
LP-184 Background</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have evaluated LP-184 in a number of solid tumors that overexpress certain biomarkers that have been identified as correlating with potential
response to LP-184. Our analysis indicates that LP-184 is expected to be a pro-drug activated by the enzyme Prostaglandin Reductase 1
(&#8220;PTGR1&#8221;). We believe LP-184&#8217;s mechanism of action is to alkylate DNA and protein macromolecules, form adducts, and
arrest cells in the S-phase of the cell cycle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Using
our RADR<sup>&#174; </sup>platform, we have derived a 10-gene signature composed of candidate biomarkers determining sensitivity to LP-184.
Genes from this signature, such as PTGR1, were found to be implicated in the potential induction of bioactivation of LP-184. We believe
LP-184 may be well positioned as a new drug candidate for individual patient genetic profiles identified as having DNA repair complex
deficiencies or other commonly prevalent gene signatures. LP-184 displayed less bone marrow toxicity in preclinical studies (dog and
mouse), had an improved pharmacokinetic profile (increased bioavailability as reflected by increased AUC), was stable in plasma, and
had an increased shelf life or stability in pharmaceutical grade material (sterile glass containers) for its class of compounds. LP-184
retained selective cytotoxicity towards solid tumor derived cell lines <i>in vitro</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe LP-184 is a non-hormone, next generation alkylating agent with nanomolar potency that preferentially damages DNA in cancer cells
that overexpress certain biomarkers indicated primarily in solid tumors such as those in prostate, pancreatic and ovarian cancers. LP-184
was developed using combinatorial chemistry approaches. Based on screening against conventional therapies both <i>in vitro</i> and <i>in
vivo</i>, LP-184 cytotoxicity appears to be mediated through the Transcription Coupled Nucleotide Excision Repair (TC-NER) pathway, via
alkylation of DNA leading to cell cycle arrest in S phase. Additional cytotoxic effects on tumors may include the generation of reactive
oxygen species, chemical modification of various intracellular proteins, and induction of the Mitogen Activated Protein Kinase (&#8220;MAPK&#8221;)
pathway followed by apoptosis. A proposed model for the mechanism of action of LP-184 is illustrated below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Working
Model for LP-148 Mechanism of Action</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="image_003.jpg" alt="" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
RADR<sup>&#174;</sup> platform has identified multiple solid tumor cancer indications that highly express PTGR1, including prostate, ovarian,
kidney, liver, lung, pancreatic and thyroid cancers. Our RADR<sup>&#174;</sup> platform has and will be employed to correlate results
from ongoing preclinical studies with gene expression data with the aim of determining the likely anticancer activity of LP-184 in these
cancer indications. With the assistance of insights from RADR<sup>&#174;</sup>, we have also conducted studies in patient derived xenografts
(PDX) models to further elucidate precise targets and potential patient groups for future LP-184 clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="background-color: white">Use of RADR<sup>&#174;</sup>
in LP-184 Development</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Using
our RADR<sup>&#174;</sup> platform, we matched LP-184 drug response data in cell lines and in <i>ex vivo</i> PDX models with gene expression
from matched RNA-seq experiments in over 100 samples to build models that predict LP-184 response using a small number of gene expression
values. (See Figure A below) The machine learning model was able to accurately predict LP-184 response. (See Figure B below) The final
model required only 10 genes - as opposed to the entire transcriptome - to make predictions, with <i>PTGR1</i> making a dominant contribution.
This suggests <i>PTGR1 </i>is required for activity or has a strong effect to enhance drug sensitivity. (See Figure C below)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #222222">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">To
test this hypothesis, <i>PTGR1 </i>was knocked down with a CRISPR-interference construct that ablated <i>PTGR1 </i>expression, and consequently,
LP-184 sensitivity was lost. (See Figure C below) Because the LP-184 model can predict drug response with any RNA data, we surveyed public
RNA-seq data to support targeted cancer indications of interest for LP-184. (See Figure D below)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #222222">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">We
observed that Atypical Teratoid Rhabdoid Tumor (ATRT) was predicted to be highly responsive to LP-184, and the presence of its characteristic
SWI/SNF-complex mutations in <i>SMARCB1 </i>or <i>SMARCA4 </i>were associated with lower predicted IC50 values. (See Figure E below) We
performed mouse xenografts with an ATRT line and validated extreme responsivity to LP-184 that was previously predicted by RADR. This
demonstrates RADR<b><i>&#174;</i></b> ability to make valid drug response model predictions based on gene expression, which can be used
to optimize drug positioning, uncover drug mechanism-of-action, and discover relevant biomarkers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_018.jpg" alt="" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disease
Background for Pancreatic Cancer, Glioblastoma, Atypical Teratoid Rhabdoid Tumors (ATRT), and Prostate Cancer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
target patient populations for LP-184 include pancreatic cancer, glioblastoma, atypical teratoid rhabdoid tumors (ATRT) and prostate
cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pancreatic
Cancer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic
cancer is the fourth leading cause of cancer deaths in the United States with a five-year survival rate of 11.5% and a 10-year survival
rate of just 1%. This means that only approximately 12 in 100 people will have survived for five years and beyond. Pancreatic cancer
has among the lowest 5-year survival rate of any of the 22 common cancers. Global Cancer Statistics 2020 estimates that for pancreatic
cancer there are approximately 495,773 new cases of pancreatic cancer globally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
American Cancer Society&#8217;s estimates for pancreatic cancer in the United States for 2023 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">About
    64,050 people (33,130 men and 30,920 women) will be diagnosed with pancreatic cancer; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">About
    50,550 people (26,620 men and 23,930 women) will die of pancreatic cancer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Targeting
a specific subset of pancreatic cancer patients that are genetically defined has the potential to increase beneficial therapeutic options
for patients and may ultimately improve survival for those with this cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Glioblastoma</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glioblastoma
is a fast-growing, aggressive type of CNS (Central Nervous System) tumor that forms on the supportive tissue of the brain. Glioblastoma
is the most common high grade glioma (HGG). The American Cancer Society estimates that approximately 24,810 malignant tumors of the brain
or spinal cord (14,280 in males and 10,530 in females) will occur in the U.S. in 2023. It also estimates that in 2023, approximately
18,990 deaths will occur from brain and other nervous system cancers. Approximately 250,000 new glioblastoma cases are estimated to occur
each year worldwide, with approximately 11,000 to 13,000 new glioblastoma cases estimated to occur each year in the U.S. Glioblastomas
usually affect adults. Treating glioblastoma is very difficult due to the brain-blood barrier and treatment often focuses primarily on
relieving symptoms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ATRT</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atypical
Teratoid Rhabdoid Tumors (ATRT) are rare, rapidly progressing, and malignant pediatric tumors of the central nervous system and are primarily
found in children under the age of three. The National Cancer Institute estimates there are 60 cases of ATRT diagnosed per year and 600
patients currently living with ATRTs, of which only 25% are in adults 15 years or older. Patients with ATRTs have a very poor prognosis
including a median survival of 6-12 months and a 5 year survival rate of approximately 32%. ATRTs are difficult to treat due to the very
rapid onset of these tumors as well as a requirement for therapies that can penetrate the blood-brain barrier. The U.S. is expected to
capture the majority share of the ATRT market with ~65%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prostate
Cancer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate
cancer is the most commonly diagnosed cancer in men in the US and the second leading cause of cancer-related death in men in the US.
The American Cancer Society&#8217;s estimates for prostate cancer in the United States for 2023 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    288,300 new cases of prostate cancer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    34,700 deaths from prostate cancer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
50% of patients who die from prostate cancer have metastases at diagnosis. The survival gains over the last decade have been modest with
acceleration in life-extending drug development occurring in the last three years. Hormonal therapy works to reduce testosterone levels
in the body to a level equal to that seen if physical castration were to occur. However, hormonal therapy can become refractory after
one to three years and tumor growth may resume. This is referred to as Castration-Resistant Prostate Cancer (&#8220;CRPC&#8221;). About
10 - 20 % of prostate cancer patients develop CRPC within five years. Typically, standard hormonal therapy involving Androgen Deprivation
Therapy (ADT) was prescribed in the past for all comer patients. Current prescribed regimens involve intensified therapy for most patients
(docetaxel for high volume disease, and Zytiga for low and high volume disease) whereas upcoming molecularly selected agents in addition
to hormonal therapy are used in an individualized approach to metastasis-directed or local therapy. Standard of care agents for prostate
cancer include without limitation (i) Androgen production suppressors, such as Leuprolide (Lupron, Eligard), Goserelin (Zoladex), Triptorelin
(Trelstar), Histrelin (Vantas), Abiraterone (Zytiga), (ii) Androgen signaling blockers, such as Flutamide (Eulexin), Bicalutamide (Casodex),
Nilutamide (Nilandron), and Enzalutamide (Xtandi), and (iii) chemotherapeutics such as docetaxel and cabazitaxel. In 2022 Pluvicto (active
ingredient lutetium Lu 177 vipivotide tetraxetan) was approved by FDA for the treatment of prostate-specific membrane antigen (PSMA)
positive mCRPC. Drug classes of new small molecules in development include PARP inhibitors, PI3K inhibitors and DNA Damage Repair (DDR)
inhibitors. The PARP inhibitors olaparib (Lynparza) and rucaparib (Rubraca) and the PD1 inhibitor pembrolizumab (Keytruda) have been
approved by the FDA for a subset of the patient population. The identification and characterization of new molecular targets, agents
exploiting new or non-parallel mechanisms of action, and the discovery of predictive biomarkers for mCRPC, are three of the major unmet
needs in the prostate cancer space in the era of precision medicine that we believe LP-184 may address.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Opportunity for LP-184</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are targeting a set of indications for LP-184 based on combining the factors of predicted response, unmet clinical need and market opportunity.
These include pancreatic cancer, glioblastoma, prostate cancer, and ATRTs. Below is an overview of relevant patient numbers and estimated
market sizes of some of the indications that we believe LP-184 may potentially address, if approved, based upon published estimates by
the Global Cancer Observatory and other published sources:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Pancreatic cancer</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Global</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(2020)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2023)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: justify">Pancreatic cancer cases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">495,773</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">64,050</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Advanced pancreatic cancer cases (65% of all pancreatic cancer)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">322,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,633</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85% of advanced pancreatic cases are treated in 1<sup>st</sup> line setting</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">273,915</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,388</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60% of advanced pancreatic cases treated in 1<sup>st</sup> line are treated in 2<sup>nd</sup> line</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164,349</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,233</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30% of advanced pancreatic cases treated 2<sup>nd</sup> line are treated in 3<sup>rd</sup> line</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,305</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,370</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Potential patient percentage in initial targeted segment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.9</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Glioblastoma</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Global</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: justify">Total glioblastoma (GBM) estimated incidence</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">13,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Number of newly diagnosed GBM patients treated (treatment rate 76.6%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,958</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Number of newly diagnosed MGMT unmethylated GBM patients</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,572</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Potential patient percentage in initial targeted segment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recurrent patients treated in 1<sup>st</sup> line (69% newly diagnosed patients received 1L)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,826</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Recurrent patients progressing to 2L treatment (70.3% recurred patients receive 2L)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,890</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,798</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Prostate cancer</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Global</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(2020)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2023)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: justify">Total prostate cancer estimated incidence (new cases)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,414,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">288,300</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">CRPC incidence, ~20% of all prostate cancer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">282,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,660</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Metastatic CRPC incidence, ~80% of newly diagnosed CRPC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226,240</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,128</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Potential patient percentage in initial targeted segment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Strategic
Academic Collaborations for LP-184</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are or have been involved in the following academic collaborations for LP-184:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
    Research Institute of Fox Chase Cancer Center (&#8220;FCCC&#8221;)</i>. Our ongoing collaboration with FCCC has yielded results that
    strongly link LP-184 efficacy to the expression of PTGR1. PTGR1 was identified by our RADR analysis as the lead gene candidate, the
    expression of which is essential to LP-184 mediated cytotoxicity. Using CRISPR engineered cells, we have now demonstrated a total
    lack of activity in tumor cell lines where PTGR1 expression is artificially knocked out. These data continue to support our RADR
    based predictions and the strategies of using LP-184 for tumor indications based upon PTGR1 expression. Our RADR analysis has identified
    a multitude of tumors with a higher than required threshold of PTGR1 expression. We have further validated the activity of LP-184
    in a panel of pancreatic cancer cell lines. We have also conducted studies to evaluate the efficacy of LP-184 in pancreatic cancer
    PDX models and in xenografts. Additional wet lab studies are ongoing to further validate RADR defined combinations with standard
    of care drugs in order to identify optimal synergistic drugs that could be eventually used in potential treatments with LP-184.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Kennedy
Krieger Institute and the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.</i> We have an ongoing collaboration with Kennedy
Krieger Institute and investigators at the Johns Hopkins School of Medicine. We sought this collaboration following multiple unique findings
regarding LP-184, including: the preclinical efficacy of LP-184 in glioblastoma (GBM); a positive result suggesting the ability of LP-184
to penetrate the Blood Brain Barrier, in amounts similar to the GBM standard of care agent Temozolomide (TMZ); and LP-184&#8217;s special
ability to kill GBM cells irrespective of the methylation status of MGMT promoter. We believe there is an urgent unmet need for an effective
therapy to treat GBM with unmethylated MGMT. Both wet lab data and RADR based gene correlations highlighted sensitivity of tumor cells
that carry unmethylated MGMT to LP-184. We have obtained additional data in an expanded panel of GBM tumor cell lines, neurospheres obtained
from patient biopsies and evaluation of LP-184 in GBM xenografts. Results from this collaboration continue to support the promise of
LP-184 for GBM.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Georgetown
    University</i>. In the first phase of our collaboration with Georgetown University, we confirmed the
    efficacy of LP-184 in a panel of prostate cancer organoid models. In the second phase, we are focusing on wet lab validation of the
    leads generated by our A.I. models of the gene dependency of most sensitive prostate cancers. This project is intended to provide
    necessary experimental data for use of LP-184 in a personalized medicine approach to treating prostate cancer. Our gene correlation
    data has highlighted the deficiency of several pathways that hypothetically would allow LP-184 to be synthetically lethal in tumors
    with such disruptions. Our RADR analysis also indicates that as many as 20% of prostate cancers carry markers that will make these
    tumors highly sensitive to LP1-84. In Phase 2 or our collaboration with Georgetown, we have focused on the development of gene specific
    isogenic engineered prostate cancer cell lines to dissect the pathways as well as extend the 2D and 3D prostate cancer studies to
    in vivo genomically defined prostate cancer PDXs. In addition, we have designed studies that will test LP-184 in combination with
    several other drugs that are known to inhibit pathways needed to repair damage to DNA caused by LP-184. The advantage of combining
    our DNA damaging agent along with a DNA damage repair inhibitor is that it is expected to substantially extend the tumor specific
    efficacy of LP-184, including prostate cancers that might otherwise not carry deficiencies in the DNA repair pathway. We expect that
    the drug sensitivity data and genomic data from these studies will further guide optimal positioning of LP-184.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
    Danish Cancer Society-Research Center. </i>In January of 2022 we entered a new research collaboration with the Danish Cancer Society
    Research Center (DCRC). The collaboration is directed to examining the most common solid tumors in order to determine the patient populations
    most likely to benefit from our drug candidates LP-100 (irofulven) and LP-184. LP-100 and LP-184 have both been shown to have a synthetically
    lethal impact in tumors that are lacking nucleotide excision repair (NER) capabilities. An additional aim of this collaboration is
    to develop improved diagnostic tools to detect NER deficient patient profiles more accurately. Initially, the collaboration is focusing
    focus on the role of NER deficiency in breast, ovarian, prostate, lung, kidney, bladder, stomach, pancreatic, and esophageal cancers.
    We expect the data, genomic signatures, and biological models generated from the collaboration to add millions of data points to
    RADR<sup>&#174;</sup>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
    Greehey Children&#8217;s Cancer Research Institute (GCCRI) at the University of Texas Health Science Center-San Antonio</i>. In February
    2022, we announced a research collaboration with the Greehey Children&#8217;s Cancer Research Institute (GCCRI) at the University
    of Texas Health Science Center-San Antonio. The GCCRI research collaboration is focusing on the effectiveness of LP-184 and LP-284
    in genomically-defined pediatric cancers, including several without any effective therapeutic approach. The collaboration is
    leveraging GCCRI&#8217;s pediatric tumor research models and knowledge base to advance LP-184 for the potential treatment of rare pediatric
    cancers including rhabdomyosarcoma, Ewing sarcoma, MRT (malignant rhabdoid tumor), Wilms tumor, and ATRT (atypical teratoid rhabdoid
    tumor). Dr. Peter Houghton Ph.D. is leading the collaboration for the GCCRI and is widely regarded as leading expert on pediatric
    cancer research and in the development of novel approaches to treating childhood cancers. An integral component of Dr. Houghton&#8217;s
    research success has been the development and use of Patient-Derived Xenografts (PDX), which are clinically relevant cancer models
    that allow researchers to test novel therapeutics - such as LP-184 - in-vivo, and to directly study how tumors respond to treatment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b>&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
    Trials and Research Innovation Center in Northern Ireland</i>. In 2019, we initiated a collaboration with the Clinical Trials and
    Research Innovation Center in Northern Ireland (&#8220;C-TRIC&#8221;) on a novel preclinical ex-vivo study focused on determining
    gene signatures correlated with LP-184 anticancer activity in human fresh prostate tumor tissue biopsies. This study was paused due
    to the COVID-19 pandemic, including the impracticality of international travel and the reprioritization of projects due to the
    pandemic. We are collaborating with other studies in the U.S. and <span style="background-color: white">over the next several months </span>
    will be evaluating <span style="background-color: white">the recommencement of</span> the study with C-TRIC. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pre-IND Enabling Animal Studies </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have conducted IND enabling studies in rats and Beagle dogs to provide supporting information regarding safety profile and selection
of the starting dose in humans in connection with the planned IND application for LP-184. These studies included (i) non-GLP dose range
finding in rats, (ii) GLP analysis of toxicity in rats, (iii) non-GLP dose range finding in dogs, (iv) GLP analysis of toxicity in dogs,
(v) analytical method development for the determination of LP-184 levels in rat and dog plasma, (vi) analytical method validation, and
(vii) pharmacokinetic profiling of LP-184 in the plasma of dosed rats and dogs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LP-284</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-284
Chemical Structure</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><img src="form10-k_015.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>General Overview</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">LP-284
is a novel small molecule and DNA damaging agent being developed by Lantern for the treatment of several non-Hodgkin&#8217;s lymphomas
(NHL) including </span>mantle cell lymphoma <span style="background-color: white">(MCL) and double hit lymphoma (DHL). </span>LP-284 belongs
to the new generation of acylfulvenes, a family of naturally derived anti-cancer drug candidates and is the stereoisomer (enantiomer)
of our drug candidate LP-184. In comparison to our other acylfulvenes, LP-100 and LP-184, LP-284 has distinct anti-tumor activities in
a variety of hematological cancers including lymphoma, multiple myeloma, and leukemia. LP-284 has the potential to be developed as a monotherapy
or combination therapy with other drugs to treat a broad array of hematological cancers. The FDA recently granted LP-284 Orphan Drug Designation
for the treatment of mantle cell lymphoma, based on LP-284&#8217;s demonstrated anti-tumor activity across a comprehensive number of in
vitro and in vivo models of MCL.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preclinical studies, LP-284 has shown nanomolar potency in several hematological cell lines. Of the hematological cell lines tested,
LP-284 had the highest potency against all 6 of the mantle cell lymphoma cell lines tested. LP-284 is also being explored for use as
a combination therapy with spironolactone. In the multiple myeloma cell line RPMI8226, combination of 10 <span style="font-family: Symbol">m</span><span style="font-family: Times New Roman, Times, Serif">M</span>
spironolactone with LP-284 significantly reduced LP-284&#8217;s IC50 by 2.4 fold. The absence of ataxia telangiectasia mutated (ATM)
function in these lymphomas and the need for new agents in the setting of relapsed refractory mantle cell lymphomas support the
development of LP-284 in this indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Additional data from in
vitro and in vivo studies supports LP-284&#8217;s development for <span style="color: #232427; background-color: white">MCL, an
aggressive form of B-cell non-Hodgkin&#8217;s lymphoma (NHL) with immediate patient needs. LP-284 treatment was demonstrated to have
significantly greater tumor growth inhibition (TGI) in mice implanted with MCL cell derived xenograft (CDX) tumors, when compared to
treatment with the standard-of-care (SOC) agents Ibrutinib or Bortezomib. The figure below describes results from LP-284 <i>in-vitro</i> and <i>in-vivo</i> preclinical studies for MCL and
other B-cell Non-Hodgkin&#8217;s lymphomas.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><img src="form10-k_016.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Planned Phase I Clinical Trial for LP-284</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are advancing LP-284 towards a Phase I clinical
trial in patients with relapsed refractory lymphomas. In addition to determination of the recommended dose range for future Phase 1B and
Phase 2 studies, we will also evaluate clinical activity correlations with mutations in DNA damage repair pathway genes. We expect to
include up to 30 patients in the dose escalation portion of the LP-284 Phase I trial, with the involvement of multiple clinical sites.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Disease Background for Mantle Cell Lymphoma</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Mantle
Cell Lymphoma (MCL) is a rare, heterogenous and aggressive subtype of B-cell Non-Hodgkin&#8217;s Lymphoma (NHL). MCL is a blood cancer of the
lymph nodes and tumor cells originating from the &#8220;mantle zone&#8221; of the lymph node and is characterized by constitutively dysregulated
<i>cyclin D1 </i>(<i>CCND1) </i>expression. MCL is usually diagnosed at an advanced stage when it is largely considered incurable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Nearly all MCL patients relapse
from the MCL standard-of-care agents Bortezomib and Ibrutinib and there is an urgent and unmet need for novel improved therapeutic options
for these patients. <span style="background-color: white">According to Leukemia and Lymphoma society about 4,200 new cases of MCL are
diagnosed in the United States annually, representing approximately 6% of all NHL patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LP-100</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-100
or 6-Hydroxymethylacylfulvene (or irofulven) exploits cancer cells&#8217; deficiency in DNA repair mechanisms. We believe LP-100 has
the potential to be an important compound &#8212; either as monotherapy or in combination &#8212; for several challenging cancers that
are impacting patients globally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recently announced data for LP-100 supporting the development of LP-100 in combination with the class of anticancer agents known as
PARP inhibitors (PARPi). In prostate cancer mouse xenograft studies, LP-100 demonstrated synergistic potency when used in
combination with the FDA-approved PARP inhibitor Olaparib. LP-100 also demonstrated synergy with the FDA-approved PARP inhibitors
Olaparib, Rucaparib, and Niraparib in ovarian cancer cell line studies. The observations from these studies are further supported by
in-silico evaluation of LP-100 in combination with PARP inhibitors using Lantern&#8217;s RADR<sup>&#174; </sup>platform. We believe
this development focus will enhance the potential to position LP-100 in earlier lines of therapy, while also opening the door to
pursue treatment indications with larger market sizes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-100
has previously been in a genomic signature guided phase 2 clinical trial in Denmark for patients with metastatic castration resistant
prostate cancer (mCRPC). 9 patients (out of a targeted enrollment of 27) were treated in the trial. The median overall survival (OS)
for the initial group of 9 patients was approximately 12.5 months, which is an improvement over other similar fourth-line treatment regimens
for mCRPC. Based on our evaluation of the synergies of LP-100 with PARP inhibitors, the decision has been made to close the phase 2 clinical
trial in Denmark, to allow the focus of LP-100-directed resources on positioning the molecule for development in earlier lines of therapy
with potentially larger market opportunities. Earlier line treatment indications where we believe LP-100 in combination with PARPi could
have potential future treatment benefits include prostate cancer indications such as HRR gene-mutated metastatic castration-resistant
prostate cancer, ovarian cancer indications such as first line platinum-responsive advanced ovarian cancer, and breast cancer indications
such as germline <i>BRCA</i>-mutated metastatic breast cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-100
and PARP inhibitors act by complementary mechanisms. LP-100 acts by a synthetically lethal mechanism of action that preferentially damages
DNA in cancer cells lacking nucleotide excision repair (NER) capabilities. PARP inhibitors have been shown to be effective in the treatment
of tumors with deficiencies in homologous recombination repair (HR). We believe the simultaneous exploitation of both these mechanisms
will enhance the development opportunities for LP-100, while also expanding potential market opportunities for existing PARP inhibitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2021, we entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for LP-100 from Allarity
Therapeutics A/S, which previously managed the current Phase 2 trial for LP-100. As a result of the Asset Purchase Agreement, we obtained
full authority to manage and guide future clinical development and commercialization of LP-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with our evaluation work on LP-100 with PARP inhibitors, we have been collaborating with the <span style="text-decoration: underline">Danish Cancer Society Research
Center</span> (DCSRC) to explore the future clinical potential of LP-100 across 9 different solid tumor types that have known deficiencies
in DNA repair pathway mechanisms. This work has included examination of the role of NER deficiency in breast, ovarian, prostate, lung,
kidney, bladder, stomach, pancreatic, and esophageal cancers, with the aim of identifying the most promising patient populations for
future LP-100 therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>History
of LP-100</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-100
shows multiple cytotoxic effects on tumor cell biology such as DNA adduct formation, RNA polymerase stalling and redox protein modification.
It demonstrates enhanced sensitivity in DNA repair deficient (e.g. ERCC3 mutant or knockout) <i>in vitro</i> and <i>in vivo</i> models.
In historical testing, clinical antitumor activity for LP-100 was observed in approximately 10-12% of patients with multidrug resistant
advanced prostate cancer with notable resolution of bone metastases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-100
belongs to the family of compounds and small molecular entities (molecular weight &lt;330) that represent a class of anticancer agents
derived from fungal toxins called Illudins. Acylfulvenes were originally synthesized and developed by Drs. Michael J. Kelner and Trevor
C. McMorris at University of California at San Diego (&#8220;UCSD&#8221;). In 1987, Professor McMorris published the first preclinical
evaluation of the Illudins as anticancer agents and a library of hundreds of acylfulvene derivatives was created, many with significant
<i>in vitro</i> and <i>in vivo</i> antitumor activity and potentially improved selectivity for tumor cells versus normal cells. The compound
Illudin S was found to be highly cytotoxic against cancer cells, but demonstrated a poor therapeutic index. Better understanding of the
mechanism of action led to the development of a novel family of semisynthetic antitumor agents, or next-generation acylfulvenes such
as 6-hydroxymethylacylfulvene, now designated as LP-100. LP-100 is a semisynthetic derivative of Illudin S, one of a series of sesquiterpene
natural products (Illudins) isolated from the Lantern mushroom <i>Omphalotus illudens</i>. LP-100 was selected for further study based
on its potential to demonstrate promising antitumor activity while maintaining a more favorable therapeutic index, compared to previously
studied Illudins. The chemical structure of LP-100 is depicted below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-100
Chemical Structure</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><img src="form10-k_017.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mechanism
of Action</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-100
leads to rapid inhibition of DNA synthesis and induction of DNA damage. LP-100 is a monofunctional covalent DNA binder that inhibits
DNA synthesis and replication, affects cell cycle and induces apoptosis. DNA repair of LP-100-induced lesions is mediated by components
of the transcription-coupled nucleotide excision repair (TC-NER) pathway. LP-100 produces damage to DNA that can only be repaired by
the TC-NER pathway. The DNA damage is unique, as two enzymes, RNA Polymerase III and Topoisomerase I (Topo 1), associated with the TC-NER
are displaced leading to irreversible inactivation of the repair pathway. Other conventional DNA damaging chemotherapeutic agents, such
as cisplatin, etoposide, doxorubicin and others, produce general damage that can be repaired by the Global Genome Nucleotide Excision
Repair (GG-NER) pathway. Tumor cells often develop multidrug resistance (MDR) making them impossible to kill using conventional drugs.
LP-100 appears to retain activity against MDR tumor cells regardless of the mechanism of resistance and tumor cells appear less likely
to become resistant to LP-100. Killing of MDR tumor cells by LP-100 reflects its unique mechanism of disrupting the TC-NER pathway. Cell-based
studies have demonstrated selective cytotoxicity of LP-100 towards a variety of solid tumor cell lines. The tumor cells cannot recover
from this damage, undergo S-phase arrest, and then irreversibly initiate both caspase-dependent and &#8211;independent apoptosis pathways.
LP-100 produces DNA damage and induces apoptotic DNA fragmentation in several tumor cell lines. Normal diploid cells, in contrast, do
not normally need repair by the TC-NER pathway unless exposed to UV light. Treatment of mouse xenografts of human tumors with LP-100
results in tumor shrinkage. Synergistic or additive activity is observed when LP-100 is combined with various traditional anticancer
agents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LP-100
Clinical Profile</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
studies of LP-100 have been conducted in multiple solid tumor indications including prostate, ovarian, colorectal, pancreatic, thyroid,
lung, breast and gastric cancers. More than 38 Phase I or Phase II trials involving &gt; 1,300 patients have been conducted with LP-100.
In prior clinical trials, LP-100 showed activity and produced regression in a variety of cancers, but failed to meet required endpoints
for clinical trial success. Objective responses were reported for LP-100 single agent therapy in drug-resistant prostate (hormone and
taxotere refractory), ovarian (platinum resistant), pancreatic, sarcoma, kidney, endometrial, and lung cancers. LP-100 also showed cancer
treating potential when administered in combination with a variety of conventional chemotherapeutics including Camptosar, GemZar, Taxotere,
Xeloda, Cisplatin, and Oxaliplatin. In a study of patients who failed prior conventional therapies, two rounds of LP-100 therapy led
to rapid resolution of ovarian cancer metastasis. In a randomized Phase IIb study of patients with metastatic hormone refractory taxotere-resistant
prostate cancer, LP-100 was compared to mitoxantrone. A total of 138 patients were enrolled and specified endpoints included overall
survival, response rate, and safety assessment. The median one-year survival increased from 22% in the mitoxantrone-treated control group
to 41% in the LP-100-treated group. Median overall survival was 10.1 months for treatment arm (LP-100 + Prednisone) and 7.4 months for
control arm (Mitoxantrone + Prednisone), i.e. a 37% increase over standard of care. Treatment was well-tolerated in all arms. The most
frequent Grade 3&#8211;4 toxicities (as % of patients in treatment/control arms) were asthenia (8%/0%), and vomiting (4%/0%). Grade 3&#8211;4
hematological events included neutropenia (22%/61%) and thrombocytopenia (23%/4%).In 2001, LP-100 received FDA&#8217;s fast track status
and a Phase III international clinical trial for LP-100 in refractory pancreatic patients was started. Clinical trials looked promising
in shrinking tumors of drug-resistant pancreatic cancer. However, MGI Pharma stopped the Phase III clinical trial because it was unlikely
for the trial to reach its objective due to a greater than expected survival benefit associated with the comparator agent (5-FU). In
2005, Phase II clinical trial results of LP-100 in women with recurrent and heavily pre-treated ovarian cancer revealed retinal toxicity.
This retinal damage was associated with dose and administration of drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AF
Chemicals</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2015, the Company entered into a Technology License Agreement to exclusively license domestic and international patent rights
from AF Chemicals, LLC (&#8220;AF Chemicals&#8221;) for the treatment of cancer in humans for the compounds LP-100 (Irofulven) and LP-184.
In February 2016, the Company and AF Chemicals entered into an Addendum (the &#8220;Addendum&#8221;) providing for additions and amendments
to the Technology License Agreement. In December 2020, the Company and AF Chemicals entered into a Second Addendum (the &#8220;Second
Addendum&#8221;) providing for further additions and amendments to the Technology License Agreement. The Technology License Agreement,
Addendum and Second Addendum are collectively referred to as the &#8220;AFC License Agreement&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Second Addendum, the Company made specified payments to AF Chemicals during the three months ended March 31, 2021. The Second
Addendum also provides that, from December 30, 2020 until January 15, 2025, the Company will have no obligation to pay annual licensing
fees, development diligence extension payments, or patent maintenance fee payments to AFC under the AFC License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Second Addendum, the Company has agreed to apply for specified orphan drug designations for LP-184 in the US and EU. The
Second Addendum also amends and clarifies other provisions of the Technology License Agreement, and provides the Company with the ability
to recover a portion of initial payments made under the Second Addendum from sublicense fees or royalty payments that may be made to
AFC by the Company or third parties prior to January 15, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company is obligated to make milestone payments to AF Chemicals at the time of an Investigational New Drug Application
(&#8220;IND&#8221;) filing relating to LP-184 and other analogs, such as LP-284, and also upon reaching additional specified milestones
in connection with the development and potential marketing approval of LP-184 and LP-284 in the United States, specified countries in
Europe, and other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
AFC License Agreement also provides that the Company will pay AF Chemicals a royalty of at least a very small single digit percentage
of specified net sales of LP-184 and other analogs, such as LP-284. In addition, the AFC License Agreement contains specified time requirements
for the Company to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184 or other analogs,
with the ability for the Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars
for each one, two, three and four year extension to such development time requirements, with additional extensions beyond four years
to be negotiated by the Company and AF Chemicals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Second Addendum, no additional payments of annual licensing fees or development diligence extension payments are required to be
made by the Company until January 15, 2025, at which time these obligations will resume. The Company will also be obligated to make annual
licensing fee payments to AF Chemicals relating to LP-100 beginning January 15, 2025, as described below under Allarity Therapeutics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a sublicense of the rights to LP-184, LP-284 or other analogs, the Company is obligated to pay AF Chemicals (a) a low double
digit percentage of the gross income and fees received by the Company with respect to the United States in connection with such sublicense,
and (b) a lower double digit percentage of the gross income and fees received by the Company with respect to Europe and Japan in connection
with such sublicense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts to be paid to AF Chemicals with respect to LP-100 under the AFC License Agreement are in many ways similar to the amounts to
be paid with respect to LP-184 as described above. In addition, the AFC License Agreement contains specified time requirements for the
Company to enroll patients in clinical trials, and file a potential NDA with respect to LP-100. Extension fees may be paid by the Company
to AF Chemicals from time to time related to these requirements. Pursuant to the Second Addendum with AF Chemicals, no additional payments
of annual licensing fees or development diligence extension payments are required to be made by the Company with respect to LP-100 until
January 15, 2025, at which time these obligations will resume.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Allarity
Therapeutics </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2015, the Company licensed various rights to LP-100 to Oncology Venture (now known as Allarity Therapeutics) pursuant to a Drug License
and Development Agreement. In February 2016, the Company and Allarity Therapeutics entered into an addendum and an amendment providing
for additions and amendments to the Drug License and Development Agreement. In connection with the Drug License and Development Agreement,
as amended (collectively, the &#8220;Allarity License and Development Agreement&#8221;), Allarity Therapeutics agreed to directly pay
to AF Chemicals on behalf of the Company certain amounts to satisfy the Company&#8217;s milestone obligations to AF Chemicals with respect
to LP-100 under the AFC License Agreement. Amounts paid by Allarity Therapeutics to AF Chemicals on behalf of the Company would then
be deducted from amounts owed by Allarity Therapeutics to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 23, 2021, the Company entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for
Irofulven (LP-100) from Allarity. The transaction included global rights to LP-100, as well as the developed clinical protocol for an
intended study in bladder and prostate cancer patients who have a mutation in the ERCC2/3 genes. As a result of this transaction, the
Company obtained full authority to manage and guide future clinical development and commercialization of LP-100. Under the terms of the
Asset Purchase Agreement, the Company paid an initial upfront payment of $1,000,000 to Allarity. The Company determined there was no
planned alternative future use for these assets outside of the clinical development of LP-100 and therefore the full amount of the upfront
payment was included in research and development expense during the year ended December 31, 2021. The Company released approximately
$459,000 from escrow to Allarity related to recertification of LP-100 drug stock during the year ended December 31, 2022. Future payments
of up to $500,000 currently held in escrow also have the potential to deliver an additional amount to Allarity based on drug trial enrollment
milestones within the 24 months following the date of the transaction. Allarity is also eligible to receive additional milestone payments
over the life of the program based on IP license milestones and regulatory filings and approvals in the US and EU, and low- to mid-single-digit
royalties on future commercial net sales. As part of the Asset Purchase Agreement, the Allarity License and Development Agreement was
terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional
Portfolio Opportunities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ADC
Program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
initiated an ADC program in early 2021, based on the recognition of antibody drug conjugates as a promising therapeutic approach for
cancer treatment, and one that has growing interest due to the potential to increase targeted cancer cell death.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently evaluating various cytotoxic agents and classes of agents to be used as potential ADC payloads. We have also selected and
ranked multiple targeting antibodies of interest with potential to be linked to selected cytotoxic payloads. Our upcoming activities
in coming months will be targeted at further evaluation, manufacturing and preclinical testing of potential ADC candidates to select
for advancement to Phase I testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADCs
can provide the ability to take advantage of the high potency of cytotoxic payloads and the superior specificity of antibodies. The drug
antibody conjugate thus provides the potential to maximize efficacy and minimize systemic toxicity. Recent years have seen multiple FDA
approvals in the growing class of ADCs for therapeutic use. This has driven increased deal-making and portfolio additions by large pharma
companies. Two of the four largest oncology licensing transactions in 2020 were for ADC assets. In addition to the acquisition of Immunomedics
by Gilead, Merck acquired Velos Bio in November of 2020 and NBE Therapeutics was acquired by Boehringer Ingelheim in December of 2020.
It is notable that both NBE and Velos, at the time of their acquisition, had just successfully completed Phase 1 trials using their ADC
approach in specific cancer subtypes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, we entered into an Evaluation and Limited Use Agreement (the &#8220;Evaluation Agreement&#8221;) with Califia Pharma,
Inc. aimed at collaborating on the in vitro and in vivo testing and evaluation of novel Califia linker technology and related payloads
to be conjugated to a Lantern targeting entity. The Evaluation Agreement expired on December 31, 2021 and we determined not to extend
it.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Additional
Research and Development Collaborations for Our Drug Candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Virtually
all of our developmental work is expected to be performed in contract labs in the near future, and most of it requires close collaboration
with these groups. Our strategic collaborations have specialized focus areas tailored to advancing our pipeline drug candidates and provide
expertise benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborator</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Focus
    Area</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Drug
    Candidate</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    Cancer Institute (NCI)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gene
    signature development and drug sensitivity prediction</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184,
    LP-284</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Georgetown
    University</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
    of drug efficacy and sensitivity in prostate and pancreatic cancer organoid models and engineered pancreatic cancer cell lines</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fox
    Chase Cancer Center (FCCC)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination
    of drug efficacy in PDX tumor models</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kennedy
    Krieger Institute and the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
    of efficacy of LP-184 in glioblastoma (GBM).</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Danish
    Cancer Society Research Center</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examine
    and develop genomic signatures of TCNER deficiency that have potential to correlate with sensitivity to LP-100 and LP-184 in solid
    tumors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-100,
    LP-184</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greehey
    Children&#8217;s Cancer Research Institute-UT Health San Antonio</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
    of drug efficacy in pediatric tumor models </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184,
    LP-284</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Manufacturing
Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own or operate any manufacturing facilities or have any manufacturing employees. We currently rely, and expect to continue
to rely, on third party contract manufacturing organizations (&#8220;CMOs&#8221;) for the manufacturing of our drug candidates for preclinical
uses, clinical trials as well as for commercial manufacturing if our drug candidates receive marketing approval. We require that our
CMOs produce bulk drug substances and finished drug products in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;)
and all other applicable laws and regulations. We maintain agreements with our manufacturers that include confidentiality and intellectual
property provisions to protect our proprietary rights related to our drug candidates. We obtain our supplies from these CMOs on a project
by project basis and do not have long-term supply arrangements in place. We do not currently have arrangements in place for redundant
supply. For all of our drug candidates, we intend to identify and qualify additional manufacturers to provide the active pharmaceutical
ingredient and fill-and-finish services prior to seeking regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LP-184
and LP-284 Manufacturing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have contracted with Southwest Research Institute<sup>&#174;</sup> (&#8220;SwRI<sup>&#174;</sup>&#8221;) for the development of a fully
synthetic route to LP-184 and LP-284, as well as for the cGMP synthesis of LP-184 API material. We have contracted with Shilpa Medicare
Limited and affiliates (&#8220;Shilpa&#8221;) for the synthesis of a key starting material relating to the synthesis of LP-184 under
cGMP as well as for drug product development and cGMP drug product manufacturing of LP-184. In addition, we have contracted with Shilpa
for the cGMP synthesis of LP-284 API material as well as for drug product development and cGMP drug product manufacturing of LP-284.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LP-300
Manufacturing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have contracted with Patheon API Services, Inc. (&#8220;Patheon&#8221;) and Curia Global, Inc. (&#8220;Curia&#8221;) for the manufacture
and supply of LP-300 cGMP API material. We have contracted with Berkshire Sterile Manufacturing (&#8220;Berkshire&#8221;) and Piramal
Pharma Solutions (&#8220;Piramal&#8221;) for the provision of services relating to cGMP drug product manufacturing of LP-300.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercialization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
retain worldwide commercialization rights for our product candidates LP-300, LP-184, LP-284, and LP-100. We plan to continue considering
out-license and collaboration opportunities in order to maximize returns and pursue successful development of our key candidates. We
currently have no sales, marketing or product distribution capabilities. However, once we have key candidates closer to FDA approval,
we may build our own specialty sales force, partner with a larger pharmaceutical organization, or out-license our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are continually evaluating out-license opportunities for our candidates at later stages of development in order to focus on identifying
and licensing additional drug candidates for novel indications and/or patient subpopulations with an oncology focus for expansion of
our pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial plans and strategy for each particular program may change as our programs advance, the markets change, we receive more clinical
data, and depending on availability of capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an extensive multi-national portfolio of intellectual property rights directed to our drug candidates, and their targeted use and
development in specific patient populations and in specific therapeutic indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 1, 2023, we own or control rights in over 80 active patents and patent applications across over 14 patent families whose claims
are directed to our drug candidates and what we plan to do with our drug candidates. We have in-licensed or acquired patents and patent
applications from AF Chemicals, and BioNumerik directed to the compounds, LP-100, LP-184, LP-284 and LP-300, and methods of using the
compounds. Additionally, we have also filed patent applications to further enhance and extend the use of these in-licensed compounds.
Our patents are directed to our drug candidates, their usage, manufacturing, and other matters. These matters are essential to precision
oncology and relate to: (a) data-driven, biologically relevant biomarker signatures, (b) patient selection and stratification approaches
that rely on prediction of response deriving from these signatures and, (c) the ability to develop novel, combination therapy approaches
with existing approved therapeutics. We intend to pursue additional patent coverage relating to the use of LP-300 as a potential linker
or linking technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on a combination of patents, trade secrets, copyrights, trademarks, license agreements, nondisclosure and other contractual provisions
and technical measures to protect our intellectual property rights. Additionally, we also rely on the patent applications, trade secrets,
and other contractual provisions and technical measures to protect the development of our genomic and biomarker signatures that help
us in making predictions about the sensitivity to our drug candidates, our patient stratification approaches, and the development of
potential combination therapies with our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
Property Portfolio by the Numbers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 1, 2023, our intellectual property portfolio consisted of over 14 patent families covered by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
    45 issued patents across our portfolio of compounds in key, commercially important geographies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
    38 pending patent applications, including six Patent Cooperation Treaty (PCT) applications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
    well as pending trademark registrations, and trademark applications in Japan, China, Europe, Canada and Australia.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy is to protect the proprietary technologies, inventions, and improvements that are commercially important to our business in the
United States, Europe, Japan, Australia and other key jurisdictions important to our business. We fully expect that additional advances
will come out of our ongoing work in developing biomarker signatures and patient stratification approaches and that these advances will
form the basis of additional intellectual property protection through new patent filings, trademarks, trade secrets, and copyrights.
We will continue to file patent applications and use trade secret laws to protect the uses of our genomic and biomarker signatures, response
prediction and patient stratification discoveries. We plan to rely on these intellectual property advances to develop, strengthen, and
maintain our proprietary position for novel therapeutics and novel formulations and uses of existing and new compounds across multiple
therapeutic areas. We also plan to rely on data exclusivity, market exclusivity and patent term extensions when available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
Portfolio</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an extensive multi-national portfolio of intellectual property rights directed to our drug candidates, and their targeted use and
development in specific patient populations and in specific therapeutic indications. Our portfolio consists of over 16 patent families
across issued patents and pending patent applications. For LP-100, we own and control two in-licensed patent families, including issued
US Patents, Japan Patents, and various issued EU Patents directed to LP-100. We have also filed over 12 patent applications directed
to our proprietary drug programs together with biomarkers and sensitivity parameters, and four additional patent applications directed
to our RADR<sup>&#174;</sup> platform. These filings include patent applications directed to LP-300 and additional patent applications
directed to new manufacturing methods for novel, synthetic illudins, and gene signatures and biomarker profiles indicating sensitivity
to LP-100, LP-184, LP-284 and novel synthetic illudins.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    patent family directed to LP-100 has patents that expire in August 2026, and patent applications, if granted, that would expire as
    late as May 2040. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    patent family directed to LP-184 has patents that expire in August 2026, and patent applications, if granted, that would expire as
    late as May 2040. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    patent family directed to LP-300 has patents that expire in March 2028, and patent applications, if granted, that would expire as
    late as March 2042. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
typically file a non-provisional patent application or a PCT within 12 months of filing the corresponding provisional patent application.
While we intend to timely file non-provisional patent applications relating to our provisional patent applications, we cannot predict
whether any of our existing or future patent applications for our existing or future drug candidates will result in the issuance of patents
that effectively protect these candidates, or if any of our issued patents or if any of our licensor&#8217;s issued patents will effectively
prevent others from commercializing competitive products. Patent protection for the composition of matter of the LP-300 compound itself
is unavailable because the compound was first identified many years ago. For more information regarding the risks related to our intellectual
property, see <i>&#8220;Risk Factors &#8211; Risks Related to Our Intellectual Property.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>RADR<sup>&#174;
</sup>Platform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or in-license any patents on our RADR<sup>&#174;</sup> platform, but we have filed at least four patent applications directed
to our RADR<sup>&#174; </sup>platform and rely on trade secrets and confidential procedures directed to protecting:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    A.I. and machine learning and training methodologies for our specific purposes in oncology drug development and drug rescue,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    curation and normalization of select data from both public and proprietary data sources, and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    developing insights that can be modeled to cover biological processes as algorithms inside our RADR<sup>&#174;</sup> platform.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LP-100</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
portfolio directed to LP-100 consists of at least four families of in-licensed patents that were filed in 2006. The patents include European,
Japanese and US patents. US Patent No. 7655695 relates to acylfulvene analogs that are directed to tumor solid tumor growth inhibition.
The nominal expiration for our patents directed to LP-100 is August 2026 and does not account for any applicable patent term adjustments
or extensions. We have also filed multiple patent applications directed to LP-100 that, if granted, would expire as late as May 2040.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LP-184
&amp; other Novel, Synthetic Illudin Derivatives </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
portfolio directed to LP-184 consists of over ten families of patents and patent applications and includes six PCT applications. US Patent
No. 7655695 relates to acylfulvene analogs that are directed to solid tumor growth inhibition. The patent applications include claims
directed to use of LP-184, synthetic illudin analogs or derivatives to treat glioblastoma or other CNS cancers as either a mono or combination
therapy, to treat rhabdoid tumors, brain cancer, brain metastases, and pancreatic cancer also as either a mono or combination therapy.
The nominal expiration for patents and patent applications directed to LP-184 ranges from 2026 to as late as 2040 and does not account
for any applicable patent term adjustments or extensions. We intend to nationalize our patent applications in the US, Australia, Canada,
EU, China, and Japan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have in-licensed patents from AF Chemicals related to the composition of matter of LP-184. We have also developed additional intellectual
property for this class of compounds related to the development of novel synthetic routes and the preparation of certain illudin derivatives
having therapeutic value. Additionally, we have filed patent applications on the use of LP-184 and these novel synthetic illudin derivatives
in the treatment of glioblastoma and other CNS cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LP-284
&amp; other Novel, Synthetic Illudin Derivatives </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
portfolio directed to LP-284 consists of three patent and patent application families and includes two provisional patent applications.
US Patent No. 7655695 relates to acylfulvene analogs that are directed to solid tumor growth inhibition. The PCT application filed in
2019 is related to the molecule itself and synthetic preparation methods of the same and has been nationalized in the US, Canada, Brazil,
Mexico, EU, India, China, Japan and Australia. A patent application filed in 2021 is directed to using LP-284 to treat leukemia and blood
cancers as either a mono or combination therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LP-300</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
portfolio directed to LP-300 consists of at least four families of owned patents. A more recent PCT patent application filed in 2020
is directed to treatment of non-small cell lung cancer (NSCLC) in nonsmokers and never smoking patients using disodium 2,2&#8217;-dithio-bis-ethane
sulfonate (dimensa) and has been nationalized in the US, Canada, Brazil, Mexico, EU, China, Japan and Australia. The nominal expiration
for NSCLC related patents and patent applications directed to LP-300 ranges from 2028 to as late as 2040 and does not account for any
applicable patent term adjustments or extensions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
filed an additional PCT application in March 2020 directed to LP-300 and its application to NSCLC, as well as biomarkers that correlate
to heightened response or sensitivity to LP-300. A recent application is directed to the use of LP-300 as a potential disulfide linker.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Confidentiality
&amp; Trade Secrecy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research
and development output, such as our employees, collaborators, contract research organizations, contract manufacturers, consultants, advisors
and other third parties. It is possible, however, that any of these parties may breach the agreements and disclose such output before
a patent application is filed, thereby jeopardizing our ability to seek patent protection. These agreements provide that all confidential
information developed or made known during the course of an individual or entities&#8217; relationship with us must be kept confidential
during and after the relationship. These agreements also provide that all inventions resulting from work performed for us or relating
to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property.
Third parties may also be able to develop substantially equivalent proprietary information, platforms or compounds, or otherwise gain
access to our trade secret</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trademarks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30.95pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own various trademarks, applications and unregistered trademarks in the United States and other commercially important markets, including
our company name, our A.I. platform, and certain compounds in development. Our trademark portfolio is designed to protect the brands
for our Company, our A.I. platform and our portfolio of compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Intellectual Property</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our intellectual property rights on the RADR<sup>&#174;</sup> platform are valuable and important to our business. We rely
on a combination of trademarks, copyrights, trade secrets, license agreements, confidentiality procedures, non-disclosure agreements,
employee disclosure, and invention assignment agreements, and other legal and contractual rights to establish and protect our proprietary
rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
exist at the intersection of rapidly moving, global industries, namely, the biotechnology industry and the A.I. drug development industry.
This is a unique and rapidly moving category with a variety of business models being developed globally. The pharmaceutical and biotechnology
industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property. A.I.
is disrupting and changing all industries, including the biotechnology industry. Although these are competitive industries, we believe
we are uniquely positioned due to our focus on oncology drug development, prediction of patient response, use of computational biology,
and the ability to both rescue and develop compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face potential competition from many different sources, including major pharmaceutical and biotechnology companies, academic institutions
and governmental agencies, and public and private research institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the companies against which we may compete have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we
do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with
large and established companies. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in
even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting
and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical
trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize medicines that are safer, more effective,
have fewer or less severe side effects, and are more convenient or less expensive than any medicines we may develop. Our competitors
also may obtain FDA or other regulatory approval for their medicines more rapidly than we may obtain approval for ours, which could result
in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete
may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic medicines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
drug candidates we successfully develop will compete with current and new therapies that may become available in the future. The key
competitive factors affecting the success of all of our drug candidates, if approved, are likely to be their efficacy, combinability,
safety profile, convenience, cost, the effectiveness of companion diagnostics in guiding the use of related therapeutics, if any, the
level of generic competition, level of promotional activity, intellectual property protection, and the availability of reimbursement
from government and other third-party payors. If any drug candidates under development are approved for the indications in which we are
currently planning clinical trials, they will compete with the drugs discussed below and will likely compete with other drugs in development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Artificial
Intelligence and Drug Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our proprietary RADR<sup>&#174;</sup> platform gives us a significant competitive advantage by using AI to select and license
drugs with a well-tolerated safety profile to quickly and cost-effectively bring drugs to market. Recently, there has been an increase
in the use of AI for drug development that we face competition in both for developing new drugs and in biomarker development. This includes
competition to the pool of already existing drug candidates that may be eligible for patient stratification. Our competition in AI-driven
drug development for oncology includes, but is not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Development
    of drug candidates</i></b>: A2A Pharmaceuticals, AI Therapeutics, Atomwise, Benevolent AI, Berg Health, BioXcel, Celsius Therapeutics,
    Exscientia, Gritstone Oncology, Deep Genomics; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Development
    of biomarkers and/or signatures for patient stratification and improved drug development</i></b>: Adaptive Biotechnologies, Concerto
    HealthAI, Datavant, Envisagenics, Erasca, and Genialis.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pancreatic
Cancer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are approved standards of care agents for treating pancreatic cancer that are dominated by FOLFIRINOX (consisting of leucovorin calcium
(folinic acid), fluorouracil, irinotecan, and oxaliplatin) and gemcitabine-based cytotoxic chemotherapeutic regimens. However, these
regimens cause dose limiting toxicities. Liposomal irinotecan (Onivyde&#174;) in combination with 5-FU and LV is recommended in patients
that progressed on gemcitabine therapy. In a small subset of patients exhibiting genetic mutations such as those with neurotrophic receptor
tyrosine kinase (NTRK) gene fusions, breast cancer gene (BRCA) 1/2 mutations, or patients with elevated microsatellite instability (MSI)-DNA
mismatch repair (MMR) status, recently approved targeted therapies such as Vitrakvi and Rozlytrek (approximately 1% of pancreatic cancer
patients), poly ADP-ribose polymerase (PARP) inhibitor Lynparza (approximately 5-8% of pancreatic cancer patients) and Keytruda (approximately
1-2% of pancreatic cancer patients) are currently included in treatment guidelines. For eligible patients, paclitaxel (Abraxane&#174;)
or docetaxel has been used in the third-line setting in combination with gemcitabine. We believe that currently, no adequate treatment
options are available for as much as 80% of advanced stage pancreatic cancer patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
agents are also being actively developed for the potential treatment of pancreatic cancer. The competition we may face regarding LP-184
for the potential treatment of pancreatic cancer includes without limitation the following agents that have not yet received marketing
approval for the treatment of pancreatic cancer: the chemotherapeutic agent-glufosfamide; the CTGF inhibitor-FG-3019 (pamrevlumab); the
tyrosine kinase inhibitor-Masiviera (masitinib); the KRAS inhibitor Sotorasib; and the PARP inhibitor Fluzoparib.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Glioblastoma</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
standard treatment for glioblastoma includes radiation and chemotherapy with temozolomide. Based on an article in the journal Genes and
Diseases (<i>Temozolomide resistance in glioblastoma multiforme</i>, Genes Dis., 2016 May 11;3(3):198-210) and other publications, at
least fifty percent of temozolomide treated patients do not respond to this treatment, and others often form resistance to temozolomide
based regimens. Bevacizumab is frequently used for recurrent glioblastoma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
agents are also being actively developed for the potential treatment of glioblastoma. The competition we may face regarding LP-184 for
the potential treatment of glioblastoma includes without limitation the following: the chemotherapeutic agents Berubicin, and VAL-083
(Dianhydrogalactitol); and the protein kinase inhibitors Paxalisib, Stivarga (Regorafenib) and DB102 (Enzastaurin hydrochloride). There
are also several immunotherapies in late-stage development for glioblastoma, including peptides and tumor cell vaccines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prostate
Cancer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
agents are being actively developed to treat specific subtypes of prostate cancer. Our approach is to leverage A.I. and biomarker data
to discover subtypes of prostate cancer and treatments for those subtypes of cancer. We believe our approach and our compounds take advantage
of this improved characterization of prostate cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are approved standard of care agents for treating solid tumor prostate cancer, but there are a lack of approved therapeutic options for
non-metastatic castration-resistant prostate cancer (&#8220;nmCRPC&#8221;) patients and castration-resistant disease in metastatic hormone-na&#239;ve
prostate cancer (&#8220;mHNPC&#8221;). The competition we may face in regards to LP-100 and one of the indications of LP-184, specifically
mCRPC, includes without limitation the following drugs:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Astellas/Pfizer&#8217;s
    Xtandi (enzalutamide), Johnson &amp; Johnson&#8217;s Zytiga (abiraterone acetate), Clovis Oncology&#8217;s Rubraca (rucaparib), AstraZeneca&#8217;s
    Lynparza (olaparib), and Novartis&#8217; Pluvicto (Lu-PSMA-617) are approved for treatment of metastatic castration-resistant prostate
    cancer (mCRPC). </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Xtandi
    Zytiga and Androgen Deprivation Therapy (&#8220;ADT&#8221;) to treat mHNPC and nmCRPC, respectively. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pfizer
    has tested Talazoparib and Enzalutamide to treat mCRPC </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BeiGene
    has used Pamiparib to treat mCRPC </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Millennium
    Pharmaceuticals has used ADT and TAK-700, a hormonal therapy that inhibits 17,20 lyase activity of the CYP17A1 enzyme, to treat Metastatic
    Prostate Cancer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe LP-184 is unique and has promise for potential use in multiple proposed biomarker profile targeted indications where there are
unmet treatment needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non
Small Cell Lung Cancer (NSCLC)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe LP-300 may have an advantage to approved drugs on the market by serving as a well-tolerated agent in combination with multiple
existing standards of care drugs for the NSCLC patient population or female NSCLC patient population. Beyond traditional chemotherapies
(carboplatin/ pemetrexed and/or cisplatin/paclitaxel), NSCLC treatments with potential use for the never smoker patient population include
targeted small molecules and biologics, which include, without limitation, the approved EGFR inhibitors erlotinib, gefitinib, afatinib,
and osimertinib; the approved ALK inhibitors brigatinib, ceritinib, and crizotinib; the approved MET inhibitor tepotinib; and the approved
immune checkpoint inhibitors pembrolizumab, atezolizumab, and ramucirumab. Many of these agents are used in specific NSCLC subtypes either
as single agents or in various combinations. Many patients with NSCLC receive treatment with tyrosine kinase inhibitors (TKI&#8217;s).
Most patients treated with 1st or 2nd generation TKI&#8217;s will eventually develop resistance to treatment, therefore requiring additional
therapeutic options. H002, a fourth generation EGFR inhibitor entering phase 1/ 2 trials may have potential for treatment of NSCLC subtypes
with various EGFR activating mutations that are common among never smokers and that also underlie resistance to other therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research,
development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution,
post-approval monitoring and reporting, marketing and export and import of drug and biological products. Generally, before a new drug
can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific
for each regulatory authority, submitted for review and approved by the regulatory authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Drug Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;). Drugs also are subject to other
federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate
federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure
to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may
subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal
to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals,
product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution,
disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidates are considered small molecule drugs and must be approved by the FDA through the NDA process before they may be legally
marketed in the United States. The process generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of extensive preclinical studies in accordance with applicable regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an independent institutional review board (&#8220;IRB&#8221;), or ethics committee at each clinical trial site before each trial
    may be initiated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice (&#8220;GCP&#8221;),
    requirements and other clinical trial-related regulations to establish substantial evidence of the safety and efficacy of the investigational
    product for each proposed indication;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination by the FDA within 60 days of its receipt of an NDA to accept the filing for review;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of a FDA pre-approval inspection of the manufacturing facility or facilities where the drug will be produced to assess
    compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&#8217;s
    identity, strength, quality and purity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of the NDA filing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing
    or sale of the drug in the United States; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;),
    and the potential requirement to conduct post-approval studies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
data required to support an NDA are generated in two distinct developmental stages: preclinical studies and clinical trials. The preclinical
and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any
approvals for any future drug candidates will be granted on a timely basis, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preclinical
Studies and IND</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
studies generally involve laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity
in animals, which support subsequent clinical testing. The sponsor must submit the results of the preclinical studies, together with
manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as
part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become
effective before human clinical trials may begin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
studies include laboratory evaluation of product chemistry and formulation, as well as <i>in vitro</i> and animal studies to assess the
potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject
to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results
of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans
for clinical studies, among other things, to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive
adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt
by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the
trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can
begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trials</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the
supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance
with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation
in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial,
dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy.
Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical
trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks
to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also
approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must
monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed
clinical trial results to public registries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the
clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical
trial to the FDA in support of an NDA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under
an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection,
if deemed necessary, and the practice of medicine in the foreign country is consistent with the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials in the United States generally are conducted in three sequential phases, known as Phase I, Phase II and Phase III, and may overlap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase
    I clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to
    a single dose and then multiple doses of the drug candidate.</b> The primary purpose of these clinical trials is to assess the metabolism,
    pharmacologic action, tolerability and safety of the drug.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase
    II clinical trials involve studies in disease-affected patients to determine the dose and dosing schedule required to produce the
    desired benefits.</b> At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible
    adverse effects and safety risks are identified and a preliminary evaluation of efficacy is conducted.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phase
    III clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary
    to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk
    relationship of the product and provide an adequate basis for product approval.</b> These trials may include comparisons with placebo
    and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase IV clinical trials, are conducted after initial marketing approval. These trials are used to gain
additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate
the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progress
reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written
IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from
other studies suggesting a significant risk to humans exposed to the drug, findings from animal or <i>in vitro</i> testing that suggest
a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over
that listed in the protocol or investigator brochure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
I, Phase II and Phase III clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor
may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients
are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution
if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with
unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized
by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a
trial may move forward at designated check-points based on access to certain data from the trial. Concurrent with clinical trials, companies
usually complete additional animal safety studies and also must develop additional information about the chemistry and physical characteristics
of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.
The manufacturing process must be capable of consistently producing quality batches of our drug candidates. Additionally, appropriate
packaging must be selected and tested and stability studies must be conducted to demonstrate that our drug candidates do not undergo
unacceptable deterioration over their labeled shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NDA
Review Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
completion of the clinical trials, data is analyzed to assess whether the investigational product is safe and effective for the proposed
indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA, along
with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA
is a request for approval to market the drug for one or more specified indications and must contain proof of safety and efficacy for
a drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
application must include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings.
Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number
of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient
in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval
of an NDA must be obtained before a drug may be marketed in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), as amended, each NDA must be accompanied by a user fee. The FDA adjusts the
PDUFA user fees on an annual basis. According to the FDA&#8217;s fiscal year 2022 fee schedule, effective through September 30, 2022,
the user fee for an application requiring clinical data, such as an NDA, was approximately $3.11 million. PDUFA also imposes an annual
program fee for each marketed human drug ($369,413 in 2022) and an annual establishment fee on facilities used to manufacture prescription
drugs. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application
filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product
also includes a non-orphan indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews all submitted NDAs before it accepts them for filing, and may request additional information rather than accepting the NDA
for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for
filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months,
from the filing date, in which to complete its initial review of a new molecular-entity NDA and respond to the applicant, and six months
from the filing date of a new molecular-entity NDA designated for priority review. The FDA does not always meet its PDUFA goal dates
for standard and priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether
they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities
are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.
The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications
for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically
a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should
be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such
recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive
discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA, it will issue an approval letter
or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for
specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will
not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identified
by the FDA. The Complete Response Letter may require additional clinical data, additional pivotal Phase 3 clinical trial(s) and/or other
significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response
Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw
the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.
Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
Drugs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition,
which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals
in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in
the United States for this type of disease or condition will be recovered from sales of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic
agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten
the duration of the regulatory review and approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market
the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major
contribution to patient care or in instances of drug supply issues. However, competitors may receive approval of either a different product
for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan
drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for
the same product, as defined by the FDA, for the same indication we are seeking approval, or if a drug candidate is determined to be
contained within the scope of the competitor&#8217;s product for the same indication or disease. If one of our products designated as
an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan
drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expedited
Development and Review Programs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs that meet certain criteria.
Specifically, new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening condition
and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies
to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product
for fast track status any time before receiving NDA approval, but ideally no later than the pre-NDA meeting with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended
to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if
it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness
compared to available therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a
meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably
likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#8220;IMM&#8221;),
which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that
a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If
the FDA concludes that a drug or biologic shown to be effective can be safely used only if distribution or use is restricted, it may
require such post-marketing restrictions as it deems necessary to assure safe use of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
a drug may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more
other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product
may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits
of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure
an efficient drug development program. Fast track designation, priority review, accelerated approval and breakthrough therapy designation
do not change the standards for approval, but may expedite the development or approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Approval
Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among
other things, monitoring and record-keeping requirements, requirements to report adverse experiences and comply with promotion and advertising
requirements, which include restrictions on promoting drugs for unapproved uses or patient populations, known as &#8220;off-label use,&#8221;
and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs
for off-label uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the
FDA in conjunction with their first use. Further, if there are any modifications to the drug, including changes in indications, labeling
or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement,
which may require the development of additional data or preclinical studies and clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also place other conditions on approvals including the requirement for REMS, to assure the safe use of the product. A REMS could
include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient
registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion,
distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards
or if problems occur following initial marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product
reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks or imposition
of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters, or holds on post-approval clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending applications or supplements to approved applications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applications,
    or suspension or revocation of product license approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal to permit the import or export of products; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted
only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce
the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label
uses may be subject to significant liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
U.S. Regulatory Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing,
sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in
the United States in addition to the FDA, including the Centers for Medicare &amp; Medicaid Services, other divisions of the Department
of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission,
the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, and state and
local governments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, in the United States, sales, marketing and scientific and educational programs also must comply with state and federal fraud
and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws. These
laws include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting
    on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals,
    including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal
    healthcare program, such as Medicare or Medicaid. Moreover, the ACA provides that the government may assert that a claim including
    items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes
    of the civil False Claims Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal false claims and civil monetary penalties laws, including the civil False Claims Act that can be enforced by private citizens
    through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting,
    or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement
    to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), prohibits, among other things, executing
    or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, also imposes
    obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually
    identifiable health information;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies
    for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions,
    to annually report to CMS information regarding payments and other transfers of value to physicians and teaching hospitals as well
    as information regarding ownership and investment interests held by physicians and their immediate family members; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
    state and foreign laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements
    and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers,
    state laws that require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines
    and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information
    related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, state laws
    that require biotechnology companies to report information on the pricing of certain drug products, and state and foreign laws that
    govern the privacy and security of health information in some circumstances, many of which differ from each other in significant
    ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
and rebate programs must also comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and
more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General
Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements
under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to
federal and state consumer protection and unfair competition laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing,
storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending
on the circumstances, failure to meet applicable regulatory requirements can result in significant civil, criminal and administrative
penalties, including damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare
programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished
profits and future earnings, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial
or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Patent-Term Restoration and Marketing Exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of FDA approval of any future drug candidates, some of our U.S. patents may be eligible for limited
patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as
compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however, cannot
extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent-term restoration
period is generally one-half the time between the effective date of an IND or the issue date of the patent, whichever is later, and the
submission date of an NDA plus the time between the submission date of an NDA or the issue date of the patent, whichever is later, and
the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise
due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must
be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for
any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed
patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors
involved in the filing of the relevant NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year
period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical
entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety,
which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept
for review an abbreviated new drug application (&#8220;ANDA&#8221;), or a 505(b)(2) NDA submitted by another company for another version
of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application
may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three
years of marketing exclusivity for a NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability
studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application,
for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use
associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original
active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting
a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled
clinical trials necessary to demonstrate safety and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>European
Union Drug Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory
controls. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting
out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the
provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime,
before a clinical trial can be initiated it must be approved in each of the EU countries where the trial is to be conducted by two distinct
bodies: the National Competent Authority (&#8220;NCA&#8221;), and one or more Ethics Committees (&#8220;ECs&#8221;). Under the current
regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported
to the NCA and ECs of the Member State where they occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU clinical trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial
authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency.
Recently enacted Clinical Trials Regulation EU No 536/2014 ensures that the rules for conducting clinical trials in the EU will be identical.
In the meantime, Clinical Trials Directive 2001/20/EC continues to govern all clinical trials performed in the EU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 61 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>European
Union Drug Review and Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Economic Area (&#8220;EEA&#8221;), which is comprised of the 27 Member States of the European Union (including Norway and
excluding Croatia), Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization
(&#8220;MA&#8221;). There are two types of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal
    Products for Human Use (&#8220;CHMP&#8221;), of the EMA, and is valid throughout the entire territory of the EEA. The Centralized
    Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy
    medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active
    substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions
    and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the
    EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of
    public health in the EU.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are
    available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized
    for marketing in a Member State of the EEA, this National MA can be recognized in another Member States through the Mutual Recognition
    Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously
    in various Member States through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted
    to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as
    the Reference Member State (&#8220;RMS&#8221;). The competent authority of the RMS prepares a draft assessment report, a draft summary
    of the product characteristics (&#8220;SPC&#8221;), and a draft of the labeling and package leaflet, which are sent to the other
    Member States (referred to as the Member States Concerned) for their approval. If the Member States Concerned raise no objections,
    based on a potential serious risk to public health, to the assessment, SPC, labeling or packaging proposed by the RMS, the product
    is subsequently granted a national MA in all the Member States (i.e., in the RMS and the Member States Concerned).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the above described procedures, before granting the MA, EMA or the competent authorities of the Member States of the EEA make an assessment
of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. Similar to
the U.S. patent term-restoration, Supplementary Protection Certificates (&#8220;SPCs&#8221;) serve as an extension to a patent right
in Europe for up to five years. SPCs apply to specific pharmaceutical products to offset the loss of patent protection due to the lengthy
testing and clinical trials these products require prior to obtaining regulatory marketing approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and Reimbursement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health
programs, commercial insurance, and managed healthcare organizations. There is significant uncertainty related to third-party payor coverage
and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products
are typically made by CMS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private
third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, no uniform
policy of coverage and reimbursement for drug products exists. Accordingly, decisions regarding the extent of coverage and amount of
reimbursement to be provided for any of our products will be made on a payor-by-payor basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasingly,
third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the
prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and
reviewing the cost effectiveness of medical drug candidates. There may be especially significant delays in obtaining coverage and reimbursement
for newly approved drugs. Third-party payors may limit coverage to specific drug candidates on an approved list, known as a formulary,
which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies
to demonstrate the medical necessity and cost effectiveness of our products. As a result, the coverage determination process is often
a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each
payor separately, with no assurance that coverage and adequate reimbursement will be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements
governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its
member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and
to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it
may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market.
There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow
favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not
follow price structures of the United States and generally prices tend to be significantly lower.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Reform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States government, state legislatures, and foreign governments have shown significant interest in implementing cost containment
programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement, and requirements
for substitution of generic products for branded prescription drugs. For example, in March 2010, the Patient Protection and Affordable
Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;), was passed
which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the
U.S. pharmaceutical industry. The ACA contains provisions that may reduce the profitability of drug products through increased rebates
for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain
Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs.
The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with
the HHS Secretary as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished
to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217;
rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price
(&#8220;AMP&#8221;), to 23.1% of AMP and adding a new rebate calculation for &#8220;line extensions&#8221; (i.e., new formulations, such
as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability
by modifying the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring
pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible
for Medicaid drug benefits. The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), have proposed to expand Medicaid rebate
liability to the territories of the United States as well. Additionally, for a drug product to receive federal reimbursement under the
Medicaid or Medicare Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities
eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP
and Medicaid rebate amounts reported by the manufacturer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects
of the ACA Congress has recently considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress
has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have passed. On
December 22, 2017, the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;) was enacted, which includes a provision repealing, effective
January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying
health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; The Bipartisan Budget
Act of 2018 (the &#8220;BBA&#8221;), among other things, amended the ACA, effective January 1, 2019, to close the coverage gap in most
Medicare Part D drug plans. In July 2018, CMS published a final rule permitting further collections and payments to and from certain
ACA-qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district
court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge
ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part
of the Tax Act. On December 18, 2019, the United States Court of Appeal for the Fifth Circuit ruled that the &#8220;individual mandate&#8221;
of the ACA is unconstitutional, but remanded the case to the U.S. District Court to reconsider whether the entire ACA is unconstitutional.
In June 2021, the Supreme Court concluded that the challenge to the ACA should be dismissed. It is unclear how this decision, subsequent
appeals and decisions, and other efforts to repeal and replace the ACA will impact the ACA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions
to Medicare payments to providers of up to 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments,
will stay in effect through 2027 unless additional congressional action is taken. In January 2013, President Obama signed into law the
American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute
of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in
additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs,
if approved, and accordingly, our financial operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products,
which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other
things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform
government program reimbursement methodologies for drug products. For example, At the state level, legislatures have increasingly passed
legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,
and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (&#8220;MMA&#8221;), established the Medicare Part D program
to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription
drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage
is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription
drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies
which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic
category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part
D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs
of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our
products covered by a Part D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the
MMA applies only to drug benefits for Medicare beneficiaries, private third-party payors often follow Medicare coverage policy and payment
limitations in setting their own payment rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we employ a total of 23 professionals: 22 full-time and one part-time employees. None of our employees are
represented by a labor union or covered under a collective bargaining agreement. We believe that we maintain strong relations with our
employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also engage outside consultants to assist with research and development, clinical development and regulatory matters, business development,
operations and other functions from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Human
Capital Resources.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees drive our mission, and we place a high level of importance on employee engagement and corporate culture. Fostering and maintaining
a strong, healthy culture is a key strategic focus for us, and we regularly engage in independent third-party surveys to gauge the satisfaction
and engagement of our team.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation approach is aimed at attracting, retaining, motivating and rewarding superior employees who operate in a highly competitive
and technologically challenging environment. The structure of our compensation aims to balance incentives for both short-term and long-term
performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
examples of the benefits we offer include medical insurance, dental insurance, vision insurance, and an unlimited paid-time off policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
substantial portion of our employees are focused on leading and advancing our drug development, biology and data science efforts. As
we progress our product candidates and grow and expand our team, we intend to continue to place a significant focus on our human capital
resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a website at www.lanternpharma.com. The contents of our website are not incorporated in, or otherwise to be regarded as part
of, this Annual Report on Form 10-K. We make available, free of charge on our website, access to our Annual Report on Form 10-K, our
Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as soon as reasonably practicable
after we file or furnish them electronically with the Securities and Exchange Commission (&#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
of our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and other filings we make with
the SEC are also available at the SEC&#8217;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC
at 1-800-SEC-0330 for further information on the Public Reference Room. Our SEC filings are also available on the SEC&#8217;s website
at www.sec.gov. Statements contained in this Annual Report on Form 10-K concerning the contents of any contract or any other documents
are not necessarily complete. If a contract or document has been filed as an exhibit to this Annual Report on Form 10-K, please see the
copy of the contract or document that has been filed. Each statement in this this Annual Report on Form 10-K relating to a contract or
document filed as an exhibit is qualified in all respects by the filed exhibit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_004"></span><b>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investment in our common stock involves a high degree of risk. You should give careful consideration to the following risk factors, in
addition to general economic and business risks and the other information included in this Annual Report on Form 10-K, including our
financial statements and related notes, before deciding whether to invest in shares of our common stock. The occurrence of any of the
adverse developments described in the following risk factors could materially and adversely harm our business, financial condition, results
of operations or prospects. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.
Additional risks or uncertainties not presently known to us or that we currently deem immaterial may also materially and adversely harm
our business, financial condition, results of operations or prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Financial Position and Need for Capital </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history and have never generated any revenues other than from research grants, which may make it difficult to
evaluate the success of our business to date and to assess our future viability. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in November 7, 2013, and to date have been largely focused on organizing and staffing our company, raising capital,
developing the RADR<sup>&#174;</sup> platform and acquiring the rights to, and advancing the development of, our drug candidates, including
conducting preclinical studies and early phase clinical trials on our drug candidates. We have not yet demonstrated an ability to successfully
complete clinical trials, obtain marketing approvals, manufacture drugs on a commercial scale, or arrange for a third party to do so
on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, predictions about
our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully
developing and commercializing drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety
of factors, many of which are beyond our control. We will need to eventually transition from a company with a research and development
focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and
delays, and may not be successful in such a transition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses
for the foreseeable future and may never achieve or maintain profitability. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have incurred losses. Our net losses were approximately $14,260,000 and $12,363,000 for the years ended December 31,
2022 and 2021, respectively. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable
future. None of our current drug candidates have been approved for marketing in the United States, or in any other jurisdiction, and
may never receive such approval. It could be several years, if ever, before we have a commercialized drug that generates significant
revenues. As a result, we are uncertain when or if we will achieve profitability and, if so, whether we will be able to sustain profitability.
The net losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase
substantially as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    the development of our drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate
    preclinical studies and clinical trials for any additional indications for our current drug candidates and any future drug candidates
    that we may pursue;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    to build our portfolio of drug candidates through the acquisition or in-license of additional drug candidates or technologies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    to develop, maintain, expand and protect our intellectual property portfolio;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    to develop, maintain, and expand our RADR<sup>&#174;</sup> platform;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursue
    regulatory approvals for our current and future drug candidates that successfully complete clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ultimately
    establish a sales, marketing, distribution and other commercial infrastructure to commercialize any drug candidate for which we may
    obtain marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional clinical, regulatory, scientific and accounting personnel; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur
    additional legal, accounting and other expenses in operating as a public company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
become and remain profitable, we must develop and eventually commercialize one or more drug candidates with significant market potential
or license one or more of our drug candidates to an industry partner. This will require us to be successful in a range of challenging
activities, including completing clinical trials of our drug candidates, publishing our data and findings on our drug candidates with
peer reviewed publications, developing commercial scale manufacturing processes, obtaining marketing approval, manufacturing, marketing
and selling any current and future drug candidates for which we may obtain marketing approval, and satisfying any post-marketing requirements.
We are only in the preliminary stages of most of these activities and, in some cases, have not yet commenced certain of these activities.
We may never succeed in any or all of these activities and, even if we do, we may never generate sufficient revenue to achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with drug development, we are unable to accurately predict the timing or amount of
expenses or when, or if, we will obtain marketing approval to commercialize any of our drug candidates. If we are required by the U.S.
Food and Drug Administration, or FDA, or other regulatory authorities such as the European Medicines Agency, or EMA, to perform studies
and trials in addition to those currently expected, or if there are any delays in the development, or in the completion of any planned
or future preclinical studies or clinical trials of our current or future drug candidates, our expenses could increase and profitability
could be further delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to
become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research
and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause investors
to lose all or part of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate
our drug development programs or commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our expenses will increase substantially as we continue to develop and begin and continue clinical trials with respect
to LP-300, LP-184, LP-284, LP-100 and our other drug candidates; seek to identify and develop additional drug candidates; acquire or
in-license other drug candidates or technologies; seek regulatory and marketing approvals for our drug candidates that successfully complete
clinical trials, if any; establish sales, marketing, distribution and other commercial infrastructure in the future to commercialize
various drugs for which we may obtain marketing approval, if any; require the manufacture of larger quantities of drug candidates for
clinical development and, potentially, commercialization; maintain, expand and protect our intellectual property portfolio; develop,
maintain, and expand our RADR<sup>&#174;</sup> platform; hire and retain additional personnel, such as clinical, quality control and scientific
personnel; add operational, financial and management information systems and personnel, including personnel to support our drug development
and help us comply with our obligations as a public company; and add equipment and physical infrastructure to support our research and
development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be required to expend significant funds in order to advance the development of LP-300, LP-184, LP-284, LP-100 and our other drug
candidates. In addition, while we may seek one or more collaborators for future development of our current drug candidates or any future
drug candidates that we may develop for one or more indications, we may not be able to enter into a partnership or out-license for any
of our drug candidates for such indications on suitable terms, on a timely basis or at all. In any event, our existing cash, cash equivalents
and other capital resources will not be sufficient to fund all of the efforts that we plan to undertake or to fund the completion of
development of our drug candidates or our other preclinical studies. Accordingly, we will be required to obtain further funding through
public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. We do not have any committed
external source of funds. Further financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as
and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our anticipated expenditures and capital commitments as of the date of this report, we believe our existing cash and cash equivalents
as of December 31, 2022 will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from
the filing of this Form 10-K for the year ended December 31, 2022. Our estimate as to how long we expect our existing cash, cash equivalents
and other capital resources to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we
could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond
our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional
funds sooner than planned. Our future funding requirements, both short-term and long-term, will depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, timing, costs and results of preclinical studies and clinical trials of LP-300, LP-184, LP-284, LP-100 and our other
    drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with maintaining, expanding and updating our RADR<sup>&#174;</sup> platform;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing and outcome of seeking regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    headcount growth and associated costs as we expand our research and development as well as potentially establish a commercial infrastructure;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of our licensing or commercialization activities for any of our drug candidates that receive marketing approval to the extent
    such costs are not the responsibility of any future collaborators, including the costs and timing of establishing drug sales, marketing,
    distribution and manufacturing capabilities;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to enter into and the terms and timing of any collaborations, licensing agreements or other arrangements;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">revenue
    received from commercial sales, if any, of our current and future drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending
    against intellectual property related claims;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of future drug candidates that we pursue and their development requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in regulatory policies or laws that may affect our operations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in physician acceptance or medical society recommendations that may affect commercial efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of acquiring potential new drug candidates or technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with purchasing data for our RADR<sup>&#174;</sup> platform;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with maintaining and expanding our cybersecurity systems; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of operating as a public company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Discovery and Development of Drug Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited experience in drug discovery and drug development and may not receive regulatory approval to market our drug candidates.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the acquisition of our rescue drug candidates, we were not involved in and had no control over their preclinical and clinical development.
In addition, we rely upon the parties from whom we have acquired our drug candidates from to have conducted such research and development
in accordance with the applicable protocol, legal, regulatory and scientific standards, having accurately reported the results of all
clinical trials conducted prior to our acquisition of the applicable drug candidate, and having correctly collected the data from these
studies and trials. To the extent any of these has not occurred, our expected development time and costs may be increased, which could
adversely affect our prospects for marketing approval of, and receiving any future revenue from, these drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the near term, we are dependent on our ability to advance the development of LP-300, LP-300, LP-284, and LP-100. If we are unable to
initiate or complete the clinical development of, obtain marketing approval for or successfully commercialize LP-300, LP-184, LP-284,
LP-100 and our other drug candidates, either alone or with a collaborator, or if we experience significant delays in doing so, our business
could be substantially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have any drugs that have received regulatory approval and may never be able to develop marketable drug candidates. We
are investing a significant portion of our efforts and financial resources in the advancement of our drug candidates and in the development
of our RADR<sup>&#174;</sup> platform. Our prospects are substantially dependent on our ability, or those of any future collaborator,
to develop, obtain marketing approval for and successfully commercialize drug candidates in one or more disease indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of LP-300, LP-184, LP-284, LP-100 and our other drug candidates will depend on several factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">following
    submission of an Investigational New Drug Application, or IND, with the FDA or any comparable foreign regulatory authority, receiving
    clearance for the conduct of clinical trials of drug candidates and proposed design of future clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation,
    progress, timing, costs and results of clinical trials of our drug candidates and potential drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
    of a safety, tolerability and efficacy profile that is satisfactory to the FDA or any comparable foreign regulatory authority for
    marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate
    ongoing availability of quality data sources for our RADR<sup>&#174;</sup> platform and raw materials and drug product for clinical
    development and any commercial sales;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and relevant global markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    performance of our future collaborators, if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
    of supply arrangements with third-party raw materials suppliers and manufacturers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
    of arrangements with third-party manufacturers to obtain finished drug product that is appropriately packaged for sale;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">protection
    of our rights in our intellectual property portfolio;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    launch of commercial sales following any marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    continued acceptable safety profile following any marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercial
    acceptance by patients, the medical community and third-party payors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to compete with other therapies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of these factors are beyond our control, including the results of clinical trials, the time required for the FDA or any comparable foreign
regulatory authorities to review any regulatory submissions we may make, potential threats to our intellectual property rights and the
manufacturing, marketing and sales efforts of any future collaborator. If we are unable to develop, receive marketing approval for and
successfully commercialize our drug candidates, on our own or with any future collaborator or experience delays as a result of any of
these factors or otherwise, our business could be substantially harmed. The regulatory approval processes of the FDA and comparable foreign
authorities are lengthy, time consuming, expensive and inherently unpredictable, and if we are ultimately unable to obtain regulatory
approval for our drug candidates, our business will be substantially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but can take many years following the
commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities.
The results of preclinical studies and early clinical trials of our drug candidates may not be predictive of the results of later-stage
clinical trials. Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having
progressed through preclinical studies and initial clinical trials. It is not uncommon for companies in the biotechnology and pharmaceutical
industries to suffer significant setbacks in advanced clinical trials due to nonclinical findings made while clinical studies were underway
and safety or efficacy observations made in clinical studies, including previously unreported adverse events. Our future clinical trial
results may not be successful, and notwithstanding any potential promising results in earlier studies, we cannot be certain that we will
not face similar setbacks. The historical failure rate for drug candidates in our industry is high. In addition, approval policies, regulations,
or the type and amount of clinical data necessary to gain approval may change during the course of a drug candidate&#8217;s clinical
development and may vary among jurisdictions. We have not obtained final regulatory approval for any drug candidate and it is possible
that none of our existing drug candidates or any drug candidates we may seek to develop in the future will ever obtain regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidates could fail to receive regulatory clearance or marketing approval for many reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials, including,
    but not limited to, the use of genomic or biomarker signatures to identify patients that may respond to drug efficacy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a drug candidate is
    safe and effective for its proposed indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to identify and recruit a sufficient number of patients with relevant genomic or biomarker signatures or other specified
    enrollment criteria in order to conduct clinical trials on our drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory
    authorities for approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical
    trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical trials of our drug candidates may not be sufficient to support the submission of a New Drug Application,
    or NDA, or other submission or to obtain regulatory approval in the United States or elsewhere;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers
    with which we contract for clinical and commercial supplies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering
    our clinical data insufficient for approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not previously completed all clinical trials for any of our drug candidates. Consequently, we may not have the necessary capabilities,
including adequate staffing, to successfully manage the execution and completion of any clinical trials we initiate in a way that leads
to our obtaining marketing approval for our drug candidates in a timely manner, or at all. This lengthy approval process as well as the
unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our drug candidates,
which would significantly harm our business, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we were to obtain approval, regulatory authorities may approve any of our drug candidates for fewer or more limited
indications than we request, may not approve the price we intend to charge for our drugs, may grant approval contingent on the performance
of costly post-marketing clinical trials, may approve a drug candidate with a label that does not include the labeling claims necessary
or desirable for the successful commercialization of that drug candidate or may restrict its distribution. Any of the foregoing restrictions
or requirements could materially harm the commercial prospects for our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not previously submitted a new drug application (an &#8220;NDA&#8221;) to the FDA or similar drug approval filings to comparable
foreign authorities, for any drug candidate, and we cannot be certain that any of our drug candidates will be successful in clinical
trials or receive regulatory approval. Further, our drug candidates may not receive regulatory approval even if they are successful in
clinical trials. If we do not receive regulatory approvals for our drug candidates, we may not be able to continue our operations. Even
if we successfully obtain regulatory approvals to market one or more of our drug candidates, our revenues will be dependent, in part,
upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for
patients that we are targeting for our drug candidates are not as significant as we estimate, or if the price we charge for our drug
candidate is too high, we may not generate significant revenues from sales of such drugs, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to seek regulatory approval to commercialize our drug candidates both in the United States and the European Union and in additional
foreign countries. While the scope of regulatory approval is similar in other countries, to obtain separate regulatory approval in many
other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and
governing, among other things, clinical trials and possible limitations placed upon commercial sales, pricing and distribution of our
drug candidates, and we cannot predict success in these jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business strategy to rescue previously failed drug candidates may not be successful, and important issues relating to safety and efficacy
remain to be resolved for all of our drug candidates. Our strategy also involves risks and uncertainties that differ from other biotechnology
companies that focus solely on new drug candidates that do not have a history of failed clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidate portfolio includes small molecules that others have tried, but failed, to develop into an approved commercialized drug.
Our strategy to rescue previously failed drug candidates may not be successful, and the use of the term &#8220;drug rescue,&#8221; &#8220;rescuing,&#8221;
or words of similar meaning in this report should not be construed to mean that our RADR<sup>&#174;</sup> platform has resolved all issues
of safety and/or efficacy for any of our drug candidates. Issues of safety and efficacy for any drug candidate may only be determined
by the U.S. FDA or other applicable regulatory authorities in jurisdictions outside the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy includes a focus on leveraging A.I. to streamline the drug development process and to identify patients that will benefit
from drug candidates that other biotechnology or pharmaceutical companies have abandoned or shelved after initiating clinical trials
under an IND application filed with the FDA, including candidates that have failed to achieve statistical significance on the original
endpoints established in the clinical trials. We use our RADR<sup>&#174; </sup>platform to assess drug candidates together with big data
sources of information to both target and evaluate sub-populations and identify new therapeutic indices and gene signatures that will
potentially correlate with drug efficacy and patient response to treatment. While we have not yet successfully received regulatory or
marketing approval for any of our drug candidates, and while we believe that our approach has the potential to reduce the cost and time
of drug development through the identification and selection of patient populations more likely to respond to therapy, our strategy involves
risks and uncertainties that differ from other biotechnology companies that focus solely on new drug candidates that do not have a history
of failed clinical development. These risks and uncertainties include, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    remaining term of the initial patents filed with respect to a rescued and repositioned drug candidate may be significantly less than
    the patent term for a newly discovered drug candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
    out-licensees, alliance partners and collaborators may view a rescued and repositioned drug candidate with more skepticism because
    of its history of failed clinical trials, thereby requiring a higher level of additional data and further explanations of mechanisms
    of action in order to overcome this skepticism and obtain commercially reasonable terms for future development or collaboration;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
    personnel and institutional knowledge relating to a rescued and repositioned drug candidate may no longer be available for us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    current standard of care in the targeted therapeutic indication for the rescued and repositioned drug candidate may be different
    than the standard of care that existed during the candidate&#8217;s last clinical trial, which will require more time and resources
    from us to reassess and redesign the regulatory development path for the rescued and repositioned drug candidate; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    rescued and repositioned drug candidate may be perceived to be in an &#8220;older&#8221; therapeutic focus area of oncology, thereby
    generating less enthusiasm and support compared to therapeutic focus areas of oncology that may be perceived as more recent.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may depend on enrollment of patients with specific genomic or biomarker signatures in our clinical trials in order for us to continue
development of our drug candidates. If we are unable to enroll patients with specific genomic or biomarker signatures in our clinical
trials, our research, development and commercialization efforts could be adversely affected. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient
number of patients with genomic or biomarker signatures we have identified and who remain in the study until its conclusion. We may experience
difficulties in patient enrollment in our clinical trials for a variety of reasons. Patient enrollment is affected by many factors including
the size and nature of the patient population with the specific genomic or biomarker signature we have identified, the proximity of patients
to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, the size of the patient population required
for analysis of the trial&#8217;s primary endpoints, the proximity of patients to study sites, our ability to recruit clinical trial
investigators with the appropriate competencies and experience, our ability to obtain and maintain patient consents, the risk that patients
enrolled in clinical trials will drop out of the trials before completion, and competing clinical trials and clinicians&#8217; and patients&#8217;
perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs
that may be approved for the indications we are investigating. We will compete with other pharmaceutical companies for clinical sites,
physicians and the limited number of patients who fulfill the stringent requirements for participation in oncology clinical trials. Also,
due to the confidential nature of clinical trials, we do not know how many of the eligible patients may be enrolled in competing studies
and who are consequently not available to us for our clinical trials. Our clinical trials may be delayed or terminated due to the inability
to enroll enough patients. The delay or inability to meet planned patient enrollment may result in increased costs and delay or termination
of our trials, which could have a harmful effect on our ability to develop drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Delays
in clinical testing could result in increased costs to us and delay our ability to generate revenue. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that the FDA or other regulatory authorities will accept our planned or future trial designs for our drug candidates.
We may experience delays in our clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned,
enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays
related to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    regulatory clearance to commence a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reaching
    agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which
    can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    institutional review board, or IRB, approval at each site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruiting
    suitable patients to participate in a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
    clinical sites with adequate infrastructure (including data collection) to conduct the trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    sites deviating from trial protocol or dropping out of a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
    patient safety concerns that arise during the course of a trial;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">having
    patients complete a trial or return for post-treatment follow-up;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adding a sufficient number
    of clinical trial sites; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing sufficient
    quantities and quality of a drug candidate for use in clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to
receive marketing approval or commercialize our drug candidates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may receive feedback
    from regulatory authorities that requires us to modify the design of our clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not have the ability
    to test patients for our clinical trials that require a specific genomic or biomarker signature in order to qualify for enrollment;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical trials of our
    drug candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional
    clinical trials or abandon drug development programs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of patients
    required for clinical trials of our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be
    slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our third-party contractors
    may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of clinical trials
    of our drug candidates may be greater than we anticipate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the supply or quality of
    our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators may revise the
    requirements for approving our drug candidates, or such requirements may not be as we anticipate; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any future collaborators
    that conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous
    to themselves but that are suboptimal for us.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are required to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate,
if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or
tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur unplanned costs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be delayed in obtaining
    marketing approval for our drug candidates or not obtain marketing approval at all;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain marketing approval
    in some countries and not in others;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain marketing approval
    for indications or patient populations that are not as broad as intended or desired;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain marketing approval
    with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be subject to additional
    post-marketing testing requirements; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have the drug removed from
    the market after obtaining marketing approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we rely and intend to rely in the future on CROs, cancer research centers and clinical trial sites to ensure the proper and timely conduct
of our clinical trials and we intend to have agreements governing their committed activities. They may not perform as required or we
may face competition from other clinical trials being conducted by other pharmaceutical companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could encounter delays if a clinical trial is suspended or terminated by us, by the Institutional Review Board or IRB of the institutions
in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory
authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the
clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial
site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side
effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of
adequate funding to continue the clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
conducting clinical trials in foreign countries, as we may do for our current and future drug candidates, presents additional risks that
may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical
protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated
with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion of, or termination of, any clinical trial of our drug candidates, the commercial prospects of
our drug candidates will be harmed, and our ability to generate revenues from any of these drug candidates will be delayed. In addition,
any delays in completing our clinical trials will increase our costs, slow down our drug candidate development and approval process and
jeopardize our ability to commence drug sales and generate revenues. Any of these occurrences may harm our business, financial condition
and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical
trials may also ultimately lead to the denial of regulatory approval of our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit
the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could
result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities.
LP-184 and LP-284 have not yet been administered in patients. It is possible that there may be side effects associated with any of our
drug candidates. In such an event, we, the FDA, the IRBs at the institutions in which our studies are conducted, or the DSMB could suspend
or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny
approval of our drug candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment
or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. In addition, these
side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel
using our drug candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our
drug candidates. Inadequate training in recognizing or managing the potential side effects of our drug candidates could result in patient
injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if one or more of our drug candidates receives marketing approval, and we or others later identify undesirable side effects caused by
such drugs, a number of potentially significant negative consequences could result, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may withdraw approvals of such drugs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to recall
    a drug or change the way such a drug is administered to patients;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional restrictions
    may be imposed on the marketing or distribution of the particular drug or the manufacturing processes for the drug or any component
    thereof;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;<br />
    <br />
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to implement
    Risk Evaluation and Mitigation Strategies, or REMS, or create a medication guide outlining the risks of such side effects for distribution
    to patients;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held
    liable for harm caused to patients;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our drug may become less
    competitive; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of the particular drug candidate or for particular indications
of a drug candidate, if approved, and could significantly harm our business, results of operations and prospects. Our approach to the
discovery and development of drug candidates based on our RADR<sup>&#174;</sup> platform is innovative and in the early stages of development;
and we do not know whether we will be able to develop any drugs of commercial value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are leveraging our RADR<sup>&#174;</sup> platform in an attempt to create a pipeline of drug candidates using biomarker identification
and patient stratification for the development of oncology drugs. While we believe that applying our RADR<sup>&#174;</sup> platform to
drugs that have failed, been abandoned or otherwise failed to meet clinical endpoints and then developing a precision oncology approach
that identifies the mechanism of action, potential combination drug usage and potentially responsive patient population is a powerful
strategy, our approach is both innovative and in the early stages of development. Because our approach is both innovative and in the
early stages of development, the cost and time needed to develop our drug candidates is difficult to predict, and our efforts may not
result in the successful discovery and development of commercially viable medicines. We may also be incorrect about the effects of our
drug candidates on the diseases of our defined patient populations, which may limit the utility of our approach or the perception of
the utility of our approach. Furthermore, our estimates of our defined patient populations available for study and treatment may be lower
than expected, which could adversely affect our ability to conduct clinical trials and may also adversely affect the size of any market
for medicines we may successfully commercialize. Our approach may not result in time savings, higher success rates or reduced costs as
we expect it to, and if not, we may not attract collaborators or develop new drugs as quickly or cost effectively as expected and therefore
we may not be able to commercialize our approach as originally expected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
RADR</i></b><i><sup>&#174; </sup><b>platform may fail to help us discover and develop additional potential drug candidates.</b></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
drug discovery or drug development that we are conducting using our RADR<sup>&#174;</sup> platform may not be successful in identifying
compounds that have commercial value or therapeutic utility. Our RADR<sup>&#174;</sup> platform may initially show promise in identifying
potential drug candidates, yet fail to yield viable drug candidates for clinical development or commercialization for a number of reasons,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">research programs to identify
    new drug candidates will require substantial technical, financial and human resources, and we may be unsuccessful in our efforts
    to identify new drug candidates. If we are unable to identify suitable additional compounds for preclinical and clinical development,
    our ability to develop drug candidates and obtain product revenues in future periods could be compromised, which could result in
    significant harm to our financial position and adversely impact our stock price;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compounds identified through
    our RADR<sup>&#174;</sup> platform may not demonstrate efficacy, safety or tolerability;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the data available for
    our RADR<sup>&#174;</sup> platform that seeks to correlate genomic or biomarker signatures with certain cancers may be influenced
    by the race of the patient which may limit the efficacy of our drug candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential drug candidates
    may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to receive
    marketing approval and achieve market acceptance;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitors may develop
    alternative therapies that render our potential drug candidates non-competitive or less attractive; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a potential drug candidate
    may not be capable of being produced at an acceptable cost.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
failure by us to comply with existing regulations could harm our reputation and operating results. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be subject to extensive regulation by U.S. federal and state and foreign governments in each of the markets where we intend to sell
LP-300, LP-184, LP-284, and LP-100 if and after they are approved. For example, we will have to adhere to all regulatory requirements
including the FDA&#8217;s current GCPs, Good Laboratory Practice, or GLP, and GMP requirements, or that of applicable foreign regulatory
authorities. If we fail to comply with applicable regulations, including FDA pre-or post- approval cGMP requirements, then the FDA or
other foreign regulatory authorities could sanction us. Even if a drug is FDA-approved, regulatory authorities may impose significant
restrictions on a drug&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses,
divert our management&#8217;s attention from the operation of our business and damage our reputation. We will need to expend significant
resources on compliance efforts and such expenses are unpredictable and might adversely affect our results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our drug candidates. For example, in December 2016, the 21st Century Cures Act, or Cures
Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation, but
its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption of new
requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have
obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative
or executive action, either in the United States or abroad. If future legislation or administrative or executive actions impose restrictions
on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.
In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or
if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve
or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to extensive regulations outside the United States and may not obtain marketing approvals for drugs in Europe and other
jurisdictions. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the United States, should we or our collaborators pursue marketing approvals for LP-300, LP-184, LP-284, LP-100
and our other drug candidates internationally, we and our collaborators will be subject to a variety of regulations in other jurisdictions
governing, among other things, clinical trials and any commercial sales and distribution of our drugs. Whether or not we, or our collaborators,
obtain applicable FDA regulatory clearance and marketing approval for a drug, we must obtain the requisite approvals from regulatory
authorities in foreign countries prior to the commencement of clinical trials or marketing of the drug in those countries. The requirements
and process governing the conduct of clinical trials, drug licensing, pricing and reimbursement vary from country to country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to obtaining necessary clinical data, we intend to pursue marketing approvals for LP-300, LP-184, LP-284, LP-00 and our other drug candidates
in Europe and other jurisdictions outside the United States with collaborative partners. The time and process required to obtain regulatory
approvals and reimbursement in Europe and other jurisdictions may be different from those in the United States regulatory and approval
in one jurisdiction does not ensure approvals in any other jurisdiction; however, negative regulatory decisions in any jurisdiction may
have a negative impact on the regulatory process in other jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
June 23, 2023 will mark seven years since the people of the United Kingdom voted in a referendum to leave the European Union, commonly
referred to as Brexit. Today, the United Kingdom is outside the European Union and mostly no longer subject to its rules. Significant
portions of the regulatory framework in the United Kingdom have been derived from European Union directives and regulations and the impacts
from Brexit could materially impact the regulatory regime with respect to the approval of our drug candidates in the United Kingdom or
the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would
prevent us from commercializing our drug candidates in the United Kingdom and/or the European Union and restrict our ability to generate
revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek
regulatory approval in the United Kingdom and/or European Union for our drug candidates, which could materially and adversely affect
our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are found in violation of federal or state &#8220;fraud and abuse&#8221; laws, we may be required to pay a penalty and/or be suspended
from participation in federal or state health care programs, which may adversely affect our business, financial condition and results
of operations. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, we will be subject to various federal and state health care &#8220;fraud and abuse&#8221; laws, including anti-kickback
laws, false claims laws and other laws intended to reduce fraud and abuse in federal and state health care programs, which could affect
us, particularly upon successful commercialization of our drugs in the United States. The federal Anti-Kickback Statute makes it illegal
for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive,
offer or pay any remuneration that is intended to induce the referral of business, including the purchase, order or prescription of a
particular drug for which payment may be made under a federal health care program, such as Medicare or Medicaid. Under federal government
regulations, some arrangements, known as safe harbors, are deemed not to violate the federal Anti-Kickback Statute. Although we seek
to structure our business arrangements in compliance with all applicable requirements, these laws are broadly written, and it is often
difficult to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible that our practices
may be challenged under the federal Anti-Kickback Statute. False claims laws prohibit anyone from knowingly and willfully presenting
or causing to be presented for payment to third-party payers, including government payers, claims for reimbursed drugs or services that
are false or fraudulent, claims for items or services that were not provided as claimed, or claims for medically unnecessary items or
services. Cases have been brought under false claims laws alleging that off-label promotion of pharmaceutical drugs or the provision
of kickbacks has resulted in the submission of false claims to governmental health care programs. Under the Health Insurance Portability
and Accountability Act of 1996, we are prohibited from knowingly and willfully executing a scheme to defraud any health care benefit
program, including private payers, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially
false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services.
Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines and/or exclusion or suspension
from federal and state health care programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In
addition, private individuals have the ability to bring actions on behalf of the government under the federal False Claims Act as well
as under the false claims laws of several states.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have adopted laws similar to the federal anti-kickback statute, some of which apply to the referral of patients for health care
services reimbursed by any source, not just governmental payers. Neither the government nor the courts have provided definitive guidance
on the application of fraud and abuse laws to our business. Law enforcement authorities are increasingly focused on enforcing these laws,
and if we are found in violation of one of these laws, we could be required to pay a penalty and could be suspended or excluded from
participation in federal or state health care programs, and our business, results of operations and financial condition may be adversely
affected. We may be unable to maintain sufficient clinical trial liability insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
inability to obtain and retain sufficient clinical trial liability insurance at an acceptable cost to protect against potential liability
claims could prevent or inhibit our ability to conduct clinical trials for drug candidates we develop. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have secured clinical trial liability insurance coverage regarding our clinical trial of LP-300 and will be securing clinical trial liability
insurance coverage before commencing patient enrollment for our planned clinical trials for LP-184 and LP-284 and other future clinical
trials. Any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in
whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. We expect we will supplement our clinical
trial coverage with product liability coverage in connection with the potential commercial launch of our drug candidates; however, we
may be unable to obtain such increased coverage on acceptable terms or at all. If we are found liable in a clinical trial lawsuit or
a product liability lawsuit in the future, we will have to pay any amounts awarded by a court or negotiated in a settlement that exceed
our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay
such amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to have improperly promoted off-label uses of our drugs or drug candidates, if approved, we may become subject to significant
liability. Such enforcement has become more common in the industry. The FDA and other regulatory agencies strictly regulate the promotional
claims that may be made about prescription drug products, such as our drug candidates, if approved. In particular, a drug may not be
promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the drug&#8217;s approved labeling.
If we receive marketing approval for our drug candidates for our proposed indications, physicians may nevertheless use our drugs for
their patients in a manner that is inconsistent with the approved label, if the physicians personally believe in their professional medical
judgment it could be used in such manner. However, if we are found to have promoted our drugs for any off-label uses, the federal government
could levy civil, criminal and/or administrative penalties, and seek fines against us. The FDA or other regulatory authorities could
also request that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us under
which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of our drug candidates,
if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not experience a faster development or regulatory review or approval process with potential Fast Track designation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a drug is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet
medical need for this condition, a drug sponsor may apply for FDA Fast Track designation. If we seek Fast Track designation for a drug
candidate, we may not receive it from the FDA. However, even if we receive Fast Track designation, Fast Track designation does not ensure
that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster
development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition,
the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development
program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Commercialization of Our Drug Candidates </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we are successful in completing all preclinical studies and clinical trials, we may not be successful in commercializing one or more
of our drug candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and
uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our drug candidates. If we are not
able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our drug candidates,
and our ability to generate revenue will be materially impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug candidates and the activities associated with their development and commercialization, including their design, testing, manufacture,
safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import are subject
to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar regulatory authorities
outside of the United States. Failure to obtain marketing approval for a drug candidate will prevent us from commercializing the drug
candidate. We have not submitted an application for or received marketing approval for any of our drug candidates in the United States
or in any other jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party
clinical research organizations or other third-party consultants or vendors to assist us in this process. Securing marketing approval
requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic
indication to establish the drug candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information
about the drug manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our drug candidates
may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other
characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. New cancer drugs frequently are
indicated only for patient populations that have not responded to an existing therapy or have relapsed. If any of our drug candidates
receives marketing approval, the accompanying label may limit the approved use of our drug in this way, which could limit sales of the
drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years, if approval is obtained
at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the drug candidates
involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or
regulations, or changes in regulatory review for each submitted drug application, may cause delays in the approval or rejection of an
application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may
decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying
interpretations of the data obtained from preclinical studies and clinical trials could delay, limit or prevent marketing approval of
a drug candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments
that render the approved drug not commercially viable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our drugs do not gain market acceptance, our business will suffer because we might not be able to fund future operations. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of factors may affect the market acceptance of our drugs or any other products we develop or acquire, including, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the price of our drugs
    relative to other products for the same or similar treatments;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the perception by patients,
    physicians and other members of the health care community of the effectiveness and safety of our drugs for their indicated applications
    and treatments;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to fund our
    sales and marketing efforts; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our
    sales and marketing efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our drugs do not gain market acceptance, we may not be able to fund future operations, including developing, testing and obtaining regulatory
approval for new drug candidates and expanding our sales and marketing efforts for our approved drugs, which would cause our business
to suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may rely on orphan drug status to commercialize some of our drug candidates, and even if orphan drug status is approved, such approval
may not confer marketing exclusivity or other commercial advantages or expected commercial benefits. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may rely on orphan drug exclusivity for our drug candidates. In the United States, orphan drug designation entitles a party to financial
incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if
a drug that has orphan drug designation subsequently receives the first FDA marketing approval for the disease for which it has such
designation, the drug is entitled to orphan drug exclusivity. Orphan drug exclusivity in the United States provides that the FDA may
not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, and except
in limited circumstances the applicable exclusivity period is ten years in Europe. The European exclusivity period can be reduced to
six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market
exclusivity is no longer justified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we, or any future collaborators, obtain orphan drug designation for a drug candidate, we, or they, may not be able to obtain or maintain
orphan drug exclusivity for that drug candidate. We may not be the first to obtain marketing approval of any drug candidate for which
we have obtained orphan drug designation for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical
products, and it is possible that another company also holding orphan drug designation for the same drug candidate will receive marketing
approval for the same indication before we do. If that were to happen, our applications for that indication may not be approved until
the competing company&#8217;s period of exclusivity expires. In addition, exclusive marketing rights in the United States may be limited
if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the
request for designation was materially defective or if we are unable to assure sufficient quantities of the drug to meet the needs of
patients with the rare disease or condition. Further, even if we, or any future collaborators, obtain orphan drug exclusivity for a drug,
that exclusivity may not effectively protect the drug from competition because different drugs with different active moieties may be
approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same
active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer,
more effective or makes a major contribution to patient care or the manufacturer of the drug with orphan exclusivity is unable to maintain
sufficient drug quantity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives
the drug any advantage in the regulatory review or approval process, nor does it prevent competitors from obtaining approval of the same
drug candidate as ours for indications other than those in which we have been granted orphan drug designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 3, 2017, the U.S. Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&#8217;s
preexisting regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is
otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The legislation
reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period
regardless of a showing of clinical superiority. Congress or the FDA may further reevaluate the Orphan Drug Act and its regulations and
policies. We do not know if, when or how congress or the FDA may change the orphan drug regulations and policies in the future, and it
is uncertain how any changes might affect our business. Depending on what changes congress or the FDA may make to orphan drug regulations
and policies, our business could be adversely impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
Breakthrough Therapy designation by the FDA for our drug candidates may not lead to a faster development or regulatory review or approval
process, and it does not increase the likelihood that our drug candidates will receive marketing approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek a breakthrough therapy designation for some of our drug candidates. A breakthrough therapy is defined as a drug that is intended,
alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical
evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been designated
as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient
path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough
therapies by the FDA are also eligible for accelerated approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation
as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our drug candidates meets the criteria
for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive
Breakthrough Therapy designation, the receipt of such designation for a drug candidate may not result in a faster development process,
review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval
by the FDA. In addition, even if one or more of our drug candidates qualify as breakthrough therapies, the FDA may later decide that
the drugs no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
Fast Track designation by the FDA may not lead to a faster development or regulatory review or approval process.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek Fast Track designation for some of our drug candidates. If a drug is intended for the treatment of a serious or life-threatening
condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA
Fast Track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular drug
candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track
designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA
may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development
program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to obtain marketing approval in foreign jurisdictions would prevent our drug candidates from being marketed abroad.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market and sell our drugs in the European Union and many other foreign jurisdictions, we or our potential third-party collaborators
must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies
among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required
to obtain FDA marketing approval. The regulatory approval process outside of the United States generally includes all of the risks associated
with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the drug be approved for
reimbursement before the drug can be approved for sale in that country. We or our potential third-party collaborators may not obtain
approvals from regulatory authorities outside of the United States on a timely basis, if at all. Approval by the FDA does not ensure
approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside of the United
States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, a failure or delay
in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries. We may not be
able to file for marketing approvals and may not receive necessary approvals to commercialize our drugs in any market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are required by the FDA to obtain approval of a companion diagnostic in connection with approval of a therapeutic drug candidate,
and we do not obtain or face delays in obtaining FDA approval of a diagnostic device, we will not be able to commercialize the drug candidate
and our ability to generate revenue will be materially impaired.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic
drug or indication, the FDA generally will not approve the therapeutic drug or new therapeutic drug indication if the companion diagnostic
is not also approved or cleared for that indication. Under the Federal Food, Drug, and Cosmetic Act, or FDCA, companion diagnostics are
regulated as medical devices, and the FDA has generally required companion diagnostics intended to select the patients who will respond
to cancer treatment to obtain Premarket Approval, or a PMA, for the diagnostic. The PMA process, including the gathering of clinical
and preclinical data and the submission to and review by the FDA, involves a rigorous premarket review during which the applicant must
prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device
and its components regarding, among other things, device design, manufacturing and labeling. A PMA is not guaranteed and may take considerable
time, and the FDA may ultimately respond to a PMA submission with a &#8220;not approvable&#8221; determination based on deficiencies
in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that
can substantially delay approval. As a result, if we are required by the FDA to obtain approval of a companion diagnostic for a therapeutic
drug candidate, and we do not obtain or there are delays in obtaining FDA approval of a diagnostic device, we may not be able to commercialize
the drug candidate on a timely basis or at all and our ability to generate revenue will be materially impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
it is possible that one or more of our drug candidates may require a companion diagnostic to select the patients who will likely respond
to a cancer therapy involving one of our drug candidates that would require a PMA for the companion diagnostic as a condition to obtaining
marketing approval from the FDA, it is too early in our drug candidates development to identify which drug candidate, if any, would require
a PMA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
drug candidate that we obtain marketing approval for could be subject to post-marketing restrictions or withdrawal from the market and
we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems
with our drugs, when and if any of them are approved. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
drug candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling,
advertising and promotional activities for such drug, will be subject to continual requirements of and review by the FDA and other regulatory
authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing
requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records
and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a drug
candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions
of approval, including the requirement to implement a REMS. New cancer drugs frequently are indicated only for patient populations that
have not responded to an existing therapy or have relapsed. If any of our drug candidates receives marketing approval, the accompanying
label may limit the approved use of our drug in this way, which could limit sales of the drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy
of the drug, including the adoption and implementation of REMS. The FDA and other agencies, including the Department of Justice, or the
DOJ, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure they are marketed and distributed only
for the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions
on manufacturers&#8217; communications regarding off-label use, and if we do not market our drugs for their approved indications, we
may be subject to enforcement action for off-label marketing. Violations of the FDCA and other statutes, including the False Claims Act,
relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations
of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, later discovery of previously unknown adverse events or other problems with our drugs, manufacturers or manufacturing processes,
or failure to comply with regulatory requirements, may have various consequences, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on such drugs,
    manufacturers or manufacturing processes;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions and warnings
    on the labeling or marketing of a drug;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on drug distribution
    or use;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements to conduct
    post-marketing studies or clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning letters or untitled
    letters;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of the drugs
    from the market;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to approve pending
    applications or supplements to approved applications that we submit;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall of drugs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, restitution or disgorgement
    of profits or revenues;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or withdrawal
    of marketing approvals;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage to relationships
    with any potential collaborators;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable press coverage
    and damage to our reputation;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to permit the import
    or export of our drugs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">drug seizure;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition
    of civil or criminal penalties; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation involving patients
    using our drugs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-compliance
with European Union requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of
drugs for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European
Union&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, manufacturers of approved drugs and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements,
including ensuring that quality control and manufacturing procedures conform to cGMPs applicable to drug manufacturers or quality assurance
standards applicable to medical device manufacturers, which include requirements relating to quality control and quality assurance as
well as the corresponding maintenance of records and documentation and reporting requirements. We, any contract manufacturers we may
engage in the future, our future collaborators and their contract manufacturers will also be subject to other regulatory requirements,
including submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements
regarding the distribution of samples to clinicians, recordkeeping, and costly post-marketing studies or clinical trials and surveillance
to monitor the safety or efficacy of the drug such as the requirement to implement a REMS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
operate in a highly competitive and rapidly changing industry</i>. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biotechnological
and pharmaceutical drug development is highly competitive and subject to rapid and significant technological advancements. Our success
is highly dependent upon our ability to in-license, acquire, develop and obtain regulatory approval for new and innovative drugs on a
cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety
of businesses, including large, fully integrated, well-established pharmaceutical companies who already possess a large share of the
market, specialty pharmaceutical and biopharmaceutical companies, academic institutions, government agencies and other private and public
research institutions in the United States, the European Union and other jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources
and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals
and marketing approved drugs than we do. These third parties compete with us in recruiting and retaining qualified scientific and management
personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary
to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even
more resources being concentrated among a small number of our competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competition
may further increase as a result of advances in the commercial applicability of technologies and greater availability of capital for
investment in these industries. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, drugs that
are more effective or less costly than any drug candidate that we may develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Established
pharmaceutical and biotechnology companies may invest heavily to accelerate discovery and development of novel compounds or to in-license
novel compounds that could make our drug candidates less competitive. In addition, any new drug that competes with an approved drug must
demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be
commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving
FDA approval for or commercializing drugs before we do, which would have an adverse impact on our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability of our competitors&#8217; drugs could limit the demand and the price we are able to charge for any drug candidate we commercialize,
if any. The inability to compete with existing or subsequently introduced drugs would harm our business, financial condition and results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to develop satisfactory sales and marketing capabilities, we may not succeed in commercializing LP-300, LP-184, LP-284,
LP-100 or any other drug candidate</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no experience in marketing and selling drug products. We have not entered into arrangements for the sale and marketing of LP-300,
LP-184, LP-284, LP-100 or any other drug candidate. Typically, pharmaceutical companies would employ groups of sales representatives
and associated sales and marketing staff numbering in the hundreds to thousands of individuals to call on this large number of physicians
and hospitals. We may seek to collaborate with a third party to market our drugs or may seek to market and sell our drugs by ourselves.
If we seek to collaborate with a third party, we cannot be sure that a collaborative agreement can be reached on terms acceptable to
us. If we seek to market and sell our drugs directly, we will need to hire additional personnel skilled in marketing and sales. We cannot
be sure that we will be able to acquire, or establish third party relationships to provide, any or all of these marketing and sales capabilities.
The establishment of a direct sales force or a contract sales force or a combination direct and contract sales force to market our drugs
will be expensive and time-consuming and could delay any drug launch. Further, we can give no assurances that we may be able to maintain
a direct and/or contract sales force for any period of time or that our sales efforts will be sufficient to generate or to grow our revenues
or that our sales efforts will ever lead to profits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain regulatory approvals to commercialize LP-300, LP-184, LP-284</i></b>, <b><i>LP-100 or our other drug candidates, our drug
candidates may not be accepted by physicians or the medical community in general. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that LP-300, LP-184, LP-284, LP-100 and our other drug candidates or any other drug candidate successfully developed
by us, independently or with partners, will be accepted by physicians, hospitals and other health care facilities. LP-300, LP-184, LP-284,
LP-100 and any future drug candidates we develop will compete with a number of drugs manufactured and marketed by major pharmaceutical
and biotech companies. The degree of market acceptance of any drugs we develop depends on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our demonstration of the
    clinical efficacy and safety of LP-300, LP-184, LP-284, LP-100 and our other drug candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing of market approval
    and commercial launch of LP-300, LP-184, LP-284, LP-100 and our other drug candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the clinical indication(s)
    for which LP-300, LP-184, LP-284, LP-100 and our other drug candidates are approved;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">drug label and package
    insert requirements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advantages and disadvantages
    of our drug candidates compared to existing</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued interest in and
    growth of the market for anticancer or anti-agitation drugs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strength of sales, marketing,
    and distribution support;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">drug pricing in absolute
    terms and relative to alternative treatments;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future changes in health
    care laws, regulations, and medical policies; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability of reimbursement
    codes and coverage in select jurisdictions, and future changes to reimbursement policies of government and third-party payors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
uncertainty exists as to the coverage and reimbursement status of any drug candidate for which we obtain regulatory approval. In the
United States and markets in other countries, sales of any drugs for which we receive regulatory approval for commercial sale will depend
in part on the availability of reimbursement from third-party payors. Third-party payors include government health administrative authorities,
managed care providers, private health insurers and other organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
reform measures could hinder or prevent our drug candidates&#8217; commercial success. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. government and other governments have shown significant interest in pursuing healthcare reform. Any government-adopted reform measures
could adversely impact the pricing of healthcare drugs and services in the United States or internationally and the amount of reimbursement
available from governmental agencies or other third-party payors. The continuing efforts of the U.S. and foreign governments, insurance
companies, managed care organizations and other payors of health care services to contain or reduce health care costs may adversely affect
our ability to set prices for our drugs which we believe are fair, and our ability to generate revenues and achieve and maintain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, some states have implemented, and other states are considering, pharmaceutical price controls or patient access constraints
under their Medicaid program. There have also been recent state legislative efforts that have generally focused on increasing transparency
around drug costs or limiting drug prices. In addition, the growth of large managed care organizations and prescription benefit managers,
as well as the prevalence of generic substitution, has hindered price increases for prescription drugs. Continued intense public scrutiny
of the price of drugs, together with government and payor dynamics, may limit the ability of producers and marketers to set or adjust
the price of products based on their value. Outside the United States, numerous major markets, including the EU, Japan and China, have
pervasive government involvement in funding healthcare, and, in that regard, fix the pricing and reimbursement of pharmaceutical products.
Consequently, our products generating will be subject to increasing government decision-making and budgetary actions. There can be no
assurance that new or proposed products will be considered cost-effective or that adequate third-party reimbursement will be available
to enable the producer or marketer of such product to maintain price levels sufficient to realize an appropriate return.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to healthcare
availability, methods of delivery or payment for products and services, or sales, marketing or pricing, may limit our potential revenue,
and we may need to revise our research and development programs. The pricing and reimbursement environment may change in the future and
become more challenging due to several reasons, including policies advanced by the current executive administration in the United States,
new healthcare legislation or fiscal challenges faced by government health administration authorities. Specifically, in both the United
States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system
in ways that could affect our ability to sell our drugs profitably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA
has substantially changed the way healthcare is financed by both government health plans and private insurers, and significantly impacts
the pharmaceutical industry. The PPACA contains a number of provisions that are expected to impact our business and operations in ways
that may negatively affect our potential revenues in the future. For example, the PPACA imposes a non-deductible excise tax on pharmaceutical
manufacturers or importers that sell branded prescription drugs to government programs which we believe will increase the cost of our
drugs. In addition, as part of the PPACA&#8217;s provisions closing a funding gap that currently exists in the Medicare Part D prescription
drug program, we will be required to provide a discount on branded prescription drugs equal to 50% of the government-negotiated price,
for drugs provided to certain beneficiaries who fall within the donut hole. Similarly, PPACA increases the level of Medicaid rebates
payable by manufacturers of brand-name drugs from 15.1% to 23.1% and requires collection of rebates for drugs paid by Medicaid managed
care organizations. The PPACA also includes significant changes to the 340B drug discount program including expansion of the list of
eligible covered entities that may purchase drugs under the program. At the same time, the expansion in eligibility for health insurance
benefits created under PPACA is expected to increase the number of patients with insurance coverage who may receive our drugs. While
it is too early to predict all the specific effects the PPACA or any future healthcare reform legislation will have on our business,
they could have a material adverse effect on our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Congress
periodically adopts legislation like the PPACA and the Medicare Prescription Drug, Improvement and Modernization Act of 2003, that modifies
Medicare reimbursement and coverage policies pertaining to prescription drugs. Implementation of these laws is subject to ongoing revision
through regulatory and sub regulatory policies. Congress also may consider additional changes to Medicare policies, potentially including
Medicare prescription drug policies, as part of ongoing budget negotiations. While the scope of any such legislation is uncertain at
this time, there can be no assurances that future legislation or regulations will not decrease the coverage and price that we may receive
for our proposed drugs. Other third-party payors are increasingly challenging the prices charged for medical products and services. It
will be time consuming and expensive for us to go through the process of seeking coverage and reimbursement from Medicare and private
payors. Our proposed drugs may not be considered cost-effective, and coverage and reimbursement may not be available or sufficient to
allow us to sell our proposed drugs on a profitable basis. Further federal and state proposals and health care reforms are likely which
could limit the prices that can be charged for the drug candidates that we develop and may further limit our commercial opportunities.
Our results of operations could be materially adversely affected by proposed healthcare reforms, by the Medicare prescription drug coverage
legislation, by the possible effect of such current or future legislation on amounts that private insurers will pay and by other health
care reforms that may be enacted or adopted in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2007, the Food and Drug Administration Amendments Act of 2007 was enacted, giving the FDA enhanced post-marketing authority,
including the authority to require post-marketing studies and clinical trials, labeling changes based on new safety information, and
compliance with risk evaluations and mitigation strategies approved by the FDA. The FDA&#8217;s exercise of this authority could result
in delays or increased costs during drug development, clinical trials and regulatory review, increased costs to assure compliance with
post-approval regulatory requirements, and potential restrictions on the sale and/or distribution of approved drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse,
false claims, transparency, health information privacy and security, and other healthcare laws and regulations, which, in the event of
a violation, could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and
diminished profits and future earnings.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any drug candidates for
which we obtain marketing approval. Our future arrangements with healthcare providers, physicians and third-party payors may expose us
to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements
and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. In addition, we may
be subject to transparency laws and patient privacy regulation by U.S. federal and state governments and by governments in foreign jurisdictions
in which we conduct our business. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback
    Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration,
    directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the
    purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare
    program such as Medicare and Medicaid;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal False Claims
    Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities
    for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal healthcare
    program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation
    to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Health Insurance
    Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any
    healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the
    Health Information Technology for Economic and Clinical Health Act of 2009, and their respective implementing regulations, also imposes
    obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually
    identifiable health information;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Physician Payments
    Sunshine Act requires applicable manufacturers of covered drugs to report payments and other transfers of value to physicians and
    teaching hospitals; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous state and foreign
    laws and regulations, such as state anti-kickback and false claims laws and transparency statutes, may apply to sales or marketing
    arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private
    insurers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the
relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to
payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Additionally, some state
and local laws require the registration of pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern
the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often
are not preempted by HIPAA, thus complicating compliance efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current
or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant
civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of drugs from government funded healthcare programs,
such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers
or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal,
civil or administrative sanctions, including exclusions from participation in government funded healthcare programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug
candidates and affect the prices we may obtain for any drugs that are approved in the United States or foreign jurisdictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell any drug candidates for which we obtain marketing approval. The pharmaceutical industry
has been a particular focus of these efforts and has been significantly affected by legislative initiatives. Current laws, as well as
other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward
pressure on the price that we receive for any FDA approved drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers
and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new
reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this legislation provided authority
for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this
legislation could decrease the coverage and price that we receive for any approved drugs. While the MMA applies only to drug benefits
for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement
rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private
payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Reconciliation Act of 2010, or collectively the ACA. Among the provisions of the ACA of potential importance to our business, including,
without limitation, our ability to commercialize and the prices we may obtain for any of our drug candidates that are approved for sale,
are the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an annual, non-deductible
    fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an increase in the statutory
    minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion of healthcare
    fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers
    and enhanced penalties for noncompliance;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a new Medicare Part D coverage
    gap discount program, in which manufacturers must agree to offer 50% (and 70% starting January 1, 2019) point-of-sale discounts off
    negotiated prices;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">extension of manufacturers&#8217;
    Medicaid rebate liability;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion of eligibility
    criteria for Medicaid programs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion of the entities
    eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new requirements to report
    certain financial arrangements with physicians and teaching hospitals;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a new requirement to annually
    report drug samples that manufacturers and distributors provide to physicians; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a new Patient-Centered
    Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with
    funding for such research.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes include the Budget Control
Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of up to 2% per fiscal year that
started in 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through 2027 unless additional congressional
action is taken, and the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types
of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five
years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we
may obtain for any of our drug candidates for which we may obtain regulatory approval or the frequency with which any such drug candidate
is prescribed or used. Further, there have been several recent U.S. congressional inquiries and proposed state and federal legislation
designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient
programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional
reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward
pressure on the price that we receive for any approved drug and/or the level of reimbursement physicians receive for administering any
approved drug we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency
with which our drugs are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result
in a similar reduction in payments from private payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
costs of prescription pharmaceuticals have also been the subject of considerable discussion in the United States, and members of Congress
have stated that they will address such costs through new legislative and administrative measures. To date, there have been several recent
U.S. congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency
to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare
and reform government program reimbursement methodologies for drug products. While any proposed measures will require authorization through
additional legislation to become effective, Congress has indicated that it will continue to seek new legislative and/or administrative
measures to control drug costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed
to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative
and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical
products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations
will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. Increased scrutiny
by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us
to more stringent product labeling and post-marketing testing and other requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Governments
outside of the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some countries, particularly the countries of the European Union and Canada, the pricing of prescription pharmaceuticals is subject to
governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt
of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical
trial that compares the cost-effectiveness of our drug candidate to other available therapies. In the European Union, a member state
may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability
of the company placing the medicinal product on the market. If reimbursement of our drugs is unavailable or limited in scope or amount,
or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially. Historically, products launched in
the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we or any third-party manufacturers or contractors we engage now or in the future fail to comply with environmental, health and safety
laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and third-party manufacturers we engage now are, and any third-party manufacturers we may engage in the future will be, subject to numerous
environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage,
treatment and disposal of hazardous materials and wastes. Our operations, including work conducted through third-party manufacturers
or contractors, involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also
produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot
eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of
hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Liability under
certain environmental laws governing the release and cleanup of hazardous materials is joint and several and could be imposed without
regard to fault. We also could incur significant costs associated with civil or criminal fines and penalties or become subject to injunctions
limiting or prohibiting our activities for failure to comply with such laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain general liability insurance as well as workers&#8217; compensation insurance to cover us for costs and expenses we may incur
due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against
potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us
in connection with our, or our contractors, storage or disposal of biological, hazardous or radioactive materials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these
laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
with respect to the operations of our current and any future third-party contract manufacturers or other contractors, it is possible
that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose
of wastes associated with our drugs, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption
in the manufacture and supply of our drug candidates or drugs. In addition, our supply chain may be adversely impacted if any of our
third-party contract manufacturers become subject to injunctions or other sanctions as a result of their non-compliance with environmental,
health and safety laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may experience challenges with the acquisition, development, enhancement or deployment of technology necessary for our </i>RADR<sup>&#174;
</sup><i>platform. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in businesses that require sophisticated computer systems and software for data collection, data processing, cloud-based platforms,
analytics, statistical projections and forecasting, mobile computing, social media analytics and other applications and technologies.
We seek, in part, to address our technology risks by increasing our reliance on the use of innovations by cross-industry technology leaders
and adapting these for our applicable needs and applications. Some of the technologies supporting our industry are changing rapidly and
we must continue to adapt to these changes in a timely and effective manner at an acceptable cost. We also must continue to obtain and
utilize data to in forms that are easy to use while simultaneously providing clear answers to complex questions. There can be no guarantee
that we will be able to develop, acquire or integrate new technologies, that these new technologies will meet our needs or achieve our
expected goals, or that we will be able to do so as quickly or cost-effectively as our competitors. Significant technological change
could render our RADR<sup>&#174;</sup> platform obsolete. Our continued success will depend on our ability to adapt to changing technologies,
manage and process ever-increasing amounts of data and information and improve the performance, features and reliability of our platform
and capabilities in response to changing internal and industry demands. We may experience difficulties that could delay or prevent the
successful design, development, testing, and introduction of advanced versions of our RADR<sup>&#174; </sup>platform, limiting our ability
to identify new drug candidates. New services, or enhancements to existing services using our RADR<sup>&#174;</sup> platform, may not
adequately meet our requirements. Any of these failures could have a material adverse effect on our operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Reliance on Third Parties </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully perform their
contractual legal and regulatory duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize
our drug candidates and our business could be substantially harmed. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon and plan to continue to rely upon third-party medical institutions, clinical investigators, contract laboratories and
other third party CROs to monitor and manage data for our ongoing preclinical and clinical programs. We also rely on these parties for
execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are
responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific
standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply
with cGCPs, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European
Economic Area, or EEA, and comparable foreign regulatory authorities, for all of our drugs in clinical development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities enforce these cGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any
of our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the
FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing
applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that
any of our clinical trials comply with cGCP regulations. In addition, our clinical trials must be conducted with product produced under
current good manufacturing practices, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical
trials, which would delay the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or
to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under
our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical
and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if
they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to
our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and
we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our results of operations
and the commercial prospects for our drug candidates would be harmed, our costs could increase and our ability to generate revenues could
be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for
whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If the
third parties conducting our GLP preclinical studies or our clinical trials do not perform their contractual duties or obligations, experience
work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy
of the clinical data they obtain is compromised due to their failure to adhere to our clinical trial protocols or to GCPs, or for any
other reason, we may need to enter into new arrangements with alternative third parties. Switching or adding additional CROs involves
additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work.
As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully
manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future
or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are substantially dependent on third parties for the manufacture of our clinical supplies of our drug candidates, and we intend to rely
on third parties to produce commercial supplies of any approved drug candidate. Therefore, our development of our drugs could be stopped
or delayed, and our commercialization of any future drug could be stopped or delayed or made less profitable if third party manufacturers
fail to obtain approval of the FDA or comparable regulatory authorities or fail to provide us with drug products in sufficient quantities
or at acceptable prices. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacture of pharmaceutical products is complex and requires significant expertise, capital investment, process controls and know-how.
Common difficulties in pharmaceutical manufacturing may include: sourcing and producing raw materials, transferring technology from chemistry
and development activities to production activities, validating initial production designs, scaling manufacturing techniques, improving
costs and yields, establishing and maintaining quality controls and stability requirements, eliminating contaminations and operator errors,
and maintaining compliance with regulatory requirements. We do not currently have nor do we plan to acquire the infrastructure or capability
internally in accordance with cGMP prescribed by the FDA or to produce an adequate supply of compounds to meet future requirements for
clinical trials and commercialization of our drugs. Drug manufacturing facilities are subject to inspection before the FDA will issue
an approval to market a new drug product, and all of the manufacturers that we intend to use must adhere to the cGMP regulations prescribed
by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect therefore to rely on third-party manufacturers for clinical supplies of our drug candidates that we may develop. These third-party
manufacturers will be required to comply with current good manufacturing practices, or GMPs, and other applicable laws and regulations.
We will have no control over the ability of these third parties to comply with these requirements, or to maintain adequate quality control,
quality assurance and qualified personnel. If the FDA or any other applicable regulatory authorities do not approve the facilities of
these third parties for the manufacture of our other drug candidates or any drugs that we may successfully develop, or if it withdraws
any such approval, or if our suppliers or contract manufacturers decide they no longer want to supply or manufacture for us, we may need
to find alternative manufacturing facilities, in which case we might not be able to identify manufacturers for clinical or commercial
supply on acceptable terms, or at all. Any of these factors would significantly impact our ability to develop, obtain regulatory approval
for or market our drug candidates and adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and/or our third-party manufacturers may be adversely affected by developments outside of our control, and these developments may delay
or prevent further manufacturing of our drugs. Adverse developments may include labor disputes, resource constraints, shipment delays,
inventory shortages, lot failures, impacts related to the COVID-19 pandemic or another epidemic or infectious disease outbreak, unexpected
sources of contamination, lawsuits related to our manufacturing techniques, equipment used during manufacturing, or composition of matter,
unstable political environments, acts of terrorism, war, natural disasters, and other natural and man-made disasters. If we or our third-party
manufacturers were to encounter any of the above difficulties, or otherwise fail to comply with contractual obligations, our ability
to provide any drug for clinical trial or commercial purposes would be jeopardized. This may increase the costs associated with completing
our clinical trials and commercial production. Further, production disruptions may cause us to terminate ongoing clinical trials and/or
commence new clinical trials at additional expense. We may also have to take inventory write-offs and incur other charges and expenses
for drugs that fail to meet specifications or pass safety inspections. If production difficulties cannot be solved with acceptable costs,
expenses, and timeframes, we may be forced to abandon our clinical development and commercialization plans, which could have a material
adverse effect on our business, prospects, financial condition, and the value of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We,
or third-party manufacturers on whom we rely, may be unable to successfully scale-up manufacturing of our drug candidates in sufficient
quality and quantity, which would delay or prevent us from developing our drug candidates and commercializing approved drugs, if any.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to conduct clinical trials of our drug candidates and commercialize any approved drug candidates, we, or our manufacturers, will
need to manufacture them in large quantities. We, or our manufacturers, may be unable to successfully increase the manufacturing capacity
for any of our drug candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up
activities. If we, or any of our manufacturers, are unable to successfully scale up the manufacture of our drug candidates in sufficient
quality and quantity, the development, testing, and clinical trials of that drug candidate may be delayed or infeasible, and regulatory
approval or commercial launch of any resulting drug may be delayed or not obtained, which could significantly harm our business. If we
are unable to obtain or maintain third-party manufacturing for commercial supply of our drug candidates, or to do so on commercially
reasonable terms, we may not be able to develop and commercialize our drug candidates successfully.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to find third party collaborators to assist or share in the costs of drug development could materially harm our business, financial
condition and results of operations. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy for the development and commercialization of our proprietary drug candidates may include the formation of collaborative arrangements
with third parties. Existing and future collaborators have significant discretion in determining the efforts and resources they apply
and may not perform their obligations as expected. Potential third-party collaborators include biopharmaceutical, pharmaceutical and
biotechnology companies, academic institutions and other entities. Third-party collaborators may assist us in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">funding research, preclinical
    development, clinical trials and manufacturing;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking and obtaining regulatory
    approvals; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully commercializing
    any future drug candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to establish further collaboration agreements, we may be required to undertake drug development and commercialization
at our own expense. Such an undertaking may limit the number of drug candidates that we will be able to develop, significantly increase
our capital requirements and place additional strain on our internal resources. Our failure to enter into additional collaborations could
materially harm our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our dependence on licensing, collaboration and other agreements with third parties may subject us to a number of risks. These
agreements may not be on terms that prove favorable to us and may require us to relinquish certain rights in our drug candidates. To
the extent we agree to work exclusively with one collaborator in a given area, our opportunities to collaborate with other entities could
be curtailed. Lengthy negotiations with potential new collaborators may lead to delays in the research, development or commercialization
of drug candidates. The decision by our collaborators to pursue alternative technologies or the failure of our collaborators to develop
or commercialize successfully any drug candidate to which they have obtained rights from us could materially harm our business, financial
condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
balances held at banking institutions are in excess of FDIC coverage.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain significant
amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits. Interest bearing
and non-interest bearing accounts we hold at banking institutions are guaranteed by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $250,000. Substantially all of our cash balances held at banking institutions are in excess of FDIC coverage. We consider this
to be a normal business risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business and Industry </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may face future business disruption and related risks resulting from the outbreak and continuation of the novel coronavirus 2019 (COVID-19)
or from another pandemic, epidemic or outbreak of an infectious disease, any of which could have a material adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of our drug candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak
of an infectious disease like the outbreak of COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Measures
adopted to slow the spread of COVID-19 adversely affected workforces, customers, supply chains, consumer sentiment, economies, and
financial markets, and led to an economic downturn across many global economies. As of the date of this report, we believe we have effectively
managed the impact of the COVID-19 pandemic on our operations. The timing of non-clinical research studies for our drug candidates by
collaborators and service providers slowed during 2020 in connection with the pandemic. The timing of manufacturing for our LP-300 and
LP-184 candidates was impacted by supply chain delivery and COVID-related staffing issues, which extended the time to launch our planned
Phase II clinical trial for LP-300 and extended the time to commence IND enabling studies and commence Phase I clinical testing for LP-184.
COVID-related staffing shortages have also impacted large numbers of clinical trial sites in the U.S. In addition, Allarity Therapeutics
informed us that enrollment in the Phase II clinical trial for LP-100 slowed during the pandemic. While we believe we have been able
to manage the disruption caused by the COVID-19 pandemic to date, there can be no assurance that our operations, including the development
of our drug candidates, will not be disrupted and materially adversely affected in the future by the COVID-19 pandemic, or an epidemic
or outbreak of an infectious disease like the outbreak of COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continued impact of COVID-19 or the impact of another epidemic or infectious disease outbreak may result in the future inability of
our suppliers to deliver components or raw materials on a timely basis or materially and adversely affect our collaborators and
out-license partners&#8217; ability to perform and advance preclinical studies and clinical trials. In addition, clinical sites and
hospitals have recently had staffing challenges and they may continue to have reduced staffing and reduce or postpone certain
treatments. Such events may result in a period of business and manufacturing disruption, the slowing of the enrollment for and
conduct of clinical trials, and in reduced operations, any of which could materially affect our business, financial condition and
results of operations. The extent to which COVID-19 or another epidemic or outbreak of an infectious disease impacts our business in
the future will depend on future developments, which are highly uncertain and cannot be predicted, including new information which
may emerge concerning new mutations or variants of the coronavirus, the severity of the coronavirus and the actions to contain the
coronavirus or treat its impact, among others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to increase the size of our organization and the scope of our outside vendor relationships, and we may experience difficulties
in managing growth. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we employed a total of 22 full-time and one part-time employees. Our current internal departments include
research and development, finance and administration. We intend to expand our management team to include an operation ramp up of additional
scientific development and technical staff required to achieve our business objectives. We also intend to expand our managerial, operational,
technical and scientific, financial and other resources in order to manage our operations and clinical trials, continue our research
and development activities, and advance our drug candidates towards commercializations. Our management and scientific personnel, systems
and facilities currently in place may not be adequate to support our future growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
need to effectively manage our operations, growth and various projects requires that we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage our clinical trials
    effectively, including our existing and planned clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage our internal development
    efforts effectively while carrying out our contractual obligations to licensors, contractors and other third parties;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to improve our
    operational, financial and management controls and reporting systems and procedures; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract and retain sufficient
    numbers of talented employees.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are utilizing and expect in the future to utilize the services of vendors and research partners or collaborators to perform tasks including
preclinical studies and clinical trial management, statistics and analysis, regulatory affairs, medical advisory, market research, formulation
development, chemistry, manufacturing and control activities, other drug development functions, legal, auditing, financial advisory,
and investor relations. Our growth strategy may also entail expanding our group of contractors or consultants to implement these and
other tasks going forward. Because we rely on numerous consultants to outsource many key functions of our business, we will need to be
able to effectively manage these consultants to ensure that they successfully carry out their contractual obligations and meet expected
deadlines. However, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided
by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain
regulatory approval for our drug candidate or otherwise advance our business. There can be no assurance that we will be able to manage
our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. If
we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors,
we may be unable to successfully implement the tasks necessary to further develop and commercialize our drug candidates and, accordingly,
may not achieve our research, development and commercialization goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract
and retain highly skilled employees could adversely affect our business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends largely upon the continued services of Panna Sharma, our Chief Executive Officer, President and Director. We do not maintain
&#8220;key person&#8221; insurance for Mr. Sharma or any of our other key employees. We also rely on employees in the areas of research
and development, artificial intelligence and machine learning services and general and administrative functions, some of which are in
the US on H-1B work visas. From time to time, there may be changes in our executive management and employees resulting from the hiring
or departure of executives or other key employees or the expiration or termination of H-1B work visas, which could disrupt our business.
The replacement of one or more of our executive officers or other key employees would likely involve significant time and costs and may
significantly delay or prevent the achievement of our business objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
continue to execute our growth strategy, we also must attract and retain highly skilled personnel. We might not be successful in maintaining
our unique culture and continuing to attract and retain qualified personnel. We have from time to time in the past experienced, and we
expect to continue to experience in the future, difficulty in hiring and retaining highly skilled personnel with appropriate qualifications.
The pool of qualified personnel with experience in artificial intelligence, machine learning, and genomics, or experience working with
the pharma market is limited overall. In addition, many of the companies with which we compete for experienced personnel have greater
resources than we have.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in making employment decisions, particularly in the biotechnology and pharmaceutical industries, job candidates often consider
the value of the stock options or other equity instruments they are to receive in connection with their employment. Volatility in the
price of our stock might, therefore, adversely affect our ability to attract or retain highly skilled personnel. Furthermore, the requirement
to expense stock options and other equity instruments might discourage us from granting the size or type of stock option or equity awards
that job candidates require to join our company. If we fail to attract new personnel or fail to retain and motivate our current personnel,
our business and future growth prospects could be severely harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and
insider trading. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
any regulations applicable to us, to provide accurate information to regulatory authorities, to comply with manufacturing standards we
have established, to comply with federal and state healthcare fraud and abuse laws and regulations, or to report financial information
or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare
industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive
practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission,
customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained
in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code
of Business Conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and
prevent this activity may not be effective in controlling unknown or unmanaged risk. If our employees engage in any such misconduct,
we could face criminal penalties, fines, revocation of regulatory approvals and harm to our reputation, any of which could form a material
adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
interruptions could adversely affect future operations, revenues, and financial conditions, and may increase our costs and expenses.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations, and those of our directors, advisors, contractors, consultants, CROs, and collaborators, could be adversely affected by earthquakes,
floods, hurricanes, typhoons, extreme weather conditions, fires, water shortages, power failures, business systems failures, medical
epidemics and other natural and man-made disaster or business interruptions. Our phones, electronic devices and computer systems and
those of our directors, advisors, contractors, consultants, CROs, and collaborators are vulnerable to damages, theft and accidental loss,
negligence, unauthorized access, terrorism, war, electronic and telecommunications failures, and other natural and man-made disasters.
Operating as a company where many employees have and are working remotely, our employees conduct business outside of our headquarters
and leased or owned facilities. These locations may be subject to additional security and other risk factors due to the limited control
of our employees. If such an event as described above were to occur in the future, it may cause interruptions in our operations, delay
research and development programs, clinical trials, regulatory activities, manufacturing and quality assurance activities, sales and
marketing activities, hiring, training of employees and persons within associated third parties, and other business activities. For example,
the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Likewise,
we will rely on third parties to manufacture LP-300, LP-184, LP-284 and LP-100 and conduct clinical trials, and similar events as those
described in the prior paragraph relating to their business systems, equipment and facilities could also have a material adverse effect
on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications,
or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization
of our drug candidates could be delayed or altogether terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disruptions
to our information technology systems, including future cyber-attacks and security breaches, and the costs of maintaining secure and
effective information technology systems could negatively affect our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
efficient operation of our businesses is highly dependent on computer hardware and software systems, including our customized information
technology systems that form our RADR<sup>&#174;</sup> platform. Information systems are vulnerable to security breaches by computer hackers
and cyber terrorists. We rely on industry accepted security measures and technology to securely maintain confidential and proprietary
information maintained on our information systems, and continue to invest in maintaining and upgrading these systems and applications
to ensure risk is controlled. Regardless of our efforts to maintain and upgrade our cyber security systems, there can be no assurance
that we will not suffer an intrusion, that unauthorized parties will not gain access to confidential or personal information, or that
any such incident will be discovered promptly. The techniques used by criminals to obtain unauthorized access to sensitive data change
frequently and often are not recognized until launched against a target, and we may be unable to anticipate these techniques or implement
adequate preventative measures. The failure to promptly detect, determine the extent of and appropriately respond to a significant data
security breach could have a material adverse impact on our business, financial condition and results of operations. In addition, the
unavailability of the information systems or failure of these systems to perform as anticipated for any reason, including a major disaster
or business interruption resulting in an inability to access data stored in these systems or sustain the data center systems necessary
to support functions to meet our needs, and any inability to respond to, or recover from, such an event, could disrupt our business and
could result in decreased performance and increased overhead costs, causing our business and results of operations to suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our operations involve the receipt and storage of sensitive data, including personal information about our employees and proprietary
business information of ours and our vendors. We may also share information with vendors that assist us in conducting our business, as
required by law, with the permission of the individual or as permitted under applicable privacy policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the utilization of information security measures, we cannot be certain that all of our IT systems or the IT systems of our vendors are
or will be able to prevent, contain or detect any future cyber-attacks or security breaches from known malware, malware that may be developed
in the future or otherwise. Cyber-attacks are rapidly evolving and becoming increasingly sophisticated and difficult to detect, and therefore,
we may be unable to anticipate these attacks or implement adequate preventive measures. Additionally, unauthorized parties may attempt
to gain access to our or a vendor&#8217;s systems or facilities through fraud, trickery or other forms of deception involving our employees
or vendors. To the extent that any attack or breach results in the loss, damage or misappropriation of information, we may be adversely
affected by claims from persons participating in our clinical trials, stockholders and others and by costly inquiries or enforcement
actions on the part of regulatory authorities. Our operations could also be significantly disrupted by these claims, as well as by the
need to spend significant time and expense to upgrade, fix or replace our systems. We could also lose credibility with persons participating
in our clinical trials and suffer damage to our reputation and future sales, if any. In addition, the cost of complying with stricter
privacy and information security laws and standards and developing, maintaining and upgrading technology systems to address future advances
in technology, could be significant and we could experience problems and interruptions associated with the implementation of new or upgraded
systems and technology or with maintenance or adequate support of existing systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to successfully acquire, develop and market additional drug candidates could impair our ability to grow. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of our growth strategy, we may evaluate, acquire, license, develop and/or market additional drug candidates and technologies. Our
internal research capabilities are limited and we may be dependent upon pharmaceutical and biopharmaceutical companies, academic scientists
and other researchers to sell or license drug candidates or technologies to us. The success of this strategy depends partly upon our
ability to identify, select and acquire promising pharmaceutical drug candidates and technologies. The process of proposing, negotiating
and implementing a license or acquisition of a drug candidate is lengthy and complex. Other companies, including some with substantially
greater financial, marketing and sales resources, may compete with us for the license or acquisition of drug candidates and technologies.
We have limited resources to identify and execute the acquisition or in-licensing of potential drug candidates and technologies and to
integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities
that are never completed, or we may fail to realize the anticipated benefits of such efforts. Furthermore, we may not be able to acquire
the rights to additional drug candidates on terms that we find acceptable, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, future acquisitions of intellectual property rights may entail numerous operational and financial risks, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure to unknown liabilities;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption of our business
    and diversion of our management&#8217;s and technical personnel&#8217;s time and attention to develop acquired drug candidates or
    technologies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incurrence of substantial
    debt or dilutive issuances of securities to pay for acquisition costs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">higher than expected acquisition
    costs; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased amortization
    expenses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
drug candidate that we acquire may require additional development efforts prior to commercial sale or out-licensing, including extensive
clinical testing and approval by the FDA and applicable foreign regulatory authorities. All drug candidates are prone to risks of failure
typical of pharmaceutical drug development, including the possibility that a drug candidate will not be shown to be sufficiently safe
and effective for approval by regulatory authorities. In addition, we cannot provide assurance that any drugs that we may develop or
approved drugs that we may acquire will be manufactured profitably or achieve market acceptance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
have obtained statistical data, market data and other industry data and forecasts used throughout this report from market research, publicly
available information and industry publications which we believe are reliable but have not been verified by any third party.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report contains estimates, projections and other information concerning our industry, our business and the markets for our drug candidates,
including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry,
market and similar data set forth in this report from our internal estimates and research and from academic and industry research, publications,
surveys and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly refer to the sources
from which this data is derived. Information that is based on estimates, forecasts, projections, market research or similar methodologies
is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are
assumed in this information. While we believe our internal research is reliable, such research has not been verified by any third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not obtain patent term extension for any drug candidates we may develop, our business may be materially harmed. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, depending upon the timing, duration, and specifics of any FDA marketing approval of a drug candidate, the patent term
of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration
as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration
Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent.
The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent term extension cannot
extend the remaining term of a patent beyond a total of 14 years from the date of drug approval, and only one patent applicable to an
approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing
it may be extended. Similar provisions are available in Europe and other non-United States jurisdictions to extend the term of a patent
that covers an approved drug. While, in the future, if and when our drug candidates receive FDA approval, we expect to apply for patent
term extensions on patents directed to those drug candidates, there is no guarantee that the applicable authorities will agree with our
assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted an
extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to
apply within applicable deadlines, failing to apply prior to expiration of the relevant patents, or otherwise failing to satisfy applicable
requirements. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors
may obtain approval of competing drugs following the expiration of our patent rights, and our business, financial condition, results
of operations, and prospects could be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability
to protect our drugs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith
America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and
in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued patents. The Leahy-Smith
Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent
applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity
of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack
the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter parties review, and derivation
proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent
the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled
to the patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory
requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention
regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation
could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our
issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly
uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened
the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and
enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws
and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and
our ability to protect, defend and enforce our patent rights in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
or our licensors may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could
be expensive, time-consuming and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
and other third parties may infringe, misappropriate or otherwise violate our or our licensor&#8217;s issued patents or other intellectual
property. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property related claims,
which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims
against us alleging that we infringe, misappropriate or otherwise violate their intellectual property. In addition, in a patent infringement
proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent
litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity
challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement.
Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant
information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative
bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review,
inter parties review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition
proceedings).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
adverse result in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted
narrowly, and could put any of our owned or in-licensed patent applications at risk of not yielding an issued patent. A court may also
refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents
do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property
litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this
type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products
and have a material adverse impact on our business, financial condition, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third
parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property
rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our drug
candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property
and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical
and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual
property rights with respect to our technology and drug candidates, including interference proceedings, post grant review, inter parties
review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European
Patent Office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 102 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability
of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive
and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting
these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our drug candidates
near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement
claims against us based on existing patents or patents that may be granted in the future, regardless of merit. We may not be aware of
all such intellectual property rights potentially relating to our technology and drug candidates and their uses. Thus, we do not know
with certainty that our technology and drug candidates, or our development and commercialization thereof, do not and will not infringe,
misappropriate or otherwise violate any third party&#8217;s intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we believe that third party intellectual property claims are without merit, there is no assurance that a court would find in our favor
on questions of misappropriation, infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold these
third-party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any
technology or drug candidate covered by the asserted third-party patents. In order to successfully challenge the validity of any such
U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present
clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction
would invalidate the claims of any such U.S. patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could be required
to obtain a license from such third party to continue developing, manufacturing and marketing our technology and drug candidates. However,
we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license,
it could be non-exclusive; thereby giving our competitors and other third parties access to the same technologies licensed to us and
could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing,
manufacturing and commercializing the infringing technology or drug. In addition, we could be found liable for significant monetary damages,
including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property
right and could be forced to indemnify our collaborators or others. A finding of infringement could prevent us from commercializing our
drug candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be
forced to redesign, modify or reposition our drug candidates, seek new regulatory approvals and indemnify third parties pursuant to contractual
agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material
adverse effect on our business, financial condition, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract
our personnel from their normal responsibilities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant
expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors
perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or
proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future
sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings
adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because
of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual
property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings
could compromise our ability to compete in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 103 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid
to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and patent
applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners
to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents,
we rely on an annuity service to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent
lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations
in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss
of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent
application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly
legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical
products or technology. If we or our licensors fail to maintain the patents and patent applications directed to our drug candidates,
it would have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, we could lose
rights that are important to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are party to license and funding agreements that impose, and we may enter into additional licensing and funding arrangements with third
parties that may impose, diligence, development and commercialization timelines, milestone payment, royalty, insurance and other obligations
on us. Under our existing licensing and funding agreements, we are obligated to pay certain specified milestone payments and royalties
on net drug sales of drug candidates or related technologies to the extent they are covered by the agreements. If we fail to comply with
such obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements
or require us to grant them certain rights. Such an occurrence could materially adversely affect the value of any drug candidate being
developed under any such agreement. For example, under the AF Agreement, we are required to use commercially reasonable efforts to research,
develop and commercialize LP-184. If we fail to meet the foregoing obligation, then, under certain circumstances, AF may terminate the
AF Agreement and may exercise the exclusive, sub-licensable and worldwide license we granted AF in and to certain of our intellectual
property to develop and commercialize LP-184. Termination of these agreements or reduction or elimination of our rights under these agreements
may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these
agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our
business, financial condition, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
these and other license agreements may not provide exclusive rights to use the licensed intellectual property and technology in all relevant
fields of use and in all territories in which we may wish to develop or commercialize our technology and drugs in the future. As a result,
we may not be able to prevent competitors from developing and commercializing competitive products and technology in fields of use and
territories not included in such agreements. In addition, we may not have the right to control the preparation, filing, prosecution,
maintenance, enforcement, and defense of patents and patent applications directed to the technology that we license from third parties.
Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, and defended
in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce, and defend such
patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right
to develop and commercialize any of our drugs that are the subject of such licensed rights could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to obtain additional licenses from others to advance our research or allow commercialization of our drug candidates. It is possible
that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all, or such licenses may be non-exclusive.
The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies
may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These
established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development
and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license
rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make
an appropriate return on our investment or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights
we have, we may be required to expend significant time and resources to redesign our technology, drug candidates, or the methods for
manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis.
If we are unable to do so, we may be unable to develop or commercialize the affected technology and drug candidates, which could harm
our business, financial condition, results of operations, and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disputes
may arise regarding intellectual property subject to a licensing agreement, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope of rights granted
    under the license agreement and other interpretation related issues;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which our
    technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sublicensing of patent
    and other rights under our collaborative development relationships;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our diligence obligations
    under the license agreement and what activities satisfy those diligence obligations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inventorship and ownership
    of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners;
    and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the priority of invention
    of patented technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain
provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement
that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase
what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse
effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that
we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may
be unable to successfully develop and commercialize the affected technology and drug candidates, which could have a material adverse
effect on our business, financial conditions, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 105 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not
the sole and exclusive owners of the patents and patent applications we in-licensed. If other third parties have ownership rights to
our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products
and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations,
and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate
the license agreements, thereby removing our ability to develop and commercialize drug candidates and technology covered by these license
agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity,
competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could
have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property and proprietary rights throughout the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting, and defending patents on drug candidates in all countries throughout the world would be prohibitively expensive, and the
laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be
able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing
products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to
territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products
may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them
from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets,
and other intellectual property protection, particularly those relating to pharmaceutical products, which could make it difficult for
us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary
rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or
interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against
us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.
Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to
grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and
our business, financial condition, results of operations, and prospects may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims by third parties asserting that our employees, consultants, contractors or advisors have wrongfully used or
disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property,
or claiming ownership of what we regard as our own intellectual property.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees, consultants, contractors and advisors were previously employed, or may currently be employed, at universities or other
pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees,
contractors and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims
that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information,
of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while it is our policy to require our employees, consultants, contractors and advisors who may be involved in the development
of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an
agreement with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment
agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend
claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a
material adverse effect on our business, financial conditions, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual
property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize
our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive.
Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction
to our management and employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to seeking patents for some of our technology and drug candidates, we also rely on trade secrets and confidentiality agreements
relating to the development of our RADR<sup>&#174;</sup> platform to protect our unpatented know-how, technology and other proprietary
information, in order to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in
part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate
collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other
third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We
cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary
technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including
our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation
of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and
time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or
unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor
or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information
to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party,
our competitive position would be materially and adversely harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights do not necessarily address all potential threats.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our RADR<sup>&#174; </sup>platform
    is not protected by any issued patents, and we may not be able to obtain, develop, acquire or in-license any patentable technologies
    or other intellectual property related to such platform;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 107 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we, or our license partners
    or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending
    patent applications that we license or may own in the future;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we, or our license partners
    or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others may independently
    develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual
    property rights;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it is possible that our
    owned and in-licensed pending patent applications or those we may own or in-license in the future will not lead to issued patents;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued patents that we
    hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our competitors might conduct
    research and development activities in countries where we do not have patent rights and then use the information learned from such
    activities to develop competitive products for sale in our major commercial markets;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not develop additional
    proprietary technologies that are patentable;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patents of others may
    harm our business; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may choose not to file
    a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual
    property.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and
prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Owning our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
stock price has been volatile and thinly traded which may impair your ability to sell your shares. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock has traded on the Nasdaq Capital Market since June 11, 2020. From June 12, 2020 through March 1, 2023, our common stock
has been relatively thinly traded, with an average daily trading volume of approximately 67,952 shares and prices ranging from a low
of $4.19 to a high of $24.84 per share. There can be no assurance that the market for our common shares will become more liquid.
The stock market in general, and shares of early stage public companies in particular, have experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to the operating performance of such companies. If we are unable to
increase the trading volume for our common shares, you may not be able to sell your common shares at prices you consider to be fair
or at times that are convenient for you, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 108 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shares
eligible for future sale may adversely affect the market for our common stock</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, virtually all of our outstanding shares are freely tradeable without restriction or are available for sale
pursuant to Rule 144 under the Securities Act. The market price of our common stock could decline as a result of sales of a large number
of shares of our common stock in the market or the perception that these sales could occur. Such sales or offerings could lower the market
price for our common stock and may make it more difficult for us to sell equity securities in the future at a time and at a price that
we deem appropriate. We may in the future sell additional shares of our common stock or equity-linked securities to raise capital. A
substantial number of shares of our common stock could be registered and issued. Furthermore, there are substantial amounts of vested
stock options which are &#8220;in the money&#8221; which could be exercised and sold in public markets. We continue to expect to issue
stock options as part of compensation. There may be further effect on our stock price upon the vesting and settlement of restricted stock
units and performance units. We cannot predict the size of future issuances or the effect, if any, that they may have on the market price
for our common stock. The issuance and sale of substantial amounts of common stock or equity-linked securities, or the perception that
such issuances and sales may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital
through the sale of additional equity or equity-linked securities. Additional dilution may also result as a consequence of shares of
common stock sold pursuant to potential future offerings as well as if outstanding options to acquire shares of our common stock are
exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of our common stock may fluctuate substantially.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should consider an investment in our common stock to be risky, and you should invest in our common stock only if you can withstand a
significant loss and wide fluctuations in the market value of your investment. Some factors that may cause the market price of our common
stock to fluctuate, in addition to the other risks mentioned in this &#8220;Risk Factors&#8221; section and elsewhere in this report,
are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale of our common stock
    by our stockholders, executives, and directors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility and limitations
    in trading volumes of our shares of common stock;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain financings
    to conduct and complete research and development activities including, but not limited to, our proposed clinical trials, and other
    business activities;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">possible delays in the
    expected recognition of revenue due to lengthy and sometimes unpredictable product development and sales timelines;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and success
    of introductions of new technologies, therapeutic approaches, product candidates and product marketing applications by us or our
    competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers
    or strategic partners;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">network outages or security
    breaches;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lack of market acceptance
    and sales growth for our drug candidates, if any, that receive marketing approval;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to secure resources
    and the necessary personnel to conduct clinical trials on our desired schedule;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement, enrollment
    or results of our clinical trials for our drug candidates or any future clinical trials we may conduct;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the development
    status of our drug candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any delays or adverse developments
    or perceived adverse developments with respect to the FDA&#8217;s review of our planned preclinical studies and clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any delay in our submission
    for studies or drug approvals or adverse regulatory decisions, including failure to receive regulatory approval for our drug candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated safety concerns
    related to the use of our drug candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failures to meet external
    expectations or management guidance;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our capital
    structure or dividend policy, future issuances of securities, sales of large blocks of common stock by our stockholders;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our cash position;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements and events
    surrounding financing efforts, including debt and equity securities;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to enter
    into new markets or develop new drugs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reputational issues;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition from existing
    technologies and drugs or new technologies and drugs that may emerge;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of acquisitions,
    partnerships, collaborations, joint ventures, new drugs, capital commitments, or other events by us or our competitors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in general economic,
    political and market conditions in any of the regions in which we conduct our business;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in industry conditions
    or perceptions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in valuations of
    similar companies or groups of companies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analyst research reports,
    recommendations and changes in recommendations, price targets, and withdrawals of coverage;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">departures and additions
    of key personnel;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes and litigations
    related to intellectual properties, proprietary rights, and contractual obligations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in applicable laws,
    rules, regulations, or accounting practices and other dynamics; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other events or factors,
    many of which may be out of our control.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences
a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition
and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and may expose us to lawsuits that,
even if unsuccessful, could be costly to defend and a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have broad discretion in the use of our financial resources and may not use them effectively.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management has broad discretion in the application of our financial resources. Because of the number and variability of factors that
determine our use of our financial resources, their ultimate use may vary substantially from their currently intended use. Our management
may not apply our financial resources in ways that ultimately increase the value of any investment in our securities or enhance stockholder
value. The failure by our management to apply these funds effectively could harm our business. We have invested and may in the future
invest our cash in interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not
invest or apply our cash in ways that enhance stockholder value, we may fail to achieve expected financial results, which may result
in a decline in the price of our shares of common stock, and, therefore, may negatively impact our ability to raise capital, invest in
or expand our business, acquire additional drugs or licenses, commercialize our drugs, or continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 110 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may acquire other companies or technologies, which could divert our management&#8217;s attention, result in dilution to our stockholders
and otherwise disrupt our operations and adversely affect our operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may in the future seek to acquire or invest in businesses, product applications and services or technologies that we believe could complement
or expand our existing product candidates and business, enhance our technical capabilities or otherwise offer growth opportunities. The
pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating
and pursuing suitable acquisitions, whether or not they are consummated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we do not have any experience in acquiring other businesses. If we acquire additional businesses, we may not be able to integrate
the acquired personnel, operations and technologies successfully or effectively manage the combined business following the acquisition.
We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to integrate
    or benefit from acquired businesses, products, technologies or services in a profitable manner;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated costs or
    liabilities associated with the acquisition;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty integrating
    the accounting systems, operations and personnel of the acquired business;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties and additional
    expenses associated with supporting legacy drugs and hosting infrastructure of the acquired business;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty maintaining
    the customers, if any, of the acquired business, including disparities in the revenue, licensing, support or business model of the
    acquired company;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of management&#8217;s
    attention from other business concerns;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse effects to our
    existing business relationships with business partners and customers, if any, as a result of the acquisition;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential loss of key
    employees;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">use of resources that are
    needed in other parts of our business; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">use of substantial portions
    of our available cash to consummate the acquisition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible
assets, which must be assessed for impairment at least annually. In the future, if our acquisitions do not yield expected returns, we
may be required to take charges to our operating results based on this impairment assessment process, which could adversely affect our
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisitions
could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our operating results.
In addition, if an acquired business fails to meet our expectations, our operating results, business and financial position may suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 111 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
and economic conditions, including inflation and changes in interest rates, may negatively impact our business, financial condition and share price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concerns
over inflation, energy costs, geopolitical issues, the U.S. mortgage market and real estate market, unstable global credit markets and
financial conditions, and volatile oil prices have led to periods of significant economic instability, diminished liquidity and credit
availability, declines in consumer confidence and discretionary spending, diminished expectations for the global economy and expectations
of slower global economic growth going forward, increased unemployment rates, and increased credit defaults in recent years. Our general
business strategy may be adversely affected by any such economic downturns, volatile business environments and continued unstable or
unpredictable economic and market conditions. If these conditions continue to deteriorate or do not improve, it may make any necessary
debt or equity financing more difficult to complete, more costly, and more dilutive. Failure to secure any necessary financing in a timely
manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance, and share price and
could require us to delay or abandon development or commercialization plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
marketable securities have had and may in the future have their market value adversely affected due to rises in interest rates. While
we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that
in the future our investments will not be subject to adverse changes in market value. We formed a wholly owned subsidiary, Lantern Pharma
Australia Pty Ltd, in Australia in September 2021 and experienced foreign currency losses of approximately $59,000 and $18,000 for the
years ended December 31, 2022 and 2021, respectively, in connection with this subsidiary. We will remain subject to the risk of foreign
currency losses in future periods, although we do not expect the impact of any foreign currency losses to be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect
on our results of operations during the periods presented in this report. Inflation has increased substantially in recent periods and
could have a greater impact on our future results of operations if it remains at current levels or continues to increase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our
stock price and trading volume may decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us,
our business, our markets and our competitors. We do not control these analysts. If securities analysts do not cover our common stock,
the lack of research coverage may adversely affect the market price of our common stock. Furthermore, if one or more of the analysts
who do cover us downgrade our stock or if those analysts issue other unfavorable commentary about us or our business, our stock price
would likely decline. If one or more of these analysts cease coverage of us or fails to regularly publish reports on us, we could lose
visibility in the market and interest in our stock could decrease, which in turn could cause our stock price or trading volume to decline
and may also impair our ability to expand our business with existing customers and attract new customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
certain of our stockholders control a significant number of shares of our common stock, they may have effective control over actions
requiring stockholder approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors, executive officers, and their respective affiliates, beneficially own approximately 20.6% of our outstanding shares of common
stock. As a result, these stockholders, acting together, would have the ability to substantially impact the outcome of matters submitted to our stockholders
for approval, including the election of directors and any merger, consolidation or sale of all or substantially all of our assets. In
addition, these stockholders, acting together, would have the ability to substantially impact the management and affairs of our company. Accordingly,
this concentration of ownership might harm the market price of our common stock by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying, deferring or
    preventing a change in corporate control;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impeding a merger, consolidation,
    takeover or other business combination involving us; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discouraging a potential
    acquirer from making a tender offer or otherwise attempting to obtain control of us.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales and issuances of our common stock could result in additional dilution of the percentage ownership of our stockholders and could
cause our share price to fall.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that significant additional capital will be needed in the future to continue our planned operations, including hiring new personnel,
advancing and commercializing our drug candidates, and continuing activities as an operating public company. To the extent we raise additional
capital by issuing equity securities; our stockholders may experience substantial dilution. We may sell common stock, convertible securities
or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock,
convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales.
Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing
stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 112 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate
declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the increase,
if any, of our share price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an &#8220;emerging growth company&#8221; and will be able to avail ourselves of reduced disclosure requirements applicable to emerging
growth companies, which could make our common stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we
intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not &#8220;emerging growth companies&#8221; including not being required to comply with the auditor attestation requirements of Section
404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements,
and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any
golden parachute payments not previously approved. In addition, Section 107 of the JOBS Act also provides that an &#8220;emerging growth
company&#8221; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying
with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We have not elected to delay such adoption of
new or revised accounting standards, and as a result, we will comply with new or revised accounting standards on the relevant dates on
which adoption of such standards is required for non-emerging growth companies. We cannot predict if investors will find our common stock
less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may
be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting
exemptions until we are no longer an &#8220;emerging growth company.&#8221; We will remain an &#8220;emerging growth company&#8221; until
the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last
day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering, or December 31,
2025; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the
date on which we are deemed to be a large accelerated filer under the rules of the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be at risk of securities class action litigation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be at risk of securities class action litigation. In the past, biotechnology and pharmaceutical companies have experienced significant
stock price volatility, particularly when associated with binary events such as clinical trials and drug approvals. If we face such litigation,
it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business and
result in a decline in the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 113 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
certificate of incorporation and our by-laws, and Delaware law may have anti-takeover effects that could discourage, delay or prevent
a change in control, which may cause our stock price to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation, and our by-laws, and Delaware law could make it more difficult for a third party to acquire us, even if
closing such a transaction would be beneficial to our stockholders. We are authorized to issue up to 1,000,000 shares of preferred stock.
This preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our board of
directors without further action by stockholders. The terms of any series of preferred stock may include voting rights (including the
right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption rights and sinking
fund provisions. None of our preferred stock is currently outstanding. The issuance of any preferred stock could materially adversely
affect the rights of the holders of our common stock, and therefore, reduce the value of our common stock. In particular, specific rights
granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell our assets to, a third party
and thereby preserve control by the present management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our certificate of incorporation, by-laws and Delaware law also could have the effect of discouraging potential acquisition proposals
or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. Such
provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. In particular, our certificate
of incorporation and by-laws and Delaware law, as applicable, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide the board of directors
    with the ability to alter the by-laws without stockholder approval;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing advance notice
    requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder
    meetings; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that vacancies
    on the board of directors may be filled by a majority of directors in office, although less than a quorum.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
by-laws designate the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal
district court for the District of Delaware) as the exclusive forum for certain types of claims, which may limit a stockholder&#8217;s
ability to bring a claim in a judicial forum that it finds favorable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
7.06 of our by-laws specifies that unless we consent in writing to the selection of an alternative forum, the court of Chancery of the
State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware)
shall, to the fullest extent permitted by law, be the sole and exclusive forum for: (a) any derivative action or proceeding brought on
our behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees to us
or to our stockholders; (b) any action asserting a claim against us arising pursuant to the Delaware General Corporation Law (&#8220;DGCL&#8221;)
or certificate of incorporation or our by-laws; or (c) or any action asserting a claim against us that is governed by the internal affairs
doctrine. There is uncertainty as to whether a court would enforce this provision with respect to claims under the Securities Act and
our stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder. The exclusive forum
provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes against us
and our directors, officers and other employees, which may discourage such lawsuits, or may require increased costs to bring a claim.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
reporting obligations of being a public company in the United States require well defined disclosure and financial controls and procedures
that are expensive and time-consuming requiring our management to devote substantial time to compliance matters.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a publicly traded company, we incur significant additional legal, accounting and other expenses that a privately held company is not
required to incur. For example, a privately held company is not required to have well defined disclosure and financial controls and procedures
or systems of internal controls over financial reporting that are generally required of publicly held companies. In connection with our
review of our previously existing internal controls as part of our preparations for becoming a publicly traded company, we determined
that our internal controls over financial reporting for prior periods were inadequate and included material weaknesses that needed to
be remedied. Although we have taken, and are continuing to take, additional steps to remedy these material weaknesses in order to assure
compliance with our future financial reporting obligations, there can be no assurance that we will be able to do so in a timely manner
or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 114 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
reporting obligations associated with being a public company in the United States require significant expenditures and will place significant
demands on our management and other personnel, including costs resulting from our reporting obligations under the Securities Exchange
Act of 1934, as amended, (the &#8220;Exchange Act&#8221;), and the rules and regulations regarding corporate governance practices, including
those under the Sarbanes-Oxley Act of 2002, as amended, (the &#8220;Sarbanes-Oxley Act&#8221;), the Dodd-Frank Wall Street Reform and
Consumer Protection Act, as amended, (the &#8220;Dodd-Frank Act&#8221;), and the listing requirements of the stock exchange on which
our securities are to be listed. These rules require the establishment and maintenance of effective disclosure and financial controls
and procedures, internal control over financial reporting and changes in corporate governance practices, among many other complex rules
that are often difficult to implement, monitor and maintain compliance with. Moreover, despite recent reforms made possible by the JOBS
Act, the reporting requirements, rules, and regulations make some activities more time-consuming and costly, which will be particularly
true after we are no longer an &#8220;emerging growth company.&#8221; In addition, we expect these rules and regulations will make it
more difficult and more expensive for us to obtain director and officer liability insurance. Our management and other personnel have
to devote a substantial amount of time to ensure that we comply with all of these requirements and to keep pace with new regulations,
otherwise we may fall out of compliance and risk becoming subject to litigation or being delisted, among other potential problems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with the rules under the Sarbanes-Oxley Act related to accounting controls and procedures in the future, or, if we
discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could
decline significantly and raising capital could be more difficult.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting
after a transition period ending with our second annual report on Form 10-K filed under Section 13(a) of the Exchange Act. If we fail
to comply with the rules under the Sarbanes-Oxley Act related to disclosure controls and procedures in the future, or, if in the future
we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price
could decline significantly and raising capital could be more difficult.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comprehensive
tax reform bills could adversely affect our business and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. government has in recent years enacted federal income tax legislation that includes significant changes to the taxation of business
entities. These changes include, among others, a permanent reduction to the corporate income tax rate. Notwithstanding the reduction
in the corporate income tax rate, the overall impact of this tax reform is uncertain, and our business and financial condition could
be adversely affected. This report does not discuss any such tax legislation or the manner in which it might affect purchasers of our
common stock. We urge our stockholders to consult with their legal and tax advisors with respect to any such legislation and the potential
tax consequences of investing in our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>Item
1B. Unresolved Staff Comments.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="a_006"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
2. Properties</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive office is located at 1920 McKinney Avenue, 7<sup>th</sup> Floor, Dallas, Texas 75201. During 2022 and 2021, we
leased office space and access to meeting facilities at this location under month-to-month lease arrangements. We also leased
additional office space in the Dallas, Texas area and in the Atlanta, Georgia area under operating leases that commenced in May 2021
and were scheduled to expire in April 2023. In March 2023, we renewed and extended our leases for office space and
access to meeting facilities in the Dallas, Texas area and in the Atlanta, Georgia area. Our operating lease expense was approximately $144,000 and $105,000 for
the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="a_007"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3. Legal Proceedings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time in the future, we may become involved in litigation or other legal proceedings that arise in the ordinary course of business.
We are not currently a party to any legal proceedings, and we are not aware of any pending or threatened litigation against us that we
believe could have a material adverse effect on our business, operating results or financial condition. In the event we are subject to
a legal proceeding, it could have a material adverse impact on us because of litigation costs and diversion of management resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>Item
4. Mine Safety Disclosures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 115 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="a_009"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock began trading on the Nasdaq Capital Market under the symbol &#8220;LTRN&#8221; on June 11, 2020. Prior to that date, there
was no public trading market for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 1, 2023, there were 9 stockholders of record of our common stock. The actual number of holders of our common stock is greater
than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by
brokers or held by other nominees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid or declared any cash dividends on our common stock, and we do not anticipate declaring or paying, in the foreseeable
future, any cash dividends on our capital stock. We intend to retain all available funds and future earnings, if any, to fund the development
and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination
regarding the declaration and payment of dividends, if any, will be at the discretion of our board of directors and will depend on then-existing
conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects
and other factors our board of directors may deem relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unregistered
Sales of Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued 26,093 shares of common stock relating to the cashless exercise of stock options
to purchase 32,538 shares of common stock. During the year ended December 31, 2021, the Company issued 11,782 shares of common stock
relating to the exercise of stock options. The shares were issued at a purchase price of $1.03 per share for total proceeds of approximately
$12,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise
of Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued 95,779 shares of common stock relating to the cash exercise of warrants for total
proceeds of approximately $300,000. During the year ended December 31, 2021, the Company issued 40,727 shares of common stock relating
to the cash exercise of warrants for total proceeds of approximately $127,000. During the year ended December 31, 2021 the Company also
issued 8,318 shares of common stock relating to the cashless exercise of warrants to purchase 11,114 shares, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe the
offers, sales and issuances of the above securities were exempt from registration under the Securities Act (or Regulation D promulgated
thereunder) by virtue of Section 4(a)(2) of the Securities Act because the issuance of securities to the recipients did not involve a
public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the securities
for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed
upon the stock certificates issued in these transactions. The sales of these securities were made without any general solicitation or
advertising.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 116 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuer
Purchases of Equity Securities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2021, our Board of Directors authorized a share repurchase program to acquire up to $7,000,000 of the Company&#8217;s
common stock. During the year ended December 31, 2022, the Company repurchased 353,667 shares of common stock pursuant to the
repurchase program for a total of approximately $2,482,000, including purchase fees. During the year ended December 31, 2021, the
Company repurchased 121,490 shares of common stock pursuant to the repurchase program for a total of approximately $940,000,
including purchase fees. The share repurchase program terminated July 31, 2022. Common stock repurchase activity under the share
repurchase program during the years ended December 31, 2022 and 2021 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Period</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total number of<br /> shares purchased</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average price<br /> paid per<br /> share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Dollar value of shares<br /> that may yet be<br /> purchased under the<br /> program</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">October 1, 2021 to October 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">7,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>November 1, 2021 to November 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 1, 2021 to December 31, 20212</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.71</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,062,763</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>January 1, 2022 to January 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">181,074</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,770,382</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>February 1, 2022 to February 28, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124,081</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,933,565</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>March 1, 2022 to March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,512</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,637,316</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">April 1, 2022 to July 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,637,316</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475,157</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None at July 31, 2022 </span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Securities
Authorized for Issuance under </b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Compensation
Plans</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below contains information as of December 31, 2022 regarding the Second Amended and Restated Lantern Pharma Inc. 2018 Equity
Incentive Plan (the &#8220;Plan&#8221;). Additional information regarding the Plan is contained in Note 6 to our consolidated
financial statements included as part of this report. The Company does not have any equity compensation plans that have not been
approved by stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 22%; font-weight: bold; text-align: center">Plan category</td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 23%; font-weight: bold; text-align: center">Number of securities to be<br /> issued upon exercise of<br /> outstanding options,<br /> warrants and rights</td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 24%; font-weight: bold; text-align: center">Weighted-average exercise<br /> price of outstanding<br /> options, warrants <br /> and rights</td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 25%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of securities<br /> remaining available for<br /> future issuance under<br /> equity compensation <br /> plans (excluding securities<br /> reflected in column (a))</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">(a)</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">(b)</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity compensation plans approved by security holders</td><td>&#160;</td>
    <td style="text-align: center">1,037,591 shares of Common Stock</td><td>&#160;</td>
    <td style="text-align: center">$6.46 per share</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">288,796 shares of Common Stock</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity compensation plans not approved by security holders</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total:</td><td>&#160;</td>
    <td style="text-align: center">1,037,591 shares of Common Stock</td><td>&#160;</td>
    <td style="text-align: center">$6.46 per share</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">288,796 shares of Common Stock</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="a_011"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
6. Reserved.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="a_012"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should read the following discussion and analysis of our financial condition and plan of operations together with our financial statements
and the related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical information, this discussion
and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially
from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified
below, and those discussed in Item 1A titled &#8220;Risk Factors&#8221; included elsewhere in this Annual Report on Form 10-K.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 117 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage biotechnology company, focused on leveraging artificial intelligence (&#8220;A.I.&#8221;), machine learning and
genomic data to streamline the drug development process and to identify the patients that will benefit from our targeted oncology therapies.
Our portfolio of therapies consists of small molecules that others have tried, but failed, to develop into an approved commercialized
drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach.
Our A.I. platform, known as RADR<sup>&#174;</sup>, currently includes more than 25 billion data points, and uses big data analytics (combining
molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications,
and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response,
and then identify the cancer patients that we believe may benefit most from our compounds. This data-driven, genomically-targeted and
biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and
advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer
drug development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy is to both develop new drug candidates using our RADR<sup>&#174;</sup> platform, and other machine learning driven methodologies,
and to pursue the development of drug candidates that have undergone previous clinical trial testing or that may have been halted in
development or deprioritized because of insufficient clinical trial efficacy (i.e., a meaningful treatment benefit relevant for the disease
or condition under study as measured against the comparator treatment used in the relevant clinical testing) or for strategic reasons
by the owner or development team responsible for the compound. Importantly, these historical drug candidates appear to have been well-tolerated
in many instances, and often have considerable data from previous toxicity, tolerability and ADME (absorption, distribution, metabolism,
and excretion) studies that have been completed. Additionally, these drug candidates may also have a body of existing data supporting
the potential mechanism(s) by which they achieve their intended biologic effect, but often require more targeted trials in a stratified
group of patients to demonstrate statistically meaningful results. Our dual approach to both develop de-novo, biomarker-guided drug candidates
and &#8220;rescue&#8221; historical drug-candidates by leveraging A.I., recent advances in genomics, computational biology and cloud
computing is emblematic of a new era in drug development that is being driven by data-intensive approaches meant to de-risk development
and accelerate the clinical trial process. In this context, we intend to create a diverse portfolio of oncology drug candidates for further
development towards regulatory and marketing approval with the objective of establishing a leading A.I.-driven methodology for treating
the right patient with the right oncology therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key component of our strategy is to target specific cancer patient populations and treatment indications identified by leveraging our
RADR<sup>&#174;</sup> platform, a proprietary A.I. enabled engine created and owned by us. We believe the combination of our therapeutic
area expertise, our A.I. expertise, and our ability to identify and develop promising drug candidates through our collaborative relationships
with research institutions in selected areas of oncology gives us a significant competitive advantage. Our RADR<sup>&#174;</sup> platform
was developed and refined over the last five years and integrates billions of data points immediately relevant for oncology drug development
and patient response prediction using artificial intelligence and proprietary machine learning algorithms. By identifying clinical candidates,
together with relevant genomic and phenotypic data, we believe our approach will help us design more efficient pre-clinical studies,
and more targeted clinical trials, thereby accelerating our drug candidates&#8217; time to approval and eventually to market. Although
we have not yet applied for or received regulatory or marketing approval for any of our drug candidates, we believe our RADR<sup>&#174;
</sup>platform has the ability to reduce the cost and time to bring drug candidates to specifically targeted patient groups. We believe
we have developed a sustainable and scalable biopharma business model by combining a unique, oncology-focused big-data platform that
leverages artificial intelligence along with active clinical and preclinical programs that are being advanced in targeted cancer therapeutic
areas to address today&#8217;s treatment needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 118 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current portfolio consists of four compounds and an Antibody Drug Conjugate (ADC) program: two drug candidates in clinical phases, one
in preclinical studies and one candidate and our recently initiated ADC program in research optimization. One of the two drug candidates
in clinical development, LP-100, was previously out-licensed by us to Allarity Therapeutics A/S. In July 2021, we entered into an Asset
Purchase Agreement to reacquire global development and commercialization rights for LP-100 from Allarity. All of these drug candidates
and our ADC program are leveraging precision oncology, A.I. and genomic driven approaches to accelerate and direct development efforts.
We currently have two drug candidates in clinical development, LP-100 and LP-300, where we are leveraging data from prior preclinical
studies and clinical trials, along with insights generated from our A.I. platform, to target the types of tumors and patient groups we
believe will be most responsive to the drug. Both LP-100 and LP-300 showed promise in important patient subgroups, but failed pivotal
Phase III trials when the overall results did not meet the predefined clinical endpoints. We believe that this was due to a lack of biomarker-driven
patient stratification. LP-300 has been studied in multiple randomized, controlled, multi-center non-small cell lung cancer, or NSCLC,
trials that included administration of either paclitaxel and cisplatin and/or docetaxel and cisplatin, and we are currently preparing
LP-300 for the launch of a targeted phase II trial, in never smoking patients with NSCLC in combination with chemotherapy, under an existing
investigational new drug application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we have one drug candidate, LP-184, in preclinical development for multiple potentially distinct indications where we are leveraging
machine learning and genomic data to streamline the drug development process and to identify the patients and cancer subtypes that will
best benefit from the drug, if approved. Our drug candidate, LP-284, the stereoisomer (enantiomer) of LP-184, is also in preclinical
development and has shown promising <i>in-vitro</i> anticancer activity in a range of hematological cancers, which are distinct from
the indications targeted by LP-184. Our ADC program commenced in early 2021 is aimed at identifying targeted or therapeutic antibodies
to conjugate with selected compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
development strategy is to pursue an increasing number of oncology focused, molecularly targeted therapies where artificial intelligence
and genomic data can help us provide biological insights, reduce the risk associated with development efforts and help clarify potential
patient response. We plan on strategically evaluating these on a program-by-program basis as they advance into clinical development,
either to be done entirely by us, or with licensing partners, to maximize the commercial opportunity and reduce the time it takes to
bring the right drug to the right patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, except for a prior research grant, we have not generated any revenue, we have incurred net losses and our operations have been
financed primarily by sales of our equity securities. Our net losses were approximately $14,260,000 and $12,363,000 for the years ended
December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net losses have primarily resulted from costs incurred in licensing and developing the drug candidates in our pipeline, planning, preparing
and conducting preclinical studies, clinical testing and general and administrative activities associated with our operations. We expect
to continue to incur significant expenses and corresponding increased operating losses for the foreseeable future as we continue to develop
our pipeline. Our costs may further increase as we conduct additional preclinical studies and clinical trials and potentially seek regulatory
clearance for and prepare to commercialize our drug candidates. We expect to incur significant expenses to continue to build the infrastructure
necessary to support our expanded operations, preclinical studies, clinical trials, and commercialization, including manufacturing, marketing,
sales and distribution functions. We have experienced and will continue to experience substantial costs associated with operating as
a public company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, although we believe we have effectively managed the impact of the COVID-19 pandemic on our operations, the
ongoing effects of the pandemic could have a material impact on our business in the future. The timing of non-clinical research studies
for our drug candidates by collaborators and service providers slowed during 2020 in connection with the pandemic. The timing of manufacturing
for our LP-300 and LP-184 candidates was impacted by supply chain delivery and COVID-related staffing issues, which extended the time
to launch our Phase II clinical trial for LP-300 and extended the time to commence IND enabling studies and commence Phase I clinical
testing for LP-184. Clinical sites conducting oncology clinical trials have also been impacted by COVID-related staffing issues. In addition,
Allarity Therapeutics informed us that enrollment in the Phase II clinical trial for LP-100 slowed during the pandemic. While we believe
we have been able to manage the disruption caused by the COVID-19 pandemic to date, there can be no assurance that our operations, including
the development of our drug candidates, will not be disrupted and materially adversely affected in the future by the COVID-19 pandemic,
or an epidemic or outbreak of an infectious disease like the outbreak of COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 119 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of Our Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenues</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not recognize revenues for the years ended December 31, 2022 and December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred for the research and development of our preclinical and clinical candidates,
which include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred towards
    consultants, laboratories and investigators that conduct our preclinical or clinical research activities; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of acquiring and
    developing preclinical and clinical study materials and lab supplies, including manufacturing costs related to our drug candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expense research and development costs to operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development costs by project category for the years ended December 31, 2022 and 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br /> December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br />
 December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">LP-300</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,870,494</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,351,814</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>LP-284</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">904,362</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>LP-184</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,104,060</td><td style="text-align: left">*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,821,349</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>LP-100</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">696,038</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,098,757</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">ADC Program</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,787</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">261,514</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RADR<sup>&#174; </sup>Platform </span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">849,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">651,904</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,831</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">385,242</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total research and development expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,602,954</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,570,580</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Research and Development costs relating to LP-184 for the year ended December 31, 2022 were reduced by $935,000 as a result of a payment
we received in July 2022 from one of our service providers in connection with the resolution of a difference of views regarding the service
provider agreement. This payment received by us offset other LP-184 costs during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Research and Development costs relating to LP-284 for the year ended December 31, 2021 are included in the &#8220;Other&#8221; category.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 120 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our research and development expenses will continue to increase as we progress our clinical trial for LP-300 and advance
toward our commencement of clinical trials for LP-184 and LP-284, advance clinical development of LP-100, and advance our other programs
and drug candidates. We expect this increase to include additional expenses associated with research and service provider agreements
for the advancement of our drug candidates and research and development efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration and completion
costs of these or other current or future clinical trials of LP-300, LP-184, LP-284, LP-100 or our other drug candidates. We may never
succeed in achieving regulatory approval for LP-300, LP-184, LP-284, LP-100 or any of our other drug candidates. The duration, costs
and timing of clinical trials and development of our drug candidates will depend on a variety of factors, including the uncertainties
of future clinical and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government
regulation. In addition, the probability of success for each drug candidate will depend on numerous factors, including competition, manufacturing
capability and commercial viability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
and Administrative</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and related costs for employees in executive, finance and administration, corporate
development and administrative support functions, including stock-based compensation expenses and benefits. Other significant general
and administrative expenses include accounting and legal services, insurance, the cost of various consultants, occupancy costs, investor
relations and information systems costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect increased administrative costs resulting from our ongoing and anticipated clinical trials and the potential commercialization
of our drug candidates. We believe that these increases will likely include increased costs for director and officer liability insurance,
hiring additional personnel to support future market research and future product commercialization efforts and increased fees for outside
consultants, attorneys and accountants. We also expect to continue to incur substantial costs to comply with corporate governance, internal
controls, investor relations and disclosures and similar requirements applicable to a public company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Results of Operations for the Years Ended December 31, 2022 and December 31, 2021 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended <br /> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: justify">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,829,799</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,020,928</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,602,954</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,570,580</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,432,753</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,591,508</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,432,753</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,591,508</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204,355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,929</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Other (expense) income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31,548</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,550</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(14,259,946</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,363,029</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 121 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Years Ended December 31, 2022 and December 31, 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
and Administrative Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased approximately $809,000, or 16%, from approximately $5,021,000 for the year ended December 31, 2021
to approximately $5,830,000 for the year ended December 31, 2022. The increase was primarily attributable to increases in payroll and
compensation expenses of $499,000, increases in other professional fees of $371,000, increases in legal and patent related expenses of
$112,000, increases in travel expenses of $137,000, increases in other general and administrative office expenses of $87,000, and increases
in rent expense of $49,000. The was partially offset by decreases in corporate insurance expense of $350,000 and decreases in business
development expenses of $96,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased approximately $1,032,000, or 14%, from approximately $7,571,000 for the year ended December 31, 2021
to approximately $8,603,000 for the year ended December 31, 2022 The increase was primarily attributable to increases in research studies
of approximately $1,471,000, increases in consulting expenses of approximately $247,000 and increases in research and development payroll
expenses of approximately $137,000. These increases were partially offset by decreases in product candidate manufacturing related expenses
of approximately $168,000, decreases in licensing fees of approximately $114,000 and a net decline in payments to Allarity Therapeutics
of approximately $541,000. During the year ended December 31, 2021, we made a one-time $1,000,000 upfront payment to Allarity Therapeutics,
and during the year ended December 31, 2022, we released an escrow payment of approximately $459,000 to Allarity Therapeutics. Manufacturing
related expenses for the year ended December 31, 2022 were also reduced by $935,000 as a result of a payment we received in July 2022
from one of our service providers in connection with the resolution of a difference of views regarding the service provider agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest
and Other Income (Expense)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income increased approximately $136,000 from $68,000 for the year ended December 31, 2021 to approximately $204,000 for the year ended
December 31, 2022. Other (expense) income, net decreased approximately $192,000 from a gain of approximately $161,000 for the year ended
December 31, 2021 to a loss of approximately $32,000 for the year ended December 31, 2022. This decrease was primarily attributable to
increases in unrealized losses on investments of approximately $540,000, an increase in foreign currency losses of approximately $40,000
and a one-time gain on loan forgiveness of approximately $110,000 during the year ended December 31, 2021, which were partially offset
by increases in dividend income of approximately $102,000 and increases of approximately $396,000 in research and development tax incentives
related to the Australia subsidiary, .</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incurred net losses of approximately $14,260,000 and $12,363,000 for the years ended December 31, 2022 and 2021, respectively. As of
December 31, 2022, we had working capital of approximately $55,924,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 122 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2021, we closed a public offering of 4,928,571 shares of common stock at a public offering price of $14.00 per share, which
amount included 642,856 shares sold upon full exercise of the underwriter&#8217;s over-allotment option. Total gross proceeds from the
offering were approximately $69,000,000, and net proceeds from the offering were approximately $64,167,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet generated any revenues from operations, other than revenues from a research grant, and we have not yet achieved profitability.
We expect that general and administrative expenses and our research and development expenses will continue to increase and, as a result,
we will need to generate significant product revenues to achieve profitability. We may never achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, our operations have been financed primarily through the sale of equity securities, and, to a much lesser extent, funds
received by us from the PPP Loan and a 2017 grant from the Massachusetts Life Sciences Center. We plan to apply for grant funding in
the future to assist in supporting our capital needs. We may also explore the possibility of entering into commercial credit facilities
as an additional source of liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2021, the Company&#8217;s Board of Directors authorized a share repurchase program to acquire up to $7,000,000 of the Company&#8217;s
common stock. During the year ended December 31, 2022, the Company repurchased 353,667 shares of common stock pursuant to the repurchase
program for a total of approximately $2,482,000, including purchase fees. During the year ended December 31, 2021, the Company repurchased
121,490 shares of common stock pursuant to the repurchase program for a total of approximately $940,000, including purchase fees. The
share repurchase program terminated July 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, we had cash and cash equivalents of approximately $37,202,000 and $51,524,000, respectively. Based on
our anticipated expenditures and capital commitments as of the date of this report, we believe that our existing cash and cash equivalents
as of December 31, 2022 will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from
the date of filing this Form 10-K. As of December 31, 2022 and 2021, we had marketable securities of approximately $17,994,000 and $19,201,000,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flow for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net cash flows used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(12,767,492</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(10,591,543</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash flows provided by (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">179,268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,530,586</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash flows (used in) provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,182,498</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,416,122</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of foreign exchange rates on cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,607</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,070</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase (decrease) in cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(14,781,329</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">33,295,063</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 123 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, net cash used in operating activities was approximately $12,767,000 compared to approximately $10,592,000
for the year ended December 31, 2021. The increase in net cash used in operating activities was primarily the result of the increase
in the net loss for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, net cash provided by investing activities was approximately $179,000 compared to net cash used of approximately
$19,531,000 for the year ended December 31, 2021. The decrease in cash used in investing activities during the year ended December 31,
2022 was primarily due to a substantially greater level of purchases of marketable securities that occurred in the year ended December
31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in financing activities was approximately $2,182,000 during the year ended December 31, 2022, attributable primarily to repurchases
of shares pursuant to the Company&#8217;s share repurchase program. Net cash provided by financing activities during the year ended December
31, 2021 was approximately $63,416,000, attributable primarily to net proceeds from our equity financing in January 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Capital and Capital Expenditure Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant and increasing operating losses at least for the next several years as we continue our clinical
trial of LP-300, commence our clinical trials of LP-184 and LP-284, advance clinical development of LP-100, pursue development of our
other drug candidates, and seek potential future marketing approval for our drug candidates which could be several years in the future,
if at all. We do not expect to generate revenue, other than possible license and grant revenue, unless and until we successfully complete
development and obtain regulatory approval for our therapeutic candidates. Our net losses may fluctuate significantly from quarter-to-quarter
and year-to-year, depending on the timing of our planned clinical trials and our expenditures on other research and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our
available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development
and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. We
anticipate that our expenses will increase substantially as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue the development,
    including preclinical studies and clinical trials, of our drug candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate preclinical studies
    and clinical trials for any additional indications for our current drug candidates and any future drug candidates that we may pursue;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to build our portfolio
    of drug candidates through the acquisition or in-license of additional drug candidates or technologies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to develop, maintain,
    expand and protect our intellectual property portfolio;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursue regulatory approvals
    for those of our current and future drug candidates that successfully complete clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ultimately establish a
    sales, marketing, distribution and other commercial infrastructure to commercialize any drug candidate for which we may obtain marketing
    approval;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 124 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire additional clinical,
    regulatory, scientific and accounting personnel;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur additional legal,
    accounting and other expenses in operating as a public company; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to develop, maintain,
    and expand our RADR<sup>&#174;</sup> platform.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that we will need to obtain substantial additional funding in order to complete our clinical trials. To the extent that we raise
additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our
existing stockholders may be materially diluted and the terms of these securities could include liquidation or other preferences that
could adversely affect the rights of our existing stockholders. In addition, debt financing, if available, would result in increased
fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions,
such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct
our business. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly delay, scale
back or discontinue the development or commercialization of LP-300, LP-184, LP-284, LP-100 and/or other drug candidates and programs,
seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be
available, and relinquish or license, potentially on unfavorable terms, our rights to LP-300, LP-184, LP-284, LP-100 and/or other drug
candidates and programs that we otherwise would seek to develop or commercialize ourselves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Estimates </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
prepare our consolidated financial statements in accordance with generally accepted accounting standards in the United States of America.
Our significant accounting policies are described in Note 3 to our consolidated financial statements included as part of this report.
Critical accounting policies and significant accounting estimates made in accordance with such policies are regularly discussed with
the Audit Committee of the Company&#8217;s board of directors. We believe the following critical accounting policies involve the most
significant judgments and estimates used in the preparation of the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
costs of research and development are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
preparing our financial statements, we are required to estimate our accrued clinical expenses. This process involves reviewing contracts
and communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service
performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost. Payments
under some of the contracts we have with third parties depend on factors, such as successful enrollment of certain numbers of patients,
site initiation and the completion of clinical trial milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
accruing clinical expenses, we estimate the time period over which services will be performed and the level of effort to be expended
in each period. If possible, we obtain information regarding unbilled services directly from our service providers. However, we may be
required to estimate the cost of these services based only on information available to us. If we underestimate or overestimate the cost
associated with a trial or service at a given point in time, adjustments to research and development expenses may be necessary in future
periods. Historically, our estimated accrued clinical expenses have approximated actual expense incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 125 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
Compensation </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted stock options to our employees under our equity incentive plan. Stock-based compensation expense from awards granted under
our plan is allocated over the required service period over which those stock option awards vest. Forfeitures are accounted for as they
occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock option awards are valued at fair value on the date of grant and that fair value is recognized over the requisite service period.
The estimated fair value of these stock option awards was determined using the Black Scholes option pricing model on the date of grant.
Some of these grants occurred at a time when we were not a public company. Significant judgment and estimates were used to estimate the
fair value of these awards, as they occurred when our stock was not publicly traded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
option award is subject to specified vesting schedules and requirements. Compensation expense is charged to us over the required service
period to earn the award which is expected to be up to four years, subject to the achievement of time and event-based vesting requirements.
For the years ended December 31, 2022 and 2021, we have incurred share-based compensation expense related to equity awards totaling approximately
$1,188,000 and $962,000, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quantitative
and Qualitative Disclosure About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates.
<span style="background-color: white">Fixed rate securities may have their market value adversely affected due to a rise in interest
rates. Accordingly, our future investment income may fluctuate as a result of changes in interest rates, or we may suffer losses in principal
if we are forced to sell securities that decline in market value as a result of changes in interest rates.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
we have raised capital through the issuance of equity securities. We had no long-term debt outstanding as of December 31, 2022, or as
of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe that our cash and cash equivalents have significant risk of default or illiquidity. <span style="background-color: white">Our
cash and cash equivalents consist primarily of cash and money market funds. Our exposure to market risk relating to cash and cash equivalents
due to changes in interest rates is limited because our cash and cash equivalents have a short-term maturity and are used primarily for
working capital purposes. </span>Our marketable securities have had and may in the future have their market value adversely affected
due to rises in interest rates. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk,
we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition,
we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured
limits. Interest bearing and non-interest bearing accounts we hold
at banking institutions are guaranteed by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000. Substantially
all of our cash balances held at banking institutions are in excess of FDIC coverage. We consider this to be a normal business risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
formed a wholly owned subsidiary, Lantern Pharma Australia Pty Ltd, in Australia in September 2021 and experienced foreign currency losses
of approximately $59,000 and $18,000 for the years ended December 31, 2022 and 2021, respectively, in connection with this subsidiary.
We will remain subject to the risk of foreign currency losses in future periods, although we do not expect the impact of any foreign
currency losses to be material. We do not participate in any foreign currency hedging activities, and we do not have any other derivative
financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect
on our results of operations during the periods presented. Inflation has increased substantially in recent periods and could have a greater
impact on our future results of operations if it remains at current levels or continues to increase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="a_013"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7A. Quantitative and Qualitative Disclosures About Market Risk.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Smaller Reporting Company, we are exempt from the requirements of Item 7A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 126 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_014"></span><b>Item
8. Financial Statements and Supplementary Data.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LANTERN
PHARMA INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vj_001">Report of Independent Registered Public Accounting Firm</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vj_002">Consolidated Balance Sheets &#8211; December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vj_003">Consolidated Statements of Operations for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vj_005">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vj_006">Consolidated Statements of Cash Flow for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vj_007">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 127; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="vj_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Board of Directors and Stockholders of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lantern Pharma Inc. and Subsidiaries</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Opinion on the Financial Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated balance
sheets of Lantern Pharma Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, and the related consolidated
statements of operations, comprehensive loss, stockholders&#8217; equity (deficit), and cash flows for each of the years then ended, and
the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present
fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2022 and 2021, and the consolidated
results of its operations and its cash flows for each of the years ended, in conformity with accounting principles generally accepted
in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis for Opinion</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/<span id="xdx_900_edei--AuditorName_c20220101__20221231_zCGnkBE5Dxl8"> <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">EisnerAmper LLP</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have served as the Company&#8217;s auditor since
2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">EISNERAMPER LLP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_900_edei--AuditorLocation_c20220101__20221231_zKnQ20EsLoTa"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">Iselin, New Jersey</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">March 20, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 128 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="vj_002"></span>Lantern
Pharma Inc. and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_zLt2yN5ck4Q8" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231_zpqHEYiRkFHh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_z105E3Rdv9dl" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_iB_zIpBXGTWClx" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_maACzMlJ_zcknEsN0hhni" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,201,786</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,524,295</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RestrictedCashCurrent_i01I_maACzMlJ_zzNq0nsRslJf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,180</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0056">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--MarketableSecuritiesCurrent_i01I_maACzMlJ_zh6zHvfg5Ezc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,994,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,201,152</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_maACzMlJ_zgyHPOSznITh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Prepaid expenses &amp; other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,985,472</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,990,953</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrent_i01TI_maCzalx_mtACzMlJ_z5Q9Vmmr07Sb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,722,737</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,716,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iI_maCzalx_zycr7M06N4W4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,245</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseRightOfUseAsset_iI_maCzalx_zfBYjapS7fX7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,687</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,943</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RestrictedCashNoncurrent_iI_maCzalx_zxj7CzvHRaH6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0073">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherAssetsNoncurrent_iI_maCzalx_zukb5LTiOtwk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,889</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,889</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Assets_iTI_mtCzalx_z3dioKIFGZyb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,836,321</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,950,477</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrentAbstract_iB_zPYJ6E8olJ87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i01I_maCzKtM_zi9vjOpzeM9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,745,407</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,174,109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maCzKtM_z7wtZApi0Dq7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Operating lease liabilities, current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,890</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,058</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrent_i01TI_mtCzKtM_maCzIdV_zV8ZIE7T7Cxj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,798,297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,326,167</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maCzIdV_zKkiDhRk2nFh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0094">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,890</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Liabilities_iTI_mtCzIdV_maCzbUJ_z51R2hrIpiEa" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">TOTAL LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,798,297</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,379,057</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CommitmentsAndContingencies_iI_maCzbUJ_zZJT8KWBVm31" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">COMMITMENTS AND CONTINGENCIES (NOTE 4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0100">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PreferredStockValue_i01I_pp0p0_maCzrsZ_zQuLHMr8uahl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Preferred Stock (<span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231_zK2EMGu2N3lg" title="Preferred stock, shares authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231_zDfFxLWUym91" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> authorized at December 31, 2022 and December 31, 2021; $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231_zcIkNHQRpTh2" title="Preferred stock, par value"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231_zbjCIYLM44oe" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares">.0001</ix:nonFraction></ix:nonFraction></span></span> par value) (<span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_dc_c20221231_z9aZ282p5wQj" title="Preferred Stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20221231_zCtWBRKdSnV7" title="Preferred Stock, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_dc_c20211231_zw2EHR981hyk" title="Preferred Stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20211231_zF4HI9Uvws88" title="Preferred Stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">Zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding at December 31, 2022 and December 31, 2021)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0106">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0107">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i01I_pp0p0_maCzrsZ_zpFqNq24Bfl6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Common Stock (<span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zpOl5UIQWPM5" title="Common stock, shares authorized"><span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211231_zaFfPmYZBcXi" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></ix:nonFraction></span></span> authorized at December 31, 2022 and December 31, 2021; $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zEXwkgXBnjD3" title="Common stock, par value"><span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211231_zoTxCdX8m7j7" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares">.0001</ix:nonFraction></ix:nonFraction></span></span> par value) (<span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zc3Rp661Kcy8" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zMsBUEb3uLbj" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,857,040</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December 31, 2022; <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_c20211231_zhxhfJ7Ri6U2" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_zsaHSr1mVnWk" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,088,835</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December 31, 2021)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdditionalPaidInCapital_i01I_maCzrsZ_zdxWfCpH0VD3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,691,194</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,685,924</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_maCzrsZ_zKmfhzFmrygi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">371,386</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">92,689</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzrsZ_zUhhs1IFFKaj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,282,870</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,022,924</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--StockholdersEquity_iTI_pp0p0_mtCzrsZ_maCzbUJ_zT5sGlZ8UoE6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,038,024</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,571,420</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_pp0p0_mtCzbUJ_zB1bwlpNrQ" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,836,321</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,950,477</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying Notes to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 129 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="vj_003"></span>Lantern
Pharma Inc. and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Operations </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_zgFW5X8QU9n7" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231_zlRVPh8IOWU3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20211231_zTN7VT4qiak8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended <br /> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpensesAbstract_iB_zohv9aMZLJTd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzEIm_zbtdI5lv3NG5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,829,799</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,020,928</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzEIm_zdqUAFtfZBX2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,602,954</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,570,580</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_mtCzEIm_msCzRyI_zEz8tJ8fw75c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,432,753</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,591,508</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_iT_mtCzRyI_maCz3yx_zyQyHcvzrXrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,432,753</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,591,508</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestIncomeOther_maCz3yx_zHLUkuteZpQh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,929</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_maCz3yx_zaWLbjZDWGR5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Other (expense) income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">31,548</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,550</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_iT_mtCz3yx_zDDBGkHJUksj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,259,946</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,363,029</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_ziQKRk4XFlQc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net loss per share of common shares, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.31</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.13</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zxriSxbosjJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted-average number of common shares outstanding, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,850,579</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,904,927</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying Notes to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 130 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lantern
Pharma Inc. and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Comprehensive Loss </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_113_zmvNLA6IFfz" summary="xdx: Statement - Consolidated Statements of Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zG1mhrRtftzg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zb7uDFgVteha" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_maCINOTzM8U_z1Wjl2Wv0yw5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">NET LOSS</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,259,946</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,363,029</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract_iB_zdJDIYkWyv76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_i01_maOCILNzjgX_zgkeZs78QOqj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Unrealized loss on available-for-sale securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">296,448</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">92,872</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01_maOCILNzjgX_zmWENNoNcVX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Unrealized gain of foreign currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,751</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_i01T_mtOCILNzjgX_maCINOTzM8U_zYlJzm8ZWC1h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">278,697</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">92,689</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCINOTzM8U_zn8IbJz46Z" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,538,643</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,455,718</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying Notes to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 131 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="vj_005"></span>Lantern
Pharma Inc. and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Stockholders&#8217; Equity (Deficit)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zHNronc58Ib1" summary="xdx: Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred <br /> Stock <br /> Number of <br /> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_z6TcXymEIop6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred <br /> Stock <br /> Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common <br /> Stock <br /> Number of <br /> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zdSW37lhvhzi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common <br /> Stock <br /> Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zD8zm2iYDooe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Additional <br /> Paid-in <br /> Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zsaGV6E1kv9e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated <br /> Other <br /> Comprehensive <br /> Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zKIuwkuVceHj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated <br /> Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BE_zFqsJVKEPvra" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total <br /> Stockholders&#8217; <br /> Equity <br /> (Deficit)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_437_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zcp0bqKrBxmk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%">Balance, January 1, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zByqT8bVaPMd" title="Beginning balance, shares" style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0214">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0207">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjWivgCgnErk" title="Beginning balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,220,927</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">622</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,358,068</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0210">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,659,895</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,698,795</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises_zqNfyXxBBkai" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued from warrant exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0218">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ9gw5866ope" title="Common stock issued from warrant exercise, shares" style="text-align: right"><ix:nonFraction name="LTRN:StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,045</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,470</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0221">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0222">-</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,475</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zJstEjvLohfc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issued from option exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzI7emV02Vh8" title="Common stock issued from option exercises, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,782</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,134</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0230">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0231">-</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zuQCy4b1A8Ia" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued from offering, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zg8WRUhFJsf1" title="Common stock issued from offering, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,928,571</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">493</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,166,361</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0239">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0240">-</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,166,854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockRepurchasedDuringPeriodValue_iN_di_zZA8K0SXJDP5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share repurchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockRepurchasedDuringPeriodShares_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zo9yga9H7sY" title="Share repurchases, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">121,490</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,654</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0248">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0249">-</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,666</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zENlTDJVmSpf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0254">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">961,545</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0257">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0258">-</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">961,545</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_zcP8mJ3IFUL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,363,029</ix:nonFraction></td><td style="text-align: left">)</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,363,029</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_z5rrY7N2mfT6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">92,689</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">92,689</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43F_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zbHR2qXMccx2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zPteJiNCDoHa" title="Beginning balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1181Br93HU7" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,088,835</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,685,924</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">92,689</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,022,924</ix:nonFraction></td><td style="text-align: left">)</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,571,420</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zGFaLy4ipQtj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zn4s7YGDXiNi" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z07N6q5lD9Qg" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,088,835</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,685,924</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">92,689</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,022,924</ix:nonFraction></td><td style="text-align: left">)</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,571,420</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises_zszNfbnyzANf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued from warrant exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeHiR30NIBO8" title="Common stock issued from warrant exercise, shares" style="text-align: right"><ix:nonFraction name="LTRN:StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,778</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">-</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,788</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zzFa6pMSP9T5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issued from option exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6w3TabrgfXg" title="Common stock issued from option exercises, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,093</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">-</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockRepurchasedDuringPeriodValue_iN_di_z0Bk5PMit5bb" style="vertical-align: bottom; background-color: White">
    <td>Share repurchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockRepurchasedDuringPeriodShares_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEgLAa2gT9O9" title="Share repurchases, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">353,667</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,482,250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,482,286</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_z35ecZC54yW6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,187,745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">-</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,187,745</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_z46mkYUYEKs2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,259,946</ix:nonFraction></td><td style="text-align: left">)</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,259,946</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_ztSwdMdiFqL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">278,697</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">278,697</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_438_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zl8G0vvrXM9d" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zGQjHDpg08ph" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLFEjgvDD6N8" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,857,040</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,086</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,691,194</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">371,386</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,282,870</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,038,024</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zZgUE5MPC813" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNE5xQtzHSs8" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNgTD677kUH9" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,857,040</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,086</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,691,194</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">371,386</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,282,870</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,038,024</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying Notes to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 132 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="vj_006"></span>Lantern
Pharma Inc. and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_112_zhqSMePX7Jq2" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zSPDmChNveWk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20211231_z2RAQqfQSHv4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z5xJgziFFbBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_maCzF5y_zLXwxK3IlPk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,259,946</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,363,029</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_zAeMS8mQDl2b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DepreciationDepletionAndAmortization_i01_maCzF5y_zYvA1hgrFIB2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,081</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,761</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InvestmentIncomeAmortizationOfPremium_i01_maCzF5y_z7U6mqx5UMY5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of investment premium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeAmortizationOfPremium" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,870</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeAmortizationOfPremium" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,506</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--NoncashLeaseAdjustments_i01_maCzF5y_z7GE6KZDbLu9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Non-cash lease adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:NoncashLeaseAdjustments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:NoncashLeaseAdjustments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,660</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_i01_pp0p0_maCzF5y_zmrTFqqQJBu6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,187,745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">961,545</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--GainOnLoanForgiveness_i01N_di_msCzF5y_zWMsZxEoRlff" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Gain on loan forgiveness</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="LTRN:GainOnLoanForgiveness" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01N_di_msCzF5y_zwbKcCWT7938" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Foreign currency remeasurement loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">58,598</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_i01N_di_msCzF5y_z3o7AY6r0rQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Realized loss on sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">128,922</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--UnrealizedGainLossOnInvestments_i01N_di_msCzF5y_zeTFrp4eeYG9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Unrealized loss on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">492,501</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">80,557</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zzQnwIuyWQ9g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_maCzF5y_zJmwHQvmSY0a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">158,402</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">71,655</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInPrepaidExpensesOther_i02N_di_msCzF5y_zHLzUJXK6MP6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses &amp; other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,033,820</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">984,463</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_maCzF5y_zhKrKQcpMh8e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">580,359</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,622,084</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i02N_di_msCzF5y_zM4Jt6moZdPe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,991</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzF5y_maCzsBn_z7eoTSSOJEq6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash flows used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,767,492</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,591,543</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_ztP7861dlQc4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzKca_zqQapIk6kOQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Purchase of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,844</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,499</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsToAcquireMarketableSecurities_i01N_di_msCzKca_zwgOZZhIt5B" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Purchase of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,912,570</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,579,180</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_i01_maCzKca_zfU1OKxFhNJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Redemptions of marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,119,682</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,093</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzKca_maCzsBn_zHrVnLaiPwGl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash flows provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,268</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,530,586</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zjoIAUWdwsd7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzZlB_zPpqZZzuYG38" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,999,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di_msCzZlB_zUfc2Lc4SPn7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,783,816</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--ProceedsFromStockOptionAndWarrantExercises_i01_maCzZlB_zR0PjVRYVD35" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from warrant and stock option exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:ProceedsFromStockOptionAndWarrantExercises" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,788</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:ProceedsFromStockOptionAndWarrantExercises" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,610</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsForRepurchaseOfCommonStock_i01N_di_msCzZlB_zN7eNu1Nppd4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Repurchases of shares including commissions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,482,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,666</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzZlB_maCzsBn_zjQtWhZrm0Dl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash flows (used in) provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,182,498</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,416,122</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCzsBn_zkKvLsuIZDT5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of foreign exchange rates on cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,607</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,070</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzsBn_zGonqvcM1VJj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CHANGE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH FOR THE YEAR</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,781,329</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,295,063</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zTmTKPjJhGS5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING OF YEAR</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,524,295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,229,232</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, END OF YEAR</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,742,966</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,524,295</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RestrictedCashAndCashEquivalentsAbstract_iB_z29f6Nrlvnd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">RECONCILIATION OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-left: -10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01E_zXgKlZ9czsek" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,201,786</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,524,295</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RestrictedCash_i01E_zqqA5Le7W0n2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,180</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_z1L3xAr7Glfl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,742,966</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,524,295</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_z1c1goHxqjgd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-cash investing and financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds_i01_zvpXX8UcFOx" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Application of deferred offering costs to public offering proceeds</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0478">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="LTRN:ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">49,324</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DebtSecuritiesUnrealizedGainLoss_i01_zLz1fAxkscz6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unrealized losses on debt securities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesUnrealizedGainLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">296,448</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesUnrealizedGainLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">92,872</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying Notes to Consolidated Financial Statements</i></span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 133 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="vj_007"></span>NOTES
TO FINANCIAL STATEMENTS</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zT3NMCMgvmdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1. <span id="xdx_826_zYbgIuijlbP">Organization, Principal Activities, and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lantern
Pharma Inc., and Subsidiaries (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company, focused on leveraging artificial
intelligence (&#8220;A.I.&#8221;), machine learning and genomic data to streamline the drug development process and to identify the patients
that will benefit from its targeted oncology therapies. The Company&#8217;s portfolio of therapies consists of small molecule drug candidates
that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that it is developing with
the assistance of its A.I. platform and its biomarker driven approach. The Company&#8217;s A.I. platform, known as RADR<sup>&#174;</sup>,
uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature,
phenotypic data from trials and publications, and mechanistic pathway data) and machine learning. The Company&#8217;s data-driven, genomically-targeted
and biomarker-driven approach allows it to pursue a transformational drug development strategy that identifies, rescues or develops,
and advances potential small molecule drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lantern
Pharma Inc. was incorporated under the laws of the state of Texas on November 7, 2013, and thereafter reincorporated in the state of
Delaware on January 15, 2020. The Company&#8217;s principal operations are located in Texas. The Company formed a wholly owned subsidiary,
Lantern Pharma Limited, in the United Kingdom in July 2017 and a wholly owned subsidiary, Lantern Pharma Australia Pty Ltd, in Australia
in September 2021. In January 2023, the Company formed a wholly owned subsidiary, Starlight Therapeutics Inc. (&#8220;Starlight&#8221;),
to develop drug candidate LP-184&#8217;s central nervous system (CNS) and brain cancer indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, the Company has devoted substantially all its activity to advancing research and development, including efforts in connection
with preclinical studies, clinical trials and development of its RADR platform. This now includes four drug candidates and an Antibody
Drug Conjugate (ADC) program directed towards eleven disclosed therapeutic targets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-100
    (irofulven) focused on combination with PARP inhibitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
    (Tavocept), which we launched in a Phase II clinical trial, the Harmonic<sup>&#8482;</sup> trial in July 2022, focused on never smokers
    with advanced non-small cell lung cancer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184
    in preclinical studies for treatment of solid tumors including pancreatic, prostate, and bladder cancers, and glioblastoma and other
    CNS cancers. Following the formation of Starlight, the Company will refer to the molecule LP-184, as it is developed in CNS indications,
    as &#8220;STAR-001&#8221;;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-284,
    the stereoisomer (enantiomer) of LP-184, that has shown promising <i>in-vitro </i>and <i>in vivo</i> anticancer activity in multiple hematological cancers, which are distinct from the indications targeted by LP-184; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ADC program commenced in early 2021, and is aimed at identifying targeted or therapeutic antibodies to conjugate with selected compounds.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s fiscal year ends on December 31 of each calendar year. The accompanying consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include all adjustments
necessary for the fair presentation of the Company&#8217;s financial position, results of operations, and cash flows for each period
presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 134 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
reference in these notes to applicable guidance refers to Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards
Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). To date, the Company has operated its business
as one segment. The Company&#8217;s consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries,
Lantern Pharma Limited and Lantern Pharma Australia Pty Ltd. All intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_807_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_ztTYvTcNMLn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2. <span id="xdx_82B_zQmod8txtjWb">Liquidity</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurred a net loss of approximately $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20220101__20221231_z2mAQGpuskhg" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">14,260,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20210101__20211231_z1tdLjXU7bw8" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">12,363,000</ix:nonFraction></span> during the years ended December 31, 2022 and 2021, respectively.
As of December 31, 2022, the Company had working capital of approximately $<span id="xdx_904_ecustom--WorkingCapital_iI_c20221231_zrtdWeDwpRu1" title="Working capital"><ix:nonFraction name="LTRN:WorkingCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,924,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2021, the Company closed a public offering of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20210119__20210120__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zRO3hhwYkJ42" title="Number of shares issued for public offering"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-192021-01-20_custom_UnderwritersAgreementMember_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">4,928,571</ix:nonFraction></span> shares of its common stock at a public offering price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pp0p0_c20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember_zBoIBiZrOCa9" title="Share price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-01-20_us-gaap_OverAllotmentOptionMember_custom_UnderwritersAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USDPShares">14.00</ix:nonFraction></span> per
share, which amount included <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210119__20210120__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z0gDpVjsHJa3" title="Number of sale of stock shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-01-192021-01-20_custom_UnderwritersAgreementMember_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">642,856</ix:nonFraction></span> shares sold upon full exercise of the underwriter&#8217;s over-allotment option. Total gross proceeds
from the offering were approximately $<span id="xdx_90D_ecustom--ProceedsFromIssuanceInitialPublicOfferingGross_pp0p0_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember_zsdaQBiRpVii" title="Proceeds from initial public offering, gross"><ix:nonFraction name="LTRN:ProceedsFromIssuanceInitialPublicOfferingGross" contextRef="From2021-01-192021-01-20_custom_UnderwritersAgreementMember_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">69,000,000</ix:nonFraction></span>, and net proceeds from the offering were approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20210119__20210120__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z1mJI3a6rYc7" title="Proceeds from initial public offering, net"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-01-192021-01-20_custom_UnderwritersAgreementMember_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">64,200,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company plans to continue to explore periodic capital raises and also plans to apply for grant funding in the future to assist in supporting
its capital needs. We may also explore the possibility of entering into commercial credit facilities as an additional source of liquidity.
We believe that our existing cash as of December 31, 2022, and our anticipated expenditures and capital commitments, will enable us to
fund our operating expenses and capital expenditure requirements for at least 12 months from the date of filing this Form 10-K for the
year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zPRgW2YHqfa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3. <span><span id="xdx_821_zhWeFP8gEcJe">Summary of Significant Accounting Policies</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84C_eus-gaap--UseOfEstimates_zXg2zPDVZuR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zSQnrYOSpXhk">Use
of Estimates and Assumptions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research
and development accruals, the inputs in determining the fair value of equity-based awards and warrants issued, the inputs in determining
present value of lease payments, and fair value of marketable securities. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zLEi4D1e7COj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zjMYeCa6GLw6">Risks
and Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations
are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including
the potential risk of business failure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extent of the future impact and effects of the coronavirus (COVID-19) on the operation and financial performance of the
Company&#8217;s business will depend on future developments, including the duration of continuation or the resurgence of the outbreak and varying virus
mutations, recovery times of disrupted research services, the consequential staff
shortages, and research and development delays, or the uncertainty with respect to the accessibility of additional liquidity or
capital markets, all of which are highly uncertain and cannot be predicted. If the Company&#8217;s operations are impacted by the
outbreak for an extended period, the Company&#8217;s results of operations or liquidity may be materially adversely
affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
marketable securities have had and may in the future have their market value fluctuate due to rises or falls in interest rates.
While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute
assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain
significant amounts of cash and cash equivalents at one or more financial institutions that are federally insured. Interest bearing
and non-interest bearing accounts we hold at these banking institutions are guaranteed by the Federal Deposit Insurance Corporation
(&#8220;FDIC&#8221;) up to $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zsCLCkkgHuH1" title="Cash FDIC Insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>
per depositor, per FDIC-insured bank, per ownership category. Substantially all of our cash balances held at banking institutions at
December 31, 2022 are in excess of FDIC coverage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 135 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zDlow0VHDCt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses,
costs for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&#8217;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as the work
is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative
future use are expensed when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMUdTwaWKak4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zG2zmHmnv8na">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers money market funds and other highly liquid instruments with a short-term maturity of 3 months or less to be cash
equivalents. Cash equivalents at December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20221231_zoyAMstiJb7a" title=" Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,271,000</ix:nonFraction></span>
and $<span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20211231_zOQWCMjuuOEi" title=" Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">631,000</ix:nonFraction></span>,
respectively, and are included along with cash under the caption cash and cash equivalents on the Company&#8217;s consolidated
balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_846_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zwqxXNZoTcW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zSq6r7GuxG3l">Restricted
Cash</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers cash held in escrow for the purposes of contractual contingencies to be restricted cash. Restricted cash at December
31, 2022 and 2021 was approximately $<span id="xdx_900_eus-gaap--RestrictedCash_iI_pn3d_c20221231_zTArnyOcC7Mg" title="Restricted cash"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">541,000</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--RestrictedCash_iI_pn3d_c20211231_ziLuzhjb51l4" title="Restricted cash"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">1,000,000</ix:nonFraction></span>, respectively, and is included under the caption restricted cash on the Company&#8217;s
consolidated balance sheets. All of the restricted cash at December 31, 2022 and 2021 relates to escrow amounts paid in connection with
the Asset Purchase Agreement entered into by the Company and Allarity Therapeutics in July 2021 (See Note 4) and is considered a current
asset at December 31, 2022, as the milestones that could require payments to be made to Allarity Therapeutics must be satisfied within
the next 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="LTRN:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"><p id="xdx_848_ecustom--PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_zURCpDLlU7B8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zIHIxYGZWJn4">Prepaid
Expenses and Other Current Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets as of December 31, 2022 totaled approximately $<span id="xdx_90C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3d_c20221231_zh9iHNiQ95h2" title="Prepaid expense and other current assets"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">2,985,000</ix:nonFraction></span> and included approximately $<span id="xdx_902_ecustom--UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_iI_c20221231_zlj9rfbKFoa4" title="Upfront payments for contractor fees, academic research studies and services, and subscriptions"><ix:nonFraction name="LTRN:UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,633,000</ix:nonFraction></span> of upfront
payments for contractor fees, academic research studies and services, and subscriptions, approximately $<span id="xdx_907_ecustom--IntellectualPropertyRelatedLicensingAndOtherFees_iI_c20221231_zdQ1HIshK7M9" title="Intellectual property related licensing and other fees"><ix:nonFraction name="LTRN:IntellectualPropertyRelatedLicensingAndOtherFees" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">256,000</ix:nonFraction></span> of intellectual property
related licensing and other fees, approximately $<span id="xdx_90C_eus-gaap--PrepaidInsurance_iI_c20221231_ztN2UxSRyOlb" title="Prepaid annual insurance fees"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">504,000</ix:nonFraction></span> of prepaid annual insurance fees, and approximately $<span id="xdx_90A_eus-gaap--InterestReceivable_iI_c20221231_zgNc0JfiF4ff" title="Interest receivable"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">592,000</ix:nonFraction></span> of receivables
from interest and tax incentives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets as of December 31, 2021 totaled approximately $<span id="xdx_903_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3d_c20211231_zidfOT2LsFRf" title="Prepaid expense and other current assets"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">1,991,000</ix:nonFraction></span> and included approximately $<span id="xdx_903_ecustom--UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_iI_c20211231_z6Qa5CahR727" title="Upfront payments for contractor fees, academic research studies and services, and subscriptions"><ix:nonFraction name="LTRN:UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">778,000</ix:nonFraction></span> of upfront
payments for contractor fees, academic research studies and services, and subscriptions, approximately $<span id="xdx_901_ecustom--IntellectualPropertyRelatedLicensingAndOtherFees_iI_c20211231_zJ96CFz4MKy6" title="Intellectual property related licensing and other fees"><ix:nonFraction name="LTRN:IntellectualPropertyRelatedLicensingAndOtherFees" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,000</ix:nonFraction></span> of intellectual property
related licensing and other fees, approximately $<span id="xdx_90E_eus-gaap--PrepaidInsurance_iI_c20211231_zeUxrx6IwIV8" title="Prepaid annual insurance fees"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">653,000</ix:nonFraction></span> of prepaid annual insurance fees, and approximately $<span id="xdx_90F_eus-gaap--InterestReceivable_iI_c20211231_zOfUnKAPK33l" title="Interest receivable"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,000</ix:nonFraction></span> of receivables
from interest and tax incentives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="LTRN:LoanPursuantToPaycheckProtectionProgramPolicyTextBlock"><p id="xdx_848_ecustom--LoanPursuantToPaycheckProtectionProgramPolicyTextBlock_zWTWF7abPwkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zE0qm2RU2T4d">Loan
Pursuant to Paycheck Protection Program</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2020, the Company received $<span id="xdx_908_eus-gaap--ProceedsFromLoans_c20200430__20200501_zvCVwJXAqTSl" title="Proceeds from loans"><ix:nonFraction name="us-gaap:ProceedsFromLoans" contextRef="From2020-04-302020-05-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,500</ix:nonFraction></span> in aggregate loan proceeds (the &#8220;PPP Loan&#8221;) from JPMorgan Chase Bank (the &#8220;Lender&#8221;)
pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan was evidenced
by a loan application and payment agreement by and between the Company and the Lender. The Company applied for forgiveness of the loan,
and in April 2021 the Company received notice that the Small Business Administration (SBA) had authorized full forgiveness of the PPP
Loan (see Note 9). Forgiveness is subject to review by the SBA for a period of six years from the date of forgiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 136 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zHur5rnvKbn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zWuyE71fys4e">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use
(&#8220;ROU&#8221;) assets, current portion of operating lease liabilities, and net of current portion of operating lease liabilities
on our consolidated balance sheets. Lease ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term
and lease liabilities represent an obligation to make lease payments arising from the lease. Lease ROU assets and lease liabilities are
recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company&#8217;s
leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement
date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term unless
it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a
straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease
term of twelve months or less, and instead will recognize lease payments as expense on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:MarketableSecuritiesPolicy"><p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zMYurijcnfJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zk5xM1PZEO64">Marketable
Securities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s marketable securities consist of government and agency securities, corporate bonds, and mutual funds. We classify our
marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date.
We may sell these securities at any time for use in current operations even if they have not yet reached maturity. As a result, we classify
our investments, including securities with maturities beyond twelve months, as current assets in the accompanying consolidated balance
sheets. Available-for-sale debt securities are recorded at fair value each reporting period. Unrealized gains and losses are excluded
from earnings and recorded as a separate component within &#8220;Accumulated other comprehensive income&#8221; or &#8220;Accumulated
other comprehensive loss&#8221; on the consolidated balance sheets until realized. Interest is reported within &#8220;Interest income&#8221;
and dividend income is reported within &#8220;Other (expense) income, net&#8221; on the consolidated statements of operations. We evaluate
our investments to assess whether the amortized cost basis is in excess of estimated fair value and determine what amount of that difference,
if any, is caused by expected credit losses. Allowance for credit losses are recognized as a charge in &#8220;Other income, net&#8221;
on the consolidated statements of operations, and any remaining unrealized losses are included in &#8220;Accumulated other comprehensive
loss&#8221; on the consolidated balance sheets. There were no credit losses recorded for the year ended December 31, 2022. There was
no impairment charge for any unrealized losses for the years ended December 31, 2022 and 2021. We determine realized gains and losses
on the sale of marketable securities based on the specific identification method and record such gains and losses in &#8220;Other (expense)
income, net&#8221; on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_z19ijevwkvY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z8fPfYRTGmrj">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities
using enacted tax rates which will be in effect when the differences reverse. The Company provides a full valuation allowance against
net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z8uNpAyOZFi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zT03SiCvtWWa">Stock-based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
awards have been accounted for as required by ASC 718 <i>Compensation - Stock Compensation</i>. Under ASC 718, awards are valued at fair
value on the date of grant, and that fair value is recognized over the requisite service period. Forfeitures are accounted for as they
occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 137 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqgEgpiqiWJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zDCIikpk1GQg">New
Accounting Pronouncements, Not Yet Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Current
Expected Credit Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016 the FASB issued ASU 2016-13<i>, Measurement of Credit Losses on Financial Instruments</i> (Topic 326). This introduces new
methodology for recognition of credit losses - the current expected credit loss (&#8220;CECL&#8221;) method. The CECL method requires
the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument, unless
the company elects to recognize such instruments at fair value with changes in profit and loss. CECL is effective for the Company on
January 1, 2023. The Company believes it will not be materially impacted by the adoption of this new standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="LTRN:RecentlyAdoptedAccountingPolicyPolicyTextBlock"><p id="xdx_843_ecustom--RecentlyAdoptedAccountingPolicyPolicyTextBlock_zxlkXvTagwD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zGsBbSls047a">Recently
Adopted Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Government
Assistance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2021 the FASB issued ASU 2021-10, <i>Government Assistance</i> (Topic 832). This introduces new guidance to increase transparency
of government assistance. It requires annual disclosures about transactions with a government, including those accounted for by applying
a grant. This includes the nature of the transactions and related accounting policy used to account for the transactions, the line items
on the balance sheet and income statement that are affected by the transactions, and significant terms and conditions of the transactions.
The Company adopted ASU 2021-10 on January 1, 2022 and has not been materially impacted by its adoption.</span></p>

</ix:nonNumeric><p id="xdx_85A_zNVPrjcBCuBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zAN0ZksGnwYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4: <span id="xdx_825_zlcyhtG80ktd">Commitments and Contingencies</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into, and expects to enter into from time to time in the future, license agreements, strategic alliance agreements,
assignment agreements, research service agreements, and similar agreements related to the advancement of its product candidates and research
and development efforts. Significant agreements are described in detail below (collectively, the &#8220;License, Strategic Alliance,
and Research Agreements&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock"><p id="xdx_89C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_zUPp1vlrXnNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below are the approximate amounts expensed for License, Strategic Alliance, and Research Agreements during the years ended December
31, 2022 and 2021, respectively. These expensed amounts are included under research and development expenses in the accompanying consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zVUnjwSUHIfc" style="display: none">Schedule
of Research and Development</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_497_20220112__20221231_zOUgZjK3bGtf" style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_498_20210112__20211231_zxxQ7bnsvSAa" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 60%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentIncomeExpense_zJTowY9OJshd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amount Expensed for License, Strategic Alliance, and Research Agreements</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="LTRN:ResearchAndDevelopmentIncomeExpense" contextRef="From2022-01-122022-12-31" id="Fact000568" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,222,000</ix:nonFraction><sup id="xdx_F20_zJyrcaOateCf" style="display: none">*</sup></td><td style="text-align: left">*</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="LTRN:ResearchAndDevelopmentIncomeExpense" contextRef="From2021-01-122021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,483,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -4.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F04_zn7AYHnTtB0c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_z2HINIcl3DNl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000570" xml:lang="en-US">Amounts
    expensed for License, Strategic Alliance, and Research Agreements during the year ended December 31, 2022 were reduced by $<span id="xdx_90F_ecustom--DecreaseInResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_z7s66XaiK7U3" title="Research and development expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc2VhcmNoIGFuZCBEZXZlbG9wbWVudCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="LTRN:DecreaseInResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">935,000</ix:nonFraction></span>
    as a result of a payment we received in July 2022 from one of our service providers in connection with the resolution of a difference
    of views regarding the service provider agreement. This payment received by us offset other expenses for License, Strategic Alliance,
    and Research Agreements during this period.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A3_z3SbIh5eGBN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 138 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_znasbpNuzUnd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below at December 31, 2022 and December 31, 2021, respectively, are (1) the approximate amounts accrued and payable under the License,
Strategic Alliance, and Research Agreements, and (2) the approximate amount of prepaid expenses and other current assets under the License,
Strategic Alliance, and Research Agreements. These amounts are included in the accompanying consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zbVBWCwKdtOg" style="display: none">Schedule
of Accounts Payable and Accrued Liabilities</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20221231_zkXhnstfatwk" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20211231_zgfYgbkPpbze" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_hus-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_zG8FxVxSRKti" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    accrued and payable under License, Strategic Alliance, and Research Agreements</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2022-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,813,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2021-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,493,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_zwfMMA3k4Gx5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements</span></p>
                                                                           <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,595,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,023,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zdSdMa76fWZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>BioNumerik
Pharmaceuticals</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2018, the Company entered into an Assignment Agreement (the &#8220;Assignment Agreement&#8221;) with BioNumerik Pharmaceuticals,
Inc. (&#8220;BioNumerik&#8221;), pursuant to which the Company acquired rights to domestic and international patents, trademarks and
related technology and data relating to LP-300 (Tavocept) for human therapeutic treatment indications. The Assignment Agreement replaced
a License Agreement that was entered into between the Company and BioNumerik in May 2016. The Company made upfront payments totaling
$<span id="xdx_907_ecustom--UpfrontPayments_c20180101__20180131__dei--LegalEntityAxis__custom--BioNumerikPharmaceuticalsMember__us-gaap--TypeOfArrangementAxis__custom--AssignmentAgreementMember_zFAjeqreVDKe" title="Upfront payments"><ix:nonFraction name="LTRN:UpfrontPayments" contextRef="From2018-01-012018-01-31_custom_BioNumerikPharmaceuticalsMember_custom_AssignmentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> in connection with entry into the Assignment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20180101__20180131__dei--LegalEntityAxis__custom--BioNumerikPharmaceuticalsMember__us-gaap--TypeOfArrangementAxis__custom--AssignmentAgreementMember_z06dfS5pNtug" title="Commitments description"><ix:nonNumeric contextRef="From2018-01-012018-01-31_custom_BioNumerikPharmaceuticalsMember_custom_AssignmentAgreementMember" name="us-gaap:OtherCommitmentsDescription">In
the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment
recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100
million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250
million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative
revenue in excess of $1 billion</ix:nonNumeric></span>. The Company has the right to first recover certain designated portions of patent costs and development
and regulatory costs before the payment of royalties described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company enters into a third-party transaction for LP-300, the Company is required to pay the BioNumerik-related payment recipients
a specified percentage of any upfront, milestone, and royalty amounts received by the Company from the transaction, after first recovering
specified direct costs incurred by the Company for the development of LP-300 that are not otherwise reimbursed from such third-party
transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Assignment Agreement provides that the Company will use commercially diligent efforts to develop LP-300 and make specified
regulatory filings and pay specified development and regulatory costs related to LP-300. The Assignment Agreement also provides that
the Company will provide TriviumVet DAC (&#8220;TriviumVet&#8221;) with (i) specified data and information generated by the Company with
respect to LP-300, and (ii) an exclusive license to use specified LP-300-related patent rights, trademark rights and related intellectual
property to support LP-300 development in non-human (animal) treatment indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is also required to pay all patent costs on covered patents related to LP-300. These patent costs are included in general and
administrative expenses in the accompanying consolidated statements of operations. These patent costs are fully recoverable at the time
of any net revenue from LP-300, with up to <span id="xdx_904_ecustom--RevenuePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--AssignmentAgreementMember_zwf8N1qM35kg" title="Revenue percentage"><ix:nonFraction name="LTRN:RevenuePercentage" contextRef="From2022-01-012022-12-31_custom_AssignmentAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of net revenue amounts to be applied towards repayment of patent costs until such costs
are fully recovered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 139 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the recovery of patent costs, the Company has the right to recover the $<span id="xdx_901_ecustom--UpfrontPayments_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--AssignmentAgreementMember_zaP9kmEn5iXj" title="Upfront payments"><ix:nonFraction name="LTRN:UpfrontPayments" contextRef="From2022-01-012022-12-31_custom_AssignmentAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span>
upfront payments made in connection with entry into the Assignment Agreement, which payments are recoverable prior to making any
royalty or third-party transaction sharing payments. The Company also has the right to recover previously incurred LP-300
development and regulatory costs, with up to a mid-single digit percentage of net revenue amounts to be applied towards repayment of
development and regulatory costs until such costs are fully recovered. No amounts were expensed with respect to BioNumerik during the years ended
December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AF
Chemicals</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2015, the Company entered into a Technology License Agreement to exclusively license domestic and international patent rights
from AF Chemicals, LLC (&#8220;AF Chemicals&#8221;) for the treatment of cancer in humans for the compounds LP-100 (Irofulven) and LP-184.
In February 2016, the Company and AF Chemicals entered into an Addendum (the &#8220;Addendum&#8221;) providing for additions and amendments
to the Technology License Agreement. In December 2020, the Company and AF Chemicals entered into a Second Addendum (the &#8220;Second
Addendum&#8221;) providing for further additions and amendments to the Technology License Agreement. The Technology License Agreement,
Addendum and Second Addendum are collectively referred to as the &#8220;AFC License Agreement&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Second Addendum, the Company made specified payments to AF Chemicals during the nine months ended September 30, 2021. The Second
Addendum also provides that, from December 30, 2020 until January 15, 2025, the Company will have no obligation to pay annual licensing
fees, development diligence extension payments, or patent maintenance fee payments to AFC under the AFC License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Second Addendum, the Company has agreed to apply for specified orphan drug designations for LP-184 in the US and EU. The
Second Addendum also amends and clarifies other provisions of the Technology License Agreement, and provides the Company with the ability
to recover a portion of initial payments made under the Second Addendum from sublicense fees or royalty payments that may be made to
AFC by the Company or third parties prior to January 15, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the AFC License Agreement the Company made annual licensing fee payments to AF Chemicals relating to LP-184 for periods prior to signing
the Second Addendum. In addition, the Company is obligated to make milestone payments to AF Chemicals at the time of an Investigational
New Drug Application (&#8220;IND&#8221;) filing relating to LP-184 and also upon reaching additional specified milestones in connection
with the development and potential marketing approval of LP-184 in the United States, specified countries in Europe, and other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
AFC License Agreement also provides that the Company will pay AF Chemicals a royalty of at least a very small single digit percentage
of specified net sales of LP-184 and other analogs. <span id="xdx_901_ecustom--LicenseAgreementDescription_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--AFCLicenseAgreementMember__dei--LegalEntityAxis__custom--AFChemicalsMember_ziBTHI0moiqh" title="License agreement, description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_AFCLicenseAgreementMember_custom_AFChemicalsMember" name="LTRN:LicenseAgreementDescription">In addition, the AFC License Agreement contains specified time requirements for the
Company to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the
Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two,
three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated by
the Company and AF Chemicals</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Second Addendum, no additional payments of annual licensing fees or development diligence extension payments related to LP-184
are required to be made by the Company until January 15, 2025, at which time these obligations will resume. The Company will also be
obligated to make payments to AF Chemicals relating to LP-100 beginning January 15, 2025, as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a sublicense of the LP-184 rights, the Company is obligated to pay AF Chemicals (a) a low double-digit percentage of the
gross income and fees received by the Company with respect to the United States in connection with such sublicense, and (b) a lower double
digit percentage of the gross income and fees received by the Company with respect to Europe and Japan in connection with such sublicense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 140 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts to be paid to AF Chemicals with respect to LP-100 under the AFC License Agreement are in many ways similar to the amounts to
be paid with respect to LP-184 as described above. In addition, the AFC License Agreement contains specified time requirements for
the Company to enroll patients in clinical trials and file a potential NDA with respect to LP-100. Extension fees may be paid by the
Company to AF Chemicals from time to time related to these requirements. Pursuant to the Second Addendum with AF Chemicals, no
additional payments of annual licensing fees or development diligence extension payments are required to be made by the Company with
respect to LP-100 until January 15, 2025, at which time these obligations will resume. Approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--AFCLicenseAgreementMember__dei--LegalEntityAxis__custom--AFChemicalsMember_zsF7ehEx02Sg" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_AFCLicenseAgreementMember_custom_AFChemicalsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--AFCLicenseAgreementMember__dei--LegalEntityAxis__custom--AFChemicalsMember_zbNHbA2TTpIh" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_AFCLicenseAgreementMember_custom_AFChemicalsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,000</ix:nonFraction></span> were
expensed with respect to the AFC License Agreement during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development
expenses in the accompanying consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Allarity
Therapeutics (formerly known as Oncology Venture)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2015, the Company licensed various rights to LP-100 to Oncology Venture (now known as Allarity Therapeutics) pursuant to a Drug License
and Development Agreement. In February 2016, the Company and Allarity Therapeutics entered into an addendum and an amendment providing
for additions and amendments to the Drug License and Development Agreement. In connection with the Drug License and Development Agreement,
as amended (collectively, the &#8220;Allarity License and Development Agreement&#8221;), Allarity Therapeutics agreed to directly pay
to AF Chemicals on behalf of the Company certain amounts to satisfy the Company&#8217;s milestone obligations to AF Chemicals with respect
to LP-100 under the AFC License Agreement. Amounts paid by Allarity Therapeutics to AF Chemicals on behalf of the Company would then
be deducted from amounts owed by Allarity Therapeutics to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 23, 2021, the Company entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for
Irofulven (LP-100) from Allarity. The transaction includes global rights to LP-100, as well as the developed clinical protocol for an
intended study in bladder and prostate cancer patients who have a mutation in the ERCC2/3 genes. As a result of this transaction, the
Company has full authority to manage and guide future clinical development and commercialization of LP-100. Under the terms of the Asset
Purchase Agreement, the Company paid an initial upfront payment of $<span id="xdx_90C_ecustom--UpfrontPayments_c20210721__20210723__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zTKtmNl1saf4" title="Upfront payments"><ix:nonFraction name="LTRN:UpfrontPayments" contextRef="From2021-07-212021-07-23_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> to Allarity. The Company determined there was no planned
alternative future use for these assets outside of the clinical development of LP-100 and therefore the full amount of the upfront payment
was included in research and development expense. The Company released approximately $<span id="xdx_90B_eus-gaap--EscrowDepositsRelatedToPropertySales_c20210721__20210723__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zKC9qLhW0M9j" title="Escrow related expenses"><ix:nonFraction name="us-gaap:EscrowDepositsRelatedToPropertySales" contextRef="From2021-07-212021-07-23_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">459,000</ix:nonFraction></span> from escrow to Allarity related to recertification
of LP-100 drug stock during the year ended December 31, 2022. Future payments of up to $<span id="xdx_907_ecustom--FuturePayments_c20210721__20210723__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z9yrlZhHK8A4" title="Future payments"><ix:nonFraction name="LTRN:FuturePayments" contextRef="From2021-07-212021-07-23_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> currently held in escrow also have the
potential to deliver an additional amount to Allarity based on drug trial enrollment milestones within the 24 months following the date
of the transaction. Allarity is also eligible to receive additional milestone payments over the life of the program based on IP license
milestones and regulatory filings and approvals in the US and EU, and low- to mid-single-digit royalties on future commercial net sales.
As part of the Asset Purchase Agreement, the Allarity License and Development Agreement was terminated. Approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z0k68lfLGzDk" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">459,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z0441kFNE6Ke" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> were expensed with respect to Allarity during the years ended December 31,
2022 and 2021, respectively, which amounts are included in research and development expenses in the accompanying consolidated statements
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Califia
Pharma</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, the Company entered into an Evaluation and Limited Use Agreement (the &#8220;Evaluation Agreement&#8221;) with Califia
Pharma, Inc. (&#8220;Califia&#8221;). The Evaluation Agreement provided for the Company and Califia to collaborate on the in vitro and
in vivo testing and evaluation of novel Califia linker technology and related payloads to be conjugated to a Lantern targeting entity.
The Evaluation Agreement also provided the Company with the right to negotiate with Califia for exclusive license rights to use LP-184
and related analogs as the payload with an affinity drug conjugate or small molecule drug conjugate targeting entity supplied by the
Company. The Company also had the right under the Evaluation Agreement to negotiate for non-exclusive license rights to use a targeting
entity from the Company with a payload and linker combination selected from novel specified Califia payloads and linkers. The Evaluation
Agreement expired on December 31, 2021 and the Company determined not to extend it. No amounts and approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--CalifiaPharmaMember__us-gaap--TypeOfArrangementAxis__custom--EvaluationAgreementMember_znUWQ8ND8Lvk" title="Research and development expenses"><span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--CalifiaPharmaMember__us-gaap--TypeOfArrangementAxis__custom--EvaluationAgreementMember_zYwcsvIr06b3" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_CalifiaPharmaMember_custom_EvaluationAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_CalifiaPharmaMember_custom_EvaluationAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></ix:nonFraction></span></span> were expensed with respect to the
Califia Evaluation Agreement during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development
expenses in the accompanying consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Patheon
API Services</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">The Company has entered into agreements
with Patheon API Services, Inc. (&#8220;Patheon&#8221;) for the manufacture and supply of cGMP material to support the Company&#8217;s
Phase II clinical trial for its product candidate LP-300. In addition to producing LP-300 API (active pharmaceutical ingredient) under
cGMP (current Good Manufacturing Practices) conditions, Patheon transferred previously validated manufacturing processes and analytical
methods for LP-300 and produced non-GMP material for use in support of non-clinical studies for LP-300. The agreements provide for payments
in stages as specified process and manufacturing milestones are achieved. </span>Approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--PatheonAPIServicesMember__us-gaap--TypeOfArrangementAxis__custom--PatheonAgreementMember_z2Ozd7B0elV1" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_PatheonAPIServicesMember_custom_PatheonAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--PatheonAPIServicesMember__us-gaap--TypeOfArrangementAxis__custom--PatheonAgreementMember_zNI7vQNSsVXi" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_PatheonAPIServicesMember_custom_PatheonAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">963,000</ix:nonFraction></span> was expensed with
respect to the Patheon agreements during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research
and development expenses in the accompanying consolidated statements of operations. <span style="background-color: white">The Company
expects to expense additional amounts in future periods in accordance with the progress of work completed under the Patheon agreements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 141 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Southwest
Research Institute</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">As part of the Company&#8217;s research
and development activities, the Company has engaged Southwest Research Institute (&#8220;SwRI&#8221;) from time to time to assist with
compound synthesis and manufacturing related activities for the Company&#8217;s product candidates. The Company has entered into agreements
with SwRI for the non-GMP and cGMP synthesis of LP-184 material and related analytical development</span>. Approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--SouthwestResearchInstituteMember__us-gaap--TypeOfArrangementAxis__custom--SouthwestResearchInstituteAgreementMember_zEBfGGWTUx5b" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_SouthwestResearchInstituteMember_custom_SouthwestResearchInstituteAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">494,000</ix:nonFraction></span> and
$<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--SouthwestResearchInstituteMember__us-gaap--TypeOfArrangementAxis__custom--SouthwestResearchInstituteAgreementMember_zU2dRsu3vpki" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_SouthwestResearchInstituteMember_custom_SouthwestResearchInstituteAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,261,000</ix:nonFraction></span> was expensed with respect to the SwRI agreements during the years ended December 31, 2022 and 2021, respectively, which amounts
are included in research and development expenses in the accompanying consolidated statements of operations. <span style="background-color: white">The
Company expects to expense additional amounts in future periods in accordance with the progress of work completed under the SwRI agreements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>The
Research Institute of Fox Chase Cancer Center</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">In September 2020, the Company entered
into a research agreement with the Research Institute of Fox Chase Cancer Center (&#8220;FCCC&#8221;), which was amended in January 2022,
as part of the Company&#8217;s research and development activities, with a focus on advancing the targeted use of LP-184 in molecularly-defined
sub-types of pancreatic cancer.</span> Approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--FoxChaseCancerCenterMember__us-gaap--TypeOfArrangementAxis__custom--FoxChaseCancerCenterAgreementMember_zYauBTp0Tky3" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_FoxChaseCancerCenterMember_custom_FoxChaseCancerCenterAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--FoxChaseCancerCenterMember__us-gaap--TypeOfArrangementAxis__custom--FoxChaseCancerCenterAgreementMember_zLI4AKLVju15" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_FoxChaseCancerCenterMember_custom_FoxChaseCancerCenterAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,000</ix:nonFraction></span> was expensed with respect to the FCCC agreements during the
years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development expenses in the accompanying
consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Piramal
Pharma Solutions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">In January 2021, the Company entered
into an agreement with Piramal Pharma Solutions (&#8220;Piramal&#8221;) for the fill and finish manufacture of LP-300 drug product at
Piramal&#8217;s Lexington, Kentucky site in support of future Phase II clinical testing. The agreement, as amended, provides for Piramal
to conduct activities in support of the cGMP manufacturing of LP-300, including analytical and process transfer activities, manufacture
of cGMP clinical batches, and performance of stability studies on cGMP batches of LP-300 drug product. </span>Approximately $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--PiramalPharmaSolutionMember__us-gaap--TypeOfArrangementAxis__custom--PiramalPharmaAgreementMember_zhXzNZeIn1d1" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_PiramalPharmaSolutionMember_custom_PiramalPharmaAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">196,000</ix:nonFraction></span> and
$<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--PiramalPharmaSolutionMember__us-gaap--TypeOfArrangementAxis__custom--PiramalPharmaAgreementMember_zVE60chqUTqk" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_PiramalPharmaSolutionMember_custom_PiramalPharmaAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">535,000</ix:nonFraction></span> was expensed with respect to Piramal agreements during the years ended December 31, 2022 and 2021, respectively, which amounts
are included in research and development expenses in the accompanying consolidated statements of operations. <span style="background-color: white">The
Company expects to expense additional amounts in future periods in accordance with the progress of work completed under Piramal agreements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>vivoPharm</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">In September 2021, the Company&#8217;s
Australian subsidiary entered into an agreement with RDDT, a vivoPharm Company Pty Ltd (&#8220;vivoPharm&#8221;), for multiple preclinical
studies, including animal studies, as part of an IND-enabling program for LP-184. The Company&#8217;s Australian subsidiary entered into
an additional agreement with vivoPharm in 2022 as part of an IND-enabling program for LP-284. Amendments to the vivoPharm agreements were
made in 2022. </span>Approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--VivoPharmMember__us-gaap--TypeOfArrangementAxis__custom--VivoPharmAgreementMember_zxd331l1i2k8" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_VivoPharmMember_custom_VivoPharmAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,030,000</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--VivoPharmMember__us-gaap--TypeOfArrangementAxis__custom--VivoPharmAgreementMember_zuOdxvFVoFn7" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_VivoPharmMember_custom_VivoPharmAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,000</ix:nonFraction></span> was expensed with respect to the vivoPharm agreements during the years ended
December 31, 2022 and 2021, respectively, which amounts are included in research and development expenses in the accompanying consolidated
statements of operations. <span style="background-color: white">The Company expects that additional amounts will be expensed in future
periods in accordance with the progress of work completed under the vivoPharm agreements, as amended.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>TD2</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">In October 2021, the Company entered
into a Statement of Work, as amended in March 2022, with Translational Drug Development, LLC (&#8220;TD2&#8221;) providing for TD2 to
serve as the lead contract research organization (CRO) for the Company&#8217;s Phase II clinical trial for its product candidate LP-300</span>.
Approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--TranslationalDrugMember_zWXQPyxg7Yz3" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_TranslationalDrugMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">789,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--TranslationalDrugMember__us-gaap--TypeOfArrangementAxis__custom--TranslationalDrugAgreementMember_zctxwFNH4G69" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_TranslationalDrugMember_custom_TranslationalDrugAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,000</ix:nonFraction></span> was expensed with respect to TD2 during the years ended December 31, 2022 and 2021, respectively,
which amounts are included in research and development expenses in the accompanying consolidated statements of operations. <span style="background-color: white">The
Company expects to expense additional amounts in future periods in connection with services provided by TD2 as well as clinical trial
site and other pass-through costs relating to the LP-300 Phase II clinical trial.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Berkshire
Sterile Manufacturing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">During the year ended December 31,
2022, the Company entered into agreements with Berkshire Sterile Manufacturing (&#8220;Berkshire&#8221;) to support technical transfer
and GMP drug product manufacturing of LP-300. </span>Approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--BerkshireSteruleManufacturingMember__us-gaap--TypeOfArrangementAxis__custom--BerkshireSteruleManufacturingAgreementMember_zFJlabO90tk9" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_BerkshireSteruleManufacturingMember_custom_BerkshireSteruleManufacturingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">689,000</ix:nonFraction></span> and <span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__dei--LegalEntityAxis__custom--BerkshireSteruleManufacturingMember__us-gaap--TypeOfArrangementAxis__custom--BerkshireSteruleManufacturingAgreementMember_zE2dv45VrTEg" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_BerkshireSteruleManufacturingMember_custom_BerkshireSteruleManufacturingAgreementMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> amounts were expensed with respect to the Berkshire
agreements during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development expenses
in the accompanying consolidated statements of operations. <span style="background-color: white">The Company expects that additional amounts
will be expensed in future periods in accordance with the progress of work completed under the Berkshire agreements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 142 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Shilpa
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">In March 2022, the Company entered
into an agreement with Shilpa Medicare Limited (&#8220;Shilpa&#8221;) for fit-to-purpose process development and synthesis of a key starting
material relating to the synthesis of LP-184 under cGMP. </span>In July 2022, the Company entered into agreements with Shilpa Pharma Lifesciences
<span style="background-color: white">for the cGMP synthesis of LP-184 API material as well as for drug product development and cGMP drug
product manufacturing of LP-184. In August 2022, </span>the Company entered into agreements with Shilpa <span style="background-color: white">for
the cGMP synthesis of LP-284 API material as well as for drug product development and cGMP drug product manufacturing of LP-284. </span>Approximately
$<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--ShilpaMember__us-gaap--TypeOfArrangementAxis__custom--ShilpaAgreementMember_zwJ3L5YykxWd" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_ShilpaMember_custom_ShilpaAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">707,000</ix:nonFraction></span> and <span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__dei--LegalEntityAxis__custom--ShilpaMember__us-gaap--TypeOfArrangementAxis__custom--ShilpaAgreementMember_zVI1xIFFuRc5" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_ShilpaMember_custom_ShilpaAgreementMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> amounts were expensed with respect to the Shilpa agreements during the years ended December 31, 2022 and 2021, respectively,
which amounts are included in research and development expenses in the accompanying consolidated statements of operations. <span style="background-color: white">The
Company expects that expense additional amounts in future periods in accordance with the progress of work completed payment schedule specified
under the Shilpa agreements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Curia</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">During the year ended December 31,
2022</span>, the Company entered into agreements with Curia Global, Inc. (&#8220;Curia&#8221;) for the cGMP manufacture of LP-300 API.
Approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--CuriaMember_zVgUp9mIZTP6" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_CuriaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,000</ix:nonFraction></span> and <span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__dei--LegalEntityAxis__custom--CuriaMember_zJquMsz13Hk7" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_CuriaMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> amounts were expensed with respect to the Curia agreements during the years ended December 31, 2022 and
2021, respectively, which amounts are included in research and development expenses in the accompanying consolidated statements of operations.
<span style="background-color: white">The Company expects that additional amounts will be expensed in future periods in accordance with
the progress of work completed under the Curia agreements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LumaBridge
(formerly known as Cancer Insight)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2022, the Company entered into an agreement with Cancer Insight,
LLC, now known as LumaBridge, LLC (&#8220;LumaBridge&#8221;) for IND filing, regulatory support, Phase I pre-trial startup activities,
and strategic program consulting relating to LP-184. Approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--LumaBridgeLLCMember__us-gaap--TypeOfArrangementAxis__custom--LumaBridgeAgreementMember_zxj6UlkiwpX6" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_LumaBridgeLLCMember_custom_LumaBridgeAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,000</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__dei--LegalEntityAxis__custom--LumaBridgeLLCMember__us-gaap--TypeOfArrangementAxis__custom--LumaBridgeAgreementMember_zVgqywFvitr6" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31_custom_LumaBridgeLLCMember_custom_LumaBridgeAgreementMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> amounts were expensed with respect to the LumaBridge
agreements during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development expenses
in the accompanying consolidated statements of operations. <span style="background-color: white">The Company expects that additional amounts
will be expensed in future periods relating to services provided pursuant to the LumaBridge agreement.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Research and Service Provider Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the agreements described above, the Company has entered into other research and service provider agreements for the advancement
of its product candidates and research and development efforts. The Company expects to expense additional amounts in future periods in
connection with existing and future research and service provider agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EU
Grant</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2018, Lantern Pharma Limited, a wholly owned subsidiary of Lantern Pharma Inc., was awarded a grant by the UK government in
the form of state aid under the Commission Regulations (EU) No. 651/2014 of 17 June 2014 (the &#8220;General Block Exemption&#8221;),
Article 25 Aid for research and development projects, state aid notification no. SA.40154. The grant was awarded to conduct research
and development activities for the prostate cancer biomarker analysis of the LP-184 drug candidate. Following the Company&#8217;s research
and development activities in Northern Ireland, the grant will reimburse the Company <span id="xdx_900_ecustom--ResearchAndDevelopmentExpensesPercentage_pid_dp_uPure_c20220101__20221231__dei--LegalEntityAxis__custom--LanternPharmaLimitedMember_zSoQxvwcWtpa" title="Research and development expenses percentage"><ix:nonFraction name="LTRN:ResearchAndDevelopmentExpensesPercentage" contextRef="From2022-01-012022-12-31_custom_LanternPharmaLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of its research and development expenses not
exceeding GBP <span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_uGBP_c20220101__20221231__dei--LegalEntityAxis__custom--LanternPharmaLimitedMember_zPK2IUUKzRZc" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_LanternPharmaLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="GBP">24,215</ix:nonFraction></span> of vouched and approved expenditures within specific categories. The grant contains some reporting and consent requirements.
The grant will remain in force for a period of five years. No payments to the Company have been made under the grant as of December 31,
2022. <span id="xdx_90A_eus-gaap--Revenues_do_c20220101__20221231__dei--LegalEntityAxis__custom--LanternPharmaLimitedMember_zmuGo2O71Iq3" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_LanternPharmaLimitedMember" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></span> revenue has been recognized from this grant through December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 143 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Actuate
Therapeutics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Company entered into a Collaboration Agreement with Actuate Therapeutics, Inc. (&#8220;Actuate&#8221;), a clinical stage
private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases
leading to fibrosis. Pursuant to the agreement, the Company and Actuate are collaborating on utilization of the Company&#8217;s RADR&#174;
platform to develop novel biomarker derived signatures for use with one of Actuate&#8217;s product candidates. As part of the collaboration,
the Company received <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c20210501__20210531__dei--LegalEntityAxis__custom--ActuateTherapeuticsMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_z4atBO4DTVkl" title="Actuate stock of restricted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="From2021-05-012021-05-31_custom_ActuateTherapeuticsMember_custom_CollaborationAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> restricted shares of Actuate stock, subject to meeting certain conditions of the collaboration, as well as
the potential to receive additional Actuate stock if results from the collaboration are utilized in future development efforts. In 2022,
the term of the Collaboration Agreement was extended to continue until March 31, 2023. Leslie W. Kreis, Jr., a director of the Company
until June 8, 2022, is also a director of Actuate. Affiliates of Mr. Kreis hold substantial beneficial ownership interests in both the
Company and Actuate. Through December 31, 2022, no revenues have been recognized under the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restricted shares of Actuate stock had a nominal value when acquired and, therefore, were recorded at a cost of $<span id="xdx_909_ecustom--NominalValueOfRestrictedSharesOfActuateStock_iI_c20210531__dei--LegalEntityAxis__custom--ActuateTherapeuticsMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zWaINJOyLoO3" title="Nominal value acquired cost"><ix:nonFraction name="LTRN:NominalValueOfRestrictedSharesOfActuateStock" contextRef="AsOf2021-05-31_custom_ActuateTherapeuticsMember_custom_CollaborationAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>. These shares do not
have a readily determinable fair value, but will be adjusted for observable price changes, if any, in future periods. There were no adjustments
to the carrying amount through December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zd6Ss8nfEK2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5. <span id="xdx_82C_z0g7DBO49wS4">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
operating lease cost recognized in general and administrative expenses in the Company&#8217;s consolidated statements of operations was
approximately $<span id="xdx_903_eus-gaap--OtherGeneralAndAdministrativeExpense_c20220101__20221231_z31nRnU5H7Wa" title="General and administrative expenses"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--OtherGeneralAndAdministrativeExpense_c20210101__20211231_z63tkB9GNhJ" title="General and administrative expenses"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,000</ix:nonFraction></span> for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="LTRN:ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock_zruYKAcwdsr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following provides balance sheet information related to leases as of December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zf6b65fg8pKi" style="display: none">Schedule
of Balance Sheet Information Related to Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20221231_zJ423jqzMxSi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20211231_zUfl7QuYrqLa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                                                                                                                                31, 2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_iI_z0vwXl3Er1ih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease, right-of-use asset, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,687</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,943</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zwDIFaYg9LR6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    portion of operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,890</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,058</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z7DYTEEFNgg9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liabilities, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,890</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiability_iI_zrtrxmFjdPO8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,890</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,948</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zKTC5JCKWBS" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 144 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zj3XVayTaE11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, the future estimated minimum lease payments under non-cancelable operating leases are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zw2FsPlAcPCg" style="display: none">Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20221231_zwzvebv5Mexl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPzhbM_z9mhXktjhgVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total minimum lease payments to be paid in 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,403</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zBZzSORla892" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less amount representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">513</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zZf7VfB8u5V7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,890</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zdPqkOGwqUkk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less current portion of operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,890</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z2I9Tv7m5zKk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zwTE0MEFHF23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2021, the Company entered into two operating leases for office space that commenced in May 2021. <span id="xdx_90D_ecustom--LeaseExpirationDate_c20220101__20221231_z9zMkwZ5Dmvk" title="Lease expiration date"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="LTRN:LeaseExpirationDate">The
leases were scheduled to expire in April 2023</ix:nonNumeric></span> and automatically renew month-to-month unless the Company provided three-months
written notice to the landlord prior to initial expiration. The exercise of lease renewal options was at the Company&#8217;s sole
discretion and is assessed as to whether to include any renewals in the lease term at inception. In March 2023, the Company renewed and extended its leases for office space
and access to meeting facilities in the Dallas, Texas area and in the Atlanta, Georgia area. The following table provides a
reconciliation for the Company&#8217;s right of use assets and lease liabilities:</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="LTRN:ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_zInnik6eGHC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zwBIZ2t26XO4" style="display: none">Schedule of
Reconciliation of Right-of-use Assets and Lease Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Right-of-Use Asset</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Operating Lease Liability</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2021</td><td>&#160;</td>
    <td colspan="2" id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20210101__20211231_zzxQ3ZVmxIz1" title="Right of use asst">$<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_981_eus-gaap--OperatingLeaseLiability_iS_c20210101_zEbhtgm62yig" title="Operating lease liability">$<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0698">-</span></span></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Additions</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetAdditions_c20210101__20211231_ztWO0s3ao4al" title="Additions, Right of use asset" style="width: 16%; text-align: right"><ix:nonFraction name="LTRN:OperatingLeaseRightOfUseAssetAdditions" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,472</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--OperatingLeaseLiabilityInAdditions_c20210101__20211231_z7G9JBWpilAh" title="Additions, Operating lease liability" style="width: 16%; text-align: right"><ix:nonFraction name="LTRN:OperatingLeaseLiabilityInAdditions" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,603</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Amortizations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20210101__20211231_z9GwPqqo3Ci" title="Amortizations, Right of use asset" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,529</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--OperatingLeaseLiabilityAmortization_c20210101__20211231_z4WHHfzgVwol" title="Amortizations, Operating lease liability" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="LTRN:OperatingLeaseLiabilityAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">71,655</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20220101__20221231_zJvVPMvypF5b" title="Right of use asset" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--OperatingLeaseLiability_iS_c20220101__20221231_zgbyKUR1DRy" title="Operating lease liability" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,948</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Amortizations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20220101__20221231_zsAfwWz9vq7d" title="Amortizations, Right of use asset" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,256</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--OperatingLeaseLiabilityAmortization_c20220101__20221231_zmuZTmLV85r2" title="Amortizations, Operating lease liability" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="LTRN:OperatingLeaseLiabilityAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">152,058</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20220101__20221231_zlz1J4108bG1" title="Right of use asset" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,687</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_iE_c20220101__20221231_zyTPt5jfwvA8" title="Operating lease liability" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,890</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AF_zDraQNMo8Qc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="LTRN:ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock_zqkWcgENXZ77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
supplemental information related to operating leases is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BA_zYpSDAjAcdBe" style="display: none">Schedule of Other Supplemental Information
Related to Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_ztmiwWU5ot2c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_zGOho28oFFX7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Weighted average remaining term of operating leases (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zyQQ82gd8P3i" title="Weighted average remaining term of operating leases (in years)"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.33</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_z0vh5280ug33" title="Weighted average remaining term of operating leases (in years)"><ix:nonNumeric contextRef="AsOf2021-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.33</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zOZyxqSgt6d3" style="vertical-align: bottom; background-color: White">
    <td>Weighted average discount rate of operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.65</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.65</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zQb6q64MDoke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also leased office space in Dallas, Texas under month-to-month lease arrangements during the years ended December 31, 2022 and
2021. Under these short-term leases, the Company elected the short-term lease measurement and recognition exemption under ASC 842 and
recorded rent expense as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zd1rX7qf8OOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6. <span id="xdx_826_zf1BYOYcsMWj">Shareholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Company&#8217;s IPO, all shares of the Company&#8217;s Series A preferred stock were converted into <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20200601__20200615__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zKpZrdEiq462" title="Conversion of Stock, Shares Converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2020-06-012020-06-15_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,438,851</ix:nonFraction></span> shares of common stock
effective June 15, 2020, with fractional share adjustments made in connection with the conversion as discussed below. As of December
31, 2022 and 2021, the Company had <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zg7SGq7t4Suh" title="Preferred stock shares authorized"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zNjqF7tqr813" title="Preferred stock shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> authorized shares of preferred stock, with <span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_dc_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcdxF2vypem9" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zqaaVR1V4MRd" title="Preferred stock, shares outstanding"><span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_dc_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztJIvOudfNV1" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTuF7EdlDQ79" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of preferred stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2021, the Company closed a public offering of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaw7nlqsMeg8" title="Issuance of stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-192021-01-20_us-gaap_IPOMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,928,571</ix:nonFraction></span> shares of its common stock at a public offering price of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2X2Lvf00vUd" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-01-20_us-gaap_IPOMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.00</ix:nonFraction></span> per
share, which amount included <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zRaECfCYLVr2" title="Issuance of stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-192021-01-20_us-gaap_IPOMember_us-gaap_CommonStockMember_custom_UnderwritersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">642,856</ix:nonFraction></span> shares sold upon full exercise of the underwriter&#8217;s over-allotment option. Total gross proceeds
from the offering were approximately $<span id="xdx_907_ecustom--GrossProceedsFromInitialPublicOffering_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z9nlwZF2sOei" title="Gross proceeds"><ix:nonFraction name="LTRN:GrossProceedsFromInitialPublicOffering" contextRef="From2021-01-192021-01-20_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,000,000</ix:nonFraction></span>, and net proceeds from the offering were approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zs5jrE2jesLl" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-01-192021-01-20_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,167,000</ix:nonFraction></span>, after deducting
underwriting discounts and commissions of approximately $<span id="xdx_90C_ecustom--ProceedsAfterDeductingUnderwritingDiscountsAndCommissions_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zSyCuYuUmedh" title="Proceeds after deducting underwriting discounts and commissions"><ix:nonFraction name="LTRN:ProceedsAfterDeductingUnderwritingDiscountsAndCommissions" contextRef="From2021-01-192021-01-20_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,554,000</ix:nonFraction></span> and other offering expenses of approximately $<span id="xdx_908_ecustom--OtherOfferingExpenses_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zUsR4OINnTMb" title="Other offering expenses"><ix:nonFraction name="LTRN:OtherOfferingExpenses" contextRef="From2021-01-192021-01-20_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279,000</ix:nonFraction></span>, including $<span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_c20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zsYuPfZ7Ccxl" title="Deferring offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2021-01-20_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></span>
of deferring offering costs previously recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 145 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2021, the Company&#8217;s Board of Directors authorized a share repurchase program to acquire up to $<span id="xdx_90F_eus-gaap--StockRepurchasedDuringPeriodShares_c20211101__20211130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zwP3mkcfcosc" title="Repurchase of shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2021-11-012021-11-30_us-gaap_CommonStockMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000,000</ix:nonFraction></span> of the Company&#8217;s
common stock. During the year ended December 31, 2022, the Company repurchased <span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_ziU77uvTMOTi" title="Repurchase of shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">353,667</ix:nonFraction></span> shares of common stock, pursuant to the repurchase
program for a total of approximately $<span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zKrm7U1P9US1" title="Repurchase of shares, value"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,482,000</ix:nonFraction></span>, including purchase fees. During the year ended December 31, 2021, the Company repurchased
<span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zhMHCx2jHPYd" title="Repurchase of shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">121,490</ix:nonFraction></span> shares of common stock pursuant to the repurchase program for a total of approximately $<span id="xdx_904_eus-gaap--StockRepurchasedDuringPeriodValue_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zwLcFQsqXBef" title="Repurchase of shares, value"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">940,000</ix:nonFraction></span>, including purchase fees. Upon
purchase, the repurchased shares ceased to be outstanding and returned to the status of authorized and unissued shares of common stock.
The share repurchase program terminated July 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zpx4XQP95Aci" title="Issuance of stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,782</ix:nonFraction></span> shares of common stock relating to the exercise of stock options. The shares
were issued at a purchase price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9e8E5duAXyj" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.03</ix:nonFraction></span> per share for total proceeds of approximately $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxDX8NAh2yAl" title="Issuance of stock, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7s18yvju3J" title="Issuance of stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,727</ix:nonFraction></span> shares of common stock relating to the cash exercise of warrants for total
proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlN92fMIdX7d" title="Proceeds from warrants exercise"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,000</ix:nonFraction></span>. During the year ended December 31, 2021 the Company also issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CashlessWarrantsMember_z2Jx54LQ8aph" title="Issuance of stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_CashlessWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,318</ix:nonFraction></span> shares of common stock relating
to the cashless exercise of warrants to purchase <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CashlessWarrantsMember_zAgqtSjTmUw7" title="Warrants to purchase shares"><ix:nonFraction name="LTRN:StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise" contextRef="From2021-01-012021-12-31_custom_CashlessWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,114</ix:nonFraction></span> shares, respectively. All of such warrants were exercisable at an exercise price
of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CashlessWarrantsMember_zbS1WEukoKh4" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-12-31_custom_CashlessWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.13</ix:nonFraction></span> per share of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx0hfPDJQsu3" title="Issuance of stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,093</ix:nonFraction></span> shares of common stock relating to the cashless exercise of stock options
to purchase <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcAcFjEGtOCb" title="Stock option"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,538</ix:nonFraction></span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb6nuJLAyHMb" title="Issuance of stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,779</ix:nonFraction></span> shares of common stock relating to the cash exercise of warrants for total
proceeds of approximately $<span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzbZmFoYJtif" title="Proceeds from warrants exercise"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span>. All of such warrants were exercisable at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4F53g3F9A26" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.13</ix:nonFraction></span> per share of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and December 31, 2021, the Company had <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zfJvt6dGqwk2" title="Common stock, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zVNTgUwyqA65" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000,000</ix:nonFraction></ix:nonFraction></span></span> authorized shares of Common Stock, of which <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20221231_zCcnhTCU6NJ1" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_z0Uk3SVXJ5F9" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,857,040</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20211231_z7HRRhFOKrVl" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zgerrfMyiAz8" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,088,835</ix:nonFraction></ix:nonFraction></span></span>
shares were issued and outstanding, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_zcwIrTM8xgt7" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,998</ix:nonFraction></span> shares of common stock outstanding and exercisable as of December 31, 2022 at a weighted average
exercise price of $<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231_zIQjzbe21mJ4" title="Weighted average exercise price, warrants"><ix:nonFraction name="LTRN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.27</ix:nonFraction></span> per share, and with expiration dates ranging from <span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zCh3Xxjp11c8" title="Expiration date of warrants"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MinimumMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">March 7, 2024</ix:nonNumeric></span> to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zlwBz2Go0tx9" title="Expiration date of warrants"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MaximumMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">June 10, 2025</ix:nonNumeric></span>. The Company had warrants to
purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_ztL2hgyJ0Caf" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">273,777</ix:nonFraction></span> shares of common stock outstanding and exercisable as of December 31, 2021 at a weighted average exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxXA4LHvAbwk" title="Weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.12</ix:nonFraction></span>
per share, and with expiration dates ranging from <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_z3txxujWdX3f" title="Expiration date of warrants"><ix:nonNumeric contextRef="From2021-01-012021-12-31_srt_MinimumMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">March 17, 2022</ix:nonNumeric></span> to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zFzaUsMF4dQd" title="Expiration date of warrants"><ix:nonNumeric contextRef="From2021-01-012021-12-31_srt_MaximumMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">June 10, 2025</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2018, the Board of Directors of the Company adopted the Lantern Pharma Inc. 2018 Equity Incentive Plan, which was
subsequently amended on December 17, 2018, February 26, 2020 and October 20, 2022. The Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and
restated, is referred to herein as the &#8220;Plan&#8221;. The Company reserved <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z7dwUgNUdsvh" title="Number of reserved shares"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,489,680</ix:nonFraction></span>
shares of its common stock for issuance under the Plan. The Plan is designed to provide additional incentives to employees,
directors and consultants to remain in the service of the Company as well as to encourage stock acquisition by members of these
targeted groups, which in the opinion of the management will support the alignment of the interests of the members of these groups
and stockholders. Options granted under the Plan are generally exercisable for up to <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zRQq2kTO1UR4" title="Options exercisable period"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">10</ix:nonNumeric></span>
years from grant date. <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_ziRpSSoNTxgc" title="Number of remain available shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" contextRef="From2022-01-012022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">288,796</ix:nonFraction></span>
shares remain available for future awards under the Plan at December 31, 2022, following the grant of options and the award of
restricted stock grants through December 31, 2022. The Company recorded stock-based compensation of approximately $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z1InlAtgdEtf" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,188,000</ix:nonFraction></span>
and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z9lNhRP2P72j" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">962,000</ix:nonFraction></span>
related to stock options during the years ended December 31, 2022 and 2021, respectively. Total remaining unrecognized compensation
expense for non-vested options is approximately $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zeFouxJC5eg7" title="Unrecognized compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,788,000</ix:nonFraction></span>
as of December 31, 2022, and is expected to be recognized over a weighted average period of <span id="xdx_902_eus-gaap--InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zQtQMGc13kM1" title="Weighted average period"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt-sec:duryear" name="us-gaap:InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod">1.8</ix:nonNumeric></span>
years. The weighted average remaining contractual term of outstanding options at December 31, 2022 is <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zMPdDsztsvm3" title="Weighted average remaining contractual term"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.26</ix:nonNumeric></span>
years. The weighted average remaining contractual term of exercisable options at December 31, 2022 is <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zYve3LXZuwG8" title="Weighted average remaining contractual term"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">6.56</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 146 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8iaSLhAL19h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity under the Plan during the years ended December 31, 2022 and 2021 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zUUItj2NWpne">Schedule
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br /> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average<br /> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br /> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average<br /> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Outstanding December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zZVhdRxrLQMl" title="Number of options outstanding, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">835,608</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_z5lob1pEOO39" title="Weighted average exercise price per share, outstanding beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.41</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20210101__20211231_zyrchipcFS71" title="Number of options exercisable, beginning valance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">610,633</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_c20210101__20211231_zaHioS0jijj" title="Number of options exercisable, weighted-average exercise price, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.24</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zaq2WlG8qVNe" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">110,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zGip72pd5LLj" title="Weighted average exercise price per share, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20211231_zKcw48HyEOi" title="Number of shares, exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,782</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zRCD9NKFuIL2" title="Weighted average exercise price per share, exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.03</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cancelled or expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20211231_zRsmUHoMgdue" title="Number of shares, cancelled or expired" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">43,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zVvRtcRp6KGb" title="Weighted average exercise price per share, cancelled or expired" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.00</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zU6Lry8J7yVl" title="Number of shares, outstanding beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">890,826</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zkULGhJ12l65" title="Weighted average exercise price per share, outstanding beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.54</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20220101__20221231_zisUrdXTZ5t6" title="Number of options exercisable, beginning valance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">687,438</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_c20220101__20221231_zNcT6IE8E399" title="Number of options exercisable, weighted-average exercise price, beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.77</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zsJAfx8CMb97" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">196,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zHmXOIrVQl6l" title="Weighted average exercise price per share, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zhucVShtxzN2" title="Number of shares, exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,538</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_z591Jknqms7c" title="Weighted average exercise price per share, exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.03</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cancelled or expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_z92LMtRNuuk2" title="Number of shares, cancelled or expired" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,897</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJMXz9agYLLe" title="Weighted average exercise price per share, cancelled or expired" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zfWtMxVQ5Mz" title="Number of shares, outstanding beinning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,037,591</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zr5tNq9SW4oa" title="Weighted average exercise price per share, outstanding ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.46</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zu6TkDEIXtJ1" title="Number of options exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">755,073</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zjNU9WeEoGNg" title="Number of options exercisable, weighted-average exercise price, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.87</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zGluRXstHgw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zETqDHuMsRsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
2022 and 2021, the fair value of each option granted was estimated using the Black-Scholes option-pricing model, using the following
weighted average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zfyjZILKeSd1">Schedule
of Weighted Average Assumptions</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zebNg2aKEHok" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_zrAg06TWqXhd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dtY_c20220101__20221231_zspC8oq5bGPh" title="Term (in years)"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:duryear" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">5.93</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dtY_c20210101__20211231_zjLkrFQsqbEi" title="Term (in years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">5.78</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_z3oLDsKXtGhl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Risk Free Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.04</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.30</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zzFQpOcVOOE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">125.35</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.70</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zAo1guIZ0QFd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_z7EQiJwxvSY3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Grant Date Fair Value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.90</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zjRCOwj73k82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of options is recognized as an expense over the vesting period and forfeitures are accounted for as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total intrinsic value of options outstanding at December 31, 2022 was approximately $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20221231_z9vOjjtW0Mzf" title="Total intrinsic value of options outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,422,000</ix:nonFraction></span>, and the total intrinsic value of options
exercisable at December 31, 2022 was approximately $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20221231_zeoouegS7ku9" title="Stock option intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,361,000</ix:nonFraction></span>. The total intrinsic value of options exercised during the year ended December
31, 2022 was approximately $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220101__20221231_zh2XTWGOkttc" title="Total intrinsic value of options exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,000</ix:nonFraction></span>. The total intrinsic value of options outstanding at December 31, 2021 was approximately $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20211231_zfscBSbxzPrd" title="Total intrinsic value of options outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,490,000</ix:nonFraction></span>,
and the total intrinsic value of options exercisable at December 31, 2021 was approximately $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231_zZxNFbsPNl3"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,490,000</ix:nonFraction></span>. The total intrinsic value of
options exercised during the year ended December 31, 2021 was approximately $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210101__20211231_zel5R7mIjCub"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    Term -</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company used a weighted average of time to vesting and maturity date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    Volatility-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    to the Company&#8217;s limited operating history and a lack of company-specific historical and implied volatility data, the Company
    has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded
    commensurate with expected term as of grant date. The historical volatility data was computed using the daily closing prices for
    the selected comparable companies&#8217; shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-Free
    Interest Rate-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company used the U.S. treasury bill rate commensurate with the expected term as of grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    Dividend-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    the Company has not issued any dividends and does not expect to issue dividends over the life of the options, the Company has estimated
    the dividend yield to be zero.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 147 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock"><p id="xdx_804_eus-gaap--CashCashEquivalentsAndMarketableSecuritiesTextBlock_zt1H2oUa5jSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7. <span id="xdx_826_zASw5XuSVl3i">Marketable Securities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:MarketableSecuritiesTextBlock"><p id="xdx_896_eus-gaap--MarketableSecuritiesTextBlock_zDgp5vSmG2Ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, marketable securities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zleHR3VOFLVg" style="display: none">Schedule of Marketable Securities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_488_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_zB8II5kyvdrk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized <br /> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_zqfLYKH39XVd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized <br /> Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_489_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_zxoKSlx76PT1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized <br /> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_ztzCC4fcTohh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br /> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_413_20221231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zt8s4WfUYz27" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,408,681</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,512</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,863</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,227,330</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20221231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zR2BKFzRUyo1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate Bonds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-12-31_custom_CorporateBondsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,522,138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2022-12-31_custom_CorporateBondsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,565</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2022-12-31_custom_CorporateBondsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,534</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2022-12-31_custom_CorporateBondsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,314,169</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20221231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesDebtMember_z5DpqkWZwse4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable Securities - Debt</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-12-31_custom_MarketableSecuritiesDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,930,819</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2022-12-31_custom_MarketableSecuritiesDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,077</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2022-12-31_custom_MarketableSecuritiesDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">395,397</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2022-12-31_custom_MarketableSecuritiesDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,541,499</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_417_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zl2XTJuYuRVa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,002,704</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">343,904</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,658,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zCSiBPIaLPUf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,023,154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,794,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20221231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMutualFundsMember_zZM2RCegHiLl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Marketable Securities &#8211; Mutual Funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-12-31_custom_MarketableSecuritiesMutualFundsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,025,858</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0945">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2022-12-31_custom_MarketableSecuritiesMutualFundsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">573,058</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2022-12-31_custom_MarketableSecuritiesMutualFundsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,452,800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20221231_zTaRiq5Xv0Pd" title="Marketable securities amortized cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,956,677</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_c20221231_zjqVUjd8Gpz3" title="Marketable securities unrealized gains" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,077</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_c20221231_zQ5JCprCoeoc" title="Marketable securities unrealized losses" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">968,455</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_c20221231_zqT6EEzStmg1" title="Marketable securities aggregate fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,994,299</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, marketable securities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none">&#160;</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_zBnhPUC2znm5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized <br /> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_483_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_zHU6pv4DreU1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized <br /> Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_zosW6frisiKh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized <br /> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_zHdG2JbYfeB4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br /> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_414_20211231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zoz7clhCAEnh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,808,056</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2021-12-31_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,003</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2021-12-31_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,781,053</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zr0syzF2qUv8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate Bonds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31_custom_CorporateBondsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,540,668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2021-12-31_custom_CorporateBondsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,869</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2021-12-31_custom_CorporateBondsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,474,799</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_410_20211231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesDebtMember_zq91oeTU5yZe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable Securities - Debt</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31_custom_MarketableSecuritiesDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,348,724</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2021-12-31_custom_MarketableSecuritiesDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,872</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2021-12-31_custom_MarketableSecuritiesDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,255,852</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20211231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zAWPe48PZirl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31_custom_MutualFundsFixedIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,002,704</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2021-12-31_custom_MutualFundsFixedIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,654</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2021-12-31_custom_MutualFundsFixedIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,966,050</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20211231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zboF29Gda8Di" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31_custom_MutualFundsAlternativeInvestmentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,023,154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2021-12-31_custom_MutualFundsAlternativeInvestmentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,904</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2021-12-31_custom_MutualFundsAlternativeInvestmentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,979,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20211231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMutualFundsMember_z5wLTpVc9iIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Marketable Securities &#8211; Mutual Funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31_custom_MarketableSecuritiesMutualFundsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,025,858</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2021-12-31_custom_MarketableSecuritiesMutualFundsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,558</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2021-12-31_custom_MarketableSecuritiesMutualFundsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,945,300</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20211231_zRlhZ4KPmIWl" title="Marketable securities amortized cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,374,582</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_c20211231_zNlQxQlRaFn4" title="Marketable securities unrealized gains" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_c20211231_zYz7ugYX5UY5" title="Marketable securities unrealized losses" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,430</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_c20211231_zf3B7uODs4Na" title="Marketable securities aggregate fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,201,152</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zS42c5tqRT52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock"><p id="xdx_893_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zD3S4X3ekUm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
contractual maturities of the investments classified as Government&amp; Agency Securities and Corporate Bonds are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zxxmaMcSh6hk">Schedule
of Contractual Maturities Investments of Marketable Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zFKQVYN97Q94" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br /> December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_iI_maAFSSDzFK8_zpQph8UOvQ3k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Due within one year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,466,590</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue_iI_maAFSSDzFK8_zkaZHCbRdXe1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due in one to two years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,802,265</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_iI_maAFSSDzFK8_zjlNIPDHbWV5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Due in two to five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,272,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iTI_mtAFSSDzFK8_zX5FPKh0XyQ9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,541,499</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zTeQwfUc0Go4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 148 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zjHkptLHdgu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents gross unrealized losses and fair values for those marketable securities that were in an unrealized loss position
as of December 31, 2022, aggregated by investment category and the length of time that individual securities have been in a continuous
loss position:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zoZR39Ayy5B5">Schedule
of Gross Unrealized Losses and Fair Values for Marketable Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48B_ecustom--DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_iI_zDwy1hDV4A6l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair<br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_iNI_di_ziH3GESJ1LHh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br /> Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_ecustom--DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_iI_z6pyKuuJHttg" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_486_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_iNI_di_zHzP426sPReb" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">More than 12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair<br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br /> Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_417_20221231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zoRJOgb7L6ll" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,184,683</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,701</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,293,998</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,162</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_41E_20221231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zhd47NlGEY4f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Corporate Bonds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" contextRef="AsOf2022-12-31_custom_CorporateBondsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,337,938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="AsOf2022-12-31_custom_CorporateBondsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,516</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" contextRef="AsOf2022-12-31_custom_CorporateBondsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,383,482</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="AsOf2022-12-31_custom_CorporateBondsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,018</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_41C_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zjZL9pav9we3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1009">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,658,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">343,904</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_41C_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zJNZC9cVQFia" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,794,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_ecustom--DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_iI_c20221231_zOAuLyDduTl" title="Fair Value Less than 12 months" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,522,621</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_iNI_di_c20221231_zDfk3C2GexJ2" title="Unrealized Loss Less than 12 months" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,217</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_ecustom--DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_iI_c20221231_zOPXSTD5jMNk" title="Fair Value Less than 12 months" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,130,280</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_iNI_di_c20221231_zdTjqvKgQV9l" title="Unrealized Loss Less than 12 months" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">914,238</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zhq4h6zW71a6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe the unrealized losses represent credit losses based on our evaluation of available evidence as of December 31, 2022, which
includes an assessment of whether it is more likely than not we will be required to sell the investment before recovery of the investment&#8217;s
amortized cost basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_80F_eus-gaap--FairValueDisclosuresTextBlock_zRnaL37h2fK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8. <span id="xdx_82A_zaVGsJuVe5f5">Fair Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use
of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous
market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions
that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the
hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes
the inputs into three levels that may be used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability,
either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - Inputs are unobservable inputs based on our assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
available, our marketable securities are valued using quoted prices for identical instruments in active markets. If we are unable to
value our marketable securities using quoted prices for identical instruments in active markets, we value our investments using broker
reports that utilize quoted market prices for comparable instruments. As of December 31, 2022 and 2021 our available-for-sale debt securities
were valued through use of quoted prices for comparable instruments in active markets and are classified as Level 2, and our mutual funds
&#8211; alternative investments were valued using NAV, net asset value per share, under the practical expedient methodology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our valuation of our marketable securities, we concluded that they are classified in either Level 2 or NAV, and we have no financial
assets measured using Level 1 or 3 inputs. The following table presents information about our assets that are measured at fair value
on a recurring basis using the above input categories.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 149 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zEaYG8oZtPAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z0M898YdEb89" style="display: none">Schedule
of Assets are Measured at Fair Value on  Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zLSnAjDHJJBk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5YWm1SAIaAf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj61Z06UW8yc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4kiayQnQQqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231__us-gaap--SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis__custom--NAVMember_zyPj3N6ms5nk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span id="xdx_F57_zoWPyx2PZ6m9" style="display: none; font-family: Times New Roman, Times, Serif">*</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of <br /> December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NAV*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--GovernmentAgencySecuritiesMember_zXxJnnijQtzb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,227,330</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1030">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,227,330</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1032">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__us-gaap--CorporateBondSecuritiesMember_zkRdivqB7cBa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Corporate Bonds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_CorporateBondSecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,314,169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1036">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateBondSecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,314,169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1039">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsFixedIncomeMember_zAZyEmis3Tj5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_custom_MutualFundsFixedIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,658,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsFixedIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,658,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsAlternativeInvestmentsMember_z7Cv7aIuNh9e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_custom_MutualFundsAlternativeInvestmentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,794,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_custom_NAVMember_custom_MutualFundsAlternativeInvestmentsMember" id="Fact001051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,794,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_zmQ5Cf10fAE1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value recurring basis</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,994,299</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,200,299</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1056">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-01-012022-12-31_custom_NAVMember" id="Fact001057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,794,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_zXDvC6zsix3e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJxYC6RcPxPb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z2pY0y4H3xPd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMPB1xoJ1e11" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20211231__us-gaap--SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis__custom--NAVMember_zCLgidun5WWj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><sup id="xdx_F50_zxgoZA08XVO4">*</sup></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of <br /> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NAV*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--GovernmentAgencySecuritiesMember_zLEbiBzDuhJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,781,053</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_custom_GovernmentAgencySecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,781,053</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__us-gaap--CorporateBondSecuritiesMember_zq24ErUzfPu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Corporate Bonds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_CorporateBondSecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,474,799</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateBondSecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,474,799</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1069">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsFixedIncomeMember_zFEJ8haMKk9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_custom_MutualFundsFixedIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,966,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsFixedIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,966,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsAlternativeInvestmentsMember_zuruSy4PifEd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_custom_MutualFundsAlternativeInvestmentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,979,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_custom_NAVMember_custom_MutualFundsAlternativeInvestmentsMember" id="Fact001081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,979,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_z7QFRjD4aJn4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value recurring basis</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,201,152</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,221,902</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-01-012021-12-31_custom_NAVMember" id="Fact001087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,979,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0C_zWzJkExXVfr3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zgPjcHnV7705" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001088" xml:lang="en-US">Certain
    marketable securities investments are measured at fair value using net asset value per share under the practical expedient methodology.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_z67O9lcC4FLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z5pslEi3XVFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9. <span id="xdx_82D_zyNUKDUjxndk">Notes and Loan Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2020 (the &#8220;Origination Date&#8221;), the Company received $<span id="xdx_903_eus-gaap--ProceedsFromLoanOriginations1_pp0p0_c20200429__20200501_zcEVeUPIOWb3" title="Aggregate loan amount"><ix:nonFraction name="us-gaap:ProceedsFromLoanOriginations1" contextRef="From2020-04-292020-05-01" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">108,500</ix:nonFraction></span> in aggregate loan proceeds (the &#8220;PPP Loan&#8221;)
from JPMorgan Chase Bank (the &#8220;Lender&#8221;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and
Economic Security (CARES) Act. The PPP Loan was evidenced by a loan application and payment agreement (the &#8220;PPP Loan Agreement&#8221;)
by and between the Company and the Lender. Subject to the terms of the PPP Loan Agreement, the PPP Loan bore interest at a fixed rate
of one percent (<span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20200429__20200501_zSFgOaCMsBZ6" title="Annual interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2020-04-292020-05-01" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction>%</span>) per annum. Payments of principal and interest were deferred for the first six months following the Origination
Date, and the PPP Loan provided that it would mature two years after the Origination Date. The guidance under the Paycheck Protection
Program was later updated so that payments of principal and interest were extended past the current fiscal year and maturity was extended
past two years. The Company applied for forgiveness of the loan, and in April 2021 the Company received notice that the Small Business
Administration (SBA) had authorized full forgiveness of the PPP Loan. A gain on loan forgiveness attributed to the PPP Loan of approximately
$<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231_zT3OtypZVXPh" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,000</ix:nonFraction></span> of principal and interest for the year ended December 31, 2021 was included in Other (expense) income, net in the accompanying
consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_zln4BcrPp9U6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10. <span id="xdx_821_zqH5G3wfBda8">Loss Per Share of Common Shares</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is derived by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock
outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities,
such as warrants and stock options, which would result in the issuance of incremental shares of common stock unless such effect is anti-dilutive.
In calculating the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remained
the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation. Potentially
dilutive securities outstanding that have been excluded from diluted loss per share due to being anti-dilutive include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zwuJprJJTnx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zojb0Sqk1uzd" style="display: none">Schedule
of Anti-dilutive Securities Outstanding Diluted Loss per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_z39VJRz7G9Bi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zKM4Xfud0d0h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended <br /> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zzGuchojeio" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,998</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember16419640" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">273,777</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNf7rIbLZ3S6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,037,591</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">890,826</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zOVBYqIqXU2f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities </span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,215,589</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,164,603</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 150 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zR7L37Mczmik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11. <span id="xdx_823_z6KDmXL5bnR7">Income Taxes</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zJOJKYwJGyJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
effective tax rate differs from the statutory federal tax rate as presented in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zG8tsmdRFPd5" style="display: none">Schedule
of Effective Income Tax Rate</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zN7VSkywOZol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zOoiJkzSJtBf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zKFNj7VbdcY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">U.S. federal statutory tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_zJrzR4nIOjXc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zOfMmD9WOO75" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">24</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">24</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_z6pYKH8Lbcu4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1124">-</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zvC3EOfeHov" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the Company was domiciled in Texas, and due to the losses generated and no revenues, it incurred no
current federal or state tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLuTdsOWUTUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities is presented
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zgyo4qLSNVdk" style="display: none">Schedule
of Deferred Tax Assets and Liabilities</span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_zA14LIzpMWB" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231_z5PGmAgbXmU8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zFfcIX0dsSs4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGz5Ms_zakLxFHEtOx9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify">Research and development credits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">862,366</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">479,849</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTAGz5Ms_zq9pL2LcZHwi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">441,939</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">427,524</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGz5Ms_zUJTV3RmYFlf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,474,825</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,837,807</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_i01I_maDTAGz5Ms_zGwtXsKXHCkb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Unrealized losses on securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,933</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentAmortization_i01I_maDTAGz5Ms_z1twsvYeGI1j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Research and development amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="LTRN:DeferredTaxAssetsResearchAndDevelopmentAmortization" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,343,382</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz5Ms_maDTANzJOa_zidORvCG5REa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,185,152</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,772,113</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzJOa_zapcO9j3mfn2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,181,492</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,767,059</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANzJOa_maDTALNzUQr_zFhxZH676Nj7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,660</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,054</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zedCptbdGsb6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i01NI_di_msDTALNzUQr_zZ6EdOsYusSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,660</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,054</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzUQr_zzRW3GvUWkSk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zrFwsZKwqmcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to a history of losses the Company has generated since inception, the Company believes it is more-likely-than-not that all of the deferred
tax assets will not be realized as of December 31, 2022 and 2021. Therefore, the Company has recorded a full valuation allowance on its
deferred tax assets. At December 31, 2022 and 2021, the Company has net operating loss (&#8220;NOL&#8221;) carryforwards for federal
income tax purposes of approximately $<span id="xdx_906_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20221231_zhVFqD9LEbC9" title="Net operating loss carryforwards for federal income tax"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,100,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20211231_zxWyUPtc0s5k" title="Net operating loss carryforwards for federal income tax"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,800,000</ix:nonFraction></span>, respectively. <span id="xdx_90E_ecustom--NOLCarryforwardsDescription_c20220101__20221231_zRLwVu3HeYql" title="Net operating loss carryforwards, description"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="LTRN:NOLCarryforwardsDescription">The NOL carryforwards generated prior to 2018 of approximately
$3,100,000 could expire over time beginning in 2035, if not used. The NOL carryforwards generated in 2018 to 2022 of approximately $26,000,000
do not expire and are carried forward indefinitely</ix:nonNumeric></span>. The Company has state NOLs of approximately $<span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20221231_zHPekJmzn6g2" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">780,000</ix:nonFraction></span> at December 31, 2022. The Company
also has approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231_zZK4d7QTuGj2" title="Research and development tax credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">861,000</ix:nonFraction></span> of research and development tax credit carryforwards for federal purposes. These credits begin expiring
in 2034. Due to the change in ownership provisions of the Internal Revenue Code, the availability of the Company&#8217;s NOL carryforwards
and research and development credit carryforwards may be subject to annual limitations under Section 382 of the Internal Revenue Code
against taxable income in the future period, which could substantially limit the eventual utilization of such carryforwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns.
The Company has analyzed its tax positions and has concluded that as of December 31, 2022, there were no uncertain positions. In addition,
interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision, for which there were
none. The Company&#8217;s U.S. federal operating losses have occurred since its inception and as such, tax years subject to potential
tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to
audit by the IRS and/or state taxing authorities. The statute of limitations expires three years after the utilization of historical losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act of 2017 (TCJA) has modified the IRC 174 expenses related to research and development for the tax years beginning
after December 31, 2021. Under the TCJA, the Company must now capitalize the expenditures related to research and development activities
and amortize over five years for U.S. activities and 15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization
of research and development costs in accordance with IRC 174 resulted in a gross deferred tax asset of $<span id="xdx_904_eus-gaap--DeferredTaxAssetsGross_iI_c20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUe9swacUCK9" title="Gross deferred tax asset"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,343,382</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zqLwUcD55nGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12. <span id="xdx_82D_z7MDZI40JoP7">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company formed a wholly owned subsidiary, Starlight Therapeutics Inc. (&#8220;Starlight&#8221;), to develop drug candidate
LP-184&#8217;s central nervous system (CNS) and brain cancer indications &#8211; including glioblastoma (GBM), brain metastases (brain
mets.), and several rare pediatric CNS cancers. Following the formation of Starlight, the Company will refer to the molecule LP-184,
as it is developed in CNS indications, as &#8220;STAR-001&#8221;.</span></p>

</ix:nonNumeric><p id="xdx_810_zUkL0PO0YaB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 151 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_015"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_016"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9A. Controls and Procedures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal
financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. The
term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information
required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized
and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it
files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive
and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that
any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives
and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on such evaluation of our disclosure controls and procedures as of December 31, 2022, our Chief Executive Officer and Chief Financial
Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Annual Report on Internal Control Over Financial Reporting.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f)
and 15d-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed under the supervision of our
principal executive officer and principal financial officer to provide reasonable assurance regarding the reliability of our financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
Management assessed our internal control over financial reporting as of December 31, 2022. Management based its assessment on criteria
established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission
(2013 Framework). Based on that evaluation, our management concluded that our internal control over financial reporting was effective
as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report does not include an attestation report of our independent registered public accounting firm due to an exemption established
by the JOBS Act for &#8220;emerging growth companies&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)
that occurred during the three-month period ended December 31, 2022 that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 152; Options: NewSection; Value: 121 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inherent
Limitations on Effectiveness of Controls.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, including our principal executive officer and principal financial officer, do not expect that our disclosure controls or
our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and
operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design
of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative
to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments
in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented
by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any
system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance
that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate
because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations
in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_017"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9B. Other Information.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_018"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 153; Value: 121 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="a_019"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_020"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
10. Directors, Executive Officers and Corporate Governance.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to our annual meeting of stockholders to be held in 2023 (the &#8220;2023 Annual Meeting of Stockholders&#8221;), which we intend
to file with the SEC within 120 days of the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_021"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
11. Executive Compensation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2023 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the year ended December 31,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_022"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2023 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the year ended December 31,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_023"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
13. Certain Relationships and Related Transactions, and Director Independence.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2023 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the year ended December 31,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_024"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
14. Principal Accountant Fees and Services.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2023 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the year ended December 31,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 154; Value: 121 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="a_025"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_026"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
15. Exhibit and Financial Statement Schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The following documents are filed as part of this report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vj_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID No. <span id="xdx_908_edei--AuditorFirmId_c20220101__20221231_zX0qhNZesWQ4"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">274</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vj_002">Consolidated Balance Sheets &#8211; December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vj_003">Consolidated Statements of Operations for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vj_005">Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vj_006">Consolidated Statements of Cash Flow for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#vj_007">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statement Schedules</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial statement schedules are omitted because the information called for is not required or is shown either in the consolidated financial
statements or in the notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are filed herewith or incorporated by reference herein:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex3-1i_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Conversion (Texas)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex3-1ii_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Conversion (Delaware)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex3-1iii_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020015132/ea123112ex3-1iv_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020015132/ea123112ex3-1v_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Certificate of Incorporation</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.(vi)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex3-1iv_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By-laws</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex4-1iii_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant (2019)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020012863/ea122016ex4-1iv_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Amendment to Series A Preferred Stock Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020012863/ea122016ex1-1_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriters&#8217; Warrant (2020)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020011747/ea121606ex4-2_lanternpharma.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Stock Certificate evidencing shares of common stock</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390021014576/f10k2020ex4-3_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Capital Stock</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amended and Restated 2018 Equity Incentive Plan dated October 20, 2022</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-2_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement dated July 23, 2018 with Panna Sharma</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020014351/ea122762ex10-3_lanternpharma.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Employment Agreement dated May 18, 2020 with Panna Sharma</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020012863/ea122016ex10-4_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement dated May 18, 2020 with David Margrave</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-3_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-4_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Investors&#8217; Rights Agreement</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-7_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technology License Agreement dated January 15, 2015, with AF Chemicals, LLC</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-11_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment Agreement dated as of January 5, 2018 with BioNumerik Pharmaceuticals, Inc.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-12_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addendum to Technology License Agreement dated February 8, 2016, with AF Chemicals, LLC</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 155; Value: 121 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020012863/ea122016ex10-16_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement dated May 18, 2020 with Kishor G Bhatia</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390020033954/f10q0920ex10-1_lantern.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">API Services Project Agreement dated July 10, 2020 with Patheon API Service</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1763950/000121390021001239/ea132545ex10-16_lanternpharm.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Addendum to Technology License Agreement dated December 30, 2020 with AF Chemicals, LLC</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex21-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex23-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of EisnerAmper LLP, independent registered public accounting firm</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference from the Registration Statement on Form S-1 filed April 16, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference from Current Report on Form 8-K filed June 17, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference from the Registration Statement on Form S-1/A filed May 19, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference from the Registration Statement on Form S-1/A filed May 12, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference from Current Report on Form 8-K filed August 21, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference from the Registration Statement on Form S-1/A filed June 8, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference from Quarterly Report on Form 10-Q for the period ending September 30, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference from the Registration Statement on Form S-1 filed January 8, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference from Exhibit 1.1 of the Registration Statement on Form S-1/A filed May 19, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference from Exhibit 10.17 of Annual Report on Form 10-K filed March 10, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference from Exhibit 4.3 of Annual Report on Form 10-K filed March 10, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management control or any compensatory plan, contract or arrangement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    confidential portions of this Exhibit were omitted by means of marking such portions with an asterisk (the Mark) because the identified
    confidential portions (i) are not material and (ii) are of the type that the Registrant treats as private and confidential.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
    with this report</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_027"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16. Form 10&#8211;K Summary.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 156; Value: 121 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lantern
    Pharma Inc.,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    Delaware Corporation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 20, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Panna Sharma</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Panna
    Sharma, Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 20, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David R. Margrave</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    R. Margrave, Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Panna Sharma</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Panna
    Sharma</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Principal
    Executive Officer)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David R. Margrave</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    R. Margrave</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>Principal
    Financial and Principal Accounting Officer</i>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Donald J. Keyser</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald
    J. Keyser</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Maria Maccecchini</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maria
    Maccecchini</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David S. Silberstein</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    S. Silberstein</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Vijay Chandru</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>Director</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vijay
    Chandru</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Franklyn Prendergast</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Director<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Franklyn
    Prendergast</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2023</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 157; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECOND
AMENDED AND RESTATED LANTERN PHARMA INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018
EQUITY INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I.
<U>GENERAL PROVISIONS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.1
<U>Establishment</U></B>. On August 29, 2018, the Board of Directors of Lantern Pharma Inc. adopted the Lantern Pharma Inc. 2018 Equity
Incentive Plan. The Lantern Pharma Inc. 2018 Equity Incentive Plan was approved by the Lantern Pharma Inc. shareholders on August 29,
2018. On December 17, 2018, the Board of Directors of Lantern Pharma Inc. approved amendments to the Lantern Pharma Inc. 2018 Equity
Incentive Plan, which amendments were approved by the shareholders of Lantern Pharma Inc. effective August 7, 2019. In connection with
the change in the state of incorporation of Lantern Pharma Inc. from Texas to Delaware in January 2020, the Lantern Pharma Inc. 2018
Equity Incentive Plan, as amended and restated, was assumed by Lantern Pharma Inc., a Delaware corporation (the &ldquo;Corporation&rdquo;).
Further amendments to the Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and restated, were approved by the Corporation&rsquo;s
Board of Directors (&ldquo;Board&rdquo;) on February 26, 2020 and by the stockholders of the Corporation effective June 3, 2020. On August
19, 2020, the Board approved the Amended and Restated Plan containing the previously approved amendments described above. On October
20, 2022, the Board approved this Second Amended and Restated Plan for purposes of effecting certain non-material revisions to Sections
1.4(p) and 2.4(a), none of which required, or were subject to, stockholder approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.2
<U>Purpose</U></B>. The purpose of the Plan is to (a) promote the best interests of the Corporation and its shareholders by encouraging
Employees, non-Employee Directors and Consultants of the Corporation and its Subsidiaries to acquire an ownership interest in the Corporation
by granting stock-based Awards, thus aligning their interests with those of shareholders, and (b) enhance the ability of the Corporation
and its Subsidiaries to attract, motivate and retain qualified Employees, non-Employee Directors and Consultants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.3
<U>Plan Duration</U></B>. The Plan became effective on August 29, 2018 and shall continue in effect until its termination by the Board;
provided, however, that no new Awards may be granted on or after August 28, 2028.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.4
<U>Definitions</U></B>. As used in this Plan, the following terms have the meaning described below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>&ldquo;<B>Administrator</B>&rdquo; means the Board, unless the Board has appointed a committee to administer the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>&ldquo;<B>Agreement</B>&rdquo; means the written document that sets forth the terms of a Participant&rsquo;s Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>&ldquo;<B>Award</B>&rdquo; means any form of Option, Restricted Stock, Restricted Stock Unit, Performance Award or Stock Bonus Award
granted under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
</B>&ldquo;<B>Board</B>&rdquo; means the Board of Directors of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)
</B>&ldquo;<B>Broker Exercise Notice</B>&rdquo; means a written notice pursuant to which a Participant, upon exercise of an Option, irrevocably
instructs a broker or dealer to sell a sufficient number of shares or loan a sufficient amount of money to pay all or a portion of the
exercise price of the Option and/or any related withholding tax obligations and remit such sums to the Corporation and directs the Corporation
to deliver stock certificates to be issued upon such exercise directly to such broker or dealer or their nominee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f)
</B>&ldquo;<B>California Participant</B>&rdquo; means a Participant with one or more Awards issued in reliance on Section 25102(o) of
the California Corporations Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(g)
</B>&ldquo;<B>Cause</B>&rdquo; means (i) if the Employee is a party to a written employment agreement with the Corporation or a Subsidiary,
&ldquo;Cause&rdquo; as defined in such agreement, as in effect from time to time, and (ii) in all other cases, (A) Employee&rsquo;s continued
failure substantially to perform Employee&rsquo;s duties to the Corporation or its affiliates (other than as a result of total or partial
incapacity due to physical or mental illness) for a period of 10 days following written notice by the Corporation to Employee of such
failure, (B) dishonesty in the performance of Employee&rsquo;s duties hereunder, (C) Employee&rsquo;s conviction of, or plea of nolo
contendere to a crime constituting (x) a felony under the laws of the United States or any state thereof, or (y) a misdemeanor involving
moral turpitude, (D) Employee&rsquo;s willful malfeasance or willful misconduct in connection with Employee&rsquo;s duties hereunder
or any act or omission which is injurious to the financial condition or business reputation of the Corporation or its affiliates, or
(E) Employee&rsquo;s breach of any non-compete or confidentiality obligations to the Corporation or its affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(h)
</B>&ldquo;<B>Change in Control</B>&rdquo; means the occurrence of any of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
If any one person, or more than one person acting as a group (as defined in Code Section 409A and regulations thereunder), acquires ownership
of voting stock of the Corporation that, together with other voting stock held by such person or group, constitutes more than fifty percent
(50% ) of the total fair market value or total voting power of the capital stock of the Corporation (measured on an as converted basis
giving pro forma effect to the conversion of any outstanding convertible preferred stock into common stock, but not assuming the exercise
of any warrant or option to purchase such shares, and giving effect to the voting rights of any outstanding shares of capital stock on
matters submitted to the shareholders generally). However, if any one person or more than one person acting as a group, is considered
to own more than fifty percent (50%) of the total fair market value or total voting power of the capital stock of the Corporation, the
acquisition of additional stock by the same person or persons is not considered to cause a Change in Control, or to cause a change in
the effective control of the Corporation (within the meaning of Code Section 409A and regulations thereunder). An increase in the percentage
of capital stock owned by any one person, or persons acting as a group, as a result of a transaction in which the Corporation acquires
its stock in exchange for property shall be treated as an acquisition of stock for purposes of this Section. This paragraph applies only
when there is a transfer of stock of the Corporation (or issuance of stock of the Corporation) and stock in such Corporation remains
outstanding after the transaction;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
If a majority of members on the Corporation&rsquo;s Board is replaced during any 12-month period by Directors whose appointment or election
is not endorsed by a majority of the members of the Corporation&rsquo;s Board prior to the date of the appointment or election (provided
that for purposes of this paragraph, the term Corporation refers solely to the &ldquo;relevant corporation,&rdquo; as defined in Code
Section 409A and regulations thereunder, for which no other corporation is a majority shareholder); or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
If there is a change in the ownership of a substantial portion of the Corporation&rsquo;s assets, which shall occur on the date that
any one person, or more than one person acting as a group (within the meaning of Code Section 409A and regulations thereunder) acquires
(or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons) assets from
the Corporation that have a total gross fair market value equal to or more than forty percent (40%) of the total gross fair market value
of all of the assets of the Corporation immediately prior to such acquisition or acquisitions. For this purpose, gross fair market value
means the value of the assets of the Corporation, or the value of the assets being disposed of, determined without regard to any liabilities
associated with such assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)
</B>&ldquo;<B>Common Stock</B>&rdquo; means shares of the Corporation&rsquo;s authorized common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(j)
</B>&ldquo;<B>Consultant</B>&rdquo; means a consultant or advisor (other than as an Employee or member of the Board) to the Corporation
or a Subsidiary; provided that such person (i) renders bona fide services that are not in connection with the offer and sale of the Corporation&rsquo;s
securities in a capital-raising transaction, and (ii) does not promote or maintain a market for the Corporation&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(k)
</B>&ldquo;<B>Corporation</B>&rdquo; means Lantern Pharma Inc., a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(l)
</B>&ldquo;<B>Director</B>&rdquo; means an individual, other than an Employee, who has been elected or appointed to serve as a member
of the Board. For purposes of clarity, a Director may include a representative of an entity with a financial interest in the Corporation,
in which case settlement of an Award to a Director in such capacity may be issued or payable directly to the represented entity (or an
affiliate entity of such represented entity), if approved by the Administrator and in compliance with applicable federal and state securities
laws and regulations in effect at such time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(m)
</B>&ldquo;<B>Disability</B>&rdquo; means total and permanent disability, as defined in the Corporation&rsquo;s long-term disability
benefits program, if any, as in effect from time to time or in the event no such program is in place means that the Participant is unable
to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment, as determined under
procedures established from time to time by the Administrator; provided, however, that for purposes of a Code Section 409A distribution
event, &ldquo;disability&rdquo; shall be defined under Code Section 409A and regulations thereunder. See Addendum A for special disability
provisions related to California Participants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(n)
</B>&ldquo;<B>Dividend Equivalent</B>&rdquo; means a credit, made at the discretion of the Board or as otherwise provided by the Plan,
to the account of a Participant in an amount equal to the cash dividend paid on one share of Common Stock for each share of Common Stock
represented by an Award held by such Participant. Dividend Equivalents shall not be paid on Option Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(o)
</B>&ldquo;<B>Employee</B>&rdquo; means an individual who has an &ldquo;employment relationship&rdquo; with the Corporation or a Subsidiary,
as defined in Treasury Regulation 1.421-1(h), and the term &ldquo;employment&rdquo; means employment with the Corporation or a Subsidiary,
as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(p)
</B>&ldquo;<B>Exchange Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(q)
</B>&ldquo;<B>Fair Market Value</B>&rdquo; means as of any date, the per share fair market value of the Common Stock (or other applicable
security, payment or consideration as the case may be), in accordance with Code Section 409A and Regulations thereunder, which shall
be determined by the Administrator in good faith on such basis as it deems appropriate and applied consistently with respect to Participants.
If shares of the Corporation are listed, admitted to unlisted trading privileges or reported on any national securities exchange or on
the NASDAQ Stock Market on such date, &ldquo;Fair Market Value&rdquo; shall mean the last sale price of the Common Stock at the end of
the regular trading session on such date (or, if no shares were traded on such day, as of the next preceding day on which there was such
a trade).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(r)
</B>&ldquo;<B>Grant Date</B>&rdquo; means the date on which the Administrator authorizes an Award, or such later date as shall be designated
by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(s)
</B>&ldquo;<B>Incentive Stock Option</B>&rdquo; means an Option granted pursuant to Article II that is intended to meet the requirements
of Code Section 422.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(t)
</B>&ldquo;<B>Listed Security</B>&rdquo; means any security of the Corporation that is listed or approved for listing on a Stock Exchange,
or designated or approved for designation as a national market system security or an independent quotation system by the National Association
of Securities Dealers, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(u)
</B>&ldquo;<B>Nonqualified Stock Option</B>&rdquo; means an Option granted pursuant to Article II that is not an Incentive Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(v)
</B>&ldquo;<B>Option</B>&rdquo; means either an Incentive Stock Option or a Nonqualified Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(w)
</B>&ldquo;<B>Participant</B>&rdquo; means an Employee, Director or Consultant, who is designated by the Administrator to participate
in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(x)
</B>&ldquo;<B>Permitted Assignee</B>&rdquo; means a person described in Section 8.3(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(y)
</B>&ldquo;<B>Performance Award</B>&rdquo; means any Award of Performance Shares granted pursuant to Article IV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(z)
</B>&ldquo;<B>Plan</B>&rdquo; means the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan, the terms of which
are set forth herein, and any amendments thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(aa)
</B>&ldquo;<B>Restriction Period</B>&rdquo; means the period of time during which a Participant&rsquo;s Restricted Stock or Restricted
Stock Unit is subject to restrictions and is nontransferable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(bb)
</B>&ldquo;<B>Restricted Stock</B>&rdquo; means Common Stock granted pursuant to Article III that is subject to a Restriction Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(cc)
</B>&ldquo;<B>Restricted Stock Unit</B>&rdquo; means a right granted pursuant to Article III to receive Restricted Stock, Common Stock
or an equivalent value in cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(dd)
</B>&ldquo;<B>Performance Award</B>&rdquo; means any Award of Performance Shares granted pursuant to Article IV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ee)
</B>&ldquo;<B>Stock Bonus Award</B>&rdquo; means any Award of Common Stock Shares granted pursuant to Article V.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ff)
</B>&ldquo;<B>Stock Exchange</B>&rdquo; means the principal national securities exchange on which the Common Stock is listed for trading,
or, if the Common Stock is not listed for trading on a national securities exchange, such other recognized trading market, if any, upon
which the largest number of shares of Common Stock has been traded in the aggregate during the last 20 days before the applicable date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(gg)
</B>&ldquo;<B>Subsidiary</B>&rdquo; means a corporation or other entity defined in Code Section 424(f).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(hh)
</B>&ldquo;<B>Substitute Awards</B>&rdquo; shall mean Awards granted or shares issued by the Corporation in assumption of, or in substitution
or exchange for, awards previously granted, or the right or obligation to make future awards, by a company acquired by the Corporation
or any Subsidiary or with which the Corporation or any Subsidiary combines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii)
</B>&ldquo;<B>Vested</B>&rdquo; or &ldquo;<B>Vesting</B>&rdquo; means the extent to which an Award granted or issued hereunder has become
exercisable, any applicable Restriction Period has terminated or lapsed in accordance with the Plan and the terms of any respective Agreement
pursuant to which such Award was granted or issued, or has become payable in whole or in part due to the satisfaction of performance
goal(s) set forth in the respective Agreement pursuant to which such Award was granted or issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.5
<U>Administration</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>The Plan shall be administered by the Board, unless the Board appoints a committee with the power and authority to administer the
Plan (either, the &ldquo;Administrator&rdquo;, as applicable). The Administrator shall interpret the Plan, prescribe, amend, and rescind
rules and regulations relating to the Plan, and make all other determinations necessary or advisable for its administration. The decision
of the Administrator on any question concerning the interpretation of the Plan or its administration with respect to any Award granted
under the Plan shall be final and binding upon all Participants. No member of the Board or any committee appointed by the Board to serve
as Administrator shall be liable for any action or determination made in good faith with respect to the Plan or any Award hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>In addition to any other powers set forth in the Plan and subject to Code Section 409A and the provisions of the Plan, the Administrator
shall have the full and final power and authority, in its discretion to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
amend, modify, or cancel any Award, or to waive any restrictions or conditions applicable to any Award or any shares acquired pursuant
thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
accelerate, continue, or defer the exercisability or Vesting of any Award or any shares acquired pursuant thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
authorize, in conjunction with any applicable deferred compensation plan of the Corporation, that the receipt of cash or Common Stock
subject to any Award under this Plan may be deferred under the terms and conditions of such deferred compensation plan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
determine the terms and conditions of Awards granted to Participants and whether such terms and conditions have been satisfied; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
establish such other Awards, besides those specifically enumerated in the Plan, which the Administrator determines are consistent with
the Plan&rsquo;s purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.6
<U>Participants</U></B>. Participants in the Plan shall be such Employees, Directors and Consultants of the Corporation and its Subsidiaries
as the Administrator in its sole discretion may select from time to time. The Administrator may grant Awards to an individual upon the
condition that the individual become an Employee, Director or Consultant of the Corporation or of a Subsidiary, provided that the Award
shall be deemed to be granted only on the date that the individual becomes an Employee, Director or Consultant, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.7
<U>Stock</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>The Corporation has reserved 1,489,680 shares of Common Stock for issuance pursuant to stock-based Awards under the Plan, all of
which shares may be granted pursuant to Incentive Stock Options under the Plan. All provisions in this Section 1.7 shall be adjusted,
as applicable, in accordance with Article VII.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>Each share of Common Stock subject to any Award shall be counted against the aggregate reserved share limit in paragraph (a) above
as one share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>The shares subject to any portion of an Award that is forfeited, cancelled, or expires or otherwise terminates without issuance of
such shares, or is settled for cash or otherwise does not result in the issuance of all or a portion of the shares subject to such Award,
shall, to the extent of such forfeiture, cancellation, expiration, termination, cash settlement or non-issuance, again be available for
issuance pursuant to Awards under the Plan and shall not be counted against the limitations in Section 1.7(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
</B>For the avoidance of doubt, the following shares of Common Stock, however, may not again be made available for issuance as Awards
under the Plan: (i) the full number of shares not issued or delivered as a result of the net settlement of an outstanding Option, regardless
of the number of shares actually used to make such settlement; (ii) shares used to pay the exercise price or for settlement of any Award;
(iii) shares used to satisfy withholding taxes related to the exercise or settlement of any Award; and (iv) shares subject to a Restricted
Stock Award that have been forfeited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)
</B>Substitute Awards shall not reduce the shares reserved for issuance under the Plan or authorized for grant to a Participant in any
fiscal year. Additionally, in the event that a company acquired by the Corporation or any Subsidiary or with which the Corporation or
any Subsidiary combines has shares available under a pre-existing plan approved by shareholders and not adopted in contemplation of such
acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the extent
appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine
the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards
under the Plan and shall not reduce the shares authorized for issuance under the Plan; provided that Awards using such available shares
shall not be made after the date awards or grants could have been made under the terms of the pre-existing plan, absent the acquisition
or combination, and shall only be made to individuals who were not Employees or Directors or an affiliate of the Corporation or its Subsidiaries
prior to such acquisition or combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.8
<U>Repricing</U></B>. Except as provided in Section 7.1, the Administrator shall not approve a program providing for (a) the cancellation
of outstanding Options and the grant in substitution therefor of any new Options under the Plan having a lower exercise price than the
Fair Market Value of the underlying Common Stock on the original Grant Date; (b) the amendment of outstanding Options to reduce the exercise
price thereof below the Fair Market Value of the underlying Common Stock on the original Grant Date; or (c) the exchange of outstanding
Options for cash or other Awards if the exercise price per share of such Options is greater than the Fair Market Value per share as of
the date of exchange. This Section shall not be construed to apply to &ldquo;issuing or assuming a stock option in a transaction to which
section 424(a) applies,&rdquo; within the meaning of Code Section 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>II.
<U>STOCK OPTIONS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.1
<U>Grant of Options</U></B>. The Administrator, at any time and from time to time, subject to the terms and conditions of the Plan, may
grant Options to such Participants and for such number of shares of Common Stock as it shall designate, and shall determine the general
terms and conditions of exercise, which shall be set forth in a Participant&rsquo;s Agreement. Any Participant may hold more than one
Option under the Plan and any other plan of the Corporation or Subsidiary. No Option granted hereunder may be exercised after the tenth
anniversary of the Grant Date. The Administrator may designate any Option granted as either an Incentive Stock Option or a Nonqualified
Stock Option, or the Administrator may designate a portion of an Option as an Incentive Stock Option or a Nonqualified Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.2
<U>Incentive Stock Options</U></B>. Any Option intended to constitute an Incentive Stock Option shall comply with the requirements of
this Section 2.2. An Incentive Stock Option may only be granted to an Employee. No Incentive Stock Option shall be granted with an exercise
price below the Fair Market Value of Common Stock on the Grant Date nor with an exercise term that extends beyond ten (10) years from
the Grant Date. An Incentive Stock Option shall not be granted to any Participant who owns (within the meaning of Code Section 424(d))
stock of the Corporation or any Subsidiary possessing more than 10% of the total combined voting power of all classes of stock of the
Corporation or a Subsidiary unless, at the Grant Date, the exercise price for the Option is at least 110% of the Fair Market Value of
the shares subject to the Option and the Option, by its terms, is not exercisable more than five (5) years after the Grant Date. The
aggregate Fair Market Value of the underlying Common Stock (determined at the Grant Date) as to which Incentive Stock Options granted
under the Plan (including a plan of a Subsidiary) may first be exercised by a Participant in any one calendar year shall not exceed $100,000.
To the extent that an Option intended to constitute an Incentive Stock Option shall violate the foregoing $100,000 limitation (or any
other limitation set forth in Code Section 422), the portion of the Option that exceeds the $100,000 limitation (or violates any other
Code Section 422 limitation) shall be deemed to constitute a Nonqualified Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.3
<U>Exercise Price</U></B>. The Administrator shall determine the per share exercise price for each Option granted under the Plan. No
Option may be granted with an exercise price below 100% of the Fair Market Value of Common Stock on the Grant Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.4
<U>Payment for Option Shares</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>The purchase price for shares of Common Stock to be acquired upon exercise of an Option granted hereunder shall be paid in full in
cash or by personal check, bank draft or money order at the time of exercise; provided, however, that in lieu of such form of payment,
and subject to the approval of the Administrator, payment may be made by (i) tendering shares of Common Stock to the Corporation having
a Fair Market Value equal to the total purchase price on the exercise date which are freely owned and held by the Participant independent
of any restrictions or hypothecations, (ii) tendering a Broker Exercise Notice, (iii) net issuance whereby &ldquo;in the money&rdquo;
Options are cancelled and the spread is applied towards the exercise of other Options, (iv) delivery of other consideration approved
by the Administrator having a Fair Market Value on the exercise date equal to the total purchase price, or (v) any combination of the
foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>Notwithstanding the foregoing, an Option may not be exercised by delivery to or withholding by the Corporation of shares of Common
Stock to the extent that such delivery or withholding (i) would constitute a violation of the provisions of any law or regulation, or
(ii) if there is a substantial likelihood that the use of such form of payment would result in adverse accounting treatment to the Corporation
under generally accepted accounting principles. Until a Participant has been issued a certificate or certificates for the shares of Common
Stock so purchased (or the book entry representing such shares has been made), he or she shall possess no rights as a record holder with
respect to any such shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>III.
<U>RESTRICTED STOCK AND RESTRICTED STOCK UNITS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.1
<U>Grant of Restricted Stock and Restricted Stock Units</U></B>. Subject to the terms and conditions of the Plan, the Administrator,
at any time and from time to time, may grant Awards of Restricted Stock and Restricted Stock Units under the Plan to such Participants
and in such amounts as it shall determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.2
<U>Terms of Awards</U></B>. Each Award of Restricted Stock or Restricted Stock Units shall be evidenced by an Agreement that shall specify
the terms of the restrictions, including the Restriction Period, or Restriction Periods, the number of Common Stock shares or units subject
to the Award, the purchase price for the shares of Restricted Stock, if any, the form of consideration that may be used to pay the purchase
price of the Restricted Stock, including those specified in Section 2.4, and such other general terms and conditions, including performance
goal(s), as the Administrator shall determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3
<U>Transferability</U></B>. Except as provided in this Article III and Section 8.3 of the Plan, the shares of Common Stock subject to
an Award of Restricted Stock or Restricted Stock Units granted hereunder may not be transferred, pledged, assigned, or otherwise alienated
or hypothecated until the termination of the applicable Restriction Period or for such period of time as shall be established by the
Administrator and specified in the applicable Agreement, or upon the earlier satisfaction of other conditions as specified by the Administrator
in its sole discretion and as set forth in the applicable Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.4
<U>Other Restrictions</U></B>. The Administrator shall impose such other restrictions on any shares of Common Stock subject to an Award
of Restricted Stock or Restricted Stock Units under the Plan as it may deem advisable including, without limitation, restrictions under
applicable federal or state securities laws, and the issuance of a legended certificate of Common Stock representing such shares to give
appropriate notice of such restrictions (or, if issued in book entry form, a notation with similar restrictive effect with respect to
the book entry representing such shares). Subject to Code Section 409A, the Administrator shall have the discretion to waive the applicable
Restriction Period with respect to all or any part of the Common Stock subject to an Award of Restricted Stock or Restricted Stock Units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.5
<U>Voting Rights</U></B>. During the Restriction Period, Participants holding issued and outstanding shares of Common Stock subject to
an Award of Restricted Stock may exercise full voting rights with respect to the Restricted Stock, while such Award remains outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.6
<U>Dividends and Dividend Equivalents</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>Except as set forth below or in a Participant&rsquo;s Agreement, a Participant shall be entitled to receive all dividends and other
distributions paid with respect to issued and outstanding shares of Common Stock subject to an Award of Restricted Stock, while such
Award remains outstanding. If any dividends or distributions are paid in shares of Common Stock during the Restriction Period applicable
to an Award of Restricted Stock, the dividend or other distribution shares shall be subject to the same restrictions on transferability
as the shares of Common Stock with respect to which they were paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>The Administrator, in its discretion, may provide in the Agreement evidencing any Restricted Stock Unit Award that the Participant
shall be entitled to receive Dividend Equivalents with respect to the payment of cash dividends on Common Stock having a record date
prior to the date on which Restricted Stock Units held by such Participant are settled. Such Dividend Equivalents, if any, shall be paid
by crediting the Participant with additional whole Restricted Stock Units as of the date of payment of such cash dividends on Common
Stock. The number of additional Restricted Stock Units (rounded to the nearest whole number) to be so credited shall be determined by
dividing (i) the amount of cash dividends paid on such date with respect to the number of shares of Common Stock represented by the Restricted
Stock Units previously credited to the Participant as of the record date of such dividend, by (ii) the Fair Market Value per share of
Common Stock on such date. Such additional Restricted Stock Units shall be subject to the same terms and conditions and shall be settled
in the same manner and at the same time or times (or as soon thereafter as practicable) as the corresponding Restricted Stock Units on
which the Dividend Equivalent was paid. In the event of a dividend or distribution paid in shares of Common Stock or any other adjustment
made upon a change in the capital structure of the Corporation as described in Article VII, appropriate adjustments shall be made in
the Participant&rsquo;s Restricted Stock Unit so that it represents the right to receive upon settlement any and all new, substituted
or additional securities or other property (other than normal cash dividends) to which the Participant would be entitled by reason of
the shares of Common Stock issuable upon settlement of the Restricted Stock Unit, and all such new, substituted or additional securities
or other property shall be immediately subject to the same restrictions as are applicable to the Restricted Stock Unit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.7
<U>Settlement of Restricted Stock Units</U></B>. If a Restricted Stock Unit is payable in Common Stock, the Corporation shall issue to
a Participant on the date on which Restricted Stock Units subject to the Participant&rsquo;s Award Vest or on such other date determined
by the Administrator, in its discretion, and set forth in the Agreement, one share of Common Stock and/or any other new, substituted
or additional securities or other property pursuant to an adjustment described in Section 7.1 for each Restricted Stock Unit then becoming
Vested or otherwise to be settled on such date, subject to the withholding of applicable taxes. Notwithstanding any other provision in
this Plan to the contrary, any Restricted Stock Unit, whether settled in Common Stock, cash or other property, shall be paid no later
than two and a half (TA) months after the later of the end of the fiscal or calendar year in which the Restricted Stock Unit Vests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IV.
<U>PERFORMANCE AWARDS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.1
<U>Grant of Performance Awards</U></B>. The Administrator, in its discretion, may grant Performance Awards to Participants and may determine,
on an individual or group basis, the performance goal(s) to be attained pursuant to each Performance Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.2
<U>Terms of Awards</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>Performance Awards shall consist of rights to receive cash, Common Stock, other property or a combination thereof, if designated
performance goal(s) are achieved. The terms of a Participant&rsquo;s Performance Award shall be set forth in a Participant&rsquo;s Agreement.
Each Agreement shall specify the performance goal(s), which may include the Performance Measures, applicable to a particular Participant
or group of Participants, the period over which the targeted goal(s) are to be attained, the payment schedule if the goal(s) are attained,
and any other general terms as the Administrator shall determine and conditions applicable to an individual Performance Award. Subject
to Code Section 409A, the Administrator, in its discretion, may waive all or part of the conditions, goals and restrictions applicable
to the receipt of full or partial payment of a Performance Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>Performance Awards may be granted as Performance Shares or Performance Units, at the discretion of the Administrator. Performance
Awards shall be paid no later than two and a half (2&frac12;) months after the later of the end of the fiscal or calendar year in which
the Performance Award is no longer subject to a substantial risk of forfeiture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
In the case of Performance Shares, the Participant shall receive a legended certificate of Common Stock, restricted from transfer prior
to the satisfaction of the designated performance goal(s) and restrictions (or shares may be issued in book entry form with a notation
having similar restrictive effect with respect to the book entry representing such shares), as determined by the Administrator and specified
in the Participant&rsquo;s Agreement. Prior to satisfaction of the performance goal(s) and restrictions, the Participant shall be entitled
to vote the Performance Shares to the extent such shares are issued and outstanding. Further, any dividends paid on such shares during
the performance period automatically shall, as provided in the Participant&rsquo;s Agreement: (A) be reinvested on behalf of the Participant
in additional Performance Shares under the Plan, and such additional shares shall be subject to the same performance goal(s) and restrictions
as the other shares under the Performance Share Award; (B) be payable in cash upon satisfaction of, and subject to the same performance
goal(s) and restrictions as the underlying shares for the Performance Share Award; or (C) be provided in a combination thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
In the case of Performance Units, the Participant shall receive an Agreement from the Administrator that specifies the performance goal(s)
and restrictions that must be satisfied before the Corporation shall issue the payment, which may be cash, a designated number of shares
of Common Stock, other property or a combination thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>V.
<U>STOCK BONUS AWARDS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1
<U>Grant of Stock Bonus Awards</U></B>. Subject to the terms and conditions of the Plan, the Administrator, at any time and from time
to time, may grant Stock Bonus Awards under the Plan to such Participants and in such amount as it shall determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2
<U>Terms of Awards</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>Stock Bonus Awards are intended to serve as a form of discretionary bonus to be paid in shares of Common Stock to Employees selected
by the Administrator. The number of shares in a Stock Bonus Award and any terms and restrictions applicable to the Stock Bonus Award
shall be designated by the Administrator at the time of grant and set forth in the Participant&rsquo;s Award Agreement. Stock Bonus Awards
may be, but are not required to be, subject to Vesting requirements and/or other restrictions. The Administrator shall have the authority
to waive any Vesting or other restrictions applicable to a Stock Bonus Award. Stock Bonus Awards shall be paid as soon as reasonably
practical but not later than two and one half (2-1/2) months after the Grant Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>In the case of Stock Bonus Awards that are subject to Vesting or other restrictions, the Participant shall receive a legended certificate
of Common Stock, restricted from transfer prior to the satisfaction of the designated restrictions (or shares may be issued in book entry
form with a notation having similar restrictive effect with respect to the book entry representing such shares), as determined by the
Administrator and specified in the Participant&rsquo;s Agreement. Prior to satisfaction of the restrictions, the Participant shall be
entitled to vote the shares issued under a Stock Bonus Award to the extent such shares are issued and outstanding. Further, any dividends
paid on such shares while subject to restrictions shall, as provided in the Participant&rsquo;s Agreement, be reinvested on behalf of
the Participant in additional Stock Bonus shares under the Plan, and such additional shares shall be subject to the same restrictions
as the other shares under the Stock Bonus Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VI.
<U>TERMINATION OF EMPLOYMENT OR SERVICES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.1
<U>Options</U></B>. Unless otherwise provided in a Participant&rsquo;s Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>If, prior to the date when an Option first becomes Vested, a Participant&rsquo;s employment or services are terminated for any reason,
the Participant&rsquo;s right to exercise the Option shall terminate and all rights thereunder shall cease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>If, on or after the date when an Option first becomes Vested, a Participant&rsquo;s employment or services are terminated for any
reason other than the Participant&rsquo;s death or Disability, the Participant shall have the right, within the earlier of (i) the expiration
of the Option and (ii) three (3) months after termination of employment or services, as applicable, to exercise the Option to the extent
that it was exercisable and unexercised on the date of the Participant&rsquo;s termination of employment or services, subject to any
other limitation on the exercise of the Option in effect on the date of exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>If, on or after the date when an Option first becomes Vested, a Participant&rsquo;s employment or services are terminated due to
the Participant&rsquo;s death while the Option is still exercisable, the person or persons to whom the Option shall have been transferred
by will or the laws of descent and distribution, shall have the right within the exercise period specified in the Participant&rsquo;s
Agreement to exercise the Option to the extent that it was exercisable and unexercised on the Participant&rsquo;s date of death, subject
to any other limitation on exercise in effect on the date of exercise. The beneficial tax treatment of an Incentive Stock Option may
be forfeited if the Option is exercised more than one year after a Participant&rsquo;s date of death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
</B>If, on or after the date when an Option first becomes Vested, a Participant&rsquo;s employment or services are terminated due to
the Participant&rsquo;s Disability, the Participant shall have the right, within the exercise period specified in the Participant&rsquo;s
Agreement, to exercise the Option to the extent that it was exercisable and unexercised on the date of the Participant&rsquo;s termination
of employment or services due to Disability, subject to any other limitation on the exercise of the Option in effect on the date of exercise.
If the Participant dies after termination of employment or services, as applicable, while the Option is still exercisable, the Option
shall be exercisable in accordance with the terms of paragraph (c) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)
</B>For the avoidance of doubt, the Administrator, at the time of a Participant&rsquo;s termination of employment or services, may accelerate
a Participant&rsquo;s right to exercise an Option, or, subject to Code Section 409A, and Section 2.1, may extend the term of the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f)
</B>Shares subject to Options that are not exercised in accordance with the provisions of (a) through (e) above shall expire and be forfeited
by the Participant as of their expiration date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.2
<U>Restricted Stock Awards, Restricted Stock Unit Awards, Performance Awards and Stock Bonus Awards</U></B>. With respect to any Restricted
Stock Award, Restricted Stock Unit Award, Performance Award or Stock Bonus Award, unless otherwise provided in a Participant&rsquo;s
Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>If a Participant&rsquo;s employment or services are terminated for any reason, any portion of such an Award that is not yet Vested
automatically shall terminate and be forfeited by the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>If, with respect to a Restricted Stock Award or Restricted Stock Unit Award, the terminated Participant was required to pay a purchase
price for the Restricted Stock subject to such Award, other than for the performance of services, the Corporation shall have the option
to repurchase any shares acquired by the Participant which are still subject to any Restriction Period for the purchase price paid by
the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>For the avoidance of doubt, the Administrator, in its discretion, may provide in a Participant&rsquo;s Agreement for the continuation
of any such Award after a Participant&rsquo;s employment or services are terminated or, subject to Code Section 409A, may waive or change
the remaining conditions, goals or restrictions, or add additional conditions, goals or restrictions, with respect to such Award, as
it deems appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.3
<U>Other Provisions</U></B>. The transfer of an Employee from one corporation to another among the Corporation and any of its Subsidiaries,
or a leave of absence under the leave policy of the Corporation or any of its Subsidiaries shall not be a termination of employment for
purposes of the Plan, unless a provision to the contrary is expressly stated by the Administrator in a Participant&rsquo;s Agreement
issued under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VII.
<U>ADJUSTMENTS AND CHANGE IN CONTROL</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1
<U>Adjustments</U></B>. In the event of a merger, reorganization, statutory share exchange, consolidation, recapitalization, dividend
or distribution (whether in cash, shares or other property), stock split, reverse stock split, spin-off or similar transaction or other
change in corporate structure affecting the Common Stock or the value thereof, such adjustments and other substitutions shall be made
to the Plan and Awards as the Administrator, in its sole discretion, deems equitable or appropriate, including adjustments in the aggregate
number, class and kind of securities that may be delivered under the Plan and, in the aggregate or to any one Participant, in the number,
class, kind and option or exercise price of securities subject to outstanding Awards granted under the Plan (including, if the Administrator
deems appropriate, the substitution of cash, similar options to purchase the shares of, or other awards denominated in the shares of,
another company, or other property, as the Administrator may determine to be appropriate in its sole discretion). Any of the foregoing
adjustments may provide for the elimination of any fractional share which might otherwise become subject to any Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.2
<U>Change in Control</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>Notwithstanding anything contained herein to the contrary, unless otherwise provided in a Participant&rsquo;s Agreement to the contrary,
upon a Change in Control, the Administrator may make any of the following determinations: (i) any outstanding Option granted hereunder
immediately shall become fully Vested and exercisable, regardless of any installment provision applicable to such Option; (ii) the remaining
Restriction Period on any shares of Common Stock subject to a Restricted Stock or Restricted Stock Unit Award granted hereunder immediately
shall lapse and the shares shall become fully transferable, subject to any applicable federal or state securities laws; (iii) all performance
goals and conditions shall be deemed to have been satisfied and all restrictions shall lapse on any outstanding Performance Awards, which
immediately shall become payable (either in full or pro-rata based on the portion of the applicable performance period completed as of
the Change in Control); and (iv) all Vesting and/.or other restrictions shall lapse on any outstanding Stock Bonus Award shares that
are subject to Vesting and/or other restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>The Administrator may, in its sole discretion and without the consent of any Participant, determine that, upon the occurrence of
a Change in Control, each or any Option outstanding immediately prior to the Change in Control shall be cancelled in exchange for a payment
with respect to each Vested share of Common Stock subject to such cancelled Option in (i) cash, (ii) stock of the Corporation or of a
corporation or other business entity that is a party to the Change in Control, or (iii) other property which, in any such case, shall
be in an amount having a Fair Market Value equal to the excess of the Fair Market Value of the consideration to be paid per share of
Common Stock in the Change in Control transaction over the exercise price per share under such Option (the &ldquo;Spread&rdquo;). In
the event such determination is made by the Administrator, the Spread (reduced by applicable withholding taxes, if any, to the extent
determined by the Administrator) shall be paid to a Participant in respect of the Participant&rsquo;s cancelled Options on or as soon
as practicable following the date of the Change in Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>The Administrator, in its sole discretion and without the consent of any Participant, may cancel at the time of a Change in Control
any outstanding Option that has an exercise price that exceeds the Fair Market Value of the consideration to be paid per share of Common
Stock in the Change in Control transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VIII.
<U>MISCELLANEOUS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.1
<U>Partial Exercise/Fractional Shares</U></B>. The Administrator may permit, and shall establish procedures for, the partial exercise
of Options granted under the Plan. No fractional shares shall be issued in connection with the exercise of an Option or payment of a
Performance Award, Restricted Stock Award, or Restricted Stock Unit Award. Instead, the Fair Market Value of the fractional shares shall
be paid in cash, or at the discretion of the Administrator, the number of shares shall be rounded down to the nearest whole number of
shares and any fractional shares shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.2
<U>Rights Prior to Issuance of Shares</U></B>. No Participant shall have any rights as a shareholder with respect to shares covered by
an Award until the issuance of a stock certificate for such shares or electronic transfer of such shares (or book entry representing
such shares) to the Participant has been made. No adjustment shall be made for dividends or other rights with respect to such shares
for which the record date is prior to the date the certificate is issued (or electronic transfer or book entry is made), except as otherwise
provided in the Plan or a Participant&rsquo;s Agreement or by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.3
<U>Non-Assignability; Certificate Legend; Removal</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>Except as described below or as otherwise determined by the Administrator in a Participant&rsquo;s Agreement, no Award shall be transferable
by a Participant except by will or the laws of descent and distribution, and an Option shall be exercised only by a Participant during
the lifetime of the Participant. Notwithstanding the foregoing, with the consent of the Administrator, a Participant may assign or transfer
an Award that is not an Incentive Stock Option to (i) one or more members of the Participant&rsquo;s immediate family; (ii) a trust established
by the Participant for the benefit of the Participant and/or one or more members of the Participant&rsquo;s immediate family; or (iii)
an entity represented by a Director (or to an affiliate entity of such represented entity), provided that there are available federal
and state securities law exemptions for such assignment or transfer (&ldquo;Permitted Assignee&rdquo;), provided further that any Permitted
Assignee agrees in writing on a form prescribed by the Corporation to be bound by all provisions of the Plan and applicable Award Agreement(s)
and subject to all of the terms and conditions of the Plan and any Agreement relating to the transferred Award and shall execute an agreement
satisfactory to the Corporation evidencing such obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>Each certificate representing shares of Common Stock subject to an Award, to the extent a certificate is issued, shall bear the following
legend:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale or other transfer of the shares of stock represented by this certificate, whether voluntary, involuntary or by operation of law,
is subject to certain restrictions on transfer set forth in the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive
Plan, as amended and restated (&ldquo;Plan&rdquo;), rules and administrative guidelines adopted pursuant to such Plan [and an Agreement
dated _______, ____]. A copy of the Plan, such rules and such Agreement may be obtained from the Secretary of Lantern Pharma Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
shares are issued in book entry form, a notation to the same restrictive effect as the legend above shall be placed on the transfer agent&rsquo;s
books in connection with such shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>Subject to applicable federal and state securities laws, issued shares of Common Stock subject to an Award shall become freely transferable
by the Participant after all applicable restrictions, limitations, performance requirements or other conditions have terminated, expired,
lapsed or been satisfied. Once such issued shares of Common Stock are released from such restrictions, limitations, performance requirements
or other conditions, the Participant shall be entitled to have the legend required by this Section 8.3 removed from the applicable Common
Stock certificate (or notation removed from such book entry).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.4
<U>Securities Laws</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>Anything to the contrary herein notwithstanding, the Corporation&rsquo;s obligation to sell and deliver Common Stock pursuant to
the exercise of an Option or deliver Common Stock pursuant to a Restricted Stock Award, Restricted Stock Unit Award, Performance Award
or Stock Bonus Award is subject to such compliance with federal and state laws, rules and regulations applying to the authorization,
issuance or sale of securities as the Corporation deems necessary or advisable. The Corporation shall not be required to sell and deliver
or issue Common Stock unless and until it receives satisfactory assurance that the issuance or transfer of such shares shall not violate
any of the provisions of the Securities Act or the Exchange Act, or the rules and regulations of the Securities and Exchange Commission
promulgated thereunder or those of the Stock Exchange or any stock exchange on which the Common Stock may be listed, the provisions of
any other applicable laws governing the sale of securities, or that there has been compliance with the provisions of such acts, rules,
regulations and laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>The Administrator may impose such restrictions on any shares of Common Stock acquired pursuant to the exercise of an Option or the
grant of Restricted Stock or Restricted Stock Units or the payment of a Performance Award or Stock Bonus Award under the Plan as it may
deem advisable, including, without limitation, restrictions under applicable federal and state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.5
<U>Withholding Taxes</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>The Corporation shall have the right to withhold from a Participant&rsquo;s compensation or require a Participant to remit sufficient
funds to satisfy applicable withholding for income and employment taxes upon the exercise of an Option or the lapse of the Restriction
Period on a Restricted Stock Award or Restricted Stock Unit Award, or the payment of a Performance Award or Stock Bonus Award. If shares
of the Corporation are Listed Securities, a Participant may in order to fulfill the withholding obligation tender previously-acquired
shares of Common Stock or have shares of stock withheld from the exercise, provided that the shares have an aggregate Fair Market Value
sufficient to satisfy in whole or in part the applicable withholding taxes. Other payment methods as set forth in Section 2.4(a)(ii)
may also be utilized to satisfy any applicable withholding requirements. At no point shall the Corporation withhold from the exercise
of an Option more shares than are necessary to meet the established tax withholding requirements of federal, state and local obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>Notwithstanding the foregoing, a Participant may not use shares of Common Stock to satisfy the withholding requirements to the extent
that (i) such withholding would constitute a violation of the provisions of any law or regulation, or (iii) there is a substantial likelihood
that the use of such form of payment would result in adverse accounting treatment to the Corporation under generally accepted accounting
principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.6
<U>Termination and Amendment</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
</B>The Administrator may terminate the Plan, or the granting of Awards under the Plan, at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
</B>The Administrator may amend or modify the Plan at any time and from time to time, and the Administrator may amend or modify the terms
of an outstanding Agreement at any time and from time to time, but no amendment or modification, without the approval of the shareholders
of the Corporation, shall (i) materially increase the benefits accruing to Participants under the Plan; (ii) increase the amount of Common
Stock for which Awards may be made under the Plan, except as permitted under Sections 1.7 and Article VII; or (iii) change the provisions
relating to the eligibility of individuals to whom Awards may be made under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
</B>No amendment, modification, or termination of the Plan or an outstanding Agreement shall in any manner materially and adversely affect
any then outstanding Award under the Plan without the consent of the Participant holding such Award, except as set forth in any Agreement
relating to the Award, or as set forth in Sections 7.2(c) and 8.10, or to bring the Plan and/or an Award into compliance with the requirements
of Code Section 409A or to qualify for an exemption under Code Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.7
<U>Code Section 409A</U></B>. It is intended that Awards granted under the Plan shall be exempt from or in compliance with Code Section
409A, and the provisions of the Plan are to be construed accordingly. The Board reserves the right to amend the terms of the Plan and
any outstanding Agreement if necessary either to exempt such Award from Code Section 409A or comply with the requirements of Code Section
409A, as applicable. However, unless otherwise specified herein or in a Participant&rsquo;s Agreement, in no event shall the Corporation
or a Subsidiary be responsible for any tax or penalty owed by a Participant or beneficiary with regard to an Award payment. For purposes
of the Plan and any Agreement, the terms &ldquo;separation from service&rdquo; or &ldquo;termination of employment&rdquo; (or variations
thereof) shall be synonymous with the meaning given to the term &ldquo;separation from service&rdquo; as defined in Code Section 409A
and regulations thereunder. Any installment payments under the Plan shall be deemed to constitute separate payments for Code Section
409A purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.8
<U>Effect on Employment or Services</U></B>. Neither the adoption of the Plan nor the granting of any Award pursuant to the Plan shall
be deemed to create any right in any individual to be retained or continued in the employment or services of the Corporation or a Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.9
<U>Use of Proceeds</U></B>. The proceeds received from the sale of Common Stock pursuant to the Plan shall be used for general corporate
purposes of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.10
<U>Severability</U></B>. If any one or more of the provisions (or any part thereof) of this Plan or of any Agreement issued hereunder,
shall be held to be invalid, illegal or unenforceable in any respect, such provision shall be modified so as to make it valid, legal
and enforceable, and the validity, legality and enforceability of the remaining provisions (or any part thereof) of the Plan or of any
Agreement shall not in any way be affected or impaired thereby. The Board may, without the consent of any Participant, and in a manner
determined necessary solely in the discretion of the Board, amend the Plan and any outstanding Agreement as the Corporation deems necessary
to ensure the Plan and all Awards remain valid, legal or enforceable in all respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.11
<U>Beneficiary Designation</U></B>. Except as otherwise designated in a Participant&rsquo;s Agreement, and subject to local laws and
procedures, each Participant may file a written beneficiary designation with the Corporation stating who is to receive any benefit under
the Plan to which the Participant is entitled in the event of such Participant&rsquo;s death before receipt of any or all of a Plan benefit.
Each designation shall revoke all prior designations by the same Participant, be in a form prescribed by the Corporation, and become
effective only when filed by the Participant in writing with the Corporation during the Participant&rsquo;s lifetime. If a Participant
dies without an effective beneficiary designation for a beneficiary who is living at the time of the Participant&rsquo;s death, the Corporation
shall pay any remaining unpaid benefits to the Participant&rsquo;s legal representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.12
<U>Unfunded Obligation</U></B>. A Participant shall have the status of a general unsecured creditor of the Corporation. Any amounts payable
to a Participant pursuant to the Plan shall be unfunded and unsecured obligations for all purposes. The Corporation shall not be required
to segregate any monies from its general funds, or to create any trusts, or establish any special accounts with respect to such obligations.
The Corporation shall retain at all times beneficial ownership of any investments, including trust investments, which the Corporation
may make to fulfill its payment obligations hereunder. Any investments or the creation or maintenance of any trust or any Participant
account shall not create or constitute a trust or fiduciary relationship between the Board or the Corporation and a Participant, or otherwise
create any vested or beneficial interest in any Participant or the Participant&rsquo;s creditors in any assets of the Corporation. A
Participant shall have no claim against the Corporation for any changes in the value of any assets which may be invested or reinvested
by the Corporation with respect to the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.13
<U>Approval of Plan</U></B>. The Lantern Pharma Inc. 2018 Equity Incentive Plan was (i) approved by the holders of at least a majority
of the votes cast on a proposal to approve the Plan at a duly held meeting of shareholders of the Corporation held on August 29, 2018,
and (ii) amended and further approved as described in Section 1.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.14
<U>Governing Law</U></B>. Except to the extent governed by applicable federal law, the validity, interpretation, construction and performance
of the Plan and Agreements under the Plan, shall be governed by the laws of the State of Delaware, without regard to its conflict of
law rules.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, this Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan has been executed on behalf of the
Corporation effective as of October 20, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LANTERN
    PHARMA INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Panna Sharma</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ADDENDUM
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>LANTERN
PHARMA INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>SECOND
AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(California
Participants)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the date, if ever, on which the Common Stock becomes a Listed Security and/or the Corporation is subject to the reporting requirements
of the Exchange Act, the terms set forth herein shall apply to Awards issued to California Participants. All capitalized terms used herein
but not otherwise defined shall have the respective meanings set forth in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The following rules shall apply to any Option in the event of a Participant&rsquo;s separation from service with the Corporation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
If such termination was for reasons other than death, &ldquo;disability&rdquo; (as defined below), or Cause, the Participant shall have
at least thirty (30) days after the date of such termination to exercise his or her Option to the extent the Participant is entitled
to exercise such Option on his or her termination date, provided that in no event shall the Option be exercisable after the expiration
of the Option term as set forth in the Option Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If such termination was due to death or disability, the Participant shall have at least six (6) months after the date of such termination
to exercise his or her Option to the extent the Participant is entitled to exercise on his or her termination date, provided that in
no event shall the Option be exercisable after the expiration of the Option term as set forth in the Option Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Disability&rdquo;
for purposes of this Addendum shall mean the inability of the Participant, in the opinion of a qualified physician acceptable to the
Corporation, to perform the major duties of the Participant&rsquo;s position with the Corporation or any Subsidiary because of the sickness
of injury of the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Notwithstanding anything stated herein to the contrary, no Option shall be exercisable on or after the tenth anniversary of the date
of grant and any Award Agreement shall terminate on or before the tenth anniversary of the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
The Corporation shall furnish summary financial information (audited or unaudited) of the Corporation&rsquo;s financial condition and
results of operations, consistent with the requirements of Applicable Laws, at least annually to each California Participant during the
period such Participant has one or more Awards outstanding, and in the case of an individual who acquired Shares pursuant to the Plan,
during the period such Participant owns such Shares. The Corporation shall not be required to provide such information if (i) the issuance
is limited to key employees whose duties in connection with the Corporation assure their access to equivalent information or (ii) the
Plan or any agreement complies with all conditions of Rule 701 of the Securities Act of 1933, as amended; provided that for purposes
of determining such compliance, any registered domestic partner shall be considered a &ldquo;family member&rdquo; as that term is defined
in Rule 701.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>List
of Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of Subsidiary</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starlight
    Therapeutics Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware,
    USA</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lantern
    Pharma Australia Pty Ltd</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Victoria,
    Australia</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lantern
    Pharma Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Northern
    Ireland</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statement of Lantern Pharma Inc. on Form S-3 (No. 333-257643) of our report
dated March 20, 2023, on our audit of the consolidated financial statements as of December 31, 2022 and 2021 and for each of the years
then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 20, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
EisnerAmper LLP</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EISNERAMPER
LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iselin,
New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
20, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Panna Sharma, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of Lantern Pharma Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably
    likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
    financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons
    performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LANTERN
    PHARMA INC. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Panna Sharma</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Panna
                                            Sharma, Chief Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, David R. Margrave, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 10-K of Lantern Pharma Inc.;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LANTERN PHARMA INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 20, 2023</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ David R. Margrave</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David R. Margrave, Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B STYLE="text-transform: uppercase">Exhibit 32.1</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. ss.1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Lantern Pharma Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ended December 31, 2022
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Panna Sharma, the Chief Executive
Officer, and David R. Margrave, the Chief Financial Officer, of the Company, respectively, certify, pursuant to 18 U.S.C. &sect;1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    <I>Panna Sharma</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 20, 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Panna
    Sharma</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    <I>David R. Margrave</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 20, 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    R. Margrave</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification is made solely for the purposes of 18 U.S.C. Section 1350, subject to the knowledge standard contained therein, and not
for any other purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'K!$P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KS/XM_%[P%\#? FL_$OXG:Y_PCG@O0;WP[IVHZLFE:SKDZ7_BWQ)H
MWA#PY8VVD>'M/U76M0O-8\2Z_I&D65M8:?<3275]"NP*68>F5^<W_!5>34X?
MV)_B'-HUO:7FKP_$_P#97FT>SU"\FT_3KW6$_:M^"3:79:A?V]M>S6%C=WRV
M\%]?06=W/96LDES#:73QB$^?FV+J8#*\QQM&,9UL)@L1B:490E44IT::FER0
M<93;N[0C).;2@FG*Z^GX)R7"\2<9<*<.XZK6HX+/>(<JRG%UL/5I4:]+#X[$
MRHU:E*M6I5Z-&<81NJU6C5IT5S59TJL:;IS^D/A;^U3\#_C)XT\4?#?P)XSD
MG^(W@G2+#7O%OPZ\4>%/&GP]\?Z#HNIRK;VFJWO@[XA>'O"^OMIIGDMX9[^V
ML)[2TEOM,CNYH3JFFFZ^@!.2RKMP3GY2&!XSG'MP=I[X)&1R/QP^-OPL_:6N
M/#W[3_[8_P =)_AI\+?&?@S]@OXZ_!GX<?#WX'^,?&GC.323K+MX^U7QWKOQ
M2UKP[\-;V?58+OPMHUMX:T/2O!5C!I7FWNIW.IRZC%8&'G?%WPMU+P;9_L8>
M!=1^+_QPO;G]NOXI>'=+_:W^*$OQA^(&G:]XQ_X1W]G7XK?$NR\)>!;F/7K;
MPU\!_#7CWQA;V?@Z[T/X-Z3X%U34_#;V'A[0]1M-?L].UF#Q(Y]CL.JD<7ET
MIRBG6IU7*&7N>%Q&:87*<ME4PE>6+J4*V)Q.)<L0JE:-/#X>C4KI.K.E@Y_H
MU?PRX;S">'KY)Q?AZ%&K*G@,1@J4:W%U+#9UE7!N;<<<7T\+Q!EM'A[!YIEV
M5Y+E+665,-E\\5FN<8["Y)2G[*AB\^I?MD9CNQ@< $YSD@G'"]>#QGN3@#CD
M$S%F&W[O48))S]W'0Y/.0 <'@^M?SZ_'C6/%?[-T_P"V7^SS\*OBE\69/@[X
M \#_ +#7Q*M]&O/BMXI\6?%?PC;?&']HCQ!X+^-_PC^%WQ0\;:]JGCM/$OQ:
M\!^'X9/ OA34/%-UXJ'B[QA+9^!M;\-CQ'X3CTC@OBI\)O'WP:^ O[?'[1G@
M'2?VF?@)X(;X>?L_:!^S=H?QA^-GQ'\1>/O"VN6_Q&TZ?XR>*/\ A$O$?Q5^
M)2:/9:WJG_"#6^@R>*;\ZTZ:7XEMK71M*\.:S.=?QK\62HNM!956J3P5#&U<
MP5/%0:HK +,76G1J?4I4*]#GR_V$*U:O@92K8O#16&FH8JIA_0R_P-HX^GEM
M9\<8+"4>),?D&#X4GB<CK4JF9OB2MPE'+Z&/PE3B"EC\OS-87BO^T:V7Y?@.
M(J5/ 9'F]>><4?;9/1S+^D;S^2,#( //3D$CN,C:-W!/'3-+YYR1M!.Y5 !Y
MY) R.V2IQ]#UP:_)#XQ_";X7_#^[\"_LE^&M"_:D^//Q1^-EWXQ^.7BBTM?V
MN/BE\.+W7]$\"IX&\)>//B#\0?B;<_$/2+K0?"UOXE\3>"9-,^%GPVAM]('B
M#7+N_P##W@C3M+CU=J^//@[)\2_C/-^SI\#_ !!\7/BIX=\'Z3^V_P#MX?!7
M4K;0OBUXGUOQ1<?!'X5^ O$?]C_"2Z^+MAJ6F>+?$]OIUG;C0=.^)5YJS^-(
MK:)=5TW5[+4UMKNVZ<1Q)+#8F&#E@/:XBI)4(QP^,C5A#&^TP,:F$K5YX"A0
M@Z-/,L+4J2IU*]6-ZD9T(0]C4J^3E7A%A\XRBOGM#BU83*\-"ICZE?,N':V&
MKU^'EA>)YX?/,%EN'XES'-*D,7CN#\[P>%PN.PN5QKP6%KT<?6G#-:&6_P!&
M2S,VWY-I(R00W&,9!(X]<$D9QP"#4RDL,G'7M]!7X4:)^R7IGB'QM^W3\(]1
M^./[3Z?#O]FN'P5K'[-NDV/[1/Q<L]5^#_B3QY\&&^(FLZROB>'Q:/$/Q(33
M/$4]E/X9TGXMZGXYT;28HK^T.GW%MJMVC_JE^R/X\\1?%+]EO]G;XD^+KA+S
MQ5X\^"GPQ\6^([R-2B7>N:]X,T;4=4NPA9BANKVXFG=<X$DCE0$*@=V79M5Q
MN(GAZ^!^IR5+$5:?^UTL5S_4\RJY7BHOV=&ERJ.)IJ>'DW-UL+5C4J1H55*B
MOG.+^!L%PYEU#,\MXDCG]">,RG"XJ$LCQV2U,*N(N%,+QID=1?6\?CX8FI4R
M>O/#YI2I2I0RW-\/5PV'JYG@:N'S*?T/1117M'YV%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5Q&O_ !%\'>&/%_@3P'K>M16/BOXF3^)+?P/I
M#VU]++KLOA'1&\1>(EBN(+:6SM?[-T=&O':_N+59E'E6WGSGRZ[>OB'X^?\
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MB6FH)HL$6K^%X(M-ETYM/?2[=LZC96=MJ<DUY)WO]H_&+_H6_!'_ (/=3_\
MD*C^T?C%_P!"WX(_\'NI_P#R%7I2P&!EB'BY8+"/%24%+$O"X=XB7LY0E3O7
M=+VGN2ITY1][24(26L(\OQ]/B?B:EE5/(Z?$F?T\EH_6/9913SG,X9526+AB
M*>*5/+HXQ8."Q$,7C(5E&@E.&+Q<;0CBL4L0^Q^$O@'3]=^)WB6T\.)#K?QE
M71H_B5?B^U=G\4)H7A:+P9I(GADOW@TX67AJ)-,7^QH=,\Q5-S-OOGDN7W_A
M[X%\+?##P-X2^'/@?2%T#P;X&\.Z/X3\*Z(EU?7RZ3X?\/Z?;Z5I&G+>ZI=7
MVI7:V=A:P6ZW%_>W=W,L8>>YF<F1N=_M'XQ?]"WX(_\ ![J?_P A4?VC\8O^
MA;\$?^#W4_\ Y"K>-&C"7/"E3C-*<5*,(QDHU:OMZL5))/EJ5VZTU>TJK<WJ
M>?6S',<32]AB<PQN)H.>%J.CB,57K4G4P.!668*I[.I4E#GPF6J.78:?*Y8?
M 1C@Z#I85*BO4Z*\DN-;^+EKY F\.>"LW-Q':Q!=<U(YED5V4,6M%"KB-LGD
MYP IS5C^T?C%_P!"WX(_\'NI_P#R%6AQGJ=%>6?VC\8O^A;\$?\ @]U/_P"0
MJ/[1^,7_ $+?@C_P>ZG_ /(5 'J=%>6?VC\8O^A;\$?^#W4__D*C^T?C%_T+
M?@C_ ,'NI_\ R%0!ZG17EG]H_&+_ *%OP1_X/=3_ /D*C^T?C%_T+?@C_P '
MNI__ "%0!ZG17EG]H_&+_H6_!'_@]U/_ .0J/[1^,7_0M^"/_![J?_R%0!ZG
M17EG]H_&+_H6_!'_ (/=3_\ D*C^T?C%_P!"WX(_\'NI_P#R%0!ZG17EG]H_
M&+_H6_!'_@]U/_Y"H_M'XQ?]"WX(_P#![J?_ ,A4 >IT5Y9_:/QB_P"A;\$?
M^#W4_P#Y"H_M'XQ?]"WX(_\ ![J?_P A4 >IT5Y9_:/QB_Z%OP1_X/=3_P#D
M*C^T?C%_T+?@C_P>ZG_\A4 >IUQ&O?#CP9XG\8>!/'VN:*E_XM^&4WB2X\"Z
MNUYJ,#:!-XOT1O#OB.2.TM;R"POSJ>C,;)EU2UOEME_?62VUS^^K#_M'XQ?]
M"WX(_P#![J?_ ,A4?VC\8O\ H6_!'_@]U/\ ^0J ,B7]G?X.3?!V7X 2^#(6
M^$$UM)9R>#?[8\1+ UO+XA/BJ2,:NFKKX@4-KY.H;EU8.&)MU86F+<97Q$_9
M;^ ?Q8\::/\ $/X@_#71?$?B_18[.WBU6:YUFPBU>RTZZCO=/TWQ=I6DZI8:
M-XZTJQN$8V>E>--/U_3;6*XO;:"T2WO[Z*YZS^T?C%_T+?@C_P 'NI__ "%1
M_:/QB_Z%OP1_X/=3_P#D*@"+P[\#OA7X3O\ PUJ7A_P?86%WX/\ AM<_!_PX
M3=:K>6^G?#2\U'2-4N?"9LK[4+FRO+&6]T'29#<7UO<WZI:?9TNUMI[B&7RW
M1OV(_P!EK0++QYI>E?"+1H-%^)6C/X?\6^'IM8\5WWAF?1CJT&NPZ?H?AJ_\
M07.@^#X+#6;6SU+2/^$.T[07T6[L=/ETE[)M/LS#ZO\ VC\8O^A;\$?^#W4_
M_D*C^T?C%_T+?@C_ ,'NI_\ R%0!Q7PZ_9/_ &>_A1J)UCP'\-=+TG6)/"VN
M^"KW5;[4_$7B74M9\*^)=5L=9UC1O$=]XGUG6;KQ-;3WVG68MF\03:E/IEC$
MVDZ7-9:5-/9RN\!_LI_ 3X8G0/\ A!? ,>@Q^%?&NJ?$+PU;KXC\8:A9Z!XK
MUCPI/X'O[W1[+5?$-]::?8-X4N9M&M?#UM!'X<TZ!A+IVDVMTB3KV?\ :/QB
M_P"A;\$?^#W4_P#Y"H_M'XQ?]"WX(_\ ![J?_P A4 <%#^R)^S?!\33\88_A
M-X;'CX:RWB6'4&?5I-#M/%+3)<GQ?8>"9=3D\#Z?XQ-VCZ@_BZR\.6_B-]3N
M;[4VU,W^H7UQ<>D)\(_A['IWQ,TE/#L2Z=\8[S5]0^)5LM_JP'B>\U[PW9>$
M=6GEE.H&;33=^'M.LM.9-&DTY(A!]I@6*\DEN'J?VC\8O^A;\$?^#W4__D*C
M^T?C%_T+?@C_ ,'NI_\ R%0!W'AGPYHW@_PWX?\ "/ARR73?#WA;1-*\.:#I
MRS7-RNGZ+HEA!IFEV2W%[-<WEPMI8VL$ GN[B>YE$?F3S2RL[MMUY9_:/QB_
MZ%OP1_X/=3_^0J/[1^,7_0M^"/\ P>ZG_P#(5 'J=%>6?VC\8O\ H6_!'_@]
MU/\ ^0J/[1^,7_0M^"/_  >ZG_\ (5 'J=%>6?VC\8O^A;\$?^#W4_\ Y"H_
MM'XQ?]"WX(_\'NI__(5 'J=%>6?VC\8O^A;\$?\ @]U/_P"0J/[1^,7_ $+?
M@C_P>ZG_ /(5 'J=%>6?VC\8O^A;\$?^#W4__D*C^T?C%_T+?@C_ ,'NI_\
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M+9Z,[:2D4FG/#=7T=SH_VC\8O^A;\$?^#W4__D*C^T?C%_T+?@C_ ,'NI_\
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M>*]<U[1+D:E);7>F7%K#;00^<_$[_@BY_P $M?C-\9OBA^T)\3_V*_A%XO\
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MWY;2T;ZNS8<J?16ZJRU(?AI\"_A'\&_@WX8_9]^%G@+0/ ?P:\&>#T\!>&/
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M^"57[2FC?LV?LB#4/VN/BM-\*/A7XU^+WC:']D]_CKJVH:?XDUCX4Z5I^CW
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MHPXNS&ME6-RK,,NA1Q^+>#IU_P"AF6[2"*6:8I%% CR2R22K&D4<2EY))9)
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M<_%37[O3?"WP&U^>;PM?A;\;OC+\.O\ @HWH7PPTGQ5\3/"/A7_@N?K'B_\
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MG_R\_D__ (F:\:?^BJPG_B-\/?\ S"?T9?\ #^GPW_T;-XL_\.CH/_S&T?\
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MV?\ $+>!_P#H45/_  Z9I_\ +SR?^)FO&G_HJL)_XC?#W_S"?T9?\/Z?#?\
MT;-XL_\ #HZ#_P#,;1_P_I\-_P#1LWBS_P .CH/_ ,QM?SF[1_D+_P#$T;1_
MD+_\31_Q"W@?_H45/_#IFG_R\/\ B9KQI_Z*K"?^(WP]_P#,)_1E_P /Z?#?
M_1LWBS_PZ.@__,;1_P /Z?#?_1LWBS_PZ.@__,;7\YNT?Y"__$T;1_D+_P#$
MT?\ $+>!_P#H45/_  Z9I_\ +P_XF:\:?^BJPG_B-\/?_,)_1E_P_I\-_P#1
MLWBS_P .CH/_ ,QM'_#^GPW_ -&S>+/_  Z.@_\ S&U_.;M'^0O_ ,31M'^0
MO_Q-'_$+>!_^A14_\.F:?_+P_P")FO&G_HJL)_XC?#W_ ,PG]&7_  _I\-_]
M&S>+/_#HZ#_\QM'_  _I\-_]&S>+/_#HZ#_\QM?SF[1_D+_\31M'^0O_ ,31
M_P 0MX'_ .A14_\ #IFG_P O#_B9KQI_Z*K"?^(WP]_\PG]&8_X+T^&R1_QC
M-XL_\.CH'3O_ ,R:.@]Z]5^('_!9G0? G@KX(>,9?V?O$FI1_&CP'K_CBWT^
M'XB:+;2>'HM"^(GBKP VFW5Q)X5F349KF7PP^J+<PQ6L<45ZEH8I)('GD_EV
M*C!^AZ@?T /ZU]8?M!C/P3_88'_5 ?B%_P"M'?%?UR/TK@Q7AGP73Q>54H97
M5C3Q.)Q=.O'^T<Q?/&EE>(Q%./-*OS1M6A";<+/W;-N+<3W,L^D;XP8G*N)\
M56XGPLJV6Y;E.(P<UP[P_%4ZV*XGP.75Y2BL$HU%/!UJE)1FFH.3J)>T47']
M@_\ A_3X;_Z-F\6?^'1T'_YC:/\ A_3X;_Z-F\6?^'1T'_YC:_G-VC_(7_XF
MC:/\A?\ XFN__B%O _\ T**G_ATS3_Y>>'_Q,UXT_P#1583_ ,1OA[_YA/Z,
MO^']/AO_ *-F\6?^'1T'_P"8VC_A_3X;_P"C9O%G_AT=!_\ F-K^<W:/\A?_
M (FC:/\ (7_XFC_B%O __0HJ?^'3-/\ Y>'_ !,UXT_]%5A/_$;X>_\ F$_H
MR_X?T^&_^C9O%G_AT=!_^8VC_A_3X;_Z-F\6?^'1T'_YC:_G-VC_ "%_^)HV
MC_(7_P")H_XA;P/_ -"BI_X=,T_^7A_Q,UXT_P#1583_ ,1OA[_YA/Z,O^']
M/AO_ *-F\6?^'1T'_P"8VC_A_3X;_P"C9O%G_AT=!_\ F-K^<W:/\A?_ (FC
M:/\ (7_XFC_B%O __0HJ?^'3-/\ Y>'_ !,UXT_]%5A/_$;X>_\ F$_HR_X?
MT^&_^C9O%G_AT=!_^8VC_A_3X;_Z-F\6?^'1T'_YC:_G-VC_ "%_^)HVC_(7
M_P")H_XA;P/_ -"BI_X=,T_^7A_Q,UXT_P#1583_ ,1OA[_YA/Z,O^']/AO_
M *-F\6?^'1T'_P"8VNM\ ?\ !<#P]XZ\?>!/ L7[.7BC39?''C?PCX,BU*;X
MEZ)=1:=+XK\1:;H$=_+;1^$87N8K)]16YDMTEB>9(FB6:(L'7^:#:/\ (7_X
MFO6_V?E _: ^ 7_9<_@]V7_HH_AGT%88OPPX)I83%U89354Z6$Q=6#_M/,W:
M=+"8JK!V==IVG3@[--.UFFFT^[*_I*>,F)S3*L-6XHPDZ.)S7*L-6@N'.'XN
M='$YKE6&K04E@E*+G1Q-:'-%J4>?FBU*,6OWAO?^"\'ANRO;VS/[-'BN7['>
MW=F9/^%GZ$JR&UN)(/,"_P#"'$J)/+WA23@'&YL9KZJ_9#_X*N_"?]J#X@2_
M##6?"6H_!_QEJ,<3^"++Q%XCT[7;#QU.D<\FH:1INJV>EZ3#9>(K2*..XLM&
MNXGEUJU^TMILLEU9RVC_ ,E&M\ZUK9XS_;6J@#&<_P#$PN#WSS[]>WICR_QK
M\2;?X>7>AS2:7XBN99[V*YCU/0DF@;13:RF2#5(M1MS'+;7MA?16UP##-;W=
MI$O]HVLCS6L:4J_@_P +9A@J]#+L%B,'C9X9U:6,ACL77>&E&%.;JSP^)K.C
M6HJ3M5IOEE*G*:IU*=6-*1[?!_TC?&G'\6Y-EU.OA>+?K>:1P<>&_P"RLBRR
MKFZJUIT5@Z&8T:>"E@\5-2BL)7==4UBE0C5I5X594:G^CXDZR*K* 0PW#YA@
MCL<X[Y'0'KQG(R\29QQP2!G.1V'7'J<<X)K^;_\ 8'_X*K^./B)\1O 7PU^-
M>N1ZEINE^!9= U+Q/;6I:7QCK.L:SIW_  C'C'6DTW0KI;7Q'ID+Z-X:UZ2[
MUC0/#MY::_>>*+C.LB&PG_/7_@H%^V5\5?AM_P %I?V=/BO\*/"_BOX[:_X3
M^'$WA/P?^SWX8\6ZMIMMXN\2^(]0_:!^'WAK0+RRT.PUNVDU.PG\3Z;XHU.W
MFT*>\D73_L-UJ&E"-=<L?YLR+)\/GGB1C_"N&;X'#\6X#(>)>('A'.%2G6P'
M#V"P^*ABI5ZE;#4,)EV95\1' T,RQ=>C2P]>CC?K%'_8<0W_ *3XN6,P'#O!
MO$V.RO,<!@^-<LPV8X'!YG@\5EV:Y;4G+&PQN4YOEV+PU#$X;.LKE@E]=P*H
MZT\?E=>A.5+,*"?]IU%?A3^RK_P66U'Q-\4_B'^S;^WO^SIXB_8F_:"^'/PI
M\0_&-+'6-1N?$G@[Q]X%\%Z#K'BCQIJ_AR?^S(+BQGTKP[H>KZSI,.GZIXU\
M/^(]/\/^)TT_Q<-;T*]T*/YVB_X+^_%Z'PQIW[3^L_\ !-CXTZ3_ ,$]M3\4
MGPU;_M(-XTTFX\5+IIUF?1H?&;?#\:!'9R:<]_$-+DM(_$@\-?VNEUI6G_$?
M4]<ABT.Z^CI^&'&U7%8G"4\HHSJ4%@72K?VMDT<%F<\TI5Z^64<DQ\\RA@\[
MQ.8T<+BJF#PV65\3B*JPU:+ITJD53ES/,\$HQDZS7,YIQ=*M[2G[.48U'5I^
MRYZ,82E%2=2,$N:+NTTS^E^BOPZ_:^_X*_>)?!7Q>\(_LN_L"?LWZS^V_P#M
M'^,/A/IWQDN--TO7AX0\$>!?!'B;0=.\3^#-2\17NH64,MQ<Z_X?U72-9NK7
M6-4\#Z9HVF^)O""S>(;K7O$FG>'IOG+QU_P7*_:-\2>)OBWXD_8^_8'UW]I/
M]F[]E^\OM&_:"^,D7C9_#L%[K>A:0+WQ9_P@5G!I&JWEOX?\-7%O?W@U>+2/
M'VJZCX9CM_$6I^&O"VF7-E=7T8#PTXQS##87%4LNPN&HXO#K%TGF6<9/E<X8
M>MB/J> JXJEF&/P]3!_VQC(U<)DL,7&A5S6O0Q$<)3=/#U:\2>98.G*<7.<W
M"3@_94*U5.48J=10=.G)3=*#C.MR<WLHSBYO6R_I2HK^8&7_ (+Z_M*^/_#W
MB_\ :1_9V_X)J_$3XD?L2?"7[39_%+XG:YX[TK1_&MM>V>E:1JFN7=GINA6G
MB33=,L/!L.K1W?B!M.M/'NEVVBK'KGB;Q)X%T\ZB^D_3OQ]_X+6VL\/[.'@#
M]@;X >)_VN_V@?VJ/A#'\;? O@>;4K+P?I?@/P#/)KU@+[XA3>?<QGQ#IWB#
MPIXJT'6_#,>N:'IFD77AG7?[4\:6%S#I5CK6U;PLXWH8C"X:KE.'C4Q$L7"O
M-9QDTZ&45<#A(X_&4>(,1#,)4<@K8; 3IXVK2S2IAY+#U*?)[2M)X:*6:8%Q
ME)59-14'%>QK<U6-2?LZ<L/'V=Z\)U/<C*DI+F33Y;7/WAHK\$?AE_P77^'=
MO\!_VJ?&/[5/P4\8?LZ_M#_L;W6@Z/\ %3]G.XU6RUO6_%.K^+=0M_#G@R7P
M!JM_::(LUAXB\53P:=?O>V\^G>&[#5-#UZV\0^*?#6O^'?$&L<-\%?\ @M3^
MT)IWQ?\ @1X5_;I_84U_]ECX/_M;^(=-T;]GKXRP>-8O$6D07?B5-)_X1'1_
M'5M=Z=:;!K$FM:?]LUN[?P3K.E6MW;:G-\.Y=%BUS5=!Q?AGQJHYDWD\8O+)
MS@X2S+*HU,R=/+8YU4_L"$L<I<01ADTX9JY9/]<B\#.%6#G-NA&O[2P7[K]\
MW[5)JU*M:G>JZ"]N_9_[/>LO9?ON3W]-O>/Z)Z*_FF\+_P#!>KQY/^SAX;\7
MW?[,L?Q,_:C^+_[5OQ@_9H^!'P"^%6K:U:67B)/A8WA2&^\7>)]9U6R\0ZK9
M+;W'BS3[9M-TW39CJUZ[IY^@:)IOB'Q)H?ZD_P#!/[]H_P#;.^/N@^/[7]LO
M]C6\_92\7^!=3TG3=+U&+QEI7B'PU\1SJEI+JMW-X>TB"\U6_P!*M_#UC<:-
M:W6H1^(O%&D:GJ5WJ%K'J.FZEI.H:-:\V<< \2Y#@L7C\VP^ P=#!XRI@G3J
M9SE7US%SHUJ.'KU\NR]XN./S#!4,1B*>'K8S"X65"%;VL4YJA7G2JCCL-7G"
MG2E4G*<%.ZHUN2*E%SC&I/DY(3<4Y<DI*235[-I'Z(4445\8=@4444 %%%%
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MZ#HH _/_ ,:?LP?M)?'[X6?&_P" W[5O[0/P&^(?P6^./P3^)'PDU[0_@_\
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MX-TCQ39B*=-<^'GBB]NK?PWXTTAK35-,U[0=,\3:+=6>HVEG<0^<?!KX3?\
M!0;X?>*?"/AWXB?M=_L^_&3X*>$K2RT^ZU37_P!DOQKH'[2_Q TVQ%U:P_\
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M\0BVU73=&\#^!K?4K.71_MVB@#\O?V4?V+_VLOV0O OA'X*?#[]J_P" NO?
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M/AO_ .0J/^':?[+?_1'OAO\ ^$3X;_\ D*OTC_B-N3_]"+-O_"G+?\C^=O\
MB3/BW_HN.%?_  V<2_\ R)_&9D>H_,49'J/S%?V9_P##M/\ 9;_Z(]\-_P#P
MB?#?_P A4?\ #M/]EO\ Z(]\-_\ PB?#?_R%1_Q&W)_^A%FW_A3EO^0?\29\
M6_\ 1<<*_P#ALXE_^1/XS,CU'YBC(]1^8K^S/_AVG^RW_P!$>^&__A$^&_\
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M_P#1'OAO_P"$3X;_ /D*C_B-N3_]"+-O_"G+?\@_XDSXM_Z+CA7_ ,-G$O\
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M *(]\-__  B?#?\ \A4?\1MR?_H19M_X4Y;_ )!_Q)GQ;_T7'"O_ (;.)?\
MY$_C,R/4?F*,CU'YBO[,_P#AVG^RW_T1[X;_ /A$^&__ )"H_P"':?[+?_1'
MOAO_ .$3X;_^0J/^(VY/_P!"+-O_  IRW_(/^),^+?\ HN.%?_#9Q+_\B?QF
M9'J/S%&1ZC\Q7]F?_#M/]EO_ *(]\-__  B?#?\ \A4?\.T_V6_^B/?#?_PB
M?#?_ ,A4?\1MR?\ Z$6;?^%.6_Y!_P 29\6_]%QPK_X;.)?_ )$_C,R/4?F*
M,CU'YBO[,_\ AVG^RW_T1[X;_P#A$^&__D*C_AVG^RW_ -$>^&__ (1/AO\
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MR?\ Z$6;?^%.6_Y!_P 29\6_]%QPK_X;.)?_ )$_C,R/4?F*,CU'YBO[,_\
MAVG^RW_T1[X;_P#A$^&__D*C_AVG^RW_ -$>^&__ (1/AO\ ^0J/^(VY/_T(
MLV_\*<M_R#_B3/BW_HN.%?\ PV<2_P#R)_&9D>H_,49'J/S%?V9_\.T_V6_^
MB/?#?_PB?#?_ ,A4?\.T_P!EO_HCWPW_ /")\-__ "%1_P 1MR?_ *$6;?\
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MO@1>?LV_'#]G>U\*:]\7/AK\1;GP;K&DV?P^\?Z?XBU'P#\8?!'Q-\*ZC?\
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M;R0@'ZK_ +*?QB7X@>"_BGXO^/E_^PK?>#_ .E:)XWL/C1^S+\:;#QI\))/
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M7P1_T*FD_P#@J3_XW7^)5_PT1^T7_P!'$_'_ /\ #V_%+_YK:/\ AHC]HO\
MZ.)^/_\ X>WXI?\ S6TO]5,1_P!!M'_P3/\ ^3%]:C_+/\#_ &UAX%\$$_\
M(J:0/KI:8_\ 15'_  @O@@#_ )%32.?^H7&3Q](\C^OO7^)3_P -$?M%=_VB
M/C^?^ZV_%+_YK?3(K]-_VO?CG\<K'_@GE_P1RU6P^-_QFL-5\0_"G]NB?Q!J
MUC\5_B!9:IKL^D?MK>,=+TJ;6M2M?$<5[JLNG:8J:=927\]P]M8QPVL3+!#"
MB95.&J].=&#Q=*3JU/9IJE-<KY)SNTWJK0:T=]5H4L3%J7NR]U7Z:ZI?J?ZS
MW_""^"/^A4TG_P %2?\ QNC_ (07P1_T*FD_^"I/_C=?XE7_  T1^T7_ -'$
M_'__ ,/;\4O_ )K:/^&B/VB_^CB?C_\ ^'M^*7_S6UM_JI7_ .@VC_X)G_\
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MC]HO_HXGX_\ _A[?BE_\UM'^JE?_ *#:/_@F?_R8OK4?Y9_@?[:O_""^"/\
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M O@@G_D5-('N=+3_ .-4H\"^""?^14T@?72T_P#C=?XE/_#1'[1?_1Q/Q_\
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M ),?UJ'\LOP/]M7_ (07P1_T*FD_^"I/_C='_""^"/\ H5-)_P#!4G_QNO\
M$J_X:(_:+_Z.)^/_ /X>WXI?_-;1_P -$?M%_P#1Q/Q__P##V_%+_P":VC_5
M2O\ ]!M'_P $S_\ DQ?6H_RS_ _VU?\ A!?!'_0J:3_X*T_^-4H\"^"#_P R
MII ^NEIC_P!%5_B4_P##1'[1?_1Q/Q__ /#V_%+_ .:VC_AHC]HO_HXGX_\
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M\#_;6'@3P0?^95T8#CEM.B49/&.8P<YP!P 3P#TR\> ?!)&?^$6T4?73X/\
MXFO\;+]D[_@I9^VK^QI\>? _[07PJ^//Q(U[Q'X-O2-1\&_$SQ_XZ\=?#CXA
M^%+QXAXB\ ^._#.M>(KJ*]\.>)+2!();S37L/$.@ZA'IWB+PSJVD^(-(TS4+
M;_5+_P""7G_!4?\ 9X_X*E?L_P!E\7_@W>OX<\9^'QIVC?&KX)>(-1L[KQU\
M'/&US9^;)I6J"W\K^WO!^LRPW=U\/_B!9V=MI?C#1H)&FM-$\2Z?XA\,:)Y>
M8Y-B<NC&I.4:U%Z.K3C)*G+HIQ;;2?V9:IM6=C6G6C4=D[-=';6_9^1^@?\
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MW_P4Q\(_%?X/>./B+X<^,W_!0W_@A!+XDUO3_ 'B&/PG\8/ OPW\#?LB:/\
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M_BGQ3>I<36T-_P"!HO&OP:\70P:KI(NH/%]DEAKVAMJ6F74-V?PY^ 'P8_:
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MFQ,)34%%-M-MV]%Z'\W%%?T0?\0O/_!53_H&_LW_ /AX?$O]?A;1_P 0O/\
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M_P /#XE_^=;1_P 0O/\ P54_Z!O[-_\ X>'Q+_\ .MH_MC+/^@VA_P"!2_\
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M-_9O_P##P^)?_G6UI_;&6?\ 0;0_\"E_\K)]A5_D?WQ_S/YWZ*_H@_XA>?\
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M)^]'VSQ=_P!$_LO_  KK/_Y5T?;/%W_1/[+_ ,*ZS_\ E77X+_\ $1E\!/\
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M3^R_\*ZS_P#E77X+_P#$1E\!/^C<_CS_ .#'X7__ #64?\1&7P$_Z-S^//\
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M_A76?_RKH^V>+O\ HG]E_P"%=9__ "KKT6BJ,3SK[9XN_P"B?V7_ (5UG_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;<?[A_7_  HW'^X?U_PKC_L+(O\ H19+_P"&?*__ )B/>_XBAXF?]'*\0_\
MQ/.,?_HG/RY_X= _L-_]$"^'G_@LN_\ Y.H_X= _L-_]$"^'G_@LN_\ Y.K]
M1MQ_N']?\*-Q_N']?\*/["R+_H19+_X9\K_^8@_XBAXF?]'*\0__ !/.,?\
MZ)S\N?\ AT#^PW_T0+X>?^"R[_\ DZC_ (= _L-_]$"^'G_@LN__ ).K]1MQ
M_N']?\*-Q_N']?\ "C^PLB_Z$62_^&?*_P#YB#_B*'B9_P!'*\0__$\XQ_\
MHG/RY_X= _L-_P#1 OAY_P""R[_^3J/^'0/[#?\ T0+X>?\ @LN__DZOU&W'
M^X?U_P *-Q_N']?\*/["R+_H19+_ .&?*_\ YB#_ (BAXF?]'*\0_P#Q/.,?
M_HG/RY_X= _L-_\ 1 OAY_X++O\ ^3J/^'0/[#?_ $0+X>?^"R[_ /DZOU&W
M'^X?U_PHW'^X?U_PH_L+(O\ H19+_P"&?*__ )B#_B*'B9_T<KQ#_P#$\XQ_
M^B<_+G_AT#^PV.GP!^'A_P"X;=C_ -OO7%=IXA_X)@?LA>*/"/PX\$ZQ\%?
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M1N/]P_K_ (4?V%D7_0BR7_PSY7_\Q!_Q%#Q,_P"CE>(?_B><8_\ T3GY<_\
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MC*$_$CQ!G"<90G"7'7&,XSA.,H3A*#XG:E&<)SA*+34HRE&2<9.,OS6\3_\
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M\%EW_P#)U?J-N/\ </Z_X4;C_</Z_P"%']A9%_T(LE_\,^5__,0?\10\3/\
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M (GG&/\ ]$Y^7/\ PZ!_8;_Z(%\//_!9=_\ R=1_PZ!_8;_Z(%\//_!9=_\
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M+LGXNR_#<7*GB,9E>!PV(S_#XO+8<095P\L7BLSE@\RJY?A\\SK X3*_8X;
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M+_P4(M?^"?GAGP;XSUG]D_\ ;!_:6\+>(=-^(>M^+-=_97^$(^*&E?"#P_\
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M74+.XTZ]MTAEN7GM+V*=[:YA6W@N)VEAE>-88)I"P2)R/Y!_@W::%K_[*?\
MP3B\!:-K/PIUC]ECQ%^W=_P4UN= B_:AE\57_P"S;\1?'GAS]H3X]7?[*GA7
MXLZYI-GJ']N6%_X4N?B#XI^#>@_$#5;7P%XX\7^$? UZTNO?$&P^&.FZE[S\
M5OV3=$\,>%_A;\(/B!X@_9U\2?!CXX?\%C_V9KW5OV9_V:=8\2P?!;X0R:M\
M'/%DWQ-^'T.CWFN"]\)Z9\7O%&CK\1O&_P +M*M?#W@_4Y_%OB.ZO/#U]#X\
M\52:T ?T_P"C:]HGB+3X-6\/ZOIFNZ5=-*MMJFC7]IJFG7#0R/#,L-[8S7%M
M*89HY(I0DC>7+&Z/M92!^>=A_P %"-<^((O?%G[./[&_[3/[2WP.TW5[S2/^
M%Z^ 9_@CX0\*>-CI6J7.C:UJWP:\._%[XN?#SQK\5/#&F:G8WUK#XNTK0=/\
M)^*$M6U+P)K?BS1+FQU6Z^JO$/P9\,^%OV??'_P=^!?@CP9\,]-U'X?_ !"T
M/P;X4\!>'M \#>%M*U[Q7HFM+#/I^CZ%9:9HNEO=Z[J7V^\N8K:%9+J:>]NG
M>1Y9&^2O^"=G[2O[.>J_L2_L^:%I7C3X>_#35/@Q\)/AC\%/B?\ "3Q)XD\'
M>$?%WP'^)_P\\/:7\.O$WPE^(/A%]6CE\&>)O#WB[0[_ $.VTJ\C@BU2-+/4
M-#?4-+U'3[RZ /T.D\4^'K;4],T&^UO2;#Q#K%N;K3?#]]J>GVVNWT*I+)(]
MII3W(O+L0K!<"9[2*:-&M[CYR(G(35_%GA?P_'%-KWB/0M#BGOH],@DUC6-.
MTQ)M2F@6ZAT^)KVY@$E]-;.EQ%:(3/) ZS+&8V5C_+!_P4P^+_P_^(?PE_X*
M3_'W2?A?^Q?\(_$G[.GB+Q_\$_#?QK\?:WXPD_;[U3]H3X!>!],U?X?^./A!
M<?#G1--\5?"6ZTOQ'+X;U7X0Z4GB;6-/U[P-IS_%7QZ=)^%WBO6K"+[Z^$O[
M+?[.OQ^_X*=?\%8]7^.OP=^&OQKETV+]BGPII.E?%CPAX?\ B'H?AK2=5_9N
MFN-;/A[0O%5CJNF:#J7B83V]OKVJZ?:VVHZO8Z7I-G<W,EMI]O&H!^V.K:WH
M^@:?<ZMKNJ:?HFE60C:\U/5[VUTS3[19IDMXC<WM[-!;0"6>6.&,RRJ'EDCC
M7+NH.==^,_"%AHMKXDOO%7ARR\.7Q@6R\07>N:7;:)>-=;OLRVNK3726%PUP
M4<0+#<.92C; P4FOYLOV6+OP=\5]8_X)(?#O]L^ZT+QM^SWX@_X);Z5XC^ _
MACXWR>'?$?PG^*W[7^@:M\,]+\4S>*%\=:M=P^/_ (Z>!/@;_9FK?![1M=TW
M6=3_ .$9\0_'GQMH3R:CX=UK4=)]$^/'PZ\"^*_V^?AO\&_ OA3]A+5_V==$
M_8=TJ[_9/^#_ .T9X3EO?V8M6\=ZO\>/C39?M:WOP-\-^#=(G^%6N_$SP?X9
MT+]GG3O%>ESB;Q-X)\&^*[L^$-.L=#\5?$F2< _H9U+7=%T:UEOM8U?3-)LK
M>UEOI[S4[^TL+6"RMWMXY[R:XNIHH8[6%[NU26X=Q#&US;J[JT\0>W97UGJ5
MK;7^GW5O?6-Y;P7=G>VDT=S:7EI=1+/;75K<PL\%S;7$#I-!/"[Q2Q.DD;LK
M U_.[\,OV./AOXB^*/\ P2V^!'QJ\5_#O]I;X>?"OX5_\%1/''A30O#?B76?
MBC\";WPOI7[0?[.-G\'?@IJ/_"P-;\8WWQ4^'W[,WA7QGX8\"^%-.\?W^MOI
MGC/X,>!O$<MM8Z[X0TB/3OZ%= T#0O"FA:+X7\+:+I/AOPSX;TG3M \.^'=
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M8O%8G%2H83#Q<,/A:,L3B,0Z.%P\)2CA\+1='"X>,YQH8:C"4H/#UK[^B?\
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M$O/[1\#_ +-WP$\&ZA_PG$OQ.^W^%/@]\._#M[_PLJ>![:;XA_:M'\.6<_\
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M]/ 7_@T\0_\ S-5_89]FM_\ GDGY4?9K?_GDGY4?\1=XS_Y_91_X9L+_ /-
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MI>#O_0OXE_\ $KS'_P"83^//_AU)^U)_ST\!?^#3Q#_\S5'_  ZD_:D_YZ>
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M3HU:5:#:^I*Z4Z,&U=72<6TI-K^3?XO_ /!,+]I?Q7\7?BKXJTQ_! TOQ/\
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M>?\ PZD_:D_YZ> O_!IXA_\ F:H_X=2?M2?\]/ 7_@T\0_\ S-5_89]FM_\
MGDGY4?9K?_GDGY4?\1=XS_Y_91_X9L+_ /- ?\2I>#O_ $+^)?\ Q*\Q_P#F
M$_CS_P"'4G[4G_/3P%_X-/$/_P S5'_#J3]J3_GIX"_\&GB'_P"9JO[#/LUO
M_P \D_*C[-;GI$A_"C_B+O&?_/[*/_#-A?\ YH#_ (E2\'?^A?Q+_P")7F/_
M ,PG\>?_  ZD_:D_YZ> O_!IXA_^9JC_ (=2?M2?\]/ 7_@T\0__ #-5_89]
MFM_^>2?E1]FM_P#GDGY4?\1=XS_Y_91_X9L+_P#- ?\ $J7@[_T+^)?_ !*\
MQ_\ F$_CS_X=2?M2?\]/ 7_@T\0__,U2'_@E'^U(1_K/ 7_@T\0__,U_,$>U
M?V&_9K?_ )Y)^5'V:W_YY)^5'_$7>,_^?V4?^&;"_P#S0/\ XE2\'?\ H7\2
M?^)7F/\ \PG\JGP\_P""9W[26@_#']HWPY?'P6=0^(7@#X>:%H+0:GK9A6\T
M'X\?##QK?M=M+X?CD6,Z1X<OTA\B*XE:Y:)7182\T?CH_P""4?[4G]_P".!_
MS%/$/?V_X1KC_.>:_L-^S0 $"),, &&.& ((!]0" 1GH0#VH^S6__/)/RK*G
MXK\8TIXBI&OEG-B:L*U7FRJA*,ITZ%/#1:B\0TDJ=*.B=G*\GKRVZ*WT7?".
MO1P6'JX#B)T\!0JX;#<O%&/C*-&MC*N.J1E)8*]2^(K3E%R2<(VC%VO?^//_
M (=2?M2?\]/ 7_@T\0__ #-4?\.I/VI/^>G@+_P:>(?_ )FJ_L,^S6__ #R3
M\J/LUO\ \\D_*M?^(N\9_P#/[*/_  S87_YH.;_B5+P=_P"A?Q+_ .)7F/\
M\PG\>?\ PZD_:D_YZ> O_!IXA_\ F:H_X=2?M2?\]/ 7_@T\0_\ S-5_89]F
MM_\ GDGY4?9K?_GDGY4?\1=XS_Y_91_X9L+_ /- ?\2I>#O_ $+^)?\ Q*\Q
M_P#F$_CS_P"'4G[4G_/3P%_X-/$/_P S5'_#J3]J3_GIX"_\&GB'_P"9JO[#
M/LUO_P \D_*C[-;_ //)/RH_XB[QG_S^RC_PS87_ .: _P")4O!W_H7\2_\
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M?B'7[V*$ZKX@U4QH)-0U"0 D!/F2PLD)MM-ML6UMN8SS3_;X   '0  ?04
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M_P#2.CQS_P").>%__G,U_!A11_J]E/\ T#S_ /"G$?\ R0?6:O=?^ H_O/\
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MFOX,**/]7LI_Z!Y_^%.(_P#D@^LU>Z_\!1_>?_Q&J^#_ /I'1XY_\2<\+_\
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M_P#5K^$:SJY!E4:522P\TXPE)/ZQ7=FHMK1RL]5LQK$56TKK5K[*/[L_C?\
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MM(R5N9+WHNZLW'$U%)<S3CU2BD^FSOVN?[K:LK@,I!!Z$<C_ #_D4ZOY+/\
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MK*V+>4G8T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#@B'_RX/JU7M'_ ,"/\T2OU%_;&_Y1R?\ !%KV^$G[?/\ ZW+XRK^W<?\
M!I%_P3+&?]!^/_3_ *+KJ/\ 3PW_ #XKW;XC_P#!M%^P#\3?@S^S3\$/$-I\
M:3X/_9>\/_%CP[\.TL?B]>6>J+8_%[XI:C\5_$O]N:F/#\LNKR_\))JEU]AD
M=;;[)8LEJ5G\J*1>>MQ#E\ZF&E%8FU.O[2=Z,4U%4JL%RKVC3;E-:<RT+CAZ
MB4[\OO1LO>ZW6^G9'^6;17^EW_Q"0_\ !,KO8_'_ /\ #Z:@?_=;%*?^#2'_
M ()E=K+]H#\?CIJ _P#=;-='^LV6=L7_ ."(?_+B/JU7M'_P(_S0Z*_TN_\
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ME+$1Q1JL<: (BJH $7_"%Z5_S^>(?_"FUW_Y/KK:* .2_P"$+TK_ )_/$/\
MX4VN_P#R?1_PA>E?\_GB'_PIM=_^3ZZVB@#DO^$+TK_G\\0_^%-KO_R?1_PA
M>E?\_GB'_P *;7?_ )/KK:* .2_X0O2O^?SQ#_X4VN__ "?1_P (7I7_ #^>
M(?\ PIM=_P#D^NMHH Y+_A"]*_Y_/$/_ (4VN_\ R?1_PA>E?\_GB'_PIM=_
M^3ZZVB@#SW5/"FFV[Z4$NM>/GZO;0OYGB+6Y,*T-RQ9-]\=D@*#;(F'4$[6&
M3G5_X0O2O^?SQ#_X4VN__)]:.M??T3_L.6G_ *3W=;E ')?\(7I7_/YXA_\
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MA>%=)ENM"T;4_$^JFWTBR\0>+/"6CSW"7>OV*O\ 16<G&#]<8 ]N?Z9'OR*
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MW_1WW[2?_AYO'7_RXH_X;N_;>_Z.^_:3_P##S>.O_EQ1_P 1ERK_ *$N:?\
MA3EX?\4\^/?^CD\$_P#AFXM_S/\ 02_X0+0?^@EXM_\ "T\4?_+.C_A M!_Z
M"7BW_P +3Q1_\LZ_S[?^&[OVWO\ H[[]I/\ \/-XZ_\ EQ1_PW=^V]_T=]^T
MG_X>;QU_\N*/^(RY5_T)<T_\*<O#_BGGQ[_T<G@G_P ,W%O^9_H)?\(%H/\
MT$O%O_A:>*/_ )9T?\(%H/\ T$O%O_A:>*/_ )9U_GV_\-W?MO?]'??M)_\
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M#_BGGQ[_ -')X)_\,W%O^9_H)?\ "!:#_P!!+Q;_ .%IXH_^6='_  @6@_\
M02\6_P#A:>*/_EG7^?;_ ,-W?MO?]'??M)_^'F\=?_+BC_AN[]M[_H[[]I/_
M ,/-XZ_^7%'_ !&7*O\ H2YI_P"%.7A_Q3SX]_Z.3P3_ .&;BW_,_P!!+_A
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MO_EQ1_PW=^V]_P!'??M)_P#AYO'7_P N*R_XC+E7_0ES3_PIR\[?^*>?'O\
MT<G@G_PS<6_YG^@E_P (%H/_ $$O%O\ X6GBC_Y9T?\ "!:#_P!!+Q;_ .%I
MXH_^6=?Y]O\ PW=^V]_T=]^TG_X>;QU_\N*/^&[OVWO^COOVD_\ P\WCK_Y<
M4?\ $9<J_P"A+FG_ (4Y>'_%//CW_HY/!/\ X9N+?\S_ $$O^$"T'_H)>+?_
M  M/%'_RSH_X0+0?^@EXM_\ "T\4?_+.O\^W_AN[]M[_ *.^_:3_ /#S>.O_
M )<4?\-W?MO?]'??M)_^'F\=?_+BC_B,N5?]"7-/_"G+P_XIY\>_]')X)_\
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M^@EXM_\ "T\4?_+.C_A M!_Z"7BW_P +3Q1_\LZ_S[?^&[OVWO\ H[[]I/\
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M5KMAKT5UX.\*ZMH.G7'ANPT_1#;V'AR*\AOM*L8Y].LU3[Z_98_9A^'.F_\
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M-5\7^!M#@M(8HK'P]XFU/P#X,U+7+&)0FIW_ (;TJ\NS+<6RR'OO"'A'PSX
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M_P"%K\-?_FQH_P"':W[</_1!=2_\+7X:_P#S8T?ZK<3?]$]G7_ALQG_RH/\
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MI\1-#UZWUT^5XA%WI%UJ"/'X8@FCN=5N9!>O.IN+C]6(\8.,?>).,8!(!(X
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M3PG^P/\ L<^!M7@\0>$_V>OAUHNO0?'N]_:D36K?3+F759/VA]1\.:UX1O\
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M#2E962RM59&5U801Y#*P92.."" 01@Y%?BK_ ,/_ +]A;_GQ^/?_ (:ZP_\
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M #X6O_?A/\*/^$>TC_GPM?\ OPG^%;5%*WK][_\ D@^;^\Q?^$>TC_GPM?\
MOPG^%.70=+1E=;*V5E.01!'G\\9_+IVYK8HHLNNOK=_@VU^ ;[Z^NJ^YH9'&
M(U"+C Z   #@#H/I]:?1132LK+9?UT2_( HHHH **** "BBB@ HHHH ****
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M"'PYO_!EIX]\&^,9O!K6L?@/X\>!;7X@^$M;\3_#_1)/B)X N]$OM4U'X?\
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M3K#4/!NNW_B70-?\#RQ:EX5ET;Q);ZSH_P"C] !1110 4444 %%%% !1110
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M@5%8+.[J-EE^%Z1LN;.\MOK\*NEKJKVU3LD?$\4)KB/PT6O/_K9G-UKS\O\
MQ#SC&UTES\M[:N/+>VMSXK !Z@'D]1[FEP/0?D*0$8[]2>A[DD=J7(]_R/\
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M  >#_P"1* .RR/4?F*,CU'YBN-_X0T_]#7XS_P#!X/\ Y$H_X0T_]#7XS_\
M!X/_ )$H [+(]1^8HR/4?F*XW_A#3_T-?C/_ ,'@_P#D2C_A#3_T-?C/_P '
M@_\ D2@#LLCU'YBC(]1^8KC?^$-/_0U^,_\ P>#_ .1*/^$-/_0U^,__  >#
M_P"1* .RR/4?F*,CU'YBN-_X0T_]#7XS_P#!X/\ Y$H_X0T_]#7XS_\ !X/_
M )$H [+(]1^8HR/4?F*XW_A#3_T-?C/_ ,'@_P#D2C_A#3_T-?C/_P '@_\
MD2@#LLCU'YBC(]1^8KC?^$-/_0U^,_\ P>#_ .1*/^$-/_0U^,__  >#_P"1
M* .RR/4?F*,CU'YBN-_X0T_]#7XS_P#!X/\ Y$H_X0T_]#7XS_\ !X/_ )$H
M [+(]1^8K"\2D'1+[!!XM^__ $]05E?\(:?^AK\9_P#@\'_R)44W@>*XC:&?
MQ/XQEB?;OC?6E96VL'7(^R=F56&,'(%#UT[@=OD>H_,49'J/S%<;_P (:?\
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M_P"'0^*?_P V='_#BS]BG_H1-?\ _#H?%/\ ^;.OV%_X1(?]#7XR_P#!ZO\
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MC/\ \'@_^1*/]5>&/^B>R7_PVX7_ .1'_P 1O\9O^CL>(W_B8YY_\TGXZ_\
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M/@/Z_K^OPLEV61ZC\Q1D>H_,5QO_  AI_P"AK\9_^#P?_(E'_"&G_H:_&?\
MX/!_\B4 =ED'H0?QHR/4?F*XX>#B/^9K\9'ZZVI_]M*3_A#3_P!#7XS_ /!X
M/_D2@#LLCU'YBC(]1^8KC?\ A#3_ -#7XS_\'@_^1*/^$-/_ $-?C/\ \'@_
M^1* .RR/4?F*,CU'YBN-_P"$-/\ T-?C/_P>#_Y$H_X0T_\ 0U^,_P#P>#_Y
M$H [+(]1^8HR/4?F*XW_ (0T_P#0U^,__!X/_D2C_A#3_P!#7XS_ /!X/_D2
M@#LLCU'YBC(]1^8KC?\ A#3_ -#7XS_\'@_^1*/^$-/_ $-?C/\ \'@_^1*
M.RR/4?F*,CU'YBN-_P"$-/\ T-?C/_P>#_Y$H_X0T_\ 0U^,_P#P>#_Y$H [
M+(]1^8HR.N1CUS7&_P#"&G_H:_&?_@\'_P B4O\ PAQQC_A*_&7_ (.USW[_
M &3_ #@4 =CD>H_,49'J/S%<;_PAI_Z&OQG_ .#P?_(E'_"&G_H:_&?_ (/!
M_P#(E '99'J/S%&1ZC\Q7&_\(:?^AK\9_P#@\'_R)1_PAI_Z&OQG_P"#P?\
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M_B]_AUI'C?1OA[K-O>Z1\1=6\)ZGIVHVMI]Z#D"OQ<^+_A#XT_\ !*KX9?M
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MQ'QQ_P##I>,O_ES1_P -1?M-?]'$?''_ ,.EXR_^7->&44?V9EG_ $+<N_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUTJSL]-MHH#!!':6L*F)I5>63W#_ (3&W_Z 7B[_ ,);5_\ XS1_PF-O_P!
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M?H'@30?&'B7Q!I7PY\%Z186\-GH?@+P#:>&_!.AVR"+2/#]FI8-Z)_PF-O\
M] +Q=_X2VK__ !FC_A,;?_H!>+O_  EM7_\ C- 'Q_9_\$R_V&['XDP_%6/]
MG_0+GQ+:?%O4OCYI^B:IXI^(.M?"O2?C?JU]=:M>_%[1O@;K'BR_^"NC?$K^
MW;Z\\26OC72_ %GXAT_Q1.WB?3]0M?$&-2'>?&[]A7]DS]HWQ:OCGXS_  2\
M+>-O$]SX?T[P=XEU":[\0Z'!\2/ ND:N=>TGX=?&32O#6LZ-H_QM^&FEZR]Q
MJFG?#CXNV'C;P-8WVH:M<6OA^*35]3:[^A/^$QM_^@%XN_\ "6U?_P",T?\
M"8V__0"\7?\ A+:O_P#&: //O&O[-OP.^(A^(O\ PF/PV\.:VOQ9^"3_ +.'
MQ$2X2]MX_%'P.=O%S'X;7D5C=VD=MX>5O'GB[RTT];2[B77+M(KI$6W6'B/C
MK^Q-^R[^TMXET[QA\:OA%HOB_P 4V/A:\\ 7>OVVL>*O"6J>*OAKJ%])J=_\
M*/B+=>"M>\.R?%#X0ZAJ4]WJ&H?"7XC-XI^'%[>WM_=77AB:>_O7G]X_X3&W
M_P"@%XN_\);5_P#XS1_PF-O_ - +Q=_X2VK_ /QF@!GP_P#AWX&^%7A2Q\#?
M#?PGH/@;P;I=YKE]I7A;PQI\&DZ!I4_B37M3\3ZRNEZ7:)%9Z;:W>NZSJ=^M
MC90P6-HUTT%G;V]JD4$98?#[P=IGQ \4_%2QT"RMOB!XT\(^!O 7BCQ1&UQ_
M:&L^#_AIK'Q!\0>!-!NE>=K06GAO6?BK\0[^Q:"VAG:;Q3?BYFN$6U6W?_PF
M-O\ ] +Q=_X2VK__ !FC_A,;?_H!>+O_  EM7_\ C- 'R+\0?^":/["_Q5\8
M^)_''Q$_9O\  WBS5/&GB<^/?%>BZG=^)S\/->^)ITYM)7XO:C\*(-=A^%T_
MQJATYOLEM\:#X/'Q3M8E0V_BZ-XXV7ZGTOX5^ M%UOXD>)-+\,:=9ZW\7I](
MN?B3J,1NO.\73Z#X5L/ ^D2ZD'G>-&L/">F6.B0?8TM0;2V0R!YRTQT_^$QM
M_P#H!>+O_"6U?_XS1_PF-O\ ] +Q=_X2VK__ !F@#D-+^ OPDT;0/@9X5TWP
M-H]IX>_9IGT:Y^!>EQ/?_9_AO/X=^&'BGX,:)+H6^[:5VT_X7>-?%'@R$:G+
M?@Z7K%S))OO5AN8_((OV"/V0;?XSP_'ZV^!'@ZW^)EOX]O?BU!=P3:[#X/A^
M,FIV6H:=J7QPC^%<6K+\*E^.FH6.K:G9W_QJ'@O_ (6G>VU]<PW/BZ1)7!^C
MO^$QM_\ H!>+O_"6U?\ ^,T?\)C;_P#0"\7?^$MJ_P#\9H HZ+\+_ /A_4_B
M;K.E>%=(MM3^,VNV7B7XHSO#)=Q^-M<T[P%X5^&%I?:Y:WLEQ:3F/P#X)\*^
M%WMXK>&TFTS1K99[>29[B6;YS^ 7_!/S]D']F+Q98^./@I\&=-\*^*=$\&3_
M  X\(ZQJGBKQ]X[F^'/PYNM5?6[SX=_":#XA^*O%=I\(O -]JK0WNH>#?AE!
MX3\-:A)8:2EYI4T6CZ4EG]-?\)C;_P#0"\7?^$MJ_P#\9H_X3&W_ .@%XN_\
M);5__C- '8=**X__ (3&W_Z 7B[_ ,);5_\ XS1_PF-O_P! +Q=_X2VK_P#Q
MF@#L**X__A,;?_H!>+O_  EM7_\ C-'_  F-O_T O%W_ (2VK_\ QF@#L**X
M_P#X3&W_ .@%XN_\);5__C-'_"8V_P#T O%W_A+:O_\ &: .PHKC_P#A,;?_
M * 7B[_PEM7_ /C-'_"8V_\ T O%W_A+:O\ _&: .PHKC_\ A,;?_H!>+O\
MPEM7_P#C-'_"8V__ $ O%W_A+:O_ /&: .PHKC_^$QM_^@%XN_\ "6U?_P",
MT?\ "8V__0"\7?\ A+:O_P#&: .PHKC_ /A,;?\ Z 7B[_PEM7_^,T?\)C;_
M /0"\7?^$MJ__P 9H ["BN/_ .$QM_\ H!>+O_"6U?\ ^,T?\)C;_P#0"\7?
M^$MJ_P#\9H ["BN/_P"$QM_^@%XN_P#"6U?_ .,T?\)C;_\ 0"\7?^$MJ_\
M\9H ["BN/_X3&W_Z 7B[_P );5__ (S1_P )C;_] +Q=_P"$MJ__ ,9H ["B
MN/\ ^$QM_P#H!>+O_"6U?_XS1_PF-O\ ] +Q=_X2VK__ !F@#L**X_\ X3&W
M_P"@%XN_\);5_P#XS1_PF-O_ - +Q=_X2VK_ /QF@#L**X__ (3&W_Z 7B[_
M ,);5_\ XS1_PF-O_P! +Q=_X2VK_P#QF@#H[P$^1@$XN+=SCLJRJ223Q[#G
M)/MS7\5/B/\ 8!_:U7Q%XA<?"F=UGU[6KF)DUW1"LD-SJ=U-#(I%X1AXI$?'
M5<[6P00/[,'\76SG)T/Q?P"/^16U?'/?'DX)]">G;'.<]M9T5R6?PMXG9B<E
MCX2U7)[\GR/Y8^E?6<+<8YIPC+'2RVC@JKQ\</&M]<I5:O+]7E5E#V?LZ]#E
MNZLE)2YM%%QUN?EGB9X1\->*U/)J7$>+SG"1R*KCZN#>3XG"X=U'F-/"TZRQ
M'UG!XSG45A*?L^14G!N3E[3F2C_&)_PP+^UK_P!$FN/_  ?:)_\ )='_  P+
M^UK_ -$FN/\ P?:'_P#)=?V=?VOH?_0J>)O_  D=5_\ C%']KZ'_ -"IXF_\
M)'5/_C%?8_\ $9N)_P#H#R;_ ,)<3_\ -Q^4?\2@>&/_ $->,_\ PZ99_P#.
M4_C%_P"&!?VM?^B37'_@^T/_ .2Z/^&!?VM?^B37'_@^T/\ ^2Z_LZ_M?0_^
MA4\3?^$CJG_QBC^U]#_Z%3Q-_P"$CJG_ ,8H_P"(S<3_ /0'DW_A+B?_ )N#
M_B4'PQ_Z&O&?_AURS_YRG\8O_# O[6O_ $2:X_\ !]H?_P ET?\ # O[6O\
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MX2VK_P#QFC_A,;?_ * 7B[_PEM7_ /C- '845Q__  F-O_T O%W_ (2VK_\
MQFC_ (3&W_Z 7B[_ ,);5_\ XS0!V%%<?_PF-O\ ] +Q=_X2VK__ !FC_A,;
M?_H!>+O_  EM7_\ C- '845Q_P#PF-O_ - +Q=_X2VK_ /QFC_A,;?\ Z 7B
M[_PEM7_^,T =A17'_P#"8V__ $ O%W_A+:O_ /&:/^$QM_\ H!>+O_"6U?\
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M_P OS2_4-B^GZG_&C8OI^I_QKQ"[O[Y;NZ5;Z]55N;A0HO+C"A9I%"@><H
M Q@=..@%5_[0O_\ G_O?_ RX_P#DBL/;K^5]>J[^AXCSJG%M?5YNS:NIPL[-
MJ^WE_5CW?8OI^I_QHV+Z?J?\:\(_M"__ .?^]_\  RX_^2*/[0O_ /G_ +W_
M ,#+C_Y(I>W7\K^]?Y"_MNG_ - ]3_P.'^1[OL7T_4_XT;%]/U/^->$?VA?_
M //_ 'O_ (&7'_R11_:%_P#\_P#>_P#@9<?_ "11[=?RO[U_D']MT_\ H'J?
M^!P_R/=]B^GZG_&C8OI^I_QKPC^T+_\ Y_[W_P #+C_Y(H_M"_\ ^?\ O?\
MP,N/_DBCVZ_E?WK_ "#^VZ?_ $#U/_ X?Y'N^Q?3]3_C1L7T_4_XUX1_:%__
M ,_][_X&7'_R11_:%_\ \_\ >_\ @9<?_)%'MU_*_O7^0?VW3_Z!ZG_@</\
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M\(_M"_\ ^?\ O?\ P,N/_DBC^T+_ /Y_[W_P,N/_ )(H]NOY7]Z_R#^VZ?\
MT#U/_ X?Y'N^Q?3]3_C1L7T_4_XUX1_:%_\ \_\ >_\ @9<?_)%']H7_ /S_
M -[_ .!EQ_\ )%'MU_*_O7^0?VW3_P"@>I_X'#_(]WV+Z?J?\:-B^GZG_&O"
M/[0O_P#G_O?_  ,N/_DBC^T+_P#Y_P"]_P# RX_^2*/;K^5_>O\ (/[;I_\
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MY^.QYI>W7\K^]?Y!_;=/_H'J?^!P_P O-'N^Q?3]3_C1L7T_4_XUX1_:%_\
M\_\ >_\ @9<?_)%']H7_ /S_ -[_ .!EQ[C_ )^/:CVZ_E?WK_(/[<I_] ]3
M_P #A_D>[[%]/U/^-&Q?3]3_ (UX1_:-_P#\_P#??^!EQ_\ '^OMUH_M"_\
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M_P! ]3_P.'^1[OL7T_4_XT;%]/U/^->$?VC?_P#/_??^!EQ^O[_C\:/[1O\
M_G_O?_ RX_\ DBCVZ_E?WK_(/[<I_P#0/4_\#AY^7D_N?8]WV+Z?J?\ &C8O
MI^I_QKPC^T+_ /Y_[W_P,N/_ )(H_M"__P"?^]_\#+C_ .2*/;K^5_>O\@_M
MNG_T#U/_  .'^1[OL7T_4_XT;%]/U/\ C7A']H7_ /S_ -[_ .!EQ_\ )%']
MH7__ #_WO_@9<?\ R11[=?RO[U_D']MT_P#H'J?^!P_R/=]B^GZG_&C8OI^I
M_P :\(_M"_\ ^?\ O?\ P,N/_DBC^T+_ /Y_[W_P,N/_ )(H]NOY7]Z_R#^V
MZ?\ T#U/_ X?Y'N^Q?3]3_C1L7T_4_XUX.=1O@"3J%Z !DDWEQ@#_O\ _P N
M:M;]=S][6R.HPNI'(]0=_/7TH^L);QMUUDEI>U];:7T]=-P6=TWMAJK])1?Y
M)GMVQ?3]3_C1L7T_4_XUXCOUWUUSGIQJ7/\ X]2>9KG][6\^G_$QR/J-^1^-
M+ZS'LMK_ !QV[[[>>WF/^VH_] M;MNM^WP[^1[?L7T_4_P"-&Q?3]3_C7B)?
M71U.N<^VI=^?[U)YFN=,ZWGGC&HYXZ\;\_Y]C1]9BMTEZSC_ )C_ +9C_P!
MM;[U_P#(GM^Q?3]3_C1L7T_4_P"->'K-K;#*OK3#GE?[18<$@\AR.""/J".U
M.WZ[_P!1S_OG4O\ XJG]8CV7?XH[=_3SV%_;4?\ H%K?>O\ Y$]NV+Z?J?\
M&C8OI^I_QKQ'?KOKKGY:E_\ %4C2ZVHRS:VH]6_M(#UZE@.E+ZS#?2W?GC;[
M[V_$/[9C_P! M;[U_P#(GM^Q?3]3_C1L7T_4_P"->'^=K62-^M9&"1_Q,<@,
M,J2-^1N'(]1TI?,USUUO\M2_^*H^M0_NZ;^_#3UU#^VH[?5:U]K75_NY3V_8
MOI^I_P :-B^GZG_&O#S+KG'.M_EJ7H?1OS]!D]JMSR:UY.G;&U@DV3&39]O+
M&3[?? >9L(/F>4(_ODMY?E_P[::Q$&F_=TM]N.MW;OZ,I9Q%J3^K55RI/XH^
M]>2C9>[NKIO?IW/9=B^GZG_&C8OI^I_QKQ#S=<&,MK8STXU+GZ?-09=<! +:
MV"3@ C4@2?0 MR>#T]*3Q4%ORKUG!?FT3_;4?^@6MIOJM+[7]W2_2]K]+GM^
MQ?3]3_C1L7T_4_XUXAYNMYQNUK/3'_$QR3UP!OY.,G [ GH#0)=;(R&UL@D@
M$?VB02.HR'QD=QVH^M0_N_\ @R'_ ,D']LQ_Z!:VF^JT_P#)3V_8OI^I_P :
M-B^GZG_&O$/,USUUO\M2_P#BJ#+K8ZMK8QR<_P!I=/7[WN*/K4-O=OV]I"_W
M7'_;,?\ H%K?>O\ Y$]OV+Z?J?\ &C8OI^I_QKQ#S=<'5M;'X:E_\5[&CS=;
MSC=K>?3_ (F6>>G&[O2^M4^\?_!D/_DA?VU'_H%K?>O_ )$]OV+Z?J?\:-B^
MGZG_ !KQ#S=<_O:W^6I>N/[WKQ]:03:T<X?6CM)5L?VB=K#!(.'X(!!(/(R*
M/K=/O#_P9#_Y(/[9C_T"UOO7_P B>X;%]/U/^-&Q?3]3_C7B'F:YZZW^6I?_
M !56]+N-4;4]/62;5#&;N(R"5[WRS&) KF02,4,:M@2%AM'1B.E-8J#:7NZ_
M]/(?_)%1SB,IPA]6JKGG&";:T<I*.W+K:^J6OH>R;%]/U/\ C1L7T_4_XUX>
M9]:9WQ)K##>P&TZ@<88@CA@.#P< 8/!Z4GVC6<D>9K.5!+#.HY &,DC?D ;E
MR3P,CU%#Q5--J\;Z_P#+R%]';;FN+^V8ZVPM9V;6C3V;UT@^BOZ-/:S?N.Q?
M3]3_ (T;%]/U/^->'>?K60-^LY;[HSJ.3QGCY^>.>.W-*9M:'5]:'U_M'_XN
ME];IO9P?I4IO\I,7]M16^%K*^UVE?T]W4]PV+Z?J?\:-B^GZG_&O#S-K0QE]
M:&XX&?[1&3@G R_)P"<#L">U'G:UNV[]:W?W<ZCN_P"^=^<=LXQGBCZW3[P_
M\&T__DQ_VRGMA*_]?]N'N&Q?3]3_ (T;%]/U/^->'F;6AR7UD#U)U''X'?@T
M>?K7]_6NI'74>H."/O\ 4'@CL>*/K=/O#_P;3_\ D@_ME6O]4KV[]+;7OR6M
M?K>WF>X;%]/U/^-&Q?3]3_C7A_G:W_?UKG_L(^_^W['\.:7S-<SC.MY/(&-2
MSCU^]3^M0_N_^#(?_)"6=1>V%K/6VC3U[?#OY'M^Q?3]3_C1L7T_4_XUXAYN
MM\#=K>3P!_Q,N3Z#YN:/,UW!P=;Z$]-2QP,Y/S= .3[4+$QD[12D_*<7:_>S
M=@>=17_,+5_\"BNE_P"4]OV+Z?J?\:-B^GZG_&O'EEU<:3<L[ZL)O[2LEC+&
M]$IB^RWS2;,L)#'D(9-IV[MN[HIJD'UT@$'7"#T(&I8/T.ZF\3"-D[)M)V<X
MIZWLK-I[*ZTU*EF\4HOZK6:E!3T:=DY36ONM?8O>]G?[_;MB^GZG_&C8OI^I
M_P :\1\S7>N=;[]M2[=?XJ3S=<SC=K>?3&I9_+=2>)@M^5>LX+]2?[:A_P!
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M^]?Y!_;=/_H'J?\ @</\CW?8OI^I_P :-B^GZG_&O"/[0O\ _G_O?_ RX_\
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MMT_^@>I_X'#_ "/> H'04M</X)GGGM;TSS33E+P!6FEEE*J8(VPID9BHW9.
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MO_K_ +;_ -#JA5_2?^0MI?\ U_VW_H=./Q1]5^IK0_CT/^OU'_T[3,P???\
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MOBS>^#?V8=,_:KU']H?XJ>.?@A\=?@EX>A\)_%3X>^%O 7@_]GB>Y^-?P_\
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MXSI)/VDW'1ZI\MGS-75]4W=)_I%\6/VS/V5O@1XRD^'OQE^._@'X;^,K;3=
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M^XT:RO/B5XVL_#-S\0_'WB_5_%J7?P^\ ?#CPCX5T?4_B%XB\(?$/Q'J&O\
MPZ\$>%7U>]Z;QY\7_P!JWX!_L\_MB?&GXX>#OV;?$K_ +X"_$/XU_""?X/\
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MZ+X#_P"/*_\ ^OM/_1"5W=<)X#_X\K__ *^T_P#1"5W==='^''Y_FS[++?\
M<<-_@?\ Z<JA1116IW!37^Z?P_F*=37^Z?P_F*:W0UNCPBZ_X^[O_K[NO_2B
M2H*GNO\ C[N_^ONZ_P#2B2H*\[OZO\V? 3^.?^.?_I4@HHHH)"BBB@ HHHH
M**** "BBB@ HHHH 1NA^A_E6A:?\@K6?^N^C?^C+FL]NA^A_E6A:?\@K6?\
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M^E-Y_P ?*C@ 6>E   #II-GC/X?_ %^>:JD #@ <'ITQM.,#I5J\_P"/D?\
M7II7_IILZ_.<3B<1C*U?%8JM4KXC$5?:UJU6;G.I4G*3<G?2-DU",8KEITX4
MZ=/EA!17U%*$*6'E2I0A3I4_80ITX124(P5:RVWNVVU9MMW;(****YR HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /1? ?_
M !Y7_P#U]I_Z(2N[KA/ ?_'E?_\ 7VG_ *(2N[KKH_PX_/\ -GV66_[CAO\
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ME^,Q]9^VG&E"-"GA(R]MB>>7/'!IJO7HTJTL.U*G,^]6GB$JV[21K<2123)
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M6"11O*[ D)&K.Y !9L*H). K$XR, DD=_P <?''@/Q9\#_VI=4^*G[4OAO\
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M1FP2H9MQ52V-NYMC[5SEMIP, D%?DWJ_Q#^+L6J_#OQWX^\3^'M:^+O[*/\
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MYFM"9>,7&'+_ +QEU.;Y$W_9^$?+:+E)QC4JIR4M5*WO.T?9\JYK_P!=Z?\
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MF?#R+4['^U=$\,:'K>EZ=X6U74_$NI>%HM%O?%WBN?6OL&BCGE_,_P /\O\
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MZWTHXI)^J2TZ;73ZKH?YP>C6MQ?W=E8:3X<L]3U.\QI:7^I0:IXAN=1U)O\
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MEO=)J\59:;)'F5_"+,:TY1_M/*G!2G;FI9A&27M'*W)3A&#ZJ[DG9+2[;/\
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M0^-G[1'A_P#;X_8L^+_[$/QRFTW6M4TO2/V8O$TNN>%[OXLW6HZM=:CK&K^
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MXD^"US)';P1*J1^9<S2SLJJ"\TLKD%F;'\>#ZC)8?L.^!9+=Y(YT_;'^,NX
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M+^V/^UY\*=;^ /@;QG^QO\((OB3^TY\;9_@W\)=#T;]L"[U7PN[:'\$_BO\
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M_=OS_P"._D.I[<4#:1D*2#@@A&P0>>/EYXYXZCI7^2_!^V5^V3/!=-<_M?\
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MBTVTFUHG=7DT[9OC_+DW?!8KE7PR5?"N4K;KV=HR33TM=WNGUL?ZJN5P?D/
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M^>OBGX ^$/AU\1OB9X)\3_LYW+_\$YO!?[:%IXE\1_L^^!?@AJ'BCX'KX?\
M%/\ P3W_ &?3X0\4Z3^S=X(\*ZK:?$#X,Z3^U9J7Q$UGQWX;\ >!/$_A^R^.
M>KGX@>*O"UWKOAW6O$GA[S?PU\&/CII'PIT'0?V;OA5\:?A/$WPV_P""X$OP
MP\,"PU[X:^*_#GA7XK?MY?LX>//@]X5T.]URYL4^&?C[XH_ NU\8M^SU'X@U
M7PWK'AYI[:YTV_\ "S^'-3OM$U4(QUYM=4K_ / M??OTV.R&%C%2E'$*,TKP
MDIQBDI0;]ZSYKI2]Y*\;JRVT_:GP3^R_\(OAQH\'A7P1\.YO#^BV_P"SQ\+/
MV6+71K75?%<\%M\ ?@E:>/-/^&/@2U2]U:ZEA@\*VGQ-\:V\?B.%QXHU)-9C
M76-<O_[,T@67S_\ %_\ 8W_8X\41^(+?XB^"_$UQ;:5\)]!U;QU\-?!OQ'^.
M6EZ?\1O /P3L=+T?P'XE^(?P>^&WC"SLOC;XL^''_"+Z!I'PX\1^*?"_C#Q_
MIVLZ#X:TWPW>SZCI6D6\'QSX]T+]DV\^&GPB\&_ K]A7X6:)^R]XQ^,>KZE^
MT#I7Q:_X)M?&7QFWA3X@:)\-M*A\%P:Q^S1I_@_X?>(O'GQ;\8KJR^&$_:.\
M4+X]^&O@W4/"VHZ9KVNZ[KFL:9/:^$?!_P"!UC8^#_ WQ!^*/[+_ (KM_P!I
MKQQ_P2M^,WPT^''Q'\7?L]:MK7QJ\*_%/P=;?'#1H/AMXH^)EGH/BO7_ (6?
M$*#X':UHO@?P[9^*O'%@OB7PXZ?#_P (>(O%.ZWTZ]%%[<[]7;I\O\M':VXH
M4I)RG[>I%N37QPN^5\D7)NIK[MY)IOW++?1?MS\7?@3X _:5T;X?:UXW7XHZ
M?_PA?B4_%'P#XI^&_P 4/C'\ O&OAOQ#K_@GQ'X/O+S_ (2;X5^*? 'C"Q^W
M^#?'/B#1-9\,:S>_8E34G35-)BU&T@-M?\ ?LZ?"CX3:IH7B?X??#Z+PGJGA
M[1/'VA6&L6MWX@FN+R'XL>-/#/Q$^).K:_=:EJ5V?%7BSQ[XY\(Z!XI\2>-?
M$CZOXJU35K:XNI-8_P")CJ(N?QOM?@_J3>-=<EU7X&?$9OV\=0_:,_97\4_L
MY?'^[^'/C*__ .$+_9?\)^#/V78O&VFZ-^T#>:3?>$/A)\*-!\'Z#^T1X1^+
M/P'USQCH\GC3XBZUXOU ?#;Q!=?$/2)KCU#PQ^RUHG@[6O@M\:='^$7B_2/C
M9XI_X*(_M3M\5OC'H>@:ZGQYMOV=/&?AC]M)]/\ "[_$6"V_X3?1O@:+B/X4
MW/P^\%+JEM\-]/\ $B?#J^T+2UUG^P9B<K_GEWZ:/=]+[Z[]?N)4>7EA]9;C
MRS<5S75VG.6G-M*SWNW+6^Q]GVW_  3L_90T?_A(]WPJU][/Q+X%^,7PML]*
MUSXH_&/5_#W@7X7_ !]TUM+^,'PT^#7A[6?'5UH7P6\!>-;4V\MYX2^$]AX1
MT>QO-.T?4-'M+&ZT/2I;+W35OV?/AEK.C?$#2]3\&W,VC_%?4/A]J7CB/^V?
M%%O'K]_\,-/\)Z1X$F2ZM]5BFTTZ-8>!?"]MY>BS:?#JG]F-+JR7T][J#W7Y
M_?\ !-3P=X2^'?B3XI>$_AQ\&?#EO\+[?P=\,[^U_:A_X9*\7_L@?&+XL^)D
MU3Q/9:O\./VCM \>>'_#>J_'#XR>$=-AL?&>O_'GP[I.B^'?$5UXVO-/U/1%
M\7'5M2U7P/X=_"2^T_Q_X1N=(^!WQ!\/?MT:;^TY^U)XQ_:E^.]Y\./&%D/'
M_P"S!XCU_P#:*'AG2]6_:"UG29?#/Q<^%/B_P=K?P TCX"_ NQ\9^.-7^&D>
MB^$=*L_"7@Z^^&VHZKIJY)--.;MV77RV]?*W4.2I*=2G+$RY::IR3E)6;ERM
M-Q<VH\O*KPWBTD]>9+]OO&OB"S\!>$_%?CSQ6M_8^'O"7A[Q!XNUZ\33[FXF
MBTGP]IEYK>KS6]I$C2W<\-A97$L=K K3SL@2-26 KG_%/Q$\-^#?AKKWQ<UQ
M];_X0?PUX%NOB3K%UHGACQ%XJUR/P?9:&/$MWJ%CX2\+Z7K/BG6KN'1=UX-'
MT32-1U><(T-K8W$X$;?B;\-_V3+?X+?!#]E5_A1\"-<\#^._B/\ \$G_ -H/
MP?\ M/7_ (?\(:_;^,_B/\6T_9X_9NN_ >C?M :A]GDUGQI\4K+QW?\ Q%TS
MP)_PL:?4_&&D7;>*_"_A:6SL4U32Q[/\+O#NO^%?VBM.^ OCF<>$?V;/V=;A
M?^"FOB?Q3XDUZRT30=!7XH>$;P>'?AEXIO=1U"UN]#T+P_\ M02?M4?M0Z[J
M&MZI!!X<7P!X2T;4+&R^'GB+3;=%[+71Z:?UHOZ_*7A*:;M64HPY)2<5%R<'
M-1DDDY7=W%)+;FLVGJOUVTO5=+UO3-,UO1-4TW7-$UO3;#6M%UO1;ZTU31M:
MT?5;2*_TS5]'U2PFN+'4])U.PN+>^TW4+*XGM;ZRGANK:62"6-VW])_Y"VE_
M]?\ ;?\ H=?#_P#P3LT^]TW]AG]ER"YT[4M#TBX^%5CJ_P /?#>M&7^V?"/P
M4\1:SK7B+]GWP1K$<[27%GJG@;X#:K\-_!VH:7=7%U>:+<Z')I%Y>WEU837<
MWW!I/_(6TO\ Z_[;_P!#K-:22\T80BH8NG!/F4<322?DJM*U_P"\KM26R:=F
MS,!P[G_:?\]YQ7Y>?'/1OB]^TA^WE\-/ _P:^(7A_P"&&C?L ^"8OCYXK\7^
M,_A;>?&#PEK'[1'[3?AOQ]\)_A5X4M?"%A\7?A2MWXD^'7P$M?C#XNO[_4;Z
M\A\,6WQ?\(7=O:SWFO65S8?J&/OO_O/_ .AFE"*-Q"A2[!W*JJL[A%C5W8 ,
M[+&B(&8E@B*F=J@"HM1DVU?>WK<FE5=&I.:2<DZJC?:,G4JI2:W=O)I]5)/4
M_!K3M'\8_!O_ ()Q?\%8?V!O&E^/%GBG]DW]F+]J;_A4VLZ-X>U31K+QG^S'
M^T-^SO\ %'XG? Z'PKX>U/XA_%+Q'::9\-?$UQ\3_P!G?0O#VH^(KR_T;PW\
M)O!^F1/J*S0ZC??1G_!17P9XD\=?'O\ X)(Z#X7\<?$'X8:@_P"VE\3[A_B/
M\,=.\!:EXP\&10_L)_M)_P"FV47Q2^'GQ4^'<,>I2A-"NG\4^!-:MVL]3N(]
M/&GZPVGZI8_JR8T.[<J-O4HY9(VWQDL3&^Y3O0EF)1\K\[\?.^Y=H)!."020
M2%)4D%25RIP2I*DCDJ67.&8&N=:65DG)OSYE;O\ Y&GUGWU/V<4[SF[-V<ZF
M']C)\MK6<O?LWJFT_/\ -K_@G_X>UCX4_M"_M<?!SXU:QXW^(W[3L7Q'\'_$
MR[_:4^($EFU_^TQ^RGXMU7Q7-^SAJ>DZ?X>M-#^'/@*7]GZ>\\=? 'QY\*OA
M=X*^'?@O3/&7AAOBQ8>#[=?C3#?7?J/_  37MKBS_P""='[ =G>6]S:7EG^Q
M5^RW:W5I>036MW:7,'P3\%17%M=6MPD<]M<V\JO%-;S1QS0R*\<B*ZL*^U"@
M)4GJ@(0X&4#,K,%.,J&9$9@" 616(+*"!55 %4!54!550%55'1550%55Z*J@
M!1P   !,IN7I>_X?UU)JUW5BTXI-RA-M72YHT52E:+TC%\J<8IVBM$.HHHJ#
MG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?6@?L;>\L.
M..00ZCMD\_0].AK_ "-?B%IFI:?JOC!UM;"?2/%WBKQ-JVGSWDV@:SJMM#9>
M*M8M)9K9K(R:YX8EN+R*5IO)N=(DU"&&U&H6NH016[U_KF:RN;&8D%EC\MW"
M@L0JN&<A5&6^4'Y1DG@ 9(-?YX?B;_@A7_P4+U'6?'VLW7P[^',E_<>*-5U'
M1+6Y^*'A:;5=9MKW6;V>"XBU"W@N]&T_R+.:*66PU2ZLG=F>$7<LJ /^R>$&
M:91EE?B!YMF6!RZ->AEJHRQN(C0]K[*OC745-R5Y\BJ0YU%WBVFXZQ;^)XUP
M>/QE'+5@,+6Q4Z=;%2J1H4Y3<8RI4(P<[*R4G%V;:T7R?X8:7HVJS12O!H^J
M:GI=D;:\U:R-GJ<E@T#R"41ZK)I\D)@TVZ>)XUF6[M9-HD-K)&Y0UI7S2:[J
MDIM/#NC:,FH72RZ9H&@6VH7FF6\UO:QVL44$OB+Q%KFJ7?F!&N)AJE]JMS%*
M9?LLJ1K':P?LE8?\$/O^"DUIIEWIDGP0^%=RE[+8RR7=U\6?"ZZA;_8RXDM]
M/N;778+=+"\+++)!?6-])')&JQF-"P>2S_X(1?\ !1>^GF?4? ?@'2+?S;>.
M-#\4_#]Y*;>0R&Y2U6R,T4:6C*/-\YXFD@NU%O:W<T<D8_;X\3<#O5\5Y*FM
M++&TUI9Z7<962D][K35WZ?!/*>)U&RR/'RNG>]&INVDTO>2V25]K6MW/QL&B
MZBD%OI]M>1W'VN9%M=!M-1M+QH+^\,NGR2WEI)<^5!J,VY8Q:@K>+ _GL+2"
MVC\O'30;E9;RUOK6_M$TYE:]:*&2:YM")(X&N6BAE(-D3*D$G[ZW3=+&7GD!
M$$W[<_\ #C7_ (* 0Z/<V*?!'PM=:JFKN;2^_P"%Z_#ZVT*30#;F Q:C8_V4
MGB6[U26:261+J'7-)T^.!HX+G0;N99)SF3_\$*?^"C;6L7F?"SX=SW$I,CQ6
M?Q@\-VALD^9!97!N!)#=1';#,)8IIU1=B89U %3XJX,3Y8\59*[=7F,&DE;3
M^';7HNA,<FXC>^18Z+OK'ZK)-:)I_$VXM-ZJ+3=]=+GXUV^FRK%))#97NHZ?
MIH,UTD*W5YIBS7"FT_M$P7L(L].N&CG)MYKVR+(5\N+[WFQI+!I=I;V3:1#J
MPDGLH!XADUM+34+ W:R<3:39W%O*AAAMQ'!*+C=<7<JW122U@F./V6MO^"&7
M_!16);B.X^#OA>)7MY-ATWXY^![?[1=&/%LVI+>"]6[LH9&+FW@%A.QV".:$
M( 9+#_@A=_P4)6+59-9^#6@7M\]HZZ%<6'QY^'-A!:7P8M#/JMK>:9JQU32X
MRRL]A:WFB7K ,L6IV\9C5*AQ3P;+1\4<-;<RY\PHJ75/5P4D_=U5FI-[BGD_
M$*5HY+FVUFHX>?*]=$_>NU>[=M4KWOJC\:[BTMREZ+&Y4:=&)A:IK6CSV]W>
M07=P9V;3+>SM-2M=.N!$ZFX6ZU.&.V"A;*[F"L[KI3R"WN!<6VGZA:W"N;2/
M6%\000V6H((HK+5;<Z7<V*G5EME:-8[J._TU+?>]XC/+&X_:73O^"'/_  4H
MFN4-WX*^'UA'->QFXU"]^(G@V755%Y&EO>7U[KFC#4?$\^FVT(WS:7#J5TT^
MY_L>FF69U./<?\$)_P#@HI#=2VZ?##PA?6=I=SV]C=6'QD\%V]G/IPN)6:9;
M#5O)O8_MNV.YBCECL2B,BW=A%<HX';3XMX*@E?BS(8O9QAG-"4;7WLJ<E%MZ
M\KM+K;EU.262<1RYN7(LR?NKX\!4@[M6LFVI/HO=235VV?DG8^+_ !3X?LK2
MQTW6--L)-/\ $:^+K?Q7X6T?1M,\<VM[+96VG1JOQ+TO3[/QQ;Z;;113&W\/
MQZO;Z=IU[<76HQ:=!JES=22=!K6JZ3K6KW^LV]WJ?A^S\0QPIXLT#4/%>N>*
M8=9N+"QM-1%S=>++NRU>\U_4O%.L)/>V.F:SI$=IH.LI;&]UMUCAN[?]4W_X
M(<_\%'Y9K1V^$7@VWDM%6""_L/C3X%L+X+N(,U]*&OVN7,+K"CVB1R"*&-71
MV<$U8_\ @AM_P4PAOK>\'PR\"-<Z;-!+875G\7/ MA@V=P;JTF:XM?(U*:]B
MN/+E2^F$%ZC1J3=<J(^N/'O!=-)+BC))N":CSYG!JW.IZ.*BIJZ;C&WNN4G:
M\M,7PUQ+->]DN/CS6>F%ES?"XI6:?*TK:IK6,=%K?\H-1TS2M%@EN#>Z5>ZW
M!=VUOI;:3=ZAK5H(+:9KA_$JZ];Z^VG7^H6<XMK*UMK"*^L6E>\$]A9- D\_
MU-^T_::M>_!C_@GWJD<YNYU_8_\ %E]JEY:D0Z@US%^W?^VY?QW4*6EU;W8*
MW327,IMM-,%A+ +AKR98R1]G7/\ P1&_X*9BY9H? N@ZT+>9_P"S=2UKXQ^#
MX-3@M9A(+I(+;_A(M8ATTW2O(LJV^HW$AC8J)26;'T5\;?\ @C3^WEXH^%O[
M''AK3OA1X%U#7/AS^S+K7@?Q7JZ?%?P]I1TC7]2_:Y_:G^(-QI4#>9;S:EIU
MUX.^(?A^74[BR22V:XN;K3[:.5K>6N7$\;\%5L;E<_\ 6/A]*%?&NK)9A&$*
M2JY;.E3E4G[.HTI57[--VO)\J:3N=-#AWB2G@\Q4LIS-N5+">S4\*^>3ACZ<
MY<L.:FN91NY.+YOM-2:2/P$LKO48O#PTB2ZT6^L+N_NO%D%S%_9\WC>PNI;9
M+*\B;4KZ.'5DBN8E%_-H=K]NMA,)M4\OS%=SCW'_  D.K?:;J]U<ZLM["$NK
MO5M4N-3UB_=KF:]N'2XNGU#4UEN;R6[FNK[R;82SM/-<3&"3#_K])_P0U_X*
M+++I_E_!WP0K6ZFWO[RU^+7@:(W8Q);K<01OK%I<H$M'"K:-- 96AC:>59I9
MB!/^"&W_  4:MHIC;?"/P/\ :)0R.;GXI?#>Z@FC2%8X9HX+J[<VUR["5IYA
M.95#H?-EDC+GUX<;<"JR?%V00DEM'.8**=E*6]!)WO\ #%NW\ST/.GPYQ1K+
M^P<S?,UK+ 3=[-P4I6DVFDE>3:;5G;M^5D&FZ;J=@FDR#5=,\1?;+Y;BWGU*
M74(-7NEECFDG;0(8D;1KV+3XK"WM'O533];F:YFN-5LFM$B.=I5S=2G7[7SY
MYRD&EB-=5U:'PYI'V.PN)#!>7L$^H?9)Y[=4^PZ*LDES$EQJ$D<<=U)Y<!_8
MSQ?_ ,$,/^"A(U.RETOP5\*_%D6JV&D:WKUU8^)_#'A6VT37;J.5;_PI;6MW
M+ITNH'1K:VTZTO\ 6['3;32=0U%[V326U2W#ZSJ.I)_P1:_X*.S^!M/\+W/P
MX\!-IEOXVO\ 7O\ A%;#XF>$M+6:..QM(([WQ%J-A)IMGJB7T5S<Z7H-W:75
MWXET&*PU*WNK+3--O[":[Z8\=\$-+EXRX>@DXO\ Y&=!7<&]')QY;7LU+EE*
M7PM;&,N&>(UK+(,VJ)QE%WPM1M<SBK)<J:;;MR\T8Q2YKW/Q52\:2&ZLM.!A
MMM2^UJB7#V&I745PIAGEBTJ>1+?[,+B*R*32PQ07#.$-GF.2YBN.N1[==1O;
M=;K5K32[U;XV-[J<>GZ?J=UJ5M:VB2Z?<VD>IZ59ZI-JUY-:VUVLUJ\D4 ^V
MP6]RD=Y#)^LGA_\ X(?_ +?]EXBAUB\^"OPY@TNQN#?QZ1-\4/">LQS)]HM%
M32UCN-8^T:FUNK3W\2ZOK>C6DXLQ#/J=K)<PVTU&V_X(B?\ !1Z0"RF^%?@>
MR@%S/*DUU\4/AU=Z<HG97\^YT@0ZK,]VK11H;RWEEN_L[M:,[VY=6UAXA<$1
ME;_7'A]V;22SFDHM.[:E'V245=NS:6[5]D8SX2XDDG_QC^:<JBG+_89<WN72
MDI*3]K*UM'S;7?1GY16VF7=SH:6\5[+I\FEP:CJL]B]SXIU#0=4O+>XCDT]?
M)BL;G2M&NXH;IK.V?5'M-.U"1-]QJULUS##<]=JVNIXMT_0M3\1:GXATZY&G
MZ7H5SJ=O<6VK*^G:.9TTN7P[X:M[#PSH^C^'-)C72?#,7A@>(I6T)+2347%Q
M;,FG0_J'I/\ P0Y_X* RSZI)JG@'PMX==[:Q&C66@>-_ NJ>$[F^BOK)4@\2
MQW?BK3=7T_2-.M7OM2GU2PT/QUK,^H6D=GI^C,MXFHV>#/\ \$,_^"BUO>7B
MVWPL^&]X\5U=/;:LGQ'\&R6FH"U/E65PEKJD\%VEI?");QAJ.E)>@S>5?V$,
MAFB'11\2."H_\UAP^EU3SBE.RE%-6?):37NZ:<CO&T91LE/A/B2>^0YF[2WC
M@9Q7/&6NS:47S7FW><GK)M,_.#3VL5&JZ!?:5X@\7:P8)WT^ZL/%NFQ:7X=\
M16UTAU'6WDM=,N(_%FAW\-M<?8]-M=;T".6&6VUFTUN;S_LS7-.\307 DL]1
MU&3PS86WA**VT.SLO#5Q!I^H7JOHEO/#96*Q/;:Q<:DEO<:AK5Y>MIUQK>JZ
M9'>ZOKUQ.T,$WZ/3?\$1?^"DT$EW;V_PP^&VIZ? LMA:P7/Q'\#K!>6Q*E-2
M$1FT]K6Z+1K-!-)]GU!U^SVVHK<16Y!V9?\ @B7_ ,% ]6MM/M]5^$'@JVO(
M)+"U?6+3XF?#B<PZ#;Z<T#Z?-IMB=#CGFCOY/M?V^TN([V9HI9[J?5+R?[;-
MZ4/%/@J#3AQEP\Y)17[W-L,VDK7<74A:%VDURW:M=-;KSY\#\0N$_:</YE*+
ME*4E3P55MS;4H.4%R\[BK:+9Z*_O7_,S3-:N;:*6YL[&1-6OK98K6TC"7UA.
MDBV5I)J%W9:B=3?[==3&\F@%C?V3Z=JT=K=Z19Z9-&P?[F_X)E%],_X*(?L5
M22ZA/9ZK?_M/_"?2;RR33IGM[VQ7QOX:NOLQO+T+>*PF*7-S/<P1S236\ 2X
MN47>/5KS_@B)_P % K#5H'\/>"?#+6]I<P23:JWQ$\+:'/J.(C%<V\%M::]<
MR7>ARP:9ID5O'J":'J*3WLJR:=% +VZ/UW^P#_P2E_;X^&O[9'[+?Q)^*'@7
MP]I/A'X?_M"_#+QQXJDTSXJ^%KF_U&TT_P 517U[J,VDZ/'=6.JOH%NL\[_;
MK@ZW?V5S_9^EW3LC0QQG?BOP;B.'\\PD.*N'JM;$Y)FV%HTZ6<X:JZE2ME>9
M4:5*,/8WG.I4JTX0BI1<I3BD[M7VR7@/B.CGN2XJ629I"CA\XRO$593P%:'+
M"GF67U)2UFX\JA"4W=2M&,I67+=?AU?3>)]1GUS1K6_;4[:+Q/KEW;PO!!?:
MA=W]UK1\.W$'AY-1V:YK>H7$%_I]N^B6:2W3QV\]Y';/!8K>QQK/ VB#1YA)
M'<:/,TK7,6JZB!;7FJ-':/:WEK/?26$DT4L,M]%;Z'81WMW="**ZU#8! _Z2
M:[_P10_X* P:QXHO-(\">$]06TUO4[CPXB_$?P]IYU6VU+599Y&M)I==MY/#
MT%C'+-??9[H!6NY/-M(9IV,:5]$_X(^?\%(['4-.GU/X'>!KJ*(S6]]=0_&#
MP9=7#6^HK<1ZKJ#PS^(=.DU7Q!/'=O<"[O+VVMI=2M[.YE*K&Y;Z3#>,?AQ"
M%&%7B_AA)0IR:EF$7)24*?)?EH6O9R6JO%QDGJM?G\3X=\7RG7JT<ASC6I43
M7U=4>=2E*=TIU5HO=T5XR<HR5[H_/W4-"\+6\T174[-KBUM[2W+:*FCKI\-]
M9R0PB%53Q-J<^O+>VL,6H76J+,]Q<7%RZS++:Q1WESH;-%DO=..DW<FJZO=O
M9K<ZH\SV.F13B"S:RFM$O+#1=3T>\M#FR\1WBWEO!>W$4TT.JZFES/JMS][S
M_P#!&'_@H']EBQ\'/!TLHFGFBMX/B_X-@DLQ$AM[;[?=7<=PTTTL9\YX-/O9
M[)9')F9I$S)T^@?\$<_V^I(YAK?PR\/:(]G:1V>B1Z5\4?"$D$EH\MXU[;ZM
MK-AJT.IV^_SO]'\G2M9A'VN6%8M*MH$4^[A?&+PP45S\:<(5.:]G+'TX)>ZH
MKVL?JZ346G91Y7>TW)R7*>'BO#GC>47./#W$$>DX1PZJ7>C;A&%>;FYNR:3L
ME=)))GP?KGA:6*[UK6(K2WAEL=T_B6VTW6--\0Z>RZI=,8;RUUK3;FXN]5AO
MDW":6UEN;*R"VFH7%X\VM0VT-1+2STZ87EI):6(N+R)K*UM9+@B:WLK=O-N[
M669F$5I#<"".*XO8YKIKBZ-U<RV^H0"2\_1"W_X)'?M\/-=OJ_P4\*7\4LP^
MRRCXU^$TUU(H4MH+6.YU.YM]0TVYTZWAM)A;Z;_9%NKSZDQO8[BT#V46.?\
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M@HHHI&04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;LLK6V]<M3+C_@Z5_8.LS=1WOP2_;&M;BW16CMV\ ?!*Z>[EVV\CVUO+8?M
MW5LLL4%R+B62YF@MD6&>(3M<I]G9KP]XWW7#&:V>MO98:_K=8]HC_6'(^9Q6
M:8*Z;33G-.ZW5G07WI-=;VU/Z4/L%EVM8_PC0C]!BC[#9?\ /M']?+7_  ].
M:_FRC_X.E/V#)<,GP8_:],&U6DNE\#_!&2& R ;(91'^T!),;DL0OV>*&28\
MR!#$DKI?TK_@Y_\ V%]7,P@^"_[7L$D L2\5[X%^"MNS?VE)]GM&C+_']DD6
M2ZDM8-ZOL7[7%=%OL,5W=6VL?#?CR5[<*9N]&]*&'>BW?^_]--KDOB7A^*;E
MFV!232_B3W;LK_[/I=Z+_+4_H^&GV/1;:$\<_NUZ;@>X'U^HJY=V-F8=*!MX
MV"Z<X4"-#M!U34G*C"\ .S9YZGGFOYMA_P '/G[#WVNWLKCX&_MA6,MPXC26
M]\#_  .AM$E5HC,MQ?#]H-K.%;>&:*ZG=Y1&+1UN(W>-@]>J^.O^#BW]CCP7
MX7^!WB'4?A!^U/?0_&CX::Q\0_"]GI7@SX27%U9:+I/QK^+GP=FAUVYN?C;9
M:1:WDWB7X6>(+Z#[#J>I6)T"\T:^GO8+FZNK*RI>&W'O-"FN%,X<Z\ITZ,/9
M852J2I4_;U(I/,8ZPHKVCNTN6[5WH7'B?AY4L1)YO@5&$*4I2]I4T52NJ4&V
ML.])5/<35]?O/WG^P6'>VBS[QKG_ -!H^PV(X^S1\<?ZM/\ "OYTKG_@YO\
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MY5H6G_(*UG_KOHW_ *,N:N.TO3]&:TMY_P#7G$?^F)%"BBBH,@HHHH ****
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MWQ)T'XDV_B6PU+PMX_\ !,WACXKV%YH/]GW6IWL.O^%]=&LZAJ=WHUC<6MI
M_O%_^RG9WG[)_P"TE^RROCB[CL?VAF_;O,_C4Z'!)=^$1^V]\5/CQ\3KL0Z+
M_:"PZP?AO)\;Y=&M"]]9#Q+'X;BNYAICZG)!;#E"ZLMFKNVC76WR_$4ZN&4J
M;I1I2@G1BFZ;4H0C4DZDDK+5QY;7YG:S3_F\[UKXP?'?QS\==0_9@_94OO@)
M\/K;X#_ WX,_$/XV?$SXY^!OB;\:[72]2^-L'CRQ^#/P>^'?PO\  _QG^!>M
M7NIQ:#\+/$'C7X@?$;QG\77@T30M2\":+HWA;QCK?B;Q!K'A'K_VW7\4:?\
M\$[/VR)/$.L:/+XWL?V(_P!H^76M?\(6.K^%]!;Q1:_ ?QG)>ZOX8TW4M<\1
M:]X>TLZBCW6D6-[XDUO5-*@$,4VLZE<PFZDSOB)^S7\:]-^,NI?'[]EGXU?#
MSX8>./'7P?\ AQ\&/C%X2^,7P:NOBK\.OB!IOP<U;QKJGPF^(>G3^$/'/PS\
M=>$?B+X*A^)WQ!\/WR'Q#XA\)>-_"NKZ'I6IZ-HVH>$M)UL^Y?&/X2:A\;?V
M;OBW\!/%/BV"TU3XP_ KQ]\&_$GCS1/#GV&UL]1^(OP_U7P1K/B[2/"-WK>I
M?98+:XU>XUBP\-W/B.]$420Z=-K4Y#WAS;3M962M?:^^M[?EMV2.>I*DWAY0
M5/D3IRG:-JMU-N;G)+WK\L>5:-6T5WK^/_@WPK\%OAQ\?/V"[WX(?LA_'?\
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M&R@M;AY)J^<Q7!F9X9RQ%7$O#1C><:<H3IQ:2?)&2BW%76THW>^NFGOX;BW
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MK_=/OC'YTZD/5?K_ $--;_UYC6_]>9X-=G_2[OK_ ,?=UV/_ #WD]J@R/?\
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M\P_L=?\ 00__  !?_)'E.1[_ /?)_P *"0>"#^1_PKU;SYO^>C_]]&CSYO\
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MP02_X)R!UD_X9P\..RE6'G>,_BS."4?> R2_$%U==Y+,C JY+!PRLX:[>_\
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M6T72^BLT=D.",@IW5/*LG@GNH9-EL$U9JSY:";5GW5U=/1N_X':;_P $,_\
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M1_PHR/?\C_A7JWGS?\]'_P"^C1Y\W_/1_P#OHT>P7\[_ / 5_F']C+_G^_\
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G1<M[VOKMU9[F$I>PP]*ES<W)%KF:M>\I2O97M\5M^@44451T'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $K HH# 2(  A$! Q$!_\0
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M]11;4E[O.VNJ3NE"FFKI2:N[6CO9M::[73L^I] 45\_?\(K^T/\ ]%<\#?\
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MQR?BWX&X&2#\,Y?Y#Q&#^&<T?58)7>:9=;K:K46G75X.RT[COY2_\!_^V/H
M,"2!GCU!'XC(&1[C(]Z6OFN\\7_%CX5W.E7_ ,2+OPIXR\":EJFGZ1J?B7P[
MH]]X>UCPC<ZK.EK8W^I:6]YJ-GJ/A\74D4%Y=VTT%S8K+]HF1XHF#?2:DD<X
M)YZ<#J>G)[>_-35H3H^S;G"M3J^TY*U*:J4Y.E*,9QYE"#4DYQ?+*";335UJ
M"DG>VC3LTU9^MNWF+11160PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=<NH=5^7KW]B7]H[6_AI?V7Q1_8"\!?$@^)OV=?BK\$OV8/ WPY3X#?!2/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44TL
M<'C_ #BC>OK^'?O^?3.!SCFB_P"=OGV7?Y7#^NO^0ZBF[U]?T/\ A1O7U_0_
MX4"OZ_<__D1U%-WKZ_H?\*-Z^OZ'_"@+^OW/_P"1'44W>OK^A_PHWKZ_H?\
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MST@\O\;OV@?$%SX5\.?LQZ)XG\;:U\-?A#?06M[JOQ MM3L/$WC'QIX>LI-
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MI:OK.D/_ &C#JFG:9:WT5S9-<Z7HMU @TQ=12[O1$"E[>WC,S'J/VK,'XO\
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M7=0^'/A_6O#EY_PLWX:VMG/$3J$QT]5_X+#WWAKX0CXE>*?V?M'TGQ-/\(?
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ME_P5.^+>D?';X]:3HOP[TKQ9\)?&'Q!^%?P=_89U/Q;I^N_#'P#\0_'WA_\
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M/1O%'AT>']=\/27VLZ-H=OK<VL:1I-KI"^H>+_B3^PQX^\,6W@OQM^R+X_\
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M#2];M]!:" >+/#5E:VS>)],O["VL* /U]HHHH **** $P/0?D*6BB@ HHHH
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M^IJ8#9/3!_/.>/KSGUXJ3>OK^A_PJ+!SD+DC@GDC_ODC P/YY."<E?F_N_\
MCH_PKQ8RY8Q3>\8M1ER1<5RI*+7-+56;;ONV;]%JGIY]WY?Y>A)O7U_0_P"%
M&]?7]#_A4?S?W?\ QT?X4?-_=_\ '1_A3]HNZ_\  H?YA;S7]?(DWKZ_H?\
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M0_X5'\W]W_QT?X4?-_=_\='^%3[1=U_X%#_,=O-?U\B3>OK^A_PHWKZ_H?\
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MZA_\Q5'_  [03_H_S_@IO_XEKJ'_ ,Q5?IWL_P [O_L:0KC''4X^][$G^'G
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M5?IWL_SN_P#L:-G^=W_V->A_K9Q!_P!!\O\ P@X=_P#H:,_JV'_DG_X/K?\
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MO#K7B?Q5:37A6ZG?2+=KR1!/\$K.'XD?\%0OVU_B/KRB[OOV>OA7^S_^S?\
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M (=H)_T?Y_P4W_\ $M=0_P#F*H_X=H1#[W[?O_!3<#_L[6_Z_CX*K[8\6_M
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MS0]:,3HX35/#>DSQF-X6=_U#B4JI#$$EB>.@SCV&.<G\<\9P#/,-A)TLFSO
MX;ZE1SK#8Y8G TIR^IX7-,MQL<'F#P%.I*I5IX#%^VP6,PN&KU:M3!.MBL+3
MK5,-2HR:HS:=6A*:G*DX-3ZRC/FLY-I:WA..EK\M[+K+1117A&X4444 %%%%
M !1110 4444 (3CDGH"<?ES^']:J7EW;V=K<7ES<P6MM:V\US<7%U,EO:VT%
MO&\LT]U.[*D$$,:-)-*[*D<2.[,JJ2++G&/HP_,5^='_  5:\8^(/!_["GQL
MM_#.I7.C:M\0F\!_!@:Q92F&^TK2?C5\0_"_PO\ $-]82H0\-]'X>\4:K]CF
M1XY(;EXYHY(I$$B]N5X*>:9IE^60DZ<L=C</A'54>=4:=6<'4J.'-'G<*,<1
M4C!-2G['D4HN<6HJS]E2J5+? KZ[6V7?>32_X!Y)HGQ8_:L_X*":OJ^I_LS_
M !"@_9:_8RTK6=7\.:-^T*GA/3/%GQY_:(O="OKG2M7\0_!?1/%<%]X*^'_P
MI@U6RNK'2/'/B?1/$.M^,$5=3T+2[&P256[8?\$U)Y0)+[_@H+_P4UO+QAFY
MNT_:EBTE;B8</*NFZ)\/M/TFR5V!86]A96UO&#M2)0,5^A/@#P-X=^&G@GPA
M\.O!VF6FC>$O GAG0_!_AK2;*)+>TTW0O#FFVFD:39P01KLCC@M+6-%1< #/
M<\=@JDC)'? P?PY&TX]_;GIS7KUN*,31K3H9%2H97E5"<X8.G# Y55QM6DG[
M*-?,<9F&69EB,7C,1&A[>M-U,/1A*K"GA\'1I45*MG'#QE%.NYSG)*4DJM2,
M(MWTBHS@HK=)6>UVV]3\QO\ AV@G_1_G_!3?_P 2UU#_ .8JC_AV@G_1_G_!
M3?\ \2UU#_YBJ_3CCT/YC_"CC/I_P+G\@I_/ZU'^MG$'_0?/_P (.'?_ *&B
MOJV'_DG_ .#ZW_RX_,?_ (=H)_T?Y_P4W_\ $M=0_P#F*H_X=H)_T?Y_P4W_
M /$M=0_^8JOTVWIN"D@$CINR<@[2.%/0X&>F2!W%2A00".A&1SV/_ :/];.(
M/^@^?_A!P[_]#0?5L/\ R3_\'UO_ )<?F$__  3-AD5HW_;Z_P""FSI(K(Z-
M^UI?LKHX*LK ^"N0P)!'<&L?PW_P2J\+^#=#TWPQX/\ VW?^"C_A?PUHT!M=
M(\/Z#^U-<:;I&EVI=I3;6%E;^"%AMX/->241(H022.P +&OU5V?YW?\ V-&S
M_.[_ .QJO]<.)53=)9E6]E*<:LJ2P60>SE5A"=.%25-</*FZD*=2I",Y0E.,
M)SC&48RDFOJN&OS>SE>UD_;5;I7NU?VM[7Z7/S$_X=H)_P!'^?\ !3?_ ,2U
MO_\ YBJ/^':"?]'^?\%-_P#Q+74/_F*K],S*HD:,*6*8W8<9!.,97;NP<C!Q
MCMG.:=O4D@*3C.>>G3'&S/.3VP,'GIF/];N(+V>/FI<RBT\OX>7O."G97X92
M?NM.Z;72]TTAX;#1MS0G%RO92K5HMVLVTI5DVK---*TE\+9^97_#M!/^C_/^
M"F__ (EKJ'_S%4?\.T$_Z/\ /^"F_P#XEKJ'_P Q5?IMN']T_F?_ (W1N']T
M_F?_ (W5?ZU\0_\ 0=/_ ,(.'?\ Z&A?5\+_ "S_ /!]7_Y>?F2/^":(4Y3]
MO[_@IPK@':__  UE<2A&(.US%<^!Y89-AYV2PS1,<"6)UXKB_%UG^W!^PAIL
MOQ&T[XH>*_V\?V8?#"2ZE\3O!/Q%T'P[;_M<_#WP=9P/+JWC/X;^-_!^G^%O
M"OQB7P_;I-J>K>"O%'AC2O$FHZ9;2)H&KW>I%HI?UG8G.0IQ\H;YB.I(&1L!
M/4GCWZ4C%98V!4,CX7#@,CJV"0R\AD*D@@Y#<@\<%0XJS.4G'-*&$SK 2DEB
M,OQN7Y-!5J=KU/8XO+LHRW'8#$PIN<L+BZ.,<J6(5&<Z%:$73F?5Z>OLI.C-
MIN$E6JU+O1)RIU*DH-)N/,HIJS;T>JX[X;?$;P?\6_ /@_XH?#WQ!9^*? WC
M_P -Z1XM\(^(--?S+35M UZQAO\ 3KN,'YXG,$ZK/;3*ES9W*R6EW''<P31K
MWBG*J<YX'/K[_C7Y=_\ !-"UB\#M^V[^S]I.V+P9\ OVX?BQH_PWTZ&/[/9^
M&O 7Q.T'P7\:=-\&:; &?RM+\*:S\0O$&EZ4 P5-*2P@5%-N6?\ 451@ >@Q
M7!G>7PRO.,=@:-6I7PM&I"IA*]:,85JN$Q>&P>/PDJD(-P52.$S##TZKC:+K
MT<1RKDE!NJ%1U:-.HU9RYU-:Z3ISE3=K_9?(Y+RDKBT445YIJ%,;J/JO\VI]
M,;J/JO\ -JB>R]?_ &V8GL_E^:/R_P#VS^?VW_\ @E*#R/\ A=7[11Q[K^SM
MXIVGZC)_.OU!3[B_[J_R%?E]^V=_R?!_P2E_[+3^T9_ZSMXIK]04^XO^ZO\
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M%] \36)O;?Q18^'8[JWUB:Q@FU"PLYU21H_QO^$'P-^*_C?]F+_@D[_P3F\
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MR')<IR[*<)B<SQ&"R/),OPU+#8:6*6%<9XNI'$8W%8BI#$XW'8F2?+!\3?\
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MQ?IT,_[-?A$)#K7AW4E^TV$SX+0_O9H[B';/$[1R*:_6N,Y&?9?Y5^9'[)Y
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M:5X@^"_Q/^$&L^&?$?A*;1O^$?UNRTBSGN/$_A7PMXST/6=>T^ZMKS5=.O\
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MXN#7G#%XAM^C]JE;=<KONC^0?X>_L2^'OV8OVEOV9]=_9[_9]\9_#J/XY?\
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M'X*F^&A\8_";Q]>?$;4=#U"+X[Z+=?"C3/!MC#X>\.ZE:E]-6*_;P=:IX?\
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M\3*$(_N92E^:7[ O_)?O^"I7_9[UM_ZSQ\$J_3ZOS"_8&R?CW_P5'E49B?\
M;@AB65>8VDA_9[^":3H&'!DA<A)5SN1B P!QG].U.5!SG(SFOL.+KKB#$1>C
MC@<CZIZOASAYM:;.*<;WZRMHTSQ<)_N\>C]IB';R^L5OZ^8ZBBBOG#H"FE<G
M\OTS_/-.HI-)VOT=_P &M>ZLWH] _K\O\C\^O^"AGPD^(OC?X9?#[XO_  5T
M+_A*OCC^R;\7?#'[17P[\(QNT%W\0+7PO::IH_Q ^%]G,LBNEW\0OA]K?B+1
M=*C8%9];_LJ, ,%-?0_[.W[1OPG_ &H?AAH7Q7^$/B2#7- U6.*WU?2IGB@\
M4^ O%$$$?]N> OB#X?:1]3\)>.O"]VS:;XA\-ZO%#?65U$7"RVL\-S+[TZ#!
M.#D$$8).#GDJ.Q.2"5 )!QFO@CXO_P#!//X)_$KQ]JOQA\"^(OBS^S+\;M=<
M2>)?BS^S'XZO/A9XA\;2JP='^(FAP6NI>!/B*VY09)_&/A;5[^;Y1+>L8[<Q
M>]A<5EF-P6&RG-\1B< \#/$U<KS7#866.IX:&+JQK8C!YEA(UJ5>6!E7Y\3A
M\1@7/$X7$5:\:F&Q>&K1CA\7"I"<JU&*J.?+[6FWR[+E56,FK7Y4HN+]UI)Z
M2NW]WAADL&*AAT'.,[",$ C'RMR=S#>=C(!MHW=/FP 2=HW 9)W$\=<,,@<#
M!*\@G/YF#]@C]H(?<_X*C?MNA1PJO9?L\R, . &D/P6!<XQES@L<DX)X/^&"
M/VAO^DHW[;/_ (+_ -GG_P"<W72LFX>22_UWR_1)?\D]Q+T5O^?)BZ^)OI@Z
MC6NJJ89?/7$)Z[JZ3UU2=T?INLJJH'IGID=R>F/\^IZT[SE_SG_"OS&_X8(_
M:&_Z2C?ML_\ @O\ V>?_ )S='_#!'[0W_24;]MG_ ,%_[//_ ,YNG_8W#W_1
M;Y?_ .(_Q-_\I%[?%?\ 0%4_\&87_P":3].?.7_.?\*/.7_.?\*_,;_A@C]H
M;_I*-^VS_P""_P#9Y_\ G-T?\,$?M#?])1OVV?\ P7_L\_\ SFZ/[&X>_P"B
MWR__ ,1_B;_Y2'M\5_T!5/\ P9A?_FD_3GSE_P Y_P */.7_ #G_  K\QO\
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M&,4E&,(1C%)))(_3GSE]/Y_X4><O^<_X5^8W_#!'[0W_ $E&_;9_\%_[//\
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M_G,M^@H_L;A[_HM\O_\ $?XE_P#E(/$8K_H"J+_M_#/\L0?I>JQ)(&"J"P1
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MPE.G_""P_P"$B;19O!\WU_\ LB?LY_$?P!^T?X U#PY^S=\>/@S\0M(_:_\
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M-8\P\;?\$M_A7XN\677BRS^-7Q[\(W$'QF\4_';PGI6CS?!?7]"\ _$'XB^
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MJ6J:=>>)_#6I73>$_%5EX@MK/2=6M)VUW2;[39K=](O_ -/D!50"<D=\ >_
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B'MG%;RV\(50(D "@ ;1T P*.WI^I:<4DVKWOY6M_PY__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $_ HH# 2(  A$! Q$!_\0
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MN(+2*:9EC;YX_;+_ &Z?@/\ L1>![+Q-\6M9O=2\6>*KE-$^%?P>\%VG]O\
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M7'F?\%G?^@?_ ,$SO_ S]IVCS/\ @L[_ - __@F=_P"!G[3M?J/Y?O\ I_\
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M\YRIT\91PZQ&%J3BI2Y(UZ>)A&-1TX^TC1JTJ%;V;4E3FKN'3@>*,#C)2H+
M9=0QE*$:E; 8[+:V$Q]"G.7)&4\-4Q<G.FJG[IUL+4QF'C43@\1%VYOS8\S_
M (+._P#0/_X)G?\ @9^T[1YG_!9W_H'_ /!,[_P,_:=K]0W!! 4C.>=WY\8(
M[?R)XIX3(Z_R/\C^E<WU^+2:R_*6GVP;_P#FP]/^TX?]"W*6]=%A)75NZ^NZ
M>7<_+GS/^"SO_0/_ ."9W_@9^T[1YG_!9W_H'_\ !,[_ ,#/VG:_4?R_?]/_
M *]'E^_Z?_7H^OK_ *%V4_\ A%+_ .;!_P!IQ_Z%F5?^$<O_ )M/RO;XF?\
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MY?%.IV\?Q0\;:#>@Z%:^%+2^DN8_TK^&7PG^$G[,'PDM? 'P;\!>&/AI\-_
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M3# N+G_@HWJ-R%.KWW_!4G]JN+5'8G[08]$L/AKX?\-I/)M5]D?A+2]"%LC
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M-!R<=L$Y^AQ_*G5SZ];>7IY^>YQ]GW2?R84444 %%%% !1110 4444 %%%%
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M:[1+<066\VGA'P9IK2+/XD^(?BVXTSPKH-C;W=P]U<7$/V&7YT^&'[$WQ/\
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MS<3PQW&EW-W?L7U6YTN;5[58[6_A!_+7_@HU_P $Z/VW_P!K?]K[]GK7M/\
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MI*EQ+3BDKXW(,14JN-U>>79MAH4Y\E[>\LVKQ<E'903E902]AHII<9P 2?\
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M0:W3\_\ T%J\Y^+7_)+/B?\ ]D_\:_\ J-:E7HS=/S_]!:O.?BU_R2SXG_\
M9/\ QK_ZC6I5I2_B4_\ K[3_ /2X&E'_ 'BA_P!?L-_ZF8<^,_\ @DS_ ,HS
M/V$/^S7?A!_ZB-C7Z(1]/S_]#>OSO_X),_\ *,S]A#_LUWX0?^HC8U^ARLJK
MECCK@=S^\90 .Y+,J@#DD@#DU>,_W_%_]A&*_P#3Z.G,_P#D9YC_ -A^-_\
M4S$$U)D<\CCKST[\^G'-><7OBW4=6OKK1O =G9ZK=6<[V^I^(]1:5/"6BW2R
MXGL9)[1X[K7M8BP4DTC2'2.TG.S5M4T^5T1YH_A];7H23Q;J^J^+Y_E,EOJ%
MP;'P^K<$K;^&M,^SZ7Y*$8A&HKJ=TJ ++>RL6<\S;6RNCB-Z]\8>%=.9UO\
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M!GP?UWQ=\(_^";&G7EYI7Q$^/&A2W/A_Q]^V^+::33->^&'P4GDCL?$/@GX
M.4N[+Q?\9K%H]6^(L8G\-^!C:Z3_ &OK,GZY?#KX>^!_A5X(\)_#3X;^%]$\
M$_#_ ,":%IOACP=X1\.V<5AHN@:!I5LEII^GV%I /+2*&&, R.TEQ/(7N;F6
M2XEDD:;PO<>";#S? _@VX\*6</@2RTS1I?!WA=]'@'@_3S:(NAZ6_AW2'0>'
M+$:?;HFF6,EC90FVB M(UMX5)Z2;5-/L[C3[.\N[:TN]6N9[32K6XGBAN-1N
M;:SN-0N+>P@D=9;N:"PL[J^ECMTD=+2WGN64112.JQ&)]M&-&C#V&%IMRITX
M_')M./M*U1QC*O7<=)591C&,?W="G1I>XUB\7]8C3P]&G'"X'#.]'#4I/WYV
M<?K&*J6C+%8MQTJ8B:BN6].C1P]%1IRO#(PO. 3SC''/'3  Z#!Z8Q[/K'N/
M$.AVCZJEWJ^FVKZ%IT6L:XMQ?VD+:+I4Z7TD&I:LLDRMI]A,FF:B\5Y="*VD
M6QO&60BVG,>C%<131QRQ,)(I8UEAD1D=)HW4.DD3*Q#QNK(RNI*$,/FSD#F2
MLK'%KK=WN[[6)Z@G17V;ESM)(]NF?\CD].YI_FJ%+8? #$D(3C;G(.,X.01@
M\@C!P:J6^J:?=W%_:6EY:W5UI5Y'I^J6UM<P3W&FWLMA:ZI%:7\,<C2V=Q+I
MM]8W\<%PL<LEE?6EVB&VN(I65^EI?<[?/75/9KJKKJ/7H[=+V3T>C5FFM5=:
MI[WLSX+_ &D?V$]!^+GC^U_:%^"_Q'\4?LL_M;Z)I=OH^F_'OX<Z=8:M!XOT
M&RFA>S\'?'+X<ZG);>%?C5X*@2(PV6E>)G@UC18Y!_8.NZ6(L-Y#%^T5_P %
M,?@3&FC_ !N_8>\._M2:18%(1\8_V,OBIX7T74M:A5 BW&K?L^_&R]\-ZUHF
MHRB*2XNAX=^(GBC3#-.D%O'8QJH/ZN>:,9V/R"<;>>#@\9YYQTR!D$D9H64/
MRJOCC!V_*00"&5L[67!R""<]LG /7'%ODC2KT*.*IQMR>UA/VD%>[A3K4ZM.
MI"DWM3:J1CKRVNT^^GCZGLZ='$T:&-HTHJG2CB/;JK1I)MJC3Q5*O#$*DKOE
MIU)5U3O)4^2+Y%^6[_\ !2'Q[,'M-)_X)K?\%'-0UM0!'IM[\(?AMH%D\IP$
M6;Q%JOQ:BT2*(G=ON1=- BC.XL5!QKSQ3_P53_::1]$\+_#'X<_\$X? -X-U
MW\3?B'XH\)_M/_M$SV#IN$?A/X5^$_L/PB\%ZI-'*D2W_C#QMXWDTNXMYI7\
M.W3"**7]5/[8TPZE_8_VZT_M?["NJ'2C<P#4AICW#6J:@;$R"Z%DUTC6PN?*
M\G[0/(+B4A*BU7Q!HF@V;:AKNK:;HE@OF;K[5[^TTVR!BMYKN4?:[R:&WS':
MVUS<OB3Y;>WGG/[J&1UM8K#TU?#Y=AJ<WKS5:F,Q33[QI5:\:-]+QC*G**>\
M6M"WC<+!?[/E6$HR2=IU:^.QG+)_:4,17A2NFDUS0J)/>,E=/Y=_99_8Y^$/
M[*&E>*9?!,?B7Q9\2OB-J%OK7QD^.?Q-UJ;QA\9/C'XDM$ECM]8\=>++M$>6
MVTU)I+70O#FC6VE^%]"LB(=&TBV22::?ZWC&$0<G"*,GJ< =??U]ZSAK6E-?
M6^F+J%DVIW>G3:O::<MY:M?W>E6\MI;W&I6MFLQN+C3[>XO[&WGO8HWM8I[R
MUC:4-<1!KRS!L85^3CE<<@ D')&""=I!^8,&R %8CDG4J5IRG4E.<WO*:NTM
ME&+>T(I6C!)**6EDDEP5*M6O4G5K595:E1\TYS:<FUHDK*,80C&T84Z<(4XQ
M2M&ZN2T50BU.PN+J\L8+NWGO=.^S_P!H6D-Q!+=6'VN(SVOVVWCD::T^T0@R
MP?:$C,\8,D(DC5F$TMW!!')+<.+>.)'DDDG9(HUCCB::1VD=A&J1Q([NS,%5
M4=B<(Q$D%FBN7T[QOX/U?5[GP]I?BGP[J/B"SL;35+O0K#7-*OM8MM-OK:UO
M+*_GTVTNY[N.SNK2^LKJWN7B$,UM>6EQ&[0W5L\O1B53V?JP^[W4E2,]\$'.
M,XZG R: 'MGC'8@^OZ=ZA9><D'Z@D$GKG Z=,X&,'MGFI/-&1\LG.3GRVZ#N
M1C(SG@$;CZ5R&I_$;X?Z+I&F^(-8\;^$=*T#6;@6>D:YJ/B71;/1]4NRL[_9
MM.U*XOH[.^G$5I=S-%:S2LD5K<R.%6&3:6;DFTFELN75/>Z=_P +?>2[=;-K
M;F5U%]TKK7Y_<?)?[37[!_P<_:.U[2_BI;7'B;X)?M+^$K-[;X>_M0?!?4/^
M$3^+OA1#@#3=3O8\Z1\0O"5Q$'L]0\%^/M+\1^';BQFN8[:VL+ETNH?FJ#]L
M;]I#]BF]M_"G_!1?P=;>,?@_;2Q6.D?\%!O@?X9NHOAW/&TEO!9S?M(_!;2S
MK7B'X#Z@\;2W6J^-- N/$?PJ-P)5$_AJSA#R_KN)<X'ER D9P5 P.GKUSP0,
MD<$X4J32O[:UU&TN;.]MH;VPN[66UO+*\MDN+2^M+J,QW%K=6\RO!<VUS"YA
MFMY8V22)Y8Y!L9A75#&.5-8?%4GBL/%<M.,U:K0C>_\ L]?6:L]51J2GAF[V
MA2<G->E1Q\O91PV,IK&X>*Y:?M';$X==%A<2HNI!)ZK#U'5PLKV5.DWSK&\'
M>,O"?Q!\,Z%XU\#^)M!\9>$?$NG6VK>'?%/AG5;+6M UO3;E0\%_I>JZ;/=6
M5Y;3!@%DAF=?O+N#*0.I#*>C*<=<$''ZU^3GB_\ X)_^.O@+XGUSXQ?\$T_B
M)H'[/_BG7[Z36/&O[,'Q"CUC5_V+_BS?SR/+?74O@C05&O?!'Q?>>9*Z^-?A
M*]G8F<1/K7@[6XQ+N]+^ _\ P4&\'^,/B%8_L\_M(> /$_[('[55Q&5L/A+\
M6KS3V\*?%%XF$4NK?L[_ !<M95\'?&30II,M'9:3<:?XUL66YAU;PC9&TGF+
MEA.>,JF"E]8IPYG.C9?7,/%).^(H0YU"%G?V]/VU+1J2I.[1+ .I"=; 5'BZ
M4$Y5*+7^W8:*U<J^&I\UZ44^9UZ$J]**NZJP\?>?Z,Y&,Y&/7/%+59'##:05
M.6X(Z,&P<GI@DG!R<XX'!%2ID$@]L_TSC_/H:Y;?A_7=GGZ^C3=U=/1=4UH_
M)K1]^\E%%%( HHHH **** "BBB@ HHHH **** "BBD) Z^A/X#K0']?>+408
MD@9ZYXP.<<XSV&._J1^(95 /WN/16YSW! Z>I'3K7A/[0G[1WP7_ &7?AMJ?
MQ4^.?CK2O _A&PEBLK/[89+S7?%&NW*L-.\)^"O#-BMQKGC+Q=K#_N-)\->'
M['4-3O'WNMMY$,\L;BI3:C3BYSFTHJ*<GZ\J3E9=^5)6U:UM4*<ZTX4Z4*E2
M<I<L8TN9S<T[-<D4Y22^U9>ZKMM13DO;+F\CLXI[BXF@AM[>"6XGGGEC@@MX
M88VDEFGGD98X88D1Y)9'.Q$7?(Z1@L?R8\8?MA_&C]LOQ+X@^"G_  3>?2+?
MP1HFKW7A3XO_ /!03Q3I<>L_"'X9ZM822Q:YX2^ /A:^^R+^T#\5[)?)0:U8
MW*_"7PI<W,$FJ^(-7O,::G/0?!S]I7_@I;,NO_M1:1XQ_9<_8=N9DN?#'[(4
M&IW/ASX^?'_34<E+_P#:VUS1KJ4> O!.HM#!=VOP.\&ZQ+JE_:3R6_Q$UI94
M.DM^M?@_P5X7^'_AGP_X*\#^'-$\(>#O"FEVFB>&_"WAK3+'1= T#2+" 6]E
MIND:3I\-O96-E:PJL4-O;Q11JN6P6Z]ZCA\&O?MBL8W\'N_4\*DM74:;EB\5
M?:E!PPV'DE[2>*7-!>I;"Y;#FG[/&YE>\::2JY=@I+5.MRMRQ^)32_<P<,#0
MU5:>+K+D/G3]E7]CGX._LH:#KZ>!;?7/%?Q&\?WL>N_&/XZ_$35I?%OQE^,_
MBH"1W\0?$#QI>@WEZ$:5AI&@V L?#?A^S9+#1-)LK9&5_K%(@$5=S@  XSC'
M XZ=!T ]J<%(SC)R,8)['KCDX_\ KT\=!]!7%5JU*TYU*TG.<FKMMM\J5HQ3
MT2C%:*,%"*5E&*22/,K5:N)J3K8BI*M4J6YJDVU+W?AIQAHJ=*FK*G""A"$4
MH0C&*Y0 P ,DX&.3FEHHJ$K:(@**** &MT_/_P!!:O.?BU_R2SXG_P#9/_&O
M_J-:E7HS=/S_ /06KSGXM<?"SXH'T^'_ (U_]1K4JTI?Q*?_ %]I_P#I<#2C
M_O%#_K]AO_4S#GQE_P $FSC_ ()E_L(GT_9<^$'3K_R*-C@<\?GQZU]EZ]<7
MOB74Y?!FE7$UI90PP3^,=:M9#%<6=A>@O;>'-,GC(EAUC7;>1I;B^B=)M$T;
M%S$\>H:GI<J?#7_!+[6[;PW_ ,$K?V)]=NT>6#2_V3_A/=&"+_6W4R>#[%+>
MQ@P&)N;ZY>&SMU569IYXU4$D _H%X*T*?0-#BMK^1+G6KZ:;6/$5X@^6\U[4
MW^TZC*IZF""0K96*MS!IMI96X^2%:K%ZX[%?]?\ $W?^*LFOO2;7D=.9?\C+
M,;_]!^-M_P"%E?KY+IYFWI>E:?I.GV6FZ9:0V%A8016]G96JB*WMH8E 2.-5
M['&79F9I&+L[,9)"^E14<AQCUSP#ZY!![=&"YR0-I(ZD5B<1"TLHE8*-R\@*
M%Y4J 3EO]K<N,X YSG->.2_M$?!*#Q[_ ,*QF^+OPZ3Q^LMO;2>#D\4Z1-K\
M-W?/$EC:75E%=,UC>W33VRVEG>&*XNFN(EBA)EC)^1?BF?$/[0&G^+]9D\+>
M(?B%\*%\5^$? _P]^&FA?%?6?@[I_COPI/XGM] ^(?QJU?Q'X9U#1]8\16%A
MJD-Q!X,T%=8_LJX\.Z.GB-+:Y/BO3KBW_/[QK\!/#7P$\4>(/ VB>'-(TWP9
MJ5QJ,OAS6+'2[2.'Q%X6NI[V+3O$&HKIMA8?VAJ,#6U[HGBS^SK=KO5;K1(X
M-,)N_C-HD-AHZ$E1AB).DX575ARQK1E64J4XTTIX5/GHPFJJFJTDHU53E.*?
M*[<M/%4ZF+KX-1Q4:F&IT:U64\'4AAG'%4JWU:GAL;)_5<9*+P]2>.A1?UC!
M2K8.G6BG52/Z)$&021@G(].#W'<?GQTYKYU^)?@#4/M]UXX\)Z/'KMY=6EK8
M^-O!7VB+33X[TG3FSINH:/J+RP0:+\1O"Z--+X4UN:2UBO41?#NI7]A#+8:M
MI/(_LB?&*?XF?#QO#7B*ZDF\??#4VOAWQ ]S/YU_K.D".6'P]XHNG!V7-U>V
M]E>Z/KM];F2SN?%^@Z]/I[MI\MBTGU>(G( *;?D7 .P@-G/16ZKP,CCC(SQ3
MH8B6'J7C3A5A4A*E7I54_95L/)6G2JV:?++11=-JO2GR8BC*,Z/,9X_ T\?2
MC"52K0JT:L<3A<30G[/$8/%T[^PQ="JXS2G1E)JI1J4ZN'Q5"=;"XO#XC"UJ
ME*/COPI^(<?B6V?1YM2EU&[M5N9-,U"^LYM.U;4["PN([&_L_$6F74%K/HWC
M/PU>-'IOBO29K>"1II;'6K6"*RU18;?V=F8C!S@@9P <X].0>HY'(['(R*\]
M^(&DSC21XBTJV4Z]X1NQXITT0HGG7QM+=H=:TMRB+).-=T ZAI9C9OFG:SGW
M![>/95\0^,/$^E2:;J7A_P !:EXZ\*:AI\5ZVH^&-;T+^VXGN0LMJT.@Z[=Z
M+;7NGRVKQS"[L]>-SN=T32YBR.TPI^VKSI8=*$4I580Q&(IQ=.E=M4G5FX1K
MU(>]"G\,JL8TKKVDI7=3$RPF#IU<:ZE6JG&E7JX3!5:D:E:[4\1#"X7V]2A1
ME;VLX2YZ5%RJQA)X>%&WI@C!RR[N&+8(P2Q&TD')(.SY05*L$^4$9.6LV#N.
M\D,!MVDC@@C@C.,CJ/4G.>1Y#%\9]&BC/]H>"_BWILK!=T,WPM\8WP5R""JW
M.BZ;JMG(0P(+1W<D;8RCE>:A?XM7=V[0^'?A9\6-?EDY1KGPQ:^#[*-2<(9K
MOQQJOATB(DCS#!;W$R)EEMG?$;=LLHS.*DYX5TN5I>TJ5,-"DN:-U)RECO9N
M.DK\TXI6O=2M&7 N),EE[M/,(59<L9<E'#8VKB+SC*<%]4AEWMVYQA/D4*<G
M)P>ME=^RN[<'A0%WG<", #KC'0'DC);L!S7SWXU\2:QK/BR7PAX:M;/7?%E@
M]NVGZ:7^T>'_  /#/$K#Q[\0)H=L0NH0['PEX.\Y-7UB=!/#%:VCWVMZ)9N+
M+XI>,+VWTOQ-XATOX9:7J$5S,NA> +J?7?&M[:6RP-.ESXUU/2["PT)#]IAB
MN3HVA37V]R;'Q!#+LD7U3POX0\/^#-+31_#6E0Z98&:6ZF"22W%S>W=PYDN-
M0U2_O)9]0U/4;F09GU'4+F[O9B3YDK8!''4PV6;8VM#,J^&KPE'+<+4O@/K*
MA&5%9KB5R.O22:JPR["WC4JJG+$XV.&485+^M9KC%*&$PU?*<'B*+IU,TQ<'
M1S.6'E=3ED^#ESPPU6HG*$L?F-I4J+G'"8%XE2G"+P9X3M?!^B0Z1;W%U?W3
M2SZAJ^K:A(9[_6M;U"47&JZO=R%F6.:_N=THM+<QV=C!Y-A86]M96EO!'Q?Q
M6^*5YX%E\->&?"GA:7Q[\3?'MSJ5KX(\%KJD?A_3[BWT&.SN?$OB?Q1XEGLM
M1M_#/@[PQ:7]D^LZHNGZIJ=Q>:AI&BZ%HVK:UJUC9R=7\3_'.E?#'P%XK^(&
MMVM[?Z=X4T>ZU:33=-2.74M6N8E$=AHVF12R0Q2:GK5_):Z58)-+% ]Y>PK/
M)'%O<?-VE:'\3/!GC"3]I3]H/XD_#;POI.E_#N[\-:W\/O#OA'4KO2/!>C:E
MJT.L"PT_XBWNO2:WXD\1WNNQ:%87TUMX2L+?Q;>6.G:;H7AFVO);-7BI-U)S
MJ5;.=65V[+>5[IVBE9]%RQC%:+E5D>I0H4\/2IT:47&E3IPHTX\SG90M'6+<
MG>>FMVVVVW=MFMJWB']L#P39'Q5K'@_X,?%O0[1&N=>^'WPP;QCX2^(-A8QO
MON7\%ZSXQU+6O#7Q%U>SMED>WT+5M/\ AE_;<R>5::K974MO9R^A_"#]HOX%
M_'JS^U?!WXJ^"/B"R:/INO7FG>'=?T^ZUS2M+U< V=SK/A_S%U;1R90]C-'J
M-I UOJ$5Q8W@MKNVEA3A=2^/+^)])U#3T_9D_:1\4>$-8L;O3KV]F\#>$/#]
MMJFCZA ]K>*_AOQG\1O"OCI;:\M)I(G@N/"\%[)#(ZBU))4<MJ7A?P=^T!8>
M!O$?P.\06OP9^*O[/OB-K/1I]?\ A6UMXE\ :?JWAJ]T?6/AOXO^&VL7/A#5
M(O!7BWP_J%K?VUE!J%CIEY-H_A[Q%H=Y=S:1:7MNG&SY6K<KV3:2=NJBU%Z/
MJI&EEJG]EM./1-.S]WX;IK>S]6?:)@1T .[!"G/RD\9(YVD'DGMCTQFN1\2^
M&Q>2VFJZ3.FG>)=.BG&F:DZM)$\;&)YM,U2%,&\TJ\VA)8WW26DGE7EDT-W;
MP2+Y9\%/B/XWUW7?'?PN^+NF^'=/^*_PRDT"_P!1U/P>-1A\'>//!'C*#4I/
M"'C[PSINM7%UK6@)?7FB^(O#NO\ AK4KS56T+Q-X=U>WL=<UO2)]/U*Z^@Y=
MV5VKG@YZ<9*#G/)').!UQCN*Y<7A:&+HNC7ASP<H2C9RC.%2$U.G4I5(M3HU
M:<TITJT'STI13A>-Z<]*=:IAY*M2:C.&JO%2A-)->SJT]%7HR3<)T)MPG"4H
MI0NYQYSP]KBZYIZ7/D2V=U#/+8:GI\I4S:;J5HX2\L92OR.(7PT4\8\FZM9K
M:Y@_=2KC\W?VCO\ E*O_ ,$Q/^R'?\%%O_33^RW7Z!7:+H'C&PU%"\>G>+0F
MAW\:X"1:_86\UQHM^1G!-[I\5YIES*/GD>/2HCQ&<?GY^T<1_P /5_\ @F-_
ML_ [_@HMGIWTG]EWISS]T@^A&#6G#=?$55C<+BY*ICL!0S'"XJI&*BL2OJ$Z
MN%QJA'W8?7<'4H5JD8^[#$QQ=*'[N%%+V<-1I4L54J4$XX?$93F6)IP<G-T7
M]2K+%8=S>LUA<3[6E&I*TIT'A:LE>4F_U(B^X/P_D*DJ./[@_P ].#^HJ2MO
M^#^;/#_S?YL**** "D/0_0T$@=3BF.ZJK$Y. Q. 21@<\=<^@ R>E"U>FNMO
MR^74'UMV;U3MZO3;O^0[)Y^;H/3'/7/\LCGZ<UY-\9_C9\,/V>_AOXK^,'QG
M\;:-\//AIX'TXZIXG\6Z\\RV.FV[2Q6UM%#;6L%U?ZIJ6H7DT%CI6CZ7:W>J
MZM?W%O8:;97=W-'$_+?M(_M*?"3]EGX5:Q\7_C#XC;1O#NF/#INBZ1ID#:MX
MT^('B[4LKX<^'GPW\*VTJZCXU\?>+;V-=/\ #GA?2EDN]0N9/,E^SZ=#>7=O
M\*?!O]FKXO?M;_$WPG^UY^WCX=E\+Z3X/U9/$_[*/[$\^H17_AGX(V[VLL6E
M_$[]H"S1/[+\=_M*7=K<&>"P634/"?PB$O\ 9NB&_P#$45QJ]CT4*"E%XC$S
MG2PT)2LZ45*K6<;ITZ$9+EJMNRJ2UC1BW.[J1ITY]F'PL)4_K6+G*E@U-K1)
M5L54CO0PKJVBO^GE=QE##1NVJM;DP[YCP5\'OBI_P4G\7^&/CE^UMX-USX6_
ML<^#M?LO%O[//[%'BNR^R>)OBKJ>CSP77A?X[?M9V:7#;H_M"-J_@#]G^\MY
M-*T5'L]2\?)J>J1-:3?L5:V]O'!%#!''##;HD,,5ND<4,4<,:Q1QPQQJJQ11
MH D2(J!(PJHJIM%2ID,=Q!!SR2IR?E S@]P/3 Q4V5]1^8HQ&(E7<4H1I4:?
M,J%"FI>SI0D[WNUS5*L]'6K5;U:DM)<L8QIJ<5C'B90BH0P^'HW6&PE.?-2P
M\6[OWI2<JU:=E*MB:W/6K2LY.,(4Z-+\]]5_9G^)Y\2^/K[PX_@S2/ 7B'XC
MZ9XYF^%\7Q"\9:8OQ EEO_&=]XLNM:^)>@>!M,\<> ;'6=4\0Z+XO3X?6TOQ
M*\+P>*?#]S'976E:+K=[9URW_#+?[1<^K>+O$MYX^^'MQK-_XR\0^*/#FEW6
MK>.[OPS!<Z[\/?B_\/-3OK&VFTT7_@JX\1Z9X[\*?:]/TZ_\31Z+-H%UJ!U#
M7W:&QF_3#*^J_I]/Y<4?)_L_I6//+31.VUXOY]/+U.-\KUYDGWNK_F?E/'^Q
M1\;Y(H4U'XA^'KS4;_X:2_#_ %;Q1-XU^(5_J$6BV6I?M S6'A'4=&.CV>@>
M.M!U;0/BOX/\+7>O>)HK&_\ #D'A"_U31=$N[BZL(++WKX=_ 7XR>![SX[W\
MOQ+&N:KXXT#6]-^'=YK?B;7=6\):7=7LFJ3^%(M1^'D'A_2+CPU#X'L+K3O"
MEM?^'O'.KMK>@64=RUCI6H[HG^W\KZK^E&5]1^8I.3D[N*7^&,K?EO\ H":7
MVD_5K_,_-+PO^R%\<+/3-*EU'XQW.C>(O#MU83>#+G3/'OQ!U^R\#V%S\6O&
M_B_Q+8I;W%OX9TSQPTO@'Q1IOA&QNO$&B6T?EZ6NDQV>F:3!IUS;=9X _99\
M>:)\)O'W@'6=?T[1=0^('QH^%_CK79?#'Q(^)NMSWWA3PEX>^#'AOX@:=?>.
MM2MM$\<C5?B+!\-O%-Q=6MO<Q6NGV_BJ'13JDT5K=WUQ^@.5]5_2C*^H_,?Y
M[G\Z;G)JUW:R6B:VM_=\K^H[KNOO7^9^67C#]F+]H"VUK4X;'Q1J_P 0].\:
M_%VYOI(-0^,WQ \(^&XO!9\*_&F\\.OXCMO"GA:+7_ G_"O[CQ!X!\-Z>WAO
MQ-XWM/'%QX.\+_VI9^&A]JEM^N\1_LF?&N]T2_-E\7[SQ!XNU?6KD7FOZQX]
M^)GAF*!(?AIX;\'^#O'ME;Z!-?1VVO?#[QEI_B;Q_;_#VUAL_"/BG4O%E\VN
M>(8-2M;;44]Y_:5TK]I+4!X*?]G/6=,TR<W6OVOC1-4?04A@LK2TTSQ=H.H6
MZZQ9W+3W6KZGX/D^%;) ZKINF?%35/$UQ!+_ ,(];7%E\D^*?A!^V!XIT3Q.
M-?U+Q?)JWCSX9^+]*O=-\(>+/AUI.@VGQ"\5?"CX<MITOB:%TT^2_P##O@OQ
M98>.?"'A_6=*N)M86XM]"OIK"YT6\OM0EJ,I*]FEM?F].EX^?Y$REM9KY-?Y
MG=Z1^S#\?/#7Q'\1_$ZP\8>$];\3OK>EW=OJ&L>//B)9S_$G1[3XF?$+Q:VF
M^*[:/P]J>G?#?3=-\*>-=*\.V/AOP=:^)/#]_>>#-/EN+>PLY]-MO#^++^R)
M\==6^'&K>"O$OQ%T+6?$NK>%O!^AW/Q$O_&?Q%U"2[L-,^!L_P -];\#W?@J
M^TV73CHJ>-+G4/&Z^*6U7^W?%J:U/'XET.#4[-KJ[]EUOP;^T[-X!MO"6E^/
MO%,.M:?\6?B(5\;Q7?PXC\9ZQ\*8/#GC/4?A[_:5S/X>?PU%>77C!_!VE7QL
M?#=IJ1T&"2.[AM6DO[L>;)X:_;ATIO#MD/%/B37EA\665XFK7&H?"2-C-J'A
MKX$W^I?\+%1-+TUKGX4:5KDG[0^DPZ9X*L?^$[@N?^$/6V34[ 6.M6CYI7O>
M"=UK9)W3]/P_R0[KEW5[=U_F<MJ7[&WQMO\ 2+(Z;X^T[P[)I]CK6G0>#-'^
M)'C^Y2V\-ZIKGP=U&Z\ Z9\8/$7A?6O%^FZ)XDO?A]XB\;W]]-X3U-?#VN^*
M(O"VG>'KSPY;RW\_L?Q5^ 'QB\72^ ?^$)^(]SX;U'PY\&O$/P[UOQCKOCKQ
M/J]XNN:EX4OM.@\1Z=X7T;PYX<M+SQE)KKZ7<WGQ*FU[2;R+2I-66+P)-J"Z
M/<6'E'B;X8_MGZEX<U*U_P"$R\7:AJUYX-OM;M-6@\0_#'2/%'AGQYJGA;XH
MV6JZ!X)U73='L+72=.%S%\-K319;Z"^CM;K4;R:ZULVKZM);]D?#G[8>L^*-
M6T^'Q)XY\+>%=4UK0(;_ %B^U/X/2W6F^"9?'W@273W\!QV6GZM=V/C73_A9
M'\0[#XN7'B2VN]/N?&]UI5_\.VU:PBL;BS&Y2WE#2[Z>G\NKTZDPLFW=+1;M
M?YE#6/V7OC#J%]X;O-'\8IX!\/V&N>$KZ]^&OA/XP^.)QID&C>'I-*:YL/B9
MXA\ ZGK7B&[T#5WDUW3;'6?"%A;>)&U:Z34KS1;JPTZ].<?V._B9'J?A35W\
M>6WB>;1O%-AXRUBS\0_$3XJ1V[^,;K2?VC/#6M>+](>5]3CLKFTT'XL?#-K'
MPY!8VWA_51\/KC098M#M6L[]N;\2:+^V-\-?!WB/Q?:^)?$=IIO@S1O%[V?A
M/0K7P'XBL[^SU6P_:&U4^([K2;#0KGQ'J?B2VUZ^^!TL$5I>"RT]5U*2;2[Z
MRB\0&OJ_]DGQ%XJ\4_!;1-:\::SXRUSQ'/XA\7Q7VH^-K#1;.]:WC\3:BNGV
MFC7OA\#1?$GA;3=/6STWP]XOL&*>*K&S7695BN[VXA1-R2O[KZ723>W?EO\
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MK-O:_$CXH7&O_$G0-*\1^,M8T>3Q%"9=/M_!-[X=T+6_#'@5_#GA?5-0\/\
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M "MT_/\ ]!:O./BW_P DK^*/_9/O&W_J,ZE7H[=/S_\ 06KSCXM_\DK^*/\
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M@G_Y55ER99_S]S+_ ,$X#_Y>8?\ "-_S_P Y_P#!.6__ #2?1_\ POSX%?\
M1:/A/_X<KP9_\O:/^%^? K_HM'PG_P##E>#/_E[7SA_PZ^_X)T?]&0_LP?\
MAG?!/_RJH_X=??\ !.C_ *,A_9@_\,[X)_\ E51R99_S]S+_ ,$X#_Y>'_"-
M_P _\Y_\$Y;_ /-)]'_\+\^!7_1:/A/_ .'*\&?_ "]H_P"%^? K_HM'PG_\
M.5X,_P#E[7SA_P .OO\ @G1_T9#^S!_X9WP3_P#*JC_AU]_P3H_Z,A_9@_\
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MG_Y54?\ #K[_ ()T?]&0_LP?^&=\$_\ RJHY,L_Y^YC_ .",O_\ EX?\(O\
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M>#/_ )>T?\+\^!7_ $6CX3_^'*\&?_+VOG#_ (=??\$Z/^C(?V8/_#.^"?\
MY54?\.OO^"='_1D/[,'_ (9WP3_\JJ.3+/\ G[F7_@G ?_+P_P"$;_G_ )S_
M ."<M_\ FD^C_P#A?GP*_P"BT?"?_P .5X,_^7M'_"_/@5_T6CX3_P#ARO!G
M_P O:^</^'7W_!.C_HR']F#_ ,,[X)_^55'_  Z^_P""='_1D/[,'_AG?!/_
M ,JJ.3+/^?N9?^"<!_\ +P_X1O\ G_G/_@G+?_FD^C_^%^? K_HM'PG_ /#E
M>#/_ )>T?\+\^!7_ $6CX3_^'*\&?_+VOG#_ (=??\$Z/^C(?V8/_#.^"?\
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M>7:TW?T-*=/VM2G2YG%U:E*DI*]X^UJTJ?-HUK%5')><4M+W7Y]?\$_+./\
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M/@=XET99O$VCW.L?%+7M<U75+F+Q/KWQ_LOBOJ+MHSRPW'POO/A7!MO+R_\
M%RS7D_;?\$WFFT'6_P#@H]\/M#MT;2_ /_!0GXW7/A2SE=X+*.3X@^"/AQ\2
M]2L?/"R>5%)XO\4ZW=731@LDNI3W$BL\BJ-"3QO^VMK&A:1IW_".^-7U;7?!
M4L.O6DWPX\.^&K&S\=:E-XFM/B1X>_X22UU^"\\.^'OAQHR^&K_X+^+-,EUJ
M7XD:U?WEO?ZGJ4=N[:?^98RE"&+KPII4Z;GSPB[J,(U84JZA'=\L'7=.%_L0
MBW:]E_1.:4X4,?BH4H6I.HJE.*22A"O2P^)C3BK_  TUBO9QZ\M.-ST'XY?#
MOX_6'CR3QM\,)_B-XSOM%^#'A3X<^%M3B\0_"RTN=+\3:GXRU>?QQX[70?$>
MEZ5I.H>)+C1=,\*_V[]GAT73]3TNZD@TI[1],_LUO/+>V_;XO)-+U*_7QG'K
MFE:O%>O;QWOP7T;P7?:QK/P@\96UMX?UCPU9:AK&J7_PN\&_%5/"2^(/$EEX
MF3Q-XDTW4GU#P]X>TIM'U)I>#UG4OVW]-\&7?P\\.^"OB8TNH>%OC,=4UZ^.
MC:O=W=WKN@_$N?P5<>'O$)U*#4-"U[PMXCT;P19V%C=Z]96>O6WBZ(66G"WM
M+S5-,[NZ^)/[=T1U!=&\&:[K$$6A^,)O TNO_#3PUI,OB^UMM(^(,D>K_$>W
MM?$4!\$>+-)UFP\"6WA#PEIJPVOCBTU&5K]+8WM_<>&L4E&_O4Y777F=O_)=
MSSF[[J2U\M?N9Z=\'[W]J30;[3?$?QOO/B%KV@6.B>$]&T_PGI?A3X7VNL:W
MXV\9^/=<T#6)_%Z>&M7\02OI/@/1[G0=;BU_3=3\):#)X>"W=[9WFI:;J,5W
M][H"$ /.,\]>,G'4 ],=<GU)/)_,[QSXK_;4L_%TOA;08?',OACP[H_@.?Q#
M\0=+^'G@*\O=?O8O%'P?UKQ5J7@G2'MWLW6^\,:_\4_"][X7N9M7U.*X\"^=
M:KI\^J:/=ZUF0>+_ -O?1_"#:78^#TBDTO1/#WB:7Q!<Z%!K>KMI_C+Q/H.A
MZAX2L=)FUOQ'JM]XU^&EAHGC[QCJ@FCUN'5M'\5^ [&S@O+RQU*R922;;YH+
MR5[;>GE][!22T]Y^;7=GZCT5Y5\'?&&M^,?!.G7/BFVNX/%NC+;^'?&4\OA?
M6?"6E:CXPTS3=./B2]\+Z7KV=2?PY_:UQ=6MC<R2W$?G6UU:)<W+VDDS>J9'
MJ/S';K^5973V:+$;I^?_ *"U><_%K_DEGQ/_ .R?^-?_ %&M2KT9B,=1W_\
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MH_\ P439S&G[<?[3!<#<8Q\9O&8<*6(R4.L;@!M8L2 H R&;;-Y7K%Y^T_\
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M&[]EK4_!WC7PM\+?@)8>%]5\3^#YK%?'.H>%HTU=?%L7B[X;:UHMQH^G77Q
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M_P#T'XC_ ,$X'_YS'NO_  ]"_P""BH&3^V]^TX.0O/QB\98WE=RJ#_;6"6'
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M,\V2 6*KN^JC;OA\$O\ W5=_P!YYG"_YC\1_X)P/_P YSZY'_!4'_@HL>?\
MAM[]IW!P5/\ PN'QF=P)*_+C62#R.H.,$$'D4U_^"GO_  46='C;]MS]IX;T
M?[WQ?\: @%& 8K)JQ4_-@A6216. ZE"PKQ,_$'X,/;7)?X/7,NIZCI\=KJ&H
M_P!LRVRS7\EG=I=ZFEG'?I9VA_M3[)?0V&GV>DHWDG35EL(KF+3T\<\1WFAZ
MAK^K7WAK1V\/Z%=3M-IFC-/)<'3HOLT0EC\Z2>Z>1#/Y\R2/=78C@EMH9;F6
M8$KOAZ]6>(P\).$HSKT(N+H82TE*M236F%B[--IVDGYHZL!G69U<?@*=7&U9
MTJF.P4*D)X?!SA*G+&86,XRA'*:<IQE%M.,9P<DVE)-W/];']GW6=5\1_ 3X
M&^(==U&ZU?7/$'PA^&>M:UJEZ_FWNIZOJG@S1;[4M2O9L#SKJ]O+B6ZN92!O
MDD=@.<5\Q:K^U3X^B\1>,-)TJ]_91_LKP[X@U3PW8ZIXE_:#@\/ZO=:[H_BB
M^T:\T._\.7.C))97]O:#36++JDT;ZXM[H;I; I=VWT5^S'S^S7^SMT'_ !8W
MX1CZ?\4#H!SCL>A'?L>*^;?%7[,WQBUWXAZMK=NO[)+>%]3/C"2/5?$?[/5M
MXG\?0MK.H7%S8V6I7K76G6&M?:TO[J\U>Y=K13<VS6<EAJD^LRZO9_+U5:OB
M%912KU$HJ*27OUM%RV5EHDMELM#*M;VU:R27MZ]K+D5O;U;)4TDH_)))6CIR
MV,27]K3XC16%E>VGCK]AG6&?PO9ZO*TG[0,FB:;>7T%Y;V^M7.E:S-'J]F^A
MV5M=C5Q??:+U$73)M%$TMS=/J5ATGBO]I?XFZ;K.MV?AG5_V4-2AB'@S6_"D
M'B'XOZKHU]XA\,>)O^$5MHI85TG1/$4<DNOZQXW\':#X7U_2I-3T9[GQ=H5Q
M?)<KJ5G9+/;?LT_&'/A+3K[Q#^SJVDZ;::E9>,E'[/?A6=?%6G:[>ZU<ZMHV
MEZ0+>SMM T1H;_2GGL?MUY<:W>:")=2OPNIWCQVK[]G;X]:I'K\]]\1/V?AJ
M%WX;T/0= BMOV;-$ETBR&E*+U'U2UUC6-7U.^T^RUF#2)-*T6'5[6RM;+0;(
MH(-4N$O["#,\S;]K?XQZYH^@>)M&US]D/1]+U$76FZA9ZA\;=,\1+%KW_"6O
M;6-EIVHZ7<VB"1/!DNFZOJUEKD.DWT6L7UMILMOI&RZEC^C;;Q#^UA>06,EC
MX2^"VHZ;J/@[1=3MM>@\5ZJTJ>(;YM'FOK6"UMX)M-U;2;73EUC[+KUM=6=O
MJ=WJ&D7<6E1V&F3V6K<2/V</BF?"ZZ0VO?LU1ZMI][>3:7=P?LS:1_PCLL,F
MGZC+8O>^'9?$3R6E\GB&_DN+N;2]7B2YT[4M=2%+:_OH+FU[#P_X!_:NTI_#
M]M=?&GX.RZ'IVCZ-:7FDZ7\%+S18VOK+7M,6^M](5/&5S%I_A_\ X1"VU#3=
M(L%B:[M-5GMKQKZ73K7[&2ZVNK]NH:]M._0^DO"D?B.#P]HR^+9]/NO$PTRT
M&N3:3;O:Z?)J1C!N39P--<%(%8E,A@LTBF5%B1TABZ(RJ,<,<XX .<GH,=<X
MY(ZA>>F:^0[WPS^VM+X@\/M8?%CX%1>&#K9N/$J2_#/Q*^L#0(FL7CL-'=_$
MAM9-2O5CU*VEO[CRH["2]L+Q+&\CL9[34,6+X3?MF(UN;C]K'PY<6T+027-B
MOP2\,0WFHA-?TK5KNT.N^9,--AN]$;Q#X2BO[;0;J6Q@;1=6CMIM76^+@'VU
M13(]XCC\UE>38@D=4,:,^T;F6,O(45FR50R2%00I=R-Q?0 4444 %%%% !11
M10 4444 %?$/_!1+X+3?'K]B_P#:,^'^EYB\81_#C7/'7PRU./RX[O1/BS\,
MXU^(/PQUFPNY 7L;NR\9^'=&#7<+I-':F=(I8D8@_;U9]]96]_!<6=S&LMO>
M03VD\;9*R07,$L,J,N<,KQRNK*>"#CZ72K3H5:=:#:G3G&<6G9IQ::_%?<V;
M8>M/#8BAB*?QT*U.K%;)N$U-)^4N1Q?]VI/T?AG[*/Q@A_:"_9I^ 'QSC6..
M3XN?!GX;_$*^MXRY6QU;Q3X2TG5=9TTF0!_,TS5I[VPFR"#+;.0S@YKZ#K\P
M_P#@C?=-/_P3D_9QM&W8T#3OB#X5@R<J+/PS\5O'&CV448_@AM[:UC@@0<1P
MQI&/E10/T\K;&THT,9BZ$/@HXFO2A>R?)3JSC&]M+\ME\C;,:,</F&/H0^"E
MC,3"GT?LXUI<B:V346HM+3W4%<9X^\+VGCGP?XN\#Z@2+#QGX4\0>%+Y@ =E
MEXCTF_T>Y<@]0L5XQ(^8XZ*<&NSJK, SJI8 '8-N0"<ER1@]0=HS_LJW-<\9
M.$HS3Y7"49QE9-1E"491;3LFKQ2M=?$M4<D9NG.%2+Y90J4YQE;F490G"<9.
M/VE>$4H_:E*,;JY^'_\ P3C_ &C_ !5;_L??L_\ PSU?5?!?AGQ'^SO\/+WX
M*>/?#?C*SU&\\7_$;XD_ ?Q_XN^#.L_"_P  LWB70[/3_$D>G^"/#FK174T'
MBS4)A\0/!TR>'1I-ZMW>_24/[6OCF?4OAGI7_"PO@!#:_$>UTK5]<\>_V+XD
M/A+X-WE_X%^(?BT?"[QM'??$'31>>+=2OO"%MINBZEJ.K>$M=DCTWQ9)J?P]
MTVY72+)O(_B-?VG_  3U_;.UWXX>)$5/V-?VX?%GA2V^*7B*>!9-%_9F_:[T
M_2[+P3X6^)^LW$L;KH'P_P#C[X=@TKPGXJ\2.;:P\.^.]"T;4M4OK2RU]S/^
MN\.F:-<6Y/\ 9VG26]U=+JS!;.SE@N;V39*-2<A)(;F\DVQG[>3).P59%GPR
ML>K&Q2JO$TXWHXQNM&2?O1J56G7H.2M)^PK\\'&Z5G%NZDCT,R@OK/UZE%>Q
MQC^M4I24:D56J.HZ^'?/&TIX>O5K07/S)0E1G&*=1M_!?PH_:K\?>.="^-'B
M?5/"?AZVN/ASX-U7Q#X>^&&G"'_A+=9N].\$^'/$L,LQN?&$WC1],UJ[U>46
M$ES\)=$B_LJXT\PZAJ&I$V;TH?VH?&4GBRR\%M\1?@"^B:AI>GZ_<?M#6NC>
M(%^$NA:A>Z1J>J?\*EU"QN?'Z02^/[A-.CUG3[^]\=Z*&\*S3W5WX;AUY+/3
MM0_0]--L%NY-06TMEOYHEAEOEMX$O)(D"A(Y+I(Q<2(FQ2L;RLBE5(7*+MB_
ML72?LDEA_9MA]@FF:YGL?L5K]CGN7N/M<EQ-:^3Y$L\EWBZDF>,R-< 3[O,&
MZN/E2NEY)W;:T;LU%WC%IO1PC"R7*ERN2EYBA&UK247"4.3VE2T5))2LN;?2
MR5W"+<I4X0DTX_FOJ/[9_C+2_"'BW7;?1_#GC+Q3#\2/$?AOPIX+\%>&O$7B
M:_;P9\.O%?C0^,?$6KZ7X"\3^/\ QZLNJ^"O"5O!X=OO$?@SP-I5OXU\5>%H
MKE+O0;ZYO1ZG\-?VJ=7\5>/M#\+^(M%T#2_#OC37?C%KO@/Q7IJZTNCZY\&/
MAW]MLK36[V[OI%@T?QKIFJ6ME_PE^C7T<5DNA^(O#>KZ(SB]U.UTG[:CTRPM
M[BYO+:RM;>\N@/M-W!;PQ7-R5P5-Q.B"6X((!'G-)C'H2#^57[>WQ3\4_&/Q
M!HW_  37_9TUJZM?C-\?-"CU#]H'QQH*>=_PS)^R;J5XVF>/O'6M7"E;?3_'
MGQ+TYM0^'_PDT*:[LM7U#5=6OO%$1MK/0?M%QOAZ+K58P;]Q0E[6I)MJC244
MIUY]XQC[MDH)RE!+5J)V8/"_6Z\:*DJ4')5L3B))RA0PF'@Y8JK4O*5_W$>6
M#7O2KNC22E.O33M?\$HI=1\7?LY_%[]IE;.:ZF_:[_:@_:+_ &B_"UG<$64]
MWX&OO%TO@#X3@R2#9;P>(? 7P]\.:[;R/A+:#74#?ZO-'AC]KO\ :6N;?QG;
M:O\ #1-;\0Z-X;M(8-'\/_ _XI:;JN@_%;7_  ;X \3Z/X!\1:3>>)=3NV\-
M:?J.I_$32C\0))-+\*^(8_#EK<V6MV>4_MG])?AYX$\)_#3P)X/^'7@;1;;P
M[X*\!^&M"\(>$]!LU9+72/#OAS2[32-'TZ)7^<I:V%I#!F3]Y)M+S9E9FKIX
M=-L;:[N[ZWM+>"]U P&_NH88HKB^^RQ""U^V3(BR71MH5$,#SM(\,68HV6,E
M#6(KJMB*M=13C.7NQ>ON1C3IP6KW<*4==KMM:6#'UUB\77Q$>:,*D_W2=HS]
MC"%*C0]HHWBJCH4*#J*+Y55E44?=2/R]N?BU^UIXS\:6MUIG@;QMH7A[2O''
M]DZ/!)X \7^%8KOP_KWCOX+VDR>/-/DUHVNJZEX%L)?'+2ZOHVO0>'-4TXZN
M+>\NK2&]NI?0/@-\<OVB?$OB3PW\-_&V@Z#KFOZ=\#M+^+GC?6Y_!6M?#[53
MJVIZ+#X0M/ACJWAW4]?N?^$=\;2_%+1O&&J3Z_)8GPQK?@&ST^XT&P@BN(=4
MN/T-\L<_,QR,')SVQW]NO][JVXUGVVBZ197FI:A9Z98VE_K$L%QJ]];6L,%Y
MJD]K:K8VLVHW42+/>RVMFB6MM)<22-! JQ1%$  R]HI:>R4?QWMY_P!7^[CY
M5W;]7_P#\D=*^-_[95M-XH\;/X=UO4$O-+M=433;_P"!OQBL=%TV^ATOX$+K
MW@;P/X%;7KR\N_$,%_JGQ*T;0O$6N:I8^%-:UK1K[4[K7-#TBXO=0?V7Q'\?
M?VG;&VU:XTOP,\>K1>,/&FEP^&9/@#\2M8EL%T6.\?X7^%Y=9TCQP--U9?C/
M9PQ:IJ?Q4TF\N/!OPDNEF\,>(+&_OKJUU1?T7\E><L[$]2QSGECR"-O\1!P!
ME,1GY %I?+'."PSD9!Y'IC.1@9/!!!)RP)P0>TCM[)-]T]-NU_ZMYARKS^\_
M. _'?]LMO$'@^PN?A#X7T+2F\87_ ((\7:CJO@[XEZA8WVK>$9O"EGK&K>'Y
MO"]UX@N=+\&_$5=>\3WOPX\4:SILFBZ9)X&>U\0:A,FM)=)AZE\8_P!M70M-
M\%:L/ GAS4-8\9>$_A3K'B:ZG^&_Q5@\&^!-8\0Z)\3=;U3P,/#'A_7_ !MX
MFCO;?7=,\(>%-<\90P7/]A0:M;:AK.CPQS:;Y7Z=F)3CEN#D8;&. IX'RG*C
M )!*Y)0J3FE,:DY.XXZ<GCC&1_M8)RW+$,5+%3BES?W8KTC_ ,%E'SM^SUX[
M^)7CC3O'9^*&D1Z=K'AWQ[K&AZ3>:=X,\3^#O#>K:!':VMYI]SX<7QI=#Q/K
MMM:1W0TW5-9U'0_#L,^M6EZFE6NH:.FGZK=^B?%K_DEGQ/\ ^R?^-?\ U&M2
MKT,QJNTC/RA@ 22/F7G@]R5!SU'.,!FSYY\6B/\ A5GQ/Y_YI_XU/X?\(UJ7
M-53_ (E/_K[3V_Q0+H_[Q0_Z_87_ -3,.?&?_!)G_E&9^PA_V:[\(/\ U$;&
MOT0CZ?G_ .AO7YW_ /!)G_E&9^PA_P!FN_"#_P!1&QK]$(^GY_\ H;U>,_W_
M !?_ &$8K_T^CJS/_D9YC_V'XW_U,Q!)1116!Q!4<I(48R3G''NK#D]@,YS@
MXQT-25%*&*C:<'<,GVY!_0TK:ZMVOY+JNMK]OE==1.Z3:O=)VMOL]O/L[.SL
M[.UGXAXB59?CA\.89"[+IO@/XCZK$"V0EQ-J/@71TD4$X\W[/>741;@K%<2
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M ,&WPP_^=O7]/%%)9OF"_P"7U/YX/ ?_ #$3_:6*_P"H;_P@R_\ ^8C^8?\
MXA7?V*_^B\_M.?\ @V^&'_SMZ/\ B%=_8K_Z+S^TY_X-OAA_\[>OZ>**?]L9
MA_S^I?\ A'@/_F(/[2Q7_4-_X09?_P#,1_,3_P 0K_[%G_1>OVG/_!K\+_\
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MP/?.>>>V0#[5&W^L'LP_EC^M$.,/A57#%0%Q@A21G ^Z2<Y4\KT))R:4_?\
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M@?ZM+F_BE2(L,LR2* ?+?;^HS,2K#( 8%0>O)!&0,@]?UXSFORG^!%V/C_\
M\%-_VN/C?8@7G@3]E;X8?#_]C#P3JZQA['5/B7K=_/\ &/X^?8+@,C&3PG+J
M/P[\'ZH6BD5]4MKZVBGQ8.AZ\)[KQ-5_!3P6*3E>RYJ\(X>FDUHY.<W[N]DV
M]$[>AESY/[1Q+7N8;*L7=[-5<5!86A32_P"?E255\L-VH5'M"1^K<7W%^G^<
M\GFB3[I^C?\ H#41_=QUY/\ //\ 7_#BB3[I^C?^@-7&]G_A?_I#//=K2MM:
M5O1J3_4_+7_@I!_R5;_@EO\ ]I&? O\ ZI'X[U^H3(<8]?+';L2V<$X/ Z$X
M/1AC(K\O?^"D'_)5O^"6_P#VD9\"_P#JD?CO7ZBL<@KQV&>_S8/Z9X[5Z.+_
M -RRQ7T=',$UW_VV#_!)^IZ6,5\#D[M=QCCY17>7UYQ2OLKN2WVWZ'Y??&C]
MN_XY>%?VE?B=^SC\ OV0C\>[SX-_#GX9_$+XB^+]5^/_ ,-_@UI.CVGQ3/BU
MO#]M:V_CN#_3XXX?"&K-?WL5V%M3&#/%#$T4C\Y#^VE_P4)N%9[;_@F=H-RL
M;.DCVW[=?[.UPD;QR>2R.\1=5=9?W14[763]V &(%>3:GI/@77?^"B?_  4J
MT;XF211> ]6_9@_87T_Q++->7MB(K2]U;XY6MNYNK /<VO\ Q,7L5BG*&$7+
MPQW*RV\DL578/!7_  3-\*V>L:59^,?@]8V6KV&K:+K>B67QNU:XCU^2U\3:
M-<:^;W1K'QE++XAUZX\1V7A?1]4C:'49[@67A_2K73H(M/@)[9+#488:+P&#
MJN6%HUIU*D\<IR]I34TY*EBZ=._O)6C"*22O=IMF+Q.'P+PU&&5Y=6Y\OP5:
M52O/,/:RE5I4ZLW/V.+ITT[SDDHPBK):7O)^N?\ #7O_  4A*B0?\$M[<QE%
MD$@_;8^ QC:)T,B2K((=CQ/&&D656,;1H\@8HK,*_P#PV/\ \%&/^D7UG_XF
MW\!/U_<\'U'4=" 00/&M(\/?\$S_  7K?AS4]/\ B_X2T>^T2T\!^-?#,VJ_
MM%>-GT#3[+6-0\->-/ NH6LVM^+!H$;>((? /AJ5-)DE2]U;P7I=YI=]IJZ-
MK_B#^TOKNU_:@_9LO+IK.W^/7PDDNA>+9_9/^$[T6.Y>XENX+2&&VCEND:X2
M:YO+6SM;BW1[>ZN)DAM@\[6]I<Q[;"_]"O ?^#<R_P#FXYWFU#IDV4KSYLS_
M %QIY3_PV/\ \%&/^D7MG_XFW\!/_C-'_#8__!1G_I%[9_\ B;7P$_\ C-?9
M94K\KJ5=6*.-S8#K]X8)!7:<9!R<,ASR0%& 00 2"",C.2.1GJ3^M'ML+_T*
M\O\ _!N9?_-PO[5H_P#0GRG_ ,"S/_YL/BV/]M+_ (*%3+*\/_!,S1)D@9DG
MDB_;K_9XEC@=&*LDSIN2%U=60I(5<.I0KN&*G/[8_P#P48!X_P""7UD<'&1^
MVY\!&&1UP1#@XR,XS@Y!P00+NOZ3^R-X:LO%]MXO\::'8V/B/7TN?&%CK'Q
MU33WUK7=#\:MK%O)?1Z7>Z;J.JW&C^+M2M)-+D,FJQK++I^EQ2W>DQ&&3ZJT
M77M(\5Z3IWB?0-8T_P 0Z)X@LX-6TG7]'O(+[2-:L+Q=\&I:7?6DDEK>6%TN
M9;>XMWDA=6(CEF"^:Z57#=<KR_\ \&YG_P#-PO[5H_\ 0GRK_P "S/\ ^;#Y
M'_X;'_X*,?\ 2+VS_P#$V_@)_P#&:/\ AL?_ (*,?](O;/\ \3;^ G_QFOLO
M ]3_ -]'_'W%&![_ )G_ !I^VPO_ $*\O_\ !N9?_-P_[5H_]"?*?_ LS_\
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M5U:B.#6/$^I7%UKVL['B272]*D30[?'C_:<_9HC5%7]H3X'QQ)&D:(/BMX#
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MMT_X89_9$]>/V<_A$/Y>$:3_ (=O?\$]O^C&?V1?_$=/A'_\R5?9J2AS@#^
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M/>:5*/#VGR2:7!I\E]?SNX33H[.^M?.FNY;NT%Q/'+8V7P4^WZK8)\1(=5U
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M1/ID6Q/F8ZZDT: B34C+ $VZ[?#+_@IOYL!'Q9\*;5$HE;^W]"4 E8@N^/\
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MH *9)]T_1O\ T!J?3)/NGZ-_Z U)[/\ PR_])D)[/_#+_P!)D?EK_P %(/\
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MAXA?X 3ZJUQ+H5]I^CZ5?6ZPV5YK&N6&H6D1U*PU.RMYSI^B6 .':W5(?9?
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M$*OU$KOS/_D8YA_V&XK_ -/S/2SC_D;9C_V&XG_TZPHHHKA/-"BBB@ HHHH
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MZK\9OC1J-\'C<WR^.O'4VJ7F@2-)$DJV7@^W\.:3:L-ECI]M$JQC[K"!5X4
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MGH?B72?AR^N2^$Y-1LM3\&Z_=/<:<WB/52/]-6W=KAV-N<G=PP_X)A:P /\
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M@X.#T/H>>H[CJ.XYIVT?W3^8_P#BJK^U\R_Z"/\ REA?_F K^UL?_P _H?\
MA)E__P [#\KO^'8>L_\ 21/_ (*.?^'Q\)?_ #LJ/^'8>L_])$_^"CG_ (?'
MPE_\[*OU1VC^Z?S'_P 51M']T_F/_BJ?]KYE_P!!'_E/"_\ S ']JX__ )_0
M_P#"3+__ )V'Y7#_ ()AZR/^<B?_  4<SDG(^.'A!<=< !?AB H4DD; IR<$
MD!0$'_!,+61Q_P /$_\ @HX1QC/QP\(Y&!CAA\,@P&.,9P5PI&T!1^J6T?W3
M^8_^*HVC^Z?S'_Q5+^U\R_Z"/_*6%_\ F /[6Q__ #^A_P"$N7__ #L/RN_X
M=AZR1C_AXE_P4;[D8^-_A  $L7)"CX8[02[%N%ZGCCBE_P"'8FM9S_P\3_X*
M.8!R!_PO'PB<$ !<,?AEORJA0IW;AC.=Q9C^J&T?W3^8_P#BJ-H_NG\Q_P#%
M4?VOF7_01_Y2PO\ \P!_:V/_ .?T/_"7+_\ YV'Y7_\ #L/6<;?^'B?_  4;
MQV'_  O#PB0.<]#\,2">/O-EN^<@$)_P[#UCC_C8E_P4;X&!GXW^$"0HSM4$
M_#$D(I+%4!" L1MQP/U1VC^Z?S'_ ,51M']T_F/_ (JG_:^9?]!'_E+"_P#S
M ']K9A_S_A_X2Y?_ /.P_*W_ (=A:QQC_@HE_P %&Q@Y'_%[_"'!R.A/PQ)
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M\*Z9#K/B#Q5J=MH=[.HU_5/[4\2^+M8U*>ZU_5M:DL+6>ST+29-,T/3-.LT
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ML:Y>6.G6T82-V#2W"Y",<C%?FJ/B#_P5'_:9D,7PT^%7PX_8!^%=\K(GC_\
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M.>XN?VATN[F?Q?XTU'7-?DGN@DVV_1&@B$:QK](_\/&_B=_TBU_X*1_^&_\
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MWKQL?M=?\%L0/^4-7P5)[X_X*:_#K'!/3/P%YSUSP<8! P*4_M>?\%L!C/\
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M^!?_ %2/QWK]3:_++_@I!_R5;_@EO_VD9\"_^J1^.]?J;7HXK_<\K_Z]8_\
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MP&&13XX\&@RN5AW>)]%4RD!6VQJ;[=(X5@S*HR%8'VKYYE_9QO[1?$CZ;=?
MZP35[6*VL W[-WA.0Z=$]\ES=V=]]GUZR.M6,D$-G!9VUTL4D=Q:V]U=&[*
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MO/#]GXZ\3^.[_+'C1K?1=,O)!@3W=H?,0?1_[/-W_P $X/V3O"LG@#X&>/\
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M^"ZO@+QS^T%^U=\&/BQX8_:BM[/]H3X]_';]HGP;X\^+GQUT[X[^&OAC-;>
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M-Y)WZ7%\T_\ /.3_ +Y;_"CS3_SSD_[Y;_"C%Q_>A_[Y?_XNC%Q_>A_[Y?\
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MT.UO=8N;>(?KX/\ @E_\80H(_P""O?\ P5%( _AU_P#8O&<9^Z#^QA@'NN>
M>>N,?-WQ!TF]_P""9?C?PS\)/V1]+^(/[<W_  5"_P""DFNZK;Z?\6?VQ_B-
M;SV>G_#_ . 6@6C:K\1_CIXK^'/@OPK9>#/V?O@5IWC&R@T+X:?"KP+H>K>,
M-:\3R:7H(G\0WMSJ*=D\?EW)5;H4L14DG)+DE352LTO?Q'+6M)<R]I-J"YI1
MBE&*;Y?/6'KIP]YJ.E]DX))Z1OS/3X8ZII;^?Z2_L%?LH:Y^R)\%O$/A'QQ\
M18OBW\8_BS\8?BG^T;\>_B/I_AU/"'A_Q-\9OC/XD/B7QC+X/\()>ZI_PC7@
MS26%AX>\-:9/J-U>G1](M]0OY7OKRYV_;P<$X SZGJ!D$C..F1@\XZCOQ7XK
M:1_P3V_X**?%/S]=_:@_X+$?'SPUJNK".Y?X?_L-?!_X%_L_?#WPC<DF5]+T
M/Q'\2? OQM^(OB33K<,D,6HZ_JEE?W:(9+R!99)%-/6?V(?^"I_P/6?Q3^R;
M_P %6?$7QMNM*M1+9?!7_@HG\&?AM\0O WC"[A!F&FZO\9?@'X8^$?Q.\'6]
M],/L\NL:5HOB2XL86&VPG\MED\*<YU)RG-WE-\TK*RYGHTDK)))122222LE9
M'=&*BE%;(_;9N@_WD_\ 0UK\2?\ @B-93ZG^PC\8M-MI5AN=1_;:_P""CVGV
MTSEPD5Q>_M:_%ZV@D<Q R!$EE1G,8+A02HR!7V!_P3__ &U;S]LGX<_$5/'G
MPRU#X'?M$_LY_%O7_P!GK]I_X-7VJVOB&P\$?%_PCIVCZO>W7@OQ5:>7#XQ^
M&GC#1->T?Q1X \6+;6AU71M0$<L#2VDMQ/\ ('_!#G5;32_@)^U7\#]3?^SO
MBA\!O^"BO[;WASXF>$;QT@UK0'\??'CQ9\6/ ^K26!*W8T'Q?X'\:Z%KGAS6
M'C2SUBV:\?3YY_LDRQS_ %V_$?\ 7]:/\GZ,^9_^"(__  2[_:%_X)F^)_B7
MXG_:2\:_"";2_&'[,O[.'PCT9?!GC'5=3(\4?"OQQ\<O$?B8W!UW0- AATR&
MQ^(_AZ#3;R*6XEO;FXOVD@MO*+W'GO[*_P#P33^,?P+_ ."O7CK]NKQ9\1?@
MSJ/P:\2?&S]O#X@6%AX?\0>)]2\:+H/[27A;]GO3OATCZ5_PB<>E->Q7GP^\
M6IXD2'7)8=+AL+*YAFOH=6MVB^X?^"D<7_!0#P_XXM/$O[+7AQ/$GP_U3PMI
M-OJ^HZ7X=/C/Q3X>U:PFU9=4M--TFUN;;5]+COK>>VOH+S3[/5K&]O)'BN(K
M27,K_B1KWQV_X*<P2QP:OX;^*UG?6\FH3S^9H'CK1//@C67RX8!_PCVAVJQ!
MH[F330EM<2V]PE@);C4([Z('YW,,^JX&O*BLIQ>(BFTJM-OD;\FFV^NC5M+W
MZ'[-P9X28#BW*Z&:U_$/A#))5U)_V?C*R>848QDX_OZ4\715-.2NG&%WITT/
M[!O%-_\ "SXFZ!=^$?$.J:-JNCZPJPWFE7VIW.B3W>R2.6W:(/<:9?@+,J.D
MD+!69<(S8(K7^'GPT\"_"OPMI7@_X>>'++PQX<T>S6RT^VM'NKF9;82R2@7&
MIW\]WJNH-YDK_OKZ]FGP=N\1JL:?R;?"CXF_\%;]?O5C\.^#O'NN122O.+3Q
ME\-O$&IZ?<VB[[.&Q$>IZ1H.GR^:L3W,[WVL6]JEP UO>7-M-)'#_4K^S+I'
MQ2T;X%?#O3_C4EK'\4HM*OI?%]OI]V+VQL[V\US5KZTL+209C2WL=*NK&RAM
M8WFBL4@6QBN;N.V6XEY\MI9;FF8SSJ?#F'PN;PP]'!K.,7@<)+'2P5*IB)0P
M-/&2HSQKHTJF)KU84W6H45+$5HVW<_&X^X.J\#X;"9=AN.LIXGRW&UZU=X#)
MLQK.GA<1*DJ4ZF+P$,5.C!U(T<.Z=6FIRFE>;C*,;?FC^Q+_ ,I@O^"W0P2?
M,_X)V8 SSC]F*[Q^&3SCC&<CU]7_ &!,_$[]H?\ X*1_M31,9M!^)7[1GAKX
M"^ KL%9(;CP7^R/\/[/X;:A?64I5&:SU'XHZK\2;P[08_M#/&';R"L7YM^$O
MVI[#X0_M)_\ !?[]KOX9"'QU%=?%_P#9$_9'^!Z:?MO(/B)^U]X#^ FD?#6Z
M^&.A20-)!K%_X6^)'C;PYIOB>RLRUY816FJ>:J_9G,?[G_L3?LZ0_LI?LK?!
M/X!/?IK&L_#_ ,'0Q>,M=C=Y1XC^(OB*]O?%OQ*\2O-*!-<OXB\>Z_XCUIKB
M=1/+]NWRA7)4?;J#A@*]:7NO%U(86G'52G1I1C6Q%1:?P[O#4UK=SG:UD[?!
M4X>RRS$8B3O]=KK!47JG4HX?EKXR:TUIPG+"X9ZI^V;ARM1;7U,JX;/'7IU/
MW>>GI^OMG!DIH4#!YXR?S&#3JXELK[];>6B_!+YW//\ /OO\E9?@D%%%% !1
M110 4R3[I^C?^@-3Z9)]T_1O_0&I/9_X9?\ I,A/9_X9?^DR/RU_X*0?\E6_
MX);_ /:1GP+_ .J1^.]?J;7Y9?\ !1__ )*M_P $M_\ M(SX%_\ 5(_'>OU-
MKT<5_N>5_P#7K'_^I\#U,9_N&4_]>\P_]3XA7A/C;P;\,_%?C:QU?Q-X8M]6
M\7^$[6QETC51=:M8:GI5F][>7.GSVMSI^HV( 74TO7@D7=/!*)N8XYE)]VKS
MC5[&]EU.[DCM;EXVD5E=(I"A*QNF<[2/N,Z[@?\ 5NZCY7(KSSS#S]_#GPG\
M(^ O%F@OX4T7P]\/KCP4VB>+K>(7-G8-X*TGP\V@36M]+:W8OEM-.\+BYLX[
MNWN%O(;.-($:28QR#S+PIXI_9+\#7MWXX\*:C\/-#O(8/L=WKMGXBN'BB@U>
M^N@L)$U_+ %O-1@OPC10D&2%@"BSPE_H!-/OCO\ ]#N =F!^X<GYG16QF,\%
M201RK9 8$ "HSIE\QC<V-P73/E2-;R>9%O #B)S&7A#8 98F16P-RD@T -\.
M_%_PCXP:^3PKKFEZ_)IC(FH+I=RMP;*28RK MQD)M$S0S&)ERLL<?FQ,T3H[
M97C+P]X \<^'+CPKXP\+VFK>']0U:&_DTV:XN[02:K%<"^M[JWN+&_MKRVND
MN0)4:UN(V+YPI7"C8_L^_!YLKC.,#]Q(,#/0 1C _/H!VI6T^^,8_P!#N?\
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MZ#I2ZE?23:A?)!#87.H7%[J=U>ZC=:EJ]^\ET+)+&RL_4**&V]6VWYNX !@
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M T'P[J6L>'M"\+Z?XJN=6T+PMHN@ZMJ.BZ3X<TG3+#2KN?3[>WD;]"_VGO\
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M=M'7Q%6<JV(FK*=1Q2BHTXH=1116!R!1110 4444 %,D^Z1ZA@/^^6I],D(
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M2]TJ_20D<1O;AC_=KZ=\-_M!? ?QC%#-X1^-OPD\3QSC="_A[XC^#]6$JD@
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M%U;PCXIL8)7L]>\&^+])GTS44BCL?%'A>XEL;-;/G?[(_P""SF@2)%:>-O\
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MH(!WMZG(9?=\MOD<T_AME6**3484:21TC5T8-)(R;MJ@R?,VT$D?> SS3O\
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ME[O/6KJ=%S5"52'V6HVDN.&(+8. 6;EG!Z#+9 #$ +L&" U0#4;<@$3  @$
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MO+H*+JZBMH8[FY"?<$\Z()9@O\(D=MO;%6Z*->_X+_, HHHI@%%%% !1110
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M5(6\\#VVHP94Y!-MJ,UU;-G^/=$=_(?<#BCDRRS;KYD[=L'@_P#YO&H9*_\
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G9R <$$# QBM8# P.@X%(!@D^N.>_?]!GBEK,R;;=V[O].B^2T/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %. HH# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\->,OVI/!GBFW?PE\=?A=\4K6]M[:YUCXAMX/OIM3\/:]<ZB_C?2-#/C71_
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M'^:/WK_,!:*3(]1^8HR/4?F*.:/\T?O7^8"T4F1ZC\Q1D>H_,4<T?YH_>O\
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MVH\G_;:CZQE'_0MS/_Q(%_\ .<+S_F_\IO\ ^6'P_P#\/#/V<?\ GR_:(_\
M$.OVN?\ YRE'_#PS]G'_ )\OVB/_ !#K]KG_ .<I7W!Y/^VU'D_[;4?6,H_Z
M%N9_^) O_G.%Y_S?^4W_ /+#X?\ ^'AG[./_ #Y?M$?^(=?M<_\ SE*/^'AG
M[./_ #Y?M$?^(=?M<_\ SE*^X/)_VVH\G_;:CZQE'_0MS/\ \2!?_.<+S_F_
M\IO_ .6'P_\ \/#/V<?^?+]HC_Q#K]KG_P"<I1_P\,_9Q_Y\OVB/_$.OVN?_
M )RE?<'D_P"VU'D_[;4?6,H_Z%N9_P#B0+_YSA>?\W_E-_\ RP^'_P#AX9^S
MC_SY?M$?^(=?M<__ #E*/^'AG[./_/E^T1_XAU^US_\ .4K[@\G_ &VH\G_;
M:CZQE'_0MS/_ ,2!?_.<+S_F_P#*;_\ EA\/_P##PS]G'_GR_:(_\0Z_:Y_^
M<I1_P\,_9Q_Y\OVB/_$.OVN?_G*5]P>3_MM1Y/\ MM1]8RC_ *%N9_\ B0+_
M .<X7G_-_P"4W_\ +#X?_P"'AG[./_/E^T1_XAU^US_\Y2C_ (>&?LX_\^7[
M1'_B'7[7/_SE*^X/)_VVH\G_ &VH^L91_P!"W,__ !(%_P#.<+S_ )O_ "F_
M_EA\/_\ #PS]G'_GR_:(_P#$.OVN?_G*4?\ #PS]G'_GR_:(_P#$.OVN?_G*
M5]P>3_MM1Y/^VU'UC*/^A;F?_B0+_P"<X7G_ #?^4W_\L/A__AX9^SC_ ,^7
M[1'_ (AU^US_ /.4H_X>&?LX_P#/E^T1_P"(=?M<_P#SE*^X/)_VVH\G_;:C
MZQE'_0MS/_Q(%_\ .<+S_F_\IO\ ^6'P_P#\/#/V<?\ GR_:(_\ $.OVN?\
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M/_SE*^X/)_VVH\G_ &VH^L91_P!"W,__ !(%_P#.<+S_ )O_ "F__EA\/_\
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M/_$.OVN?_G*5]P>3_MM1Y/\ MM1]8RC_ *%N9_\ B0+_ .<X7G_-_P"4W_\
M+#X?_P"'AG[./_/E^T1_XAU^US_\Y2C_ (>&?LX_\^7[1'_B'7[7/_SE*^X/
M)_VVH\G_ &VH^L91_P!"W,__ !(%_P#.<+S_ )O_ "F__EA\/_\ #PS]G'_G
MR_:(_P#$.OVN?_G*4?\ #PS]G'_GR_:(_P#$.OVN?_G*5]P>3_MM1Y/^VU'U
MC*/^A;F?_B0+_P"<X7G_ #?^4W_\L/A__AX9^SC_ ,^7[1'_ (AU^US_ /.4
MH_X>&?LX_P#/E^T1_P"(=?M<_P#SE*^X/)_VVH\G_;:CZQE'_0MS/_Q(%_\
M.<+S_F_\IO\ ^6'P_P#\/#/V<?\ GR_:(_\ $.OVN?\ YRE'_#PS]G'_ )\O
MVB/_ !#K]KG_ .<I7W!Y/^VU'D_[;4?6,H_Z%N9_^) O_G.%Y_S?^4W_ /+#
MX?\ ^'AG[./_ #Y?M$?^(=?M<_\ SE*/^'AG[./_ #Y?M$?^(=?M<_\ SE*^
MX/)_VVH\G_;:CZQE'_0MS/\ \2!?_.<+S_F_\IO_ .6'P_\ \/#/V<?^?+]H
MC_Q#K]KG_P"<I1_P\,_9Q_Y\OVB/_$.OVN?_ )RE?<'D_P"VU'D_[;4?6,H_
MZ%N9_P#B0+_YSA>?\W_E-_\ RP^'_P#AX9^SC_SY?M$?^(=?M<__ #E*/^'A
MG[./_/E^T1_XAU^US_\ .4K[@\G_ &VH\G_;:CZQE'_0MS/_ ,2!?_.<+S_F
M_P#*;_\ EA\/_P##PO\ 9P/6R_:(/_=G/[7'_P Y2FO_ ,%#_P!F^-&=K/\
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MAG^M?*&D>!];L_VU?&OQ!C\-7-KX5UC]G#P3X8;Q3%9QPZ?JGB32/B'XHO\
M^R9KJ+:UW?Z;I-[!+&LP=K>SN1'$ZHQ0_6%<]E%\L9.2Y8R]YIR3E?W6U9-*
MS6R>WF:!112$9]_4>N,X'MR>M-M+=V J7E[:6$+37MS;VEN-JF>ZGBMH%9OE
M57GF=$5G) 1<[CU&>Q9WMM>Q^=:3V]S"<XGM;B*YA8@*2/-B9EW!60X)SM8'
MIBOYZ/\ @Z(T^WU'_@DQX_M+C1K/Q")OC?\ L](FB7KQP6VK3O\ $C38XM,D
MNY"HL1J3.+!K_?&]FER]R)(Q&77\8OV#?C!XP_X)Y>!O^"[O[0?P=^!/@O\
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MF>>.#G!^AP<5_/+KOQ4_X*.6/@O]K+]G[X:_%;X@_'KQ7^R+^WM\-OA]X_\
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M$GPT\3>&K^/Q;I6K6VM_#"W\'?$@>+]:\5>&_&K^+-=\4^&=#^%MK::3X7L
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M'@SQ'\2_$WQ*\06VA^%/$GQ,\16?S;;Z[^UMX6^&MSJGQ%^(GQIU;XV:M/\
M!_P7\7/V=M(^&7[2'@6?XH_&C4OC1X*\0?$*U^&GQD\0_$+QGX$U/PEJ?@?3
M_B;X6L-1_9@^P>%]"^#>L:9KOB;0/"=KX)T?PIHU ?O+X9^ 7P=\&^/+7XF^
M%/AYX9\.^.K#X6Z!\$[#7]&LFL)M/^$_A;4FU?PWX!L;."5--L_#FBZ@QN-/
ML[6RA,!58ED\E!&/$M5_8!_8XU/3?AAH%S\%/#>G6WPA^(7BWXL_"U= UWQ?
MX3U;PGX\\:^(H?%WCK6])UCPWXDTC7);7Q;XABM=3\6:%=7UUX<UUX+6'5])
MNK6"&!?SZ^!FG?%2T\+^./&NB^)?VE/V@KKX(?";Q!X7M?!.I^-?BMX$8_'+
M5_'?B34O&^A:YX<\6:V/&NI>./A-\/O%?AS2M)DN)M1U#5_#FAZ=>?#R,ZKK
M>D6\/&?"OPO\?-0^*GP^\=>+-.^/%SX'\'_%#XH^'?V?/$NL>%?VD_#7A^/Q
M!\5/@?\ LZ:GX%O?''P_\2^(OB1\>M(^"U]\9O#OQ0LM:UOXR:=;>'/!T=M?
MQ^(]%\":1K&CZ9<@'[*/^SG\%/\ A!H_AJ/A[HI\#P_&@?M%0^&5GU-;-?C8
M/VA&_:M'Q"21=0%V-6_X:&=OB@8/M']EG6RUL; Z.?[-K@_#_P"S9^RAXI\(
M>*/"WA[X<^!=8\(7G[2NJ_'[Q;I6GR7T]A)^U!X;^)EIX]U?Q[J!6^$L?C+2
MOBAH-EKMY$)$LXM9L KV9A#1-^37PHTO]I72OAWI^J?$OQE^U+XC\+6NN_LN
MZ5^V3\-_#_PG_:9\*_&+PE#X>\._'74_B?XC\%^)?$/Q ^)-K\:=2UWXOZE\
M#/#OQ]@_8UU[Q-X/UWX-?#_Q:O@2;QWI_BG1M.U;]-_V _"FN^$/@CXILM<T
M7XDZ)#J_[0G[2'BSPLOQ>%Y_PL/5O 'BOXS^,=?^'WB/7QJL\^NQ1^(/!M]H
MNJZ'9>*EL?&ND^';G2-(\=:-X?\ &>GZ]H6F@'O,WA3X0_"#Q%\3/CA-IWAO
MP9XA^);> K/XH^/+J6:UD\2MX51O"/P_AUJ>6:2W5M,37FT725MX8"[ZBL<O
MFNRL..UC]DW]FS5/ GQG^'6N?"7P;<^ _P!HCQCJ7CKXS^'KV*Z%CX^\>^(K
M[29[CQ3J4S7PN;3Q+)JVDZ)?:5J>C7.G7VF:WI^F:EHTMGJ=I:W"?GK^V%X2
M^)GC?XH_%7PAJ&@_M,>(=2U[Q)^S-=? '3?AS!XPNO@?)X)T#XA^%M:^+]YX
MUGTJYB^'%B^FWED-1\9:-\2;NR\4^(+*QTB;X>Z/X@M=/O/L_P [>*8/CW\5
MKOXR:[XW^'O[4GAKX4VVN_LO_$?Q3X'\.:3^TE+K?@?QOX)_;*6]^)6B^$[O
M4/&&L^)?C#K/A#X*RV'BK7M2_9^^'EG\/O$WAO1]%M_ L?C3Q#X;T_1+, _6
M/P)^P+^R)\,_ ?B/X:^#_@OH=EX3\9?$WX8?&+QBFJZ[XR\4>(_%_P 2O@MX
ME\">+_A-XJ\5>.?%7B/6O''B.[^'NO\ PS\"W?A:SUCQ%>:5I5KX<L])@L1I
M$EW8S_2'Q"\ >#?BMX&\7_#'XB:!IWBSP-X]\/:OX4\8>&-4$IT_7_#6O6DV
MGZMI-\EO+!.;6^L9Y;:<Q312%';8ZM@C\QO@AKGQX\4_M]:IK]WX1^+W@SX5
MV_A?]K?P?X]\,>*-)^-2^#;6^T#XH? +2OV8O%LGBWQ]XL;X6^,;WXI?#GPQ
M\2_B=X!T[X+>!3%\)_#WC3Q7\/OBAXDT?Q[)-I'B7ZU_;1\0>*?#WP9E'A?P
MKXQ\0C7O&?@?PYXDU/P59?%#6]6\$>$]6\16<6O>-YO"GP3U#2_BUXTTG1+7
M)U/PKX'U"QU+5;>=H[N\M=)6^GC.NC:?22T:L[II]&GJO/8#SG]F/_@ES_P3
MY_8V\7WOQ!_9D_9+^#GP@\=7FGMI4WC+P_H$]]XEM]/8_OK6PUOQ!>ZQ?Z7'
M/RET=-GM&N8M\5P98V9:]8\2_L]?LK^#O@5\4/A#XJ^'7P\TOX ?&#7O&4_Q
M5\&>(+=Y_!WC+Q#\?/%CKXOFUN*_GN';4?'GC3Q2K%[>:"1=;U.VDTW['.D#
MQ_FAX&^&O[7_ (Q^%.C:_P"/M8_:=T+QWX-^":W/A#2;?Q;XI\,B7Q]:_M,>
M,)=&U76/#L'C#7KG6O$$_P '(/#MM/I7B[7?$5\O@C47TK7'?6)+Q8.5\;K^
MU%\4?C3JKV_PK^,D7A.ZU9KOXI?#?6-"^+E]X4T7Q%X _:V_8^\0_"Z1_%WQ
M \9M\+/&[ZKX$L/C!XKTB3]GCP?)X8\*^%;;6]'\2^)O[0MK73@7;=Y-R?=M
MOY:[>BWW>H'T%\=_^"3/P$;X"?&'P1^RMX#\!_#'XL_%_P ->!_AMXK\8?$S
MQ/\ %GQK#\4/@EIOQ<\ >.OB9^S=\2/&.H>--7^):?"_XT^!_"?B#X4:HOAS
M6DU7PGHOC/6-0\+107!GM[KEO^"<'["GC/X"?&[XD_'R;7?A+\/_ (>>)/AS
M=?!BP_9Z_9R^)?QC^*GPSN_'/A?XBS?\)C\3/B!XB^+OBGQ!Y/Q0\&ZIX7O_
M (6V.C^$+/2;;1;%O%>F>*!<ZY!%#IWBNO:?\<_'>NI:_%>^^/OB_P"$_P#P
M3R_::^&GP)U76?AEXA^)'B3Q]\48+J^U_P <W7QY\1:3\+C/XW^..L^'/@'\
M1?V+?#_BS6]"\/MKOA#XT7?[9VGP^$[GP_HB^()_;?A[:?%VS^*%W8_M(Q_M
M5Z+X5U#QW^U,W[/NH_#?1_B/KOA[3_'.J_M\?M=:CI=_\2],^%=EJT5II]Q^
MS[/^S3J?P3\0?%:Q@^&MMX-_X2RQGUK3M0UB]LM6 /U2\%?!WX:?#?Q#\2O%
M/@;PCH_ACQ)\8_%L'COXFZOIZW"W?C3Q?;:)IWAN#7M5\^XFC:^BT'1].TP?
M9HX(1;6L7[K>"Y\'^(?_  3^_8^^*_Q<A^.?Q#^!GACQ-\34U7PIKM]K-SJ?
MBFST;Q-KG@6YL+SP9K/CCP/IFOV/@3Q]J_A>YTO3)M!U+QKX:UZ\TQ]+TTVL
MT8L+00_.W[#OQ/UCPIJ-E\'O'<'QD\7ZEXOU-K+P/\:OB%X5^-/@>^^*<_@C
MP1-JGCOQ+XK^%OQ^OE\<?#G6[::WT^'Q+XBT'3X/AM\0?&'B.-_ NFZ5IVGW
M-CIWTA^W):_&6]^ >I0_!:ZUBQUB/QM\-[CQE=^&=.\2:SXM@^%L'C+29?B#
M<^&M#\&^)O!OB[7I[+1$DO=?T/PEXGTWQGJ_@NW\4:?X'LO$_C.?P_X0\0@%
M=?V ?V1Q\=K#]I*X^$D&I_&+2O'&H?$S1]>USQM\1M>T'1OB)J>EZUHMYXXT
M7X=:SXOOOAOH_BL:;XFUR*RUW3?"5MJ.E3:K=7FESV=[)]IJ&X_X)[?L;3:)
M\%/#\7P+\-:3IG[.OBCQEXO^")\-:OXN\+:E\/==^(OB.]\7^/6T?7O#?B+2
MM<FTCQMXEO[G5_%?AO4M1OO#>OW?V<ZGI-REI:)!^>5EI/[5]K:_ Z3P5XL_
M:0^(_P (X;^^\4_M+:Y9>&/BW\'/$'_#/6J_M27FM?#'X?\ P@^'/QXU+7_C
M4_Q5^&-EI_B6R^+-W/>IX[\9_L56'B[P7H?A_P 1_&KQ_P#LK:GX!\[T+5_V
MJ_'7PV\?ZQ^SMJW[4.M?M OJ/_!0S3OBCXA\<W'B^Z^%MQX3TWXN?'7PO^SQ
MIWP;U#Q!XE\,_"_Q%XWM/$6C_#27X/6_PH\2P7?A+X5:!XWT'XGZ[X!\7:TN
MA>(@#]5/'W[ 7['7Q!^'_A+X=^+_ ()>'?\ A#OAQXA\>>,O!$&A:[XN\$:O
MX-UKXE:]KOBKXB7^A^,?!WB3P]XMT>W\9:WXCUS4O$^GVVO0Z3JC7TD-Y9R6
MT4$,7??#+]G7]FWPK#\%_%'PJ^'G@+2[3X+> /%OP[^".L^$ )-.\(_#[X@W
MGA>^\9:-X:N+.]GL;JP\5:CX*\,WNKWMQ]NO+Z^TB*ZDO#<2W4DWYX_##X9_
M&'QAJ/PD*?%;X_\ BSX0P_$'X[>)KW3(/"/[2O[/T.EQ:=\-M&MO ?@[QKHG
M[07BG4?C%XI\-Q>-(FU_PVVM7\GAG4/$,M\EK;WEB9PW&^'/@U^U'XTT_5-7
M\<Z[^U%H.L6/Q*_9"\.:!8>'_B+XF\(Z;:_#2\\ >#4^/L=MH>A:O:Z1+8:A
MKU]XF7QSJ4]I+JD>HV4$EG/"^E6;( ?IW8?LA?LUZ7XD\)^+]/\ A%X4MO$O
M@/7?VB?$WA#65&I->>']=_:U\37'C']H_4K)Y-0=4F^+?B:ZN-7\2K(DD(N'
MVZ;'80HD2\YXZ_9'^%D_P6^&WPS^'&EZ3\*KW]F_X>:QX,_9/\86%K-JDW[-
M]Y-\$/$W[/\ X?\ $7A2#5[Z>*^?P[\-/%.K>&4C\02:B+C2KRX2XE>Y<7(_
M*7QCX3_;3L[Z#P5K/Q$^-WPT\#6;?M!^!OV;_B/;_#?]HGX^^)_"OQ&L_P!M
M7]HW3?AUK_CZR^#GQ'T74+_3[;]G:R_97O?A7XE_:"T;QG\*/$/@2S^*&B>-
M/$?A:'Q/XFL/'G7?%3X%_M1>*O@GX]>.3]H[Q)\0/B_\6_\ @J=\/O&>@7GQ
M"\2BQ;X&7'C?]L#4?V3;31-$GU^'0?!FEQ:1H7P$T_X1ZWX=CT?4X=$UJUM9
M+A'\7>('NP#S+]B[_@D[\6OV7/BO^SY\5?%5_P# 7X%^'/V;/#/BB3XI^)OV
M?_'?[0&H:G^T]>7W@J^TO6]0^(WA+XAZ_)\-?!WA#5]?NK[XI^(;#2O#T^K0
M^+6*Z/=Z?:R7-Q<_JE\8OV%/V,?VM]?TSXP?%/X2:%X_\1ZEX+L?#EMXXT7Q
M5XX\'7GB[X?R/<:MI?A[Q+>_#_Q1X77QQX5634;NXL='\5IK.F01W]TMO;)%
M=3H_Y^_%C6_C/\0/B#X6TKX'>!?VC['P1;VGA_PS;6?BKPC^TQ%<^/O@?XE\
M!^/AXK\6^+K_ .)^O^#?AGX0$'B:ZT_PI?\ @#QCX,U_X[W&JZ?I7B'^S=,\
M/2Z-JS?K]\ =(U+P]\#?A'H6M:?=:3K&B_#7P9I>J:7>H$O--O[#0+&VN[&[
MB1G$=Q:S(\,Z!CAE8 G!- 'GGP7^'/[*G[//@KXL>+?@AI'PU^$?PRN_&_Q
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MX9T;28]3TQ?[+N5?3F:U/YL7%W\<_AMHX>^O?VB_A_\ %CP?+83^(?$&L?\
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M4=%UB]\4>#=+;P?\0/#DOQ/^#D7CCX1^&?%GB@--XG@\/ZUJ?B/3/GGX=/\
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M23LI3A%^]\,)4H2<II\L9-UE*G!IWC&27=--Z)I7LKZ]==EOTWOIOT/V)(0
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MG[:RA*I&WLYKG]G*-.35YNRE*?-#M&+N]8H3DUIRJ^G7NF]=-THOYM)+=G[
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MU[2;>TT*'XS)\3=)TOPY<:[X?LM*@M/&7C=O$@!XK\1_^"H_AZ'X(?$/QO\
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MB@ HHHH **** "DVC()&2!C/^??G\O2EHH **** "BBB@!  /U_4Y/ZTM%%
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M\JL[N4U=I61^PP(X (.,@GOG']2"2><FG$@=37\M7PZ\4?\ !9GP_P#L]?\
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M+$."E]6Y_83QCCB'&I##U*$:L*=:M"*<L7"+LZ=6]I62BKRY:4*CY-??7O\
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MX\SY;KS3E[KW4DOA:T^X_@]J+/\ !_P=I"/F"UU7QC?3HI^5[NZ\5:DL*RX
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MA+Q!IMW>_P!H?V9K>A7<^FZI9QS^8\4BQW<$D:W$($<Z,D@RI0U^X/B;XW_
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M^,?PN\>^(=:\8W/Q$9M:\<>(X+V\\/W\^F6NO02?T;K;J@4!L!2#@*@!P4V
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M*KJWT^&Y@;4+S5CX>\-#3Q#81?"'C+Q1JGC'6HM=UA;87T'@SX7^"8A:1&&
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M'P5IVD:+X>^'&D10ZE;:KH^LR7VJQWT NKR\MUMUL;3]7OVD- \ > /^"O\
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M)U?3[W3KZ(C,-U;2Q')4UN!PQQM<9!Y92HXXQGUZX]0"1P02 /HHHH ****
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MKPAB*E&E@_K6'PV'J87"<\E0E..)P]#E<?2M-\;ZSK^DVJ^&K&RUR2/3+?\
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M  [;PU^RJGA7XZ_M'SW?C;X'^ _A9K_P*_:=C^#?PO\ V:/A$EU!X:TSQ?\
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M#Q+X?\,^($^%^N^ O$_Q*TS0=4^#OQ%&E>"[GPWXW\,>V?LT?L+_ +:_P_\
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ML_%*Y^-O#/Q:_;I^-5I\'/&?QMO_ -O#X6^"_AU^TK\+_BQH/Q>T;]FKPO\
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MH **0GI[G'Z'^M+23NVNWK_E;\0"BBBF F /P'N3CZ\DTM%% !1110 4444
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ME6"FK)QK8VOF59:2C3HRO&/W=#*I6C+$5+*-^6E1E9)>\N6>)C3HR4;.TJ>
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MP1>_;&_9+L_!G[7WQ9G_ ."Q'[47[9.@?!SP39>*/C!X4_;9T?6_ FO?L_\
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M:M*+B_N?3L^HM%%%8E'%C_DH1_[%$_\ IW2NSQT]O\,<_G7&#_DH1_[%$_\
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M&%ZJ,')R#C!(ST %?RM_'WX@_MB?#I/^"B?@+X/2?'7Q]J/Q!\4?\%0+N_\
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M&# $9Z \XS@CJ0.G.0>!\P([4ZOYX;_]K'_@I5H'Q2_:C\<WFGR:[X,_9_\
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M-?-_A?Q9X@L+6XF\-:F/C#X6L66&>!9%TSXJ>&HB9/*M-:TK4TL#J\XBMO\
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MH:IX3\+ZGJ%_<>'+K4+[4/#VD7E[?W7@^[FU'PE<WMW<6<D]U<>%M1NKF_\
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M\#3^(O!%IX+/[1=QX\^)WCCPYJ#Z5H_P5T_7_B1/X+UC5_$ND^'/!W7^/?\
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MWXV00?#6+^PM$LK+]K/PC\9].M/ <GC+4VT/PEXK\,:C#IVL2Z6UU[+\"_\
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M226[DVE%=VWHM;;)Q.<(1YIM);)/F;D_Y8Q@I3G)Z\L(1<I.R6]S].OVS/\
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M@ZXFA?V-JNLZMX@T3Q>?&D,US;F_\,^(O#?AC298;B*.ZCM]1\RQ3YS\)?\
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ML- .M:=>:#XEU+5-<^QR>*;Z-]+T2SYA/VBOVV_VY/&__!NWX+UW]K;]I/\
M9)U+]N+]G3]I6V_::\9_L[>-M5\">,OBM9?#O1-;N;KXAKX<T/3SX.M_B/\
M$KPEX)6\\#^.QX5UC4?A]K_C+_A)O"NF6O\ 96G6<UJO)WO&35^>.L%SU4VG
M*\^:,I+W7[9?6:\;^[*GO'+ZHK6YX6Y>2::G:%)Q4DK04)QC-)ITE]6H2MK&
M=FI?VRWVE6$.E6'AK5H+7PCX1:V,%A\/O#@>[\0^(K)&!>UU :6CSP6,P=1K
M.G:.L\+OYPU3Q+=Z;<W,+6]2M+28:/)XKM(M(T'3IH&\+_#RQCBO;_4[VP51
MI\M_8Z89HKQM/ B:PT33S-I>FNBWVH7\Y2(V7\W7_!"GQ/\ '#X9?M9?\%I/
MV'_B%^U=\</CA\(?V./V@_@)I7P+\5?M%^)(?BM\7M"T7XHZ;\<SK>AVGC+5
M8;R_OYM5T_X?>!FAT2&TD\(0:QIGB#Q)X:^''AG7O'7BA)?Z2T#:?#-J%JD7
M@VQN?+2Y\5^*F.J^--8WX$45E8WTUQ):>8K!M/AU6:XEM9E:R'@Z)"N'&;DH
MR3E"3E-IJ3BU4J.U1TY\LY.M4C)PE6BL3C7&34)X6+3CG4H0A*4&HSCR4TTX
MQ<94J=G3C./-",:-.47.-&3P^$YTG..)DFV3+)::I!XL\36C7?B.>*YT[P5X
M3M9([B?3HKE4-VL;J7MVU:]5(SKFM!A9:=9HMI'.T2 W!%:WF@&\AM7M[[XE
M>-WCN[J[$1DL=)M[1%MK>[DCWJ8_#7A>U80:?9,Z/KFIM(A?[5J.H:A%=TO3
M]3GDGE\.Z?/I!O(UCO?&7BX/J'BC4HE)V_V=HL\B26EN26DMQJTFEV5A<*6B
M\*75M(">WT7P_9:.EPT9GN[V]>.;4=5OI?M&IZC/&"JRW5P B[(P2MK:VT5O
M8646(+*TMX$6(95*L(W2<9-1C#V48Q2Y:3<Z=&24W"CA8U&ZE2BYU,3B:S=3
M$.*^'2G1E*2DDU>4ZBK-R;YZL5&=:+E&,JN)<$J=.LJ=/#X>CRPH*5K39X7\
M.Z?X5T.QT'38Y$L[%9<27#B2[O+NYGDO=0U2_N/O7>I:OJ,]UJFIWD@,UYJ%
MW<W,V9)79N<\0Z7-I.N1^-],MI9I(;%-+\265J"9M5T2%VFM[F&-,F;4- N'
MFN;2,C=-:W%_9QM&UP6'HH QC_)XQS^'%(P!'0<'(SCJ#G\QR<@@@_C7+&K.
M,I5)?O'54X5X2>E6%1+VT)2YM+M<_,K.,H0<6G!7[94*;IPII<BI2ISHN/Q4
MITK^SE'ORWE'E=XRC.<6K2/&A9:/H]OJ,JPVVI_#7QDEQ=:E$J"ZT_1[G5$:
M/4+F:':VWPYK"L7U!2NW2KSS9YEAMY)GAK7VE6%KH*>&O%\T]YX4@>TO/#'C
M:.Y8W?A][1TET:?4]5A,DNE:CH\BI)I'BS<=/N;>%8M7GM;E@NI]Q<^&KVQN
M;J_\*WL&ES7$KW-YH][ ]WX>U*9P6DE:WBDBNM(OILE'O],F2!W+3W^EZG($
M4\?&PT>=8;5F^'FH7,PC32M31=9^'>LW<C%2-.GAELH;.:Y8SFTAM;GPKJMS
M-B\U'P_?1J().V$U-WC5DYWA.]^6JITH>SA6FDIRCB(4VZ<L12A7H8FE98JF
MES6\^5%PM%T4HVG!))NFX5)\\J,-8PEAW4M4A0J3I8C#U;_59O0@UBR-S%I4
MOB]IXKW0V:Z\,_%/PY!&ZV_VI4C-QJEK;1W!TJ.^MBRZY!<6][X+U*VB>YN;
MG3DN(=.M8[^T6:>R\0:NCV.I0VBQZ=\3/ X^TV=SISYEBAUO2\7KMIDA='%O
M/%KNC(R&[>]TT+&JV=J:/-G#_#74YYRV5(UWX::O<SL&+8/]EVUG//+*1(0G
M@7Q!J>H-)AM3ME6:<EC32)Y+JZ@?X?ZC/*TDFLZ0ZZQ\/]9N'8-OU6TDCLHK
M.>:0Q/<7-_;>'M1:5OLMAXEOU!DDUA)1Y5%6NI1ARI64)N]2G&,/:7IS;YJE
M"A]9PKDY2>"HN[64X)WOR^ZXNI[2ZO.,?W<JDI^S7M86C"G6K/#8E)**QE9(
MS+_2X9)(_$E]')#>RPH8/B9\.6:22XMHMQBEUW0[?[<U_9JP53'Y'B/3V;?-
M<0V,$?R\3K5H9Y+?Q1J.E3>(X-K+I_QC^"<DA\5V$4$A9O\ A(_"&F27=WXA
MLX)DW7MOH \5'4[HFWF\$V5G#(X])O NE--J%\K>#+R<^>_B[PYC4?!FJNX)
M2Y\0:7*ACM?. 1[BYU*VAD@C9;73_%[RDRCS+Q,D.EZ@_B/7HM7^']]=".9?
MC;\*&CU;P7K=N%98G^(WA:YM-8M[.(VL5R]QJ/BO0?$6@>'-,D672OB=I&JW
M'^B[T9R;CR\R;4J5%J[;T5X05)N<H)-*6&PTJZ:7*\M:DTN'%TH1C-RY&HN-
M6KSI<JY9-QG552*I*=XKV>+Q"P\XM\RS'FA"]%V_MVWM/%%U%:_$[2+5Y[:P
M^+?PBN5T?XE^'FA\J.]MO$7AW3)XCJLMC';S2>(K;0)EU)YVAT.+X:2LLY,\
MDA\16$>M7$5K\8-(TZXDMXO&O@)X_"OQA\(7:HKW-GK&BVLNE&?5+-)U.I:?
M9R>&]:LH(S:-X0U*]E>-J=\)3-%XM\6Z:]E>WEI:O8?M&_L\M//9:MI\4,/V
M*?QQX%*^*;\:=&D\T.G6FN6OQG\ :58PW&O:AXA\+W-U#:P27D%Q>+9>+];M
MX?$UO):Q?V)^T)^S_(\'B6+3(W)MQXI\%6DNO2Z_H]O,Z0_9M+G^)GAW4[V.
MYU6_\%>%[2%(X-^:"479Q49.G3<7'W9M2O3IRI2@H2?-)/#8>>&KS>E7*ZC<
MHOBFJB<U-PFI0C5FIIR3IJ4$JE95:=1U(QY&HXG&4L3AZ<K.EFU%)2.U\-^,
MO$R6=Q?^'=4M/C'X:M)5MM1AM5M/#7Q4\/3)&9!8:SHNHIIFFZCJ,:L@DT[6
M(?!FM6\"O).FIW<BK)Z/X=^)O@7Q!>0:58>(K"'7KDW(/AG5FDT/Q9!);H9K
MB*Z\+:Q%8Z_:RPPXN"LEBH:W9+N(O:RQS2>#RE];MK/Q3J<$/Q#T^"%K?1_C
M=\$)&TSX@Z+!"_-MXG\):7<7=SK5O8R^6^H:?H4WBC3]5U(LNH?"W2+&!T#;
M.UL+_P 1>&_B?J.CZ)\<D\)1ZA8>'/B/X*46?Q!\+6UREQ#J</B3P!;3PZ5X
M@O+*UDO#J%]X:CMO$BWU_-I^A_"^V>:ZF.+P>#J>VE6C6IRA"O&$L+'#1<L:
MHS^K4<33Q'L,)"%2M'DKN<<OS&$.:5.AB9I)ZO,,SI*C]5EA:JE5PDZD,:\9
M.,<!*K36-KX:6%CBL?.I3H3]IA8P_M+*I34(UL1A*;FX?8 8<$'@\G//7&#N
M (Q@@CIQC/M)^/X_Y_*N"\-^//!OB9;5="\0Z9J,LXNUBL([F.'5(IK Q#4+
M.YT>X^SZI87FFR30)J>GWEG#=Z9++'%>1PR$J.Z0@J, @$9 /( STR../_U$
MUXTHU*;Y:M.=*:2;C4A.E)K;F4:D8MQ;4DI1=2#Y=*DF[+ZJAB*.(BYT*M*M
M"[BY4:M.JE)*[C*5*<XQFHR@W"2ISCS>]32LV^BCC)Z9[^OMFB@Z#Y=_:<_9
M[U']H*W^#-MIWBVS\)'X4?'/PY\8;F6]T";Q FNVVA>"_'_A.3P];QV^M:*V
MFW-S-XU@OTU61[^*!-,FMFTV5[M+FW_.3PK_ ,$D/$'P\C^$4W@;XH_"B&Y^
M%7PE_P""?/PN@TG7/@KJ$OAC4KC]CGX>?M,?"OQ_XP@L-+^(>GWFG>(?B9X2
M_:'@N/!-Z+VZNO >K> M''B.?X@:1,NFV7V5_P %!?VU/$7[#OP@\/\ Q#\&
M?LL?M$_MA>.O'GQ$T?X4^ OA%^SGX2/B'5Y?%GB#1->UK3-8\?ZV4NH_ /P[
M1_#SZ/J?C,:3XCN++6-=T2W'AZYM);J_L/S6^$'_  <*?""\^$W[<GB;]KS]
MFCXY_L8?'#_@GMX=\+>)_CU^SGXRNO"_C+Q+JVG?$!H;?X>6WPM\4R2^"M.\
M3:KXMO=1\,VNGKXATOP?HU[!XU\):UH>LZ[X?U&\UC3P#U7]GO\ X(]?\*A\
M0_#K5?&?Q \!_$*#X6?%CP[XSTK4M1\-_%_7_$/C?PGX/MO&T7A>Q\96?Q*^
M.?C[P1I'CBPNO%XU"3Q'X#\)^&]*N+^*_G3P_;I?6]OIV1;?\$I?VC;OX@>)
M?C)XV_:B^%GQ)^)2ZQ\'/$/AB+QM\&/B'K7PY\::O\(_&7[16M+-\:_ EW\>
M9M$O-'USP]^T+=QZ7X3^$UK\,/"_@KQUX \"^-M.TK5H].O=!U#G/V*?^"\?
MAG]H3XG:_P#!O]JO]DKXT?L#>.YOV?-<_:X^%)^)NIQ?$+PO\5OV9_#VC-XB
MU?Q]8ZWX9\,Z+J&A^)--\-Q3^(;SP0V@ZL1IMM=1VVNW>J_9].F\G_9@_P"#
MCWP)\??C_P#L^>"/'O[&'[0'[._[,_[:7CGQ-\-OV*?VM?B'K_A"Y\-?&GQI
MX8U'^R?[(\5> [.WL[WX<KXBU@V/AWPW+IGB?XBS:CXBU_0;9K2VT6[O]=TL
M ^FOB;_P2:\>_&O4?C5#X^^.7@'PKX<^-WQ6F^,VNW'P:^$6L^#/&'AKQ1XS
M_P"".WQ-_P""47Q*T/PCJNM?$GQ/867A73+GQ7X<^//P@CO;&\U#P?/!XI\$
MZ_<>*)-5L/%MEU.C?\$O_&/B#QW;_%'XO>//@%/XHN-9U>^U7P+\(OV?M6\#
M_!.SM1^RK\6/V;-!U#PEX&\2?%#QO?:/XNO+CXN:GXC\<Z]?:YJR:]X6\,^!
M/ -E9Z<_AE_%.J?I7JG[1'P9T3X^>$/V7M6\<65G\>?'WPW\5_%WPE\/'T_7
M);[5_AUX(UO1?#?B;Q*FJPZ7)X=LX-/UGQ!I5G'8:AJ]IJVHF:YN-,T^\M=.
MU*>T]KH _++]D[]@CXG?LR?&#0/&-M\6/A[+\.],^!O@'X7^+_"/@[X>^-M(
MUKXL>,_ WPX\$> ;'XE^+)_%OQ6\;>$O"^LQ)X2>=YOASX4\+ZEX@TR72=+\
M6:GK1T875[^I:YP">I )'H<#('XY/XTZB@ HHHH XL?\E"/_ &*)_P#3NE=I
M7%C_ )*$?^Q1/_IW2NTH **C=MI3KUQP/7_ZP/Y4GF+@'!Y!Q@<X&.G '\L$
M$ 9J'-)V?=+9[N_^7SZ7LPM^/E_7^?R):*8&5L=.^,],#/M@=.WIU.,4[(Z$
M]\<^IZ#G]/7U)I*HG9]'UO=?^DK] %HIH(Y[#/'8<_@.WU_E0,Y;MT('/^&.
M3UQGZYI\^VF[L];VW[+5W5K:,!U%%%6 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %<;H'_(R^,O^OK2O_2
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M?B%^R]J/[67C.V^(O[0OC#2?@5XJM_B/\3;GXC7FH6_B7X9WUQXV\4^ M?\
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MJ\>:3>>&_%NF^(/'WQ \)>++3XDZMXM@BTWPC*;W5?%6J:T_AO3O#&F#6O\
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M,#],?AZ=?ZC\*^?3;UO?2W3LOR>BV327<^WNWJU_G;7R[):6ZV/R"_X+)_\
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M#VAS?6;N,>?EC1=I->]RIRCIS?S6LGNVD+WO[MNFKO;STT?D?QYZG\9?"/\
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MMZ=%HVK>(+_4-.M]?T/P;\,O!-KI^H:EH#SC2?#XM+NTN9KBQFCB .<\/_\
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MK>&O@U\93X1_9]M/A-K'A7_@DVOQ,\%V6F^-KGXE:YXW_P""E_C;1OA/JK^
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M^BTGP'XI^(WB2WU[3]9TS]D33;?PYXGB3ZZL_P!LKXC_  8_8JT'XBZK\1_
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MB#XC^"-;^)_@Z;]@VUT;XM6&C>(6\7>'M)_99U;3KCXB0^%M?U_5-6U:PO\
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M\(_!;XH_&[XP6'BGQAXJ\;?'35=/NO$UQK]UIEII&FZ5HFJ^)M7T#1]*\/\
MAW3-%T:2YTR3Q;JEG/XKU.RO_&&MZ=#I-CKFNZA#I%BL7T]110 4444 %<;H
M'_(R^,O^OK2O_2 5V5<;H'_(R^,O^OK2O_2 4 =E1110 5'("58#<2RX !P.
MO7/8\_B!CM4E% 'Y>>//^"3/[-WQ'^.7Q1^/7B'Q!\4XO$_Q9T;QWI'B+2=-
MOOAG:V=G)\2O!FE>!?%NHZ?XTD^%ES\9=1CDT#1--A\.^$_%OQ1\3_#WP)+
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M_#;XX>-;'QS\#?%<^L?$6+X7? WX.^%?&/@875K^S-\2M,^'UA8_$/\ 9_\
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M45Q?_"(W/_0V^*O_  86O_ROH_X1&Y_Z&WQ5_P"#"U_^5] ':45Q?_"(W/\
MT-OBK_P86O\ \KZ/^$1N?^AM\5?^#"U_^5] ':45Q?\ PB-S_P!#;XJ_\&%K
M_P#*^C_A$;G_ *&WQ5_X,+7_ .5] ':45Q?_  B-S_T-OBK_ ,&%K_\ *^C_
M (1&Y_Z&WQ5_X,+7_P"5] ':45Q?_"(W/_0V^*O_  86O_ROH_X1&Y_Z&WQ5
M_P"#"U_^5] ':45Q?_"(W/\ T-OBK_P86O\ \KZ/^$1N?^AM\5?^#"U_^5]
M':45Q?\ PB-S_P!#;XJ_\&%K_P#*^C_A$;G_ *&WQ5_X,+7_ .5] ':45Q?_
M  B-S_T-OBK_ ,&%K_\ *^C_ (1&Y_Z&WQ5_X,+7_P"5] ':45Q?_"(W/_0V
M^*O_  86O_ROH_X1&Y_Z&WQ5_P"#"U_^5] ':45Q?_"(W/\ T-OBK_P86O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %> HH# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^,I?#-A?W&L:)X82"PU5KZ&WG71_$[V<?AK7@#D/V[_^"D?Q7_;3_P"",_\
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MFSN=(U:Z@M+ME6[1_P"N>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[:8X]/\ DWZOM#:?[Y_7_&C:?[Y_7_&N_P"LY)_T)LP_\2%?_.$FTOYE_P"
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MMJ?_ $/U?9W'(\SD=1GI]>:7:?[Y_7_&CZSDG_0FS#_Q(5_\X0M+^9?^ ?\
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MA7_SA"TOYE_X!_\ =#XQ_P"&_OV<_P#GV_:._P#$)OVU/_H?J/\ AO[]G/\
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M_P" ?_=#XP_X;^_9S_Y]OVCO_$)OVU/_ *'ZC_AO[]G/_GV_:._\0F_;4_\
MH?J^S]I_OG]?\:-I_OG]?\:/K.2?]";,/_$A7_SA"TOYE_X!_P#=#XP_X;^_
M9S_Y]OVCO_$)OVU/_H?J/^&_OV<_^?;]H[_Q";]M3_Z'ZOL_:?[Y_7_&C:?[
MY_7_ !H^LY)_T)LP_P#$A7_SA"TOYE_X!_\ =#XP_P"&_OV<_P#GV_:._P#$
M)OVU/_H?J/\ AO[]G/\ Y]OVCO\ Q";]M3_Z'ZOL_:?[Y_7_ !HVG^^?U_QH
M^LY)_P!";,/_ !(5_P#.$+2_F7_@'_W0^,/^&_OV<_\ GV_:._\ $)OVU/\
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M?J9)_P % OV<8D>1[;]I#;&C.VW]B/\ ;6D;:@+-M2/]GQG=L#A$5G8\*I)
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M1M#GC_7*/Z\?E6Q;:C9W8!@GCD!&048..W *YR>1^= %ZBD!!Y'(QG/;FEH
M**** "BJ=W?6UBADN)$C08RS,!@GH,=?R]>AYQ@GQCH0.#J%L/K(O^(_D* .
MJHKE/^$RT'_H(6W_ '\7_&C_ (3+0?\ H(6W_?Q?\: .KHKE/^$RT'_H(6W_
M '\7_&C_ (3+0?\ H(6W_?Q?\: .KHKE/^$RT'_H(6W_ '\7_&C_ (3+0?\
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M'X@T"2]NWTV_C_>VS7$I3[QKSSX>_ +]E'X3_$_QC\:?AM\*?AUX,^*OC_\
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M? _AG]H^P_:QT^RUKXH^)/@EH6E^/+FS\2^*-%\.^%)/!>J:'>:U;:#^S?\
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M_#KQU?>'[2W\1>'-'\*>(8?%WA3P\M_IS6<FJ>&/"OBV"/Q3X8\+ZV-2\/\
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M_"9:#_T$+;_OXO\ C0!U=%<I_P )EH/_ $$+;_OXO^-'_"9:#_T$+;_OXO\
MC0!U=%<I_P )EH/_ $$+;_OXO^-'_"9:#_T$+;_OXO\ C0!U=%<I_P )EH/_
M $$+;_OXO^-'_"9:#_T$+;_OXO\ C0!U=%<I_P )EH/_ $$+;_OXO^-7+?Q-
MH]TP6*]MW8C("RJ3[_+G/^/;/. #?HIBR1OC8P;/3'?OQZ].<=.]/H ****
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MQ%_P5E_:J^'DVF?#'QY^R1\!Y?VA_&/CK_@GUIO@'P]X,_:I\5ZU\'9_ /\
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MD#$B'5[^%.6!.%CC51S]U0!P *W=0_X\Y_\ KF__ *":P/!/_(N6O_7[K?\
MZ?=2H Z;R(/^>,7_ '[3_"CR(/\ GC%_W[3_  J6B@"+R(/^>,7_ '[3_"CR
M(/\ GC%_W[3_  J6B@"+R(/^>,7_ '[3_"CR(/\ GC%_W[3_  J6B@"+R(/^
M>,7_ '[3_"CR(/\ GC%_W[3_  J6B@"+R(/^>,7_ '[3_"CR(/\ GC%_W[3_
M  J6B@"$VUNP(:"%@>H,2$'Z@KS6#>>&-/N"TUHG]E7@):.[T\"'YP<J9[5=
MMM<JW1_,3SMI(BFB8[QTE% '(:7JUU;WC:-JX1+^,>9'-&#Y.H0$[!<6^?\
M:7$L>0\$A,<NX!))>O!R,CH>17)>,;?&F+JT0(NM$F2^C=1\QM0R)J$3'KL-
MIOFQ_P ]K>!N=N#T&GSBXM8I0<AT1L]LE0, 9X P* +M%%% '':E/(GBCPY;
MACY<\^H^8N>&":3?2#//9U1AZ$9["NOV)_=7_OD?X5Q6J_\ (W^%O^N^J?\
MIFOZ[>@!NQ/[J_\ ?(_PJ,- 96@&PRI''*Z #<L<K2K$Y'H[0RA?4QOZ5XWX
MS?X]Q7^J2_#^W^%MYI1B$&B67BG_ (2FWU%+EM-A_P")CJ^HZ;<O;_8HM:>=
M)=+T_2Y+LZ3;FXCOWOYXK.#\V?VW?%7_  4NTKQ9\/%_9?O/!VAP7'A+7?\
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M)X9&SS%;0+T3D [RBFJ054CH5'\J=0!3U#_CSG_ZYO\ ^@FL#P3_ ,BY:_\
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MGPL^,.F^/=5T[]FKXJ^';,S"\NKWPCXTDTOPSK%L]]!'K/A?7KO_ (2&ZO\
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M %T3_P!IUW5<+X\_Y L__71/_:= '<+T/^\__H;4ZFKT/^\__H;4Z@ HHHH
M**** "BBB@ HHHH **** "N&\=';!X>8=1XELP/;-AJ>>WH,=NM=S7"^//\
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MQ_LO4/B?:>"O#4'Q$OM,2QL]+BT^\\:Q:6GB2ZL1IFG:?IXLY]3DMULK"QM
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ML1@X>PK*<RBBBOYZ/Z!"BBB@ HHHH *^$OV\]4T?1/"_P&UC7AH)TBP_:4\
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MMZ56-C9&;[0;.U-QYXN?/\B+SOM(M6L1<>;L\SSA9,UGYN[?]E9K?=Y+%#:
MP,#H.!0!^.W_  6MN[RR_9<^'#V5Y=V4LG[0WA2.62RN[BTDEB_X5K\6G,4D
MD$D;M'YL43^6Q*[XTD*ET5A_-YX0U;1I=2N1X\\3^-;3118LT<GA[4-2N]9:
M\%W:;8["VEG73YY6MOM64U:^TVP$9D<7@NTM89OZ/?\ @MO_ ,FM_#;_ +.)
M\*_^JU^+U?S"D ]?\_Y]>OH:_P!8/H?Y?A\7X$8>E*]&>(XJXQC];H4\+'&4
M;8_)&I4,15P6)E"22:7.JT5SR:IW=G_#GCWB*F'\3*LTW4A3R/()>PJSK/#S
M;P^8\RG2A7IIJ=U[3D]FY\L>:3:N=_XJU/18/[-/@SQ?XRU M+XA755U6]UB
MV$,4>O7)\,S6S3M;9>Y\.26L>I6JK,;74K6XN#>RKJ"V6F?OO_P0ZOKZ]\!?
MM#?;;Z^O1#X[\&+%]MO+B[\H/X8NR_E?:))/+WE5W[-N_:N[.Q<?SD@ 9QW_
M ,_Y_P#U5_19_P $,/\ D0OVB_\ L??!?_J,7M>M]*S T<'X"\34XWK3AF?"
MUL37I83ZTU+B:$K2JX?!8/F45+V</<@U22IM2C<X/!#$U*WB=DS?[N,L'G*=
M*G.O[&T,GFE:G4Q5>*]Y.IL[3E)Q<;M'[NT445_D2?WD%%%% !1110 5P'BG
MGQ+X..#P-<SD>VE5W]?GA^W?8?MFC5/V>];_ &._'_@7PIJ%EX^U73/C!I_Q
M-\':#XN\$Q_"G4=.M-0UWXA7EI</I7C"[U'X?MHBBR\->!_%7A_5?%2>))["
M2XC:&WU'3+I4W5JQI*=.GS*;YZG,H+EA*5FXQE;FY>6-UK*45;72*D^2#GRR
MG:WN05Y.[2;2;2LKW>JT3/T.7H/H/Y4M<+\,_'WA3XI_#_P3\2? OB6P\8^"
M_'GA70O%GA7Q7I<%Q:Z=XCT+7=-M]1TW6;.TO%2[L[?4+6X2YCL[M$N;59/L
M]PHFC<5W519K1[K1Z-;>3U_KN7T3[I/[PKA?'G_(%G_ZZ)_[3KNJX7QY_P @
M6?\ ZZ)_[3H [A>A_P!Y_P#T-J=35Z'_ 'G_ /0VIU !161K.NZ/X>TV\UC7
MM4T_1-)L$62]U75[ZTTO3+-'D2%'NM0O9H+2U1Y9(XD>>6-&EDCC!+R(K<'_
M ,+Q^#(X/Q:^&61Q_P E \(D\=<YU@<@\'OG-:TZ&(K)RHX?$5DI<K=+#XBJ
ME+^5NEAZB3ZV;3LT]FF\*N*PU!J-?$X:A*2YHJOB,/1<HW:YHJM7HN2NFKQ3
M5TU>ZL>IT5Y;_P +Q^"W_17OA?\ ^' \)?\ RXH_X7C\%O\ HKWPO/\ W4#P
ME_\ +BM?J6-_Z \9_P"$F*_^9C+^T<O_ .AA@%ZX[!+\\8CU*BO.=/\ C!\*
M-6NX-/TGXF?#W5-0NG$=M8:=XV\,7MY<2$X"06MMJDL\SG!PD4;L2" ,UZ"L
MRL2,," "<C&,C/\ GCD<C(!(QJT:U%Q5:C5HN5^55J56DY6W<55I4G)+JXJ2
M75HVI8G#UU)T,10KJ-N9T*]&LHWVYG1K5E%O6RDXMI-I-)LEHIF\8)YX&>P[
MX[GUKC;SXC^ -/NKFRU#QOX/L+VSE>"\L[SQ1H5K=VDL;*DL=S;3W\<T$D4C
MK')%*B2([*I4$@&:=.I5;C2IU:LEO&E2JU9)-V3E&E2JN*<O=3DHIR]U-R]T
MJI6HT4I5JU&C%W2E6K4J,6TN9J,JU6E&345S-1E)J/O-*/O':T50L=3L=3M;
M>^TZY@OK&[B2>TO;.>"[M+J"3E)[:YMI98)X7'S++%(R,.A)XJ\K!AD?KU'L
M:333LTXO6ZDG&2L[-.,E&2::::<4TTU))IHJ,HS2E&491:34HR4HM-)IJ47*
M+33334G&2:<7)--K7"^//^/;P]_V,UG_ .F_5*[JN%\>?\>WA[_L9K/_ --^
MJ4BCL[?_ %2_1?\ T6E3U!;_ .J7Z+_Z+2IZ *>H?\><_P#US?\ ]!-8'@G_
M )%RU_Z_=;_]/NI5OZA_QYS_ /7-_P#T$U@>"?\ D7+7_K]UO_T^ZE0!<\5>
M*?#G@?PSK_C+QAKFD^&/"?A71]1\0^)O$FO:A;:3H>@:#I%I+?ZMK6L:I>R1
M6FG:7IEC!/>7]]=2QV]K:PRSS.L<;$>&_P##8/[+3>)8?!T'[07P@O/%$^@^
M)_%$>B:?X^\.ZC>CPYX*TBXU_P 6:Y-'8WMQ]FTGP]HEK<ZKJE_<F&VM[&":
M?S'2*0KV_P >O'FJ?"WX*_%+XDZ+X>T3Q9JG@3P+XD\66?AOQ+XRT?X>>'M9
MDT+3+C4&L=<\<>(8IM"\*Z5-%!(+_6M7C.GV-L));IDB#2+^-7@OQOHNA^+/
MB+\)M=_:.\'I\4_CMX'_ &F?%L=GX0_;M\#Z[\0O@)<6W@*TUV+X>_ ^&3X8
MPVGPF^"_@/1X=9UWP?)J6H::OP^OO"\7BS58/&-JTZ>%[_<TJ3K8JO3HTZM2
M&#PJO%U98ZK9TVZ<IQ=6C",HRE3IVK56_9T;U)1MMAL-B\QJUL'E>!Q6,QF
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M0K>PUSXJ?$GP#K'A2_DU#35U6VF\!V/B_4+Y]#\_4-&$VDZ+]I^\*^??C?\
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M[!XR%*57,<;AZ485)0J*$I8AQ="G4FOD(\(^'CH?6*O%T,#2]IBZ:>9>!/\
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MKK6H7ALM*<^O2#*D9P&PO/3OUSP0>,@C!'!!!Q7F7PDUG3_%'AF^\66?PO\
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MX>TL+*"25W,%K%'B-/2#\2_"X* P^+@7=8U'_"NOB%N+N2$&/^$7R-Q'RD@
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MP+K.FZ[=W_Q0O-6M=+U'3(]%?3-"BTK5/"7AX7VNQZAK>G:U<V]_XG\>>$=
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M[KO[!M_P3+_X+4ZR3IFN_P#!270=$TB\ AU'4?"?Q ^*UAKD-NY".;27P_\
M#SP=J;N4.?+B\1Z:CE0LDX!W+]+?!?\ X(Y1_LE_#7XD_$#X)>,]'^,'[?7B
MCP[J^E^!/C]\=9M4T7PA\,M;\8;]*\2^+_!^AZ58^/\ 5-/\1VFE:GJVHP>(
M-:/BKQ-K>II%I-SK6E:#K6O6EQ]6^+?"CA?%9EF>3XG(,3FO$6/C/'0RW,.)
M<YK9C5KYK',H8?-<YSS(LFP'#?#%/,W1S#.:668#,<TS+"X1X"CRT9.,_D/]
M4/%OBO"99EN=8/B##Y5PS@)4\!4S/*^&\EIX"EALKGELL3E>2Y-GN=8[B7BF
MKE:Q&793/,L?EV49?B,<L=54ZU*Z_G_O_@'KWQ0^*G[/O_!(_P"!6KP7 \)^
M-9?&'[5WQ&T1&O\ 2=5^/][I(B^+/B*:5;AK?4O!_P"S!X"@N?A1X!B>6P@U
MGQA!XJW)]L\265XWZ\^$?^"_7[#7[.WAS2_@-X&_9W_:!TKPE\&K>3X8:#9V
M$?PG^SC3_!%Q/X>%SYMQ\1H+FZGOY;"6_N[Z\C&H:C=W4]]J -W<3$_8/_!)
M/_@EUKG[!=O\4/'7QGU_P=X]^//Q%N[?0XO$G@^^U[6=*\/_  YLGMM6DTZW
MU;Q-HGA[6+G7_%_BLS:UXQNI--2&Y31?"T*2SS65W/-\>>(O^">W_!<'4_$?
MB/4-#_;V^&FGZ+?^(M>U#1K";QIXR22QT>_U>\NM)L72+X$RQ126>G26UM)%
M#/-'$\3*DTB@.?.S7B;P\XUSK%9%G^=9;B^'>'J%'&83-\RXASSANCQ+Q9G-
M5XKB?/::RGA[.YXF/^ZY;EU#&X;"K 9;@(4L-[DE&?I91PKXC<#Y)A.(N'\F
MS/!\2\18BM@L5E.6\-9+Q16X9X0R6E2PW#'#]2.:\19)3PU16Q&9YC7PF)QD
ML=F6.JU<3+G4YO\ %']I7]OSX$>)?VY])_;1_9A^'GC#PK!XGL+BW_: ^$/Q
M4M_!%KX6^*<6NZ?/X0^)6A;/#'B+Q/I\FA?&'X=7$FC^+8]2LH;BQ\61OXSM
MAJ&J7QFL_P!%?^"6GC_6_P!D+_@H)IOP"^$O_"2?%']D']N+PI:_$[X,ZI:J
M-1N]-\)+IFOZSX4\;ZRHDDM['Q+\,'T7Q7\%_CE;^?!<G6/#ZZI=+(-#T"RN
M_H(_\$Z/^"Z@_P"<@/POXR0/^$X\:?U^ Q/.!G! X[<Y_3K_ ()Z_L??M+_!
M'_A)_'W[:OQQT[]H7XTS?;_"GPXU73;J?5]!^%OPSU1M&U7Q1I?AC5-3\)>$
M-7@U/XB^)M(T?4/&<(T\:?+!X/\ ":6[R3Q:A)/V<;<:<%87@K$9/EF9<+9Y
MAGP\N%HY5@^(N(L[S7%4Z=:-?AO,:F)S#A/)TL3PKCE6JX;'SQ*Q$<JK5,H?
MM*4Z$J7%P-P/QOB^.<+G&997Q5D5=<2_ZU2S?&<+Y#P_E6"=:C[#BC 1P^ X
MISN-2AQ7@52I5L L*Z#S6G#-54I557]I^I$1)C0D8)&2!T!_,_EGCI7$^//^
M/;P]_P!C-9_^F_5*[A %50!@ <#C@=N@ _("N'\>?\>WA[_L9K/_ --^J5_(
M2V7ITM;Y6;7W-KLV?VI_7]7;?WM^K.SM_P#5+]%_]%I4]06_^J7Z+_Z+2IZ8
M%/4/^/.?_KF__H)K \$_\BY:_P#7[K?_ *?=2K?U#_CSG_ZYO_Z":P/!/_(N
M6O\ U^ZW_P"GW4J .KHK,UN74X-'U6;1;:UO-9BTZ]DTBSOKA[2RN]42VE?3
M[6\NHTD>VM+B[$,-S.B.T,+O($8J ?Y_]7_X*"_\%8_#W[2?@']DG6_V/OV/
MX/C?\1_AEKGQ9\.:;;?M!>.KGPM)X0\-WM]IVK27GB;_ (1)!::FEYIMTMKI
MPT^X\^+RI3<QJ9#%$ZD86YE+5I+EA*6KT2TZOH95*T*7+SJ;4FHQ<(2G[SVB
M^79R>D4_B=TMC^A.BOR(^)G[>W[2?PRM/V<?V<G_ &=O 'CG_@H_^T'I?C+Q
M'/\ !3PC\4+N+X&?"CX?^%_$&OV?_"T_'WQ1OM%DUI?"<FBZ?9S6NG6'AYM5
MUW7K7Q-HFES1WFEV,&JO\+_MH_MC?!7]HSX+_ #]NOX ?"FRT']HW4M1\-_"
MG]H']E+Q5\0_''PYTCQY81026_@?XG>&_'/A32O%/A9]6>]L;'3_ !2\XTFX
MOKZS%M:7FG6_BK4?""=6*:3YM6DVH2<8REM&36D7JM]KJXO;T[V]_P"*,6_9
MRM"4TG&,WM"3NDXN[BVD]6?KI17Y(>+OVXOVF_CE^T)\8OV=_P#@GO\ !SX0
M>-(?V;M3M/"?QT_:%_:1\<^+/"7P@TCXFW,4\MQ\+/!.@_#S0M?\:^,O$6A"
MWN;/Q-JR#3M.T#6+*^TV_MTA;0]1U_U?]C[]LGXK_%CXL_&/]F']I_X%)\#/
MVD?@CI?A[Q1?OX/U[4O'?P5^*O@'Q.R1:?XW^&/CB\T31IXQ9W%QIUMK?A77
MH$UG2SJNF;YI=13Q'I/AD]K'F45=W;BI6?*VKW2ELWHUIV?9C5:FY**<M92A
M&7))0E*-[QC-Z-Z2VT]V6NC/T8HK\6OB=_P5>N_ 7_!1GP[^R;!\--+U#]GV
MR^(?PM^ /Q3_ &@?[:O6NO!W[1OQN\"^,_&OPS\ VFGP@:-/9ZB-%T+2=5EN
MK@76EW$OB6:[^SR:/:VE[^F7[0WQ2U3X/?"7Q1XU\/>'9/&GC?.C^%?AMX'C
MO[?2SXW^*/CK6M.\&_#CPK/J-W=V5KI6G:SXRUW2+;6]9GN88-!T,ZEK=Q(E
MMITK+,Z].$*M23?)14Y5&HR;]Q7DHQ2;G)VM",4W.;C3BN:<41+%48TZ]5R;
MAAE/VMHR;_=QYI*"2O4;2<8*%^>HXTH^_.*/-?VCOCUXY^$.L> M+\.:5X(.
MG>-HM>B;Q!XIOO$.J7VF7NA69U:[GA^'_A"TF\9:]HMCHT<NI:OJ^AQ7MOH\
M*O)KG]CV<:7MS@?LP?&Z;Q?X@^)/@CQ)\8?"WQ1O]*U;P]KGA+Q)I4.E>'QK
M>F^*/#T-]KN@Z)X?BF2\>P\%>(K34M,59S>:M9V]U:1ZS,LQCC3X=^#_ .S]
M^T3XZ^,GB/QGXCMO@&WCGX'Z_P"'[/QUXL^(-QXY^,&J_$OX^:IX5\)?$JSU
MK4M5T*'X10Z'X/\ @=X<\4:):_"7X,Z%;:E\*?AUXI\4ZQXCT^#Q%\1/"FA>
M/+'V[7/A=\3OB9\7?B;X2\3^#?V?_$7C"]^'7PMN_$WB^[@\76VA^"KA]=^)
M5KH?B'P!IJ17'C&3Q#=Z+!8O? >*]#2#4],B635;JQDB6+X/&8C.:688;-J$
ML?6HU<P^K4,GJK$JG*%7+\5&I3IK#U*5-<]?#*K!XJCB9T*\9SAC(X-5'5^"
MQV)SNCF.%S>B\?7P]?,5A</E%6.*]E*G5R[$TZU*G]5J4Z:<\1A55IRQ.'Q3
MPU:-2M]=IX.->+_4E&)(!)ZD'.1GY21P>0?7D@]1V-3U\K?!+4O&7@CQMK/P
M!^('BJ]\=7GA_P (Z-XY\ >.]3C$6L^*/!5U<2:!K6G^(U66Z636O"7B:..W
M6]>ZGN=1T?6=)ENI6N;>>2Y^J:^TR_&QQ^&5;V53#U85*N'Q.&K.G*MA<5AY
M1AB,/4E2<J=1TY3@X5:;Y*U"K0KP2C648_;Y?C5C\,JWL:F'JPJ5</B<+6E3
ME6PN*P\HPQ&'J3I.5.HZ<Y0<*M-\E:A5H5X*,:JC##\3_P#(M>(?^P'JW_I!
M<56\*?\ (%L/^O:/^0JSXG_Y%KQ#_P!@/5O_ $@N*K>%/^0+8?\ 7M'_ "%=
MQW&]<K.T$PMO)^T&&3[/]HW^1YX1O)\X1XD,/F%?-"'<4W!><5R'PWC^(L7@
M+PA'\7;GP3>?%!/#^G+X]N_AO8Z[IG@*?Q3]G3^V9?"&G^)]1U;Q#9^'WO!(
M=-@UG4[[44MO+%U<22[C57XK/X;7X:^/U\8^.;CX8^%;CP;XCLO$/Q'L_%=K
MX$OO ND7^DWEE?>+=.\;7LL-IX2U/P_!<-J>F>(YY431K^WM]0))@ /0^%-(
MC\/^&/#F@PZOK'B"'1-"TG2(->\0ZF^M^(-<ATVPM[*+6-=UJ0+)J^LZFD O
M=4U1U5]0O9Y[ME5IB *_*WTY[*\)+[*;M4ORO=<T4KIV;TW5_>MVC??NVOAW
MZ?%MTU9CZK_R-_A;_KOJG_IFOZ[>N(U7_D;_  M_UWU3_P!,U_7;T#$(R"/4
M$<].?7'/Y5\]>-_ .M^&M5M?'GPD\">'/%/CI+SQ!<7D?C3XD^,O#&E^3K<%
M[<W8LH[6R\4:3'-J.K3HCB70OLVFV\D]Q90B8K$WT-119/=)^J3[][]W][ ^
M'-3T7]I#Q%XDL?%%Y\%/A-I6N0:[I-]#--\9/'&KZ<+;0;_4;33+C4SIEKX:
MM["^M8/L6LI!:>$_%MI?0W=]HU\D=S:QWEU)XF\-?M'>._"TTWCOX2_!K6_%
M%U=G1;+1=&^,?Q*\)Z9H/A'4=1\-7U[<ZEKNEZ9]I\0ZK!<VDEZ8+"QT%DD\
M-I;65^R:Q'-;_;NQ/[J_]\C_  I=JC@*,?0>F/Y$CZ&C^OT ^0-;3]H/QEX>
MDL/$GP2^'8:PN[8:1H,7QG\1Q02VFH:?XB\/:C<WOBW2-&TS4([N#0M41+[3
M3X?O;: W,\VG:GKEXT$FF8DL?[2%AX-T'P)8_L\?#.Y\,K-!IATJ/]HKQ9+)
MH6DZ9J-O?:3<W?B>_P#!EIK^H#RK<R,UJ+F\%_#IVDR0S:5JU_JF@?;)53G*
MJ<]<@'/UR.:7:O\ =7OV'?.?SR<_4^M 'QGI.F_'_P  '4_"W@WX'?#6Z\):
M_JVI:IJ.K-\;O%SW@34E33;R\-KXAT2^U.36!IMA:7=MHEGJ^FZ/=S3"T/B/
MP]+'/JDVUX7T+XT>"[76[SPM\+/AK!J]UI7@?3$CU3XP>.)[35XO#7AXI=6Z
MM?:#XE_L&VM=0O;S1]*FMX[VZEC1M1UEM6V6TDWUD54]54XZ9 I-JGJJG\!_
MA0!\8>%]-_:!TG6->\677P.^&EIJ\=Q(^BVMC\<O%M\VJ6WB;7IM;\5O>V^I
M^'IM"T>_M;Z_URZLEMH;N"5=3M;.SN--L[":TNH8?#_QZ\0WY\0^)O@S\.=/
M\7V36^N1WD/QE\:Q:#JGB[0M3\'V_A^4:?I,;"QT*/2](U_4+F&]TW4SJ,EI
MX5M[[389=0\0)IOVMM7^ZOY#_/8?E1M7^ZOY#OU_.@#X:\5Z;^T3X^N;R3Q/
M^S[\.1;1(^A3V\7[0'BZPO-;\./+'K$4.E7?A_1M'ALI9=4ATO[9J6IVD-[;
M2V6LZ7;Z?JFE_8=5U3Z:^%.I?%/5?#,MQ\8/"WA/PCXK35KR&WTWP=XFO?%6
MDW&B(EM)IM_)?ZAIFESVVI2M+<PZAIRQW<%K/;;K;4;V"6.9O2PJCHH'?@ <
M^OZG\Z,#C@<=.!Q]/2@#CO$W@'P=XME6]U[PKX9UG58;-[&RU/6M"T[5;BS@
M+O-'&KW4+2R6L-Q(UR+/SDB:1I"#&TKO7F'@+]GSP?X=TO4K3Q;H'@7Q=?WG
MBCQ5K-I>1>"-/TRSTS1-8URZOM!\/65G>W.NWR1:)I4MM9W,USK-[#=:BM[<
MZ/:^'/#\ND^%-"^@:* /-O\ A3?PF_Z)KX&_\)?1O_D.N+\8_ #PAK3>'&\,
M>'_ /AC^R?$NA:QJHD\!:3J3:OI6GZSIMQK&C!TEL?LR:SX=CUWP^7F2\M[>
M76H-8:TN)]'MK>?WVCKUH _-.^_:)_9KTA+C4/$'[,WBCPKX:BOM4LK?Q?XJ
M\ _#/0= OX-)DU[S]8LEOO%JZT^C7D/AG6AH-]+H\9\3ZM!8^&O#4.K^(-=T
M#3]4U] ^/W[)6L>'O$GB75/@_+X0M/"O@*]^(^J:3XE^&?AR/Q>GARQ\5S>$
MS,/!&C7NL^+H8[N>30M9L-5OM&M?#E]X:\4Z+K5OK9LUU-]/_16C XXZ<CV.
M",C\"1]": /RF\(?'3]D'P?JOQ,TOQ3<R?$349?%7CWX@66FQ?L\:K8:IX&\
M"Z;>:A87/AI-$M]&N-9O](\'P>#?$\\/B$Z99VNLZ?I@ELX9]6UC2(O$';R_
MM._L-H0@\%V"S;)'DM[SX4+I4ULL>D>'=9\R]&KV.GIIULMKXK\/O=ZAJ4EE
MI6E66I0:[K6H:;X:>/6I/T<6WMUN);M8(5NIX8+>:Y6)!<36]J]Q+;02S!1)
M)#;R7EW)!$[%(7NKAXU5IY2TU 'Q[X=T#X*_M!>"+O5_A'X6T'PV-&^(/A6W
MGU7Q+\)I]$N+NV\+>(_!_C/6M-_L#7;+P_JYTKQIX/E?1(KV>.![2'7I7NK)
MKJPO-+KW@?!OX3=_AKX&]O\ BE]&Z>_^B'GZ5Z510!YM_P *;^$W_1-? W_A
M+Z-_\AUQFB_ #P98>-O&OB'4?#O@>_\ #VNVOA&W\+^%X?!EA;1^%Y= M=37
M6=0DN[BXOEN]1\0WE_;/,^FVNAZ?!9:/I<9TR;51JFM:O[Y10 4444 <1XM^
M&?PX\?WOAW4?'?P_\$^-=0\(7[:IX3OO%OA70O$EYX7U-Y;2=]2\.W.LV%[-
MHE^\VGV$S7FF/:W#2V-G(TA>U@,?;@ =/4G\3110!DWN@:%J6H:-JVHZ-I6H
M:KX=N;R\\/ZG?:?:7>H:#=ZCI]SI.H76BWMQ#)<Z7<7VE7EWIEY-8RP27.GW
M5Q93,]M-)$VMTHHH ^:OVB+7X[M;>#)/@:+N6:#6G;7;'2]8\"Z#=WMRUQI0
MT8>)]7^(/AWQ3:P?"^*Q7Q(WC6/P;I%S\2VU1_!]SX8M]1TNU\3:1J7RM\#_
M  U_P4CB\=_#2'XR>/=$N/A<]C=R_$NXDLOA/:>.HK[3/"?Q.TJ&SLK+POX>
MUC2Q%XH\9>./!'B:"]TW7[AM*TOX(>%X)+:P'C_Q_P"%Y/T](!Z@'ZC/\Z-J
MYS@9]<#/?O\ B?S/K22222226B2222[))))>227D*R[7]=>_>_=]MV?G1!%_
MP45T/P[HGA+P_-\+_$6J>'O#.B7^L?$SXL6FB^(M:\>^(]1T;PU-K>@'3?AM
MK_PBT+0WT/Q)<>.($UJW\'Z=IHT&Q\#16ECKU]<^)+R/Z%_9^NOVFKZ?Q9<_
MM#V'PYT>V6+08?!FG>!+*XCNY+K&J2>,KW6+^7Q=XIAN=)_M-K"Q\"A%TW4[
MSPE:6'B'Q5:Z7XJU[5_"'A'Z2VKP-JX!R!@<'&,CT../IQTI J@Y"J"<Y( !
M.>3R!GD@$T66]E=;.ROK:^N^ME?6SLKIV0679;WV6_?;?S/&_P!H*U^*M]\(
M_%MI\$K^73/B;.FBKX=O[:+PU/>V]N/$FC-XC.FP^,3'X7EU23PL-;BTM-;N
M+.Q?47M5?4-/8I?6_P 5Z;=_\%2(Y/A_HMWIW[/;Q/X:TUO'WC:^TY[FXL]?
MC\27>@WK)X=TKQ]HUOK=Y/X,$?C;48]-7P_H0\875K8:2UOH^GW>B:A^G) /
M4 XZ9 ./SI-JC@*H Z# ]<^GJ2?KS3M_7K^'WIC[^>_GZK9_-,^!/B __!03
M1_'>J7_PSA^$'BCP3K%SIMYIFB>+EM(3X4DE\&_#'3]5T G3KWPQJ]WX=3QI
MHOCO7[/Q1/K_ (@\2:?8^+_$UE)X6\20:5\/K'2^/\9W?_!3ZQM+[3O"MI^S
MOXGEU77KG2[+7K/0[CP9?>&/#,=I?6L/B":QUWXE>---U?7;V2\M=5M8_LCV
M&C:GHEK87?A[Q#I.MZ@^G?I9M7&-HQZ8&/\ / _*DVK_ '5_(>N?3UY^O-*R
M[+^ON_7T%9=E]R_R! H50HPN..O3MUYY]^:=113&%<!XJ_Y&7P=]-<_]!TJN
M_K@/%7_(R^#OIKG_ *#I5 '2^(;/4]1\/ZSIVBZU-X;UC4-)U"QTKQ';65CJ
M=SX?U*\LY;>PUNWTW5(;C3-1GTJ[DAOXK#4;>>QO'MUM[N&2WDD0T?!.E:]H
M'@[PEX?\5^++OQ[XIT3POH.D^)?'-_I.D:!?>-->TW2[2RUCQ9>Z%X?M[30=
M%N_$>HPW.L7&DZ):6ND:;->/9Z;;0V4,$:](V=@QU^7 R!DY P<\8]1WKPG]
MFF/X(V7P>\,:#^SI9PZ9\(/!UYXO\!>&-)M]/\4:7!H]YX$\::_X3\5:1!:>
M,K:V\0-#IGB[2-=LXKRZ6:UU!(EO])N[W2+FPNYG9\K=M%*-VHJR<HR24IVN
MF[-QBW:5G9739+^);?"^KN[--M+;1=;7UWMH>]5POCS_ ) L_P#UT3_VG7=5
MPOCS_D"S_P#71/\ VG2*.X7H?]Y__0VIU-7H?]Y__0VIU #"B'J.?7)!_,']
M/PH$:#HN,\<$CU]^V3CTI]%*R?1;WVZZZ^NKU\WW8;;)?<O\@INQ2<X&>GI_
M*OQX_;1O/VY+C]K.TC_9^U'XD6/P9^'_ .Q3\5/B9JUMX>UT^&_#NJ_&JUUK
MQ%8>"M/T_2S^SG\6X?C=XZD6VT=+3X03_$WX+1QZ6_\ ;RZKKS3C36_.%/CU
M_P %8-?^ NI_#;]E>']L7XN^+OB-9_L]7?PR^-'Q^^ _A#X.?$OX<_%3PA\'
M_B9\5?VK_#E^?C;\//V=?!VK_L__ /"T_#?[,7PGT_Q%\2-!TWQ)X@/QZ_:&
M\._!OQ-XTG^$>DV/@TLGND[=TG^:8']4NQ?3]3_C1L7T]J_ S]MW]I3]J'Q-
MH/P,^(WP\?\ ;;_9S^'_ ,2?V'OBA\9/AKX=^ _[,VK?%CXKW'[=%[;_  SU
M3X/?L^_M&>$KWX+?%#4O ]MH6DZWXAL[+PAXNTKX;^ _'7B)/'-EX^\9V1\&
M:#!'QWQ[_P""@7_!2CX->'+;5->\#?"+PAXD\:_M)>./@%\/O!%C^R!^U'\>
M/$\D'PF_8?\ B=^T?K/B73-!^%_QETSQ1\7['XH_&WP;IWPB\,^(/ 'AC3/"
M7@?P=::WXQOM2\77%S./#8TGNE]R_P"!_70'KOK:S5^EMONZ=C^B/8N2<<D
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MB^<>W_"5^-N3[5^XI_J/YBN#O?A=\-]2^(&C_%C4? '@J^^*/A[0+SPKX?\
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M.C3JU(4%4GA^)_\ D6O$/_8#U;_T@N*K>%/^0+8?]>T?\A5GQ/\ \BUXA_[
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M9\ -_2P$(Q\[D9]>HP>,_CG(YZ=,4%" 3O;H3UX]3QP.?PQD\XQ@ _F'U/\
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MO@VWP:\&7/CWP=J$7Q.CG\0^3_ G_@J1^U!;P^ +'XJZCX *?$[QCX8T&_\
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MVK3DEO;N5;.6 27,[@ROOTQ4"9P2<^O/KS]3G)/4G)/7A] !1110 4444 ?
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M%/\ P4,_;7\8_LG_ +3?Q@\9_LY?$7PIXW\)?&7X*^#/@")_V'OVA='\1R>
M?C/8_"'^V_$?Q+_9QUGXFR^./$:_L^^)O&OCOP[\9/%'PD^(?B?0= M? FL:
MKI&E>,Y_">H6'B?*_9\_;@_X*1?&SP1^T98>./@._P ,OBWI/[!&F_&[X,:)
MHG[(O[1.@:/X1_:-U#X.>%K^Z^%_Q#\3?';Q5X0M_$_Q+G^,&L^(I?"WP5\!
M^$?%6CM\/=-TVT\1_&>U\>^'O&'AN[X/X@S?\%+_ (+:I\3&\<?M)_M'^.;W
MP3^SI_P2[O/C!XE^#WP<^&_C;P!X5\6?'G]H/XM?#;_@HG\6OV:_!UE^S-<>
M*_'&H_!OX2?"O1?B+\/O!6HV'C^]^'-EXPNO&GB7X7>-8-0\-> 7\L^#W[2/
M_!27QK\??V:]5TC4/VC/#W[-.GS?!/P/\4_$?Q(\/:1\1]$U2X\:_MC?\%$O
MA1J?CG7M+_X8A^!/Q+^+?@CXK^$/@U^S?H_A3Q[X;E_9FU+]FGP=\2?@S\:/
MBUX=^(?@GQ1\1/$<X!WNB?\ !1+_ (*:>)/$^E?#[X:_ [4/&UM/\,?V<]'G
M^,7Q7_X)V?M=_![PW;?%;X@_'#_@G[X"\:_$FZT"_P#B;IJ^(?AK'\,_VG?V
MCO&MYX/%_P###QCX-UO]F#QQ?:W!8_#_ ,(ZMXA\0>/ZK_P5I_X*.7MW\9=&
M^&?A#]GWXB:KX,^,&K_#_P )7.E_LI_M6:[:W/P\\'^-/VR_ LO[2.E>'OAI
M\2/B)XG^,W[-7C_QC\#/V</AO9_$[X507#^ OB3\;OB9INO:+>Z%X&^'FN?$
M#]U?V ]4^.VJ_LY20_M(>+_%'CWXK^&?VAOVT?A]>>.?%_@O0OAWKWC+P-\,
MOVS/C[\.O@]XJD\(>&-"\.>'=-TOQ#\'?#'@35?#USHVD1:;K/A^ZTK7;.[U
M2+45U6]]^\ ? OX+?"C6O&WB7X6?"+X7_#3Q%\2]6&O?$?7_ (?_  _\)>#=
M:\?ZX+O4]0&L^-=5\.Z1IU_XIU47^M:S>_;]<N+ZZ^V:MJ=UYOVC4+R2< ^7
M_P!@SXG?M&?$?2/VC(/VFI7M_&O@G]J/XR^%/"GAQ?@5X^^$=CX8^$MKXJO;
MGX36.B^,_%[Q:-\?=#U+P!<:!KNE_%;P?I.BPW5OJ@T3Q5IMIXQTO6[2V^MO
M%7_(R^#OIKG_ *#I5=_7 >*O^1E\'?37/_0=*H [PG:@/H!U]\"N$\ >(O&G
MB.U\32^./A\_P[O-*\=>,] \/6;^*M%\6'Q3X)T37+G3_"'Q!6XT1$BT5/'.
MC16^OKX5U$'6O#0NO[+U9FNX78]T^?+X]%_IU]O7_"N#\!Z%X[T.7QJ?''CV
MV\=QZUXZUS7?!<=MX/LO"!\#^ [ZVTN/0O %R]GJFIGQ;=Z%<VVI7,OC*\&G
M7VK#4TM[C3+86$;3&FM^6ZY;7<N;5M.UI<MN_,KVMR\SO9=5Z.^WE:_7OL>@
M5POCS_D"S_\ 71/_ &G7=5POCS_D"S_]=$_]IT#.X7H?]Y__ $-J=35Z'_>?
M_P!#:G4 %?S^_&K_ (*C?%?X)_MC?M&?#]?''[/OC_PG\%?CK?\ PU;]D"RT
M.]TK]IJ;X+:%_P $R/ '[;.O?M/#Q[9_$?6)=(\#:)\5?$FJ_#;7M5\1? ]O
M :Z(;#1=.\7P_$1M+TGQ'_0%5#^S+#SKJY^QVGVJ]B6"\N?LMN;B\MT4JEO=
MS&,R7$"(Q18I69%4[5 &00#\-/$/_!:.[^'>H>'? ?Q._9Z\%:/\</%?P[^'
M'Q6\._!WPS^TSHFKZ[XB\$_$C]G?]K/]H>UU#PU>>+/AAX .M6_A*P_9HT;X
M>^,O$B:=;> ])\<_$2Y@/BXZ;X1M[SQ;EZW_ ,%3?B+\1?V$_A)^UAX;\1?L
MT_LO:+\7?VR_!'P!L_C%XN\;S?'+X0:'\%]8\4WF@W?Q?UK_ (2Y/V6]2\':
MEKLNGW;:7X0^(T7AG6?#6GW.E7VN6,EWJL6E0?M7\2/A3\//B]X&\:_#;XD^
M%-*\6>"/B+X(\2?#;QGH=_%)"NM^!_%VFSZ1XB\.27]A+::I9V.I:?<2Q,VF
MWUE<6\ICN[2:"[@@FCX[X-?LV?!KX!^%O$7A#X:>$[BSTSQEXQN_B%XVO_%O
MBCQ=\3?%?CCQS>:/H'AV7Q9XV\<?$W7O%_C/Q=KT7AOPIX6\-6&H>(=>U&72
MO#7ACP[X<TLV>B:'IEA:@'XE?#O_ (+;?$NZUOP'\-O$G[._P]\=>*]5^ OQ
M*^,US\3K'X]^!_V:? ?Q>\,>%]9_;4T_X8_%[X(^$?V@=0>2?X$?%_0/V1O#
M7CW5?%NH?$_7%^$O@W]H;PCXDO+SQOX,\'ZYXPU3ROQ[_P %R-+MO"OAKXZS
M? /X-?%#6+"+X4VGPP\.:G\7#H/A+X7?';QO;?\ !5/P%XPT7PY\<?%7[/D/
MB:U\5^,+C]BNX_9Z?QAIW@NV^%%EK/Q+U'5_^%FW'P)T[Q/\3/$G]-=UI&FW
MMQ;W=Y8V5W=6D=Y#9W-U9VUS<6D&HI'%?P6T\T;RP0WT4445Y%&ZQW44:).L
MBJ /G[X]?LB_L_\ [3'A_P *>&/B_P"";S5M)\#RZP?"9\)>-?'WPKU31++Q
M'X0UOX?^)="M=>^%7BCP7KK^%O$W@?Q'KGA3Q#X4N-1F\.:SHNHRVFH:9.([
M=H0#\N?%?_!976_A[?>.8_B-\#?A-X$T&#5_VC?!GPB\7ZO^TIXEN]!\9>//
MV8OVU/@/^Q!XRTWXC367[.3#X2^'_&7Q&_:$\):G\.O%1F\9:+_9^E:P?B;>
M_#'27MO$(\)T/_@N-X[\4:9I/Q/G^#_A+3? 5SHGP%^*^@_"'X=_$=/'_P"T
M?XL\ _%7_@EW\<?VZ-=T#6?!^J>"]+TQ]'/C[X8W/PN^'7Q&\'ZE;6_BW7?#
M6K6DUAI[V6N6 _HGTKP7X3T+PYH_A#1O#FA:9X5\/Z+8^&]#\.V>DV$.C:3X
M?TRWL[33]%T_3E@^RVVEV=MI]A!;V4<8@BCLK4*@\B+;L_V98?:5O?L=I]M6
M-(EN_LMO]I6*)KEXHEG\OSECB:\O&B02!8VNKDH%,\FX _ Q?^"V_B%[*VN]
M)_9^^"WQ!TKPMJ/Q,O\ XJ?$'X1_MA+\1/@Y?> /AAXP_8*\-ZWXJ_9I^).F
M_ "VL/V@;ZV/[>.B:!K.FZU8?"#0_#WQ9^"7Q>^%U]XM>YTW3?$%U_0"ISG(
MQ@D?D< _C6;!HVEVUO':6VG:?;VL,<L45M#8VL5O%%/,MS-'%#'$L4:37*+<
M2HBJDDZK,ZF0;JT@,#'7Z_\ U_\ (H 6N%\>?\>WA[_L9K/_ --^J5W5<+X\
M_P"/;P]_V,UG_P"F_5* .SM_]4OT7_T6E3U!;_ZI?HO_ *+2IZ *>H?\><__
M %S?_P!!-8'@G_D7+7_K]UO_ -/NI5OZA_QYS_\ 7-__ $$U@>"?^1<M?^OW
M6_\ T^ZE0!U=%%% !1110 4444 %%%% 'A?C_P#9X^%_Q&U__A+?$&A:A;^,
MH]*BTBQ\:>&O$WB3PKXITNTMWN'MOL&IZ#J^GA9;:2[GDB,\$Z2%O*NDG@ B
M"_ CX4:K\)?!L^AZ_P"(Y?&?B?6O%?B3Q?XI\630_9YM:U?6[Y1!=30O-(RW
M$>BVFEV5VZY6>ZMIYHE@ADCC7W.BO.CE.70Q_P#:5/"TJ6-<:T9UJ452]K+$
M*G&K5K0@HTJU>4*4*2Q%6G/$1H\U%5_9SG%^;#)\MIX_^TZ>$HTL<U7YZ]*/
MLG6GB(THU:U>%/EI5Z\H4:=)5ZM*=>-'GI*LZ=2:"BBBO1/2,/Q/_P BUXA_
M[ >K?^D%Q5;PI_R!;#_KVC_D*L^)_P#D6O$/_8#U;_T@N*K>%/\ D"V'_7M'
M_(4 <S\3O#R>)--\-V4GQ)\4_##[%\0?A[KT6J^$M6\/:/?^)Y?#OBS3M:'P
MXU*7Q'I&M6U]X:^(J63>$O$^CZ=;VNO:KH>I7UGH>K:1J4MOJ$'I$9)7)ZEF
MX[#D\#V'3CC^0\6^-L_PKAL_AK'\5?A]<_$*UN?C3\+H/ ]M;?#75/B8/"GQ
M2'B$7'P^^(%S;:7HVLGP7;>#==MX]6?XE7Z:;I?@AXTU6]UG3$43U[4A!4$#
M YX^AQ_GOV(!! ;ORPT=KU+-J*BVI14K-/G>MD^=63^'1LE)<TGU:BGOLD[:
M/W5N_AU?VKNQQ6NM'9ZYHNK7)D2ST^6^:X=()YW19M-N[="L5O')*X:655^5
M&QG)PN6$+?$CPHIPU]? ^G_".^(3^HT[!Z=1UZ]"*[B6"*8;9$# D$@C.2.G
M7\.GI5!M'L&/-O%WZQJ?PY!Z=/YTBCE?^%E>$O\ G_OO_"<\1?\ RNH_X65X
M2_Y_[[_PG/$7_P KJZG^QM/_ .?>+_OTG_Q-']C:?_S[Q?\ ?I/_ (F@#EO^
M%E>$O^?^^_\ "<\1?_*ZC_A97A+_ )_[[_PG/$7_ ,KJZG^QM/\ ^?>+_OTG
M_P 31_8VG_\ /O%_WZ3_ .)H Y;_ (65X2_Y_P"^_P#"<\1?_*Z@_$GPD01]
MOON>/^1=\1?_ "NKJ?[&T_\ Y]XO^_2?_$T?V-I__/O%_P!^D_\ B: /)O#5
MW\(/!VL>/]?\+Z9'H>M?%3Q=:>/OB)J5AX7\1177B_QE8>!/!7PQL_$>M2&P
M;[3J=OX ^'/@?PI', @&D^&-*@VEH-[=:/B/X1  &H:@ .@'A[Q%CH1_T#<G
MKT)/Z+MZS^QM/_Y]XO\ OTG_ ,31_8VG_P#/O%_WZ3_XF@#E/^%D>$O^@AJ'
M;_F7_$?88_Z!W<=??YAAN:#\1_")X.H:C@\$?\(_XBP1W&/[-[].2?I75_V-
MI_\ S[Q?]^D_^)H_L;3_ /GWB_[])_\ $T <I_PL?PEQ_P 3#4>!@?\ %/\
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M?>+_ +])_P#$T <M_P +*\)?\_\ ??\ A.>(O_E=1_PLKPE_S_WW_A.>(O\
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M<?\ ,O\ B/I[9TXX_#@>F*ZS^QM/_P"?>+_OTG_Q-']C:?\ \^\7_?I/_B:
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M (3\&:KH6G0>,M<_)W5C\/Q\(/\ @Y";X<7OAN\T+5?^"87QV\=22>&/C?\
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M177B_6/&6K>"-1TNX\-:CXKU;Q9?7GBG4O$5YIDVL7WB.[N=;NKR74;B:XD
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M1U?X7Z;H^E>,?B_XJN/B%_:OB+X<^"=*U+X?QZ-?O!X#_8+]K3_@F?\ !/\
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M?:K9:K+;WMS>76E6.H\!\1OV4_VV/"GP,^!'P$@_8<_:L\8>*?C1_P $M_\
M@C3\#3XA\%_#BQUCP-\)/B=^RY^WE>_'KXN>&/C=KT_B+3[GP!?Z+X#@B=86
MTS4Y;74KVVCU^+1-/%QJ=L ?WR@8SR3DYY[< 8^G%+2 @]#GDCCU'6EH *X7
MQY_Q[>'O^QFL_P#TWZI7=5POCS_CV\/?]C-9_P#IOU2@#L[?_5+]%_\ 1:5/
M4%O_ *I?HO\ Z+2IZ *>H?\ 'G/_ -<W_P#036!X)_Y%RU_Z_=;_ /3[J5;^
MH?\ 'G/_ -<W_P#036!X)_Y%RU_Z_=;_ /3[J5 '5T444 %-V@8 R .  Q
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M+XQ/I&M:IJB^!=.M]9^$0LO"6F>(=.\<7-M\J?LC_"_]M[6]-^$OC2^_:/\
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M^')M;\7>'-5=-,;P!X:%_P#V[XXU2^2YMM%\-V&H:F]I=FV%N_K  &-N  N
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M-=4^#MO?ZGIFCZC\5D\7VUF=+.M>+-(TC4],\-ZE:GYE_;Z_X)S?L^_L)?\
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M1J,CKJNKQP?V=:6/V>_^"G?[$?@?6==TO6O$W[/7[6/PD^&WQ(;0]+\;>+O
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M Z65K9PV_P!N*",Y(.22, @ <<<EN^3U[]*8DJR$@*PP,G< .^.Q/^1]:EH
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M:>%?"<CJ>L:^(M9TQYSD;8$D8D!2:]*KY_\ B)I4WCGXJ?"SPO::[KFE:?\
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MSX?\+_"5?B#I8\$^(] ?XM:)H7VGQEY%NX!X%\66_P""@G[ ]Q^P+\9/ /\
MP4"\<_\ !0']JW]NGXS^$/@]XX_93^*WB7P!%^QU\4H?B%\,_%/C/Q)\3_V;
M[?X8_"B/QI\"_A)\ 9[/2/&^J_$#P^_BG3-6\ Q6C>(;)9M?L-"U3V#]EK_@
MLG^T_:?'SQ-\'?V]/V>/@SIGPGTO]L>?]@*U_;:_9%\=^,?$GP$T#]L%O"?@
M[Q'IOP;\=^ OBOIFD?%;1]"U36O%3_"V/XS06C^$-/\ B_IT?@[6-&TW3=2'
MBFT_*W]G[0?''_!/WX]^/O\ @K_X)_8'^,\G_!-?Q1X6_:K\!?L@?LP^&M,^
M)WB7XB?LA:-KL7P[\6:'^U'HGP$\;:E>ZA\"_AG^W/XZ\">/8_%.D^"/ _A:
M#X2> _$7@/5-5G3P+K2V>K=M^R;XP\.?MQ_\$\?V0/\ @F;^RG_PL']H'XG_
M !4^-_PA_:P_X*>_M=S?#CQWX(^$G[/_ (@B_:&\.?MF_'I=4^+/BSPMX;TC
MXA_M$^)_B7:Z=\'_ (6>!? ,'B#^T-)TWQ!K7B/6_">B^$)'G /[8 2>HQ[?
MY]^/?J.*6FKG!SQR<9&#@\]L=R>?S).274 %<+X\_P"/;P]_V,UG_P"F_5*[
MJN%\>?\ 'MX>_P"QFL__ $WZI0!V=O\ ZI?HO_HM*GJ"W_U2_1?_ $6E3T 4
M]0_X\Y_^N;_^@FL#P3_R+EK_ -?NM_\ I]U*M_4/^/.?_KF__H)K \$_\BY:
M_P#7[K?_ *?=2H ZNBBB@ KQKXU_&7P!^SY\*_&7QD^*.L2:+X&\"Z5'J.KW
M%K:3ZCJE]<7=W;:3H?AWP]I%JKWFN>*O%6OW^F>&O"?A_3XY=1U_Q'JVF:/8
MQ275W%&_LM?FQ\3=._X:!_X*!?"'X2ZK&M[\+OV/?AEIO[67BW23Y<UAKGQ]
M^)OB'Q3\,_V<!JT$D+":'X<>'/!OQM^(-C;,^8?&%SX!\01H+S0;.6( \*T#
MPI??ME?$"WT?]NWQUJG@G3];AAU7P%_P3I\$^+-8\-^%-"T"\M1K&EK^U9XW
M\)3Z=J7QN^+%_IGV#5];^%D7B.R^"_@Z,OH)\*_$"^2Y\5ZAZ?XUTKX"?"SQ
M5HOPB\&>&/A[^S!\.O#5U =4T;0/@QIWA.'Q-#"%N8=9\+0^'?"VH^'?B'I4
M]O)#I_A[0I;>32[;Q%!K6N_$O2==LM"T3P/XPY/7O NO_"_]HOXE_M(?$W1(
M-0LM$U/Q+XR^&O@31?$.@)XS^)":9#9:=+>^&](O-0M;B^M? _A.Z/B#Q BH
M\ZF!%MH+G=&)OTTT#Q'X>^*/@&Q\0^%-::Y\->-_#CSZ3K-@Y2:&UU:TEM3,
M$#%K74]-E>2*YM9=L]CJ%K+:SB.:&3: ?@K^R[\!/V-K_P#9=\!I\;/@;XC\
M&Z[HGQ!^/>H?"C]I+X9^$_%OA'QC\,/AKJWQR^*7B7X-VWA;]J3X1R67B?[-
MX/\ AC<>'!-]B\3:OX;TBQTFXT;Q-:3:=HFJVR?>OP]^,'Q@_9>^)GP]^!/[
M3'CD_&OX+?&35K'PK^S!^V+<66B:7XAU'Q?JD$ESX8^!?[25OX:MM.\'S?$#
MQ38PM'\*?C+X4TSP_P"&OBY=VZ^&=7\.:%\0)K";QG^<WPE^)DW[+W@CX%?L
MX_M+Z%^T#\+/&/[,/P\T?X-W-SX,_9U^,WQ:\'>//"'POM;+0]&\<_L_>+/A
M3\.?&'@WQ!H7QGT?1M*\7^)+3QE+H6N>'O$<NKZ-\5;#4-#\"^$O!NK^I7?[
M5'PE\?\ [&EI^SW^T=^R[^W%\/?@K\0OA]=^'[KXZ:Q\#;)?"7@;2;C5(-4\
M%?%#2]/\/^.]=^,>A:5\+=5O_!6O:!\06^%\.E^%M3TSP[KU]<Z7;+!<( ?O
MM;GYG_W0.1@Y!(((XY!X(['@X/%6Z^1?V%_BUXT^-'[,7PT\5_%!8(_B_H,7
MBCX3?&M+80I;M\:/@?XSU_X/_%6\M8((XHK6QU;QQX)UK6M-MHT"1:;J=HB%
MD56/UU0 4444 8?B?_D6O$/_ & ]6_\ 2"XJMX4_Y MA_P!>T?\ (59\3_\
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M(AO['QS=>%;S5=&UCQAHEK96/AO5]4M-:UJ"7^Q8+:SU2[TZTLG'H--4 *
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M3%8W$RK59P]A/ZI04:&"J.O+DJTZO;@L5A,,JDL9E=''*-3$RI/VU=59)8/
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MDQDY7]V<4DG><.3FO?2*<G+W;6ES1C>\7&ZN7J***V+"N \5?\C+X.^FN?\
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M:;=7VG:Q]BUS3+ZV_M2POKRRU#ROM=K=7$$L<S_3]?D1_P $?_VR/C/^V?\
M!7QYXY^/VN^%8_B-I'B/X7R-\.-%^%'COX1>(OAUH/C_ /9_^%7Q+:/Q9H?C
MGSGU2Q\5>-O%/CK6?A)XA\.ZQXDTC6_@.OPNU;6];/Q!U'QQI.D?KO0 5POC
MS_CV\/?]C-9_^F_5*[JN%\>?\>WA[_L9K/\ ]-^J4 =G;_ZI?HO_ *+2IZ@M
M_P#5+]%_]%I4] %/4/\ CSG_ .N;_P#H)K \$_\ (N6O_7[K?_I]U*M_4/\
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M<_88_P""?'@_]C_0[37/$_CC6?CG\>KG0=3T#6/BWXILK;2[+P_HGB'Q+?\
MC;Q+X/\ A-X,M9+C3?AWX4\2^--5U+QAXREM[C4/%GQ#\67/]N^.?$6L"P\/
M:7X?_1_RTSG:N>A) YZXSQVR?SYS2#RR2H521R?E]\=<8_7ISTH @MR-[<C[
MHZ?4Y_GS]:MT@50<@ 'IP /Y4M !1110!A^)_P#D6O$/_8#U;_T@N*K>%/\
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M1=O>444 %<+X\_X]O#W_ &,UG_Z;]4KNJX7QY_Q[>'O^QFL__3?JE '9V_\
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MXI>&OA[\3O%WQ-U[X2? Q?$?@*VM/V;/ GB3]J#1-!\'^&_AW\0=%^)7A'X
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MH_X2?QM_T*.G_P#@]NO_ )45Z1Y47]Q?RH\J+^XOY4 >;_\ "3^-O^A1T_\
M\'MU_P#*BC_A)_&W_0HZ?_X/;K_Y45Z1Y47]Q?RH\J+^XOY4 >;_ /"3^-O^
MA1T__P 'MU_\J*/^$G\;?]"CI_\ X/;K_P"5%>D>5%_<7\J/*B_N+^5 'F__
M  D_C;_H4=/_ /![=?\ RHH_X2?QM_T*.G_^#VZ_^5%>D>5%_<7\J/*B_N+^
M5 'F_P#PD_C;_H4=/_\ ![=?_*BC_A)_&W_0HZ?_ .#VZ_\ E17I'E1?W%_*
MCRHO[B_E0!YO_P )/XV_Z%'3_P#P>W7_ ,J*/^$G\;?]"CI__@]NO_E17I'E
M1?W%_*CRHO[B_E0!YO\ \)/XV_Z%'3__  >W7_RHH_X2?QM_T*.G_P#@]NO_
M )45Z1Y47]Q?RH\J+^XOY4 >;_\ "3^-O^A1T_\ \'MU_P#*BC_A)_&W_0HZ
M?_X/;K_Y45Z1Y47]Q?RH\J+^XOY4 >;_ /"3^-O^A1T__P 'MU_\J*/^$G\;
M?]"CI_\ X/;K_P"5%>D>5%_<7\J/*B_N+^5 'F__  D_C;_H4=/_ /![=?\
MRHH_X2?QM_T*.G_^#VZ_^5%>D>5%_<7\J/*B_N+^5 'F_P#PD_C;_H4=/_\
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MZ?\ ,([4O_"3^-O^A1T__P 'MU_\J*](\J+^XOY4>5%_<7\J /-_^$G\;?\
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MG_\ @]NO_E17I'E1?W%_*CRHO[B_E0!YO_PD_C;_ *%'3_\ P>W7_P J*/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %> HH# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM*URVTCQ3I-KJUK8:_I+R32:1X@TQ;DZ=KVD2RR3:5J]K>6$K-);N3^"T/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+G_#./[3/_20KXY_^&8_9#_^<%1_PSC^TS_TD*^.?_AF/V0__G!5W_V;@O\
MHH<M_P#"/.__ )W$\TOY)??#_P"2/,/B]_P2O_9<^,_[0GQ__:8\0)\1/#_Q
M&_:A_8Z\9?L/?'*'P7XQBT'PUX[^#GC:PN-(O]5U+26T2]G'Q'TK2&TS2O#W
MC&+4$?2K#P_HMLFGRQV]TM[\.>"/^#:'_@F?X<A\$:)X]3]I[]H/X<_#:?3[
MKP+\&/CS^T]\2_%_P8\-W&DNSZ9]A^'.BWGA;0&L;1I)4.AW,%QX?O+:>YL=
M1TF\L+JXM9?TR_X9Q_:9_P"DA7QS_P##,?LA_P#S@J/^&<?VF?\ I(5\<_\
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M.?\ X9C]D/\ ^<%1_P ,X_M,_P#20KXY_P#AF/V0_P#YP5']FX+_ **'+?\
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M ,X*C^S<%_T4.6_^$>=__.X.:7\DOOA_\D?:G/H/S/\ A1SZ#\S_ (5\5_\
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MOY)??#_Y(^U.?0?F?\*.?0?F?\*^*_\ AG']IG_I(5\<_P#PS'[(?_S@J/\
MAG']IG_I(5\<_P#PS'[(?_S@J/[-P7_10Y;_ .$>=_\ SN#FE_)+[X?_ "1]
MJ<^@_,_X4<^@_,_X5\5_\,X_M,_])"OCG_X9C]D/_P"<%1_PSC^TS_TD*^.?
M_AF/V0__ )P5']FX+_HH<M_\(\[_ /G<'-+^27WP_P#DC[4Y]!^9_P *.?0?
MF?\ "OBO_AG']IG_ *2%?'/_ ,,Q^R'_ /."IDG[-W[33QNB_P#!0WXZ1LR,
MJR+\%_V06:-BI"R!7^ +(Q1B&"NK*2,,""11_9N"_P"BARW_ ,(\[_\ G<'-
M+^27WP_^2/MBBJ]K#)!!#%-</=3)#%'-<R1Q127,L<:K)</' D<$;SN#(Z0Q
MQPHS%8XT0!18KR.^EM=/-=_+T+"BBBF 4444 %%%% !1110 4444 %%%% !1
M17-^(?%.F>'8X1=--<7UV_E6&EV41N=1OY20H2WMU^8KN(#2MB-<$9+X4N,9
M3DH0C*<Y?#&*;;[[;6ZMM)*[;23:&TE=NR[G24@(/_ZB.OUKS=!\1->Q(UQI
M_@RS<[DMUMTUK6O+XVF<L8["W=AGY5=WC((DC)^42'P;KQPY^('B;S>N1#IX
MA.!P/(6'CGDAG).,9%:NC&+2GB*-.76*]I5<7U3=&G4IW6S4:DDGIS29/-?:
M+MWT7X-IGHM%><-;_$31,26U_IOB^U09>SO;==%U8J",B"ZCDELIGP#S/Y0/
M&%)S6]X>\6:=K[3VJK<:?JUF/]/T;4(_L^H6I& 6,1/[Z')^6>+*89-P4L*F
M5)J+G"<*T(NTITG?E?\ ?@U&I!^4H=M=5<YE>SO%[I/JMKIZK\;^1U-%'6BL
M]]2@HHHH ***XS7?&-MI5TNDV%K=:[K\J;XM(T\(9(D/2;4+ALQ6,'(8R2Y.
MP;MFT[A4(RG)0A%RD]>B22W<I2E"$4NKE./E=Z--I*[=K?/\%=OY)G9T5YPN
MF?$+5\RZAX@L/#,3 $:?HEBNI7* X.V;4+QHT$H'#>1')&0,J_:E_P"$.U^,
M;X?B%XD$N.#<V]A<PYS_ !0-#&#[C>!@'UK1T8+26*H*6SC&-:HD^WM*=&46
M^]N9)Z<SW%=O:$G]VOGO^9Z,"#THKS5[OQ_X=!DO(++QEIJ<R3:;%_9FN11@
M;F<6$AEMKPJ VV.WE\U_[HY-==H/B'2_$5I]KTRY\]58QSPNGE75G,"08+NW
M8[X)5((*N,'!VD@4JE&<(\^DZ=TO:4WSP3>T9V2G3E_=JPIM_9<U?E:DF[:I
M]FFG_EVV;W-RBBBLAA1110 44A.!GW'ZD#_/]:X+4O&KR7TVB^%-/?Q%J\)V
MW3I(L&D:8<$9U#46S'O!!_<0YE9E,0/FJR"Z<)U9.,(\SBN:3NHQA'^:<I-1
MA'SDU=Z)-Z";25W_ ,'[CO<C.,_Y_K[^E+D>HKSD:!XZU#][JGC"/2BPR;'P
M[ID12+.>!?7V9I#ZEH0 20,C#$/@_P 2P_/9?$'7/.&2!J%E8WT!/HT3"W.T
M]#MD!&00..+]E3_Z"Z%^RC7E%-;KVD:+CIU:ND^MM17>_++_ ,EO_P"E'HU%
M>:-K_B_PS\WB;3+?6])0_O-;\.1R?:+6/<<S7^DR N$506E>T9HX4&2TC$*.
M\TW4K'5[."_TV[AO+2X7?%/"P9''H1U1UR-Z, Z'A@#4SIR@HR]V=.3M&K3D
MJE)NU[.4?@EVC4C"3L[)I-C4D[[IK=/=?H_DVB_11168PHHHH */ZTR21(U9
MW=8U12[NY"JB+RS,S$*% !R21@9/:O.Y?&6J:U/)9^"-+CU-(7:&X\0ZD[VF
M@P2@X9;=E4SZC)'U9+8!02,DHV\7"G.HWRI6BKSG.4:=.">W-.;C%-]$FY/9
M1U0FTM_EU;\K+7]/,]'HR/4<]/>O._\ A%_%]YF34_'=W;NPYM]#TRULX(_]
ME9IC//*HR1N=8R?0<DM/A;Q=:_O--\>ZA+(O2+6=,LKV!\9(5VC^SRH#_>17
M89^[Z7[*GUQ=!.VSC7Y?3VBHN/S^'SMJ*[_EE_Y+?_TKYGHU%>:KXNUOP_)'
M!XUTN*WLWD6*/Q)H[R7.D%V(5!>PRJ+O3RY.T/(I1G!"+M^:O1(9XKB..:"1
M9HID$D4L9#QO&PW(ZNORLK*05()![&HG3E3Y>:SC--PG"4:E.:5K\M2#<6XW
M7/'2<&TIQ3:&FGM\^C3[6?\ PWF34445 PHHHH *.E5+Z^M=.M9KV]N(K6U@
M7?-/.P2*- 1DLQ[G. !EF)PH)XKSY/$WBCQ/SX1TR"PTICA/$7B%98DNE./W
MFF:7$IN)U.<QS3-' ^.2IXK2%.512DN6,(6YZDY1A3AS7Y5*4G\4K/EC%2G*
MSY8Z7$W;N[]M7_7GMYGI8(/0^A_/I^=&1ZC\Z\[/A+Q/<?-?_$#61*<$KI=A
M8:? OJJH%N'(SG!9LD#D9H/AWQM8?O-+\:G4-N#]C\0:7!)#+CG!O+/9<0].
M2D#\$8&15>RI_P#071OV<,0H^G.Z/+\VE'SMJ*[_ )9/[OR;3/1:*\]LO&EQ
M9WD.E>,-./A^_G<16M\D@N=!U*0\!;:^4?Z-(W!%O=D2#)W,IPM>@J<@'Z^G
MK[<?E43A*FU&:7O+FBXRC*$X_P T)Q;C./=Q;Y7I)1DFAIIJZ_R:^3L]>CV%
MHHHJ!A1110 49Q_*L?7-=TSP_9-?:I=);1 A(Q@R33RG[L-O F9)IGQA40=3
MEBHR:XU-0\>^(\/IMI9^$=-?F.YUF(WVM3(P.V1=-0I!;#!!V7,J2@'*[AUU
MA2G.+J-QITDVO:U9>SIMK[,6US5)?W:<*C7VG"ZYI<DM-6^RW_R7S9Z5D>M)
MD9QZC/?I_G\:\[_X0[Q!(=UQ\0?$9E&"WV:WT^VAR<GB%(9<#)X!E88X' I&
MTKX@Z3^]TWQ)8^(D4$FPUZP6PED &2L>H6&[]X>BF6)8\GYB% -/V5-_#BJ+
M?2+C7IIOM[2I1C%7Z7LGLI=0N^L9+_P';Y-GHU%<3HGC*#4+PZ-JMG/H'B!0
M6.EWQ0K<H,YFTV[4^1?0X&28R'QG"D*S#M1G'/7_ .O6<X2A)QFN622>ZDFG
MM*,H2G"2?>,Y6ZV=TFFFKI_H^O1I/H+1114C"BB@G )]!F@ H) ZD#Z\5S7B
M'Q3IGAU(%N6FN;^[8QV&E6$?VG4;Z7!PD%NO(&[ ,C[4'(!8C%<V%^(>NGS'
MN=-\&63@E+=(5UK6=A/'GLSQ6,#E2#B-GDC8$.H/%:PI2E%3E*%*FVTIU9<J
MDUHXP@E*I4:TTA![Z-V=I<ELKR?:.KU_!==VMCTG(X[YZ8Y'Y]*3(]>F/UZ5
MYU_PAVNGYV^(?B42]3MAT](<GK^X$##_ ,B''8TPP_$31!YEO?Z;XPM$Y>TO
M+==&U4IW$%Q"TUG,X]9C%NQPH/6E1B](UZ+ELD_:T^9]$I5:4*:;V7-.*;TN
M#DUJX32[V3M]S;_ ])HKE?#_ (LT[Q TUO&)[#5+,XO]%U&/[/J-FPP#OB.1
M)$2?DFB9E(*[@I.#U0.>>M92A*$G&<7&2W35GKMY-/=--IJS3::8TT[-.Z?8
M****D84444 %,9T0Y9@NX@#<0!GGIDCTR?\ ZQP^O(/C*!_86C'N/$-K@]Q_
MH=\?T(!'H16N'H?6<11H<SA[:3ASK7EM"I.]NOP6TUU\B92Y8N5KVMIZM+]3
MUW=\Q !/\AQ_4C'.,G/84!@6*X((YY& 1QDCUQD9],\U^!__  <LW%G;_P#!
M)_XFMJ-[X;TW2S\=OV1H=7O?&EWXBL/!4&D3_M,_#"/5&\9WGA*>T\40>$18
M/<?\)-)X<N8-;313>G2IH]0^SLOXJ?$W]N[XQ?L3?LI?LG>&?^":?Q\_9CU3
M1_%_P:_:_P#%G[1GPZ_8R^$OC+]HG]GG]F;X(>'?CLUKXB_X*4^![GXN2:Q\
M=H=7^"%WJ>I^&?$'@#XH>+/$GPB^)_BMM</A[P;'9^#KJ6]Q6J_K^NA1_<[1
M7\<_Q/\ ^"NGQVTW_@IO^SE\&/V>_P!JGQE\0_A$G[8/[$O[+'Q1\$_$X?LL
MW.E_&/X3_'CX4>'KG7OVB/A_X&^&GP"L?B\?!OCK4O%?@CQ]X7_:*D^.O@GX
M:7GC/Q79^"? OPFU7P?JEM8Z?Y]\*OVQ?^"JGQL^*W[$7AE?^"CGB;P/H'[=
M?Q@_X*X_"?4(-%_9A_9=U2X^"_A?]@?6O$GB+X;:UX)GU;X:N==\;>);7PI?
M>#O$NJ^+Y+S1?^$0UJV;3_#\'C71E\97[ _M8)P,X)^G^>W6J%MJVF7EY?Z?
M::A97-_I3V\6JV-O=VT]YIDMW;K=VD>HVT4KS64EU:L+BV2X2-IX")H@T9#'
M^"[XB?\ !;']M^]^$7[.WBOQ9^W]IW[+GB/QG_P1,O?VO_#L6E_L_P#P/\6_
M\-+?MR>!_C_\4/ASX,^&4<'BKX:^(%\-S?'K2?"5C::UH/A*/1=&AO;">X\'
MZ7H-D-1M;GL/BS^V?^UU^SE\7O\ @I5\;_A]'#\!/B7\;OVQ_P#@B)X)_:Y\
M7'3_  YIB_LV> _BI_P3GM/$_P 7+C_A,OBIX#^+WP]^#R:5\4;71OA*OQ.^
M+OPZ^(/A7X?'Q:UUJFAW6M2V%]; ']V-%?F__P $G?C/\;?C_P#L/?"WXG?'
M_P")?PK^-'C[5-=^*NAK\7?@WXE\*^+O!?Q&\->"_BGXN\'^&O$$FO\ @/PS
MX.\!:CXI@T[1%T'QE?\ @/PUHW@O5?%&BZKJ_AG3=.TB_M;"V_2"@ HHHH>P
M'/\ B?7H/#FD7&HR(T\P,<%C9QY,U[?3MLM;6)5!9FDDZ[1N"*Q7Y@ <7POX
M;?37DU_7W6]\4:F UY>2%633HY"#%I6GY(2"VMPXBD>/;]IES_RS,42T=24:
MU\0M%TQSNLO#>E3>()(CDI)J%S,MG8%UXR;90UQ$2<AL]C6#\4O[?5]'>TTV
M[U#0;.\L-8O6TRUTZXNK"^T+Q!I&K"[N6U&ZME@MSI5M?PVTMN)%6X:3[?MM
MMBS;N3IT81@_>KQ52JTO>]E*5J-)/=1G9UI\K7,W"$KQC*+G=WO91O;IM\5^
MEK+3M9]SV$E$QG(+9 Y.20-Q&,\D*"2!SA2>BG"LZJ0K$@D$@9 ) P&.-P)"
MEE#, 0I9<GFOG/Q'<>/)KKPKJ @BU(VVDZ3<:3KNEV^D7.@Q>(M5\/\ B#2K
MVXFN+J[BN&-YK%]HJV]O913VEU8R016,C7L\PM]74#XRF^)PEM;&9O[/1-/B
MO8+?2Y-,3PUK>L^#+V9+F5KPZJCR6VB^)[<R2VB2+?L\UEOM(<7.%M_=:MH_
M=MMI;Y/1;?(=T[-.+NKK57=U=?>M;GN^Y"Q7.6P,C=R =V,C.1G:V,CG:QZ
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MYB+)U)273V<I>SIQ=^6,6TDY2O"DOB;U?1]%Y:=>_F6<#_\ 5D=/<<T8Q_\
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MQ]JO[-W@/4?#&EZIKGQE_9S\::M<^+?$OBWP=ILW@WX8?'#P)\0O'%C8^)?
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MO=-N;V/6?$VL1Z9H$FH3^&?"MGKFMW>J6?A/PQ-JP74Y-"T&"X2RL9+N.!W
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M)7X*?#'X1W[_ +//QAT;]K;X6S^&O!7C34?BQ<21ZMH.GV>D0FSTJQMM1O\
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MG Y7BI4W@,9BN;"X.OAJN*]IAO:86K3E_9\YPEA,7&4KU_>XARG#Y9@LMSS
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M/B"W^-GAOP_HVB^'[GX-ZYC^)?\ @KM^VA^RW^V]_P %(9_C+\#[3XL?LS_
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M$-5L]<T'Q%I#3?97O])O]/EFCNHK:\/]GWJKB;3]32;3+V*WOX7MZ_)'5/\
M@G'\0D_88^''[-'@[4/!G@WQ?X&_:@TC]I!M(T7XN?&'P7X$LX[3XR^)/BAK
M7@CX>?%/X'^#O@O\1_A%IVH#Q#/+HH^%'@+P!HO@S5KO4M/\/>'+?P[.L5U\
MWZ%_P2 ^/%CXJ_9TN?$_Q;^!/B[PE\!_ ?BSPQ:V]G\/=9\ >/+C1_B#X+_;
M&\)>-_@L/C)X9T*Y_:/\2?#O5C^U#X?:7XJ>+OVA;GQ_JL7P[UGQKXF\$:W\
M<_B5XE^+D@!_1@FKP2(DD<BR1RF5871A(DS0H[S)$R,Z2M$D<C2K&7*)&[.
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MY?6_\ZD/_!&+XJMX$\5:!+XI_9<T[Q/XT^ GPI^%-[XI\.?!GPGX4U;P[9_
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MA9TO [@'TC1110 4444 4KFX$2EF8*BEBS$JH5(\EW=G9555 9F9F5%52S,
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M*-5_^0Z/^$^\,_\ /S>_^"C5?_D.@#IOL4?!QTZ=/K_=IZ6R+],Y/)[9QC@
M=>>/7OS7+?\ "?>&?^?F]_\ !1JO_P AT?\ "?>&?^?F]_\ !1JO_P AT =D
M  ,#IDG\R3_6EKC/^$^\,_\ /S>_^"C5?_D.C_A/O#/_ #\WO_@HU7_Y#H [
M.F/&KCD<_P#UCP?;DY[^]<?_ ,)]X9_Y^;W_ ,%&J_\ R'1_PGWAG_GYO?\
MP4:K_P#(= '3FSC)R0/S/]02/P//?-,-A"?X0/<$Y_E7-_\ "?>&?^?F]_\
M!1JO_P AT?\ "?>&?^?F]_\ !1JO_P AT =,ME&HP ,<]_7'M[4ILXSU4?G_
M /6^GY5S'_"?>&?^?F]_\%&J_P#R'1_PGWAG_GYO?_!1JO\ \AT =,+*,'(5
M>F._YYQD'Z?7GI0;-,YXP,\'WX/)!S^/TKF?^$^\,_\ /S>_^"C5?_D.C_A/
MO#/_ #\WO_@HU7_Y#H Z#^SHMVX+R"3V]^IX)Z_XU=BB$8_#  _#))[DX'L.
M@S7)?\)]X9_Y^;W_ ,%&J_\ R'1_PGWAG_GYO?\ P4:K_P#(= '9,-PP<CIT
MZ\'/?/I5:2U1SZ]SGN><]!WX[?TKEO\ A/O#/_/S>_\ @HU7_P"0Z/\ A/O#
M/_/S>_\ @HU7_P"0Z .A;3HF_A[CG@^G')'';C%2"QB'502>IR>O^'MDX]:Y
MK_A/O#/_ #\WO_@HU7_Y#H_X3[PS_P _-[_X*-5_^0Z .F^Q1?W1^9_PI?L:
M#MTZ?,?Y 8_3_P"OS'_"?>&?^?F]_P#!1JO_ ,AT?\)]X9_Y^;W_ ,%&J_\
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MO_@HU7_Y#H Z?[&GH.1S@G]!MQC\!CL/1/L,/]P?F?\ "N9_X3[PS_S\WO\
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M4:K_ /(= '9T5QG_  GWAG_GYO?_  4:K_\ (='_  GWAG_GYO?_  4:K_\
M(= '9T5QG_"?>&?^?F]_\%&J_P#R'1_PGWAG_GYO?_!1JO\ \AT =@Z!AVSQ
MR?Z_@3[BJQM$/9>3D]/KQE3W_'W]>8_X3[PS_P _-[_X*-5_^0Z/^$^\,_\
M/S>_^"C5?_D.@#IOL4?H/_'?_B/\_B:46:#C''N?KU  S^)^F*YC_A/O#/\
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MQ>8-T8E1HRX&,A=Y&2 >2!C@]J -FBFHP<;ATY_S[T,P12S$!5Y))P .Y)/
M '- #J*R6UW2%8J=3TX,,Y!O;<$8..09,@^H/([TG]O:/_T%-._\#K?_ ..4
M :]%9']O:/\ ]!33O_ ZW_\ CE']O:/_ -!33O\ P.M__CE &O161_;VC_\
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MV]H__04T[_P.M_\ XY0!KT5D?V]H_P#T%-._\#K?_P".4?V]H_\ T%-._P#
MZW_^.4 :]%9']O:/_P!!33O_  .M_P#XY1_;VC_]!33O_ ZW_P#CE &O161_
M;VC_ /04T[_P.M__ (Y1_;VC_P#04T[_ ,#K?_XY0!KT5D?V]H__ $%-._\
M ZW_ /CE']O:/_T%-._\#K?_ ..4 :]%9']O:/\ ]!33O_ ZW_\ CE']O:/_
M -!33O\ P.M__CE &O161_;VC_\ 04T[_P #K?\ ^.4?V]H__04T[_P.M_\
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MRQM_.L+L#'RRWFFPSVEPP #C3[)<>8S%P#MJ*** "N/F_P"1]T__ +%/6/\
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M^";3/_D6D_X1/PJ>GASP^?\ N#:9WZ?\NM?BUX#_ ."K7QP\3^)?V3=#U/\
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M^1:Z&B@#GO\ A$O"W_0MZ!_X)M,_^1:/^$2\+?\ 0MZ!_P"";3/_ )%KH:*
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M+D2B[-C9FX$AM+?R^,E\064;LH^,,"A6*A&A\(,PQG@G^S<D\<D]>O0Y,?\
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M_P#P'\(?_*V@#V:BO&?^$CLO^BQ6_P#X#^$/_E;1_P )'9?]%BM__ ?PA_\
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M/:#HNA"ZE.7NAI&FVNG"=\DG=+]G\TDELE\[CFOD3]E[_@GK^SG^R??S>)/
M.CZWXD\?W%K/82?$7X@:A9Z[XIMM.N@JW6G:*FGZ;HOA[PY:W2@Q7LF@Z%I^
MH:E 1;:I?WT"+&/MT1%2"&& <XV\]0<;B2<9W?F/[O/\T>+?B)@^.L;EV'RF
MC7I93E$,3*C6Q=)4,1C,7C/91KUO81J5I8?#TJ="%.A&K4EB)J4I5HQ:C?\
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M"U#Q@^C>(E\,V>I7BQV]QK1T#6?L4;M(-.NC^[/0C]HS_@IG&Q$W_!-#X92
M9YL/V_?"<^?]T7W[/NEDY[;MGOBO$.@]J_;>^,&O_ []F+]H;XL^%%LY/%'P
MO^!'QC^)/AB+4X3=:;)XC\"_#7Q+XKT"+4K3>GVK36U;2K07]JKI]IM3- '0
MON'^?%XLEU#QWX@U/Q7\2-9U;XG>-=9N7NO$/CCXBWDGC'Q;X@U"0EI[W4M9
MUK[3-M=RPM=-LUM-%TFW":=H6EZ7I4%KI]M_6C_P4/\ CK^W)KO[&O[5>G>/
M?^"?6C^!_#^H?LU?'O3]?\6:=^VI\)O$Y\,:)>_";Q?;:OXA'AC_ (5_I.K^
M(CHFFR7&JC1M-FAO]6^RC3K-TNKJ%A_)5J+RHM]);KYLZ+</;J0/WDB+(T2X
M#?==E56 88#'Y@.1_1/@-@,%BH<35<1@\)B:L*V4483Q.%P^*=.E4HXZI4C3
MCB*-?EYJD:4G&'L^=Q2<E!3O\SQ%4J0>#C&=2,9>U<HQG*,6TXJ,GRN+]U2>
MMWI?0P1X6\+XX\->'>.PT'2O7G_EUQQU/UH_X1;POU_X1OP[C_L Z5QG_MU_
MEFOVQ\5?L[_#30/$/C'2/#W[//@)_@!9?L=?&SQW\#OVH-1\3>+==UOXX^.]
M'_9$N/'</BG4KW5?B5?_  _BU+1OB;/J6K6^F>&OA]X0D\#:EH=KX<EN5ACF
MM]0[9_\ @EA\)-/\;?#_ ,(ZCXN^,,VH^)_ 'Q;N]?T;1/$N@:AI&A>/OAEX
M@^$VGV.LZS\5C^SLH\&?"'QAH?Q)O=4TOQ1K/P<USPI'<:3HU^/BM)X/\01>
M)XOTV7%7!]*,9XK*\)AU4H1Q%*,<HR;%SE26'JXBLJD<%AYQPU>A"FZ>*H5Z
MOM<+B'"A7I0J\\'Y/U+&M+DK.?O.#<JU6G:5TM.>?O)-Z-+EFO>3::/P9_X1
M7PQQ_P 4WX=Y_P"H%I/_ ,C<_AFD_P"$5\,8S_PC?A[KWT'2OSQ]ESCG_P"M
M7[.:'^Q9\%O"OA'POXPUU/'6LZ9X^_8_U3XJZ[9>.M1\/:1XGMO%^D_%O]DK
M1-:;X;>')? .A/X4TV;2OBKXPLO WQ)L_%OQD\/>*]$D^W:9K5MJ-KX@TJ+U
MSXN_LF_L\_%7Q[XN'P]^'6L>'=/\"_$C]M/PUX9^"'[/LGPW\/\ Q:^+<?[/
M'CO]FOX5:)HOAKQ#XHTG5]"NH%@\9^.OBF9+[PMX@\1+X5TK5K8-K.L2ZCXC
MB3XHX5^L>R620EAXQJJMC%DN40ITITZM7#Q@Z-3!*3JSQ-"=.4'B*=.C3?UB
MOB:5",I(^IXOD<O;ZW5H>VJ<TDX.=XOVK5DDU9^\W913;2?X#_\ "+>%ST\-
M^'L^G]@Z5G_TE_SVH_X1;PQW\->'AU/.@Z5V_P"W7OG K]P_A=_P3M^"":=^
MRAXJ^*6L>/)3\9/B=X3\(^+/ MC\2O#$VG:YH_Q,^#GQ@^)'@-_#OBRR^&'@
MZ'0-6L/$WPZT?P)XIL]"\5_$NUO/$6KZCH,/B7PSXCTN;2$H?#[]@SX0?$_2
M/AE;Z\/B7X!UJ/P+X=LO%7@W1-1^%>F_$?X>Q>)OVH/VH_AWXK^-GQ_U+Q/I
M-CIGBCPS^SQX<^&/@_1_BPGA'P]X2N[VXU?2Q;:AX(TZ+3(;FZO%/!M-S?\
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M$[X :7X0L_%_C74M47Q-I?P^TZ;QL ?T)>3%_P \H_\ OA?\*/)B_P">4?\
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MFBD'0<YX'(Z'W_&EH **** "BBB@ HHHH **** /S;_X*=?\DR_9;_[22?\
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M WP^\&^'=FGPVEO)::!9S30R7C3W,W5F(G_EHV?48![]^O&3CG R<#DUR/\
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MMMIMS)?2W-]J>I2Q"%M1U.Y-S<+ &+>1;J%C@LX"V':&TAACD?+R!W9F/04
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MQW^S-XJ_:-^*'ASR=)O$^%_AK7=/U3X@^+)('CTC^SM*O(+VX\*:=?,HAO\
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M-E_;D_\ $./C5_\ *&O(_BY_P4L^+/PQ^-7[0/PV\"_"#X?_ !WB\%_%[5_
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M">/CQ:VPW$6\"EV5W*Q(-SHV]')"@ED?YT8_,K?,I!YK^F3_ (8[_P""0?\
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MO_C- '<45P__  L7PC_T&(?^_%U_\9H_X6+X1_Z#$/\ WXNO_C- '<45P_\
MPL7PC_T&(?\ OQ=?_&:/^%B^$?\ H,0_]^+K_P",T =Q17#_ /"Q?"/_ $&(
M?^_%U_\ &:/^%B^$?^@Q#_WXNO\ XS0!W%%</_PL7PC_ -!B'_OQ=?\ QFC_
M (6+X1_Z#$/_ 'XNO_C- '<45P__  L7PC_T&(?^_%U_\9H_X6+X1_Z#$/\
MWXNO_C- '<45P_\ PL7PC_T&(?\ OQ=?_&:/^%B^$?\ H,0_]^+K_P",T =Q
M17#_ /"Q?"/_ $&(?^_%U_\ &:/^%B^$?^@Q#_WXNO\ XS0!W%%</_PL7PC_
M -!B'_OQ=?\ QFC_ (6+X1_Z#$/_ 'XNO_C- '<45P__  L7PC_T&(?^_%U_
M\9H_X6+X1_Z#$/\ WXNO_C- '<45P_\ PL7PC_T&(?\ OQ=?_&:/^%B^$?\
MH,0_]^+K_P",T =Q17#_ /"Q?"/_ $&(?^_%U_\ &:/^%B>$CTUB'T_U%UU[
M?\L: .XHK)TO7=)UI'?2[^WO!&=LJQ2 R1-C.V6/AXVP<[7"MCG&.:UJ "N.
M\;?\@W3?^QE\.?\ IVMJ[&N.\;?\@W3?^QE\.?\ IVMJ .P7H/H/Y4M(O0?0
M?RI: "N/F_Y'W3_^Q3UC_P!.VAUV%<?-_P C[I__ &*>L?\ IVT.@#L****
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M7QMX=O"N;K1?$_A+Q+%I^LZ)K.G3;[2^LKJVPL\3M;RW$#1S/]/2P..S+A[
M4\NP6+S"KA<YSAXFE@<-B,95P]/%83)WAZM:EA:.(JTJ=>6'KPI59TU2G*C4
M@JG/%P?+*I3I8BHZLX4TZ-!Q=22A%\LZ\96E)J+LY137-=-K1IGT[X2_9Z^
M?P_\,Z+X+\!?!#X0>"/!_AM_$<GASPGX1^&G@OPWX9\/R>,K2YT_Q?)HN@Z-
MHMEI>EOXJL;V\LO$C6-M;MKMI=W-KJANH)Y4;\R[G]I'_@ESX:_9;^'/[0OQ
ML^!WP:^$_@7]NGX;Z'\2?%G@G4_V=M ^(.J^+?!7PW\/:?X[O_$GQMTOX<>
M/%-OK'@'X%Z3)I6L:_\ $#QK;2^"/AXUSHA;6M-OM5T.*Z^L3_P4Q_X)_$';
M^V#\ L]L_$/0Q_[<9Q]!STXK\M8/A]_P1JC\(_"[P;<_MXVVM:=\#'O;'X(7
M?BKX_P#@3QAJ'PE\&:UI%IH7BCX;>$/^$K\(:S8-X'\4:;I'AG^TK3Q#8:[K
M5EJ7A#PIKWAS7=!U_1+;5#Q?ZM\1_P#1/9[_ .&7-O\ YVE?6\+_ -!.'_\
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M/#DUY%X8'C&;Q#XDUNR@M;_A3]D;]ECQO\'/&_Q<\%>"=>\6ZWK7PG\(^*_
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MVL0Q1ZSI&DW]EX1 P:.-@QD#QJPDX <%5(?:,8W @XQQT'' ]/\ @B2/C_\
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MD3S_ !K\0^-!XOCU73@#]C<KD#)R<X&6R<=>_;OZ4[ ]_P S_C7X.^,_C_\
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M\7_^%7KG_P F4 =EM'3''3'MQD?CCGU_$T;5QC QZ=ORZ9]^M<;_ ,(3:?\
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M3_H.^+__  J]<_\ DR@#LBH.,@'!R 1P"#D$#U!Y!ZCM00#P1D>AZ?E7&_\
M"$VG_0=\7_\ A5ZY_P#)E'_"$VG_ $'?%_\ X5>N?_)E '9  '..2,$]R!G
M)]!DX],G'4UAVWAGP]:>(=6\76VA:+;>*M>TG0= USQ+;Z99PZ_K.@^%KO7]
M0\,Z+JFL1PIJ%_I/AV_\6>*;S0]/N[B>TTJY\2:]/816\NKW[SY/_"$VG_0=
M\7_^%7KG_P F4?\ "$VG_0=\7_\ A5ZY_P#)E '9X'\_UZ_A[=/RI-H P  !
MT X _#I_^L^IKC?^$)M/^@[XO_\ "KUS_P"3*/\ A";3_H.^+_\ PJ]<_P#D
MR@#LMH(P0",@X/(R,8Z^F 1[@'K1@9SCD=">3T([^Q/YGU.>-_X0FT_Z#OB_
M_P *O7/_ ),H_P"$)M/^@[XO_P#"KUS_ .3* .R(!ZCOG\>N?KF@J#P1GKUY
MZ\'KZ@D?0D=":XW_ (0FT_Z#OB__ ,*O7/\ Y,H_X0FT_P"@[XO_ /"KUS_Y
M,H [$CCY0 >WMSST_'^O!->3?"GX"? _X%0:W:_!3X._"WX16OB6XM+SQ%;?
M#+P!X5\"P:[=6"7$>GS:O'X9TK3$U!M.AN[J'3A="5+"&YGAM%@BE=&ZC_A"
M;3_H.^+_ /PJ]<_^3*/^$)M/^@[XO_\ "KUS_P"3* .SHKC/^$)M/^@[XO\
M_"KUS_Y,H_X0FT_Z#OB__P *O7/_ ),H [.BN,_X0FT_Z#OB_P#\*O7/_DRC
M_A";3_H.^+__  J]<_\ DR@#LZ*XS_A";3_H.^+_ /PJ]<_^3*/^$)M/^@[X
MO_\ "KUS_P"3* .SHKC/^$)M/^@[XO\ _"KUS_Y,H_X0FT_Z#OB__P *O7/_
M ),H [.BN,_X0FT_Z#OB_P#\*O7/_DRC_A";3_H.^+__  J]<_\ DR@#LZ*X
MS_A";3_H.^+_ /PJ]<_^3*/^$)M/^@[XO_\ "KUS_P"3* $\2XGUWP7:QL&G
MCU>^U%X@<LMG!HNHVDMP5'(C2XOK:+<0!NF"@]<=I6'I7A[3M(DFN+=;B>\N
M%2.>_O[NYU"^ECCR8XFNKR6:81(22D0<1H2=J DD[E !7'>-O^0;IO\ V,OA
MS_T[6U=C7'>-O^0;IO\ V,OAS_T[6U '8+T'T'\J6D7H/H/Y4M !7'S?\C[I
M_P#V*>L?^G;0Z["N/F_Y'W3_ /L4]8_].VAT =A1110 445\W_LO?M;_ +/7
M[9G@/Q%\3/V:_B/9?$_P1X3^)'C3X2:_KUCHOB70HK#X@?#^]ALO%.A?8_%6
MC:'J%PEDUW97-GJMI:W&CZOIU]9:CI.H7MG<QS$ ^D**@NIC;VUQ.!N,$$TP
M7(7<8XV?&XY SMQDC ZFOP2\,?\ !6WXXZ+^SI\+OCA^T!\'?@E\.-+_ &E_
MV!O'?[='[/GBCX?>/_B9\5-(TBQ^'GP_^$_Q)\4_#'XU^!;WX9^ /$.F:S8^
M$_B[H^KZ+KW@'Q3XKT[Q,_AKQGI-S;^%;NR\,3^, #]]**_,;XA?\%:OV3/A
MEX9O/$WBJ^\<6::5)\?]/U_1DT+0O[6\,>(_V>?VK/A_^Q3KOA;Q5+=^*K/0
M_#>I^//VCOBCX(\%?#'4M7UJU\*^(-&U:[^(6K^(_#GPZT#Q%XKTK#\(?\%?
M?V8_B#:>![KP#X8^-_CP^*?!GQV^(7B:+P%X&\/^/8OA1X-_9B^(=]\+?CUK
MGCW6/!?C?7O#NK0^ _&EG!IVG6OPHUCXEW_Q4MM9\/ZC\$[7XE6.MZ?<3 'Z
MJT5^*7Q#_P""R?@KPY\%="_:2\(_"#QYXC^'&M?LJ?M8_M/^&_!$UU\,]3\;
M_%+PQ^SGJ'[,-I::_P"!/B!\,_BO\2?@]I?@B7_AH1HO%\VL^(M1\8Z9)H>L
M6]MX7BU[PAK/AO4OL+P=_P % OA%XL\?>'/A#>^$_BGX(^,VN?'_ /X9QU#X
M1>+M"\)'QOX0\:K^S!!^UY<>(/%!\+^./$_AF/X=VOP;O=.N)O&VA^(==TMO
M%^H6O@BW$_B-I;*  ^ZZ*_-#Q_\ \%0_@WX+\6?$SP?IOPZ^-GC"3P+K7QM^
M&OAKQUI?@_2;'X3_ !6_:+^ ?P6\3_'KX@?LV^!O&>H^(XM23XBZ9X"\%>,G
M37O$/A;1?AA>Z_X+\9>#=)\>ZKXW\.:AX;CR/A!^W7X_\.?\$Z?@K^VK^U7X
M&B?Q1\3_  AX.\=Z]X)^&&E_#CX36/A+2OB3#_;'AC3WOOCC^T_?^!6T[2]'
MN;*./QCKGQE\/:AXZ2YTG4;;X<>!_$OB#_A6NB 'ZC45^,?AC_@L#X U37/&
M^O)X*\5>/_A;XJB_9AU#]E73_AIX=L;/XI_$_1?CQ^Q=XR_;9UW4?%EO\3O'
M'@?P5X8'A;X2?#WQGXH,>LZ[X5FBL="D\.Q0:[XPU'2=+OO7/AK_ ,%8_P!G
M7XIZE\*1X?\ !OQXL?!GQ4N?V>_#3_%C6?AYI,/PQ^&_Q3_:L^&7A?XP_L^?
M!KXEZYI_C#5-2TKX@_$CP#X_^&.I6LOA[1O$_@7PWJOQ5^&_A'QKXW\->,?%
M^E:%( ?J!17XD^-?^"T'@K3?@OH7[2W@3X#?&_Q%\*_%'[*_QL_:;^'7A#Q=
MX)T_X>_$OXW>$?AUXE_9%\.^'?''@&?6/&4VD>%OA?<WO[3Z6NLZK\0-,TSQ
M/KMIH<_B_P"'?A[Q/X0M](U'QGZQ\._^"F@O/VF?BQ\ _B[\$?BQ\/\ 2M*_
M:<^#G[.GPX\?Q^#-'OO"7AGQ9\8_V+/@9^TQX9^&_P </$FD_$;Q)!!\5-3\
M8>.OB!X2CN/AQI'B'X=>'[&T^'-GXK\4:5?^,M#U7Q$ ?J]17X\>$O\ @M5^
MSAXMM_!NKQ_!C]K70?"/C7P1^S?\7K/QSXD^$7AVP\*Z/\!OVK_'D'PM^"/Q
MVU^YM_B)>ZE:?#_Q3\1I+KPPVEVNEWOQ+M+/2M7\?-\/V^%MA-XY'V5^RM^V
M;\./VO[CXMS?"SPUX\M/#/PB^(?B;X6:CXQ\51>!++2?$'C7P3XO\6>"?&6A
M:?H.A>//$?Q!\(:YX8UOPE/)JWA7XP>"OACXQCT76_"OB&W\-W.B>(M/OY #
MZ]HK\7=8_P""OO@WQGXO\'?#[X(^$IK;QUI_[2_AGX+?&?PK\4)_!NLWGAKP
MCXX_9K_:T^,_@SQ3H&K?!;XI>/O"]MK>K^*/V9=0\/ZAX4\3:_:>./"=G:Z_
M:^-? /AK4+_PW=S=+\$/^"N/PT\:_#S]GS4?'7P^^)UUXL^(/PR_8_\ ^%Q^
M-OACX#;4O@/\)OVD_P!L;X/^"?B7\(OV?=0\1:]XJM_%,?BGXCWOQ \#:/X/
MEL](\2^%- N?BA\)]+^)/CSPIJ/CC2'N #]?:*_+KX8_\%>OV/\ XQ>(_#_A
M3X>ZG\0]=UWQ6W[&47AFR7P-):OK\W[<7@>Z^*/PT@TE+O5(I+V;X?\ PQM&
M\?\ QU6!7_X5=X<N+-]0^WZC=1:<WO/BG]NGX(^#_%WBSP5K*>.6UCP3^U+\
M//V/]<.F>$9]5A;XN_$[X!>"?VD?#+:=%87<VH:GX9_X5SX_T 7^I65A)J$?
MB1KK0[32+UX8[B< ^S**_,[0?^"G/PS\=?\ !/\ ^.'_  43^'7PP^)6O_"#
MX0_"'XC?&?0M'U/4_A3!K7Q4\(?#SX;GXC7FH^&M0\%_$?XA:/X?@:U2[T3Q
M!H_C.YT+XA^!/$>B^)/#?B_X>Z9XGT.;0I;J_P#!3?X26'C;PUX%\7_"C]H+
MP/?3ZO\  +PA\5O$.L^#/"6J^"?V=/B3^U+KL'AK]GWX9?&KQ+X2\>^(HK/Q
M5\2];U3PG;6TW@&T\>^'/!=M\0/A]J/Q1U_P'9>+]*FD /TDI,#T'Y5^7?CW
M_@HU%\'OVTOBC^SI\2_AIXONOA3X8TK]A?3]&^,/@;PW;:IH_@?QS^VA\6?B
MI\$_"]K\9]2U7QCITMGH&O\ Q*\/?#KPIX0D\#>%/$.I:5<^(=;UOQI%9>%;
M0ZWIL?CC_@KA^S-\.?B%\=OA7XNT#XLV_P 0/@3<^ X+SPGX;T7P#\1O$7Q
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MA1\+/VN8_A;XU^)_@6-/V?O'W[5/[)?[//C[X[_$?]FN;Q5X-\;:AKUSXJ\
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M]XJ^/UC\<_#G[/\ \)=!_;0\8?#'X3^*OVJ/$OB2^^%^L>)?VL?A%XQ_8V\
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MF?X>:K^U[XFU.Z^''Q@^(W[3/QS\1?LB> _B==:%\:M8T?XG_%+X'_LQ^,?
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M6N?V3O[<M=9\1^''T[7?%GA]V\#^']1U76FMM&4 Y#]FK_@C#\+_  )^S)X
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M_P #=&_^3J .RHKC?^$DUW_H2=:_\#=&_P#DZC_A)-=_Z$G6O_ W1O\ Y.H
M[*N.\;?\@W3?^QE\.?\ IVMJ3_A)-=_Z$G6O_ W1O_DZJ=[)J_B-;.SG\.ZA
MI$<&IZ;J+75W<Z=-'ML+N*Y,6RTNY92\@0HIV%5;!8XH [U>@^@_E2T#@ >E
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %1 HH# 2(  A$! Q$!_\0
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MHHH **** "BBB@ HI"RC@GGT[\=?R[^G/H:7K0 4444 %%%% !1110 4444
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MN],UG1=7TZYM[_3=2T^ZN+.]LYX;BWFDBD5S_(+_ ,%+_#GAO]C;]KK]N_\
MX*&_LH_MR_\ !.WQ9\9-;^%7@"Q_;S_X)S_MQ+\+]5N_B+9?"7X.:%;^'-)^
M%M[)K=G\6?"GB3X@?#]/#R>#OAFEK:>%OB+XSUNS&J>(]>M8_#GA;P]_3=^P
MA\:-&_:+_8O_ &5_COX=^%<?P/\ #_Q7^ /PL\;Z#\'[:WM;?3/AMHNN^$-*
MN]*\'^'EL-+T*QE\*:+8M#:>$[NST+0[2_\ #4>DWMOHVE0W"6%N ?65%%%
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M $;UX+_\"_$O_P OZ/\ AW'^Q%_T;UX+_P# OQ+_ /+^CV/#_P#T,<Y_\,V
M_P#GV'O=H_\ @;_^5GVUN_V6_*C=_LM^5?$O_#N/]B+_ *-Z\%_^!?B7_P"7
M]'_#N/\ 8B_Z-Z\%_P#@7XE_^7]'L>'_ /H8YS_X9L!_\^P][M'_ ,#?_P K
M/MK=_LM^5&[_ &6_*OB7_AW'^Q%_T;UX+_\  OQ+_P#+^C_AW'^Q%_T;UX+_
M / OQ+_\OZ/8\/\ _0QSG_PS8#_Y]A[W:/\ X&__ )6?;6[_ &6_*C=_LM^5
M?$O_  [C_8B_Z-Z\%_\ @7XE_P#E_1_P[C_8B_Z-Z\%_^!?B7_Y?T>QX?_Z&
M.<_^&; ?_/L/>[1_\#?_ ,K/MK=_LM^5&[_9;\J^)?\ AW'^Q%_T;UX+_P#
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M+]B3_HWGP9_X%>)O_E]1_P .XOV)/^C>?!G_ (%>)O\ Y?4>QX?_ .ACG/\
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M-_\ RL^V=W^RWY4;O]EORKXF_P"'<7[$G_1O/@S_ ,"O$W_R^H_X=Q?L2?\
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M]B3_ *-Y\&?^!7B;_P"7U'_#N+]B3_HWGP9_X%>)O_E]1['A_P#Z&.<_^&;
M?_/L/>[1_P# W_\ *S[9W?[+?E1N_P!EORKXF_X=Q?L2?]&\^#/_  *\3?\
MR^H_X=Q?L2?]&\^#/_ KQ-_\OJ/8\/\ _0QSG_PS8#_Y]A[W:/\ X&__ )6?
M;.[_ &6_*C=_LM^5?$W_  [B_8D_Z-Y\&?\ @5XF_P#E]1_P[B_8D_Z-Y\&?
M^!7B;_Y?4>QX?_Z&.<_^&; ?_/L/>[1_\#?_ ,K/MG=_LM^5&[_9;\J^)O\
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M\%NOV3/$?@W0]3\'>"OVC?'WQ<\1?&OQA\ -*_9:^'_PRT+QO^T1>_$#X?\
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MXG^($U[=76D^-_'^CZ]X>.D6UOI6M^']!OO%?AKP_P"+_%>B:[?BW1W[(?\
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M "DH_P"$9U;_ *'7Q/\ ]^_#O_RDKL:* .._X1G5O^AU\3_]^_#O_P I*/\
MA&=6_P"AU\3_ /?OP[_\I*[&B@#CO^$9U;_H=?$__?OP[_\ *2C_ (1G5O\
MH=?$_P#W[\.__*2NQHH X[_A&=6_Z'7Q/_W[\.__ "DH_P"$9U;_ *'7Q/\
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M\26T&OFT^)FD:K\*H@#]5_\ A&=6_P"AU\3_ /?OP[_\I*/^$9U;_H=?$_\
MW[\._P#RDK\9/V*O^"[G[,O[1_[/GQ$^/GQ[?PW^R?%X!^&=_P#M$W?@;6M>
M^*?C[Q#;_LNQZ]8>"](^+^L7UY\ ?AKHNJ:EJ7C^:_\ !=SX/^#5W\:;"UUJ
M+2+#3_&>LZKKD>E6?TQ^V1_P5!^$7[$_QV_8X^$?Q4\%^.)?"G[6]SXLAN?C
M#916>G^$?@78:)XH^#OP^T'Q)\6].UW^S]9T/POXA^(_QV^''@Z]UN>.TMO"
M-WK:7/B%8$41$ _0/_A&=6_Z'7Q/_P!^_#O_ ,I*/^$9U;_H=?$__?OP[_\
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M1XSU3X?^#M0M]4^+EOX6L=*T&[\5::+&/5M;33M.N;.[M=;MKQ]%FBU"3A_
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MG;X4_P""8@\6_&,_LV^&=.\'Z!>WI\4>%A\2O&7A+PG\4M/^*]SX-\6^)8_
MR:-<>'/&>J6!\,>-;?1O"^BWNJ^";_4]$L[[3)[Z34%_2VB@#\;/%'_!"_\
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M\9Z#H6HW]C)\K>!O^" 6H_#WP=X\/A;]L&#0OC)XC^,/["'Q^\)_$+1/V;=
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ML\/\:_W%]Z '?97_ .?RY_[YM/\ Y%H^ROQ_I=SQS]VT_P#D6I_.B_YZQ_\
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MP#_R+47_ &&/%/\ ZE.M5V+=#]#_ "KCO /_ "+47_88\4_^I3K5 '94444
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M'/Q$\-+^RW\)+R)3+X,N+M_B7XSMI;C3-+FUD0SK%'H#);7;'7;XNZ22IQ"
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MM_\ 9<Y_=^#,9/'_  JN]!Q_X1K9Q[9SZFN;\0_M&_L<^%?L?]OWW@O3S?\
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M'_R+47_87\4?^I1K-==)_JY/]QO_ $$UR/@/_D6HO^POXH_]2C6: .QHHHH
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M?X$>.M ?X0>(?%/Q\\/:GXF^*UAXRU/Q!X'2UFT&U^%?C'7]'^(UG\./O_\
M9W_;P^#'QTN_A;\/XM<:#X[^.=(^.">)OAMH?@[XSK:>"/%?[+GB'X>^!OVB
M=,UG4/B9\)OA7XJ\+Z'X+\>?%+P'HGAC5/BIX&^&FM?$'3_%_AK6?#WAJ:'4
M)H[0 ^X:*_.?Q%_P56_8U\(:G\1_#WBGQ)\7]!\7_##XB?"[X7:YX"U#]F/]
MI%?B%K?BSXW^)OB#X*^#<?@/P)#\*YO%?Q!T?XF^,_A9X\\+^$_$'@_2=8T:
M[U+0EFN[VRTO6-!U'5/(OB#_ ,%EOV6K+2_A&GP5C\??&GQ7\6/'?[*_AUM%
MMOA-\=?"6@_#/PY^TS^UW!^R1::G\:O'=_\ "34/#'P5\:Z)XK\/_&)M$^%W
MQ8NO!OBOQAXF^$.N^"X8M)O-5T?4+@ _76BOBSXA?\% OV8?A7\?K']F?QGX
MH\<VGQ0FU;X*:%JTNF_!?XR^(?AUX.U3]I#Q'KO@OX!VGQ ^,&@> ]2^%/@2
M?XO>.?#FI^!_!$7BGQCI4FK>+EM-#5(KF_LA/\\Z'_P5_P#V1O%6F>%?B5H7
MBO7;?]GSQ/\ "'XP_%C3_B?XP^%7[27@/Q9XQLOAAXU_9/\  .F?\*3^%7B/
MX 6^H?&SPUXR\8?M9^"_ .B^(/"?B.'6?$/Q2BL_A]\+/!OQ2U*?Q?=> 0#]
M6:*_,K5/^"LW[(\NDV=MX1UGXDZ]\1M8\)_'7Q':_#;5?V?_ -I;0=;\#R?L
MYW^G:#\7E_:"CL?@GXEUO]G70?A]XE\0^$--\6>)/B5X9L8X[#QEX3USPGIO
MC&S\5>%4UWA/!/\ P5O^$_C^YTW2M$\#>-++5;'X[? GX$^+M2\0>#?CWI_@
M'Q#XA^-W[*FB_M6V8_9T\667[/NJZA\9]>LO"WB#3=-T3P;XP\+?!+6_$FGR
MV7C.Z'AKP[XN^&$OC\ _7"BORNOO^"SW[ &C>&+'Q=XD^(?Q2\(:3/XS^,/@
MO58_&7[-'[2'A35O!\G[/?B3P-X)^.GBWQYHVO?"NPU3P5\-OA-XY^(_A+P-
MXY^)/B2UT[P7HOC*ZUCPW-K3:MX1\86V@_J@#D9((]CC(_(D?D30 M%%% !1
M110 5Q]I_P CWKO_ &+/AK_TX^**["N/M/\ D>]=_P"Q9\-?^G'Q10!V%%%%
M "-T/T/\JX[P#_R+47_88\4_^I3K5=BW0_0_RKCO /\ R+47_88\4_\ J4ZU
M0!V5%%>.Z]/H?BCXG:%X2_X22]:33/"7CC4=;T/PWXVUG0KZTOH]4^&BZ3-K
M=KX7UK3;Y66PU>[?3X]3!18+^6:!"+CS& .E^(-YJMM8:#;:/J]WH5QK'BW0
M-&GU.PMM*NKZWLKZY;[4+2/6M.U;3%EF2(0F6YTZY\N-Y#$J3%)4Y.ZT/5-)
M^(?@"6_\:>)?$J2V?C2)+36[7P9;V\#_ -F6#_:87\.>$O#]Z9T5&B5);N:T
M,<TK26LDZ6T]M!XO\&:)HMUX%U"VO?%4D\/Q#\,B--5\?>.=9LF:9KN B73M
M:\27VFW#;)6\H7%K+Y<NR:$)/'%(GJ&N:)X<\0PP0:]I.AZY!:RFZMH-9T_3
M]4AMKCRW@-S!'?13)#/Y$TT1F0*YADEB+!7-%TK-J^O3Y?EN3+6+5[73UWZ/
MH?AS^UW\)_#=_P#MB:-\;--N=:CU3P;_ ,()J=AI-O;6<'AVYU;P'XCU>6:&
M\@73A>F"]UJRO/M\EM>V[W*227,,BO-YA^?/V@/AM9?M'>+-&\9^+)M8T*_T
M/PQ#X4MK7PO'"EE-8V^KZOK*W-S_ &S9ZO<M>M<:S/$[QSQPM!# #$9-[M\D
M_P#!4CX.?$S7_P#@IUX7\+_"^>2ST36='^!^E:'H]OXKB\-:4NH:_P")==NY
M[5-/M9['3[2R:]U0PI(;3'V<(T_VEE:23XI_:@_9M_:6^''Q>^'OA[Q!=2Z=
M?:KH?AW4H;;3OB8MU;36]QXRUC3$>9K#4C"LLEQ:3QNDF6$*J3NC*X_LW@KA
MVG7RC@3$2XMP6#S:KP:Z^!IRHS6+P67Q6(>*P\%&<(SC[2G[T_9SDE-N-113
M3_AOCS,U3S_CO"1R2OB<BEQ;6EFU?G7U*>;4_9?4UB)2O*GB*D6HTJ:E&$VX
MKD<I19^N/PN^$6A_".+6[?1;_6]1&OSZ?/='6_L)>%]-CNXX%MC96-CMC=;V
M7SUD$A.U/*,?SY_'3X^?\$R?A+\)M*\.:EHOCGXMZA+KNIZI;3KK,OA!XHX[
M2RCN8Y+<6/A&Q.]Y9"&,C.IBR %.6;]5?V>?A[X[^'\?C"'QT1YNJWVD2:6$
MUU-;41V4.K178#+/*+4EKBWV)F-9"N1\D0 _F?OO@'^TA>B6.[U*\NP'N/*6
M\^)DERB.[,"\:W&I2!&((!*@'  .<"OX#^DAP=BLEX_QG%CXXPM6'&=:$U3C
MA)T5%9-E.2X).5>=2I2Q',M4J5"@H)?O)5)\S/\ ;7]F%QYB.*/#W'\%8&5;
M@2CX94,K684\1B88R/$D>*<XXOQU!4Z7U95<M_LQIW4ZE7VZJ-*24>4_0/XI
M?\$T/@[X$^&'@[QQIOQ ^*MWJ?B2X\,0W=GJ%SX-_L^V&N>%M1UZY-LMMX3M
M[K-O=6:06XN+F4"#<9"\F&%/]EO]C7P,?C-H)3Q)X]DSI'B?&U]!89&BW&"&
M&@-SD@KZ$]#DU]>>-OB9X4\0?L]_![X?65]?7/B_P?HOPSL_$D$]A>1V\=WX
M:^'-QX;ULP:K,/(OA'K$H6*:-W-S"7NHW= C2?AKXNTWQWXL^/OCKPSX+U?5
M(-6D\2^));.*+Q->:'##:6,;7-VB7"W=O% @MTDQ A G.R#:0W/\T8"KF>:_
M7<-B,WJ4:-&A5E6JUHPE3E2]JJ>K5.#C>+B[Q:?NRU3N?Z/<.U.*,]RC.L'F
M6?XO XE2S;EQF.P]*3AA%CI4,-4<84:3<(4H<U.Z<JD7=U)7N???Q(_X)C_"
M+QW^VY?7FI^-OBW8W&LZKH4-PNG2^%$6$6GPUTZ-# ESX0N""5LT+"3>?F<C
M;@%<KXV_\$\_AC\,?'!\+Z1XQ^)][9_V'I>K>?J[^%S=B>_DO4EB'V/PO:0^
M4GV5-@\H2$LY=GP,?G/+X;^*T?Q'C^'TVNZR/';W-O;QD>-+V0"XFT==7A(U
MW[?M'_$K9!YC3[58^0Y"Y 3Q+X7^*FB>-]*\#>(-:U:;Q7K)T6WL4;QA>ZC#
M+_;5X]AI2/J;:A/%%&UR'W*\FVWC+2$ L=_O?5\TG'"T7Q1&<*&"A]6I.E"\
M<#06DZ:=+GE3@K<TKS:UYI.[1[N4\+9AE.(H1P?%]*&&J9?/$XO"4\+57]I8
MR2@JN</VBJ^S7LH).$'&G!1M[-7/LG3_ -B[P'=ZA86LGBCQ_LN[^QM':.3P
M_O5+FZA@9U#^'F7>BR%DR"-P&05!%?;'C/\ X(6?LY^-Y]/BU/XI?M$VT>ER
MW<,#V-W\.8S(EW);B5I3-\.9\$?9HRA7:J_,6!!%?E&/V=?V@U(99.00RD?$
M&(,K#!5U(OAAD;E2"2K8(.1FM(? W]IXNJC7=8#.P S\6+T99B!U&K'OC).*
MQIUL;0K0JX;C*C0J0=HRC"E?WER\JYJ,EJGRVM?6QQ\1Y+C\^P]/!T_$.AA<
M')6Q>$]A*M3Q;C5I5*"DZ/U>4'2E!I*$_>=3WDU&Q'/_ ,$MO@M#//#_ ,)W
M\76$4\T89KKPB"1'*Z D#P>!DA>2 !GH , 1#_@EU\%\\>.?BZ3@C_C[\)$'
M)Z8_X1#UYZ8/0]>/*? WA+XE_$?4M4TOPKJ-_=WND6PO+Y+OQ3<:<B0M="S#
M))<W(25S<'#!78[2TN2H->FC]G3]H,<[U(ZY_P"%@Q?7C%[VQD>^.O;U:N;<
M0T)>SJ\<2I5$H2<)QH*2C42E&3B\-=*<7>+:5UVL*IP)P_AY1H5\PRV%6,:3
MFIK%1D[P34VI8GF2J6E.-]TW;1'^A!_P2R\"Z=\,O^">G[)7@'2+K4+W3/"O
MPBT;2K.[U8P'4IX8KW4"LEX;6WM+<S$RG<8K:)2 ,*#DG[_'(!]:_/C_ ()4
M:)K/AO\ X)U?LAZ#XA_Y#>E_!_1+74_]-_M ?:4O;XOB]#N+D8(Q(&.1@9XP
M/T&7H/H/Y5_1652E/*\ME.K[><LOP;G7T_?2^JX:]5627[QMU-$E[^RV7^%W
M'U&GAN.^-L/1E&5'#\8<4T*,H7Y)4J'$.;TJ3A=M\KIPBXW;?*XW;>K4C((/
M<8_.OP6^/W_!7/XC? _]HO\ ;^_9YD^$/A;6-:^$7A#X3:%^PY/%?ZLLGQZ_
M:'^(/A?]G.RUKX8_$82:K;1:?I^@?$/]L+]GF_GO/#(L+NS^%5Q\0_%=[)Y7
MA"^O+;]Z&^ZW3H>O3IW]J_([XR>._P#@DWH/[05WJWQ:UCX%S_&_PY^U!96W
MQ'\2:_XYTO3[CX*?'37OV&_%>GZ/XU^*UUX@\7:-I/@'1-=_94\#'P#HVMO
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MQX?U_2O'WPXD^!&H^-/"=CX%UB/XJ_#S1-6TNYTFZT/1/C%'%XK /GSXS_\
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M%_%'_J4:S0!V-%%% !_G\J*B:-R<K,R#T"QD?^/*3^N/:F^5+_S\/_W[A_\
MB* &V?\ Q[I]9/\ T8]6:H6D<IMTQ<.!F3C9$?\ EJ_?95CRI?\ GY?_ +]P
M_P#Q% $]5;'_ (\[7_KWA_\ 0%J01R][AS_P"(?^R54LT?[':_Z0ZY@B/*P]
MT4]XQW(% &C14'E2_P#/R_\ W[A_^(I#%+@YN9,8/(C@R..HW1LN1U&01D<@
MCB@#+O-9TCP]H+ZSKNIZ=HND:?9Q3WVJ:M>VVFZ=90XC3S;N]O)(;:WCWNJ;
MY9%4NRJ"690=M3N4-QR,C!!!'8@C@@CD'N#7#Z!X48^!M*\*^+]6E^(&W28+
M+6=1\4:3HKOXB93YC3ZII4%G_91+-L'DI;F(>2C-YDFZ1NR$4H  N'  P/W<
M/;_@ 'Y  =@!Q0!3UG6-)\/Z7?ZUKNI6&C:-IEK->ZGJVJWEMI^F:=9VZ&2>
M[OKZ[DAMK2WA0%Y)YY$C0#+,*Y4^%7UF[UE]>U6'Q%X,\0>%M#T7_A ]6T?1
M;[P_!/:RZG-JFJ//);2W&I_V[;7UA:7-C?//8PII4,L )G81ZWB<>'AHUS:^
M,+G1CX?U1K?1;VW\1KI?]CZA)K-S#IEGI5U#J<9LKPZK>74%A!8S*YO+BXBM
MXT>21%/F.GZ]XDU7XFC0M4_M7X?Z/X3FE@\,6]WJG@VYLOCU8ZCX.TVZU/4=
M*TE#)XETNU^&VJW:Q7*+%;/-=.DUSOLI!#$ >Y(NQ H"A5 "JHPJJH 50!P
M     !T KB=/\8IJ?BWQIX,FT[^S[OPQIV@ZG:SRZMH]Q-KND^(+.]9=4M=(
MM;R76+"PL]2T^^T<W6J6=K!?7MI<?8)+A8)_*[$QR@9^T.<=0(XOQZ1D_H?I
M7@-U<>-+SQCIGBNW\ >)M%>QT7XK6.N6MI<?#YSXUM_#%[;V7PVTS6=6F/\
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MKPK^S+;^"[;PQ9?LBZ1\!=%^)/QE^)KW_B2[U'X??">UT;P*/AK?>'OA+/\
M%3X :S\0/B=IEA+\=OL/Q \?_!WQ-H.K>,/BS9?"J;XY^+-;U&_Y7XZ?\$]_
MVQOCK\1/B#\9/%OPI^ >OZIX_L/VT])\"_#[Q!^TY\2K)O@%K?[0OPH_X)U^
M ?@9\6-&\9Z'\&2+CQ-\*_%/[)OQ+\;>(M'\)V.E77@C6?%VC^*OA9XI\3^,
MM*M;VY /JSX!_P#!&[]C'X*WUC/\/_$_Q1UR[^'_ ,1OV??$%C'?>,? <DGA
MS4?V6_&/Q/\ BC\(?!>N?\(?X \.7&N#2=3^/'BVZ\5Z]X\DU[XM?$*SUC3=
M7\?^/?$FM2-KM]TVF_\ !'G]F70O$6AZUX<\=_M">'-,M/&OPZ^(7C/P7H_Q
M%T2#PC\6_%?P<_:U\??MI?!_4/B9:S^"KG5]2B^&OQG^)WC8Z#8>'=:\,6&J
M>%=3T[1O&-MXGNO"G@_5-!^"/BM^Q-\9_AKX_P!=^'7PWMH= ^)_[8W[3GQ$
M\'^+?C1\+I?&-KK?Q,_8_P#VD/@UX)TK]L;XD?$NZ\,^$K+1?@I\9/@AXA\&
MV7Q)^!WBKQAXQU?3=7^(TFC^%_ VKP:Q\4M9\-0X.B?L%?M7_&'0_CAK'PQ\
M/Z'^SY%J?Q3_ &_/">K>*K[XP^.=,^(/[4_@*_\ ^"G>D^-_A=\*O&GAOQ9\
M&_%WAWP!\-M*^ /P@\??"_P'XGU[1_C#X7\.?#_XLZ3%X \&^(?AC\4/BKX9
MN0#](O%__!-Z/XL?MU_$_P#:=^*'Q.\8+\)M=M/V']>\,_ _P+XKGT#PYXW^
M)'[&OCKXM_%'P=K/QTT^7PM)J&M:)X*^)WBSX=_$#X?:7X/\;:):ZQKWA*XL
M?B/8>(/#$4.@7_(ZU^P-^PKK(^!W[$=[XE^+=YXM_9V_8JG^$/PXTK0_$?B3
M_A,/A_\ !O6_B]\"O'_PY^,'BGX@>'/"8T?P;\3])^-/[$7@CQ-\#?$7B35_
M#L/BOQ#\+/B+%HOA+QMIWASQ59:,EU^QC\6K7]C7]G_X-V>AGXAVWPR_:&U_
MXN?%/]FSXR?&#P[/X5^,/PGU[Q/\9M9TS]G_ %'XA?##X(^ ?A]I7@'X8Z[\
M1?A[\2/AC\)M/^#-K\)[#3_@KX(_9RO)(OASYOC2TZ']A_\ 88^(?[/7Q(\<
M_%;XB77@&;QYXR_9!_9Y^!UGXR\/:KK7CWQ/X1USX>?&#]K[QQJG@A/%OC70
M-)U[QSX&^&WP\^+'[/'PR\'>-?$OV7Q#\2K'X1Q:MXL\+^'+BRL[64 [_P
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MA[6?$GPQ\/>-)OB-J/@V3]H6U\97_BKQ!I_QHM+SQ;KYOOTO^*_Q?^'OP/\
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M[,UMJ-@$0B]E:0.)LLL;(J[=K>S?%G]@3X&>"=.T&]T75?B4\NJW5U'="_\
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MX2;Q"%U*W^#/P(\,_"?X?R1Q:[I0\;WO@*]\42)X<O/%-U96'W?10!^6\_\
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M<Z7*[*5D>*'I/LMM_P ^\'_?F/\ ^)K+U?4O#GAZS;4=>O\ 1=#T])(HFO\
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M^+/AH_P<\3_';P)X(N?C./A%XT\<Z;)X%7]C'Q=^T/X^7PCJS>+_  OX7O\
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M_@ZUUS6%\*> ?A7XNUB'Q_?_  >\!?$GQ[/\0+[5;OX?Z#/X:&3^PMXE^/\
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MB,'A\'5RR>&=""JX?+YX3#T%2=2*:P]-VC*\)?LW\<OVEO'-]\4_%=Y/KOA
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M_9&N7=C:W5UI&H:??G3]4FM9]+;3M/O&L#J'[&03RP2QS0NT4L;;HV4#@_Q
MCH01\KJ?O(2" 2<?!<3<,9SPCF<LISS#0H8I4J=>G*C5CB,-B</5;A#$82O!
M0]M1=12ISYZ6'JTIQE"M0A-6?[CX<^)/"/BKPW3XIX,S">.RUXFK@<72Q6&J
M8',,MS"A&%2M@<PP%>4ZV'KQI5*-:E-2K87$T*U*MAL35IM\GK3RE3@12./5
M?+ ^GSR(?TIGGG_GA-^<'_Q^N<N_%N@Z5H-UXC\0ZOI'A[2=-C5]8U36]1LM
M)TK3%,B1++>:EJ$UO:6T$LLL2127$T:M)*D6?,)0>.>,_P!K/]G#P'X:U/Q9
MK'QA\%ZGIFD+:O=67@747^)_BJX%W>V]A"NC^!/AM;>+/&^O2K/=1/<0Z#X>
MU*6SLUN-2NU@TZRO;NW\",9R^"$Y]/=A4DK]FXPDMO/Y+<^^492^&$Y:VO&G
M4DD^S<8-)^K/?K68B!!Y$IYDY!@_YZ/ZS5X_^T#\=?"?[.'PC\:?&SQ[9>)+
MOP?X&MM)NM8M/#%EIVI:]+'J^N:9X=MAIUE?:MI5G.R7^KVDMQY^H6RI:I/(
MK/(B12>$_#'_ (*$_LK_ !;DLT^'OC^\O],&KW.E:QX@\9^$?&GP9T/1EAC\
M4B6^BO/C=X>^'/\ PD]M::UX6O/#>KIX,7Q%<>'];NM.M=>BTUM2TX7GCO\
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MN-*<7*<G')\WC[-S52G0A)X!TJ-.?/43]E3M";A+V52454I.I"U0^%^C^_\
MC9<8.K*I.'#7$'-#VRKT</&3RMT<-0J^TK>TA1IWIU)QJ.E4K0E.CST[5#]%
M:\\^(_PN\%_%C3O#FD>.M)?6=.\)_$#X?_%'0H(]3U72S:>./A?XLTOQQX(U
M=Y=)O+*6ZBTCQ-HNFZA)IEV\VEZDMN;/5+.]L99K:3T.BOZE/[F/C/1OV OV
M5?#_ (/^+_@32OA@L'ACXWZ=;Z+XTTZ7Q?XVN7TWP[I?BCQQXY\+>%_AS?W.
MORW_ ,)O"_P_\;_$KQYXP^&>@?#2X\+:7\-O$/B>_P!1\#VN@O#8K:\O9_\
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MF1[_ )'_  HR/?\ (_X4 +129'O^1_PHR/?\C_A0 M%)D>_Y'_"C(]_R/^%
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M!YGQE*CB,/A_;_5\-B*4_$"=+$8;#O$XEX?#5J53#8?ZSB%0P]%5ZWM?K?\
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M_+]?^"5?P/=5;_A8/QD^90<'5? 8()'/!^'_ !ST]L5]C_ 7X#^'?V>O!)\
M^$]:\0:QHYU[5O$!NO$[:7/JC76K):QRP>?I&EZ/9BV@%G%]G L1-\\GFRN"
MFWWFBO=ROA/AO)<6\=E.3X+ 8MTJM#ZQAX5(U/8UG!U:?O8BK&TW3@W>#UBK
M6./)/#_@OAO'+,\BX<RW*\>J-7#K%86&)C55"O[/VU).KC<1!0J*E34TJ:NH
M)7MH%%%%?1'V(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'VG
M_(]Z[_V+/AK_ -./BBNPKCK0_P#%=ZY[^&?#0![9&H^*,C/J.] '8T444 %<
MM<^#]&NI6F;^TH6)=A'9ZQJEE &=VD<K;VMW%"A>1V=RJ#>[,[<L:ZDG )].
M:Y6X\7Z;!*T:VFMW:JSH)[#0M6O[9WB=HY42YL[2>W=HI$>-PLA*R(ZD K0!
M7_X0G1_^>FM?^%%K?_RPH_X0G1_^>FM?^%%K?_RPIW_"::?_ - KQ1_X2VO?
M_*^C_A--/_Z!7BC_ ,);7O\ Y7T -_X0G1_^>FM?^%%K?_RPH_X0G1_^>FM?
M^%%K?_RPIW_"::?_ - KQ1_X2VO?_*^C_A--/_Z!7BC_ ,);7O\ Y7T -_X0
MG1_^>FM?^%%K?_RPH_X0G1_^>FM?^%%K?_RPIW_"::?_ - KQ1_X2VO?_*^C
M_A--/_Z!7BC_ ,);7O\ Y7T -_X0G1_^>FM?^%%K?_RPH_X0G1_^>FM?^%%K
M?_RPIW_"::?_ - KQ1_X2VO?_*^C_A--/_Z!7BC_ ,);7O\ Y7T -_X0G1_^
M>FM?^%%K?_RPH_X0G1_^>FM?^%%K?_RPIW_"::?_ - KQ1_X2VO?_*^C_A--
M/_Z!7BC_ ,);7O\ Y7T -_X0G1_^>FM?^%%K?_RPH_X0G1_^>FM?^%%K?_RP
MIW_"::?_ - KQ1_X2VO?_*^C_A--/_Z!7BC_ ,);7O\ Y7T -_X0G1_^>FM?
M^%%K?_RPH_X0G1_^>FM?^%%K?_RPIW_"::?_ - KQ1_X2VO?_*^C_A--/_Z!
M7BC_ ,);7O\ Y7T -_X0G1_^>FM?^%%K?_RPH_X0G1_^>FM?^%%K?_RPIW_"
M::?_ - KQ1_X2VO?_*^C_A--/_Z!7BC_ ,);7O\ Y7T -_X0G1_^>FM?^%%K
M?_RPH_X0G1_^>FM?^%%K?_RPIW_"::?_ - KQ1_X2VO?_*^C_A--/_Z!7BC_
M ,);7O\ Y7T -_X0G1_^>FM?^%%K?_RPH_X0G1_^>FM?^%%K?_RPIW_"::?_
M - KQ1_X2VO?_*^C_A--/_Z!7BC_ ,);7O\ Y7T -_X0G1_^>FM?^%%K?_RP
MH_X0G1_^>FM?^%%K?_RPIW_"::?_ - KQ1_X2VO?_*^C_A--/_Z!7BC_ ,);
M7O\ Y7T -_X0G1_^>FM?^%%K?_RPH_X0G1_^>FM?^%%K?_RPIW_"::?_ - K
MQ1_X2VO?_*^C_A--/_Z!7BC_ ,);7O\ Y7T -_X0G1_^>FM?^%%K?_RPH_X0
MG1_^>FM?^%%K?_RPIW_"::?_ - KQ1_X2VO?_*^C_A--/_Z!7BC_ ,);7O\
MY7T -_X0G1_^>FM?^%%K?_RPH_X0G1_^>FM?^%%K?_RPIW_"::?_ - KQ1_X
M2VO?_*^C_A--/_Z!7BC_ ,);7O\ Y7T -_X0G1_^>FM?^%%K?_RPH_X0G1_^
M>FM?^%%K?_RPIW_"::?_ - KQ1_X2VO?_*^C_A--/_Z!7BC_ ,);7O\ Y7T
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M)?QG^(GBCX.S?M(^)OB+HFH_$?X9_LY^+[6YU+P[X9^&'BGQ+X9\&7FK7EB
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MOVCM3\7^#]?\[P[H>@:-\2H-&O\ 0_$_B+P;;1:?J-O8ZU9:V-%M=*U"QD8
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M (WU[Q+::U\++/Q_X*^'GC6^\$>(]-\&^--9-Y%>^&;[5X=8 !_06"" <C!
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M[\<==;Q7XTUO6M9\9WVK^&[>.2P^P:IC?L^_\$.?B1!IO[/^@_&#X#> M/\
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MR?"CXGWK:U%-JLFI^(/^$V\4WEGKP.KPZDEL^EJBVEI]GGEA=VU"ZSZF38'
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M)OA2ZF\0QZ9I_P 2/#-XF@?$7PGX>2\U[4].U]1Y4^JV=GI&J:[XI@\+ZM%
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M?YNU#_@L+\</#U_^VE8-XX^&'B31/%]S^U3XC^&7PYMOBFMA^U3^S5H7@?\
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M$]&_X)F_L^_M-?#/XL>,/B-^TEX'^-VC>+]>_8T_9'^$_P 3_'_QJ_:$\/\
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MM-,TO5=6(B_LL[_&K_XJ? ;4EET32OAM#;:WJ/A#QI<Z/);:-X+%G:1>'/A
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M_'?OUI]?YCK9>B\];:Z]=;Z]=UHT?Z:[:;6TMMMHM.FEM.FW0****8!1110
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MX-_#2\^'-]X=NO'4LWPO^-DWQZ\-C4O$-E=1R^-Y?V6-4_8_>WU01Z):F\T
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M!T?PGJM[XEO/$%G_ &MJ=UKMC<0OH'@FPUZX\-BSLM'_ .$ML=%\9MXBTGQ
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MT;Q!\?=+DU2UT_0]+YCX6_M/R^!/@)X4^)US^T3XC'[=?B36?ASX._;XTO\
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M%.BSPOXQTKP!XK\5?$;XC:_\)+I?8_@'^VE^W!\1_&?PA\3_ !(\$_#SX?>
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MCTKQ%XGN=6\_\+_MP?M(>//$E]K4_C63QGI>OP?\$V_&7PF^ MW\,M:^ OQ
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M_P#0I>+O_ '3/_EQ0!V5%<;_ ,)?+_T*7B[_ , =,_\ EQ1_PE\O_0I>+O\
MP!TS_P"7% '945QO_"7R_P#0I>+O_ '3/_EQ1_PE\O\ T*7B[_P!TS_Y<4 =
ME17&_P#"7R_]"EXN_P# '3/_ )<4?\)?+_T*7B[_ , =,_\ EQ0!V5%<;_PE
M\O\ T*7B[_P!TS_Y<4?\)?+_ -"EXN_\ =,_^7% '945QO\ PE\O_0I>+O\
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M4C4G&/NJ:C[IV-%<=_PFVG?] OQ/_P"$UJ__ ,BT?\)MIW_0+\3_ /A-:O\
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MK_\ R+0!V-%<=_PFVG?] OQ/_P"$UJ__ ,BT?\)MIW_0+\3_ /A-:O\ _(M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_008.jpg
<TEXT>
begin 644 form10-k_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "/ :0# 2(  A$! Q$!_\0
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MD-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'Q-^WO^R9I_P"V7^SMJWPOC\<WOPK\?>%_
M%G@KXR?!;XN:;:6M]?\ PK^-'PHU^T\7_#[QTNG7Q$5[8Z?J%H=.\4:;(8AJ
MWA36-?TDL!J!Q^?GQ/\ "O\ P68_:6^%'B/]E[XEZ-^Q9^SKX-^(^A7'PS^*
M/[7WPU^*?C[Q]XAU?X?^(X1X=\67OP;^".N^!?#">#O''C'1+NZL-';QEXZU
M?3/"NJ:L6C_M:2PTXR?3?_!::YN;+_@DM_P42N+2XN+2Y@_9'^-+17%O+/!-
M$?\ A#-57*W0P_*D@\C&3DX85^%/_!1+6]9A_P"#?+_@D]?V^KZG%?W/Q7_X
M)A"?4%U"Z-]+FRL;D"XO#=_;6"WMK;-DN71[,%<;5V ']8GP;^$_@OX#_"7X
M:_!3X=Z>^G>!/A/X#\*?#KP=I]Q,US<VV@>#M#LO#FDK=W6,W=Z+&RC_ +1O
M0%,DA9RG)KU.BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P
M]_:=U'1/!G_!;G_@GQXR^--Y8:9\+/$/[+'[3GPQ_9_UOQ'<6\'AW3/VKM8\
M5^ =7U;3+6ZOGCL+#QKXR^#EC>Z=X60'^U-9%AJ6D:2DC/)&S?\ @MC?:!JO
MAG]ACX:^%KFSN/VI/%'_  4/_97\0?LW:1I<EK+XVLK_ ,'^.DUCXG>,K6U+
M&_M/!'ASX5CQ8?B#J0']D1Z/>"'5B%O@*]*_X*X?'7]GKX:>"_V5?@M^TY^S
M1H_[3WPX_;*_:Z^&7[,I\,>(+O3+*Q\$:OXGM/$6L6'Q.M&NM/OKUM:\-C0&
M.DC0-1\-ZL'OODUS2]I#^)?#;PC^PS^P=_P5%^ G[(OP:_929/C-^T?^SE\5
M_B5#^TOXH^(OBKXB^,?!OA+X;:J;1_AU:WOQ/O\ QGXOL]"U\_:E*>'O$VCZ
M6&6R5]+U/)\L _>>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\NO^"V7_*(W_@HU_P!F
MC?&G_P!0Z_K\(?\ @HO_ ,J\G_!)?_LK/_!+_P#]-MG7[O?\%LO^41O_  4:
M_P"S1OC3_P"H=?U^$/\ P47_ .5>3_@DO_V5G_@E_P#^FVSH _LCHHHH ***
M* "BBB@ HHHH **** /F;]H;]KG]G;]D]/A3=?M$?$_1_A7:?&_XJ^'?@G\-
M=2\0V.NS:3K_ ,4/%UMJ-WX<\+76KZ-I^IZ=X:.H6NCWK_VYXDFTGPW$;<F7
M5HR5#=I\6OCO\*_@:WPW_P"%H^+(_"A^+_Q3\*?!;X=&72-<U4>(_B?X[-^O
MA3PLAT2PU'[!)J:Z5>LE_J;:;I*"U_>ZE%N"O^/7_!;[X+_#?]HW6_\ @F!\
M"?BYX>B\4?#3XL_M_P"G>"?&6AO<75G//I&L?L]?'BU^U6=U98O=/O\ 3KTV
M>HZ5J*$#3=6M+!R1D ?G_P"/_C9\3O"VO?L/?\$WOVJO$MQXA_:E_9*_X*B_
ML?3>"?B!JF+>^_:G_9/U8?$BQ^$_[0.DXQ]N\5:=8VG_  K_ .-NGV&6TKQ_
MHYU8OM\1HJ@']=5>.?&GX[?"#]F_X<:[\7/CK\2?"?PM^&?AE;<:SXO\::Q;
M:7I4%S=W)M+73+9V)DO];U*^:.PTC0M-CO\ 5M7U%AIFE:;)*\:-_,S^VM^T
MO\9=?NOV[?BK\!OVE_\ @H]\4?%G[..N_%:V^'5Y^R!\+OAQX!_8@^ 6H?!W
MPO\ VS=> _C)XL^+?_$N^.VN>&]=TJ[/QLU'3=3U7!O-0\):-I.E?V;S].?%
MGQE/\?OVUO\ @@EK/[1,.B:I\*?B9\"/C/\ &_3]*U2UMH/ &O?MG#X(?#;Q
M)\/_ /B4W8:QOM=\.>%?$'Q.\0_#S3M15CI>K6?]K:.1J^F# !^E'[/G_!3W
M]AC]J?Q_%\*?@W\=+#4?B5=:;/K6D?#_ ,:^"_B3\(_&/BG1K(^9=:KX+\/_
M !;\%>!=1\::=8VO^G3WW@Y=733UP\Q1 P'Z"U^'/_!>RQT.Q_9!^&OQ"T:*
M"W_:+^'W[7O[)]]^RCKFGQQCQ]:?&'6/CMX+T:YT7P/=1K_:.?$G@:[\6Z=X
MLT_3V4:KX5&H?VJK)IR,O[A1[]B;_OX^?ZX.>OOC_P#50!)1110!_./_ ,'
M,8N/'O\ P1?L_P#GM_P5G^!\Q^MIX0\=9[C^]]?ITK6_:*Q<?\'*_P#P3Q3_
M )]/^"??[3\WU/\ PE%X/S[?7':LS_@O=']H^,G_  1+L_\ GX_X*L_"B?\
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M\0/AI\*= ^'^B_#[5M;\1:I8?$OPEJWPTTJQTCP-X]\.?$/PR?#OB#PQ\1M
M2SMI(/%WAJ72=1!:174:9?RZ<WVO10!^9GP9_P""5W[._P *?BOX0^-OBSQM
M^TA^T]\3?AG)?R?"+Q'^UG\>/&7QUC^$%Q?6K65SJ7PZT'Q.Z>']"U\V.VQ_
MX3 Z7J7BP*V1K"L,K\;?M;_\$\_V^/AE^T/\0_VYO^"7O[7?B+2_B=\1M1T[
M7/BY^QE^TOX@U/QC^R_\7KC1M-315@\%"['V[X1:[+8VEL(K[3WBTW>$(UC2
M-)#Q-^_E% 'X,_LC?\%S/A/\0?B99_LH?M[?#'Q3_P $Z?VX;<P6,WPC^.;_
M -G_  Z^(U_Y5L#JWP3^,=P5\(^*=&U._ CT>QOM0T]M3!C71-0\3GS):_>%
M)$E5'1PZ2#?&Z]"/8]._?KSD<5\F?M>?L/\ [+/[=WPPO/A)^U3\&_"7Q8\*
M3Q7']F3ZU:FW\4>%M0NK?8VJ^"?%UB;'Q!X5UG&2NH>'M3TV3*@.6"LH_"V7
M]G?_ (*W?\$;Y&U;]C_Q?XB_X*C?L%Z/<>?>?LJ_&C7$@_:N^#/A47:&ZL_@
MW\3!&1\0+#3;%Y%TS0;[37!6W*1>$HV1M88 ]<_X+K R_M%_\$-K+_GO_P %
M1O ,Y]_LO@_6#C\=PI_Q=;SO^#G/]D&,'(L_^"9_QWE_\"OB/@?UKNOV@/VL
M/V-_VG?@O_P3P_:F^)/[+G[4'CSXW7_QXO\ XA?L7_LK1>#==\$?M&2?'7X<
MZ'XGM?%XU7PAJ^N>&/#P\)^"]"LM5UWQ1XB\::M_P@ TFTT+6F:0WVF*_6_!
M?XS?LW?''_@H%I_Q.^.W[)W[17[)G_!0_P"&'[*_C:U^'OAGXQ3:5JT/Q _9
MNO?%5E>^-]3^&5Y\,/&_C3X9?$+6O#GBDVNGZOIVX>+_  PNL6'_ !+?[*U)
M9  ?N)7Y5_M]?\%?/V0/^"?36'@SQ[XGUCXL_M&>*-MI\./V4_@=IY^(/QX\
M<:O>QW']E6H\*Z2SGPQ8Z@Z*1J?B)M+# L-*BU5PMB?S/U;]I3_@KG_P5QU2
M^\)_L5_#WQ5_P2__ &)I-3N-(\1?M=?M!^%+BQ_:G^)&FV.IW5CJY^"'P<O7
M2\\$1WZ6MU_9FNZBR:BK@./%>E2G^RC^G?[ W_!(O]CW_@GI!?>)_AAX3U3X
MC?'WQ/$TWQ%_:C^,VI/\0?CQX]U6Z@4:M<W?B_6=W]AV6I?.6TKPY'I>GMO(
MU,ZDZ&1@#\O4_9$_X*M?\%A9(-=_X*!^/]<_X)R?L/:U*)[;]A?X ^)3_P -
M#?$_P^;NT-K;?M!_%A0[>&K+4=.5O[3\&Z:I7%WY>K>$-)U9 R_O7^RO^QY^
MS1^Q1\,--^#_ .R]\'/!WP@\"V4=N9K+PQI20:GKM\!C^VO%OB"]\S7_ !3K
MA))?5/$.IZGJAW;?, "K7U!10!\U_M-_LE_LY?MF?##5/@]^T]\(/!7QD^'^
MJ E=&\5Z:MS<:3?9 CU;PYK"M'KOA?7;, &/7_#VHZ7JB_,!(%^0_@7<?L7?
M\%3?^"0-Q/XC_P"";?Q%UC]OS]BS2YUN]3_8#_:*\2^9\8_ASH"-<O=VO[-_
MQCO"CWL>FV;JND^#M2"JXM /[&\5:K("W]1%% 'Y._L#_P#!8G]D+]OR[U#X
M<>&M:U_X'_M/^%M^G_$3]DSX]V!^'_QR\(:O9QVIU:WM/#VLK&/&5EI[W84:
MAX<:_*CYM8T[2F;8/UBK\QOV]_\ @DQ^QU_P4.L;+6/C!X*OO!OQM\.0;_AY
M^TK\([\^ _CQ\/+^T1AIEUH_CC24\S4;/3V^SO'HGB*+5-*Q$HBCB8>:/RMC
M_:(_X*V_\$<)'TW]L7PEXB_X*B_L&:1-Y&G?M7?!K0A#^U=\&/"ZWC*+[XV?
M#$O(OC_1],L"#JGB"PU'<T=J-4G\694:,0#^HNBOD;]D;]N/]EK]NSX7VWQ<
M_97^,?A'XL^$Y8K4:G;Z/?\ E>*/"FI7ELMW_8/C7PE=[?$/A?6HMQ1K'5=,
MAW!'.FM?P@/7B'[>G_!5?]CC_@G;I%E;?'#X@R:W\6_$XV?#G]G;X:6*^.?C
MM\1+^ZQ!I=IX>^'^DR#4;*SU"]GMK"'7M?;2=&+RA%U&60;" ?I17X4?MD?\
M%R?@M\(_B3/^RO\ L5_#OQ9_P40_;CNVNK&Q^!7[/LBZKX3\#:@ 575/C-\6
M;1-3\(^"M%TN[(&KV*/J6K:;]W6AX8CQJ0^23\%O^"N__!9-O[2_:<\1^)O^
M"4O_  3^UB=9;;]G#X6ZH)_VROC9X5:[NU^S?%CXAL$7X86&NV'V9Y= T[3L
MB*Z.DZOX1U7 U9_W(_8Y_8._90_8&^&MO\*_V5?@[X7^%V@"*#^V-3TZT^V^
M,/%][;0@+J?C?QG?%_$'BC4"%7]]JNH.%.[RUC5V4 'X[_"S_@E!^V-^VQ\3
M/ _[2W_!9O\ :-O/$3^"?$^D>/?A5^P-^S;XBU7P;^S;\*M>T35;35M NO'_
M (@T:]&O?%'Q5IIM+7??KJ;,K?:U_P"$KU/1W_LNOTA^.G_!+G]GSXU_%WQ!
M^T#X?\<?M'?LU_&KQOINDZ1\3/B!^RG\=?&7P1U7XJ6'AVW%IX<C^).F:,+W
MPWXIO] L2VGZ3K^H>'CXFM]/?RDU;RE5%_2RB@#\J_'W_!'G]B[XB_LA>(OV
M,M2\,?$#2O 7B?X@K\9]5^(NF?%'QA<_';4_CM;'_1OC?X@^*^M7^H^(_$OQ
M'R SW_B0ZOI!B$>EKI(TO3]/B3\Q1X[_ ."P7_!&98D^*>F>)_\ @KG_ ,$]
M= 1(E^)7A2U\G]N;X'^&+);P-=>-O#S&1/BWHF@6%K;/)J<;ZIJ+J&&J:UX7
MC"*/ZCJ* /B3]BS_ (*%?LC_ /!0CX>GXA_LL?%_0?B!:V*6Z>*O"+N=%^)'
MP^OW/.E^/_A_JK)XC\*WBD[(Y=0TX:9J)#-H^J:FBB0?;=?A_P#MK?\ !$#]
MG_\ :%^(,W[3O[,GC+QE^P3^W%I1N+WP_P#M*_LYJ/#G]O:L53%M\6/A_92:
M?H'Q#T2_>TMAJY(TG5]2"YFU;4T_T"3RO]F']NW_ (*4_LX?'OX:?L8?\%0_
MV7-4^)-Q\2O%%OX&^$/[?O[*/A[4O$?P6\>:C<W=X-+_ .%Q^"+2RBU#X2Z@
M;(VHU;73I^E:/&ZF5M&725?6* /Z%**_)GQY_P %1;R/XF?%?P%^S;^Q)^UE
M^V#H7P!\;W_PT^-'Q/\ @MI?POTOP1X:^(OA^"POO%?@+PK=_$_XC>"-3^)W
MBKP;9ZI:IXJTWP7INIQ:9JMT-'.HG5@8ASGQQ_X*\^!O#7[)7P3_ &F_V6/V
M?OCW^V5KG[2OB*^^'_P9^$GPO\":O9>)HOB+I%Q?:?X@T#XQW%_8NWPB7P;K
MVE:KHGBR3Q!IK/I>J:??Q!'">90!^L_B'Q'H'A+0M5\3>*-;TGPSX=T.PN-2
MU?7O$&IVND:)I-A:J6N=0U35K]X["QLHT7>UY>R(H7<Q(Y%?SO?&#_@MW\1/
MVGO'VO\ [,W_  1/^ \O[9WQ7TR:XT;QG^U1XLAU/PK^Q?\ !.X?Y3J>J?$&
M[.F_\+!O]-#?;H].\.O_ &=JWV55T5_%>YM+/%^'/^"5G[='_!3G7=*^+7_!
M:CXW/X2^#,=]:Z[X._X)H?LO^(=4\-_"O2+5+NZN[6U^//Q#L+P:]\0=<"M:
M'5=/T[5-30$'^R/%FDJKZ4O]#WP@^"_PG_9[^'_A_P"%/P2^''A'X5?#CPM;
M_9- \%^!-"L/#OAW3+?Y4REG8HJM=/E/-O79K^^D&^1Y",J ?B-^SA_P0PT/
MQ!\4=(_:T_X*L_&/5_\ @HU^UA;3+J.@Z5X\M7MOV9O@K<_:EN[;1/A/\$W!
M\.W=EIX6 K?^)-,,4LMHFJ#PQ%K!.IC^@*SL[6PMK>RL[>&TM+2&"UM[:WC%
MO#;06H5+:"VMT0*MNBKM4*0 O ^7A-"B@#\9OVZ_^"*G[,'[7GC&S_:!^'>I
M>*?V.OVTO#<K:EX-_:S_ &<+Y_ _Q &L6N19?\+ TW2#I^F_$+1W/EQ:H-5\
MK5Y-,/\ 98UI=) AKX9T?_@I=_P4*_X)5:MIWP]_X+%_!RY^./[-T=U;Z-X>
M_P""F?[+OA:ZUOPY!!L-K:7/[1OPGT:S&H>#;[_1@=6U[3--TU6?<NBZ1XHE
M+-7]/]8>L:1I7B#2]1T3Q!I6GZWH^K6EQ8:EHVL6-KJ6E:E8W8^SW-G>V=V)
M+&]L[U&"O97@=9%=@ZL!L4 \R^!_Q_\ @S^TQ\.=!^+G[/\ \4/!GQ9^&WB.
MV,^E>,? ^O6FNZ5*25/V:Y%H"UE?Q_\ ,1TW4$T_4]/8M'+$A;*^TU_.9\<?
M^"'?B/X)_$?7_P!J;_@C/\>=0_8*^/VJ7AU?QG\$'2Y\1_L=_'&X#6=V^E>-
M?A0PO]/\&7E\;78NI^&],;2]+-YG2='TB3.IB_\  '_@N;/\,?B5H?[*G_!7
M[X(:A_P3Y_:3U"=-*\/?$K5;JYU3]D3XU7/VLV0U3X=?&$R7VFZ%]L<6S26'
MB/49-+TP781_%>_9& #^B2BN;_X2;P[_ &!_PE?]O:1_PBW]F?V__P )/_:E
MG_PC_P#8'V/[;_;?]L_:O[-_L?\ L_\ T[^T/-_LWR?WOF8^:OY_?CS_ ,%R
M;GXJ_$W7/V6/^"/GP-U#_@H#^TEI\\FE^)OB9ITMQHG[(/P4N1<_8O[6^(?Q
MA#V&G^)_L3N\@T3PYJ<.F:O';;=*\5&1&4@'[>_''X__  9_9F^'.O?%O]H#
MXH>#/A+\-O#EL)]5\8^.->M="TN(Y/\ HML+L!KW4'/&GZ;IZ:AJ>HN%2**0
MC+?STZO_ ,%*O^"AO_!5G5-1^'W_  1X^#ES\"/V:YKJYT;Q%_P4S_:?\+76
MDZ%=P;/LM[=?LY?"?6K(W_C&]S<DZ5K^J:=J4:L$&M:1X7D4-7IOP-_X(=:_
M\:_B/H/[5'_!97X[:A^WK^T!I]PNK>$/@F4N?#W['?P.N2]Y=KI7@GX4*MAI
M_C&[L3=;#J?B32UTO4_LF=6T;5GV:F?Z%](TG2M!TO3M$T'3;'1='TBTAT_3
M-*TBQM]/TS3K*S"VMM:65I9B.RM;.R4,$LHP!&J81$"[2 ?A7X)_X)T_L>_\
M$O/V/OVWOCQ^U5XF^,?[:NI_$_X-Z[XI_;E^*GQHU2Y^(GBWXR^"/!VE^(M7
MO/#'A[P/>ZUIWA_1-%TV/5]7'A733J7]KZ>7LE?Q:HT[36TSYE\=?!C_ ()B
M_LZ_LL_LK_MC?%KX@?\ !0'XS?L?_%7QY^S>GP'_ &9/BC\?/B/\4_A+X4UW
MXO7%CK'P>_M_X->)_%FGC4=%^'C_ &6^/A_Q'XG\<Z3HW]D)_9.CZOA?-_43
M_@ME_P HC?\ @HU_V:-\:?\ U#K^OPA_X*+_ /*O)_P27_[*S_P2_P#_ $VV
M= 'ZL?MQ?\$D/'/Q+^/.L?MV?L#?M3?$;]CG]N*\TO0=.U_4_P"TM5\7? +X
MXZ?X;M;6QT?PS\8OAC?MJ%@=.2PMAIXU'2M/==.<#5O[$DU8?VF/"?@Y_P %
MO/B!^S/X_P! _9E_X+8? 6X_8K^+>ISG1_!?[47AI=1\5?L8?&VXLP -3TKX
M@V9U%OA]>ZD$6^DT_P 1.=,TH7@769/"IVZ6/Z0:\D^,WP5^$?[0GP^U_P"$
MOQP^&_@_XK_#GQ3 ;77_  9XYT&R\0Z%J-N-R%GM+U&"W:*',5[9[;^Q=E>-
MU;:2 =SX>\1:!XMT/2?$WA;6M(\2^'=;L+?4M(UW0-1M-7T35[&[4/:ZAI>K
M6#R6%[9R(V];RRDD5E*D'  KHJ_F(\0_\$L?VZ_^"8VMZM\5_P#@BQ\<'\8_
M!>2_NM=\8_\ !-']I[Q#J?B7X5:C:R7EM=:C:_ 7XAZA>_V]\/M=<"Y&EZ?J
M.IZ8NX_\3?Q7JX*:4_Z3^#_^"G&@^&_V)M*_:X_;#^ GQH_9$\3W'C(_"J3]
MG3Q?X<N/&7QB\4_%A]?/AGP]X,^$WASPS%_:/Q-N_B)KBD_#IM/TS2SJ^EDZ
MO(NFZ.#JE 'ZH45^06A_\%8K;PSXN\!:1^UI^QA^U=^Q1X$^*WBW1O OPX^-
M'QOT;X;:I\+;SQKXEN39^$_"WQ!U?X8_$;QQJ'PDUOQ+>A;'21\0],TC2'U>
M[L=(;6!JC;%]>^/W_!3+]G_]F;]MS]F+]A_XLP^)?#_C#]K'PQXAUKX<?$B?
M^RA\.K/Q#I.N+HVD>!/$5U]N&IZ-K?C*^#:?X4OGTO\ LG4]6:QT;^TQJVH1
M* #]'Z*^4_&G[4GA7P9^UE\$OV1+SPWXGN_&7QQ^%_Q>^*6@^*[,Z0/"NCZ5
M\'[SP79ZMINL+=ZA'KAU'4SXULSI+Z;IFI6 %K?C4GB)%?4OGP^9Y/FQ^=C/
MD^8OF^O3=NZ>V,]\4 3T444 %%%% !1110 4444 %%%% 'XX_P#!3^S_ &5?
M&OQ+_8T^$WQZ^*'QD_9<^-'BGQS\2=?_ &0_VP?AGXAT'P%8_";XK>'/!5I:
M>(/ NJ_$+Q->/X?%_P#%;POJUSIVD_#SQCX;U;1_BG'H^H:2@WZ;L/B?P$^*
M_P"TM\!/^"B/P(_9#^+/[4?PE_X*'>&?C!\(/C)XIT7XF0?#7P%X'_:E_9KT
M[X;VOAN]?4OB;=_#&]?P=K?PL^*=YJUIX>TO4UTGPKJS^*K+3D&G:IM.WZ)_
MX*=_M%_#7X=^-OV#OV6?C#^S;\._VD?AS^WM^U!:?L_>*=&^)2:;J'AWP;8C
M0+G5K?QE;>'M9\/^(M-U[4;"]N;,+9.-*/D_;2FJQ.5#>7_!;Q?^S!^Q?_P5
M&\._\$UOV9OV+_@O\%=%^*_[(_B7]IGQ1\6_AUIFD^%==OM1\)>/K/P?8^#]
M6TFPT W>MZ0+.ZN=12_O_$W_ !*YBJ1:64+, #]P:*** "BBB@ HHHH *8ZK
M(K(ZAE[CU_P(Z<'-/HH _!?]L+_@A1\'OBC\2;S]J#]AKXJ^.O\ @FY^V=<S
MM-??&/\ 9W']E^#O'@OG*ZM:?%?X3V%]IGAWQ1_:"7+2-?Z<VE2?VFJZKK"Z
MR_%>]?L$?\$;?V2_V$]7O_BS:V&O_M"_M9^*I&OOB!^UW^T%=GQ]\:/$FKWB
M6G]K7.@ZKK+ZA_P@EA?R6N38^'734G0B/5M8U7:&K];J* "BBB@ HHHH ***
M* "BBB@#^;7P;\/_ (;_ !:^*G[5WQ?_ .">W_!1KXK_ /!/CXIZ3^T/\4(O
MVI?V8?C!HWPH\<?"S_A?OAJYL]'\1?$CQ7\!?B=>GQ!X,T7XB6EGI/BT^+OA
MYXZ\,:3\0-(O+'6@V\;%_1+_ ()-?M)>-/VH_P!DE/B%X\\-?##3_$GAWXR?
M''X77WC7X(:7<:+\'/C6_P ./B-K/AJZ^._PQM+P-(OA7XJW]G>^(0?[1U;&
MJM?JNL:HH_M!O:?CE_P3S_89_:=\86GQ"_: _9+^ OQ=\=64-M:0^+_'OPT\
M+Z]XEDL;4EK6SN]6O=/>^O+),@"POY'B7E=F%%?5'AOPSX<\&:!H_A+P?X?T
M;PIX6\.V%KIFA>'/#>EV>BZ'I&G6:[;;3=*TG3[6+3[*TLU4B.TL$54"X" '
M# '3T444 %%%% !1110 5X5\?OV</@1^U5\--8^$'[1/PH\%_&#X:>(8RNJ>
M$_'&CP:I9"X965-3TNY8_P!HZ)K=@#G2]>T"_P!-U?2F/F:7J<4@4K[K10!_
M,#_Q#4^#O^$D_P"%,/\ MW?M>-_P3(^WGQ-_PP$?B)JA\/\ _"3\@>&?^%E?
M;_[=_P"%0BU_TO\ X0W^S!J7]I?O/[:\W_B:5_07\!/V=/@7^RU\.-%^$'[.
M_P */!?P@^&_AV$)I'A/P-HUOI.G^8% >]OF!^V:SK5]E3J>O:M>ZCJVJLAE
MU34I'"D>YT4 %%%% 'Y=?\%LO^41O_!1K_LT;XT_^H=?U^$/_!1?_E7D_P""
M2_\ V5G_ ()?_P#IMLZ_=[_@ME_RB-_X*-?]FC?&G_U#K^OP>_X*,'/_  ;P
M_P#!)?U_X6K_ ,$O_P!-+LQF@#^R:BBB@ K\/?\ @K9JME\+/CM_P2L_:K^*
M#"R_9C_9S_:^\57/QX\3W,5S=>'/AO<_%3X)^,_AO\)OBAXO"[5T;PMX.^(>
MK6-GJ_BZ_0:1X4&M?VMJDE@F'K]PJY[Q!H.A^*=%U7PYXGT;2?$7A_6K"ZTS
M5] US3[35=$U:PO%^RW6G:GI5\LFGWUE?(Q1[*^61)-SHX8;@H!^*7_!;SXY
M_!+QG_P3?^-?P'\+>-_!'Q+^,_[67A[1O@O^S#\-_!?B31?%?B_XC?%_QEK^
MDCP/J?A'2]%O-0O&L/!FH6G_  G^K^+P%TSPMI'ARZUB75$9(0_@'[4_[*G@
M[]J3_@IA\$?V5_CRMSJUGXP_X(Y?%_POK'B2PD6+Q'X;\?:/\>/@Y_9?Q/\
M".JJ0VA^./!GBJTMO%WA+Q!9$E-7L]Q!0*M?L'\#_P#@GU^PY^S9XRU#XA?
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M5/A=X(O_ (U^'_!6K_#71OBI=^&],F\<:9\/]:O!>ZMX-MO$+VAU$>&=1O\
M-[-IA?\ LYY=SF,>8=WSOI?_  3/_P""?6A7/BV[T?\ 8T_9TTZY\>:S9>(/
M$\EI\*?"UO\ VGK-GXBLO%]IJ38T[;8WD7BG2['75?3?[.SJ=G9.XW('8 ^Z
MJ*** "BBB@ HHHH **** "BBB@#^=K_@M;_R>G_P0._[23V'_J(6U4/&W_*T
M9\#O^T5/Q1_]7)I-7_\ @M;_ ,GI_P#! [_M)/8?^HA;50\;?\K1GP._[14_
M%'_U<FDT ?T:4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.<$Z>-;6[72]P!72ULUVA@2/K&@ HHHH **** "BBB@ HHHH **** "BBB@
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? %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_009.jpg
<TEXT>
begin 644 form10-k_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #- HH# 2(  A$! Q$!_\0
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MO[F=/$]UX-\2IX4^(_@72OB#X;UV*#Q5\(/'-UXLTZVN-.T[4I-5U6X-A_9
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MB>'OAHT.N:]\++@ZO=VFI-J/S]\:O^"A?QS_ &;?!W_!;?XE?!*Y\7P?M ?
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M)T\LS><9)_"XRCD\HR4NCC)I]&S[O$>&?&F%KUL+BL!E.%Q.'J2HU\-BN,>
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M#^E_#Y9/$7BO4+3PKIVD>$-$L_ ^BMX&L?#!T/PA)J&CZ+%81ZIJ$EP[4_\
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MBO\ I&Q^U3_X7'[,?_S\*/\ AL+]HK_I&Q^U3_X7'[,?_P _"E_;N7?SXO\
M\-6<_P#SE#_B'?%G_/C(O_$W\.__ */SV;]H']DCX2_M/_LW:O\ LH_&63QU
MXC^#OB?P]H/A/QG8V'CKQ!X<\3^-?#N@+9^7I?B7QGX?GT[Q)=0:K+I]E<>(
M)+34+"YUMX&AOYY;.[OK2X\2\ _\$S?V=_AK/\!&\-^*OVCY=/\ V6?"^L>$
M_P!G+P[KO[1_Q;\0^#_@[9ZM\(O$GP(M]4\+>#M8\177AF]\4>&OA/XN\1^#
M?!GBCQ1I/B'7/".E:OJ4.A7UC_:-_P#:I_\ AL+]HK_I&Q^U3_X7'[,?_P _
M"C_AL+]HK_I&Q^U3_P"%Q^S'_P#/PH_MW+OY\7_X:LY_^<H?\0[XL_Y\9%_X
MF_AW_P#1^>@_L3_L*_L]?\$^?A7?_!']F32O&/AGX6WOBG4O&D7A7Q5X_P#%
M_P 1(-)\1ZXL1U^^T74O&VHZSK6G1Z[<00ZAJ5A'J+:=)J8FO[>TM[F\OI;K
M?_:)_9)^'_[2/B?X/^./$7COX\?#GQK\#-6\2ZIX"\3_  /^-?Q ^%%T8?&=
MKHUEXJT7Q;HOAO5(O"GCS1-9MM TN$VGC/0-;ETF*.]CT"YTE-:UQ-1\?_X;
M"_:*_P"D;'[5/_A<?LQ__/PH_P"&POVBO^D;'[5/_A<?LQ__ #\*/[=R[^?%
M_P#AJSG_ .<H?\0[XL_Y\9%_XF_AW_\ 1^6/''_!,G]COQC\*_@A\)].^'VL
M_#?3/V;I_B%<? _QA\,?&?BOPK\4OA_+\9/#OBGPE\<+BT^)?]HW_BW7M0^.
M/A_QQXQ3XO:SXNU+Q#KGCWQ%XAN?B%KFIS_$NQT7QEI?*_%#_@DG^PG\4O!/
MPL^'=U\*-7\#^$/A/\!=4_91T?2_A5\0/'?PXN?$O[*WB&X\,7WBG]G7X@Z_
MX;URT\1^-OAKXGU/P=X?U;57UK5YO&4.L1ZUJVD>+=+U#QAXTN/$71?\-A?M
M%?\ 2-C]JG_PN/V8_P#Y^%'_  V%^T5_TC8_:I_\+C]F/_Y^%']NY=_/B_\
MPU9S_P#.4/\ B'?%G_/C(O\ Q-_#O_Z/SW_X_P#[+OP>_:1_9_\ $_[+GQ!T
MC5=.^!_C/PO:^!?$G@OX>ZUJ/PY@O? =K:Q6 \#6U]X1;3+_ $7PI-IL,.F7
M&E:#<:8KZ7"NF))'8-+;R<:O[%'P.'[&LG[!,D'CFX_9NE^#S?L_'P[/X_\
M$[^)X_@J=&3PJOPYC\>+=IXM&A)X*C7P0L[:H^M'PL6L9-4:X)NJ\R_X;"_:
M*_Z1L?M4_P#A<?LQ_P#S\*/^&POVBO\ I&Q^U3_X7'[,?_S\*/[=R[^?%_\
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MX@T_7H/'=OXB>/29;#3-*ETVTT?28[/L?^&IOV^?^D7GBC_Q,']FC_Y:T?\
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M$DO\2M#MO%6M>.]6\21_%/Q/)J'B/1_$WCK6/#OBOQ/HNKXOQI_X(S?L)?M
M>(?VFO$7Q*\!^/+MOVP/#/P=\%_'[0M ^+OQ \)^%/%WA'X 7?@Z^^#OAO3O
M#'AK6],T?P?I?@.Y\">'GTJ'P=;:$]UY6H+JTVH+K.K"[[+_ (:F_;Y_Z1>>
M*/\ Q,']FC_Y:T?\-3?M\_\ 2+SQ1_XF#^S1_P#+6@#C_'G_  1I_83^*EK^
MUG;?$_P%XZ^(4O[;UC\&X/VC-3\5_%OQ_?ZMXNU?]GFUBL_@AXNTC48=;MKG
MP;XL^'%K"MII&J^$VTA-2L)K[2_$UIKNF:C?6ESK^.O^"2G[*OQ-^%>C?!_X
M@ZI^T1XW\*Q>&O'G@WQ]J'C3]I+XM^-/&?QP\+?$^Y^%\WCC2?CAXU\7>)==
M\2?$)K^V^#?PZTOPWJ]YJ-IX@^%^E>';*T^$FK> S;V\L6S_ ,-3?M\_](O/
M%'_B8/[-'_RUH_X:F_;Y_P"D7GBC_P 3!_9H_P#EK0!]/>._V:?AWX^\1_L]
M^)+N;QEX9?\ 9?\ $UQXM^$?A_P+XQU;PAX/T[6+CP5J7PW U_PGI$L6A>*K
M"Q^'VO>)_!VDZ;K]E>V.D:1XIUUM+M[+4+BWO[;Y9\8?\$G?V0?''Q\_:0_:
M9UG1_B=;?&#]KCX0>(O@'^T'KV@?&'Q[X=TWX@_"#Q)X%L/AS<>"[WPQHVK6
M?ARQCTOPKI&C67ASQ#I>FV7B_0+G2;+4M-\16^H+-<3V/^&IOV^?^D7GBC_Q
M,']FC_Y:T?\ #4W[?/\ TB\\4?\ B8/[-'_RUH \PC_X(C?L%PV-MI\7A7XL
M16MK^QQ?_P#!/Z*./XZ?$Q7;]C[4O$.H>*;SX(3SC7O/N/#\VLZI>S#6)I9/
M%D5LT6GPZ^FGVUM;1:'C#_@BM^P-XWT/P;X8UOX>>-AX8\,_L^_"O]E'Q%X>
MT[XJ^.M-TSXO?LX_ _Q?X;\<_"+X3_&2.TUA)_&VE^ ?$/A+03I/B9KBP^(%
M]X>M+CP1K_B[6/!.JZQX>U#O_P#AJ;]OG_I%YXH_\3!_9H_^6M'_  U-^WS_
M -(O/%'_ (F#^S1_\M: .&^-O_!%_P#81_:#\0?M.>)/B9X&^(5]=?MAW/P4
MN?VA-.\/_&'XA^#]"\=K^SC8:?IOP-LTT7PQKFEV'ARQ^&]EI.F0:#;>&XM)
M67['%+J[:E-YDLGY\_&__@F!_P %)->_:[_:@_:'^ /[7GQ-^!GB_P"+?Q=^
M&WB'X+^(_"OQD\+:Y\!?"_PR\%?#CX0^ ]03X\_!?XC_  -\7?$/Q7XTNY/!
M7C'6)_AW\//'6G_"/Q=<ZGX=M)M1^']L^L30?>_C;]O[]L3X>^+/@YX*\4?\
M$RO&EKX@^//Q UKX8_#:VM?VL?V;KV'4_%V@?"?XE?&O4[34+B+5MNEV<7@#
MX2^-;]-0G5H'O[.QTLE;C4[7=Z1_PU-^WS_TB\\4?^)@_LT?_+6@#Z/_ &JO
MV0_V>/VU_A--\%?VE?AMI_Q'\!CQ%H?C/1[:35-<\-^(_!WCCPQ)<2>&_'7@
M'QMX3U/1/&'@3QIH8N[VUL?$OA/7-)U0:7J6KZ%/<W&AZSJVG7WB&I_\$WO@
M=XM^'WQ%^'GQ6\;?M&_&ZR^)_P (?$_P"\1>(/BW^T#\0O%'B>P^#'CDZ9'X
MY\">%[N#4M+TSPT/'-GH^G:9XZ\:Z5I%O\2O&VE6MI8^*?&NKPZ9I2V//_\
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M:?K=S=Q7^HZ_=ZUJ&KZK=7G:_P##4W[?/_2+SQ1_XF#^S1_\M:/^&IOV^?\
MI%YXH_\ $P?V:/\ Y:T >0?%K_@A?_P3R^.9\23_ !3\%?&_Q;J'C+X/_#/X
M)^,]5U/]J_\ :6EU/QQX2^$'BRS\;?#Z]\<W1^*;'QKXE\-^(].LK[3=:\5I
MK+V#6T*V%O:&-6'J7Q6_X).?LE?&OXK^"OCE\2(OC3XC^+?PR\;>!O'WPO\
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M/7QY\,?#_P ,_&+5D^*GQ'D\%?$1OA=X5B\!^ _$OB;X6GQ.OPWO?%WAOP5
MOAO2?$ \+1W6EV%UK$VEK9ZEXC\1WVK>-C]J7]OHG'_#KSQ1SQ_R>!^S1_\
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MLV'B+0/%6B:%YE\./^"D6C_$;XP>(/@E'^Q_^V1X2\8>!+C]GM?BH_BCPU\
M[FU^$VF_M0SZO:_!_7_'&F>"_P!HGQAXO.C:E<:'JB^+G\*>%_%&H?#*VLKO
M5/B3IWA32+*^O[;Q[X,?LB?&G6_VR_B=^U#\4?!/_"O/!OQV^/7A[]H?4?A_
M?>+O"GBC7_"<7[-/[+'P]_9A_9]^'GQ"L/"^H:QX4U+Q%XS\:^,OC5^T7/K'
M@KQ'XPT+P2_PH^"^CW&MMXCU"^CTWS;XX_LH_M5^,/B3_P %H?$'@WX'>!/%
M>E?MA_LM?LZ_"?X"Z?\ %+Q]I-IX'^)NM_"'P7\8O"GQ#\,>/+#P?XFA\6>%
MM,\76?Q2AM?!AU%[;2-:^P:E!XZO/"6F2QP:D?=]R"WF_P#P*7_R1^WUGJFD
M:C;VEWI^IZ;?6E_'YUA=6E_:W-O?0YP9;.>":2*YB#90R0LZ;P5W=2'?VEI1
MN+*T74=/>ZU*.[FTZV6^MS<:A#I[0K?S6,'F^;=QV+7$"WCVZ2);--$LS(TB
M!OYN? O_  30_;!\/?"W6?&_@3PC\*OA=^UO\$O^"E7C_P#:F_8X\9?$36/A
MU\0[.P^$/[5'@_PS\+_VE=+\?Z;\-/AWX#\&>#%O/ _CWXE^/?$/@#X9:7I?
MA_Q!\=/A]X<N=&6^T:S\/^,/$?<>)/\ @ES\2/"GQ0\2?#;X1_#+P<OPOM?B
M_P#\$Q_B%^R'^TM<ZWX7;Q=^QG\*OV*KSX8:=\;?@NUEKI;XAV]]\0O#/@;X
MMZUX!G^%^BZYX6^)?C']K7XP:3\9KGP!I-_XG\1^+3[ON06\W_X%+_Y(_H-.
MJ:0'U2,ZEIX?0U1]:3[=;;]'26U6_C?5%\[.G(]BPO5>]$ :U(N$W1%7*KJ6
ME-!9W8U'3C:ZC':S:?<B_MS!?Q7TUG;V<ME*)3'=1W=QJ%A!:O TBW$][:0P
MEWN8!)_,:?\ @F]^V/'\$/%/AL?LP?L_ZK^T+\'O%WA:\UOX]S?'C4O"7B7_
M (*?_#OPG^W%X5_:VU/P'XWU;1/#.O7_ ,*[SXJZ'I7BBZ\<>*/C'9>*[G3?
MCMK_ /8VCV5Q\'/$GC76+OYE^.'[!7PX\6?'7P5^Q_9_L._!2T^+WQ;_ ."3
M?_!11/A]\#-=^*W@7XIO^S7X[^,W[6WP:U[X6_%7Q/\ $SXBW\&N:-;^ /&'
MC7X@?$-]5_9^\-:_<_!K6-<\?>&/V<?"OC+3--U'Q'KI]WW(+>;_ / I?_)'
M]</A+XE?#[QWXB^(OA+P?XLT3Q%XD^$?B>P\%_$S2-*O5N[SP3XMU3PEX<\>
M6'AS7EBREGJ]QX.\7^&/$7V+>\T6FZYITLZQM<*E=[Y(]OS-?FA^PM^RO\0_
MV:?CK^VWJ/C+PAX.UC2?C5\0?@9\1?#G[1-E=Z!:>/?BS>>'_P!D']G'X)?$
M.W\9^%-/T8ZWHVK7/Q@^#WQ*^*>MW.K^)[_3M4U+XIPZOI2ZCK6J^+[RT_3:
MC[ON06\W_P"!2_\ DB#R1[?F:/)'M^9J>BC[ON06\W_X%+_Y(@\D>WYFCR1[
M?F:GHH^[[D%O-_\ @4O_ )(_._\ ;,3;^T'_ ,$T1QS^UYXK/KT_96_:"]>?
M\@]:H?\ !-GGP]^V;_VD@_;3_3XH2#_/].E:7[9__)PO_!-#_L[OQ7_ZRM^T
M'69_P38_Y%W]LW_M)!^VI_ZM&6O&R_\ Y&?$'EC,NM\\EPUS] XI27!_A9;K
MD'%S>KU?_$1<U2O=N]EHK[:VW/T@HHHKV3X ***_G$_X*3?$?_@H=KO_  4<
M\.?LH?L%?&;Q/X%\:>//^"=WBKXT^!-*GUKX5:9\)_!_QE\&_M8_"CP7%\6?
MBHOQ%^'OQ&U;6/A_9?#/Q/XP\.>*/ _@[PWXFU?Q/=7FA7&C^'-/U6RNO%^D
M ']'>1ZBC(]>O2OY2?VNO^"_GQ@^'+_\%(_@Y\*/A1\&(/BO^R1^SY\;/'_@
MKXI)\3[KQOX:M?%'P:_:T^%O[*?B!O%_@NR\*-81:Q=Z;\6=-^*NF>%8?%FL
M6O@7Q7H.J?!3X@7NK:SH_B;6-*]9UW_@KY\8?@G\8/C;\*+3X3Q_'KXM^,/V
MPOBI\-OASH6O_M&^!?"7P%TK2_@=_P $]?@5^U+JW@_X9_$_6O@Y\/[+P79_
M$N7Q5:>'/!EI\4=9\16=GX@UCQ]\6=8\:RZ1HD'P]U@ _I=HK^8;XY?\%W?C
MEX9U3]MGP#X+_9O^%>B:M\!M!_X*L:%\*?B%K'QA\1^+EUCQ[_P3?^$GP$^+
M\FN>.OAO:?"WPW;6&A^+O"O[0&AF#P[H7Q(UV>X\3>&]4T>?Q!I6@75MXI;^
MA']G+Q?XH\?_  $^#GC7QM?>&=3\8^)_AMX/UKQ7J'@[41JOAF\\17VAV4VL
MW&D7HTO1 ]O+J#7+20KI-@EG<>=9);JMN"0#VBBBB@ (!X(R/0U^:7_!.4#_
M (27_@H_P./^"EOQPQ^/PH^ 6?S[U^EM?FE_P3E_Y&3_ (*0?]I+?CA_ZJ?X
M!4 ?I;117+Z9XW\%ZWJU]H&C>+_"^KZ[I8N6U/1=,U_2;_5M.6RNOL-X;[3K
M2[EO+06EZ#9W)N(8Q!=?Z/+LF^2@#IV&01Z@C]*_"_\ :#_X*C?M">%/A9XZ
M_:*_9I_9ETWX_?"GX4?MH_%+]F3Q#\.(->O+'XX?$KX9_LQ^'/B#>_M3?&GX
M3&'4H_"UQKWA3Q7\*_B?X;^&7PGN[?5=3^(/AOP7;>-K3Q/!K?C#3?AOI/[H
M9!!P03CMS^@/]17YX_ #]C'PI\./$^M>*/"7Q8U?7OA-<?M4_%O]LOX+Z'X7
MO]-ATWP]XT_:/T'Q7;_&OPMXDU*!=8TOXA^ KKQGX_\ B?XT^'TUF^@W'AJ#
MXFW?ADVES)\/_#'BBZ /$?@;_P %/]#^*^L_LW>/=(U/X9_$G]EG]L[]H#X@
M?L_?L_?&+X;2>(=*U'1_%VG?!?4_CM\,--^(FA^*-1OY;B^\6:#X&^+_ ,.?
M'%K90>'?$'PR^+_@KPWX7U;PK?KXL\2/\,_U\!R >F1G%?G-I?\ P3B^"_A7
MXA?L_O\ #O3],^'7P*_9X_:$^-7[8F@_!OP]83SZ=KG[4?QD\-^/?"!\2QWE
MY=M8>!_AKX"TKXM?%OQ#I/PY\.:<\&H^.?&/A>YT?4? ?A+X8'PE\0/T,O\
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MP1_PDG?_  N_X)R_LI_ /XF^!OCKITGB?3?B1HGB_P#:.UV^U_Q7\0$O]/\
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M/C[0(;W2[.\T46'BSPG\1+7P-XY\#>,_#&A?6VD_\$^?V.M#USX#:YH_P/\
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MT_XGS:[#XVTF#Q#X?>\^/'B:QO? R:'H>J7-KX>\/W-MXWT^6[U.W'R-I_\
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M0^&O#>HZ)\=GU;4-+\,>)/BIXWT*'P)\/_[5C$A&"./J1UZ\@YP> 1G& !C
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M &A?^"MWQR\7ZOXH^%WC#5?CKX1M/"'[8W@SQG<?ME:!8_";]F72?BO\)/\
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M>@1?'?QK\/;/PYI]W8_U=C&..G;'3%,\M?0CIC!(Q@8'?TSSUY)SFG@   <
M# 'H!0 5^?W_  31_P"3=OB3_P!I ?\ @K#_ .O2_P!L:OT!K\_O^":/_)NW
MQ)_[2 _\%8?_ %Z7^V-0!\3?\%)_A#\7_'7_  4__P"",7Q6^&W@_P =2^$O
MV>==_;GUGXK?%WP_\&?$?Q:\-?"G3_BI^S]HG@KP-%KUGI-DR2R^./%6FMH%
MK!I]W+J&A3BV\5:A;V=E86=Z?QQ_8YT[_@J_^R/^QY_P3D^!WP6^ G[5O@=?
MAWXG^)OBW]I#P?:_ ;P79>#!:^+?^"I>@:SJ>F>)(M>TZX\>Z]K'B']C[XC>
M+]3AT;P^VG^%?#GA>YFU70-5U3XB>#]0NOA)_;,45CDC/.>IZ_GWP,CH<<BD
M,:'L>PZMT'X]^_KWS0!_*OX@^+'_  5JU/P5^TAK?@>U_P""@$VL^+_VHOAQ
M\-OV?/AA?_ OX6Z=KOP\_9IT5/%'@S6?C)\3?B;XP^&_PXL?^$L^//C&SN_B
MOKV@?"33O&&F_!#P-8_#/P9?Z]\/(/&_BCQ#X9]!^%/B/_@L;\1_"_Q(\:ZA
MXU_:7\'_ !=^'?\ P2A_9X^)?PM^$7BOX*?!?P3\,_C+_P %(]1_9Y^,_AGX
MU>$/&>M>*_@W%;VT.G?%.Y^%?C-/A[X>\?> ?"DGC*^L9WDL_"GA[Q+X?TG^
MF?8OICZ''8#^G7K[T>6G(V\''&3P1G!'/!Y)R,<\]: /YMO^"=WPW^-]IX/_
M ."NWCKXP?#G]I_4+O\ :#\'?L_:_P"']:_:#^#EUX;^*_Q@URT_X)\?#WX<
M_$>Q3P)X>\">%TUO4]$^*^B^*/!+Z1H?@N(3Q6^FMY>J/J!U*^_+S]D#]G[_
M (*%?L=^"]0^+1_9M_:(T[XV#_@BK\&?V=/V7=:_9G^!>AZ;?>'OB7\+?B=)
MXB^,7PC_ &G?AS\5'\3VNJ_M+V'B 0ZC\)OCGK<$/PIUSX'VNN1_#[PCXI^)
MNMV?@S6O[C/+0=!C/7D\X&!SG/2CRTZX^G)XQG''3O0!_(;K'A/_ (*A_%/P
MYX5UWX\>#?VL=<\0^'_V1/\ @MO\#4\)3_#7P/XH\%^*?B%?^-M.?]CNW^*'
MP[G\(>*?!OC_ $SQW\#(W\+>'/%'B_1]5TCXBWOA>P\.37^NZEXJ\8P?$+Z:
M_8 U3_@JMH?QX_9 ^'OQ-\(?$'P=\#]$\$:#X=^+/PZN?@U\/OAI^SY\/?V8
MO#?_  3J_9QB^&,OA27P_P##SPC9>&_C];_MX?\ "X/"?B3X7>%-:DU3PSX5
M@UW31\/=$^".B?"K6=/_ *5Q$@Z ]_XF/4Y)Y)YSSGUH$2#MZ]V.,]3R?ICT
MQQB@#S'XY?\ )%/C#_V2WX@_^HGJ]>#_ /!.?_E'O^PC_P!F:_LP?^J2\#U[
MQ\<O^2*?&'_LEOQ!_P#43U>O!_\ @G/_ ,H]_P!A'_LS7]F#_P!4EX'H _%?
M]B_]F[_@H)\8O@M?>*O@C_P4$N_@7\,[;XQ?'KP_X?\ AF?A1H/BD:&^D?&/
MQE'K%S'K=U+#=7":WKLNI:T8)%86KW[0+*R1HL?UC_PPO_P5:_Z2PW?/_5"/
M#OO_ -/?'7M_05[S_P $A,?\,@79(R%_:(_:@.,9/'QR\<'@8)[=!WZ#-?0M
MG^W=^S3J7QC@^!.D^)O&NM^.KKXOZO\ L_VFHZ#\$_C=KOPONOC9X:^'^J_%
M'Q=\,H?C;I/PZO/@X/%7@OP-H6NZMXPM)?',<'AR^T#Q+X7U.Y@\7^%?$V@:
M1\!D7#. Q6399B*F*SN-2M@J-2:I<0YW0I*4G6NJ=&AC:=&E!62C"G3A&*22
MBDDC^F_$SQBXMR;Q!XQRG!97X=2PF6\08[!X>6.\*/#?,L;.E2IY9:>+S''<
M-5<;CL34<Y3KXO&5JN)KU&ZE:K.<I2?P!_PPM_P59 P/^"L-V!S_ ,T(\/=\
MY_Y>\CJ?QYZT#]A?_@JTO3_@K#=]^OP(\.GJ<GK=GJ>]?MAH^K:3X@TK3-=T
M/4=.UG1=:T^SU;1]7TF\MM2TK5M*U&WCN]/U/3-1LY);2_TZ_LYH;NRO;266
MVNK::*>"62*17/DOCCX_?#CX>_%_X'_ OQ%<:Z/B+^T-)\2!\--/TOPKXAUC
M2KFU^$_A1/&/C?4O$GB+3--N=$\'Z9IVF7.FV=I?>)+W3K?5M=UG1M"TQ[K4
M]2M[<^M_JCEO_07G_P#XDW$'_P \#X?_ (CGQK_T*?"_3;_C3?A;II;3_C%N
MVGH?E7_PPS_P5;_Z2PW7_AAO#?\ \E4?\,,_\%6_^DL-U_X8;PW_ /)5?MS)
M(L2;S&Q 4LRHC.X &3MC16=VP"%C16=WPJ*2>/@/3?\ @I]^QMK?@[X0^/-!
M\7?%GQ#X>^/7Q)^*/PB^#R>'?V3_ -K?7_$?C_XA?!;3/%&L?$W0-!\%:-\"
M[[QG(/"VF^!_&UU+J]SH%MH.IKX+\7IHFJ:E+X7UV.P/]4<M_P"@O/\ _P 2
M;B#_ .> ?\1TXV_Z%7AA_P"*;\+?_H7/D+_AAG_@JW_TEANO_##>&_\ Y*H_
MX89_X*M_])8;K_PPWAO_ .2J_6KX-?&OX8_M ^ K+XE_"3Q-%XJ\)WFIZ_H,
ML\FE:YX<UO0O$_A+6K[PUXO\'>,?"'BO2]"\8^!?''@[Q+IFI^'/&'@CQGH&
M@^+?"FO:=?:-XAT73=2M)[6/P3XL?M^_LU?!;XRZI^S]XTO?C3?_ !>T;X7V
M7QIU/PA\,_V3OVL?C<;7X6W^MWGANV\9-KOP5^"'Q \,R:7_ &_I]]I%PD.L
MR7EEJ%K/;7EK;R(11_JCEO\ T%Y__P")-Q!_\\ _XCIQM_T*O##_ ,4WX6__
M $+GPA_PPS_P5;_Z2PW7_AAO#?\ \E4?\,,_\%6_^DL-U_X8;PW_ /)5?>NA
M?\% _P!CWQ3XX_9>^'OA?XU:)XGU[]M+PKXV\9_LNZAX:T#QGK_@;XQZ'\-M
M!F\3>/4\-?$_2?#-W\-+;7_"6AVT]]K7@_7O%ND>+[,0O;OH7VL" GQ+_P""
M@'[(WP@^)_Q-^#?C_P"+,>E?$?X-?!G0OCY\3_#^F>!_B5XKB\&_#KQ9XDNO
M"/@D:KKWA'P9KOAMOB!X_P#$MLFB_#OX-6>KW7QC^(.H:CH4'@OP%KO_  D6
M@MJ)_JCEO_07G_\ XDW$'_SP#_B.G&W_ $*O##_Q3?A;_P#0N?!7_##/_!5O
M_I+#=?\ AAO#?_R51_PPS_P5;_Z2PW7_ (8;PW_\E5]T?\/!/V:AX8\>>)I)
MOCA'/\-/'NB?##Q;X"_X9-_:JN/C*GCOQ%X,B^(NE:%X9^!]G\%[GXO>/XI?
M +S>-;G7_A_X+\4>%[#PEINN^([_ %RVT?P]KMYIW/\ B?\ X*<?L1^$/#?P
M7\;:U\8+[_A /CUX5^#GCKP-\2-)^$_QI\2?#'1/!/[0GBBS\$_!'Q=\9?B5
MX;^'6K>!OV=/#GQ0\7WG_",>$-6_:!U_X96>IZ[IWB+3%E2Z\)^*$T<_U1RW
M_H+S_P#\2;B#_P"> ?\ $=.-O^A5X8?^*;\+?_H7/C?_ (89_P""K?\ TEAN
MO_##>&__ )*H_P"&&?\ @JW_ -)8;K_PPWAO_P"2J_0#1OV[OV7M=_:.M?V4
M++QYK-O\:M6N/'NG>%=/UGX7_%KP[\/OB'K_ ,*+.RU#XK^$/A5\;]?\":9\
M$?BQXY^%EI?;_B1X(^&_Q#\4>*_!,VF^);/Q%H^GWO@_Q=;:&R']O#]F.\^$
M_B_XTZ5XN\7:]X*\$?&;Q7^SSJ]CX;^"WQO\1_$G4?C7X'\7W'@3Q5\-_!OP
M6T/X;W_QD^(7B71_$UEJ=O-:^!/ ?B*&72M&UOQ3;SR^%-%U37+,_P!4<M_Z
M"\__ /$FX@_^> ?\1TXV_P"A5X8?^*;\+?\ Z%SX"_X89_X*M_\ 26&Z_P##
M#>&__DJC_AAG_@JW_P!)8;K_ ,,-X;_^2J^KKC_@JE^Q*NC_  /UO2/'7Q2\
M:VG[1^@?%3Q'\&K/X8_LI_M;?%?Q!XMM/@?JESH?QATJY\*_#3X%^*_$WA/Q
MC\,];L[O1?&W@#QII'A[QSX=U>VETW4O#L%ZAAK[-^$OQ8^&_P =OAKX(^,/
MPA\8:%\0/AC\2/#6E>+_  /XT\-W0O-&\1>'M9MUN;&_M)&2*>)BA,-W97D%
MMJ&G7L5SIVHVMK?VMS;1'^J.6_\ 07G_ /XDW$'_ ,\ _P"(Z<;?]"KPP_\
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MRK*P^5E)S/VV_P#D];_@E/\ ]EU^.W_JA=>K\L/A?_P1A_X)D?MO?$C]M?\
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M /"9^#_^AL\-?^#W2_\ Y*I#XR\&G!/BOPUD9Q_Q/M+[\'I=]Z_GQ_XAJO\
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MWQ3XXU?5]&\-:CHGB'PN_P"".'PX\$_'W3=&UCXUC4OV(OAA\ _V%/AQ\,?
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M_/\ Z/\ B&J_X(?_ /1AVC_^)$?M>?\ S_Z /K+5O^"6W[*&K7GQ:UO_ (:
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MPU\">$_#":E/;2:OJ\>CIJNOZAJVNWFI:I> ']7W_"9^#_\ H;/#7_@]TO\
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MX?\ VM?^"?O[/WA3]IKP-H7BOP38:5XP^.'C#]LGQM\0_C)\%OAYX_U+X@^
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M^-)Q_=_]!_QH ^+_ /@GWX%\<?#;]E?PUX/^(W@W6O 'BVT^*O[5.OW7A;Q
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M<X51@ _X"?\ QW_&C)]#^G^- "T4F3Z']/\ &C)]#^G^- 'PM^U?_P G)_\
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MQ=\!>'=0M_B%K6B(MYXK,^C7R1>)+K6+[3-8DL]46TM/2/V3_P!D?X7?L;?
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M (=A? +_ *+)_P %%/\ Q:[_ ,%,?_HK:/\ AV%\ O\ HLG_  44_P#%KO\
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M-=\5^$M+\&:)XA\2V6N^#M#FU+Q38^)-,TR1_"CZ0?$EQ<65GI=Q=P@'+?\
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M:_1:B@#\Z?\ AV%\ O\ HLG_  44_P#%KO\ P4Q_^BMH_P"'87P"_P"BR?\
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M54DTX?\ !,;X $@#XR?\%%3DL ?^'KG_  4QQE20PS_PU;U!!!'4'@@5^/\
M\ /A/^W[\#_B7^R_H_QK\":GXYU7X4?#3]CSP;X+^%^I^ O'_P 8OAO\-OA+
M\5?'GQUUG]LB]^'GQR\(ZU<Z#X#_ &A_V3/ %S\.? .@^-+^;5-<\9_#SX)_
M#/X?^ (=7UG]H+[9<?I]_P $P/A\WP_U']LV3P?\--!^'_P ^)/[1WA_XK_
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M'=7O]%\9^/=1M]%B$5E9#PGH_AKPY=6LHTN:_OOGK_@D%_R:#=?]G$_M/_\
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MK\O/^&5?V@O^DJG_  4/_P#"9_X)B?\ TM>C_AE7]H+_ *2J?\%#_P#PF?\
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M&0N?^$8_X)BXW')"Y_X=K8W$ D#J1R 12C]E/]H0]/\ @JE_P41Y&[_D5O\
M@F-]T'!;_E&M]T'@GH#P30!^H.!C&!CTP,?E2U^7O_#*?[0@&?\ AZE_P41Q
MSS_PB_\ P3&QQU!/_#M; ([CJ!R<4G_#*O[07_253_@H?_X3/_!,3_Z6O0!^
MH=?G]_P32_Y-V^)/_:0'_@K#_P"O2_VQJ\^'[*G[01('_#U3_@H>,D#/_",?
M\$Q#W]/^':_/TKXO_8+_ &9/CEJ7P/\ ']QIG_!2S]NWPA;VW[;O_!3#1I=)
M\+^&_P#@G6^F7FH^'?\ @HY^U3H&K^++EO%W_!/SQ;JJ>(?'NJZ;>^.?%T%G
MJMKX7MO%GB+6X/!'AKP9X,30?!^A ']"5%?EY_PRK^T%_P!)5/\ @H?_ .$S
M_P $Q/\ Z6O1_P ,J_M!?])5/^"A_P#X3/\ P3$_^EKT ?J'@'J,]_Q]:/Z]
M:_+S_AE7]H/( _X*J?\ !0\ECA0/#'_!,0DGT '_  36R3[ 4?\ #*O[0>=O
M_#U/_@HANSC'_"+_ /!,7).<$ ?\.ULG!X..AX/- 'ZAT5^7O_#*?[0F&/\
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M]C7+?_5!@C],XW_Y(KP8_P"R,XI_]>GQ6?>=%%%>\?F04444 %%%% 'Y>_\
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M%% 'P'_P4W_Y-$O?^SGO^">7_KQ7]E&OT"N/^/B?_KM+_P"AM7Y^_P#!3?\
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M>(_!/[.NE?M!^+?ACXI\ _!_3M4\'_#NW^+.L_!GP/IFWQGX-\"B?3%\4O\
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M\-2VUC\3/B7X<_X0[4;D?$/^Q;FTLM-\:^-;,ZJMG?0V6FZSJ:78MK>I-/\
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MOA=_X@)X(_\ GYU^F-% 'YG?\,Q?\%$_^DBWPN_\0$\$?_/SH_X9B_X*)_\
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M(_\ GYT?\,Q?\%$_^DBWPN_\0$\$?_/SK],:* /S._X9B_X*)_\ 21;X7?\
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M4 ?F=_PS%_P43_Z2+?"[_P 0$\$?_/SH_P"&8O\ @HG_ -)%OA=_X@)X(_\
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MO_$!/!'_ ,_.OTQHH _,[_AF+_@HG_TD6^%W_B G@C_Y^='_  S%_P %$_\
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M0_!_3(8M0^+OBOQ)\*M;T.ZT;4+73-:^"%S>://9V^L7-A" 87_#,7_!1/\
MZ2+?"[_Q 3P1_P#/SH_X9B_X*)_])%OA=_X@)X(_^?G7Z8T4 ?D9\7/V:_\
M@H19_"CXHW6H?\%#OAI>6$'PX\=27]G;_L'>"[*>[LAX6U875M%=Q_')FMY)
MX#)&DP5Q&S!BC@%3]5_\$ZBI_P""?7["A12B']C?]F(JI.XJI^"?@@JI8@;B
M!@9P,XSBO=OCE_R13XP_]DM^(/\ ZB>KUX/_ ,$Y_P#E'O\ L(_]F:_LP?\
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M5?V.=._:R_8W\3_&23P1^RE_P3L^'G@WQ[K'[0OPHM+O]B'X^_L<^-O&]O\
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MMO)XMO[JVNKFWN;S7VU"XG@N)XI)"DTBOZ%10!\]Q?LE?LM0:!H_A6#]FWX
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M"O$^E)X>\5^#_">IW>D7%UX?\*^(M$B31/$/A[1I[32-6TM%TW4;2>T40#\
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MI/X(7T7QS7P^WP<N[3XF^$;G3_B4?%VK7GA[PA%X2U&VU.XM-5E\7^)-/O\
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M'C&<BC_AFW]LD]/^"KW[3W/(_P",<?V .1QR/^,8O<5YW^W#K?[2O@_]IO\
M9Z\7_LH^++OQ%XG\*_"7]IWXF_$']D74?$_E>#_VO_A;\-_'7[,&A:M\/_"6
ME:OJT>@?#[XZZ!H_QA\3^,O@K\6]%L+#^T_'NA>&_A;\3]6D^%?C#5[O0?E7
M]GW_ (*-:GK?C'X#? WX97WA'Q';?%^TTWXNZ/XE_:M^,OBK1?C-XO\ A?\
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M  S9^V5_TE=_:>_\1Q_8 _\ H8J^Z** /A?_ (9L_;*_Z2N_M/?^(X_L ?\
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MX+\>>,;GQ'H7Q)\;7?CW2P#]F?\ AFW]LGH/^"KW[3I^G[./[ /_ -##_/\
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MSO;B] /J/_AFW]LD_P#.5[]IWV'_  SC^P!D_P#FL/;OZ9&>M+_PS;^V4?\
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M2Q R236Y\7_^21?%O_LE7Q*_]0?7JP/^"<__ "CW_81_[,U_9@_]4EX'H \
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M4_\ Q-&]_P"Y^I_^)K\P/^&//V_/^DK7CW_Q%/X!?_$4?\,>?M^?])6O'O\
MXBG\ O\ XBC^ULQ_Z)G-_P#PJR+_ .>P?ZD<*?\ 1X. _P#PS>)W_P!!!^G^
M]_[GZG_XFC>_]S]3_P#$U^8'_#'G[?G_ $E:\>_^(I_ +_XBC_ACS]OS_I*U
MX]_\13^ 7_Q%']K9C_T3.;_^%61?_/8/]2.%/^CP<!_^&;Q._P#H(/T_W/\
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M?\*-_P""G_\ T>I^PA_XK3^/'_TT^C_A1O\ P4__ .CU/V$/_%:?QX_^FGT
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MVK^?VD_^"6N"/^3S/C%W]/\ @FU^W83^0!)]@3T!K[IR/4?F*_.KX@?L6?\
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M $T^@#Z^R/4?F*,CU'YBOD'_ (4;_P %/_\ H]3]A#_Q6G\>/_II]'_"C?\
M@I__ -'J?L(?^*T_CQ_]-/H ^G;OPGX3O[C4KN_\+>%M0N]9@M[76+N_\/:-
M>W6KVEG):36=IJUQ=64LVIVMI+I^GRVMM?23PVTVGV4T"1R6T)CT-*TG1]"L
M8M,T/2M)T/3+<RM!IFBZ=9:3IL#SRM-.T%CI\-O:1--,[RRM'"C2RLTDA=V+
M5\I?\*-_X*?_ /1ZG["'_BM/X\?_ $T^C_A1O_!3_P#Z/4_80_\ %:?QX_\
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MU&:TU6R]A?X(?\%0)'>0_MJ?L(9=V<X_X)I_'C +,6('_&U#@ G '0# ' H
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MV=G)8:G+&][9R6=H]O-&UM"4^6/^%&_\%/\ _H]3]A#_ ,5I_'C_ .FGT?\
M"C?^"G__ $>I^PA_XK3^/'_TT^@#ZAM?#'A>QUBZ\0V7AGPS9>(+_P"TF_\
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H)%^''@G1/!RZ^VBKJ&K+I#:P-&&HG2UU34AIYN3:#4+P1?:9 #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_002.jpg
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %F ?0# 2(  A$! Q$!_\0
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MR@?U._:[,()-ZA6"C=Y;\*NXKO&S,:(VX!I J+(=F0[!3QOCGXB>!?AIX/\
M%/Q"\>^*]"\&> /!'AC7/&/B_P 7^(K^VTKP]X8\+>&;*YU#Q!KFJ7]YY=I:
M:=I5A:W%UJ%U+($MH%W. )(Q( ?S^67BC]LO7/\ @H#_ ,%&/@Q\$/CA\0O
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M(U8W!\12:=%K>H:'I&N:EI:W.F?O)::C:M9I/)=1&-@621OW0:-I5CC(1\.
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MU'67T_0AJ.EZ58R1_F+X$_81^+W[-G[2O[*'[37[&FD7]I^R7^VKXL_9Y?\
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M<7EU>:@/[51I\&"K&5UR64-(W[LLL:-Y>W;MW+'AL?>$LR-F.5DI6L(&SO\
M,<%MV&=B,^4(<#G*J4#95"HS)*1C?P ?S8?\$5?#_P"TA\,_C-\3OA/\2/\
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M96,C*^W*[R!A%554$8?8JK@(6((>4/N$C@@'\;WBG7_^"A<_PM^*4'PGU/\
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MV:O%VI3G9M6?*VI*Z4HQ9^K7VZR_Y_+7_P "(O\ XND-_8CK>V@STS<PC/\
MX_7YT?"#Q+^PU\7K'3[>V^&'P.\&>.KCQ1XJ\&:C\*/%MQ\*5^(VC^)O!WB#
M5/#FLZ1<Z!H&JZV;FZ%YI-Q=68L9KA+O37BOX7,1?9]-6G[./[/%T9 WP,^%
M\?EA",^#]$<G?NX(^P@JR[<$8//M65:C5PTW3Q$)49Q;353W4VG9J,K\D_\
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MX\;^"/"OC58=;DM_V=?BYK'@'X<>(-6AB2R?Q'9:)X$U$>#5U:XAMX8]4O\
M0888=0GMFN[R.YOKMY'Z'Q!^QIIK^']:C\/?'O\ :HTG7KC2[VWT75KS]HSX
MD7MEINL7-M)!INHW=E_: 6\MK&^E@NY[-@J7,$3PL0&(K'DP$)05+&.3K)\E
M-T':+37-%U%4E%[JUU&_17T/+3FIU*=2#A4IRM*.KY$[\M.M=1=/%12O6P]I
M*DI0?M)\R/N?(.0#TZ^U+7YP?#']I[Q)\']7\6?"+]JAHVU_P)H?PT3PU\0O
MAI\-/C3XLT;XD:?J7A"-M7U?4]1M/#'B.VC\26VKVCPZC:I?K))/<HZPD.N/
MM;X;_%3P#\6O!VD^._A_X@@\0>&-<;4TT_4$M+_3Y7ET?6-1\/ZI;W6FZK:6
M6J:;=:?K6E:AI=Q;:A9VMQ'>6DL3Q K3KT<11N_9JI!)/GA)R5I1YE:T>U[[
M6::WT*/2:*KPNC892QWEP-RLN0AY(#A2%S]TXPP.5)!!JQ6,)2DKR@X.^S=W
M;N]K>C ****L!,C.,\UY9\3/">I>-?"6O>%K+Q'J/AQ=;-K8W]_I5K%<7TFA
M2:K#/K^F6R2W%G+;G6](-UH5SJ5I=M>6$5X;S3X%NXH@/"OVEOC+\2?AAXU^
M&FD>#_ATGCWPUXQ_XDOBC4=.M_$&J:_\/;[6/%_A+PYX=\5W?AS18H6UKP/+
M=:U<V/BNZL=4M]9\+@:?XE:TG\.:?XAN+2?XD?&SX@^!/A]\:?$]O\'/$@D^
M$^GF_P#"[:G<QZC8_%&VMM6C@EDT2VT>VU'6K4/:N)X87AEG47";8I=LF0#\
M_;O_ ((X^ QX=O? UC\=OB/H?@:TE_:)L?A]X4;PUX0U&T^&O@[]I+X]_"#]
MI/7/ _A_4KV^DNKOP]X+^(/P?C;P;!JTLD=C8>+M8TS[)+:6NE6MC[;\2_\
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MFF>3?KI$BZF(M1.JZ1?-/%%%*I0 GM?^3KO$7_9O?@C_ -67X\KZ%C_U<?\
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M8-%$SQR%FB7S0I)C>5D10RF?=NC>81@//RRNYF W*!7E?[/OQ<?XW_"7PO\
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M=SLFDWRS2>EU?LM=CTS_ (2[]H;_ *-_\)?^'TMO_G9T?\)=^T-_T;_X2_\
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M ,[.OHVBF!\Y?\)=^T-_T;_X2_\ #Z6W_P [.C_A+OVAO^C?_"7_ (?2V_\
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MQJ\6^&?B@WQJ?XA7&I:5X\T^V\*ZA\0K_1]7:^\-7O@+PSK&[P[X@T#]GO\
M9LTC6-+^W:C<M)=VW@O7(;;4DU#3)O%-_=V-QI^E 'WY$08T(Y!1>3C)^4<G
M'!/N./3BGU\A>-?VH7\"?M ^#/@M=^"KNZT+7?#MEJNI^,H+Q'&G/JP^*'V2
M:*TCB,$NG:'/\+HM&\1G[0+T:]\4OAII]A:;[V[4^@? 'XV3?&_X<1^/I/#%
MYX4DG\8_$_PNNA:@NI+J%M'X#^(_B?P1IUU>0:CI.DWB7&LV.A6FK7%M'9R)
M8S7[VHFE6V:4@'F'C75?B3IO[5.IK\/? OA/QNTO[/\ X+.J1>*_B)=^!(=/
MB3XE^.C#-9?9/A[XY:_FD(<2(YL%Q'&/,5@CGNAXK_:C(!'P*^$@! Q_QD;X
MC'&..!^S\X''8.X'0.P&X\UH'B&[U+]KSXBVMYH&I:3;:-\!?A_9V&KW5WH,
M^G^)8'^(_CI[G4-(BTW6-0U.UMK&>3[+<KK.GZ?)Y@W* @+'ZR@;=#"V -T4
M;8#*X&4!P&0LC 9^\K%6ZJ2"#0!\Y_\ "5?M1_\ 1"OA)_XD=XC_ /H?*/\
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MMK"S:<;9C:6Q<PQ_8%?*G[(?_)(_^ZP_M%_^KS^(M 'U71110 4444 %%%%
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M6^*=)'Q3\1QZKXA^&?C7XG?$6/7?%BZ;H8\4WGBSQK\4'FOO$7B8WNZ.]O\
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MH]RUEIMX+.=#?V5O.TB( <I;)&/VJ_$:E08_^&?/ [[#DHK)\2O':J40G:C
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M_P *W_B6/P_J6I1>*#XD\3:_K%[9W*WZZ_\ V=HEKX>^R2W=['??L0?M _\
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M>M/"T'A1-(LK6?3=6TO4+V>]MEN_+EKZ=/[+EX?^;F?VJOP^)FAC^7@@4?\
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M"VJ:-XJU)]?T"5-3,FL>';>-/%6G2^&I([*?Q+9ZEI%W%?\ W?0 5\>?M%_
M7Q%\<G\)G1?$,WP_U'P=)XDO(_$MEIXO-0U&V\2>'-4\/W'A>13;)?+HURVH
MQZCK,NFWVGW[QPI:V274T^H&U^PZ* /)_@CX"U+X8?#+PAX#UCQ!?^*=2\-:
M):Z?=Z_?F8O?2J\TFV(W+R7 M[-9%LK7[1))<M:V\#W+M.SFO6*** "BBB@
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MW_"N=-@\;:GJ'G-XBL]:\268M["VUIDOOT#TY'2%BZ["[APAC9'3,:$HS/\
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M)')&DL;#P=X4 >*0;HY$W>.U+1NIW(X!1AT)((J)1E&W-&4;[<T91OZ72O\
M(F,HRUC*,O\ "T_R;/H:2Q@EE,LJF3)9BCX:/+1>22%(X)C&TX.#R<98FH%T
MJT5Y)%0AI)#*PXVF0H(BQ  +'R52$;RVV*-(UP@(/@W_  OK5?\ H@7[0_\
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M'HR.1R,CMG- 'T717SK_ ,+XU;_H@7[0W_A(>$3_ .[]4_@7XUZ9XQ^(5QX
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M%<"WT%G4LB7=JZ%A&PWJ[@%HZ\&^$7C/XC?LNZ9XU^#6H_L_?M&?$_P)\/\
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M1NGR6BO*I*5V_=5D[/=K2X?E!\3/^"V/[/\ \%_$GB/P7X\^"G[1VFZIX/\
M!EIXU\1L-!^&:QZ9I-U\//B#\5YH8K>^^)FG:A?-:^ ?ACXOUK3Y+33I(=8M
M+;0OL+2?\)%IC2>?_&;_ (+:_!3P'\69O"'A_2M</@_X0_%WQ[X)_::\0:SI
MEC?ZGI7@WPQ\#OVI/B)%XB^$DGAGQ1JL6OZQ_P )E^RWXKT'5](UJ.RFTO3X
MEN]2M].99(8?V$NOV?\ X$WS(UY\%_A/=F.PL])0W/PY\'7&S2M/TJ[T.PTM
M/.T5]FFV.C7]]I5I8+BUMM.O;NQAB2UN9XI')\ O@8EW=Z@GP9^%2W]_=7]]
M?7P^'?A 7M[>ZK;ZW::I=WEX-&%S=W6IVOB;Q);:E<7,LLU_;^(==@NY)HM7
MU!+B0/A3X]?\%3/@Q^S!\//@A\1/B3\+?CE#I?QU;Q_<:5I5IH'@NW\0>#]+
M^&]YI\?B;5O&%EK?CW284TR*TUBQU#1I] O-<;6]-FMYM.MR;JRAN+VE?\%3
MO@QXAU?X>6/A[X:?&C4]"^*?QU^(_P"SAX*\>2>'_#.F^!]7^+GPV/Q&@U'P
ML-3O_%D&HVEUJNH_"GQMI>EIJ&D6DZWUA9P:C!8R:I81S?=&I?!/X/:UI6B:
M#K?PN^'NMZ%X8B:#POH>L>#/#>J:/X7MGM[>T>T\-:9?:9/9:!:-;VL$9MM)
M@M(2$'R<#&_8_#WP)I=Q>7>F^#_#.GW>H^('\6ZA=66A:5:W%_XLE5(Y_%-[
M-!:1R7?B6XCCCCN-?N&EU:>.-(Y+QD4+0!^;_P ,?^"M7P1^+VK?!ZR\%?"7
M]H*]TGXU_#_QM\7O"OBB?P?X7BTFT^$7@+4_A/I>O_$?4;"+QK/XHO-%M+WX
MR^%-.N-,\,>'_$7BBTURP\4:#<Z%'J>B&&ZYKXM_\%G/V9?@]?\ BC2]<\"?
M'#6-3\%^/O%O@7Q+I.C>&/"=EK5A!X/^'%Q\5;OQK%H_B[QOX6U#4/!>L^#K
M.]U#POJ>GP7-UK\EK<6=E8&^L]2M;#]--'^$_P ,/#E]8ZIX>^'W@KP_JNEQ
M:[!I6JZ)X6T+2=3TF'Q1=VNH>)H=*O["PM[K38O$5_8VFH:]%92P1ZQ?VT-]
MJ*W-W&LPJZU\&?A!XF69?$OPM^'7B3[5/>W5P?$'@CPSK+7-QJ-G+INHSSG4
MM+N3--?:;<7&G7DLFZ2ZL9YK6=GAE=6 /R&^-?\ P6J^$/A?X&_%?Q?\._!/
MC>V^+/A7X:?&O5_"WAWX@:%IQ\(V_P 4/A=!^U+#I_@OQ?J_A/Q7?R/I/B#6
M/V0_BS;S^)_#5QJ&B:99Q>'%O=6L]0\165LGIC?\%A/V>-/\#ZUXXM_"?Q/\
M;V7AC]G3XB?M-^);CX=Z/X>UO3-*^&'PXNOB;I&IZI=/=>*-/N=.NK_Q1\'_
M !?X:DT?4[>/6O ^NWOAG0_B1#X9U37[>%/KGQO=_LK^!?$VB_#3QCX:^$^B
M:QXJ\/\ C"3PWX/N_AOHEU-XG\-ZOXDL--\<6^E6@\-3VVIVNH^(/&4%SXPT
M>SDGNKBWUB\UW6--NK"YN]0M=+Q#X?\ V5/"ND^*M:U?P9\#+?3]*&J^&_%<
MO_"*?#V]EAB^)6JP:?K7A_5K.RTJ\O,>/_$+6^FZMH=Q B^(K](1J=K+.))5
M .9^ _[<7@'X[_$KQ[\(+?X??%7X8_$7X>>#/!GQ$U7PU\4M%\/:1<:QX&\?
M22+X:\6>$;OPYXH\4Z9XHT29D%KJ5QI5]-<:'K!.A:Q:66K!;5^MF8/^V/H#
M@%0_[,7B1]K  C=\6O!S8(' (SBO2OA\?A1XGDUSQ'X L_"-W<66JWG@S7/$
M7AJPL(+EM0\)"UTR^\.76KV%M"]Y%X?D@@TTVD=Q-8Z=)8PZ?"(GTU8;?S69
M53]L?0$0!43]F+Q(B # "+\6O!RH /0*!CVH ^IZ*** "BBB@ HHHH ****
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M$YP3<E&AAJM:5N6E2?O\OY\_"CP#^TAX$T;7_!'P;^._[/?B+P#X:\<^-8]
M@^(/PX^,OC[QYX/L]=\1W?BNQ\!>+/$G_"^[6[NM0\(:;XCLK"WCO(;6_DTA
M+>YN;:%9T->MCP_^W40I'Q3_ &1"'SM_XL+\:1G'7(_X:-^7\?;U!K1\0_!.
MX\-:_?\ CWX+ZW;_  VOM2\577Q&^,'AKPCX*\&7][\>-:ATW2+!-.UW5-=:
MSDTO6;G1= M_#UMKME>65P3):7-U,'M2[^L_"_QQKWCSP]!K/B?X?^)?A9K;
MW5U;R^#/&5[X;O-=MK>S,<::F9_"FL:]HTUAJ+-YEC-!J4K,JL)HXI 4&LL7
M255K$Y?@*U2;OS8O!JLTHZ7IM8F@^2^_NM.34[Q;Y7>(A0G1^OY?7>+PLW*$
ML,X_[?A:VEXXAP;H5(W<I\U%.4(^YB8T,0G2?R7\3/B'^US\#8/ WB_XA>/O
MV6M9\$:K\6OA7X!\4VNB_"KXE^#=1M=(^(7C33/"L^J6GB3Q'\=/$.D6$NE?
MVA]O9]0TJ:V2*)RX*L17V5%\7?A'&D0;XI_#H.B*C;_'/AAGW*H7YR-4"EP<
MAB  6SC XK8\5>"?#'C_ $:X\/\ C/P[X>\4^'KN2U>\\/\ B?1K'Q!HUU+8
M7*7=M--INI)-9RS6\Z)) \UO((I%5]K9X\T/[+'[-$< #?L\_ QY J(9#\(O
MA\H9LJI8QKX>:- S9)"J43)*KA145?J]7EO1I48)IQCAJ4:5."NFE&FZE3EC
M'5I*I/=WD[Z<L6W&+E;F:5^6]K_/\?.^VQ[1I7B#0]=MDOM$U;3]8L)5+0ZA
MI5U#J-A.%FGMW$%[9O-:S&*>VGBE6.5FB>,K(%)7.J94'5OT/^%?E5^R[^T)
M\$?V?_!?CKX4>+W\0>!-0\,?M ?M%K9>&-*^#7Q4N=-TWP[J'QE\7:AX5.F2
M^%O 6H:-)I=WH%S:7.G2V$SVK6CH$90H4_2+?MU?LR X/C3QB#UX^"/QX;/O
ME?AF![>V *QJTL53F^2$:T&WR1C[LI07VN9\RDT[<W*K:Z:6*/L/S8_[WZ-_
MA52Z'G>7L(.U@YRQ3)5XV52PPPC)7>P&061,JPXKY&_X;K_9C_Z'7QE_X8_X
M\_\ SM*/^&Z_V8_^AU\9?^&/^//_ ,[2H_VS_H"G_P"#(_\ R &KX'_9*^&7
M@GQ1\2/%>G:=?7NI?%BULK7XAQZCJ6[1_%T^G>(]=UZP\0W_ (;LH[/0;7Q5
M;0ZS;^';OQ#9V4>J:_X8T'P]IWB*XU-]!T9[/R'Q]X4_9>L_CIX;;Q9XO'AC
MQZWPSM?@AI^CKK"Z;HI\(?$36-0DTOP3B:)Y7U+Q)=;E2VN+BXM88TTJYOX+
M:XE\.SS^]_#?]K#X'_%?QD/ '@+Q7?:KXM?2;_7X=&UGP5\0/!MW/HND2Z9!
MJVH6O_"9>$]"BN8K&;6M,BD$,SDO=1CY?FVV_%O[,WPJ\;_$KPS\6/$.D3WW
MBGP\R/;Q23(=$U&ZM(+V'0[W7M(,9@UF_P##(U&^E\/SWQE2PN)H9FBG%E9K
M!3]K3E&%:FZ<YP52,>T&KIM[.VJNK)VT0'Q9\;-:_9$\?'P5JWC_ .-MQK^O
M^#-4N=!\+_\ "-0^'8M3\-RQ?M%_";Q'<^)6TS4-$O#9VGP[\3_#SP)X2\37
MMI!<7>D>$;/7!J=BMU<:@]IJ_"YOV)?@]\)-9\,>$_B'9?$_P9X2U_PYXBU'
M1(;Q?'/B/2?%5[IESX,.JF#PY:6.HOJFLMX'UK5+\:O-J,>FRZ9J$-I%I^F6
M^F647V%K?[+/P(\3ZS-K_B;X5^ ]<U:;4+O6'O[SPU:K=2:OJ6K1Z_JNJ3M#
M,D4]]J>MH-2O9VA#W%RD33M)^^\Y^C_LL_ 70-&\2>'M%^%?@K2=#\7W%E>>
M)=(T[1_LNGZU?:>;AK34+^W6X<2ZA%)>7A-ZKQW%Q%<RPW;W".X:P/@7Q1KG
M["FA>(OCO9ZY\0+G2_\ A:FJ:-IGQ+M[ZV76O"VKZ;\1[^\\=:C;:&-5T+58
M?[$_M;QA/XG\4:R@EF\':GJQ6VU/1?L&G0CO_A98_LQZM\5/!WB:QM_B ?%9
M\9:]\3_ VN>,M!U#3_"5QXE^+VA^)],_LG2_$RVPM]2FT6P\(>,-*M/#&N:A
M=:AX?USSX]7@/B"XM;F3[(O_ -FSX*:E-J5Q?_#'P'?W&KW6EWVI7&H>%-)U
M*:^O-#AT^'1KFZ>^BF,D^FC3+,P.OEAS!"]PD\L2RB/1/V:_A!X8U^S\1^&O
M!]AH%]8ZO8Z]#!I3WD&FRZUIFCZIH.F:K=:8UW)8W&I:;I^N:N;2],$<WVR_
MN+^Y:ZNY'F8 P_!2A?VHOC@ K(!\#_V8/D<EG4GQE^TRQ5V/WWRQ+.?F=B68
MEB2?I>OFWPBNS]J?XZ+G<5^"?[,8)P!G'C/]ID=!P!@8 YXZDG)/TE0 4444
M -9U3&XGYB0, G)"LV. <<*<9P"<*/F(!Q9/$N@0ZO#X?FU>Q@UVXL%U.WT>
M>=(=2N+%I+B%;F"SD*SS(9+6Y3$2.^8)?EPA-:5Y*(83(6QM/ $33%V*L$58
MT!=V+E2JH&=F 559F /X@?M7?$31/&W[6G@'PQJNJ?#34XO#VJ:9X M/"'BW
M6?!?B'6/ 'BZZ\3M9ZOXST7P?J_[8?PQT2T\=:YX9\0Z=>>!/%MS\'/%7Q!\
M)VC37.D@7$MGIK@'ZM_'+X+:)\=_ TW@7Q%>ZQIEB?$?A3Q78ZAH\]K%?6.L
M^#/$5CXET:=([R*:VEA:^M%^T07$+HZKB2%Q\K>=_"C]ECPK\+/B@GQ.T;4?
M$SZK8?"'0/@E8VNH7VFRZ?-X#\)W5G-X3L;U+2UBN-0U'0([![:#6+R8W5S%
MJ5Y)-CSTM=/^A="L;7P7X6T;P_'J&JW]CX5T+3M%CUGQ9K=SJ^N:A;:)8V=@
MFI^(/$.I22W>JZM=Q1BXU/5M0F>[U&^::YN'>:=F.S!J<<UQ':N$BN)(3<?9
MVE7[0L0E\G>83MEVI+^YE?9MBF!C8@E"P!\N?M<^%-"UKP!X3U35_#NBZM?^
M&/C-\!M3\/7^J:?I][=Z%J+?%[P1;/>Z'<75K=RZ9?+$[H+ZV\NX1&,<;,LL
MA7ZV P /0 ?E7S1^U3=>7\,M.B>,G=\6_@0J,KH!S\9O!!_>%RJQ@JA(9CY>
M1M9U9D#_ $N#D ^H!_.@!:3 ]!^5+10!5\MBFTH3_P "4=\]<_TK*U&&3; 8
MHRSK,A*JT8EVK+$S^6[D!"57!;(]>" :WZKW )V 8ZD\XQQCU(Y^G(Y^HJ+Y
M9)VO:^GFTU?KM>YE4A2:DYQD[VOR2E&<E>_+S0<9<LFDI*^L7)/24K_&GPXU
MCXC?#+7] ^"OQ"M?&/C>ZU+P[\1?'B_&A/L3^$V:?XB2R:+X!OHS,=4LO$-I
MH?B/3+?2?M@BM]0MM"O38/.MM/%%]AIJ-J7\D.WF*NYE\N4D(,#><1D%>VX$
MJ6(7.X@'RSXI_!CX?_&SPOJ'@CXH>'[+Q7X4O;FSU#^R;I[RU>#5;%)!::C:
MW^G7EI>6EY9+(39SVDL,UN\DY\YS(@C\.T_Q[\5/AAK]C8_%G2+[XB0>-/%"
MZ;X+N/@A\*_%UMH'PX\.B2*SC?XK:OK7C7Q);6;0F2.XD\000:5;RV,5Q+_9
M88,IQI2FISIU8OV=U[&<>9O5-RYV^9<JLE'9WDUM9+UJJJYNEBZ$</0S&7OX
MW".,:7]I8J46ZF)H1YXT\+6JTJ?M*U.BJ.6TEAJ=/#86G6Q4W5^R5F2X/[L,
MVP L"K*/GSMP7"AL;3G!.#BK"C"8(QC<<9Z<DCD9'I6'IET[RW;E2\92V9"D
MZS #]\N>  0Y4LCJ666,)(,9*C=1MP!R,G/ .>A(_I6E2-N91DMOB6JVVWWU
MMOHUH>53E.4$YPE"7O+WHN+E%2DH5>224H*K%*I&G+WH1:C+74^,_P!N2X;3
M?@9I^M7-OJ5U8>'_ (W_ +./B75VTK2M3UN\MM#\._'3X?ZQK>H)I.BVFH:I
M=1:?IEC=7=Q'9V=Q-Y,,CK&V"*NP?MR_LQI)<L?'7B':\_RD?"3XRLIVHJ,%
M<?#\HP#JR_(Q&5-?6UY&TL+*K!&!1D<H'"R*V4;#$ ['"-U# C*E2 1'%#*2
M[&=VR?E!8D*@+%0"'W$X<@EBV<#&,"LX5L.J=&G5P^)K3PW/[.5&M[._/&$7
MSNI"K%V5W[WO.^CNDS0^5O\ ANC]F+_H>O$7_AH_C-_\[ZC_ (;H_9B_Z'KQ
M%_X:/XS?_.^KZO\ )E_YZG\Y/_BZ/)E_YZG\Y/\ XNK^LT/^@#'?^%5'_P"9
MP/E#_ANG]F+)'_"=^(>!D_\ %I/C-GCV_P"%?>G_ .JO5/A5^T!\)/C8OB)O
MAIXK;Q"?"6HV&D^(X)M \4>'[S2-1U2R34=.M;NQ\3Z)HMXKWEC(ES R0/&\
M9R'R"!ZP4<'!E<G&<JT@ ZC!^?ZGL.G<"OD?X-KN_:<_;*B8NRIXB^ A!:25
MCF3X3V<^5WN2A4L8U6,HGE[08SGF_:T:D*WLL)BJ52E1IU$ZV*HRA)RJ*$DT
ML/!I6:::GIINK@?6U^',<83O* PW%"%*LI<.H+*8MWF@@$C9TQG'P5\5?VYO
MAS\+/&GCCPAK?A/QM>:C\-;J(:]/8W?AFRTF+3)_ G@3QS>:Q'?:EJEC#':6
M6G^/M*AEM9KI-=DN+:^O'TX:6L=ZWWW<P&>,*',;*Z2*RC)#(P/]Y2 PRK;6
M4E&9<\UY;KOP2^&/B:^NM4\0^!?!VM:I>ZA%J]UJ6K>%]%U.\GU:VT[2])M]
M4GEO[6X:748M.T+0;-;YF-R;;0]*A,HCLT6I ^;=:TG]G[]H*Q^!OQ'^(_A7
MQ/-=WVA>#?BY\,M)UVR\2V-]X-U#1]8T7XH:-K%V="DFL=*\2:3>:';VUR@O
M(H-0T>XU/PQ?+JOA_5KFWKQSQ'\8OV2?&_P>O_B5KOPMO].^'WCGXH:#:?$+
M5H=-TC3=7TO7+'PE#\7?#GCK7Y=.U;S]7AO=&UW1;M4TLWFMPW6OIH\^G'5O
M/TP>SZK\<O"OPP^*_A_]GW2?AM=VND7WB?1?!^A6OA2ST*UAE;7+3P[KFM^(
M8M :XL[J7PAI)\6//J46A65P;=?#'BF^N9'MM/&G2_/WCS]I;P=X(D\*Z'H7
M[)&NVWB27XCW_AB*/4_A?ILWAO0O[&^*-AX5\<RO>^'+1(87UK2M2\5:AX0U
M^Q>?0=6N(EN+Z>72[JZ,@!ZO^R0_P@@OK^S^ G@'QEX-\$ZKX"T?Q3'<76N>
M'+OPS+<0:S>>&!X>U/0K76=2\9:!XS\'WOA[5_#%]9:W'!Y*Z=J]@EQ>R6\4
M\OM4G'[8OAWC'_&,'B'@G<1_Q=CP;P6_BQTSP#U  XKRG]E[]HOP-\5=?\0^
M$O OP2\;_"J7P[X=MYM5NO$GASP_X=TS[/:^(=6T71-*TVTM;JTO[N!;RWUB
M]M9]-LGT2"[O+ZT%U/?W"M-ZM(V[]L7PZVW;N_9@\0G;S\N?BQX-./F ;CT(
M!'< T ?5%%%% !1110 4444 %%%% !1110!\9_MWZ1\0M;_9W\>V?@+QX? ,
M2>%O%%SXPU&S\-W6L>(+_P *IH5W%>Z7X9UR+XC_  NM/ VJ7TLL-K<>,-1\
M3V]KI&CSZG<22V$2RZI9<7_P3^N-*O\ ]G?2ETG6?#NMVMCXJ\7V$,7@G4=)
MUKP9H=S%=:;%?:!X6\4:/\0OBM:>)-)TFZ8F\UF+QWXAC&MWNJ:=*;.33$TV
MP]@_;)T+Q9XH_9I^-?AWP'H^K:_XTUKX:>*+#PSI&@W]]INMW>KRP0&R&CW6
MGW6GW"ZG'.J2VL<6I:;-.R-#%?6_F.U>/?L/WWQ(T?X?:E\/OB?X3^/B:[X2
MU6:]3X@?&ZQT/3)_&NF:I@:<GA^QTWX@>/;K28=(:UN+.;1+K5K6"$01:M9S
MSS:H]C;@&=XR_9*\3>(_B3\<_'NC_%[6=+TWXQ^&6\+W6E0IJ%O<Z%8-IGPQ
MAO+.'6+#5+21+0+\-+R'1TL6M+[1;+XG>-[NSN[;4&M9X?KOX.^$-7\$> /"
M_@[Q!K[^*=4\+:'HNCR^()+.VTZ34&TVR2W>5K2Q6WMXD2Y2>",)#&9X(4EO
M/.OY+R5_1&U6S4X8R<!_F\B;9OCW9B\PH$\\JKNL&\RE$9BHRN^Q'>0REP@;
M=&61U*X9'7DQM@G:^W:^T\[64]3@ 'R)\'?#7A_PU^U+^U?:^'](L=)M]1\/
M?LZ:SJ*6,*P_;=5O+#XH1W5]=.OSRSRPVUN&9V("QJ0!EBWV-7YZQZ+\:=9_
M:U_:4N/AA\0/A_X,TV/P5^S=#?0>+OAMJOC:ZO9VTWXHR!H9K/QMX/6Q54GB
M 1DO@ "2Z,7C7V;_ (0G]KC_ *+E\%?_  P/B#_Y\M 'U)17RW_PA/[7'_1<
MO@K_ .&!\0?_ #Y:/^$)_:X_Z+E\%?\ PP/B#_Y\M 'U)5>6VBF_UBAAQP1Z
M8QR""<'D9Z$\5\Q_\(3^UQ_T7+X*_P#A@?$'_P ^6C_A"?VN/^BY?!7_ ,,#
MX@_^?+1L)Q4E:236]FKK^ET[???Z4GLX$CGD1 KLC,6RWWE5F5C@X^4\C*D9
MZ@C(KY&^*6@:O\./$NO?M ?#O2/%/C/Q+K.B?##X;:[\/K*_>;2=5T+2OB#Y
M5]XLT[3T@GEB\7>'-"\3^(9I3;^3:7]IIH34$F\FWEAZ1O!/[7.UL?''X*D[
M3C_BP/B#KCC_ )K(>_J"/7BN?UWX:_M<:MH^J:5+\>_A)8KJEC>:=_:.E_ G
M6[75=.-[;36L=]I=U)\79H[;4+&69+NTNI(G$,T*2B.0@*9JKVL;2;<H)RC)
MJ\K)?"F]==+QOK;9V3.C"8J6$Q=";@ZE"K+V6(C9->SY?BJ/=1BDE%VT:TM*
MS?U5ITK&%V-TLV)Y5$JK%B0$J0RI$75%/\"B20B/:78N65=')? 9\JQ'*MM)
M!(P<J01V(V\$9!SFOR^\(6_[9OPIN_&'PQ\2?&2S\;Z#\+O 6A>,+/XQ^)?V
M>M7\2:W\26U.X\7R:UX6TZV\/?$C3H=9\9^%K'0]/633]/L([_5(-8TR1(9)
M[HLWLGP\U+]I7XD>"_"OCKPU\<_A;'H/BG1=-UK38-:_9@\;>']7@L]1MS/!
M#J&BZK\6K74=,NXD!$]G=P1S0$+O7#H64+SIQYHM<T;.+3VV]=;7^?0UK99B
M,+"G5BG5P514W2Q$$YJ+K*I4I4JL]7&K.*FU%J]DE*496B?<B1K&BHN0J*JJ
M-S'"J, <G/ '?G]*=@>_YG_&OE$^%_VL%P6^.7P;&[[O_&/'BGDD@8'_ !>
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M'[6$2S_#33X!.EK+-\6/@-&ETQL?,LW;XR^#%CO+4:A#>V@O+4N;FV-QI]S
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M>'_"%CX*T?Q1XFM?&GC";X<^#]-L[/XERV$/B77;RU^-'PB@^)\:I<7EE'X
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M"D^*,0\5-XJET:+0Y8F\;>+/^$7-A &2(GP5'KR^#C=[22VJ-IQU$-B3S6<
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M-%DTQK(:C:A]1U5X9-/TC4GM?HOX?_M&>"OB#X%L/&]G/_8_]H/XO1/#>J-
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M:))5Z.-P'0C/\+#)PR_=<9.&!':I: :3W2?K_P .B#:_]T?]]?\ UJ"CG@@
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MKU_#J5_'>7L^H^0;+2[+1])TFPFE"FVT?0-)L;72="M"LCV]C!.;BYGEN8R
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M'/$7A_64T=HK;48]%U73]072G>%I8(+U+&>461DMXVFMXYEB\VW7S85:+#4
M;WV6V_Y]X/\ OS'_ /$T?9;;_GW@_P"_,?\ \35'4=<TC2+&\U/5-2L]/T_3
MK:\O;^\N[B.&WL[33XI)[VYN)78+%!:PQ2S3RL0D<<;NQ !JVM[:N(RD\;"5
M5:,JZD.KA2A4@D$,'3:<_-N&,@T -F@MT0%;>W#,P5288NISC@K\Q.,!1\S'
M '-?./Q:_:*\(?!K7]$T+Q=X7\92-XCTJ>[T#4="\&3:SHFM:T=>\,^&].\&
MVNJQW5O'9^+=6U3Q7I$.E6VK0Z?H=Y)/);3:]9SPA9/==,\3^&O%6AV^O>&]
M<T;Q'H-\9?L>L:-J-KJFDWGV:\FL+G[/J%C)<VDWV>\MKBVD97=(KJWDBD*O
M&P7ROQI\#OA;\0];N/$'C30IM=U.;P\F@/\ ;O$/B:WT@:7;ZK8:W:N_AZP\
M1V>A-JFGZMI5AJ5CK:Z=%JMC>VEM<VFHVTR#(!Z3X'\2^&_B#X+\)>//#4MK
MJ7AOQMX;T/Q;X=U&*V\N/4-!\1Z;;:QH]ZD<J"1%NM.O+:<*PR!)U(P3U/V6
MV_Y]X/\ OS'_ /$URNF:CX-\*6_@_P $VU]X;\//=61T+P7X6@N[+3FNK7PU
MI(FETKPUI#2I/<6^AZ+:"9[2QAE%AID"R.%MX_,KJH[F"9BL4J2$!6.QE88<
M,4.03PP1L>NUO0T 'V6V_P"?>#_OS'_\337M[9$=_L]L-JLV6CC51M!.6;;\
MJC')[#)JS4<N3%( %8F-P%96922I #*H9F4GA@H)(R ": /DGXP?M;?"OX'>
M(KKPYX_M=7T^\C\'VWC33FLM"MM3@US39/$:>'[VVTH6^H+?27^D%_M^HQ36
M$-N=/WW5E=W30F"3Z8\/7^F^(-(L=<L'T[4-+UBTMM4TB^LX,6UYI6H0)=Z=
M=1-("TBW%I+%+Y@"HQ<E%";2WF'CKX$?"WXE7EU>>// UAXJN[RQM]+:XU?^
MT+N2RTRWO+/4W@TIA?P1:&-0U#3=-GU9=%AM6UE+"VM]76X"H4]@TNWCM+2*
MUAM8K*"UCAMK>U@@2V@@MK>"*&WB@@B_<0PQ1(D<4, 6."-5AQE"2 6OLMM_
MS[P?]^8__B:/LMM_S[P?]^8__B:GHH @^RVW_/O!_P!^8_\ XFJHTNV65)DW
MQO'*904*@-N=7,;KMVR1C#",.&:$.WDM&3D:-% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!\0?M?\ [,_B;]H+PIHFD^&-=M?#
M_B;P]XHUKQ9X8\6C6)-(O?!>N77@SQ!X;LKZ+1+GPWXN\(_$3P_K U5/#WQ!
M\ _$?0-6\,>(O!.H:W#:K8ZS_9KQ?/ND_LI_M?S^+O#EEXG^.\(^&%A\0(M0
MUVS^'WQ6^)GA'6M6\ Q^)_C_ *U-H-AI2>&7B\/V6FZ/\3?A=X.TGP[9^+;B
MW@TWX4:7Y&OV5A'INGV'ZN^4@SC< 26(#-C+')."2!GT& .P%!B4]V!R#D,0
M<C'?WP,CH>I% 'Y>W/[+/[5R>'_"FGQ?M!S3>*_#'PP\7:3_ ,)5<>-/&::9
MXA^(_A[XG?"+7/@?J7BG0VTRZU#4M%UCX=_#;7/#/QM>/48UUV]\;:^-.T/4
M;.Y26WP]6_9+_:IU;X\^&?%.M_$KPKXI^"G@[XS?"7XA>%O"?B#QOXW\1Z_8
MP_#_ %OQK+K'BN*V\1>&;NVT[QIKWA[Q7;Z7<Z?IVOOHC2Z<&BN;=?LLEM^K
M;0*0^UG4N2Q(8Y#$ %@QRP( P,$ 9; ^8T+;HG"%E^[GDMG: %/S[@" .H'4
M ]A@ _(SXD_LI?MOZ]XR\<Z_\./VCK_P>NN^./$&J>$IM6^)OBK7-$\*>&;_
M .(7AK4M&TVZ^'<WA(Z'J.F^'_ :>.- /AIKN2SU.]UK1FNM4D-H^H6KO$'[
M)?[9FM>(IYE^/]_%X1OM#N]('A"7XK^.I],\/VGB1/'NG^(;":0^&5O/&26U
MOXBL]3T[6]<N5UB,2:;I%N=,7P9HNJ7_ .N1@0E2Q9BK*RY=@ RG*D*&"Y]>
M/FZ'()!8;2 JJ[!A<X) 9@#U )!Z\?@ .E 'XS_#G]BG]M#X;MKW_"'?&#PE
MX'M/$VM:=XKU;2]+\<>+_%'A2^\3:5'X+LQ/JOA[6/!VDWNI1^)-(T?Q'9^.
M-3LM<T3Q'XBU";P_X@U34-8ELKO29/V)TNS-M+=N'D:.5D$>YY64J@(!S,SM
M)(I+(9@R;XEB5XRZ%SIB"( ?(O QT_7'3)IRQJI+ <D => !G  Z #)Z"@!]
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %:>%W5S&
M45RK[&D3S561D5%;9QD+M!(SE@6&1P:_'3P;^P#^TO\ ##3+71/AA\:/#WA'
MPO'?6$6G>!4\7_$R\TKP#HD%G\/;V71O!OBR/3++QIK7@O2O$?A'7;7X;_#[
MXA:EXGG^&'@[Q9>^$]#^(-[X6MK;PM#^RE,,:G&<\ +U/(!R,^_OUH _*?2/
MV*OVFM)^$T_AY/VC_$MUX_UC]G_Q=X(\0WVJ_%SXU:[IO_"\;;7=;O?A9\5?
M#7B+6KR_UCP]86.C>+O$&E^/M(M?#PB\0)I/@J&"Q\CP^CR;_P 4/V3/VJ]7
MBUA/AE^T,-$>[^-EA\0?#UQKWC#XI17WA3P3=/9>,/%/@J&[T^[O[?7;2?XD
M3>);;P_8:MIATW2?AUJ>E>'M\BZ'':W?Z<>6HZ%AZX8\^F?IVIX& !DG'<\G
M\30!^27B7]B?]IH?!?X+_#?X=?&/2/ASK?PXU#XTWFNWOA+XA?%+P9X?U;_A
M/?B+:>,?!7D6?A+2M.O=3_X1RQCOX;RVU=H((;R]O(+(WMEJMU)''??L:?MG
M:AHNH::?VI[VS6WDU-O#,-A\1?BM%>6N@7#:_8:=X$U3Q+]G_M&^MK))?!WC
MJV^(;V$_CNS\1>')_ \DNI^"]0N;B3]<L ]1FH_*7.1U+!CD C@$8 QP#_/G
MK0!^*6L?\$]_VH;C5M0\56'Q>\(_\)DGC#7/&'A3Q1=_$;XNCQ)X8EC^&OC?
MX:>"M)'B4:'>:KJ-MHNBZQX7M]=NR+,^*K73M5C\06.JFXA#_H]^SE\,/BO\
M,M!US3/BK\1(OB-?77BWQ!JOA[4&EU2YU+2O#6L)IMU;Z%JVJWR6$.NW.F:M
M'J_V._AT#1Y%TFZL+>]?4M3MK_5M4^D%C"Y[Y]0.WI@4NP;M_.1[\<C'3I0
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M3+=O?V6D1>(+RQ6WCNVF:[M-!FAUNZME0S6^D2QZE*B63K.?Q$U'_@G;\!_
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M%'V^S)P+A-P42,O.](V:15ED3&Z.)VAE5)7"QN48*Q-?E]X#_8R_:6\,>.O
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M<CQSPI^Q9^U-JS'P7J__  4?U?XB^*/A3X[T/Q+XGT)M&U>\2%/^$J\)^/\
MX:Z'X_T_3O&D?BO3I;WP9::C;7X74X+/Q1I6LQ 6UKI6GQ0S@'[<)>6TGW)0
MWRJQP&X#[MN[Y?E8A&.QL.,<J,BH_P"TK ]+N \!B1("%5G5 7(SL!=E3+[?
MF('<9_"_0/\ @F]^W%IFLGQC9_\ !2SQ9!XCU+6+36O$WB73/ >M0CQ7%;Z+
M8:%IMOK&F7/BV[L?$=MX;\/+<V'A5=3?41Y=^);Z2YN[.&ZKUCP]^PA^T!IW
MBOQOX[UC]LKQQJ/Q"\4_LWP_ [POXWO?#_F>)?AWJ]WXC^&WC-M5TN^FN[C2
M[^QT_P 1>"O%\UII%YI">(;JU\910ZEJL[6PU)@#]>Q?6A=8Q<1EVV[5# DA
MSA"!_=<_*K?=9P4!+_+3EN[=G:,2CS%*AD(8,"PC*C!4=?-C''=P.O%?B_J7
M[%W_  4&N/&][%I_[=/BB+0+SPG\6-2NO'EU;ZFD*^,O$OCC49/!/A9?A-8:
MG;V.EZ1X=\$ZK#:7&NZ/XDCWWOANSGT^UCGNKJ>7)E_8N_:L\<>$-9\#:!_P
M4C\87_B70_$OB'P9\7/%&CQ>)=1O[>*\_9X^&7@#2_ $>AZ+XWCTWP)KMGK]
MQK'QRU*^_LN37I+GXD:1]GNM+M=)LYKH _;-K^S4%OM$; .\9,9\X"2-@KQG
MR@^)%8A3&<.&.W;GBFR:C8Q123RW4,4$2[Y)Y)%2%4R!N,K$1E2S*F0Q_>'R
M_O@J/Q'N/^"<O[8NG>!?%'A#P1_P43\>?#N+6CK$NAV_ASPSK&GZ;X8O];^+
M0\<K+874_BB3Q1<&/23<^&9KN\\1ZAJ>JQZM<6TDJ6EG:VP^DO'?[#WQG^)'
MQ7\ >,O&G[3VI^*?AOX/^(_P-^(]Y\']9\+R-X9U/4/A5X>\,:;JUMNBUD Q
MZOXET#6/'EB+NUGM_P#A(/&^MIJ]I?6^DZ$UL ?I3'?6DV/)N(YLN8QY3>9\
MP9TQE<@#='(NXX4LCC/R-B-M2L48H;A3(%9S$JN\VQ K.WE(K2$)OC#D+\CR
MQ(V'EC5_R.\5?L%_MM:QXJU:_P!'_P""BOC_ $OPEJMOJ\%MH9T+58-9T".]
M^*.O>,]-2PUW1_%.F6U]=:9X2UY/ TFKW>C0WVH6/AWP]+<K_H]RL_97/_!/
MGXO#XM:3\0M/_;*^*<.F:!)XSL-%M=0&KZKXF@\">+/C;\/OB=!\,M5\3W7B
MHWFO^&]"\)^'_&7P]TO4KTPZO#!KWAC7':34?!T!OP#]0/[2L/,>+[7!YL:1
MRO%YBF013$K#+L!+&*9U:.&508YI4>*-FD1E#OM]IR!,&*J&*JKNX!4.,HBL
MP8J0P4C=@]*_(OP1_P $_OVKO#DOQ]\4:[^VI/X@^)WQ7\+>%O"'A+QU#X+U
MS3M1\%>%?#/QBU?XGOX,>^D\;7WB"XT+4]%\2>*? ,.KV.MV7BK0=+UY]4TO
M5#J&GV6VY9_\$_\ ]JVY\6?$V[\0?M__ !8/@WQ#9_%E?AEI/A^?Q-H^M?#S
M5_%D!7X9:QJ6HQ>*UM?%Z_#2ZN+B632+JUL-*\0PV>EP3V]J1?278!^M"W]F
MY14N87:0 H$<,2&5G7A<X+*KL@."X1R@;8V$&H617?\ :(POR#+$H,O&LR E
MPN"T3>;SC$8>0X2-ROP'\/OV3?VB?"7Q=TWQOXB_;'^('C;P):>-=<U34_AQ
MJ^G(-#U[P)JOPS@\,Z?X1\H7C7OA_7/#_P 05G\=V7C'2-9_TRQ-OX<OO#\C
MQ'6&\./_  3^_:_TC3_!VB^&O^"COQ?GTW2/&'B/6_$NH>)-+GN_%>J^%;[X
M9V/@/P[X*TK6+?7_ .R]/M="UNWD^(,FJ7GAW4+NZ\3Q6@2.WL#>6]R ?K7%
MJ>GSHKPW<,B-*8 R-E3< LIML@<7*LCH]L<3HZLC1A@0&KJVFM(8EO8#*,AH
M]X\Q"-IQ(GWH\AXROF!=PDB*Y$L>[\IOCE_P3Z_:.^-;_#7^T?VV/$MG:>!=
M"^"][J.CKX)6WT37OBO\*[[2;S4?B7%::9XDLK[2-6\37]G=^(DDM-5:XTW5
MS:::\E]X=:\TZ9\7["/[7YUMYM6_X*'?%/7O#@U#P_-;:=_8T?A?6H=+MOB7
MX;\5^,=,O]?\+7^GS:P_B_P=;>+/!NG7Y@TV[\$1:MI3Z2]_#8WL>H@'ZL_V
MEI^6'VVV+*&+()D9P%#LQV EB L;MD @JCL"0I(1=3T]U9X[RWD5 "3'(KY4
MB1E90A)=&$4I1T#*_ER!"Q1@/RL\>_L ?M(^*=*U?PII_P"W;\44\$:KX4\<
M>$Y?#VN65]J,MYH_B;XH7.N:?H_B#51XB^VZW:Q_"/4;GX8:OJZOI_B&>[TS
M3O%&G:A83WVL6=QC6_\ P3Q_:.T'XM_ GQSX(_;'UGPAX+^%OPX_9-^'7CGP
M#I?AW68;3XK6'[.\UU!XM;7YH_%:6S6/Q&T;4M4L(]*OK34X=%GO/MQEN[L/
M-( ?K;+J-C"',ES$HC1)'^;<0D@E9"%7+-N2"9P%!.R*1\;4)$?]KZ5Y4TQU
M&R6&WC66YE>ZA1+:)HQ*LERS.!;HT9#JTVQ60A@<$$_BYXF_X)A?M,GXQ^/O
MBU\-/VY/%/P[O/&]WXEM[Y+'1O$6H:KJ'@W5/CU\8OC+HG@74M4U7QAJ$=II
MWAW0_BAI_P --$UC0[/3]3\.Z%X7MK[P^EC(]O8VGJ/Q]_X)U^/?B]?_ +62
MZ/\ %OPMH^F_M3>!/V8?!FHZAKO@_5-:\5^&9_V<+W4M677H=2@UZRT_4=6\
M6ZI=6$KW$VFQQ:0NEQ3+:W]S(CVX!^J3ZMID:"66^MHHC%).)I95CA,$,23R
MSB5RL?DQPR+*\N[RUCW.6VHY6P;VU!93/&&0;G4L R+L$FYU^\@$;+(=P&(R
M)#B,AJ_*[XO?\$U=0\?6_P *_"7A'XRW/@7X=? ^U\0)\*;"'0KK4_%WA_3=
M=\/6>@:I\.-=\57FMRW'C;X<^*1;O>>)6UV,>+%$EQIVG:TFGW2167*>!O\
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M=-76?[,TSP)9_#^RC?7!I(U&:2+1=,M1)<W,TMY>QW=[;:A<78N+II>CT?\
MX)%>!]$UK4=8M_CW^T1<6&L>./"WQ%U/PG<>+?#L>EWOBGPG\)4^#]C<7FIV
M>@6VN76E7&B1V&NRZ)+J$FGQ^*?#WAW4X[;_ (E%D$_8:B@#XP_9F_8W\*_L
MO)JMOX*\7_$'6-/USP/\*O"&H:5XP\1S:]IHU?X6>%[CPO+X]MXKEY9;;Q)\
M1;:?[?XZ%M-%::CK)EU5X#?2-,WV<!@ <#  P!@?@.P]!2T4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10-k_011.jpg
<TEXT>
begin 644 form10-k_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &/ HH# 2(  A$! Q$!_\0
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M_@SAG_YSG\5'_#N3]N;_ *-K\9_^#?P'_P#-?1_P[D_;F_Z-K\9_^#?P'_\
M-?7]J]%'_$Q/%?\ T).'ONS;_P";@_XD'\,/^BPX^_\ !G#/_P YS^*C_AW)
M^W-_T;7XS_\ !OX#_P#FOH_X=R?MS?\ 1M?C/_P;^ __ )KZ_M7HH_XF)XK_
M .A)P]]V;?\ S<'_ !(/X8?]%AQ]_P"#.&?_ )SG\5'_  [D_;F_Z-K\9_\
M@W\!_P#S7T?\.Y/VYO\ HVOQG_X-_ ?_ ,U]?VKT4?\ $Q/%?_0DX>^[-O\
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M/^BPX^_\&<,__.<_BH_X=R?MS?\ 1M?C/_P;^ __ )KZ/^'<G[<W_1M?C/\
M\&_@/_YKZ_M7R/6BC_B8GBO_ *$G#WW9M_\ -P?\2#^&'_18<??^#.&?_G.?
MQ4?\.Y/VYO\ HVOQG_X-_ ?_ ,U]'_#N3]N;_HVOQG_X-_ ?_P U]?VKTF1Z
MC\Q_GN*/^)B>*_\ H2</?=FW_P W!_Q(/X8?]%AQ]_X,X9_^<Y_%3_P[D_;F
M_P"C:_&?_@W\!_\ S7T?\.Y/VYO^C:_&?_@W\!__ #7U_:OD>M%'_$Q/%?\
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M /-?1_P[D_;F_P"C:_&?_@W\!_\ S7U_:O11_P 3$\5_]"3A[[LV_P#FX/\
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M<W_1M?C/_P &_@/_ .:^C_AW)^W-_P!&U^,__!OX#_\ FOK^U>BC_B8GBO\
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MK_Z$G#WW9M_\W!_Q(/X8?]%AQ]_X,X9_^<Y_%1_P[D_;F_Z-K\9_^#?P'_\
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MK3X/ACX=T[0+RQTS1/ :>#M"L4;5(M-NK/PU\1]-^&7Q(T+5=.UJ_BOU76_
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MH_X93_:._P"B/^)?_ GPW_\ +ZOWRP/0?D*,#T'Y"O2_XBQG?_0MRG_R^_\
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M\7RC)*491J\/2C*+U4DXY54BTULU*2?1]%^!O_#*?[1W_1'_ !+_ .!/AO\
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MV7XO_P""8NE?&*ZEU7]H[]K;]J/X^>(;3X,_'SX!^%M5\2']G_P':^%/A_\
MM(?#N[^&GQ*O;3PQ\(/@1\/O"FK^/]5T8Z1JD?C37]%U.33-:\/V,7A[3-"\
M,:EXE\,ZYZ!\:/\ @GIX%^+WB;XB:M;_ !<^,?PW\+_'OX6>"/@I^T]\/_ =
MWX!'A[]H#X9_#Z#Q1IVBZ+XAU#Q3X$\2>)_ FJ:IX7\:>*?A_P",/%'PGUSP
M/XA\2^ -772);^TUKP]X)\2>%@#A_$G_  5G_9?\(ZO_ &)XBTKXM:??VN@_
MMPZYKZIX.TB_B\)/^P9K7B[3_B-HGBB73/%=ZNF:]\5/#_P^\?\ Q$_9_LL3
M0_$/P!X,UW6K^Z\,7<=GIEYX9??\%+/C\_QN\+?#S3?V4/&JV5W^WSXM_92E
M\%&Y^%%U\3?&O@W3O^"=VO?M=:;K.DZ@_P >;7P!X'\3>'O&\&CGQQ=>,==M
M=('P\O++3] L-3\=7FL:?X=^@/B1_P $JOV9?BCX^^,?Q"U_4_B;9ZG\;_C!
M^SI\8_%.CZ)XDT*P\.Z7J'[/.C^(/"Y\%^%M.?PK<3:/\/\ XW^#O&WQ*\(?
M'S0'O+NY\=:%\3_B!'I^I^'+[Q#<7J>FZ;^PMX M/VB;C]HF;X@?$B]U*+]I
M&Y_:G\.> Y9O!D7@[PU\3M;_ &1-2_8R\70V]Q;^$(_%VJ>%O%'PXO;+Q+-I
M&L^)KR[TCQ[I%M?:'J=AX:N;WPO<@'D'Q\_;ZGC_ ."7_P 5/V]_@!HTVB:I
MH7PM\1^+?"_A[XP^%9=4O?"_B?PKXON/!'B?0?''A/P-XJN$UW4?"/B/2M?T
MV\L/!7C74M-U^\TQ'\,>(]8TV^L-0N8/ G[86M^&_ /Q(^*/BCQIX[_:2T;P
MQK7@;PC:^$O#/[&/Q#_9%UGP]K'BS5+R"3Q'KOBS]I[QQX0\"KX$TO3(I-2\
M6^,-9U_PUX9\(V6DRPW&JZAXDUWPYX:U3V>[_8)^$%Y^Q?XG_89?Q+\14^$_
MBJR\:6-]XB36/#W_  L&"+QU\2]9^*FJ-::LWA=O#\<EMK^N75GIYD\,2I'H
MT=O;S)<72->OW7[5W[+/A7]JWPE\/O#WB'Q3KO@[5_A3\6_"_P ;?A_XAT71
M? WBVVT_QWX3TCQ+H&GR>(? OQ.\+>-_A]XUT8Z/XOUS[/IOB3PQ>RZ!XB&@
M^//"-[X=\?>$?"?B?10#Y<\+_P#!5;X7_$KPCX1USX,_ C]H;XX>*O$7A#]H
M3Q_KOPN^$]I\%?%7C'P7X+_9E^,^L?L__$?7+G68OC5!\,_'DNM_%30-8\._
M"71?A!X^^(NM?%M--U#5/!EC?Z7I>K76GUO _P#P4CUC6O'_ ,7/ACJ'[,WQ
M<UKQ[I'[4?BSX$_ GP+X-N?A1:^)OBEX*\$? CX;?&KQ7\2]?D\=?%_PSHOP
MYL/"FG>.['_A([7XAZAX)U>VD\8?#GPC9^'KSXAZEXB\,Z%%H?\ P2UTGP=<
M7^L?#W]KW]JCP'XUUJY_:*TSQ+\1_#TWP+M?'GB#X>_M/_%J7X_?$?P5/?#X
M*+H6C:CX>^->M>._'7PB^('A7P[H'C;X7P_$/Q)X6T/5)?#5OX?T[1NVU7_@
MG-X?A^)7BOXP?#O]H3XX_##XB:K\7KCXQ^#/$&C)\+O%LOP_U7Q/\$?!/P'^
M*GA&)/B-\.O%[^.O _Q8\-?#?P#XI\2V?Q(G\5>)=,^(?A+1_%'A3Q1H:I=Z
M;= '1? K_@H=\.OVCOBSX9^$7PN^$7QWO]4N_A1I_P 6/B9XEUSP[X$\.^%/
M@)!=?$[]H;X':A\._BM<ZA\1AK3_ !6\-_&_]F/XH_"[7O"OP[T/Q_91ZSIJ
M:[IFNZIX+MM7\2Z9]_U\:_LT_L/?"7]EGQ5J_C+X>ZW\0=8U[Q'\(? 7PE\5
M7WC?7-(UN?Q5/X-^,7[1GQ]USXH:Y-8^'M'DF^)_Q2^+'[4WQ7\7?$G4[)[+
MPO?WU[I<7AOPGX7M+![>Y^RJ "BBB@ HHHH **** "OYSO\ @H@%/_!P+_P;
MXY"M_P 2/_@IKU&>5_9A@9>_56&5]'&<<8K^C&OR[_;W_P""5/PM_;[^+/[.
M/QS\1?M$?M:_LV_%G]EC3?BQIOPH\??LG?$WPC\+_%>G1?&?3= T/QK-<:_X
M@^&_CO589[KP_H4GA^,Z+=Z/%-HVN:Y8ZC%?Q7<(M@#\VO\ @[#ATQ_^"6GA
MZ'6M(U/Q'H\G[8O[-B:KX?T:WGO-8U[37U?Q&M]HNDV=K<V5Q=ZEJ=H9;*PM
MH;RUFGNIHHXKF"5DF3\Z/V*O _P^_9O_ ."F>D?M@?L<_P#!/;]O[_@F!_P3
M@^!O[(GQSUW]OT_M4?#/XP^!]"^*5[I6B>(-4\$2> _A)K?BWXO>)/'GB#PQ
MJL7AK6%B\#/<ZN\.E:AY'AS3C!<7'C#]SO%7_!#[X7_$[]G?Q!^S9\=?VW_^
M"B_[1GA+6_C?\)/CQ9>*?CW\??!7Q(\?>$O$?P>.IOHOAKP?K.J_""/3-%\%
M>(9]2:Y\6Z4NASZEJ-U:VES8:UI4T1=_VO;:< L 0>Q /<8]1D9'&#_*@#\!
MOVAO$?[''_!;?]G?PIXD^&'QG^-WQ0_9\^!GQA\;^)O'O[*7@;PYX\_9P\:_
MMO\ CWX5_"BU\;:'^SY#=?&2;X#>+[S2(?\ A,/#^N1C2]6M/!U[KFI:/-KN
MO:+?>'+/7=!_FF\#_$/QG#^P9XC_ &&H_%OQQ^!WP]^,?_!Q7\'/V//B%^R1
MXM\;_$/_ (6U^R#^QK\;;_6=>TW]GS4?BEJU_<:Y=Z-X\A\%7E\;KPAXAU[P
M[>VL&O2W.MZU=>+_ !$]U_:3^WQ_P3I^&/[>=M\#?$>L_$GXK_ ;XY_LQ_$6
MX^)O[/7[17P,UG0]%^)_PTUW5;&VT[Q5HUO+XCT+Q)H6L^"?'%CIVD0>-?"N
MI:4]IXAAT/2K:\F.GQWEE??'MG_P0._91D_99^,O[/OBWXI_M'>.?BA\>?CY
MX>_:K\>?ME:]X]TF/]J!/VC_  7?&]\!_$WPSXITOPS9^&?#[>!TN-5TKPQH
M5MX7FL=/T;Q#K\:2_P!JWZ:Q  ?S5_MN:IXH_P"">9_X+5_\$[OV1O'OQ-^%
M7[,&I^-_^"7T'@?0;'XC^-O$-]\!=-_:ID2P_:%T/P#XN\5ZOXF\3:):_%FR
MM$@U>*_U*_']B/<Z;;VSP3EC^UO[ 7P=\%_\$^?^"ZW[2/\ P3Y_9B;Q5X<_
M9*^)/_!-?X;_ +7\GPHU[Q]XW^(6B> _C9X1^-VE_!"XU3PY>^/M>\4ZUI=Y
MXY\+:Q=ZUXL8:M'+KEU!I*W,4^G:!X?M](^N-(_X(2?LQ:Q\!/VS?A'\>_BO
M^T-^TI\0_P!O75_AWX@_:"_:9^)?BOPQ:_&Z76/@H+9O@7<_#Z\\+^#]'\)^
M"K?X07%I!>^%;%?#.K6=U)/?:1XACUCP=+:>%K#Z!_89_P""8?@G]C7XJ?&7
M]H?Q/\>_CY^UE^TO\<O#'@'P#XN^.W[1NM^&-7\6Z=\-OAI81V/A;P%X7M?"
M7AGPQIND:-))#:ZMXFN)8K[4O%6O65IK6K7DM^D\UP ?IY1110 4444 %%%%
M !112;E_O#\Q0 M%1RS10Q232R1Q10QO)++*ZQQ1QQJ7>221B$1$0%G=B%50
M68@ FOEGQU^VM^S1\/SHZZM\4=#U5M?LM8OM)/A$3^+[:XCT5KF&>*?4] 2^
MTC3I[N_MFTG3DU._LTN]198ED6$231@'U552^O['2[&]U34KRUL--TZTN;[4
M+^]N(;6RL;*SA>XN[N[NIWC@MK:V@CDFN)YI$BAB1Y)'5%9A^0NI_P#!1KXI
M_$N;P=%^S_\  ^]@TKQ5K]W\/M1\4>/(;F]T[2?'&JF!/#L%IK/ARYNO#UA#
MI&F:CIOBO7_[=\_S;5KK3XK1+:S?6+CP:_\ @O\ 'OXGMH/B[]IOXI:MJ^I?
M#3Q=K>@:AX21M+$>L>"((?'FJ^);:U\2^#;G0])T[5/$VK?#CQIX%FF_LF]N
MH=*N=!!NXXK2#1H #[B^+'_!27X-^&I;'PY\)TN?C%XL\4Z%>R>%;OPT;&3P
MG;^*+NYO='\+:%XBGN]5TS6!-JVMVT7G6NF6,]V-*N;*^@+)J=@TGQ9K\G[3
MG[3,^E^)_CEXBNOAG\+8-9LOAU\5?A'H%QXK\#ZO#X=L1J?B?6/&3>!O$5CK
M&FSF>UT#6[U-2\0:C>2V=UX(NH(-+DLA!%)]7>"/V?\ X5_"Z#QU\/='\&:?
M=:M:^++S4/!.H^+H+'6=5'BFQU.?5O\ A#8/%VKP-/H0^)/PI3PAIVG1+=6&
MGZRB>)X0T^H6&KAO4X=/\.:3:07_ (H\8W#:Q?>$V\::K_PCMNNK75]I'A'1
M]/U/P3XL\+^((YY-,G\5VUSX!USQSHFF7JZ@-6\.ZIXXT&?3M=BT:YOI #YS
M^&GP5\$_"[Q%I'@?PU8V[:[X9U+QG"GC;4;30;?QU>^%]3^(%IHWB8OK"VNF
M)<69^'>C^(_%UK;QGR8-$\2:E;VBOIQM5D^F=-_L+P5J6GZ?X[NM/EU'PK:Z
M?KD,.EPM>66AW_B&V\-Z]XJU*\M+B#31K?AWP)XE\.:#X[FU'PIK+:MH/AGQ
M$S>(-+L-#L;G5M0Y?5O$%QX6\._$/6="_L+X;:'\.[FVU7Q#X>L+.SO/"4>C
M'7]2\-Z]K$&H/96>IWFFQZ]X5OQK6A3(FE:M\($\*Z5H&@>%O$]I8S6/PG\0
M_P!K729]8U#X>? 72H_$J>.?#?A.?P/XD6X>RD^%GB>VEU6Z@\/VFFZQX<DB
MU;3/"6G^(?$GA/4OM\.G:='X*O\ 1]&13I>BSPZA48RG*,81E.4FHQC&,IN4
MF[)1C&[DV]$EK<F<X4X2J5)1A"$>:4YRC"$8K>4IR:C%63=V[:=3["^.?Q5T
MKPUX'\42^*M2TW1+C2/#Z:C/X/TAK+^TM!\3V=CKWPJ\7Z1X<T,-::EJ/A2^
MU#QEX!\4Z&+I)(8M/UZX\9V=W/;FU:'X1^(O[0/Q'^.^O_$#PW\']"O= ^''
MCN6TUK0O'^NV.MZ#XATB.RU#7?$'B/3GUW2;O5M%TN36-9\3Z_X(U*VTG[=<
M:AI%O92?:)+*[O/.Y71O@_XA\::QHOC_ ..VN7GBCQEI]I::,^DWB:'?6,OA
M[0+#^S/#>F:M>65C##=OIT,MT\L4)F6]WQ27MU<W+WTEQ]":;IVGZ18VNF:5
M8VFFZ991+#:6-C EM:6\8+';%!$ @+2/))(YW22R2-)+([G=7UN6<*5Z]JN8
MN>&I-*4:$&GB)1TTJM<U.DI?RM3E%+WHWDK?!9SQSA</ST,IC'&5U>+Q-2-L
M)3>JO",DIUI)I\O+RPFU\22N_&?#7P1TB+5+GQ=\0+^Z^('C;7+*4>)[KQ!)
M'JVDW^KWLB/?:F([^R74+^]=8;:+[;J=S-,TL4]T(XI9U9/;X88H888((8K>
MV@B6&WMH(UBM[>% %CBAA0".**-0%CCC5$1>%4# $U%?<87!X7!4U3PM&%&*
M5FXQ2E.]KRG.RG)RLFU*;IIKW:<=;_F>.S+'9E5=;'8FKB)MZ*<K4X)7Y8TZ
M*2I044VE*,%4:?OU)A11172<0444?UH :025 #%B0 J\DEB%   .220JC@DG
M Y-?%/QQ_:'N;6ZO?!?PYOQ!+;226FO^,+5E>2*Y3<EUI/AN8'9&UNW[C4==
M3]X)5FMM)D@DB:^?TW]H[XE7'@?PA%HVC7+V_B7QB+FQMKB%RMQIFBPHJZMJ
M4+JI,5Q.TL>EV,RGS(I)[JXC8/9YKY+^!WPA?XF:U-=:F9[7P7X?EA75)X28
M)]4O742P>']/F3!B>6/%SJ-VC%[&SEC6/RK^_M'K[/A[*L)3PM3/<U2>%HMK
M"T9+FC4J0;M5J4VK5%4FG2H1?Q3ISE)QA&,I?DW''$>:XK-*'!7##DLTQL8+
M,,33FZ<\-1J0=6-"->+4L/36%E/%8ZLIPG1I2ITX-3K-QX7P?\._&_Q"N+A_
M"^AW>JQBX<:AK5W*EMID5R_[R7[=K6HR1Q37CL^^6""6YU!F;>T#9)KM?$W[
M/?Q3\,6#ZE-HEIKEI$I>Z_X1B]&LW5HBC<7FTYK2TOY8@H;S&L;6\$1&Z9DB
MS*/TOTW3;+3+&TTS2-/M]/TO3H%MK+3K"V6&TL8$QMBAAB7:BDY9W;,LTK23
M3R23R22-:.58@ JP8=BI7'L<$'/'3V[XK:KQEC'74J.&PL,.OAHU$XU90O>-
MJJJP=&?(DH1C&48Z1]Y(SPWA!E$<#R8_,<RK9C4@G/%4)0I8>G7E%N:AA\10
MJ5L1!3;YOK6(A6K6E.4N:::_(WP/\1?&'P_O&O/"NLRV<+R#[=I4X-WH>HLK
MD21:AI4CB)I2P=/M,#6VHPLI\F]A*G=^B7PD^-7A_P"*-NUEY<>A^+K6W:XO
M_#TMQYT=U!& 9M3T.Y8(^H6$>Y3<Q,GVS3E:,7 FMI(+Z;.^*?P+\+?$:.XU
M*T2'P]XQ="T>O6T&VUU.4*0D'B.RA4"\C<A =3A1=8A!,KSZA'%'82_GEJNE
M^*_ASXJ-C>I=^'O%&@7<-W:W5O*PDA<,QM-2TV[0&*ZL;I=S03*)(9X'>WG5
MG%S;CU)TLIXKP\Y4Z4<)FE.#^**I5;M.SJ3IJ*Q=%M6]H^:=)WF^5IL^8C7X
MJ\+L=0AB:DLWX9KU91LIU)862E).K&C[2:J93CZ=->T<)3^JXATVX4W34IO]
MAQW_ ! Z],#U_7WIU>+_  7^+%K\4?#KRW"PVGBO1%AM_$FG182*0RAUMM:L
M(RI"Z?J;1R9@#$V-ZLMH=T?V:2;V9<<\8]?K@=/:OSK%86O@J]3#8FFZ=6D[
M23LU)-VC.#7Q1FK24MGS:=4OW;+LPP>:X+#YAE]:-?"8F"G3J*+A).WOPJTV
MKTJL9J4:M*=JE*JITZBYXRNZBBBN<[@HHHH _*W_ (*-_P#(R_![_L6_&7_I
MZTBOS9K])O\ @HW_ ,C+\'O^Q;\9?^GK2*_-FOZ:X(_Y([(_^O>)_P#4W'G^
M6GT@O^3P<:_]A65?^J'*CT'X5_\ )5?A5_V5/X<_^IOH=?WWU_ A\*_^2J_"
MK_LJ?PY_]3?0Z_OOK\,^D?\ [YPC_P!@.<?^I> /[/\ V?/_ ")_%+_L;\)_
M^JC-C\R?^"F7Q^^*'P*LOV*=-^&?CCQE\/;;X\_MN^#_ (%_$KQ'\-OAAI/Q
M>^)4?PVU7X ?M'?$6_M? 7@K5O OQ,CN]=E\5?#3PC-<W=IX$\1WMGH%OK,B
M620F>[MOD+P=_P %/]:^"WB/]H+PM\5?&&L_%30=)_:8^!G[.7P!UG]I'PUX
M8_8Z^)UMX^^(G[/OB+X[_$?_ (7Q:7W@KP-9^$?@=X3\#>#[_P 8?#OXMCX*
MZ9KWCR[F\2^ O#7A;QU?Z%H>NZY^QOQ;^ GPX^-VL_!'7O'^GZC?:E^SU\9M
M,^/?PRET_6+_ $E--^(^D>!/B#\-[/4-2BLI8X]:TT>%/B=XNLY-'U!9;"6X
MO+:]>(W-C:O'XU\2/V%/@A\2/B!XQ^+LES\0?!?Q>\5^)_A'X[L?B;X"\:7F
MA^)O!'C_ ."?@_XB_#OP5XS\&6]Y;ZKX;M=3G^'GQ6\>> ?%^DZ]H'B#PEXZ
M\&Z_>>'/%WAS6-,FFMY?YH/]%#YI\'_\%/-5^,&C:1%^S[^S%XN^,?Q!L/AW
M\5OBC\2/!6E_$CP7H^F:/X:^$_Q7\1_!E+/X7>/;B"]\-?&+7?C+XO\ !WBN
M]_9^>T;PEX.\;>%-%DUSQGXT^&<]W9Z7-2\._P#!7#X3^*/CI)\)])\)VESH
MLOQT^*G[-=I?VWQ)\,7_ ,6M/^*OP=T#QW=^,M5\:_ 33;6\\3>"O@[#XX^&
M?C/X26_Q+O\ 7KN^B\=P:!?:MX+TOX?^)M.\;CW'Q+_P3C^"'B/2?#-BGCK]
MHOP_K6E^"/'WPQ\9^/M ^/'CF#XE?&/X:_%7QA=_$'XB^"/BCX\U&\U/Q%?:
M=KWC;4-1U_0=9\)7O@_QA\*1J>J>'_@KXE^&WA+4]0\/W._;_L)_##PUXHUW
MQ7X#\2_%'P[IMQX@^(WQ*\-_!:#XC:W9_ '0?C3\3_#OB70_&/Q-'@.PA6XU
M&[\2S^+?$'B/5?"&NZIKWPOMO'VMZK\5]&^'MA\5KI_&3 'P3\6O^"K?QKTW
M]F[P]\5/"'[+,/@/QW\9OV?/A/\ M2_LXZ5\2/B-HOB/1O$_PI\1_'+]G+X7
M_$G1/B;%X6LK.?X=?$WPGHW[2_PWUK3/#UM>^*M U>T\4//!XK_MKPKXC\+6
M_P!5P?\ !0J=/%^CS7_P'\0V/P)\5_M&_%/]DOP?\:%\;:%<7>M?'#X1P?$#
M3/$,L_PZ_LV'4M.^$>L?$?X4?$'X3^%/B"->O=>U'Q;I&FZIJGP\T/P/KEKX
MKB\X^$?_  24^%&E_LR^!_@S\;?'/Q:\>^-="_9.^%/[+\7BJS^*_B2ZM/@W
MH7@B/X7>*=?LOV=;G4M-LKOP_I>K_&#X3^"O'ZZ[XUTOQ/XNUA/!7@3PQX@O
M9_ G@_PYX)T;Z,T__@GY\#K'XC0>/I];^*VJZ5IWQ(\?_&_0?A1J?C^[?X0^
M&OCW\5M!\6>'_B5\;-"\(VME:3VOC/Q;!X\\<:S+I$VKW/PX\.^-?%_B/XA>
M#/ GAKQWJUWXCD /C^7_ (*^7&G>!OV=?'GBK]FF;X;V'[2_PC\/?'KX:Z?\
M6/C[\,_ADOB[P#XNNO!<?A;X=^!?'GB^UTSX+^)OVJM;TKQ1=^+;?]GO5/BG
MX4$7A*UT2\N/B#'K?B"X\/:%^T2,6!SC(9@< CH?0\].OZ9')^ _&_\ P3A^
M GC;X9^#?@N_BCXW>&/A%X=_9T\/?LD>+?AOX6^+6O6GA'XQ?LX^&M%?P]IO
MPS^*.EZHFL)=R-I%SJNFW/Q&\&/X*^+\VF:]KVC#XA)HFK76FO\ ?,:Q1(L<
M0CCC10B1H$1(T0!%1$0!52-5"*H "@ =J+/L_N8KJ]KJ^UKJ]^UKWOY6N2T4
MWS$P6WIM! )W# )( !.< DD #U(I0RDX# GK@$$X]:+/L_N?^0WIH]'YZ?G;
MNA:*** #('4XIN]./F7G)'S#D#@D<\X/!].]-E*A<LVT9Y.0,8!.?PZD>@/U
MK\6OC+XG\83_ !@\;7E]KFL6^JZ'XKU6QT>6UO[NV.D6&F7LD>D1:6(9(C9(
MEDEO.6MA%]IEF:YG\YYY'DF<E",6TW>5O^#L[^A\EQ=Q72X3PF$Q-3 UL<\7
MBGAH0I5:=&-/DHNO4E4J5%)7]FFZ<8Q]YIIM:7_9V]O;2RM9[V\NK6TL[2*6
MYN[NZN([>UM;:"-I9[BYN)&6*""&-6DEFE=(XT5F=E )KP;0?VI?V>_$OB:'
MPIHGQ>\%W^MW5R+*RM$U!K>VU&\D8)%::5JMW#!H^JW$T@"00Z??7,D[LBPH
M[,H/Q)^VW\2/$OB']E#X2:C9SSI8?$76M$M/'5S:_NXKR>PT#5+]])NA#^[C
MM+_Q#ICW,UI\J2R::MJZ/&9(F_'HJD@,<B+(K<&,C< !R/4@@@$$$," <\5:
M>B:V:Z^>O;T=_N/QGQ'\=L7PEQ#@\HR7)<%F.'67Y9FF-Q..KXFG4Q%'-,/]
M=H4,#'#-0I^SP+<ZF+K*M3C6:2I^RC4:_J#^,7Q=T;X/>&H-=U.QN=6N]1OQ
MIFCZ/:2QP2WEYY$MS*TMS*DB6MK:V\#R7$XAGD!,4<=O*\J@8'P-^/>C?&6+
M6;:+1[GP[KNA+:SWNF7%W%J%O-97K21V]Y8W\=O9F5!-#)#<036D$ENYA(,J
M3(]?"GBWQ#KWBW]CG]G'Q%XLN;B]\13W\UF=0OF9[W4-.T^R\3Z58:C=S,H>
MXFO]*TW2KRXNW8O>23+<RN\LWF-T_P"Q*\@^)_B>,;O*D\!7C2]-I>'Q!H(B
M+X&"R":95.0!N<8.<#%U)>V4$URNUUIU3=[W\C['#<<YEC^,N'L+A^6CDF=9
M7D^,C@JN'IRQ,(YQE,LS4Z]=IUXXBC-*FE"4*$J:YYTY<\94_P!1#@XP1P<^
MO8@_H:_DF^%>@_$?1?@+^R_^T!9>#3X&U3QE_P %0]%^'_B+]L/P[^U-\3_$
M/Q?/AGQ;_P %,/&OPM@\,:[\#-8T+1_ GBGP?\1[>31O@%XM\,ZY\0M;T/P?
M\//%TOC:P\.^)-5\!Z/X8K^M=0" 3V.?QZ<_CS]<>E<._P +OAM)X9MO!4GP
M^\#OX-L]<@\3V?A)O"6@'PS:>)K3Q2/'-IXCM=".GG2[?7[7QL!XQM]8AM4U
M"'Q4!X@BN$U8?:ZU9^Q:]=_^'_2Q_/C:?\%7?VOM(^%WB7]IG6_A#X.G^&OB
M;X*?MP?%;PC\./%Y^&7@&?P//^R]I/B[4O"-EINNZ)^T-XY^,'Q4BT'4O#-O
MX._:F2[^ _@R^^'VM:VWBBULO NG>&[CPEXA^A_C'^U;^U_\(?B5\,?V9M#^
M*OP1_:'^(WQ@^(^EV">-_@S\,_"%G\3/AIX;B_9_^)_QFU7PGK/P5^(/[1WA
MGX>_\)/\0IOAT-?^".J:K\6I-1U+X06WQ(O[[P5XLU;X=6OBOQ;^M.A_ 7X'
M^&/&'C/XA>&O@[\+/#WC[XCVUY9_$+QOHGP]\(Z5XM\=6FHSI=:C:^,/$5CI
M$&K^);?4;F*&YOX-8O+R*]N(8I[E)9$5AR=M^R1^RM9_#J_^$%G^S7\ [/X3
MZIXAC\6ZE\,;3X/?#RV^']_XI@AM;:W\2WG@^'PZGA^XU^VMK&QMK;6)=/;4
M+>VLK2V@N([>U@BC /QE_P"'B'[87B7P5\1O%*^/?V1?A1J/P"_8"US]L7Q5
MI.IZ=8?$JU^*WB3P#\>?VHOAA>VD.N^!_CYK7A3P%\)_&?AOX%>%[_Q4/#/B
M_P")?B3X3>-?'=MX7/C/Q)<:)<Q:[T/PA_:?_:O\5?M&?%+X&67Q=T3PM<?'
M;]M[XBZ=X+\4?$_X?W?B<_ 'X=_#_P#8!_95^/LW[._@+PW/XYTG2];^)NN:
MU\49M6L8-6>RTRV\-_#_ ./OCUO"-SJFHVUEX<_434OV(/V;=>^,-I\7_$WP
ML\"^*I]"^$_PF^$7@7P)XF^'OP]UOP!\,M'^#'B_XC>,?!FN_#?1K_PI/<^$
M/$-K>?$:]T]IM)U"VL+;3/#WAB/2M-TZYTY[BZ]*\6_LS?LY^/O^$T_X3GX"
M?!CQB?B/K?ASQ-\0V\4?"[P/KS>//$G@[1QX>\(^(?&3:IH=T?$NN^%_#X_L
M+P[K&L&[U+1=% TO3;FULAY% 'XN?#+_ (*,_MA?&'P9\8/&_AS6_P!D?PQ!
M\ ?V.O%?Q;N9?&T.K^$_AC\;_C!IO[2?[?'[+7@+QK:_%CQ'\3H/#_PD_9G^
M(]U^RQX,^-NG2:G<^)]1MO#_ (MT_08?BS+H,UYXSD_0S]@W]H;XF?%__A?7
MP^^-EY?0?%?X'_$7PYH&N^$_%/PCL_A#\1_">@^-/ 6@^+O#=OX\T[P=\3OC
M3\'O%5SJTMQK6J>&/&/PB^)VLZ!?>$9]%TK7]*T?Q;HVM3:K]D1?"CX80:5>
M:%!\./ 4&B:AX$TGX6W^CP^#O#L>E7WPQT"#5[70OAS>:<FG+:77@/1+;Q!K
MMOI'A":%_#^FP:UJT5II\4>I7BS0?#3X0_"CX*^'G\(_!WX:> /A1X4EU.XU
MF;PS\./!_A[P1H$^L7<-K;7>JS:1X;T[3;";4KFVLK*VGOI('NI;>TM8'E,5
MM L8!Z-12;E_O#OW';K^7?THW*,Y8<=>1QTZ_F/S% "T4FY?[P_,>_\ @?R-
M+D<<CGI[_3\C0 4455DO[&*XM+26\M([N_69[&UDN(4N+U+9%DN&M(6<27*P
M1NDDS0JXB1E=RJL"0"U17#R?$SX<QQZ-(WQ \$(GB/5W\/\ AV1_%>@JFO:_
M')'#)H>BLVH!=4UB.66*)],L6FO%DEC1H0SJ#QFK?M'_  #T/3]1U35?C1\+
MK/3]'\10^$M6NW\;>'Y(M,\2SK<O'H=_Y-_(UKJ>RSO9GM)A')%;V-]<2[(;
M*Y>( ]KHKYKUS]L#]FGPX_B^'5OC+X+CN? QL4\1VEG=W6JWD$VHW$5I;P:9
M::5:WMQXDGCNI4M[Z#PXFJ2Z9-NCU-;,I(4X_4_V]_V4-*NK^SF^+FDW4VG^
M&+?Q6SZ=H_B2_M+VRO+.UO[;3-+O[;2'L=1\426U[;%_"UM</KUM,\UK>6-M
M=65_!:@'V)7F_P 6O&2_#CX7?$OXALMNX\!> ?&?C;9="1[=QX5\.:IKNRX$
M#QS&W;[$5G6*2.0Q%EC='((^4V_X*3_LH+<Z) ?&FM&'6=$N]8FOAX1UT6GA
M^6V6^\O0_$2O MYI^O7LNGR0V=C':7,4INM,N)+J&RU2PNKCXU_;(_X*=? S
M7?V1/CYI/A;0?B+/XA\<?!#XW>%8;#5-#T73!X7O=0\"ZIHNEW^OWA\17>G7
M-CJ-WK%K)!'X=NM=O;:W6=M3M+&X$%K<=.#H_6,9@\.TW'$8S"4)):WC5Q>%
MIRTZMQJ2276[6YP9KB7@<JS3')\KP.69EC>?1N#P>7X_%J2333:>%C):2^#9
MI,[W_@D%_P % OB__P %!_A+\6/B!\7/ _P^\&7WP^^(&C^!],A^'47B6.PU
M-KKP9I'BG5+F\B\1:QK<T4T,FLVL-O';7.Q8B?,W2. OZ_IG8N0 =JY Y .!
MD ]P*_D#_P""*G[8GAO]E+]C7XAZ??\ @#Q-XSUOQ3^U)J^HR3VEU:Z'X>L_
M#[_";X;Z;&K>(;BVOX)O$RW?AC69++PPUG;2:A9B2^7488;><C]@_$G_  5#
M\26\7Q1C\.?LV>*S<> =9TJR2Y\1ZI?V:Z1IFH:G<:6EU\2=*M/#DEWX+U6^
MN(8(=)T>*\U>">ZO&M[G5K<V<+ZI['%F%PF!XDSG!8&A##X3"XUT:-&FY.%-
M*CAI24>>4Y/WYS;;DU>Z26R^1\+LRS3./#WA'-LZQ=7'9IF634L9C,565-5*
MU2MB,<E*7LJ=.#M3HTE%QA"]-1DXRNJD_P!>Z3(]1STY'-?C[J__  4!_:7O
M-6\=Z;X8_97N[$Z)\.]/\;:=:Z_%XDO-5T&TDM_#%[J/B'7XK:'28/$6C"TU
M_P RTT30VTKQ!;1SZ?=:AL6#6+;3J5K^UG^WOXFU[P9I^A_ ?PGIH\9_#/5=
M1T>VOK#4+>SO/$$&C>*;J#Q!-K&I^((XO"MTU[X9NY=)^'7BEK>_NX(CIM]J
MJ-??VSIGSQ]Z?L?N7^\/S%&Y?[R_F/;_ !'YCUK\3=%^.'_!1O6;3X3:[/!X
M-\.Z%J6OCPIK>IZOH?AJ"TO[[7K>U\0Z)JWQ"TJ!KK6](L6\*:M8ZKIDG@:"
MW62R@EN-8M[>ZE:UDY?3[S_@H7K^@>"-1U+XXVNCR67QDU/P_=*MWHB:I'':
M7GAFUN==UM_#6@OHWB_P/9ZGJ;6VG^&GCD-T=1BB>UNK74=-M]' /W;K)U?7
M]#T"PN]4UW6M)T73;#R1?:CJ^HV>FV%D;ATCMQ=W=Y-#;VWGR2Q)#YTB>:\B
M*FYG4'\'?%?P%_:/UCPY\2=/\8?M1>(M0N-"^*-QK&DZ2]]XOOK'78_#\7Q2
MBUKQ?)+'J%C/X4FT^U\ >)-2TOPOIT]UH$)\/^1'*-3GT.[M.AU']A?3-?\
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MOX'>#]0\/6ECXVUOQUX&\=:FD%CX@M?!6MZWX7UK2]*NK/Q!92>$C<W2^%O
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M*N_HBBD!R,TM?"GZ:%%%% 'Y6_\ !1O_ )&7X/?]BWXR_P#3UI%?FS7Z3?\
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M-4T#0M*\$^'M0^+1NK30]!T675I/"7A^>S7Q!J%LMLMV?#_Q#.H:#J%P]O\
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MB@A6VE:>*&SMM52>*VC$[&1Y CW,_P JS3/$%C7U$%EC2(96*-0D40 6.-%
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M?_4WT.O[[Z_@0^%?_)5?A5_V5/X<_P#J;Z'7]]]?AGTC_P#?.$?^P'./_4O
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MU--/_M.[T\:Q=M<:5KVJ2:5927>IV0*Q&!-D5Q*7N%^I #W['/;&?;'0=.
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MX+$8=5L'-Y34H8)O".KE]7"5YPE4I1<\//D/RH_;H\"?%OX6?'_]KCXVZ?\
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M'#PE_P"G^PK^E2Y_X_;O_KXN/_1S5\1XN_[UDCZ_5\Q7R>(P[?Y(_H#Z'O\
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M:QU"SNK*\A(6XLKVVFM;J%MQ/[VVN4CGB)8$X=%)Z@=:]?TO]H'XP:7,DO\
MPE\FJ(I!:UUC3-)O() ",K(ZV4%[@XP3%>PMC(4J3D>SZ9\</AU\4H(O#?QG
M\+:;IEQ*1#9>)[5YO[/M99 09/MV[^V/#+;F7]^EU>Z;M+M?W-K &W-XK.<'
M[^+P>&QE&*O.IE=2I]8II7;E]5Q47[6*2O*-.3G;2"<K)N&"X=QS4,%F6+R_
M$O2G3SBE0EA:DI6BJ;QV$2="4FU%2FHP7Q3E&-VO _ WQ6U_P>\%G<O-K7AX
M%4?2KJ7$UG$7 9M)NI-[6K(OS"T<M9RGCRH7/GC[)T+7=*\1Z7;ZQHMTEY87
M(PK &.:"9 OG6MU 27MKJ!V59X9"2I*D%T=';Y9^*GP,USP#?6EUHC7/B?PM
MK5Y;66C:A;Q"XU&"\U&58]/TS4H;.)899;UY(HM-U"T06NHR-Y*PVMP\4,_-
M?#GQ5JG@7QBNES*TMC?:M#H.NZ;'*DJ_:!>G3EO+9D+0F^TZY<^7*C^5<P>;
M;NYB:&2'#%8;!9GAWCL#*'M8TYU'&'*I34%-U85:5U*C5BX2C&,HQ<JGNJW-
M&3[<#CLQR3%RRW-8550]I"E[2?-*-%SY)4JE&HTXU:3A*-3W922IV=VVXKI_
MVN_VKK7]FCP[X?TCPOHVG>-/CE\1TO!\./!>HO*^CZ1I=E.EMJ/Q&\=06<T-
M_P#\(OIMW*MCI&CV\EK=^,-:C.GVEU965GKFKZ5^2&JZ3J-U\2?ASXI_:0T_
MX_\ [27QK^-4'CR\\':/\-O -M\0M<MM'^'5KX9U+QF=,\/G6_"?ACP%X.T)
M/&/AV&VTW27T^QFN]1BCAM)[H75Q-K>._&TOQ/\ V[OV@/$.OF.:/PC\1=3^
M$OANT9C+'I'A;X5SS^#]/L+-96!@M[G5;/6/$-Q"JA1JFO:G.KD3X'WEJ/[-
MUI\>OC+^R=XTU36O$VA?#CX+>&?VD;7QF_PX^-OQ>^!/Q%N-7^*NC_!^P\$0
MZ'XE^"?B;P1XKU30DF\$>(6\4Z5=>+K#2HV/A^ZN=.U=TM_[.^BQ\*_!G#^#
MEEN'BL[S+!8;%X[,94Z=2O2CC:5'$0P.%J.+=&A0P^)P].LZ'L7BL1[2I5E-
M0H*'Z?AJ$)3<&[PIR<>6]O:2A)Q<Y+JYR4GOI%)*UKOR'P'XN_8\\9^-?@E\
M)M%U_6=#^(?Q\'QOTKX?^$_&O@'Q%X+U2'QU^SEKW_"-?&'X3^,H]<M;<^$O
MBMX8U"'5KJP\)ZAY@\5:)X=U[7?">I:SI=O97.H>!^/_ !O\!]3U7PQX8^'W
MPU^/GQ@\2^++'XYZI8:!\)/@\_B?5-.TC]GCX^WW[,_Q.U;7X=3\1^'HM+L;
M3XQ:?-H&A2+-=3:_I\MMKMI MC-(\/TCX._X)L^)HH[WP7X[\9V6B>#?#&D_
MMD6_P>^+&E^/=9^(?QM\"^.?B'^W%X)_:G_9.^.=YKOBS1XM8\<?%+X96?AV
M'5_'/B/Q_P"(?$GB+Q1XNT-]'\>ZO\0]+\7^(-9U+POX-?L,?%C1_$'P5\6?
MM6^(['2-=\*_!W]M#3/B6_[)/[2O[1?P9B;XM_M.?\% 9?VI[%/"FK?#+7?A
M+XPUSX;6W@+4-4C.G^+M=NAX:\5_V78Q:5JEU:Q>+(OB\MXHXFGBJ;A6JSE.
MHG*;3>DI+G?;173E=M)M6ZGH2HT5%JW*K;)__:O^OO/S^^(8_9P\36OP@DT#
MQ]H$UY^T7_;</P?\+7]O?:5XU\63>'+7Q9<>*X)O FKV=GXKT$^#KGP/XNT;
MQBWB+2-,M?#7B71;KPYJLEOK4]K:7/H/[-G[9/QG_8;\067AO49=9^)G[.,M
M\D/B+X3ZC=&[O?"MA+/NN=?^$>H7LN_PSK>GJ\MT/"ZW$'A'Q'F>TO+72=1N
MHO$-AW2_ #XA^"/@C^PQ\-?$%SX+?6OV7/BSJNN^-[G3-40VFK^!=-^'W[2O
MPY\(ZAI5W9>'-(3Q+XXU?3?B5\/=9\:W>IZ=I%[K/B*X\;>)=<U35?$$US?Z
MY\_?&^.RN3?(51@3)@%5SG(Y."""<GU)_#-?O7#^)J\1Y;6ROB3!T,=@*U+#
MMTZ\:D72JRP2=2I0JISG@\3A\1S0IXK"RC6I/2+JQ4H5?'Q-*--^THM4YOW=
M-I;Q2J)6YX23:DI77*VTDTK?UC^$/%_A/XA>$?"OQ \!:]9^*? WCGP_IWBC
MPEXBL&)@U31-4A6:WEDB<+-97T#>99ZGIES%!>:9J%M<V-[;V]U!+"G15^+W
M_!$OXC:MKOP6^/'PBOI)[G3/A#\4O#WBCPK+<2NT>G:-\8=*UJ?5O#]G$TCB
M&U3Q9X)UKQ))$BQQ->>)KV9/FD,:?M".@[U^%\29.^'\^S7)76E7CE^,E2HU
MYQ4*E;#5*='$X.I5A&ZA6EA,105>*;2KTJSBW&<+<,G%\DH)1C.$9Q@G=0WC
M*$7NXQG&2BWJU)=@I#GM_D]O_K_ECFEHKQ'_ %M]VO1[/RV:>JGS^?\ 7]>M
MUH>>_$#X<Z+\1+;3X]5N]3TZ^TF=I].U;2IT6[A6;RTNK::*X26UO+2XB4H8
M[B%S Q\ZW>-FD63Y"\>^"M4\#Z_)IIL]6O\ 1I[87FF>(TTYSITT*(KW5I>S
MV[S0V-YI^]$G^T-;Q3%TEM\^:L=??W<=.^?_ *U)C*/&P5HY 5DC<;XI$(PR
M21,"CHRDJR.&4J2IR":]3 YKB,':FW[7#14K49/E4)2:;E3<8.=]%ISM-73T
M/#S3(<)F7/5A;"XR4H.6*ITU.5505E2J0G-4^2W_ "\44XR::B^77\S]PXQD
M\9X].QYQP1R#CD$>H%*#D9'>O:/B+\&CX*TKQ!XNTO6[G4-#M+PZC+HUY9O-
M?Z-IUU)&)Q:WMFKM?VEG>SR2%;FUM?L&E;)&G>*SNF;Q.*6*5(Y(72:*50\4
ML3!XY$(&UT;.2I'J 00RD!E8#Z^A7I8FDJU"?/"ZBWRRCRSLFX-25TU>U[M.
MUT];+\\Q>#Q."K/#XFE[.K9U(I3C-2H\THQJ)IV][EYK74HWLX)+F;B#G(&?
M<D>W '8G Y_R*M[8V>IVS6.IV-GJ-B_,EE?VL%]:R<]6@NHY823T)*AB.YZ"
M[16T92A)2A)QDMI1;4EVM)6DK?W917DSDE%3BXR2E"2:E3DN:G)/=2IRYH2N
MM'S0=TDK::^27GP*^$-_,9Y_A_HD;LVYOL,FI:;&2>O^CZ?J%M;JN ,+'$BC
MJ "<#JO#/@'P5X,8R>%O"NC:)<NACDO;2VW:BT9&&1M2N7GOC&0 &B6YCC<@
M%T;G/8T5TSQN-J4_95,7BJE+1.G/$XB4&ETDG6?,O*5T^O8\ZCDN3X>NL5A\
MIRNAB4W)8BCEV"I5U)[R5:&&A5C)V5Y1G&6GQ;W:N1G/M[?AT' ]N.>*=117
M*M/Z7Z)+[DO\_3/RM_X*-_\ (R_![_L6_&7_ *>M(K\V:_2;_@HW_P C+\'O
M^Q;\9?\ IZTBOS9K^FN"/^2.R/\ Z]XG_P!3<>?Y:?2"_P"3P<:_]A65?^J'
M*CJ/!G_(Z>"O^QP\)?\ I_L*_I4N?^/V[_Z^+C_T<U?S5^#/^1T\%?\ 8X>$
MO_3_ &%?TJ7/_'[=_P#7Q<?^CFKXCQ>_WG)/^O.8?^I&'/Z ^A[_ ,BKQ _[
M&_#7_JKS8CHIK,%QG 'J2!_,CKT^M(7';D#DD8.!^!_/)X]Z_'+-[)O;9-[N
MRVN[>>WFC^RKJ]KJ_175WTT6[U[7'T5&)$/ 923T 93^@8G\@3[4N[MU.>."
M.^#U^G7WZ<&GRR_EE\XR7YH$T]M?N_SM\M_*R=GG@$^E>6_&CXP>#O@+\,/%
MWQ9\>W#P^'?"&GBY:SMWC74=?UBZ<6NA>%M%64%)=9\0:G);Z?9*4>*W\R6_
MNMEE97,J>G%NV0>.V,@\8_B)Z_R.,\X\0_:!_9Z^&7[37P_G^'7Q1TZ_NM-2
M\&L:#J^BZE-I6O\ A3Q%'9W=A:>(=#N5$]F]_;VU[=6SVNK:?JFE7EK<SVU[
M87$;KLUH1I.M2^LQJK#.I'V_LX7G[)-\ZAS6BV[<KNU:,G)7./,'CU@,8\LA
M0EF#PU=8'ZW.5+"K%\J5%XB<5*4*=W.7-RVE*G2BN:-21^.G["'P?\9?MD?M
M"^*_VX_C_;)?^'O#_BUKCP/H5Q%+-H6M>/M'AMX]!TS1X+HR>9X#^"VFC3A:
M(RLNJ^+H])6[N+R73?%4$W[^?,6+$DDLS,2<EBW+$GJ23R20.V<D$MQW@#P)
MX5^%_@?PG\.?!&E1:+X1\%:%9>'] TR$EO*LK)#NGN)6_>76HZC=2W.IZK?S
M%KC4=5O+V]N&>XN97;L0QR!C&??GN1Q[X/?BNK,<;/&XAS4)4\/2A&EA:+34
M:5&G'E3@M(IS^.;6KG*2NSRN&,BAD&6+"SJO%9CBJD\?G&/J)>VQV98ERJXB
MK.4I2G[*$I^RPT&X\E&E#FA&5K.HHHKSSZ(**** "FMQM)( W#J<>W]:=77^
M -8T_0?&OAO4M8L[*_T5-3AM=9L]0M8;RTFTK4<Z??-+;W$<D4AMX+E[N+<O
M$UO&<KU$5)RA3J3A!U)0IU)Q@FHN;A"<E%-II-\ME=6;LGOIK0IQK5Z-*514
MHU:U*E*JX\RIJI4A3]HXIJZ@YJ4E?X5+M9_2_P"QTK'6_'C@?(FEZ"K'/!:2
M[U1D_P#'4?KZ''%?2WQY8+\'_'Q)QG0I%!_VGN;=%]^68 8[FNJ\+>!/"/@^
MYU*\\+Z#IVB2:REJ-0.FI)!!=+9&=K0BV$AMHA&;RY(-O%%O$@W[@J;8OB1X
M1D\=^"=>\)PZBNE2:S;V\(OVMS=K;BWO;:\;=;K/;&591;&!@)T*K(7YV[3^
M68O,:&,SJGF"C.A0>(P<YJKRN<(TG0]I*7)=:.$WRJ[2TWT/V_ Y7BLOX;K9
M;S4\1BEA<P4/8W4*E7$QK3I0CSM=:L(MMI-]4M5^/@ZD^O;Z<=>GX4ZO2/B7
M\-;KX8ZM;:/?^(M"UJ\NX&NS;:6+R.\L[?<%BGU"VG@\FU6Z.[[,BW<TTOER
MOL\M?,;S>OU*C7I8FG&O1G&I2J<TH3BI*,ESSLUSP@[-6^S;LVM3\2Q.&K82
MO5PV(INE6HRY)TW*,G'E5HIN$YQORJ-US7[J+=@HHHK0P(;B,RPSQ9P)8)8L
M]<>;&\>0,CGYP1S@XP00:_0OP(D$7@GP?!;ZBFKQVOA?0[,:DI0M>-9Z?#;/
M+,$FN0ER'C9+J,W$LD5TLT,Q6:.1%_/DDCIC/7GVY_R> /7IGZM_9XU;0X?"
MUSX1M=0=]:TW4-7UZYTJ<_O;;2]7OHFAN+,+!%&NFM>3/$T0DFFBU&2[FF,:
M742CQ<]I2G@X5$Y?N*O.XQCS)PJQ<92DTKPC3<(M]W4C:^I]+PK6C2S&I3DH
M)XG#.G&<JCC+FI5E4A2C%OEE*K*<I15N:T'W5_H2L?Q7J,VC>#/$>HVKM#>7
M(TOP];W*$K+:KXBOULKZYAD&#%<1:<MTMM,C+)%+*#&Z,<G8SU]O_P!=9VO:
M++XH\-:]X8MI(X[_ %2VMI]&>9Q'#_;VD7D.J:3#-*01%#>S6[V,LF#L2X)Q
MTKXC&*3PU90OS<CVWLM7MY?UH??UE5EA\3'#IO$3PV)CA[?%[9T*BAR*Z?M&
MU.$5=2YJEDXRY91_%7]H#]J_Q9X"_;&^,7P.N?\ @H)-^Q'\-OAA^R[^RY\3
M? 7A_0_V7/ GQ]U#Q_XK^*>N?M*V/CZ\NCJW@#Q=XMGBT:V^%7@6TTOPMH5[
M87%^VI7L&DQ&_NTDA^E?@Q^W_P#'GQI\._AEX+^)O[$_QE\3?M4:=^Q+\)?V
MK_VBO#'P\3P%X&\+>$+KXH:;\:+7PK\/M$T+XG_$+3O%\'Q=^(WB;X'ZE8>'
M?@]<07UUX3N/%%O8>+_&&F+X?U:^D]>^$/AS1_ ?QZ^-?QT_MKQ':^.OB[\.
M?@-\)?&'A74?LEGIOARQ_9RU/XTZAH$VGQQVT>JPZMJ]W\;_ !%#XA2_N[JR
M$>C:(VEV\2/>SWN;\0_AU;:YXQ_:&^)OA7XL>.OAM\1/V@/@1\,?@-/XO\)I
MX=FU;X9Z?\*=5^.&K^'?'OP];6M,OX8?'PN/CQXFDAO==BU;3-,O=$\-:G9:
M=]IM+H77SD9PY5%Z-)74K;I:WO97;[]69T.(<LCEE"GRQIQAAX0E"T8>RG#W
M)P<7RR52FU*,HM)J<90E[UTO)OA?^U/\+/VQ?#GB_P =_!C1O&-Y\)M$NO#N
MCZ!\5?$.CQ^%]'\=^*-0\-6?B'QIX<\(:/?W2^*TU/X,W^IZ?X#^)=[K6D:7
M8Z-\5[/Q1X!TJ?5-<\!^+/[-_1KPQK=QXG\&^#/$UZQ?4-:\.6DFJRG'^DZI
MITTVDWUYA0%7[9/8M<D*!S(=V3DG\H/@/^S+X(_9RF\2?"W]G*3Q39_#OQ_K
M'A:]\(? ^]U(:[X:^'_C/3_"]GX8\;>)_!^LZDDWB>U;XM?V/I7CKXKP:UJV
MH:1=_$2#Q7\284T[6/&_BN:[_6W2]'M_#6A>'?"UK.EW!X8T2RT5KR/(2^O+
M=2^I7R#H%N]0DN9@.HWX.,;5[<L3>*J2C?D4+-KX;M*WE?L?/Y+5IXK.,ZQ.
M!;>6JCA:/.[KGQ?M56A%IJSJT\/.O-M>]"A547-0J0IRM9P<?KV[_P"!I"P&
M?4<XXY'J/4>N,D=Q6%XJ\4^&O GAO4O&/C'4VTKP_I;0P.\,,EWJ.J:E=[ET
M[0="T^(B74];U*5?+M;2/:L:>;=74EO:1RSIX'%XU_:'^(]O+?>!=,TWX0>'
M'+-I[G3-.\5>.;FVX6*;5=5UJ"]T&PFE7]\]AI&D21VC/Y2:E>J%D'U.&P=;
M$ISBZ5'#PER5,5BJBHT(U+)N$)*-2I6G%27M(4J,_9N4(RE&<XPE[.-S+#X*
MI"@X8G%8RI3]M3R_ X=XC%NAHEB:S=2E0PM"=1^RHRQ$XRK.,ZE*%6G3J5(?
M318 9.<'H2,#ZY.!^OOTIK>4Z7$%Q;6E]97MK<V%_I]_;PWFG:EI]Y"UM>Z?
MJ%G<J\%Y97D$CP75K,C0SPL4=64\?!WBV+]KKPTTE_8?'3QDTZ;F,%_I/@S4
M[%RAR%DT^]\,S6N#D[D6.,-QC"CCG_ O[;FO^%=<M?"G[3/A[1['2;J5+:+X
MO^#K";38]'FDE\J.Z\<^#TDN[232,LIOM?\ #CVQTV-?/N-!^R)=7D'K?ZM9
MA5H3K8"M@LU44Y2H8"M66,<4G*7L</BL-2>(G"UXQHU(8B6CH0<U%/YNIQYE
MF QE+#YS@LVX>52I"%/,<QI8:IEU*<Y*$/K..R^MB%@(MR4:F(QF$^J4(MO$
MXFC%JM#Q;XP_\$MKVTU>_P#$?[(_Q'T7P)I^HS/<3_!GXG7.M+X2TB27?)-#
MX&^(.E6NM:II.C(Q"V7A[Q%H.K"QW^18ZY8Z;#::;;_(NI?\$YO^"A/B.[&F
MW5C\&=*M9'*-KFI?&6UETI$9&!F6/3/#VH:U)&,!E0:0)=N#L+!C7]&[J$VE
M9;>>*6**YMKFUGCGM;VUN$6:UO+.XA9HI[.ZA99K:>-BDD3*0<Y 0 =1^?&3
M@\'/?U!]\U[6 \1^)\#1A2]O@,P4(\M/$9EEU/%XR*45&+EB'7P<L3*FDHOZ
MW0KUZ<HN-2M4G[24_N?:0DO>AJ[)JC6<:?,EO:"G!*5U).,K233A>+N?E5^R
M5_P2P\#? SQ;HWQ>^.7B^Q^.7Q<\/7-OJGA#1-,TRZT[X2_#_7K69I;7Q!:V
MFK%M8\=^)=*E6*XT/5-;M=)TC1[Q5U.T\-IK%GI^JVGZL/))*[RS.TDLC,\D
MC$LSNQ+,[$\EF))/O^5,4<A5&6/ "JQ))Z*  68G& %!8GH/33_L?5 JL]E)
M"&X7[2\%H[MV5([F6%W+9!&%QC\C\OG.>YEGF+6.SG'2Q6(]G[*CS\E*CAJ"
MDYK#X/#0Y:6$PZG*4W2HP7M*C=6O5Q%6U2,I3G'EIP]RFVY1IIR2E+6]26KE
M-K5.=I.-VHI-G(^*M+U'7/!GC_0='+#6M?\ A[XZT/1MG#G5]4\+ZI::<%((
M;>;J2,(5(;=@+CG/X">+/$G@[Q%K?[/GB3QM\%_VJM8T#P9X"^)>B^'_ -I'
M]A/QG\5M/_:;^ OCGQ+J/@66]\!^(/AM\)=0MM>\<?!#XGZ-X;MKW69M2\-_
M$WPWH_Q!\!>'(/%/@C2[/4+/Q-%_1!-;:AI<L4\L%S:2I(LD$CQE4,D;AE,<
MH)@<JP4_+(P. 2&!K\]_C;^RUXZTSQ?K7Q8_9QMX-57Q)>WFM>,OA"U]9:5?
M6^NW6;G5M?\ A]=ZE/:Z;?66KW327^H>%[N[L9['4KBXET66Z@NX=+L^G*99
M=B\-C\IQ^(I8.GCIX7$83&SY?81Q>$IRH/#8BJVX4(8FG4YJ-:=Z<:\)*I*F
MIJ2^-XG_ +9RG,,IXFRS!5\QCEN'Q>!S/+:$*DL;]1Q]2CB:6-P-))/%5,/B
M*4J6(P]*$\3+#5(2I4<4L-6@?G9\._!?QL^-/QC_ &,/B#^VI\.O%_Q%\"_!
MG2/^"F>L^ -0^/WA#P./B'I?A?6OC/\ L2:O^QIKW[6'@3X6Z=8_":[_ &A+
MKPQX,^)/B?PUH8\+/>6NJ^!O#_C+5M"TOXS^&+^^TKX>_9\\->-?AM\2_'6N
M_$#X2_$+P;\/?&/@/Q;<_L7^'O&.LOXD'['G[/FJ?&CQ9XJ\1?LH>,-._LNS
MD^&OC_QC>Z[X)^+EAI5YJOC"XT[P'::/^SM'XG@M?V;+"VUC])/%?Q!^,ED]
MQI&K?"?XO6&J0N89;"7X7^.Y)Q*-IVQ?9M FCO,@KB2V:='4Y5S@FK?PY_8Y
M_: ^/VLV5_\ $;2=:^"/PJDF6?6-<\4P+IOC[7-/#CS=-\%^"KW=K%KJ%XA"
M)KWBFRTK2M-C?^TK:VUYX/[-F^TRGA?*L@='-,RS;"T,-A9RK1F\3@J\J]X-
M^SH4,/7JU<7.K&$50A2IM*5:-252G!J:_+.*/$?.>*:>(R#AS(L?F.9YCA_J
M?LJ.!S+#T\'=S7UG%8W%X7#83+,/1J\JQ>*QV*I488?GIU55FE1J?;'_  3F
ML]17]FW6];O(WBT_QE\:O'&N^'"P95GTO2]&\,^$KZ]BXP8Y?$&@ZM;*RED?
M["&4_,17H/[0NO:'?76A>$E$TVO:%,OB6XES,EI8VFIV5Y8V4+%91#-=W2I+
M<A)X6DM;:.WFA*B^<GZ.T/1/#7@CPMH/A3PMIL'ASP5X(T"UT70=+MRTD.E:
M%H]L<>=(Q:>[NI$CDN]0OIVGO-0NY)KJ9I+B61G^"O%?BZ'Q[X@N_%L&E_V3
M%JD%E#;V\@B:[>STZ 6MK<7LT441FGN$0SH)5:2"WDAM-Y6 .WS="O+-\^S/
M.O85*-*MBJV(I0YHTY48UX4:6#ISYD^:I/#45/$**DI5)S<III<WWD<'+AK@
MO(.&:N*H8K%X? 8;!XJ<*<YTZ[PSK8K'U<.YV]E1CCL95IX:5=*JJ-*G:FY5
MJBI8 Y [?3_/^/U-*>AQU[4#C]:#T./2O=/F^GR_0]T_9]TC6I/%>KZZ+>)/
M#MOH%SI#7DB1/--KES>Z9<K9VD@F$]N(-.03WDGD-%(DBPA]WF"OKRO"?@!I
M>KZ?X-U&ZU*9&L]<\1W>I:!;K)&_V?2XK2UTJ5I-L*213W6H6-W(R223AH4M
MIHV"RA*]VKXG-ZGM,PKKW'[+DH1<-I1IP6LNBJ<[DII:*R2;/U#A^@Z&4X9.
M-:$JSJ8F4:RBI1E6FM(J*M[-1IQY/>D]9WLVT3VKVZW""\7?9S1W%K>( 2S6
ME];RV5T!@$D^1/)C&2&QP037S>WVKPY9^,/A/XGN9;)=3\.ZYX<358%0F]T#
MQ#I5]I-MXBTD2_Z/<QS65R;B)2SQ17L4FG716:&8'Z)P/\_Y_P Y/K5#6=(T
M7Q+81:7XETN#6+.V>22QD:26TU/2GESYKZ5JMKY=Y:"0D-+ 7EM)653-;R;1
MCYW&X2==1J4G%5*<;)2;M*-V[;6NFW:_<[<9AJU?V%;"UXX?&X24Y4)S4G1J
MPJJ*JX>OR-3C3J.$)PK0O[&K&,ZD*E)SB? =U\$M4\(_!']D[X8_!K]H_P")
MGPB\3?L<^!_ GP\\!_$+3=-T?Q+HOQ$\+>$?A3IOPBU;0_C7\(;^]TOPCXXT
MCQ3HFDV7B&!;+4O#_B#P)XSLK+7? _B;2@FHVFJ^<?"/X/WGPYN/B3ING>,-
M;^+WQ;_:,^,NL_&/XG>,K[PYX:\$Q^+/B)K/A+P9X#CDT3P1X,M;?P[X*\,:
M#X&^'OA32EC:ZUO5;E=+U+Q7XR\5>(O$.KZAJDOWM>?!/P,ZS3/XH^(<-I%%
M-<26B7'AR7:D4;S,BWTNDJYC6-2-TMM-)MY+M)\U?-=SX\M;#3[W2? 7A]?!
M]IJMJ;36=:GU&;6_&6M64@'FV-WK\\5LNEZ=<_>N--T.UL8Y\*D\TL?F(V&!
MR',\RJ<D80I4H27MJTIQ2IQ:3O&/O.<W;2*C9VW3:/D,\JYM4A['.<32PN#K
M2<YPPM:.,Q.(4'>:HPHPI0I7O9UL14C""DK1G*,8OO+'PA;?$GXG>&?AWH]X
M+KP[X)\.:9X=U37;+(AN[+PZTUUXJUBS8;E0:SXDU.\L=-D!>/-S:7+*86"5
MU/Q_^(WVN]B^$/@E8]/\*>'3;Z-J,-EB*/4=1M&CBCT<-\H.EZ2ZB">-GQ=:
MFLIN2PM$$FU^SUY'@[X9?%3XE%%^UVEO<:?IQ*@870]*^WV\:'LM[JNL6T,B
M;2I-M$2#M%?)-E=,FHVM_>2R32"^BO+V9_GEEE^T">ZF<$9:223?(PR=Q;&"
M"N?N\#@Z=7'^S:Y\!P_3H8+"4IJ_-C72=3$8B25TZL5+EIN47[/GM%28L7BI
M8')J'L4J.-XB=3%8F5.5Y4LLP]2.%PF"I3:YE&I*C:I:2C*--RDTG8^*/@;_
M ,%!OV.OVDO&VF?#KX,_&F'Q5XRUW2_$NN>%M'U7X?\ Q7\!P^-=+\%7/V?Q
MA=> =;^(G@3PIX?\>GPM)F77[?P=JNM76FV:RZA<0+8P7%Q%]GJDC$*J$L0S
M #!W*JLQ9>=I4*I;(;&WYL[1D_@I\(?^"2OCJS_8;T[P%\6?B?\ $?Q#^TSX
M._9?_;0^#_P2^'GBOXKZ'KG[-GP \=_M1:#\2_!USKO@.S\'^"M/U2-_$?A;
MQ)H^G:YK>NZWXPN-!M=:U\V=B+JWACBM:Q^P[^TU^T)XNUGQ!\?/@YX0\&^
M_B%\??\ @EWKWCOX4Q?M V7C&:7X,?LH_!/XQ?"?]H*PUG7_  C%X=CNY_%=
M]XH\/W=IX8\/7$K>*O#&OBVNM0EU#3M<MK7OABLRC&"KX)3JU8\T94VU&%W&
M$85U&52,)IMU)6FTH)W46DGPUL!E$ZDWALT5*A1G*G45=1=6HH/G=7#\T*#J
M0J4[)*4+K$>TBG."C*?[9^%/&_AOQNGBJ3PS>7MY'X)\9>(? 'B66_T'Q!X?
MCL_%'A;[%_;5O9MXCTS25UO28/[0M/L?BC0FU+PMJ_F-_8^LWXBF\OKFAF5@
MA1DD99W5&&'*VP'VAU1CED@+H9W"F.(,#*P4Y/X?C_@F_P"-?&'Q*CLOBQ\/
M/ 'C'X#VO[1?_!3;XAV7@?6O&<.J:"O@#]H3X7?![PA^RW:W'A07*BZCT+6_
M!.JS?\(Y=)/'\.[K3-&UXPQ7T6GW5O\ /W@/_@F;^V)IOQ<_9H\9?$.7_A*[
M_P #^#O^"?$!^)^E_&OX2Z5K?[/%Q^R]\/?#/AOXU>!K74_%/P9^)7QE\0Z7
MX[\2Z%K^NPZ;\#/&WAGP/\8H/'&HZ1\5;K1WM!X@>GCL9%I1RZK4O.45*$Y*
M*Y:D[2D^5RC%P=/EFK1YHR]HZ:;DICEF7SBV\VI47R*3A4C&5VZ$96C)5(<S
M]I&LZD+J2C:-'VC45+^Q[X$?''P1I>D:9X&UR+4/#9MY@NGW^KZM+K&B$R,A
MCM1>W<<,^@PK.@:UM)XFTRT=BD=]#NCB/Q]XDCN-)\7^(5C91=:9XJUEH7 ^
M4W%EK=S) _&,H7CCD##;N3YC@9%<_(0[N0N%9V(4 !0I8_+A21@9(!4D$8VC
M!%!).2<Y/][DGL,[B?0<GOP,Y J\-EF&P6+Q>)H<[^N1:JT9)RI.I&LYRJ0J
M>[**K\\_<M9*W-))-&6-SK$X_ X#!8I0;P$KT:L%R.5*5&-+V=2FFXN=%0A[
M.::YYMIQ5Y3?Y;_M6Z;>_ []LGQKXLCCN%\#?M#71^._@'5G;_1[H^+)8&^(
M.A&= 8O[7\'_ ! _MO3]4L!^_LM/U#PY?7:0?VU9H_8^)?VR?&OA?XC?LT^
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MM/:'\!? ?QVUKP4MY+/\+O''PFT_4[;Q3^T)\(Y;>WCB\$0^.O$$6A>'=?\
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M>^&?A/P/>?M)_L]:/\8?%'@#PV&N/"FG:KK/@[2?$UGIT:SVUJ=1MM,GU62
M2WEJ&O8XH1>),(8\?/GQY\ ^-/BM^P#_ ,%+?A9\-_#>J>-/B)\2/V*_C3X+
M\"^#M"M_M>N^*/%7BCX;>/-$T'0M(LPRM<W^IZK?VEE;1@J&FN(E)&ZO!_\
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M^S/^P#_P1/\ %'[%7[0?AJZ_9%_X*<V'QX^,W[7^L>'-'L/V5M;_ &6_A_\
M&/XF_%>T\7?#?XH0:[.NN^./&-CXZ2RT'P6=,?6+6XTE+35OLNI:E+:Z3P+&
MXM*-L9B;*?-'_:*UE4T=U>IO=)J]UV7?TWE>5MR;R[+^:5-4YMX+"INDMHR_
MV?X.UU;LUI;]!?B+_P %BD\ 7OQ\^,&C?\$[O"'BG_@F/^RI^V=;_L*?'/\
M:ENOC+I</QNB\;V7BGPQX'\9_&+PI\+)?!=Q=:S\-_"/BSQ;X?T2T3_A.EUK
MQ6=:T:_TS5-&)\0Z9X3_ %!^+'@J'X?>/-7\-64LMQI:+:ZEH\TSB25M+U*
M30))-_RW:VG6YLO/',ZVZS, \C(/YPOC3^R9^W#'^S1_P4(_X(L^'OV)?VB/
M$FL_MD?\%2=1_: ^%G[7^G>'M&E_9-T+]F+QU\;/A/\ &)_'?CSXIQZYMT'Q
MIX3L?AN]CX@\ /IDFLR/K'V?23?:S8)HU]_3/^T3J^GZI\4=0M]+F6:U\/:5
MI'ADRJPD5[G3(IYKI=^ &>VFO6LY2H7$]O,O\(-?4<*8K%U<PQ%.=6M5I3PU
M2=5U*DZD8U8SI^RE)RDU&3;G%:KFO:SLCXOCG Y=0RG#U*.'PN'Q$,72IT50
MI4:,ITI0J>UC:G"FYP48QDVU)12O=-V?B5%%%?H!^5!1110 4R094J>C ACS
MP#@'I@YQT(.1U%/IK=/KP/K@_P#ZJ/TU];:V[:VMKI9N^EP^3?DFTWUT:U3T
MT:U3L^A^KWP2\6-XO^&OAG5)I?/O[:R_L;5F) D.I:0?L4TD@/(:ZBA@O.0
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M/3G';/<8X]B:0$YP1C\1^/Y>WX@5X!KVI?M+6BO<V]UX L%RS_8X/ %O<VH
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MJQ !99$5PV!TRK!OQ/;@?I#KDNFP:-K4^L0&YTB#2-3GU:V"EC<Z7%8W#ZC
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M^OBX_P#1S5_-7X,_Y'3P5_V.'A+_ -/]A7]*ES_Q^W?_ %\7'_HYJ^(\7O\
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M .AK4_\ #=+_ .;6_O2/SI\V+^^OYT>;%_?7\Z_1?_A9FO?] [PY_P""MO\
MY(H_X69KW_0.\.?^"MO_ )(I?VUB_P#H74__  X4_P#YB#_5?!_]#6I_X;I_
M_-A^='FQ?WU_.CS8O[Z_G7Z+_P#"S->_Z!WAS_P5M_\ )%'_  LS7O\ H'>'
M/_!6W_R11_;6+_Z%U/\ \.%/_P"8@_U7P?\ T-:G_ANG_P#-A^='FQ?WU_.C
MS8O[Z_G7Z+_\+,U[_H'>'/\ P5M_\D4?\+,U[_H'>'/_  5M_P#)%']M8O\
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MC>(_$]WH?@O5=2\"VMMX1E\;Z9II\>6WAE)O#^G^*+32-2U>SU'V_P"(ND?
M/QWX)^'W@3Q!HEU?>&?A;\)/B!\$? UA!XO\3V4VE?#;XF?"2'X%^,M&GOK3
M5(KO5+W4/AI;Q:+;ZWJ,MQJVEWJ#7K"[M]99[Q_NWXA?LL_ #XF7USK.N> E
M\-^);N0S77BGX:ZG<>!-6OKF1V>6\U6PTM'\.:S>3.[-->:GH5S=RL5+3D#G
MP;4O^"=GPNO78V?QE^.VG6KC'V29?AUJK(I).U+M_#-C(PVEE_?POC.\88DU
M]/0Q'!%>2JUJ&-RZ<DI3H2P"QE*,G9.,,1A)5/:12BG%U,/1G9)2:W7PV+H>
M*F#I.C065YXH.488O#9Q#+*LU>4HU9X;-:49T9MRO4BL3B*:DY>SG*'+;\W?
MV@]$^"WQ4T#PYX<\8:7J%_I'A#X1_$OX%:!;6?B[Q)I;6_PP^+/ACP=X/\=:
M!<W-CJ45S>W.IZ%\/?"$5KKEY++K>EWND"_L;V"XOM1:ZX[PMX-^)/[5_C\_
M#WX96;RHUQ ?&/C:YAG;PI\.]"F8F\UOQ%J(4VOVL6?FMHOAY9AJWB&_46MK
M#%;"\O[/]9M!_P""=/[-.EW4-YXDE^*WQ.>':S67C+QO#HVB7#@?>N-.\ Z3
MX8N9HR_S-;2ZH\++B-E:(O$_V=X;\.^&O!GAZS\)^"?#7A[P3X3L&:2R\,^$
MM'L=!T2":0*);IK&PBB2YOI]H>YOKLSW=S+^^N)I).:]I\9Y'DU&HN'<%B<5
MF$H*%+'9AAJ6#PN%E'FY<0L,IU<5C9TY252C1J?5L*Y12Q'/%R@?&U?#'C3C
M'%48\:YI@,IR&G-SKY;E6/J9IFV-IS<?:X.&84</A<#E%'$4E.CBL3368XU0
ME*&$I0G*&)H?/7Q.^$^C^&O /@JQ\%6T_P#8WPH\'Z#X#M8IV#WDW@SPW80:
M=IM_=,%"2W5G+%+=7\H 7R]3NKH PVAW> >'=?U7PKK>E^(M$N#:ZII-R+JU
MD969'P'BFMKB,;3):7<+36MY!G+V\LJJ1(%=?T9**RLKA71U*.DBJZ.C@JR.
MCAD='!PZ,I$BED;*N17QO\4?A7/X6FGUS0;:2;PO,^Z6"$-)+H#.P'DSC)DD
MTP.2+6[&[[,C&UN=@2*XN?E,IS"-:,\'CIJI*I[7]Y5::Q#KRG.NJL7IS5*E
M2I447=<U5*+5K+]0SW)GA'1QN4TO8TL-&A3]CATU/"PPM/#T<'*C&'\*G1H8
M3#4YJFW'EH)QLGROWKQ)X;\,_M)^&XO&7@R:UTCXBZ1:I:ZQHUW*L7V@1J2F
MG:DR*Q$>X2-H6O+')#)$YLKP#8RZ;\8:SHVL>'=1N-'U[3;W1]4M21-97T)A
MF49(61,YCN;=\;HKJU::VF3#PS2*<B30?$.M^%M4MM;\.ZE=Z3JEM_J[NU<!
MC&VTO;W$3!H+JUDV*9K2YBFMY, R(Q -?4VG_M&^%/%FGV^C?&+P%9:RD2E5
MU?3+2"]B61@J-<+IMY)'>Z=*RC,LNEZC*SGF.!%PB7"AF.47IX:A/,LN<_W6
M'C-0S#!IWE[./M'[.M3MK&+FG&.G,FTGSU:^4Y^E5Q>(IY1G#2C5Q,J<YY9F
M#BHQE4FJ<7/"UW;WJBA:4KR<).4FOD($GC)]^ "/;GCGM]<YX(HRP')R>3VZ
M X/U]<<'W[5]?-HG[(VL,;B#Q+K.@[@K&T^U>([58O6,+JFEW[<'LL\@R/D8
M \RI+^R1X387<*:GXSNXB&CMIXM=U-)&&< PWJ:5HL@/<7)= 6!VA:V6<\RM
M#*<YE4>GLW@9Q2DMTJLJL<.NOO2=EOJ[)X/AR2]Z>=9!"AHW6_M.,Y<NOO1P
MZI_6&]O<46WTLDW'YY\!?#;Q9\2=16Q\.6#-:1R;-0UZZ26/1=+'(8W%TJ'[
M1=#AH]/LQ+=RL1E(80]S'Z]\9]%^%?@+PUH_P\T"S&M>.]/G%[JGB02&&[LC
M.$:\356MBT,LNH+&D5EH;"2/1K8"]W1WC0KJ:^,_VF-<U'3O^$>\ :-;>!-"
M2)[:*XMUM6U=;<C9Y=@MI''IVAKL8@FT2XNDR7M[NWD <?,ZBXN[H1QBXO;V
M]N %1?,N;R[NIG+$ #S+BYN9Y"S,Q$DCL2S9&6"I4,PQN(I8K'KZEA<,G4HX
M"C5G[6<[2:K8S$QBHR<(NWU:'[N[O*5URMUJV5Y=AJV#RU+,L7BX^QQ&;5L.
ME2ITN://0RVBU4DY3FHJ6*E>M33GR4I/EB:EEIVG1Z5JWBGQ/KEKX3\%>'VM
MDUOQ'=VUQ?R?:[QL6&@Z!HUF'OO$GBG52&73=#L3YSHLD]S+;0QKYO5:3\8_
M&,7AFUMO D7@WX"?#2#4K?3[?XD?&35?#$WC+6-4UV\(T]W;7KNQ^&_AG6]8
MG=;33=$C3Q==S1)#;V,X9)(8_#OVHX=>\"ZI^S9X>\16TEEX5D\/^-?$)B0Q
M/97'Q&F\0K!K!OI4)MY-:TGPC)X>M+-7=I;6QNM3CM2(9+YI/GSQAXL^'VD?
MM-R^/?C?X:\)ZY\.+C]CG0O W[,/C#XK_ _QE^T3\#OAE\?V^+?Q8UG]HZQ\
M7?#_ ,"VUWJ.E>-?BY\*+_\ 9[L_#.IS3>'-5\>^'/AOXD\%^%/%"7UGK/A_
MQ)UYG"5+*:6:O#4<P>)JUOJU*;E4P6&A1Q&)POM*E.E-/%8B=2A4;E7DEAE.
MA"GA:D:E2N>9D-:.*XBQN1_7:V3_ -FT\+2QLZ$E1S+&5<3A<'CI488BI"3P
MN$C1QM"G0C05/$8N-#&8ROBH_N,/#]7-7_9Y^)GB&S67QS\9OB+J1OI[:V:"
M?QUJ?A[2;BZO)$BM;>WTC1+G1=#-Q<SO'%:VUG8KY\DB16T)W!3X9XV_9@\,
MZ+=1:?J?Q&DT?6;DQ&SL-3^)<^F:S>?:)#%"UK9WOB""_N!//^[@:*-O.D!C
M0LX('YA:SX/_ &@?VL/V</@!^RW\)_V=]+^#EE^SCX)_:5^,'A"R^(&M_&3X
M!>$_AA\<O#OQW^,OP3_X)R>(_ >G_$KP_P#&CQ=9O\/M"\(^*/VBQ\ ]8\06
M^G_!O3Y?@AH%IK&B^'+'PCILQ\4-'^+/[8GBW]LGX\^'?A9^SSX5OOBY_P $
MX/V2VN?!?[6_[&'B[XV>(_\ A9,W@#]K:\\8?"OP%J]_\2_AM!X8U[P1XFU)
M?"/BC3+CPO\ $C9K6I^&-7N-+FL+FVTWQ%\IA.(<_IS4:5&%*+EI2H8:%&FU
M%J]H4Z%.$DDM&X7]V^K]X_0,?PAPG5I3EB9RKS22=3$XROB:MYJT5*I5QM2=
MW>*O?1.]XK;[,\2:)\3?@_J:6'AK]I'QCX+U*W>(P>'=4^*\UQ&))C^X7_A$
M?&&M:AI]PMPS@QQRZ-,ESN5,3 @55\)_\%"?B-X'U>UT7XLP_#[XV:-/<R0R
MZQX)U3PMX2^*<42,9;FYL[#1KT>"_%EU9VZ2.FD2:-X29D5I9]=38VSX*_9^
M^&=UXB^)WQ1^(4NA>#M#\'/X:_X)[W&GZ?\ M(?LXV7QJ^,VO:5X9_8)_9QM
M=:L;'X\>+_$7@34M*\3:%J5A?^$O$VKVO@359M*^)NF:_K>HV%KJ\EUX;M?/
MH? WPST#]K']K#Q/I7PF\"^&K:7PU^RZW@[Q!IOPT\,:''%>0>#OBQ;>+)/"
M^L6>@V217N[4;*V\2/HER+B0W=M#JKL\\:O]_E4GGD,-'-LEP.(CBJOL'6>'
M>&Q=*#A.JZM/&82C0Q,:B5*5.#G*O%U)4XSC*-XGX_Q)AH<*+'8CASBC-\JJ
M8"@\1&A1QU/%Y;6J*M0A2HU\KS/$8W+ZT9.O&4HT*5"K.$9J-53E)Q_IV^'/
MQ'\#_%SP7I?Q"^&_B"#Q'X5U626T:X\F6RU31-8M0IO_  YXFT>X(N]$\0:>
M)(C<6-RNV:"6WO[*:ZTZ[M+N;M@<C_/UXSSWK\8O^"8&K>(9_C1\=],TK[0_
M@"3X8Z/J?BI=A;3K?QO#XOL;/P+,2%,4.KWFD2^-+;Y1'+=:=8XN"\=A:A?V
M;#>O/OTP/4CT[D]O3&"?D.)<ECD.>8O*Z5:6(I4H87$4)U.15X4,;AWB:=#&
M*%HQQ>&BO9UGRT^=.E4=.,JK2_0/#KBRMQKPE@L^Q.&IX7%O%9IEN,C0C56%
MQ&*RC'/ XC&X!59U)+!XN?+4I4_;5UAJT,?A(UZT</2J')^/?$6G>$_!WB+Q
M!JMG_:-AI^FR"XTTK W]HB\DBT]++9<_N)%N9;R..5)@8WB+J>E?GU"BQ11Q
MJBQJB*BHJ+&J!5 "+&OR(JXVA5^4 #'6OKOX\>+Y]#T&P\-6^G-=/XS%];7=
M]*DJVNFZ;I8M;B>17,,D$UY=SS06T-O(R,D#3W08-$F?D9>_IG('H".!] ,#
MUX.2>I]'(J3A@Y5'%IUJTI1ES)QE3A'V:M!2O&2GS7<H^\K-6Z\G%6(C5S&G
M1C)2^JX=0J1]DHRIUJTE5<75=G43HQIM1C>--JS:D]7444W+$[0#DG"@?>8]
M@N>,_7CGDCK7L_Y-_<G)ZNR5DF]6MK)MM1?S7EZ_IIZMM);7;2NMU^5__!1O
M_D9?@]_V+?C+_P!/6D5^;-?<O[=WQ*\.>-OB;H?AGP].+]OAII>K:)KNI1.K
MV4VOZIJ%O=7^E63*"9FT,6D=IJ$^[RQJ3W5E'N-A+*_PWCTQCMDC/X\U_4?!
M>#Q-+A/):%:F\/5CAYU94Z_[J485\3BZU)N,E=.I1K4JL8M*7LYQDTKV/\JO
M'''8'-O%KC;$Y?CL)B,*LQPV&6*A7A]7GB,ORW+\!C*5.LE*%2>'QE#$4*B@
MVE4P]=*3]E.W3^#/^1T\%?\ 8X>$O_3_ &%?TJ7/_'[=_P#7Q<?^CFK^:OP9
M_P CIX*_['#PE_Z?["OZ5+G_ (_;O_KXN/\ T<U?G_B]_O.2?]><P_\ 4C#G
M]%?0]_Y%7B!_V-^&O_57FQ$?\/Y_U[5ZQ\#8-2E^(ME-9W\5K96NB:Y)K%G(
M0&U2UDCM+:UMX28VR]KJ$MK?MB2(^5;OEY-HBD\G;H?T^O;]?\FNZ^%)T6'X
ME^$+K6+JXM)8KN^M=#\E"R76MZII=UIMM978%M<D6UQ;SW2L=UL@F\DO=1H&
M5OQ3&1<L'BXK=X:M]GGO[J=N6Z[;IZ;[)G]L9;-4\PP,Y6Y5C<+\5=X=)^TE
MKSZIV3TBXOF;44TY7/O>BBBOS\_6P4M&PD1WC=,,DB,4="IR"K*5*D'G@CH,
M8P,>+_&[XCW7@R_^"2OX:\*^*I/B3\>O WPEO[KQ9HMGJUWH^C^)]%\8ZE=:
MMI%Q/"]Q_:]G-X<M(K074EQ9&*XNC- [I%M]G;D'_/\ +G\N?3G%?B?_ ,%2
M6_:C\&_$_P#9Q\1_ KQUXB_L7XB_$+PKX=\-^$);'1?$.C>%/VD/#RZKI/P^
M\4Z':Z]I&K+HDGB?PQXNU>*_LK1H-#OKGPM>ZQJVG7E]''>1YU).$>>-XR3B
ME*%XR2<HII2@X3Y6M&N?E=W>.IM1IJO-4JDH.#4I.-6*J4^:,+*7+/FAS)1B
MD^1.T8Q3LE%?MO+=3SQQP/,_V:#Y8;6/;#:0@?=$-M"L<$0"A=HC15& 0!DY
M@P,Y_+V^G?\ H.<5R_@CPU>^#?!WA3PEJ/B?6_&VI^&_#VD:-JWC/Q)?3ZGK
MWBW6+"QAAU?Q-J]]<DS2WNNZFMYJ<J';%:BYCLK6.*TMX(4ZFK226EK25VEU
MNTWS+=NZ3]]REL^8REN[M2L[)V[7BG%.[A:UH\O*U%^[RQDU(P.??K4D$UQ:
MOYMI/-;RX"[X)'B=ATVDQE2P;@%>A.!BHZ0^N <<X(# ^Q4\-]#E3T8,I*D:
M35FDUV>J?JG=?@.,I1:<92BUJG&333^3^?:]G9M7/'/B/\2+OPW\5OV>O!H\
M-^$=9A^,GBSXAZ!K.M:YHEA=ZSI%OX,^%7B3Q_87>CW+6Q5[B^U'0[?3[O\
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MQP^Z<DJ=I)XK\-_AS_P4/_:$N/V-OVZ;?Q-\:KUOVEO!/@#]GG]K'X;>(HO
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M%*I@9YG1JXS%8G#IM1Q%6C2Q.'P^&591J.%%U,1.G#D=7$2GS*'Z >!OC_\
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MX_\  7CZT\8_'+QO9?$7X=_$:YT+QE%=?M)>,[#XB?&KPO<WTL6K:1K?P_\
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M9@\4J@M<JX>*5<Y20#F7^&7PKN5+GP/$B_>)T[Q3XJMX,[22P2+6'B48&<#
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M-E^B_0\H^-NH:QIWPZU9M'M(;HWEYI6F:JTV,6>B7]ZD-]>QYNK4F>*3[+%
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M\-YZ_;SGZ_8[K-?'WQ2_Y*5X^_['3Q%_Z=KJNW*/^1EB?^P"C_ZL:IX_$?\
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M?B/]NWXJ!1\)_P!BCQ+H=C<D"UUWXLZA<>&[98V) N7@\22?#V*5!C+"UGO
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M/;^H]OSY]*D"A<X[G-+17SO];O3TNW;Y>FR27Z!_6MW;2VEV[:=K>=PHHHH
M_FQ_X+N?\E'_ &</^Q'^)?\ Z?\ P77X2+T'T'\J_=O_ (+N?\E'_9P_[$?X
ME_\ I_\ !=?A(O0?0?RK^]/"3_DW'"__ &#8O_U9YD?X@?2J_P"4@_$C_L.R
M?_UFL@.A\&?\CIX*_P"QP\)?^G^PK^E2Y_X_;O\ Z^+C_P!'-7\U?@S_ )'3
MP5_V.'A+_P!/]A7]*ES_ ,?MW_U\7'_HYJ^>\7O]YR3_ *\YA_ZD8<_7/H>_
M\BKQ _[&_#7_ *J\V(CT/Y?3/&?PZU]C? 6#5H/ 1.IV,-E%<>(=6N]%:,J9
MK[1G2SCMM0N-MS.%D>ZBO+:.(K;,D%JC& &0R2?').,'&<$$C&<C(R,9&<],
M9&>F:^Z/A%8S:;\-_"-O<:R-<>2PEOA?+(TL20ZC=3WT&G1%I[@(NCQ3KI+Q
M!U2.:REVPP9\I/P//9\N"A!<K]IB:7Q*;:]GS37*XM15V^67,]8Z)/5']X<*
MTW+,JE3W[4<'5=XR@HWJR5+WHR3DVH*<XN*T<97:E*"EZ31117R!^AB'/;_#
ML>^#C!P> 3Z ]*_*;]OW]K_X?? [XD_ ?P9\2/#'CS3HO!?Q:^&O[0]GXDT7
M3--UO0_%W@/P]I/Q%\/>*M,T@#5=.O+3Q=H/B"^T^QFT;44BT^XL[VRU9-;B
M2YDMH/U9)ZCGZ],?CV^O3ZGBODO]J+]DCP7^U1>_ F\\5".)?@W\6]-\<7BF
MVDE_X2;P4\8F\5?#^5USY=KXGU32/"=Q<22_NH+72KV)5\R\W)G53<&DU&[6
MK:BE9W^*34;Z?"]S?#N"JQ]I%RCRU$^64E)7IR6T+R::;C>SCK9NUSZ)\">(
M[WQAX*\(>+M2\,ZIX+OO%?AO1_$LWA+7)[6YUSPXFMV,6I6^CZ[+8DV(UNRM
MKF&+5[>SDGMK/4A<V45S<K;BXDZRD>0R2O(Y'F.[.^0%)=R6/&!_$=H*_*P
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M+=^-+?4/B#<&57W^;N\<:AXA2.4, 08HXEC!*Q*J$K7VUY:$@XZ=.3_+.*<
M!TKPL=QUQGF47#&<3YW.D[?N*685L'AE9-+EPV7++:,4HMQ2]FU9[O<^LR;P
M2\(<AJ*MEGAOP=3Q":E];QF2X;.<<YW3=26-S^6?XES;5Y2<U*4O>NGH<UX<
M\%^$/!MDFF^#_"_A[PGIT2)''I_AG1=-T&Q1(UVHJVFEVUK;A47Y4 CPJ@
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M$#P]I.I:E=^#_$LVC:C!-/HNKM%<QR+,(FGBC$S>V5^2W['7[$?CG]G3XO\
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M*>65%/ UZV*PF(P,Z^(IU,/7P=.!^VBH\CI'&K/)(Z1HB@EG=V"JJ@<DLQ
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M;U+*TTN^O_\ !*GQ)X.U3]L3]D>;]F^"[MOA[?:9\1HM0M9VU4ZC#\/#\/\
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MY^V:I7]_8:38WFJ:K?V6EZ9I]M+=ZAJ>IW,-AIUA:0C?+=7M]=20P6UO&O\
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MN;:X^%_A;Q9XB:9-1\.^$-3^(VK?$34?"^DW,7F7@C_@C[\)_!/PQF^#-O\
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M^'=CX'\=^(/!7@+XB+#)H?[5>C_LY?&#QQX0TEO@7\:/CM^RM\._BKXR\:>
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M?$7CN]\!>)4U[3)](\??#^W>SUK2K?7-3OM=D]\^$O["'AOX<_&S3OVD=?\
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MP9U:_M=$NM$O+B7[1<I\.M=U)H='O= N+J6YN;+PIKMYHK:!$TEKHU_=:?\
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M#O#0-SJEC<7_ ,R/+KS:+HT;.+RYM=<CC?3Y_P!95GG1=B3S(F,!$FD1 !G
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M,:=<32-)+!87KV5S(WFD2\M7],FT>@]>1Z]?S[U.MQ<(-J7%PBXP%6:55 ]
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MQ%FO#.)S&EG7#V2YO_8N0X/,<#A7D>45\=_96/XGQ&!RK$4<3A\!C9YO5P^
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M4U6UU&R\=>)?%UA=7^K>0^'?^"DG[='BKX>_LZSZ?X9^"T_Q*^,_[".G?\%
M=:G\)_!#Q]XK^'N@^&/&5GX)L_ WP7C.O?M*> ]3L+;0]5O_ !#J_P 8?CKJ
M&L7=GX4T_6_!&E6'PL>*XN?$DO[8+^SI\ !\7IOC\OP6^&0^-MS$T<_Q4'@C
M0?\ A.I'E\.Q^#9;Y_$@L3J)U:?P:D7@V;7#.-5G\&6\'A:6^?P];1:='QWQ
M6_9O_9&UKX;>%K+XN_ GX+:U\*?V?O"&H'P=I'BCX;^&M4\*_##P#H&@64&J
MZ)X<T1M(N+72/!R>&_#6EV>I^%-.LQH>IZ7H.EV-YI-[#IMA!" ?G/9_M\?M
M8:_J^L_$6#P]\ O!WPC\%_M*?\$X/@/XD^$U_IOB7X@?$W4(?VY/"7[)EYXZ
MNK?XU>$_B=:_#6*_^$NO_M002^$=5T#P'XM\-_$/3?"-W93RZ-;ZM8^*%^4?
MAC^W+^T'\,]%TC6?B/XW\$?$;XL2_ O]KIO"7Q&\0^'/VC+G2-3\7O\ \%4/
M W[*7P=\ +^SS\+OB)X]MOB-K5_J/B[1/#O@>RTC0M/^(^OZD?!GPPM?BC\/
MO#&L>,O%US_0A!\-?@UXJTVZUJ+X>> =7TWQUXC^'GQ5U"^F\(Z++'XF\6^
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MK7A[]:]$_8I_9&\.2V4V@?LT_!'19=/\9^&OB1:2Z9\./"]E+%\1/!_A75O
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M-IK5IJ-U!<F:/6/$]E)K.I-;[V;[!<3+=62S0 %8DF:+[5'&F!.S;G/HEO\
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M$:MK4^F-'*K*%E6&X@8,6".,*?H#PQX6T3PAH\&AZ#9_9+*%GD9F;S;J\N9
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MWP5J^N_9M&M->?5;^QM+@ ^NZ*0'.>,8."/?\/\ .*6@ HHHH _FQ_X+N?\
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ME"K5H5HN%:C4E2JPEO&K3?+43Z->T4G%K24)0DK*40HHHJR!K?@.H!/3G_\
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MI7U/^NW]D']JKX9_$/P)^PQ_PUC^T#^SOX*_X**>+OV9OA)??$7]F_QWX_\
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MQ=G/V:_V:NDYK115Z6KT['LO,<N3:>/P-U!3?^V87^&[6E_&V>_S/CG]I_\
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M-&#%D06HBC!\SZ;^$?PBT[PW8V'B7Q%:QWOB>[ABN[:WN466V\/0SQI)%%#
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M37M5U._\2Q:MX,^(7Q<\;:59^*O%<VKZ]\1O U[=>&?BQ;^*=$\1^*-#U/\
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MJ-WK^G7$_P ,/A)\2/"6C^(-(T+QSX*=/[ \1Z_^FM !1110!_-C_P %W/\
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MPN%P.#P\'*<W"AA<)0PV'HPYISERTZ,;N3E-U)RG4GX]X-^.WPT\>>-?COX
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M9Y\>_!#PY_P4.U'P?\*OASX:\>?'+]I7XW?%WX4VDMSH_AK0?B/_ ,)'\*?
MFG>"-7\>:[\/%?Q!I%EKOCO3?$$6MWERB>,]-AN=3UI+<WEY#/=@'W-8^'_
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MT;Q?HOC.P^-O[)'Q/\5O\1[:[L=&\;_#'QAXD^$?@30M8 /2_P#@NV<_$?\
M9P/_ %(_Q+_]/_@O_.>AZCBOPD7H/H/Y5^[/_!=D@_$;]F_!R#X(^)N"<<_\
M5#X,]/T]N<#H/PF7H/H/Y5_>GA)_R;CA?_L&Q?\ ZL\R/\0/I5?\I!^)'_8=
MD_\ ZS60'0>#7C3QEX,DDD2*./Q=X5DDDD9$BCCCUZP:2261V5(HXTW/)))A
M$52S,H!-?T8W7C/P2;NZ8>-O!9!N96!'B[PV<@R,PQ_Q-"",=\>_3&?YKBH(
M(('((Z#OUJ'[-!_SQ@_[\I7L\6<'4N*JN"JU,?5P3P<,1!*GAJ5?VGMZD*C;
M=6I#EY.2R23O=M[)'A>$?C-BO"C"Y]AL-PYAL]6>XO+L5.>(S+$8!X5Y?A<5
MAHPA&AA,4JJK+%.<I3<'!P48J2DVOZ7++XA>&M-E>?3/B-X;TR>10KS:;X\T
M:PED09PDDEGK,+NH.2%D8@$Y4 G-5IO''A"YEDGN?'?A&>>9M\MQ/XR\/S3R
M/W>6:75GDD;'\3LQ.>2<"OYK/LT'_/&#_ORE'V:#_GC!_P!^4KY#_B$.$4N=
M9Y7C-Z2FLMPJG)=G+V_1Z]?0_87],/-W&,/]0<!R1?,H/B7,I0YVK.2@\JY(
M7[0C%/[2=D?TP6OQ(\/V4$UM8_$KP_8V]QDSVUEX_P!)M+:<L"',UO;ZW%#*
M7R=QD5F8G))-4H_&_@^#!M_'7A&W8 J&M_&>@0-M)#8+1:LC$;@K;2=I*@D%
M@&K^:S[-!_SQ@_[\I1]F@_YXP?\ ?E*2\(,(FVL\KJ4FG*2RW"IR:5DY/V^K
M2TOVTV!_3#SAJ$?]0L!RT[\D?]9<S<8WWY8O*^6"?6-.,(M^];FLS^E3_A-_
M""H\:>._"2)(29(T\:^'UCD)_P">D::N$DS@9,BODC/7&(_^$S\&?]#OX,_\
M*WPW_P#+2OYK_LT'_/&#_ORE'V:#_GC!_P!^4JEX185?\SW$_P#ANPO_ ,O)
M_P")P<U>_A_ES]>),SE^,LK;^X_I0_X3/P9_T._@S_PK?#?_ ,M*/^$S\&?]
M#OX,_P#"M\-__+2OYK_LT'_/&#_ORE'V:#_GC!_WY2G_ ,0BPO\ T/<3_P"&
M["__ "\/^)P,T_Z-]EO_ (D68?\ SJ/Z4/\ A,_!G_0[^#/_  K?#?\ \M*/
M^$S\&?\ 0[^#/_"M\-__ "TK^:_[-!_SQ@_[\I1]F@_YXP?]^4H_XA%A?^A[
MB?\ PW87_P"7A_Q.!FG_ $;[+?\ Q(LP_P#G4?TH?\)GX,_Z'?P9_P"%;X;_
M /EI1_PF?@S_ *'?P9_X5OAO_P"6E?S7_9H/^>,'_?E*/LT'_/&#_ORE'_$(
ML+_T/<3_ .&["_\ R\/^)P,T_P"C?9;_ .)%F'_SJ/Z4/^$S\&?]#OX,_P#"
MM\-__+2C_A,_!G_0[^#/_"M\-_\ RTK^:_[-!_SQ@_[\I1]F@_YXP?\ ?E*/
M^(187_H>XG_PW87_ .7A_P 3@9I_T;[+?_$BS#_YU']*'_"9^#/^AW\&?^%;
MX;_^6E)_PF?@O_H=O!?K_P C9X:Z^O\ R%*_FP^S0?\ /&#_ +\I1]F@_P">
M,'_?E*/^(187_H>XG_PW87_Y>'_$X&9_]&^RW_Q(LP_^=)_2?_PF?@L=/&W@
ML?\ <V>&O_EI2_\ "9^#/^AW\&?^%;X;_P#EI7\U_P!F@_YXP?\ ?E*/LT'_
M #Q@_P"_*4?\0BPO_0]Q/_ANPO\ \O#_ (G S/\ Z-]EO_B19A_\Z3^E)?&G
M@M6#'QMX,."#_P C=X<'0Y[:I^(XYZ#FOF[X)>)_#&A^-OC5X=N/%/A>WM%\
M5C5],FF\1:-':7-M-J&LPN]I<RWPAN?W$VG%O(=PJCYF).!^'WV:#_GA!_WY
M2E^SPX \J(@= T:L!]!CC/?%=5#PMP]'#XW#_P!M8B<<93HP;>!H+V4J&(CB
M(3C%8AQEM.#32_B.5[I)^=B_I89CBL;E6-7 N7TJN5UL944(Y_CY1Q%/&X)X
M2I1F_P"S8N"34*RFHR;=-0Y4FY+^D_\ X3+P8/\ F=O!?X>+?#7]-4KB?B'\
M4M"\.>%;R]\/^*O"&H>(+RYL=&T2WC\1>'KS;J&IS&&.ZE@746C,-K"L\Q-R
M4M3*(4N'$+N#_/+]F@_YXP?]^4H^SPCI# .W^I3IZ5A2\)<'3JTYSSFO6A":
ME*E+ 8>,:B3OR2<:Z?*W;F6JDDXM--HZL3]+S-ZV'KT:? N PU2K2G3CB(<0
M8^4Z+FN7VD(RRN*<HJ_*^9-2Y9)IQ1^YEK\//!FN ZG\2OC!I>O^(;B (YL/
M'/A>.TTT'<PMK>>XN;@W"P2.Q @@LM/)!\FU<,T[^075X?@GXTLM:TOQ+X1\
M1:>1<PV5[#X@T2XAU+3[A%BN]/OH[2^GFTO4DB*DR(,"41W=H\]NTD)_)+[-
M!_SP@_[\I2B"(=(H1](E'\J]6CX?2A*I'$9Y5Q.&JPE3GA99;A:5.,9)IJBZ
M=?\ <JUM(Q=VKN[;;^:Q?TDI58T*N"X#PF7YAAJRKT<VCQ)F.+QM2LFFZN,E
MBLNG'%3;YWS7I-2GS1M**O\ T&>&OC_\)_$5M$\GC'0?#]^R S:;K^KZ99&*
M3C<L.H-<?V==Q]&BD2X25UY>WB)(KI+SXO?"C3%\V[^)?@0!06"P>*-'OY&
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MOX'/[/LO^?.T_P# >#_XS1_9]E_SYVG_ (#P?_&:^#_XEPP7_17XW_PS8/\
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M^ \'_P 9H_L^R_Y\[3_P'@_^,T?\2X8+_HK\;_X9L'_\WA_Q4%SC_HU>4?\
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M/B3\*H=1OH+.UOM0B\8^#X[Z]M].:Z;3X+N\35%N;F"Q:^O39P32/%:F[N3
MD9N)C)>_X7-\(_\ HJ_PV_\ "[\+?_+BOX&_[/LO^?.T_P# >#_XS1_9]E_S
MYVG_ (#P?_&:/^)<,%_T5^-_\,N#_P#G@'_%07./^C5Y1_XF&;?_ #A/[Y/^
M%S?"/_HJ_P -O_"[\+?_ "XH_P"%S?"/_HJWPV]/^1Z\+=/3_D,5_ W_ &?9
M?\^=I_X#P?\ QFC^S[+_ )\[3_P'@_\ C-'_ !+A@O\ HK\;_P"&;!__ #>/
M_BH+G'_1J\H_\3#-O_G"?N-_P6Y\6>%O%GQ _9VN?"_B;P]XFAL_!GQ)BNYO
M#VMZ9K4=K--KG@]X8[I]-NKI;=I4CE:(3,AF6*7R]WE2;?Q#"J0..P[G_&HX
MK:&#/DPQ0AOO"*.- ^ 0-VQ%SC/&<X_&IZ_<N%.'8<+<.Y9P_3Q<\=#+:=:G
M'%U*,:$ZRJXK$XF\J,*E6,.5XCDM&I)/D4M')I?Q?XG^(%?Q+X^XBX[K992R
K6MQ!6P=6>6X?%U<92POU3+L!EZC'%U:&&JU^=8%5>:="FXNJX6DH*4O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>form10-k_012.jpg
<TEXT>
begin 644 form10-k_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $L 2P# 2(  A$! Q$!_\0
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MAVWM;&#P1:F[U>\T[6_#Y^&OPS'^W#\'_P!C'_@J;XL\8?\ !)NQ^.7[9'P
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M6;J[\/Z@Q\((K>&+5=1LDCOF_P")HS6X:4 ^%_V1OB?\1_B__P %E?CYX_\
MC3^R?X^_9#\76'_!-CX2Z+#X:^*_C3X*^./$/B#P[:?M#>/-1_X2.W\0?!CQ
MMX^\.66A173O8R6&K^((-52[LI[FXTVUM3;R2?OCH.OZ#XETZ/5?#>N:1XBT
MJ5Y(X=3T/4K/5M/D>)MLD<=[83W%O(\1^615E+(W# &ORY_:X_9U^"G@WQG^
MT]^V_P#M >/OB /A-XE_8P\.?LT?$;X9> _#VL_\)#<>%M"^*.I>+6N?#?B'
MP==3^,M3U?QU?^*8? DOAJPT>V26ROI&DU2&&YG\CPW_ ()M^"?A9>_"OXL>
M/M!^(^D?!RS^+7QWUCXAK^S[^SSI_B#PO\/OV?+6X^%_PG\+Z%\+KR^UO2YA
MXV\?+X6\+:#XW^)GC31=%\(>'=0\>>-=?TO1O"]K:Z,-1U, _=&BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MH(!!!Z$8/T-%!. 3Z<T >5?&W5?AQX>^$OQ,U_XO6&EZK\*M#^'GC/6/B5I6
MMZ39:]I&J^!-,T*[O/%&G:GH^HPS6FJ6=[I,5S#<:=.!%?*P@G#HQ _!3_@V
M3^ 7PM\'_L.?$?\ :K^&GP_T7X9Z=^W=^U%\?OCGX5\&:/8:SIL7P]^"/AOX
MF^)?A?\ !OX8Z?9:W>7]S:^'M#TGP?K'B?0@E[J EL/&J@:C<6D=C;6/T1_P
M<!?$'7M,_P"">VO_ +/W@#4H[#XM?MQ_%;X5?L8?#(>;LG_M3XS^)[>V\4:@
M%#Q,;+1? >D^*-1U"0SVL0BA2V-W%<75NDGZG?LY_!/PY^S=\!O@K\ /!T<4
M?A3X*?"?P#\*] \B(0)-IW@3PSIOAR"[>++,)[X:>;RX9W=WFGE>1WD9V8 ]
MH5=JJI.X@ $G)).,$\DGGGOWQ2[5P!@8'3CT_P#U"EHH *",@@]#P:** &[5
MQMP,<C'UZTN!Z#^9_$GD^^>M+10!6GMEG(W8('\+J'0G#8+(V58!BKJ&! =
MX&[DT_[.CB)$($2L=S"""WB4L0 698XT!;"@;B"VT*"Q  &K10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%(WW2.>1CCKSQG\.M(Y(5F&25!; QEL G;T/7IQSZ&LC5M972=+U759;2\N(
M]+TR_P!3:UM;::>]NTL+62Z>WLK6)'GN;F98_*A@BC>629DC2-F95(!_.5\=
M=/\ $'[:_P#P<0?LN_"ZW\//<_!7_@E!^SOXJ_:+^(?BJ%7O]/;X^_M0BST+
MX?\ @O5P MCIVJ6_AGP-I7BWPH]R]Q?36^F>-UMX;5(C/)_28A)121@E02/0
MD?4_S/U-?@A_P0;\&^./'O@7]L7_ (*"_&OX<^*_AO\ &K_@H)^U1XK\<3>'
MO&WAC7_!WB#1_@1\&XY/AK\ _#4OA_Q%:Z=J$-AING?\)AKMC?3:;;/J?_"5
M3W):XA^SRG]\0,# Z#@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 (<XP.^1GTX//_ZL_2OSL^*'[=4'PU_X*,?LT?L!3?#ZZU.X_:,^
M!GQ;^,$/Q*AUR*"+PM/\,+ZSLXM#ET![5FU"+5H9+N26^2]A>TE%M$EO<1RR
MR6_Z*5_.]^U5_P K'G_!,;_LR3]K+_T\6E ']#R!@OS  [F/!SP23UPOKZ#Z
M4^BB@ HHHH **** "BBB@ HHH)P"3T')H *,CKVX_7@?G7Y__MU?\%,_V0/^
M"=>G?#:7]J/XAZQX2U;XR7GBK3_A5X5\+^!_%WQ \7^/+[P4OAMO$EIX>T#P
MAI6IW5Q<:>_C#PQ 5N#;K+<ZU910F8M)L^ M3_X+2_''XIV6[]A[_@D5^WU^
MT:MVL:Z/XR^+VA>%OV1_A3J4CL$EN4\2?$.]\2>,(+*S>.XCDFN/ %K]HNH#
M#:%X)XKT '[]NX12QZ+C. 3@$@$X4$\ YZ8'4D+DAB3*X!4/R2/N-C@@'Y@-
MN,G (8@D-M)"L1_-<T__  =$_M(:XL45G_P3I_X)Y_#F]5IVN7F\5_M#_%_1
M[4QFXMK21 _B#P-K>IR.(;*]D^S^#XH+>2XN8,7<,4$GK>D_\$8?VA_BG:2'
M]N/_ (+ ?MY?'R6\#RW?A+X$ZGX2_9!^&*O=DFZMCH?@6S\5^++BSABC@@MA
M'XST]BR3W,D -V(+0 _8#QO^U+^S/\.-<T;PK\0?VB/@=X$\4>)-;T[PKX?\
M-^,/BUX"\-:_K?B?6[BWL]'\/Z1I&KZ_::AJ&MZG>7=I:Z?IEI!)=W=Q=V\5
MO'))-&K?S;?#+]ISXR?L:_\ !2__ (* _M ^/_%6J^(?^"?/C/\ ;4\._ +]
MI>\\1:KJ-_IW['WBN^^$?P]C^ GQHT33E>_O1X!^*'Q)\7Z+\)OB#%IUE%H?
M@TZA8^-M>N--L;$/??I+\%/^" /_  2C^!/B/1?'WA[]D_0/'7Q)\/ZWIGBO
M2_B%\9O%?C+XL^+E\4:)J@UO2/$$NJ>,]<U))-8L=1@LYH+DV@\L6MO%@QP+
MGWGX5?L#6.BZM_P4?TSXTZCX3^*GPK_;]^*6H^*M0\"VV@:EI<FB_#[7?A5H
M'POU[PCXEO=0U;4H-8U6ZM].O+ZWU32;32K>W6:$)!'<Q+<  P/^":.L:WJ_
MB?\ X*5'6M;UO6ETW_@IE\=M*T?^V=7U#5QI6A6GPX^"C:9H^D"_N;G^S=%M
M8I6ET_2[$0:?;I<L]M OFL6_47_/I_.OYX?@%JWPZ_X((^#O"7P!_:H^+GQ?
M^,?@?]L/]L;XMZQX _:PU#P)<7G@CX/6^I>'/A'X7^%_P^_:L^(NH>*[J32/
M%?B"WL_[$\(^+=/T>71/$D?AG6I[NS\/0Z-*US_0G;7<5RB-#(EPC1Q2I/ R
MR031S)')'+#*N4EC>.19$="5="'7 8  %NBBB@ HHHH **** "BBB@ HHHH
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M=_P3OU#QS\#_ -@36-*BL8_!_P 2_P!HKQ-I+>!_V@?CQINJ0VL%]X\TC1-
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M /A6/!<T=[97?A+XN^,OBA_PGI^(?_"8/!<VNHQ>*CH \(?\(#!+:2V"ZO\
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M6:*WO9M%OKU+6>6(^;%%.8W>("15*D&OPW_XA@?^"''_ $9!<_\ B4/[9/\
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M%% !1110 4444 %%%% !1110!\EZQ^S/I.K?ME^#/VR6\7:G#KG@O]FGQ_\
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M=INE6EMK?P5NO$<GPXL=+M(-.$LEGX T[P#)K6H:CJNH>([G6KN^>5?WZHH
M_G7TO3_^#@W]C31-=;7=>_9A_P""O7PQL%CU"+3M5TJP_98_:BFT>*QM[-]
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M>$DT&^DGTR/0?$$^I7-MJC7?A?\ P42\9>.?^"KO[8,?_!'#]F[XAWW@_P"
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MTFO4* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_003.jpg
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $K DD# 2(  A$! Q$!_\0
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M )&C_P#BJ/\ A#M>_P"?#_R-'_\ %5ZM11]<GV0?V/0[O\/\CRG_ (0[7O\
MGP_\C1__ !5'_"':]_SX?^1H_P#XJO5J*/KD^R#^QZ'=_A_D>4_\(=KW_/A_
MY&C_ /BJ/^$.U[_GP_\ (T?_ ,57JU%'UR?9!_8]#N_P_P CRG_A#M>_Y\/_
M "-'_P#%4?\ "':]_P ^'_D:/_XJO5J*/KD^R#^QZ'=_A_D>4_\ "':]_P ^
M'_D:/_XJC_A#M>_Y\/\ R-'_ /%5ZM11]<GV0?V/0[O\/\CRG_A#M>_Y\/\
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MG-7_ (>+ZJ9HXFD2YN?M$\Q9=T1&P!4!(QG8,MR0,@=:Z8G)S2446%<****
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MFG="'C_2?$Y/5+&VQ_VTE.?_ $%1^=:E8NAO,MUJ4%\B1Z@T_P!H=4<LK1L
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M<F2><NZ^9(QRQP" !GH/2IAX5T($$:<N1S_K9/\ XJC41L9) YHHHI@%%%%
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M6MIN<P2)N56QYUPW,<.?0#YW]% ]:EMO".D1P#[3;"YN6)>:<NZ^9(3EFP"
M,DGBCKH'0WMC?W3^5)DXQGI6.OA;0U8,-.4$'(_>R=?^^JV*8@HHHH ****
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M\:]#W,G_ (#]?T04445QGL!67X@G@CTEX)XIIC=L+>.& @/([= ">!T))/0
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MR?\ @/U_1!1117&>P%%%% !1110 4444 %%%% !6?)8:2-0,DL-J+RY4H=Q
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M/7VJ636;];JYCBGB>91(#:FW.;< X1BV?FSQ]<\=*W[F\^S>6 K.TA( !QP
M23^ %9MMXC#Q_P"EVKPLP1HD@D^T%]V<#"C(/!XQ^-+J!0GU?5[76I;$F*81
M0DC*JIEPF?,"@[C\W&!QP>]+8ZVEO)/<76II<VCR*GVH0%$SY>0 !D=>./IU
MK4;Q%8()=S7 2,$AO);;)@@'8<88@D#BE&O18G=K;4%$*H3FV;+;N@ [GU%
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MV@:'9^&]"M-(L5Q!;)MW'J[=6<^Y.34[NQ2T5S2SGD]:***HD**** "BBB@
MH(!!!&0>"#WHHX[D =R>U >AX+XKM+WPQK@TZV;%K#?QZC;$]L!@,>_./PKU
M;P-HC:+X:B$P/VNZ/VB<MURW0?@*\K\9ZA=>(M8;4[=2]I]M33K8#^+(8Y'Y
M9_$5ZOX*UT:]X:MYG?-U!^YG'?<.A_$8->7AK>V:Z:\OWZ_UV/M<Y4OJ*:MS
MWC[7UY?=O^O]XZ&BBBO4/B@HHHH **** "BBB@#S?X@?\AZ#_KU7_P!":N4K
MJ_B!_P AZ#_KU7_T)JY2O:H?PXGQ>._WF?K_ )&[X._Y&NR_X'_Z U>K5Y3X
M._Y&NR_X'_Z U>K5PXSXUZ'N9/\ P'Z_H@HHHKC/8"BBB@ HHHH **** "BB
MB@ HHHH KW5L;AH75PC1L<Y&<J00P_(]?:H[;2K*SAABM;>.!(G$@$2!=S $
M9; Y.#5RB@#*;086\P?:[L(RLL<99&6$,<L%!4YS_M;N.E12^&+26T6U-Q<B
M%0@V?NV7*YP=K*1T/3&.F ,5M44K(+G+IX8F36A*CHMF(1;@B3+&()MV[2GW
MO]H-^':M&#PY907\UXK2F64@G.T8^8/U"@GE1]XGC@5KT4P,Z[T:*[9V%S=0
M>9N$ODN!YBMU4Y!X^F#[U*NFVZ^=C?\ OE*M\W8L6X_$FKF#C.#CUHH JSZ?
M!<2O*X;S&"88'E"I)!7T/)JA#X:L[;SC;22P/(XD5XDC5HR"3P=F3U/WMU;-
M% &0WA^%D1!>WRH,>8HD'[[#EQNRN>I/3'I4O]C)MV?;;SRPY9$WKA 005!V
MYVG/<D],$5I446 PHO"EC#;"W2:<1^:)F 6(;V  '1,#@=5P?>K-IX?LK+[6
M(00MT"& 1 5!))PP4,>O\1-:E% 7*\=L4O)+AF!RBQH /NJ.3GU)/\A5BBB@
M HHHH **** "BBB@ HHHI@5KZ\AL;;SIUD:,NJ82(R'+' X )I)M0L[>$3RR
MJJ;6(;:2<*<'MGJ14EU ;FW,2S-"V0RR( 2I!!!P>#TK._LA([D23ZE.T0W^
M5"^P*FY@QYQD\@=>F:0#X]?TJ5)2LQ"QC<X>!U[@$8*\MD@%1SDCBI8M7T^X
MD@CCD+22E@B>2P9<<'<",ICWQU%)/I$4P.)I8W#.Z.N,HS.'R,CL0.OXT^RT
MT6<K3-<2SSN&$DD@ WDD'.  !T P*-0%FU&RM;@PR/MD";W*Q,0J]?F8# Z<
M GGM4']L6\LL(AC9PY RZE&0EPI!5@"#SFEO=*CO)9EDNI$@NH_+FM\*5EP,
M \C(('IZ5'9>'[:RCB5'YC;=E(DC#'<&Y"@#L!0KC)KW5K2QF2V8%I79!L6-
MBHW, -S ;5]>2,XI1K5BT4TJ22NL1 ;9;R$G/ *@+EAP>1D<=:2YTLW%WYPO
M)XHV*-+"@7;(4.5R2,CWP>:S/^$-L1:S6\<NQ)'#<6\?09^5OE^?KU;)!YHU
M#0:UWHL.J_:PMXSF?!PLK1[S'N#H@!#$CNHXK8N-2M8=/2]_UL$B[E*+DL I
M;@8R3@=*9:Z4EG+$RW$K1PA?+C;;A2$V9SC/(Q4KZ?$]K#;EG"Q9VD8R<J5_
M]F-%M- TOJ+IUU)?:=!=2Q")Y5W[ 6. >GWE4_F!5JFQH(XDC!)"J%!/M3J;
M$%8Z>)M,.G:K?33B*'2I9(KS<>8RG^(QCUS6RHRP'O7R1J_B"Y/CW6DCCEO+
M"\U4R3:>K$+=;)#M4X&?RJ).Q48W/?? =A=:I=7?C?5XBE]JB[+*%NMK:#[J
MCW;J?_KUW-8WAO5[[6=-6XOM N=&; VPSNIR/8#D#Z@5LTUL)[A1113$%%%%
M !1110 4R8%H) L8E8J0(R<!^.F??I3Z* /&O$'C/PG.OAVVL2FER:?KT4M[
M931>4T 4,&8@<$ ]Q7?>$=<T+76OYO#E@8[!)-LEX(O*2>3T4=3@'J<=:\E^
M-_@R7_A+-.U73H=QUAUMG51_R\# !_X$,?D:]M\.:%;^&?#MCHUJ!LM8@K,/
MXWZLWXG-9QCKZ&\JDFG=O7?7?U[FI1116A@%%%% !1110 4444 >;_$#_D/0
M?]>J_P#H35RE=7\0/^0]!_UZK_Z$U<I7M4/X<3XO'?[S/U_R-WP=_P C79?\
M#_\ 0&KU:O*?!W_(UV7_  /_ - :O5JX<9\:]#W,G_@/U_1!1117&>P%%%%
M!1110 4444 %%%% !1110 4444 %%% Y- &;K&NVFB+#]H6>::<D0V]M'OD?
M R2!Z#N3ZUE#Q+)K\ZZ9X:.R^92]S+=PL/L*CC+(<9<G[HSC@G.!3?%.GWL6
MI66O6=M)=BVB>WN+:,9D,3$-OC'=@1RO<54T/7$NI+N:QD62.>,(T@!!4@G
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M8US'A+P#HGA&,RVL(GU*0EIK^909'8\G']T>PKJ**5AW"BBB@04444 %%%%
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M7CUN>=FOI8(+NW%K>0K&K">,$D8)Y0C<>1Z^M6I="CG\/V^D2W,K1P>3B8*
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MO5JX<9\:]#W,G_@/U_1!1117&>P%%%% !1110 4444 %%%% '*^,M3N;%[&
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M^O6:.34F4/"ZL>96?KPO1>H( %>J(HC14!)"J%!/L,4K%)M]!:***0PHHHH
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M5K;"$37^H7HMX&M[<7,BX@5EV$J%4?-MXR<\46871BZ+KNI2)X>TZ_NF:_\
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M[D>M=M_PL#2O^?>]_P"^%_\ BJ\WHHJ4(5'>04,;6H1Y86MZ'I'_  L#2O\
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M_P#?"_\ Q5>;T4?5:8?VKB>Z^X](_P"%@:5_S[WO_?"__%4?\+ TK_GWO?\
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M?\^][_WPO_Q5>;T4?5*8?VKB>Z^X](_X6!I7_/O>_P#?"_\ Q5'_  L#2O\
MGWO?^^%_^*KS>BCZI3#^U<3W7W'I'_"P-*_Y][W_ +X7_P"*H_X6!I7_ #[W
MO_?"_P#Q5>;T4?5*8?VKB>Z^X](_X6!I7_/O>_\ ?"__ !5'_"P-*_Y][W_O
MA?\ XJO-Z*/JE,/[5Q/=?<>D?\+ TK_GWO?^^%_^*H_X6!I7_/O>_P#?"_\
MQ5>;T4?5*8?VKB>Z^X](_P"%@:5_S[WO_?"__%4?\+ TK_GWO?\ OA?_ (JO
M-Z*/JE,/[5Q/=?<>D?\ "P-*_P"?>]_[X7_XJC_A8&E?\^][_P!\+_\ %5YO
M11]4IA_:N)[K[C;\4:Q;ZWJ<=S;)*B+"(R)  <@L>Q/K6)1171&*BE%'GU*D
'JDW.6[/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>form10-k_015.jpg
<TEXT>
begin 644 form10-k_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %> 5X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%/&R+?Z9=:CHE_YVE:E?6TX!_.!X_P##?CW_ (-J_P!J?6?C7\,-&\4>+_\
M@B;^UCXZL;KXV_"S14U'7+K]A;XWZ_>#3H_'7@31X7?[%\-_$%O_ &=9%;5
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M#*1T)&,]Q_(_AD9H _)__@E/_P %4_AM_P %*/AAXCM[[P[?_!+]K'X&ZB/
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M_:4_9U^%=M\2]/W166JZ+:_$5]+U37?#^J0^1>G3UM-4@==T3'[\_P""I?\
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MO!%&%CBAAB58XHXU5(T540!0!3W4ET*CO\QP,;00<'U.3E>N#DC!YH _+?\
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MA\^/=LSEBQ0*"N2PY( W9.%P[ #*HRNP"D&OPT_;T_X+M?LU?LO?$&+]E_\
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M^$&F6EM\)]+\7WNC:C>/X:U;R;OXB0ZAX9U^*RN)T\9>";U5SJ&E_:/ZJT5
MB!45455"*$VA% P@52!M"KP!@8'  '% #Z*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *,@=2!17G?Q2^(W@KX.?#[Q[\7?B5X@LO"7PZ^&
M'@SQ%X_\=^)]2E\K3M \)>#M)N]?\0ZQ>,%=O)T_2K*ZNG6-6ED$(CC3?(A8
M _('_@N'_P %"/&7[(7[/7A3X"_LWV,_C/\ ;S_;E\4C]GW]D_P!H<EM)K>F
MZGXB$>F^+OB[J,$LB-;>'OA_8ZE:65G?*LI;QKXA\*O-;KX?M?$NJZ-]0?\
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MNR"".>000>X-?@O^VI_P09^ GQN\?W'[4O['OC;Q'_P3W_;HT9[C5_#7Q_\
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M?$OC'Q5X+UCQ/XLU^Z@M8Y]9\2>(]6U37M<U)[G5-8U&^U"ZN+J7?_X=0?\
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M.)%5#CY@JY/S#)VA22#CYB!@EE#=CTQ0!+1110 4444 %%%% !1110 4444
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M+D?ARZAT7Q5X4^)FF^'?#5O=^'[O5K'QM<6.J6D2_7/_  3<^ ?[0.J_'O\
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M?@S\/[\!&N+'X2_"/QU\8;,YD.8X=6\8>(?@;+M:':RW#Z,=DC,#;ND>Y_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /S=_P""E7[7DO[+'PF\$>'?!WP?T']H;X^?M0?%?PS^SM^SM\#/%6I6
MFD^#?&WQ*\5I/>#5_'VJW6FZJ+#X>^ ]&T^_\8^,GAT^XO;BPTD:;9W&GSWT
M.IV7PK\=V_X+&_LD?!?7?VKOBY\5_P!B_P#;O\!?"/1+;XP?'O\ 8T\,?LM:
M]\$;CPEX.\#:0?%7CB?]EKXV:E\5?B/J7B[Q=\-_[/N]6\$O\5?AQ9WOBC2=
M$=X+/1O%5_IFE)VO_!9B&^^$OCW_ ()Q_MY:MI&LZ]\&?V(/VL+_ ,4?M"C0
M=(O_ !!>^"OA-\7?A]K'PQU+XLRZ/IEM<ZA/I7PWU35-/U77[BT@F>RT2:\O
M6CVPR2+[)^W%_P %/_V-OA+^QA\3/BGX8^.7P@^-.N?$CX4>)]$_9Z^%GP[\
M::+\0?%W[0'Q$\<>%=1TOX<^ ?!GA/P?>:MXEUF7Q;KVJ:9INH-I^ER-I5G<
M7EW?"*.V=$ /TB^"'Q=\ _'_ .#OPO\ CG\*];_X23X:_&'P%X3^)?@37##)
M;3:EX4\::'8^(-#GN[.<_:+'4/[/OX(]1T^Z2*\T^_2XLKV&*[@F0>HU\"_\
M$LOV>/''[)__  3I_8U_9U^)JQP_$?X5? /P'X>\>V$5U#?1:+XPFTM-7\1^
M'(;ZV>2UOH?#6K:E=Z!%>6LDEK=1Z:L]L[PR(Q^^J "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH JWEG:W]I=65Y:VUY:7MO-:7EG=P1W-K
M=VMS&8KBVNK>97BGM[B%FBFAE1XY(V9'5E)!^1/AI_P3]_8=^#'Q(O?C!\(_
MV./V9/AG\4[ZXN+Z7X@^!_@G\//#7BZ.^O99)KZZL]<TC0+.^TV>[EDDFNI=
M-GM9+II',[LS,3]BT4 ,C4HNTG/)(''R@\[<JJY"G(#$;B.6).33Z** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>form10-k_016.jpg
<TEXT>
begin 644 form10-k_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %H IX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MINY?[R_F/\:4$'D$$<C(.>0<$?@00?0\4 +1110 449 ZGKP/<^E(2!U('U(
M% "T444 %%&0>A!HH **** "BBF[E/1E/XCW]_8_D: '44A(!P2 ?0D ]_\
M _D?2C<N<9&>#C(S@Y(/X@''T- "T4A('4@?4COT_.C<OJ._<=L9_+(S]10
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M_$?3/A?\1?!$1O-1\-+X=U'QU#J%SH]YI^NS:9_;M_=V7A$ _2/6_P#@NS\
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M/$UOXTM?$JQ:_;W<>GQZ;%IT:O'?K?*D(_GI_9J_X*V?MC_ '_@G!_P0FLM
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M_NHM9U'2]'O=760:I?:5I=Q=RV-N ?R!_P#!*+_@H[XF_9[_ &'S_P %?/\
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MU^%?Q*\&V/CUV\":[XCTC6O%6CV-Y\=/B)X?L] U'X4ZIJ7C_P .>#M-\/\
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M66MW??"/2_%?PST;QCH'AWQIXV\6:;JFD:YXRT"UDO=+ATS5/&%C\5_L/_\
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MP_\ "_QY_P""BWB_]G;Q]\ _A;\/OCEX"\6^'+NQ\+:/X1DU/P3<?$+Q)<>
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M$]>E\:_#G_A!M/TJ+79;+P[K6J:IX=$>IK<6HT;Q9::+K$<JSS)IQM'ANK@
M_8522!GKZC&#SPPP3PPY R<9Q2T 8Z44 %%%% !1110 4444 %%%% !1110
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MXW$ _K!R@(^4\$8.TX&3QR>V6_GGBN5\>^/O!/PL\%>*OB/\2?%?A[P)\/\
MP/H.J>*?&7C3Q9J]CH/ACPOX;T2TEO\ 5]<U[6=2GMK#3-+TZS@EN+N\NIHX
M88D)9AP*_A]_X)X> _\ @JU\1],_X)N_MI?!+X3_ +4FN>(?B)\6OA;\0_VQ
M/VM/BM_P5"^%OQD^#/[37[.7Q-UB>S^-7A2[_9'OO&MEH?PZN_ L>JO:?"GP
MKX8\,:5XU^%5WX8G\,:KI6N^/M.T^YTK]E/^#G]M5'_!*7Q=+=1ZS-\((OVB
M/V7I?VE(M"^V_:Y/@)%\8?#S>)DE&G@WK6Q\4#P:2+<%Q-Y+C(!H ^K/V?\
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MSPY8(D+S_P \'_"1?$7_ (*;?\%%_P#@G[^RW^TQ\?/C9\/O@?<_\$5OA/\
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M'C?XM>#O"OQ=M(O"/B/1DT[XSW.F>&K+P\OQFTN6+XEW<MCK)/B9KO7=1\T
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M-)LC_F_#X^'G_LHWQY(/]10!_:3^UU^V!^S[^PI\#/$7[1_[4'C:Y^'OP?\
M"FI^&]'U[Q3:^%/%WC2:RU#Q;KEEX=T*$:#X&T+Q%XAN%O-7O[6W>:VTJ6&V
M$GG7,D42LXP/BE^W9^RO\'?V3M/_ &X_&OQ3M1^RYJ^A?"[Q/H_Q3\-^'?%G
MC*SU;0/C-XA\*^%?AQJ>G:!X4T+6/%5U#X@UKQKX<M#''H9N=,%^\FK0V,=G
M>FW_ #;_ .#CB&SN/^":.H0:CI]AJUA-^U5^Q5#?:5JUG!J.E:G9R_M0?#)+
MG3M3T^Y5[:^T^]@9[>\L[A'ANK>22"56CD8'^<__ (*87^M?\$Q/V5OV[O\
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M/B[X!M/'=WXQLC/8^)_$5UX7U*YT/3?%NKVFO-<>)/!^C^,=7?6?%UG>ZQ=
M']WF]<C(*EN.5P21GC/? YX)XYZ9Q\Z?M'_M8? ?]DS3_A'JWQY\87/@ZQ^.
M7QW^'?[-7PRN+;PMXL\5'7OC)\5?[7_X0;PM/'X2T37)=#M]8.A:F'\1:ZFF
M^&].>"--2U:T>YM5F_GU^ D/Q,_X)X?\%@/VP_V3/V<M5_:;_:>^"U[_ ,$N
M?"O[:'A']E_XG?'_ %CXF^(+WX^Z-\>;?X5-I_PS^(?QW\2:@?!Q\:Z-<ZC>
M>(I-7\1QV>KZQ?6\NJ3SV'ASPII^B^=?\%G_ (R_M0_M#_L>_P#!/GQ'XJ_9
MDUW]A[X[P?\ !<?]C#PC\*_!OQ[\4> OB[I<FJ1>%?'-_P""/BCXA_X4OXFU
M:POO DGC#6[G2M6\+Q:SI_B:Y@\):R8_LL.I:7<R@'])_P <?VLO@1^SAXP^
M '@/XO\ C"Y\,>*/VH/BO9_!+X*:=;^%_%?B%/%GQ)O[&;4K70KB]\-Z+JUC
MX;BDM())3J_B:YTC1X\$2WZ8;;]%[E;G#'!_NGUR>W8C)]<#&<C/\?G[=/@_
M_@ICX<_;;_X(GS_MR_&K]D/XG^"[G_@I-X-C\%:9^SG\'?B5\-_$FG>)AX2U
MB2XOM?U/QQX]\86-_H?]E)=0)865M9W@OIH+B2ZN(8_+BX:V\%>)/V\?"_\
MP7@_;$_:#_;,_:G^"WQI_8*_:C_:Y^#/[,/A[X2_M(^./@S\/OV7?AQ^ROX
M@\2_"3X@+\-_"&N:5HFOW7Q1U/[=!X]U[Q39ZA#XZ@\-ZG)X7NM(U.>XU"W
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M*7_0N_%S_P 2H_:M_P#GVT?5\A_Z&N:?^&&C_P#/X+R_EA_X,?\ \K-C3O\
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M_P!"[\7/_$J/VK?_ )]M'_#N;]E+_H7?BY_XE1^U;_\ /MH^KY#_ -#7-/\
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MXEUS2M3%[+8ZM8W^GB.TCM_\.YOV4O\ H7?BY_XE1^U;_P#/MH_X=S?LI?\
M0N_%S_Q*C]JW_P"?;1]7R'_H:YI_X8:/_P _@O/^6'_@Q_\ RL_(^3_@B/\
M"W]J_P#X*=_\%9_CO^WQ^S-9^.?@/\=+O]AN;]D_QS9?%K7?!7B;7;3X??LR
MZI\,/VAM&:[^"'Q+\*_%#0O"E[K]IX6TKQ!X1\?'3/#7C271]'UJSTC5_P"Q
M;#4[3]D;C]@G]D6>T_91TZ+X(>'=)TO]A[7$\2?LKZ/X9U+Q5X3T3X2:VOA^
M7PNU[I^B>&M?TK2_$OG://.EU;>-;7Q):7FH2OK5U;RZT[:B>>_X=S?LI?\
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M>HO%'J&KV]_J:+>KSW_#N;]E+_H7?BY_XE1^U;_\^VC_ (=S?LI?]"[\7/\
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M$)1)X9%W1RQR+ND3<CJR[XI&BE3<I(W12H\4BYRDBLC ,"* ):*:'4]"./\
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MFOQIX(^,WAWPW?>)/#MC\&(-!&N3MIVL?TJ;1C'.,8QD]/3KTI!&J@ ;@ "
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MP'\8?LN?!:3X7^,OV*/A]\)?BA^W#^U'\;]2^"?Q>U#Q5\1O^"5/[#4'B/\
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MM##PEX7N?A8VIV/B'P)9V/@GXQ^*%^'WB_PWXXL+CQ;I&D^*M9UGX-:7X&\
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M'2O"=OX!TZ\L-92P%Q:Z[9> K2V\"6_B6$KXBC\$V\/A%=4'AZ-=- !^0?\
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M!_B_QJWQ7L/!_B[PS\:M9#Z;<2>#7X7X3?\ !7#]L+XKK\(/@':_!O\ 9_\
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MU+3M.UC3-=TN2X'VW4O&?B+Q1I-S-:>&=(\,Q2-\2?\ !6S]K'Q=\3;'X,?
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MB%>6^J_#7XJV7A76OA/?A-7TGXEZ?<:1)X^MM CG\0Q_K'J/[$G[(&K^'?\
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M-G.]I=2K%=6\]O(5FBD10#I:*** "BBB@ HHHH **** "BBB@ HHHH ****
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MWAC5Y=#UK0?$=EIWB#2--N]1\+^(O#?BC3HKOP]XAT;4KWV.@ HHHH ****
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MX%\(W]_>W+F6YO+V\T#3[BZNKB0\R3W$\DDTLAY>1V8\FO)?VS?^3/OVKO\
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MGX1>/M<O;^_A\&>';54&K6]A:V^FJ+:RBFGNI;CY_P#^$]_:G_Z/I_:P_P#
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M_P#$N7B-WX;_ /#Y/_YT']5.1ZC\Q33(@SE@,=>>/7K] ?R-?S!?\)[^U/\
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MJSMH9(H8]K?C3_PTI^U=_P!'D?MM_C^VI^U1_3XNFOU,_P"#@O\ Y2*^$/\
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M:/Q]TSXG^+O#=Y^UIK_@[0M1^*_QO\-?M8A=(^!L2?\ !/3X:>!_^"C?P2^
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MMVL.A!/0@\Y!&0>/>OR3_P""R/[5'QY_9-^ /P7\6_L\^*_#_@OQC\0?VE=
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MXK_=L3_V"XK_ -1L2:T?XU#_ +",-_ZDX<_'+4O^0EJ/_7_>_P#I3+7Z'_\
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M%E907-Z\37$\5I;)+(PB3'Z45\1?!S_D^?\ ;;_[)Q^Q]_Z;/CE0!]NT444
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M;<W'[+/[)US.8+"PAM[2$SW$TMQ,8XE,T\LDTFZ1V8_RJ^.O^2I_'#_LX_\
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M_I3+7Z'_ /!([_D2/VO?^SSM<_\ 69OV7Z_/#4O^0EJ/_7_>_P#I3+7Z'_\
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M]A).-\+!S3JIRN[VLK^'B,PQ-+'QP\'35)SH1?-#FDU/DYO>YE:_,^FGS/\
M08_X.%23^S-^RZ#V_;7\.#IC./V9/VIQGJ>N<U_+W!_Q\0?]?"?^AI7]0O\
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MR[_U9Y688K_=<7_V"8K_ -1L0?T@_LF_\FL?LT?]F_\ P:_]5UX<KZ KY_\
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MFM3+LZKPS-8WC7"YGA(QPV"RK&8W#RK8",L1;%86BZ<8RC449IH]X_X-VO\
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MMUS\KE!-'T1\,?\ DOO_  4)_P"SR?"O_K O[#E+\1O^3C?^">/_ &=MX_\
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M ."7?_*,_P#X)W?]F+_LD?\ K/\ \/:^ZJ_+C]CSPK_P4&_9X_9__99_9O\
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M'- 'W)44WW#]17Q"?^"CW[( )!^(?C'(+*?^+#?M"=5^]_S2OIZ'H>Q-1O\
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M#?\ SJ:/^%R>"?\ GW^)_P#XC[^T-_\ .IK\+_XAKXC_ /1O>.__ !"^*_\
MZ'3](_UNX2_Z*GAK_P 2#)/_ )[GJM<-\2_^2;?$G_LG7CW_ -136:P_^%R>
M"?\ GW^)_P#XC[^T-_\ .IKD_'OQ8\(ZEX"\>:;8:=\5+S4=1\#^,=.L+2#]
MGS]H9I[N_P!0\.ZG:6=K$#\*E4RW-U-%#'N8*7E4$@FNO >''B+#'X"4_#[C
MN,(X_ 2E-\&<5*,(PS#+JDY2E+AZ,8QC"G.3<IP2C";<DHLQQ/%O"<L-B8KB
MGAMN6&Q,4EG^2-MRP]>*48K-FY2<I1C&,5S2E)):L_J)_9-_Y-8_9H_[-_\
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MC]M?]F_XM>--&^'O@/QEXEU;Q9KYU%=*L+_X2?&/PS:3G2M,O-8OO.USQ5X
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M]XG\ >$?$/Q3^(.K(EM!<:[XDTQ=4UF^AO?$&MV5H;K48?RTTWXQ_M*_'O\
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M:]H^B>([G1;SQ#I&E:O) VH:?IFO7GAOP[=:U8VEQ#:ZI<Z#HLU]%/)I5BT
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M^"?PYF^#_P '?A7\)[CQ5J_CF;X9?#KP5X D\::_9:/INM>*V\'^&],\/?\
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M-3\0ZGX<\)>#9M"\1S_$_7/&FF:S+>Z[I^F-HWB>_P#&GB*\\>V/B6!-1O\
M4-5U76]?AUU&NM?F^W5_AYI?[,/B#XD^)/$'PY\&_"E?BUX!.H^$_$?B+1_A
M]HN@?$/P_!K,\>LZMHYUR;0-,\0_V5J]U>0:I?K8W<VF7]Q>0WUPT\MU"\GY
M\7__  1[^'VN^&]3\)^(O%W@6[T"+P)X_P# O@G2--^ .@:;I/A*7Q'H/[2W
MAGPC\0)=*F\::EIM_P#%#PIIG[14UUJOBW2[;PTGB36_"SZGI>F^$%\0FST;
MT'X0_P#!,R+X5_M+>&OVA&^*?AWQ'+H'Q)\:_%.;S/@S::5\5=6U;Q=X/^/'
M@A/ ][\83X]U*Y?X0V5A\>=5\4WG@)_![S:C\1_"/A?Q5;^(=,@_M/1KH ^L
M;'0_V.OC#K=YX"M/"O[/WQ,U/PUHO@KQC+HZ^#O ?BZQL=)G\7?%2'P1JUA<
MOH][HTTFF^.- ^,#Z>FEW$U[X=\0IXKO)HM-O-9N9=0Z:3]GC]EO4],30I/@
MA\ =0T3Q%J^K^+X]%D^&7PYN]*UW7-;NM!UG7O$Z:>VB/:ZIJVKWWA?PQJ^K
MZVL4]Y?W?A_0[^]NII=)TV2V_->Z_P""-'P\O_#WBO16^(.@>%M5U3P7%\-/
M!OCKX7_!70OA]X\^'W@.+Q#^V5J5W%HGB6T\6:E=6WB_Q)HG[7^HZ!XR\2:"
MOAO3O$K>"([Z7PO:VWB>?2=([WX/_P#!*3P#\*O%W@?XA1>(/!B>-? ES\'+
MK0K[PM\-?%=M:>&V^&WQQ_:H^,OC.S^'^H?%#XS?&/Q]X"T?XQI^T_J7AOQA
MX>TKQ[<>'[2/P_=S6&EOHGB7_A$]" /?/B!KG_!.[P$UI\4OB/IG[+>A/XM\
M>?&'P./B)KO@7P%Y^H>-]"U+Q=H7Q\LM9\4OX=GELY=)U'PSXUT_XM:SK=_:
MZ9:G2M9_X2_45CCNGD]'\<?$[]DCX2?%*"7Q_K7P>^'_ ,6;3P1XX\<0>(]?
MTC0]$\0VG@R[TNY\3?$&^C\<3Z9"+7^W/#_PEO/%'B'1QKB:KX@\/?"V]\13
M:?J&D^!+R^TSYONO^"=0\;ZEIV@_&GXG:;X_^"GAOXY_M0_&/P_\,_"OA/XC
M_"C6M>TO]JSQ=\9/&/COX8_&+QOX8^/-W8_%/P+;W7Q<DT:?PS+X*\.>#?&7
MAW1)-(\=^#O$<6K+)IEGXX_L&?$#XQZWJ.EM^T7)'\'&^$_Q=\$>&? /Q \!
M^+_BCXL\%^/OC7X?^)OA3QO\5M(^(&H?&O0M-OM0?P=\0+;X9>&O#^L> [Y?
MA]\)(O'7@[X;:SX/U'XF:QXFTT ]HL=9_8?^)^J? N4:?^SWXG\1>+KKXKZ3
M^S[8:WX/\&OXQ;4?A_J=W)\<=(\!Z%X@T.+Q/X<U7P1K^B75M\6-&M[#2;[P
MYXHL&TWQ;:V6N11VY^@-5^#OPFUVPUG2]<^%_P .=8TSQ%97FF^(=.U7P-X8
MU&PU[3M1T/PYX9U"PUFSO-,FM]3L[[PWX.\(^'[RUODGM[G0_"WAS29XY+#1
M-+@M/SF^ G_!+JW^"?Q"^!7Q17]H_P")&L>(/@YXL\>ZW<>#K3PMX+/PQU;P
MYXU/[1EU'X'\.W'Q#L/B?\>?"^F6&L?M&:WKFO:WJOQ_\9>(OB%JF@:9>^,K
M_4+NR\,S^$OUAH \FO?@+\$-2T?1_#VH_!SX47_A_P /:MX:U[0-#O/ASX/N
M='T/7?!F@6GA7P=K6CZ9<:/+9:9JWA/PO86'AOPUJ-E!!>:%H%C9Z-I<UKI]
MM%;KZPHP ,Y]S_G_ !/J2>:6B@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** $8!@0<X..A(/!R"",$8(KSCQ#K?PM_9_P#A
M9XB\7:[<>%OA9\'_ (0>"-=\5>(+^.TL_#W@WP'X"\&:/=ZYKNI-9Z;;0V6D
MZ'H.C6%Y?W$=I:I#!;V\C1PE@ ?2*^;?VR?@GKO[2O[(G[4O[.GA?7=-\+^)
M?CW^SM\:O@SX>\3:S%=SZ1X=UOXG?#CQ)X*TK7-4@L%>^FT[2;[6X+^\ALTD
MN9+>"1(8W=E4@&#;_MU?L?W@\#-9?M#_  SO4^)GA?X%>-? +V.O)>1^+/"G
M[37CR^^%_P !-=T:2VCE2ZL/BE\0M,U'PCX7D#!KG6K&ZM+A;<P2%>L\'?M7
M?LY?$+X@O\*O!/Q@\&^)?B)'XB^-/A*3PCI=_)/J\?B;]G35O VA?'#1)(?(
M6--0^&FK_$OP'8>)H'D#6TWBC3/)\]))&C_ F3_@W\\7:9X_^*VE>%OCAX<T
M7]FCQAXX_8:\0?#+X4Z%-X\^'WBGX&>"_@3^UCJW[6_[1'PS^&?C[X=W>@^)
MO"6B>-/B?XV^*OB?X&ZUX9U[1?$7PHN_'L.AZ/?Z'8^$]&U1O9?@_P#\$J?V
ML?V4/C?X*^+O[.?Q.^!7BVW\,?'3_@HMXKDTG]HGQ+^T)XX\0O\ "3]M_P"(
M'[*?BW0;*_\ B+?ZQXK^('CCXK^"-._9UU"S\0^+?'OB?6V\2ZAXBM[^]U'4
M+L7-]$ ?KK\1OVU/V4?A'\<OAK^S/\2/CS\._"7Q^^+RZ9)\._A+J>M*?&OB
M&#7-5N]"\/W9TBUBN)=(LO$NNZ?J&A^&+[73IEGXEUG3M1TK0I]0O["\MX9/
MVAOVQ_V;?V5;;1[WX]_%'3_ %KK_ (4^-'C;2))= \7>)#?>&?V>/A_JOQ2^
M,NHQ1>#_  _X@E#^!O >B:KKU[I\BQZGJ0L9M-T.SU35]FGO\5^-OV&OVF-'
M_;"_:K^-GP"^+GPN\,?"W]O7X:?"+P!^T'<>+M(\;P?'?X.ZG\&?A[XZ^&/A
M[QC^S=XH\(ZC::#=7=WX=\86^L6>C>/$M[;PGXXTR\\3:9>W\6NW^D+^0_P[
M_P"#<KXS^!/V=S\&].^,'P:T+6V^'?[6'@'6;[11XN;P7XNUKXX_\$]V_8I\
M+_%>+P9IO@KPEHW@'QAKFJPZ7XS^,<&G:=XKUWQ9;Z18ZEXE^(?Q(\<"Y\17
M(!_4K;?&OX5W?Q)T+X.6_CG0I?BIXF^%NH_&O0/ 8FE7Q)J?PITG7O#WA;4O
M'-OIKPK-_85EXC\5^'='N)G"2I?ZO:0>279@FO\ #;XE>#_BSX!\%?$SP1J%
M_?>$/B'X=TKQ7X2NM:\.^)/!NLZAH>MZ?%JNG3WGA+QGH_A[Q=H5W+I\\5S-
MI&OZ%I>L62-LOK&WD5U'YT_$_P#9(_:DM?VWOV>/VKO@5XH^ $VA^!OV3M7_
M &1_BUX4^+<'Q'CU2^\(^+/C!\*OB1XE\6?#NZ\&(UJ/$-MI_P .'T[1+3Q)
M)%IYO+]9+XF$%X_R\^%?_!OM\1/ NK? ;QI>_%[X1V7Q9^">D?\ !-7PEX>^
M,7A3PQXBM?B=X,\&?LA_!SXM?"S]H#2?AKXPN[5-3\.K\;'\>^&=1LK&-K71
MM;B\&:1;_$&PU%-'T&&P /ZD(IX9@3#+'*!)+$S1,)%66"1H9XF9"562&5'B
MEC)#QR*R.%8$5+7XR_\ !&S_ ()B^*_^"97PT^)_@7Q=XF\$>)=2\<77PM@G
MU3X<W6J:?X;\5W/PN\ IX$E^*&L^ Y?"/A#0O!_Q)^(]M!8W_P 0+C3_ /A-
M/$7B:^TRPU'QM\3O'FM0KJP_9J@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .<U+Q ;.X>ULM+U'6+F&.&:YAT\6I:WBN#*('E%U=6PQ,890FPLV8GR  ,
MYW_"5:G_ -"7XF_[XTK_ .6M+I@'_";^*A@8_L;POQ_VW\0?XG\SZUV6!Z#\
MA0!QG_"5:G_T)?B;_OC2O_EK1_PE6I_]"7XF_P"^-*_^6M=G@>@_(48'H/R%
M '&?\)5J?_0E^)O^^-*_^6M'_"5:G_T)?B;_ +XTK_Y:UV>!Z#\A1@>@_(4
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M_L+:M^GA?6B/UYKL]J^@_(4 <9_PE6I_]"7XF_[XTK_Y:T?\)5J?_0E^)O\
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MUS_@HW^P7X9\2:[X/\0_MA?LXZ-XG\,^(-0\+Z_HFH_%SP=:ZAHVNZ)XDO\
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M1*\.>VE6@'L! F!]!7:5Q?P[_P"1*\.?]@NT_P#1"4 &O_\ (T>!O^PMJ_\
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M^//B+^WU\:_$'[3WP[^(G_"6ZI\.M)\6:K%X>^$EG\+OB7'XJU+P#X,_;4^
MUI^S3\7?A]JFC_L7^!/ L,_CCX!6>I?$SXLP?\-8_'EM8\1>,=;@T?X;?!I?
MA-X^^%_P] /Z9Z*_,+]@+XQ_M-_&?QM\=]-^..ID:)^R]>Z-^R5K<_\ PBWA
MGP^OQA_:.^&WB#QKKOQ2_:,TU]'LW6W\$?$WX.^)_P!FS7/"WAG0K_3]$\&>
M--;^+W@S4=%&J^&+==-_3S(Z9&?3(H 6BBB@ KC?#W_(Q^.>3QK&F8&>.?#>
MC9XZ=J[*N-\/?\C'XZ_[#&E_^HWH] '94444 %%%% '&:7_R/'BK_L#>%_\
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MS3X9O$,%/]IC_@H3^S?J^K?&SX1?%K]FKP_^TU\-?A?\,OB'\9M%M+>3X?\
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MX_?%?XB?$/0_V>==\%>!_A[HWPJMM5UZ/]I?P)^T]\1? UC_ &M\1?B_\/\
MP?HUUH7AG]DOXHS>-;OQ%XFT;0](NKCPI;:9JVMG5;^31_=_B#^SA\!/B_-\
M,%\:KK'B+4/@=;:QI_AR['Q2\<#6+CP[XH\':?X=\8^%/B9?VOBI=0^)_@[Q
MUX5DT2?QQX<^*$WBC2/%LT6A^(]<M[W5;?3M33YJ^$G[*?[!?PD^).CO\/'\
M7>+_ (H?#WXG?#OP4=4USXW_ !_^/>O?#GQU\)/V=_C'J7PO\)>.-4\4>./'
M</P[T/PG^SQ^T)\06T'3_&\^@^$K^T^(?A>>Z;5/&^L>"[B[ .2\!?\ !6OX
M4?$/P]X<U31?V=_VJK3Q'\2_#_P+\5?L_P#PZUGPW\%;#QK^T7X?_:!NOB1'
MX3U+X< ?'J?PIX5BT+3_ (1?$+Q'XS3XZ^*_@]/H?A?0?[<MHM5LM1TI[^>Z
M_P""LWPE_LSQ?J^A?L__ +5'BW3_ (6?!Z[^+7QON?#_ (.^%*Q? ^XTOXQ?
MM#?L\:_\,OB%-KGQJT:"X^(/A?XX_LO?%_X>^*[WP-+XS^%_AN'0&^)&L_$N
MS^#MOJGQ%TS0^-7[//\ P3X^!_P8L]=\<Z#XP\*_#_X&_!G3_"?A_P :_#7Q
M/\?]6\5_"+X?_L8^'OB1\:]+O-&\<?"_5]4\5>!_%?P]T:W^(@C\33ZOIOB?
MQN-8N_A/J&H>*QXOM_!FL_0_@+]C7]FOP?X5\6:+\*M.\6>$+?QOX \-?"KQ
M-XQ\!?&CXKZ7X]U+2? 7Q,^,7Q3M]1N/B?IGCG_A-W^(UW\6/CI\8_&7Q ^(
MTWB%_B'\0?%7C;Q!<_$?Q!XEEE,<8!P'C+]NJ31O@_\ LL_&#P1^SW\0_B=:
M?M3?&+PI\+/#W@_PI\3_ -F/4]=\.:3XKTCQWKMEX]?QGH'QT\2? [QEHUQI
M/@@ZCI=OX%^+VO#4K/7-.,M]I]];:EIUIX9\'/\ @J&NJ^#O&>H_&SX)^._!
MVK^&X/VO/%?A/QA'K'P#\ ?"+XQ^ _V5OVL!^S;XAD\!>)_BI^TCHS>"M9TN
M;Q;\*3J-Y^T+-\$_#?C#4/$UWK7P_P!1U30T-O8_7W_#$O[/L?P:\'? NTT3
MQKIO@WP%\4=0^-WA;6-*^+'Q2TWXE:?\8-<^(/BGXI>*OB3+\6+/Q?#\1[_Q
M5XU\<^.O'&L^-;W4/$UU#XJB\9>)M'UFVN]#U>ZTU\'QG_P3\_94\=^&O#GA
M;6_ &M6UCX,O_'NM>"K_ ,/?$GXF>&/$/@WQ%\1_VB?AU^UAXC\3^&/$F@>+
MM/UO2?$47[07PF^'OQ%T#5H+[[1X:N_#D6@Z&;'PK?ZKH5^ >)? /]O;X<?M
MU^-=3^">@?LX>,O%'P5\:?L_ZWXG\=>-?'6L_ #Q7\.T-S\:OVB/V8_'_P &
M_'?@_0OBCXSA\;Z7<^*_@#XWT*+Q5\-O^%M?"SQWI6IQ7=MKC^$+S3?$&N>,
M>"?VUOV(OV5_%W[0OP;^"_[-_BW2/&W@#QK\)]"UOPW\&M4_9C\>^(OC?XH^
M)'[07@[]C_P'#9:KX8_:/U[4?#&HZ!\2/&O@;PY+X=_:@U+X*:_X.\'ZPMQ;
M:!::9X=\4VOA_P"\OA+^Q)^SW\#/&'ASQU\+M#\<^&_$OA[1?B'H-Q>W'QC^
M+_B9?&MG\4?BKX\^.'BRZ^*4'BWQQKT7Q4UM_BU\4OB3X[T3Q'\05\1^(/#.
MN>.O%#^'M2TVVU:YMFX+PG_P36_9 \%ZW/KVB> ?%SW7_"3^'/%6CV.L?&;X
MT>(/#W@^[\)_M%>&/VL?#^E>!/"VM^/[_P -^"/#%C^T#X0T/XA/X9\,:5I>
MB7TMNWAK4;.[\'%/#T8!QWPK_P""GOP#^*_[4<G[(6G^'_'WAKXL6T_B/P[?
MIK^J?!?5;+2OB=X(\!:!\1/'_P *=8T3X??&/QO\1M)UWP3HVLZGIVH?$#4?
M -M\!_$/B?P?XF\->!/B]XMU9-!@U[S[XG?\%>?@7\)M.\0ZSXM^$?QST_2+
M3]H#XJ_LV^ =7UW4?V:?A[H_QG\?_ F_^+.G?&R]^'.L_%G]I'X?:39>$?AS
M<_"'5K>ZUWXG7OPW_P"$SU+Q-X-\/_"ZS\>>)K[5]%T3[<\)_LP?"CP+\8_&
M/QP\'+\0/#GBGX@7U]K?C+PQI7Q=^*=M\']?\6:II6BZ'JGCB\^!Z^,/^%1K
MXVU/2O#VD0:CXFM_!L.IWUY;3:Y=32^(+_4=6N^2\8?L2_L]^,O"^C^%Y]"\
M:>%CX:^,7Q0^/?A7Q9\.?BS\5/AK\1?"GQ4^-.M^/-?^*GB#PW\1O WC'0?&
MFD6/CB\^)OCBWUWPK;:VOA"XTS6QIB:#'9:7HT.G 'RPG_!53X3^.=4\1^'O
MA9X>\<6J^'G_ &3-6C^('CC1/AI!I.N>%_VJ?B%^S9X?\%7ND_!+4OCWX%_:
M?32->T#]H:T@L/BCKOPDT+X4Z+XC\)>.;1O$?BGQ#X/@\!>+'>$O^"IGA_XF
M:U\#=/\ A?\ LS_&[Q+IWQA_:PUW]E._N-3\<?LOZ'XF\":[X<^!GQG^.&N^
M(?%7P\M_V@=:\<>"]1\/:+\'=0D\3?"GXP:+\)/C!HFA2ZM?/X(N?%UEX<\
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M_ GAKQLFFQ^---AU\8NG_L*?LZV/P7^*_P "9M(^(.L^#_CCXNM_B!\6-?\
M$'QH^+^N?%3QIX[L+'P-I6C^,=0^,6H^-I_B?:>(] TGX9?#[2M U+2?%6GS
M:-8>$-%M[#R!!(9@#XH^&W_!5R[3P[X[TOXB_ _XB_%3XF_#KQ;^T$VIZ-^S
MUX&G\!^(+CX&_LW>$/V?O%7Q*^.WC3X'?M:>,_@S\4/@S<:#J'[27@#PC:?
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M> 7'P9_X)-^-O&5C^S'JO@[X0W^K:GX%\._&+P_?:IX\O(U^/OAS]M:?XA^
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MX6VVHZ'I^G:=\./&#^*_AUHNEZ%IGA?2?#EAH6C6.E6O?C]D3X(7_P %=.^
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MXX74-9^&WP>1O'GQ*N=+B/B2UTOX=Z99:=X<\)^!M.N-<\4ZM:ZEJ\GZ"44
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M:3_S_P#B7_PJO$7_ ,LZ/^$&TG_G_P#$O_A5>(O_ )9T =G17&?\(-I/_/\
M^)?_  JO$7_RSH_X0;2?^?\ \2_^%5XB_P#EG0!V=%<9_P (-I/_ #_^)?\
MPJO$7_RSH_X0;2?^?_Q+_P"%5XB_^6= '9T5QG_"#:3_ ,__ (E_\*KQ%_\
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MJO$7_P LZ .SHKC/^$&TG_G_ /$O_A5>(O\ Y9T?\(-I/_/_ .)?_"J\1?\
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M_P LZ .SHKC/^$&TG_G_ /$O_A5>(O\ Y9T?\(-I/_/_ .)?_"J\1?\ RSH
M[.BN,_X0;2?^?_Q+_P"%5XB_^6='_"#:3_S_ /B7_P *KQ%_\LZ .SHKC/\
MA!M)_P"?_P 2_P#A5>(O_EG1_P (-I/_ #_^)?\ PJO$7_RSH [.BN,_X0;2
M?^?_ ,2_^%5XB_\ EG1_P@VD_P#/_P")?_"J\1?_ "SH [.BN,_X0;2?^?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>form10-k_017.jpg
<TEXT>
begin 644 form10-k_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $L 2P# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'3K2WMHY+B>6=UB#32R2%G;H* "BBB@ HHHH **8S[>V<].<=P#_ #  ZDD
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MN%E@DDL[F(7%I<)%=V5T)[*[@ANK::-=KQ]X"\'?%+P3XP^&_P 0_#VF>+_
M?Q \+Z[X+\:>%-:MUNM'\2>%O$VFW6CZ]HFIVYPTUEJ>F7MU9W**Z$Q2L597
M"L/YB?\ @BAX]\8_\$YOVP/VB_\ @@G\>?$6H:OH?PZFUK]HG_@G1X^\1%Q<
M_$K]F[QOJ6H^*/$_@:*[D%G:W/B#P9?W6HZU<V.F:?'$_B/3/C5]GV:%X;TC
MS #^J6BF1LS+EMH.YA\IR,*Q7W].G4=P#D!] !36=5^\0.^3T [DGH .I)[
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M$TZ'.3Y-EIEC;6T8))V1CFNJIJ$E5)ZE03GKD@=<$C]3]33J "BBB@ HHHH
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MSQY\/=8DA5'.J^#/%EMJFA3SO!"FH06MMJUHK6&HV<LOS%_P44_X++?L4_\
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MJ:YK^HV6C:/IMG"I>6ZO]4U*>VL;.WB0%Y9KBXCCC4$NRX./P]_:@_X.._\
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M>.? GA+P7IOC+PIHOCB[OX/"5SK?A[4[*]TF_LO[:20ZI:7>GVWVFYM;B*,
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M$/F/Y87<V;5%     !T P/H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>form10-k_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %? G # 2(  A$! Q$!_\0
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M%?&PE8E/!\H:6L/5?^"T?_"*_#7XL_&/XA_LV3^#_ _@C]F:_P#VIO ^E_\
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MG3X)Z7HOP6UC6?%UG\:3\:-1\!'XW+K0\/Q_&S0O#OPY\)2_!^W\S0'\-_\
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MUQ#X[OO&VFZ'<>&8O ^A#0&\2>(#XC_X2#2%1@H+?)D*%(8 ].^$/[-OPT^
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M,I\&_P#YFJX_^(Q^''_0YA]TST?^)%?I/?\ 1N(?+C#@Y??^\_+J?UQ^+O\
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MC_PRGP<_^9NC_AH[_@L-_P!):?BQ_P"&4^#G_P S='_$9/#C_H<T_P#P&?\
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MGZ?XAF^+NO7VK:%XF^$WQ/\ ''Q<\%R:#JA'FS);^(?B!XTBE7Q5_P )<_\
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M_P 2\X#_ **W%?\ A/'_ .3/XX_XJ=<2?]&>X0_\2G$__(']O/\ PLSX7_\
M11OA_P#^%?HW^-'_  LSX7_]%&^'_P#X5^C?XU_$%_:,_P#SUE_\";G_ .+H
M_M&?_GK+_P"!-S_\73_XEWP?_15XK_P1'_Y,K_BI_P 1_P#1IL+_ .)AB_\
MYF/[??\ A9GPO_Z*-\/_ /PK]&_QH_X69\+_ /HHWP__ /"OT;_&OX@O[1G_
M .>LO_@3<_\ Q=']HS_\]9?_  )N?_BZ/^)=\'_T5>*_\$1_^3#_ (J?\1_]
M&FPO_B88O_YF/[??^%F?"_\ Z*-\/_\ PK]&_P :/^%F?"__ **-\/\ _P *
M_1O\:_B"_M&?_GK+_P"!-S_\71_:,_\ SUE_\";G_P"+H_XEWP?_ $5>*_\
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M  (CKJ^I9K_T-UIM[L?T2)^MY5_T)ONXCQ*^[W?\SP__ (7UI_\ T3;XR_\
MANM7_P#B:;_POK1/^A"^+O\ X;+6?_C->Y[3_=_\CI_C3OG]/_(R5R.AF_\
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MHHH **** "BBB@ HHHH **** "BBB@ K_4;_ .#-K_E%OXV_[.?\?_\ J/\
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M/*&HK1Q]I44=N:;Y7:]]+J*UT=V2LNYIK%8SWI.^FK2^[5OT^_33Y?\ A_\
MLS>#M#L_@1JWQ/GA^./QI_9^T+Q+H_@_X\>,] T6R^(B:KXTTB31?'6N*/#T
M4&B:++XOT 1P7$*@1M"R(-LC$-]545Y<GQ6^'-W\2K[X.VGC3P[=_%+3/"6F
M?$+5? *:FDOBBP\$:OK+:#I'B^31]^]-#FUV)K47+D*LBA2X=HHY/#/0/4:*
M** "BBB@#SOXG2ZK%\/_ !<=#TO^V]8'A[539Z/]K^P?;6\H@C=SMX/WL#.2
MI.'KQK]DKPIKGPS_ &=OA[X,\57UW=7'A6QU72?[5U]RFJ7NEIKFNG06UI-I
M71F'ATZ#E6+*@"@@&10_MWQ!-DG@;Q>+^*UFL3X0\1F\&J[?[,*)I#DC5RW\
M#J,,<;MF\##;2/E7]B[PY%XC_9)^'^B>*M+TW4]&U.SU"\L[(:H=3TV_TM]<
M;6]$._/*DE&90 4$>YLA@  ?7<?BKP[+TUS1C]-87]=V*_S*/^#S*ZBO?^"E
MWP7N()()[>Y_8]\!-:W5K\QO ?B?\7!RPR, D 8.!\HXK_2(E^ /PEGV^?X/
MM+@#_0;5C>:L!9Z>)#JX1?WQ*GS1C:0V2R)OW;A7^;%_P>.:#I/AO_@I-\$-
M)T2Q@TZPM?V/O 04*!U_X6?\7/O9YZ9P ,D]Q0!^6GQWM/&7[-G[''[#/Q,^
M&OQ9^(]CJ'QO\(^/]0U_P_=W.F-X<T1]"UXJD>A*-$!42EPTA=YY%$8"L<L6
M_)SQ+XGU[QEXDU/Q)XIU.ZUG7-<O_MNJZG=,&EO9F*EI)#A=S,%4  !0 JX&
M,G]//VQOBG\./&W[$/\ P3G^'WACQ;IFN^+/AIX$^*EEX^\/69(U+PSJ6K^(
M$;1X]7<C&]H@[H3C( XR<5^4,6[>)"KD1LK/@\;21@_@.>*]A<5<6\19;+"\
M19YQ-GD85*CA'$592@DIU%17+*,U*,8<D8MZR2C.2<I-GU?&RP2SJE_9BM%\
M)\&J4M.9R7"E&-57OO%N22TY7)\NDFWFT445XY\H%%%% !1110 4444 %%%%
M !1110 4444 %?ZC?_!FU_RBW\;?]G/^/_\ U'_ U?Y<E?ZBW_!G3,(?^"57
MC^8^?_HW[3WQ.O,6YXS_ ,(9X!. #U; .T?W@#V.0#^N*BOAN]_;$A@DG_L[
MX%?&O6H+31O[:N[O3/#>E.+#3#P209 2.,8)_$5SUE^W"EW?_8)_V?\ XV:;
MC1XM9U<W>A#-@NM,IT<-\P!,H!4$!0F00I(^8 _06BO*/A=\09_B9X7A\1GP
MEXM\&#[2]G_9/C2P73=5*(%QJ84YW[LG & 3D?+FO5Z /(?'OQQ^%?PRD\,6
MWC[QWX<\)W'C+Q(/!OARWU:\5?[2\4L&_P").A7_ ):C@$-Y8Y!W!>*]5B/F
M#)XZ_I^?]:_-[Q_^S?X/T_\ : \4_M+_ !8^*4TN@Z/8>![WP%X2\/\ @/2C
MJW@G5O#P.@G6=8?2-!\6GQ^7E.(3/X7"^#D&4D\G$H_2&UF\Z,'N/Y?YZ_\
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MA7SQ\5OVD_AU\,=,N;[4M6M9Y]ICLT1VV:AJ:#:FEP@!&U25E)RD#%5&,-O
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M\Z?V0=&\#Z1\7?%]]H?B(0:A_P (+XZ/VJUO3J/]GD.#_;@(!Y4 LH.,D 9
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M3:T[]IGXNWGQ?N_B[J/P^U2?P9I>@P1>%? VB)JFHZUX=8ZSX*/CS6AKL/\
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M9''0GT'2O\VW_@\2L+W1O^"C/P0L-1U2YUG4+;]COP%:7EW= !C(GC?XB!F
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M%1=[Z\64H<7?^D\4I^?W'IYQF"S+,YXSO&DO_ (TXK_TA%>BBBO+/,"BBB@
MHHHH **** "BBB@ HHHH **** "O]03_ (-!YOLW_!)/XJW'_/I^T+\7;P?\
M \'^&?Z1Y_6O\ONO]/S_ (-!=.EUG_@DM\3=+@G\B;4_VA?BAIRN!G!E\(>&
MHD';[Q?+'/ !],5O2VWM[T=?^WH@;G_!(3X\77Q+_;6\1>$KKPII^FK'\._B
M5>F[NKW^T.?[=1UY_NDX#CJ5)7'-?N_H>M^-HO&'@:(_$?\ 9_LS)=8U"STF
M#21JGBK2QXP&@#1O#H?P^?$,9 (\,;XMJ&7+N2P9A^*7_!)[_@A;^T9^P/\
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MP]I6D)H>K^%?$2V/B*$WNN:H]Z3HV@-H>K_VQK86617T%+8"W20_\(MS RH
MID /=_'?@KPOX7\7?!BXT/2;>WNM5^-(O;RZVM>,6/@CQ\3@DEDR2 #G*$')
M8J2/J6O"OBW_ ,C/\!_^RPI_Z@_CVO=: &J%YQS_ #_I3J\E\7?%[PKX4'D"
MX.I:AGBUM.6Z=R>/PYYS@U\@?%/]H*9=+GU7Q%K=KX2\+J-HM?M@_P!.!P,
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MWB#0#KOB#PW;>&M>E7Q"L\4?_"*SW"B)?/E+;I8Q]OT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<CK/B'PYX=FTFWUG5M.TYM>U9=&
MT=;H@?;M1<,%TE"5(+,5.T$@94[@,9/75QWBCPAI'C"T@L]:BFN;.UU73-;2
M"WN-N-2TAV:$'[I*9 5E# LRY.#0!XS\1?$>AZYXK^#<&DZWIM_/H/QM&CZQ
M!:78+V>J?\(-XZ']E2*%'[P%2I!&<(.@.!J?M%:QJV@_";Q;JFB7&GP:O:V0
M:Q.J:J^D:.-18_*-;UUG<:-H?!,LW!Y50%R0>>^(/@K0]#\=?"#5[& G5M>^
M-9O+V[NPU^Q(^&7C\-PVTKC VDD'DG('-<-^U[\+;_XG>&O *7/B]M,\(^$_
M';:SX[^'\GAG2O$>G?%G37T77-(T70=7>55.BV\?B">#Q$LL64\R&2.79)'L
M&N'^K<T/K;BH7]^ZU:[+_@?/0Y\3L]^O_MQ\&>%?BIXX^)'AWP__ ,(/H?AN
MYUBZL_\ BI/B%]L_M+X06&J<_P!N_P#"#_\ ,S_$#\*]7^'WP-GU'7;?5I_[
M2^(_Q Y_XJSQ#_S .I_XD>A_\BQX?'7I_/%?1OPI_9SM=.T32-,BTNV\ ^"-
M+LC9Z+X;T>S_ +.DM-+ +%408;0G('"KD_A7V+H_A[1_#%@+#1;6"TM^3A0<
M'V.!DX^H'<\@U[.*XEE]3>!R*+R+)K:03BFU?N]$O7?LS!85R:6,U?W_ 'V/
M&O#7P!\+16+CQO::?XQN+E>=.U2S34?#:'&0R:',C0DC'.X%1WY%=AX#^+GP
MV^)&O?$KPKX&\6:7XDU;X.>,?^%??$;2; X?PCXK_L&WU\:+K(9<!O["UG2I
M%7YARC$Y+ >N5DP:99V4DTUE!!:RW5P+R]:VME#7C 8^<CN?E.X$X/..2:\$
M[S6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKF/$F@V
MOBC0M4\/7L]U;VVJV1L[JZL;DV.H#<.J.J?+D$<DX()4#!! !O\ [K_.VO\
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M3%O#8->[&,7O>[E"&GGJVMWMJ0T445R'E!1110 4444 %%%% !1110 4444
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M_C#0M#\:D$^'=?\ $_AE==\/6WB0J/LO]MEQ\Z,X^KZ* /S5^"/PK_:E\,>
M_P!FVV\6^*_ H\<>!O _BNV\2V7C^[UOQIXELM5\0,%T?2-9UW0_$T<?CP^%
M?#_]C>&V\3HZ-(V^Y =IB[_6GV']I'_H8O@O_P"$GXU_^:>OD3XN_L@?$OX@
M?MY_ O\ :?T+Q3X7M? _PZT?3+35H+V?6O\ A.M#_L1/B =;T7P2L07P[_PC
MOQ33QKH4/C?S?+E;_A'$7+.R,WZ50_ZD?0_RH \+EB_:*B3SI_%/P4MH0.I\
M&>- /^^F^(^T_0&L&6[_ &AEO8/(\3? *:P.E-K-W<MH_C!7M;#!/F+_ ,5/
MM?0FVY$NX/\ *6+!02-W]I+P7XJ^(WP(^*7@CP1HOPY\2>+_ !/X-U/2/#OA
M_P",2ZY_PK+4M3=3Y:>-AX=1O$+Z ?F:46IWEQ%D$28/X+>$O^"/W[0FC:7X
MNM(_&?P@MQKWPMT_1CILGB'QMJ&D^,+R+5_A\->^#WC%H_"WA9-!^#+W'@O6
M?$,$?AOPC:OX43QU=>$+7P//;VX:4 _>J*+]HJ5/.@\4_!2YA(ZCP9XT(_[Z
M7XC[1]":L?9?VBO^AH^"G_A%^-O_ )XM<Y^RK\+O$7P1^ 'PK^$GBS6;+Q!K
M_@7PCI^A:SJ.F&_.E+);.P32M#.LO),=!\/6[1:# A8R+;PQ%X[2</&8/VJ/
MA-X^^.7P$^)_PG^'OQ(C^$?B7Q_X<O/"]OX_&A#Q++I>G:K)"NKJENFO^&&D
M7Q!H^_P_O-Q_HIE9T+[(W !,=0_:&%[,Y\2_L_?V1;Z7]KN]3&C>,6<'<5W/
MM\3F-8P 7)+[<$=68+6?X]^''Q8^*G@[7_ /C^X^ GBWP3XPTG4=%\2^'=4\
M!>,Y-.US2Y, (X'Q'<[&X+=0O#[AA2/P?L/^"57QP^$_@76-.^)WQK_9]O[O
MQ/X=^$'PQTFX\1WOQ%\.^&OC-XDCU[P)'X>^#OCL:W-XRQX:\.+X$_X1OP N
M?&4K)XA DBBDCF2+]H?V<_BA\)OAAI_PN_8OUOXX>#?&G[0_PN^'?A/POXB\
M,/J:/XGO[W0O!$%V\WD.RS(3X?C&O1H8FN(O"JI*;=H07H H:=^RQ8>%?".C
M>#K/X9?L:Z9X/\,:4+&QTFZ^"3:EIFGZ8O0$ZWXD.(\@DM(VPYPS;=H'/3_L
MK>'/MT[3_ 7_ ()__P!DVMILNM3NOV?]&W66I[@IT@CS=NT [\N0^T[=OF$(
M?,?^"AGB/X2?M$_ _7O@#X=_:2^$G@OQS>?&7X?^#+O0/$7C[2M*T_7?%>@:
MQX?\=ZY\&/'.JZ)!XNE\.GQ?X:!\SS_#4TL91%*99G'YJ_"7_@F#\:-7^#WQ
MX^%]G\?/V<OBQXQTSXC^ O#'CFTTG5_%[^!_&'COP-K_ (^\;Z]HWQNT&+P]
M)+X?U_PAX<^*OA[PWX,\-,GB^-(_ _A1F?P61*(@#]H;/]DNQLR9++X,?L,V
M^<\VO[-ZK]<%/$2C\@.OY]39_!SQ7X;A-Q8^&/V1=#@Q_P ?-I\']6TT^^"/
M$^W/_ C]*T+'XN_"#]FKP+\)_A=\7_CEX,TWQ5IGPKU46NJ^*_$-MI^J>,-)
M^ W@[0C\6/&CEYE5O^$:B#>(?%Y!S"+AFF"Y<)\V_M[_ +/_ (@_X*!_LP_#
MS2/@1X^\$-I&K>-? 'Q;T3Q;J6KZR/#6O^%Y- UK^PM<TC7- \,^*UC'F:YH
M_B.,'PK=!A"H^T^#Y77Q5" ?4]K'\?;"]-K9:S^S[IVCP V)NK'P[XR1AXE+
M;?[)724\4(JX!WX242A.57<"!U/V3]H__H9_@K_X17C7_P">+7X.R?\ !'O]
MI*X\#Z[X=F^)_P (+K6M5^(VF:TURM[\1=/TW6I%T;Q[X?/Q\U_;H#*?C3X1
MD\<:)XC\%>&(V>%)/A]X;#^/552:_I#LK0VEK;0SS&ZN+>T6T-R^T-=\#J,D
MYRO3L23TH \:FC_:$B_UWBGX&6W_ %]^#?&@_G\2!_/GJ:U_ MQXTCEU5_B)
M+\.I<VPU;0-1\&KK%E]KTPJW]L2:VNN-(NY93$Q9)#&(V9I=K+NC^%_VZ?V(
M?%?[3OBO0/'7@#Q/I/ASQ'I7P0^,7PGU:W\6^(O&3>&_$&F^.];\#Z]I&@-H
M'AYV\/#0_$Q\/ZYX7\=>)3!%XP3P9XC2& RL&2/\]?%7_!'G]I'6/^$&G@^(
MOP?N?^$8\">%K'5])U;5?&;:9J(T/6];US7?V90%\-,R_LZ>*W\0!7,@4I_P
MCWAMF\#!$+4 ?TH0^5Y8\G'E\XQG'Z\_G4M?-7[*OPM\2?!#]GGX.?"3Q7X@
MA\4>)_A[X(T_PQK>JV:Z@VFMJ5LB1JNCOJ\S7!T7P_"RZ': %W6TAB$D=O()
M(#]*T %%%% !1110 4444 %%%% !1110 4444 %%%% !7.^)O#>A>+]!U7PO
MXCTRUUG0]<LGL-6TN[R8KZPD^\DBJ59AN"D9*_,!\P( KHJ* /G'3?V9/@5H
MVG-HVE?#;1-.T9MSKHUJ=3&F*RB5O[6_LH'8-;_XFDJL[QM( Q;S04PK-!_9
M<_9[\+:]H_BK0OA;X<TWQ!H!VZ1K*?VF-2L&WG5BJ;I&PRO\^&#$8V'+CRZ^
MD:* /%_%WP'^$_C;58-=\4_#[PYK6K6S%FNI=.3=>*5^4:SMV'6P#\V;A)7/
M*D#BO/?#'[(?P*\*Z8NE6_A276!]M\3WS7?B#5M6U/51_P )P]N=<0NTP4"4
M:-HJCY-V-'A(*,F9/JJB@#PN^^ _P@U/0=!\.W7@'0_[.\,6 T?PNXC>RU+P
M_IY?^UQ'HVMH1XBT3;+DR)'<Q2J1M(VDN<VX_9P^#UYJ#:O?^ =+U#5AJ^GZ
MZ-5U6;5-1U 7VA%3H2EGN'8Z/#M(_P"$>W+:8DP]N[#*_0U% 'CE]\&/A7K.
MHZOJ6M> _#FM7^NWOVZ\NM5LO[1=[\(@+IYJR_V0B'2XB7A _>8CWE\Q/VGA
M;PSHGA#2+;0/#EFFGZ5;RZG>6MEC B_MO69M<U<C.<JUSJ;,H))5F*\XR>OH
MH **** "BBB@ HHHH **** "BBB@ HHHH X_PMX8L?#%A<V5G<7]S!=ZKJ&L
M,^I79OY"^KR,[+O8Y,08G8G8,_S'<2.PHHH *Y/Q1J\OA[PWK^NV]E<ZQ-H6
MCZIK-KH]FR_;=0;2M+>0:8F3S+/+\HRQ.^11ANC=910!^9?AG]ICPI\+M:OM
M+O\ X2?'.V\8^);SPS9>(M*O;#^U--T[571M;##7"P_AU]@P((8<<'FO7M._
M;$T37K;Q=-HOPM^+]ROAKP]_PD]G<7GAG^S3XCTK_A+3H!31"SMO;<I?<1GR
MUVE25,E?9OE'_GL?T_QJ;8/4_I_A0!\(7?[='A73;^?1-0^$OQLMM:M.;W2D
M\'O?ZC8^Y3>V<X_B+'K5Z?\ ;5T+3M4U'0[[X2?&'^V-"O?L>KK:>&6U+2K
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P $Y+'X>>'I=!N_VT_^"@_Q.BE^+'P:^*T.H?$K]IB7Q%J^GWOPBUJ;5?\
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MWJNO:QH?AB?PQ\(L^(?'6F>&9)_BG+9^#H_&$D-NGC:8&62/TGXM_P#!5?\
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MG7/$7Q8L?ASXS\1_"_3=4U_7M EE\:C5?#_B0PG0?A;\/&F_X3OP\?%AN?\
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MIVZ*VT.0<X!8YP1][CV>K>N_]?YG%7_V;;H[?.]K>O?T/3?/'_/0_P#?(_\
MB*Y_7IA_8NLCC_D$ZI_Z:3[\>G3&?:L/_A5W@7_H7+;_ ,"M5_\ C]-/PN\!
M21^4?"]CM_NDZ@![?,74G'O3T\OQ_5&'^U_US$W@&>)O!GA%6D.T^&O#^".I
M_P")3"%Z$=LY^@Z\5V?G)$..3]. >W0G^O<UPT'PL^'\,,$$/AK2A#;_ .K'
ME$!?KB0[O?)_#%)_PK#P)W\/6X_'4?\ XX*=T^J2TNDW9M)+MY'-AXYGA\,L
M,U!N*LG=Z:*^K7>S_([_ ,P>A_S^-6Z\A\%Z79:)XH\;:;ID"VUA;_\ ","U
MM4^Z-NCD'!)SU'?WQVKUIR<+[\G]/\:EIK?O;[COP^(5=/1*UT[;::/R)***
M*1TA1110 4444 %%%% !1110 4444 %%%% 'P=_P4JN?#]C^PI^T]?>*M%N_
M$GA^V^%6KM?^'[?6]:\.MJ( 5=@UGPZ!XAAPS(S&/[_E_=)9F7C/V$M&\6_\
M,.>&],M?$GB7_A,+C2/'RZ3KUYI&K:7XDL=2;6]=_L-FT7XA(\FY ,HOBAE5
MV(63 (>/W+]MG7M6\*?LH?'SQ'H?PT\!_&+5=$^&WB.\L_AC\6;S1]/^&7C!
MDB9QHWC:3Q"5T >'V5%\UKK?N50@ +,6\D_X)L?$?1/BE^R7\.O'6A?"OX9?
M!7P_KMSXE;2/A]\(X?!FF^"M,7^VW.!I'@#Q)XN\+Z)KC&$A[:/Q5/.KR*^
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M(?#&ZM6.F7.J:5X4DTNS^&[Z1H,DFK#+7$R>/?\ A*&($!,D=O; 1;?L\04
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M.DW \%Z2#J-E_;*@;X-8UTRLK)&>-D*,QV@G!#5WW]E:Y_PE7]L_VG:?V/\
MV/\ 8_[)^P#^T/,W;]_]L[L[?,YVYW9[_P 5=7*/,&!QT_3\_P"M 'Q1^R=^
MS9I?P4B\77UUJVF>)M=U35O['M+VRTA=/6QTOP1_Q((]Z[6_XG;8<NX*D +M
M)7S-GTU-?./B!:@6.I"'_A&]3M/[2.DE=.!.K:&VW^V-V"2H8^61M!!<#*YK
M:T'1K#0HKF*SFU"Z^U79N[MKN\.H,-08*7!)Y4DJ"=I'W5R00,=)YL/K^I_Q
MH F_@_X#_2N1\-:+=Z/%JZ7VIP7_ /:>L:AK"FWM18&T757+A<^8[$CYOF;Y
M\G<2Q'/6[QZ']/\ &C>/0_I_C0 ;!ZG]/\*?3-X]#^G^-&\>A_3_ !H ?111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\>>"=&UC6="\0^%K;_A7WB'QCX^UW6O"8DVJ?&$^A^' (W6%'G^SS^Q[^RB
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MASX?U/P+K?B;P+H^KZ4B>&!!X</Q2U[6M5\,CQ7%<2Q^-I=#\/H-L<$4UQ>
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MU3P%X2L]5U4:C8:!H^N-HO\ ;7DF8G7/M'B&70[5WD::1"R2L(HV,*'ZHHH
MQ=6TZPUG3;_2=7MX[G3]1M+^SO;.?!%W8N&20=>FUAC(. ^<=#7R9X3_ &)_
MV?O 7B+1O$/@SPMK7A(Z'XNC\9KI.E>(M8B\.W^K:*)5T!-:T5\P3:-X3,1;
MP;"FQ8.I\Q2F[[-HH CDC$@P?\^Q[XKX[U3]BK]G^\NO'LNE>%-1\+M\4M0%
MW\2G\.ZJR1^+2=8USQ#NUM=9%X8%.O:_K4H3P\T39D7Y@&VI]D44 5H(888A
M#"N(0#WZ9Z\]Q@ ?UJS110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !3-@]3^G^%/HH *9L'J?T_P
MI]% #/+3^Z*/+3^Z*?10 4SRT_NBGT4 ,V#U/Z?X4;!ZG]/\*?10 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %,V#U/Z?X4^B@!FP>I_3_"GT44 %%%% !1110 4444 %%%% !1110 4444
G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>25
<FILENAME>ltrn-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaaFybP9z5Z8iekhvWB0bYkK3yYtdnXUHCEbs9N2QdAM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:LTRN="http://lanternpharma.com/20221231" elementFormDefault="qualified" targetNamespace="http://lanternpharma.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://lanternpharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
	  <link:definition>00000005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit" id="StatementsOfStockholdersEquityDeficit">
	  <link:definition>00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/OrganizationPrincipalActivitiesAndBasisOfPresentation" id="OrganizationPrincipalActivitiesAndBasisOfPresentation">
	  <link:definition>00000008 - Disclosure - Organization, Principal Activities, and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/Liquidity" id="Liquidity">
	  <link:definition>00000009 - Disclosure - Liquidity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000011 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/Leases" id="Leases">
	  <link:definition>00000012 - Disclosure - Leases</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ShareholdersEquity" id="ShareholdersEquity">
	  <link:definition>00000013 - Disclosure - Shareholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/MarketableSecurities" id="MarketableSecurities">
	  <link:definition>00000014 - Disclosure - Marketable Securities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/FairValueMeasurements" id="FairValueMeasurements">
	  <link:definition>00000015 - Disclosure - Fair Value Measurements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/NotesAndLoanPayable" id="NotesAndLoanPayable">
	  <link:definition>00000016 - Disclosure - Notes and Loan Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/LossPerShareOfCommonShares" id="LossPerShareOfCommonShares">
	  <link:definition>00000017 - Disclosure - Loss Per Share of Common Shares</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000018 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000019 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000021 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000022 - Disclosure - Leases (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ShareholdersEquityTables" id="ShareholdersEquityTables">
	  <link:definition>00000023 - Disclosure - Shareholders&#8217; Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/MarketableSecuritiesTables" id="MarketableSecuritiesTables">
	  <link:definition>00000024 - Disclosure - Marketable Securities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
	  <link:definition>00000025 - Disclosure - Fair Value Measurements (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/LossPerShareOfCommonSharesTables" id="LossPerShareOfCommonSharesTables">
	  <link:definition>00000026 - Disclosure - Loss Per Share of Common Shares (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000027 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/LiquidityDetailsNarrative" id="LiquidityDetailsNarrative">
	  <link:definition>00000028 - Disclosure - Liquidity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetails" id="ScheduleOfResearchAndDevelopmentDetails">
	  <link:definition>00000030 - Disclosure - Schedule of Research and Development (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical" id="ScheduleOfResearchAndDevelopmentDetailsParenthetical">
	  <link:definition>00000031 - Disclosure - Schedule of Research and Development (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" id="ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails">
	  <link:definition>00000032 - Disclosure - Schedule of Accounts Payable and Accrued Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000033 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" id="ScheduleOfBalanceSheetInformationRelatedToLeasesDetails">
	  <link:definition>00000034 - Disclosure - Schedule of Balance Sheet Information Related to Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails" id="ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails">
	  <link:definition>00000035 - Disclosure - Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails" id="ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails">
	  <link:definition>00000036 - Disclosure - Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails" id="ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails">
	  <link:definition>00000037 - Disclosure - Schedule of Other Supplemental Information Related to Operating Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000038 - Disclosure - Leases (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
	  <link:definition>00000039 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails" id="ScheduleOfWeightedAverageAssumptionsDetails">
	  <link:definition>00000040 - Disclosure - Schedule of Weighted Average Assumptions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative" id="ShareholdersEquityDetailsNarrative">
	  <link:definition>00000041 - Disclosure - Shareholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails" id="ScheduleOfMarketableSecuritiesDetails">
	  <link:definition>00000042 - Disclosure - Schedule of Marketable Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails" id="ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails">
	  <link:definition>00000043 - Disclosure - Schedule of Contractual Maturities Investments of Marketable Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails" id="ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails">
	  <link:definition>00000044 - Disclosure - Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails" id="ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails">
	  <link:definition>00000045 - Disclosure - Schedule of Assets are Measured at Fair Value on Recurring Basis (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/NotesAndLoanPayableDetailsNarrative" id="NotesAndLoanPayableDetailsNarrative">
	  <link:definition>00000046 - Disclosure - Notes and Loan Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails" id="ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails">
	  <link:definition>00000047 - Disclosure - Schedule of Anti-dilutive Securities Outstanding Diluted Loss per Share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" id="ScheduleOfEffectiveIncomeTaxRateDetails">
	  <link:definition>00000048 - Disclosure - Schedule of Effective Income Tax Rate (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
	  <link:definition>00000049 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lanternpharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000050 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="ltrn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ltrn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ltrn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ltrn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="LTRN_UnderwritersAgreementMember" name="UnderwritersAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_LicenseStrategicAllianceAndResearchAgreementsMember" name="LicenseStrategicAllianceAndResearchAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_BioNumerikPharmaceuticalsMember" name="BioNumerikPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_AssignmentAgreementMember" name="AssignmentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_AFCLicenseAgreementMember" name="AFCLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_AFChemicalsMember" name="AFChemicalsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_AllarityTherapeutiesMember" name="AllarityTherapeutiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_AssetPurchaseAgreementMember" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_CalifiaPharmaMember" name="CalifiaPharmaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_EvaluationAgreementMember" name="EvaluationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_PatheonAPIServicesMember" name="PatheonAPIServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_PatheonAgreementMember" name="PatheonAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_SouthwestResearchInstituteMember" name="SouthwestResearchInstituteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_SouthwestResearchInstituteAgreementMember" name="SouthwestResearchInstituteAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_FoxChaseCancerCenterMember" name="FoxChaseCancerCenterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_FoxChaseCancerCenterAgreementMember" name="FoxChaseCancerCenterAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_PiramalPharmaSolutionMember" name="PiramalPharmaSolutionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_PiramalPharmaAgreementMember" name="PiramalPharmaAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_VivoPharmMember" name="VivoPharmMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_VivoPharmAgreementMember" name="VivoPharmAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_TranslationalDrugMember" name="TranslationalDrugMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_TranslationalDrugAgreementMember" name="TranslationalDrugAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_BerkshireSteruleManufacturingMember" name="BerkshireSteruleManufacturingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_BerkshireSteruleManufacturingAgreementMember" name="BerkshireSteruleManufacturingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_ShilpaMember" name="ShilpaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_ShilpaAgreementMember" name="ShilpaAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_CuriaMember" name="CuriaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_LumaBridgeLLCMember" name="LumaBridgeLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_LumaBridgeAgreementMember" name="LumaBridgeAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_LanternPharmaLimitedMember" name="LanternPharmaLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_ActuateTherapeuticsMember" name="ActuateTherapeuticsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_CollaborationAgreementMember" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_UnderwritersMember" name="UnderwritersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_CashlessWarrantsMember" name="CashlessWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_TwoThousandEighteenEquityIncentivePlanMember" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_GovernmentAgencySecuritiesMember" name="GovernmentAgencySecuritiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_CorporateBondsMember" name="CorporateBondsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_MarketableSecuritiesDebtMember" name="MarketableSecuritiesDebtMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_MutualFundsFixedIncomeMember" name="MutualFundsFixedIncomeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_MutualFundsAlternativeInvestmentsMember" name="MutualFundsAlternativeInvestmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_MarketableSecuritiesMutualFundsMember" name="MarketableSecuritiesMutualFundsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_NAVMember" name="NAVMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" name="StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises" name="StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_NoncashLeaseAdjustments" name="NoncashLeaseAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_GainOnLoanForgiveness" name="GainOnLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_ProceedsFromStockOptionAndWarrantExercises" name="ProceedsFromStockOptionAndWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds" name="ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock" name="LoanPursuantToPaycheckProtectionProgramPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock" name="RecentlyAdoptedAccountingPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock" name="ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" name="ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock" name="ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_ProceedsFromIssuanceInitialPublicOfferingGross" name="ProceedsFromIssuanceInitialPublicOfferingGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions" name="UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_IntellectualPropertyRelatedLicensingAndOtherFees" name="IntellectualPropertyRelatedLicensingAndOtherFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_ResearchAndDevelopmentIncomeExpense" name="ResearchAndDevelopmentIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_DecreaseInResearchAndDevelopmentExpense" name="DecreaseInResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_UpfrontPayments" name="UpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_RevenuePercentage" name="RevenuePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_LicenseAgreementDescription" name="LicenseAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_FuturePayments" name="FuturePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_ResearchAndDevelopmentExpensesPercentage" name="ResearchAndDevelopmentExpensesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_NominalValueOfRestrictedSharesOfActuateStock" name="NominalValueOfRestrictedSharesOfActuateStock" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_OperatingLeaseRightOfUseAssetAdditions" name="OperatingLeaseRightOfUseAssetAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_OperatingLeaseLiabilityInAdditions" name="OperatingLeaseLiabilityInAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_OperatingLeaseLiabilityAmortization" name="OperatingLeaseLiabilityAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_LeaseExpirationDate" name="LeaseExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_GrossProceedsFromInitialPublicOffering" name="GrossProceedsFromInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions" name="ProceedsAfterDeductingUnderwritingDiscountsAndCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_OtherOfferingExpenses" name="OtherOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise" name="StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" name="DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" name="DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization" name="DeferredTaxAssetsResearchAndDevelopmentAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LTRN_NOLCarryforwardsDescription" name="NOLCarryforwardsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>26
<FILENAME>ltrn-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lanternpharma.com/role/Cover" xlink:href="ltrn-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/BalanceSheets" xlink:href="ltrn-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/BalanceSheetsParenthetical" xlink:href="ltrn-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/StatementsOfOperations" xlink:href="ltrn-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/StatementsOfComprehensiveLoss" xlink:href="ltrn-20221231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="ltrn-20221231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/StatementsOfCashFlows" xlink:href="ltrn-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/OrganizationPrincipalActivitiesAndBasisOfPresentation" xlink:href="ltrn-20221231.xsd#OrganizationPrincipalActivitiesAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/Liquidity" xlink:href="ltrn-20221231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ltrn-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/CommitmentsAndContingencies" xlink:href="ltrn-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/Leases" xlink:href="ltrn-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ShareholdersEquity" xlink:href="ltrn-20221231.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/MarketableSecurities" xlink:href="ltrn-20221231.xsd#MarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/FairValueMeasurements" xlink:href="ltrn-20221231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/NotesAndLoanPayable" xlink:href="ltrn-20221231.xsd#NotesAndLoanPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LossPerShareOfCommonShares" xlink:href="ltrn-20221231.xsd#LossPerShareOfCommonShares" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/IncomeTaxes" xlink:href="ltrn-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/SubsequentEvents" xlink:href="ltrn-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ltrn-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/CommitmentsAndContingenciesTables" xlink:href="ltrn-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LeasesTables" xlink:href="ltrn-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ShareholdersEquityTables" xlink:href="ltrn-20221231.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/MarketableSecuritiesTables" xlink:href="ltrn-20221231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/FairValueMeasurementsTables" xlink:href="ltrn-20221231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LossPerShareOfCommonSharesTables" xlink:href="ltrn-20221231.xsd#LossPerShareOfCommonSharesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/IncomeTaxesTables" xlink:href="ltrn-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LiquidityDetailsNarrative" xlink:href="ltrn-20221231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ltrn-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfResearchAndDevelopmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical" xlink:href="ltrn-20221231.xsd#ScheduleOfResearchAndDevelopmentDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ltrn-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LeasesDetailsNarrative" xlink:href="ltrn-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfWeightedAverageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative" xlink:href="ltrn-20221231.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/NotesAndLoanPayableDetailsNarrative" xlink:href="ltrn-20221231.xsd#NotesAndLoanPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="ltrn-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="loc_us-gaapInvestmentIncomeAmortizationOfPremium" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInvestmentIncomeAmortizationOfPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_NoncashLeaseAdjustments" xlink:label="loc_LTRNNoncashLeaseAdjustments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LTRNNoncashLeaseAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_GainOnLoanForgiveness" xlink:label="loc_LTRNGainOnLoanForgiveness" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_LTRNGainOnLoanForgiveness" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGainLoss" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ProceedsFromStockOptionAndWarrantExercises" xlink:label="loc_LTRNProceedsFromStockOptionAndWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_LTRNProceedsFromStockOptionAndWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/OrganizationPrincipalActivitiesAndBasisOfPresentation" xlink:title="00000008 - Disclosure - Organization, Principal Activities, and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/Liquidity" xlink:title="00000009 - Disclosure - Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/Leases" xlink:title="00000012 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ShareholdersEquity" xlink:title="00000013 - Disclosure - Shareholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/MarketableSecurities" xlink:title="00000014 - Disclosure - Marketable Securities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/FairValueMeasurements" xlink:title="00000015 - Disclosure - Fair Value Measurements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/NotesAndLoanPayable" xlink:title="00000016 - Disclosure - Notes and Loan Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LossPerShareOfCommonShares" xlink:title="00000017 - Disclosure - Loss Per Share of Common Shares" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/IncomeTaxes" xlink:title="00000018 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LeasesTables" xlink:title="00000022 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ShareholdersEquityTables" xlink:title="00000023 - Disclosure - Shareholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/MarketableSecuritiesTables" xlink:title="00000024 - Disclosure - Marketable Securities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/FairValueMeasurementsTables" xlink:title="00000025 - Disclosure - Fair Value Measurements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LossPerShareOfCommonSharesTables" xlink:title="00000026 - Disclosure - Loss Per Share of Common Shares (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/IncomeTaxesTables" xlink:title="00000027 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LiquidityDetailsNarrative" xlink:title="00000028 - Disclosure - Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetails" xlink:title="00000030 - Disclosure - Schedule of Research and Development (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical" xlink:title="00000031 - Disclosure - Schedule of Research and Development (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xlink:title="00000032 - Disclosure - Schedule of Accounts Payable and Accrued Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000033 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:title="00000034 - Disclosure - Schedule of Balance Sheet Information Related to Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:title="00000035 - Disclosure - Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails" xlink:title="00000036 - Disclosure - Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails" xlink:title="00000037 - Disclosure - Schedule of Other Supplemental Information Related to Operating Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LeasesDetailsNarrative" xlink:title="00000038 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000039 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails" xlink:title="00000040 - Disclosure - Schedule of Weighted Average Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000041 - Disclosure - Shareholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails" xlink:title="00000042 - Disclosure - Schedule of Marketable Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails" xlink:title="00000043 - Disclosure - Schedule of Contractual Maturities Investments of Marketable Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue" xlink:label="loc_LTRNAvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="loc_LTRNAvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails" xlink:title="00000044 - Disclosure - Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000045 - Disclosure - Schedule of Assets are Measured at Fair Value on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/NotesAndLoanPayableDetailsNarrative" xlink:title="00000046 - Disclosure - Notes and Loan Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails" xlink:title="00000047 - Disclosure - Schedule of Anti-dilutive Securities Outstanding Diluted Loss per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="00000048 - Disclosure - Schedule of Effective Income Tax Rate (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000049 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:label="loc_us-gaapDeferredTaxAssetsUnrealizedLossesOnTradingSecurities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization" xlink:label="loc_LTRNDeferredTaxAssetsResearchAndDevelopmentAmortization" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_LTRNDeferredTaxAssetsResearchAndDevelopmentAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000050 - Disclosure - Income Taxes (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>27
<FILENAME>ltrn-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lanternpharma.com/role/Cover" xlink:href="ltrn-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/BalanceSheets" xlink:href="ltrn-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/BalanceSheetsParenthetical" xlink:href="ltrn-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/StatementsOfOperations" xlink:href="ltrn-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/StatementsOfComprehensiveLoss" xlink:href="ltrn-20221231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="ltrn-20221231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/StatementsOfCashFlows" xlink:href="ltrn-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/OrganizationPrincipalActivitiesAndBasisOfPresentation" xlink:href="ltrn-20221231.xsd#OrganizationPrincipalActivitiesAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/Liquidity" xlink:href="ltrn-20221231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ltrn-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/CommitmentsAndContingencies" xlink:href="ltrn-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/Leases" xlink:href="ltrn-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ShareholdersEquity" xlink:href="ltrn-20221231.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/MarketableSecurities" xlink:href="ltrn-20221231.xsd#MarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/FairValueMeasurements" xlink:href="ltrn-20221231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/NotesAndLoanPayable" xlink:href="ltrn-20221231.xsd#NotesAndLoanPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LossPerShareOfCommonShares" xlink:href="ltrn-20221231.xsd#LossPerShareOfCommonShares" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/IncomeTaxes" xlink:href="ltrn-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/SubsequentEvents" xlink:href="ltrn-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ltrn-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/CommitmentsAndContingenciesTables" xlink:href="ltrn-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LeasesTables" xlink:href="ltrn-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ShareholdersEquityTables" xlink:href="ltrn-20221231.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/MarketableSecuritiesTables" xlink:href="ltrn-20221231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/FairValueMeasurementsTables" xlink:href="ltrn-20221231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LossPerShareOfCommonSharesTables" xlink:href="ltrn-20221231.xsd#LossPerShareOfCommonSharesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/IncomeTaxesTables" xlink:href="ltrn-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LiquidityDetailsNarrative" xlink:href="ltrn-20221231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ltrn-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfResearchAndDevelopmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical" xlink:href="ltrn-20221231.xsd#ScheduleOfResearchAndDevelopmentDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ltrn-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LeasesDetailsNarrative" xlink:href="ltrn-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfWeightedAverageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative" xlink:href="ltrn-20221231.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/NotesAndLoanPayableDetailsNarrative" xlink:href="ltrn-20221231.xsd#NotesAndLoanPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="ltrn-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" xlink:label="loc_LTRNStockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNStockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises" xlink:label="loc_LTRNStockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNStockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_70" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/OrganizationPrincipalActivitiesAndBasisOfPresentation" xlink:title="00000008 - Disclosure - Organization, Principal Activities, and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/Liquidity" xlink:title="00000009 - Disclosure - Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/Leases" xlink:title="00000012 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ShareholdersEquity" xlink:title="00000013 - Disclosure - Shareholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/MarketableSecurities" xlink:title="00000014 - Disclosure - Marketable Securities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/FairValueMeasurements" xlink:title="00000015 - Disclosure - Fair Value Measurements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/NotesAndLoanPayable" xlink:title="00000016 - Disclosure - Notes and Loan Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LossPerShareOfCommonShares" xlink:title="00000017 - Disclosure - Loss Per Share of Common Shares" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/IncomeTaxes" xlink:title="00000018 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LeasesTables" xlink:title="00000022 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ShareholdersEquityTables" xlink:title="00000023 - Disclosure - Shareholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/MarketableSecuritiesTables" xlink:title="00000024 - Disclosure - Marketable Securities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/FairValueMeasurementsTables" xlink:title="00000025 - Disclosure - Fair Value Measurements (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LossPerShareOfCommonSharesTables" xlink:title="00000026 - Disclosure - Loss Per Share of Common Shares (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/IncomeTaxesTables" xlink:title="00000027 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LiquidityDetailsNarrative" xlink:title="00000028 - Disclosure - Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_UnderwritersAgreementMember" xlink:label="loc_LTRNUnderwritersAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNUnderwritersAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_WorkingCapital" xlink:label="loc_LTRNWorkingCapital_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LTRNWorkingCapital_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="loc_LTRNProceedsFromIssuanceInitialPublicOfferingGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LTRNProceedsFromIssuanceInitialPublicOfferingGross_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_60" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetails" xlink:title="00000030 - Disclosure - Schedule of Research and Development (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical" xlink:title="00000031 - Disclosure - Schedule of Research and Development (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LicenseStrategicAllianceAndResearchAgreementsMember" xlink:label="loc_LTRNLicenseStrategicAllianceAndResearchAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNLicenseStrategicAllianceAndResearchAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_DecreaseInResearchAndDevelopmentExpense" xlink:label="loc_LTRNDecreaseInResearchAndDevelopmentExpense_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LTRNDecreaseInResearchAndDevelopmentExpense_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xlink:title="00000032 - Disclosure - Schedule of Accounts Payable and Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LicenseStrategicAllianceAndResearchAgreementsMember" xlink:label="loc_LTRNLicenseStrategicAllianceAndResearchAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNLicenseStrategicAllianceAndResearchAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000033 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_BioNumerikPharmaceuticalsMember" xlink:label="loc_LTRNBioNumerikPharmaceuticalsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNBioNumerikPharmaceuticalsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AFChemicalsMember" xlink:label="loc_LTRNAFChemicalsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNAFChemicalsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AllarityTherapeutiesMember" xlink:label="loc_LTRNAllarityTherapeutiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNAllarityTherapeutiesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CalifiaPharmaMember" xlink:label="loc_LTRNCalifiaPharmaMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNCalifiaPharmaMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PatheonAPIServicesMember" xlink:label="loc_LTRNPatheonAPIServicesMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNPatheonAPIServicesMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_SouthwestResearchInstituteMember" xlink:label="loc_LTRNSouthwestResearchInstituteMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNSouthwestResearchInstituteMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_FoxChaseCancerCenterMember" xlink:label="loc_LTRNFoxChaseCancerCenterMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNFoxChaseCancerCenterMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PiramalPharmaSolutionMember" xlink:label="loc_LTRNPiramalPharmaSolutionMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNPiramalPharmaSolutionMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_VivoPharmMember" xlink:label="loc_LTRNVivoPharmMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNVivoPharmMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_TranslationalDrugMember" xlink:label="loc_LTRNTranslationalDrugMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNTranslationalDrugMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_BerkshireSteruleManufacturingMember" xlink:label="loc_LTRNBerkshireSteruleManufacturingMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNBerkshireSteruleManufacturingMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ShilpaMember" xlink:label="loc_LTRNShilpaMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNShilpaMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CuriaMember" xlink:label="loc_LTRNCuriaMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNCuriaMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LumaBridgeLLCMember" xlink:label="loc_LTRNLumaBridgeLLCMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNLumaBridgeLLCMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LanternPharmaLimitedMember" xlink:label="loc_LTRNLanternPharmaLimitedMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNLanternPharmaLimitedMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ActuateTherapeuticsMember" xlink:label="loc_LTRNActuateTherapeuticsMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNActuateTherapeuticsMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AssignmentAgreementMember" xlink:label="loc_LTRNAssignmentAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNAssignmentAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AFCLicenseAgreementMember" xlink:label="loc_LTRNAFCLicenseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNAFCLicenseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AssetPurchaseAgreementMember" xlink:label="loc_LTRNAssetPurchaseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNAssetPurchaseAgreementMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_EvaluationAgreementMember" xlink:label="loc_LTRNEvaluationAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNEvaluationAgreementMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PatheonAgreementMember" xlink:label="loc_LTRNPatheonAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNPatheonAgreementMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_SouthwestResearchInstituteAgreementMember" xlink:label="loc_LTRNSouthwestResearchInstituteAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNSouthwestResearchInstituteAgreementMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_FoxChaseCancerCenterAgreementMember" xlink:label="loc_LTRNFoxChaseCancerCenterAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNFoxChaseCancerCenterAgreementMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PiramalPharmaAgreementMember" xlink:label="loc_LTRNPiramalPharmaAgreementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNPiramalPharmaAgreementMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_VivoPharmAgreementMember" xlink:label="loc_LTRNVivoPharmAgreementMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNVivoPharmAgreementMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_TranslationalDrugAgreementMember" xlink:label="loc_LTRNTranslationalDrugAgreementMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNTranslationalDrugAgreementMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_BerkshireSteruleManufacturingAgreementMember" xlink:label="loc_LTRNBerkshireSteruleManufacturingAgreementMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNBerkshireSteruleManufacturingAgreementMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ShilpaAgreementMember" xlink:label="loc_LTRNShilpaAgreementMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNShilpaAgreementMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LumaBridgeAgreementMember" xlink:label="loc_LTRNLumaBridgeAgreementMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNLumaBridgeAgreementMember_270" xlink:type="arc" order="272" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CollaborationAgreementMember" xlink:label="loc_LTRNCollaborationAgreementMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNCollaborationAgreementMember_300" xlink:type="arc" order="302" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_UpfrontPayments" xlink:label="loc_LTRNUpfrontPayments_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNUpfrontPayments_330" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription_330" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_RevenuePercentage" xlink:label="loc_LTRNRevenuePercentage_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNRevenuePercentage_330" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LicenseAgreementDescription" xlink:label="loc_LTRNLicenseAgreementDescription_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNLicenseAgreementDescription_330" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_330" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDepositsRelatedToPropertySales" xlink:label="loc_us-gaapEscrowDepositsRelatedToPropertySales_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEscrowDepositsRelatedToPropertySales_330" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_FuturePayments" xlink:label="loc_LTRNFuturePayments_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNFuturePayments_330" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ResearchAndDevelopmentExpensesPercentage" xlink:label="loc_LTRNResearchAndDevelopmentExpensesPercentage_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNResearchAndDevelopmentExpensesPercentage_330" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_330" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_330" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_NominalValueOfRestrictedSharesOfActuateStock" xlink:label="loc_LTRNNominalValueOfRestrictedSharesOfActuateStock_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNNominalValueOfRestrictedSharesOfActuateStock_330" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:title="00000034 - Disclosure - Schedule of Balance Sheet Information Related to Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:title="00000035 - Disclosure - Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails" xlink:title="00000036 - Disclosure - Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails" xlink:title="00000037 - Disclosure - Schedule of Other Supplemental Information Related to Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LeasesDetailsNarrative" xlink:title="00000038 - Disclosure - Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000039 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails" xlink:title="00000040 - Disclosure - Schedule of Weighted Average Assumptions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000041 - Disclosure - Shareholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CashlessWarrantsMember" xlink:label="loc_LTRNCashlessWarrantsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LTRNCashlessWarrantsMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_UnderwritersMember" xlink:label="loc_LTRNUnderwritersMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LTRNUnderwritersMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_LTRNTwoThousandEighteenEquityIncentivePlanMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_LTRNTwoThousandEighteenEquityIncentivePlanMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_320" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_320" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_320" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_GrossProceedsFromInitialPublicOffering" xlink:label="loc_LTRNGrossProceedsFromInitialPublicOffering_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LTRNGrossProceedsFromInitialPublicOffering_320" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_320" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions" xlink:label="loc_LTRNProceedsAfterDeductingUnderwritingDiscountsAndCommissions_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LTRNProceedsAfterDeductingUnderwritingDiscountsAndCommissions_320" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_OtherOfferingExpenses" xlink:label="loc_LTRNOtherOfferingExpenses_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LTRNOtherOfferingExpenses_320" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_320" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_320" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_320" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_320" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_320" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise" xlink:label="loc_LTRNStockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LTRNStockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise_320" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_320" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_320" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_320" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_320" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_320" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_320" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_LTRNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LTRNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_320" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_320" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_320" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_320" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_320" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_320" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation_320" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_320" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod" xlink:label="loc_us-gaapInsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapInsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod_320" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_320" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_320" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_320" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_320" xlink:type="arc" order="34" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails" xlink:title="00000042 - Disclosure - Schedule of Marketable Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_GovernmentAgencySecuritiesMember" xlink:label="loc_LTRNGovernmentAgencySecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNGovernmentAgencySecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CorporateBondsMember" xlink:label="loc_LTRNCorporateBondsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNCorporateBondsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MarketableSecuritiesDebtMember" xlink:label="loc_LTRNMarketableSecuritiesDebtMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNMarketableSecuritiesDebtMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsFixedIncomeMember" xlink:label="loc_LTRNMutualFundsFixedIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNMutualFundsFixedIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsAlternativeInvestmentsMember" xlink:label="loc_LTRNMutualFundsAlternativeInvestmentsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNMutualFundsAlternativeInvestmentsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MarketableSecuritiesMutualFundsMember" xlink:label="loc_LTRNMarketableSecuritiesMutualFundsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNMarketableSecuritiesMutualFundsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities_150" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails" xlink:title="00000043 - Disclosure - Schedule of Contractual Maturities Investments of Marketable Securities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails" xlink:title="00000044 - Disclosure - Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_GovernmentAgencySecuritiesMember" xlink:label="loc_LTRNGovernmentAgencySecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNGovernmentAgencySecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CorporateBondsMember" xlink:label="loc_LTRNCorporateBondsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNCorporateBondsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsFixedIncomeMember" xlink:label="loc_LTRNMutualFundsFixedIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNMutualFundsFixedIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsAlternativeInvestmentsMember" xlink:label="loc_LTRNMutualFundsAlternativeInvestmentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNMutualFundsAlternativeInvestmentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_LTRNDebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_LTRNDebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_LTRNDebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_LTRNDebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000045 - Disclosure - Schedule of Assets are Measured at Fair Value on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_GovernmentAgencySecuritiesMember" xlink:label="loc_LTRNGovernmentAgencySecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_LTRNGovernmentAgencySecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaapCorporateBondSecuritiesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapCorporateBondSecuritiesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsFixedIncomeMember" xlink:label="loc_LTRNMutualFundsFixedIncomeMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_LTRNMutualFundsFixedIncomeMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsAlternativeInvestmentsMember" xlink:label="loc_LTRNMutualFundsAlternativeInvestmentsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_LTRNMutualFundsAlternativeInvestmentsMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:label="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:label="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:to="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:label="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:to="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_NAVMember" xlink:label="loc_LTRNNAVMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:to="loc_LTRNNAVMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_510" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/NotesAndLoanPayableDetailsNarrative" xlink:title="00000046 - Disclosure - Notes and Loan Payable (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails" xlink:title="00000047 - Disclosure - Schedule of Anti-dilutive Securities Outstanding Diluted Loss per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="00000048 - Disclosure - Schedule of Effective Income Tax Rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000049 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000050 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_NOLCarryforwardsDescription" xlink:label="loc_LTRNNOLCarryforwardsDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNNOLCarryforwardsDescription_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross_50" xlink:type="arc" order="4" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>28
<FILENAME>ltrn-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_UnderwritersAgreementMember" xlink:label="LTRN_UnderwritersAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_UnderwritersAgreementMember" xlink:to="LTRN_UnderwritersAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_UnderwritersAgreementMember_lbl" xml:lang="en-US">Underwriters Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LicenseStrategicAllianceAndResearchAgreementsMember" xlink:label="LTRN_LicenseStrategicAllianceAndResearchAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LicenseStrategicAllianceAndResearchAgreementsMember" xlink:to="LTRN_LicenseStrategicAllianceAndResearchAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_LicenseStrategicAllianceAndResearchAgreementsMember_lbl" xml:lang="en-US">License Strategic Alliance and Research Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_BioNumerikPharmaceuticalsMember" xlink:label="LTRN_BioNumerikPharmaceuticalsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_BioNumerikPharmaceuticalsMember" xlink:to="LTRN_BioNumerikPharmaceuticalsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_BioNumerikPharmaceuticalsMember_lbl" xml:lang="en-US">BioNumerik Pharmaceuticals [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AssignmentAgreementMember" xlink:label="LTRN_AssignmentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_AssignmentAgreementMember" xlink:to="LTRN_AssignmentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_AssignmentAgreementMember_lbl" xml:lang="en-US">Assignment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AFCLicenseAgreementMember" xlink:label="LTRN_AFCLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_AFCLicenseAgreementMember" xlink:to="LTRN_AFCLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_AFCLicenseAgreementMember_lbl" xml:lang="en-US">AFC License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AFChemicalsMember" xlink:label="LTRN_AFChemicalsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_AFChemicalsMember" xlink:to="LTRN_AFChemicalsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_AFChemicalsMember_lbl" xml:lang="en-US">AF Chemicals [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AllarityTherapeutiesMember" xlink:label="LTRN_AllarityTherapeutiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_AllarityTherapeutiesMember" xlink:to="LTRN_AllarityTherapeutiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_AllarityTherapeutiesMember_lbl" xml:lang="en-US">Allarity Therapeuties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AssetPurchaseAgreementMember" xlink:label="LTRN_AssetPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_AssetPurchaseAgreementMember" xlink:to="LTRN_AssetPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CalifiaPharmaMember" xlink:label="LTRN_CalifiaPharmaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_CalifiaPharmaMember" xlink:to="LTRN_CalifiaPharmaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_CalifiaPharmaMember_lbl" xml:lang="en-US">Califia Pharma [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_EvaluationAgreementMember" xlink:label="LTRN_EvaluationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_EvaluationAgreementMember" xlink:to="LTRN_EvaluationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_EvaluationAgreementMember_lbl" xml:lang="en-US">Evaluation Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PatheonAPIServicesMember" xlink:label="LTRN_PatheonAPIServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_PatheonAPIServicesMember" xlink:to="LTRN_PatheonAPIServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_PatheonAPIServicesMember_lbl" xml:lang="en-US">Patheon API Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PatheonAgreementMember" xlink:label="LTRN_PatheonAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_PatheonAgreementMember" xlink:to="LTRN_PatheonAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_PatheonAgreementMember_lbl" xml:lang="en-US">Patheon Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_SouthwestResearchInstituteMember" xlink:label="LTRN_SouthwestResearchInstituteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_SouthwestResearchInstituteMember" xlink:to="LTRN_SouthwestResearchInstituteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_SouthwestResearchInstituteMember_lbl" xml:lang="en-US">Southwest Research Institute [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_SouthwestResearchInstituteAgreementMember" xlink:label="LTRN_SouthwestResearchInstituteAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_SouthwestResearchInstituteAgreementMember" xlink:to="LTRN_SouthwestResearchInstituteAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_SouthwestResearchInstituteAgreementMember_lbl" xml:lang="en-US">Southwest Research Institute Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_FoxChaseCancerCenterMember" xlink:label="LTRN_FoxChaseCancerCenterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_FoxChaseCancerCenterMember" xlink:to="LTRN_FoxChaseCancerCenterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_FoxChaseCancerCenterMember_lbl" xml:lang="en-US">Fox Chase Cancer Center [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_FoxChaseCancerCenterAgreementMember" xlink:label="LTRN_FoxChaseCancerCenterAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_FoxChaseCancerCenterAgreementMember" xlink:to="LTRN_FoxChaseCancerCenterAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_FoxChaseCancerCenterAgreementMember_lbl" xml:lang="en-US">Fox Chase Cancer Center Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PiramalPharmaSolutionMember" xlink:label="LTRN_PiramalPharmaSolutionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_PiramalPharmaSolutionMember" xlink:to="LTRN_PiramalPharmaSolutionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_PiramalPharmaSolutionMember_lbl" xml:lang="en-US">Piramal Pharma Solution [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PiramalPharmaAgreementMember" xlink:label="LTRN_PiramalPharmaAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_PiramalPharmaAgreementMember" xlink:to="LTRN_PiramalPharmaAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_PiramalPharmaAgreementMember_lbl" xml:lang="en-US">Piramal Pharma Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_VivoPharmMember" xlink:label="LTRN_VivoPharmMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_VivoPharmMember" xlink:to="LTRN_VivoPharmMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_VivoPharmMember_lbl" xml:lang="en-US">Vivo Pharm [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_VivoPharmAgreementMember" xlink:label="LTRN_VivoPharmAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_VivoPharmAgreementMember" xlink:to="LTRN_VivoPharmAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_VivoPharmAgreementMember_lbl" xml:lang="en-US">Vivo Pharm Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_TranslationalDrugMember" xlink:label="LTRN_TranslationalDrugMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_TranslationalDrugMember" xlink:to="LTRN_TranslationalDrugMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_TranslationalDrugMember_lbl" xml:lang="en-US">Translationa lDrug [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_TranslationalDrugAgreementMember" xlink:label="LTRN_TranslationalDrugAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_TranslationalDrugAgreementMember" xlink:to="LTRN_TranslationalDrugAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_TranslationalDrugAgreementMember_lbl" xml:lang="en-US">Translational Drug Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_BerkshireSteruleManufacturingMember" xlink:label="LTRN_BerkshireSteruleManufacturingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_BerkshireSteruleManufacturingMember" xlink:to="LTRN_BerkshireSteruleManufacturingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_BerkshireSteruleManufacturingMember_lbl" xml:lang="en-US">Berkshire Sterule Manufacturing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_BerkshireSteruleManufacturingAgreementMember" xlink:label="LTRN_BerkshireSteruleManufacturingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_BerkshireSteruleManufacturingAgreementMember" xlink:to="LTRN_BerkshireSteruleManufacturingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_BerkshireSteruleManufacturingAgreementMember_lbl" xml:lang="en-US">Berkshire Sterule Manufacturing Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ShilpaMember" xlink:label="LTRN_ShilpaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ShilpaMember" xlink:to="LTRN_ShilpaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_ShilpaMember_lbl" xml:lang="en-US">Shilpa [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ShilpaAgreementMember" xlink:label="LTRN_ShilpaAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ShilpaAgreementMember" xlink:to="LTRN_ShilpaAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_ShilpaAgreementMember_lbl" xml:lang="en-US">Shilpa Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CuriaMember" xlink:label="LTRN_CuriaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_CuriaMember" xlink:to="LTRN_CuriaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_CuriaMember_lbl" xml:lang="en-US">Curia [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LumaBridgeLLCMember" xlink:label="LTRN_LumaBridgeLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LumaBridgeLLCMember" xlink:to="LTRN_LumaBridgeLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_LumaBridgeLLCMember_lbl" xml:lang="en-US">Luma Bridge LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LumaBridgeAgreementMember" xlink:label="LTRN_LumaBridgeAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LumaBridgeAgreementMember" xlink:to="LTRN_LumaBridgeAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_LumaBridgeAgreementMember_lbl" xml:lang="en-US">Luma Bridge Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LanternPharmaLimitedMember" xlink:label="LTRN_LanternPharmaLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LanternPharmaLimitedMember" xlink:to="LTRN_LanternPharmaLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_LanternPharmaLimitedMember_lbl" xml:lang="en-US">Lantern Pharma Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ActuateTherapeuticsMember" xlink:label="LTRN_ActuateTherapeuticsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ActuateTherapeuticsMember" xlink:to="LTRN_ActuateTherapeuticsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_ActuateTherapeuticsMember_lbl" xml:lang="en-US">Actuate Therapeutics [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CollaborationAgreementMember" xlink:label="LTRN_CollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_CollaborationAgreementMember" xlink:to="LTRN_CollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_CollaborationAgreementMember_lbl" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_UnderwritersMember" xlink:label="LTRN_UnderwritersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_UnderwritersMember" xlink:to="LTRN_UnderwritersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_UnderwritersMember_lbl" xml:lang="en-US">Underwriters [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CashlessWarrantsMember" xlink:label="LTRN_CashlessWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_CashlessWarrantsMember" xlink:to="LTRN_CashlessWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_CashlessWarrantsMember_lbl" xml:lang="en-US">Cashless Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="LTRN_TwoThousandEighteenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="LTRN_TwoThousandEighteenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2018 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_GovernmentAgencySecuritiesMember" xlink:label="LTRN_GovernmentAgencySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_GovernmentAgencySecuritiesMember" xlink:to="LTRN_GovernmentAgencySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_GovernmentAgencySecuritiesMember_lbl" xml:lang="en-US">Government &amp; Agency Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CorporateBondsMember" xlink:label="LTRN_CorporateBondsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_CorporateBondsMember" xlink:to="LTRN_CorporateBondsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_CorporateBondsMember_lbl" xml:lang="en-US">Corporate Bonds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MarketableSecuritiesDebtMember" xlink:label="LTRN_MarketableSecuritiesDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_MarketableSecuritiesDebtMember" xlink:to="LTRN_MarketableSecuritiesDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_MarketableSecuritiesDebtMember_lbl" xml:lang="en-US">Marketable Securities - Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsFixedIncomeMember" xlink:label="LTRN_MutualFundsFixedIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_MutualFundsFixedIncomeMember" xlink:to="LTRN_MutualFundsFixedIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_MutualFundsFixedIncomeMember_lbl" xml:lang="en-US">Mutual Funds - Fixed Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsAlternativeInvestmentsMember" xlink:label="LTRN_MutualFundsAlternativeInvestmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_MutualFundsAlternativeInvestmentsMember" xlink:to="LTRN_MutualFundsAlternativeInvestmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_MutualFundsAlternativeInvestmentsMember_lbl" xml:lang="en-US">Mutual Funds - Alternative Investments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MarketableSecuritiesMutualFundsMember" xlink:label="LTRN_MarketableSecuritiesMutualFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_MarketableSecuritiesMutualFundsMember" xlink:to="LTRN_MarketableSecuritiesMutualFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_MarketableSecuritiesMutualFundsMember_lbl" xml:lang="en-US">Marketable Securities - Mutual Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis_lbl" xml:lang="en-US">Security Owned and Sold, Not yet Purchased, at Fair Value [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_NAVMember" xlink:label="LTRN_NAVMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_NAVMember" xlink:to="LTRN_NAVMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_NAVMember_lbl" xml:lang="en-US">NAV [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses &amp; other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (NOTE 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock (1,000,000 authorized at December 31, 2022 and December 31, 2021; $.0001 par value) (Zero shares issued and outstanding at December 31, 2022 and December 31, 2021)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock (25,000,000 authorized at December 31, 2022 and December 31, 2021; $.0001 par value) (10,857,040 shares issued and outstanding at December 31, 2022; 11,088,835 shares issued and outstanding at December 31, 2021)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other (expense) income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share of common shares, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average number of common shares outstanding, basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized loss on available-for-sale securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Unrealized gain of foreign currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" xlink:label="LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" xlink:to="LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises_lbl" xml:lang="en-US">Common stock issued from warrant exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises" xlink:label="LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises" xlink:to="LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises_lbl" xml:lang="en-US">Common stock issued from warrant exercise, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Common stock issued from option exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Common stock issued from option exercises, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued from offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued from offering, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Share repurchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Share repurchases, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_2_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" xml:lang="en-US">Amortization of investment premium</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_NoncashLeaseAdjustments" xlink:label="LTRN_NoncashLeaseAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_NoncashLeaseAdjustments" xlink:to="LTRN_NoncashLeaseAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_NoncashLeaseAdjustments_lbl" xml:lang="en-US">Non-cash lease adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_GainOnLoanForgiveness" xlink:label="LTRN_GainOnLoanForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_GainOnLoanForgiveness" xlink:to="LTRN_GainOnLoanForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="LTRN_GainOnLoanForgiveness_lbl" xml:lang="en-US">Gain on loan forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency remeasurement loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xml:lang="en-US">Realized loss on sale of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaid expenses &amp; other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash flows used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchase of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Redemptions of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash flows provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ProceedsFromStockOptionAndWarrantExercises" xlink:label="LTRN_ProceedsFromStockOptionAndWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ProceedsFromStockOptionAndWarrantExercises" xlink:to="LTRN_ProceedsFromStockOptionAndWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_ProceedsFromStockOptionAndWarrantExercises_lbl" xml:lang="en-US">Proceeds from warrant and stock option exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Repurchases of shares including commissions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash flows (used in) provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of foreign exchange rates on cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">CHANGE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH FOR THE YEAR</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING OF YEAR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">RECONCILIATION OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds" xlink:label="LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds" xlink:to="LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds_lbl" xml:lang="en-US">Application of deferred offering costs to public offering proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized losses on debt securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Principal Activities, and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes and Loan Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Loss Per Share of Common Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates and Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock" xlink:label="LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock" xlink:to="LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock_lbl" xml:lang="en-US">Loan Pursuant to Paycheck Protection Program</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Not Yet Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock" xlink:label="LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock" xlink:to="LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Balance Sheet Information Related to Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:to="LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Supplemental Information Related to Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US">Schedule of Contractual Maturities Investments of Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Assets are Measured at Fair Value on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities Outstanding Diluted Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_WorkingCapital" xlink:label="LTRN_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_WorkingCapital" xlink:to="LTRN_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued for public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of sale of stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="LTRN_ProceedsFromIssuanceInitialPublicOfferingGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:to="LTRN_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_ProceedsFromIssuanceInitialPublicOfferingGross_lbl" xml:lang="en-US">Proceeds from initial public offering, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from initial public offering, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC Insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid expense and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions" xlink:label="LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions" xlink:to="LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_lbl" xml:lang="en-US">Upfront payments for contractor fees, academic research studies and services, and subscriptions</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_IntellectualPropertyRelatedLicensingAndOtherFees" xlink:label="LTRN_IntellectualPropertyRelatedLicensingAndOtherFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_IntellectualPropertyRelatedLicensingAndOtherFees" xlink:to="LTRN_IntellectualPropertyRelatedLicensingAndOtherFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_IntellectualPropertyRelatedLicensingAndOtherFees_lbl" xml:lang="en-US">Intellectual property related licensing and other fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid annual insurance fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US">Interest receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoans_lbl" xml:lang="en-US">Proceeds from loans</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ResearchAndDevelopmentIncomeExpense" xlink:label="LTRN_ResearchAndDevelopmentIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ResearchAndDevelopmentIncomeExpense" xlink:to="LTRN_ResearchAndDevelopmentIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_ResearchAndDevelopmentIncomeExpense_lbl" xml:lang="en-US">Amount Expensed for License, Strategic Alliance, and Research Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_DecreaseInResearchAndDevelopmentExpense" xlink:label="LTRN_DecreaseInResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_DecreaseInResearchAndDevelopmentExpense" xlink:to="LTRN_DecreaseInResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_DecreaseInResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Amount accrued and payable under License, Strategic Alliance, and Research Agreements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3_lbl" xml:lang="en-US">Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements &#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_UpfrontPayments" xlink:label="LTRN_UpfrontPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_UpfrontPayments" xlink:to="LTRN_UpfrontPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_UpfrontPayments_lbl" xml:lang="en-US">Upfront payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="us-gaap_OtherCommitmentsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDescription_lbl" xml:lang="en-US">Commitments description</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_RevenuePercentage" xlink:label="LTRN_RevenuePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_RevenuePercentage" xlink:to="LTRN_RevenuePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_RevenuePercentage_lbl" xml:lang="en-US">Revenue percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LicenseAgreementDescription" xlink:label="LTRN_LicenseAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LicenseAgreementDescription" xlink:to="LTRN_LicenseAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_LicenseAgreementDescription_lbl" xml:lang="en-US">License agreement, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDepositsRelatedToPropertySales" xlink:label="us-gaap_EscrowDepositsRelatedToPropertySales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDepositsRelatedToPropertySales" xlink:to="us-gaap_EscrowDepositsRelatedToPropertySales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDepositsRelatedToPropertySales_lbl" xml:lang="en-US">Escrow related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_FuturePayments" xlink:label="LTRN_FuturePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_FuturePayments" xlink:to="LTRN_FuturePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_FuturePayments_lbl" xml:lang="en-US">Future payments</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ResearchAndDevelopmentExpensesPercentage" xlink:label="LTRN_ResearchAndDevelopmentExpensesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ResearchAndDevelopmentExpensesPercentage" xlink:to="LTRN_ResearchAndDevelopmentExpensesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_ResearchAndDevelopmentExpensesPercentage_lbl" xml:lang="en-US">Research and development expenses percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Actuate stock of restricted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_NominalValueOfRestrictedSharesOfActuateStock" xlink:label="LTRN_NominalValueOfRestrictedSharesOfActuateStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_NominalValueOfRestrictedSharesOfActuateStock" xlink:to="LTRN_NominalValueOfRestrictedSharesOfActuateStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_NominalValueOfRestrictedSharesOfActuateStock_lbl" xml:lang="en-US">Nominal value acquired cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease, right-of-use asset, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments to be paid in 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less amount representing interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Present value of future minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_3_lbl" xml:lang="en-US">Less current portion of operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_3_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_OperatingLeaseLiability_3_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_OperatingLeaseRightOfUseAssetAdditions" xlink:label="LTRN_OperatingLeaseRightOfUseAssetAdditions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_OperatingLeaseRightOfUseAssetAdditions" xlink:to="LTRN_OperatingLeaseRightOfUseAssetAdditions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_OperatingLeaseRightOfUseAssetAdditions_lbl" xml:lang="en-US">Additions, Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_OperatingLeaseLiabilityInAdditions" xlink:label="LTRN_OperatingLeaseLiabilityInAdditions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_OperatingLeaseLiabilityInAdditions" xlink:to="LTRN_OperatingLeaseLiabilityInAdditions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_OperatingLeaseLiabilityInAdditions_lbl" xml:lang="en-US">Additions, Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortizations, Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_OperatingLeaseLiabilityAmortization" xlink:label="LTRN_OperatingLeaseLiabilityAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_OperatingLeaseLiabilityAmortization" xlink:to="LTRN_OperatingLeaseLiabilityAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_OperatingLeaseLiabilityAmortization_lbl" xml:lang="en-US">Amortizations, Operating lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_4_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_OperatingLeaseLiability_4_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining term of operating leases (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate of operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LeaseExpirationDate" xlink:label="LTRN_LeaseExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LeaseExpirationDate" xlink:to="LTRN_LeaseExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_LeaseExpirationDate_lbl" xml:lang="en-US">Lease expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price per share, outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options exercisable, beginning valance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Number of options exercisable, weighted-average exercise price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price per share, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of shares, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price per share, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares, cancelled or expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price per share, cancelled or expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, outstanding beinning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price per share, outstanding ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of options exercisable, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Number of options exercisable, weighted-average exercise price, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xml:lang="en-US">Term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk Free Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend Yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Preferred stock shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_2_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Issuance of stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_GrossProceedsFromInitialPublicOffering" xlink:label="LTRN_GrossProceedsFromInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_GrossProceedsFromInitialPublicOffering" xlink:to="LTRN_GrossProceedsFromInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_GrossProceedsFromInitialPublicOffering_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions" xlink:label="LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions" xlink:to="LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions_lbl" xml:lang="en-US">Proceeds after deducting underwriting discounts and commissions</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_OtherOfferingExpenses" xlink:label="LTRN_OtherOfferingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_OtherOfferingExpenses" xlink:to="LTRN_OtherOfferingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_OtherOfferingExpenses_lbl" xml:lang="en-US">Other offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferring offering costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xml:lang="en-US">Repurchase of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xml:lang="en-US">Repurchase of shares, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Issuance of stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from warrants exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise" xlink:label="LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise" xlink:to="LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Stock option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Purchase of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Expiration date of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Number of reserved shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xml:lang="en-US">Number of remain available shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod" xlink:label="us-gaap_InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod" xlink:to="us-gaap_InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod_lbl" xml:lang="en-US">Weighted average period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Total intrinsic value of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Stock option intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Marketable securities amortized cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US">Marketable securities unrealized gains</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Marketable securities unrealized losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Marketable securities aggregate fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_lbl" xml:lang="en-US">Due within one year</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue" xlink:label="LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue" xlink:to="LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue_lbl" xml:lang="en-US">Due in one to two years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_lbl" xml:lang="en-US">Due in two to five years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" xlink:label="LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" xlink:to="LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US">Fair Value Less than 12 months</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US">Unrealized Loss Less than 12 months</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" xlink:label="LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" xlink:to="LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_lbl" xml:lang="en-US">Fair Value Less than 12 months</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xml:lang="en-US">Unrealized Loss Less than 12 months</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_lbl" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_lbl" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US">Fair value recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="us-gaap_ProceedsFromLoanOriginations1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoanOriginations1" xlink:to="us-gaap_ProceedsFromLoanOriginations1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoanOriginations1_lbl" xml:lang="en-US">Aggregate loan amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Annual interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Total:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_lbl" xml:lang="en-US">Unrealized losses on securities</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization" xlink:label="LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization" xlink:to="LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization_lbl" xml:lang="en-US">Research and development amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Net operating loss carryforwards for federal income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_NOLCarryforwardsDescription" xlink:label="LTRN_NOLCarryforwardsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_NOLCarryforwardsDescription" xlink:to="LTRN_NOLCarryforwardsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_NOLCarryforwardsDescription_lbl" xml:lang="en-US">Net operating loss carryforwards, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Gross deferred tax asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_WorkingCapital" xlink:to="LTRN_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_UnderwritersAgreementMember" xlink:to="LTRN_UnderwritersAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_UnderwritersAgreementMember_doc" xml:lang="en-US">Underwriters Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_doc" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions" xlink:to="LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_doc" xml:lang="en-US">Upfront payments for contractor fees, academic research studies and services, and subscriptions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_IntellectualPropertyRelatedLicensingAndOtherFees" xlink:to="LTRN_IntellectualPropertyRelatedLicensingAndOtherFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_IntellectualPropertyRelatedLicensingAndOtherFees_doc" xml:lang="en-US">Intellectual property related licensing and other fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock" xlink:to="LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock_doc" xml:lang="en-US">Loan Pursuant to Paycheck Protection Program [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" xlink:to="LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises_doc" xml:lang="en-US">Stock issued during period value common stock issued from warrant and option exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock" xlink:to="LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock_doc" xml:lang="en-US">Recently Adopted Accounting Standards [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ResearchAndDevelopmentIncomeExpense" xlink:to="LTRN_ResearchAndDevelopmentIncomeExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_ResearchAndDevelopmentIncomeExpense_doc" xml:lang="en-US">Amount expensed for license, strategic alliance, and research agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_DecreaseInResearchAndDevelopmentExpense" xlink:to="LTRN_DecreaseInResearchAndDevelopmentExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_DecreaseInResearchAndDevelopmentExpense_doc" xml:lang="en-US">Decrease in research and development expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LicenseStrategicAllianceAndResearchAgreementsMember" xlink:to="LTRN_LicenseStrategicAllianceAndResearchAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_LicenseStrategicAllianceAndResearchAgreementsMember_doc" xml:lang="en-US">License Strategic Alliance and Research Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_UpfrontPayments" xlink:to="LTRN_UpfrontPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_UpfrontPayments_doc" xml:lang="en-US">Upfront payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_BioNumerikPharmaceuticalsMember" xlink:to="LTRN_BioNumerikPharmaceuticalsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_BioNumerikPharmaceuticalsMember_doc" xml:lang="en-US">BioNumerik Pharmaceuticals [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_AssignmentAgreementMember" xlink:to="LTRN_AssignmentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_AssignmentAgreementMember_doc" xml:lang="en-US">Assignment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_RevenuePercentage" xlink:to="LTRN_RevenuePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_RevenuePercentage_doc" xml:lang="en-US">Revenue percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LicenseAgreementDescription" xlink:to="LTRN_LicenseAgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_LicenseAgreementDescription_doc" xml:lang="en-US">License agreement description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_AFCLicenseAgreementMember" xlink:to="LTRN_AFCLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_AFCLicenseAgreementMember_doc" xml:lang="en-US">AFC License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_AFChemicalsMember" xlink:to="LTRN_AFChemicalsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_AFChemicalsMember_doc" xml:lang="en-US">AF Chemicals [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_AllarityTherapeutiesMember" xlink:to="LTRN_AllarityTherapeutiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_AllarityTherapeutiesMember_doc" xml:lang="en-US">Allarity Therapeuties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_AssetPurchaseAgreementMember" xlink:to="LTRN_AssetPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_AssetPurchaseAgreementMember_doc" xml:lang="en-US">Asset purchase agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_FuturePayments" xlink:to="LTRN_FuturePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_FuturePayments_doc" xml:lang="en-US">Future payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LanternPharmaLimitedMember" xlink:to="LTRN_LanternPharmaLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_LanternPharmaLimitedMember_doc" xml:lang="en-US">Lantern Pharma Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ResearchAndDevelopmentExpensesPercentage" xlink:to="LTRN_ResearchAndDevelopmentExpensesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_ResearchAndDevelopmentExpensesPercentage_doc" xml:lang="en-US">Research and development expenses percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ActuateTherapeuticsMember" xlink:to="LTRN_ActuateTherapeuticsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_ActuateTherapeuticsMember_doc" xml:lang="en-US">Actuate Therapeutics [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_CollaborationAgreementMember" xlink:to="LTRN_CollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_CollaborationAgreementMember_doc" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_NominalValueOfRestrictedSharesOfActuateStock" xlink:to="LTRN_NominalValueOfRestrictedSharesOfActuateStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_NominalValueOfRestrictedSharesOfActuateStock_doc" xml:lang="en-US">Nominal value of restricted shares of actuate stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock_doc" xml:lang="en-US">Schedule of Balance Sheet Information Related to Leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises" xlink:to="LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises_doc" xml:lang="en-US">Common stock issued from warrant exercise, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LeaseExpirationDate" xlink:to="LTRN_LeaseExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_LeaseExpirationDate_doc" xml:lang="en-US">Lease expiration date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock_doc" xml:lang="en-US">Schedule Of Other Supplemental Information Related To Operating Leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_NoncashLeaseAdjustments" xlink:to="LTRN_NoncashLeaseAdjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_NoncashLeaseAdjustments_doc" xml:lang="en-US">Noncash lease adjustments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_GainOnLoanForgiveness" xlink:to="LTRN_GainOnLoanForgiveness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_GainOnLoanForgiveness_doc" xml:lang="en-US">Gain on loan forgiveness.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ProceedsFromStockOptionAndWarrantExercises" xlink:to="LTRN_ProceedsFromStockOptionAndWarrantExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_ProceedsFromStockOptionAndWarrantExercises_doc" xml:lang="en-US">Proceeds from stock option and warrant exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds" xlink:to="LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds_doc" xml:lang="en-US">Application of deferred offering costs to public offering proceeds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_OperatingLeaseRightOfUseAssetAdditions" xlink:to="LTRN_OperatingLeaseRightOfUseAssetAdditions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_OperatingLeaseRightOfUseAssetAdditions_doc" xml:lang="en-US">Additions, right of use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_OperatingLeaseLiabilityInAdditions" xlink:to="LTRN_OperatingLeaseLiabilityInAdditions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_OperatingLeaseLiabilityInAdditions_doc" xml:lang="en-US">Additions, operating lease liabilities,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_OperatingLeaseLiabilityAmortization" xlink:to="LTRN_OperatingLeaseLiabilityAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_OperatingLeaseLiabilityAmortization_doc" xml:lang="en-US">Amortizations, operating lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_UnderwritersMember" xlink:to="LTRN_UnderwritersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_UnderwritersMember_doc" xml:lang="en-US">Underwriters [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_GrossProceedsFromInitialPublicOffering" xlink:to="LTRN_GrossProceedsFromInitialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_GrossProceedsFromInitialPublicOffering_doc" xml:lang="en-US">Gross proceeds from initial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions" xlink:to="LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions_doc" xml:lang="en-US">Proceeds after deducting underwriting discounts and commissions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_OtherOfferingExpenses" xlink:to="LTRN_OtherOfferingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_OtherOfferingExpenses_doc" xml:lang="en-US">Other offering expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_CashlessWarrantsMember" xlink:to="LTRN_CashlessWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_CashlessWarrantsMember_doc" xml:lang="en-US">Cashless Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise" xlink:to="LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise_doc" xml:lang="en-US">Warrants to purchase shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_GovernmentAgencySecuritiesMember" xlink:to="LTRN_GovernmentAgencySecuritiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_GovernmentAgencySecuritiesMember_doc" xml:lang="en-US">Government Agency Securities [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_CorporateBondsMember" xlink:to="LTRN_CorporateBondsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_CorporateBondsMember_doc" xml:lang="en-US">Corporate Bonds [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_MarketableSecuritiesDebtMember" xlink:to="LTRN_MarketableSecuritiesDebtMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_MarketableSecuritiesDebtMember_doc" xml:lang="en-US">Marketable Securities Debt [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_MutualFundsFixedIncomeMember" xlink:to="LTRN_MutualFundsFixedIncomeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_MutualFundsFixedIncomeMember_doc" xml:lang="en-US">Mutual Funds Fixed Income [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_MutualFundsAlternativeInvestmentsMember" xlink:to="LTRN_MutualFundsAlternativeInvestmentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_MutualFundsAlternativeInvestmentsMember_doc" xml:lang="en-US">Mutual Funds Alternative Investments [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_MarketableSecuritiesMutualFundsMember" xlink:to="LTRN_MarketableSecuritiesMutualFundsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_MarketableSecuritiesMutualFundsMember_doc" xml:lang="en-US">Marketable Securities Mutual Funds [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue" xlink:to="LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue_doc" xml:lang="en-US">Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through secondth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_NAVMember" xlink:to="LTRN_NAVMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_NAVMember_doc" xml:lang="en-US">NAV [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_NOLCarryforwardsDescription" xlink:to="LTRN_NOLCarryforwardsDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_NOLCarryforwardsDescription_doc" xml:lang="en-US">Operating loss carryforward, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:to="LTRN_ProceedsFromIssuanceInitialPublicOfferingGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_ProceedsFromIssuanceInitialPublicOfferingGross_doc" xml:lang="en-US">Proceeds from initial public offering, gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:to="LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average shares, warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="LTRN_TwoThousandEighteenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_TwoThousandEighteenEquityIncentivePlanMember_doc" xml:lang="en-US">2018 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" xlink:to="LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_doc" xml:lang="en-US">Fair value, less than 12 months.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" xlink:to="LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_doc" xml:lang="en-US">Fair value, more than 12 months.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization" xlink:to="LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization_doc" xml:lang="en-US">Research and development amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_CalifiaPharmaMember" xlink:to="LTRN_CalifiaPharmaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_CalifiaPharmaMember_doc" xml:lang="en-US">Califia Pharma [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_EvaluationAgreementMember" xlink:to="LTRN_EvaluationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_EvaluationAgreementMember_doc" xml:lang="en-US">Evaluation Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_PatheonAPIServicesMember" xlink:to="LTRN_PatheonAPIServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_PatheonAPIServicesMember_doc" xml:lang="en-US">Patheon API Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_PatheonAgreementMember" xlink:to="LTRN_PatheonAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_PatheonAgreementMember_doc" xml:lang="en-US">Patheon Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_SouthwestResearchInstituteMember" xlink:to="LTRN_SouthwestResearchInstituteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_SouthwestResearchInstituteMember_doc" xml:lang="en-US">Southwest Research Institute [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_SouthwestResearchInstituteAgreementMember" xlink:to="LTRN_SouthwestResearchInstituteAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_SouthwestResearchInstituteAgreementMember_doc" xml:lang="en-US">Southwest Research Institute Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_FoxChaseCancerCenterMember" xlink:to="LTRN_FoxChaseCancerCenterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_FoxChaseCancerCenterMember_doc" xml:lang="en-US">Fox Chase Cancer Center [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_FoxChaseCancerCenterAgreementMember" xlink:to="LTRN_FoxChaseCancerCenterAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_FoxChaseCancerCenterAgreementMember_doc" xml:lang="en-US">Fox Chase Cancer Center Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_PiramalPharmaSolutionMember" xlink:to="LTRN_PiramalPharmaSolutionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_PiramalPharmaSolutionMember_doc" xml:lang="en-US">Piramal Pharma Solution [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_PiramalPharmaAgreementMember" xlink:to="LTRN_PiramalPharmaAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_PiramalPharmaAgreementMember_doc" xml:lang="en-US">Piramal Pharma Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_VivoPharmMember" xlink:to="LTRN_VivoPharmMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_VivoPharmMember_doc" xml:lang="en-US">Vivo Pharm [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_VivoPharmAgreementMember" xlink:to="LTRN_VivoPharmAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_VivoPharmAgreementMember_doc" xml:lang="en-US">Vivo Pharm Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_TranslationalDrugMember" xlink:to="LTRN_TranslationalDrugMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_TranslationalDrugMember_doc" xml:lang="en-US">Translationa lDrug [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_TranslationalDrugAgreementMember" xlink:to="LTRN_TranslationalDrugAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_TranslationalDrugAgreementMember_doc" xml:lang="en-US">Translational Drug Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_BerkshireSteruleManufacturingMember" xlink:to="LTRN_BerkshireSteruleManufacturingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_BerkshireSteruleManufacturingMember_doc" xml:lang="en-US">Berkshire Sterule Manufacturing [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_BerkshireSteruleManufacturingAgreementMember" xlink:to="LTRN_BerkshireSteruleManufacturingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_BerkshireSteruleManufacturingAgreementMember_doc" xml:lang="en-US">Berkshire Sterule Manufacturing Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ShilpaMember" xlink:to="LTRN_ShilpaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_ShilpaMember_doc" xml:lang="en-US">Shilpa [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_ShilpaAgreementMember" xlink:to="LTRN_ShilpaAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_ShilpaAgreementMember_doc" xml:lang="en-US">Shilpa Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_CuriaMember" xlink:to="LTRN_CuriaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_CuriaMember_doc" xml:lang="en-US">Curia [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LumaBridgeLLCMember" xlink:to="LTRN_LumaBridgeLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_LumaBridgeLLCMember_doc" xml:lang="en-US">Luma Bridge LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_LumaBridgeAgreementMember" xlink:to="LTRN_LumaBridgeAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LTRN_LumaBridgeAgreementMember_doc" xml:lang="en-US">Luma Bridge Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_2_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_3_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_GainOnLoanForgiveness" xlink:to="LTRN_GainOnLoanForgiveness_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_GainOnLoanForgiveness_3_lbl" xml:lang="en-US">GainOnLoanForgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_2_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_2_lbl" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_3_lbl" xml:lang="en-US">Restricted Cash [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_2_lbl" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_2_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" xlink:to="LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_3_lbl" xml:lang="en-US">DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_2_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_2_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>29
<FILENAME>ltrn-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lanternpharma.com/role/Cover" xlink:href="ltrn-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/BalanceSheets" xlink:href="ltrn-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/BalanceSheetsParenthetical" xlink:href="ltrn-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/StatementsOfOperations" xlink:href="ltrn-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/StatementsOfComprehensiveLoss" xlink:href="ltrn-20221231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="ltrn-20221231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/StatementsOfCashFlows" xlink:href="ltrn-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/OrganizationPrincipalActivitiesAndBasisOfPresentation" xlink:href="ltrn-20221231.xsd#OrganizationPrincipalActivitiesAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/Liquidity" xlink:href="ltrn-20221231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ltrn-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/CommitmentsAndContingencies" xlink:href="ltrn-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/Leases" xlink:href="ltrn-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ShareholdersEquity" xlink:href="ltrn-20221231.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/MarketableSecurities" xlink:href="ltrn-20221231.xsd#MarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/FairValueMeasurements" xlink:href="ltrn-20221231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/NotesAndLoanPayable" xlink:href="ltrn-20221231.xsd#NotesAndLoanPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LossPerShareOfCommonShares" xlink:href="ltrn-20221231.xsd#LossPerShareOfCommonShares" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/IncomeTaxes" xlink:href="ltrn-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/SubsequentEvents" xlink:href="ltrn-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ltrn-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/CommitmentsAndContingenciesTables" xlink:href="ltrn-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LeasesTables" xlink:href="ltrn-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ShareholdersEquityTables" xlink:href="ltrn-20221231.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/MarketableSecuritiesTables" xlink:href="ltrn-20221231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/FairValueMeasurementsTables" xlink:href="ltrn-20221231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LossPerShareOfCommonSharesTables" xlink:href="ltrn-20221231.xsd#LossPerShareOfCommonSharesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/IncomeTaxesTables" xlink:href="ltrn-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LiquidityDetailsNarrative" xlink:href="ltrn-20221231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ltrn-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfResearchAndDevelopmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical" xlink:href="ltrn-20221231.xsd#ScheduleOfResearchAndDevelopmentDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ltrn-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/LeasesDetailsNarrative" xlink:href="ltrn-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfWeightedAverageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative" xlink:href="ltrn-20221231.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/NotesAndLoanPayableDetailsNarrative" xlink:href="ltrn-20221231.xsd#NotesAndLoanPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="ltrn-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lanternpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="ltrn-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" xlink:label="loc_LTRNStockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNStockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises" xlink:label="loc_LTRNStockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNStockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="loc_us-gaapInvestmentIncomeAmortizationOfPremium" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInvestmentIncomeAmortizationOfPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_NoncashLeaseAdjustments" xlink:label="loc_LTRNNoncashLeaseAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_LTRNNoncashLeaseAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_GainOnLoanForgiveness" xlink:label="loc_LTRNGainOnLoanForgiveness" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_LTRNGainOnLoanForgiveness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGainLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ProceedsFromStockOptionAndWarrantExercises" xlink:label="loc_LTRNProceedsFromStockOptionAndWarrantExercises" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_LTRNProceedsFromStockOptionAndWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds" xlink:label="loc_LTRNApplicationOfDeferredOfferingCostsToPublicOfferingProceeds" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_LTRNApplicationOfDeferredOfferingCostsToPublicOfferingProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/OrganizationPrincipalActivitiesAndBasisOfPresentation" xlink:title="00000008 - Disclosure - Organization, Principal Activities, and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/Liquidity" xlink:title="00000009 - Disclosure - Liquidity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/Leases" xlink:title="00000012 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ShareholdersEquity" xlink:title="00000013 - Disclosure - Shareholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/MarketableSecurities" xlink:title="00000014 - Disclosure - Marketable Securities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaapCashCashEquivalentsAndMarketableSecuritiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/FairValueMeasurements" xlink:title="00000015 - Disclosure - Fair Value Measurements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/NotesAndLoanPayable" xlink:title="00000016 - Disclosure - Notes and Loan Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LossPerShareOfCommonShares" xlink:title="00000017 - Disclosure - Loss Per Share of Common Shares">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/IncomeTaxes" xlink:title="00000018 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="loc_LTRNPrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LTRNPrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock" xlink:label="loc_LTRNLoanPursuantToPaycheckProtectionProgramPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LTRNLoanPursuantToPaycheckProtectionProgramPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock" xlink:label="loc_LTRNRecentlyAdoptedAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LTRNRecentlyAdoptedAccountingPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LeasesTables" xlink:title="00000022 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="loc_LTRNScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_LTRNScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="loc_LTRNScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_LTRNScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="loc_LTRNScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_LTRNScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ShareholdersEquityTables" xlink:title="00000023 - Disclosure - Shareholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/MarketableSecuritiesTables" xlink:title="00000024 - Disclosure - Marketable Securities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaapMarketableSecuritiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapMarketableSecuritiesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaapInvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapInvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/FairValueMeasurementsTables" xlink:title="00000025 - Disclosure - Fair Value Measurements (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LossPerShareOfCommonSharesTables" xlink:title="00000026 - Disclosure - Loss Per Share of Common Shares (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/IncomeTaxesTables" xlink:title="00000027 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LiquidityDetailsNarrative" xlink:title="00000028 - Disclosure - Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_UnderwritersAgreementMember" xlink:label="loc_LTRNUnderwritersAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNUnderwritersAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_WorkingCapital" xlink:label="loc_LTRNWorkingCapital" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LTRNWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:label="loc_LTRNProceedsFromIssuanceInitialPublicOfferingGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LTRNProceedsFromIssuanceInitialPublicOfferingGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions" xlink:label="loc_LTRNUpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LTRNUpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_IntellectualPropertyRelatedLicensingAndOtherFees" xlink:label="loc_LTRNIntellectualPropertyRelatedLicensingAndOtherFees" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_LTRNIntellectualPropertyRelatedLicensingAndOtherFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInterestReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapProceedsFromLoans" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetails" xlink:title="00000030 - Disclosure - Schedule of Research and Development (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ResearchAndDevelopmentIncomeExpense" xlink:label="loc_LTRNResearchAndDevelopmentIncomeExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_LTRNResearchAndDevelopmentIncomeExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical" xlink:title="00000031 - Disclosure - Schedule of Research and Development (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LicenseStrategicAllianceAndResearchAgreementsMember" xlink:label="loc_LTRNLicenseStrategicAllianceAndResearchAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNLicenseStrategicAllianceAndResearchAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_DecreaseInResearchAndDevelopmentExpense" xlink:label="loc_LTRNDecreaseInResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LTRNDecreaseInResearchAndDevelopmentExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xlink:title="00000032 - Disclosure - Schedule of Accounts Payable and Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LicenseStrategicAllianceAndResearchAgreementsMember" xlink:label="loc_LTRNLicenseStrategicAllianceAndResearchAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNLicenseStrategicAllianceAndResearchAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000033 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_BioNumerikPharmaceuticalsMember" xlink:label="loc_LTRNBioNumerikPharmaceuticalsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNBioNumerikPharmaceuticalsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AFChemicalsMember" xlink:label="loc_LTRNAFChemicalsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNAFChemicalsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AllarityTherapeutiesMember" xlink:label="loc_LTRNAllarityTherapeutiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNAllarityTherapeutiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CalifiaPharmaMember" xlink:label="loc_LTRNCalifiaPharmaMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNCalifiaPharmaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PatheonAPIServicesMember" xlink:label="loc_LTRNPatheonAPIServicesMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNPatheonAPIServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_SouthwestResearchInstituteMember" xlink:label="loc_LTRNSouthwestResearchInstituteMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNSouthwestResearchInstituteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_FoxChaseCancerCenterMember" xlink:label="loc_LTRNFoxChaseCancerCenterMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNFoxChaseCancerCenterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PiramalPharmaSolutionMember" xlink:label="loc_LTRNPiramalPharmaSolutionMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNPiramalPharmaSolutionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_VivoPharmMember" xlink:label="loc_LTRNVivoPharmMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNVivoPharmMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_TranslationalDrugMember" xlink:label="loc_LTRNTranslationalDrugMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNTranslationalDrugMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_BerkshireSteruleManufacturingMember" xlink:label="loc_LTRNBerkshireSteruleManufacturingMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNBerkshireSteruleManufacturingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ShilpaMember" xlink:label="loc_LTRNShilpaMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNShilpaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CuriaMember" xlink:label="loc_LTRNCuriaMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNCuriaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LumaBridgeLLCMember" xlink:label="loc_LTRNLumaBridgeLLCMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNLumaBridgeLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LanternPharmaLimitedMember" xlink:label="loc_LTRNLanternPharmaLimitedMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNLanternPharmaLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ActuateTherapeuticsMember" xlink:label="loc_LTRNActuateTherapeuticsMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LTRNActuateTherapeuticsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AssignmentAgreementMember" xlink:label="loc_LTRNAssignmentAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNAssignmentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AFCLicenseAgreementMember" xlink:label="loc_LTRNAFCLicenseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNAFCLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AssetPurchaseAgreementMember" xlink:label="loc_LTRNAssetPurchaseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_EvaluationAgreementMember" xlink:label="loc_LTRNEvaluationAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNEvaluationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PatheonAgreementMember" xlink:label="loc_LTRNPatheonAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNPatheonAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_SouthwestResearchInstituteAgreementMember" xlink:label="loc_LTRNSouthwestResearchInstituteAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNSouthwestResearchInstituteAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_FoxChaseCancerCenterAgreementMember" xlink:label="loc_LTRNFoxChaseCancerCenterAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNFoxChaseCancerCenterAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_PiramalPharmaAgreementMember" xlink:label="loc_LTRNPiramalPharmaAgreementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNPiramalPharmaAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_VivoPharmAgreementMember" xlink:label="loc_LTRNVivoPharmAgreementMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNVivoPharmAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_TranslationalDrugAgreementMember" xlink:label="loc_LTRNTranslationalDrugAgreementMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNTranslationalDrugAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_BerkshireSteruleManufacturingAgreementMember" xlink:label="loc_LTRNBerkshireSteruleManufacturingAgreementMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNBerkshireSteruleManufacturingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ShilpaAgreementMember" xlink:label="loc_LTRNShilpaAgreementMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNShilpaAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LumaBridgeAgreementMember" xlink:label="loc_LTRNLumaBridgeAgreementMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNLumaBridgeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CollaborationAgreementMember" xlink:label="loc_LTRNCollaborationAgreementMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LTRNCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_UpfrontPayments" xlink:label="loc_LTRNUpfrontPayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNUpfrontPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_RevenuePercentage" xlink:label="loc_LTRNRevenuePercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNRevenuePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LicenseAgreementDescription" xlink:label="loc_LTRNLicenseAgreementDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNLicenseAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDepositsRelatedToPropertySales" xlink:label="loc_us-gaapEscrowDepositsRelatedToPropertySales" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEscrowDepositsRelatedToPropertySales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_FuturePayments" xlink:label="loc_LTRNFuturePayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNFuturePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ResearchAndDevelopmentExpensesPercentage" xlink:label="loc_LTRNResearchAndDevelopmentExpensesPercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNResearchAndDevelopmentExpensesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_NominalValueOfRestrictedSharesOfActuateStock" xlink:label="loc_LTRNNominalValueOfRestrictedSharesOfActuateStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNNominalValueOfRestrictedSharesOfActuateStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:title="00000034 - Disclosure - Schedule of Balance Sheet Information Related to Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails" xlink:title="00000035 - Disclosure - Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails" xlink:title="00000036 - Disclosure - Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_OperatingLeaseRightOfUseAssetAdditions" xlink:label="loc_LTRNOperatingLeaseRightOfUseAssetAdditions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_LTRNOperatingLeaseRightOfUseAssetAdditions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_OperatingLeaseLiabilityInAdditions" xlink:label="loc_LTRNOperatingLeaseLiabilityInAdditions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_LTRNOperatingLeaseLiabilityInAdditions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_OperatingLeaseLiabilityAmortization" xlink:label="loc_LTRNOperatingLeaseLiabilityAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_LTRNOperatingLeaseLiabilityAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails" xlink:title="00000037 - Disclosure - Schedule of Other Supplemental Information Related to Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/LeasesDetailsNarrative" xlink:title="00000038 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_LeaseExpirationDate" xlink:label="loc_LTRNLeaseExpirationDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_LTRNLeaseExpirationDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000039 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails" xlink:title="00000040 - Disclosure - Schedule of Weighted Average Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000041 - Disclosure - Shareholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CashlessWarrantsMember" xlink:label="loc_LTRNCashlessWarrantsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LTRNCashlessWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_UnderwritersMember" xlink:label="loc_LTRNUnderwritersMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_LTRNUnderwritersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_LTRNTwoThousandEighteenEquityIncentivePlanMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_LTRNTwoThousandEighteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_GrossProceedsFromInitialPublicOffering" xlink:label="loc_LTRNGrossProceedsFromInitialPublicOffering" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LTRNGrossProceedsFromInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions" xlink:label="loc_LTRNProceedsAfterDeductingUnderwritingDiscountsAndCommissions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LTRNProceedsAfterDeductingUnderwritingDiscountsAndCommissions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_OtherOfferingExpenses" xlink:label="loc_LTRNOtherOfferingExpenses" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LTRNOtherOfferingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise" xlink:label="loc_LTRNStockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LTRNStockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_LTRNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_LTRNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod" xlink:label="loc_us-gaapInsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapInsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails" xlink:title="00000042 - Disclosure - Schedule of Marketable Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_GovernmentAgencySecuritiesMember" xlink:label="loc_LTRNGovernmentAgencySecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNGovernmentAgencySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CorporateBondsMember" xlink:label="loc_LTRNCorporateBondsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNCorporateBondsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MarketableSecuritiesDebtMember" xlink:label="loc_LTRNMarketableSecuritiesDebtMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNMarketableSecuritiesDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsFixedIncomeMember" xlink:label="loc_LTRNMutualFundsFixedIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNMutualFundsFixedIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsAlternativeInvestmentsMember" xlink:label="loc_LTRNMutualFundsAlternativeInvestmentsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNMutualFundsAlternativeInvestmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MarketableSecuritiesMutualFundsMember" xlink:label="loc_LTRNMarketableSecuritiesMutualFundsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNMarketableSecuritiesMutualFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails" xlink:title="00000043 - Disclosure - Schedule of Contractual Maturities Investments of Marketable Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue" xlink:label="loc_LTRNAvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_LTRNAvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails" xlink:title="00000044 - Disclosure - Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_GovernmentAgencySecuritiesMember" xlink:label="loc_LTRNGovernmentAgencySecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNGovernmentAgencySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_CorporateBondsMember" xlink:label="loc_LTRNCorporateBondsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNCorporateBondsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsFixedIncomeMember" xlink:label="loc_LTRNMutualFundsFixedIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNMutualFundsFixedIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsAlternativeInvestmentsMember" xlink:label="loc_LTRNMutualFundsAlternativeInvestmentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LTRNMutualFundsAlternativeInvestmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_LTRNDebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_LTRNDebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_LTRNDebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_LTRNDebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000045 - Disclosure - Schedule of Assets are Measured at Fair Value on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:label="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_GovernmentAgencySecuritiesMember" xlink:label="loc_LTRNGovernmentAgencySecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_LTRNGovernmentAgencySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaapCorporateBondSecuritiesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapCorporateBondSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsFixedIncomeMember" xlink:label="loc_LTRNMutualFundsFixedIncomeMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_LTRNMutualFundsFixedIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_MutualFundsAlternativeInvestmentsMember" xlink:label="loc_LTRNMutualFundsAlternativeInvestmentsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_LTRNMutualFundsAlternativeInvestmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:label="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:label="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:to="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_NAVMember" xlink:label="loc_LTRNNAVMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:to="loc_LTRNNAVMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/NotesAndLoanPayableDetailsNarrative" xlink:title="00000046 - Disclosure - Notes and Loan Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="loc_us-gaapProceedsFromLoanOriginations1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapProceedsFromLoanOriginations1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails" xlink:title="00000047 - Disclosure - Schedule of Anti-dilutive Securities Outstanding Diluted Loss per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="00000048 - Disclosure - Schedule of Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000049 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsGrossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:label="loc_us-gaapDeferredTaxAssetsUnrealizedLossesOnTradingSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization" xlink:label="loc_LTRNDeferredTaxAssetsResearchAndDevelopmentAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_LTRNDeferredTaxAssetsResearchAndDevelopmentAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lanternpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000050 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ltrn-20221231.xsd#LTRN_NOLCarryforwardsDescription" xlink:label="loc_LTRNNOLCarryforwardsDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LTRNNOLCarryforwardsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641113652544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 06, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lantern
Pharma Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001763950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3973463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1920
                                            McKinney Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">7th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dallas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(972)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">277-1136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LTRN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,002,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,857,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">Portions
of the registrant&#8217;s definitive proxy statement for the registrant&#8217;s 2023 Annual Meeting of Stockholders to be filed pursuant
to Regulation 14A within 120 days of the registrant&#8217;s year ended December 31, 2022 are incorporated herein by reference into Part
III of this Annual Report on Form 10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EisnerAmper LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Iselin, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641111702624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 37,201,786<span></span>
</td>
<td class="nump">$ 51,524,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">541,180<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">17,994,299<span></span>
</td>
<td class="nump">19,201,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses &amp; other current assets</a></td>
<td class="nump">2,985,472<span></span>
</td>
<td class="nump">1,990,953<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">58,722,737<span></span>
</td>
<td class="nump">72,716,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">48,008<span></span>
</td>
<td class="nump">30,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">47,687<span></span>
</td>
<td class="nump">185,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">17,889<span></span>
</td>
<td class="nump">17,889<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">58,836,321<span></span>
</td>
<td class="nump">73,950,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">2,745,407<span></span>
</td>
<td class="nump">2,174,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">52,890<span></span>
</td>
<td class="nump">152,058<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,798,297<span></span>
</td>
<td class="nump">2,326,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">52,890<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">2,798,297<span></span>
</td>
<td class="nump">2,379,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (NOTE 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock (1,000,000 authorized at December 31, 2022 and December 31, 2021; $.0001 par value) (Zero shares issued and outstanding at December 31, 2022 and December 31, 2021)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock (25,000,000 authorized at December 31, 2022 and December 31, 2021; $.0001 par value) (10,857,040 shares issued and outstanding at December 31, 2022; 11,088,835 shares issued and outstanding at December 31, 2021)</a></td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">95,691,194<span></span>
</td>
<td class="nump">96,685,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(371,386)<span></span>
</td>
<td class="num">(92,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(39,282,870)<span></span>
</td>
<td class="num">(25,022,924)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">56,038,024<span></span>
</td>
<td class="nump">71,571,420<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 58,836,321<span></span>
</td>
<td class="nump">$ 73,950,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641110348864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">10,857,040<span></span>
</td>
<td class="nump">11,088,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">10,857,040<span></span>
</td>
<td class="nump">11,088,835<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641110432800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 5,829,799<span></span>
</td>
<td class="nump">$ 5,020,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,602,954<span></span>
</td>
<td class="nump">7,570,580<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,432,753<span></span>
</td>
<td class="nump">12,591,508<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(14,432,753)<span></span>
</td>
<td class="num">(12,591,508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">204,355<span></span>
</td>
<td class="nump">67,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(31,548)<span></span>
</td>
<td class="nump">160,550<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (14,259,946)<span></span>
</td>
<td class="num">$ (12,363,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common shares, basic and diluted</a></td>
<td class="num">$ (1.31)<span></span>
</td>
<td class="num">$ (1.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">10,850,579<span></span>
</td>
<td class="nump">10,904,927<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641113511296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (14,259,946)<span></span>
</td>
<td class="num">$ (12,363,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(296,448)<span></span>
</td>
<td class="num">(92,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Unrealized gain of foreign currency translation</a></td>
<td class="nump">17,751<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(278,697)<span></span>
</td>
<td class="num">(92,689)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (14,538,643)<span></span>
</td>
<td class="num">$ (12,455,718)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641113329888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">$ 32,358,068<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (12,659,895)<span></span>
</td>
<td class="nump">$ 19,698,795<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,220,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises', window );">Common stock issued from warrant exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">127,470<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">127,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises', window );">Common stock issued from warrant exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued from option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">12,134<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 12,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued from option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued from offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 493<span></span>
</td>
<td class="nump">64,166,361<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 64,166,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued from offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,928,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Share repurchase</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">(939,654)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(939,666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Share repurchases, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(121,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">961,545<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">961,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,363,029)<span></span>
</td>
<td class="num">(12,363,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(92,689)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(92,689)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,109<span></span>
</td>
<td class="nump">96,685,924<span></span>
</td>
<td class="num">(92,689)<span></span>
</td>
<td class="num">(25,022,924)<span></span>
</td>
<td class="nump">71,571,420<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,088,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises', window );">Common stock issued from warrant exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">299,778<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">299,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises', window );">Common stock issued from warrant exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued from option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued from option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued from offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Share repurchase</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (36)<span></span>
</td>
<td class="num">(2,482,250)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (2,482,286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Share repurchases, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(353,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,187,745<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,187,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,259,946)<span></span>
</td>
<td class="num">(14,259,946)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(278,697)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(278,697)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,086<span></span>
</td>
<td class="nump">$ 95,691,194<span></span>
</td>
<td class="num">$ (371,386)<span></span>
</td>
<td class="num">$ (39,282,870)<span></span>
</td>
<td class="nump">$ 56,038,024<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,857,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued from warrant exercise, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common stock issued from warrant and option exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641113163360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,259,946)<span></span>
</td>
<td class="num">$ (12,363,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">10,081<span></span>
</td>
<td class="nump">6,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of investment premium</a></td>
<td class="nump">81,870<span></span>
</td>
<td class="nump">140,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_NoncashLeaseAdjustments', window );">Non-cash lease adjustments</a></td>
<td class="nump">144,600<span></span>
</td>
<td class="nump">90,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">1,187,745<span></span>
</td>
<td class="nump">961,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_GainOnLoanForgiveness', window );">Gain on loan forgiveness</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(108,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency remeasurement loss</a></td>
<td class="nump">58,598<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized loss on sale of marketable securities</a></td>
<td class="nump">128,922<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">492,501<span></span>
</td>
<td class="nump">80,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(158,402)<span></span>
</td>
<td class="num">(71,655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses &amp; other current assets</a></td>
<td class="num">(1,033,820)<span></span>
</td>
<td class="num">(984,463)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">580,359<span></span>
</td>
<td class="nump">1,622,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">33,991<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(12,767,492)<span></span>
</td>
<td class="num">(10,591,543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(27,844)<span></span>
</td>
<td class="num">(15,499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(3,912,570)<span></span>
</td>
<td class="num">(19,579,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Redemptions of marketable securities</a></td>
<td class="nump">4,119,682<span></span>
</td>
<td class="nump">64,093<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by (used in) investing activities</a></td>
<td class="nump">179,268<span></span>
</td>
<td class="num">(19,530,586)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">68,999,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,783,816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_ProceedsFromStockOptionAndWarrantExercises', window );">Proceeds from warrant and stock option exercise</a></td>
<td class="nump">299,788<span></span>
</td>
<td class="nump">139,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of shares including commissions</a></td>
<td class="num">(2,482,286)<span></span>
</td>
<td class="num">(939,666)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows (used in) provided by financing activities</a></td>
<td class="num">(2,182,498)<span></span>
</td>
<td class="nump">63,416,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of foreign exchange rates on cash</a></td>
<td class="num">(10,607)<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">CHANGE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH FOR THE YEAR</a></td>
<td class="num">(14,781,329)<span></span>
</td>
<td class="nump">33,295,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING OF YEAR</a></td>
<td class="nump">52,524,295<span></span>
</td>
<td class="nump">19,229,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</a></td>
<td class="nump">37,742,966<span></span>
</td>
<td class="nump">52,524,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>RECONCILIATION OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">37,201,786<span></span>
</td>
<td class="nump">51,524,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">541,180<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds', window );">Application of deferred offering costs to public offering proceeds</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(49,324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesUnrealizedGainLoss', window );">Unrealized losses on debt securities</a></td>
<td class="num">$ (296,448)<span></span>
</td>
<td class="num">$ (92,872)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Application of deferred offering costs to public offering proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_GainOnLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_GainOnLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_NoncashLeaseAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash lease adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_NoncashLeaseAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_ProceedsFromStockOptionAndWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from stock option and warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_ProceedsFromStockOptionAndWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of purchase premium on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641194744256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Principal Activities, and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Principal Activities, and Basis of Presentation</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zT3NMCMgvmdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1. <span id="xdx_826_zYbgIuijlbP">Organization, Principal Activities, and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lantern
Pharma Inc., and Subsidiaries (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company, focused on leveraging artificial
intelligence (&#8220;A.I.&#8221;), machine learning and genomic data to streamline the drug development process and to identify the patients
that will benefit from its targeted oncology therapies. The Company&#8217;s portfolio of therapies consists of small molecule drug candidates
that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that it is developing with
the assistance of its A.I. platform and its biomarker driven approach. The Company&#8217;s A.I. platform, known as RADR<sup>&#174;</sup>,
uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature,
phenotypic data from trials and publications, and mechanistic pathway data) and machine learning. The Company&#8217;s data-driven, genomically-targeted
and biomarker-driven approach allows it to pursue a transformational drug development strategy that identifies, rescues or develops,
and advances potential small molecule drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lantern
Pharma Inc. was incorporated under the laws of the state of Texas on November 7, 2013, and thereafter reincorporated in the state of
Delaware on January 15, 2020. The Company&#8217;s principal operations are located in Texas. The Company formed a wholly owned subsidiary,
Lantern Pharma Limited, in the United Kingdom in July 2017 and a wholly owned subsidiary, Lantern Pharma Australia Pty Ltd, in Australia
in September 2021. In January 2023, the Company formed a wholly owned subsidiary, Starlight Therapeutics Inc. (&#8220;Starlight&#8221;),
to develop drug candidate LP-184&#8217;s central nervous system (CNS) and brain cancer indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, the Company has devoted substantially all its activity to advancing research and development, including efforts in connection
with preclinical studies, clinical trials and development of its RADR platform. This now includes four drug candidates and an Antibody
Drug Conjugate (ADC) program directed towards eleven disclosed therapeutic targets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-100
    (irofulven) focused on combination with PARP inhibitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300
    (Tavocept), which we launched in a Phase II clinical trial, the Harmonic<sup>&#8482;</sup> trial in July 2022, focused on never smokers
    with advanced non-small cell lung cancer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184
    in preclinical studies for treatment of solid tumors including pancreatic, prostate, and bladder cancers, and glioblastoma and other
    CNS cancers. Following the formation of Starlight, the Company will refer to the molecule LP-184, as it is developed in CNS indications,
    as &#8220;STAR-001&#8221;;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-284,
    the stereoisomer (enantiomer) of LP-184, that has shown promising <i>in-vitro </i>and <i>in vivo</i> anticancer activity in multiple hematological cancers, which are distinct from the indications targeted by LP-184; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ADC program commenced in early 2021, and is aimed at identifying targeted or therapeutic antibodies to conjugate with selected compounds.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s fiscal year ends on December 31 of each calendar year. The accompanying consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include all adjustments
necessary for the fair presentation of the Company&#8217;s financial position, results of operations, and cash flows for each period
presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
reference in these notes to applicable guidance refers to Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards
Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). To date, the Company has operated its business
as one segment. The Company&#8217;s consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries,
Lantern Pharma Limited and Lantern Pharma Australia Pty Ltd. All intercompany balances and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641116004976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_ztTYvTcNMLn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2. <span id="xdx_82B_zQmod8txtjWb">Liquidity</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurred a net loss of approximately $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20220101__20221231_z2mAQGpuskhg" title="Net loss">14,260,000</span> and $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20210101__20211231_z1tdLjXU7bw8" title="Net loss">12,363,000</span> during the years ended December 31, 2022 and 2021, respectively.
As of December 31, 2022, the Company had working capital of approximately $<span id="xdx_904_ecustom--WorkingCapital_iI_c20221231_zrtdWeDwpRu1" title="Working capital">55,924,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2021, the Company closed a public offering of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20210119__20210120__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zRO3hhwYkJ42" title="Number of shares issued for public offering">4,928,571</span> shares of its common stock at a public offering price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pp0p0_c20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember_zBoIBiZrOCa9" title="Share price per share">14.00</span> per
share, which amount included <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210119__20210120__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z0gDpVjsHJa3" title="Number of sale of stock shares">642,856</span> shares sold upon full exercise of the underwriter&#8217;s over-allotment option. Total gross proceeds
from the offering were approximately $<span id="xdx_90D_ecustom--ProceedsFromIssuanceInitialPublicOfferingGross_pp0p0_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember_zsdaQBiRpVii" title="Proceeds from initial public offering, gross">69,000,000</span>, and net proceeds from the offering were approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20210119__20210120__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z1mJI3a6rYc7" title="Proceeds from initial public offering, net">64,200,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company plans to continue to explore periodic capital raises and also plans to apply for grant funding in the future to assist in supporting
its capital needs. We may also explore the possibility of entering into commercial credit facilities as an additional source of liquidity.
We believe that our existing cash as of December 31, 2022, and our anticipated expenditures and capital commitments, will enable us to
fund our operating expenses and capital expenditure requirements for at least 12 months from the date of filing this Form 10-K for the
year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115887696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zPRgW2YHqfa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3. <span><span id="xdx_821_zhWeFP8gEcJe">Summary of Significant Accounting Policies</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_zXg2zPDVZuR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zSQnrYOSpXhk">Use
of Estimates and Assumptions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research
and development accruals, the inputs in determining the fair value of equity-based awards and warrants issued, the inputs in determining
present value of lease payments, and fair value of marketable securities. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zLEi4D1e7COj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zjMYeCa6GLw6">Risks
and Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations
are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including
the potential risk of business failure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extent of the future impact and effects of the coronavirus (COVID-19) on the operation and financial performance of the
Company&#8217;s business will depend on future developments, including the duration of continuation or the resurgence of the outbreak and varying virus
mutations, recovery times of disrupted research services, the consequential staff
shortages, and research and development delays, or the uncertainty with respect to the accessibility of additional liquidity or
capital markets, all of which are highly uncertain and cannot be predicted. If the Company&#8217;s operations are impacted by the
outbreak for an extended period, the Company&#8217;s results of operations or liquidity may be materially adversely
affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
marketable securities have had and may in the future have their market value fluctuate due to rises or falls in interest rates.
While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute
assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain
significant amounts of cash and cash equivalents at one or more financial institutions that are federally insured. Interest bearing
and non-interest bearing accounts we hold at these banking institutions are guaranteed by the Federal Deposit Insurance Corporation
(&#8220;FDIC&#8221;) up to $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zsCLCkkgHuH1" title="Cash FDIC Insured amount">250,000</span>
per depositor, per FDIC-insured bank, per ownership category. Substantially all of our cash balances held at banking institutions at
December 31, 2022 are in excess of FDIC coverage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zDlow0VHDCt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses,
costs for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&#8217;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as the work
is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative
future use are expensed when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMUdTwaWKak4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zG2zmHmnv8na">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers money market funds and other highly liquid instruments with a short-term maturity of 3 months or less to be cash
equivalents. Cash equivalents at December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20221231_zoyAMstiJb7a" title=" Cash and cash equivalents">1,271,000</span>
and $<span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20211231_zOQWCMjuuOEi" title=" Cash and cash equivalents">631,000</span>,
respectively, and are included along with cash under the caption cash and cash equivalents on the Company&#8217;s consolidated
balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zwqxXNZoTcW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zSq6r7GuxG3l">Restricted
Cash</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers cash held in escrow for the purposes of contractual contingencies to be restricted cash. Restricted cash at December
31, 2022 and 2021 was approximately $<span id="xdx_900_eus-gaap--RestrictedCash_iI_pn3d_c20221231_zTArnyOcC7Mg" title="Restricted cash">541,000</span> and $<span id="xdx_902_eus-gaap--RestrictedCash_iI_pn3d_c20211231_ziLuzhjb51l4" title="Restricted cash">1,000,000</span>, respectively, and is included under the caption restricted cash on the Company&#8217;s
consolidated balance sheets. All of the restricted cash at December 31, 2022 and 2021 relates to escrow amounts paid in connection with
the Asset Purchase Agreement entered into by the Company and Allarity Therapeutics in July 2021 (See Note 4) and is considered a current
asset at December 31, 2022, as the milestones that could require payments to be made to Allarity Therapeutics must be satisfied within
the next 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_ecustom--PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_zURCpDLlU7B8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zIHIxYGZWJn4">Prepaid
Expenses and Other Current Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets as of December 31, 2022 totaled approximately $<span id="xdx_90C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3d_c20221231_zh9iHNiQ95h2" title="Prepaid expense and other current assets">2,985,000</span> and included approximately $<span id="xdx_902_ecustom--UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_iI_c20221231_zlj9rfbKFoa4" title="Upfront payments for contractor fees, academic research studies and services, and subscriptions">1,633,000</span> of upfront
payments for contractor fees, academic research studies and services, and subscriptions, approximately $<span id="xdx_907_ecustom--IntellectualPropertyRelatedLicensingAndOtherFees_iI_c20221231_zdQ1HIshK7M9" title="Intellectual property related licensing and other fees">256,000</span> of intellectual property
related licensing and other fees, approximately $<span id="xdx_90C_eus-gaap--PrepaidInsurance_iI_c20221231_ztN2UxSRyOlb" title="Prepaid annual insurance fees">504,000</span> of prepaid annual insurance fees, and approximately $<span id="xdx_90A_eus-gaap--InterestReceivable_iI_c20221231_zgNc0JfiF4ff" title="Interest receivable">592,000</span> of receivables
from interest and tax incentives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets as of December 31, 2021 totaled approximately $<span id="xdx_903_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3d_c20211231_zidfOT2LsFRf" title="Prepaid expense and other current assets">1,991,000</span> and included approximately $<span id="xdx_903_ecustom--UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_iI_c20211231_z6Qa5CahR727" title="Upfront payments for contractor fees, academic research studies and services, and subscriptions">778,000</span> of upfront
payments for contractor fees, academic research studies and services, and subscriptions, approximately $<span id="xdx_901_ecustom--IntellectualPropertyRelatedLicensingAndOtherFees_iI_c20211231_zJ96CFz4MKy6" title="Intellectual property related licensing and other fees">379,000</span> of intellectual property
related licensing and other fees, approximately $<span id="xdx_90E_eus-gaap--PrepaidInsurance_iI_c20211231_zeUxrx6IwIV8" title="Prepaid annual insurance fees">653,000</span> of prepaid annual insurance fees, and approximately $<span id="xdx_90F_eus-gaap--InterestReceivable_iI_c20211231_zOfUnKAPK33l" title="Interest receivable">181,000</span> of receivables
from interest and tax incentives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_ecustom--LoanPursuantToPaycheckProtectionProgramPolicyTextBlock_zWTWF7abPwkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zE0qm2RU2T4d">Loan
Pursuant to Paycheck Protection Program</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2020, the Company received $<span id="xdx_908_eus-gaap--ProceedsFromLoans_c20200430__20200501_zvCVwJXAqTSl" title="Proceeds from loans">108,500</span> in aggregate loan proceeds (the &#8220;PPP Loan&#8221;) from JPMorgan Chase Bank (the &#8220;Lender&#8221;)
pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan was evidenced
by a loan application and payment agreement by and between the Company and the Lender. The Company applied for forgiveness of the loan,
and in April 2021 the Company received notice that the Small Business Administration (SBA) had authorized full forgiveness of the PPP
Loan (see Note 9). Forgiveness is subject to review by the SBA for a period of six years from the date of forgiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zHur5rnvKbn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zWuyE71fys4e">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use
(&#8220;ROU&#8221;) assets, current portion of operating lease liabilities, and net of current portion of operating lease liabilities
on our consolidated balance sheets. Lease ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term
and lease liabilities represent an obligation to make lease payments arising from the lease. Lease ROU assets and lease liabilities are
recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company&#8217;s
leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement
date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term unless
it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a
straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease
term of twelve months or less, and instead will recognize lease payments as expense on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zMYurijcnfJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zk5xM1PZEO64">Marketable
Securities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s marketable securities consist of government and agency securities, corporate bonds, and mutual funds. We classify our
marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date.
We may sell these securities at any time for use in current operations even if they have not yet reached maturity. As a result, we classify
our investments, including securities with maturities beyond twelve months, as current assets in the accompanying consolidated balance
sheets. Available-for-sale debt securities are recorded at fair value each reporting period. Unrealized gains and losses are excluded
from earnings and recorded as a separate component within &#8220;Accumulated other comprehensive income&#8221; or &#8220;Accumulated
other comprehensive loss&#8221; on the consolidated balance sheets until realized. Interest is reported within &#8220;Interest income&#8221;
and dividend income is reported within &#8220;Other (expense) income, net&#8221; on the consolidated statements of operations. We evaluate
our investments to assess whether the amortized cost basis is in excess of estimated fair value and determine what amount of that difference,
if any, is caused by expected credit losses. Allowance for credit losses are recognized as a charge in &#8220;Other income, net&#8221;
on the consolidated statements of operations, and any remaining unrealized losses are included in &#8220;Accumulated other comprehensive
loss&#8221; on the consolidated balance sheets. There were no credit losses recorded for the year ended December 31, 2022. There was
no impairment charge for any unrealized losses for the years ended December 31, 2022 and 2021. We determine realized gains and losses
on the sale of marketable securities based on the specific identification method and record such gains and losses in &#8220;Other (expense)
income, net&#8221; on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_z19ijevwkvY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z8fPfYRTGmrj">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities
using enacted tax rates which will be in effect when the differences reverse. The Company provides a full valuation allowance against
net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z8uNpAyOZFi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zT03SiCvtWWa">Stock-based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
awards have been accounted for as required by ASC 718 <i>Compensation - Stock Compensation</i>. Under ASC 718, awards are valued at fair
value on the date of grant, and that fair value is recognized over the requisite service period. Forfeitures are accounted for as they
occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqgEgpiqiWJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zDCIikpk1GQg">New
Accounting Pronouncements, Not Yet Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Current
Expected Credit Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016 the FASB issued ASU 2016-13<i>, Measurement of Credit Losses on Financial Instruments</i> (Topic 326). This introduces new
methodology for recognition of credit losses - the current expected credit loss (&#8220;CECL&#8221;) method. The CECL method requires
the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument, unless
the company elects to recognize such instruments at fair value with changes in profit and loss. CECL is effective for the Company on
January 1, 2023. The Company believes it will not be materially impacted by the adoption of this new standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_ecustom--RecentlyAdoptedAccountingPolicyPolicyTextBlock_zxlkXvTagwD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zGsBbSls047a">Recently
Adopted Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Government
Assistance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2021 the FASB issued ASU 2021-10, <i>Government Assistance</i> (Topic 832). This introduces new guidance to increase transparency
of government assistance. It requires annual disclosures about transactions with a government, including those accounted for by applying
a grant. This includes the nature of the transactions and related accounting policy used to account for the transactions, the line items
on the balance sheet and income statement that are affected by the transactions, and significant terms and conditions of the transactions.
The Company adopted ASU 2021-10 on January 1, 2022 and has not been materially impacted by its adoption.</span></p>

<p id="xdx_85A_zNVPrjcBCuBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115891120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zAN0ZksGnwYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4: <span id="xdx_825_zlcyhtG80ktd">Commitments and Contingencies</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into, and expects to enter into from time to time in the future, license agreements, strategic alliance agreements,
assignment agreements, research service agreements, and similar agreements related to the advancement of its product candidates and research
and development efforts. Significant agreements are described in detail below (collectively, the &#8220;License, Strategic Alliance,
and Research Agreements&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_zUPp1vlrXnNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below are the approximate amounts expensed for License, Strategic Alliance, and Research Agreements during the years ended December
31, 2022 and 2021, respectively. These expensed amounts are included under research and development expenses in the accompanying consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zVUnjwSUHIfc" style="display: none">Schedule
of Research and Development</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_497_20220112__20221231_zOUgZjK3bGtf" style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_498_20210112__20211231_zxxQ7bnsvSAa" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 60%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentIncomeExpense_zJTowY9OJshd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amount Expensed for License, Strategic Alliance, and Research Agreements</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,222,000<sup id="xdx_F20_zJyrcaOateCf" style="display: none">*</sup></td><td style="text-align: left">*</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,483,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -4.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F04_zn7AYHnTtB0c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_z2HINIcl3DNl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    expensed for License, Strategic Alliance, and Research Agreements during the year ended December 31, 2022 were reduced by $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc2VhcmNoIGFuZCBEZXZlbG9wbWVudCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_ecustom--DecreaseInResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_z7s66XaiK7U3" title="Research and development expense">935,000</span>
    as a result of a payment we received in July 2022 from one of our service providers in connection with the resolution of a difference
    of views regarding the service provider agreement. This payment received by us offset other expenses for License, Strategic Alliance,
    and Research Agreements during this period.</span></td></tr>
  </table>
<p id="xdx_8A3_z3SbIh5eGBN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_znasbpNuzUnd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below at December 31, 2022 and December 31, 2021, respectively, are (1) the approximate amounts accrued and payable under the License,
Strategic Alliance, and Research Agreements, and (2) the approximate amount of prepaid expenses and other current assets under the License,
Strategic Alliance, and Research Agreements. These amounts are included in the accompanying consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zbVBWCwKdtOg" style="display: none">Schedule
of Accounts Payable and Accrued Liabilities</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20221231_zkXhnstfatwk" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20211231_zgfYgbkPpbze" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_hus-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_zG8FxVxSRKti" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    accrued and payable under License, Strategic Alliance, and Research Agreements</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,813,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,493,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_zwfMMA3k4Gx5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements</span></p>
                                                                           <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,595,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,023,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A0_zdSdMa76fWZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>BioNumerik
Pharmaceuticals</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2018, the Company entered into an Assignment Agreement (the &#8220;Assignment Agreement&#8221;) with BioNumerik Pharmaceuticals,
Inc. (&#8220;BioNumerik&#8221;), pursuant to which the Company acquired rights to domestic and international patents, trademarks and
related technology and data relating to LP-300 (Tavocept) for human therapeutic treatment indications. The Assignment Agreement replaced
a License Agreement that was entered into between the Company and BioNumerik in May 2016. The Company made upfront payments totaling
$<span id="xdx_907_ecustom--UpfrontPayments_c20180101__20180131__dei--LegalEntityAxis__custom--BioNumerikPharmaceuticalsMember__us-gaap--TypeOfArrangementAxis__custom--AssignmentAgreementMember_zFAjeqreVDKe" title="Upfront payments">25,000</span> in connection with entry into the Assignment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20180101__20180131__dei--LegalEntityAxis__custom--BioNumerikPharmaceuticalsMember__us-gaap--TypeOfArrangementAxis__custom--AssignmentAgreementMember_z06dfS5pNtug" title="Commitments description">In
the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment
recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100
million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250
million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative
revenue in excess of $1 billion</span>. The Company has the right to first recover certain designated portions of patent costs and development
and regulatory costs before the payment of royalties described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company enters into a third-party transaction for LP-300, the Company is required to pay the BioNumerik-related payment recipients
a specified percentage of any upfront, milestone, and royalty amounts received by the Company from the transaction, after first recovering
specified direct costs incurred by the Company for the development of LP-300 that are not otherwise reimbursed from such third-party
transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Assignment Agreement provides that the Company will use commercially diligent efforts to develop LP-300 and make specified
regulatory filings and pay specified development and regulatory costs related to LP-300. The Assignment Agreement also provides that
the Company will provide TriviumVet DAC (&#8220;TriviumVet&#8221;) with (i) specified data and information generated by the Company with
respect to LP-300, and (ii) an exclusive license to use specified LP-300-related patent rights, trademark rights and related intellectual
property to support LP-300 development in non-human (animal) treatment indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is also required to pay all patent costs on covered patents related to LP-300. These patent costs are included in general and
administrative expenses in the accompanying consolidated statements of operations. These patent costs are fully recoverable at the time
of any net revenue from LP-300, with up to <span id="xdx_904_ecustom--RevenuePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--AssignmentAgreementMember_zwf8N1qM35kg" title="Revenue percentage">50</span>% of net revenue amounts to be applied towards repayment of patent costs until such costs
are fully recovered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the recovery of patent costs, the Company has the right to recover the $<span id="xdx_901_ecustom--UpfrontPayments_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--AssignmentAgreementMember_zaP9kmEn5iXj" title="Upfront payments">25,000</span>
upfront payments made in connection with entry into the Assignment Agreement, which payments are recoverable prior to making any
royalty or third-party transaction sharing payments. The Company also has the right to recover previously incurred LP-300
development and regulatory costs, with up to a mid-single digit percentage of net revenue amounts to be applied towards repayment of
development and regulatory costs until such costs are fully recovered. No amounts were expensed with respect to BioNumerik during the years ended
December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AF
Chemicals</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2015, the Company entered into a Technology License Agreement to exclusively license domestic and international patent rights
from AF Chemicals, LLC (&#8220;AF Chemicals&#8221;) for the treatment of cancer in humans for the compounds LP-100 (Irofulven) and LP-184.
In February 2016, the Company and AF Chemicals entered into an Addendum (the &#8220;Addendum&#8221;) providing for additions and amendments
to the Technology License Agreement. In December 2020, the Company and AF Chemicals entered into a Second Addendum (the &#8220;Second
Addendum&#8221;) providing for further additions and amendments to the Technology License Agreement. The Technology License Agreement,
Addendum and Second Addendum are collectively referred to as the &#8220;AFC License Agreement&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Second Addendum, the Company made specified payments to AF Chemicals during the nine months ended September 30, 2021. The Second
Addendum also provides that, from December 30, 2020 until January 15, 2025, the Company will have no obligation to pay annual licensing
fees, development diligence extension payments, or patent maintenance fee payments to AFC under the AFC License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Second Addendum, the Company has agreed to apply for specified orphan drug designations for LP-184 in the US and EU. The
Second Addendum also amends and clarifies other provisions of the Technology License Agreement, and provides the Company with the ability
to recover a portion of initial payments made under the Second Addendum from sublicense fees or royalty payments that may be made to
AFC by the Company or third parties prior to January 15, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the AFC License Agreement the Company made annual licensing fee payments to AF Chemicals relating to LP-184 for periods prior to signing
the Second Addendum. In addition, the Company is obligated to make milestone payments to AF Chemicals at the time of an Investigational
New Drug Application (&#8220;IND&#8221;) filing relating to LP-184 and also upon reaching additional specified milestones in connection
with the development and potential marketing approval of LP-184 in the United States, specified countries in Europe, and other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
AFC License Agreement also provides that the Company will pay AF Chemicals a royalty of at least a very small single digit percentage
of specified net sales of LP-184 and other analogs. <span id="xdx_901_ecustom--LicenseAgreementDescription_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--AFCLicenseAgreementMember__dei--LegalEntityAxis__custom--AFChemicalsMember_ziBTHI0moiqh" title="License agreement, description">In addition, the AFC License Agreement contains specified time requirements for the
Company to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the
Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two,
three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated by
the Company and AF Chemicals</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Second Addendum, no additional payments of annual licensing fees or development diligence extension payments related to LP-184
are required to be made by the Company until January 15, 2025, at which time these obligations will resume. The Company will also be
obligated to make payments to AF Chemicals relating to LP-100 beginning January 15, 2025, as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a sublicense of the LP-184 rights, the Company is obligated to pay AF Chemicals (a) a low double-digit percentage of the
gross income and fees received by the Company with respect to the United States in connection with such sublicense, and (b) a lower double
digit percentage of the gross income and fees received by the Company with respect to Europe and Japan in connection with such sublicense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts to be paid to AF Chemicals with respect to LP-100 under the AFC License Agreement are in many ways similar to the amounts to
be paid with respect to LP-184 as described above. In addition, the AFC License Agreement contains specified time requirements for
the Company to enroll patients in clinical trials and file a potential NDA with respect to LP-100. Extension fees may be paid by the
Company to AF Chemicals from time to time related to these requirements. Pursuant to the Second Addendum with AF Chemicals, no
additional payments of annual licensing fees or development diligence extension payments are required to be made by the Company with
respect to LP-100 until January 15, 2025, at which time these obligations will resume. Approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--AFCLicenseAgreementMember__dei--LegalEntityAxis__custom--AFChemicalsMember_zsF7ehEx02Sg" title="Research and development expenses">125,000</span> and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--AFCLicenseAgreementMember__dei--LegalEntityAxis__custom--AFChemicalsMember_zbNHbA2TTpIh" title="Research and development expenses">145,000</span> were
expensed with respect to the AFC License Agreement during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development
expenses in the accompanying consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Allarity
Therapeutics (formerly known as Oncology Venture)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2015, the Company licensed various rights to LP-100 to Oncology Venture (now known as Allarity Therapeutics) pursuant to a Drug License
and Development Agreement. In February 2016, the Company and Allarity Therapeutics entered into an addendum and an amendment providing
for additions and amendments to the Drug License and Development Agreement. In connection with the Drug License and Development Agreement,
as amended (collectively, the &#8220;Allarity License and Development Agreement&#8221;), Allarity Therapeutics agreed to directly pay
to AF Chemicals on behalf of the Company certain amounts to satisfy the Company&#8217;s milestone obligations to AF Chemicals with respect
to LP-100 under the AFC License Agreement. Amounts paid by Allarity Therapeutics to AF Chemicals on behalf of the Company would then
be deducted from amounts owed by Allarity Therapeutics to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 23, 2021, the Company entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for
Irofulven (LP-100) from Allarity. The transaction includes global rights to LP-100, as well as the developed clinical protocol for an
intended study in bladder and prostate cancer patients who have a mutation in the ERCC2/3 genes. As a result of this transaction, the
Company has full authority to manage and guide future clinical development and commercialization of LP-100. Under the terms of the Asset
Purchase Agreement, the Company paid an initial upfront payment of $<span id="xdx_90C_ecustom--UpfrontPayments_c20210721__20210723__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zTKtmNl1saf4" title="Upfront payments">1,000,000</span> to Allarity. The Company determined there was no planned
alternative future use for these assets outside of the clinical development of LP-100 and therefore the full amount of the upfront payment
was included in research and development expense. The Company released approximately $<span id="xdx_90B_eus-gaap--EscrowDepositsRelatedToPropertySales_c20210721__20210723__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zKC9qLhW0M9j" title="Escrow related expenses">459,000</span> from escrow to Allarity related to recertification
of LP-100 drug stock during the year ended December 31, 2022. Future payments of up to $<span id="xdx_907_ecustom--FuturePayments_c20210721__20210723__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z9yrlZhHK8A4" title="Future payments">500,000</span> currently held in escrow also have the
potential to deliver an additional amount to Allarity based on drug trial enrollment milestones within the 24 months following the date
of the transaction. Allarity is also eligible to receive additional milestone payments over the life of the program based on IP license
milestones and regulatory filings and approvals in the US and EU, and low- to mid-single-digit royalties on future commercial net sales.
As part of the Asset Purchase Agreement, the Allarity License and Development Agreement was terminated. Approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z0k68lfLGzDk" title="Research and development expenses">459,000</span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z0441kFNE6Ke" title="Research and development expenses">1,000,000</span> were expensed with respect to Allarity during the years ended December 31,
2022 and 2021, respectively, which amounts are included in research and development expenses in the accompanying consolidated statements
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Califia
Pharma</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, the Company entered into an Evaluation and Limited Use Agreement (the &#8220;Evaluation Agreement&#8221;) with Califia
Pharma, Inc. (&#8220;Califia&#8221;). The Evaluation Agreement provided for the Company and Califia to collaborate on the in vitro and
in vivo testing and evaluation of novel Califia linker technology and related payloads to be conjugated to a Lantern targeting entity.
The Evaluation Agreement also provided the Company with the right to negotiate with Califia for exclusive license rights to use LP-184
and related analogs as the payload with an affinity drug conjugate or small molecule drug conjugate targeting entity supplied by the
Company. The Company also had the right under the Evaluation Agreement to negotiate for non-exclusive license rights to use a targeting
entity from the Company with a payload and linker combination selected from novel specified Califia payloads and linkers. The Evaluation
Agreement expired on December 31, 2021 and the Company determined not to extend it. No amounts and approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--CalifiaPharmaMember__us-gaap--TypeOfArrangementAxis__custom--EvaluationAgreementMember_znUWQ8ND8Lvk" title="Research and development expenses"><span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--CalifiaPharmaMember__us-gaap--TypeOfArrangementAxis__custom--EvaluationAgreementMember_zYwcsvIr06b3" title="Research and development expenses">100,000</span></span> were expensed with respect to the
Califia Evaluation Agreement during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development
expenses in the accompanying consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Patheon
API Services</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">The Company has entered into agreements
with Patheon API Services, Inc. (&#8220;Patheon&#8221;) for the manufacture and supply of cGMP material to support the Company&#8217;s
Phase II clinical trial for its product candidate LP-300. In addition to producing LP-300 API (active pharmaceutical ingredient) under
cGMP (current Good Manufacturing Practices) conditions, Patheon transferred previously validated manufacturing processes and analytical
methods for LP-300 and produced non-GMP material for use in support of non-clinical studies for LP-300. The agreements provide for payments
in stages as specified process and manufacturing milestones are achieved. </span>Approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--PatheonAPIServicesMember__us-gaap--TypeOfArrangementAxis__custom--PatheonAgreementMember_z2Ozd7B0elV1" title="Research and development expenses">218,000</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--PatheonAPIServicesMember__us-gaap--TypeOfArrangementAxis__custom--PatheonAgreementMember_zNI7vQNSsVXi" title="Research and development expenses">963,000</span> was expensed with
respect to the Patheon agreements during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research
and development expenses in the accompanying consolidated statements of operations. <span style="background-color: white">The Company
expects to expense additional amounts in future periods in accordance with the progress of work completed under the Patheon agreements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Southwest
Research Institute</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">As part of the Company&#8217;s research
and development activities, the Company has engaged Southwest Research Institute (&#8220;SwRI&#8221;) from time to time to assist with
compound synthesis and manufacturing related activities for the Company&#8217;s product candidates. The Company has entered into agreements
with SwRI for the non-GMP and cGMP synthesis of LP-184 material and related analytical development</span>. Approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--SouthwestResearchInstituteMember__us-gaap--TypeOfArrangementAxis__custom--SouthwestResearchInstituteAgreementMember_zEBfGGWTUx5b" title="Research and development expenses">494,000</span> and
$<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--SouthwestResearchInstituteMember__us-gaap--TypeOfArrangementAxis__custom--SouthwestResearchInstituteAgreementMember_zU2dRsu3vpki" title="Research and development expenses">1,261,000</span> was expensed with respect to the SwRI agreements during the years ended December 31, 2022 and 2021, respectively, which amounts
are included in research and development expenses in the accompanying consolidated statements of operations. <span style="background-color: white">The
Company expects to expense additional amounts in future periods in accordance with the progress of work completed under the SwRI agreements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>The
Research Institute of Fox Chase Cancer Center</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">In September 2020, the Company entered
into a research agreement with the Research Institute of Fox Chase Cancer Center (&#8220;FCCC&#8221;), which was amended in January 2022,
as part of the Company&#8217;s research and development activities, with a focus on advancing the targeted use of LP-184 in molecularly-defined
sub-types of pancreatic cancer.</span> Approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--FoxChaseCancerCenterMember__us-gaap--TypeOfArrangementAxis__custom--FoxChaseCancerCenterAgreementMember_zYauBTp0Tky3" title="Research and development expenses">148,000</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--FoxChaseCancerCenterMember__us-gaap--TypeOfArrangementAxis__custom--FoxChaseCancerCenterAgreementMember_zLI4AKLVju15" title="Research and development expenses">202,000</span> was expensed with respect to the FCCC agreements during the
years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development expenses in the accompanying
consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Piramal
Pharma Solutions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">In January 2021, the Company entered
into an agreement with Piramal Pharma Solutions (&#8220;Piramal&#8221;) for the fill and finish manufacture of LP-300 drug product at
Piramal&#8217;s Lexington, Kentucky site in support of future Phase II clinical testing. The agreement, as amended, provides for Piramal
to conduct activities in support of the cGMP manufacturing of LP-300, including analytical and process transfer activities, manufacture
of cGMP clinical batches, and performance of stability studies on cGMP batches of LP-300 drug product. </span>Approximately $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--PiramalPharmaSolutionMember__us-gaap--TypeOfArrangementAxis__custom--PiramalPharmaAgreementMember_zhXzNZeIn1d1" title="Research and development expenses">196,000</span> and
$<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--PiramalPharmaSolutionMember__us-gaap--TypeOfArrangementAxis__custom--PiramalPharmaAgreementMember_zVE60chqUTqk" title="Research and development expenses">535,000</span> was expensed with respect to Piramal agreements during the years ended December 31, 2022 and 2021, respectively, which amounts
are included in research and development expenses in the accompanying consolidated statements of operations. <span style="background-color: white">The
Company expects to expense additional amounts in future periods in accordance with the progress of work completed under Piramal agreements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>vivoPharm</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">In September 2021, the Company&#8217;s
Australian subsidiary entered into an agreement with RDDT, a vivoPharm Company Pty Ltd (&#8220;vivoPharm&#8221;), for multiple preclinical
studies, including animal studies, as part of an IND-enabling program for LP-184. The Company&#8217;s Australian subsidiary entered into
an additional agreement with vivoPharm in 2022 as part of an IND-enabling program for LP-284. Amendments to the vivoPharm agreements were
made in 2022. </span>Approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--VivoPharmMember__us-gaap--TypeOfArrangementAxis__custom--VivoPharmAgreementMember_zxd331l1i2k8" title="Research and development expenses">1,030,000</span> and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--VivoPharmMember__us-gaap--TypeOfArrangementAxis__custom--VivoPharmAgreementMember_zuOdxvFVoFn7" title="Research and development expenses">119,000</span> was expensed with respect to the vivoPharm agreements during the years ended
December 31, 2022 and 2021, respectively, which amounts are included in research and development expenses in the accompanying consolidated
statements of operations. <span style="background-color: white">The Company expects that additional amounts will be expensed in future
periods in accordance with the progress of work completed under the vivoPharm agreements, as amended.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>TD2</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">In October 2021, the Company entered
into a Statement of Work, as amended in March 2022, with Translational Drug Development, LLC (&#8220;TD2&#8221;) providing for TD2 to
serve as the lead contract research organization (CRO) for the Company&#8217;s Phase II clinical trial for its product candidate LP-300</span>.
Approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--TranslationalDrugMember_zWXQPyxg7Yz3" title="Research and development expenses">789,000</span> and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--TranslationalDrugMember__us-gaap--TypeOfArrangementAxis__custom--TranslationalDrugAgreementMember_zctxwFNH4G69" title="Research and development expenses">158,000</span> was expensed with respect to TD2 during the years ended December 31, 2022 and 2021, respectively,
which amounts are included in research and development expenses in the accompanying consolidated statements of operations. <span style="background-color: white">The
Company expects to expense additional amounts in future periods in connection with services provided by TD2 as well as clinical trial
site and other pass-through costs relating to the LP-300 Phase II clinical trial.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Berkshire
Sterile Manufacturing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">During the year ended December 31,
2022, the Company entered into agreements with Berkshire Sterile Manufacturing (&#8220;Berkshire&#8221;) to support technical transfer
and GMP drug product manufacturing of LP-300. </span>Approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--BerkshireSteruleManufacturingMember__us-gaap--TypeOfArrangementAxis__custom--BerkshireSteruleManufacturingAgreementMember_zFJlabO90tk9" title="Research and development expenses">689,000</span> and <span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__dei--LegalEntityAxis__custom--BerkshireSteruleManufacturingMember__us-gaap--TypeOfArrangementAxis__custom--BerkshireSteruleManufacturingAgreementMember_zE2dv45VrTEg" title="Research and development expenses">no</span> amounts were expensed with respect to the Berkshire
agreements during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development expenses
in the accompanying consolidated statements of operations. <span style="background-color: white">The Company expects that additional amounts
will be expensed in future periods in accordance with the progress of work completed under the Berkshire agreements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Shilpa
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">In March 2022, the Company entered
into an agreement with Shilpa Medicare Limited (&#8220;Shilpa&#8221;) for fit-to-purpose process development and synthesis of a key starting
material relating to the synthesis of LP-184 under cGMP. </span>In July 2022, the Company entered into agreements with Shilpa Pharma Lifesciences
<span style="background-color: white">for the cGMP synthesis of LP-184 API material as well as for drug product development and cGMP drug
product manufacturing of LP-184. In August 2022, </span>the Company entered into agreements with Shilpa <span style="background-color: white">for
the cGMP synthesis of LP-284 API material as well as for drug product development and cGMP drug product manufacturing of LP-284. </span>Approximately
$<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--ShilpaMember__us-gaap--TypeOfArrangementAxis__custom--ShilpaAgreementMember_zwJ3L5YykxWd" title="Research and development expenses">707,000</span> and <span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__dei--LegalEntityAxis__custom--ShilpaMember__us-gaap--TypeOfArrangementAxis__custom--ShilpaAgreementMember_zVI1xIFFuRc5" title="Research and development expenses">no</span> amounts were expensed with respect to the Shilpa agreements during the years ended December 31, 2022 and 2021, respectively,
which amounts are included in research and development expenses in the accompanying consolidated statements of operations. <span style="background-color: white">The
Company expects that expense additional amounts in future periods in accordance with the progress of work completed payment schedule specified
under the Shilpa agreements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Curia</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="background-color: white">During the year ended December 31,
2022</span>, the Company entered into agreements with Curia Global, Inc. (&#8220;Curia&#8221;) for the cGMP manufacture of LP-300 API.
Approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--CuriaMember_zVgUp9mIZTP6" title="Research and development expenses">285,000</span> and <span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__dei--LegalEntityAxis__custom--CuriaMember_zJquMsz13Hk7" title="Research and development expenses">no</span> amounts were expensed with respect to the Curia agreements during the years ended December 31, 2022 and
2021, respectively, which amounts are included in research and development expenses in the accompanying consolidated statements of operations.
<span style="background-color: white">The Company expects that additional amounts will be expensed in future periods in accordance with
the progress of work completed under the Curia agreements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LumaBridge
(formerly known as Cancer Insight)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2022, the Company entered into an agreement with Cancer Insight,
LLC, now known as LumaBridge, LLC (&#8220;LumaBridge&#8221;) for IND filing, regulatory support, Phase I pre-trial startup activities,
and strategic program consulting relating to LP-184. Approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--LumaBridgeLLCMember__us-gaap--TypeOfArrangementAxis__custom--LumaBridgeAgreementMember_zxj6UlkiwpX6" title="Research and development expenses">82,000</span> and <span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__dei--LegalEntityAxis__custom--LumaBridgeLLCMember__us-gaap--TypeOfArrangementAxis__custom--LumaBridgeAgreementMember_zVgqywFvitr6" title="Research and development expenses">no</span> amounts were expensed with respect to the LumaBridge
agreements during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development expenses
in the accompanying consolidated statements of operations. <span style="background-color: white">The Company expects that additional amounts
will be expensed in future periods relating to services provided pursuant to the LumaBridge agreement.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Research and Service Provider Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the agreements described above, the Company has entered into other research and service provider agreements for the advancement
of its product candidates and research and development efforts. The Company expects to expense additional amounts in future periods in
connection with existing and future research and service provider agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EU
Grant</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2018, Lantern Pharma Limited, a wholly owned subsidiary of Lantern Pharma Inc., was awarded a grant by the UK government in
the form of state aid under the Commission Regulations (EU) No. 651/2014 of 17 June 2014 (the &#8220;General Block Exemption&#8221;),
Article 25 Aid for research and development projects, state aid notification no. SA.40154. The grant was awarded to conduct research
and development activities for the prostate cancer biomarker analysis of the LP-184 drug candidate. Following the Company&#8217;s research
and development activities in Northern Ireland, the grant will reimburse the Company <span id="xdx_900_ecustom--ResearchAndDevelopmentExpensesPercentage_pid_dp_uPure_c20220101__20221231__dei--LegalEntityAxis__custom--LanternPharmaLimitedMember_zSoQxvwcWtpa" title="Research and development expenses percentage">50</span>% of its research and development expenses not
exceeding GBP <span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_uGBP_c20220101__20221231__dei--LegalEntityAxis__custom--LanternPharmaLimitedMember_zPK2IUUKzRZc" title="Research and development expense">24,215</span> of vouched and approved expenditures within specific categories. The grant contains some reporting and consent requirements.
The grant will remain in force for a period of five years. No payments to the Company have been made under the grant as of December 31,
2022. <span id="xdx_90A_eus-gaap--Revenues_do_c20220101__20221231__dei--LegalEntityAxis__custom--LanternPharmaLimitedMember_zmuGo2O71Iq3" title="Revenues">No</span> revenue has been recognized from this grant through December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Actuate
Therapeutics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the Company entered into a Collaboration Agreement with Actuate Therapeutics, Inc. (&#8220;Actuate&#8221;), a clinical stage
private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases
leading to fibrosis. Pursuant to the agreement, the Company and Actuate are collaborating on utilization of the Company&#8217;s RADR&#174;
platform to develop novel biomarker derived signatures for use with one of Actuate&#8217;s product candidates. As part of the collaboration,
the Company received <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c20210501__20210531__dei--LegalEntityAxis__custom--ActuateTherapeuticsMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_z4atBO4DTVkl" title="Actuate stock of restricted shares">25,000</span> restricted shares of Actuate stock, subject to meeting certain conditions of the collaboration, as well as
the potential to receive additional Actuate stock if results from the collaboration are utilized in future development efforts. In 2022,
the term of the Collaboration Agreement was extended to continue until March 31, 2023. Leslie W. Kreis, Jr., a director of the Company
until June 8, 2022, is also a director of Actuate. Affiliates of Mr. Kreis hold substantial beneficial ownership interests in both the
Company and Actuate. Through December 31, 2022, no revenues have been recognized under the Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restricted shares of Actuate stock had a nominal value when acquired and, therefore, were recorded at a cost of $<span id="xdx_909_ecustom--NominalValueOfRestrictedSharesOfActuateStock_iI_c20210531__dei--LegalEntityAxis__custom--ActuateTherapeuticsMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zWaINJOyLoO3" title="Nominal value acquired cost">0</span>. These shares do not
have a readily determinable fair value, but will be adjusted for observable price changes, if any, in future periods. There were no adjustments
to the carrying amount through December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115799408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zd6Ss8nfEK2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5. <span id="xdx_82C_z0g7DBO49wS4">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
operating lease cost recognized in general and administrative expenses in the Company&#8217;s consolidated statements of operations was
approximately $<span id="xdx_903_eus-gaap--OtherGeneralAndAdministrativeExpense_c20220101__20221231_z31nRnU5H7Wa" title="General and administrative expenses">144,000</span> and $<span id="xdx_903_eus-gaap--OtherGeneralAndAdministrativeExpense_c20210101__20211231_z63tkB9GNhJ" title="General and administrative expenses">105,000</span> for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock_zruYKAcwdsr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following provides balance sheet information related to leases as of December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zf6b65fg8pKi" style="display: none">Schedule
of Balance Sheet Information Related to Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20221231_zJ423jqzMxSi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20211231_zUfl7QuYrqLa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                                                                                                                                31, 2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_iI_z0vwXl3Er1ih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease, right-of-use asset, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,687</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">185,943</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zwDIFaYg9LR6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    portion of operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,890</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">152,058</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z7DYTEEFNgg9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liabilities, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,890</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiability_iI_zrtrxmFjdPO8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,890</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204,948</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AD_zKTC5JCKWBS" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zj3XVayTaE11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, the future estimated minimum lease payments under non-cancelable operating leases are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zw2FsPlAcPCg" style="display: none">Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20221231_zwzvebv5Mexl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPzhbM_z9mhXktjhgVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total minimum lease payments to be paid in 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">53,403</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zBZzSORla892" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less amount representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(513</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zZf7VfB8u5V7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,890</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zdPqkOGwqUkk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less current portion of operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,890</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z2I9Tv7m5zKk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zwTE0MEFHF23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2021, the Company entered into two operating leases for office space that commenced in May 2021. <span id="xdx_90D_ecustom--LeaseExpirationDate_c20220101__20221231_z9zMkwZ5Dmvk" title="Lease expiration date">The
leases were scheduled to expire in April 2023</span> and automatically renew month-to-month unless the Company provided three-months
written notice to the landlord prior to initial expiration. The exercise of lease renewal options was at the Company&#8217;s sole
discretion and is assessed as to whether to include any renewals in the lease term at inception. In March 2023, the Company renewed and extended its leases for office space
and access to meeting facilities in the Dallas, Texas area and in the Atlanta, Georgia area. The following table provides a
reconciliation for the Company&#8217;s right of use assets and lease liabilities:</span></p>

<p id="xdx_890_ecustom--ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_zInnik6eGHC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zwBIZ2t26XO4" style="display: none">Schedule of
Reconciliation of Right-of-use Assets and Lease Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Right-of-Use Asset</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Operating Lease Liability</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2021</td><td>&#160;</td>
    <td colspan="2" id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20210101__20211231_zzxQ3ZVmxIz1" title="Right of use asst">$<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_981_eus-gaap--OperatingLeaseLiability_iS_c20210101_zEbhtgm62yig" title="Operating lease liability">$<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0698">-</span></span></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Additions</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetAdditions_c20210101__20211231_ztWO0s3ao4al" style="width: 16%; text-align: right" title="Additions, Right of use asset">274,472</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--OperatingLeaseLiabilityInAdditions_c20210101__20211231_z7G9JBWpilAh" style="width: 16%; text-align: right" title="Additions, Operating lease liability">276,603</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Amortizations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20210101__20211231_z9GwPqqo3Ci" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Right of use asset">(88,529</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--OperatingLeaseLiabilityAmortization_c20210101__20211231_z4WHHfzgVwol" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Operating lease liability">(71,655</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20220101__20221231_zJvVPMvypF5b" style="text-align: right" title="Right of use asset">185,943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--OperatingLeaseLiability_iS_c20220101__20221231_zgbyKUR1DRy" style="text-align: right" title="Operating lease liability">204,948</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Amortizations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20220101__20221231_zsAfwWz9vq7d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Right of use asset">(138,256</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--OperatingLeaseLiabilityAmortization_c20220101__20221231_zmuZTmLV85r2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Operating lease liability">(152,058</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20220101__20221231_zlz1J4108bG1" style="border-bottom: Black 2.5pt double; text-align: right" title="Right of use asset">47,687</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_iE_c20220101__20221231_zyTPt5jfwvA8" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability">52,890</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AF_zDraQNMo8Qc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock_zqkWcgENXZ77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
supplemental information related to operating leases is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BA_zYpSDAjAcdBe" style="display: none">Schedule of Other Supplemental Information
Related to Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_ztmiwWU5ot2c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_zGOho28oFFX7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Weighted average remaining term of operating leases (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zyQQ82gd8P3i" title="Weighted average remaining term of operating leases (in years)">0.33</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_z0vh5280ug33" title="Weighted average remaining term of operating leases (in years)">1.33</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zOZyxqSgt6d3" style="vertical-align: bottom; background-color: White">
    <td>Weighted average discount rate of operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.65</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.65</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A1_zQb6q64MDoke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also leased office space in Dallas, Texas under month-to-month lease arrangements during the years ended December 31, 2022 and
2021. Under these short-term leases, the Company elected the short-term lease measurement and recognition exemption under ASC 842 and
recorded rent expense as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641113447888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zd1rX7qf8OOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6. <span id="xdx_826_zf1BYOYcsMWj">Shareholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Company&#8217;s IPO, all shares of the Company&#8217;s Series A preferred stock were converted into <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20200601__20200615__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zKpZrdEiq462" title="Conversion of Stock, Shares Converted">2,438,851</span> shares of common stock
effective June 15, 2020, with fractional share adjustments made in connection with the conversion as discussed below. As of December
31, 2022 and 2021, the Company had <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zg7SGq7t4Suh" title="Preferred stock shares authorized"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zNjqF7tqr813" title="Preferred stock shares authorized">1,000,000</span></span> authorized shares of preferred stock, with <span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_dc_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcdxF2vypem9" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zqaaVR1V4MRd" title="Preferred stock, shares outstanding"><span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_dc_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztJIvOudfNV1" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTuF7EdlDQ79" title="Preferred stock, shares outstanding">zero</span></span></span></span> shares of preferred stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2021, the Company closed a public offering of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaw7nlqsMeg8" title="Issuance of stock, shares">4,928,571</span> shares of its common stock at a public offering price of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2X2Lvf00vUd" title="Share price">14.00</span> per
share, which amount included <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zRaECfCYLVr2" title="Issuance of stock, shares">642,856</span> shares sold upon full exercise of the underwriter&#8217;s over-allotment option. Total gross proceeds
from the offering were approximately $<span id="xdx_907_ecustom--GrossProceedsFromInitialPublicOffering_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z9nlwZF2sOei" title="Gross proceeds">69,000,000</span>, and net proceeds from the offering were approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zs5jrE2jesLl" title="Net proceeds">64,167,000</span>, after deducting
underwriting discounts and commissions of approximately $<span id="xdx_90C_ecustom--ProceedsAfterDeductingUnderwritingDiscountsAndCommissions_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zSyCuYuUmedh" title="Proceeds after deducting underwriting discounts and commissions">4,554,000</span> and other offering expenses of approximately $<span id="xdx_908_ecustom--OtherOfferingExpenses_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zUsR4OINnTMb" title="Other offering expenses">279,000</span>, including $<span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_c20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zsYuPfZ7Ccxl" title="Deferring offering costs">101,000</span>
of deferring offering costs previously recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2021, the Company&#8217;s Board of Directors authorized a share repurchase program to acquire up to $<span id="xdx_90F_eus-gaap--StockRepurchasedDuringPeriodShares_c20211101__20211130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zwP3mkcfcosc" title="Repurchase of shares">7,000,000</span> of the Company&#8217;s
common stock. During the year ended December 31, 2022, the Company repurchased <span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_ziU77uvTMOTi" title="Repurchase of shares">353,667</span> shares of common stock, pursuant to the repurchase
program for a total of approximately $<span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zKrm7U1P9US1" title="Repurchase of shares, value">2,482,000</span>, including purchase fees. During the year ended December 31, 2021, the Company repurchased
<span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zhMHCx2jHPYd" title="Repurchase of shares">121,490</span> shares of common stock pursuant to the repurchase program for a total of approximately $<span id="xdx_904_eus-gaap--StockRepurchasedDuringPeriodValue_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zwLcFQsqXBef" title="Repurchase of shares, value">940,000</span>, including purchase fees. Upon
purchase, the repurchased shares ceased to be outstanding and returned to the status of authorized and unissued shares of common stock.
The share repurchase program terminated July 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zpx4XQP95Aci" title="Issuance of stock, shares">11,782</span> shares of common stock relating to the exercise of stock options. The shares
were issued at a purchase price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9e8E5duAXyj" title="Share price">1.03</span> per share for total proceeds of approximately $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxDX8NAh2yAl" title="Issuance of stock, value">12,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7s18yvju3J" title="Issuance of stock, shares">40,727</span> shares of common stock relating to the cash exercise of warrants for total
proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlN92fMIdX7d" title="Proceeds from warrants exercise">127,000</span>. During the year ended December 31, 2021 the Company also issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CashlessWarrantsMember_z2Jx54LQ8aph" title="Issuance of stock, shares">8,318</span> shares of common stock relating
to the cashless exercise of warrants to purchase <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CashlessWarrantsMember_zAgqtSjTmUw7" title="Warrants to purchase shares">11,114</span> shares, respectively. All of such warrants were exercisable at an exercise price
of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CashlessWarrantsMember_zbS1WEukoKh4" title="Exercise price">3.13</span> per share of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx0hfPDJQsu3" title="Issuance of stock, shares">26,093</span> shares of common stock relating to the cashless exercise of stock options
to purchase <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcAcFjEGtOCb" title="Stock option">32,538</span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb6nuJLAyHMb" title="Issuance of stock">95,779</span> shares of common stock relating to the cash exercise of warrants for total
proceeds of approximately $<span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzbZmFoYJtif" title="Proceeds from warrants exercise">300,000</span>. All of such warrants were exercisable at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4F53g3F9A26" title="Exercise price">3.13</span> per share of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and December 31, 2021, the Company had <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zfJvt6dGqwk2" title="Common stock, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zVNTgUwyqA65" title="Common stock, shares authorized">25,000,000</span></span> authorized shares of Common Stock, of which <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20221231_zCcnhTCU6NJ1" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_z0Uk3SVXJ5F9" title="Common stock, shares outstanding">10,857,040</span></span> and <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20211231_z7HRRhFOKrVl" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zgerrfMyiAz8" title="Common stock, shares outstanding">11,088,835</span></span>
shares were issued and outstanding, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_zcwIrTM8xgt7" title="Purchase of warrants">177,998</span> shares of common stock outstanding and exercisable as of December 31, 2022 at a weighted average
exercise price of $<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231_zIQjzbe21mJ4" title="Weighted average exercise price, warrants">9.27</span> per share, and with expiration dates ranging from <span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zCh3Xxjp11c8" title="Expiration date of warrants">March 7, 2024</span> to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zlwBz2Go0tx9" title="Expiration date of warrants">June 10, 2025</span>. The Company had warrants to
purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_ztL2hgyJ0Caf" title="Purchase of warrants">273,777</span> shares of common stock outstanding and exercisable as of December 31, 2021 at a weighted average exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxXA4LHvAbwk" title="Weighted average exercise price">7.12</span>
per share, and with expiration dates ranging from <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_z3txxujWdX3f" title="Expiration date of warrants">March 17, 2022</span> to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zFzaUsMF4dQd" title="Expiration date of warrants">June 10, 2025</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2018, the Board of Directors of the Company adopted the Lantern Pharma Inc. 2018 Equity Incentive Plan, which was
subsequently amended on December 17, 2018, February 26, 2020 and October 20, 2022. The Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and
restated, is referred to herein as the &#8220;Plan&#8221;. The Company reserved <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z7dwUgNUdsvh" title="Number of reserved shares">1,489,680</span>
shares of its common stock for issuance under the Plan. The Plan is designed to provide additional incentives to employees,
directors and consultants to remain in the service of the Company as well as to encourage stock acquisition by members of these
targeted groups, which in the opinion of the management will support the alignment of the interests of the members of these groups
and stockholders. Options granted under the Plan are generally exercisable for up to <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zRQq2kTO1UR4" title="Options exercisable period">10</span>
years from grant date. <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_ziRpSSoNTxgc" title="Number of remain available shares">288,796</span>
shares remain available for future awards under the Plan at December 31, 2022, following the grant of options and the award of
restricted stock grants through December 31, 2022. The Company recorded stock-based compensation of approximately $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z1InlAtgdEtf" title="Share based compensation">1,188,000</span>
and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z9lNhRP2P72j" title="Share based compensation">962,000</span>
related to stock options during the years ended December 31, 2022 and 2021, respectively. Total remaining unrecognized compensation
expense for non-vested options is approximately $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zeFouxJC5eg7" title="Unrecognized compensation expense">1,788,000</span>
as of December 31, 2022, and is expected to be recognized over a weighted average period of <span id="xdx_902_eus-gaap--InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zQtQMGc13kM1" title="Weighted average period">1.8</span>
years. The weighted average remaining contractual term of outstanding options at December 31, 2022 is <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zMPdDsztsvm3" title="Weighted average remaining contractual term">7.26</span>
years. The weighted average remaining contractual term of exercisable options at December 31, 2022 is <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zYve3LXZuwG8" title="Weighted average remaining contractual term">6.56</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8iaSLhAL19h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity under the Plan during the years ended December 31, 2022 and 2021 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zUUItj2NWpne">Schedule
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Outstanding December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zZVhdRxrLQMl" style="width: 11%; text-align: right" title="Number of options outstanding, beginning balance">835,608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_z5lob1pEOO39" style="width: 11%; text-align: right" title="Weighted average exercise price per share, outstanding beginning">6.41</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20210101__20211231_zyrchipcFS71" style="width: 11%; text-align: right" title="Number of options exercisable, beginning valance">610,633</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_c20210101__20211231_zaHioS0jijj" style="width: 11%; text-align: right" title="Number of options exercisable, weighted-average exercise price, beginning balance">3.24</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zaq2WlG8qVNe" style="text-align: right" title="Number of shares, granted">110,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zGip72pd5LLj" style="text-align: right" title="Weighted average exercise price per share, granted">10.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20211231_zKcw48HyEOi" style="text-align: right" title="Number of shares, exercised">(11,782</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zRCD9NKFuIL2" style="text-align: right" title="Weighted average exercise price per share, exercised">1.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cancelled or expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20211231_zRsmUHoMgdue" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, cancelled or expired">(43,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zVvRtcRp6KGb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share, cancelled or expired">15.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zU6Lry8J7yVl" style="text-align: right" title="Number of shares, outstanding beginning">890,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zkULGhJ12l65" style="text-align: right" title="Weighted average exercise price per share, outstanding beginning">6.54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20220101__20221231_zisUrdXTZ5t6" style="text-align: right" title="Number of options exercisable, beginning valance">687,438</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_c20220101__20221231_zNcT6IE8E399" style="text-align: right" title="Number of options exercisable, weighted-average exercise price, beginning balance">4.77</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zsJAfx8CMb97" style="text-align: right" title="Number of shares, granted">196,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zHmXOIrVQl6l" style="text-align: right" title="Weighted average exercise price per share, granted">5.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zhucVShtxzN2" style="text-align: right" title="Number of shares, exercised">(32,538</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_z591Jknqms7c" style="text-align: right" title="Weighted average exercise price per share, exercised">1.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cancelled or expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_z92LMtRNuuk2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, cancelled or expired">(16,897</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJMXz9agYLLe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share, cancelled or expired">13.19</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zfWtMxVQ5Mz" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding beinning">1,037,591</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zr5tNq9SW4oa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, outstanding ending">6.46</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zu6TkDEIXtJ1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable, ending balance">755,073</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zjNU9WeEoGNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable, weighted-average exercise price, ending balance">5.87</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zGluRXstHgw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zETqDHuMsRsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
2022 and 2021, the fair value of each option granted was estimated using the Black-Scholes option-pricing model, using the following
weighted average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zfyjZILKeSd1">Schedule
of Weighted Average Assumptions</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zebNg2aKEHok" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_zrAg06TWqXhd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dtY_c20220101__20221231_zspC8oq5bGPh" title="Term (in years)">5.93</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dtY_c20210101__20211231_zjLkrFQsqbEi" title="Term (in years)">5.78</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_z3oLDsKXtGhl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Risk Free Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.04</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.30</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zzFQpOcVOOE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125.35</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90.70</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zAo1guIZ0QFd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_z7EQiJwxvSY3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Grant Date Fair Value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.55</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zjRCOwj73k82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of options is recognized as an expense over the vesting period and forfeitures are accounted for as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total intrinsic value of options outstanding at December 31, 2022 was approximately $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20221231_z9vOjjtW0Mzf" title="Total intrinsic value of options outstanding">2,422,000</span>, and the total intrinsic value of options
exercisable at December 31, 2022 was approximately $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20221231_zeoouegS7ku9" title="Stock option intrinsic value">2,361,000</span>. The total intrinsic value of options exercised during the year ended December
31, 2022 was approximately $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220101__20221231_zh2XTWGOkttc" title="Total intrinsic value of options exercised">136,000</span>. The total intrinsic value of options outstanding at December 31, 2021 was approximately $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20211231_zfscBSbxzPrd" title="Total intrinsic value of options outstanding">3,490,000</span>,
and the total intrinsic value of options exercisable at December 31, 2021 was approximately $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231_zZxNFbsPNl3">3,490,000</span>. The total intrinsic value of
options exercised during the year ended December 31, 2021 was approximately $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210101__20211231_zel5R7mIjCub">213,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    Term -</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company used a weighted average of time to vesting and maturity date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    Volatility-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    to the Company&#8217;s limited operating history and a lack of company-specific historical and implied volatility data, the Company
    has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded
    commensurate with expected term as of grant date. The historical volatility data was computed using the daily closing prices for
    the selected comparable companies&#8217; shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-Free
    Interest Rate-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company used the U.S. treasury bill rate commensurate with the expected term as of grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    Dividend-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    the Company has not issued any dividends and does not expect to issue dividends over the life of the options, the Company has estimated
    the dividend yield to be zero.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115893552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p id="xdx_804_eus-gaap--CashCashEquivalentsAndMarketableSecuritiesTextBlock_zt1H2oUa5jSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7. <span id="xdx_826_zASw5XuSVl3i">Marketable Securities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--MarketableSecuritiesTextBlock_zDgp5vSmG2Ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, marketable securities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zleHR3VOFLVg" style="display: none">Schedule of Marketable Securities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_488_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_zB8II5kyvdrk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized <br/> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_zqfLYKH39XVd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized <br/> Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_489_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_zxoKSlx76PT1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized <br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_ztzCC4fcTohh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_413_20221231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zt8s4WfUYz27" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,408,681</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,512</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(184,863</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,227,330</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20221231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zR2BKFzRUyo1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate Bonds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,522,138</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,565</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(210,534</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,314,169</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20221231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesDebtMember_z5DpqkWZwse4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable Securities - Debt</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,930,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(395,397</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,541,499</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_417_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zl2XTJuYuRVa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,002,704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(343,904</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,658,800</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zCSiBPIaLPUf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,023,154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(229,154</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,794,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20221231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMutualFundsMember_zZM2RCegHiLl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Marketable Securities &#8211; Mutual Funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,025,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0945">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(573,058</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,452,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20221231_zTaRiq5Xv0Pd" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities amortized cost">18,956,677</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_c20221231_zjqVUjd8Gpz3" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized gains">6,077</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_c20221231_zQ5JCprCoeoc" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized losses">(968,455</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_c20221231_zqT6EEzStmg1" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities aggregate fair value">17,994,299</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, marketable securities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none">&#160;</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_zBnhPUC2znm5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized <br/> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_483_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_zHU6pv4DreU1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized <br/> Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_zosW6frisiKh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized <br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_zHdG2JbYfeB4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_414_20211231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zoz7clhCAEnh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,808,056</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(27,003</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,781,053</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zr0syzF2qUv8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate Bonds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,540,668</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,869</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,474,799</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_410_20211231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesDebtMember_zq91oeTU5yZe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable Securities - Debt</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,348,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(92,872</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,255,852</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20211231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zAWPe48PZirl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,002,704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(36,654</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,966,050</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20211231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zboF29Gda8Di" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,023,154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,904</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,979,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20211231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMutualFundsMember_z5wLTpVc9iIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Marketable Securities &#8211; Mutual Funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,025,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(80,558</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,945,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20211231_zRlhZ4KPmIWl" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities amortized cost">19,374,582</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_c20211231_zNlQxQlRaFn4" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_c20211231_zYz7ugYX5UY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized losses">(173,430</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_c20211231_zf3B7uODs4Na" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities aggregate fair value">19,201,152</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zS42c5tqRT52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zD3S4X3ekUm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
contractual maturities of the investments classified as Government&amp; Agency Securities and Corporate Bonds are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zxxmaMcSh6hk">Schedule
of Contractual Maturities Investments of Marketable Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zFKQVYN97Q94" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_iI_maAFSSDzFK8_zpQph8UOvQ3k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Due within one year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,466,590</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue_iI_maAFSSDzFK8_zkaZHCbRdXe1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due in one to two years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,802,265</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_iI_maAFSSDzFK8_zjlNIPDHbWV5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Due in two to five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,272,644</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iTI_mtAFSSDzFK8_zX5FPKh0XyQ9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,541,499</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zTeQwfUc0Go4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zjHkptLHdgu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents gross unrealized losses and fair values for those marketable securities that were in an unrealized loss position
as of December 31, 2022, aggregated by investment category and the length of time that individual securities have been in a continuous
loss position:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zoZR39Ayy5B5">Schedule
of Gross Unrealized Losses and Fair Values for Marketable Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48B_ecustom--DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_iI_zDwy1hDV4A6l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_iNI_di_ziH3GESJ1LHh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_ecustom--DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_iI_z6pyKuuJHttg" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_486_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_iNI_di_zHzP426sPReb" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">More than 12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_417_20221231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zoRJOgb7L6ll" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,184,683</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(26,701</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,293,998</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(158,162</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_41E_20221231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zhd47NlGEY4f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Corporate Bonds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,337,938</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,516</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,383,482</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(183,018</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_41C_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zjZL9pav9we3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1009">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,658,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(343,904</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_41C_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zJNZC9cVQFia" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,794,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(229,154</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_ecustom--DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_iI_c20221231_zOAuLyDduTl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value Less than 12 months">2,522,621</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_iNI_di_c20221231_zDfk3C2GexJ2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized Loss Less than 12 months">(54,217</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_ecustom--DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_iI_c20221231_zOPXSTD5jMNk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value Less than 12 months">14,130,280</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_iNI_di_c20221231_zdTjqvKgQV9l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized Loss Less than 12 months">(914,238</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A7_zhq4h6zW71a6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe the unrealized losses represent credit losses based on our evaluation of available evidence as of December 31, 2022, which
includes an assessment of whether it is more likely than not we will be required to sell the investment before recovery of the investment&#8217;s
amortized cost basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115857808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--FairValueDisclosuresTextBlock_zRnaL37h2fK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8. <span id="xdx_82A_zaVGsJuVe5f5">Fair Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use
of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous
market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions
that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the
hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes
the inputs into three levels that may be used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability,
either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - Inputs are unobservable inputs based on our assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
available, our marketable securities are valued using quoted prices for identical instruments in active markets. If we are unable to
value our marketable securities using quoted prices for identical instruments in active markets, we value our investments using broker
reports that utilize quoted market prices for comparable instruments. As of December 31, 2022 and 2021 our available-for-sale debt securities
were valued through use of quoted prices for comparable instruments in active markets and are classified as Level 2, and our mutual funds
&#8211; alternative investments were valued using NAV, net asset value per share, under the practical expedient methodology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our valuation of our marketable securities, we concluded that they are classified in either Level 2 or NAV, and we have no financial
assets measured using Level 1 or 3 inputs. The following table presents information about our assets that are measured at fair value
on a recurring basis using the above input categories.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zEaYG8oZtPAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z0M898YdEb89" style="display: none">Schedule
of Assets are Measured at Fair Value on  Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zLSnAjDHJJBk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5YWm1SAIaAf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj61Z06UW8yc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4kiayQnQQqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231__us-gaap--SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis__custom--NAVMember_zyPj3N6ms5nk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span id="xdx_F57_zoWPyx2PZ6m9" style="display: none; font-family: Times New Roman, Times, Serif">*</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of <br/> December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NAV*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--GovernmentAgencySecuritiesMember_zXxJnnijQtzb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,227,330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1030">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,227,330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1032">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__us-gaap--CorporateBondSecuritiesMember_zkRdivqB7cBa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Corporate Bonds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,314,169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1036">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,314,169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1039">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsFixedIncomeMember_zAZyEmis3Tj5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,658,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,658,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsAlternativeInvestmentsMember_z7Cv7aIuNh9e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,794,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,794,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_zmQ5Cf10fAE1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value recurring basis</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,994,299</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,200,299</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1056">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,794,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_zXDvC6zsix3e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJxYC6RcPxPb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z2pY0y4H3xPd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMPB1xoJ1e11" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20211231__us-gaap--SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis__custom--NAVMember_zCLgidun5WWj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><sup id="xdx_F50_zxgoZA08XVO4">*</sup></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NAV*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--GovernmentAgencySecuritiesMember_zLEbiBzDuhJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,781,053</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,781,053</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__us-gaap--CorporateBondSecuritiesMember_zq24ErUzfPu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Corporate Bonds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,474,799</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,474,799</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1069">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsFixedIncomeMember_zFEJ8haMKk9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,966,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,966,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsAlternativeInvestmentsMember_zuruSy4PifEd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,979,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,979,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_z7QFRjD4aJn4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value recurring basis</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,201,152</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,221,902</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,979,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0C_zWzJkExXVfr3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zgPjcHnV7705" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    marketable securities investments are measured at fair value using net asset value per share under the practical expedient methodology.</span></td></tr>
  </table>
<p id="xdx_8A8_z67O9lcC4FLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641112470720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes and Loan Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes and Loan Payable</a></td>
<td class="text"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z5pslEi3XVFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9. <span id="xdx_82D_zyNUKDUjxndk">Notes and Loan Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2020 (the &#8220;Origination Date&#8221;), the Company received $<span id="xdx_903_eus-gaap--ProceedsFromLoanOriginations1_pp0p0_c20200429__20200501_zcEVeUPIOWb3" title="Aggregate loan amount">108,500</span> in aggregate loan proceeds (the &#8220;PPP Loan&#8221;)
from JPMorgan Chase Bank (the &#8220;Lender&#8221;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and
Economic Security (CARES) Act. The PPP Loan was evidenced by a loan application and payment agreement (the &#8220;PPP Loan Agreement&#8221;)
by and between the Company and the Lender. Subject to the terms of the PPP Loan Agreement, the PPP Loan bore interest at a fixed rate
of one percent (<span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20200429__20200501_zSFgOaCMsBZ6" title="Annual interest rate">1.0%</span>) per annum. Payments of principal and interest were deferred for the first six months following the Origination
Date, and the PPP Loan provided that it would mature two years after the Origination Date. The guidance under the Paycheck Protection
Program was later updated so that payments of principal and interest were extended past the current fiscal year and maturity was extended
past two years. The Company applied for forgiveness of the loan, and in April 2021 the Company received notice that the Small Business
Administration (SBA) had authorized full forgiveness of the PPP Loan. A gain on loan forgiveness attributed to the PPP Loan of approximately
$<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231_zT3OtypZVXPh" title="Debt face amount">109,000</span> of principal and interest for the year ended December 31, 2021 was included in Other (expense) income, net in the accompanying
consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115814496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share of Common Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share of Common Shares</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_zln4BcrPp9U6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10. <span id="xdx_821_zqH5G3wfBda8">Loss Per Share of Common Shares</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is derived by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock
outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities,
such as warrants and stock options, which would result in the issuance of incremental shares of common stock unless such effect is anti-dilutive.
In calculating the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remained
the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation. Potentially
dilutive securities outstanding that have been excluded from diluted loss per share due to being anti-dilutive include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zwuJprJJTnx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zojb0Sqk1uzd" style="display: none">Schedule
of Anti-dilutive Securities Outstanding Diluted Loss per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_z39VJRz7G9Bi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zKM4Xfud0d0h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zzGuchojeio" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">177,998</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">273,777</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNf7rIbLZ3S6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,037,591</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">890,826</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zOVBYqIqXU2f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities </span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,215,589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,164,603</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115984336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zR7L37Mczmik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11. <span id="xdx_823_z6KDmXL5bnR7">Income Taxes</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zJOJKYwJGyJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
effective tax rate differs from the statutory federal tax rate as presented in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zG8tsmdRFPd5" style="display: none">Schedule
of Effective Income Tax Rate</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zN7VSkywOZol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zOoiJkzSJtBf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zKFNj7VbdcY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">U.S. federal statutory tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_zJrzR4nIOjXc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zOfMmD9WOO75" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_z6pYKH8Lbcu4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1124">-</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A2_zvC3EOfeHov" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the Company was domiciled in Texas, and due to the losses generated and no revenues, it incurred no
current federal or state tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLuTdsOWUTUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities is presented
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zgyo4qLSNVdk" style="display: none">Schedule
of Deferred Tax Assets and Liabilities</span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_zA14LIzpMWB" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231_z5PGmAgbXmU8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zFfcIX0dsSs4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGz5Ms_zakLxFHEtOx9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify">Research and development credits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">862,366</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">479,849</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTAGz5Ms_zq9pL2LcZHwi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">441,939</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427,524</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGz5Ms_zUJTV3RmYFlf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,474,825</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,837,807</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_i01I_maDTAGz5Ms_zGwtXsKXHCkb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Unrealized losses on securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,640</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,933</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentAmortization_i01I_maDTAGz5Ms_z1twsvYeGI1j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Research and development amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,343,382</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz5Ms_maDTANzJOa_zidORvCG5REa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,185,152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,772,113</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzJOa_zapcO9j3mfn2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,181,492</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,767,059</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANzJOa_maDTALNzUQr_zFhxZH676Nj7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,054</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zedCptbdGsb6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i01NI_di_msDTALNzUQr_zZ6EdOsYusSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,660</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,054</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzUQr_zzRW3GvUWkSk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zrFwsZKwqmcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to a history of losses the Company has generated since inception, the Company believes it is more-likely-than-not that all of the deferred
tax assets will not be realized as of December 31, 2022 and 2021. Therefore, the Company has recorded a full valuation allowance on its
deferred tax assets. At December 31, 2022 and 2021, the Company has net operating loss (&#8220;NOL&#8221;) carryforwards for federal
income tax purposes of approximately $<span id="xdx_906_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20221231_zhVFqD9LEbC9" title="Net operating loss carryforwards for federal income tax">29,100,000</span> and $<span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20211231_zxWyUPtc0s5k" title="Net operating loss carryforwards for federal income tax">22,800,000</span>, respectively. <span id="xdx_90E_ecustom--NOLCarryforwardsDescription_c20220101__20221231_zRLwVu3HeYql" title="Net operating loss carryforwards, description">The NOL carryforwards generated prior to 2018 of approximately
$3,100,000 could expire over time beginning in 2035, if not used. The NOL carryforwards generated in 2018 to 2022 of approximately $26,000,000
do not expire and are carried forward indefinitely</span>. The Company has state NOLs of approximately $<span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20221231_zHPekJmzn6g2" title="Net operating loss carryforwards">780,000</span> at December 31, 2022. The Company
also has approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231_zZK4d7QTuGj2" title="Research and development tax credit carryforwards">861,000</span> of research and development tax credit carryforwards for federal purposes. These credits begin expiring
in 2034. Due to the change in ownership provisions of the Internal Revenue Code, the availability of the Company&#8217;s NOL carryforwards
and research and development credit carryforwards may be subject to annual limitations under Section 382 of the Internal Revenue Code
against taxable income in the future period, which could substantially limit the eventual utilization of such carryforwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns.
The Company has analyzed its tax positions and has concluded that as of December 31, 2022, there were no uncertain positions. In addition,
interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision, for which there were
none. The Company&#8217;s U.S. federal operating losses have occurred since its inception and as such, tax years subject to potential
tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to
audit by the IRS and/or state taxing authorities. The statute of limitations expires three years after the utilization of historical losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act of 2017 (TCJA) has modified the IRC 174 expenses related to research and development for the tax years beginning
after December 31, 2021. Under the TCJA, the Company must now capitalize the expenditures related to research and development activities
and amortize over five years for U.S. activities and 15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization
of research and development costs in accordance with IRC 174 resulted in a gross deferred tax asset of $<span id="xdx_904_eus-gaap--DeferredTaxAssetsGross_iI_c20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUe9swacUCK9" title="Gross deferred tax asset">1,343,382</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115927376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zqLwUcD55nGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12. <span id="xdx_82D_z7MDZI40JoP7">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company formed a wholly owned subsidiary, Starlight Therapeutics Inc. (&#8220;Starlight&#8221;), to develop drug candidate
LP-184&#8217;s central nervous system (CNS) and brain cancer indications &#8211; including glioblastoma (GBM), brain metastases (brain
mets.), and several rare pediatric CNS cancers. Following the formation of Starlight, the Company will refer to the molecule LP-184,
as it is developed in CNS indications, as &#8220;STAR-001&#8221;.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641113533056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Assumptions</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_zXg2zPDVZuR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zSQnrYOSpXhk">Use
of Estimates and Assumptions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research
and development accruals, the inputs in determining the fair value of equity-based awards and warrants issued, the inputs in determining
present value of lease payments, and fair value of marketable securities. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zLEi4D1e7COj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zjMYeCa6GLw6">Risks
and Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations
are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including
the potential risk of business failure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extent of the future impact and effects of the coronavirus (COVID-19) on the operation and financial performance of the
Company&#8217;s business will depend on future developments, including the duration of continuation or the resurgence of the outbreak and varying virus
mutations, recovery times of disrupted research services, the consequential staff
shortages, and research and development delays, or the uncertainty with respect to the accessibility of additional liquidity or
capital markets, all of which are highly uncertain and cannot be predicted. If the Company&#8217;s operations are impacted by the
outbreak for an extended period, the Company&#8217;s results of operations or liquidity may be materially adversely
affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
marketable securities have had and may in the future have their market value fluctuate due to rises or falls in interest rates.
While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute
assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain
significant amounts of cash and cash equivalents at one or more financial institutions that are federally insured. Interest bearing
and non-interest bearing accounts we hold at these banking institutions are guaranteed by the Federal Deposit Insurance Corporation
(&#8220;FDIC&#8221;) up to $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zsCLCkkgHuH1" title="Cash FDIC Insured amount">250,000</span>
per depositor, per FDIC-insured bank, per ownership category. Substantially all of our cash balances held at banking institutions at
December 31, 2022 are in excess of FDIC coverage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zDlow0VHDCt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses,
costs for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&#8217;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as the work
is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative
future use are expensed when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMUdTwaWKak4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zG2zmHmnv8na">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers money market funds and other highly liquid instruments with a short-term maturity of 3 months or less to be cash
equivalents. Cash equivalents at December 31, 2022 and December 31, 2021 were approximately $<span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20221231_zoyAMstiJb7a" title=" Cash and cash equivalents">1,271,000</span>
and $<span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20211231_zOQWCMjuuOEi" title=" Cash and cash equivalents">631,000</span>,
respectively, and are included along with cash under the caption cash and cash equivalents on the Company&#8217;s consolidated
balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p id="xdx_846_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zwqxXNZoTcW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zSq6r7GuxG3l">Restricted
Cash</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers cash held in escrow for the purposes of contractual contingencies to be restricted cash. Restricted cash at December
31, 2022 and 2021 was approximately $<span id="xdx_900_eus-gaap--RestrictedCash_iI_pn3d_c20221231_zTArnyOcC7Mg" title="Restricted cash">541,000</span> and $<span id="xdx_902_eus-gaap--RestrictedCash_iI_pn3d_c20211231_ziLuzhjb51l4" title="Restricted cash">1,000,000</span>, respectively, and is included under the caption restricted cash on the Company&#8217;s
consolidated balance sheets. All of the restricted cash at December 31, 2022 and 2021 relates to escrow amounts paid in connection with
the Asset Purchase Agreement entered into by the Company and Allarity Therapeutics in July 2021 (See Note 4) and is considered a current
asset at December 31, 2022, as the milestones that could require payments to be made to Allarity Therapeutics must be satisfied within
the next 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p id="xdx_848_ecustom--PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_zURCpDLlU7B8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zIHIxYGZWJn4">Prepaid
Expenses and Other Current Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets as of December 31, 2022 totaled approximately $<span id="xdx_90C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3d_c20221231_zh9iHNiQ95h2" title="Prepaid expense and other current assets">2,985,000</span> and included approximately $<span id="xdx_902_ecustom--UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_iI_c20221231_zlj9rfbKFoa4" title="Upfront payments for contractor fees, academic research studies and services, and subscriptions">1,633,000</span> of upfront
payments for contractor fees, academic research studies and services, and subscriptions, approximately $<span id="xdx_907_ecustom--IntellectualPropertyRelatedLicensingAndOtherFees_iI_c20221231_zdQ1HIshK7M9" title="Intellectual property related licensing and other fees">256,000</span> of intellectual property
related licensing and other fees, approximately $<span id="xdx_90C_eus-gaap--PrepaidInsurance_iI_c20221231_ztN2UxSRyOlb" title="Prepaid annual insurance fees">504,000</span> of prepaid annual insurance fees, and approximately $<span id="xdx_90A_eus-gaap--InterestReceivable_iI_c20221231_zgNc0JfiF4ff" title="Interest receivable">592,000</span> of receivables
from interest and tax incentives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets as of December 31, 2021 totaled approximately $<span id="xdx_903_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3d_c20211231_zidfOT2LsFRf" title="Prepaid expense and other current assets">1,991,000</span> and included approximately $<span id="xdx_903_ecustom--UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_iI_c20211231_z6Qa5CahR727" title="Upfront payments for contractor fees, academic research studies and services, and subscriptions">778,000</span> of upfront
payments for contractor fees, academic research studies and services, and subscriptions, approximately $<span id="xdx_901_ecustom--IntellectualPropertyRelatedLicensingAndOtherFees_iI_c20211231_zJ96CFz4MKy6" title="Intellectual property related licensing and other fees">379,000</span> of intellectual property
related licensing and other fees, approximately $<span id="xdx_90E_eus-gaap--PrepaidInsurance_iI_c20211231_zeUxrx6IwIV8" title="Prepaid annual insurance fees">653,000</span> of prepaid annual insurance fees, and approximately $<span id="xdx_90F_eus-gaap--InterestReceivable_iI_c20211231_zOfUnKAPK33l" title="Interest receivable">181,000</span> of receivables
from interest and tax incentives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock', window );">Loan Pursuant to Paycheck Protection Program</a></td>
<td class="text"><p id="xdx_848_ecustom--LoanPursuantToPaycheckProtectionProgramPolicyTextBlock_zWTWF7abPwkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zE0qm2RU2T4d">Loan
Pursuant to Paycheck Protection Program</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2020, the Company received $<span id="xdx_908_eus-gaap--ProceedsFromLoans_c20200430__20200501_zvCVwJXAqTSl" title="Proceeds from loans">108,500</span> in aggregate loan proceeds (the &#8220;PPP Loan&#8221;) from JPMorgan Chase Bank (the &#8220;Lender&#8221;)
pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan was evidenced
by a loan application and payment agreement by and between the Company and the Lender. The Company applied for forgiveness of the loan,
and in April 2021 the Company received notice that the Small Business Administration (SBA) had authorized full forgiveness of the PPP
Loan (see Note 9). Forgiveness is subject to review by the SBA for a period of six years from the date of forgiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zHur5rnvKbn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zWuyE71fys4e">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use
(&#8220;ROU&#8221;) assets, current portion of operating lease liabilities, and net of current portion of operating lease liabilities
on our consolidated balance sheets. Lease ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term
and lease liabilities represent an obligation to make lease payments arising from the lease. Lease ROU assets and lease liabilities are
recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company&#8217;s
leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement
date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term unless
it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a
straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease
term of twelve months or less, and instead will recognize lease payments as expense on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zMYurijcnfJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zk5xM1PZEO64">Marketable
Securities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s marketable securities consist of government and agency securities, corporate bonds, and mutual funds. We classify our
marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date.
We may sell these securities at any time for use in current operations even if they have not yet reached maturity. As a result, we classify
our investments, including securities with maturities beyond twelve months, as current assets in the accompanying consolidated balance
sheets. Available-for-sale debt securities are recorded at fair value each reporting period. Unrealized gains and losses are excluded
from earnings and recorded as a separate component within &#8220;Accumulated other comprehensive income&#8221; or &#8220;Accumulated
other comprehensive loss&#8221; on the consolidated balance sheets until realized. Interest is reported within &#8220;Interest income&#8221;
and dividend income is reported within &#8220;Other (expense) income, net&#8221; on the consolidated statements of operations. We evaluate
our investments to assess whether the amortized cost basis is in excess of estimated fair value and determine what amount of that difference,
if any, is caused by expected credit losses. Allowance for credit losses are recognized as a charge in &#8220;Other income, net&#8221;
on the consolidated statements of operations, and any remaining unrealized losses are included in &#8220;Accumulated other comprehensive
loss&#8221; on the consolidated balance sheets. There were no credit losses recorded for the year ended December 31, 2022. There was
no impairment charge for any unrealized losses for the years ended December 31, 2022 and 2021. We determine realized gains and losses
on the sale of marketable securities based on the specific identification method and record such gains and losses in &#8220;Other (expense)
income, net&#8221; on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_z19ijevwkvY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_z8fPfYRTGmrj">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities
using enacted tax rates which will be in effect when the differences reverse. The Company provides a full valuation allowance against
net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z8uNpAyOZFi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zT03SiCvtWWa">Stock-based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
awards have been accounted for as required by ASC 718 <i>Compensation - Stock Compensation</i>. Under ASC 718, awards are valued at fair
value on the date of grant, and that fair value is recognized over the requisite service period. Forfeitures are accounted for as they
occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Not Yet Adopted</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqgEgpiqiWJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zDCIikpk1GQg">New
Accounting Pronouncements, Not Yet Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Current
Expected Credit Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016 the FASB issued ASU 2016-13<i>, Measurement of Credit Losses on Financial Instruments</i> (Topic 326). This introduces new
methodology for recognition of credit losses - the current expected credit loss (&#8220;CECL&#8221;) method. The CECL method requires
the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument, unless
the company elects to recognize such instruments at fair value with changes in profit and loss. CECL is effective for the Company on
January 1, 2023. The Company believes it will not be materially impacted by the adoption of this new standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p id="xdx_843_ecustom--RecentlyAdoptedAccountingPolicyPolicyTextBlock_zxlkXvTagwD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zGsBbSls047a">Recently
Adopted Accounting Standards</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Government
Assistance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2021 the FASB issued ASU 2021-10, <i>Government Assistance</i> (Topic 832). This introduces new guidance to increase transparency
of government assistance. It requires annual disclosures about transactions with a government, including those accounted for by applying
a grant. This includes the nature of the transactions and related accounting policy used to account for the transactions, the line items
on the balance sheet and income statement that are affected by the transactions, and significant terms and conditions of the transactions.
The Company adopted ASU 2021-10 on January 1, 2022 and has not been materially impacted by its adoption.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Pursuant to Paycheck Protection Program [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently Adopted Accounting Standards [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115824112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock', window );">Schedule of Research and Development</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_zUPp1vlrXnNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below are the approximate amounts expensed for License, Strategic Alliance, and Research Agreements during the years ended December
31, 2022 and 2021, respectively. These expensed amounts are included under research and development expenses in the accompanying consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zVUnjwSUHIfc" style="display: none">Schedule
of Research and Development</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_497_20220112__20221231_zOUgZjK3bGtf" style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_498_20210112__20211231_zxxQ7bnsvSAa" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 60%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentIncomeExpense_zJTowY9OJshd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amount Expensed for License, Strategic Alliance, and Research Agreements</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,222,000<sup id="xdx_F20_zJyrcaOateCf" style="display: none">*</sup></td><td style="text-align: left">*</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,483,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -4.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F04_zn7AYHnTtB0c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_z2HINIcl3DNl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    expensed for License, Strategic Alliance, and Research Agreements during the year ended December 31, 2022 were reduced by $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc2VhcmNoIGFuZCBEZXZlbG9wbWVudCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_ecustom--DecreaseInResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_z7s66XaiK7U3" title="Research and development expense">935,000</span>
    as a result of a payment we received in July 2022 from one of our service providers in connection with the resolution of a difference
    of views regarding the service provider agreement. This payment received by us offset other expenses for License, Strategic Alliance,
    and Research Agreements during this period.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_znasbpNuzUnd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below at December 31, 2022 and December 31, 2021, respectively, are (1) the approximate amounts accrued and payable under the License,
Strategic Alliance, and Research Agreements, and (2) the approximate amount of prepaid expenses and other current assets under the License,
Strategic Alliance, and Research Agreements. These amounts are included in the accompanying consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zbVBWCwKdtOg" style="display: none">Schedule
of Accounts Payable and Accrued Liabilities</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20221231_zkXhnstfatwk" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20211231_zgfYgbkPpbze" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_hus-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_zG8FxVxSRKti" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    accrued and payable under License, Strategic Alliance, and Research Agreements</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,813,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,493,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_zwfMMA3k4Gx5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements</span></p>
                                                                           <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,595,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,023,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641110513152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule of Balance Sheet Information Related to Leases</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock_zruYKAcwdsr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following provides balance sheet information related to leases as of December 31, 2022 and December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zf6b65fg8pKi" style="display: none">Schedule
of Balance Sheet Information Related to Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20221231_zJ423jqzMxSi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20211231_zUfl7QuYrqLa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                                                                                                                                31, 2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_iI_z0vwXl3Er1ih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease, right-of-use asset, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,687</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">185,943</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zwDIFaYg9LR6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    portion of operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,890</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">152,058</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z7DYTEEFNgg9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liabilities, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,890</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiability_iI_zrtrxmFjdPO8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,890</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204,948</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases</a></td>
<td class="text"><p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zj3XVayTaE11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, the future estimated minimum lease payments under non-cancelable operating leases are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zw2FsPlAcPCg" style="display: none">Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20221231_zwzvebv5Mexl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPzhbM_z9mhXktjhgVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total minimum lease payments to be paid in 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">53,403</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zBZzSORla892" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less amount representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(513</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zZf7VfB8u5V7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,890</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zdPqkOGwqUkk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less current portion of operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,890</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z2I9Tv7m5zKk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock', window );">Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities</a></td>
<td class="text"><p id="xdx_890_ecustom--ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_zInnik6eGHC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zwBIZ2t26XO4" style="display: none">Schedule of
Reconciliation of Right-of-use Assets and Lease Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Right-of-Use Asset</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Operating Lease Liability</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2021</td><td>&#160;</td>
    <td colspan="2" id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20210101__20211231_zzxQ3ZVmxIz1" title="Right of use asst">$<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_981_eus-gaap--OperatingLeaseLiability_iS_c20210101_zEbhtgm62yig" title="Operating lease liability">$<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0698">-</span></span></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Additions</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetAdditions_c20210101__20211231_ztWO0s3ao4al" style="width: 16%; text-align: right" title="Additions, Right of use asset">274,472</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--OperatingLeaseLiabilityInAdditions_c20210101__20211231_z7G9JBWpilAh" style="width: 16%; text-align: right" title="Additions, Operating lease liability">276,603</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Amortizations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20210101__20211231_z9GwPqqo3Ci" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Right of use asset">(88,529</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--OperatingLeaseLiabilityAmortization_c20210101__20211231_z4WHHfzgVwol" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Operating lease liability">(71,655</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20220101__20221231_zJvVPMvypF5b" style="text-align: right" title="Right of use asset">185,943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--OperatingLeaseLiability_iS_c20220101__20221231_zgbyKUR1DRy" style="text-align: right" title="Operating lease liability">204,948</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Amortizations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20220101__20221231_zsAfwWz9vq7d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Right of use asset">(138,256</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--OperatingLeaseLiabilityAmortization_c20220101__20221231_zmuZTmLV85r2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Operating lease liability">(152,058</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20220101__20221231_zlz1J4108bG1" style="border-bottom: Black 2.5pt double; text-align: right" title="Right of use asset">47,687</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_iE_c20220101__20221231_zyTPt5jfwvA8" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability">52,890</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock', window );">Schedule of Other Supplemental Information Related to Operating Leases</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock_zqkWcgENXZ77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
supplemental information related to operating leases is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BA_zYpSDAjAcdBe" style="display: none">Schedule of Other Supplemental Information
Related to Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_ztmiwWU5ot2c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_zGOho28oFFX7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Weighted average remaining term of operating leases (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zyQQ82gd8P3i" title="Weighted average remaining term of operating leases (in years)">0.33</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_z0vh5280ug33" title="Weighted average remaining term of operating leases (in years)">1.33</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zOZyxqSgt6d3" style="vertical-align: bottom; background-color: White">
    <td>Weighted average discount rate of operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.65</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.65</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Balance Sheet Information Related to Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Other Supplemental Information Related To Operating Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115806688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8iaSLhAL19h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity under the Plan during the years ended December 31, 2022 and 2021 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zUUItj2NWpne">Schedule
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Outstanding December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zZVhdRxrLQMl" style="width: 11%; text-align: right" title="Number of options outstanding, beginning balance">835,608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_z5lob1pEOO39" style="width: 11%; text-align: right" title="Weighted average exercise price per share, outstanding beginning">6.41</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20210101__20211231_zyrchipcFS71" style="width: 11%; text-align: right" title="Number of options exercisable, beginning valance">610,633</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_c20210101__20211231_zaHioS0jijj" style="width: 11%; text-align: right" title="Number of options exercisable, weighted-average exercise price, beginning balance">3.24</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zaq2WlG8qVNe" style="text-align: right" title="Number of shares, granted">110,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zGip72pd5LLj" style="text-align: right" title="Weighted average exercise price per share, granted">10.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20211231_zKcw48HyEOi" style="text-align: right" title="Number of shares, exercised">(11,782</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zRCD9NKFuIL2" style="text-align: right" title="Weighted average exercise price per share, exercised">1.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cancelled or expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20211231_zRsmUHoMgdue" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, cancelled or expired">(43,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zVvRtcRp6KGb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share, cancelled or expired">15.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zU6Lry8J7yVl" style="text-align: right" title="Number of shares, outstanding beginning">890,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zkULGhJ12l65" style="text-align: right" title="Weighted average exercise price per share, outstanding beginning">6.54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20220101__20221231_zisUrdXTZ5t6" style="text-align: right" title="Number of options exercisable, beginning valance">687,438</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_c20220101__20221231_zNcT6IE8E399" style="text-align: right" title="Number of options exercisable, weighted-average exercise price, beginning balance">4.77</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zsJAfx8CMb97" style="text-align: right" title="Number of shares, granted">196,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zHmXOIrVQl6l" style="text-align: right" title="Weighted average exercise price per share, granted">5.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zhucVShtxzN2" style="text-align: right" title="Number of shares, exercised">(32,538</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_z591Jknqms7c" style="text-align: right" title="Weighted average exercise price per share, exercised">1.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cancelled or expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_z92LMtRNuuk2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, cancelled or expired">(16,897</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJMXz9agYLLe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share, cancelled or expired">13.19</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zfWtMxVQ5Mz" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding beinning">1,037,591</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zr5tNq9SW4oa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, outstanding ending">6.46</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zu6TkDEIXtJ1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable, ending balance">755,073</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zjNU9WeEoGNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable, weighted-average exercise price, ending balance">5.87</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zETqDHuMsRsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
2022 and 2021, the fair value of each option granted was estimated using the Black-Scholes option-pricing model, using the following
weighted average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zfyjZILKeSd1">Schedule
of Weighted Average Assumptions</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zebNg2aKEHok" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_zrAg06TWqXhd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Term (in years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dtY_c20220101__20221231_zspC8oq5bGPh" title="Term (in years)">5.93</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dtY_c20210101__20211231_zjLkrFQsqbEi" title="Term (in years)">5.78</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_z3oLDsKXtGhl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Risk Free Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.04</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.30</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zzFQpOcVOOE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125.35</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90.70</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zAo1guIZ0QFd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_z7EQiJwxvSY3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Grant Date Fair Value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.55</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641116725056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><p id="xdx_896_eus-gaap--MarketableSecuritiesTextBlock_zDgp5vSmG2Ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, marketable securities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zleHR3VOFLVg" style="display: none">Schedule of Marketable Securities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_488_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_zB8II5kyvdrk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized <br/> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_zqfLYKH39XVd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized <br/> Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_489_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_zxoKSlx76PT1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized <br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_ztzCC4fcTohh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_413_20221231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zt8s4WfUYz27" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,408,681</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,512</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(184,863</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,227,330</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_41D_20221231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zR2BKFzRUyo1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate Bonds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,522,138</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,565</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(210,534</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,314,169</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20221231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesDebtMember_z5DpqkWZwse4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable Securities - Debt</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,930,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(395,397</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,541,499</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_417_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zl2XTJuYuRVa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,002,704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(343,904</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,658,800</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_419_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zCSiBPIaLPUf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,023,154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(229,154</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,794,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20221231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMutualFundsMember_zZM2RCegHiLl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Marketable Securities &#8211; Mutual Funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,025,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0945">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(573,058</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,452,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20221231_zTaRiq5Xv0Pd" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities amortized cost">18,956,677</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_c20221231_zjqVUjd8Gpz3" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized gains">6,077</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_c20221231_zQ5JCprCoeoc" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized losses">(968,455</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_c20221231_zqT6EEzStmg1" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities aggregate fair value">17,994,299</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, marketable securities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none">&#160;</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_zBnhPUC2znm5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized <br/> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_483_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_zHU6pv4DreU1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized <br/> Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_zosW6frisiKh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized <br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_zHdG2JbYfeB4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate <br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_414_20211231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zoz7clhCAEnh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,808,056</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(27,003</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,781,053</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_416_20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zr0syzF2qUv8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate Bonds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,540,668</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,869</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,474,799</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_410_20211231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesDebtMember_zq91oeTU5yZe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable Securities - Debt</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,348,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(92,872</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,255,852</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_413_20211231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zAWPe48PZirl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,002,704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(36,654</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,966,050</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_41B_20211231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zboF29Gda8Di" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,023,154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,904</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,979,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_414_20211231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMutualFundsMember_z5wLTpVc9iIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Marketable Securities &#8211; Mutual Funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,025,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(80,558</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,945,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20211231_zRlhZ4KPmIWl" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities amortized cost">19,374,582</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_c20211231_zNlQxQlRaFn4" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized gains"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_c20211231_zYz7ugYX5UY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized losses">(173,430</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_c20211231_zf3B7uODs4Na" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities aggregate fair value">19,201,152</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Contractual Maturities Investments of Marketable Securities</a></td>
<td class="text"><p id="xdx_893_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zD3S4X3ekUm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
contractual maturities of the investments classified as Government&amp; Agency Securities and Corporate Bonds are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zxxmaMcSh6hk">Schedule
of Contractual Maturities Investments of Marketable Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zFKQVYN97Q94" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_iI_maAFSSDzFK8_zpQph8UOvQ3k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Due within one year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,466,590</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue_iI_maAFSSDzFK8_zkaZHCbRdXe1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due in one to two years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,802,265</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_iI_maAFSSDzFK8_zjlNIPDHbWV5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Due in two to five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,272,644</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iTI_mtAFSSDzFK8_zX5FPKh0XyQ9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,541,499</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zjHkptLHdgu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents gross unrealized losses and fair values for those marketable securities that were in an unrealized loss position
as of December 31, 2022, aggregated by investment category and the length of time that individual securities have been in a continuous
loss position:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zoZR39Ayy5B5">Schedule
of Gross Unrealized Losses and Fair Values for Marketable Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48B_ecustom--DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_iI_zDwy1hDV4A6l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_48A_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_iNI_di_ziH3GESJ1LHh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_481_ecustom--DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_iI_z6pyKuuJHttg" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_486_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_iNI_di_zHzP426sPReb" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">More than 12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrealized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_417_20221231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zoRJOgb7L6ll" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,184,683</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(26,701</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,293,998</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(158,162</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_41E_20221231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zhd47NlGEY4f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Corporate Bonds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,337,938</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,516</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,383,482</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(183,018</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_41C_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zjZL9pav9we3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1009">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,658,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(343,904</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_41C_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zJNZC9cVQFia" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,794,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(229,154</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_ecustom--DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_iI_c20221231_zOAuLyDduTl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value Less than 12 months">2,522,621</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_iNI_di_c20221231_zDfk3C2GexJ2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized Loss Less than 12 months">(54,217</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_ecustom--DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_iI_c20221231_zOPXSTD5jMNk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value Less than 12 months">14,130,280</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_iNI_di_c20221231_zdTjqvKgQV9l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized Loss Less than 12 months">(914,238</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115828944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets are Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zEaYG8oZtPAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z0M898YdEb89" style="display: none">Schedule
of Assets are Measured at Fair Value on  Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zLSnAjDHJJBk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5YWm1SAIaAf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj61Z06UW8yc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4kiayQnQQqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231__us-gaap--SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis__custom--NAVMember_zyPj3N6ms5nk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span id="xdx_F57_zoWPyx2PZ6m9" style="display: none; font-family: Times New Roman, Times, Serif">*</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of <br/> December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NAV*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--GovernmentAgencySecuritiesMember_zXxJnnijQtzb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,227,330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1030">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,227,330</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1032">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__us-gaap--CorporateBondSecuritiesMember_zkRdivqB7cBa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Corporate Bonds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,314,169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1036">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,314,169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1039">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsFixedIncomeMember_zAZyEmis3Tj5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,658,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,658,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsAlternativeInvestmentsMember_z7Cv7aIuNh9e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,794,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,794,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_zmQ5Cf10fAE1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value recurring basis</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,994,299</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,200,299</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1056">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,794,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_zXDvC6zsix3e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJxYC6RcPxPb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z2pY0y4H3xPd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMPB1xoJ1e11" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20211231__us-gaap--SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis__custom--NAVMember_zCLgidun5WWj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><sup id="xdx_F50_zxgoZA08XVO4">*</sup></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NAV*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--GovernmentAgencySecuritiesMember_zLEbiBzDuhJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Government &amp; Agency Securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,781,053</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,781,053</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__us-gaap--CorporateBondSecuritiesMember_zq24ErUzfPu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Corporate Bonds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,474,799</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,474,799</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1069">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsFixedIncomeMember_zFEJ8haMKk9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual Funds &#8211; Fixed Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,966,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,966,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsAlternativeInvestmentsMember_zuruSy4PifEd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Mutual Funds &#8211; Alternative Investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,979,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1079">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,979,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_z7QFRjD4aJn4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value recurring basis</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,201,152</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,221,902</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,979,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0C_zWzJkExXVfr3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zgPjcHnV7705" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    marketable securities investments are measured at fair value using net asset value per share under the practical expedient methodology.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115887696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share of Common Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Anti-dilutive Securities Outstanding Diluted Loss per Share</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zwuJprJJTnx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zojb0Sqk1uzd" style="display: none">Schedule
of Anti-dilutive Securities Outstanding Diluted Loss per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_z39VJRz7G9Bi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zKM4Xfud0d0h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zzGuchojeio" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">177,998</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">273,777</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNf7rIbLZ3S6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,037,591</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">890,826</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zOVBYqIqXU2f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities </span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,215,589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,164,603</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115876400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zJOJKYwJGyJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
effective tax rate differs from the statutory federal tax rate as presented in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zG8tsmdRFPd5" style="display: none">Schedule
of Effective Income Tax Rate</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zN7VSkywOZol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zOoiJkzSJtBf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zKFNj7VbdcY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">U.S. federal statutory tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_zJrzR4nIOjXc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zOfMmD9WOO75" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_z6pYKH8Lbcu4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1124">-</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLuTdsOWUTUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities is presented
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zgyo4qLSNVdk" style="display: none">Schedule
of Deferred Tax Assets and Liabilities</span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_zA14LIzpMWB" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231_z5PGmAgbXmU8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zFfcIX0dsSs4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGz5Ms_zakLxFHEtOx9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify">Research and development credits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">862,366</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">479,849</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTAGz5Ms_zq9pL2LcZHwi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">441,939</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427,524</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGz5Ms_zUJTV3RmYFlf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,474,825</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,837,807</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_i01I_maDTAGz5Ms_zGwtXsKXHCkb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Unrealized losses on securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,640</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,933</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentAmortization_i01I_maDTAGz5Ms_z1twsvYeGI1j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Research and development amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,343,382</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz5Ms_maDTANzJOa_zidORvCG5REa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,185,152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,772,113</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzJOa_zapcO9j3mfn2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,181,492</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,767,059</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANzJOa_maDTALNzUQr_zFhxZH676Nj7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,054</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zedCptbdGsb6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i01NI_di_msDTALNzUQr_zZ6EdOsYusSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,660</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,054</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzUQr_zzRW3GvUWkSk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641110459520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 20, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,259,946<span></span>
</td>
<td class="nump">$ 12,363,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,924,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LTRN_UnderwritersAgreementMember', window );">Underwriters Agreement [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued for public offering</a></td>
<td class="nump">4,928,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per share</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of sale of stock shares</a></td>
<td class="nump">642,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Proceeds from initial public offering, gross</a></td>
<td class="nump">$ 69,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net</a></td>
<td class="nump">$ 64,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_ProceedsFromIssuanceInitialPublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from initial public offering, gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_ProceedsFromIssuanceInitialPublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_UnderwritersAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_UnderwritersAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641113426448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC Insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,271,000<span></span>
</td>
<td class="nump">$ 631,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541,180<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,985,472<span></span>
</td>
<td class="nump">1,990,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions', window );">Upfront payments for contractor fees, academic research studies and services, and subscriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,633,000<span></span>
</td>
<td class="nump">778,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_IntellectualPropertyRelatedLicensingAndOtherFees', window );">Intellectual property related licensing and other fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,000<span></span>
</td>
<td class="nump">379,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid annual insurance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,000<span></span>
</td>
<td class="nump">653,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 592,000<span></span>
</td>
<td class="nump">$ 181,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Proceeds from loans</a></td>
<td class="nump">$ 108,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_IntellectualPropertyRelatedLicensingAndOtherFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intellectual property related licensing and other fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_IntellectualPropertyRelatedLicensingAndOtherFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments for contractor fees, academic research studies and services, and subscriptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115155056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Research and Development (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_ResearchAndDevelopmentIncomeExpense', window );">Amount Expensed for License, Strategic Alliance, and Research Agreements</a></td>
<td class="nump">$ 5,222,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 4,483,000<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts
    expensed for License, Strategic Alliance, and Research Agreements during the year ended December 31, 2022 were reduced by $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc2VhcmNoIGFuZCBEZXZlbG9wbWVudCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_ecustom--DecreaseInResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_z7s66XaiK7U3" title="Research and development expense">935,000</span>
    as a result of a payment we received in July 2022 from one of our service providers in connection with the resolution of a difference
    of views regarding the service provider agreement. This payment received by us offset other expenses for License, Strategic Alliance,
    and Research Agreements during this period.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_ResearchAndDevelopmentIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expensed for license, strategic alliance, and research agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_ResearchAndDevelopmentIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641110424864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Research and Development (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LTRN_LicenseStrategicAllianceAndResearchAgreementsMember', window );">License Strategic Alliance and Research Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_DecreaseInResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 935,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_DecreaseInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in research and development expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_DecreaseInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_LicenseStrategicAllianceAndResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_LicenseStrategicAllianceAndResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641113317568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements &#160;</a></td>
<td class="nump">$ 2,985,472<span></span>
</td>
<td class="nump">$ 1,990,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LTRN_LicenseStrategicAllianceAndResearchAgreementsMember', window );">License Strategic Alliance and Research Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Amount accrued and payable under License, Strategic Alliance, and Research Agreements</a></td>
<td class="nump">1,813,000<span></span>
</td>
<td class="nump">1,493,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements &#160;</a></td>
<td class="nump">$ 1,595,000<span></span>
</td>
<td class="nump">$ 1,023,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_LicenseStrategicAllianceAndResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_LicenseStrategicAllianceAndResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641111155968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 23, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,602,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,570,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LTRN_AssignmentAgreementMember', window );">Assignment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_RevenuePercentage', window );">Revenue percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_BioNumerikPharmaceuticalsMember', window );">BioNumerik Pharmaceuticals [Member] | Assignment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Commitments description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In
the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment
recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100
million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250
million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative
revenue in excess of $1 billion<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_AFChemicalsMember', window );">AF Chemicals [Member] | AFC License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_LicenseAgreementDescription', window );">License agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, the AFC License Agreement contains specified time requirements for the
Company to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the
Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two,
three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated by
the Company and AF Chemicals<span></span>
</td>
<td class="text">In addition, the AFC License Agreement contains specified time requirements for the
Company to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the
Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two,
three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated by
the Company and AF Chemicals<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_AllarityTherapeutiesMember', window );">Allarity Therapeuties [Member] | Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_UpfrontPayments', window );">Upfront payments</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDepositsRelatedToPropertySales', window );">Escrow related expenses</a></td>
<td class="nump">459,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_FuturePayments', window );">Future payments</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_CalifiaPharmaMember', window );">Califia Pharma [Member] | Evaluation Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_PatheonAPIServicesMember', window );">Patheon API Services [Member] | Patheon Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">963,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_SouthwestResearchInstituteMember', window );">Southwest Research Institute [Member] | Southwest Research Institute Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,261,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_FoxChaseCancerCenterMember', window );">Fox Chase Cancer Center [Member] | Fox Chase Cancer Center Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_PiramalPharmaSolutionMember', window );">Piramal Pharma Solution [Member] | Piramal Pharma Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_VivoPharmMember', window );">Vivo Pharm [Member] | Vivo Pharm Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_TranslationalDrugMember', window );">Translationa lDrug [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">789,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_TranslationalDrugMember', window );">Translationa lDrug [Member] | Translational Drug Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_BerkshireSteruleManufacturingMember', window );">Berkshire Sterule Manufacturing [Member] | Berkshire Sterule Manufacturing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">689,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_ShilpaMember', window );">Shilpa [Member] | Shilpa Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">707,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_CuriaMember', window );">Curia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_LumaBridgeLLCMember', window );">Luma Bridge LLC [Member] | Luma Bridge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_LanternPharmaLimitedMember', window );">Lantern Pharma Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 24,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_ResearchAndDevelopmentExpensesPercentage', window );">Research and development expenses percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=LTRN_ActuateTherapeuticsMember', window );">Actuate Therapeutics [Member] | Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Actuate stock of restricted shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_NominalValueOfRestrictedSharesOfActuateStock', window );">Nominal value acquired cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_FuturePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_FuturePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_LicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_LicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_NominalValueOfRestrictedSharesOfActuateStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal value of restricted shares of actuate stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_NominalValueOfRestrictedSharesOfActuateStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_ResearchAndDevelopmentExpensesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_ResearchAndDevelopmentExpensesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_RevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_RevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDepositsRelatedToPropertySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Escrow deposits related to property sales in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDepositsRelatedToPropertySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_AssignmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_AssignmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_BioNumerikPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_BioNumerikPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_AFChemicalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_AFChemicalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_AFCLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_AFCLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_AllarityTherapeutiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_AllarityTherapeutiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_CalifiaPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_CalifiaPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_EvaluationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_EvaluationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_PatheonAPIServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_PatheonAPIServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_PatheonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_PatheonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_SouthwestResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_SouthwestResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_SouthwestResearchInstituteAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_SouthwestResearchInstituteAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_FoxChaseCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_FoxChaseCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_FoxChaseCancerCenterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_FoxChaseCancerCenterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_PiramalPharmaSolutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_PiramalPharmaSolutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_PiramalPharmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_PiramalPharmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_VivoPharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_VivoPharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_VivoPharmAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_VivoPharmAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_TranslationalDrugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_TranslationalDrugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_TranslationalDrugAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_TranslationalDrugAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_BerkshireSteruleManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_BerkshireSteruleManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_BerkshireSteruleManufacturingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_BerkshireSteruleManufacturingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_ShilpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_ShilpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_ShilpaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_ShilpaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_CuriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_CuriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_LumaBridgeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_LumaBridgeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_LumaBridgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_LumaBridgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_LanternPharmaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_LanternPharmaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LTRN_ActuateTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LTRN_ActuateTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LTRN_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LTRN_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641113315248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Balance Sheet Information Related to Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset, net</a></td>
<td class="nump">$ 47,687<span></span>
</td>
<td class="nump">$ 185,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">52,890<span></span>
</td>
<td class="nump">152,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">52,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 52,890<span></span>
</td>
<td class="nump">$ 204,948<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641110252944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments to be paid in 2023</a></td>
<td class="nump">$ 53,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amount representing interest</a></td>
<td class="num">(513)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">52,890<span></span>
</td>
<td class="nump">$ 204,948<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of operating lease liabilities</a></td>
<td class="nump">52,890<span></span>
</td>
<td class="nump">152,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 52,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641110245280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 185,943<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">204,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_OperatingLeaseRightOfUseAssetAdditions', window );">Additions, Right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_OperatingLeaseLiabilityInAdditions', window );">Additions, Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortizations, Right of use asset</a></td>
<td class="num">(138,256)<span></span>
</td>
<td class="num">(88,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_OperatingLeaseLiabilityAmortization', window );">Amortizations, Operating lease liability</a></td>
<td class="num">(152,058)<span></span>
</td>
<td class="num">(71,655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">47,687<span></span>
</td>
<td class="nump">185,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 52,890<span></span>
</td>
<td class="nump">$ 204,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_OperatingLeaseLiabilityAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortizations, operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_OperatingLeaseLiabilityAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_OperatingLeaseLiabilityInAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions, operating lease liabilities,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_OperatingLeaseLiabilityInAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_OperatingLeaseRightOfUseAssetAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions, right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_OperatingLeaseRightOfUseAssetAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641115220064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Other Supplemental Information Related to Operating Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term of operating leases (in years)</a></td>
<td class="text">3 months 29 days<span></span>
</td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate of operating leases</a></td>
<td class="nump">4.65%<span></span>
</td>
<td class="nump">4.65%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641117151200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_LeaseExpirationDate', window );">Lease expiration date</a></td>
<td class="text">The
leases were scheduled to expire in April 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_LeaseExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_LeaseExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641113174672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, outstanding beginning</a></td>
<td class="nump">890,826<span></span>
</td>
<td class="nump">835,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price per share, outstanding beginning</a></td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="nump">$ 6.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable, beginning valance</a></td>
<td class="nump">687,438<span></span>
</td>
<td class="nump">610,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Number of options exercisable, weighted-average exercise price, beginning balance</a></td>
<td class="nump">$ 4.77<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, granted</a></td>
<td class="nump">196,200<span></span>
</td>
<td class="nump">110,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share, granted</a></td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="nump">$ 10.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, exercised</a></td>
<td class="num">(32,538)<span></span>
</td>
<td class="num">(11,782)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share, exercised</a></td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of shares, cancelled or expired</a></td>
<td class="num">(16,897)<span></span>
</td>
<td class="num">(43,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share, cancelled or expired</a></td>
<td class="nump">$ 13.19<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, outstanding beinning</a></td>
<td class="nump">1,037,591<span></span>
</td>
<td class="nump">890,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price per share, outstanding ending</a></td>
<td class="nump">$ 6.46<span></span>
</td>
<td class="nump">$ 6.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable, ending balance</a></td>
<td class="nump">755,073<span></span>
</td>
<td class="nump">687,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Number of options exercisable, weighted-average exercise price, ending balance</a></td>
<td class="nump">$ 5.87<span></span>
</td>
<td class="nump">$ 4.77<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641116909520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Weighted Average Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">5 years 11 months 4 days<span></span>
</td>
<td class="text">5 years 9 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">3.04%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">125.35%<span></span>
</td>
<td class="nump">90.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant Date Fair Value</a></td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="nump">$ 7.55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641105873456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 20, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,482,286<span></span>
</td>
<td class="nump">$ 939,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,166,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,538<span></span>
</td>
<td class="nump">11,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,857,040<span></span>
</td>
<td class="nump">11,088,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,857,040<span></span>
</td>
<td class="nump">11,088,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,998<span></span>
</td>
<td class="nump">273,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.46<span></span>
</td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="nump">$ 6.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,187,745<span></span>
</td>
<td class="nump">$ 961,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Total intrinsic value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,422,000<span></span>
</td>
<td class="nump">3,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Stock option intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,361,000<span></span>
</td>
<td class="nump">3,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,000<span></span>
</td>
<td class="nump">213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=LTRN_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of reserved shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,489,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Number of remain available shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,188,000<span></span>
</td>
<td class="nump">$ 962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,788,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Expiration date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  07,  2024<span></span>
</td>
<td class="text">Mar. 17,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Expiration date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 10,  2025<span></span>
</td>
<td class="text">Jun. 10,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,093<span></span>
</td>
<td class="nump">11,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,779<span></span>
</td>
<td class="nump">4,928,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,667<span></span>
</td>
<td class="nump">121,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,093<span></span>
</td>
<td class="nump">11,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,667<span></span>
</td>
<td class="nump">121,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,482,000<span></span>
</td>
<td class="nump">$ 940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LTRN_CashlessWarrantsMember', window );">Cashless Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_GrossProceedsFromInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="nump">$ 69,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="nump">64,167,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions', window );">Proceeds after deducting underwriting discounts and commissions</a></td>
<td class="nump">4,554,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_OtherOfferingExpenses', window );">Other offering expenses</a></td>
<td class="nump">279,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferring offering costs</a></td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock</a></td>
<td class="nump">4,928,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Common Stock [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock</a></td>
<td class="nump">642,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,438,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_GrossProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_GrossProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_OtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_OtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds after deducting underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average shares, warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining weighted average contract period of financial guarantee insurance contracts, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 55<br> -Paragraph 32<br> -URI https://asc.fasb.org/extlink&amp;oid=99379334&amp;loc=SL5751133-161288<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)(5)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=99382878&amp;loc=SL5749324-161292<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=LTRN_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=LTRN_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LTRN_CashlessWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LTRN_CashlessWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=LTRN_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=LTRN_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641111829312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities amortized cost</a></td>
<td class="nump">$ 18,956,677<span></span>
</td>
<td class="nump">$ 19,374,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities unrealized gains</a></td>
<td class="nump">6,077<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities unrealized losses</a></td>
<td class="num">(968,455)<span></span>
</td>
<td class="num">(173,430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities aggregate fair value</a></td>
<td class="nump">17,994,299<span></span>
</td>
<td class="nump">19,201,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LTRN_GovernmentAgencySecuritiesMember', window );">Government &amp; Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities amortized cost</a></td>
<td class="nump">5,408,681<span></span>
</td>
<td class="nump">3,808,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities unrealized gains</a></td>
<td class="nump">3,512<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities unrealized losses</a></td>
<td class="num">(184,863)<span></span>
</td>
<td class="num">(27,003)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities aggregate fair value</a></td>
<td class="nump">5,227,330<span></span>
</td>
<td class="nump">3,781,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LTRN_CorporateBondsMember', window );">Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities amortized cost</a></td>
<td class="nump">7,522,138<span></span>
</td>
<td class="nump">9,540,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities unrealized gains</a></td>
<td class="nump">2,565<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities unrealized losses</a></td>
<td class="num">(210,534)<span></span>
</td>
<td class="num">(65,869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities aggregate fair value</a></td>
<td class="nump">7,314,169<span></span>
</td>
<td class="nump">9,474,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LTRN_MarketableSecuritiesDebtMember', window );">Marketable Securities - Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities amortized cost</a></td>
<td class="nump">12,930,819<span></span>
</td>
<td class="nump">13,348,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities unrealized gains</a></td>
<td class="nump">6,077<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities unrealized losses</a></td>
<td class="num">(395,397)<span></span>
</td>
<td class="num">(92,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities aggregate fair value</a></td>
<td class="nump">12,541,499<span></span>
</td>
<td class="nump">13,255,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LTRN_MutualFundsFixedIncomeMember', window );">Mutual Funds - Fixed Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities amortized cost</a></td>
<td class="nump">4,002,704<span></span>
</td>
<td class="nump">4,002,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities unrealized gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities unrealized losses</a></td>
<td class="num">(343,904)<span></span>
</td>
<td class="num">(36,654)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities aggregate fair value</a></td>
<td class="nump">3,658,800<span></span>
</td>
<td class="nump">3,966,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LTRN_MutualFundsAlternativeInvestmentsMember', window );">Mutual Funds - Alternative Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities amortized cost</a></td>
<td class="nump">2,023,154<span></span>
</td>
<td class="nump">2,023,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities unrealized gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities unrealized losses</a></td>
<td class="num">(229,154)<span></span>
</td>
<td class="num">(43,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities aggregate fair value</a></td>
<td class="nump">1,794,000<span></span>
</td>
<td class="nump">1,979,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LTRN_MarketableSecuritiesMutualFundsMember', window );">Marketable Securities - Mutual Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities amortized cost</a></td>
<td class="nump">6,025,858<span></span>
</td>
<td class="nump">6,025,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities unrealized gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities unrealized losses</a></td>
<td class="num">(573,058)<span></span>
</td>
<td class="num">(80,558)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities aggregate fair value</a></td>
<td class="nump">$ 5,452,800<span></span>
</td>
<td class="nump">$ 5,945,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LTRN_GovernmentAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LTRN_GovernmentAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LTRN_CorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LTRN_CorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LTRN_MarketableSecuritiesDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LTRN_MarketableSecuritiesDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LTRN_MutualFundsFixedIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LTRN_MutualFundsFixedIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LTRN_MutualFundsAlternativeInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LTRN_MutualFundsAlternativeInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LTRN_MarketableSecuritiesMutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LTRN_MarketableSecuritiesMutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641113630560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Contractual Maturities Investments of Marketable Securities (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Due within one year</a></td>
<td class="nump">$ 5,466,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue', window );">Due in one to two years</a></td>
<td class="nump">5,802,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Due in two to five years</a></td>
<td class="nump">1,272,644<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 12,541,499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through secondth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641113366016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss', window );">Fair Value Less than 12 months</a></td>
<td class="nump">$ 2,522,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss Less than 12 months</a></td>
<td class="num">(54,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss', window );">Fair Value Less than 12 months</a></td>
<td class="nump">14,130,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss Less than 12 months</a></td>
<td class="num">(914,238)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LTRN_GovernmentAgencySecuritiesMember', window );">Government &amp; Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss', window );">Fair Value Less than 12 months</a></td>
<td class="nump">1,184,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss Less than 12 months</a></td>
<td class="num">(26,701)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss', window );">Fair Value Less than 12 months</a></td>
<td class="nump">3,293,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss Less than 12 months</a></td>
<td class="num">(158,162)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LTRN_CorporateBondsMember', window );">Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss', window );">Fair Value Less than 12 months</a></td>
<td class="nump">1,337,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss Less than 12 months</a></td>
<td class="num">(27,516)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss', window );">Fair Value Less than 12 months</a></td>
<td class="nump">5,383,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss Less than 12 months</a></td>
<td class="num">(183,018)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LTRN_MutualFundsFixedIncomeMember', window );">Mutual Funds - Fixed Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss', window );">Fair Value Less than 12 months</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss Less than 12 months</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss', window );">Fair Value Less than 12 months</a></td>
<td class="nump">3,658,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss Less than 12 months</a></td>
<td class="num">(343,904)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LTRN_MutualFundsAlternativeInvestmentsMember', window );">Mutual Funds - Alternative Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss', window );">Fair Value Less than 12 months</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss Less than 12 months</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss', window );">Fair Value Less than 12 months</a></td>
<td class="nump">1,794,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss Less than 12 months</a></td>
<td class="num">$ (229,154)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, more than 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, less than 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LTRN_GovernmentAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LTRN_GovernmentAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LTRN_CorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LTRN_CorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LTRN_MutualFundsFixedIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LTRN_MutualFundsFixedIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LTRN_MutualFundsAlternativeInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LTRN_MutualFundsAlternativeInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641111305280">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Assets are Measured at Fair Value on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17,994,299<span></span>
</td>
<td class="nump">$ 19,201,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis=LTRN_NAVMember', window );">NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,794,000<span></span>
</td>
<td class="nump">1,979,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,200,299<span></span>
</td>
<td class="nump">17,221,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_GovernmentAgencySecuritiesMember', window );">Government &amp; Agency Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,227,330<span></span>
</td>
<td class="nump">3,781,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_GovernmentAgencySecuritiesMember', window );">Government &amp; Agency Securities [Member] | NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_GovernmentAgencySecuritiesMember', window );">Government &amp; Agency Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_GovernmentAgencySecuritiesMember', window );">Government &amp; Agency Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,227,330<span></span>
</td>
<td class="nump">3,781,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_GovernmentAgencySecuritiesMember', window );">Government &amp; Agency Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,314,169<span></span>
</td>
<td class="nump">9,474,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities [Member] | NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,314,169<span></span>
</td>
<td class="nump">9,474,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_MutualFundsFixedIncomeMember', window );">Mutual Funds - Fixed Income [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,658,800<span></span>
</td>
<td class="nump">3,966,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_MutualFundsFixedIncomeMember', window );">Mutual Funds - Fixed Income [Member] | NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_MutualFundsFixedIncomeMember', window );">Mutual Funds - Fixed Income [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_MutualFundsFixedIncomeMember', window );">Mutual Funds - Fixed Income [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,658,800<span></span>
</td>
<td class="nump">3,966,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_MutualFundsFixedIncomeMember', window );">Mutual Funds - Fixed Income [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_MutualFundsAlternativeInvestmentsMember', window );">Mutual Funds - Alternative Investments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,794,000<span></span>
</td>
<td class="nump">1,979,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_MutualFundsAlternativeInvestmentsMember', window );">Mutual Funds - Alternative Investments [Member] | NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,794,000<span></span>
</td>
<td class="nump">1,979,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_MutualFundsAlternativeInvestmentsMember', window );">Mutual Funds - Alternative Investments [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_MutualFundsAlternativeInvestmentsMember', window );">Mutual Funds - Alternative Investments [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=LTRN_MutualFundsAlternativeInvestmentsMember', window );">Mutual Funds - Alternative Investments [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Certain
    marketable securities investments are measured at fair value using net asset value per share under the practical expedient methodology.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis=LTRN_NAVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis=LTRN_NAVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=LTRN_GovernmentAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=LTRN_GovernmentAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=LTRN_MutualFundsFixedIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=LTRN_MutualFundsFixedIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=LTRN_MutualFundsAlternativeInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=LTRN_MutualFundsAlternativeInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641112136320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes and Loan Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoanOriginations1', window );">Aggregate loan amount</a></td>
<td class="nump">$ 108,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Annual interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoanOriginations1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoanOriginations1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641111731120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities Outstanding Diluted Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">1,215,589<span></span>
</td>
<td class="nump">1,164,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">177,998<span></span>
</td>
<td class="nump">273,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">1,037,591<span></span>
</td>
<td class="nump">890,826<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641113510784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Permanent differences</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(24.00%)<span></span>
</td>
<td class="num">(24.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total:</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641105806928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">$ 862,366<span></span>
</td>
<td class="nump">$ 479,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">441,939<span></span>
</td>
<td class="nump">427,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">6,474,825<span></span>
</td>
<td class="nump">4,837,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities', window );">Unrealized losses on securities</a></td>
<td class="nump">62,640<span></span>
</td>
<td class="nump">26,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization', window );">Research and development amortization</a></td>
<td class="nump">1,343,382<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset</a></td>
<td class="nump">9,185,152<span></span>
</td>
<td class="nump">5,772,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(9,181,492)<span></span>
</td>
<td class="num">(5,767,059)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">3,660<span></span>
</td>
<td class="nump">5,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(3,660)<span></span>
</td>
<td class="num">(5,054)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from unrealized loss on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139641117385488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net operating loss carryforwards for federal income tax</a></td>
<td class="nump">$ 29,100,000<span></span>
</td>
<td class="nump">$ 22,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_LTRN_NOLCarryforwardsDescription', window );">Net operating loss carryforwards, description</a></td>
<td class="text">The NOL carryforwards generated prior to 2018 of approximately
$3,100,000 could expire over time beginning in 2035, if not used. The NOL carryforwards generated in 2018 to 2022 of approximately $26,000,000
do not expire and are carried forward indefinitely<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 780,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">861,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="nump">9,185,152<span></span>
</td>
<td class="nump">$ 5,772,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="nump">$ 1,343,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LTRN_NOLCarryforwardsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforward, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LTRN_NOLCarryforwardsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LTRN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:LTRN="http://lanternpharma.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ltrn-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
        </entity>
        <period>
            <instant>2023-03-06</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-192021-01-20_custom_UnderwritersAgreementMember_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:UnderwritersAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-19</startDate>
            <endDate>2021-01-20</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-20_us-gaap_OverAllotmentOptionMember_custom_UnderwritersAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:UnderwritersAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-20</instant>
        </period>
    </context>
    <context id="From2020-04-302020-05-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="From2022-01-122022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
        </entity>
        <period>
            <startDate>2022-01-12</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-122021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
        </entity>
        <period>
            <startDate>2021-01-12</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:LicenseStrategicAllianceAndResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:LicenseStrategicAllianceAndResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:LicenseStrategicAllianceAndResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-01-31_custom_BioNumerikPharmaceuticalsMember_custom_AssignmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AssignmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:BioNumerikPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AssignmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AssignmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AFCLicenseAgreementMember_custom_AFChemicalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AFCLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:AFChemicalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_AFCLicenseAgreementMember_custom_AFChemicalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AFCLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:AFChemicalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-07-212021-07-23_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:AllarityTherapeutiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-21</startDate>
            <endDate>2021-07-23</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:AllarityTherapeutiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:AllarityTherapeutiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CalifiaPharmaMember_custom_EvaluationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:EvaluationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:CalifiaPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CalifiaPharmaMember_custom_EvaluationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:EvaluationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:CalifiaPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PatheonAPIServicesMember_custom_PatheonAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:PatheonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:PatheonAPIServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PatheonAPIServicesMember_custom_PatheonAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:PatheonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:PatheonAPIServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SouthwestResearchInstituteMember_custom_SouthwestResearchInstituteAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:SouthwestResearchInstituteAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:SouthwestResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SouthwestResearchInstituteMember_custom_SouthwestResearchInstituteAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:SouthwestResearchInstituteAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:SouthwestResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_FoxChaseCancerCenterMember_custom_FoxChaseCancerCenterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:FoxChaseCancerCenterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:FoxChaseCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_FoxChaseCancerCenterMember_custom_FoxChaseCancerCenterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:FoxChaseCancerCenterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:FoxChaseCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PiramalPharmaSolutionMember_custom_PiramalPharmaAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:PiramalPharmaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:PiramalPharmaSolutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PiramalPharmaSolutionMember_custom_PiramalPharmaAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:PiramalPharmaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:PiramalPharmaSolutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VivoPharmMember_custom_VivoPharmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:VivoPharmAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:VivoPharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_VivoPharmMember_custom_VivoPharmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:VivoPharmAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:VivoPharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TranslationalDrugMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:TranslationalDrugMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TranslationalDrugMember_custom_TranslationalDrugAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:TranslationalDrugAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:TranslationalDrugMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_BerkshireSteruleManufacturingMember_custom_BerkshireSteruleManufacturingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:BerkshireSteruleManufacturingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:BerkshireSteruleManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_BerkshireSteruleManufacturingMember_custom_BerkshireSteruleManufacturingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:BerkshireSteruleManufacturingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:BerkshireSteruleManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ShilpaMember_custom_ShilpaAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:ShilpaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:ShilpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ShilpaMember_custom_ShilpaAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:ShilpaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:ShilpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CuriaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:CuriaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CuriaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:CuriaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LumaBridgeLLCMember_custom_LumaBridgeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:LumaBridgeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:LumaBridgeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_LumaBridgeLLCMember_custom_LumaBridgeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:LumaBridgeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:LumaBridgeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LanternPharmaLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:LanternPharmaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-05-31_custom_ActuateTherapeuticsMember_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:ActuateTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-31_custom_ActuateTherapeuticsMember_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LTRN:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LTRN:ActuateTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-01-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="From2020-06-012020-06-15_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-192021-01-20_us-gaap_IPOMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-19</startDate>
            <endDate>2021-01-20</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-20_us-gaap_IPOMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-20</instant>
        </period>
    </context>
    <context id="From2021-01-192021-01-20_us-gaap_IPOMember_us-gaap_CommonStockMember_custom_UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">LTRN:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-19</startDate>
            <endDate>2021-01-20</endDate>
        </period>
    </context>
    <context id="From2021-01-192021-01-20_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-19</startDate>
            <endDate>2021-01-20</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-20_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-20</instant>
        </period>
    </context>
    <context id="From2021-11-012021-11-30_us-gaap_CommonStockMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CashlessWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LTRN:CashlessWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CashlessWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LTRN:CashlessWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LTRN:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LTRN:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">LTRN:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:CorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MarketableSecuritiesDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MarketableSecuritiesDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MarketableSecuritiesMutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MarketableSecuritiesMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_GovernmentAgencySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:CorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MarketableSecuritiesDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MarketableSecuritiesDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MutualFundsFixedIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MutualFundsAlternativeInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MarketableSecuritiesMutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LTRN:MarketableSecuritiesMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_GovernmentAgencySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_custom_GovernmentAgencySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_custom_GovernmentAgencySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_GovernmentAgencySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NAVMember_custom_GovernmentAgencySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NAVMember_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MutualFundsFixedIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsFixedIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsFixedIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsFixedIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NAVMember_custom_MutualFundsFixedIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MutualFundsAlternativeInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsAlternativeInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsAlternativeInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsAlternativeInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NAVMember_custom_MutualFundsAlternativeInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NAVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_GovernmentAgencySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_custom_GovernmentAgencySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_custom_GovernmentAgencySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_GovernmentAgencySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NAVMember_custom_GovernmentAgencySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NAVMember_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MutualFundsFixedIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsFixedIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsFixedIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsFixedIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NAVMember_custom_MutualFundsFixedIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsFixedIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MutualFundsAlternativeInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsAlternativeInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsAlternativeInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsAlternativeInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NAVMember_custom_MutualFundsAlternativeInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">LTRN:MutualFundsAlternativeInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NAVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">LTRN:NAVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-292020-05-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember16419640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0001763950</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0056"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0073"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0094"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0100"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0106"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0107"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0207"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0214"
      unitRef="Shares"
      xsi:nil="true"/>
    <LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0221"
      unitRef="USD"
      xsi:nil="true"/>
    <LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0240"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0282"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0293"
      unitRef="Shares"
      xsi:nil="true"/>
    <LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0352"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0363"
      unitRef="Shares"
      xsi:nil="true"/>
    <LTRN:GainOnLoanForgiveness
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <LTRN:ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0674"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0696"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2021-01-01"
      id="xdx2ixbrl0698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember"
      id="xdx2ixbrl0937"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      id="xdx2ixbrl0941"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2022-12-31_custom_MarketableSecuritiesMutualFundsMember"
      id="xdx2ixbrl0945"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2021-12-31_custom_GovernmentAgencySecuritiesMember"
      id="xdx2ixbrl0957"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2021-12-31_custom_CorporateBondsMember"
      id="xdx2ixbrl0961"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2021-12-31_custom_MarketableSecuritiesDebtMember"
      id="xdx2ixbrl0965"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2021-12-31_custom_MutualFundsFixedIncomeMember"
      id="xdx2ixbrl0969"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2021-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      id="xdx2ixbrl0973"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2021-12-31_custom_MarketableSecuritiesMutualFundsMember"
      id="xdx2ixbrl0977"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0983"
      unitRef="USD"
      xsi:nil="true"/>
    <LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember"
      id="xdx2ixbrl1008"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember"
      id="xdx2ixbrl1009"
      unitRef="USD"
      xsi:nil="true"/>
    <LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      id="xdx2ixbrl1012"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      id="xdx2ixbrl1013"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_custom_GovernmentAgencySecuritiesMember"
      id="xdx2ixbrl1030"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_GovernmentAgencySecuritiesMember"
      id="xdx2ixbrl1032"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_custom_NAVMember_custom_GovernmentAgencySecuritiesMember"
      id="xdx2ixbrl1033"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateBondSecuritiesMember"
      id="xdx2ixbrl1036"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateBondSecuritiesMember"
      id="xdx2ixbrl1038"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_custom_NAVMember_us-gaap_CorporateBondSecuritiesMember"
      id="xdx2ixbrl1039"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsFixedIncomeMember"
      id="xdx2ixbrl1042"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsFixedIncomeMember"
      id="xdx2ixbrl1044"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_custom_NAVMember_custom_MutualFundsFixedIncomeMember"
      id="xdx2ixbrl1045"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsAlternativeInvestmentsMember"
      id="xdx2ixbrl1048"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsAlternativeInvestmentsMember"
      id="xdx2ixbrl1049"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsAlternativeInvestmentsMember"
      id="xdx2ixbrl1050"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1054"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1056"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_custom_GovernmentAgencySecuritiesMember"
      id="xdx2ixbrl1060"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_GovernmentAgencySecuritiesMember"
      id="xdx2ixbrl1062"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_custom_NAVMember_custom_GovernmentAgencySecuritiesMember"
      id="xdx2ixbrl1063"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateBondSecuritiesMember"
      id="xdx2ixbrl1066"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateBondSecuritiesMember"
      id="xdx2ixbrl1068"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_custom_NAVMember_us-gaap_CorporateBondSecuritiesMember"
      id="xdx2ixbrl1069"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsFixedIncomeMember"
      id="xdx2ixbrl1072"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsFixedIncomeMember"
      id="xdx2ixbrl1074"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_custom_NAVMember_custom_MutualFundsFixedIncomeMember"
      id="xdx2ixbrl1075"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsAlternativeInvestmentsMember"
      id="xdx2ixbrl1078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsAlternativeInvestmentsMember"
      id="xdx2ixbrl1079"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsAlternativeInvestmentsMember"
      id="xdx2ixbrl1080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1084"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1086"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1124"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1125"
      unitRef="Pure"
      xsi:nil="true"/>
    <LTRN:DeferredTaxAssetsResearchAndDevelopmentAmortization
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1145"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1163"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">Lantern Pharma Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-39318</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">46-3973463</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">1920                                             McKinney Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-12-31">7th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">Dallas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">75201</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">(972)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">277-1136</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">Common     Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-12-31">LTRN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2022-01-01to2022-12-31">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2022-01-01to2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">51002262</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-06" decimals="INF" unitRef="Shares">10857040</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2022-01-01to2022-12-31">Portions
of the registrant&#x2019;s definitive proxy statement for the registrant&#x2019;s 2023 Annual Meeting of Stockholders to be filed pursuant
to Regulation 14A within 120 days of the registrant&#x2019;s year ended December 31, 2022 are incorporated herein by reference into Part
III of this Annual Report on Form 10-K</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">EisnerAmper LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">Iselin, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">37201786</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">51524295</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">541180</us-gaap:RestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">17994299</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">19201152</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2985472</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1990953</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">58722737</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">72716400</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">48008</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">30245</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">47687</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">185943</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">17889</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">17889</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">58836321</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">73950477</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2745407</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2174109</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">52890</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">152058</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2798297</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2326167</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">52890</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2798297</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2379057</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">10857040</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">10857040</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">11088835</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">11088835</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1086</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1109</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">95691194</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">96685924</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-371386</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-92689</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-39282870</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-25022924</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">56038024</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">71571420</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">58836321</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">73950477</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5829799</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5020928</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">8602954</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">7570580</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">14432753</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">12591508</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-14432753</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-12591508</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">204355</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">67929</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-31548</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">160550</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-14259946</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-12363029</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-1.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-1.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">10850579</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">10904927</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-14259946</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-12363029</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-296448</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-92872</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">17751</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">183</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-278697</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-92689</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-14538643</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-12455718</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6220927</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">622</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">32358068</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-12659895</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">19698795</us-gaap:StockholdersEquity>
    <LTRN:StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">49045</LTRN:StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises>
    <LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5</LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises>
    <LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">127470</LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises>
    <LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">127475</LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">11782</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">12134</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">12135</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4928571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">493</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">64166361</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">64166854</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">121490</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">12</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">939654</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">939666</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">961545</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">961545</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-12363029</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-12363029</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-92689</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-92689</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">11088835</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1109</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">96685924</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-92689</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-25022924</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">71571420</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">11088835</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1109</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">96685924</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-92689</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-25022924</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">71571420</us-gaap:StockholdersEquity>
    <LTRN:StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">95779</LTRN:StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises>
    <LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">10</LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises>
    <LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">299778</LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises>
    <LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">299788</LTRN:StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">26093</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">3</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-3</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">353667</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">36</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2482250</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2482286</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1187745</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1187745</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-14259946</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-14259946</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-278697</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-278697</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">10857040</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1086</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">95691194</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-371386</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-39282870</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">56038024</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">10857040</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1086</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">95691194</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-371386</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-39282870</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">56038024</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-14259946</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-12363029</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">10081</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">6761</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">81870</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">140506</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <LTRN:NoncashLeaseAdjustments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">144600</LTRN:NoncashLeaseAdjustments>
    <LTRN:NoncashLeaseAdjustments
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">90660</LTRN:NoncashLeaseAdjustments>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1187745</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">961545</us-gaap:ShareBasedCompensation>
    <LTRN:GainOnLoanForgiveness
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">108500</LTRN:GainOnLoanForgiveness>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-58598</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-128922</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-492501</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-80557</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-158402</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-71655</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1033820</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">984463</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">580359</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1622084</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-33991</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-12767492</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-10591543</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">27844</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">15499</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">3912570</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">19579180</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4119682</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">64093</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">179268</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-19530586</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">68999994</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">4783816</us-gaap:PaymentsOfStockIssuanceCosts>
    <LTRN:ProceedsFromStockOptionAndWarrantExercises
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">299788</LTRN:ProceedsFromStockOptionAndWarrantExercises>
    <LTRN:ProceedsFromStockOptionAndWarrantExercises
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">139610</LTRN:ProceedsFromStockOptionAndWarrantExercises>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2482286</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">939666</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-2182498</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">63416122</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-10607</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1070</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-14781329</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">33295063</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">52524295</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">19229232</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">37742966</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">52524295</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">37201786</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">51524295</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">541180</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1000000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">37742966</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">52524295</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <LTRN:ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-49324</LTRN:ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds>
    <us-gaap:DebtSecuritiesUnrealizedGainLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-296448</us-gaap:DebtSecuritiesUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesUnrealizedGainLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-92872</us-gaap:DebtSecuritiesUnrealizedGainLoss>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zT3NMCMgvmdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1. &lt;span id="xdx_826_zYbgIuijlbP"&gt;Organization, Principal Activities, and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lantern
Pharma Inc., and Subsidiaries (the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company, focused on leveraging artificial
intelligence (&#x201c;A.I.&#x201d;), machine learning and genomic data to streamline the drug development process and to identify the patients
that will benefit from its targeted oncology therapies. The Company&#x2019;s portfolio of therapies consists of small molecule drug candidates
that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that it is developing with
the assistance of its A.I. platform and its biomarker driven approach. The Company&#x2019;s A.I. platform, known as RADR&lt;sup&gt;&#xae;&lt;/sup&gt;,
uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature,
phenotypic data from trials and publications, and mechanistic pathway data) and machine learning. The Company&#x2019;s data-driven, genomically-targeted
and biomarker-driven approach allows it to pursue a transformational drug development strategy that identifies, rescues or develops,
and advances potential small molecule drug candidates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lantern
Pharma Inc. was incorporated under the laws of the state of Texas on November 7, 2013, and thereafter reincorporated in the state of
Delaware on January 15, 2020. The Company&#x2019;s principal operations are located in Texas. The Company formed a wholly owned subsidiary,
Lantern Pharma Limited, in the United Kingdom in July 2017 and a wholly owned subsidiary, Lantern Pharma Australia Pty Ltd, in Australia
in September 2021. In January 2023, the Company formed a wholly owned subsidiary, Starlight Therapeutics Inc. (&#x201c;Starlight&#x201d;),
to develop drug candidate LP-184&#x2019;s central nervous system (CNS) and brain cancer indications.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
inception, the Company has devoted substantially all its activity to advancing research and development, including efforts in connection
with preclinical studies, clinical trials and development of its RADR platform. This now includes four drug candidates and an Antibody
Drug Conjugate (ADC) program directed towards eleven disclosed therapeutic targets:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;LP-100
    (irofulven) focused on combination with PARP inhibitors;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;LP-300
    (Tavocept), which we launched in a Phase II clinical trial, the Harmonic&lt;sup&gt;&#x2122;&lt;/sup&gt; trial in July 2022, focused on never smokers
    with advanced non-small cell lung cancer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;LP-184
    in preclinical studies for treatment of solid tumors including pancreatic, prostate, and bladder cancers, and glioblastoma and other
    CNS cancers. Following the formation of Starlight, the Company will refer to the molecule LP-184, as it is developed in CNS indications,
    as &#x201c;STAR-001&#x201d;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;LP-284,
    the stereoisomer (enantiomer) of LP-184, that has shown promising &lt;i&gt;in-vitro &lt;/i&gt;and &lt;i&gt;in vivo&lt;/i&gt; anticancer activity in multiple hematological cancers, which are distinct from the indications targeted by LP-184; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
    ADC program commenced in early 2021, and is aimed at identifying targeted or therapeutic antibodies to conjugate with selected compounds.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s fiscal year ends on December 31 of each calendar year. The accompanying consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and include all adjustments
necessary for the fair presentation of the Company&#x2019;s financial position, results of operations, and cash flows for each period
presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
reference in these notes to applicable guidance refers to Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards
Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). To date, the Company has operated its business
as one segment. The Company&#x2019;s consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries,
Lantern Pharma Limited and Lantern Pharma Australia Pty Ltd. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_ztTYvTcNMLn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2. &lt;span id="xdx_82B_zQmod8txtjWb"&gt;Liquidity&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company incurred a net loss of approximately $&lt;span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20220101__20221231_z2mAQGpuskhg" title="Net loss"&gt;14,260,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20210101__20211231_z1tdLjXU7bw8" title="Net loss"&gt;12,363,000&lt;/span&gt; during the years ended December 31, 2022 and 2021, respectively.
As of December 31, 2022, the Company had working capital of approximately $&lt;span id="xdx_904_ecustom--WorkingCapital_iI_c20221231_zrtdWeDwpRu1" title="Working capital"&gt;55,924,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 20, 2021, the Company closed a public offering of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20210119__20210120__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zRO3hhwYkJ42" title="Number of shares issued for public offering"&gt;4,928,571&lt;/span&gt; shares of its common stock at a public offering price of $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pp0p0_c20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember_zBoIBiZrOCa9" title="Share price per share"&gt;14.00&lt;/span&gt; per
share, which amount included &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210119__20210120__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z0gDpVjsHJa3" title="Number of sale of stock shares"&gt;642,856&lt;/span&gt; shares sold upon full exercise of the underwriter&#x2019;s over-allotment option. Total gross proceeds
from the offering were approximately $&lt;span id="xdx_90D_ecustom--ProceedsFromIssuanceInitialPublicOfferingGross_pp0p0_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember_zsdaQBiRpVii" title="Proceeds from initial public offering, gross"&gt;69,000,000&lt;/span&gt;, and net proceeds from the offering were approximately $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20210119__20210120__us-gaap--TypeOfArrangementAxis__custom--UnderwritersAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z1mJI3a6rYc7" title="Proceeds from initial public offering, net"&gt;64,200,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company plans to continue to explore periodic capital raises and also plans to apply for grant funding in the future to assist in supporting
its capital needs. We may also explore the possibility of entering into commercial credit facilities as an additional source of liquidity.
We believe that our existing cash as of December 31, 2022, and our anticipated expenditures and capital commitments, will enable us to
fund our operating expenses and capital expenditure requirements for at least 12 months from the date of filing this Form 10-K for the
year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-14260000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-3"
      unitRef="USD">-12363000</us-gaap:NetIncomeLoss>
    <LTRN:WorkingCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">55924000</LTRN:WorkingCapital>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-192021-01-20_custom_UnderwritersAgreementMember_us-gaap_OverAllotmentOptionMember"
      decimals="0"
      unitRef="Shares">4928571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-01-20_us-gaap_OverAllotmentOptionMember_custom_UnderwritersAgreementMember"
      decimals="0"
      unitRef="USDPShares">14.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-01-192021-01-20_custom_UnderwritersAgreementMember_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      unitRef="Shares">642856</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <LTRN:ProceedsFromIssuanceInitialPublicOfferingGross
      contextRef="From2021-01-192021-01-20_custom_UnderwritersAgreementMember_us-gaap_OverAllotmentOptionMember"
      decimals="0"
      unitRef="USD">69000000</LTRN:ProceedsFromIssuanceInitialPublicOfferingGross>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-01-192021-01-20_custom_UnderwritersAgreementMember_us-gaap_OverAllotmentOptionMember"
      decimals="0"
      unitRef="USD">64200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zPRgW2YHqfa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3. &lt;span&gt;&lt;span id="xdx_821_zhWeFP8gEcJe"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zXg2zPDVZuR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zSQnrYOSpXhk"&gt;Use
of Estimates and Assumptions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research
and development accruals, the inputs in determining the fair value of equity-based awards and warrants issued, the inputs in determining
present value of lease payments, and fair value of marketable securities. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zLEi4D1e7COj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zjMYeCa6GLw6"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations
are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including
the potential risk of business failure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
extent of the future impact and effects of the coronavirus (COVID-19) on the operation and financial performance of the
Company&#x2019;s business will depend on future developments, including the duration of continuation or the resurgence of the outbreak and varying virus
mutations, recovery times of disrupted research services, the consequential staff
shortages, and research and development delays, or the uncertainty with respect to the accessibility of additional liquidity or
capital markets, all of which are highly uncertain and cannot be predicted. If the Company&#x2019;s operations are impacted by the
outbreak for an extended period, the Company&#x2019;s results of operations or liquidity may be materially adversely
affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
marketable securities have had and may in the future have their market value fluctuate due to rises or falls in interest rates.
While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute
assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain
significant amounts of cash and cash equivalents at one or more financial institutions that are federally insured. Interest bearing
and non-interest bearing accounts we hold at these banking institutions are guaranteed by the Federal Deposit Insurance Corporation
(&#x201c;FDIC&#x201d;) up to $&lt;span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zsCLCkkgHuH1" title="Cash FDIC Insured amount"&gt;250,000&lt;/span&gt;
per depositor, per FDIC-insured bank, per ownership category. Substantially all of our cash balances held at banking institutions at
December 31, 2022 are in excess of FDIC coverage.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zDlow0VHDCt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and Development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses,
costs for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&#x2019;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as the work
is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative
future use are expensed when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMUdTwaWKak4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zG2zmHmnv8na"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers money market funds and other highly liquid instruments with a short-term maturity of 3 months or less to be cash
equivalents. Cash equivalents at December 31, 2022 and December 31, 2021 were approximately $&lt;span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20221231_zoyAMstiJb7a" title=" Cash and cash equivalents"&gt;1,271,000&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20211231_zOQWCMjuuOEi" title=" Cash and cash equivalents"&gt;631,000&lt;/span&gt;,
respectively, and are included along with cash under the caption cash and cash equivalents on the Company&#x2019;s consolidated
balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zwqxXNZoTcW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zSq6r7GuxG3l"&gt;Restricted
Cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers cash held in escrow for the purposes of contractual contingencies to be restricted cash. Restricted cash at December
31, 2022 and 2021 was approximately $&lt;span id="xdx_900_eus-gaap--RestrictedCash_iI_pn3d_c20221231_zTArnyOcC7Mg" title="Restricted cash"&gt;541,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--RestrictedCash_iI_pn3d_c20211231_ziLuzhjb51l4" title="Restricted cash"&gt;1,000,000&lt;/span&gt;, respectively, and is included under the caption restricted cash on the Company&#x2019;s
consolidated balance sheets. All of the restricted cash at December 31, 2022 and 2021 relates to escrow amounts paid in connection with
the Asset Purchase Agreement entered into by the Company and Allarity Therapeutics in July 2021 (See Note 4) and is considered a current
asset at December 31, 2022, as the milestones that could require payments to be made to Allarity Therapeutics must be satisfied within
the next 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_zURCpDLlU7B8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zIHIxYGZWJn4"&gt;Prepaid
Expenses and Other Current Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets as of December 31, 2022 totaled approximately $&lt;span id="xdx_90C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3d_c20221231_zh9iHNiQ95h2" title="Prepaid expense and other current assets"&gt;2,985,000&lt;/span&gt; and included approximately $&lt;span id="xdx_902_ecustom--UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_iI_c20221231_zlj9rfbKFoa4" title="Upfront payments for contractor fees, academic research studies and services, and subscriptions"&gt;1,633,000&lt;/span&gt; of upfront
payments for contractor fees, academic research studies and services, and subscriptions, approximately $&lt;span id="xdx_907_ecustom--IntellectualPropertyRelatedLicensingAndOtherFees_iI_c20221231_zdQ1HIshK7M9" title="Intellectual property related licensing and other fees"&gt;256,000&lt;/span&gt; of intellectual property
related licensing and other fees, approximately $&lt;span id="xdx_90C_eus-gaap--PrepaidInsurance_iI_c20221231_ztN2UxSRyOlb" title="Prepaid annual insurance fees"&gt;504,000&lt;/span&gt; of prepaid annual insurance fees, and approximately $&lt;span id="xdx_90A_eus-gaap--InterestReceivable_iI_c20221231_zgNc0JfiF4ff" title="Interest receivable"&gt;592,000&lt;/span&gt; of receivables
from interest and tax incentives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets as of December 31, 2021 totaled approximately $&lt;span id="xdx_903_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3d_c20211231_zidfOT2LsFRf" title="Prepaid expense and other current assets"&gt;1,991,000&lt;/span&gt; and included approximately $&lt;span id="xdx_903_ecustom--UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_iI_c20211231_z6Qa5CahR727" title="Upfront payments for contractor fees, academic research studies and services, and subscriptions"&gt;778,000&lt;/span&gt; of upfront
payments for contractor fees, academic research studies and services, and subscriptions, approximately $&lt;span id="xdx_901_ecustom--IntellectualPropertyRelatedLicensingAndOtherFees_iI_c20211231_zJ96CFz4MKy6" title="Intellectual property related licensing and other fees"&gt;379,000&lt;/span&gt; of intellectual property
related licensing and other fees, approximately $&lt;span id="xdx_90E_eus-gaap--PrepaidInsurance_iI_c20211231_zeUxrx6IwIV8" title="Prepaid annual insurance fees"&gt;653,000&lt;/span&gt; of prepaid annual insurance fees, and approximately $&lt;span id="xdx_90F_eus-gaap--InterestReceivable_iI_c20211231_zOfUnKAPK33l" title="Interest receivable"&gt;181,000&lt;/span&gt; of receivables
from interest and tax incentives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--LoanPursuantToPaycheckProtectionProgramPolicyTextBlock_zWTWF7abPwkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zE0qm2RU2T4d"&gt;Loan
Pursuant to Paycheck Protection Program&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 1, 2020, the Company received $&lt;span id="xdx_908_eus-gaap--ProceedsFromLoans_c20200430__20200501_zvCVwJXAqTSl" title="Proceeds from loans"&gt;108,500&lt;/span&gt; in aggregate loan proceeds (the &#x201c;PPP Loan&#x201d;) from JPMorgan Chase Bank (the &#x201c;Lender&#x201d;)
pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan was evidenced
by a loan application and payment agreement by and between the Company and the Lender. The Company applied for forgiveness of the loan,
and in April 2021 the Company received notice that the Small Business Administration (SBA) had authorized full forgiveness of the PPP
Loan (see Note 9). Forgiveness is subject to review by the SBA for a period of six years from the date of forgiveness.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zHur5rnvKbn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zWuyE71fys4e"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use
(&#x201c;ROU&#x201d;) assets, current portion of operating lease liabilities, and net of current portion of operating lease liabilities
on our consolidated balance sheets. Lease ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term
and lease liabilities represent an obligation to make lease payments arising from the lease. Lease ROU assets and lease liabilities are
recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company&#x2019;s
leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement
date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term unless
it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a
straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease
term of twelve months or less, and instead will recognize lease payments as expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zMYurijcnfJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zk5xM1PZEO64"&gt;Marketable
Securities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s marketable securities consist of government and agency securities, corporate bonds, and mutual funds. We classify our
marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date.
We may sell these securities at any time for use in current operations even if they have not yet reached maturity. As a result, we classify
our investments, including securities with maturities beyond twelve months, as current assets in the accompanying consolidated balance
sheets. Available-for-sale debt securities are recorded at fair value each reporting period. Unrealized gains and losses are excluded
from earnings and recorded as a separate component within &#x201c;Accumulated other comprehensive income&#x201d; or &#x201c;Accumulated
other comprehensive loss&#x201d; on the consolidated balance sheets until realized. Interest is reported within &#x201c;Interest income&#x201d;
and dividend income is reported within &#x201c;Other (expense) income, net&#x201d; on the consolidated statements of operations. We evaluate
our investments to assess whether the amortized cost basis is in excess of estimated fair value and determine what amount of that difference,
if any, is caused by expected credit losses. Allowance for credit losses are recognized as a charge in &#x201c;Other income, net&#x201d;
on the consolidated statements of operations, and any remaining unrealized losses are included in &#x201c;Accumulated other comprehensive
loss&#x201d; on the consolidated balance sheets. There were no credit losses recorded for the year ended December 31, 2022. There was
no impairment charge for any unrealized losses for the years ended December 31, 2022 and 2021. We determine realized gains and losses
on the sale of marketable securities based on the specific identification method and record such gains and losses in &#x201c;Other (expense)
income, net&#x201d; on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_z19ijevwkvY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_z8fPfYRTGmrj"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities
using enacted tax rates which will be in effect when the differences reverse. The Company provides a full valuation allowance against
net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z8uNpAyOZFi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zT03SiCvtWWa"&gt;Stock-based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
awards have been accounted for as required by ASC 718 &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt;. Under ASC 718, awards are valued at fair
value on the date of grant, and that fair value is recognized over the requisite service period. Forfeitures are accounted for as they
occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqgEgpiqiWJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zDCIikpk1GQg"&gt;New
Accounting Pronouncements, Not Yet Adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Current
Expected Credit Loss&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016 the FASB issued ASU 2016-13&lt;i&gt;, Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (Topic 326). This introduces new
methodology for recognition of credit losses - the current expected credit loss (&#x201c;CECL&#x201d;) method. The CECL method requires
the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument, unless
the company elects to recognize such instruments at fair value with changes in profit and loss. CECL is effective for the Company on
January 1, 2023. The Company believes it will not be materially impacted by the adoption of this new standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--RecentlyAdoptedAccountingPolicyPolicyTextBlock_zxlkXvTagwD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zGsBbSls047a"&gt;Recently
Adopted Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Government
Assistance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2021 the FASB issued ASU 2021-10, &lt;i&gt;Government Assistance&lt;/i&gt; (Topic 832). This introduces new guidance to increase transparency
of government assistance. It requires annual disclosures about transactions with a government, including those accounted for by applying
a grant. This includes the nature of the transactions and related accounting policy used to account for the transactions, the line items
on the balance sheet and income statement that are affected by the transactions, and significant terms and conditions of the transactions.
The Company adopted ASU 2021-10 on January 1, 2022 and has not been materially impacted by its adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85A_zNVPrjcBCuBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zXg2zPDVZuR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zSQnrYOSpXhk"&gt;Use
of Estimates and Assumptions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research
and development accruals, the inputs in determining the fair value of equity-based awards and warrants issued, the inputs in determining
present value of lease payments, and fair value of marketable securities. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zLEi4D1e7COj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zjMYeCa6GLw6"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations
are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including
the potential risk of business failure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
extent of the future impact and effects of the coronavirus (COVID-19) on the operation and financial performance of the
Company&#x2019;s business will depend on future developments, including the duration of continuation or the resurgence of the outbreak and varying virus
mutations, recovery times of disrupted research services, the consequential staff
shortages, and research and development delays, or the uncertainty with respect to the accessibility of additional liquidity or
capital markets, all of which are highly uncertain and cannot be predicted. If the Company&#x2019;s operations are impacted by the
outbreak for an extended period, the Company&#x2019;s results of operations or liquidity may be materially adversely
affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
marketable securities have had and may in the future have their market value fluctuate due to rises or falls in interest rates.
While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute
assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain
significant amounts of cash and cash equivalents at one or more financial institutions that are federally insured. Interest bearing
and non-interest bearing accounts we hold at these banking institutions are guaranteed by the Federal Deposit Insurance Corporation
(&#x201c;FDIC&#x201d;) up to $&lt;span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zsCLCkkgHuH1" title="Cash FDIC Insured amount"&gt;250,000&lt;/span&gt;
per depositor, per FDIC-insured bank, per ownership category. Substantially all of our cash balances held at banking institutions at
December 31, 2022 are in excess of FDIC coverage.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zDlow0VHDCt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and Development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses,
costs for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&#x2019;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as the work
is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative
future use are expensed when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMUdTwaWKak4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zG2zmHmnv8na"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers money market funds and other highly liquid instruments with a short-term maturity of 3 months or less to be cash
equivalents. Cash equivalents at December 31, 2022 and December 31, 2021 were approximately $&lt;span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20221231_zoyAMstiJb7a" title=" Cash and cash equivalents"&gt;1,271,000&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20211231_zOQWCMjuuOEi" title=" Cash and cash equivalents"&gt;631,000&lt;/span&gt;,
respectively, and are included along with cash under the caption cash and cash equivalents on the Company&#x2019;s consolidated
balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1271000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">631000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zwqxXNZoTcW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zSq6r7GuxG3l"&gt;Restricted
Cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers cash held in escrow for the purposes of contractual contingencies to be restricted cash. Restricted cash at December
31, 2022 and 2021 was approximately $&lt;span id="xdx_900_eus-gaap--RestrictedCash_iI_pn3d_c20221231_zTArnyOcC7Mg" title="Restricted cash"&gt;541,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--RestrictedCash_iI_pn3d_c20211231_ziLuzhjb51l4" title="Restricted cash"&gt;1,000,000&lt;/span&gt;, respectively, and is included under the caption restricted cash on the Company&#x2019;s
consolidated balance sheets. All of the restricted cash at December 31, 2022 and 2021 relates to escrow amounts paid in connection with
the Asset Purchase Agreement entered into by the Company and Allarity Therapeutics in July 2021 (See Note 4) and is considered a current
asset at December 31, 2022, as the milestones that could require payments to be made to Allarity Therapeutics must be satisfied within
the next 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">541000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1000000</us-gaap:RestrictedCash>
    <LTRN:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_ecustom--PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_zURCpDLlU7B8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zIHIxYGZWJn4"&gt;Prepaid
Expenses and Other Current Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets as of December 31, 2022 totaled approximately $&lt;span id="xdx_90C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3d_c20221231_zh9iHNiQ95h2" title="Prepaid expense and other current assets"&gt;2,985,000&lt;/span&gt; and included approximately $&lt;span id="xdx_902_ecustom--UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_iI_c20221231_zlj9rfbKFoa4" title="Upfront payments for contractor fees, academic research studies and services, and subscriptions"&gt;1,633,000&lt;/span&gt; of upfront
payments for contractor fees, academic research studies and services, and subscriptions, approximately $&lt;span id="xdx_907_ecustom--IntellectualPropertyRelatedLicensingAndOtherFees_iI_c20221231_zdQ1HIshK7M9" title="Intellectual property related licensing and other fees"&gt;256,000&lt;/span&gt; of intellectual property
related licensing and other fees, approximately $&lt;span id="xdx_90C_eus-gaap--PrepaidInsurance_iI_c20221231_ztN2UxSRyOlb" title="Prepaid annual insurance fees"&gt;504,000&lt;/span&gt; of prepaid annual insurance fees, and approximately $&lt;span id="xdx_90A_eus-gaap--InterestReceivable_iI_c20221231_zgNc0JfiF4ff" title="Interest receivable"&gt;592,000&lt;/span&gt; of receivables
from interest and tax incentives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets as of December 31, 2021 totaled approximately $&lt;span id="xdx_903_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3d_c20211231_zidfOT2LsFRf" title="Prepaid expense and other current assets"&gt;1,991,000&lt;/span&gt; and included approximately $&lt;span id="xdx_903_ecustom--UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions_iI_c20211231_z6Qa5CahR727" title="Upfront payments for contractor fees, academic research studies and services, and subscriptions"&gt;778,000&lt;/span&gt; of upfront
payments for contractor fees, academic research studies and services, and subscriptions, approximately $&lt;span id="xdx_901_ecustom--IntellectualPropertyRelatedLicensingAndOtherFees_iI_c20211231_zJ96CFz4MKy6" title="Intellectual property related licensing and other fees"&gt;379,000&lt;/span&gt; of intellectual property
related licensing and other fees, approximately $&lt;span id="xdx_90E_eus-gaap--PrepaidInsurance_iI_c20211231_zeUxrx6IwIV8" title="Prepaid annual insurance fees"&gt;653,000&lt;/span&gt; of prepaid annual insurance fees, and approximately $&lt;span id="xdx_90F_eus-gaap--InterestReceivable_iI_c20211231_zOfUnKAPK33l" title="Interest receivable"&gt;181,000&lt;/span&gt; of receivables
from interest and tax incentives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</LTRN:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2985000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <LTRN:UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1633000</LTRN:UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions>
    <LTRN:IntellectualPropertyRelatedLicensingAndOtherFees contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">256000</LTRN:IntellectualPropertyRelatedLicensingAndOtherFees>
    <us-gaap:PrepaidInsurance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">504000</us-gaap:PrepaidInsurance>
    <us-gaap:InterestReceivable contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">592000</us-gaap:InterestReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1991000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <LTRN:UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">778000</LTRN:UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions>
    <LTRN:IntellectualPropertyRelatedLicensingAndOtherFees contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">379000</LTRN:IntellectualPropertyRelatedLicensingAndOtherFees>
    <us-gaap:PrepaidInsurance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">653000</us-gaap:PrepaidInsurance>
    <us-gaap:InterestReceivable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">181000</us-gaap:InterestReceivable>
    <LTRN:LoanPursuantToPaycheckProtectionProgramPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_ecustom--LoanPursuantToPaycheckProtectionProgramPolicyTextBlock_zWTWF7abPwkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zE0qm2RU2T4d"&gt;Loan
Pursuant to Paycheck Protection Program&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 1, 2020, the Company received $&lt;span id="xdx_908_eus-gaap--ProceedsFromLoans_c20200430__20200501_zvCVwJXAqTSl" title="Proceeds from loans"&gt;108,500&lt;/span&gt; in aggregate loan proceeds (the &#x201c;PPP Loan&#x201d;) from JPMorgan Chase Bank (the &#x201c;Lender&#x201d;)
pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan was evidenced
by a loan application and payment agreement by and between the Company and the Lender. The Company applied for forgiveness of the loan,
and in April 2021 the Company received notice that the Small Business Administration (SBA) had authorized full forgiveness of the PPP
Loan (see Note 9). Forgiveness is subject to review by the SBA for a period of six years from the date of forgiveness.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</LTRN:LoanPursuantToPaycheckProtectionProgramPolicyTextBlock>
    <us-gaap:ProceedsFromLoans
      contextRef="From2020-04-302020-05-01"
      decimals="0"
      unitRef="USD">108500</us-gaap:ProceedsFromLoans>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zHur5rnvKbn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zWuyE71fys4e"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use
(&#x201c;ROU&#x201d;) assets, current portion of operating lease liabilities, and net of current portion of operating lease liabilities
on our consolidated balance sheets. Lease ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term
and lease liabilities represent an obligation to make lease payments arising from the lease. Lease ROU assets and lease liabilities are
recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company&#x2019;s
leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement
date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term unless
it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a
straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease
term of twelve months or less, and instead will recognize lease payments as expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zMYurijcnfJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zk5xM1PZEO64"&gt;Marketable
Securities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s marketable securities consist of government and agency securities, corporate bonds, and mutual funds. We classify our
marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date.
We may sell these securities at any time for use in current operations even if they have not yet reached maturity. As a result, we classify
our investments, including securities with maturities beyond twelve months, as current assets in the accompanying consolidated balance
sheets. Available-for-sale debt securities are recorded at fair value each reporting period. Unrealized gains and losses are excluded
from earnings and recorded as a separate component within &#x201c;Accumulated other comprehensive income&#x201d; or &#x201c;Accumulated
other comprehensive loss&#x201d; on the consolidated balance sheets until realized. Interest is reported within &#x201c;Interest income&#x201d;
and dividend income is reported within &#x201c;Other (expense) income, net&#x201d; on the consolidated statements of operations. We evaluate
our investments to assess whether the amortized cost basis is in excess of estimated fair value and determine what amount of that difference,
if any, is caused by expected credit losses. Allowance for credit losses are recognized as a charge in &#x201c;Other income, net&#x201d;
on the consolidated statements of operations, and any remaining unrealized losses are included in &#x201c;Accumulated other comprehensive
loss&#x201d; on the consolidated balance sheets. There were no credit losses recorded for the year ended December 31, 2022. There was
no impairment charge for any unrealized losses for the years ended December 31, 2022 and 2021. We determine realized gains and losses
on the sale of marketable securities based on the specific identification method and record such gains and losses in &#x201c;Other (expense)
income, net&#x201d; on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_z19ijevwkvY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_z8fPfYRTGmrj"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities
using enacted tax rates which will be in effect when the differences reverse. The Company provides a full valuation allowance against
net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z8uNpAyOZFi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zT03SiCvtWWa"&gt;Stock-based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
awards have been accounted for as required by ASC 718 &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt;. Under ASC 718, awards are valued at fair
value on the date of grant, and that fair value is recognized over the requisite service period. Forfeitures are accounted for as they
occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqgEgpiqiWJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zDCIikpk1GQg"&gt;New
Accounting Pronouncements, Not Yet Adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Current
Expected Credit Loss&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016 the FASB issued ASU 2016-13&lt;i&gt;, Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (Topic 326). This introduces new
methodology for recognition of credit losses - the current expected credit loss (&#x201c;CECL&#x201d;) method. The CECL method requires
the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument, unless
the company elects to recognize such instruments at fair value with changes in profit and loss. CECL is effective for the Company on
January 1, 2023. The Company believes it will not be materially impacted by the adoption of this new standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <LTRN:RecentlyAdoptedAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_843_ecustom--RecentlyAdoptedAccountingPolicyPolicyTextBlock_zxlkXvTagwD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zGsBbSls047a"&gt;Recently
Adopted Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Government
Assistance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2021 the FASB issued ASU 2021-10, &lt;i&gt;Government Assistance&lt;/i&gt; (Topic 832). This introduces new guidance to increase transparency
of government assistance. It requires annual disclosures about transactions with a government, including those accounted for by applying
a grant. This includes the nature of the transactions and related accounting policy used to account for the transactions, the line items
on the balance sheet and income statement that are affected by the transactions, and significant terms and conditions of the transactions.
The Company adopted ASU 2021-10 on January 1, 2022 and has not been materially impacted by its adoption.&lt;/span&gt;&lt;/p&gt;

</LTRN:RecentlyAdoptedAccountingPolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zAN0ZksGnwYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4: &lt;span id="xdx_825_zlcyhtG80ktd"&gt;Commitments and Contingencies&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;General.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into, and expects to enter into from time to time in the future, license agreements, strategic alliance agreements,
assignment agreements, research service agreements, and similar agreements related to the advancement of its product candidates and research
and development efforts. Significant agreements are described in detail below (collectively, the &#x201c;License, Strategic Alliance,
and Research Agreements&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_zUPp1vlrXnNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
forth below are the approximate amounts expensed for License, Strategic Alliance, and Research Agreements during the years ended December
31, 2022 and 2021, respectively. These expensed amounts are included under research and development expenses in the accompanying consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zVUnjwSUHIfc" style="display: none"&gt;Schedule
of Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20220112__20221231_zOUgZjK3bGtf" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20210112__20211231_zxxQ7bnsvSAa" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 60%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ResearchAndDevelopmentIncomeExpense_zJTowY9OJshd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Amount Expensed for License, Strategic Alliance, and Research Agreements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,222,000&lt;sup id="xdx_F20_zJyrcaOateCf" style="display: none"&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,483,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -4.5pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F04_zn7AYHnTtB0c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_z2HINIcl3DNl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amounts
    expensed for License, Strategic Alliance, and Research Agreements during the year ended December 31, 2022 were reduced by $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc2VhcmNoIGFuZCBEZXZlbG9wbWVudCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_ecustom--DecreaseInResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_z7s66XaiK7U3" title="Research and development expense"&gt;935,000&lt;/span&gt;
    as a result of a payment we received in July 2022 from one of our service providers in connection with the resolution of a difference
    of views regarding the service provider agreement. This payment received by us offset other expenses for License, Strategic Alliance,
    and Research Agreements during this period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_z3SbIh5eGBN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_znasbpNuzUnd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
forth below at December 31, 2022 and December 31, 2021, respectively, are (1) the approximate amounts accrued and payable under the License,
Strategic Alliance, and Research Agreements, and (2) the approximate amount of prepaid expenses and other current assets under the License,
Strategic Alliance, and Research Agreements. These amounts are included in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zbVBWCwKdtOg" style="display: none"&gt;Schedule
of Accounts Payable and Accrued Liabilities&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zkXhnstfatwk" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231_zgfYgbkPpbze" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_hus-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_zG8FxVxSRKti" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amount
    accrued and payable under License, Strategic Alliance, and Research Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,813,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,493,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_zwfMMA3k4Gx5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements&lt;/span&gt;&lt;/p&gt;
                                                                           &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,595,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,023,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zdSdMa76fWZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;BioNumerik
Pharmaceuticals&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2018, the Company entered into an Assignment Agreement (the &#x201c;Assignment Agreement&#x201d;) with BioNumerik Pharmaceuticals,
Inc. (&#x201c;BioNumerik&#x201d;), pursuant to which the Company acquired rights to domestic and international patents, trademarks and
related technology and data relating to LP-300 (Tavocept) for human therapeutic treatment indications. The Assignment Agreement replaced
a License Agreement that was entered into between the Company and BioNumerik in May 2016. The Company made upfront payments totaling
$&lt;span id="xdx_907_ecustom--UpfrontPayments_c20180101__20180131__dei--LegalEntityAxis__custom--BioNumerikPharmaceuticalsMember__us-gaap--TypeOfArrangementAxis__custom--AssignmentAgreementMember_zFAjeqreVDKe" title="Upfront payments"&gt;25,000&lt;/span&gt; in connection with entry into the Assignment Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20180101__20180131__dei--LegalEntityAxis__custom--BioNumerikPharmaceuticalsMember__us-gaap--TypeOfArrangementAxis__custom--AssignmentAgreementMember_z06dfS5pNtug" title="Commitments description"&gt;In
the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment
recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100
million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250
million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative
revenue in excess of $1 billion&lt;/span&gt;. The Company has the right to first recover certain designated portions of patent costs and development
and regulatory costs before the payment of royalties described above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the Company enters into a third-party transaction for LP-300, the Company is required to pay the BioNumerik-related payment recipients
a specified percentage of any upfront, milestone, and royalty amounts received by the Company from the transaction, after first recovering
specified direct costs incurred by the Company for the development of LP-300 that are not otherwise reimbursed from such third-party
transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, the Assignment Agreement provides that the Company will use commercially diligent efforts to develop LP-300 and make specified
regulatory filings and pay specified development and regulatory costs related to LP-300. The Assignment Agreement also provides that
the Company will provide TriviumVet DAC (&#x201c;TriviumVet&#x201d;) with (i) specified data and information generated by the Company with
respect to LP-300, and (ii) an exclusive license to use specified LP-300-related patent rights, trademark rights and related intellectual
property to support LP-300 development in non-human (animal) treatment indications.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is also required to pay all patent costs on covered patents related to LP-300. These patent costs are included in general and
administrative expenses in the accompanying consolidated statements of operations. These patent costs are fully recoverable at the time
of any net revenue from LP-300, with up to &lt;span id="xdx_904_ecustom--RevenuePercentage_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--AssignmentAgreementMember_zwf8N1qM35kg" title="Revenue percentage"&gt;50&lt;/span&gt;% of net revenue amounts to be applied towards repayment of patent costs until such costs
are fully recovered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to the recovery of patent costs, the Company has the right to recover the $&lt;span id="xdx_901_ecustom--UpfrontPayments_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--AssignmentAgreementMember_zaP9kmEn5iXj" title="Upfront payments"&gt;25,000&lt;/span&gt;
upfront payments made in connection with entry into the Assignment Agreement, which payments are recoverable prior to making any
royalty or third-party transaction sharing payments. The Company also has the right to recover previously incurred LP-300
development and regulatory costs, with up to a mid-single digit percentage of net revenue amounts to be applied towards repayment of
development and regulatory costs until such costs are fully recovered. No amounts were expensed with respect to BioNumerik during the years ended
December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;AF
Chemicals&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2015, the Company entered into a Technology License Agreement to exclusively license domestic and international patent rights
from AF Chemicals, LLC (&#x201c;AF Chemicals&#x201d;) for the treatment of cancer in humans for the compounds LP-100 (Irofulven) and LP-184.
In February 2016, the Company and AF Chemicals entered into an Addendum (the &#x201c;Addendum&#x201d;) providing for additions and amendments
to the Technology License Agreement. In December 2020, the Company and AF Chemicals entered into a Second Addendum (the &#x201c;Second
Addendum&#x201d;) providing for further additions and amendments to the Technology License Agreement. The Technology License Agreement,
Addendum and Second Addendum are collectively referred to as the &#x201c;AFC License Agreement&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Second Addendum, the Company made specified payments to AF Chemicals during the nine months ended September 30, 2021. The Second
Addendum also provides that, from December 30, 2020 until January 15, 2025, the Company will have no obligation to pay annual licensing
fees, development diligence extension payments, or patent maintenance fee payments to AFC under the AFC License Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the Second Addendum, the Company has agreed to apply for specified orphan drug designations for LP-184 in the US and EU. The
Second Addendum also amends and clarifies other provisions of the Technology License Agreement, and provides the Company with the ability
to recover a portion of initial payments made under the Second Addendum from sublicense fees or royalty payments that may be made to
AFC by the Company or third parties prior to January 15, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the AFC License Agreement the Company made annual licensing fee payments to AF Chemicals relating to LP-184 for periods prior to signing
the Second Addendum. In addition, the Company is obligated to make milestone payments to AF Chemicals at the time of an Investigational
New Drug Application (&#x201c;IND&#x201d;) filing relating to LP-184 and also upon reaching additional specified milestones in connection
with the development and potential marketing approval of LP-184 in the United States, specified countries in Europe, and other countries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
AFC License Agreement also provides that the Company will pay AF Chemicals a royalty of at least a very small single digit percentage
of specified net sales of LP-184 and other analogs. &lt;span id="xdx_901_ecustom--LicenseAgreementDescription_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--AFCLicenseAgreementMember__dei--LegalEntityAxis__custom--AFChemicalsMember_ziBTHI0moiqh" title="License agreement, description"&gt;In addition, the AFC License Agreement contains specified time requirements for the
Company to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the
Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two,
three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated by
the Company and AF Chemicals&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Second Addendum, no additional payments of annual licensing fees or development diligence extension payments related to LP-184
are required to be made by the Company until January 15, 2025, at which time these obligations will resume. The Company will also be
obligated to make payments to AF Chemicals relating to LP-100 beginning January 15, 2025, as described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the event of a sublicense of the LP-184 rights, the Company is obligated to pay AF Chemicals (a) a low double-digit percentage of the
gross income and fees received by the Company with respect to the United States in connection with such sublicense, and (b) a lower double
digit percentage of the gross income and fees received by the Company with respect to Europe and Japan in connection with such sublicense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
amounts to be paid to AF Chemicals with respect to LP-100 under the AFC License Agreement are in many ways similar to the amounts to
be paid with respect to LP-184 as described above. In addition, the AFC License Agreement contains specified time requirements for
the Company to enroll patients in clinical trials and file a potential NDA with respect to LP-100. Extension fees may be paid by the
Company to AF Chemicals from time to time related to these requirements. Pursuant to the Second Addendum with AF Chemicals, no
additional payments of annual licensing fees or development diligence extension payments are required to be made by the Company with
respect to LP-100 until January 15, 2025, at which time these obligations will resume. Approximately $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--AFCLicenseAgreementMember__dei--LegalEntityAxis__custom--AFChemicalsMember_zsF7ehEx02Sg" title="Research and development expenses"&gt;125,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--AFCLicenseAgreementMember__dei--LegalEntityAxis__custom--AFChemicalsMember_zbNHbA2TTpIh" title="Research and development expenses"&gt;145,000&lt;/span&gt; were
expensed with respect to the AFC License Agreement during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development
expenses in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Allarity
Therapeutics (formerly known as Oncology Venture)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2015, the Company licensed various rights to LP-100 to Oncology Venture (now known as Allarity Therapeutics) pursuant to a Drug License
and Development Agreement. In February 2016, the Company and Allarity Therapeutics entered into an addendum and an amendment providing
for additions and amendments to the Drug License and Development Agreement. In connection with the Drug License and Development Agreement,
as amended (collectively, the &#x201c;Allarity License and Development Agreement&#x201d;), Allarity Therapeutics agreed to directly pay
to AF Chemicals on behalf of the Company certain amounts to satisfy the Company&#x2019;s milestone obligations to AF Chemicals with respect
to LP-100 under the AFC License Agreement. Amounts paid by Allarity Therapeutics to AF Chemicals on behalf of the Company would then
be deducted from amounts owed by Allarity Therapeutics to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 23, 2021, the Company entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for
Irofulven (LP-100) from Allarity. The transaction includes global rights to LP-100, as well as the developed clinical protocol for an
intended study in bladder and prostate cancer patients who have a mutation in the ERCC2/3 genes. As a result of this transaction, the
Company has full authority to manage and guide future clinical development and commercialization of LP-100. Under the terms of the Asset
Purchase Agreement, the Company paid an initial upfront payment of $&lt;span id="xdx_90C_ecustom--UpfrontPayments_c20210721__20210723__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zTKtmNl1saf4" title="Upfront payments"&gt;1,000,000&lt;/span&gt; to Allarity. The Company determined there was no planned
alternative future use for these assets outside of the clinical development of LP-100 and therefore the full amount of the upfront payment
was included in research and development expense. The Company released approximately $&lt;span id="xdx_90B_eus-gaap--EscrowDepositsRelatedToPropertySales_c20210721__20210723__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zKC9qLhW0M9j" title="Escrow related expenses"&gt;459,000&lt;/span&gt; from escrow to Allarity related to recertification
of LP-100 drug stock during the year ended December 31, 2022. Future payments of up to $&lt;span id="xdx_907_ecustom--FuturePayments_c20210721__20210723__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z9yrlZhHK8A4" title="Future payments"&gt;500,000&lt;/span&gt; currently held in escrow also have the
potential to deliver an additional amount to Allarity based on drug trial enrollment milestones within the 24 months following the date
of the transaction. Allarity is also eligible to receive additional milestone payments over the life of the program based on IP license
milestones and regulatory filings and approvals in the US and EU, and low- to mid-single-digit royalties on future commercial net sales.
As part of the Asset Purchase Agreement, the Allarity License and Development Agreement was terminated. Approximately $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z0k68lfLGzDk" title="Research and development expenses"&gt;459,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--AllarityTherapeutiesMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z0441kFNE6Ke" title="Research and development expenses"&gt;1,000,000&lt;/span&gt; were expensed with respect to Allarity during the years ended December 31,
2022 and 2021, respectively, which amounts are included in research and development expenses in the accompanying consolidated statements
of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Califia
Pharma&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2020, the Company entered into an Evaluation and Limited Use Agreement (the &#x201c;Evaluation Agreement&#x201d;) with Califia
Pharma, Inc. (&#x201c;Califia&#x201d;). The Evaluation Agreement provided for the Company and Califia to collaborate on the in vitro and
in vivo testing and evaluation of novel Califia linker technology and related payloads to be conjugated to a Lantern targeting entity.
The Evaluation Agreement also provided the Company with the right to negotiate with Califia for exclusive license rights to use LP-184
and related analogs as the payload with an affinity drug conjugate or small molecule drug conjugate targeting entity supplied by the
Company. The Company also had the right under the Evaluation Agreement to negotiate for non-exclusive license rights to use a targeting
entity from the Company with a payload and linker combination selected from novel specified Califia payloads and linkers. The Evaluation
Agreement expired on December 31, 2021 and the Company determined not to extend it. No amounts and approximately $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--CalifiaPharmaMember__us-gaap--TypeOfArrangementAxis__custom--EvaluationAgreementMember_znUWQ8ND8Lvk" title="Research and development expenses"&gt;&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--CalifiaPharmaMember__us-gaap--TypeOfArrangementAxis__custom--EvaluationAgreementMember_zYwcsvIr06b3" title="Research and development expenses"&gt;100,000&lt;/span&gt;&lt;/span&gt; were expensed with respect to the
Califia Evaluation Agreement during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development
expenses in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Patheon
API Services&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;The Company has entered into agreements
with Patheon API Services, Inc. (&#x201c;Patheon&#x201d;) for the manufacture and supply of cGMP material to support the Company&#x2019;s
Phase II clinical trial for its product candidate LP-300. In addition to producing LP-300 API (active pharmaceutical ingredient) under
cGMP (current Good Manufacturing Practices) conditions, Patheon transferred previously validated manufacturing processes and analytical
methods for LP-300 and produced non-GMP material for use in support of non-clinical studies for LP-300. The agreements provide for payments
in stages as specified process and manufacturing milestones are achieved. &lt;/span&gt;Approximately $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--PatheonAPIServicesMember__us-gaap--TypeOfArrangementAxis__custom--PatheonAgreementMember_z2Ozd7B0elV1" title="Research and development expenses"&gt;218,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--PatheonAPIServicesMember__us-gaap--TypeOfArrangementAxis__custom--PatheonAgreementMember_zNI7vQNSsVXi" title="Research and development expenses"&gt;963,000&lt;/span&gt; was expensed with
respect to the Patheon agreements during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research
and development expenses in the accompanying consolidated statements of operations. &lt;span style="background-color: white"&gt;The Company
expects to expense additional amounts in future periods in accordance with the progress of work completed under the Patheon agreements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Southwest
Research Institute&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;As part of the Company&#x2019;s research
and development activities, the Company has engaged Southwest Research Institute (&#x201c;SwRI&#x201d;) from time to time to assist with
compound synthesis and manufacturing related activities for the Company&#x2019;s product candidates. The Company has entered into agreements
with SwRI for the non-GMP and cGMP synthesis of LP-184 material and related analytical development&lt;/span&gt;. Approximately $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--SouthwestResearchInstituteMember__us-gaap--TypeOfArrangementAxis__custom--SouthwestResearchInstituteAgreementMember_zEBfGGWTUx5b" title="Research and development expenses"&gt;494,000&lt;/span&gt; and
$&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--SouthwestResearchInstituteMember__us-gaap--TypeOfArrangementAxis__custom--SouthwestResearchInstituteAgreementMember_zU2dRsu3vpki" title="Research and development expenses"&gt;1,261,000&lt;/span&gt; was expensed with respect to the SwRI agreements during the years ended December 31, 2022 and 2021, respectively, which amounts
are included in research and development expenses in the accompanying consolidated statements of operations. &lt;span style="background-color: white"&gt;The
Company expects to expense additional amounts in future periods in accordance with the progress of work completed under the SwRI agreements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;The
Research Institute of Fox Chase Cancer Center&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;In September 2020, the Company entered
into a research agreement with the Research Institute of Fox Chase Cancer Center (&#x201c;FCCC&#x201d;), which was amended in January 2022,
as part of the Company&#x2019;s research and development activities, with a focus on advancing the targeted use of LP-184 in molecularly-defined
sub-types of pancreatic cancer.&lt;/span&gt; Approximately $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--FoxChaseCancerCenterMember__us-gaap--TypeOfArrangementAxis__custom--FoxChaseCancerCenterAgreementMember_zYauBTp0Tky3" title="Research and development expenses"&gt;148,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--FoxChaseCancerCenterMember__us-gaap--TypeOfArrangementAxis__custom--FoxChaseCancerCenterAgreementMember_zLI4AKLVju15" title="Research and development expenses"&gt;202,000&lt;/span&gt; was expensed with respect to the FCCC agreements during the
years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development expenses in the accompanying
consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Piramal
Pharma Solutions&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;In January 2021, the Company entered
into an agreement with Piramal Pharma Solutions (&#x201c;Piramal&#x201d;) for the fill and finish manufacture of LP-300 drug product at
Piramal&#x2019;s Lexington, Kentucky site in support of future Phase II clinical testing. The agreement, as amended, provides for Piramal
to conduct activities in support of the cGMP manufacturing of LP-300, including analytical and process transfer activities, manufacture
of cGMP clinical batches, and performance of stability studies on cGMP batches of LP-300 drug product. &lt;/span&gt;Approximately $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--PiramalPharmaSolutionMember__us-gaap--TypeOfArrangementAxis__custom--PiramalPharmaAgreementMember_zhXzNZeIn1d1" title="Research and development expenses"&gt;196,000&lt;/span&gt; and
$&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--PiramalPharmaSolutionMember__us-gaap--TypeOfArrangementAxis__custom--PiramalPharmaAgreementMember_zVE60chqUTqk" title="Research and development expenses"&gt;535,000&lt;/span&gt; was expensed with respect to Piramal agreements during the years ended December 31, 2022 and 2021, respectively, which amounts
are included in research and development expenses in the accompanying consolidated statements of operations. &lt;span style="background-color: white"&gt;The
Company expects to expense additional amounts in future periods in accordance with the progress of work completed under Piramal agreements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;vivoPharm&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;In September 2021, the Company&#x2019;s
Australian subsidiary entered into an agreement with RDDT, a vivoPharm Company Pty Ltd (&#x201c;vivoPharm&#x201d;), for multiple preclinical
studies, including animal studies, as part of an IND-enabling program for LP-184. The Company&#x2019;s Australian subsidiary entered into
an additional agreement with vivoPharm in 2022 as part of an IND-enabling program for LP-284. Amendments to the vivoPharm agreements were
made in 2022. &lt;/span&gt;Approximately $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--VivoPharmMember__us-gaap--TypeOfArrangementAxis__custom--VivoPharmAgreementMember_zxd331l1i2k8" title="Research and development expenses"&gt;1,030,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--VivoPharmMember__us-gaap--TypeOfArrangementAxis__custom--VivoPharmAgreementMember_zuOdxvFVoFn7" title="Research and development expenses"&gt;119,000&lt;/span&gt; was expensed with respect to the vivoPharm agreements during the years ended
December 31, 2022 and 2021, respectively, which amounts are included in research and development expenses in the accompanying consolidated
statements of operations. &lt;span style="background-color: white"&gt;The Company expects that additional amounts will be expensed in future
periods in accordance with the progress of work completed under the vivoPharm agreements, as amended.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;TD2&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;In October 2021, the Company entered
into a Statement of Work, as amended in March 2022, with Translational Drug Development, LLC (&#x201c;TD2&#x201d;) providing for TD2 to
serve as the lead contract research organization (CRO) for the Company&#x2019;s Phase II clinical trial for its product candidate LP-300&lt;/span&gt;.
Approximately $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--TranslationalDrugMember_zWXQPyxg7Yz3" title="Research and development expenses"&gt;789,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231__dei--LegalEntityAxis__custom--TranslationalDrugMember__us-gaap--TypeOfArrangementAxis__custom--TranslationalDrugAgreementMember_zctxwFNH4G69" title="Research and development expenses"&gt;158,000&lt;/span&gt; was expensed with respect to TD2 during the years ended December 31, 2022 and 2021, respectively,
which amounts are included in research and development expenses in the accompanying consolidated statements of operations. &lt;span style="background-color: white"&gt;The
Company expects to expense additional amounts in future periods in connection with services provided by TD2 as well as clinical trial
site and other pass-through costs relating to the LP-300 Phase II clinical trial.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Berkshire
Sterile Manufacturing&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;During the year ended December 31,
2022, the Company entered into agreements with Berkshire Sterile Manufacturing (&#x201c;Berkshire&#x201d;) to support technical transfer
and GMP drug product manufacturing of LP-300. &lt;/span&gt;Approximately $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--BerkshireSteruleManufacturingMember__us-gaap--TypeOfArrangementAxis__custom--BerkshireSteruleManufacturingAgreementMember_zFJlabO90tk9" title="Research and development expenses"&gt;689,000&lt;/span&gt; and &lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__dei--LegalEntityAxis__custom--BerkshireSteruleManufacturingMember__us-gaap--TypeOfArrangementAxis__custom--BerkshireSteruleManufacturingAgreementMember_zE2dv45VrTEg" title="Research and development expenses"&gt;no&lt;/span&gt; amounts were expensed with respect to the Berkshire
agreements during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development expenses
in the accompanying consolidated statements of operations. &lt;span style="background-color: white"&gt;The Company expects that additional amounts
will be expensed in future periods in accordance with the progress of work completed under the Berkshire agreements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Shilpa
&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;In March 2022, the Company entered
into an agreement with Shilpa Medicare Limited (&#x201c;Shilpa&#x201d;) for fit-to-purpose process development and synthesis of a key starting
material relating to the synthesis of LP-184 under cGMP. &lt;/span&gt;In July 2022, the Company entered into agreements with Shilpa Pharma Lifesciences
&lt;span style="background-color: white"&gt;for the cGMP synthesis of LP-184 API material as well as for drug product development and cGMP drug
product manufacturing of LP-184. In August 2022, &lt;/span&gt;the Company entered into agreements with Shilpa &lt;span style="background-color: white"&gt;for
the cGMP synthesis of LP-284 API material as well as for drug product development and cGMP drug product manufacturing of LP-284. &lt;/span&gt;Approximately
$&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--ShilpaMember__us-gaap--TypeOfArrangementAxis__custom--ShilpaAgreementMember_zwJ3L5YykxWd" title="Research and development expenses"&gt;707,000&lt;/span&gt; and &lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__dei--LegalEntityAxis__custom--ShilpaMember__us-gaap--TypeOfArrangementAxis__custom--ShilpaAgreementMember_zVI1xIFFuRc5" title="Research and development expenses"&gt;no&lt;/span&gt; amounts were expensed with respect to the Shilpa agreements during the years ended December 31, 2022 and 2021, respectively,
which amounts are included in research and development expenses in the accompanying consolidated statements of operations. &lt;span style="background-color: white"&gt;The
Company expects that expense additional amounts in future periods in accordance with the progress of work completed payment schedule specified
under the Shilpa agreements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Curia&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="background-color: white"&gt;During the year ended December 31,
2022&lt;/span&gt;, the Company entered into agreements with Curia Global, Inc. (&#x201c;Curia&#x201d;) for the cGMP manufacture of LP-300 API.
Approximately $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--CuriaMember_zVgUp9mIZTP6" title="Research and development expenses"&gt;285,000&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__dei--LegalEntityAxis__custom--CuriaMember_zJquMsz13Hk7" title="Research and development expenses"&gt;no&lt;/span&gt; amounts were expensed with respect to the Curia agreements during the years ended December 31, 2022 and
2021, respectively, which amounts are included in research and development expenses in the accompanying consolidated statements of operations.
&lt;span style="background-color: white"&gt;The Company expects that additional amounts will be expensed in future periods in accordance with
the progress of work completed under the Curia agreements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;LumaBridge
(formerly known as Cancer Insight)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In May 2022, the Company entered into an agreement with Cancer Insight,
LLC, now known as LumaBridge, LLC (&#x201c;LumaBridge&#x201d;) for IND filing, regulatory support, Phase I pre-trial startup activities,
and strategic program consulting relating to LP-184. Approximately $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--LumaBridgeLLCMember__us-gaap--TypeOfArrangementAxis__custom--LumaBridgeAgreementMember_zxj6UlkiwpX6" title="Research and development expenses"&gt;82,000&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_do_c20210101__20211231__dei--LegalEntityAxis__custom--LumaBridgeLLCMember__us-gaap--TypeOfArrangementAxis__custom--LumaBridgeAgreementMember_zVgqywFvitr6" title="Research and development expenses"&gt;no&lt;/span&gt; amounts were expensed with respect to the LumaBridge
agreements during the years ended December 31, 2022 and 2021, respectively, which amounts are included in research and development expenses
in the accompanying consolidated statements of operations. &lt;span style="background-color: white"&gt;The Company expects that additional amounts
will be expensed in future periods relating to services provided pursuant to the LumaBridge agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
Research and Service Provider Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to the agreements described above, the Company has entered into other research and service provider agreements for the advancement
of its product candidates and research and development efforts. The Company expects to expense additional amounts in future periods in
connection with existing and future research and service provider agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;EU
Grant&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2018, Lantern Pharma Limited, a wholly owned subsidiary of Lantern Pharma Inc., was awarded a grant by the UK government in
the form of state aid under the Commission Regulations (EU) No. 651/2014 of 17 June 2014 (the &#x201c;General Block Exemption&#x201d;),
Article 25 Aid for research and development projects, state aid notification no. SA.40154. The grant was awarded to conduct research
and development activities for the prostate cancer biomarker analysis of the LP-184 drug candidate. Following the Company&#x2019;s research
and development activities in Northern Ireland, the grant will reimburse the Company &lt;span id="xdx_900_ecustom--ResearchAndDevelopmentExpensesPercentage_pid_dp_uPure_c20220101__20221231__dei--LegalEntityAxis__custom--LanternPharmaLimitedMember_zSoQxvwcWtpa" title="Research and development expenses percentage"&gt;50&lt;/span&gt;% of its research and development expenses not
exceeding GBP &lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_uGBP_c20220101__20221231__dei--LegalEntityAxis__custom--LanternPharmaLimitedMember_zPK2IUUKzRZc" title="Research and development expense"&gt;24,215&lt;/span&gt; of vouched and approved expenditures within specific categories. The grant contains some reporting and consent requirements.
The grant will remain in force for a period of five years. No payments to the Company have been made under the grant as of December 31,
2022. &lt;span id="xdx_90A_eus-gaap--Revenues_do_c20220101__20221231__dei--LegalEntityAxis__custom--LanternPharmaLimitedMember_zmuGo2O71Iq3" title="Revenues"&gt;No&lt;/span&gt; revenue has been recognized from this grant through December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Actuate
Therapeutics&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the Company entered into a Collaboration Agreement with Actuate Therapeutics, Inc. (&#x201c;Actuate&#x201d;), a clinical stage
private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases
leading to fibrosis. Pursuant to the agreement, the Company and Actuate are collaborating on utilization of the Company&#x2019;s RADR&#xae;
platform to develop novel biomarker derived signatures for use with one of Actuate&#x2019;s product candidates. As part of the collaboration,
the Company received &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c20210501__20210531__dei--LegalEntityAxis__custom--ActuateTherapeuticsMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_z4atBO4DTVkl" title="Actuate stock of restricted shares"&gt;25,000&lt;/span&gt; restricted shares of Actuate stock, subject to meeting certain conditions of the collaboration, as well as
the potential to receive additional Actuate stock if results from the collaboration are utilized in future development efforts. In 2022,
the term of the Collaboration Agreement was extended to continue until March 31, 2023. Leslie W. Kreis, Jr., a director of the Company
until June 8, 2022, is also a director of Actuate. Affiliates of Mr. Kreis hold substantial beneficial ownership interests in both the
Company and Actuate. Through December 31, 2022, no revenues have been recognized under the Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
restricted shares of Actuate stock had a nominal value when acquired and, therefore, were recorded at a cost of $&lt;span id="xdx_909_ecustom--NominalValueOfRestrictedSharesOfActuateStock_iI_c20210531__dei--LegalEntityAxis__custom--ActuateTherapeuticsMember__us-gaap--TypeOfArrangementAxis__custom--CollaborationAgreementMember_zWaINJOyLoO3" title="Nominal value acquired cost"&gt;0&lt;/span&gt;. These shares do not
have a readily determinable fair value, but will be adjusted for observable price changes, if any, in future periods. There were no adjustments
to the carrying amount through December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_zUPp1vlrXnNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
forth below are the approximate amounts expensed for License, Strategic Alliance, and Research Agreements during the years ended December
31, 2022 and 2021, respectively. These expensed amounts are included under research and development expenses in the accompanying consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zVUnjwSUHIfc" style="display: none"&gt;Schedule
of Research and Development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20220112__20221231_zOUgZjK3bGtf" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20210112__20211231_zxxQ7bnsvSAa" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 60%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ResearchAndDevelopmentIncomeExpense_zJTowY9OJshd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Amount Expensed for License, Strategic Alliance, and Research Agreements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,222,000&lt;sup id="xdx_F20_zJyrcaOateCf" style="display: none"&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,483,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -4.5pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F04_zn7AYHnTtB0c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_z2HINIcl3DNl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amounts
    expensed for License, Strategic Alliance, and Research Agreements during the year ended December 31, 2022 were reduced by $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc2VhcmNoIGFuZCBEZXZlbG9wbWVudCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_ecustom--DecreaseInResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_z7s66XaiK7U3" title="Research and development expense"&gt;935,000&lt;/span&gt;
    as a result of a payment we received in July 2022 from one of our service providers in connection with the resolution of a difference
    of views regarding the service provider agreement. This payment received by us offset other expenses for License, Strategic Alliance,
    and Research Agreements during this period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock>
    <LTRN:ResearchAndDevelopmentIncomeExpense
      contextRef="From2022-01-122022-12-31"
      decimals="0"
      id="Fact000568"
      unitRef="USD">5222000</LTRN:ResearchAndDevelopmentIncomeExpense>
    <LTRN:ResearchAndDevelopmentIncomeExpense
      contextRef="From2021-01-122021-12-31"
      decimals="0"
      unitRef="USD">4483000</LTRN:ResearchAndDevelopmentIncomeExpense>
    <LTRN:DecreaseInResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember"
      decimals="0"
      unitRef="USD">935000</LTRN:DecreaseInResearchAndDevelopmentExpense>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_896_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_znasbpNuzUnd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
forth below at December 31, 2022 and December 31, 2021, respectively, are (1) the approximate amounts accrued and payable under the License,
Strategic Alliance, and Research Agreements, and (2) the approximate amount of prepaid expenses and other current assets under the License,
Strategic Alliance, and Research Agreements. These amounts are included in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zbVBWCwKdtOg" style="display: none"&gt;Schedule
of Accounts Payable and Accrued Liabilities&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zkXhnstfatwk" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231_zgfYgbkPpbze" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_hus-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_zG8FxVxSRKti" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amount
    accrued and payable under License, Strategic Alliance, and Research Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,813,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,493,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_hus-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_zwfMMA3k4Gx5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements&lt;/span&gt;&lt;/p&gt;
                                                                           &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,595,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,023,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="AsOf2022-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember"
      decimals="0"
      unitRef="USD">1813000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="AsOf2021-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember"
      decimals="0"
      unitRef="USD">1493000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember"
      decimals="0"
      unitRef="USD">1595000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2021-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember"
      decimals="0"
      unitRef="USD">1023000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <LTRN:UpfrontPayments
      contextRef="From2018-01-012018-01-31_custom_BioNumerikPharmaceuticalsMember_custom_AssignmentAgreementMember"
      decimals="0"
      unitRef="USD">25000</LTRN:UpfrontPayments>
    <us-gaap:OtherCommitmentsDescription contextRef="From2018-01-012018-01-31_custom_BioNumerikPharmaceuticalsMember_custom_AssignmentAgreementMember">In
the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment
recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100
million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250
million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative
revenue in excess of $1 billion</us-gaap:OtherCommitmentsDescription>
    <LTRN:RevenuePercentage
      contextRef="From2022-01-012022-12-31_custom_AssignmentAgreementMember"
      decimals="INF"
      unitRef="Pure">0.50</LTRN:RevenuePercentage>
    <LTRN:UpfrontPayments
      contextRef="From2022-01-012022-12-31_custom_AssignmentAgreementMember"
      decimals="0"
      unitRef="USD">25000</LTRN:UpfrontPayments>
    <LTRN:LicenseAgreementDescription contextRef="From2022-01-012022-12-31_custom_AFCLicenseAgreementMember_custom_AFChemicalsMember">In addition, the AFC License Agreement contains specified time requirements for the
Company to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the
Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two,
three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated by
the Company and AF Chemicals</LTRN:LicenseAgreementDescription>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_AFCLicenseAgreementMember_custom_AFChemicalsMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_AFCLicenseAgreementMember_custom_AFChemicalsMember"
      decimals="0"
      unitRef="USD">145000</us-gaap:ResearchAndDevelopmentExpense>
    <LTRN:UpfrontPayments
      contextRef="From2021-07-212021-07-23_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">1000000</LTRN:UpfrontPayments>
    <us-gaap:EscrowDepositsRelatedToPropertySales
      contextRef="From2021-07-212021-07-23_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">459000</us-gaap:EscrowDepositsRelatedToPropertySales>
    <LTRN:FuturePayments
      contextRef="From2021-07-212021-07-23_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">500000</LTRN:FuturePayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">459000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_AllarityTherapeutiesMember_custom_AssetPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_CalifiaPharmaMember_custom_EvaluationAgreementMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_CalifiaPharmaMember_custom_EvaluationAgreementMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_PatheonAPIServicesMember_custom_PatheonAgreementMember"
      decimals="0"
      unitRef="USD">218000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_PatheonAPIServicesMember_custom_PatheonAgreementMember"
      decimals="0"
      unitRef="USD">963000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_SouthwestResearchInstituteMember_custom_SouthwestResearchInstituteAgreementMember"
      decimals="0"
      unitRef="USD">494000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_SouthwestResearchInstituteMember_custom_SouthwestResearchInstituteAgreementMember"
      decimals="0"
      unitRef="USD">1261000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_FoxChaseCancerCenterMember_custom_FoxChaseCancerCenterAgreementMember"
      decimals="0"
      unitRef="USD">148000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_FoxChaseCancerCenterMember_custom_FoxChaseCancerCenterAgreementMember"
      decimals="0"
      unitRef="USD">202000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_PiramalPharmaSolutionMember_custom_PiramalPharmaAgreementMember"
      decimals="0"
      unitRef="USD">196000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_PiramalPharmaSolutionMember_custom_PiramalPharmaAgreementMember"
      decimals="0"
      unitRef="USD">535000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_VivoPharmMember_custom_VivoPharmAgreementMember"
      decimals="0"
      unitRef="USD">1030000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_VivoPharmMember_custom_VivoPharmAgreementMember"
      decimals="0"
      unitRef="USD">119000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_TranslationalDrugMember"
      decimals="0"
      unitRef="USD">789000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_TranslationalDrugMember_custom_TranslationalDrugAgreementMember"
      decimals="0"
      unitRef="USD">158000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_BerkshireSteruleManufacturingMember_custom_BerkshireSteruleManufacturingAgreementMember"
      decimals="0"
      unitRef="USD">689000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_BerkshireSteruleManufacturingMember_custom_BerkshireSteruleManufacturingAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_ShilpaMember_custom_ShilpaAgreementMember"
      decimals="0"
      unitRef="USD">707000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_ShilpaMember_custom_ShilpaAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_CuriaMember"
      decimals="0"
      unitRef="USD">285000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_CuriaMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_LumaBridgeLLCMember_custom_LumaBridgeAgreementMember"
      decimals="0"
      unitRef="USD">82000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31_custom_LumaBridgeLLCMember_custom_LumaBridgeAgreementMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <LTRN:ResearchAndDevelopmentExpensesPercentage
      contextRef="From2022-01-012022-12-31_custom_LanternPharmaLimitedMember"
      decimals="INF"
      unitRef="Pure">0.50</LTRN:ResearchAndDevelopmentExpensesPercentage>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_LanternPharmaLimitedMember"
      decimals="0"
      unitRef="GBP">24215</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_LanternPharmaLimitedMember"
      decimals="0"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="From2021-05-012021-05-31_custom_ActuateTherapeuticsMember_custom_CollaborationAgreementMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <LTRN:NominalValueOfRestrictedSharesOfActuateStock
      contextRef="AsOf2021-05-31_custom_ActuateTherapeuticsMember_custom_CollaborationAgreementMember"
      decimals="0"
      unitRef="USD">0</LTRN:NominalValueOfRestrictedSharesOfActuateStock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zd6Ss8nfEK2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5. &lt;span id="xdx_82C_z0g7DBO49wS4"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
operating lease cost recognized in general and administrative expenses in the Company&#x2019;s consolidated statements of operations was
approximately $&lt;span id="xdx_903_eus-gaap--OtherGeneralAndAdministrativeExpense_c20220101__20221231_z31nRnU5H7Wa" title="General and administrative expenses"&gt;144,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OtherGeneralAndAdministrativeExpense_c20210101__20211231_z63tkB9GNhJ" title="General and administrative expenses"&gt;105,000&lt;/span&gt; for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock_zruYKAcwdsr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following provides balance sheet information related to leases as of December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zf6b65fg8pKi" style="display: none"&gt;Schedule
of Balance Sheet Information Related to Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20221231_zJ423jqzMxSi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231_zUfl7QuYrqLa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                                                                                                                                31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_iI_z0vwXl3Er1ih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    lease, right-of-use asset, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;47,687&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;185,943&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zwDIFaYg9LR6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
    portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;52,890&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;152,058&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z7DYTEEFNgg9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;52,890&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiability_iI_zrtrxmFjdPO8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;52,890&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;204,948&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zKTC5JCKWBS" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zj3XVayTaE11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2022, the future estimated minimum lease payments under non-cancelable operating leases are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zw2FsPlAcPCg" style="display: none"&gt;Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20221231_zwzvebv5Mexl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPzhbM_z9mhXktjhgVl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Total minimum lease payments to be paid in 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;53,403&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zBZzSORla892" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(513&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zZf7VfB8u5V7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,890&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zdPqkOGwqUkk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less current portion of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z2I9Tv7m5zKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease liabilities, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zwTE0MEFHF23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2021, the Company entered into two operating leases for office space that commenced in May 2021. &lt;span id="xdx_90D_ecustom--LeaseExpirationDate_c20220101__20221231_z9zMkwZ5Dmvk" title="Lease expiration date"&gt;The
leases were scheduled to expire in April 2023&lt;/span&gt; and automatically renew month-to-month unless the Company provided three-months
written notice to the landlord prior to initial expiration. The exercise of lease renewal options was at the Company&#x2019;s sole
discretion and is assessed as to whether to include any renewals in the lease term at inception. In March 2023, the Company renewed and extended its leases for office space
and access to meeting facilities in the Dallas, Texas area and in the Atlanta, Georgia area. The following table provides a
reconciliation for the Company&#x2019;s right of use assets and lease liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_zInnik6eGHC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B3_zwBIZ2t26XO4" style="display: none"&gt;Schedule of
Reconciliation of Right-of-use Assets and Lease Liabilities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Right-of-Use Asset&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Operating Lease Liability&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20210101__20211231_zzxQ3ZVmxIz1" title="Right of use asst"&gt;$&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_981_eus-gaap--OperatingLeaseLiability_iS_c20210101_zEbhtgm62yig" title="Operating lease liability"&gt;$&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0698"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Additions&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetAdditions_c20210101__20211231_ztWO0s3ao4al" style="width: 16%; text-align: right" title="Additions, Right of use asset"&gt;274,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--OperatingLeaseLiabilityInAdditions_c20210101__20211231_z7G9JBWpilAh" style="width: 16%; text-align: right" title="Additions, Operating lease liability"&gt;276,603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Amortizations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20210101__20211231_z9GwPqqo3Ci" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Right of use asset"&gt;(88,529&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OperatingLeaseLiabilityAmortization_c20210101__20211231_z4WHHfzgVwol" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Operating lease liability"&gt;(71,655&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20220101__20221231_zJvVPMvypF5b" style="text-align: right" title="Right of use asset"&gt;185,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeaseLiability_iS_c20220101__20221231_zgbyKUR1DRy" style="text-align: right" title="Operating lease liability"&gt;204,948&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Amortizations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20220101__20221231_zsAfwWz9vq7d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Right of use asset"&gt;(138,256&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OperatingLeaseLiabilityAmortization_c20220101__20221231_zmuZTmLV85r2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Operating lease liability"&gt;(152,058&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20220101__20221231_zlz1J4108bG1" style="border-bottom: Black 2.5pt double; text-align: right" title="Right of use asset"&gt;47,687&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiability_iE_c20220101__20221231_zyTPt5jfwvA8" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability"&gt;52,890&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AF_zDraQNMo8Qc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock_zqkWcgENXZ77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
supplemental information related to operating leases is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BA_zYpSDAjAcdBe" style="display: none"&gt;Schedule of Other Supplemental Information
Related to Operating Leases&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td/&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_ztmiwWU5ot2c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20211231_zGOho28oFFX7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td/&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Weighted average remaining term of operating leases (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zyQQ82gd8P3i" title="Weighted average remaining term of operating leases (in years)"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_z0vh5280ug33" title="Weighted average remaining term of operating leases (in years)"&gt;1.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zOZyxqSgt6d3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average discount rate of operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.65&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.65&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zQb6q64MDoke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also leased office space in Dallas, Texas under month-to-month lease arrangements during the years ended December 31, 2022 and
2021. Under these short-term leases, the Company elected the short-term lease measurement and recognition exemption under ASC 842 and
recorded rent expense as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">144000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">105000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <LTRN:ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_ecustom--ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock_zruYKAcwdsr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following provides balance sheet information related to leases as of December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zf6b65fg8pKi" style="display: none"&gt;Schedule
of Balance Sheet Information Related to Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20221231_zJ423jqzMxSi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231_zUfl7QuYrqLa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                                                                                                                                31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_iI_z0vwXl3Er1ih" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    lease, right-of-use asset, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;47,687&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;185,943&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zwDIFaYg9LR6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
    portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;52,890&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;152,058&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z7DYTEEFNgg9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;52,890&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiability_iI_zrtrxmFjdPO8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;52,890&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;204,948&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</LTRN:ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">47687</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">185943</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">52890</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">152058</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">52890</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">52890</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">204948</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zj3XVayTaE11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2022, the future estimated minimum lease payments under non-cancelable operating leases are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zw2FsPlAcPCg" style="display: none"&gt;Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20221231_zwzvebv5Mexl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPzhbM_z9mhXktjhgVl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Total minimum lease payments to be paid in 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;53,403&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zBZzSORla892" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(513&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zZf7VfB8u5V7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,890&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zdPqkOGwqUkk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less current portion of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z2I9Tv7m5zKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease liabilities, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0690"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">53403</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">513</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">52890</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">52890</us-gaap:OperatingLeaseLiabilityCurrent>
    <LTRN:LeaseExpirationDate contextRef="From2022-01-01to2022-12-31">The
leases were scheduled to expire in April 2023</LTRN:LeaseExpirationDate>
    <LTRN:ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_ecustom--ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_zInnik6eGHC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B3_zwBIZ2t26XO4" style="display: none"&gt;Schedule of
Reconciliation of Right-of-use Assets and Lease Liabilities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Right-of-Use Asset&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Operating Lease Liability&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20210101__20211231_zzxQ3ZVmxIz1" title="Right of use asst"&gt;$&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_981_eus-gaap--OperatingLeaseLiability_iS_c20210101_zEbhtgm62yig" title="Operating lease liability"&gt;$&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0698"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Additions&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--OperatingLeaseRightOfUseAssetAdditions_c20210101__20211231_ztWO0s3ao4al" style="width: 16%; text-align: right" title="Additions, Right of use asset"&gt;274,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--OperatingLeaseLiabilityInAdditions_c20210101__20211231_z7G9JBWpilAh" style="width: 16%; text-align: right" title="Additions, Operating lease liability"&gt;276,603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Amortizations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20210101__20211231_z9GwPqqo3Ci" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Right of use asset"&gt;(88,529&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OperatingLeaseLiabilityAmortization_c20210101__20211231_z4WHHfzgVwol" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Operating lease liability"&gt;(71,655&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAsset_iS_c20220101__20221231_zJvVPMvypF5b" style="text-align: right" title="Right of use asset"&gt;185,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeaseLiability_iS_c20220101__20221231_zgbyKUR1DRy" style="text-align: right" title="Operating lease liability"&gt;204,948&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Amortizations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_di_c20220101__20221231_zsAfwWz9vq7d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Right of use asset"&gt;(138,256&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OperatingLeaseLiabilityAmortization_c20220101__20221231_zmuZTmLV85r2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortizations, Operating lease liability"&gt;(152,058&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iE_c20220101__20221231_zlz1J4108bG1" style="border-bottom: Black 2.5pt double; text-align: right" title="Right of use asset"&gt;47,687&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiability_iE_c20220101__20221231_zyTPt5jfwvA8" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liability"&gt;52,890&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</LTRN:ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock>
    <LTRN:OperatingLeaseRightOfUseAssetAdditions
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">274472</LTRN:OperatingLeaseRightOfUseAssetAdditions>
    <LTRN:OperatingLeaseLiabilityInAdditions
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">276603</LTRN:OperatingLeaseLiabilityInAdditions>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">88529</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <LTRN:OperatingLeaseLiabilityAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-71655</LTRN:OperatingLeaseLiabilityAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">185943</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">204948</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">138256</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <LTRN:OperatingLeaseLiabilityAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-152058</LTRN:OperatingLeaseLiabilityAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">47687</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">52890</us-gaap:OperatingLeaseLiability>
    <LTRN:ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_ecustom--ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock_zqkWcgENXZ77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
supplemental information related to operating leases is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BA_zYpSDAjAcdBe" style="display: none"&gt;Schedule of Other Supplemental Information
Related to Operating Leases&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td/&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_ztmiwWU5ot2c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20211231_zGOho28oFFX7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td/&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Weighted average remaining term of operating leases (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zyQQ82gd8P3i" title="Weighted average remaining term of operating leases (in years)"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_z0vh5280ug33" title="Weighted average remaining term of operating leases (in years)"&gt;1.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zOZyxqSgt6d3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average discount rate of operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.65&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.65&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</LTRN:ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31">P0Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2021-12-31">P1Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-12-31" decimals="INF" unitRef="Pure">0.0465</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2021-12-31" decimals="INF" unitRef="Pure">0.0465</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zd1rX7qf8OOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6. &lt;span id="xdx_826_zf1BYOYcsMWj"&gt;Shareholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Preferred
Stock &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the Company&#x2019;s IPO, all shares of the Company&#x2019;s Series A preferred stock were converted into &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20200601__20200615__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zKpZrdEiq462" title="Conversion of Stock, Shares Converted"&gt;2,438,851&lt;/span&gt; shares of common stock
effective June 15, 2020, with fractional share adjustments made in connection with the conversion as discussed below. As of December
31, 2022 and 2021, the Company had &lt;span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zg7SGq7t4Suh" title="Preferred stock shares authorized"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zNjqF7tqr813" title="Preferred stock shares authorized"&gt;1,000,000&lt;/span&gt;&lt;/span&gt; authorized shares of preferred stock, with &lt;span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_dc_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcdxF2vypem9" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zqaaVR1V4MRd" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_dc_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztJIvOudfNV1" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTuF7EdlDQ79" title="Preferred stock, shares outstanding"&gt;zero&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of preferred stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 20, 2021, the Company closed a public offering of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaw7nlqsMeg8" title="Issuance of stock, shares"&gt;4,928,571&lt;/span&gt; shares of its common stock at a public offering price of $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2X2Lvf00vUd" title="Share price"&gt;14.00&lt;/span&gt; per
share, which amount included &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zRaECfCYLVr2" title="Issuance of stock, shares"&gt;642,856&lt;/span&gt; shares sold upon full exercise of the underwriter&#x2019;s over-allotment option. Total gross proceeds
from the offering were approximately $&lt;span id="xdx_907_ecustom--GrossProceedsFromInitialPublicOffering_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z9nlwZF2sOei" title="Gross proceeds"&gt;69,000,000&lt;/span&gt;, and net proceeds from the offering were approximately $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zs5jrE2jesLl" title="Net proceeds"&gt;64,167,000&lt;/span&gt;, after deducting
underwriting discounts and commissions of approximately $&lt;span id="xdx_90C_ecustom--ProceedsAfterDeductingUnderwritingDiscountsAndCommissions_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zSyCuYuUmedh" title="Proceeds after deducting underwriting discounts and commissions"&gt;4,554,000&lt;/span&gt; and other offering expenses of approximately $&lt;span id="xdx_908_ecustom--OtherOfferingExpenses_c20210119__20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zUsR4OINnTMb" title="Other offering expenses"&gt;279,000&lt;/span&gt;, including $&lt;span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_c20210120__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zsYuPfZ7Ccxl" title="Deferring offering costs"&gt;101,000&lt;/span&gt;
of deferring offering costs previously recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2021, the Company&#x2019;s Board of Directors authorized a share repurchase program to acquire up to $&lt;span id="xdx_90F_eus-gaap--StockRepurchasedDuringPeriodShares_c20211101__20211130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zwP3mkcfcosc" title="Repurchase of shares"&gt;7,000,000&lt;/span&gt; of the Company&#x2019;s
common stock. During the year ended December 31, 2022, the Company repurchased &lt;span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_ziU77uvTMOTi" title="Repurchase of shares"&gt;353,667&lt;/span&gt; shares of common stock, pursuant to the repurchase
program for a total of approximately $&lt;span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zKrm7U1P9US1" title="Repurchase of shares, value"&gt;2,482,000&lt;/span&gt;, including purchase fees. During the year ended December 31, 2021, the Company repurchased
&lt;span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zhMHCx2jHPYd" title="Repurchase of shares"&gt;121,490&lt;/span&gt; shares of common stock pursuant to the repurchase program for a total of approximately $&lt;span id="xdx_904_eus-gaap--StockRepurchasedDuringPeriodValue_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zwLcFQsqXBef" title="Repurchase of shares, value"&gt;940,000&lt;/span&gt;, including purchase fees. Upon
purchase, the repurchased shares ceased to be outstanding and returned to the status of authorized and unissued shares of common stock.
The share repurchase program terminated July 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2021, the Company issued &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zpx4XQP95Aci" title="Issuance of stock, shares"&gt;11,782&lt;/span&gt; shares of common stock relating to the exercise of stock options. The shares
were issued at a purchase price of $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9e8E5duAXyj" title="Share price"&gt;1.03&lt;/span&gt; per share for total proceeds of approximately $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxDX8NAh2yAl" title="Issuance of stock, value"&gt;12,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2021, the Company issued &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7s18yvju3J" title="Issuance of stock, shares"&gt;40,727&lt;/span&gt; shares of common stock relating to the cash exercise of warrants for total
proceeds of approximately $&lt;span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlN92fMIdX7d" title="Proceeds from warrants exercise"&gt;127,000&lt;/span&gt;. During the year ended December 31, 2021 the Company also issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CashlessWarrantsMember_z2Jx54LQ8aph" title="Issuance of stock, shares"&gt;8,318&lt;/span&gt; shares of common stock relating
to the cashless exercise of warrants to purchase &lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CashlessWarrantsMember_zAgqtSjTmUw7" title="Warrants to purchase shares"&gt;11,114&lt;/span&gt; shares, respectively. All of such warrants were exercisable at an exercise price
of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CashlessWarrantsMember_zbS1WEukoKh4" title="Exercise price"&gt;3.13&lt;/span&gt; per share of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company issued &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx0hfPDJQsu3" title="Issuance of stock, shares"&gt;26,093&lt;/span&gt; shares of common stock relating to the cashless exercise of stock options
to purchase &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcAcFjEGtOCb" title="Stock option"&gt;32,538&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company issued &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb6nuJLAyHMb" title="Issuance of stock"&gt;95,779&lt;/span&gt; shares of common stock relating to the cash exercise of warrants for total
proceeds of approximately $&lt;span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzbZmFoYJtif" title="Proceeds from warrants exercise"&gt;300,000&lt;/span&gt;. All of such warrants were exercisable at an exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4F53g3F9A26" title="Exercise price"&gt;3.13&lt;/span&gt; per share of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and December 31, 2021, the Company had &lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zfJvt6dGqwk2" title="Common stock, shares authorized"&gt;&lt;span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zVNTgUwyqA65" title="Common stock, shares authorized"&gt;25,000,000&lt;/span&gt;&lt;/span&gt; authorized shares of Common Stock, of which &lt;span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20221231_zCcnhTCU6NJ1" title="Common stock, shares issued"&gt;&lt;span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_z0Uk3SVXJ5F9" title="Common stock, shares outstanding"&gt;10,857,040&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20211231_z7HRRhFOKrVl" title="Common stock, shares issued"&gt;&lt;span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zgerrfMyiAz8" title="Common stock, shares outstanding"&gt;11,088,835&lt;/span&gt;&lt;/span&gt;
shares were issued and outstanding, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had warrants to purchase &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_zcwIrTM8xgt7" title="Purchase of warrants"&gt;177,998&lt;/span&gt; shares of common stock outstanding and exercisable as of December 31, 2022 at a weighted average
exercise price of $&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231_zIQjzbe21mJ4" title="Weighted average exercise price, warrants"&gt;9.27&lt;/span&gt; per share, and with expiration dates ranging from &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zCh3Xxjp11c8" title="Expiration date of warrants"&gt;March 7, 2024&lt;/span&gt; to &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zlwBz2Go0tx9" title="Expiration date of warrants"&gt;June 10, 2025&lt;/span&gt;. The Company had warrants to
purchase &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_ztL2hgyJ0Caf" title="Purchase of warrants"&gt;273,777&lt;/span&gt; shares of common stock outstanding and exercisable as of December 31, 2021 at a weighted average exercise price of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxXA4LHvAbwk" title="Weighted average exercise price"&gt;7.12&lt;/span&gt;
per share, and with expiration dates ranging from &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_z3txxujWdX3f" title="Expiration date of warrants"&gt;March 17, 2022&lt;/span&gt; to &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zFzaUsMF4dQd" title="Expiration date of warrants"&gt;June 10, 2025&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 29, 2018, the Board of Directors of the Company adopted the Lantern Pharma Inc. 2018 Equity Incentive Plan, which was
subsequently amended on December 17, 2018, February 26, 2020 and October 20, 2022. The Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and
restated, is referred to herein as the &#x201c;Plan&#x201d;. The Company reserved &lt;span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z7dwUgNUdsvh" title="Number of reserved shares"&gt;1,489,680&lt;/span&gt;
shares of its common stock for issuance under the Plan. The Plan is designed to provide additional incentives to employees,
directors and consultants to remain in the service of the Company as well as to encourage stock acquisition by members of these
targeted groups, which in the opinion of the management will support the alignment of the interests of the members of these groups
and stockholders. Options granted under the Plan are generally exercisable for up to &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zRQq2kTO1UR4" title="Options exercisable period"&gt;10&lt;/span&gt;
years from grant date. &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_ziRpSSoNTxgc" title="Number of remain available shares"&gt;288,796&lt;/span&gt;
shares remain available for future awards under the Plan at December 31, 2022, following the grant of options and the award of
restricted stock grants through December 31, 2022. The Company recorded stock-based compensation of approximately $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z1InlAtgdEtf" title="Share based compensation"&gt;1,188,000&lt;/span&gt;
and $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z9lNhRP2P72j" title="Share based compensation"&gt;962,000&lt;/span&gt;
related to stock options during the years ended December 31, 2022 and 2021, respectively. Total remaining unrecognized compensation
expense for non-vested options is approximately $&lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zeFouxJC5eg7" title="Unrecognized compensation expense"&gt;1,788,000&lt;/span&gt;
as of December 31, 2022, and is expected to be recognized over a weighted average period of &lt;span id="xdx_902_eus-gaap--InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zQtQMGc13kM1" title="Weighted average period"&gt;1.8&lt;/span&gt;
years. The weighted average remaining contractual term of outstanding options at December 31, 2022 is &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zMPdDsztsvm3" title="Weighted average remaining contractual term"&gt;7.26&lt;/span&gt;
years. The weighted average remaining contractual term of exercisable options at December 31, 2022 is &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zYve3LXZuwG8" title="Weighted average remaining contractual term"&gt;6.56&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8iaSLhAL19h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity under the Plan during the years ended December 31, 2022 and 2021 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zUUItj2NWpne"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Outstanding December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zZVhdRxrLQMl" style="width: 11%; text-align: right" title="Number of options outstanding, beginning balance"&gt;835,608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_z5lob1pEOO39" style="width: 11%; text-align: right" title="Weighted average exercise price per share, outstanding beginning"&gt;6.41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20210101__20211231_zyrchipcFS71" style="width: 11%; text-align: right" title="Number of options exercisable, beginning valance"&gt;610,633&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_c20210101__20211231_zaHioS0jijj" style="width: 11%; text-align: right" title="Number of options exercisable, weighted-average exercise price, beginning balance"&gt;3.24&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zaq2WlG8qVNe" style="text-align: right" title="Number of shares, granted"&gt;110,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zGip72pd5LLj" style="text-align: right" title="Weighted average exercise price per share, granted"&gt;10.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20211231_zKcw48HyEOi" style="text-align: right" title="Number of shares, exercised"&gt;(11,782&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zRCD9NKFuIL2" style="text-align: right" title="Weighted average exercise price per share, exercised"&gt;1.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Cancelled or expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20211231_zRsmUHoMgdue" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, cancelled or expired"&gt;(43,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zVvRtcRp6KGb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share, cancelled or expired"&gt;15.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zU6Lry8J7yVl" style="text-align: right" title="Number of shares, outstanding beginning"&gt;890,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zkULGhJ12l65" style="text-align: right" title="Weighted average exercise price per share, outstanding beginning"&gt;6.54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20220101__20221231_zisUrdXTZ5t6" style="text-align: right" title="Number of options exercisable, beginning valance"&gt;687,438&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_c20220101__20221231_zNcT6IE8E399" style="text-align: right" title="Number of options exercisable, weighted-average exercise price, beginning balance"&gt;4.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zsJAfx8CMb97" style="text-align: right" title="Number of shares, granted"&gt;196,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zHmXOIrVQl6l" style="text-align: right" title="Weighted average exercise price per share, granted"&gt;5.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zhucVShtxzN2" style="text-align: right" title="Number of shares, exercised"&gt;(32,538&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_z591Jknqms7c" style="text-align: right" title="Weighted average exercise price per share, exercised"&gt;1.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Cancelled or expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_z92LMtRNuuk2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, cancelled or expired"&gt;(16,897&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJMXz9agYLLe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share, cancelled or expired"&gt;13.19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Outstanding December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zfWtMxVQ5Mz" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding beinning"&gt;1,037,591&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zr5tNq9SW4oa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, outstanding ending"&gt;6.46&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zu6TkDEIXtJ1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable, ending balance"&gt;755,073&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zjNU9WeEoGNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable, weighted-average exercise price, ending balance"&gt;5.87&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zGluRXstHgw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zETqDHuMsRsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
2022 and 2021, the fair value of each option granted was estimated using the Black-Scholes option-pricing model, using the following
weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zfyjZILKeSd1"&gt;Schedule
of Weighted Average Assumptions&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zebNg2aKEHok" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20211231_zrAg06TWqXhd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Term (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dtY_c20220101__20221231_zspC8oq5bGPh" title="Term (in years)"&gt;5.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dtY_c20210101__20211231_zjLkrFQsqbEi" title="Term (in years)"&gt;5.78&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_z3oLDsKXtGhl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Risk Free Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.04&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zzFQpOcVOOE8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125.35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90.70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zAo1guIZ0QFd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_z7EQiJwxvSY3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Grant Date Fair Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zjRCOwj73k82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of options is recognized as an expense over the vesting period and forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total intrinsic value of options outstanding at December 31, 2022 was approximately $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20221231_z9vOjjtW0Mzf" title="Total intrinsic value of options outstanding"&gt;2,422,000&lt;/span&gt;, and the total intrinsic value of options
exercisable at December 31, 2022 was approximately $&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20221231_zeoouegS7ku9" title="Stock option intrinsic value"&gt;2,361,000&lt;/span&gt;. The total intrinsic value of options exercised during the year ended December
31, 2022 was approximately $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220101__20221231_zh2XTWGOkttc" title="Total intrinsic value of options exercised"&gt;136,000&lt;/span&gt;. The total intrinsic value of options outstanding at December 31, 2021 was approximately $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20211231_zfscBSbxzPrd" title="Total intrinsic value of options outstanding"&gt;3,490,000&lt;/span&gt;,
and the total intrinsic value of options exercisable at December 31, 2021 was approximately $&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231_zZxNFbsPNl3"&gt;3,490,000&lt;/span&gt;. The total intrinsic value of
options exercised during the year ended December 31, 2021 was approximately $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210101__20211231_zel5R7mIjCub"&gt;213,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    Term -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company used a weighted average of time to vesting and maturity date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    Volatility-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
    to the Company&#x2019;s limited operating history and a lack of company-specific historical and implied volatility data, the Company
    has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded
    commensurate with expected term as of grant date. The historical volatility data was computed using the daily closing prices for
    the selected comparable companies&#x2019; shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-Free
    Interest Rate-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company used the U.S. treasury bill rate commensurate with the expected term as of grant date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    Dividend-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    the Company has not issued any dividends and does not expect to issue dividends over the life of the options, the Company has estimated
    the dividend yield to be zero.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2020-06-012020-06-15_us-gaap_SeriesAPreferredStockMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">2438851</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-192021-01-20_us-gaap_IPOMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4928571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-01-20_us-gaap_IPOMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">14.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-192021-01-20_us-gaap_IPOMember_us-gaap_CommonStockMember_custom_UnderwritersMember"
      decimals="INF"
      unitRef="Shares">642856</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <LTRN:GrossProceedsFromInitialPublicOffering
      contextRef="From2021-01-192021-01-20_us-gaap_IPOMember"
      decimals="0"
      unitRef="USD">69000000</LTRN:GrossProceedsFromInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-01-192021-01-20_us-gaap_IPOMember"
      decimals="0"
      unitRef="USD">64167000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <LTRN:ProceedsAfterDeductingUnderwritingDiscountsAndCommissions
      contextRef="From2021-01-192021-01-20_us-gaap_IPOMember"
      decimals="0"
      unitRef="USD">4554000</LTRN:ProceedsAfterDeductingUnderwritingDiscountsAndCommissions>
    <LTRN:OtherOfferingExpenses
      contextRef="From2021-01-192021-01-20_us-gaap_IPOMember"
      decimals="0"
      unitRef="USD">279000</LTRN:OtherOfferingExpenses>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2021-01-20_us-gaap_IPOMember"
      decimals="0"
      unitRef="USD">101000</us-gaap:DeferredOfferingCosts>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2021-11-012021-11-30_us-gaap_CommonStockMember_srt_DirectorMember"
      decimals="INF"
      unitRef="Shares">7000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_DirectorMember"
      decimals="INF"
      unitRef="Shares">353667</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">2482000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_DirectorMember"
      decimals="INF"
      unitRef="Shares">121490</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_DirectorMember"
      decimals="0"
      unitRef="USD">940000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">11782</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.03</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">12000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">40727</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">127000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-12-31_custom_CashlessWarrantsMember"
      decimals="INF"
      unitRef="Shares">8318</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <LTRN:StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise
      contextRef="From2021-01-012021-12-31_custom_CashlessWarrantsMember"
      decimals="INF"
      unitRef="Shares">11114</LTRN:StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_custom_CashlessWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">26093</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">32538</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">95779</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">300000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">3.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">10857040</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">10857040</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">11088835</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">11088835</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">177998</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <LTRN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">9.27</LTRN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2022-01-012022-12-31_srt_MinimumMember">2024-03-07</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2022-01-012022-12-31_srt_MaximumMember">2025-06-10</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">273777</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2021-01-012021-12-31_srt_MinimumMember">2022-03-17</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2021-01-012021-12-31_srt_MaximumMember">2025-06-10</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">1489680</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="From2022-01-012022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">288796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="0"
      unitRef="USD">1188000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="0"
      unitRef="USD">962000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="0"
      unitRef="USD">1788000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod contextRef="From2022-01-012022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">P1Y9M18D</us-gaap:InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">P7Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-01to2022-12-31">P6Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8iaSLhAL19h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity under the Plan during the years ended December 31, 2022 and 2021 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zUUItj2NWpne"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Outstanding December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zZVhdRxrLQMl" style="width: 11%; text-align: right" title="Number of options outstanding, beginning balance"&gt;835,608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_z5lob1pEOO39" style="width: 11%; text-align: right" title="Weighted average exercise price per share, outstanding beginning"&gt;6.41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20210101__20211231_zyrchipcFS71" style="width: 11%; text-align: right" title="Number of options exercisable, beginning valance"&gt;610,633&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_c20210101__20211231_zaHioS0jijj" style="width: 11%; text-align: right" title="Number of options exercisable, weighted-average exercise price, beginning balance"&gt;3.24&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zaq2WlG8qVNe" style="text-align: right" title="Number of shares, granted"&gt;110,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zGip72pd5LLj" style="text-align: right" title="Weighted average exercise price per share, granted"&gt;10.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20211231_zKcw48HyEOi" style="text-align: right" title="Number of shares, exercised"&gt;(11,782&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zRCD9NKFuIL2" style="text-align: right" title="Weighted average exercise price per share, exercised"&gt;1.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Cancelled or expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210101__20211231_zRsmUHoMgdue" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, cancelled or expired"&gt;(43,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zVvRtcRp6KGb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share, cancelled or expired"&gt;15.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zU6Lry8J7yVl" style="text-align: right" title="Number of shares, outstanding beginning"&gt;890,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zkULGhJ12l65" style="text-align: right" title="Weighted average exercise price per share, outstanding beginning"&gt;6.54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20220101__20221231_zisUrdXTZ5t6" style="text-align: right" title="Number of options exercisable, beginning valance"&gt;687,438&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iS_c20220101__20221231_zNcT6IE8E399" style="text-align: right" title="Number of options exercisable, weighted-average exercise price, beginning balance"&gt;4.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zsJAfx8CMb97" style="text-align: right" title="Number of shares, granted"&gt;196,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zHmXOIrVQl6l" style="text-align: right" title="Weighted average exercise price per share, granted"&gt;5.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zhucVShtxzN2" style="text-align: right" title="Number of shares, exercised"&gt;(32,538&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_z591Jknqms7c" style="text-align: right" title="Weighted average exercise price per share, exercised"&gt;1.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Cancelled or expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220101__20221231_z92LMtRNuuk2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, cancelled or expired"&gt;(16,897&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zJMXz9agYLLe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share, cancelled or expired"&gt;13.19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Outstanding December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zfWtMxVQ5Mz" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding beinning"&gt;1,037,591&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zr5tNq9SW4oa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, outstanding ending"&gt;6.46&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zu6TkDEIXtJ1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable, ending balance"&gt;755,073&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20220101__20221231_zjNU9WeEoGNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable, weighted-average exercise price, ending balance"&gt;5.87&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">835608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">6.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">610633</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">3.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">110500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">10.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">11782</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">1.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">43500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">15.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">890826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">6.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">687438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">4.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">196200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">5.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">32538</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">16897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">13.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1037591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">6.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">755073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">5.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zETqDHuMsRsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
2022 and 2021, the fair value of each option granted was estimated using the Black-Scholes option-pricing model, using the following
weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zfyjZILKeSd1"&gt;Schedule
of Weighted Average Assumptions&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zebNg2aKEHok" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20211231_zrAg06TWqXhd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Term (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dtY_c20220101__20221231_zspC8oq5bGPh" title="Term (in years)"&gt;5.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dtY_c20210101__20211231_zjLkrFQsqbEi" title="Term (in years)"&gt;5.78&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_z3oLDsKXtGhl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Risk Free Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.04&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zzFQpOcVOOE8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125.35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90.70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zAo1guIZ0QFd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_z7EQiJwxvSY3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Grant Date Fair Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2022-01-01to2022-12-31">P5Y11M4D</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2021-01-012021-12-31">P5Y9M10D</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">1.2535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.9070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">4.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">7.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2422000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2361000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">136000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3490000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">213000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_804_eus-gaap--CashCashEquivalentsAndMarketableSecuritiesTextBlock_zt1H2oUa5jSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7. &lt;span id="xdx_826_zASw5XuSVl3i"&gt;Marketable Securities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--MarketableSecuritiesTextBlock_zDgp5vSmG2Ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2022, marketable securities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zleHR3VOFLVg" style="display: none"&gt;Schedule of Marketable Securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_488_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_zB8II5kyvdrk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortized &lt;br/&gt; Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_481_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_zqfLYKH39XVd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized &lt;br/&gt; Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_zxoKSlx76PT1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized &lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_ztzCC4fcTohh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate &lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20221231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zt8s4WfUYz27" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Government &amp;amp; Agency Securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,408,681&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3,512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(184,863&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,227,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20221231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zR2BKFzRUyo1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate Bonds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,522,138&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(210,534&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,314,169&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20221231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesDebtMember_z5DpqkWZwse4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable Securities - Debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,930,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,077&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(395,397&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,541,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_417_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zl2XTJuYuRVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual Funds &#x2013; Fixed Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,002,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(343,904&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,658,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zCSiBPIaLPUf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Mutual Funds &#x2013; Alternative Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,023,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0941"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(229,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,794,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20221231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMutualFundsMember_zZM2RCegHiLl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Marketable Securities &#x2013; Mutual Funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,025,858&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0945"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(573,058&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,452,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20221231_zTaRiq5Xv0Pd" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities amortized cost"&gt;18,956,677&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_c20221231_zjqVUjd8Gpz3" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized gains"&gt;6,077&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_c20221231_zQ5JCprCoeoc" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized losses"&gt;(968,455&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_c20221231_zqT6EEzStmg1" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities aggregate fair value"&gt;17,994,299&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2021, marketable securities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_zBnhPUC2znm5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortized &lt;br/&gt; Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_483_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_zHU6pv4DreU1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized &lt;br/&gt; Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_481_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_zosW6frisiKh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized &lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_zHdG2JbYfeB4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate &lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20211231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zoz7clhCAEnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Government &amp;amp; Agency Securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3,808,056&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0957"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(27,003&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3,781,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zr0syzF2qUv8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate Bonds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,540,668&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(65,869&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,474,799&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_410_20211231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesDebtMember_zq91oeTU5yZe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable Securities - Debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13,348,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(92,872&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13,255,852&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20211231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zAWPe48PZirl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual Funds &#x2013; Fixed Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,002,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0969"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(36,654&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,966,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20211231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zboF29Gda8Di" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Mutual Funds &#x2013; Alternative Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,023,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(43,904&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,979,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20211231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMutualFundsMember_z5wLTpVc9iIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Marketable Securities &#x2013; Mutual Funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,025,858&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(80,558&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,945,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20211231_zRlhZ4KPmIWl" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities amortized cost"&gt;19,374,582&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_c20211231_zNlQxQlRaFn4" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_c20211231_zYz7ugYX5UY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized losses"&gt;(173,430&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_c20211231_zf3B7uODs4Na" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities aggregate fair value"&gt;19,201,152&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zS42c5tqRT52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zD3S4X3ekUm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
contractual maturities of the investments classified as Government&amp;amp; Agency Securities and Corporate Bonds are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zxxmaMcSh6hk"&gt;Schedule
of Contractual Maturities Investments of Marketable Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zFKQVYN97Q94" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_iI_maAFSSDzFK8_zpQph8UOvQ3k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Due within one year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,466,590&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue_iI_maAFSSDzFK8_zkaZHCbRdXe1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Due in one to two years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,802,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_iI_maAFSSDzFK8_zjlNIPDHbWV5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Due in two to five years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,272,644&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iTI_mtAFSSDzFK8_zX5FPKh0XyQ9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,541,499&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zTeQwfUc0Go4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zjHkptLHdgu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents gross unrealized losses and fair values for those marketable securities that were in an unrealized loss position
as of December 31, 2022, aggregated by investment category and the length of time that individual securities have been in a continuous
loss position:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zoZR39Ayy5B5"&gt;Schedule
of Gross Unrealized Losses and Fair Values for Marketable Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48B_ecustom--DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_iI_zDwy1hDV4A6l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_iNI_di_ziH3GESJ1LHh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_481_ecustom--DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_iI_z6pyKuuJHttg" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_486_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_iNI_di_zHzP426sPReb" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than 12 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;More than 12 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_417_20221231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zoRJOgb7L6ll" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Government &amp;amp; Agency Securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,184,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(26,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3,293,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(158,162&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20221231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zhd47NlGEY4f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Corporate Bonds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,337,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(27,516&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,383,482&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(183,018&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zjZL9pav9we3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Mutual Funds &#x2013; Fixed Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1008"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1009"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,658,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(343,904&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zJNZC9cVQFia" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Mutual Funds &#x2013; Alternative Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1013"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,794,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(229,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_iI_c20221231_zOAuLyDduTl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value Less than 12 months"&gt;2,522,621&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_iNI_di_c20221231_zDfk3C2GexJ2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized Loss Less than 12 months"&gt;(54,217&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_iI_c20221231_zOPXSTD5jMNk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value Less than 12 months"&gt;14,130,280&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_iNI_di_c20221231_zdTjqvKgQV9l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized Loss Less than 12 months"&gt;(914,238&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zhq4h6zW71a6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
do not believe the unrealized losses represent credit losses based on our evaluation of available evidence as of December 31, 2022, which
includes an assessment of whether it is more likely than not we will be required to sell the investment before recovery of the investment&#x2019;s
amortized cost basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_896_eus-gaap--MarketableSecuritiesTextBlock_zDgp5vSmG2Ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2022, marketable securities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zleHR3VOFLVg" style="display: none"&gt;Schedule of Marketable Securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_488_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_zB8II5kyvdrk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortized &lt;br/&gt; Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_481_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_zqfLYKH39XVd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized &lt;br/&gt; Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_489_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_zxoKSlx76PT1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized &lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_ztzCC4fcTohh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate &lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20221231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zt8s4WfUYz27" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Government &amp;amp; Agency Securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,408,681&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3,512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(184,863&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,227,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20221231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zR2BKFzRUyo1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate Bonds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,522,138&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(210,534&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,314,169&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20221231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesDebtMember_z5DpqkWZwse4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable Securities - Debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,930,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,077&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(395,397&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,541,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_417_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zl2XTJuYuRVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual Funds &#x2013; Fixed Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,002,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(343,904&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,658,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zCSiBPIaLPUf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Mutual Funds &#x2013; Alternative Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,023,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0941"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(229,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,794,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20221231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMutualFundsMember_zZM2RCegHiLl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Marketable Securities &#x2013; Mutual Funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,025,858&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0945"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(573,058&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,452,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20221231_zTaRiq5Xv0Pd" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities amortized cost"&gt;18,956,677&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_c20221231_zjqVUjd8Gpz3" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized gains"&gt;6,077&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_c20221231_zQ5JCprCoeoc" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized losses"&gt;(968,455&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_c20221231_zqT6EEzStmg1" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities aggregate fair value"&gt;17,994,299&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2021, marketable securities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_zBnhPUC2znm5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortized &lt;br/&gt; Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_483_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_zHU6pv4DreU1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized &lt;br/&gt; Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_481_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_zosW6frisiKh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized &lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_zHdG2JbYfeB4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate &lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20211231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zoz7clhCAEnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Government &amp;amp; Agency Securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3,808,056&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0957"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(27,003&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3,781,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20211231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zr0syzF2qUv8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate Bonds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,540,668&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(65,869&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,474,799&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_410_20211231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesDebtMember_zq91oeTU5yZe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable Securities - Debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13,348,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(92,872&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13,255,852&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20211231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zAWPe48PZirl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual Funds &#x2013; Fixed Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,002,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0969"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(36,654&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,966,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20211231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zboF29Gda8Di" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Mutual Funds &#x2013; Alternative Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,023,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(43,904&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,979,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20211231__us-gaap--FinancialInstrumentAxis__custom--MarketableSecuritiesMutualFundsMember_z5wLTpVc9iIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Marketable Securities &#x2013; Mutual Funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,025,858&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(80,558&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,945,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20211231_zRlhZ4KPmIWl" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities amortized cost"&gt;19,374,582&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_c20211231_zNlQxQlRaFn4" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_di_c20211231_zYz7ugYX5UY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities unrealized losses"&gt;(173,430&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_c20211231_zf3B7uODs4Na" style="border-bottom: Black 2.5pt double; text-align: right" title="Marketable securities aggregate fair value"&gt;19,201,152&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">5408681</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">3512</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">184863</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">5227330</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2022-12-31_custom_CorporateBondsMember"
      decimals="0"
      unitRef="USD">7522138</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2022-12-31_custom_CorporateBondsMember"
      decimals="0"
      unitRef="USD">2565</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2022-12-31_custom_CorporateBondsMember"
      decimals="0"
      unitRef="USD">210534</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2022-12-31_custom_CorporateBondsMember"
      decimals="0"
      unitRef="USD">7314169</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2022-12-31_custom_MarketableSecuritiesDebtMember"
      decimals="0"
      unitRef="USD">12930819</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2022-12-31_custom_MarketableSecuritiesDebtMember"
      decimals="0"
      unitRef="USD">6077</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2022-12-31_custom_MarketableSecuritiesDebtMember"
      decimals="0"
      unitRef="USD">395397</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2022-12-31_custom_MarketableSecuritiesDebtMember"
      decimals="0"
      unitRef="USD">12541499</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember"
      decimals="0"
      unitRef="USD">4002704</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember"
      decimals="0"
      unitRef="USD">343904</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember"
      decimals="0"
      unitRef="USD">3658800</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      decimals="0"
      unitRef="USD">2023154</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      decimals="0"
      unitRef="USD">229154</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      decimals="0"
      unitRef="USD">1794000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2022-12-31_custom_MarketableSecuritiesMutualFundsMember"
      decimals="0"
      unitRef="USD">6025858</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2022-12-31_custom_MarketableSecuritiesMutualFundsMember"
      decimals="0"
      unitRef="USD">573058</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2022-12-31_custom_MarketableSecuritiesMutualFundsMember"
      decimals="0"
      unitRef="USD">5452800</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">18956677</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6077</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">968455</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">17994299</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2021-12-31_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">3808056</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2021-12-31_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">27003</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2021-12-31_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">3781053</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2021-12-31_custom_CorporateBondsMember"
      decimals="0"
      unitRef="USD">9540668</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2021-12-31_custom_CorporateBondsMember"
      decimals="0"
      unitRef="USD">65869</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2021-12-31_custom_CorporateBondsMember"
      decimals="0"
      unitRef="USD">9474799</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2021-12-31_custom_MarketableSecuritiesDebtMember"
      decimals="0"
      unitRef="USD">13348724</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2021-12-31_custom_MarketableSecuritiesDebtMember"
      decimals="0"
      unitRef="USD">92872</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2021-12-31_custom_MarketableSecuritiesDebtMember"
      decimals="0"
      unitRef="USD">13255852</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2021-12-31_custom_MutualFundsFixedIncomeMember"
      decimals="0"
      unitRef="USD">4002704</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2021-12-31_custom_MutualFundsFixedIncomeMember"
      decimals="0"
      unitRef="USD">36654</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2021-12-31_custom_MutualFundsFixedIncomeMember"
      decimals="0"
      unitRef="USD">3966050</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2021-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      decimals="0"
      unitRef="USD">2023154</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2021-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      decimals="0"
      unitRef="USD">43904</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2021-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      decimals="0"
      unitRef="USD">1979250</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2021-12-31_custom_MarketableSecuritiesMutualFundsMember"
      decimals="0"
      unitRef="USD">6025858</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2021-12-31_custom_MarketableSecuritiesMutualFundsMember"
      decimals="0"
      unitRef="USD">80558</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2021-12-31_custom_MarketableSecuritiesMutualFundsMember"
      decimals="0"
      unitRef="USD">5945300</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">19374582</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">173430</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">19201152</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zD3S4X3ekUm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
contractual maturities of the investments classified as Government&amp;amp; Agency Securities and Corporate Bonds are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zxxmaMcSh6hk"&gt;Schedule
of Contractual Maturities Investments of Marketable Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zFKQVYN97Q94" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_iI_maAFSSDzFK8_zpQph8UOvQ3k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Due within one year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,466,590&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue_iI_maAFSSDzFK8_zkaZHCbRdXe1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Due in one to two years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,802,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_iI_maAFSSDzFK8_zjlNIPDHbWV5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Due in two to five years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,272,644&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iTI_mtAFSSDzFK8_zX5FPKh0XyQ9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,541,499&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5466590</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <LTRN:AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">5802265</LTRN:AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1272644</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">12541499</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_zjHkptLHdgu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents gross unrealized losses and fair values for those marketable securities that were in an unrealized loss position
as of December 31, 2022, aggregated by investment category and the length of time that individual securities have been in a continuous
loss position:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zoZR39Ayy5B5"&gt;Schedule
of Gross Unrealized Losses and Fair Values for Marketable Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48B_ecustom--DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_iI_zDwy1hDV4A6l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_iNI_di_ziH3GESJ1LHh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_481_ecustom--DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_iI_z6pyKuuJHttg" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_486_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_iNI_di_zHzP426sPReb" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than 12 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;More than 12 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_417_20221231__us-gaap--FinancialInstrumentAxis__custom--GovernmentAgencySecuritiesMember_zoRJOgb7L6ll" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Government &amp;amp; Agency Securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,184,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(26,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3,293,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(158,162&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20221231__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsMember_zhd47NlGEY4f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Corporate Bonds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,337,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(27,516&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,383,482&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(183,018&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsFixedIncomeMember_zjZL9pav9we3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Mutual Funds &#x2013; Fixed Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1008"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1009"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,658,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(343,904&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsAlternativeInvestmentsMember_zJNZC9cVQFia" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Mutual Funds &#x2013; Alternative Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1013"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,794,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(229,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss_iI_c20221231_zOAuLyDduTl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value Less than 12 months"&gt;2,522,621&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_iNI_di_c20221231_zDfk3C2GexJ2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized Loss Less than 12 months"&gt;(54,217&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss_iI_c20221231_zOPXSTD5jMNk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair Value Less than 12 months"&gt;14,130,280&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_iNI_di_c20221231_zdTjqvKgQV9l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unrealized Loss Less than 12 months"&gt;(914,238&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">1184683</LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">26701</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">3293998</LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">158162</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_CorporateBondsMember"
      decimals="0"
      unitRef="USD">1337938</LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_CorporateBondsMember"
      decimals="0"
      unitRef="USD">27516</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_CorporateBondsMember"
      decimals="0"
      unitRef="USD">5383482</LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_CorporateBondsMember"
      decimals="0"
      unitRef="USD">183018</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember"
      decimals="0"
      unitRef="USD">3658800</LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_MutualFundsFixedIncomeMember"
      decimals="0"
      unitRef="USD">343904</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      decimals="0"
      unitRef="USD">1794000</LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="AsOf2022-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      decimals="0"
      unitRef="USD">229154</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2522621</LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">54217</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">14130280</LTRN:DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">914238</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80F_eus-gaap--FairValueDisclosuresTextBlock_zRnaL37h2fK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8. &lt;span id="xdx_82A_zaVGsJuVe5f5"&gt;Fair Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use
of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous
market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions
that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the
hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes
the inputs into three levels that may be used to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability,
either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 - Inputs are unobservable inputs based on our assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Financial
Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
available, our marketable securities are valued using quoted prices for identical instruments in active markets. If we are unable to
value our marketable securities using quoted prices for identical instruments in active markets, we value our investments using broker
reports that utilize quoted market prices for comparable instruments. As of December 31, 2022 and 2021 our available-for-sale debt securities
were valued through use of quoted prices for comparable instruments in active markets and are classified as Level 2, and our mutual funds
&#x2013; alternative investments were valued using NAV, net asset value per share, under the practical expedient methodology.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on our valuation of our marketable securities, we concluded that they are classified in either Level 2 or NAV, and we have no financial
assets measured using Level 1 or 3 inputs. The following table presents information about our assets that are measured at fair value
on a recurring basis using the above input categories.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zEaYG8oZtPAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_z0M898YdEb89" style="display: none"&gt;Schedule
of Assets are Measured at Fair Value on  Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zLSnAjDHJJBk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5YWm1SAIaAf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj61Z06UW8yc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4kiayQnQQqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231__us-gaap--SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis__custom--NAVMember_zyPj3N6ms5nk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_F57_zoWPyx2PZ6m9" style="display: none; font-family: Times New Roman, Times, Serif"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of &lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;NAV*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--GovernmentAgencySecuritiesMember_zXxJnnijQtzb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%; text-align: left"&gt;Government &amp;amp; Agency Securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,227,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1030"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,227,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1032"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__us-gaap--CorporateBondSecuritiesMember_zkRdivqB7cBa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Corporate Bonds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,314,169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1036"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,314,169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1038"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1039"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsFixedIncomeMember_zAZyEmis3Tj5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual Funds &#x2013; Fixed Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,658,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1042"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,658,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1044"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1045"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsAlternativeInvestmentsMember_z7Cv7aIuNh9e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Mutual Funds &#x2013; Alternative Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,794,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1048"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1050"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,794,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_zmQ5Cf10fAE1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,994,299&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1054"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,200,299&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1056"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,794,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20211231_zXDvC6zsix3e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJxYC6RcPxPb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z2pY0y4H3xPd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMPB1xoJ1e11" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20211231__us-gaap--SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis__custom--NAVMember_zCLgidun5WWj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;sup id="xdx_F50_zxgoZA08XVO4"&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of &lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;NAV*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--GovernmentAgencySecuritiesMember_zLEbiBzDuhJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%; text-align: left"&gt;Government &amp;amp; Agency Securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,781,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1060"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,781,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1063"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__us-gaap--CorporateBondSecuritiesMember_zq24ErUzfPu" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Corporate Bonds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,474,799&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1066"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,474,799&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1068"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1069"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsFixedIncomeMember_zFEJ8haMKk9d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual Funds &#x2013; Fixed Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,966,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,966,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1074"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsAlternativeInvestmentsMember_zuruSy4PifEd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Mutual Funds &#x2013; Alternative Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,979,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1078"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1079"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1080"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,979,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_z7QFRjD4aJn4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
    value recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,201,152&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1084"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,221,902&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,979,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0C_zWzJkExXVfr3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zgPjcHnV7705" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
    marketable securities investments are measured at fair value using net asset value per share under the practical expedient methodology.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_z67O9lcC4FLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zEaYG8oZtPAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_z0M898YdEb89" style="display: none"&gt;Schedule
of Assets are Measured at Fair Value on  Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zLSnAjDHJJBk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5YWm1SAIaAf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj61Z06UW8yc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4kiayQnQQqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231__us-gaap--SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis__custom--NAVMember_zyPj3N6ms5nk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_F57_zoWPyx2PZ6m9" style="display: none; font-family: Times New Roman, Times, Serif"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of &lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;NAV*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--GovernmentAgencySecuritiesMember_zXxJnnijQtzb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%; text-align: left"&gt;Government &amp;amp; Agency Securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,227,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1030"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,227,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1032"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__us-gaap--CorporateBondSecuritiesMember_zkRdivqB7cBa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Corporate Bonds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,314,169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1036"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,314,169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1038"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1039"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsFixedIncomeMember_zAZyEmis3Tj5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual Funds &#x2013; Fixed Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,658,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1042"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,658,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1044"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1045"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsAlternativeInvestmentsMember_z7Cv7aIuNh9e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Mutual Funds &#x2013; Alternative Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,794,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1048"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1050"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,794,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_zmQ5Cf10fAE1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,994,299&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1054"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,200,299&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1056"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,794,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20211231_zXDvC6zsix3e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJxYC6RcPxPb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z2pY0y4H3xPd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zMPB1xoJ1e11" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20211231__us-gaap--SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis__custom--NAVMember_zCLgidun5WWj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;sup id="xdx_F50_zxgoZA08XVO4"&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of &lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;NAV*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--GovernmentAgencySecuritiesMember_zLEbiBzDuhJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%; text-align: left"&gt;Government &amp;amp; Agency Securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,781,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1060"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,781,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1063"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__us-gaap--CorporateBondSecuritiesMember_zq24ErUzfPu" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Corporate Bonds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,474,799&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1066"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,474,799&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1068"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1069"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsFixedIncomeMember_zFEJ8haMKk9d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual Funds &#x2013; Fixed Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,966,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,966,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1074"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_hus-gaap--InvestmentTypeAxis__custom--MutualFundsAlternativeInvestmentsMember_zuruSy4PifEd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Mutual Funds &#x2013; Alternative Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,979,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1078"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1079"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1080"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,979,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_z7QFRjD4aJn4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
    value recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,201,152&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1084"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,221,902&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,979,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0C_zWzJkExXVfr3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zgPjcHnV7705" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
    marketable securities investments are measured at fair value using net asset value per share under the practical expedient methodology.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">5227330</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">5227330</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_CorporateBondSecuritiesMember"
      decimals="0"
      unitRef="USD">7314169</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateBondSecuritiesMember"
      decimals="0"
      unitRef="USD">7314169</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_custom_MutualFundsFixedIncomeMember"
      decimals="0"
      unitRef="USD">3658800</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsFixedIncomeMember"
      decimals="0"
      unitRef="USD">3658800</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      decimals="0"
      unitRef="USD">1794000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_custom_NAVMember_custom_MutualFundsAlternativeInvestmentsMember"
      decimals="0"
      id="Fact001051"
      unitRef="USD">1794000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">17994299</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">16200299</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-01-012022-12-31_custom_NAVMember"
      decimals="0"
      id="Fact001057"
      unitRef="USD">1794000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">3781053</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_custom_GovernmentAgencySecuritiesMember"
      decimals="0"
      unitRef="USD">3781053</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_CorporateBondSecuritiesMember"
      decimals="0"
      unitRef="USD">9474799</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateBondSecuritiesMember"
      decimals="0"
      unitRef="USD">9474799</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_custom_MutualFundsFixedIncomeMember"
      decimals="0"
      unitRef="USD">3966050</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsFixedIncomeMember"
      decimals="0"
      unitRef="USD">3966050</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_custom_MutualFundsAlternativeInvestmentsMember"
      decimals="0"
      unitRef="USD">1979250</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_custom_NAVMember_custom_MutualFundsAlternativeInvestmentsMember"
      decimals="0"
      id="Fact001081"
      unitRef="USD">1979250</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">19201152</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">17221902</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-01-012021-12-31_custom_NAVMember"
      decimals="0"
      id="Fact001087"
      unitRef="USD">1979250</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z5pslEi3XVFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9. &lt;span id="xdx_82D_zyNUKDUjxndk"&gt;Notes and Loan Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 1, 2020 (the &#x201c;Origination Date&#x201d;), the Company received $&lt;span id="xdx_903_eus-gaap--ProceedsFromLoanOriginations1_pp0p0_c20200429__20200501_zcEVeUPIOWb3" title="Aggregate loan amount"&gt;108,500&lt;/span&gt; in aggregate loan proceeds (the &#x201c;PPP Loan&#x201d;)
from JPMorgan Chase Bank (the &#x201c;Lender&#x201d;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and
Economic Security (CARES) Act. The PPP Loan was evidenced by a loan application and payment agreement (the &#x201c;PPP Loan Agreement&#x201d;)
by and between the Company and the Lender. Subject to the terms of the PPP Loan Agreement, the PPP Loan bore interest at a fixed rate
of one percent (&lt;span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20200429__20200501_zSFgOaCMsBZ6" title="Annual interest rate"&gt;1.0%&lt;/span&gt;) per annum. Payments of principal and interest were deferred for the first six months following the Origination
Date, and the PPP Loan provided that it would mature two years after the Origination Date. The guidance under the Paycheck Protection
Program was later updated so that payments of principal and interest were extended past the current fiscal year and maturity was extended
past two years. The Company applied for forgiveness of the loan, and in April 2021 the Company received notice that the Small Business
Administration (SBA) had authorized full forgiveness of the PPP Loan. A gain on loan forgiveness attributed to the PPP Loan of approximately
$&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231_zT3OtypZVXPh" title="Debt face amount"&gt;109,000&lt;/span&gt; of principal and interest for the year ended December 31, 2021 was included in Other (expense) income, net in the accompanying
consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromLoanOriginations1
      contextRef="From2020-04-292020-05-01"
      decimals="0"
      unitRef="USD">108500</us-gaap:ProceedsFromLoanOriginations1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2020-04-292020-05-01"
      decimals="INF"
      unitRef="Pure">0.010</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">109000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_zln4BcrPp9U6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10. &lt;span id="xdx_821_zqH5G3wfBda8"&gt;Loss Per Share of Common Shares&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share is derived by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock
outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities,
such as warrants and stock options, which would result in the issuance of incremental shares of common stock unless such effect is anti-dilutive.
In calculating the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remained
the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation. Potentially
dilutive securities outstanding that have been excluded from diluted loss per share due to being anti-dilutive include the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zwuJprJJTnx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zojb0Sqk1uzd" style="display: none"&gt;Schedule
of Anti-dilutive Securities Outstanding Diluted Loss per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_z39VJRz7G9Bi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zKM4Xfud0d0h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zzGuchojeio" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;177,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;273,777&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNf7rIbLZ3S6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,037,591&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;890,826&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zOVBYqIqXU2f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Anti-dilutive securities &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,215,589&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,164,603&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zwuJprJJTnx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zojb0Sqk1uzd" style="display: none"&gt;Schedule
of Anti-dilutive Securities Outstanding Diluted Loss per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_z39VJRz7G9Bi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zKM4Xfud0d0h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zzGuchojeio" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;177,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;273,777&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNf7rIbLZ3S6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,037,591&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;890,826&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zOVBYqIqXU2f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Anti-dilutive securities &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,215,589&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,164,603&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">177998</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember16419640"
      decimals="INF"
      unitRef="Shares">273777</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1037591</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">890826</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">1215589</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">1164603</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zR7L37Mczmik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11. &lt;span id="xdx_823_z6KDmXL5bnR7"&gt;Income Taxes&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zJOJKYwJGyJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
effective tax rate differs from the statutory federal tax rate as presented in the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zG8tsmdRFPd5" style="display: none"&gt;Schedule
of Effective Income Tax Rate&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_zN7VSkywOZol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231_zOoiJkzSJtBf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zKFNj7VbdcY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;U.S. federal statutory tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_zJrzR4nIOjXc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zOfMmD9WOO75" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(24&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(24&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_z6pYKH8Lbcu4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1124"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1125"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zvC3EOfeHov" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and 2021, the Company was domiciled in Texas, and due to the losses generated and no revenues, it incurred no
current federal or state tax.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLuTdsOWUTUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tax effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities is presented
below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zgyo4qLSNVdk" style="display: none"&gt;Schedule
of Deferred Tax Assets and Liabilities&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231_zA14LIzpMWB" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231_z5PGmAgbXmU8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zFfcIX0dsSs4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGz5Ms_zakLxFHEtOx9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: justify"&gt;Research and development credits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;862,366&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;479,849&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTAGz5Ms_zq9pL2LcZHwi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;441,939&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;427,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGz5Ms_zUJTV3RmYFlf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,474,825&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,837,807&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_i01I_maDTAGz5Ms_zGwtXsKXHCkb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Unrealized losses on securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,640&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentAmortization_i01I_maDTAGz5Ms_z1twsvYeGI1j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Research and development amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,343,382&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1145"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz5Ms_maDTANzJOa_zidORvCG5REa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,185,152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,772,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzJOa_zapcO9j3mfn2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,181,492&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,767,059&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANzJOa_maDTALNzUQr_zFhxZH676Nj7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Net deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zedCptbdGsb6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i01NI_di_msDTALNzUQr_zZ6EdOsYusSk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Fixed assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,660&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,054&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzUQr_zzRW3GvUWkSk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1163"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zrFwsZKwqmcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to a history of losses the Company has generated since inception, the Company believes it is more-likely-than-not that all of the deferred
tax assets will not be realized as of December 31, 2022 and 2021. Therefore, the Company has recorded a full valuation allowance on its
deferred tax assets. At December 31, 2022 and 2021, the Company has net operating loss (&#x201c;NOL&#x201d;) carryforwards for federal
income tax purposes of approximately $&lt;span id="xdx_906_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20221231_zhVFqD9LEbC9" title="Net operating loss carryforwards for federal income tax"&gt;29,100,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20211231_zxWyUPtc0s5k" title="Net operating loss carryforwards for federal income tax"&gt;22,800,000&lt;/span&gt;, respectively. &lt;span id="xdx_90E_ecustom--NOLCarryforwardsDescription_c20220101__20221231_zRLwVu3HeYql" title="Net operating loss carryforwards, description"&gt;The NOL carryforwards generated prior to 2018 of approximately
$3,100,000 could expire over time beginning in 2035, if not used. The NOL carryforwards generated in 2018 to 2022 of approximately $26,000,000
do not expire and are carried forward indefinitely&lt;/span&gt;. The Company has state NOLs of approximately $&lt;span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20221231_zHPekJmzn6g2" title="Net operating loss carryforwards"&gt;780,000&lt;/span&gt; at December 31, 2022. The Company
also has approximately $&lt;span id="xdx_903_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231_zZK4d7QTuGj2" title="Research and development tax credit carryforwards"&gt;861,000&lt;/span&gt; of research and development tax credit carryforwards for federal purposes. These credits begin expiring
in 2034. Due to the change in ownership provisions of the Internal Revenue Code, the availability of the Company&#x2019;s NOL carryforwards
and research and development credit carryforwards may be subject to annual limitations under Section 382 of the Internal Revenue Code
against taxable income in the future period, which could substantially limit the eventual utilization of such carryforwards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entities
are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns.
The Company has analyzed its tax positions and has concluded that as of December 31, 2022, there were no uncertain positions. In addition,
interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision, for which there were
none. The Company&#x2019;s U.S. federal operating losses have occurred since its inception and as such, tax years subject to potential
tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to
audit by the IRS and/or state taxing authorities. The statute of limitations expires three years after the utilization of historical losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Tax Cuts and Jobs Act of 2017 (TCJA) has modified the IRC 174 expenses related to research and development for the tax years beginning
after December 31, 2021. Under the TCJA, the Company must now capitalize the expenditures related to research and development activities
and amortize over five years for U.S. activities and 15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization
of research and development costs in accordance with IRC 174 resulted in a gross deferred tax asset of $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsGross_iI_c20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUe9swacUCK9" title="Gross deferred tax asset"&gt;1,343,382&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zJOJKYwJGyJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
effective tax rate differs from the statutory federal tax rate as presented in the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zG8tsmdRFPd5" style="display: none"&gt;Schedule
of Effective Income Tax Rate&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_zN7VSkywOZol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231_zOoiJkzSJtBf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zKFNj7VbdcY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;U.S. federal statutory tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_zJrzR4nIOjXc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zOfMmD9WOO75" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(24&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(24&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_z6pYKH8Lbcu4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1124"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1125"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.24</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.24</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLuTdsOWUTUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tax effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities is presented
below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zgyo4qLSNVdk" style="display: none"&gt;Schedule
of Deferred Tax Assets and Liabilities&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231_zA14LIzpMWB" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231_z5PGmAgbXmU8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zFfcIX0dsSs4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGz5Ms_zakLxFHEtOx9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: justify"&gt;Research and development credits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;862,366&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;479,849&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTAGz5Ms_zq9pL2LcZHwi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;441,939&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;427,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGz5Ms_zUJTV3RmYFlf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,474,825&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,837,807&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_i01I_maDTAGz5Ms_zGwtXsKXHCkb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Unrealized losses on securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,640&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentAmortization_i01I_maDTAGz5Ms_z1twsvYeGI1j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Research and development amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,343,382&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1145"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz5Ms_maDTANzJOa_zidORvCG5REa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,185,152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,772,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzJOa_zapcO9j3mfn2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,181,492&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,767,059&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANzJOa_maDTALNzUQr_zFhxZH676Nj7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Net deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zedCptbdGsb6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i01NI_di_msDTALNzUQr_zZ6EdOsYusSk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Fixed assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,660&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,054&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzUQr_zzRW3GvUWkSk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1163"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">862366</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">479849</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">441939</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">427524</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6474825</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4837807</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">62640</us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities>
    <us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">26933</us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities>
    <LTRN:DeferredTaxAssetsResearchAndDevelopmentAmortization contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1343382</LTRN:DeferredTaxAssetsResearchAndDevelopmentAmortization>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">9185152</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5772113</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">9181492</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5767059</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3660</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5054</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3660</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5054</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">29100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <LTRN:NOLCarryforwardsDescription contextRef="From2022-01-01to2022-12-31">The NOL carryforwards generated prior to 2018 of approximately
$3,100,000 could expire over time beginning in 2035, if not used. The NOL carryforwards generated in 2018 to 2022 of approximately $26,000,000
do not expire and are carried forward indefinitely</LTRN:NOLCarryforwardsDescription>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">780000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">861000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">1343382</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zqLwUcD55nGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
12. &lt;span id="xdx_82D_z7MDZI40JoP7"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2023, the Company formed a wholly owned subsidiary, Starlight Therapeutics Inc. (&#x201c;Starlight&#x201d;), to develop drug candidate
LP-184&#x2019;s central nervous system (CNS) and brain cancer indications &#x2013; including glioblastoma (GBM), brain metastases (brain
mets.), and several rare pediatric CNS cancers. Following the formation of Starlight, the Company will refer to the molecule LP-184,
as it is developed in CNS indications, as &#x201c;STAR-001&#x201d;.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">274</dei:AuditorFirmId>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000568"
          xlink:label="Fact000568"
          xlink:type="locator"/>
        <link:footnote id="Footnote000570" xlink:label="Footnote000570" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts
    expensed for License, Strategic Alliance, and Research Agreements during the year ended December 31, 2022 were reduced by $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc2VhcmNoIGFuZCBEZXZlbG9wbWVudCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90F_ecustom--DecreaseInResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseStrategicAllianceAndResearchAgreementsMember_z7s66XaiK7U3"
  title="Research and development expense">935,000</xhtml:span>
    as a result of a payment we received in July 2022 from one of our service providers in connection with the resolution of a difference
    of views regarding the service provider agreement. This payment received by us offset other expenses for License, Strategic Alliance,
    and Research Agreements during this period.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000568"
          xlink:to="Footnote000570"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1033"
          xlink:label="xdx2ixbrl1033"
          xlink:type="locator"/>
        <link:footnote id="Footnote001088" xlink:label="Footnote001088" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Certain
    marketable securities investments are measured at fair value using net asset value per share under the practical expedient methodology.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1033"
          xlink:to="Footnote001088"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1039"
          xlink:label="xdx2ixbrl1039"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1039"
          xlink:to="Footnote001088"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1045"
          xlink:label="xdx2ixbrl1045"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1045"
          xlink:to="Footnote001088"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001051"
          xlink:label="Fact001051"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001051"
          xlink:to="Footnote001088"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001057"
          xlink:label="Fact001057"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001057"
          xlink:to="Footnote001088"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1063"
          xlink:label="xdx2ixbrl1063"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1063"
          xlink:to="Footnote001088"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1069"
          xlink:label="xdx2ixbrl1069"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1069"
          xlink:to="Footnote001088"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1075"
          xlink:label="xdx2ixbrl1075"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1075"
          xlink:to="Footnote001088"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001081"
          xlink:label="Fact001081"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001081"
          xlink:to="Footnote001088"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001087"
          xlink:label="Fact001087"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001087"
          xlink:to="Footnote001088"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M6?47MM2JE$I_@<T.8-/(T/U;L"#IG-9.".P1>NZ/!_T_M+RLV@E;:E5>I9W
M!]F)OV@<GWU/(26#;DH$C&\A&@J1U0QP9LUG74+LFX,:8SN&(\"E(\ '.8(_
M60Q^E?!BPHYK)X/W*-7 LNH ;*E5894. !_D #8SPL5*5CZ405*KGT'?H_B-
M:AV .:HQM6,X *]T -Y!#F"HYB6+<APU=TXV&+6%"V;%&FKFJ,8E"L<P %YI
M +R##$#>'9$/GFG.N#;CV*/SS-(S$@049$ D+ 2U]*S: %MJ57JE#? .6GT8
M)V"RT5TFX&NA[9][=.I6Z,UAC6$=PPQX.Y5$!ZT]W">4S]5H]BLHR 48J&1)
M4GV;,PO64K-;0W0,4^"5IL#;L^B@2@RA0STSB28,?144R06%=$U25;"V6_)0
MK$EK09K/40O2JA^PI58%6?H![Z!UB/$"4C=CH_L_RX[,<8UA'<,6>*4M\ Y:
M=AAETS@*U,0KT3] ;:;VOE6UP5KM(E=3]<.OMQ>NXV#<Q=?M5QV=T@1X!YF
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M%8,O#[27-Y+-BS/A>R8ERXK+&25J)+2!>CYE3*YO]#'SYM\*G7\!4$L#!!0
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MGUXL1:5$D:=<0TI6&A_XC;0B8DWNMB"YR;4BE^3'ZI:\??UN9FM<U+C:2;O
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M"0  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;*U6VV[;.!#]%4*[*+K
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MUZWQ(03*&N#_A93F86 7&)Y6Q4]02P,$%     @ L(!T5E!7W&M)!P  K3<
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M4E5[/F%LRB(SGN.RC/D$1+_2<I545)4/6O2(?+"E'!>J8&E+&8.P:[NF4)Y
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MV>@7;B9HEMB)O!W/12,UJ%YJC/,\CH+]DYN0;5A10/8R8+NBTAJ\>DB7[Q[
MLODAKX66<HJT%_V 4*0*@6)ZE/2(7;/1)Z9>G[3N#U?T';*'\HT>LG9[]$P4
MJJIIMI6(RM CKM-FAN'!>P()*Q[EZQ,<R5MQU?/W_=G]*QIC^6)"Z_P5/I]4
M+UHT;JKW/K[ZQ6,$O7+,-N#2^.Q 4$7U*D5U4&:Y?!OA(2O++)%?M\P/62$,
MX/=-EI6O!^("^Q=:1O\'4$L#!!0    ( +" =%9:GU3]H@@  &L4   8
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M_M%RB133KD2'6EX3,VDHCVW%>6F#S%.;;,E,&=BPFX4ZW_T&,1"'/@(,=SX
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M S:?KM<93K8J:#/*F4S[0S*JW:=K3W0C];LPY,J['864'%G)%KZ#-#IRTY'
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M>G9Z(&-'=Q'=DG\#,W$QN@5_G&,Z,)X>P/VI<[&[( ;]CZ)>_Q=02P,$%
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M"ESPE70/>OT)VWI. R_7TL8OK)M8=DX@7UFGJS;9*ZB$:D;^TI[#3L*(OI+
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M/6#Q!F!>P&>M7&WA@^+(7P.DI.XHL1@DWA7O(CY@.8%IGD"1%<4[>--CR-.
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MZN[3W:=;K9QNM+FS*R$<>ZA*9<]Z*^?6)X.!S5>BXK:OUT+AS4*;BCO<FN7
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M+<#[A499-S=DH/UUY?S_4$L#!!0    ( +" =%:=7)9#$0,  (4&   9
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MZKF.MJ&_[H-LA_AN/.[$R0#^K_N+WODJ=$7MQ]H.#\#G"">F*(6^!VYQS$!
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M00A\LI)M"\NH;(!HP@X%!FJ:.2118BTWK+@1T^ON"E"Z5U[.<NA I5 36>(
MN.0A 8D(U'6P79F3/>$*5LRM68$)XUJN<R &@NVX#K;CP6"[U>X^R/RY2)7U
MR'7$35^,#1+JCS&FGCRCSJ%U959K60"=X1,<"5"L)*MGR Q ;0X$[9!39__C
M8#!XYLFWH)K56GE-7C(2"_.@;,%.8-6BS(/ST)Y6KC6\5J7+PN1F 4_+1;J4
MB(<#\8EWI8A+X'OM3=IN:<$_DRH[[ ?/))>J8V44Y0!%^M+9=%0Q9NPF^(.!
M/UFF#@>IJ27D96L#&3U%'V\.=YF5#KIVCKPH1V!S]"3JB=ZK8[;T%/(:*H44
M'(<,(:YZ(346G#UH6R+977WZ[</U_N3\A8"FZ&G->_#6&@#P,Q='D#X2JLSV
MC^_.II/35Z[A[E'G.2(#T9\1V<A1*T;;H@;0*1MD#4A5QN\VP@9P#.!5;RY0
M>LV %,$F#\CM1(J%2E:E#_8D;:?D$W AU%BL :"B+=<$6Q6 "/)0G:H(&-C>
M 0RBYH%[\WGBE@ M '>,X7KE-O1D*I<;O!2Y;EPE)@,L7$??HN= *JA+,P)S
M;2*S3 >_ 3(#D#+^W28IW-?CQP 7Q 44C/<?EYJX@'*7*,OR3;,CLP;'+8P7
M,[B259E.(?6!^!#TMVV\VNZ.Z07W@99F&[9UK6XX <4F^QQ*G CCHUZ:%7Z!
MTQ9Y$&B$6\D-\4<H9J%OB" S& SU["8)J8]X_E3:I!<JQ5(^0'B9L;Q$3!?M
M*.#'^ [,#>LC],[SDB#6D^<I,@<B3#%K<S#! $0( P$0^8RPR9>EQM:/"NSF
M&C:'!UIHV"U'_)<3"(C7*;*?W\P(,@GY.%E)/;$'@!J%^(C(1Z.MK7G02'ER
MYDQ>>I5096 Y_ (<=N0D7G3Q '9#CN8(C+9O 5K4;80^%K.M%CA'4?L@,T,-
M#S&:=#)TD^]9\N!JVRH (!6*-+HRMEU)Z )9RY?M$H>>JPP.0O;'<TA$CEH9
M8(9@(TRD?0I3[.NM!Q1'@2-PO#1(E:&4@: S6=S3&YU-:;]%*2FMJ]K#Q?O
M@;A&A>*TQ_:5OJ^,1='"WIO\0,X]';]Z?_WABC].7KT0Y9J4^[V8'H]'X_%X
M*!F?U,GX9#@9MR'FNH&8OFP\2&E'-FX73RWRXG97594:YX/J8EE'M2JA>&G9
M6K^RONN2;VU1F5@->Q*>:L?I"960-3F2(+D_-1SPCFK%J(7'OLPVS8,D;$W
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M1RA/7XV&EZ2.U_MW\7HUE-<XV!T)O852H)5W4X!$&+[V+$6?2).=9V)U5BI
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M*TOT(7.L%XZ]<47OQJT/!Z+2-@"!39O:V]G.EH#M-K=N2!=ED^.<?=%8BCF
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M$H_W!_3/7KO5LJ8:KR2_8X4I9\$X@ (WM.'F5NZ^X%[/T.'EDFO_A5T;FY(
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M,!A1F\EN2G<;+=9V,BZ%ICEKER7]V* T O2^$$+O-L9 _ZNT^ ]02P,$%
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M:F20R;(6+AM:%*XZ7 EM:DUWFP$Q9R0[P#Q?"Z$/#3M!_8_$[#]02P,$%
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M1>T,Z'ZCE#T(+D"WN-._4$L#!!0    ( +" =%:]]7C(^ (  /,)   9
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MF.*K#*1QP/65$/II8B[^YIT7_0902P,$%     @ L(!T5@L.T*W3"P  8VT
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MM7?;:'?3Z&O72OQ'F;PGKG="W)'KD*_W/OGI76_#[)A/](5XCDDAQ8H*5O3
M_#?J1+/W#<V96>H4V#$^BS<8U[5@PB&8Z/J._/37OSA3[Y<^5G0X:\_9-GK1
MV[JN5W''>[A?6,&HB%>5WR[8DPJK:^W(A'U7@;I@/36]MA)UV/]0K&G,/AZK
MN%XP\<2.+W6[1[_T>0<2YB-A00V;5#"=C)XN9].1>SX97YP^=9T :33:-7HV
M.1M-9J.M4:.;Q]MN'EN[^:HH^#*K.O9J*1BK/OWK$TL?F/AW7Q];<4/[& GS
MD;  "0N1L @$,[QELO66B=5;OJX?A4H69$U?JJ36YR!6PE '0<)\)"R8[%R/
M[F0T&KT* 4B3$0AF]/QTV_/3-]+!$\M*1M9,Q*KGU3BZK^^MC*%]CX3Y2%A0
MP\X[?3]Z/WG5\P<<$X$J973HV;9#SZP=>LWSSV7*!/]&[M2@*E5V2LECJH:C
MF_!/_DL&IP>KT:$>@(3Y2%B A(5(6 2"&3XUV_K4[ ^G!RMAJ(,@8?[LD(@>
M($V&2%@$@AD]?[[M^7-KSW=O=!>LB 5?:RVDSP&LH*$.@(3Y]B;>9$=RQ8C.
M@Y+H3ZK-:YJ];&Z.ZCO\6)T(E2(Y3?A_U"W^[=W/WFA$>":9R&B2O)P817E!
M!/N]Y((MB,SU=:/_Z"/:\/RS8 F5ZH#FJCH2+.9KOCG5*CQ7>WE6E>L-V+23
MMHG(7V@B7S8%$M71B[Q\2!A9\"57T#PC<9F62:5(D(Q)5<<Z^9=K7;UWSFAT
ME/(D41U\0IZY7"E6+"I3-*D_TT(UOK'08_LQ%Q6X8V=CXX')9\:RR@IIK%1G
M]IVZ&LG6K/YV9.R>C#J[7V^I-SCDP:AV[WEI3K.J.E45S,MDH6YY8\9T#3K
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M90-P?B.E.73L MVCE/X&4$L#!!0    ( +" =%;;OFTC]0,  +$/   9
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;+5778^C-A3]*Q:MJE;: <QWIDFD
M^=BJ?=AVM*-V'ZH^.'"3H &<M9UD]M_7-H00,)F)9O8E8+CW^)R+[9,[W5/V
MQ-<  CV71<5GUEJ(S;7C\'0-)>$VW4 EWRPI*XF00[9R^(8!R71263B>ZT9.
M2?+*FD_ULP<VG]*M*/(*'ACBV[(D[-LM%'0_L[!U>/ Y7ZV%>N#,IQNR@D<0
M?V\>F!PY+4J6EU#QG%:(P7)FW>#K.QRK!!WQ3PY[WKE'2LJ"TB<U^".;6:YB
M! 6D0D$0>=G!'12%0I(\OC:@5CNG2NS>']!_T^*EF 7A<$>++WDFUC,KL5 &
M2[(MQ&>Z_QT:0:'"2VG!]2_:-[&NA=(M%[1LDB6#,J_J*WEN"M%)P-%(@M<D
M>/V$8"3!;Q)\+;1FIF7=$T'F4T;WB*EHB:9N=&UTME235^HS/@HFW^8R3\P?
MY;K(M@4@ND2/@J9/Z*^-KN^-JF\NOJ&?[T&0O."_H"OT(W(07Q,&?.H(.;O"
M<-)FIMMZ)F]D)NRA3[02:XX^5AEDIP".I-UR]P[<;[VSB/>0VLC''Y#G>IZ!
MT-WKT_$9.GY;2E_C^2-X'[]N5;W^O5EPP>3R_,]4HQHB,$.H/7O--R2%F24W
M)0>V VO^TP\X<G\UZ7LGL!.U0:LV.(<^_W-;+H"I95,OB ]('A)<D"K+JQ5:
MP"JO*GEGJD$-'&E@=<SLYLG$3;QHZNRZZ@QA?ABY21MVPCML>8=G>7_1&QLR
M1'; Y$&%X!E8FG- &Y:G\E>*THHN$%3/F'281G88].28@@)L%A.U8J)7?@2J
M=RT_J"&+0@IH2:,=*4B5@HE\-"ASE,2!G_3H&\*P&_F^64#<"HC?(F#??*PK
M\\?J*ER,*XP'E0_L..[I&P;YMA>8U26MNN3"/;)BI!+]PZ]FF0P*C">1=.,>
M3T,8=L-.V G32<MT\EZ[XHR$R:"&H1W[/0'#(.S:WLBNQN[1Q]P+:WV08*3:
MH'7K>.5[X6#9F^(PCA-OA&_'=_%[5?R\$#RLI^WVB_Y2U*D([RC"N[#HJ=J$
M12%U42:);W(V0MLSU#5*)OUM:8H+_-'UCH]FC<^ZXR7U?[4F?UADW\:3OJ0Z
M+.R&A2-RCFZ,WV;'X^:%ASZ+73\.)[C/^T7?/N5^=&3\72P9],4HR>BU_?\7
MQJAPY,C'1TO&;_)D:+[(N%WAH=7&8>@.#E)#7,^Y3Q4</1E_7U-^A<2AVX9V
M,MC[+QAW+<_I-#\EL)7N"3E*Z;82=2_1/FW[SAO=;?6>WZI^5#=51YBZF?U$
MF/R;P5$!2PGIVK%<.:SN#^N!H!O=8BVHD V;OEW+GAJ8"I#OEY2*PT!-T';I
M\_\!4$L#!!0    ( +" =%;!/"PE[@(  %<(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;*U6R6[;,!#]E8%:%"G0:K6\I+8 +TG;0X# :1,410^T
M-+:(4*)#4G;\]R4E6[4=1<BA%XO+O#?O<1L/MUP\RA11P7/&<CFR4J76EXXC
MXQ0S(FV^QES/++G(B-)=L7+D6B!)2E#&'-]UNTY&:&Y%PW+L5D1#7BA&<[P5
M((LL(V(W0<:W(\NS#@-SNDJ5&7"BX9JL\ [5S_6MT#VG9DEHAKFD/ >!RY$U
M]BZG?1-?!MQ3W,JC-A@G"\X?3>=[,K)<(P@9QLHP$/W9X!09,T1:QM.>TZI3
M&N!Q^\!^77K77A9$XI2S!YJH=&3U+4AP20JFYGS[#?=^0L,7<R;+7]A6L=V.
M!7$A%<_V8*T@HWGU)<_[=3@"^.$K '\/\-\*"/: H#1:*2MMS8@BT5#P+0@3
MK=E,HUR;$JW=T-SLXIT2>I9JG(KN]+%("H; E_!0>L8$QAL4>@MA+/7FKLUR
M2[B8H2*4R8_P&=Z# S(E N7045J$H7+B?<))E=!_):'GPPW/52KA*D\P.25P
MM/K:@G^P,/%;&6<8VQ!XG\!W?;]!T/3M<*]%3E"O:%#R!:_P73T55.W@]W@A
ME="G]$_3&E44G68*<W,OY9K$.++TU90H-FA%']YY7?=+D[__1';BME.[[;2Q
M1S]09'!!<]@A$?)CD]=V@K!"@N=!5IV+#B1DUW2RIF]C&AR(/+>!Z<1E6+L,
M6ZGG5#["M4"$.5'89++">]4U,T_G)G)M-W [0V=S;*$YS@OJL!-]W5I?MU7?
M/6=$4:;/79.V[LN<GNV'07BFK2'.M0=NKUE;K];6:]4VHQN:8)[ +XHL:=)7
MX0?':<^4M46<B.K7HOJMHKX*DBO0+R;"-:$"[@DK&O>UHND?9>[8@S-U+V-Z
M=AB>"72.WN@,Q:HL71)B7N2J>NOJT;HZCLNB<#8^T56S*G+_:*J2>T/$BNJG
MFN%24[IV3Q\V496QJJ/XNJP$"ZYT72F;J:[\*$R GE]RK@X=DZ#^+Q']!5!+
M P04    " "P@'16/ 5[-"P/  #JL@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T,2YX;6RUG?]OV[@9A_\5(3<<;D"76-_E7AK@&E)<A[477-?=#X?]H-I,
M+-26?)*<M,/]\9-DQ30E^I6U^Z1 V\0A'])^WTC4(Y*Z?LJ++^5*RLKZNEEG
MY9N+555M7U]=E8N5W"3E9;Z56?V3^[S8)%7];?%P56X+F2S;2IOUE3.;!5>;
M),TN;J[;U^Z*F^M\5ZW33-X55KG;;)+BVUNYSI_>7-@7SR_\DCZLJN:%JYOK
M;?(@/\KJT_:NJ+^[.E"6Z49F99IG5B'OWUS\9+\64=!4:$O\.Y5/Y='75O-6
M/N?YE^:;=\LW%[.F1W(M%U6#2.K_'N6M7*\;4MV/WSOHQ:'-IN+QU\_TN'WS
M]9OYG)3R-E__FBZKU9N+Z,):ROMDMZY^R9_^+KLWY#>\1;XNVW^MIWW9P+NP
M%KNRRC==Y;H'FS3;_Y]\[3Z(HPKVJ0I.5\'I5_!/5'"["NZY+7A=!:]7P3G5
M@M]5\,_M4M!5",[M4MA5"-M@[3_=-C0LJ9*;ZR)_LHJF=$UKOFCCV]:N(Y)F
M32I^K(KZIVE=K[KYN$H*N<K72UF4WW\7.7;XH\5_WZ75-^L')JLD79?6AZ0H
MDB9C_FK]S?KTD5D__.6OUU=5W7K#N%IT+=WN6W).M&1;[_.L6I46SY9R::C/
M1^H[!."J?MN']^X\O_>W#DG\1Y)=6L[L5?W7L4UOB*[^(7^\M-S3U=E(Z[NZ
M==MOJ\],'P==G<E%W;K=5G<,U>/SJYLZ+\ZO/B-"X1[2T&UY[@G>[3HI2RN_
MMSY6^>*+]=L_ZY];[RJY*?]CZ-S;/<PSPYJC]^MRFRSDFXOZ\%S*XE%>W'S_
MG1W,?C1%&0EC2!A'PF(D3(!@6JYXAUSQ*/K-77VRDD4AEU;9)DO9',)**]E5
MJ[Q(_VL\MKPED5,S!@EC2!C?PX(6UHQ"'F_L6?OG^NKQ.!G.+"= G=/B[!_B
M[$^)\ZOG0*=EN3,'F>1-#3(2QI P[@^"UP_O: D!ZI 6V. 0V.#_"FP]4BZK
M)%NFV8,INB1T:G21,(:$\6 TNJ,E!*A#6G3#0W1#,KJ_R.VN6*SJRX/F?+X/
M[2OK,5GOI"FJ)&QJ5)$PAH3Q/<P_BIGC18X3!;W8#LO-W7D0](H)4-^T $>'
M $=D@-_5Q]\D6^S#N_\%/AE=DC0UND@80\(X$A9'@Q0(/#L((M_K)0&H52T)
MYH<DF)-)L!^GY]O&)Y@"3]:>&G@DC"%A?#XX%+N.[T:]7^IA*=L.(Z<73E#'
MM'#:,^4!9F1 ;_/-)L]Z9V1Z3$T3IP892F-0&N]HQQ%T?./ ^NR2 M5#/=Y'
MWL>>'N_30VN:-CG62!J#TGA'TZ^-(C^<>8-8&TK61:/(]?NQ!O50C[6C8NU,
MC_7(:)M&3@XXDL:@--[1S@FXH>2)@(-ZJ =<V32;%# W=T<C\*?&WF95:0PR
M5*1!:0Q*XQU-"UT8SN?]4[6AG!.Z81CV _P2!LQ6"LRF'=BO[2V6^@HZ>91%
M\B M^546B[2.^+9(%_(5'76H#(/2&)3&.UIT?#EUZ83]F"/;%"B:GAE*FMFT
M-1O)#&,^0+T9E,:@--[1CO,AN/3ZU^#&4H.K+S/+/I32XZ?<F$W+L4'\"MG<
M4:[/TM8BSZHB652[9&U5LM@88PFU9% :@]+XR.<86-]D4I168&WV=PT=VUHF
MWTP'Q!C:,8&BZ0FD])M-^[?VCFY[>WY99\QF*[,R.7653J,F9PM4OT%IW!Z*
M-=N.PM#S^[_\!@,7V'Z_G$!U3X^R<G V+>'^E5?U42"M#PAI5J:+O8%KAGM[
M)3,^O(>:.2B-06F\HVDC.L]Q#)?NPX*N-S==N;^$>+.5>;//5V_]##"&&NKB
MH#0&I7%[*-H<-[ -H39X.W.H7T+*.4K*.;24&_TM?Q[<&9T-#9\:>"B-06F\
MHVE'=S<8QMTQV#G;'88=U3L][,K-.;2;<V9V]#P+ZUVVD%DS^<JZ6R>9]=M[
MN?DL"^.L&)HZ.=Y01P>E<2@MAM($BJ;GCG)]SEXM@692.5#-!Z4Q*(U#:3&4
M)E T/6>4+G1H7?AAUQQ3FJ3IZ,M.$ALS!NH,H30&I7''X R]:!Y$@],*=&X=
MBJ8G@U*+SD2U.$U T/3)Z0&5BU :'_D<[=G>0!B/'E#CB*+I":.,HT,;Q^.C
M1Y,I=>(DZ3KYO);4403J'*$T!J5Q9S@9SXFB<-ZWCM!6!8JFYX2RF YMWZ9(
M*!HU.16@RA)*XQVM)Z$BPW7*L. \&"H+@>J>'F6E&AU:-7[*"KG('[)F@H@6
MYOJZM/G:J"-HYN1P0YTCE,8=@W,,C>%&-BM0-#TIE)ET:#,Y&#]L99'F9D$!
ME9!0&H/2^,AG9K=#!6O^?*^BOOP_=:\"VB^!HNFYHE2F0ZO,/SO6A)I-*(U!
M:7SD<PR[FUWN<P*YI_,'V2^!HNF+QI0?=6D_^K[.E<UN0UHQ&C%YL1C4@D)I
M'$J+H32!HNF)HHRJ:R.MF LUJ5 :@](XE!9#:0)%TW-&F527GC7)OV[38C^<
M72;5Z%PZFC8Y9Z F%4KC(Y_;^Z2XM*Q9^,IJ5@=[QCPY@V!W -/B9H%Z0WIJ
M'*U6IH7I^^3K^'D'NT@9NTH9NTP9NTX9NU#Y)62JJV2JZT'/.U!Y"J4Q*(U#
M:3&4)E T/6>43W5IGSKUO ,UJ5 :@]+XR.>VWU!CMC]K^,8T^9, @7H_>F8H
MJ^K25K6;$O#S?NH/>?*!.E4HC4%I'$J+H32!HNGIHO2L&T)//E Q"Z4Q*(U#
M:3&4)E T/6>4O74G+NXV9@K4VT)I#$KCKF'R:#";NSV!;RAF6N&+ZIL>6V5;
MW9&)H^U-N9/+0.C:DZ,*M:E0&H?2XHYVO!#$OIRY_=B_A"GUE"GU:%,Z9=,&
M&C4U$: T!J5Q*"WV#+-0#3=M48WJF:!4J$=/+AW;N8&N/CGZ4/<)I7%ON'[;
MM'L#M%&!HNG15U+3.VLI>#<B)*X@:,[D-(#J3"B-0VDQE"90-#U;E.?TH-LR
M>E#E":4Q*(U#:3&4)E T/6>.=F<D]=AY5Q T8W*F0$4GE,8[VO%)9NZ'X;Q_
MDAD6\^9.Y(=V?_3P$G+24W+2HQV9:7<W8X"A5A)*8U :]X;S.UW?#8+^+@.&
M<K9C>_/!\/ E'*.G'*-'.\:)V_?1M,EQAHI&*(U[PSF9;G\.KZ&,W9< J%[I
M\552T*/G;$ZZ$(0:02B-06D<2HN]X<1/K^^,!*I)/0^4Z/-HT7=7Y LIEZ5U
M7^2;PPVFPX)28SI M1^4QJ T[@WW8'2-VRA#)V.B:'I&*#WHT7J0CVX40P,F
M)P#4$$)IW!LZ/??2[FM?:)L"1=,WVU:&T*<-X9@7HJM/#3Z4QJ T[AM6B1ND
MOZ&82?JC^J:'5>D^_ZQ]'G7A8_UAL;20BRHO2 E$LR?''.H"H30.I<50FD#1
M] Q2RM"'KBCWH>(02F-0&H?28BA-H&AZSBAQZ-,3),_5!#1F<K(,%VR'IKUW
M&;19;FC6:  ,Y8P& -4[/79*X/FTP)MH &C:Y!!"51Z4QCM:?Q/_X66!H>#<
M,^PNA.J>'NBCYZN,;!6YO^BC1P#89ZI@'ZJ"?:H*DA9#:0)%TQ-%.4$_@(X
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M- ZEQ5":0-'T'% 2-1S9J%(6J2RMGZR[HC4B<GG.E2]THBB4QJ T#J7%4)I
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MPY?;-)0AS\#+2W4OC+)78 J^W5R"EW^^FL^DFCH'F"T/T[S?3X-;IKGDRS>
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MQ:9X?^I62"GBXN,]#U8\S0W4]W="R-\7^2M9Y2MXB_\!4$L#!!0    ( +"
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M $I[T)FD(:50*C7=;\"A-HILIDDS?/;6[W$>.,[3SPT- YU@8%N>TWR)X,"
M'&= @Z!G_[&7/F?C)S/=2RHUW35 B]SN2@YP4L"D4M/]!H#)41 S_+S]@MB.
M#]SX+(/+#8&0[B;@28[SI%GFO?8C/KX(X\AJHR;)@6>YVYF,)$5@*C7=;X#
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M]_C<X]/D3G9<W,DMHH*'/&-RZFR5*LY<5R9;S(D\Y04RO;/F(B=*3\7&E85
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M%K.1?7GIDGB\3=J/CYWI*-)99:/3\O^!6K7NWI70W,?_(7+):H4X70"R=YE
M.Y'M%;>=:+%N;HGW0L.=LQFNX+. 2F, [Q="Z.>)N7CV'QKY3U!+ P04
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MC3B"*0 -&!+'=A_<V8^B]3X5M?\[&_T&4$L#!!0    ( +& =%:7BKL<P
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M    '@  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-V<ENPC 4!=!?0=E6Q'B
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M2P$"% ,4    " "P@'16.<U:;.X    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "P@'16F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( +" =%8O;7:RA0@  ,0U   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "P@'16=X7ARP,&  !B&
M&               @('($   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ L(!T5H'JWFWB @  X0D  !@              ("! 1<  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( +" =%9#AZ]LJ0,
M #D+   8              " @1D:  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " "P@'16N(8GZQ\#  !F"0  &               @('X
M'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ L(!T5E!7
MW&M)!P  K3<  !@              ("!32$  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( +" =%9JH!%#10@  -PB   8
M  " @<PH  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "P
M@'166I]4_:((  !K%   &               @(%',0  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ L(!T5MZ_I^^\ P  W@<  !@
M         ("!'SH  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( +" =%;E;<7T^PT  " E   9              " @1$^  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ L(!T5IA]L/?3%P  ;T\
M !D              ("!0TP  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " "P@'16L@JU8&T%  !0#0  &0              @(%-9
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( +" =%9,*,'R
M^ <  )P2   9              " @?%I  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ L(!T5N_5_%\:!@  :P\  !D
M ("!('(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "P
M@'16>L.G>^0&  !U$@  &0              @(%Q>   >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( +" =%:BYQ5M4@(  "H%   9
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M970R,"YX;6Q02P$"% ,4    " "P@'160JB:Q\0#  #3"@  &0
M    @(%MH   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M +" =%9B:67TB 0  &T-   9              " @6BD  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ L(!T5C@2\_7] P  *@D  !D
M             ("!)ZD  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " "P@'16T5?:>JT%  "_#P  &0              @(%;K0  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( +" =%9FRH&,B0,
M +H(   9              " @3^S  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ L(!T5N^^\Z:5 @  Q04  !D              ("!
M_[8  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "P@'16
M.&JT-?P#   V"0  &0              @('+N0  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( +" =%;.+7O7U ,  )T0   9
M      " @?Z]  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ L(!T5IG/)S7@ P  E@X  !D              ("!"<(  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "P@'16/%'ZX>T"  "%!P
M&0              @($@Q@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( +" =%9;9UF,? (  ,0%   9              " @43)  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ L(!T5KWU>,CX
M @  \PD  !D              ("!]\L  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " "P@'16"P[0K=,+  !C;0  &0
M@($FSP  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( +"
M=%8O*D<N^0(  $D+   9              " @3#;  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ L(!T5O++BULB P  X0H  !D
M         ("!8-X  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    " "P@'16#MY?*3<#   ?"P  &0              @(&YX0  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( +" =%8)G_IQ;@(  #P&
M   9              " @2?E  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ L(!T5IY/O.^* @  H 8  !D              ("!S.<
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "P@'16V[YM
M(_4#  "Q#P  &0              @(&-Z@  >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( +" =%;!/"PE[@(  %<(   9
M  " @;GN  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
ML(!T5CP%>S0L#P  ZK(  !D              ("!WO$  'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " "P@'16+\4/2R@&  ".)P  &0
M            @(%! 0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( +" =%:.K43";P(  +X%   9              " @: ' 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ L(!T5LZY_/$T!
MTQ4  !D              ("!1@H! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " "P@'16F#XQ1X8(  !O5   &0              @(&Q
M#@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( +" =%:.
M/"(2: (  +,&   9              " @6X7 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ L(!T5@<&+W,K P  O L  !D
M     ("!#1H! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M  !($P  #0              @ ';)P$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( +& =%:7BKL<P    !,"   +              "  48K 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( +& =%9F1EL*?@0  &DA   /              "
M 2\L 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "Q@'16.(-O)L0!   -
M'@  &@              @ ':, $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " "Q@'16@(3XG< !    '@  $P              @ '6
L,@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .@ Z ,T/  #'- $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>164</ContextCount>
  <ElementCount>266</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization, Principal Activities, and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/OrganizationPrincipalActivitiesAndBasisOfPresentation</Role>
      <ShortName>Organization, Principal Activities, and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Notes and Loan Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://lanternpharma.com/role/NotesAndLoanPayable</Role>
      <ShortName>Notes and Loan Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Loss Per Share of Common Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/LossPerShareOfCommonShares</Role>
      <ShortName>Loss Per Share of Common Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Shareholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/ShareholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/MarketableSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Loss Per Share of Common Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/LossPerShareOfCommonSharesTables</Role>
      <ShortName>Loss Per Share of Common Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/LossPerShareOfCommonShares</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/LiquidityDetailsNarrative</Role>
      <ShortName>Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/Liquidity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of Research and Development (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetails</Role>
      <ShortName>Schedule of Research and Development (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Schedule of Research and Development (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical</Role>
      <ShortName>Schedule of Research and Development (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>Schedule of Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Schedule of Balance Sheet Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails</Role>
      <ShortName>Schedule of Balance Sheet Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails</Role>
      <ShortName>Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails</Role>
      <ShortName>Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Schedule of Other Supplemental Information Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Schedule of Other Supplemental Information Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/LeasesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Schedule of Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails</Role>
      <ShortName>Schedule of Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Shareholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative</Role>
      <ShortName>Shareholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/ShareholdersEquityTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails</Role>
      <ShortName>Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Contractual Maturities Investments of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails</Role>
      <ShortName>Schedule of Contractual Maturities Investments of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails</Role>
      <ShortName>Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Schedule of Assets are Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Assets are Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Notes and Loan Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://lanternpharma.com/role/NotesAndLoanPayableDetailsNarrative</Role>
      <ShortName>Notes and Loan Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/NotesAndLoanPayable</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Schedule of Anti-dilutive Securities Outstanding Diluted Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities Outstanding Diluted Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Schedule of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Schedule of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lanternpharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lanternpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>ex10-1.htm</File>
    <File>ex21-1.htm</File>
    <File>ex23-1.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ltrn-20221231.xsd</File>
    <File>ltrn-20221231_cal.xml</File>
    <File>ltrn-20221231_def.xml</File>
    <File>ltrn-20221231_lab.xml</File>
    <File>ltrn-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_009.jpg</File>
    <File>form10-k_011.jpg</File>
    <File>form10-k_012.jpg</File>
    <File>form10-k_015.jpg</File>
    <File>form10-k_016.jpg</File>
    <File>form10-k_017.jpg</File>
    <File>form10-k_018.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="617">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 617,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 164,
   "dts": {
    "calculationLink": {
     "local": [
      "ltrn-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ltrn-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ltrn-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ltrn-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ltrn-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 422,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 107,
    "http://lanternpharma.com/20221231": 11,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 121
   },
   "keyCustom": 38,
   "keyStandard": 228,
   "memberCustom": 42,
   "memberStandard": 19,
   "nsprefix": "LTRN",
   "nsuri": "http://lanternpharma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://lanternpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://lanternpharma.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://lanternpharma.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://lanternpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Shareholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://lanternpharma.com/role/ShareholdersEquity",
     "shortName": "Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Marketable Securities",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://lanternpharma.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://lanternpharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Notes and Loan Payable",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://lanternpharma.com/role/NotesAndLoanPayable",
     "shortName": "Notes and Loan Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Loss Per Share of Common Shares",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://lanternpharma.com/role/LossPerShareOfCommonShares",
     "shortName": "Loss Per Share of Common Shares",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://lanternpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://lanternpharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://lanternpharma.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://lanternpharma.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "LTRN:ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://lanternpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "LTRN:ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Shareholders\u2019 Equity (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://lanternpharma.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://lanternpharma.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://lanternpharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Loss Per Share of Common Shares (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://lanternpharma.com/role/LossPerShareOfCommonSharesTables",
     "shortName": "Loss Per Share of Common Shares (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://lanternpharma.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Liquidity (Details Narrative)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://lanternpharma.com/role/LiquidityDetailsNarrative",
     "shortName": "Liquidity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "LTRN:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://lanternpharma.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-122022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "LTRN:ResearchAndDevelopmentIncomeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Schedule of Research and Development (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetails",
     "shortName": "Schedule of Research and Development (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-122022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "LTRN:ResearchAndDevelopmentIncomeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "LTRN:DecreaseInResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Schedule of Research and Development (Details) (Parenthetical)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical",
     "shortName": "Schedule of Research and Development (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "LTRN:DecreaseInResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Schedule of Accounts Payable and Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails",
     "shortName": "Schedule of Accounts Payable and Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_LicenseStrategicAllianceAndResearchAgreementsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_AssignmentAgreementMember",
      "decimals": "0",
      "lang": null,
      "name": "LTRN:UpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Schedule of Balance Sheet Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://lanternpharma.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails",
     "shortName": "Schedule of Balance Sheet Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails",
     "shortName": "Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails",
     "shortName": "Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "LTRN:ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "LTRN:OperatingLeaseRightOfUseAssetAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "LTRN:ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Schedule of Other Supplemental Information Related to Operating Leases (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://lanternpharma.com/role/ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails",
     "shortName": "Schedule of Other Supplemental Information Related to Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "LTRN:ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Leases (Details Narrative)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://lanternpharma.com/role/LeasesDetailsNarrative",
     "shortName": "Leases (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Schedule of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://lanternpharma.com/role/StatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Schedule of Weighted Average Assumptions (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails",
     "shortName": "Schedule of Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Shareholders\u2019 Equity (Details Narrative)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative",
     "shortName": "Shareholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Schedule of Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails",
     "shortName": "Schedule of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Schedule of Contractual Maturities Investments of Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails",
     "shortName": "Schedule of Contractual Maturities Investments of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails",
     "shortName": "Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "LTRN:DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Schedule of Assets are Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Schedule of Assets are Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-04-292020-05-01",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLoanOriginations1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Notes and Loan Payable (Details Narrative)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://lanternpharma.com/role/NotesAndLoanPayableDetailsNarrative",
     "shortName": "Notes and Loan Payable (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-04-292020-05-01",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLoanOriginations1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Schedule of Anti-dilutive Securities Outstanding Diluted Loss per Share (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails",
     "shortName": "Schedule of Anti-dilutive Securities Outstanding Diluted Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Schedule of Effective Income Tax Rate (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://lanternpharma.com/role/ScheduleOfEffectiveIncomeTaxRateDetails",
     "shortName": "Schedule of Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://lanternpharma.com/role/StatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - Income Taxes (Details Narrative)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://lanternpharma.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "Income Taxes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://lanternpharma.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Organization, Principal Activities, and Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://lanternpharma.com/role/OrganizationPrincipalActivitiesAndBasisOfPresentation",
     "shortName": "Organization, Principal Activities, and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Liquidity",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://lanternpharma.com/role/Liquidity",
     "shortName": "Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "LTRN_AFCLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AFC License Agreement [Member]",
        "label": "AFC License Agreement [Member]"
       }
      }
     },
     "localname": "AFCLicenseAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_AFChemicalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AF Chemicals [Member]",
        "label": "AF Chemicals [Member]"
       }
      }
     },
     "localname": "AFChemicalsMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_ActuateTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actuate Therapeutics [Member]",
        "label": "Actuate Therapeutics [Member]"
       }
      }
     },
     "localname": "ActuateTherapeuticsMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_AllarityTherapeutiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allarity Therapeuties [Member]",
        "label": "Allarity Therapeuties [Member]"
       }
      }
     },
     "localname": "AllarityTherapeutiesMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Application of deferred offering costs to public offering proceeds.",
        "label": "Application of deferred offering costs to public offering proceeds"
       }
      }
     },
     "localname": "ApplicationOfDeferredOfferingCostsToPublicOfferingProceeds",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset purchase agreement [Member]",
        "label": "Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_AssignmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment Agreement [Member]",
        "label": "Assignment Agreement [Member]"
       }
      }
     },
     "localname": "AssignmentAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through secondth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Due in one to two years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_BerkshireSteruleManufacturingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Berkshire Sterule Manufacturing Agreement [Member]",
        "label": "Berkshire Sterule Manufacturing Agreement [Member]"
       }
      }
     },
     "localname": "BerkshireSteruleManufacturingAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_BerkshireSteruleManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Berkshire Sterule Manufacturing [Member]",
        "label": "Berkshire Sterule Manufacturing [Member]"
       }
      }
     },
     "localname": "BerkshireSteruleManufacturingMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_BioNumerikPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioNumerik Pharmaceuticals [Member]",
        "label": "BioNumerik Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "BioNumerikPharmaceuticalsMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_CalifiaPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Califia Pharma [Member]",
        "label": "Califia Pharma [Member]"
       }
      }
     },
     "localname": "CalifiaPharmaMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_CashlessWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless Warrants [Member]",
        "label": "Cashless Warrants [Member]"
       }
      }
     },
     "localname": "CashlessWarrantsMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement [Member]",
        "label": "Collaboration Agreement [Member]"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_CorporateBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds [Member]",
        "label": "Corporate Bonds [Member]"
       }
      }
     },
     "localname": "CorporateBondsMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails",
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_CuriaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Curia [Member]",
        "label": "Curia [Member]"
       }
      }
     },
     "localname": "CuriaMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, more than 12 months.",
        "label": "DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss",
        "verboseLabel": "Fair Value Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, less than 12 months.",
        "label": "Fair Value Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_DecreaseInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in research and development expense",
        "label": "Research and development expense"
       }
      }
     },
     "localname": "DecreaseInResearchAndDevelopmentExpense",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_DeferredTaxAssetsResearchAndDevelopmentAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development amortization.",
        "label": "Research and development amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsResearchAndDevelopmentAmortization",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_EvaluationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evaluation Agreement [Member]",
        "label": "Evaluation Agreement [Member]"
       }
      }
     },
     "localname": "EvaluationAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_FoxChaseCancerCenterAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fox Chase Cancer Center Agreement [Member]",
        "label": "Fox Chase Cancer Center Agreement [Member]"
       }
      }
     },
     "localname": "FoxChaseCancerCenterAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_FoxChaseCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fox Chase Cancer Center [Member]",
        "label": "Fox Chase Cancer Center [Member]"
       }
      }
     },
     "localname": "FoxChaseCancerCenterMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_FuturePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future payments.",
        "label": "Future payments"
       }
      }
     },
     "localname": "FuturePayments",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_GainOnLoanForgiveness": {
     "auth_ref": [],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on loan forgiveness.",
        "label": "GainOnLoanForgiveness",
        "negatedLabel": "Gain on loan forgiveness"
       }
      }
     },
     "localname": "GainOnLoanForgiveness",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_GovernmentAgencySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Agency Securities [Member]",
        "label": "Government &amp; Agency Securities [Member]"
       }
      }
     },
     "localname": "GovernmentAgencySecuritiesMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails",
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_GrossProceedsFromInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from initial public offering.",
        "label": "Gross proceeds"
       }
      }
     },
     "localname": "GrossProceedsFromInitialPublicOffering",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_IntellectualPropertyRelatedLicensingAndOtherFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intellectual property related licensing and other fees.",
        "label": "Intellectual property related licensing and other fees"
       }
      }
     },
     "localname": "IntellectualPropertyRelatedLicensingAndOtherFees",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_LanternPharmaLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lantern Pharma Limited [Member]",
        "label": "Lantern Pharma Limited [Member]"
       }
      }
     },
     "localname": "LanternPharmaLimitedMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_LeaseExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration date.",
        "label": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "LTRN_LicenseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement description.",
        "label": "License agreement, description"
       }
      }
     },
     "localname": "LicenseAgreementDescription",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "LTRN_LicenseStrategicAllianceAndResearchAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Strategic Alliance and Research Agreements [Member]",
        "label": "License Strategic Alliance and Research Agreements [Member]"
       }
      }
     },
     "localname": "LicenseStrategicAllianceAndResearchAgreementsMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails",
      "http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_LoanPursuantToPaycheckProtectionProgramPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Pursuant to Paycheck Protection Program [Policy Text Block]",
        "label": "Loan Pursuant to Paycheck Protection Program"
       }
      }
     },
     "localname": "LoanPursuantToPaycheckProtectionProgramPolicyTextBlock",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "LTRN_LumaBridgeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Luma Bridge Agreement [Member]",
        "label": "Luma Bridge Agreement [Member]"
       }
      }
     },
     "localname": "LumaBridgeAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_LumaBridgeLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Luma Bridge LLC [Member]",
        "label": "Luma Bridge LLC [Member]"
       }
      }
     },
     "localname": "LumaBridgeLLCMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_MarketableSecuritiesDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities Debt [Member]",
        "label": "Marketable Securities - Debt [Member]"
       }
      }
     },
     "localname": "MarketableSecuritiesDebtMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_MarketableSecuritiesMutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities Mutual Funds [Member]",
        "label": "Marketable Securities - Mutual Funds [Member]"
       }
      }
     },
     "localname": "MarketableSecuritiesMutualFundsMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_MutualFundsAlternativeInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual Funds Alternative Investments [Member]",
        "label": "Mutual Funds - Alternative Investments [Member]"
       }
      }
     },
     "localname": "MutualFundsAlternativeInvestmentsMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails",
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_MutualFundsFixedIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual Funds Fixed Income [Member]",
        "label": "Mutual Funds - Fixed Income [Member]"
       }
      }
     },
     "localname": "MutualFundsFixedIncomeMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails",
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_NAVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NAV [Member]",
        "label": "NAV [Member]"
       }
      }
     },
     "localname": "NAVMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_NOLCarryforwardsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforward, description.",
        "label": "Net operating loss carryforwards, description"
       }
      }
     },
     "localname": "NOLCarryforwardsDescription",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "LTRN_NominalValueOfRestrictedSharesOfActuateStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal value of restricted shares of actuate stock.",
        "label": "Nominal value acquired cost"
       }
      }
     },
     "localname": "NominalValueOfRestrictedSharesOfActuateStock",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_NoncashLeaseAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash lease adjustments.",
        "label": "Non-cash lease adjustments"
       }
      }
     },
     "localname": "NoncashLeaseAdjustments",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_OperatingLeaseLiabilityAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortizations, operating lease liability.",
        "label": "Amortizations, Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAmortization",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_OperatingLeaseLiabilityInAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions, operating lease liabilities,",
        "label": "Additions, Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityInAdditions",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_OperatingLeaseRightOfUseAssetAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions, right of use assets.",
        "label": "Additions, Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAdditions",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_OtherOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other offering expenses.",
        "label": "Other offering expenses"
       }
      }
     },
     "localname": "OtherOfferingExpenses",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_PatheonAPIServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patheon API Services [Member]",
        "label": "Patheon API Services [Member]"
       }
      }
     },
     "localname": "PatheonAPIServicesMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_PatheonAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patheon Agreement [Member]",
        "label": "Patheon Agreement [Member]"
       }
      }
     },
     "localname": "PatheonAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_PiramalPharmaAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Piramal Pharma Agreement [Member]",
        "label": "Piramal Pharma Agreement [Member]"
       }
      }
     },
     "localname": "PiramalPharmaAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_PiramalPharmaSolutionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Piramal Pharma Solution [Member]",
        "label": "Piramal Pharma Solution [Member]"
       }
      }
     },
     "localname": "PiramalPharmaSolutionMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets [Policy Text Block]",
        "label": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "LTRN_ProceedsAfterDeductingUnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds after deducting underwriting discounts and commissions.",
        "label": "Proceeds after deducting underwriting discounts and commissions"
       }
      }
     },
     "localname": "ProceedsAfterDeductingUnderwritingDiscountsAndCommissions",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_ProceedsFromIssuanceInitialPublicOfferingGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from initial public offering, gross.",
        "label": "Proceeds from initial public offering, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingGross",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_ProceedsFromStockOptionAndWarrantExercises": {
     "auth_ref": [],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from stock option and warrant exercises.",
        "label": "Proceeds from warrant and stock option exercise"
       }
      }
     },
     "localname": "ProceedsFromStockOptionAndWarrantExercises",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_RecentlyAdoptedAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently Adopted Accounting Standards [Policy Text Block]",
        "label": "Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "RecentlyAdoptedAccountingPolicyPolicyTextBlock",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "LTRN_ResearchAndDevelopmentExpensesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses percentage.",
        "label": "Research and development expenses percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesPercentage",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "LTRN_ResearchAndDevelopmentIncomeExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expensed for license, strategic alliance, and research agreements.",
        "label": "Amount Expensed for License, Strategic Alliance, and Research Agreements"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncomeExpense",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_RevenuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue percentage.",
        "label": "Revenue percentage"
       }
      }
     },
     "localname": "RevenuePercentage",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "LTRN_ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Balance Sheet Information Related to Leases [Table Text Block]",
        "label": "Schedule of Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "LTRN_ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Other Supplemental Information Related To Operating Leases [Table Text Block]",
        "label": "Schedule of Other Supplemental Information Related to Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "LTRN_ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities [Table Text Block]",
        "label": "Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "LTRN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average shares, warrants.",
        "label": "Weighted average exercise price, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "LTRN_ShilpaAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shilpa Agreement [Member]",
        "label": "Shilpa Agreement [Member]"
       }
      }
     },
     "localname": "ShilpaAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_ShilpaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shilpa [Member]",
        "label": "Shilpa [Member]"
       }
      }
     },
     "localname": "ShilpaMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_SouthwestResearchInstituteAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Southwest Research Institute Agreement [Member]",
        "label": "Southwest Research Institute Agreement [Member]"
       }
      }
     },
     "localname": "SouthwestResearchInstituteAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_SouthwestResearchInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Southwest Research Institute [Member]",
        "label": "Southwest Research Institute [Member]"
       }
      }
     },
     "localname": "SouthwestResearchInstituteMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued from warrant exercise, shares.",
        "label": "Common stock issued from warrant exercise, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCommonStockIssuedFromWarrantAndOptionExercises",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "LTRN_StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase shares.",
        "label": "Warrants to purchase shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfWarrantsExercise",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "LTRN_StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value common stock issued from warrant and option exercises.",
        "label": "Common stock issued from warrant exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonStockIssuedFromWarrantAndOptionExercises",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_TranslationalDrugAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Translational Drug Agreement [Member]",
        "label": "Translational Drug Agreement [Member]"
       }
      }
     },
     "localname": "TranslationalDrugAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_TranslationalDrugMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Translationa lDrug [Member]",
        "label": "Translationa lDrug [Member]"
       }
      }
     },
     "localname": "TranslationalDrugMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_TwoThousandEighteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Equity Incentive Plan [Member]",
        "label": "2018 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_UnderwritersAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters Agreement [Member]",
        "label": "Underwriters Agreement [Member]"
       }
      }
     },
     "localname": "UnderwritersAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_UnderwritersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters [Member]",
        "label": "Underwriters [Member]"
       }
      }
     },
     "localname": "UnderwritersMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments.",
        "label": "Upfront payments"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments for contractor fees, academic research studies and services, and subscriptions.",
        "label": "Upfront payments for contractor fees, academic research studies and services, and subscriptions"
       }
      }
     },
     "localname": "UpfrontPaymentsForContractorFeesAcademicResearchStudiesAndServicesAndSubscriptions",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LTRN_VivoPharmAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vivo Pharm Agreement [Member]",
        "label": "Vivo Pharm Agreement [Member]"
       }
      }
     },
     "localname": "VivoPharmAgreementMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_VivoPharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vivo Pharm [Member]",
        "label": "Vivo Pharm [Member]"
       }
      }
     },
     "localname": "VivoPharmMember",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LTRN_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://lanternpharma.com/20221231",
     "presentation": [
      "http://lanternpharma.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r450",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r450",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r450",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r450",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r450",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lanternpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r263",
      "r383",
      "r395",
      "r419",
      "r420",
      "r431",
      "r435",
      "r438",
      "r495",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r263",
      "r383",
      "r395",
      "r419",
      "r420",
      "r431",
      "r435",
      "r438",
      "r495",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r256",
      "r263",
      "r289",
      "r290",
      "r291",
      "r359",
      "r383",
      "r395",
      "r419",
      "r420",
      "r431",
      "r435",
      "r438",
      "r491",
      "r495",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r256",
      "r263",
      "r289",
      "r290",
      "r291",
      "r359",
      "r383",
      "r395",
      "r419",
      "r420",
      "r431",
      "r435",
      "r438",
      "r491",
      "r495",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r480",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.",
        "label": "Amount accrued and payable under License, Strategic Alliance, and Research Agreements"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r118",
      "r391",
      "r400",
      "r401"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r17",
      "r20",
      "r85",
      "r350",
      "r396",
      "r397",
      "r466",
      "r467",
      "r468",
      "r475",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r4",
      "r437"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r475",
      "r476",
      "r477",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lanternpharma.com/role/LiquidityDetailsNarrative",
      "http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails",
      "http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r93",
      "r99",
      "r114",
      "r139",
      "r177",
      "r180",
      "r184",
      "r194",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r318",
      "r320",
      "r330",
      "r437",
      "r493",
      "r494",
      "r534"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r110",
      "r119",
      "r139",
      "r194",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r318",
      "r320",
      "r330",
      "r437",
      "r493",
      "r494",
      "r534"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Marketable securities unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Marketable securities unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r190",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Marketable securities amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Due in two to five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r481",
      "r482",
      "r544"
     ],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfContractualMaturitiesInvestmentsOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r51",
      "r189",
      "r201",
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Marketable securities aggregate fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r38",
      "r112",
      "r422"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets",
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r39",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r32",
      "r38",
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "CASH, CASH EQUIVALENTS, AND RESTRICTED CASH",
        "periodStartLabel": "CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING OF YEAR"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r32",
      "r88"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "CHANGE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH FOR THE YEAR"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash FDIC Insured amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r139",
      "r155",
      "r156",
      "r158",
      "r160",
      "r167",
      "r168",
      "r194",
      "r214",
      "r216",
      "r217",
      "r218",
      "r221",
      "r222",
      "r238",
      "r239",
      "r242",
      "r246",
      "r253",
      "r330",
      "r421",
      "r459",
      "r473",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Expiration date of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Purchase of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LiquidityDetailsNarrative",
      "http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails",
      "http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r13",
      "r95",
      "r103"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "COMMITMENTS AND CONTINGENCIES (NOTE 4)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r57",
      "r208",
      "r209",
      "r418",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Number of reserved shares"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r475",
      "r476",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheetsParenthetical",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheetsParenthetical",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheetsParenthetical",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r437"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock (25,000,000 authorized at December 31, 2022 and December 31, 2021; $.0001 par value) (10,857,040 shares issued and outstanding at December 31, 2022; 11,088,835 shares issued and outstanding at December 31, 2021)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r21",
      "r124",
      "r126",
      "r133",
      "r387",
      "r393"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r98",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r58",
      "r137",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r234",
      "r235",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Notes and Loan Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/NotesAndLoanPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r89",
      "r90",
      "r223",
      "r342",
      "r429",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/NotesAndLoanPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r12",
      "r89",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Annual interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/NotesAndLoanPayableDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r193",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Unrealized Loss Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r193",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Unrealized Loss Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "negatedLabel": "Realized loss on sale of marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails",
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]"
       }
      }
     },
     "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails",
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesUnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Unrealized losses on debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferring offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Gross deferred tax asset",
        "totalLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r84",
      "r525"
     ],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r84",
      "r525"
     ],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r84",
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Net operating loss carryforwards for federal income tax"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r84",
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "verboseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r83",
      "r84",
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r84",
      "r525"
     ],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities": {
     "auth_ref": [
      "r525"
     ],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from unrealized loss on investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Unrealized losses on securities"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrealizedLossesOnTradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r84",
      "r525"
     ],
     "calculation": {
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r36",
      "r176"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r134",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r154",
      "r155",
      "r158",
      "r159",
      "r160",
      "r164",
      "r325",
      "r326",
      "r388",
      "r394",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share of common shares, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Loss Per Share of Common Shares"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LossPerShareOfCommonShares"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of foreign exchange rates on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Total:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r140",
      "r301",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "U.S. federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r523",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r313",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r62",
      "r108",
      "r128",
      "r129",
      "r130",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r166",
      "r195",
      "r255",
      "r294",
      "r295",
      "r296",
      "r310",
      "r311",
      "r324",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r350",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EscrowDepositsRelatedToPropertySales": {
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Escrow deposits related to property sales in noncash investing and financing activities.",
        "label": "Escrow related expenses"
       }
      }
     },
     "localname": "EscrowDepositsRelatedToPropertySales",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r231",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r328",
      "r356",
      "r357",
      "r358",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r231",
      "r257",
      "r262",
      "r328",
      "r356",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r231",
      "r257",
      "r262",
      "r328",
      "r357",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r231",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r328",
      "r358",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investments in certain entities that calculate net asset value per share or equivalent measured at fair value on a recurring or nonrecurring basis.",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair value recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r231",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r356",
      "r357",
      "r358",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r191",
      "r192",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r204",
      "r205",
      "r236",
      "r251",
      "r322",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r427",
      "r484",
      "r485",
      "r486",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails",
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Foreign currency remeasurement loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r206",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r302",
      "r303",
      "r308",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r299",
      "r300",
      "r303",
      "r304",
      "r307",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r470",
      "r531"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Prepaid expenses &amp; other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining weighted average contract period of financial guarantee insurance contracts, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average period"
       }
      }
     },
     "localname": "InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeAmortizationOfPremium": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization of purchase premium on nonoperating securities.",
        "label": "Amortization of investment premium"
       }
      }
     },
     "localname": "InvestmentIncomeAmortizationOfPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Schedule of Contractual Maturities Investments of Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Total minimum lease payments to be paid in 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r10",
      "r139",
      "r194",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r319",
      "r320",
      "r321",
      "r330",
      "r425",
      "r493",
      "r534",
      "r535"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r94",
      "r101",
      "r437",
      "r474",
      "r487",
      "r529"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r111",
      "r139",
      "r194",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r319",
      "r320",
      "r321",
      "r330",
      "r437",
      "r493",
      "r534",
      "r535"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flows provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r32",
      "r34",
      "r37"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r23",
      "r37",
      "r96",
      "r104",
      "r109",
      "r122",
      "r125",
      "r130",
      "r139",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r157",
      "r177",
      "r179",
      "r183",
      "r185",
      "r194",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r326",
      "r330",
      "r426",
      "r493"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://lanternpharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://lanternpharma.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "NET LOSS",
        "negatedLabel": "Net loss",
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LiquidityDetailsNarrative",
      "http://lanternpharma.com/role/StatementsOfCashFlows",
      "http://lanternpharma.com/role/StatementsOfComprehensiveLoss",
      "http://lanternpharma.com/role/StatementsOfOperations",
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r177",
      "r179",
      "r183",
      "r185",
      "r426"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total operating lease liabilities",
        "periodEndLabel": "Operating lease liability",
        "periodStartLabel": "Operating lease liability",
        "verboseLabel": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails",
      "http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails",
      "http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liabilities, current",
        "terseLabel": "Less current portion of operating lease liabilities",
        "verboseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets",
      "http://lanternpharma.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails",
      "http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets",
      "http://lanternpharma.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails",
      "http://lanternpharma.com/role/ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets",
        "periodEndLabel": "Right of use asset",
        "periodStartLabel": "Right of use asset",
        "verboseLabel": "Operating lease, right-of-use asset, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets",
      "http://lanternpharma.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails",
      "http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "negatedLabel": "Amortizations, Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfReconciliationOfRight-of-useAssetsAndLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r347",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate of operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r346",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining term of operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfOtherSupplementalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Principal Activities, and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/OrganizationPrincipalActivitiesAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the nature and terms of commitment.",
        "label": "Commitments description"
       }
      }
     },
     "localname": "OtherCommitmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Unrealized gain of foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r62",
      "r123",
      "r126",
      "r132",
      "r335",
      "r340",
      "r341",
      "r386",
      "r392",
      "r466",
      "r467"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive loss",
        "verboseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfComprehensiveLoss",
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r120",
      "r121"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Unrealized loss on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "General and administrative expenses"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchases of shares including commissions"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheetsParenthetical",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r2",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, shares issued",
        "verboseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheetsParenthetical",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, shares outstanding",
        "verboseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheetsParenthetical",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r437"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock (1,000,000 authorized at December 31, 2022 and December 31, 2021; $.0001 par value) (Zero shares issued and outstanding at December 31, 2022 and December 31, 2021)"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses &amp; other current assets",
        "terseLabel": "Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements",
        "verboseLabel": "Prepaid expense and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets",
      "http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails",
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r423",
      "r428",
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid annual insurance fees"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from initial public offering, net",
        "verboseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LiquidityDetailsNarrative",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLoanOriginations1": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.",
        "label": "Aggregate loan amount"
       }
      }
     },
     "localname": "ProceedsFromLoanOriginations1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/NotesAndLoanPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLoans": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from principal payments made on loans related to operating activities.",
        "label": "Proceeds from loans"
       }
      }
     },
     "localname": "ProceedsFromLoans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Redemptions of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from warrants exercise"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r56",
      "r102",
      "r390",
      "r437"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock": {
     "auth_ref": [
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.",
        "label": "Schedule of Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r78",
      "r107",
      "r542"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lanternpharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r460",
      "r472",
      "r543",
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash [Default Label]",
        "periodEndLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows",
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RECONCILIATION OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r460",
      "r472"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r417",
      "r461",
      "r472"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r69",
      "r100",
      "r399",
      "r401",
      "r437"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r108",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r195",
      "r294",
      "r295",
      "r296",
      "r310",
      "r311",
      "r324",
      "r396",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r131",
      "r139",
      "r174",
      "r175",
      "r178",
      "r181",
      "r182",
      "r186",
      "r187",
      "r188",
      "r194",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r330",
      "r389",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LiquidityDetailsNarrative",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Number of sale of stock shares"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LiquidityDetailsNarrative",
      "http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails",
      "http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Anti-dilutive Securities Outstanding Diluted Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LossPerShareOfCommonSharesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Assets are Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r115",
      "r116",
      "r117",
      "r167",
      "r238",
      "r239",
      "r240",
      "r242",
      "r246",
      "r251",
      "r253",
      "r431",
      "r459",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group of financial instruments held by a broker-dealer for their own account (proprietary securities) for trading or investment purposes that are carried at fair value including securities sold, not yet purchased.",
        "label": "Security Owned and Sold, Not yet Purchased, at Fair Value [Axis]"
       }
      }
     },
     "localname": "SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of financial instrument held by a broker-dealer for their own account (proprietary securities) for trading or investment purposes that are carried at fair value including securities sold, not yet purchased."
       }
      }
     },
     "localname": "SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAssetsAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r462",
      "r463",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock based compensation",
        "verboseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend Yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk Free Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Number of remain available shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Number of options exercisable, ending balance",
        "periodStartLabel": "Number of options exercisable, beginning valance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Number of options exercisable, weighted-average exercise price, ending balance",
        "periodStartLabel": "Number of options exercisable, weighted-average exercise price, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Number of shares, cancelled or expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of shares, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Total intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares, outstanding beinning",
        "periodStartLabel": "Number of shares, outstanding beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Weighted average exercise price",
        "periodEndLabel": "Weighted average exercise price per share, outstanding ending",
        "periodStartLabel": "Weighted average exercise price per share, outstanding beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price per share, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted average exercise price per share, cancelled or expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price per share, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r267",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Term (in years)"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Stock option intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Share price per share",
        "verboseLabel": "Share price"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LiquidityDetailsNarrative",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r44",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r139",
      "r155",
      "r156",
      "r158",
      "r160",
      "r167",
      "r168",
      "r194",
      "r214",
      "r216",
      "r217",
      "r218",
      "r221",
      "r222",
      "r238",
      "r239",
      "r242",
      "r246",
      "r253",
      "r330",
      "r421",
      "r459",
      "r473",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r15",
      "r62",
      "r108",
      "r128",
      "r129",
      "r130",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r166",
      "r195",
      "r255",
      "r294",
      "r295",
      "r296",
      "r310",
      "r311",
      "r324",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r350",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lanternpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r166",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lanternpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r62",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Common stock issued from offering, net of issuance costs, shares",
        "terseLabel": "Issuance of stock",
        "verboseLabel": "Number of shares issued for public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LiquidityDetailsNarrative",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r2",
      "r3",
      "r62",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Actuate stock of restricted shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r3",
      "r62",
      "r69",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Common stock issued from option exercises, shares",
        "negatedLabel": "Number of shares, exercised",
        "verboseLabel": "Stock option"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfStockOptionActivityDetails",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r62",
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Common stock issued from offering, net of issuance costs",
        "verboseLabel": "Issuance of stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r62",
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Common stock issued from option exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r2",
      "r3",
      "r62",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Repurchase of shares",
        "negatedLabel": "Share repurchases, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r2",
      "r3",
      "r62",
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Repurchase of shares, value",
        "negatedLabel": "Share repurchase"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative",
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r49",
      "r437",
      "r474",
      "r487",
      "r529"
     ],
     "calculation": {
      "http://lanternpharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets",
      "http://lanternpharma.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r138",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r255",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/LiquidityDetailsNarrative",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Liquidity"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/Liquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r191",
      "r192",
      "r236",
      "r251",
      "r322",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r484",
      "r485",
      "r486",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfGrossUnrealizedLossesAndFairValuesForMarketableSecuritiesDetails",
      "http://lanternpharma.com/role/ScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lanternpharma.com/role/LiquidityDetailsNarrative",
      "http://lanternpharma.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails",
      "http://lanternpharma.com/role/ScheduleOfResearchAndDevelopmentDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://lanternpharma.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r169",
      "r170",
      "r172",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesOutstandingDilutedLossPerShareDetails",
      "http://lanternpharma.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r154",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted-average number of common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lanternpharma.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=51888271",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)(5)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99382878&loc=SL5749324-161292",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99379334&loc=SL5751133-161288",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r439": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r441": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r442": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r443": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r444": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r445": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r446": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r447": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r448": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r449": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r451": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r452": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r453": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r454": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r455": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r456": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r457": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r458": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=35711157&loc=d3e42546-110969",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001493152-23-008241-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-008241-xbrl.zip
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MQ2)O4PY6Z#/7?5$<8E]F5=WXARE16_63100"6B G;II4M"J.K*L_%PHN_?_
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MFI4%4JT&FQK46 A+/6[I\0YC=1RYX1C[3.=U2HM4Z:L1L.+""KHN!4C<V!W
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M%8RPOLC6MO/EI9+.P6Y;:J;P]+YT:U6=H][T]W3*,#)^@1P6=%:^%S,WM]?
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M!W(KVV:=@!%V=M1G*Q%RA*5["=7V=\E;G.\-!N+3]R$<]]Y?VWOS:_9>VA+
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M3NE'B7:L>2>#';.:J\JA;>/V%FC99L;/AO=2F-G]#73M#?""KU[*&5E_!WH
M=O^(-K@!;? X\  A@/V]YAP_OA'Q]-7;PW\CU.?I3V<_O_GA_P%02P,$%
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M&\==O;"[G;)WKU:&L9,;Q^.)S1>.[)6_.V5M6A/@_U:KD2^<!5X#2&?$FM#
M3<*$BQ6;Y#PRZ=T&Z5,=DUHM6\Y.[^\[NCPCUM_QRU(>(UL8V$+VYF7N71F\
M3-ZK^O6.SEWEU 5%KB&^Y2D/F&]JS,TZU_1B_K*[(+L#6G68BVQ:<I-9Q]FT
M,_;:-\ERX /R\;SSW7[+$7X9TO]02P,$%     @ L8!T5M[6%:Q:!P  '"T
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M-@#3H ]3L]Q5#QQP9W[1TS/BP\R/(;>SJI,DQ5%2^$YKW0KD.CAA2CX(E1\
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M[0_(^&HVY^"QGUBRSM,'?7V"T&\M<&@VY^!0>,SRIIW>XZQZ_# ;S82KI2I
M'K@\EE?@>,"W,<U]A%L[-,SQ;3_"I_A)%-1;:FS:YDWLK:FO<?K=+VNQ& Q]
M+B?$J4<5;RX?%X=II)\&E]&DK+=JX[3)6QA5_<C\C--D*/.I^5QX^$U7\,BA
MK?#2H8K[Q[\5ITB-_SA[W*O2YZFG#:G/Q.0JXH1%R0%P^8=L._I.V7<3/^/
M7N9'M._L\5[A)_KSP@+TA^I(IY^SH?_&;GVK4;&SE7-#DP_9!LPCU#<S/:2M
M>@/^;[>ZAZ0V,-=#JB:7%BBIP&YS.:1FU0^I.<]#FJKM5.NX"LC?? SR-Y\
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M&3SFCE<VA#\?_<(^?3R[D^C@FGO>_[VX>1MQGY@Z[HNATP7)<LZ[,<A>YB8
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MS1:8T/\<;(5)]^3RWVEK!^X'DBL( U+_A>LHJPO$X;@C,@DS@V[-"1B:R?#
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MG*W&NVE+I*^;[_1E4R]875%73*Q0K\#<"N6JNGC*8O65VCYKMCKUEE85M'Y
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MVA],I66@P)8%Q0EBW)\/,<XTI)F)9O2RLHAFHQR%$8>C=_Z=1B+VA&H)1AW
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MP1I&W/5%0 ^-$_BU<I69#Y,(7F.LKU]=R<:;#D,Y)[>&K^$O.9K8#6/<(GQ
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MA!G8K)0),-YT==EUGP=T/^S2?\V5F=DAI'%E*I;'?3:J@5;EI2XWT4V.VEN
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M5G HN.L:1@"OT:4/_PW@S>++"-/ BTW;+7R#N016RLW'<P K7<34]E,GT<H
M)8?-CQQ\*XX9PF+T>S/ITHO$%5>+@U>F3J7PJYKS(\# )*QL;,:+'/%2T^%4
M'YMNN'[JP2%1#V)8>N"T=N!Q0"U 3?3:AZ&@""]E@<1P:4?T=#8=\T>@*\;.
M.FR_(Y!N5E?4P;-(Y>41D9C!RNHS_#F]=3F/.%^PE_\VICQBFOOIBP2[FZ98
M!S+L UTFHZ&F3-F%3/9LQV7FL^YJP$LX8)ZC[4(9@TB)_6LFU[*AQL^/43\.
MGP;*\C!B'<B9-_ .@")QI3ZV(P-.PR%:FD-R$TC!0*,9TYQX@+8/'P]QR)9:
M3(+]QPK,X2(]1.,\DF4*2L^/Y)8!=L,W+&,(#RME1$R;JDLJJ>G5X9+KAK>(
MLPU%U<<H"D/QX76LYGP,TRA.$8F2B 6Q27+4$W[RO)\-[L:UJ]W1^Y1CO&-9
M04,_D.0$A^%=,9HZEG7R+W+O9,YW8D+Q^FQ@TT@"RO.E*FD2@%B5( ZG!3P7
MNC(%0/(A>LC51N312[;.;VAS"23)THA$<H<8"A-$FV G]PUJ(P:/TPIJE+)R
MH!0'QV"6TN8F@$!QQX G_= C . :4C+V(%E8K$LK'<5.T@<'!D8][/^NY]J/
MS\30,TBIC -^9GPX%(7N,S^A[$ @V?PSD;E C%"%V#^8-*PZ1Y/3:/H #H/,
MZV*3;P)?8L,6W#HVKD=QG]#M-?@8X--EA)Z(<2[JZ@K5K062K>0F"=%'*(=4
M#QC/3.Y0$PRQRBW!&YGGD"(C KK /&M\.NN&2@32F /XB\-9 6$!V"2@4O).
M#G'HY@DH+QJ+!;I5]"8TB&XZQP/4,!@*QYHJ$<^)J DT&@Z!4&A$FGD_J!74
M$\"O2':BI-:; <TW(:FO1&G83>AEJOF+@)<R^I<)-$,>27@#[PZK9N1M55(!
MWJ5]\.7066>=.(R&>/ U?!_P8D&WH7\!W;(.J$OQ0!$MO\'4*OAN0\O;'&G2
M^M7T PZ'T3:CW;+3*)N$"7)7G0 #KO2HH::9"D4;PFK/D'*S5E=(&31XKP7S
M8#W>P PTZ4^$:^"VP(L(\%G6%E"59P2Q<F)*14X>I^H2JK09+?"R@>5,4@QE
MU8-V&X7IL# 8G=3  ;P.HJM\D0'(_!Q?Z*E5#BI?'B9^&?$Y#DP>KP?A55C+
M=+AZ+Q7>1*%K+-^/4LZER%3J^6T4"">6T_E1#T1YZ])(<RU<96<U5 0H46^@
M1W'![>19CE23A#"%4Y$7X-T 9OD .Z@RU)JP1I9@%AZ&MYQ0 *3<CU5O:06<
M':EFU>GM87:Q.2E.L! D\M#K%-'*W4X>!Y:F2DZ2?%K$+F5N -<&LG@#O=(@
MAVJ%VF0')S<G2)N>H#XQ12/"F!H3C;(19-((Y4(1:I/PFD5>7*C-)25RHL&N
M4?I#RK7$[2-KQ.AO%'&?KD59X^F79S2W3.",)$KA'@S[4!ZW)MOL*?+C,=MI
M9!69!=I(>W7E!Y>V.Z@ 60W[F&XCL<N)A]PEZZ=H'P !#\VD/9GQH>4G+-S4
M&QD=W!N#B1"UJ=MU(E0$)NQ23B6B($2"'BI)DJ\\*<ZN _F8%-CQ6Z:<*^D*
MQB'3ZCD9^D2:''#&)5\'DZV< 6U5F;]\7O:9MH1S&77&@,I/(X4U#T0L 6A<
M Z-"+V4T^3[(110%5Z1GR!/KBR' L&H]K9)P4&R+)%4G&F >G^SE@JN."P#2
M@YN1X<0*<Y;Q77,LN$?P0TQ&7XX4';>_ U@*/$'M3)US!%H8GC29I'BX/D-K
M$.\]@@7'JOP,2"F2\D&:\K30G#GOB %VX(1+\L8LM9@IP.$$(&L*U!8M:BEJ
M^(#2MZ?YG>C7.8J:]#CY/51>^P.@H(\C\WKQ*X/[N1X4@(0A\ AJ[>J-C9GD
M],"BIZ"6MQN)G+38)G^4F7/+\?U)+8(;Q;FDN9 R8XOJQL1<*%PCQQH^+<RF
M%#3KKH=DNZ(32HL14MPP#IN2(@)?25D#&IH/8@*I^AHT<%,].,+I,M1>PU-M
M@T@G$.C-R@DM:F-1VA1>-44O;?TQ=H*E)+RZ8FPKS)XEMU?&N$ QV Q$0@-:
MYXA@:L^=J)1W0P.%\@3T66MR)%6NB#SF1'(,!'IHC 6DI&GC8[&Z759?BG"(
MO9!8UC%I$'K<1T@SSBVX01J(OU/$*,4F=>U\[8A>73*8WCGI0PIU2;V;QAA^
MJ/V#3.H(AH(DSV1D!Z\(^'J@=';T,$IE2ZEZTG(R="AE1@YJ)68AX^#4Y@@W
MF80>&RG"BW-R).#<BY=6<[@]E \L>$K65/P6'W3!);R]L*C^+3%[?-SM0?LV
M6JGN9,"^>4? WH;CEUX#OC ^_=65S*D/XJ:+ 1HPTE##D5XD%$7*(-9N])Q5
MS.*\EH9%LP2%'0#-D%H$C,6!$$RU[R#G]5A=,07W)N2CG$A?-R\VG:,PE*K7
M 2ZA[0T$AA%4 I8.IAT=M'4LC3I6Q5PMUG.R>$@6(V*T8?18F.62YTJ*()?
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M0&E.OBAD\R-H8/(.>?N"=-#!5-E<(HN*:=>RV$4^YIY5W4B1,"6N+>&Z( B
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M56\LDAV.-+] @#2=$& VU3H[']:=]?J&TY=PE&+!P3@D;628]&9;=@Z(1P%
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M0NL$5R>X[EEP=>+KG@;[6D64C%"B,&S4>-D1\M7;GG4^V 31PF$K!E3:B(T
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M]_Z%=#HZ^Z7RFRF&86.H#K<@?8*$?^:WTT$<_7AR]-/3-Z\L'PW6Y,VK,]K
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MCOG:UM:$#=9MRM=^R+N)L:;\$&U*RI07I;3MUE$EI9$[9M/#(MM2'=KRJ5N
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M:4)6:&^:U8MDMLSHR.;5.9V!6X8XE'.PNXN'>0G#IJ$,A3UL)!1N&I*<T.&
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M*0$6%O/CL> *.>%:".<$R+JR<TZ7(6T2A'?("&X<*ZY S"V)PN8&*D5ZJ)-
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M&=PL76 3+/[:/K^B#U3G&+MM @EV]E2A@D'2V([.=<0^-?.%M%O;W0$,<7A
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MWD6N4U+R<63YP%<7),VOBHP#04?YI&1\N1.S*!6=E=T9_M[6T8EO$457^RC
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MZ+%T_;KP(!\G<YBK21F3TS7_;_SO!UT,.K'_)/=I0M,Z]GX?)O/+)[K+\H$
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MPQ'[VA/!<-\%"12<AE];^8>P:S[XP4IR4'0^T]BDB6+/Q  =&.^"?%&T<YM
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MATRWG/N-K;0*1!0OC";A75\=^%K,35C#-\,,*VAF2UC:(57FID:E]FCTJK&
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M+-3,&=8\O'&!AQ='[J\TS'EAZ93'M9+,?HZHV-%,VFT1<<(C2^<C5!O-&5.
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MY!*"S=77 %S^>L;49XK']X?B\;LH'G\Z%(\__KC!@S5AG3FHSLV-8X:[&")
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M'MN6>K=3\)3ROB<IG(FF\3<WG**7[L YK>BXR;2>4"@/&%= L 'U9W%/]E]
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M^9\5&B"GACO?R2G<^6C,0FDZ%,Z8^>.9Z(,_GX \(1TQ40P-:0$83=<32E.
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M9K[(BJ6 L] [/%Z7YGA%<CDL)0=RV.J@4>#5M\=G'<7=PBI6E1M$R@1>-7.
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MEB80#AUFZ_-07PL6)60E,6@$%]SA%N]X]0/WAZ6RCQ>(BEL/Y9?*#:Y6^R4
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ME2,*E)505/&7&#]+1KUWG=?]&]=M>R8X\+<Q BK?U!,2MA$&*<JZFH&]9V#
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MD)R(T;UQ-?FB]^8-DW'ER.F+"_56,HMPOU;&C:>.#69(1,2ZV_&T>NC6J![
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M/,L&Z=:9]OV;..GM$GJT[7TN7A^0DY_,)WB>_:_H$->\+ -)-(]F/3&2@I\
M1PCX6.(3]&DHF&X*<GWM?"UXHD<_UH!"I\AEHSH8D7=&QQ:#ZHQ_SO<8%\?7
M ,\6=FFU]]T.#)W-6(DL0FY#>%,4HS!7U^!<D;:(\\S;63Q*Y;1>_?I")49,
MSJM)*_EI\3XQ6KFW01]JI?6_]UM<>UZC!"QJ^"$09+>TCS 9V('V<EMN7'H
M1]\O*0Y_-A>';Z,X_.5<'/[E2'(;_'V4*'M!<56S=ZZ;4>]WZT$N0HD\*(>7
MAA!B36G'[RY697_RE*'"EK7H_B-[\H15%L^8.L_4G7 TR2?.7O]Y]JVRR"&O
MYC\6HD.Z)U3,:E-K!;$82(9JY6.U8UO*?$464-O9@J;1&&4-_LK-HV F<U?:
M1,0"V5H$IE"Z8?H?"_&Y%Y+]A##:!_""'\Q*_1&D*HSMK"\YQAKZ3H(NT5RW
M:C(MRDZ@ST$33XI@7@TQ#PVTT:?J!T=T4'W/F?3%T)7<%!Q?@K:-SP7'BN5&
MF*QI<:Q^U/7H?^?5]'N=/^5?F=T<'22[LF<:T8YV^I)W>/GKG$?W_Q7\ZJ7+
MQ-92  1#CF-!N>]S%='-%&B5;2C&"HD+34$R#5_MCQ*U#GX_+YMVUW#[_Y*,
M!).LOJ2HU+4A;5T:&3E:]>58R+7@M+=?B3C[>[?/A$S@DF+A=;,<)%(;.C]6
ML1\MRZ.QF1) $C-B<44M"MJZH;UR>Y$@*X9+J;MV9%*ZM10=!<0;/9&>F[TK
MMK^.-9E7[4>M6F:7K#NM&R 140@EKI?XH[.CE?8&Y.UU@>79MND1O(?F]VM%
M$K$P'\@)PX8 =DW.&"<DRUC_#%@$M64I.#I.T)C^@3)\Q:0FKKXJ:44'>7??
M2FR+*7V64GH.C> 2<( :=](&/_2M=9L&?IUKM_P,%>T7_J_3$U7+PR_GY?FK
MCUE@MEH%\^A:GT*Z=I*X]JE+XSZ)*/%64@B-/E'0YH@V#^P#-6>*D%8KRI6X
M]71]S2G-K_MW"M].3V+&.Q8 %5#P07PEYY4TB52N6)D-$@T4IF]64$3J*DM-
M4[*&%"(6PD6S= 8@ S7.Z<FU-C\R=TZ@08@IA)BDH&U$O$U;BNPTXT 3_=&U
M+[%"GI-+"7KZQYW4<O3B00=CQUB*:X<H,OAV]\I-_346Y2VG<2Y,A@!(1S;U
M6&ZWG].YZ]/ZNP7 /GU1T(99=*6(%EQ?7Y]7X$UO:ZG<G-.A;FSZV%2])[3R
MO]*B'1T.YB$#EL*J.J&*80+7P#O#KPD(8%5VN)!>ZK><+<*&?$F+@L9[]I]*
MW04^;5LT.<7$COT.H6ZS#:QCR@W  'YF^OCXM7/)T_SO@0;CX&O+=[KX2_];
MH%O/5$5]_(TOS_Y3N3@-*RCPVZ8S06]T[ .)#)DAZV(&FJ$;"D'&O7/JI#]^
M^DGQ*;[W^,^?K#ZU@YC^/"CM^(N?!#9IM?+'7SW]+"$OB"'_\9<C[#]D&!HF
M6T/%K*EI0E&.AH^YE!TI4H1D1S'N:-C"O<=:#>0)JH_(^9'1,)DOP>X>:9!Y
MQO 77AKAUD60Y_U^\"#/FET9<2Q_8#MDM[$;-(=5HEU'RIK8P(%&@%8 6P[.
MPP5-&D6RZ_I@)H W(AT1Q#_>-LT67WS\Z%'V,GO7DR4@Y^+;\Q?G>?9CT0&<
MUB/F?W[^[#Q[\NC/GWUUGKV1]O.EE<3I!K3,Z1IG7SYZ=$;_=?;HZ=-'')E8
MHTD9CB7KAIT<RGE&@1P_CSWMQ'/I!>+G4EO%PX#9[=SR_+*Y.A< M1@2I=LP
MC/6-9C+6 ^A']EHXKVH.)#-CF>*G7)'_H^0L9LAC" %"NLKUHHE3)->P7P9T
MI%@YH_[?E(M2=4MN''=.?AF_G,YI47O9["(*L(D[>MJN<-OS[ 4"Y\[FSD_8
MAV9-TO:8LR9]P-,3?[^I!RM5<8$;BU151*67.FLGD]_I+QYLTO8#!>\_SP7O
MVRAX?S47O._Z,7ZK(1)?J5S]O_^C^/\?/?HL:*PO_OJ*+!RYBA?GV5NT [XD
M<]6TOU4Y_%Z^F%\]=U)#SN;*:7MH65LZ= M*F+XART9_;JHK;FCFXH,H"N"4
M0T_G>?;_-8.UZC'2$G"K]5#YGG+Q0[2O3V!9K#F#%;"6%9 GO3!<"Q BQ\P3
M&@N66FN0^&WG5:Z: Z?'-V9]V/>(,>D<4(4^ERYX,Y*G%I81<C0B_246CF#I
M06N1;#*94$:2;0KEJQQ/JT2FS7+)WJC(*"F#)GL2UKP3I:&Z2 E*&]>FIU/[
M@:P1J-I;C@M7I/]">,P#L@G-H^X>3XF5:ZN&>M^AT"OX1/$75+4#?,GD"&D'
M>UO$$/_#9]?QT=2!GDFRJWM:14S'C>!SU'R^QP7"*CT_/;F(VJ9X+3!$PO1)
M$,<QS8 @*>B)A:2;7LT@'#@*A)#)QQ=6CL+#<NM[IYA3%H[PC9-(,_/1LYC=
M,(D/P)#<SZ-J\5<<1!TH2;V@S4O_$M\T7>F[8KYU2K-O]?/YV/HM^6.1^-,&
M1ZO!Z&XB2[-AEN%]H :L@8760X25%+G![<K5 ZRQMI06VK;C$3*LI==94R5,
M (?^)7J'($>'IDVHT+FKHAJ,3;\;)&&G=LZ?48 S,]U4K>08G94%U@.7'J^,
M..P\^PVI<._E<OHMLLK73G0QXDQP]BUZ?D#I\(4U7^OKY%<;FLM!7L=T[:&\
MI)):5F$B9X*6D!:8E!T\]TR+6KC)*7*7\]Y2(6\OGK_]2S?L,-=??(:YIG^C
M'-3#V]%.W: ]XD2BL)/.QZ2PQ>C&".B%]+4O=H4*5>0/(9W!2A-RF+L@N"#B
M$MJ^@FS;;L,YJI$ H::V#W0_?M2I,X'[2*""RZP1H9[N+F;7%\@!<CKC.^7:
M:C#1&2%TJ=:4J6T7S"07":2AZ]YQVE]9S96,CX$JF0!5\-)I/+3]];$6;E-4
MZUQ F:+((;RH:>\ADM-7DENV])2T!85'BX:B#67G:(GU@K YZ\58TR/KG8GG
MH9;$FZ V&!51#&E$N*!#56%@$(60].S5!0/MU!J>T ;L]PQC0)/0@6'EV?#_
ML1Z]EFC-"MPH/(W)'<P^SEUZD!\9,[%C5H"DM3_PX7(FW*\#\V%'9>EU!1@-
MEA4?I/\MV7?\Q?[)KCTS1S7RO\I:4;!"N /#*?B&+ S<:@@4)*07;M]HC5Q[
MCME^<"^2">+@8(<R.IJ(T-5;AI;<PBLQ<+&G. J'!:?H4O1FPF_(+$L.?"UX
MZ[YX+^W$WG*$W>UE>KA!F.F*!X2D=#]7JU8/]Q*;*\%]3&S15.BG$V$,43PR
MJ4:_B2-S@<"2)2"CQYWWU]UP3^GT')@0+89JA(T$=5]/,8/_M_.[#? 5I4FU
M^%0[.<.&XZLG^H[C2PLWKN0&>.WQ M:#PB\I=H^+Y8;; B =9B7UA/U\=DQ_
M[QWQ#DM$SGJ_6'(YK^.U)J]>RGDU.52ZRMBE94?HIW++:E?9OSW^+'_R^:/\
MT:-'O!K^[?&3_.GG3_F_;>$P<4TF17G/:?;T,3FG3QX]><(_$VHO+1JQ8@";
M/SU31J>$+MIH/Y@UC/EYV#<>[Y.)M4P+?! ,<]Q%HYF< \FVX*)[]2:6RO/N
MV10#5"YZ/U&M\1]#6W;J@>5BIL,^LK9<L<F^(_=5'YPL(SKAJ<WA<TFSKB81
M[846B>^DXG!B#2R6331Y67^/@]J1-MNU@%M\2@S926X?$F]/M'YT^Z>"!T)_
M 7;SW*<T[1=P)974N:/U?V@OA/$_68'Z]C%;P5M(Q1P^UG?@)3:VD@SQL^4D
M1&W:3YV@ JN]T&[_QP,P"M/6+907XW+BN-SXLQ\VJ38>K4K^#RZJ1;7'C[_!
M1)7R?UB)+E0F/_YZDR]$G^+7?A7]ZM<;^9-;'_I7GW_QU:\X]ML<K!TG,L+#
M5,94GB%Y-"XRW^4U&M;2K_ B?IM+WX,YONV=_VOO_S_LAF=A$];7P B/)1_'
M"4>3(8Q8%8..;B ]/.8L2A2VMVAI]&>S/=9#O1<@K)OMS&QG9CMS3^W,R+%H
MLL505I)N!%1DW51EXT7@(E-A[+EP1;@ HTE'#AS/JG*)@(0Q'<$4'<B)MU'7
MXE%_18%Q=Q^7]@$PY><SF/(6P)2?/YK!E'/8/(?-<]C\BTXWC9ISG_#/K0E5
MJ99[JPFB#Y69A0;A\=TYIMBS,W%V>F>G=W9Z'[!9&/6GWXQ#FJW!; UF:W!/
MK8%DL61\$?.;!] =I,V8I'@R12;9L1@<EAV#[,TF8S89L\FXIR8#Z#4!E,@8
MO;H!*&J @<T#PB)7%<'%$'"%JI/A471EO6Z+0,K%^)$(!\%)^=34I,3HVT('
M<A0&/)N;V=S,YN:>FIM-V:I_$@O4J3^11TY++KQ<T,58>A6SH98&!M=V35V[
MZFO\938'LSF8S<']- >,*#RP!Y6[A#&(=GPD\VH 0?2W>XQIP1K=0HRCB/_S
M>UZ#NX]PQN^;TY.%8^EI:;/?QL!2]&7!PX-@C^DB<6XJ]'RDOB*#@EO1]AN'
MI]P#$@.1Q5',=@WXADHP)T(@R:JWT96F(6:BW V,"0T/*EU%V]>N16]_J6A4
M%83*I+7DH(^CR*3?3/C@C+'V]"3TE<0$!1I,\S_'O7:3 \Q-GMQ36X*\D@/X
MDA5$CS7I*=_5SC&^66619*\4O:@H1UU?XU:ZJ.5.>@<;/++S?7HLOGC@H^?I
MSZ(80BA^.U=5LJ_W'Y.+&$<(QX,#R78*Z?3>[K!KNOXL?%??(_,PG)^>_"@
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M1RT.:E,!GT#)K_%JCLG,Y2'M HJ; VOS];\.4O3 IB :\'.131F*#^I=B.A
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M!2EEGKH+,=]MD Y:-1A^U^0)]60DR9.J"&R*=COK\MRI!X&+&"CYQBRJH@+
M]5G^S+=23+F WE5D);B((]&8@67!3YQ&3.%*9KTU.1K>%,F:P_$8>2;&E:NJ
MA,J1&@@15>9 ]_M-E+@LFW(@@N4IAF_.0 OS8#AY\ 3IDC]FC7B7B6+7\3;9
MG)TSTR/X@-U@=^.XX1@_-^BJ8]7+LF/9CX@Y>=ZGOU/P]CVR(?HJ?Q%E>*K)
M6<74EATV)U;, ;NEZ(+0ZFNN;Y_K<D9:S4BK?VWD?VBDE=^61K^PV)9=YV49
MLU=R:HKB"NUN7%F$*D/+$I\XK[Y]GH= ]N7S"V/XY\QJRWL(N$UZD"D-2Y8%
MT^A)$[85.>#L4QM)LT:GK$Y\2)4Y=?RBRZGI."+$D1]U1(PN,!=\Y^K.7/"]
MIS9,XV18(AGD1_+P?IQHN1@2CR:;.[9GPS$;CH=A.#P/U-;S3\'KR;IB[>"1
M]$WE6DOR,58$*CO%<B^BOI5J798=_:(O.XE\]E:]_/D^D"@48AB'D?AL:&9#
M,QN:>VIHBI7[[X%ECMG&U)><W5;=%4]I9QJ=7!VS?./' 5;%M2FN,TC4B#?C
MB^YD/SALPI7,Y5%ZNU$YWN2M8A:;7[GE\_?N[OQJ[NZ\C>[.IW-WYYQS?!@Y
MQSGS^-N<B5)S"BQ%7.,+T&QA1B(?O*7#,^O<LG6]9T)2-M;(AW8_+:NA R_M
M7C6YM/3V0\WXM'>]C^5;5[DK5/XNJV9!QYSXVG,D/SO8LX-]7XV)AWGO7,N:
M]+7(L39!OF_,$LVU\7G3SYM^WO3W?=,K1%3A+EY0>M=T_=D$IB76O05T+T!9
M)Y)R1ZG=[^X"GHW$;"1F(W%CCK\;:-/O4_5W!2^4[>H,O0#[43Z-?U*ZMAL)
M0= GLX&8#<1L(!Z4@;C9,B2[G[MD!$"[+FNZD!LEWJU(R [(KBVE,6=7+-\7
MER"/!RZ_J(YH:-W=%3Y;D=F*S%9$!QLRD]Z$<)^CL+*7]0W,[6A 6#=5V<P&
M8#8 LP&XIP8@-,C(&*MBJ)<;AAF.*NJA%8+3%3/4YW>_]#V8X]D.W)/!%D8W
M4].>'LB]5\9:I!<%5^C!@[,=N&.7O@=S/-N!>S+8<.HKOB$05R\0_/>@[^B8
M$,+36.,W0VU@XSCAL"OV33OST,U&838*]]DH3*G-HC< Q!Z<9)1.:_R_8E?&
MQ#"_'1W=@VF<_[4?Y#5Y;<SF()P^VO?.3 T+MV^T=U[IJL;M\,?;T.1(Z.G>
MH9)M'; WMI2<GDR7K['(6G=5TH-)>=Q_*73[=B!E <7&MGCO\JC=K=^TKI Z
M^4=I#W)-?ANKI.>Q9PLF"8Z!C6;C.$7%)"E.H*RX059>.2L\T\$4:<5$HU]N
M1!K-=1T8;*8'A[]''#;*6\.$DO)F[<&:-;,)1>O#U*"OR\ZE[#;9S>0VV?>;
M:88\^A\\INN,G O+1"BO#M=(O# PM96K+_O-/I<51ZNU&Z1E$H]7=^654R(3
M&K)0N0SUKH7#PD9(:(S*\*8JNHX4.,)+T^I(&#L-(R$FFGP9\<PPU\3,^G/W
M'X091E+C%1: ?^GD =^\3A/[57;IFJ-ET6.I9#T9*]3B]MG>%6V<6&,S)%HP
M@:1GW.\KK'S@+^F$!K >R$(T0W>,PR1:?<QNV;J8$F_:^IZ?GGR?VON8K3#F
MO:-'@)GZN*9D8\Y<@"F09P8[U8_$WPQ\JNT9C?K2'=#]G0N30TK=PS_(^ >3
M3=*X\;HHF9>SVS37RF_4\:O6!$?2*MFW14ECH:_LRMXI,^#IB?5H,R,@3?KE
MYNC$2']W-1X*'1!<5L4T##5>-KV+M7*E%77I/%G3HFR"VH?T<\-T%$LW]-(-
M1?N!]D>KIV4WK->8A(@EJG/]HEB^YTLJ]]/J8&Y6 YN[NJG]7]8E<XMCWE8.
M7(-5Q#UA#\F4EP-MR?:Z@&VL_4PV;9C(9M&Y]JH092.^'(UE?*UXR>YPZM-R
M9EOL>2"5XC #+6'?"<_4)"D&_ E91]%B"T>J6'[Z&.<D4U!:)BMX#_22R<'
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M7+O,ZY'S.K\N]E(2KERQZEA/F)NGC-;]J KY1-#"%^QIYF6,M'\XX$"]N:H
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M!PI1=LQF+S3M[&^8FU D0Z^3G )_O10!./?DM+I8U=UJW/48?J9S\V*UHOV
M35KJ-^[;OJ_1V,8,  ]UZMQ '[N3M)7H%-'MKW43W.'A?G-@>VB/7-;G-6,'
M;KAD!R=\[-#P;F4<,9,M,A]B)5R2 YC)]9=AK=H<LE>1:M?=^HD<5/IQZ+*#
MX? ;]DM=WP;4U5K"7)L(!84!H;OB)X&'(Q(%8E-9%H0-Y;@%5--=ANS4[O!O
M:8LIB(#SQ)H/->UE_!E/'H ),EY"U#'Y*8Q-JCK;A4]/[,IGQ4N0K*?BQSFH
MB 9]2S/FGXVAV @,?&R>0',6-)>M&88]#V55*_!GZN!?A$]@]3UT$NB3YF]X
M";V&-2%R[Y/'V]5];P&>7PPG\_%ES)N2WJP%7^JO\OMON9R+,_>*,G%-[Z41
MQ#M[;.QGC$OE+WWVQ1=_+ W"8?O/BD/'MI[B9> 8^M4E'6(YA>89;[+EGH<F
M;&JN7ID)3!MNW]57;(MLM]%#//:E_'B$7)0+<W2+Y ]-X9<>%-A4]ZR<JN6
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M+Q/59?1/L;8F@8L\<8U=;KWE(O8CC]RV6S]G%-S;CU^?8B;5;$1Z-+0ZD]R
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M.59]0-P2/^%GQCL&D1V9NLSQBS:S+OQM^3!B]E08HBPL?LW;]XP..O#7L/2
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M[C].^"K% / !1T*%NC?F><5_&&=$&TN@%"*LF#02.MT9B;[IYZCJ]FP,?8!
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MS0B-6G]B-O/%@EE!=EJ.US;]Z3+T(;^<]OU<:HNO<&F^JHGD1B3+]+$<QJ4
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M#H1Z;R$-1(3VI06$"NG?L!325=U:6"M^BU(OBI@U$:%PF$(&S+4TUHQ<44C
M EGT8]$<-/TD+D^OJQT37W';?#\."I>&NF4Y'4NA#(FBH5[<];K&[RX%086R
MI!M*"U7'E0IV*,M<P6._83^>\LO/Y!ZR87QB=HSCZ]IM!"-T =EFLZYB!S-+
M^69GSWK1<I].G[G0-PZ?<<)J@ <O=/B;# UG=_%( O5WWK75>GOC[<W$P-S=
M,J0,,N*4\:AB>1MP"*MN^[L28,E$KT[+,_%AR5,JI9Z1\=B$8[-VMSS?K+DG
M12W5W(LVV%O2=,,&R38SFAX A_@8I#@LG?CY%<W$_8\8^#H'UA DA=T-]P/&
M26?WK/C!1]72=?$O\V I;WN)-@F(9+_E.M+[%.=9QON7\?YEO/_>V<C-#+S@
M6/*_-):4)3-J;)3J[F5]7B-MW[6,#+0*?L-#"Z)AJCWUUPVL@DZNL:L4:;4>
M+1#0C9$#W.B4B_0*(MB0_97T=W9CHV5892<S256I;B2!55:=KOI+^7'QNN:!
M #22,2^&?L8UI@+D P(N9Y-:%J'6VT"A,W3\%.";G62N?%+*S[(0ZYKS3W5X
M=>+PN3(*#R:#@**I>L$5,J[&2VNB=-[(X)E:8-U5ZV#6.KX=C_G$*A0*@$)P
MU><M!\,D+!Q-BZE>3/7C,]7?(*M_B:Q>5LQU=0/6Q5P:9>YI$NVKYA)%RT?(
M%/7#-IQ34"=&[9]C70QD8:I(WG+!>,,ATQ-GB)_BBJ)^Q;R32'Y!%<_%$W1D
MO<=>T0'GP7[)+0&I77!BP%G'N(56-^Y9@.QJ-<]O[F F,:WT6L%WN"XBWIVV
MS]B =^N$Q6&D@EX>,M:NC +K?M7"3Y76%U<'QB!3GFE"<YDRC*T6_95=#Q<M
MZ-F$&P-YV;I3Q%^JPF@LC6]K T6G5T<;9BU%]:$+;,JT'#+%E;)K?B++CEM@
M<0J+4UB<PN-S"HI^_S8!+WG5K]K.6 @$2K\"E-1^I/W89U]\\4<8X[]^^^K%
MB_(V5Y+,T0;X;@S$P*[VJ\NPPXC-.EBAZ$96X0H+-I9]:)DG=KG7HH^X!G<%
MLM(,^WX@=FRQ2XM=6NS2M+0N9N1@1$=6'"U5:CS]%%:73;MM+\2L?$V15+NK
M5T(48! %_;N$(?FB-*1K#0C77@?>(]6&U!(\9RG0]V+=5#0E1FE9<)PB+-]U
M D&R1FCZ?8#151OZDJJ+8!0M )>QB2;KY*+QKNX-KY\"Z:W:R9I#'HK=<.(/
M^W.+R5M,WF+R'J;)\Z'8*^NV%:\DBU1;\^/(#:P& XQITLBU9 [FEFQX)\ZP
M=8'!JY:=>CHM6)>-_ATH6Y!Q9HT_HWEGRBIF4FG[?3V037Q M,V+<5F,RV)<
MIC3,E(.U%TRP)(U:1\<GBYY'XUASP/[(@87D$@X=E"Z1];9[:0$IVQ2;*AG.
M%R;;+O7/54/&XQ$$9HN+"Y73A':QID2O=SV1/@TT(&#D^>",SO 0MI"Q-]B@
M!2(I1;D_$(+HAU?M>L3 GA_;'>T"9;+C71WAX/E8?22L%*[)'>]MA/:WC.!'
M7#;M9ZZC($&(".B+L6;>E288S ;,M]MPA?G>_'/XQ[YK=^/VHAH2"ORP)!S'
M6NP^@!S*8X44&G@\GW#&K#'W\RM#AD-\3X059>=?1JG6-:^G/RM>Q&$Z;M(F
M,D2!\VQ;?J;9NY$N[$6:&CCD:!.C0[<I/8**<[TX*>_!,6?"P)*QEHIYX_1/
M'FSDOCL /#I&4O\LF=2>;V-5=ZMQQT01*Z4ZQ5](*W==<VM;.N$<9>G3JW,^
M6A"@X-ENAM P16+ Y!;=6-CM=2]H#CU<CKUNG954P]P^4F[&^\"_/U1X\%OP
M[U\L^/?[P+]_MN#?/T7\^[OVQ%^+?5(22<P+ 0B:,QL<8%@1YV%.&HPA#+?U
M[MDES&]#+"J;"WA$*21(!#\RQ\3SP3Q"'2<LL;J<0CL1;=E*(@IR>B=[KA,B
MD+597+]L'=<\/4GSFBFZ]HM&4UP&X%W@? L,-[)[O^5QT.V*1'2:<17GLP%%
MKW3@R5=%K+Y!E?.9?"7#F-*OIVFO'/$;DX:Q-SCM9*+!^<;3$[29RKSU-$'T
M.SA#G /8\"M YXKB@%9;Z>$-O2HKMSKB%Q=;,15//K=KW$ E;YA;T%6Q^,QO
M=JCJ;4(3T$I'CLR4"3Y_Y'@+Z:GZ>&ON1<9P"QLGLKA@2UU?TLU<&\<36F]M
MVHY,4^5>+.]'1LM-!A;=OA(B0G"4'+XD>R&EOB(9 ,[>BQO>\!0U^@[TV>-8
MK^I]C*KN]#(>TE3QHW8)]S\2]0.8Q;G%8:/C;N+&3ZSSGLL(@#B:KE?C5OLG
M(.)*/ U'$?QBM=9NYI]9AHT2B$?;X\P%C(M,U3L* C52^@4;M7=:@S5>M3B"
M>DS)81:VOTP6?0(W/"L)\*[(-VU<7<:,E(9"?\C5APO7EW2&5?@X/0UGE.#I
M9)#\R,F:4>@IX_RV(Y#1Z7O[4PHTN#DKSLL=NPGK9Z+YM&&>V4&I.\WQ_'2\
MC".$C_J8Q2/1FCL1-$CACFD?@-3$_B#G;?0L(/XMU<PO(B6*L^*E,G6(@TTR
M!.32I^Y^*I3DJ3=F^39*+0TQ"P#_!KRW77W1@I _\L60^P:X$?=2-Y[M:-U>
M-XR1YS&X(%/].H*?D_L8N9H91"9JR ;Q'Y*37HS:^]$Y^04T8^7;>,:4Y>>[
M[UZ4!_2K\3NPHW4L<,^%-("!CZ@YP ;X& /<A1QCYM?C$V+<CG'"H[>2;-C2
MDG6BI68%%IXM6;.!9B[P"0L3*+@%RA(91"K]"JE@.B6B&/L_L5 ZM7L/]%#J
MG/,M<FU&1A"AW(K:*CF'H@M?DF2$=)?9'#2XU:[:XQERWZ8'75H_B/:21NO1
MJ'DAIT1QJB0E&8^1NI>[4HA-K<R$ZL,QH]$^D>R%XZU&<DR\0&.<E.<1WW1&
M1)J$"*,.U1 :'6N<V1V@<+LQ'1:\:CSH*M+F]F&PQU[3$[]NIDI=3/QB2A\<
M \A@D'^Z$T8OY7T7:BJ5;)3;SDU^13X)K*GYQ6+%7_*N"0_9)V2Z/DE;_1WH
M]I\_??:TA%T&MJSX_KS:50AA1)VH197I'7)OGYX<DF^+Q>>%86A"B'9!,,V7
M>O'RQ5GQ B,DRK^761=\ -VA."(A5-"BE=/FE*NI$%$R$2 9RM$?W'(:?^8Y
MHQ5X;LT+YV/BF41QHR(+I13='L(4]0>J;RP0G 6"\]%!<.BP-V.U+2>\]3KW
M%I TL3U B?;&$K?8I'>D];U13;/]/$[$#C:(FD-)1D)?L"M_( C@AP=G62S*
M8E$^/HL2J]U:T9%^8-OI. !GA+MQ%]4'J@ST4^QH31@I3<S]48T /)P_X.\X
MHN,>R@.Q'4O(L1B(Q4#<9;&9N,=TLGV* 9#2<LZ)*WU:SQ: [,NRFEGF%R-]
M*4%[FZNQAEYH;+D%SS0!.M8 (O5(V&N]>:0[%"JE?O-B@!8#M!B@C\@ H<!]
MH$&5R.IYW2QA-14H BN3=.ARE#(BENJB"U*H 5:65:;^E4W(Y_0/"H Z%%'_
MD_Z.P=7/2JX4??%O9'!J6EV[>0)::/M&K@EM9"%37:HE5UHLT6*)'HDEHJN'
M& IE-D4',F3I$U&X1%;QP6S!@V.,_^+I@IB_#\3\[Q?$_ =#S"\.;'%@'YT#
M<[F\T\R4%4=P5L(KU.N(?5X"V<4.+';@$=H!8,LR^LRHVKL1T2--<E.!_]5X
MOJU7!K?X40;G#^%O]4HFXA]2X7^Q'XO]6.S';UPL%^2\D%H:_-=(0J5@Y\4T
ME%MV(@9R2 >T&(S%8"P&XU$8#*GA.Y,!"3$@F8QU4(E# &#L*^9.[ _02UV?
MZ^HP8EH!Z#EGR .B$EOLQV(_%OMQ+_9#P>%/7J(,&)1(\/MQ6+5\N1]"'P W
M_[:A!4 SAOM[4,H.I=&:,O5_;5P*=6."YJ)<!3(FG2./HK11_!SS[)U^"].X
M,CI<]&8!AJ $"132D#M?7<://A#ZKV7JX7U-/:1Y*9E-\B.9-BF;1FSCO*R0
M3,AT95]CD$ '#9Q*-49W^G0=+X?VYW%]$8;B9<OC8=O3DS3E\"RJ8L[)8FS!
MSE54%Q<\J3N$-,&#T#YIQMLLC\S(&@'7IACW_*/G_Y>E'BCJ[_G8W-#>AP<'
M"UJG(Z.TEL_X1LMB+41?3(>"OL60SQ<GN6Y5J>@-$H3!,?HOGM,W-7J3$7G^
M]/GGQ=AL0>F2ADOI?%_P5"G^2X: >3J)KEV]#DWBT'BQH[>ZHIWP4_6&;I9N
MYH>PK</&S8L\O_5)XL'YP3[_R/IP!:C3<+/G4@M/C\2'*%-]IF_M[A>#UV[&
MBYYPW<H8!W_*8:.0A $7 :,W_[)T@$O!#YN:&6GX3?6VK]C0@F!E,MV5'J;;
M'/2+C)7D8)#8;&+\Y36KB,^1'9R>W'VJ)9N]=G_F!M+3L+@\ITTGS;$;XRSA
MO^:O@*7.O^#TA-EX! I_'B"8-?9\\KX9.[Z'PREY>[,=6"9$9#';<_2D./:U
ML?-XY!V3IN+@W,SBZ<DZZ)#4T,[OMW.PNV#:.F/,M"%$+<*5JJ&N!'=)QI*6
M/UR+$9)JG;#\.7RORDE"G508:723ZPAE#_B+#@M(B3#;$CI*[O:IB2X<&UDU
MV)[>@ [1?D(NY)/SF?^@(V?L09SR">_! 1]!QEIP:&M^,VE!LG$\3_V+C5SY
M-M8#0;-&H;ULPXOO_\UL"-F<,E_T=VK_MF2AP)R1GSI7A<LN%>? Q290CIY?
MF>UN?7$YJ $B<R/<%RSWZA]<_FU8A/*2!<'P;F]X'*DZH+ZQU4S-M\Q/JOTV
MW] 7PM+D+;8?93\K7MP^XPRO&%]R), Z-%K>+4+\]I=,/1?+T/.CO^&?F&TW
M>L5LGB[OCVD& #)8Q!"(^93I#*3[#4]+=RC6<!-N%,F..:(G"6!W@5D6\+TO
M-?9@AIDK);U=1]MZ(R$TF1O^C$1 LF0+HQ$$3MA^)C1K9F8I;J18H^+ _/:H
MZ/3D[F&1@/F%I^O6$*GXM1$2V"#O-T0J?GF$9+KB]Q,B*2L%^X'X)*,WQ"LW
MGF,EZU#Z$WWK*6^=/&,P]W&-)95"RKC%0$G$(C*KM,?J(;)4#G6C>5X(K^?V
MU>\.&/PH$X@NO!7EFW:K(;KP9;X88H:DGJV,E\7?@=B],55$EGNL>N@C^MM"
MRG5$I"?N*^P36\.DP^U'8Q/?2]I0&2N\Z #;5LE?;)2C9W'CV'!/A%;"D<DD
M)MI8LZ^J5BMDNMB1QCT%ACJ^RK9%X'! IV^/MY1$/')*,]M,Z4\4G4%:"F(8
M93>0M 1.38X9EAH/\/FX?6W,-;24]^;I'A[ ]=D"<+T/@.L?%H#K!P.X/N(H
M[6_)!YD+CI4C<9TQ0$,D S5TMH<@[LHY!7,DA%Q,>0B%:4LCFUVKKM51$!ZR
MAJ'.8NZ<;7+#C+D@P253?GT98'7G'+6K+1NUEH908+BQ/V6^O$R?)<I 0)N>
MMA\%K5ILY&1+KJ1$:'HE"2,M<:/81D)(_79-5 _)$/NCS(TUN(A+S=:9<\PJ
MH10^L[0GQ6O*\8,@,@8?BE^CFXJ:&/&]T/_!._)%<[I$89;D9Z]LDX=KS4H-
M%I:/0B*.8))?<7.AP1J<\;8Z#UL+$+%%TF4'GEKU==!LUSRDC/!1VY7[YQ7^
M2PS:.4(;!\[9;%?FS*M#$!)L$7XLU$1(9*@!9E_&@<4;.N/H7$9V3YP<[-<Q
M'9F%R?<3N&%N*4J$;L%VZ>ABE; L!>*Z^[X>R9$%6@)M0\UV7E9-M:[*6&I3
M9OA;JQ1U[_C73T\RIGW=MN"(E)JM7Z%^@8W$JA3"<'E<VH [;]R1RXL? ST=
M.@.#@H]1&=P/Z)_-D .C?"E$L%R9B)TAGV_!\FLR;W\7LZ!T!TDF0(WU6A-2
MR;TB0H"<0E=#&:PR" '*SY+\/\GQ [,N$$ %\>Q75;V5VP819AUZ>[R3-UHR
M$PM*/H6*&JG. 9=IN2XI[$XK-3'6,-QQZ0&:!N:WV.\/RGO>#Z'2)C1?0NB9
MN7A!=Z\?;?3?9K-285I(DW6B1'>AR%M15+5%GG)L"3YD@#3!Y(5M7*VWYBI*
M>DY&-BK5?<J=]_A9M>,764*OH-[$]\W;.="]D3-O>MJ4/5=Q..R3VG29:VD(
M:>@Y%[6Z'8<_JM'!M-0HZ6^W-V?%7^N>+L$[@66F+'ZC>&!L5I=8EI#63D[D
MNH4:@I)]RELRS89TC _INRGHX#+8]L;*Y>99.$K,XIPM\V,LP<5'>',27'R[
MH0@\F-2)%Q[,09$@L!2!:(9$LA9'<\%I:4,;"V?6=;V*#9V<J=A<:*[JKE6;
M7)KR&,CBJTW@\SPO[G@=XAE!@=!)=4 +!:8VDK%@*:NQLZ)H%V>C:^O7R=7X
MN&4G\2'&.8]Z,[^/EJ^@;HYMZGP75\)4O'[+25"7K7^8[WO-94N_29MQ%[A9
MR[(@MY^ (^JFGNN(PWJ);5!JKL[;+I845F$ME6E%&E&NO-ZB2CSVO"3Z'*VX
MY% B5$,47%S7/8H1(%^J_K?JUMQ9-N<CE[NN>E Z?Y\)_/BE7;?=:XM;4*.7
M+L_1QPBGZ2Q*:>I56#K$GOQRT)O95KN=RD?KXOP*R _N))Z<%,WCIZ?K1V?,
MJB'!?1MNM\BJ),DCVJ+G)+PL O+/5*+6^><9RR^T.;:0'1I4(;+N7VN+;JCP
M<XS2L7'[>:37;239_LHQB%-YB^-_+<UE $E19A\[?>+<S#O8 9D)IEU+_\\V
M=9L@ >EZ4:;*SE%DIM KA#>KP-US))H]_=^*G\/?XJ?0O#H]L2Y$=F3D?*3M
MKVTT$ N*!B]%/N/^V$:FN.QG)M=1$4QI' HT5^]-\N9UH?S)IBH"5U/1'>*%
MH9TJ?R*>QBM>BM>I^KY="46/***9CE04^]I$[=3,=1VZ.'YCC;5G(N,]LHOV
MLC[7_V1NY[SDQQX8,G2Y$T85;58R[1-R#)^<)WRQY?W,[5<X+SH#?+;4I+DC
M"C%I%&I=99(M>^*?P6X*R&N %+ _P#YC7.@H^T\/ C?962^W#]%QXM"<GB@V
M%Q9)I8EY&P?:J^U-"/W42,VZ!6>C(!N1UF/"A#:[4ZTIOV;KFA09+BI.1LG^
M1WYU%RKBJ&OZ%)]8NOP&$G69;8I/D7U ^X:RXH&GC508/$.*]7T 6%F7@*(O
M%.N:1AGI<5CI>: :WHX35ZFNO)#9Z>AIDL\KW3-BI:)J7;<P$-Y=?$('X),[
M\?F(@#]YQ8$X*,>PZ.=.G84*>19)Q_-71;!GIR<Z3W!PO5DM4RQUMZ_JSL($
MG899<_VDW:?Z6FMP.-.'1H!WQ/4A6II/,L6GYTA-_YA4<S-SU5)+BTJ0GS .
MX?F"0[@/',(?%QS"@D.X?T]@ R6*:B8#9Q*Z'%&Y9%@+X&:D+8%32^T3^9@!
M'Y0(#;#ET_I,>)JKU(S>VPA(U.J$LHSP%MG>7^5]U%/L(6PFT5) ZT!R\(-<
M+38!?E7:VX_@>NW"?A2  WD/J31V"(0IU$5XS2OIQKU@W6IK3<2G*3<U0E#Z
MR("20C.GZFDM/#S^<'4I@I$ZG6"M7H%4<,\@JC.W')#?X0W?FI[..$7H)YE/
ME5)(#:[L)].WG+_:TY,[1A8/Z!P_:B-U_WV'?V@ST1T*VJ_;;5!TD01L1;7Z
MYUCWNK==_%<:$;L%@^O >:-U\H:PNFQ$FY RJM#W3+&\T52*Z_P_O/CJA_^@
M<\*/^O/??TE/]W?\7[2P/>TMQDJ?%0^P'[#D2>^@1^"<C_6"K%5D8/:^W5_6
M_:  =#9>(V,%I'EMBL>;X1JC6KP;JZ&*@F_8NOP#18NA)+_:MN/ZB0AGVI;K
M63"-/,8-?1&R?&X>1Z'/GX,9U0:SN6%5 ?#%,V'G#,J79>$G<&E;=,%9"%<O
MZ:!AZE73!>.)X=K'Z<D_ M#TI0P:=73>>'A;ISGX$+D3QK5J2(@F.+PF;FKA
MM?6NU9NZ:=HK_6;ZHU5'H<$3TROVU]V&:AT54*MUM3?5R3[$L^RB@R:$M0ZY
MN9L[*WYDEZ6=;G^7<)-M%PNH<0F0PV2@(0#[U;Y>BR2J5,^8V=T/'6!A&DYE
M,_/D^1A6HG*J$:'!+K7A-\ A%M#U>TUY*!=/!>:#[U&4"=9!;QFR?=A5\,(%
M]D_2XJ/7@ E=?N;7&-GHZQUYX:H)[=BCK\]U,?1-MCQ%7S4]"UW$I#F\*2@!
MZ?490LH3V)ES[I45%V/546X<+)Z[CJVO0H EK1GK4DQX%[&?%SAK/*7A7T;I
MIS*GOY1K[T(0@)J\:([!5I=UN H2OLAP)YVFBQ;UP+8KCBZMI0/"L0DM;/5Z
M>U-HO3+!:/BE]5IWV^W#4',L2UO)5?K3 OE\RFOGL2R.%[N $1S^^XFC$3<3
M3SR]5<J%PQ"D<F'OFV,_&;O TLFW,?R"6SBYB&/<>W&[9L^4/6R3Q&<%JLI]
MCR?NI J(1<:'>#L)2P O+AMA >('&)S0X9=TL,MB$VP:!H&9JX%*T&KW*6=X
M5>U3*QZ(*8K&FSYD=P!\<*.=F7@FUX&^<2U5V4G8L*XW&X:I31O\!PC<@>?F
M],%NQJU.H4S""D71EID&\J \EA1$B_@+Q](^:9J\Y4)>L]U]F:2*W0L$SC<R
MQO">GX3X9_!CO5!?RHYV04\O8/%:0+_VJ6*,YO?VG5=:A9SKA%(:9\B1G;$,
M.HS1UMC)U/*:(9=DQ#"6E2W1,-8,W;2:9V("2F1^X<4B>1]WCA'E+2']1WAS
M%-+_P$$ :^!N94:OA4'[P84 /Z%3_DH[Y0\LL%Y>]2_.WCHV& CM/ +"H5?A
M "A,-9*K?AC7-L47?S@8=,',2WXY[< EJ\VABW@@J2:PRY5:Q2B3*NHYW+3-
M>K2:/<Q;#!36%%]NI;)_G1J&+DZXA?(%\6>7JR@S./^P3H.8>Q;PZ3H,=%<"
M_URRSD_AAOGXP&]RR$0[<=QKH$7>N;&)9 O\<<[PB0Q,A?'N+?#43$0G>*QX
MK)*('8JPL9X7$6-Z$&G/VBB[GKJ;XN4/W^,<[]J&XUX;1N= $A&BY5YM<]'*
MY'$ZX]G9MF'UE-4DF\%'W:&F.'X/J]$"K5]@.B*['L:GVX8+GPH>JE#J[E/E
M,6%D.+;BQL]EV$(]G0P 9N4U)(W4Y($[_I)V4F#)!,*V/%M2W3O86XV,CG7D
M8V435:R4I=(S&=I5*]/D7,7VUH7+"*L:$6&] J=9LZZZM=[C7$Z-=[5N:1UL
MN["=KCC3ME6ZJ\=;\P@'NRZN(PPW?@R!NZ?:.%C]Y>6K.#PDGW3]4\:,CQ3,
MPI[24Z-GQW&R#M1]\]4+F0AYB6R*@_$7;B9#D_/O9-) 8>B3$9/3DZ_I,;>[
M>E6\H-0%T?#77[^PMP].17UI@8YR]EC35Y52N]]N)W#_)NTJEPT\I%ATL<'W
M?,,_Q U"&9#;C+IWK9S#NSZB6848C[8@6=V]E>-XHR+SP?&"N=V3R5C5^ZD=
M5IH$?+9&@D=13P3?HRD5S^(<@MZ9$3V-&'^).Y>-LX"ZU!:A@)&;2^L'K0,E
M=^1Y&LG:M\%@PZ<G\;1^_=T+#7+N=KH402'EGE%8 356\T2)DP5)MUI#*TM>
MX]056*%<-2\-+%?"6773CF*<X2+3BV';0X^#9Z+FEGM3&H'JX:^LZD(9[8[L
MF3),.K+ Z2UDH!EZ,UF/ZK _=_!*N-9W'IP?$?KZ2/;1"N.C86.U0WO1MIXE
M1EPQNSBK%JS^\MVK,E_+V_ Q!T"<_'5V@6SQ,)U*BV[AVA5>!)Q[&#EK'>H3
MQLM\MN!E[@,O\_F"EUGP,N\ .;G)3+VGZ>J]H?3)F&1,\!9@*9LO)^ %<DVY
MG=$JJ;8H>Z-#A,MQ3A1[%6WC2@U;MLI53\X4%Z:OG7,R,:+G563(ZE)AV=QY
M0CS,=5Y)K])D,+>.S.&@:,UBQFZ]<)[\'0*3$9=L69@1@4 87?G@**YNAP"
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MJEBWUPUM<F:'8*%@QL[<%!?;]IP'"NVJX(163X#<'_^NV95P_07=DG/51N+
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MXM=,%48^RR;V=R8G^BS[FVVPR-QK@4;Z*"5)J70T8ORQIFCD\;(W5G7N=)8
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M)G+UHR](W2;/6.-0&?Q2G*(D]J2  :^OZYIE*8H*<?]B/AD#^#N=9=]RJ:,
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M<1B 1U1:.>('_H[E92/6NAA/++ZMA_!JIU;EVT;OT]<Q@0TUI>YMY=XJ*9]
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M14>QQ5/C4TNB11[!#6PW^5+ML.U'QE0KO\P_3<:_X-,Z_@Z=J'H(S;[X1_#
MMH(3QXM\*O=&/!5=UVWP /R1KV5![D-(I*=9&-*UUYSP'VT!\97((5JXBIT@
M35+0EJG4$4X=#.OH/"2#'1P0<\#P*[XE=UB0"R-NC>['L$$:6ONM:5<V6^"I
MACHXDJ<GVZ%%&@0>U;;AW8B.C:AEC%TIW<8<K-B>%=5,[RASH93#$\FOD+,^
MM!R8-/0!W$ X1^S=XC73:Z<'-J>+2ZKH:&71;QX2O%X:&)_F20L;V1?')@@M
MK@T/BO9XR_TBW;!!K+!Z3-F7>3N_TU2JCV$DVD(T&+*=7,_C_<UI0UXV86M;
M##3AU<?[7R,;W&)!7\*"5!3!)23>3T]X6\@U5@%;E(]/I,1$A"1CQ5G>.*24
M765"]8L2&BPV()J.JFIN\#C^MK(SSDY/*.0LJJ[QP[4@C+\9T:XO7.W6R'U:
M"!^&[^^S&O@Q"TLSA+1"1#?UGQ]FV<TUS+F&.=<P?^=@$_ZHR)IIVY7:"#$1
M>^8A\HN0,XPM&XI9YAAQ/H>^M]:#? -!J78&3LU69+8BQV%%4CT75$EA 62\
M51FBDJ+KFF7)7V(1NI'S,IN$V23,)N$X3,*J7*_+Y5#U.^]6!+8JWO8>,]GM
MNMYMNKU0R0=15NO<<T!F@S$;C-E@')G!,)*ZD(@),CJ</1Q[$=W *4V8DLI=
M%LN=EF-QD:M&<JIEO6Z+2'UC-BBS09D-RL=A4)!+)1^$_B_Q0)9TRV;C.)7)
M *+\H%E(N/5+&J&"BK26U (V"OB+H#^XI*%&B9,HEDW=-"OOS,@X_)VDDKJ;
M[<]L?V;[<RSV!]B#O1JIX1[4 /A"*J=8T^*4E\2=S<)L%F:S<!QF02%)6NOM
M%.!D(8Y"0+P%X"X:9$3 TBOACO^;$?@*ZF+?FRGH+P:IBCV;.=DZVY39IAR3
M36&$O =N66/?&[=3L[+95LW./1JBO'D/SWMXWL/C&JJT9(4&*,:/%JUF"FKG
MT%"%QB:.$7#X=]80X].7,\/$;!-FFW!L-B'JN,RXTA%3V7$[VW515K*\T:U'
M(46 0>\A1!^'?9A1TN\?)5UD'=V\7),UJ7M;218:;NG4N4)?K6^U#-T]$3Q:
MB4R*JFJ6QN_@L]B73;.Z*:LJ(C]"XKV^+&EMT4BZSD4MGS0%?"D "3LTAZ+Y
M@FY9MM)+T&>5*SHT%=0#>HW/LN_BW@T.='GUQXT*"@.7+EC?=RHML SCEBZ0
M!;+V.FIZ@KYXX\ CVX+^25N.]MJ$LD6!8:(IZ:KLDJ'R(_!_;MMFR16#N %J
MJ@WI]&2:[^(C6IT?W79\%:W4TQ-=&\#JCQO?T#'>=0.Z?'A][.DX&]D+-]BT
MW.5 7X/N\]TK;Z(![O2$ME;"3%/4$^T Z.OF_;%QKM>F)>RPPKC0IBZ>A]_#
M+(06<!.P9YO2#6A2^I@[H,_G#N@'Z8!^,7= 'UCV<P?T[WC4[YE02YH33>4J
M4JJ)(0)EO9:L_9B>WB@],C19=+<15-Q*ER5]IR#!$&=M[E_^"![X:ZT%GYY
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MP7CX8O9P#CZO.;::C_IC?V#.,ZU*"D*$1]"]I9.1ETR#-"RWL+!'R FED$3
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MDLH0.7XOBMA2611/IP<. V[>5+NP'5J:\B[T=7/=)NK1_L5E _JEI[HS.1M
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MO; P6J"JB]0.NDC4?/_)U<6U %^^,%Y$S+-FDH\8J#(7,S1N6?:%XK_1U<,
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MT4,)IC(U:$(=4-^$]SN(+!:.8_QH9UBR43FT^@[:A:BJ]6S,-F-]. '_VLY
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M,BQ,RHC@A3WTN#-!*'8>]2<05I<'(L\P;4JYEAY(T2!0/3MUL%,'.W6P9>I
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MS]IY^'@)9'TA-]R!L!NL2069Y*&YP 'AU1GNK3M6KN4&C($8GB3S:OA(#M.
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MP";&\RGR$%6YM>Q["XF[+!]?_NOV>W@T"UD\FO"SNK_7Q_Q W6CSK=<MW1R
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MB0#N:S8(S?]J7S1C]T5S+%."^AX0M?@[Z45[,>$W$CR01:&]N"/Y>]_5'6U
MA&9/)2(7$L@T4\ZE.#6=(<^@0(;0:+/4,ZQ9D*)^&KHU8LO]#PC\[7WX",O:
M"L]-/)6_5GA>N<R$;!X>>&D%K"E!]YI(-968C.B9%Z@="N5!&J8*O1H!K-[V
MBV>L0-9!IJD,C99VM[U,!OKQMJK3!(97HK(7S[E>2?["V0K\_P5(1DS.6NS2
MZ/3?D.5;YE;N>FHV$TZZ=S3 TI)&A)\D%6J1B$MRJ+9I@KI4 -VL0O4* &X9
M"OD0?)(FX -= FVQ.:#C-0?87BTG+:-JJ2JZ9P.B;Q5,A\-3+ 5KFV@,B?S;
M-1S:8X<% 3K995<U".]B:K$-(2^_XH E[[%H%.L9FE@G*WO)[Y-F\]JKHL.K
M0E-]F*24%2!^G]:@&2H4JD$BOD-O"Y1Z6;!<K]"2%TQ$R<AW/#!MC:9*R=>(
MZ8%K\@L:<CY,#QW7!*]""@\0RCJ;8:]3%4IE2BSOY;&DI4E2\"G!YD$RPJ[)
M"OZX&DR?(^PA=_'#<-O[\K,J03MLWT]NVK;;'S!#A]A@V8Q,!YK 9LD*3 N(
M+/?A:'!'Y NJ0[^K:W)+T[%$E69=O:I=.EP8#Q->G?0=^A:%E:# SR(W93.Q
M>V;E*+&+4U\'J@'%:HIK<8^;?@[9"@E-7/)FVW%EW3LGPG<ZK!XZ#ST3T!8H
MM?2"AG4TJ&BO_U9?D>&_I#>KE+?-*DMI5JF_GV85;,KCW/$^./J#E44TC5$V
M@S$^9!*JTXC,,7C3G4P[IN$R=5V-ZDG\//ZUZ2M+H@!!/Q,-?D#,N@[O:O<*
MNV\/ DHP[IO9S/T I;#_I7OO2TPR^WU_L>_>-\E_O.\?-V_W^0.(-C-1QD=K
MB*AV5%D-LTO\?:*&B08"8T0EQBBV#,;7#$XV.[BV=YC%PG6$N A>/QU?9 ?E
M14DUA/C5246 1-- /11\B%E,A+5T6J"+:@QJ@&E;K&@FJ3IYA\$K']MB\\QZ
M2NM6?YG_-]#;]&4%K4ZW?EW:H>FVG&;+=)T3$^$&( !D)#4QU80FIND?\C1V
M[GZ^W+4O+\Z-TOMI3RI&VY/VG\;?^Z92=UZ=WX^MG2_G&K$E%6)?LC.4MLU&
M&ZI31#\/Q)^+D":R9*@.@CR@^0Y=":]HUA*!]Z_@X3<"V+J7JG-J$+FE4G2*
MRZ>!45)@Y'8;[F"^D"\\/<%/A6*I\#0N]IO?3P:N_=SK[DB.YL!N+MF+IQAA
MZK]IR=@.NZ6TX4G%:A+6'>5UD-(1(AU.2Z2"1Z0")5+!4<Y__[BOM8;U%1!I
M7@B'-!(5<Z5J*95$@JL%(0(;H@F$[818 M;^%Y&6-&Y%'*\!%/:^$![<RV::
MR)F1+X3M!44:FM8SQASD@>9 N\!$?B[[($6/],L']+M/VBGE8WHPEJ,\JH?#
MP8U;\ [F,?BVI/-!?)O@PU<"F%G)-8KEM)-XN[+[#R2HEQK,-;(9O\,CQYA?
M9&I6%2Y'4*8(9X=9682GQE'LI[;MJLHA7C\Z#NV6V*&J31:(?[+IY TNB0H-
M*HE 0#P]>8\"G_:JT[0L&)<&EG/S5;.?GOBMN8>VH:$%;7AVLVNI^)$+O*C"
M0[QFUM&MK)/'X?KH@_R&<.*H$W/8Q*#;%8:<V'/&-U>E7F_X\_FL7/3%HHO"
M .HU<%>2AMO%L%F(6I,DYW342A:IA0;_B5".$N8IC2[LO4^).UYHW@%=]LZ7
M,I$']5RE5DB4S(QPK $"L@@F,#8A!H3>HDPW(+8W1N+BQ*A_UOA42LYK^ :A
M)OX.1&J XP)\MAB++(5?Q_OFZ;[VR[HZD!L>G^'2V=8'4-P(_Y[(44DT2$#3
MI*PSD2^F8*Y%1V5<<_8IE/=2E/H 2IF0%%Z>'*.LW*M6(N))M!R%$Z;7F/Q#
MH-BI<><[ON] /.6[AX.'W_;7,[D4)Y[((_&_>+%L1MX)_#,#@39/+IU>'L?(
MHVJYF*M7XB!W ]+(-G5%<@>$)!U7UR7U%;KE;2\!X/KK]V(])EGOKLP7+)FX
M8@@K@0U(?"K;]E 9LQFOA,,3:T.57/ )=N*A;R=RX$&@-!P'A&M.R68U60\B
M%)[ FZ?2L9L@^VQ%_KZOW0P>-,UC8KY5!KE -QE6"SE*XE3S=S::;1Y'ITP6
MJC92 -&1LVEF#YSL08">,S-A0Q"A4U/TW1AYA?[9:4FN6C_;M5D9D-!VDD2=
MFE[OB_G*N6(Z\VV=OG<9G1OHLL$+<!"1'7Y67P?DU2K+4T,<G,4Y+%FS>;Y>
MMTW_VY DHD4+77*U':)2#:QE9R42'1>04_"#""0#O[?= <N'9S/H%K!W&'![
M]J1'E=!P1%_#UX. /41N:YBY'V&B'7(:]$VX"0YZ([4M50$,'[GM9?EM!,A1
M%(T!G=BF:U$_0^>AY;ULYA&2'[JF N0.8O"X%EF 1K&[L6Q"3@H38?4]^3C6
M@6H#3)Q@)0!YM&LQPO%]PEHU6OB1HY7VJH%9-A<H2NP'ESV-E6Y 2SJO*A"?
M([R EUO0O!.<!EF_KLJ$X(6B1)PNIR>H!%[NT"$$PKB99DO' .93R.]^XP4H
MV0POS(D+I7WD2[^&S!#9).9)B1KT4IG7)M$1A%V3LD(BDO-T#W@:7]]T'XL_
MO_[IR.7WDQ$JL8S0EW!>J/ T[CVJQ]?U[E'[C$C&6[??A\@6]+'X!!&SPYPD
MWA%_-*RZY?/FO4T,JR->=Q3DP?*!P(/!#\(0NN+X^O#AEWM3> ^\%F*NZL'3
M^/:[8?V\NAW\Z)&[1[:7S1#..@H4JS7]8K6/QTP?T-IYFQ)&*::",9M96PEC
M6M$BE/Q$JQ8M (EQV0JF*6&D)3&V('5E2Z7F$2,-4)P7P"@JL=7Z%*:/(_!0
MM#@1)D=NMRV7F'TYUO\R<.GAB-_V*F-?8 HAOHX<DC/:;<F8QJ"@-_!D\A,8
MI#QJG_)0K^[5?RB83@ 1.6)6&DYN";P6D?9HI:$_KF"JNDYSI76='[::!LM=
M  X,..M&LY\/T,Z'GT)*JB2.<DO^UM/X_$@K'Q;4VL'5[_>HL?)/X]\7/]4#
MN7IR/JSN?(%-V?1:W4-ID",3UT@T?K:*:G,5%7?+64$BRB@X;4.!DCZ.P&E#
M:>!O5"TF5O41.8V=,JK#*O^[$*HV4)Y::M?5J2 &G@ H6J("U';/\#L1>Q".
MVY/\86R$?XCF$=XBRGB+<!@^RQ7Y2^A@]S1/SN\[0,P/\:TYOC(30 2]QG5\
MNBT L5$ 6A]&%-].1"\OTT0T7*(GMV!_[WZ/> 7(JQD^@A YTLBU((R(=@D:
M55X%;=NT"'.]:)9K2Y\.KAY.#W<+C<_01(1A;\Y^XM0UB.RJ%H9$&:"Q$]>8
MY#$8!F<4%<(L$J:+<$F"S2*R*S7#7-_89($U]F^+V5'$LJ.XUVP;INM@R3VN
M\T7&$<L2[BJ;Z;L.;]VQU#;<;"((D+0P,4RS+1?;D3Q00UNU7K2VRBPH*-O%
M%@"'F8*=#F14B1U'K%EFU"3A(9*?=7E$/L36[5]X9B&S BH.#P&M48'PG!!M
M\V)LY&'9#(]>40,*EJ%C&97?"]W3NCU]Y+^2!;T,PW2D%G8E*3AU<D\ZC>^(
M"F&X4A:BW=-XWA[),5!F2,AX$.:BMFTN]J&Q+55 'G][$+9L0?02(I.T8TPA
M9V:K^H@W-9%5;W7P!@H@['J-M>EI53S4_E' [E$HM$TAVGLJ<0[H]YF/T-%=
M\ 4<D D8 +<P@DX8ID-8 _4[EN435T!"C0\1Z)Y&WCWTX] 0!8;(<X[&GU5_
MQBI;3=R"%1-Z.%#\P.U17_%JDJ>! LW!X]EE L!X#;H16[:INQ!Z T?60ME(
M[8W 3F$Q=)@E]2A1.K)+*1@,C.>9;8$;%0F#J,-<.N!J^B!6R/\1X23ZD[YW
M2F/OO'<Q0 0'^S0(4?N0)O#%O&80?G)<T26'OZL*:^4D?R=; A'"SZ!%Y" :
M'9A*-8U=+?07OX6#K+D'-034]29;;<G&,TU%"&^%%W9=&9Q0U1,^TC%=@G2H
M8K<F>3^G^ %#M$:P6:^-Y?#4;YYQ!T#?U(IIF,0+WSFE^VLB$4.5IO;!^<'S
M<_>K^]6O-(7O2?!%B7V3T7^:.<&1]ZVB^+1824U"$A\>1@]0HII6#@NI8&&[
M[*3QC.BOH<?&LGO:0 )L[RZQ0O>DVPB&,,AY=OO\EIF>2H\]_L =@!Z/U!Q;
MV%M%;R$\%:F,RIRHX0^B#69I]JQLFSV7TNS9V#9[ON^(U@VSO6$PNF]Y']'H
M*V:N1J'(UK$@Z:?X]M/X4#>'^8>OAP?.>PAPW01"P\*NMJ&K#36;;Q*#^71Z
M-2@_EDY0)#H/!%O",'U@JWZJ86 1Q6^1-?!12: I!_+((@(ZA[<-%#[@5;!O
MY 2OUW&5D?\'XF+BN\&Y(WMP.^2+-)$!:X3B$]V;:(9Q*8R$:4;'DFUR3=O4
MUJ66;ULW7<6#Y!BXQ$*SF??M#TN*\Q8!ZY_8)($I23XT3D[X.E\(+3,)S\81
M;P&CJ==6AQ:E9A&W%69KJ5%JP\*@82F;T6P>^ #:'_#)XG(;,UQ">$X-1#2(
M$&'$]DQH8NO0N5+$IDD,'M!<$\*IO4!#.3&HH$M9AGXKJ&]!$KOD_ ,K'O94
MP^>0CWUQWBR+0LQ9HC'@/T>^'T7514+A27D_Y%],_/[3^.)>N1O*C]_DYW=1
M=Q+.K-2?QB?%<?]KWWBI&_+.%]@N%7'H)PD[W^96-ON>!7(KJ%H4P*_HFX8Z
MXF&)#@["\_,0+/Y(XWKHXEDNCW@ 2I2$,=1=R!]#K _"+ACR+/%".P@*@K-'
M)&Q+10\RFQ&B%GN4BT)QC/ANU?!O"U.5<8=OK,"P3>= MC#(_ #1F%!HP!PU
M+\B!G;5JLA<:H*N-"[],$QQ(?O4JH@2%7+%62(\3Q/93STXPUDY]]?WQX.*W
MZUX=:6]#L-GZK*/EW:54<N6@7,3OE*:V"HUHL"8L63?9O$BZ6W_(&U%"N,7D
MZ!TSLM* 5;(9%GLAETY5G;]SL-=;F07$NG<L3+6DJ?V0M5"=:"U,]]BG\?#/
MZX_+7^9=^[&Q$B-B+2<:8UT0L7'[IVK53MS7DY*.3A2C!U%5A!3KMBFV6>S5
M&ALH]S!R#'%@NVV9PUB7DGNY+O8(L+J_-H-);6'NF/$)/G)/N@G^0K0BLID(
MZ 4.Y)Q@..2# 2;AFF)K-0"+"-;"7=,R1E?M@]J%#[@26M,DC1=\R1), D 2
M"<%6E%-57#S 2G$Z0C K0#MWQ[W?K4I!+Z^0$+-#JH2-HXEMA%%EK]F^KH_J
M]A!+)FATB,@(6&DAC8X(9:P8(OR\1+L8&=I2=9EAU;%KQ9.& UGCR&5L?J,P
MTKH)A;32M6NU<421UU1'6XHPM $7;A3!:2,+E='8#XP[%485%:1/MZHJ01N#
M5/[,Z<<E <)L8'3#<##52E81M\$<C]T0*43H05P5EL*DU:2L+-FK3F72H2\K
MF&:.7V3?M6F>5G8TNZ-!M(70 W*N\"*#<)K?*+3M[9G'E&)=R"JP'HO"V\2V
MN0*7\H >.C+>A&!+76P#G_EA3^/[FX/!X;E^7]NO+VHTK;Y\]?3KZ>O/DU^/
M9T9YYPO;;C9S)#:[X98EMF=Z=5<9=-F:/+/MT3NT0(<BC:,P4><U+L0W3Q*9
MY1"[7YEDFAP$6M/%F\$O!F4.QBIQ]DJOH7V]U+XW*KVBT/^-C^)1Z,3E3^[^
MGKBDE5@WQ5RC7IEHW_CN>CJ1B[[TN1]T+++<:Z9ECDWKP,O"'*M$'+6)PNEK
M;9X"NJ7#KLC.;UD5(OSHMHABUFAK3"C6I/]N6)W6MV-3]HTF]E)?MX&=+&1_
M.BIF;MBK@RD@WD#C%T'2?(^P@E0$B>5O>#41KFHI'0V/7#*7;B6;61$=<Y/X
MJ.;S$118Z3#3@;@UUQ:43CJC&S3<E'-,+Q$WAU\7('.(2Y3OA:^G=N];[<('
M3!(?"45L^$QF#2HL:<7S??0NPWY3#W_65:ZFQ*DZZ6"UN)U#C"Y]ZQ//*T:X
M>H5IH0-Q+HOWK[<WHRN]%1&BLF&XM/B.U;2ET3TD.;WWK02Z,)^*6XC)YK0]
ML,!G.A&; A%Y6>$-47?:"]3@A,C8O6SGSSK:<;G3"? UK0?UOC6)>-'WK(1\
MC>(D\OE+Y@A(7OTD9H/E5U!"D %_65?7VX9%<=^E%[6P?5>8UKXK+6#?\3",
MTKFZ*Y[;QS>=C;'O%@_:-!J3XU?3VG>E==AW[#2JW^7*@=R[J15K?Y-]MV!"
MKE:K;[QU5UC<NF,\<M:H'AR/RQ??1M6-M^X6/-A2K?%6UMW1%-8=.Q#U_M5Z
MK9X.3Q_J:[3N%DUB5R9Z1(M;=\=367>\+*!S;WQK7G\KE?0U6'<+DJ]03U<P
M[\*Z*Y8QS/B^P\?GIFQ<NQ9@!SIW)M%4[9[:?B82RZ%)C&LZCG'J"/)\SWL:
M/]X]'M?DUO7P^?F=EN\=Y?_TBS?WQ;NRLO,%R)#-<$) DH230O)I(3%B;"OZ
M-L+Q .3Z"WDD42\B'P2MI^)(C<G;UA, 3($%;)30^7RYE$>(TGR^0DR9\<O!
MP_#L1_//W:V>@ JJPY=G@?_$M\7"?.9W\^7=4I[^5"&286ZAG:_G*BE"&]JF
MNUU+Q<FJL $?&O83D)+U%UY?7TNP6J_'$#=\=GUA6EWRG0/,D.[+QG/@6^?0
M+FWQ[Q!#5+A:\+&4ZR4DD0^$!OZFIN2D&^AZ[5!M?$2(9X+U>DL;6T?2IX/F
MS='M9X#8H>A#?.U8V*!")RM,J,UF6B-)IEMF$\P\& !F,!/*\)1OBV9V6ZHS
MA+E7X8PO_)MN-C #C#Z8C0(@_]<ES&BP]C[X"KP\1TL-R3DT!Y:F,U\XCHD-
MT]%XQRU\X+8/_8?['(2@J0!,D<TP;*1/M_O-S[0?V75ZIH7%^ AD';,00J)L
M!FGTR>:)Z<;G/4![]#X:!!6Q""'))679;_(NVB3/6N,195Q[96-6HH"2_F,_
M<!)YEF;'ZK;9<2G-CH7\MMMQ:?82WTO4PEE]I>DYD0VJ>@[X:A,J(<095RG?
M>AI_=:V*9;Q\:QF5#U4G6B.&N#LZJA4Z([M,7D:WO_[JT&T4?:F%H1QY4(6A
MGRI&<<!4\9'Q.7*'#68, A$B% ?,'L>I$U<>+#3^U0X6Y!.#PPQ^0+*T;L_9
M-3N[+F":<FB)FRM_PBJ-@>>\F#B"/5(4H_##!.Q)?^P 5*_.]-5L!C[B6E)J
M92!RO$06RG,,ELJA&F,A>F"?8,1@:Z%!34T= 95HM1VONJ7+@6.@1EID><*+
MR'/,%N$6:GUQ_,\@0"0Y 0T#<YY%A'^/V4#\V\@!0IBO;78--.<HF"4KIHR
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M.# XROL4>IL4T5\S.KK<[]/,M:(1(Q<3-8!FQ=(>':U%W%2-F&/7H72',.%
M)!L\EI,#<D1MGV[056%(9$LZA\1*&+5UTSR\(<Q7*_^'$$67'8PJD->R_1(?
MA/Q7\)>);M+ I+4)2\G4H.44P.,Q#:P;%(X@<>AM:!)P6SSU'(UQ\)T2&T?%
MUZ:EWV\=L_U\:MNNJM"JRFNT=6_)^:HV<2L<2VL3TPP_UH2 PK%I=52PUEB2
MML*3M/G*9!N4[5!DPUE3M0$^CV1KR[*S?U4^O'MXUCU#EI^V#7L PEG>MB0;
M]SG)Q)V?2$FYW K/Y9*??*,XF3R\/B]E\[/XX)[A?,OV7TPOG(Q03&!72M<<
MA.M^LRQO7U7Q-I%[#/X8AI\T&DV+Y5NA,8J5J)D.V1?4I)"G,3X6<P;!(]7P
M2%T=<AG4F ^] "\ZO=>!/&ILYN+4X /W4#2I-&!(+U:"B$6@+(?FJVFTC6S?
M!;^/O)/U'S(OHK0GG:NVKJG2XY[TS5(U(H?/K#T0MPIQ2]M$TH6D#O06P&,P
MWEC/L=(B&*BMVV;H:XPN1$QTH/0'\S7DUQ<6>Y?4,W4:6'5D2M^6:JC$H88?
M(>IJV3UM "I%A2/'^!LQRWMTHE:," 7O.\%=@NHE[GC9@D<LN%Z^7]R,)J3_
M[N*U9:X0&V8F7V%R1A!%-\R^!G?L1=8)"P][*I218LP$ S2H32WT*W*TV ,.
ME$;@'3 :3!NU4US[(9?AE_05#_"&JXX@0'%A1/C39:$\?=).N:;9 /WR*)]>
MGEV-SLTK/U!R&2"81RL@1&J0=A8J!/5(D_SU;;1').B2J#,P+D<,',9LBDDC
MLR@'8)XJL>!T8M.I(& U YW]CJQ9E(HYJ>4Z7HVSK,"U56FNQ&Q!AA<_3^Q1
MXA:W>W"0@.@/R/BC7#21C$LA_T1N)4*)/@\#=SC;"O6%;%E8\$/3T6N, JU>
M%K$3NG3[Y&MMSI+LGRE1.\?TXW8[DFJW"5O]WXYCN>I.R$ B*LU6U2M:$&5T
MS]%.OR-/Q308!AJX(*@'.B[2O_@T5JJW=MWH''TK]G8VB,[$];XTP>FNA$.V
M]>+!TSC?K1T2,[0QO"WO?*%[\LYD6Y[]EB5BJ I-SFX BVRK5&4)9@D1(%V6
MQL6,A-*'N7U0 PUF:+@A).P<3E4Q"#9C-B.GETF+$W"Q"HPEEYN&T@RL*:U:
M>EPJ&#?&?>5K[=%/-)Y,WMXDGVB:!:6E!(+"9=ZYPN7%Y@I/3=5P,?*X6G*>
M]QLGE[VSC2!JI#QX;I+FTSU!7APP3XGNVR505B\-EZ=3T3:\92WF5YU]68>
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M?09K;?6,L0G%E$NK0)I0@W3\-#ZTY.^7%V;]>WLU$RG?4Q=>*+6/TV1OW<%
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MCM5657]IVACSB 5=GI0VB<,(S ?@+CTV30<(''?.7IRJ<O)G^"SB2XK%I%.
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M*>(*>2'##^O9AW)]8!+5L&58;M.?1[,_\C]R+8_@5QC8OS0-%E,7E$UH/E/
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MTX+P$TW"#8AI3* I/YJ6C'&=N"'-*E/)JZPY"OGZ[W_M[7''N/-_N"LP@K[
M8D\.T65<I%#F]O8\F@(\S5_EP_;I/U&BU6\+%:;-5VX6560W.84%6#DJBWYJ
M$=I(==OQ7AAC'JZ^<#?]'D!0 Y6ERE^X"[AV,GQ>&(A"40B_]=E[#7\54)='
M6?]^!E1'81U$Y>->DX#&A,5[]+!</,/&/"3[1!DBM8 2>L.KAX%":!E (?)(
M7>COWZ:_E^;7T2OB:' [_@KLNF1U\/]'3X[Z+&G8OJVF*S\D\Y'0PVL0&>\*
M8*U,*+,>JIU98K7[@2U\$XU;J?C0>%@U1!_SP5P8-NCZ\CXW4N<JENX'M<9+
M\;?3N-/RZH>OP0ZY8(O^88Z?:T)>C/&DI!>6E+1]G0$6H,!JN.W'#%H[;/>*
MSXWNB5A?7]W^6LZE9N_NC,5,>838(TS+QP<>D 67';P<MH;+\3=7<+]!ZDV5
M.HAYI: V/W<_T,BWZ_S=Y?'Y7=#1:Z@=0%"QCY0Q7:H-_Y&5ZB]?CC[4D[;V
M+*D:8O'8,!N@0@])TPZP7^L:L*4!^OLM^T "+L; T>"@<GI:?.P_*V8"5?W^
M-[E_FR;W^2N'W]Z&,O^*,#]>9=GI.AI>I.@$F5L=;%,--WTBJ?H!-5%OI%>*
M[*?6^9_OW_+5WW<)M D(/NQA&P&PM@+=U1C0?0[_"J'[XA3;@ ]>C>\-[;5<
MNKH1UH%R!()L!\[K4W >X'L8^Y2*[4&]7FC)-T:GDX#(:+=-TD9WEXO1\23W
M^'I@^,@0\D'2S;V/E6-5EW19Q;"F!98F#8&^@MR\E\$8,;I[>R?H<='IS]MP
MB>T'B/I!S2G 5<4J_&K=_AF(Y60*/ETE5A@-'K'K?  @][]2%V[\#,XAI1Q_
M8X6Q1';OZ=''YTIJ7U2M3<M5<T_N?M;!+1N3+O*%7(4O56;WJ]U0SXNU'LU\
MFG&3YY7GBX+X5LYJQI2)6/3J)@]+J!3X2FEV&]*I2$VDYU"R7#5)&6]6T(EB
MF<_/T95AM:8MPN%2BKENF#T#@V8'AJ[XROA://A^/+B^[1M"0E5ZN*O)HWH\
MH#@*U5SF3*H'&ZQ?;T>=Z[(D7.:+HL@+<\QC>W<3*U*B]>,\;9$OEF97$;Z[
MDTZ+S1#K40LYOIB?W;)IVR91K8^C5[$XXA71>:' "Z6$9BM%6QP'2UD<4=$C
M1)YG>Q0/>T^/O_Z^6*20?.<GMM5()SRWQR%8&RM13\(JF([[I:\;(E_-Y_C*
M').]4M<(8&TJ.AG4E_A<>7;__0U@/2WJ,AFTYZM%/C_'",<I&G+CE+Z*ZDI,
MCA0+ E^HKBI'8ITUF^(>/QDTVP)-M %57LZ <FQ'THZ!9*UC]94HI[IL=(EG
M/FGB[YLSYX]S?2>MS7RB '$4(HXFW M?. H:QV!+C<R+Q8::@OYE)5^!S^5$
MOKQ4]]SD#:APN@RVN]Y37_<ZJJ(0> 8(651?FZ:6J^;+'[[N36A(_9XMD 3H
M)5_(\]6EJ.6-V!])X)0O%2M\9:F&B+-%?75545_3;&+JDJT^DU,=*PWI&&A/
MZM<;ZL'5J71^==O:A,,^4@.$(.9"(+\W%U',.F<:'2SO\LV)>5XHQN@)?"MN
M7[;4//^=5TT6A,EJ\MVA-X5*.A$&$ZOQLE?F:%_.6DCB< 6^7"U,:+"1F.]]
MN32\*+]-"#N>-?'WAWA=)^UOZODRTUB6N$-.-BPB/?.>A1$V.S;$$&-V\;98
M%/-0P@I>:;'(5XIO)6$@ID.>UT H;KN!$ ^^4F,;),DJQ7*>S\7)*)NR##8A
M".,.8<1WJGRA*,[E2UC9)(CMLC]AJ'QB<VUI&[0YQ=PZ!]PO4- 462@6:EM[
M(UVK3\7?S[FKH.GDC\AJ4<FO_Y)AK42GSL=I32R?H,Q7BR6^-$?L>JG9\>F@
MI*,D2N-"Y/7P='?[H%1.>H/\#/)R@O*K-I:Z;9+ 5D^I2#998HL)[B"IXL 0
MT?TLGM5[9MT@ACP_T6FTV&]%JMNT/;@LV55+%3 '%D^IG4AX,TV\==)<8<GB
MR!!)/=V4CHX&#;O;%F:I2;_F,9AQL599MHS%N;22+//5:H$7YTB'64IF18YZ
M25.?A@U/[-A83Q$AZRGR[GN*Q+[22 ^2$8QF_4;B;AI06[G?B-ZYNJV+ [U;
MS/J-!'C-)])OY-MMJ?=<.#3)[5J:7VQ/OY$XVKM$]QLQK%^EEJE:ZO<$FF-L
M=;^1::)C:K^1;\J)>-;\TR('A3?3;Z003&V(M=^(,2C+6J=>.]([6;^1#?8;
M$=;5OZ*2J_"Y8NFM]+"8-YI8G)*5NR5;W9CC9TVT*9;Y7"[KUC'5E[(V,5&N
M"" F5CR-V6JMM)1:B^[68>:L_N!8?+I]KF3=.K8C&T=(KA2\RA<+.;Y4>BO)
M-W$>[)PZLY2EZ*9/^\;)(Z4B7XFS5T*6CKN [HY7V!7*!;Z\1(ADA=S;W%*Z
M>U;?BZ>J8)";VV+_+\GZ7L2L7Q.J5\_S^4*%+XNI+-N,OW*E-"4Q]3T5>*Z%
MN*HB7RG/[KCY9BH\U\6Q(!SY2G$9Q&8=)C)HT@O-E#*AQ4V5J1TF:K^N2*%R
M]5<UUU0=].8[3(S*OJS#Q 0#I)H9(&NBEWR)+\U1L/IFS8]$&DQ42R4^5TRF
MP<3!JI)^>H.)IG$L5D\4J7*H9@TFTN6+B5GE9 TF4NF3+N<SGW2:-6\2;#-G
MEZ?,39VP"9!,UXAJN0HWH+5VC5@NF6K.KA'%E_.;WIU<54_7Y,#.ND:DP8^>
M=8U(1=>(\I0\K_>$K]28!DFR2B7'%[.F$>F(2L38-*):*/+YK&G$%C:-R,70
M-(+998-KK?.W\/VJ>_I+>V--(X05ZV&K?+Y<X(N5V<&[+:[A3Z2^*41>%]K/
MUY_:M72L%];<-&).0Z:R@*-CB\YU@?GCB_=F<,_VSZ#LM/_\+M[^*;Z7W@RK
MRI1RGB_,,9MQ.WLS'*[0F\$EJ5;^H.Q<'EJ%"^E-]69871>).8$7YD@DB:\W
M@_NE"Z<+UI'\]=^>?]256OU^T"B(<M%^NKXIBDN48Z^YB\/05H8.Z-@TNK1Y
M1DZ _]E&N)$&L62IAYX@$VEKF!Q"GKFZ)EF6VE*)<M"OP])X-&"C_Y!L)(G^
M(1#I#:+U!KYYH!GRXX<A9%;#.GB59>\'A_E&X7>>/-YVJZN>2;HZ,MQTR.Z.
M'" !8+4]2> VIU #S'&RCSI.LKB@>F="[2,GZ0HW4E?"22;!EUG/"ROK>+$Z
M7\=Y,V,+^SQT4+L?O+YVI1]RHU/J (,UY Y1' VH!L@CQ#W<CX!P0KR&1!3I
MQMV*)A4CB)W9LV*-U>75XZ!S].#X^\^[/Q?5\L]J @7C"S@3%ZH-G^J\6"M2
MX\98#<G>K:X?;0HDQH](GR9R\QN* ;=>H,(&;@ 8;EZ(]DQ^P)<[%G8%H$T!
MT)#L2K7C1N,0Z*QR/^C]['4JMY?//_./B5;<5Z(K[@\= CQK=U2= Z;D^D0R
M1U&::,UL*?Z:V?D/(XG^9$6^4"KQQ6K2D^USY7OBA2+GQ8>+BS]PR)<ZN>D
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MK+7^Y8M.%# T&O#9"\/^0^PK!_".E[2:'=@C0P6#<*/RL-V_>LA?E+I644]
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MU2W0-/B=4W?-:UCGT,%;RQ4PLJ'<]U3E7NG=.U>@0:(9IW'<OI3J/ZR#OZ6
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MOB).W0& T994W:)XIAT+7"7M-=-V; =$(/"U:B@\3B8'8)FL!C!PBC0;X\Y
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M^H!T&O'GG!ZZ?]P:/3QH=NV%9YN&PZB;FJ]JQP"3& ^65:Y2E@\(FI;S4X0
M;8W1B][WX*,"PW)DF;CU)WXL#9F!^M@4KFT H*X-C[3F%\=Y'X<]*5XQX:77
MTR!T-JR@UZVW]?RH.'7=/^_0-218S ^U*P13\1CV@"K4P*/7 ]-25ED(-A0L
MP0\B86-I'7QJ+NZD]"NQ>%\09QD5E.@1"SR/KH/")U+*9?3KC*+Q--Q..CZ?
MO0D-N<$4M7*B*6H'0,$T;^,TR!'(DM.R-,YT'\ HCU02Y9'Z4,K.M1_?.09U
MB4KES#%52U%EIKBHRKER;=)3G662H:K(N&K37 77SQIFP<AHNR>[)V_"^X:]
M6_G,D16[(TO,'%FI%B?#K.>IB&HR*N*J=GVSNW-Z>IJ\=%^32(F[DDG,):F<
MA1PJ9Q-TK('YGF,9:\PU4#?,'KT9<2=XC45'4E:LM&E]3//>(U.3J1M#M3@\
M8O0;8!<=]P 5#F^R<'-M]EG9+96];CIQ>#%JAM'K/O-HH8.!W?F92]-X[0<Y
M-9B)X_?D,.A%EL;\NX10/R,Z4'#.?,?0%*0IECO= 6'+.A&*>>XC N#&XND/
MW+2!'\$2C= 201DU:P3TPO*LT/,(BV.:=5 :T3BJ>YGG@ICC%*GO^Q)IXXX)
M@<+L!C'_#4(4$A52PGY(,H4GSF="*!-"D4((5YI#C(R)#RX&Z;&[DXF/!<6'
MF*CX$/>]DJT^=^DWL\1@J>LX/Z#A'%8&1W]/K9YP3B?\\]JEKA#]P",8!,M\
M$YD8RL30%I+EJ!C*)RJ&\ON^P+D.%8990]+EQI3 MI&]GC:TM02[GG&G?C)L
M=OO*)$XF<;:1+$<E3B%1B5/8YZ[\Y**@'PUW3-R<CP:6]LA9/XU,G+QS<;*1
M!(A9T:="%GV*/?J4SZ)/J9:WD=$G,:%N;F[TZ2X+/DT*/B7:X$LHHE^WHS95
M>Z0GGM]HFFO(':)@L5!FHB3#U!^E3VR@1,MOWJH8LL,2%C$3&M4XG7] $TZI
MRJ:U\)A$_D^:=Q:-^T#UA57=J"I<>!=#FG"BQOPP.M!^_@]$:-"( ;0+ YRT
MI1,U;74)(,68H?PH?(H)Q(0%2*A/#(+H"T8K#'[$*->X>HF7-]=,_ UQ:M0,
MZ?^NUX^.CH]78.)8B\PDKF/B/(#_?GZXS^6$#U^O_4K\TU 5_G50A7_%JO!#
MC6V/5;/[[V?I*_?QJEZ[/.!.#[D+8WSZ8^6>*$3=VZOAB!K#Q+=.E>AAC[]S
M3YV+O\3Z]1,]):N,;80O_C/TP0]?Q7)APJ#"N(1#6,@F;1 >[XG1,B%!&GZ9
M, <]!10L?OA:Q\XE&NVIKW 'DD;K0!H=@E.+O<[XD^<$(R$GH".2./C\V@\^
MU<(K/W+T@=)$:>9.X\1<<V^ T1\ZZ>=H0L. +22(0B8) G(H3B6'T:PRH?R%
M.WIR,%?@XR'-"K _O5U"*662(TPJI:FD4I>L#G>,_4_?+#V4,\$14$.9%KT0
MFJ\Z1!81CBIKBPZYDMT=M^CNF'EYEO?RB%ONY0G<WTFS[)9ZPA,'NZ8-S3CP
MH^2<Y9T,=9(;M&&F,C32-QR!!Y9&+SK:#2KK?^@'^-F/K([QHG-$I<7D;OMX
M.:QS0FU/0QT%#/]AG6DJS BPC;>2@Y.)\4R,@QC/;XD8=X.9F;!.4>8-S:P*
M8IO$/:)0:!-%)DU3HL(TE%TUE%;%4JUB#WAF@G4EP<K2FB)DZTAB5',\,6H)
MP;:6"XTK1-B.+D*J/$;IO.;DE"C(XSR@A$_DD%BRJ=+&6FMWCYCMYD<Q5^#%
M?(47B\5/*YD1">,IOR]LA0?DHY2L/>%YD3JVW;/^^?SYY>5EWR+R?MMX_EPS
MY0YV,_Q,E+9D?@;;7OHLE$OY:C'W.9?+":*0K^9R(ORUFL^+GXDDB+E23FA9
M GG-[PGJO2;1]H[[';OK"^@]6'T/0,$Q\_]X*BY.C&'=BMJBPZ?<)J- OK3[
MW<<;\BI9 3ZE-?+&KQ5=AVM@"#%CB(09(GT<<4@TZ07,R\TPQ78IC'S&'TGS
M1SH8Y-2_6(6MJ$Q;#'%#83NXH;D%W" 4!9<;\H(@,E9X3@4GU' P+'4A8U@Q
M;5RR7>JCF#%,@@RS(7ZIL<G);EF\VU0Z=8RR!>I$V/_XK"9!>IF%%;:P-L0F
M!_T]N&=8F9:8@:="YI5*E 4*&[QD'!LFG9+P2S)-;&R <R>KF3-J A]LB3-*
MW@(^$,1**4_Y "BNQ)A@0WK XX&A>P4^#*O4L)-ZB]!I>331V>.43&O,Y)8M
M<4TE8N ES"W"GK!97KG%X30O=&JRG_0?TB%B+M,A$[AB2UQ4RC9PA5 NE"E7
M"*4<U2&BQQ6]CF1VI?7R1J-'9'A"=Q5%^,)-<*"8CFDBG 60$7?N6;=KX*?A
MZ4R=S&2<+7%5/::><82<4"B62Y];0NX1134R3GXSZB24&,+J@WJJ38M"-L42
MJ5<@0FY?^+^MX(2UL &80KD]@1)MG)*<X% \+M*/"@98Q:MO/-41;=A3_0K8
MAV-YYI>R;6 5FYAC56R9:)]-TN+_MQ4DO:T>)N 1<3,"_JC;TXP^O537<*8D
M_1OCDS-'ZW-BGF<<1?.'KR1=E[@&M=TR\3^!5_);PBNM+> 5H9 O"NQ>72Z)
ME%'RF[Q"#+F@IO#.#ZG/"16J7W(I89TMTSB%+>&B;?3E A<54J=NQEGF4();
M.?S<;)O2,\GTS01.*6X)IVRO;;:AR[?GR\7N9%V=N:KP(NYS3J9'9G-'*6..
M9)EC0YHD\NY_JL,^<-"C%_*X5ML=V]HPQVR#$BG_=\8GR?))>3-\<D/DC@YT
MV.YSYRH<B$7&+_J2[D@F6%]%>M>'_U+SJW;,U3NDBP0.ZY^?US-U,YN/*AD?
M)<Q'PH8BZS7+@DU&7ETD&B[TV*@8]I@=J ;KO/K(7=&[OTP<VV6I4UW>SQ32
M!$:J9HR4-"-MR.5<4Q0PW9PNNM#FT$['I&E2OJ*^ :&TN':*KRU)XFTK9@W,
M*68#<V(?F%/(!N9DO5?29)*.]&.).SLAEYR_,,D665OJ:!=*6^!I_ZY:'</D
M3KB#CF2K66AW(N]L2:%->PMX)0\_*F".VU.NBCENR"L;,DBO3O%W=$XH=V4:
M#T2>D TAY(9#NG:'H#\^>#]SD<S!1.*67.TZJ><B ?^:KZ+&R8O%0G%$X] ,
MB37G6+N9>8O=\8+.\D,,]C;O>&_=/%Y]_D'B4D@4DDG2C<I_%87X\U_/58O.
MK6HX34M55 E+X3:B>E:=;9#@54?,K_&,\_&?,<YC0 D)QWRD6CHQ:]T>2,CS
M\RN>4T/SRLQ@7EF/S2N3@GEE+3JO; .$D:XA*/DU\GL^ 7X/2I7<0HQ@Z/W1
M*Y$=FN)^V8(G@$*N'--R)):B>$W[MPMY:4\H?)0^T6BY4%3<?SE8),AFE\,B
MIFIC1>W1J]R1]#8H:9D2GU#-%W@,<=04HV?3J7C!^O >!2F?$[U9YPW);$HZ
ML?8N7S72]U8!@U_<3+ C3>-7@ [%-=*AN$8Z#";&9'2X#1)1!(FX-E(4$Q:)
MUBR9B/0V+ZT*%>YVO[%?W_>I2L@7<S-)KYHKI97TTB0"8QW(L-[.\N]34@@Y
M8?_THI&LK(@-VE-=4W7"X/M]<'W.G>J63<>B'KHSW]_U_+>,^[:0^QKU;]O*
M?3?2JZ$;W3ZH9)OHM'LT#OP*E4!E7)CN(\VXT.7">NW\#7%A7=)D1V/WN'-5
M?VQ*%LEX,N/)[>+)PZ/C-\23.(Q;5S.6S%ARBUGRO';PAECR7&H2+>/&C!NW
ME!NOKH_>$#=>F01#HIG5FC'E]C)E84L8LFX @AEXM/S@%%/*))F&50XE6^*.
M58UP']D$<+<*CC$QXU\,N<BPJ 0_47"&MSOV$Y87/NU'DT&6Q;7%D[MCS_A/
MN+0N1M45C%1F4 [-56Z91I>&!:]II@Z;Z,(UO!'W'/R#=OIH[ GNO.9:SU0U
M#DO=,!=R J]L_NQC/>R$)PBM];#KCFGBR5X3># XX,K>=_> SQR0DD+Y/9UO
MPN4[*63FSS7WM&F]3?4]'7;"S<E3?]CB>SIL\H8.>Z;DKCEM@(P3A?=TP@EW
M"DTS.U--77E/AYUP[>!:#_NG(YEP:]7ZHPPMY/9^PI(LZ;0'7S 4CNAX:X/O
M]>SA8J3W<>X)5[NED,D]%G?[]C N%][':2<\5&FMI^T[EO8%+P,WL\ZGG/W#
M6SS[W+Y0ID/B=.!F+4+>?_?/VY0[G%O)_4ZX/>&9-QLY\<)^/COO:#0FT> E
MD=-6Z/0MBX$H<?"2U&:2&B,'IJ%Q!M9N]'$45X_HEF0;H*A[&BY.GY"PM (>
MP<%V[,UW<<!)-%!((H0$")14G0$(Y]7"(6LVUMT@LWIU.W9'M7RN?@%6YXRN
M2B-*P/Q=(K&GNI+Y2,>S.<#-_NNT30! *V$%K&H]<A]1^P/+/W[BFD26'(M0
M>X!]N*5Z8B4:&+"*@)0(IQLV? ]7A-]B'.NCZO[&-2_L?@_7E>PA8P/K@4PB
MV1:&PGJF^HR3Y=PPF/^U+/*51;YFH7U+(L08 ';YJ0-LB[R8.'6O.TLA(_DU
MD?RVT+QCZJK5\>B>ZA^JP$QJ@+Y1\D\4;%7Y?Q^D^YQ8AA^XWXUM._\VOY["
MW7]W1RCM>S<#.AM ^/*=:SA=@+(/,JOY=:T[WK*#<G^HTGXCR/PQ\_Z%8>_N
M2+V>!I(*^&3_36QJJ?:^I:R];^SM?8M9>]]4"YD$!MLVOS9.3RYJ-[?71XWD
MA7O\&WA#LMWKE+&[8QOTLFP" ZHF==70>WW08P,=.4+QH_+);Z,QJQD,6\^_
M?'?@VJU@FTYZ[U?"=ADVZF@2#B<XH.D&WU/A\TW2D;06NAEP)=J%ACU!ES:)
MH\-K=$7)L3N&"?M2WK!VRFXY:\W/AXWCC__?!W%AG,;:2Y#U"G4SO>F,$CJ9
MA$^K(]4GJ"(U"M)92^&"F$\]A(5RPB"FB73>&6O7&$2'1)->T'M==X-KH&_?
M^PEE8+U?SCW$\/(_#!06'199=#B?ND,YZ/\S%:81;T!SW!NP":C_5;]^MCY[
MM6/AN>?JU_= 8%O#X:D BU((@X21"<_5.RIIC;=QS&@G RM36IG22EQI'4K/
MJL)=[R.FVZ;T3#+-E8$5Q9- )@R2$*UXZFNLR_#V9_YLI:]SI@MZ3E]SX$Q&
M1W.3$-WU)\/?->/%<R.W# W^A:EJ/6):-,=-]SS-[&.[.R&G->:'J3I]4Y;0
MZTIAP)\:[*<X(<?"B0\T5W)-_N?,USQ)>B2HS<85 ULT\"968O75_=O\BN'2
MH0C9:C[%R*"O"[SXGPUTF%GK:85W"T>UAC#GC6IKV?DE<7YB;AWGAT;]Z/&M
M8EJN%%6)%CXI->,FG-[F"33&#22>6) =P.8/(&9V3]X:V82C.*/2]6X &RW2
M@A6> 3[!'TNO*8=PE9)MP]SB[29Z7IX-GZQ@H2Y!!G647_ -&Q5CX8.,$#>W
M 1#H'_TY6PSV,:GQ*9/N;]L&29-TV'J.RC;POC:PA?R^O7>.F7&^C%37NP%Z
MT6 P3PV?)6R?;]O1;/T=(\TQ\>@H[W:4*Z<T</X1A/#(-2%@]^%9O;5@F+TO
M!]2O6]+/*+'Q#%MH):3)!MAZ/9EMX'UM8 OY?0NR_ Q=TA3N;)_[3OH64RP9
M16[2^)=4$Q[T<K(.#,E4MGY7F:#8(L. B00&8D@N9,2WL8!"=NE_LY?^E,N"
MK>>=; /O:P-;J/O3?TD ^:=*\%]9)K+<474UNR5L=@->OM'6;R03#EMD#% Q
MX$F$D"S(J"^[&:0._=G-(+L99!O(1$#B(B"['[@I1(U]KJ%J36):-E'U[(KP
M#JX(F91(C91(DVT0RA8:%0I;RT^;$@@9JC*[/K/KT[*!MZKPWL(>ME!II]^T
MOU,?I#Y7[TBZ8CJ939\NK@K*CK=_+YF$2+UI0&6!5PSO"H1,&&S6GL]8-3/I
MTTKJV0;>K.6QG2(@L^>Y8U/2'[6^SEV9!&<]M27+SLSZ93;@&]_;L9%,2J1&
M2J3)-O#D 0-R2"AD B$S[;>#8^<V[9,:0KVF\9>S1N>6OW"7/9QL9?W#G0,/
M9]-S8YF>6UIV>FZ"\VV#B;JPW.>FH?3I7SIV5X.__/]02P,$%     @ L8!T
M5N#+3O]D_@( .W\# !    !F;W)M,3 M:U\P,#$N:G!G[+EI5%-IURT:1$1$
MI!-0$*(BH"*FE$YIDE($1 J"H/204D0Z@4) (H1$0?I.1: $)2H@($U46B$D
M0@(II9">"$A:I17840A;2'/RGN_>[X[[O7?<\ISSX]X?)QE[9"39>?*LM>9<
M:\[QB#^*61"E<W8.=A I*2G([Y(G1#P)L?G7N_^EQ[\6^5]=0TK\%J*\56IA
M\V_24OLAFY2EI)6EQ%0(% *1DOF/&R#_QT-JD_1FF2VR6^6VR4MN:%*";)*2
MEMZT65I&9O-FR;>)DN\AFY5E5/8=.[5%]?PEV?U1.X_?OO=TJ^[I5YUJKH/
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M^ /7>ZO"-"Q:7^6?:7F5%'YF7BXLJO)VU)[K3V1G"PAY)HYD:!A4H2S/4^?
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MIRG>/*M#D5PDU#NX3:V1L0<().6'/:_U$!E[#J='*K6DP_=A/Y"U!6IEF#\
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M.B(7P3O[([Y(H-;.U_8SYQOS9).QA\G=.#DL [<+^98P_KT')=\8AE=%2_0
M9X_'C1L:Q:CL+X5^YN<!)#]0N&(6W]3<4FE3$^(A9X&:^V/K 4/01N)C+-\(
M*R7P3<XB7RU!C$NSBSH5L_":JP10KXB:IQA2NEWXK$F(E!C>K3, _PU/FNN/
MYQC9=,/*/H9J3'QIRJD=W(TY?&^BF^-XDF ROFIM<4CAK6 6W!!#-M>#O1L:
M@A.21FN.[<6KP$_.B;: BQNN$EG]._8 YC*/3(6.9SDCM\V1I3!./,DXE"-J
MZ.<#<-$"<FC B;4HWV5F492Z6FUE_,QSMFUT(Z0X(N-HSA-/WU!XM]6.'1<
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M_*NMA3^,'@9&'I"L=R44VFRT)E#)Z[PKFEKSOE&S83<KX:L(!B902PV&1?M
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M-CUM2BG4JO\K^X?=-J--%W?7L;D;LN[6E&OIGAB/SSE^I<_@XMZ;\5-F/QY
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M"Y"Z[R+7SI"TP$?9%81BEK*09N3,[S6(G#0=^-:K!Q7N2\,.UY+H<N.SU\6
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M/=P=-"+QK8*:#C8!G](V BNKR%&WMXX8K0</ 5&C"\EX= G_J;*O\VA-B[.
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MH\Z>'7U 4X[.QSG;%+;Y8P L/INI<P=B"1?&::++@%LVVD;B#[BUH=+'2>6
M&^]L.<#D8UGX#.ZR5IL7X+@RRAE(RH'-)?X@+8N(%3)U)J/=!0PM*%^P-TH4
MF'!>DY8N,2PSM/(O9G.KA@XJI,YP?ZEIQ(U3^(OS%D3/N!7<"Z1?)&&0+C)M
M='^6IY?/A&"1C4FEK96_:5&'UTH.*E'!7SP\'JP7&."E+ E=_^1IP9>Q;U-_
M-$,,#@W 4B^'&K9"0: )3Z&S%S'%-$ K$Q.EC]';"#O$PJ:V$>@)D"7TD#:W
M6A"*!0QJ@IF<:PGQ CL63C\2[0 HS@9&9)!0Q"# G[V C%G-OP9R,[[+$,B9
M20.HC#%MB[JO<5#A(XUE"9E\9/*3U]V3[)'>:D1FAF*&F:>FR*<6=*#;R(QF
M[,5OL<Z<*$# XC,E9DA%PH%N=C.+@./#^7>BBF(9Z;6)YF1.JWG=@/6L(UXS
M!K8!#9J;LFUP<HMPG#G6,2'R@]R2@=N]G,50NXM?!8OS"F"$^,Q7U[2]I:;P
M+DDB1 %;/^W5TEI<RO%22/],^LV+WQWT]?3&8?.&QXFZ-=4?GUP=L;P;*<_@
M!152%Z[1?XY;16!TR! /M><- 7U^[]R"D)PY:0G1M=OQ5!FB'I4#;Z=>'%]@
M+ZR=)=E!97<E*J \*N-8WB_3,H2*Q!-<'C)"C*\@6H,9%(8+[QV>C5[W &!F
M?^.NL*-(]/FONSG,NL5Y.[YE-FD;Q!=;R$MR#7&YH#<OT)*5C!O'M&/TT"N@
M!<%HAZ4F)$/P1RG?Y#W4$2(>\N>3U\!]7$4G+Z"^*[#P0K4U;054Q5J<M )[
MTUMP?.9RXH[&!$"&N$RTJ24T<9AEWPXJM./49(ACTB3A1B:GQTU@PNE6 .F=
MO6_\<=*<EJAJ H;/;C4"AFO+!.><HA*KB8> W@P;*HK0Y#OXAS@BUX)V -"B
M"^9/CT\<"9IX"[V$W9+O+UI2<<N.0D+Q%F*$]*^-X.^3>H^@=C&:Z (I6N:&
M#1@/UQ(Q"FPD1:^7-0K^?EYQ1H_H<'/))_K38:]UWSUU&*'+PL?3ZYZ?4I]R
MV+S\JPS12:M7F-\(BOD1G3+$!6XC?GXYH"] M>/S,+_"&X@;1ALP:3)$'9.-
MN@A;#UH2D\OOIL4*LC&ZA')1"S1QMQM_*VK1H:5\-U[!Q;:B,C@JB0S\&1 T
MG60;V+2.QQPS%C6,PMM)W5PU9A1FG,F/R)/L$F^$\CLGUP/^%V!EN$<NN!T$
M>.-,JR6D*Z2E_@D]%31=EN#%>R110_[L(I5,X;N(@_W6,L0O$U $ZV%(=*A)
MR*E!-GD<UB$C2(7]NU&T4E-IFC57G<0*=91FH02DB@@ZQ/4#X4H3]G&@\<YX
M1A$Q$>0&0_P-VPF1L]O'W\H0X<$Q;BSOY^,-YDGXD\WEU5;[3@Z";H)"MODO
MJ'&QJ%E:T7)"_#N)PUPI0T1CEDL.@PHL>7? K<?.'Q&KS<H0#87S"K>GR/4I
M!57\WM3SG]IPFI9LRU2<]B"+W%#SJ.8$V-2!UH,VWI7L[M</AAYN9%QL":HD
MS!X$\_*UOQ\[]^OYP;-4WZ[EM]K:= P2['^E!B)^'%[DEQ3.%XOUQB16TMI6
MU3U\)A3)E+LM5E%$U\+%NA@%'_PRJ+"+M&JPMB66]\Z88WO,=# 8.B?(GJ@B
M*T.#^V*\?/>/-AA:L<?-ATO+HR+BD#>)>I!<UE>LA%($M%50DL!D/DF,EAR'
M3/EFGN;HV4.C/PM:;PK5P&0KV[)# G\^,H[.)JO 0V=QJVHD8397I[_.AMH#
MHVVY9BXCB?LL:\U)>E/;9E3;HQ9I'IN7@V(>5Z*>+6QB<5>3>LB_R-OK"/X>
MZ0WF<60F306]7K()P'=PQRY^Y7>QF9<7,4B+1K/N(-RX>I<#K0NE3_!E%XXW
M?GYZ'Z)ST+]!\< $O[5)B,WRGF:J-G8/-Q2R6Q5 RZ<Q<OW>5%P+/\<U(>>*
M9 B-1+-DRPG?(&E=8XUSU_*.1U<GB4Z8QN^+.0Q\S<D$U/SC6Z >08GPC%]W
M]=.A 11;\8_<T];EISM0?<WRQ,<%2ZG,2'(&3;/%!8P7[9;>(JD1'89;MT@<
M(#M +,2EDYS@WM -4 \?M3::N\(ZUK.C5 -ZPNN7O\EH(ZM"^*X=!#O?-!9Z
M<W^BE,R9U -=J7SRRL HN8W*F(Q<RF!4=U>27M :/K&0.63=5E/XN3QI_-MI
ME"*W^>T"\@KB7F@"^"2DS7T0+.2@M09@"T)R6Z _"Z,J.0)AXGF8<13O;"._
MF&8$8=JY*G,2' ^E'8VVZ5](I*YJ%X1HL]&Z0S94=1>!Y8"\EC\Q$$3D4(L9
MV"NPZ^I=2W@]P0XUA<H 1]%9R%E@;N(!/(7PNQN'6G\EI FYF:<D1VZS$@48
MM6C;@M(=0R3'&54.O^J=FT\^ZS#)L.XRE!9:NB3XB**1>663*Z&*1#[R JT!
MU8Y3(C $"FSLFPE1+D"=5Y5;VZ9VY)VF;)(9<4=Q>RL&,@,7VDA:#T;Z3R;V
MZKPC*D%,4 $':&>,R!"NST",O/[Y3)6Q&"VKF:S>):0+@CC(QX_1.QS./A6'
MX B-<^CU!&<1"VR]+J#I2S @-J/Z+O"]B7)+>A.M1GH=R$U-=/1\P?@-=*4(
M8A7X,='-#>=KTN^<*MW$[*,_?-S8$)3-H#+#90C(1,YN,L2;?)X;AYN!JEN8
M=^;GRBW%6ADB"JE*C!T@XL6^$C4Y.^VI(*P4\BD76W4(GCQ1?12P**2T[XIG
M.S SK+$9I2OJY2T!*UE@FN@5V(4=>C]"1%;..I0-U\@0?C\=6#89,L%?1ML$
MP(,.G^99(&4OU BJBTH@*Z">MW%^=.X',.LK+6TQ!'!MJ)4MSD+F93*RD7;I
M\.1Z*!VD=STD_M&'MI2XC<*;QXF'0$MJH_VWA;53..1H![P&:$!KM\H0E[+'
M6Y7^XU=^%PC.76A4'?1"?(CT&J/3JC1EJQR38D.9RQ>B*+@&!>KQ$+.##0];
M0,O<!MQX\D$(<VOV] RU?%;O<Q4?E7H6C0)7/1I.>*??!J]L&JK^T ^_NWT!
M8TD^@7K#%-5)_VQ1Y*,NTI#,:+D<-"^V+:R1>$'YPOARB"ER (='.;O<Y 2A
M)1?@4:%_#E%.RZH-Y E+5Z"BEF$X2DWDJA#B.:K$3<F[+%XJ;Y(A?(#:I_$Q
MR5IW2M6D?Y)/HL9:0^+;, ]'YUT 5 >Y/N\):-+Y\[GH.X&GHBQIH1,>+&33
MEM? ZV>:T!:@VX56=6B"WS2_$U@SX0WA8H4]ONS0=0 VC1C'S_4/!&PHEVN)
M&^]",U_;FRTOM3CRN4,_=2V?3V<Q+LNQ87BW,>K,2"P*P@;T$0W%#O#K5B-I
M/FDME.\WL-!B=P(,ZV1J)#+62/#2"O1&R(3EW_RHRH;)"CKB9 -8\3]EV!0_
M+2XN<>;(@= JG%,JH\ZO+*Z>898G_..KAG]]:>#/3\@0H\,,."]0AD!;KKTB
MIU.3S/I4&4+3[O*!U3+$/<X\N4R3[1K"M.#=L3NUZC?PZ@Y"I\,?I>=L -<*
MN>'@2PL3S?=^/9C/X[(.715]3'ZREX!B>=R-N1%ZKH3RYDRH>\B["41]_?87
M.S&W(7+G8[1*:<S64 7-W".7MD73AJ/YE1[%+*RJ:7RU1\,U:9WW^Z0#EC>.
ME/^0(;K("O$X[<T 9RO#L7M'U'&;K^<;/Q0=C3?X/6[[JWM_F X>PM0S-C?[
MM+\8$KW81-=4;#2&6I]_1_U5;CQ$.L:LQT!G:7--,L3OR7PFK/KSFM'[+1C^
M.+F.*U5=R)#7W.\07H;XL^H;%<I]@I&NJL=+3+O)S^&S,D2FE8"[9&'O+T,H
MW_24(9[3.L/=[DDXND;E7S6E-^02UR!#G& N&7.5Y02:"7!_WALOMW6#T@(9
M8HKZ\Z)WAPGKYYW7$M>W-/C2D298XP/S/0K<1)2W'"Y=:^1^K3Z3_$,=>O7_
M'N\]N7&;R)<A^K)MY<O<;)*DP1MZL\E3C_DXB6V<I0RQGJQ[0PY4X_AYZBM_
M4<3?XW+$BN10;N_ZB7W5SXO27S11H/X9\I)J.!?RE1_^)YE] \1+M0WDGC[C
M]48Y&*S0ZB?0'*KWCRSXE?P4_@X:)0KN)G]S:Y6CYZO+SV.OO#D]A94A]FZ5
M9]J:,]PO2"@?;2Y?69A.!L;83$FFY,1V?:SQ5Z/&[_0N'^3<"[$"^0U5["Y#
MS#I'<S^!"H\9,PJP8:78G/JCG*N"K'623SM['-,;/9O8^T9?=!94R&A1YH<X
M\\FIIQ*HE)'0]0^ #]>[+C68QB9TX]5GOQ*HA[,Z5\?JF?W>,O0QN2H]]9#7
M]J\5[]9M>OP0O>.$#;@S-O+]C>JPBYP1MI?3@>"W0E]+#F_(..;,"ZS:W;>#
MV9?T#A>[,0I35 GT%:F]0+[P@$ZEDW!K!V_S2UV\JJNU":5W1\ND7_37JM<W
MIS]\W[QYH''?<.5J=X?@'K+ZC__*3L@SD!W[0GZ@2S&9?R (=I/7I5H$A_DM
M^#0#UK<OE"&N8')>_=R'';O</IJ)K?XV[H9TL3S0_48_M^;2SU_C_5CSGS,=
M(]@/-<'9>9KRA(Z0V_\O)N"-*S.8[:X_<YT<3@;F,6-X^/*B'.?ZGXB?'R+_
M?>*K-LGEJTPK5BX]._$_%"3N-"WYPG$=3.BD  ?_#EO]A+GY9ZHSYGK_'M??
MI+[ ]KT,\6U]#Q.@RX__[;^[*FNY_',* GI'J9OD.B9#VB55:38DXVC_%A2_
MY/URI3L#ORI"5U;,B#"K8*,]R7>BSY^M.>%DI 3,Q>])KIAL)T=9^Y@7M9SA
MQ.,UKNRC))S9\KCS;<X,-'KM4,7AHN=?#\WX5'G997:?+/'PB[H[EQ_ED-G0
M&.48$T:TZQ-F 5"UQ?I@?,= 'DKS$MMC>[=]?I$WZQCP^(:KG7N\A_TY5[O!
M(N_F9,Q[O.B2,:RG(&0:PYZ6[,]"F!)[IB7[/PBFH80,KWXGMB$4AXXZN=^7
M6]T5DY4"PPC?41O'*J8"X:Q \.G@,#Z"V?*D-*GQG$E1<G;FQH(C.B\VY+U^
M7[]])^;?3]T>KW<FR_ZDC>[Q<U77E6SU+MV,VYFTM<)9F5)FZCHCJ;NNL)D;
M>L2EH?CAH[!O3H*6LV%_"<LZ6RP/Z+SMVM;9<?/+I/&U:98NM>N8\,"92^<V
M;HGCN*I=,U_MH79-+2U3$OZS<+Q_IB1NC/:WE/7OD)K^T^;&_;>QV'\!ZR'R
M?ZKR/?^M1;YO7Y?W4)+1;68]]F^*S_OGTXJD!5V2?GG<A&G/ 6S&U\')3HKP
M%!;_XQ\2 =_G$C!E-"UYQ]<9U_$4\Z,@SC*\N2IQMDQ225PG0UPU%H>=L8>P
M -7IFPR10X=,<(ZF^F[&3/)Y>+B!"9GTSG'+(ULM^^;0FH0U7"Q8>_U.Y-)\
M#3--@M'0NYZ7+4C1YQ1H+3ZHN)7WV3$ES/E!Z\6=P^59,^.ZHR>OE!D \JJ+
M)G4'H,"(5@.PJX='54Y>.D+[<O[3;_$'P>+-%4'ZWN_/5>5M>;;F@:=FP:1J
M16IY>L.W^FL5!WR""[/RKA)[<'V=*4B(KI[^<EN?,%0GI^Z5EJ7BSFXS@9O>
M /N3SMO7ZG>OMACK$?[RN5IYSN'/8G>7P3/_-3*;_E?1IF+^AZOV_Z!\+]C7
M_CYA5U=%"DZ\9RUZ-=SQPQC>AV2C85I#$H<(A\PNI?]C+0+F9RY%*.@ ;AEU
M6+KM[K#1TNO#4)IHA;2DQ;V<8+Q[&*T%:7T] *Q,O4=(8A6,AJKU130-?.O!
MLL\SLBSFK:&*1\?KFXH/C^#Q&S)^W3?Y,8H>]_'5>U#@=.)ES+$S,_TOK/P,
M-A*] C,%.SZ^K_IC"]]8I_%V=**?^TZ+T'TO3%X+J$'+OOTNN&D40N/1.XE6
M.S]"!D]7N][9,;GN8-E6K91+/9\<7D8=\*[TN'2OW>> QYUK'R)=/7 <E?^2
M$H;0_E/V7)$+[O_)G_].4V0V(D-$?$0!?2C$#P-B/.1T?HGH!O20@_Y&V1BW
MR.V.Y'"J2LRX]N6&WDM,9$TB!AESWI5Y-R2(X,CJ"QZ?<; HCZU\$SS1:WB[
MQ6KB72#+VLKU]RO[LJ:<-QL;N.7N=#F)7I_U_*O?EC=$%YTFN=VH"$*&9IUZ
M*3I0E__H4?;#T0M+AF H$E4H-.E\:^FCX\2R[#QP<\=K8]]*):VCA<*( RI1
M>P[<V>9+5[![3O=1.7NQ&-=I44<6)-9\P;RWN_]>S2&E5?C]LQF9_ZF-K$WJ
M)VU_",7P=FF+(]@.([24XZ<LG-C]$DQ%2#KE(*CR+$G#1YJ-;<B]:E(<%ORN
MI?)N@'-2RCVW6$N1JJ5$/484^K@HZ@.T"YAZX308O*^71U.VLJ[W&-CWZF-_
MR8VQ;*UC[B8;\D,G ++(&W($]L;N%?(74IW,^>>^.Y\:SYYR4+EQQW#/W(A?
MO1WSCRQD@_0:=ML%CV"WC\^U(Z^\R,'F0@3>;)?9"[!A^U>6TZXUCU^YJ@0$
M/-GLZF?FK%(2?4T8X>U--7ETS=BC^KKI$+.21?M]ZX*EP(ENW4/@FIT[JV#%
M^JCSUW&"P2?EXD-Y^MH&)R-YH/WWK9N,_+;TEWL0BAX45^P9D=?J;/(JU!JX
M@PMX<I?!O4QDXF;2^HE(V 3*KX4HV&$ZR*3,HSQ;ZP83]GR<MCV_==$V\QX4
M9?+LV?#GA9J$B=L_"CJF\7F,\*9^Z-//[XG2A*55,L2*:FDZ.1J;@5MC/BHZ
M!ED"=FPC57 Q]R31D_?, J4,E0?422L#@_R!VC*!(UXOQE\OHQPTZQC5;BXM
M+)MY\#9XMB[X[;N&@J4[!<P6\-;O:Q ZS]L0<?EYRXRO](9*%78O21Q-Y47_
M$"K>)51"AUSW$Z"-^1)N1GWP2.L:3##[Q+F>-==B!D3?(CRJ#QL.EQ W6D8"
MWV+.F/I4N>;J:9#[5#;VUI/,V;[L",+X]0*4NM(!Y&K7;P]TDS:<_I-PLFFU
MPYO'?YR.SUM#01OEGHOO'C]<Z5-Q_ONLGT11+N]9/W\.AMX"CS(!;^18<J=M
MZ\HG-!&>(HJ2EK6ND9R&BBN@[/;FLQ5\?>KE26VP]@J?2"#[CLKK41.Z=F3&
MX4/)G.U2Z)7*J)?Y(4$AP8%NB4E;X-@9Y@.N1'L?Z>7Y+HE:M@=$%F_%P:\<
M3NIE4.[  XN3FYOZ/DNP/$^<#I-M;K6[^"5H=[DEI-R]:M95_YR0?&%PICEI
MH2$#S!$]8&0SF ^SS.:_,#7J)0S+%U^8<Y^-7IT^MV*KXDO3\">Q)X^?WEEZ
M)/O5PP"#SU2+L$LQ.V[7[W<U\O M6-FXZNAPL'KE7DUD857!P2J?&A=_58_$
M=]B34T,'$TV'TS<?*C?KP#TMK,NY?O7:\?=#)=]^_GW7Q5B8Q6THG.L7GY:<
MA"A@6'N@%X7US%]D(LV"5T%)7>.H;.(N1B1I$Y0*1/!Q%R2FX)HNUT&7#[3<
M^88>QR-]C:MJ;/"JD!MK9.F.+?AVO+RJ$UDA#_0&\G$9(H];CYGS!%E\E#S+
M*'&0B< D!W:$^TG;^B1.D^N I,LR1&/+=F&RN0.WH^C2.#W]^[,8U\S$/?BM
M9B?N<5G)87HGA\QKUMZGC3N8/>\AS#J\COQH'7>M[GT]YKO_[(XR2HT7O<-R
M>T'H5.6Q&=?"$9,;@A,Y%WTN,<\^Z%:IY!0-M/67S_W8Z'<_1N-VA8WY=E+W
MN"GZT(>7]SA[Q9L67LWUROG3I&GNG-A%(B?GBU;0A,@7J@)X$%[XFL'#C0^Z
M#,*H%P+:BAC/Q&30,0"BQ/,F7$&M;(&A;SM8V[3RZ=V=R;EG'5.<0C2'-]1M
M?[L5=X-;ORA13X+7T,3:1 <IE1Q-'LMO0RG98,;)?,:<&(P0G8)D"+&EY!"(
MS;"L3NQ=1<@7E4!TT+E]O#15@%&&1G<#!?76(T:V?2W^-1U<+:)5_!TO_B[U
MN<%9?[59DG(KW![)\%46D%(H#+:?T?+UG*-0E5--R:<;)*ME0:H7.EL.X' 6
M[!-UM\"A"H/FFC5]E=UZ_9P!-O_!]ZECTX\]2O9_*.B_%FD9%;J#=?#0YJ%+
M0Q'8@NH8U_O$W.2 UPZ.9QZ_=&^?G(6XD%P@?[TFC\QE>7FL$_O!@S@=)UT>
M0Q5^2VYD<G!C/^Y N@"7TZK9)S$#F#RYRM'T(]'K1FL6$GO5H';BNJ3J2T#A
M)>/ZP:U$G&"VQVH?,!4O8&K,MFX>[J2)Y:*^@BS]"[:#AS JF!.Y"CS_5(6\
M1BH%]8C1QLPVVO%(KJMI':T&L=K\Q;2%Q"-$+T9*.:=HA+)BYHU;W+)82\^"
MK_XM2BONTL[X*RY]=7&U9$_^UAF^4^N$O_(U7YK*L7B]'P?TD9<8S@H997^=
M"" 6Z"9$NNDZ_K%-EZ17LM70QG_BJT-C7$".GT?=R;PC>S5F?7VJHD&ZWM4S
M!\Y<=ZBKG8D_(S<&%>X>?AMC'&L#."[&$ 2=D$<E2_K,21^@\IE=C R2#J#
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M)^+?:R4*UW.>$2S8Z[ R>01O5\T;<6)RR42VE3H'".(OA9VERJO9+G<1+#!
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MX#B+3^UB6ZS!NC%HWV2MH6H7^EQDSO8"G[4H0R'7\2;5MS"AR7\M)(@E81Z
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M1%^*! 'J(P(-;F<Y +I3T?VM8P=1;XZ6BH'_BK5<@WM>F(,O3HW!>,0#D"T
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M9-7WR)P:=0['&*AW9[NK<)QG&IP1R4:U!#DRN^5-FB5:] =,R>8\HQB*@EA
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M0K8*SEI=#>\%Q7O@2+"JD6! TH)4+=JR9#)*T1X>H%[[P(Z0S>)'QJ$;^+=
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MZ=^O,H?<F#-(E0;7_@*( QKQ7];R]36X\6S6[/-/#[T0T9OF";>%"U&+V\M
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M(8G*+%4*H233+<[>YYZSN_<9__.O_YS[W[4LUZHWU%??]P[/\[Q)#:G,I>0
M.B*/2SO\?5;"C6!IXWSG,?)Q2+4;[,":"+CHB:J,?J/'<$"@]AS&M_/+JJ;>
M57$WGQ@O<_+SW-5ZVN&YV\[H\P\Z'%RJSQMM8H9WIQY^EGD>;5M%_XY7Q)\/
M_H'##-I)WW.$*<B<Z@6:/RXRGQ(',J2*)4@J9XH)DB?X 'PB0[53AO)K!IO9
M !71T-@H7E,7PQ".ZW0.DFO"*Y/M^#KKN ,'P)ZO!H&<2<F^P:GM=J%6^_'W
M5K>N<QII8/X]IQ_0'C1*U7<FO5WQ[$B:5T?[,S-7(FNTDZA7ZJ2G;^X9M'=
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M%2]?'DA=*?:&8X-/J.7DBR]W.!X?"N26IF?P:IT\#T"QV<\.947R.<IG5WU
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M?>"\#4]Q18T)#Z\ GRZ._4X*9U5MB>E]A'Z9W-1A-AB$_:A M!),-@P/_FA
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MTK.-:1Z075)QF(X?NP=-%UM7EO1<4I3'*'!.Y =03+MF!UM6CP>IB/R.?S.
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MT<@:E,QJT<>ZR?NABU*GP -EX/GX)V,#M9][J$^]W_?T;H>#V1??MC7G5UM
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M+K@ML<Y>W/.RO[[:,5Y$%&[?&L'=1D?DT"=%WRI@SCG/M;#LN 8(]:6P"YE
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MEG%$>M7-8'T=V']1C(]:C>$E5V"U$AFTF#*[>AH]O=K@ +MQ^@)W!:36<\5
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MDS=-U&Q_B7ONT7'.(R!-,PF>^#:>^3JN_)^*!*'+<4UK&Y?>;=HS7WT_./:
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M-MS)=B2(& A!7MVD]9][G3S:(:7R4K8H6Z0A=F!K%'.@R1C^$#:B\37D%&&
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MZ6#_.(!PV4'PZDQ?$!S+Y<0AI+%YF J?0_XDTL_U!MH&2>T &%CACUP:!=+
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M#>?S]-6MXDZ]]+JZR4LAN,,ZM;&C:AVI:W -UDTM@E;D6D,+L_^6_0QLXMB
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M!\,3?P/P" ;@6_\$P,&N'UE_UG,.AJ3);2%$Q( Q!T/OOP&8 I_\9P!69]O
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MW_9HLF/L-?0AY#LJ!EV;@.4,.>0(%,TE+Z%%"X#1:97$5;".,)#LK#C"62J
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M-[*EUS22W[&NN.O7ISCT!LF7!Z_#(XI"D0N<RZ8'2NYRCN$O$V08>K0HO?P
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MR$F2XB;]S+ K65HDQ0WFB0](+C\ 6B)ST?D-6-G7^KNC;@$;(8E%*WY;^PR
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MLPF,!B\KR6-K14879P46%GLM:DD+K1?2+20/&;)TVQ*0&%E \B-JTAP%H?5
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MXHV.0ZZ><!\I>A*(O$KKYC=QF0N'JU=+<NARQ"A>?459[ ,:<V>WY0&^I\I
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M]O_1I:S_^.F-E.?LU>82R(9[:P+,@&:A+G@6D.$>$]AVL@TV=:IRY8"ZPSF
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MU<9'O=(5F2(RJT&L 9YGDZ/4=M6I"&H>#"%!3PY*"7=P4V$702&]V./=;L%
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MGMO]\F[!!<^/SUZLE/]HFSX4[5&I"=F6>M.:]CN_<OXQZJN0/@(;.O.S9E%
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M1'9G!TK5MTXU >_ \.Q)%)YED=?BH&\T97D?\]@]<4U[^TM+K/)&F>LGX'N
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M]WPF<L#\THL)8T4YLZ+4JS5W;*XV90(Y;')TTRJA%E@"U$ME,&/O*"6*J-"
M!@ZUET^J!$V9?F# ;LY+A>[&*6-3*[+_AD551L=3^9LO^XI+1K,C2JRF:.N>
M9MBL]@$0XO4F0"<G_>==S+<2Q=V+7N:BITV:TVX22 LYCJP@@5R&#M:.FLQ8
M% DOP6JL;^)=!2;H>R-@I2LH*!)J@V6LK7I&$DA"MAG@TU*FB#:%QC=M\1!J
M?S+?EI[1CR["99ZDSS5)9?NM.)RW5S]B-,5+SS.H%3:T")-ODB6\96YIV@<>
M;P]/IL>.]3?("0X+K<%50!>'%E4Z[+=2]W/(;C"01^VL"67X@[;#Q^V=>TO/
M<DVN)%S3M?:J22NJKZZ.?""Z7@Z5/ZTK'X9Q>':;_4U%*NCUS>]==[#_1K7]
M:. 8(?!?Y!X36 ]_P2N"4!;V)D(A@.B/C".NO0(WQ0?P2NNEJDIID/"166%P
MP\A,D*SV_@?;.;E8>"@(@':.& P(W=*)T(85/$X+7+EW 1'GM9,7VX;8-*4F
M@;26K<8Y+D2,9':2I5.!'_,&L;*'&P_D<V*C*)>9FREO#&Y0-HJ-A-O)/V\O
M$^M.IJ$V&31M$^X'*"DA4K4GM.'EI\SK=DD@*X<8TX2MO?L-YQ1Q[IWP@]C-
M$TW;^WTBH2WI8HUXZ7OW@7>EM!V,Y2\#9=P@-@H*"CHIE<Y<5\%!/ S$A@'.
M+)U6 U7\5:I847A4E&WN#21VBI7J $IL$W1BQ!",@V\1HL$PX!9_L34;T=N@
M4P(:G (,;I]^Q+9 66KNX8FZF>-)/6QB7-,F:;R>@DC^=3!/$"KN1U3^W-1K
M] Y9D<X:ED"XLD\(GPB[:N@4/YARN\ :%VK/BVW6[4D@K\>O* $I7@,-<JJM
M7;@J*,1ENO=+5P&:YQH?8M;NFG&+\EM5>'4D,_*Z>S@V,H1_ /V*FJ]&^/J5
MX9!)&+H7W/_ MKW9:,U65Z,7UZ).B>0;145_VR9#+7^FND1,I<@3?>1#6:I<
M3R!HE/P&!@73^1$ N4UDP$:VDA+(L/G&TS]8,XR>5G+"LOFR21LRELEP^@5-
M,!P0[N4T0CLT-U #+@./X>N T]&YF*OH8>+,60'6#U%MW0X=LF5!$^$:G_%'
M .Q,F< &?P+T82%F&IT=:?L)NL+-O/$V2AQQO3D,"##IGQ_:<;[$"V2R$&T&
M<CC*,:I.?Q57W:WW=]N(NQHS@>0H_*%1Q VU]!3B>?)&<9?F:E&M-$L8L2QF
M._'FRRDO+9 C)<30=!M* :Z"EZU'02?(-?(=%#8,W&.<^@)_$/3Q*< KIW80
ME'A9/<WRUJUDM6JD^A1\(Z\GVJ>.E[R8/+]TU?HV DT:K&T5&X@J":OQ:X#\
M-EC*B+R(\O-G]A+(VF_@H5"6!NHT!6SGP?BO1?D-[L7"S4#D%P>T4_@"LT4"
M@8A[&09ORI(JP.^=KGT-B*=XF0&"*9AO.9!7"\BWU6HE>96^6[!%VJF^F.SE
MZ^>I'3J;<";?L7K+.P8TDV$""SQ]/=; <-M2(S^CZMQ9HK=4_J]9!:9SB-N(
MS;8-1CS;46R,>#>:\A(;VR0')K*Z6\#6LU0#(AH=8(1-SD!PC[ ,H,/6^2/H
M#)UX @PD2\>^'%X9*Y*Z:UFE'K ^[HY2\1ST73OUG3F?R**3&K0 =Y9T\(;O
MQ2,&.'2A#'"H.5L%C!XM"="[:825!;N.OP14;A*<CFB?^$:V[?=WPSFYKFD0
M^U,>CNW$_&CE7P*/Y8K;4!O%A]UQ=(?^:E0T>2UQ- M6?@R00#JA2NA:4^L8
M\1Z0PZ*W8\&]^>U(1FAG1DQET8CGA"X;MFDZVXS,3B?-.])+V;PJE*(AJK:Q
MAO1BHM(SPD"HZ'R\7V@B[32+HH2J2._64+A\_PY11I.R%^6V@5:,.D6.@?':
M5D,/+H,.'P]PVZ)OF*QU[F5%QHBQ[JJVW]7QC<]VI=N5%B\,/A]>QN:__=9F
ME:[[8(_;OMR=^:4-_4JYF0'=(WMG,@*<:P]9#]VWMSS6H61O"?EY^4P=:JS:
M&0PS#'*OR#ZR\^+O1[9H?=L>\_;(UBUEW\\!G6W,)%6X#C FG3SDAM@!46@T
M![K%_ (V@:ABEU(>)H'(GGZZ>;+./RTV[$7[4[M+6,'7\H&+?2P[XX$VU7M?
MMCS)%*&-*" O@-D8FXU;ZGPJ\WV[@+ZT#3>X8$O<@F,Z557V.72VP;<#R3'<
MD]!8\8[4&3Y!NS_WU:;)VO#@4()FPSUW2U]L>TIB\1=WU5NTY5GU1VV46MP!
MJP=^7ZQ>].4Y[COB8%]T6K$RI+S[U0]JP3/FOM/OCFA?'KZ'@G9\3G@5[HK)
M=RJ!^STLZ!JT:7]GE;55'W/2Q-Z_.N+5\)!=41=0RW$<(^=-+L)4X0=%=?UO
MO06J;41%UR'/R1]0T[TA[L,Z#FJTO *MS=/&A=I=0ZWB9*5-6LH8!J(#FJ06
M74U++L&'@(/^UU2T<MTGF1O-(XMLPO3:6\)JUK*GV5[IYW-WDO>RFFJI1KJQ
M&>@+KS:U15\:Q2-&F:H81I(I*L;\"-LSPK4_^7,%-3AKU1FZ0<BQ_!>-;&GI
M<_,:]K1#K_HUP.OPR_A]55-/[U2Y12'EJ]2<^2KQ.;9/94NPN365<L4HC["[
MOTV75M7=C9Y=U1::Z.*?I7THK2:HQDC$.'SR0 ;6H,4QL<\^V+?@E5>OW7YS
M;*3_Y1)_IUH$8GG86D8YI<C6]=JK_I/VJ??N9P3D%B^57*<.,X8MC,1[\!>I
M(2Z&]@"1D_)$._G*M[XQL!S833\7>I>=@3D.?\ N<6!@TE^M[)-]0GKWX;+K
M?(%KVUV&5,)S@5NTUC85.F(C7'O0_8O>\S1E\2'A[S;[C>1DGP>&856%^X]L
M?]6_\M%VBFE6:5'N_8<E*5GY'B;9(X'^+ ?^G2]-.4\F5*BNMB'/OTPYT](6
MZ1O;2K;Q:<N$E(P'5 ^;_=?"SDQ1SM_-.6">NN>243H^M<+CG4K&2S?]MK0]
M3RI^:*\[89O[@#:&06M?^A'@IEZVZ\28ENZU!Y]?@KZ[:(ZWGU.1(D940B/W
M^L3[\)%)"\W,W"1XI9=;0T?#[!"J*;MN]M[C\]\^I+,')\)[.N<86I[V91B8
MIEA_JO++JP=L;")\W]H=2O;N%1[-Y]E5KZBLE#W<OH_=)?X[:VOCUAU_8#:,
M =PY*4]#\] ,I'0 V31M<O3=>>] 0*LSPY'3%7PSS;Z K-BL_:WA^<X:9]6S
M1E5GXM_Z7KQ3]64_0WGV89I:UEAFD7L/WFD..2!?S>L+.5>5=J*T5$\?7Z\;
MUUW]00^[J^;,EX>Y"MH-U8^47=/O= 77FGQO#0G2FQ_*<+XWF5N+VV:WNL:9
M+GN-O<?EB<N%L(#?_"KD'F8%N0K4#C;R7FE'PN!0.9T0;6UMG:@ T]+XB07D
M49>$WNJB"SM3_2-,%U12C -LG&SJ33#5>0ON6</T]K+D('39>KPKF)?W+M_+
MHSDH7 )1@^]L''O&F0',-[L-X[KL*S(F;4^<SSQ=59[PV\&PN,\NGW@4J?LU
MIMF9@6B!E="7QV3HQ#C2?< <P-C68I]MJ*N7>Y=4DI <Z?(/,G]!NU'MZAK6
M/[.-4,_?^?E[>+&;-3^=,=]EL,D5[>Q\QC@_I*2Z++X:4]1;7J;/3IEJM8F?
M-<A-&V-;F+H_21RWWL;(-(^@PR-"#W9?RG&;JNBLFRSI^W&J(GL6XZJ]5O=A
ME2"X7NT2U5W)!&B/#%O_6DZ9/BOL8&PYJ5@8]OO+H$)HB.DYWJ>TQ(MIZS?Y
MC=@MU9PJ'\B144XJ>V<_W)'G^L[6.7AIVBXO\MZ][S6=^>^ *#ZIWD:OJH>$
M4*\N4?DPK5KG4@.V<C[5'/A@CPW)K'<5'O7IW=&O<>&NVD*QURC7*JDK3M'$
M$J0#.9:'F+!$HJ)1)IA+K=8P6B GP'<.S$^;)9L*S5J+<4&._2$6,AX5_0/E
MD7E3-#FL4<.QVZ0-%4.>0$;D;,[*1V[39U[WCF?3S!+E%@8R;0;T2C9;G5B(
MVU[W'9MS\Q&#P=!^_0J:YIQ4,3?TDA:"A>Y*9SA5/OT-F]/P$K.UP4+:##=9
MW'=84C660 :[V5F[)1#!NBT)[NUAEX(P!:ZV&@-5U_95C?@\11HT=W>25U*=
MZ)]'QZAUE'VX$*7T,$Q 0N?^'_L=#[^S5H6[#I_<EX?;.ZB]Q38MP*XZYYM3
M?3V5Z T8)!+1PR;(OJ;MTV(3T9-YQ'JP8C $!?U"V@A2F\,1\3K]^KM\S_=R
M]S=X7WJ>+-]0W^',Z[ZO1DB_3*N)5Y*W*'+N)]8P4X1A_CPJ?T,_04WH $[[
MYPT3WF94CS5@&U" >JOBT#15/$BLV95175QW20)I,U"9MO//GU()+[V9,P7?
M!2C4%MFRDF5:+RV\QE7'LN15G?L6](R'6C.^JCJU5[OO]6_PW=T_1JLJX')+
MW_%$,>00C@6T1=7-.,_DL_YXPZM53B_KJ/[DTP^T[K'-RBJDNG+=#D"FN0S4
M^2::+<EC8K "+5R:W:_^;G,N30-8LH/H%<4_*O+*E=D1W>[P\:.--5D+GA?8
MKIPP.;M\NQ?N*/?]B9ONLS1-= -2U/K:+NL/%)S?F=?UP*;=^.6<R_=2RUWL
MW*_LQV1#+#2#HZ*J^<#M4_#$:%6TVP_[L0]*FVNKPHUR9Z@VEN_JM;Z:P1*8
MJA]3J%"&(IO[_&F!K7;=9SO N8,O_LWI>7L4RM-S^F2Z?X3VD(<E.C\S7LLX
M97&35=,9-2QPEG^C+R7_D@_0REG#^,*X?,+< (CH&-$I?YUXX=W56E4UF81M
MD=E&(8)C+A=5VG-B'(JO?DE:;E"[G%/0RJI_-]-@<56[+_M<W]<^+4"Y@5+_
M( 1G."TH>J7UZAPFTV+G[/29C/X9YP1K5Q_\,9\@3$!=1N3SB-7WZ"=K^_WW
M^X]\_.CJOV$.C;ORK;'VUD+J!Y^7=QE3OEH"S[9UH[]E)UT3&O[^^BI.YR+U
M,?K\2 H?3X)BM'/L!QH]',J;]W<I[C4&7!Y95HD>OSA7&5B!KQQST]5]C0@1
M4&!UHG F6Y6KC0[T?]X%^' R[0H^NV^ZY WHLC7S^,DP^^P^]XC$P\$]BN:,
M/L]A&PS?S&5L1'_UU2]5"NM*]$+Y<># U9HT!UPZ^U)V[7.WTO3":0:I'4I*
M$^\ SKR\JR5 QLV$P)+<GB?*LVIK[8PXG_;/RQO3&"MD^+93Z^F\)=LAIM<$
MGY^VN&R<[\^:WF/RQ3<C@C%M7'?]>9]'MR@_$/O,;:KVSD1=CMMDGY_;M_8/
MII?:VU.R\K:4E-JK*[!;ED9_Y&3T/GGEPM4^,>==UQ!Q,3[7P^TM-^C\Q8Z]
MI=H']RN6Z_2,W+L1[K0YT1YC\/39K8:K8?C7GFDO')Y\+4UO'+2;R/I(+#TW
M%N!2%U\S.WSE7'!3?)ZN29AAM4W]I,Y[SA2,5PLW<G<[V"GM[&N+?"L?<N?V
M-^W"B?2T,USNX3.GDW%^.U;LWE*,]3]C%;]KS&;7]7OP6CNP#"#9Q73L GN!
M9V/7^SF" !(6"&6O9(9EH.]M0_MCBJ<OX+CG&Q^EY(4H9&U)<679HL?7G_W@
M1NL;'N4QX^;#JI)=4/M&P-@SY+8S7=@ ?G$PDVNWJ7ANU:#U!I)I@S$*^_IH
MQ:YLUSO]&YL+2AO//SGAT_B26ETT9*N<ZE;^J2ITP-LVPAUD TIN)6/1F#&]
M4O*:CORUI6ESOFG?L^R\-YXVVQ';TF=__^5GNV?/LE77]6$?7?MAO6XDWLKC
M7;<5WS_@=5Y"Q[DQE$N;]A&;;JOJD%!5X'M$2'%I=6#^WL8JC_QJ,((=VY'Y
M:+2^3ZPEM,H0=]NU?O8 )1"V25P;!H/1?K#4T+L[U<UVX<?LZLD"PQJ^RF),
MAPL[P?W\]0?<IH-X3)]#*Y>YL4G;;Z,YH\BHIAP(ZDBCI5N-T>1T4CR=K8"8
MY&+KL%QFI8<[.CVTU2YEU*I6)=0KY/LPV/[MJQ.U60[Y'!FQ806WK*K1#3OC
M[DU0N5SNFW_K^XAO27R$;9'CI:6<Y!S*_0X=#-,OA6/3OW#,N-:XR(*?8%A?
M?[UOM'>_2SO>2_;)"4ULU4W96*NT$0G$]MY[Y::D8_AT=VX$9X.6W7X-U6>U
M KAJ6(O>[FSYZW:#16:[%WQVE6\9.'SD@FZ'%_4!!9. OO8Q7SNW7+/'<>^U
MUX4GO03?%AWK'\+UA7AJ:<9QP(?=W^?!0&(W3Q$W"Z]YU]\HOH:-]P8V'#5U
M[T+O.O3N6_N^DQ^T]IRA7X?KX=&5</E: -:.2HSJ4*'?:]#4!)#ME'BGC*!)
MTTO=.6@OE?YY.Z_IHYZ[N^SC+V.<J'CWB+!"M].?=BT;/]';3%1_[-LW.&$2
M[B]ZP"\,]-\EUNZKEOL\^WM?7NVK ^Z#@UMV1#DE1#S4&TM9'KYW8M[7,O>N
M7U!W@:7&@Z7+IAXTKWV?\/:ARO-U>:+*(;M\OXU^=9J9J^_:Y'JY8S**36CI
MUROD@<_3UP]Y,"=#C=.H'@>]_@_&WCNHR2Z,%XP5!1%%BM*B5)$F2F]1D2Y$
M0%HH41!I0D0Z!/*)]*K43UJD1KI 0B>1+B BH4D-"0+2$X0026'Y]MZ=W7MG
M=V;_.).9S+R3G.<\SZ_,^YQS_EW1U)(_/RCS$Y]@T:$L*W_J_?Q&T+[/<_R\
MXZ<V1\>2!_TNN4ATK[4EU1=EDU8CS\N;&R4Z6SXTI#(GFJ%@;F*D["%< 3>G
MS89YR)?[4CA(S(+DH-<4R(PMPXSVGN?*M_=?3=Y\HN',QU/R+Z78N9TDEL;8
M1R7=J;P)Q2-HDKA>KB3L,25'1K/Z!:R+*?TD5'R[:D7$*.ATP#S8H)WV8<EK
M7L3?T0^,[RUK0GFI)LV\B1PVR_#&3^Z8%4P^;\JU"4RY!U*1;!H-\'[:[5<Y
M33.QG"PXL&@(\X8]F=J;/^4P7E.4,V5"44W$ "\O'"?),Y/B$<G",%*U*-?5
M]9P4U*VUP\R<$=ZEZ?"68V/:1>%>AY(?(W\&&::#VRAGDFNWU,D![1)^)*#(
MNCX0T+=PMQXWN=6N6OKW4#[Q]6&2N0%,)=H/M6[#5S0YNRDGL=E6FK>2XB@B
M0#JSKR6^THS0R%8=)RLM\\KFJIA[EKR2GC<V3\M4[S-_59^6Z]#JJOR'O5WO
M?;E+91_W]]VOK<<5.V \77#BB05*UB32SSQAN3Q 35VM_.;&'U@"2QX>,8'I
ML%X!)4"O.N$W>@0RD]R/G9BNK^M9I NB7!0"(0Q4?L:D=/U$S3C';]U(6-#4
MW.@\5S!JZD=)76+F-U%?@OAT9(<O98R4?8.'D^:-YPBV]Y?OM<)]:16K9I@)
MBTFJBSA9+Z3<KF1-]E%UX*YI[UQP9-]8KZH*5K)IG 'Z2%!I])\/G'UH>L=H
MN'Q\*2%<= <\6ALU%/*IW\.U@M"87N6X/BK6L=+B_".\L&&/OI^RKB[A>&^-
MM+XRB=]>."1TMS86<[9_LG7T::<(YT?WO.KXE(7_JER6*]/[/#N(_-&%V@S=
MK&A_%_R(JY.C?UW=+X$YKFQF>[JVK#K 9ZU%A07FEQU,S]R8I/KXY:LQ7?CY
M2!7&6C4@N_0$<X<ZF_1ZXX,?^S*@A", 3U%'@;;EDFI?V+#.]G<[C+H-*37Q
MHZFN^?MQVY5K6EYE7W->-KTV"I#HGIO[ZG+6=C&8(FI>1TNFQ#D:IC'L:4,E
M [!PE6R_</Z>6OZJ\^6*MKB&'-*451M44B5%_<E"EC4Z9GT);#3WW3(^R?-/
M7X-GO<EI2&:NYYJ7%\KC3JJDM-S#H-L>!S:3 D^"&W+"$KV\!2.*10VHONZR
MVS4*U[T;<14J:&5MD.V4S\[U @]OA966;#,LMYZO7YA'D.^%;+_\]_]&SU5*
M[-WMO]$2+W7'B)JQ5Q@YZ"GW>K/Q]6-3OZ>OI*>=!B0BF^[2\JP(<JNN/-_/
MN]Q5ZI@+O,/_VN%'KW.(/#H($YB[C+91<O'R/,S_2WM/*>K[ ZG#Z]R&FT22
M.!_(<6]ML^2"-QZUBYY?B3S0_R!*<;X?YAKNYY/LJU4A/]<K%)AF]U>V/H"O
M0),V^O$^9UD#19?40@?&!?RK7'MVA!+4,U.-GAS@K6X[ KSP.(!,MS9@4_P^
M=4JB@LKMSXDF+)B*'"MN8Z!V^WX5!LBU;K%NX3FCMU^0=:,UUOQ'N[YX8U/;
M^-9'7$+?]U6S\9?R9TM]).RU=<WJ#+>O^_EQB_>-_DI8;F^-J V1I7*BUJYP
M:?;P0PP2E-6S'Q3\EMC:Y./P]O;F^R#TKNKX]W]4*S1V!X1I_\6F]5K;6XY=
M*+Z5;HF*&B0:]0XT$U^Q*[Y.PQ_; +SG'1M?"PC67G-:)_1#@4L0^[]5_J7#
MYX8'2UVE)?@R5_?_5?I;52J^(_)B,^-8Y('BD+QG<R519?"GE*K0LEJEP,#
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M/LO[6P6QJ%JSC(]OOQ8?LK#[!S6_08-' "E_9+%'"=5;*7_,R).5?@2XX:W
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MT[!R:P*VM</"7EX]V+MK+"CCKIQ#7E&#U%5U]>\VR[;Z^*2\%OX[1MJ680A
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M!AQKDCLTQ%TMNVK8*WFO+=;A&P)A=WOT*@?4%0(S8/XM@:,>*XB3EHC."T<
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M]8PP(FX2@B)F4E^^G^S9I1OZ7G#AF+D]0N$AI1M3&[G!Q8&O/53]L[)8-W9
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M/M5RJW_]6.R7B4S^7M!)N/3B$>"RQ^1,4TR[%?T%HE,++D62$R'?A7ABA2C
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M'*:*M':77SW#\\D4]RNOHM=IMI!PXY01%3]JHF.*6'5N4$-3G9-\N#Z%$X!
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M>GNCH %0X<(%U."7(XZ9LN.M+\NU9'>B\KQ9?,7L\V,4?4 N*T4%P</@MV:
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MB(P;>TTM7\+[G%K#E2[/9O=W*K&<3#_2KVIL6>!@@$$R%?L7"7K6<861;NO
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M(A2P])UVD88L,],_.G*/@G3'9Z/H=COYM;UL$1 CF;:W<8R>SY#@I$0 $4G
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M-XJ=RTX?XT7\4'-S%&%<S$MELQ";Y%7$LF)$<DK!SP0%YGF #0&RKC8#P_F
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MG@)#3"ID?"C1: GAM/(G]MB;#F>"]!HS3.3[-5.>VP8G5(F*2R]7F$BC2C.
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MW);YMVNZ1Q;D_WNKN/#?<S-@,.=0^> R&XG>W\'C=D8]K+-+EWF #UC[5AX
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MUZM<$9XMX1 7A8*01O?&Y)^WB2-CC''Z:W7#RT6[N2R\+/(!K-G*//:6M(R
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M;LKU79$K.T5_]$G:<.6?5QH7;W\K[S"YF?.1]\/1(\Y6EVK".!_?%KC]^)'
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MJB)%#G*_$VICDJB0G)\6,9.2ZZ].]Q_KW7+GC&,F+1.Q ;A@_:R/*L\E-A#
M5;-09=:IRW0!0\4<G:PR#-V4(3."D$\R^;B^^=RZER7<1+_1TLJ-++\JZ^NK
M\XUW4&J"RM'0J#^K8[O]GZEV]//X)PP/4J9+ 0'SY4CRJ*#Q=1)%#^*OW+";
M[O"$5=GU!^8,'/]8J(\0_Y0FGILT^[4&-GQ;R2N!@/G,PSB?N@< <+HS>@!S
M'GT-*=1%-'V%EF#[]],M/N02E:'H-L%&_)@G6V$)Z(>&% _F_Z;-V*Q4?8*4
M;^.G*\_B,"Z^S.R"&2U)/5$WM!S52S)J^YN41EE4Z43WKX_U@G&:3[X+EY68
MUUM_-"MX\->>>L:*99G)N>CW=@4:^1OC>_U(GM>_EQH5KS^Y"CNE@:+(=3]^
M3Q7(&3@5E (U-Y_PTBX]]WYFK.+"5RL['#3*>A29;99M-UR!F+:HC^D^6)AI
M4>(0(D;,,">P*"T?KJ@DLZE*>'!$M]!!://O%)C":!]"YU? $&?T;)_PT#'W
M<(,/AF*]"<H/"#<\FEX+$M+R#-SW<"FU<X:.4L-&IW'#D-\!O+,S,R=RF\;4
MCAQC)<+Q5'T>X-IIX;YH)96$HTC31Q!CA$4#E:S4C>&!+3VN'ZM[XO:NXFJJ
M/2ZIZX=-GSQASJWIB.V&J=K(Q2(G8>MA\'Q"-M5<2TS/)-L"$)N'%^<J0^;L
M]6CA':G69Q#%%=W!E9^H0V0Q36/K;KZ^@/VC&UM[1*+]@]GOB^9E(BD'#]5C
MT:)W^1VM8P!'Z5,O/)Z\LGO_7G8+FA)1Y29=VF+GG%4&S>X& GNV,H.Q+T0I
MMLE\4&O+H+$"V1G9<5NE0'UD_]>;UDU@L/\9[LZ)[;^M+6KA,9 0HQ?$Z^ZK
M15VA;E)_O7YLT4W,.-B:)78)YOB7R@_Y^/B\6+TY .</3-4447FBY$?)G^DO
M7=E'N.(T\[[M:3I;O)8G?H7_W?)YV%]'?.O'XD!W8$P0@G.]V\+X;%E)P;>#
MBJ'9;79.7F S(L8E1H)+6TP^%[88/<L3PSH39G3CO$@( C=CW^<]:BSO]AVI
M0I]:2S&XZ@KCN^EWP/5OF\&#Q%N1..I %U%RBFC@EFM0@#*COGIKZ+XUJ[K>
M5E$^Z?%C)8#.V-S!R#R8<)2 IPC$/*A_R4]O@%YH^<O,C@'K%+A5Y28?JB&]
M45P%ERC+'[,-,%L(Q/[,2)4ED5MN48+TOVOK=/,N:QB<+;7_/?W*T<'+RZL_
M?RUYQ/ J2J(2:6M3N5OQ3,X(Z5(] W[CB9UQ,J:=S1HHM;\1N46P'?7R4MRU
M021YIT&>>#TO#R-Z" DEJ-6=P:J>'QDR^>!@:PA[IJAT!2X'>:)X(FWVZTS+
M=/,35U=>6SWO2_%R,9.+3?"8/']?A;8<4.+VSMTYUDDQ.DJ;@"AC\%,+&.;?
M= >N 022"L'\FCF1VV;#7RL]5,^X<;2"A/T 6<9/":YLKSQ$.#5@>5P$;_W;
M_^Q?]I.*HZ22U*,J<M73(OHCI\E#86**3JW1O1R1&Y-S?:Y/SO?R?V"S@:?\
M(^+KYQ6%.$.^V4[D- EUZ1,P_?(3Y5K9P*W"7/)XP<5;CP(#K<U]AZ7/&K@.
M\?&2,*)?+1!1R$Q?!4>C(_[?=JV86\9Z-O@ 0ZVORHEN'9Z!G^K^\;2PIUW-
M\>5_._W;JFFW-;XL#P)+ZBGM*A,[NG((,F^,5] S;FF^GV,/?HB//+DY9W9O
MM&Y RY6="8-Y=AB/92M-F8R]^ZG6$Q,KB5C-]^>EZCEW0H!U3ZGF6L.4M2=_
MA$OM#02PWI,5Z\2A U['0Q!'&+.%U>YG-!>I*UXW^AJ/W\X%BDCP9K<QA>?2
MFM<QCHH%GIZ(4/\@O&G#1 J9;&1D;&)PXEG8_<IGU>R(Z6$Z[I1OH&<0U-KV
ME%2U-.WR:+P@]HO";GK=RV=)]^1<MXV*[.>\4NZ4J"S=CR/%WVI_F3$PR?"D
M)IXK+O79Y]+XGM]8,C+X>3LFEM!4PEJ1#2%XW8BO2?(J:LD3=R-%28QGW$(Z
MO4:<\HZ5AIR='XVQ?E\@7+\8?'4FP]RJ\(^TS)^<4AL[4]\]E[J:VF%/5>-[
M[GGCE?/QD(I[1E'P5_4XJ^::Z(,-]\OAKMD7XF1N#" '.8P#;BGX=M&Z]U)P
MQ##C$'B^76ADQV;*PDXZ/#U(<9;GK(=\U;$/&Y6*SF$C/]-C0AJO"+/E36(K
MND0"D.9B\!="G,XL=0Q%!<J)5[@%N4H!722#OSJ<(^\[!4D9>CF/7N'5@SDA
M8"4VT&Y4GB3SC9U!1C;UWM!T;\@J)#TA#']64%;*J.13&_!FGGG/6$7?N\.O
MMR4EA##VL+ZTIC] /G]6S"EEP77[+1)9)822[OWZB"V7D>;:+4/9O!^'X]2O
M-H;VB&K;/:.XSF0$I$2OTVV@/-IWVPMN><\&5C2F"(97F5TK @>;=YN<#XR9
ML<<-&+=Z_KDA\T]NXQA"?[XUK?>KQI46N.E:* %BM7%<+;4_"+'7?Y[<>S^G
M 7?ZW<]WJBL:9T>'#T$1UIS=ZO$BEE16@D+EVPG:D^[]NXMDN8'FH#KN09-0
M__R:>W5.\DVQ/A7)S%6%N)2/!?E[K] 376Q0O6+6&0\8J7<,';&U_=E2W1H1
MU6U\2B14%^1HDT9<5'@@0H@T\A[&>GD]) @.^ 2Z2!&4[67NE& Z9/%>\/8?
M?=11@S0![+C"^J\Q74FDKDAFE=2Q^\9W6=/VS8T$^>>7<3=M)SV\*U+2?4."
M^-52C:1P6W^VR'C.ZAO^<&1RQ_F2:PZ6UKS#N9_>N\CV;#O^5!PG,U?[*W&-
M(S5X/N]M2V\&;_=PC@CN\2_6B*EECD;=Z]BQ]]G:0<_R^#=SS0RZLSBI1P$C
MUDE'&NL6)V/?-F%]FBX_TZ<B].CK=@%A[0_=:HK#F] $S2@R&MO0[?+ X<Y[
MI'7OV3K%%!<AAY9V>ZLIK2K&(J85L^["W4.H--,WV N;.TS;?<-WV(6)BN=*
ME5G=*T0IJV>0"%QC:HQ(Z,V#)R-$+0]6DK8D.WSES&J5S4EE"KA+:^[([VI@
MTYY9CN8$#D&W1YZCKR"M3>,]>3KQG!AW,/?<"I=E75WK*$43W4QIE8Z(F/FF
M3BS,YH^<]51TSQGJ.\ P> /W!D/E#$?KH*\T3P='E*Z,_@2R"&2E2,2N44@2
MQPC,2G OD:$WBEVW,!Y#.&%C+-,61Q^$GA]9-6^HKJ8=4PE^CC\614&<^8S,
MNA3/%Z\!YS%!&<951)8V1('&?FOC)1]U/WKPOK5"]G'DU51LM$_)==7S#I1W
M^QHM4;$W-% IA7)1RN7VR%\V'O[S-4U[$8_CO[M<%P@J&_U5<<*(1RW_?0[2
M*'T.B^?+?A3G;^0RLMOHKZ KXU-:GTGB!I^>@>KY-AN,?4\JFEHM*49F.,!2
MASA7)V>F5F["DJ#_RER$BX^TR\K!O4P?!+,TKK+MHUHI@?CP@-DQ:C[]=_26
M2Q;WY"7#75D9^"3IU<_EM;?W!*W=^+!*/&O)! :O'NL4MVZU9Y +M;GCK4J,
M]T Q_! DA)*MU'WK]2FM4Q4?S:WEEF$S[=F0C"VN"_L01GC8"',*&7"XBP&N
ML-D@&O+RQ2'H5!O_C*F/V.C/H3(DH4,S:FI3T7Y*J>+$>$X*:^M*];<:C^$!
M1UZ8)Y\)W-\ZM:L7&=[Q(MBGWC#!+C464^?M%_KK5\6@6:>"@K#5U/-@&[0@
MF6M35^P;5<']%S6YK/(Q/[;(<#S1<UNZ_/F.];#$VX/:.Y@*R,IFH8/];[6#
M@$Q',4*DI.9YZ86X%K4A$8<GMP\>QWYUTG5A"%JE)>_<Q,!,7:X6^ :%^-3F
M GFFHY^&-\BC;#-!3)YYI;F0V5:M6IA#]K05TQS<+)_8^M[U)/*KD^KXKP-^
MV\B/065(#X4GGP13$_799>"@KXA=)$]@$!?+E?+'T&(P88/7ZX1U8<4JGA[,
M\=55@8EL/L.B/D^X9P5@^W50J4J0.\A+47[CZH^UQ*!U,-8^YW,YF ?3P0&>
MSVMJG4W.FT-*M&==J!NKJG":J,H#LDF0.'530X1V>MPS=[\9DTW+L8=J4>LU
M!049N"0.^IG6AO=2"=M0&B\R^-6"O!KFW;6&K^B]H)=$T<&"3>.29?=B?</^
MWAM)[W.SFQ7YOLEUWNA^ZBMS[0$OZF. W!.-_+3HFA).P<;&QD\5BLBBDPV,
M9+H02H%9U*:*'ID]3AU:RSW8?,6Z^KMIXAW9"",":XJO=N/JI)^YN45TIH%C
M50?/DZ<\5>QES&H2?7(\!"UTFWVN+',7>IC/Z,,E#M ,=1S-N.AEBXP;)=2#
MT#W[5RUU+P%&QIQ_XCZ,#!CM%K]4_SGL#!12_^-20U.X?KCEV/G%/87KW&\^
M?39L&^(N=Z^N:L=033" C$PG=-* )%T4WG+9614JL&I^IYRA#T240-JU#2F;
M_!^J%0N*[[\<S$IZ9AL"/8M$7W08U?O\K'C4PUHS/B?PP+F4]VYQ.PC$!3KR
M^SB( :I:Q)QOV"L2740&=?&<TCA=HUK\=,6R2"BN^WJB29WM^(S&>-S)[Z(
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MIR/8I \;+?]'"J+7QU2&0HL:RW;^<PLG;2:X:O"8UY!U[0I=4+(:R^IJ->.
MB-B,?JA**3"2+LPMO=][]IBH]XVD!-MO_\OS9A-8MU,Q>T*?#T$C]G=KBSV)
MFO@P'6CVQSK70Y!_%:,QBI5J4_!?7H ?X\8N05CH_CJXLW+XP:)ZZ)0179-=
MHG(/07C8[L[N8O)S^?%P;N1+AZAG83RB8:!;E 2V XP^NME,G_OSFO]:^_R1
M?[B>*B?8[:X:Z?.#S/[G^+_;9?^GVV5WHZ\5W_QO/U:#9PN;+Q C]L3H".;9
MXL?_93O(CT(S&$<78L$)>BR\V2%H%/N-C5(;=HZ"69%PFL'>U@C>U1[#.J5
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M2355B81;VQ:*Q'OP #)%:PD%R-1YI;W>\#STE#*P!!W3AI'%A+K:.&(ZVW@
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M!NNM- M*7_=J]=D8YJ?/JURDEFR1A>$*[KDG/.?[2 V5B\).*R_N/+]U=V7
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M"'JJ$]@+%F HDX9$488TQ?>Z@FRN'9X/0@LB>Q!MG$!7%_AXVU6&#>!&R99
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M<AQ2CQ!*F?-5&VK!"P0XFMP7=>L]Y4V,*CHV:&)R>0?I<K3[@]>D/7D/N%I
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MK>O)Z\ESMV3H[FLP"2$*U713*N3>06Z(F#^,]HDN0P*^K/27)1UM77]FKS3
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M%+=,C;X/3>\]L=<[W/A^9M?Y8G<NK#=$(L6NGA=.+6V8\MF 3='[H$,+P]@
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MD/!9!'1JF""-%-WG&#*8\?7@V+-G)RQ!O)7%+$#A'R;HGS&EBA']W\D0V5W
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M3-!2+:9].,-8$%9/"DE"^#)!*9W@1W"HK[>Q *R&Z#L X5^-/P9X$8,"J6C
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MKZ8/XMM+\5FO2%9?MFY\_XB.ZUYA@A+/>O:,XV;RKV1<RV)Q<%MVY^7])?Y
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M35@DOH)T-OO0!*8VWWJIA&_0M;JR$S*PG8!6G&Z* /, X?T&].5"G_$,8[4
M"<>K"[(49*;LNWP[KM69R0"\Q6.MN7#8VX %N6YK77K(%VWG&2TC2=<@@R-*
MB@NTQFG?F]S3XE^7" QPNNYI6;-^JIY?>"_]VLS^R4:=[V:R\LL2M&5Z%Q-T
MCPD"7 MT/ V:4ZY]H9G4^.M(Z*22KLK ;N?^PC.H2ZL8 07!]^T3/K&M(=RP
M&NN6-/ )ZQ BU[980#Y>Z)E9$'W?UBK4,1TI3^(PWRF6KS"X7ON<..4*1\DI
M1KQ97FNML?+] W$HL;H9,%'[W->JRDI;MHJS^(6_[8W79E/5/VQM;(LWUSIP
M_HJ<>9DUCB,0O_$Y]2%\0?(>C\Y.7\R];/+"MMM$JYWH5S^&QFPK)(LA-:E]
M27+>U(2B/9AK6CV\=*DG8.-JUVSW:9\WEK7N;USC"ZJ!G:LMB=!.G.+A(15*
M*<!BQ&''OC'.N+@'6/KZE'D"EXBQKL.5%A3'?@-J?J2J'%:7(:[67BI),2HI
M2[&C.+V,%/WJ=A."E_BKY9O[7Z. /9E$4(F7\(@=7A1:Z9KP)C?6R,>?[NEY
MLNZ*3-*NCQW5<9-5%W1(=P :M"DX;3 ?3'VP4 >UA$PK/3:M?:E$$^KTK@O3
M=B!)A6& %/6M%G*1&T5U/Z.5YQ)181\;%+Q(6*@'9[8&Z?871C8EP"U%7KXR
MJ]YX&!.2$K*Y*2#I<I] [M:-.9LCC&KH>=4B\B7/)GJT<2?/]8^11)SC1'U-
MEZ(G$Y1S\.?P*A_P#BI@SB(WL)1@<3IS[Z6[E/<IV_"O.SE3A[:E2U^_Y6+?
MM;:KW,JUU#@MCR3J&^84_PX<@ 3H_VJ ^&+2G75$U%\OX@'C@_5A*^N_[R]/
MJZM6MI7.VF3]@O<%[./>/$P-,[[]N%K@ QP5[F[7MYT!:>7+,+2H\H/R0[RW
MH@B*2943*^^10P<I@XLI"^KMJ"Y4<YJ;JN%JO,Q8C7+  T'.[Z<OS%W\Z95P
M/.;YVQ?U/[@$^;PV5[TH\=-36$+MC3#8-6F[[X3UZ1JG]AZMCG-7&MP"SWW3
M%_]H?],A-^JYL8*X=I3\YF:AAV?;9C<:]6'L4G:#.'L9.Z4IEW$.'G3D.);&
MQ=<+^1XCO*$BM%ODP9*V(K424AR8B!Q \KH&"GI\'0A'!,ID$B7_CK16TAJ=
MS;.-ZL07V+%Z7#'KJFNR!%Y0V(FZ3PPY*H&BWJ/J$8E)\U1!(RW2KP-Q5;"N
M?H;TE)9?4\.GSN*=C<+=";]9T[^*N5R([3FE6_/>J'EQ'O<-]2',Z[-O_4F8
M>=RGYMFXS0U4AGWOPIP7HW'6_M J?N?GBS+,KQ6&*ZUIOP)_[2E(?D]<C(TR
M[,Z:U;TBMGWE0P:'$]LQ$V-2[4$6J=90)A!KS LW!0HH[%=GMN,5X'RSQAP!
M,?>J>!I?5 267C@2J#64XT5XU4^%):C%I.KW;>_2Q!<WU7G67#)J-X4&DA$E
M")]QO!<U!1BD<!&CDHR5&*-H6<"+ #D)&Q\L%$FB2*/JQ5K]B1,H\0:55N5Y
MR(UN4<;I&?OK)F'$$+82:/]^@;[?[+6DJPTBSIG/-0UR8%K-M1.P*I4!T%SD
M3P*X_MQ=>4IQ@^XY0ER]M<?-+6.\;G6!)K4]S#W7]KP!^N%TWJQU+;7=<;O\
MX_L15GD6I),>Z[HEB'?Y\4S1S^%'IL?XKERTD+VPS#IURJ)67UR8^^7OEPG1
M5<^;AUQN6&'A[X+#47#<D]%3&)W0RRMD",%YD,=B /(6F784[+I2/0!%P1#'
MM\0)X./P>T *:3PA"MKJC,5P,<8QO S%U4E8BQD%O#G;!&?[HET-!!(6>>+'
M#@JM"0C^]8/9Q]K(U(<:L#.'PQ),T%/M$J]/G45CZ3\M&QPM:^X5=<Y08H;=
MZHT+"VFX77KD=SK 6U,V+KXD^#WKE5>MW,:PP[F%#CE].7V0@+E&*4CQO5R6
M"9OWJ< _-704$^2?C0^WG=VS>X000"O2]*8,@\CE1FY$0[ PXIXDY"GT!!Q"
MY&$EJ=,$"QB<IF_\C8]3G!,C$4>XA+5CU04!P2$PVV9W5,5"378DEXWO +Y@
M@ D2F_.+.=%27:'-EXDDVX>DBT#YFA@",&NL"$,.N$F"?&NG)@*GPTD;?,F>
M%\F^6=W\%!P!3!-<)(*'%@7=@4!JRE3\I>_9J?%ZY)4,0[[(2B!AO'^1I353
M<6#% 86Q2\N%50RTQ]SKN(RXMG!7ALXAS7=S8VY.;NK!1?U*@:'+E]!4T ?9
MY<:MRE,G[R,X6!XO95"@CTH%Z1V80 S+.J)E?W.$J"X</RIS"<BF[!-\-^,:
MX=K ?CE,E!A TP3L0B@5-D#1B7K1(01W %C:T+0!;C]C>-58T-J'K.D^$2]'
M4TXGKF1$KMU7C\#P6E1VXY$^Y$7J(;T&[D:I<0$0)(A0_$<T*Q!XJ O(42LH
M-5LNE,?QXG![BEEV9D33MW22YTORH=,4@V=5!RH1A"!XK!;6/%&/+&H2Y1,.
M0(KL04 P)JA_X0RYI 23>?KQKX9'D ?=V+7W#^F6K'L.QA72?@O%\*_RP7T?
M[OM*-5[4)['YZHM]T&.$PI6/*.$DO2U>X\C3!Y$3KU"0_8ADUR>(UI3-*GH5
M$2'"&#W:DMZEAH#FH25<B-YH&':',+K])*;]2+A#A%9S4-N;1XE1#\0.2M1D
MT,!$A(!;8*=E-UD]R38GECU5RU#N: 9.>N4N] E&$FZSU..\9%Q4QAB!'&><
MC<=!!%H1V;H8$7@D:3$++W\DHI!;@4O68!!<FU)=17DXN4^8KLI^PF"Q(]AP
M#1E07U+"KZ43$:FT2^1]:[):$@'#-7"G%H0P6[@;OA/Q83762X]4[)M[D5U_
MB!<\@Y%!\\1_A:"@Z<8:<,TIPP=(4 7 3\FCSM.;F"!O.RY <F"1S_C,*E*,
M)E?)&'="M!HQ00G=4<1L\/K139D2;*!8@THF"+2GRCZ$/MD"^)?=^F:,XFVJ
M@F7A8]TR08R^FN_0?6=T+"^=T0I:/U?^B/._J1F*$A<W.PYUX%$S- UB=B8"
MA.:CN5,4$RI@<,4&FCD02; 37T>#4?D'<_;YX]8]L[M=&^EQ1GM<UAY7;(SD
M#Z4*\K]\1W79II%&(^R^NE'A*=0" 'EX"V@BK"3$R\+O4%;2XF6 F@&9\Q3D
MHVZY>E@>P6QVH"FY4W$@3FVQUUBI8_+G[.Z'QM.39V?Q9MTN][4;W.P+;'.U
M8 OH3^6/C&'-]%R(3P-D2$8'2+IS> DNTD(9QM:/VM@1V=.V&!* E73L4,R+
M@C0MA)3KNHS"E*BEJ$$/S5.+S$@B;J,6#=O5B4&2UV9]<O:L)0-KZ>Q8,#M#
M"-9B#A00%@5I.F3=IQ%\&5^TVP=[)%W(;>EU_DA!603/&H//KSO*)\I7%9.6
MQ^"W4;0F+TE,115%V!@,V[B[NO8)Q&@+L?R>WMZ\="BQ#N5MA3QQS=Y\=PA9
M!W-U:Q)M3(<DV!^IQPO"SFSWQ]BE[47F&WEA'[K*'ZCD7]B(P6I:![T)N )&
MK;<U:U>7J7Y^][N^CL*W67^H">LBQB=2Z@<A+?M]&'ZX)[F=)E<S@!#4QB0S
M!*9H8:]&"%P5L03]W6R!!7_-@,ZXV:1?J44#LP]G[>?]WES%W6MS<.KYG08B
M(Z49HXLM""P3E+P@ ^A31)<@_1!)N"(YYZWQ/X]M0U(8HC.&HH3$JJ_?_6.B
MR=LIZA$C$3VG\/Y1!87>BM?:4$K5"QY?$<-54^01M8+#BXRQ3O @ O#LU.U=
M3#HRN8C-VE8[P#4FY!%-UX<T4-E7[@H$2 H28X,,C&[UB::HW.\V?C0OXL$[
M-FO)0^6"!>&^^[UB _$^XGLUJ"ITG=6J/A)$DML1@U0=/[5RWM@K7XSP]-=
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M.TXZ_(9D$Y%AUHV^(ZW59\0.)F? >7I[[9F@DR]*+[-6(UHZ64M>W3ZWY-P
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M@Q?6:\A57]$E[Q:K-;*K+\4;^1]5<^\W;QI\)MP"U?+7@CI! Q(7SG\\*9O
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M-]E/WV#_W^>!SOY"T)X.)@EYY<TV:HY[/@J-S7KR.QKTY8Q]L<A*""7J.NB
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M<+^&$([1T4S0*@GBBZ%9- DP03OX)E1Q(Z$X#O3=<NS"JV.@,=&.W?&0'$R
M^IPO-9J>8\C?"&P3]S-/692M=\HDA1/ )ZHP:308?CB5V-U!9I0N"#5W9VW8
M&+S1$75T"S#86#.P&N;0#.#,>/-=;T$EV2.Y+G-X(/G"+2O[YZ_OAD6K.:=4
MR'@63X=IA ?MG!LJ/C\6?/%ZC6[9;,'RUT]SXJ9JHQ>^Y=_)QHX)U=ZY$*GQ
M/@U7Y^3^O&S42M6BT,GVIJ)5R:4:@QP;W2,[=U)T:Y\)LA _-&*"B$:P B:H
M=!I,?AR_B-@-0[8L,N1F4Q%_MIR7$<-(0 4\^.XP !!=&N]U0["[PJ6AR3.>
MEV8;NYT)JN:DH<[]5/76H(>,_?Z8UN9 S-U)K0;%39'CR(&W55O3N-'EP-^N
MQP48>7")(\.9#5>B]+5.Q"O@O\.5*?*OWXW4+MAVICQNK+KGP\/;+IG^^;3X
M8_>-SLB>8CE.;24^[3^>X#4EPF<X/71SIU2DCQAH/S#;>T_LETPOX8'*I%B2
M?=]2>.&+&9[J-1LS$J2%X/CBT&#?/7O/'3JQ/:BBR#M)]!G0S]=D5P_:Z^9E
M!3N+EOIX#N(<7$IM;%2"3M#+'PZ\Z0]U"G\U]7RV"M%__#"."9H8BA]' -F>
M"DS0"LJ")@MM7Z1+^6X>+=?3/2*4$7N3>K:H;JWP<U5;7<6ZCFMI4:2$C7^M
M_^S#_1G1AYNZ\C.S#YL_!QD^X!:&S;?7+3T+=_U">)XW_BGLF9Z8%.OCG+59
MG'[3K%(8[YE6.8=2OI0:J[ G:]/)%ODW:APT;>H<ZZR%G8H)/I*VV@KBX6K.
M%1!POF#N@QI[XMJ88+$B!S$L8MWQN9L[2NEFDL3;$I+".:MB'W:1RJ9RH. _
MG;?M\ESM.8^L,K+T/QQ$KJ6]-O]<Y);Y\4F''E@G?)RM)93=::VO =(>!MT]
M/K ?J_CLMO!FXSR]+575+;[H79RKJ#7^KO#"MKB'VDUQ*X=I>I&9V\/EAA:+
M0<S_D4+V_W&NQ;T*'?:[QW,VK/U!<[W S;$'SNQZ=SG?09\?!_']:"&UTZ3$
M2<+TZA\ ^-"0)C+Q!JZXA) !QOL8ERA1@QM%Z?.((=UX-L;7MU.;-&4"$\01
M^.XK8&K3,1,1B$+-: <Y0J>#-R4^_MB5EHGV;D[_,/9^A6\ @#;>>W[QO)9D
M[I,Z\@)G5X&\424^T^!SE9B2Y6*D:-#][)8E.QZ@")OQS;M;\4E=YE"3UY;/
MT\^DQ_T$QCN'&WX&TQ3M"OG71(>!*FL>STK?<U,EY[ZL-/!]AP"7,2&8 [WQ
M;]M')F<#BZ%1Z_@>(4*:-9@@GB/@.TR0TQ[1LW21\O =\HK)<)7UH0AC%L^W
ME4I>=*4,O2"H!O89%#R!6_(]@=\L7R_([TRJG;%-J=I(WC&9VOJY&%7I[K(^
MDPS9DN11HXJ3.A+<[IU0?HD><^;5O7WL*Z?8,YABL7?B.$3I_C+_UZQ/F+29
MP,?]/_6XC4V@[)E5$N\#%M>IG(6U);O+)<&P$9=Y[8E?L._6_1W#[+Y_FK@H
M.GS2SWV_G;T(XYY5PY**&A(''3/%WT]%A&G7?2Q>FZURRH391JSCZFSME\.I
MH;3/'?1<3,#<>):$\Y9@.*6)&E% K$XG']H#_C4;#8=&L&>5QE)3D7[:OL_=
M^-(.$6VJ&5&N0:754G:\F:_7\7Z?=!O:9YD@ HB.[F-G2.A2X8JE"$)IM\UX
M8SC%CW5[BJPOS5BXK)'+HFB898'66XI]N+8I>>'C8YP*BVQXXAI ,@2O7]H(
MDS'NJJ2(P0LQ;\OLN$SGE@%7<EERE4-XE562_DQ AM+8FS^G[>:?^,J_*6K/
ME-+6&[)/?UT\][RPX5*'=71XO=6OD1TX5)-H]W\&[Y]_-W)1#YF@B@QZ*1-$
MD>D^4GWC 1A#3" $4#N1>*@</P'E9X)\1Q>_8=PIJ/&!T7F1L1#A.;C=Y*YD
MG <*R>OO*;MS9C+84++>QENUX,;A:6=,QT4MG@O>+FR!1)U%<IAOLAI(CFI-
M$5 Z7*3 =I-EEW;:&<)D6>_;+1<?]ZV/=E&+*WH79<*_UZB._<9PAXIUM^OT
M$L*E3IS5,^9+F;GP'B]$$8MY6^;XU"L]K.3\VT(TCU;)#['[\ 7E5%C@<==&
ML'#1C2K7C!^VE=+WX?CG43:X&JTWN],-=K.8_SSB<YM'QFIIF_L[H8!Z:W;J
M AL2<)?0/,\$=2,(;)SO%<7OLD#4-@M7EX[8?1_V@! *N<<3QWH,L5SO?\U"
MBG*T^Z]YOUC5-WVFD;50')^%O-I>0[MR_WR<Z!2@<]ZZWK:&?R)(K?&\O\N"
MO7_M'Q1L.Z&VZ^;XNLE&U4Y*VP'=+H\)4FR/MG"++V:"_I/\C&4,(-NKD8?^
MGO"_6IH!+P1Y"PW& P_731'$T9 C O0_&LI$K>ZDV:%.=F512(O:RYYT<6R#
MTLV37JJ*J\]AW@[.;"NRCY\]>, '78$^"W-B3P/DC(9"QX5#J=9Y*R_AH<U#
M/_::W0M[K+C$DZHR!W2=V;,'"=6O"1N.M26&?VU6-C5,'L!;A M6Q RBDSW2
ML'=#(TNN3C:^$ZLU#W[A,E'R?$M5@;W3%<S_GP9%[?GH<UU]M(!53G97[[!2
MBMM[9Q)S$4?% 73BMCC-\8LQ'^-C%(9_%Y*$X3>T)B_:S^*(,IGEH^&O@1#[
M3ERIR_VFK;NWT%_S^^EW$\?YW=S_XBX-Z&P(_07%?K])KU)!JBW]L% <((3I
MEZKKIG"'4MDYK,'I!\GL1=*E]_14I%;2ANKNK.&2@B/UVN7+LW-)\1 "A*_4
MDE<.2V'%AHFHBR>,O-7GM1YTO_G2*]#G_?'">Q>SW 9<G (SD[A%/$FI34]+
MP#YBEN;K-HH;_^DZ$;U"TYK=:F""S!5?'S$&GHQA@N0FL_&!U)FC5.6?RHIM
M'\SFROOS1_8N.B?43LRHAB 75R *<UV<9[2I?P*22"LI6W.'NH/;-$?T1?7Q
M1($CSVW,2L>P0\@3R):OPV&'AL _,\W^.;@10F@"SHDD20:(,$%'[WLA,I\Y
MG*'<@6!.PY EZSC[&S^MO2G&!:1Q09NJ$978! _CI#HSKJ3H(/R%/9*Q#KT%
M$<B74BHXVQU"@GPM7;E\I+?ORT]K?[Y+(N8GA?$D9:A*C%P:\/(/BY2=/R-[
MRE3I>)_/UT:+U9!'<(?22V3UQ.X@GN)\#=AP?ZD,Y2^)B,G*YJ^#1.DSN)MN
MECZ7Z^3F%.;<7N;<L&YYR+($@UODA%GP+(5&9P7FA]HJJPZ3E'\ <$^;IP3W
M;3Z5AZ(\=I)/^Z:QY)]A?\=Y=E^X67?70P)5=R/"5R(GLS#OH)&'8I&HMZ']
M^:)A6KO(G98,I$J_K]YF5ZJ>8SI@)TXOR!HB/OBNILMAG?;[?B-L77.8H$RH
M))?.7*BS=<=79\L!?(=7^-(*4]*Z64C0X^M0#H8>W"#;KF 8PX4J,<?=B@W2
MO.6?9T:)>M)M6?-DD@9=Z@G9Q*5+>]G*^)1\U"FJ=[NUSK$\LML<P<X6]CW;
M\2NB= %%;M_B"4:+TJLQ=S%/)5Q5VSJ:8#O#3- )U.'?ES/WLD_ 6HXJ,3&G
M>E$8[]N&@YL1I'5OO,L<T9F]XN]%=#&E3U4<[_0RPHQ+!Q);I+3/(>Z10G>G
M)?3S!5"P+P[%^1(PN(>[0HQ0\5Q>A4.#HF=AT0O7B!\2CL55-F.(:H<'GC//
M?WQ:LRM _GE>H!4Q^=D,[RJ/#Y(O2;$W$^X-^.]]UG*]"BN@E2I%_D!N?E.;
M*]=Z[4/S^0^OL15:P<WG;G.8.X'JV(K.+J2Z;JV^P%MM^SR<= [8JFS$7SM;
M7FOV>BW\ZMN!NEO6ROD<0L[YOZ_^,%$1%KGRZ<:Q6Z"KH#Q;I",NZ);"6)E/
M\ _#WKSY/BZA$<G^D3.Y+YTDWV74B2_A?N3F)F8\Q_^\'A80K/RP(OA>@5/Y
MY/J7CHK '?-1\S\5WC-K7=^TISU7N\R<8N>TVD5#H@+RJT1,'NSSJW98R,JE
MIC_]J._#.?<6^XCC0_7<NHBHSV##5M7(4Z5G;M\'-#(T;E=A@P=9A6]7O<M]
MPVYJ75E%O;NE%)'N5F=4/GM34:3K^/169-Q69&P4:CLD)SAMW* M7_Y"B;6=
M(/OO#//?<Y\$@K_]^)OV>6X?WJ71%24V+JPZ2,\LLX^*];\/O71\$'LA'W\Y
MJ-S"8\[ZG-X8!VA/Z(\/K-'%TXKB%)6+VA8.''%S&[1T<YN[_C.SZ&=F_G:A
MCF<C%:J3'G'3NZ<EES52>KYE#O0I6 !6"*JUZM!4_KO7W(D[ZLY5V:5$^[ZZ
MM7:UNVU3*L$*)[TU^J+8&D^=XGJ>97[[T=OC3WOECSTP$WF8U](:K^CKM[=?
MTB"MO5\<P>NWVE$1#5=^&3L[[>81C')"%V[5/7P5;RJX>M$HW@$QO/,:%X"_
MV=7MN!X#OVA^.5>_*:@B0EX9M/I;6>GTET>]WA=S!K@;/L]7M=YI#&YHF/Y8
MKCV(O5Z/R?^,<G6^[L8Y#,I+\LI0PEIZX)S@N+!0UQW;\]>#^D*TVH,Y_57Q
MEZLDZZV,-PMT>T1'(QBJ'FVQ<T$Z."+FVY0OM9+>]6>#-)[PGLH$I5MZ&UG,
MTGZBY^V?\1V>AT *F@BEI=-D)FAS4<61,05I]WX[*C4!R6)P-EMSIZH$0PB.
M+MSU0Y\JCW$6RX@)Z\FF'2;!3$K[$.;:&[ZS+LA[Y&AYG^JV++,",\7(2!^A
MKK6%G[=\8_RK"U=J?Q4&NKZ(M-%!M4>]^_.-"3KN"9106)>V:8+;U#P@A]PR
MV/D_&'O3<"C?-_Y_6B1)8PE9IY)LH:R1S*<%(627;5+98[)E,&;*OBM"UDGV
M94R6H2PS=B'9R2AC1I)E,A/&C3%^OL?O_^#_\/?@NN_KZ7W=Y_E^O][G<1\S
MQ%?($ J9&Q&P=ZPG]/CK6UB/H2I@J3-'D;7K\Y7N*(W]U>Q<$N8M0=);<N B
M>;O%+#[.4::&,5].XJ&\4)HME0?%7K>?#C(CA;5GV1?45]SWQ9OH_P*"'5*'
MVUI?B_A>ZO92O?:\O+PVZM$W\@R4)524"ER6H3T\ #TF1AR MMR <Z@H\7UP
M"5H$(HK^);)GFG( HH_-'8.^' DZ#$L[TPS.,54!V+X?I5JAVV;WP\!5NW>4
M?"^,C1V^P*JTEJ^0)@BIUA=.\MK3LHH@*IBNL5=V%2A7AR,_%8E_G)"\L>=/
M.,PRI^#"6T%O7!@*9U;WY*:89XCJ#Q_X,_W3?+KTIT>S6&QR@=!CNTS@7A2K
M+VV.;_K=TL;^C6-]<W=YC3*O_SW2WG'#4>Z<J\II3M='=J ;MAU9Y']HU-D#
M4)T!+PM- 4\C<&V0=<P&ZS$Q"JA4P,1:?2@F3N8=]2MO*W;+E-%,2+XW='TR
MN7B?]"8-/C=:/+UMJN?1I_Y\6RN@NE/AS3_9<HN!M\\^T(0Y!,_A!^:SY V=
M(,4P^GTXKS>#Y<O@C!YWG,SJ4D&J3JO'TI=F:\Y$!86A^1'Z4SPF@447ZA-V
MK\-]QVD/>L[6-)V15@G"S<F>X$U%7;T*(K4>24_M$M](2H>])-+O?^"D">.>
MINCR(1)EI(ZQY8>/O4H?>9H'MFS_E;"_%Q51QJF3NG_$>__\[N5IG$,'B[_;
M%FMC]2D]WL,R.10O;Y0A:I=4GQ:M;E.\:)H,\98V3?(Q3<!<N7!\#/U;<VPL
M^92NZF\%L'ZTK!6%((R#NA@ERTY@;;ESY:CR8:*!"S9MOG=7#K=&^!\AE=85
MLI_U_FK*B9_1YQ+I^-+1:V"&#8'V_G2WII,[<(D%ET9P,)-I'2B]A7KB\P<O
MODMPI?S*96>!2?CFWO<Q:T1Q&NG?2?>[&9(7&>5/'YW4K>L^DO:?B 3BKT+W
M <CC!0QP/P"E1/K_0HH"[T]^^2+5(3IU2V181&3SR[ Y;.Q<;N6YF)J<3JJ6
M?;/7IA_/S";JE]-49?]/J9UASG.#8A$624]+4MK+1$ID!Q1$HOQ-^4V5%#6_
MY?CY^:IN.Y@!'_:ST'#T+/0_NDPT\C&F ==C$N P[3811'MA)@)$L@5,H+83
M?_'>39\+UN\S[MIGYL/%(Z[QVWMF[@8E-SBXU#4VZEE!#LF'KP&7 @&SY1"8
MA2UR#%)F0<'$LE=7D8&JEV7<_I/^PPFQ;C4IW9(=Z%*F=[-T=BC4,%M1Z.\
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M;?U$"O>^NW5K*C.6&0Y$AS#@\\H=R@G-KT92"AF:%$@7.DYSJ7.H AJ#^KD
MY?28DVH]9+<@?'&BG0^8IOVVR%"[P7P%_6@/.KM@C%,W^#U7$7P(1Y0IEC %
M$JM-7%/%K>@>HY_!5J^RN>D9TVM0ZDZ@\NG5 JF[J=VAO6_*,,="-)HQ<1:R
MZ<X$:TWM@1[>B:>?^4IU"VKW/Q' RYDVH;[Y]#YF\L?QS3V',#%N,>A,+A6+
MS<_/+S;DP)9@L<3H#TV-C4T1:C'<"*F4<X_OIERZ:_W@ #1YJ(EF@'YOE9-,
MOSXS%(^F"4\J?WXAW/2!S'BR'"[\P?C.U '(&Q='4 ?N["FA1C""!+'EQEUB
M*D&,)0:D+L!/VLUY;HNV94^S-"F*#E;C-3@U!\V$;<>&\;)&T8RI:%<UX>8)
MH33/%^E=?L'B%3L9[U$SFF0.HB<XZ@#$?87HQ:/,; *.,5(- 3]H,D$36'<&
M;%U\Z-!>2<UQ@@(9\%EK#:;C.@O ='Y/V#D:B_LX@1<(HWH43P;FYHON.DD]
M+!CNUC;-05'_!V8.3Z!@M.>KAE]/F'#@TPW>6WTQSV\=3^)]_GPPYE17!Q+*
M4&">IY<L]7CCSK /T4)(K0J=8M^82 4GSD&:]M,),DT1[/.(U/_P,7VF#&@<
MDD,SNIAN/9R0G%^:ZUT!?+AY0A'M%*D_(C4=)&$8R'/6#ARK^CLG1$.]0D9$
MYI22DG+@^%?%#4><TUP'[<]*6[%ZV]RPW;_&XK0<9+."H4.0>\6&6?LZ(+>>
MRM9$M-P98=VH0O+2PW$]QC? <<W0))0"ZVXZ6S H-FH3%PFK-XM7UA5#2K6,
MJA'/K(0>@+IADHXLWZP>-B06QI!L; S5B*6:\=\Z456B@2GT+/#9TT5WV*"4
M5XC<1'>'89$9I,[(IOL!*/K)/#G)61GHKUH1ADE"]M"W 1L=+09J;QX7B6MP
M\C<[M+ &WXJ%?)L#$$6SV^R8)Y%7!UJXW&P:[[<0+M^YT+W[.YN^MYEKN5]Q
M '++]^WM,YY"'4&Z3FX.J5J-X8<T328.0$]A$-CR+NKS^_9&DF33$]?@^0J?
MZJUPH9]ZA(SRV1[!.0R(ES1XUBNA=@6"!Z_U57FQ)1@G*O9TD8\F\(=Q*-&5
MGM*"WKN 8&[8T2MGLDT.L[+E9_K]K&9>O'=B3*.HX]2'$Y_R/WQW]8?MMG1#
M-F7[5O=)-P6S6'U,,-R,C<81H"P<F_,K*Y5AP!+49!8P,%&'B(#F5B((>\Q=
MHZ=VKL\L]1"D&; $'=L S>[KJ=WYPDQ/AFTTTKK<6_1,?"D@;#Y"D$8T47_C
MZ5W=DN?HZ AW!BQ:1Y&R?Z=O6H-IXWR!/I3&3F8/D?'K?;@$=*-,(OL8ZT[S
M/D8'2L'%ZIX%(@M7FR'1?Y&6!R"NK%1=:80 U;3B@R.BJ)T/B&!J%=)[FJ(.
M*5DSGB43Y(-S1KQ@KOREKVYGAL9D2#^WMX)^9*8S!LQ2WR!%][$X'5."ZB1!
M>EE7<(+ S?(C MZ4X7C2H0%+ 7XUK-O_^T.>,CIC_(J.025"SFUD3L-S\\:%
ML+#R97L-3-4/C?>Z)9_V_P]E;QX/9=OWCT^72I&F[/M4%!$2LINK7 @Q(828
M)%DF)MDFQLS58E^F"&6;[$E,Q9!ULB=I[#)BS*ADRTRVD]E^TWU?U_.[[^?[
M+-_O'UXOKYG#>1S'9WN_WX?S/#]\-%UP+\"_ #PV CA%S:&S54?771GSKSA/
MT'8EBW79&*6TL6&/:+@$T&0[$$8&ES5)Y.<I'AK1#&_:HZ411#-Z5-,5).X-
MBZ_IDB)GTHNJ(M6J4XY;V:DX]"E($T66CUL*QP1=RX_2T%-[C_[<.F>2^=ES
M])&AQ$IQ\[6<P:Z2A_4LV,M&@,K:\WU .]<1B<.HCF=-?@NPSWR*/LQ\OS#N
M^_OU2R_X ;AT/_WDI8L?$JZYHM)A;T;N[E#X&<.P)J28[6-K ?ET4E(DJ1:_
M+%@^[R7'3& L]]S#B**/#(5?9.Z*;Z,*!DH=)-.-JYPZ)>=%< EFAX#IZ!B#
MQ>TXOH<C<*5N[M\;T9M[@K\@:Y0$# 53#J:A=K2<6U<AT2Y]RPSHEK&'V]=J
M@S7;7<L3.QT#AK+T)9(*-*O43MEU5\GJI^[R$FDO.Z(WNYMFKY-;DAL>>.N-
M6KICS=3/ZG.UZ9<K2J/=CI9-'O<O2EJU._O?G/,*R;YPA)4N7#C;]#6G_:=J
MQDW/G];((T=^7)6(U-G1D"!@J"*Q"EZR8JQT\>,&ZHN\2]IO$E.<*MBM*,K(
MG:=LI-1GN<["6F(0SLV7=DWC3;ORE@Z]B3M[)<?"X4A%T,),#+3BPP8EN#!$
MQN%H2^8(,QOT+%U5^:'P;[^K-UB>.72P"SW'@J"=F?H]D(EB&J0++RMR'.TT
MB]Q71Z@2$?UH![660E0N1"@MN81>]K1%@A_Z2?4J_SS-6?+XUKYM[>-EG?@E
M%;+$ RVG[%2W>_/B;#=9\X,903K@P_?F$]I.>4XVSCYVU,^';[&NY6_EZP>%
MU>2X(EJ6_2C?MWU#[J05<#\[#H'+C%B;W%KBUQY::MU73XW!L/F:X4)O"W%G
MT-\GN?_3CZ.^^1KT?=8_S\M-\<7LQP7D0>[YI O1((Q7?J]*X,S,IDGZGIX+
M5A*_.B?[,84FZ;CE3*V4X6[APBGN0%8HVL!,]<V8[U!NNSJCF/;E_+2PG>/M
M*@VV@=[ZR&C1 "W>3K9^\HMVR[ ]8DFJ]YT)R,I@::\2<^HN^)F\[!9UAMJ=
MRP,E%>ASBMA'(Y^Z^P^@]P,-2,8PK+6.E/,3?M"=/ /=@WH76'^A+T@\0JR4
MG.C[TM;_Z!N7M'X5#;ESO9Z?K,<OF= <.X8KK"_TN:B]>'Y6I]C^=H%4>I6J
MM;ZCU^3$<-Z5X51#FR"*AIB>E,O=8/*3G]^I+4M?RZ\U>$1&P4>V-3PT/HGN
M-XW&GL#FC62*[E.$&1Q*F]@*W?XBE-6\@!6*<7?%?ACZ>FNQ^*M774.,5/EL
MY,VB)+7__Q6R;]<VV*:J17^*"0Q@SOX)F@$)/I4N+4K66")0"502?8>%^(4=
M< W, (3H>A\C &2\A8.O,J!=L!2^Q%6= (K=&/IMI+L8^:%FB]DJV_;6W;)J
M*'+W=M5X(MMBABH &+<5R+8PM>+"*JD'4</=LKLR?S303:7.#,95O:!V7,&4
M$NYBS-!*P/)3[A /!"8A8!/4#A(8H[S8"&LC2'')?&)N=I!]CCG]BO$1>A"E
MU:EXBM&#8Q^>A>Q L>P8D9UR&N N,R&F9G*5^Z(79-SDA"Y)%HCL7)KME+4D
MT$QEJ1=!W]$JK CTP:9AC/HB7E)+"WO=5&5F+H$K!YAW2T%KTX@SL+AY7SHR
M"2K<K,2$FS/8XV ZQ_9\_?B)6JR41X#4=N@"\D1C'?Y9_BE/^W;ED:/;Y]$>
MP"5*1&5E>2?N-^N2[^[Z<6B+JL"'J)JSV?9#:.CLN1P^H\Y)78M<1OB5H)[O
MO,TVK+ALJU! %-)MO#&N7>&]94Z'3*AOE$!KU;@3I[%@L]U 3\]!]L4: *>U
M1*5#DV7[ZV.OXKJAKW#MA EJUV:4?M<\]\!"8,%I(&A6Z[= )LK)LQGP]@N@
M4^-:M9BE-3BAA9Q:%U'VH"^?3I(Y!*X46QJ(9ZC3/N:R#%%4&*<((\8E*XHR
M>:!D(BY!49MA%L^ NP)6S YZ?9>6&.#49B9\CY:=I(4Y# CU\*6*F$8K! W)
M\@Q].QP0@CK;"<1;#>DF*M74@#CWF>#E0H;@.<[35FG,AQP8CJTQ"T_!'FQ&
MT D""Q@A!CS51*(*E4N+H<9BQ%#C].6Q<J867WS\B2KNH#A/I\[4#VEH[DX.
MUXWBDF@LQ+OE%T2)1A>V/H>(]5M)P,N9J7$_OD*QVJ>E@5$&B1Y1SOB UF9:
MI33+^,R2Y>Q*T 8,_4X621Q0;[N)BIOKI.!BN^_,/DZ7JTP]]O%'@(DIW;BV
M-L-^V+>%<!\#QG3R$47E+M0?/O%Z[C(#_O8/ ,[2X0Y0ZWJZRX&5<F#<@P30
MF/%VG,H77-W/\[*8TID&,^F B +%L64]6%)4*-J=1 (2JS\!!'>^9$:?*10D
M9M8N0\#=^)?495,"V@=@^=*H^S#]7 C#JAL\29J96ZZG(2F6FUYC1&QRZX[<
M&>R?K;L#&J7N(7^]5Z>]Y77-V'H_L@LN6,+X'/49(K&L&PV+;35F7C.*PYN5
M*_E'S0C.AT'J])<RPVE@:?89(J>,NV,*)47[T8*@(150W>/TN3]_F.C1M,3@
MIZ>@'=Q#8X7C>-C0>I5UFYV^75.!<;^EA?]24?[@H[ Z[*^>!,\ '(UT7W<E
MC4^OB& )M@^##G305.)/\$7=Z54/ $\SU"AKB>^<!@UK$)\$L^%//[M->DZY
M+U#VN6[HNXQ%UDR2E5TB-7X)%>Q,/J3.;KJ0CDW$RS3+T*!)^(,_T!*L4_X8
M*=(@*0AV$ 7NP8 !,M]-D%I,914:"WC2\?LQ[RG0#D)<@0*4T50VU+R79?:)
MK4]B'$%!/9E9^?1U4NTON71JY15CA2VFLX%O!5J*4>.S*PFU*RDXIB9KPQJX
MPT1T4?=#_460,_OC&7-T\A+YU\T9WR.BQC(9R1UP :0N,E$V.):NM>\2^P_&
M"8S,&!<<8-23%$Z6GH^JCVV6H'$\]$&0%P7RG!H,"-C<2"-R'G/EV.:,\DX\
MI/P.1A48[T+RZ53W]#ZF9W9'KYD$4$ZKO[>.%T8MD"V8$M,D&EF4&D@2/3%N
M1VP<[*I; 0/I'S?HDPXU+.V?(F)<(0L&UI&YUBHQUBJ/&? 29)AC!@JT.-FZ
M.(I %PFL^XXK@"#QJ3Q3ZB)@H14KU36MR$0F$$G[/(!D>@0N9 :Y&TCNF3[(
MB(]CV]&3J]3-A]=EPDT1UO7-6W,;ZIQ4DC_L'D2&=-T33K?J($],MA?LY63P
M0%>A":17H[@TC#30='G<))I)<AQGWV: .V7U.X-@':YX$;96T P$C'"!"Q+)
MXBA<.R4^V23@A3O:G!E7J=!:_HQRYE@387B8!_+A@2CD3JXB<VZIGSXE-1-_
M#^L'D\),D0YB^1MG^PSSF7%--U:<[<PWU$7.RW P99Q?,T2:#1DHM!YC+KX9
M0M= NA(9]7>;?6?YZ^QN$8RKA0#6>K!]WV5;ZZ-+8<6@F-Y9Y.3DAB9P^RD*
MWV5V@E/1NLO-WTP02)W!WI_6']' J**LG)/;\ ?X->DY>#?@U.&E*>M2%:X2
MCPQ>GVN)VR*&U=X[5SO0;(6M[/?UH55%S,+6>:!]F 'J#A/$;+\M#7D/H\=6
M9?IUMD#^>,W4K&*P.K 'FE6J@.%?QQA^Y8&GHZ8VXW2GW.?<B$-SP\1\J0L>
M$R_2=[T<6_,8#R>.KLT'8W?I4@$5P>5-NI:\)_H*T%:)/@HD,@7;S20!$5U)
M]\WN?%='QEPW,@$O@ TBWX<07>K0.K08E1G!^V@IE@Y;#XBE$7:@<MM;#P[4
MYHO1->MI,:Y=^H+=%%S24WW*-&&MO ,Y(;@Q/DI"0F.QM=G=+8BWN!FM.,A!
MJ#]9RB*H".W1.%(+-$LQLVEE-3,K<6:_,;3:JL S]7?"1,"N ,+[=#(-GT 2
M;?:8)4BA:NCVI460 Y\NN\U+A?CG& C.(U.P"!YHPIPVEVAB/K.B^ MN=Z"E
MZ'QZ&1"ZB#G.("1A- #P6:9*O&YEQ&LW9'@_V'&\BFBJ>8B252#N16G_F;L(
M.PY?/KGR&4OQVPC%=4+VL8_Q0(J8_6!QM/]0$%^SW5=4@(@VRU*H70I"&_HY
M/>X MDSS-=($7@KO$:_R?N:O#7>'2W_Q<+L>Y@O!UU,9L"GL!:"^%/U'\Y"9
MN-<>Z,SS8>[GQMC1T?NN42W4CN_8:Z9^,\>2Y2Y[^I]J G@@6Z9S]\/;?K*7
ME26CCM[7F0R<#Q'RT._IYP/>%*<^:)DKC=9([L**:)J)H)3HY'98HJQ$5BP3
MYL@0C&M5O(2&<IJ(9,J];B,7$F/U#T"[8I$DKX<\B++E'HR!T#+K6IA6[68[
M &\"9=K+#7#Y&'3Z&U8.A*'X8XF12R1ZD'E/(RP>ZT^^D_.CG%%SMI5IU=FG
MH$3ON:,GC(^?EAGZ%AWCVFFFFS;NF=FL4S@O=; 761G82/ZT%-84>Q).1NKW
MNM7S0/R2GEW*-AYHU5R UU+?&H-C,2JCA##(?K1E,U _8XO<N9@S_60NW_7<
M$-M.LS'']$=I2575AYRJ1U+(D#*+H!"-M0AFF[K*UX(&_L;G.24FAQG(C<AA
ML]\04$&3O<R,&3Z'FM0Y,\8^\YN'.V6QL7[Y*%.GW4SG3<T040-&VTS2K6UE
M>F64 $E]3DS7)+8,O4JG?5I_- PN-0VH=U,GL!/UD,?X6K^E929Y!I(X; W4
M5/HK[LJ=)6XNWYOE@:017"V@GXY+&%/4 I28?C,K2[D,1"?V]0NXHHDY2PY]
M$[%"$>NAD-L-V$&WN!* R%-$%/;^LM-9 #Z;%:?AU7,!Q*W@J[P TD3?!:9>
M^=T79B9LQ69F+ _TIQ.]-#LVJ%49=19YT!.MDW'>+A":<,!_<&'Y6=_,?)B;
MTMA5IJA'7>:Q!QU.MF6O.)Q;TQ ^:_ A22Y,0P;0ZBQGS,>"HV-L#WIBLQ@M
M2.D,,,Q8=!UIMJ8#A^*^P43\75P4E=Z\&246BO17:N)]Y#=%Y9IT4V5MFWRS
MF6+M5(8=(04O)M?M=7J$*X?PDF60>ZXSL<L:C/$SS)5E+3I^)Y7;3Q+EJF-Z
M7"$[P[1BL>(84 !\+_%=<W0U&X)S;@&"]?" 1X2L&6'&MJ1EK-FT#-$HTAU;
MR>%S/N!8>?+U 8RR!X X RB5+5#XIN-[<1B0HNT=:M.M'6+_LE\@<ZX3+W]V
MT\5+&I&JW[Z9)=L3>X1Q,>N(&_["8)7,TEKG\(UJ)1#' DOQV0A-O@0\I&VU
MFJ+EXB\#AKM:R%TM1Y")!?OB'0"?H/ 0B3PIR &-:V-9R#T>+9\9[K<IVY_^
MR';J"%ZJL975?_P90X6^NF%4WK:LID5)GHDK5.E9D4#5MT'V$,*PB8H28[I8
M6:#I+>5:%#X);5RZF!-<&5K" P7.W[P\O]'OK?=%7V>AL1I7.FEUNK!R?JP>
MFA;ERA:5H[]'^=$%.\ REP*P!RQS$4P/:P#)#.VFUF8GH<_0(%(HVUFK90<&
M=9:$"X.(<OO3V;*OAIL-GZ-Z.J;WQS:'A+Q 6S&_)4NEH4W];M,^:=Y@.^AR
MY5DZ7:17V&XM$>[$(&8$OA]]E)'<A9'';3P<XAZ"" 1BE#/>9C,!E4[\Z]WW
M6'I 1^? 0@1W!_-H"N8D8R5!5T3+HW[ ?8]@LHF>+^+&M,JPUI+&"U6!]8V_
ME/G.MVN0!Z7_2XN,2C2CRS?RZ/O*2:L@X\]*3Q\J[DS-\?5_=\3"OV/WV?TS
M-C-S$E](.TR<&$T]D#WHO73RW4:O_"*V^KAN:.1,OXH-XX/7_N&EL%)22RR]
MCO%!LN[D=R:GSK@>X;^L,=)4.VG]Z-5Z+F VZG/[!KQ/ZG3-Y)/3/WYV#NKZ
M;J0WU?V8JK\U)_VYX1T3.=$SL_!+).UL543+P [TTDL8N^^'^3+W-?H/4B^*
M!KI2[KR)T?5:^(T,N7&IF4#\B(U\TQLGU*)QI< 37E 5CMOF'G0HE&LVX0N!
M+A,[-T+\I/F!E[7SE:OO\]WS6I>NVWS;2 ZVMXHLW6K(S*ROUYAB5<\UW+F#
M"V7W:^A%@7NV<L)O5647_?S>&#9$"9LL=%^G/G/X+YN4/,B+F"5MM7V9FUQT
MG*HJCHRP1L9LOSSP.DV'_?VOWCTXY2^Q,P5F\+F'8[A<%@GXSO\LV^'86(XQ
M^@(/I#W9CX4?L?N7OCMJT+]'F2%_\$"SQ>SCT193V!G^X)/U.=S6/W+_I0G+
M1:S^)I8YR!5'4Z=XH!XKP&%9*IP'NF/.;I]&;&^)_EM7& ?VWX-6L9$\D *$
M9E7K.<[=!5X5ODU8_/)7*YC81W=U/FUO._T]NZIQB^D;./PI>9:"\R_(3FM$
M7XB>KS_5RO*$(RJG)%NSW><WYS\IQ%F";SS\%'L8)^-H+2,@"'I@;R78R96:
M)PF>0+LQ6[%Q4N[./<EZL,23T^S 9+M1S94?0;_^P]-^F-9TR7MT.5CS:+Q-
M*W*/!:W7Y>.0015E:GE.]5J$S_(^0Y# @XLW/;X:L+I>I>\ B>[HOH6Y<(Y=
MQ[G3JF8[2^#S_OKN+"J8[4=+Q-*P;70[^]E.R>T;$3F6A>"[[.,S3C2/!@WD
MCWTYJ_TT$?-.;6&#ZA.3'>-1SI-3>U<*8SEY]3O@$EE^GYZ'5@G=OBZWP[%$
MR<34@)YY8UK:>6][V>&+^0::[B,C8NEYAZ;27[>7S,I^NI8'K\T_MQACZ*V"
MFGP^045,!51LYSP6R1@67/V(VE[%>ZG]TZ7/7H8^:%"Z>UN)NZ4D(+#U928O
M<XO4Q .EX1@$R5-?4YRBNS4L+S\,N5RA2NS7<,X-9M4A!P,+"F*HV5M1_YOW
M8!3-11[HM_BMV.;Q]9_*?\6;/H'P'=M>_/<TQ=^X*UPC:#O.OXG %H)\DUR%
MC[_+^+?N4KB_A_P=>*9%/T@,5>QCC_\]-E4WDAMYH+>%7&^D'@>=>$:P5.,/
MB,S.L"_,E-^,UGH<TLZ]^[C?54+UB\ "E%S^4R+0]77-J*>I; #R^N.[2:K/
M025JY8870L</R:\M;H'?13D._BY"*4^OQ#]=)Y<_$UQ0W7-OYY&[.T"Q\@(I
M=WI ,]?VOU&\FV\!T@], 3T'=>\6E)[Q2>NX8]DY^]5KK])7>;&\AST[O\R-
MJXSQ!QUR5@!!?A=$\T!FF-K<BSY"Q0("=]ZNR=\\WGEG? 3<F0<>&3D_EUK,
MFI@IV &:^_I6*>_N[9D*$YJ^;XQ99/VO^R)V0^*?<9Z=C""\-]BR$DC+"QD(
M6Q,?_'KO@;C\W.&;H7_JY(6W/R,_%7@J_KEWGHM=R?G;,&JF10NS/[-Y(!5I
M:(/>7,P.S65TM?%FS,DW'T/J6T,+\D,_QMPNWKS]4<HTM#XO[[>H2!#F;.Y_
M)&8_A\H.P\9J_>4UXU\):B+=\WOQ=Q(<&;J%=SJCG?=%X.&]S 53L()I!?Y_
M+ /[.=2B=?+42H^I$<-P0_'1\GLCR*_ LOK/TRD.1L(!<>@'C6\DP@-V]SGE
MW\Z\,[XM."(?7L*_! ]$A<*0WEM@&^1?XR%_3?MO!<J<D=HM/G/O;O-O^\]\
M"=_Y1?'IJCV%-*68+VB/XL"^!9Z\)/\ U&/B,SR Q7])6=IA&O_TW3S>?@HL
ML[:[PDYWJO1:->5RWY?9:.+X*TW.$*OW65'2J__N;3M[SDF3,8\D03/X@2&=
M7=W1<R1^H2IXU&ZM?.?AI^6/*,7BL2+'$.)8OF]8,::WKODMYA]UT^$?M4X"
M\N_[D##[:_\1_Z])4E;9LM9B[2UJTN^-.G*N?J^[.?+0&<4AN0\:J;GG@CY1
M0I.VD!ORPR;A19A>TLY:?.+8](E:YGKV_=+DSK%IP]R+;Y@W7)>K U\?060L
M.L&>F\Y-Y/PFLD36>N -2NB\$F.-U9F\-/WY_N>QC6R=YP_$=<R%WSVW-]AW
M\3<82!%%$.$\-CL9"*\5? N+@TH3/7?W=43A<&BS\-P6,?N6-R,W:B=\1O6$
M=R"1D>%(9(C)=>.CCWI/.+RY;7,JY;?I/#4Z]%6(FN[)E;T<0O;',C6GTO4$
MUS0!Q<*XNR3]EY5GG=5'$%RO@:*,T?*<K\ZSMQ%+^<6#!/^6E8O+BI1-LS]=
MI&6@<RK#[,W2OXSE/85OZI'>BHE_?@^XFO&7Y9K?C-@<]_3/IL3[3E%7-/]O
M\.D_*ES:/T;?!=NXQ^>E5)#KY:,*#.9:8X[_$9L@=V[[Y2)96D90(..="6%G
MZ,7RF(RHZKP*>&WNURQ\7^MD.L5^?"3K[YNIG:1GTCS&!0KE63@>R-FL^&;D
MS:@_C9GYU,*5M8J\!I^PZA^U*Q$$'BA]%<J*'# +0%3&-*')^D '$_$6_QM7
M&K4X"^Z<PH#W 0*T\;AUL#BJW#UW[G1.,'[OPV+BG="C/TJC=<R]2P,&=C>,
M$(TKC86O12<_?L0-!F#M^'KH<HNO8"<6@O9F9B_),<!=!]P7>" 1C A:>KA9
M%QNP[-.V^;Z> DTPTV7;,<N2Z1PE6D_">K\92O,Z$#V#W-\R%W<D?)B(%+5]
MT19=7\P#W;T_2<!QM;!MQB0_SP 7[&]H=TYE"3,;5]MS=+G9M@1#QH+1MDSX
M&49WQ=X=FF%\Q2PS[R4_HB=G+6QUJ_&/"];R [:JA!'56:BVL@+MTKK\@=W:
M=Y_FB9Z;4PG8.INSG:3' [T\A6Z2L=H;VWE]@CJ^Z-!SE;&F_:KOUN=C1F5P
M&^D39IH2+Q]\T+Z4)/$UH9M^\LWSVIN#A59[*HP^Y3"^/?*,(AY_?RM5UO[D
MU_+C9X,KDRKZCW>5S3^SD4P=_1JI7JFTJL)5>%J>P<)@V^Q^1O% W>Y>U;!0
MHHGH@6NK]X6*BYY)@WB@>'\5#F2.+4[E@43'^;7FFQK)?B,:_!:_ %XM]MOB
M1\ZG,?5D@[M]G-9HK:ULQI<HK1IN52O<=K[>'%;IO=T=M(Z9KB:0F(WXQWC&
M\DX>J)C-MQY?I]#=%R#L+@<>:/\ ;!M*!HZ3N$>K^6'\P1F3O\0#&9-8LF??
M]"C8FVV^4@%NO]TY6[T+NEZ3 /UNA@7.=) X(H*C+WF@7B@;XL$#94,>DQC+
MTF<Z,%02PRGD.VP9&;6#S98J, U) K/%;';P0/H<'FB7_OK<QIMF^= ,\MWM
M?0>_[U&J1GPB!8$GA6F;2TV,S<ZKLYT4([3/*%J*L( 5-CD8@HQY-H5H[*\]
M0H4U-"=U?Z13.L['.V2="@Y/SC=ZSVC3JW553LR!?LM]BV<XKDQ&]'5A%,?Y
M8F.XRZCD( IOD^$V:&)'H\:?GE887<O-=Q%L)N:>&]"=&.J#I;5](XH&C-=E
MO],^I9\O*\G:ERS<\V1#^.#C"Q^4_FQW+'6O4OOT@:":HOV@6#;-L<.6<R'3
MZ.%<J9'7T*E,"$+HP49]N<M)H'DU&855ZG9\ZYQZ.>)8^$5UQS9ZH3O*T+G"
M)D\IJ1PFNSB,;4EIR2L6FNZO^&FIN,5:_67S>P;0^A6V^*Q9_$9="[=@'S<F
MIDV<"D3<Q0YR^0'! S$UD#Q0^=UW[$3" %X(&&[GGKI+7^DP*G&OJA4M@BDC
M0B!9RLEH4;7/%O(X<<:N=)F+1J\/9NTZIY#T5*TDC*)-OK$/"UZ'.L'Q7PL.
M79?Y*!3G^V@.N#RNV:667HCK^WZS6UTP(:S2I>-B%D3,/#[P0J6T2X=KL8-C
MQ5'[%MF1\EZ73)L05M)$8/M8_CX7R59%HMG%>9=+GTTO'3\K(9JG/N;8\MS2
M^DW9K&JOH449YBH/U%$KQL6M<H7X"T]$/,.N2EBQC<] ^; !G2GC@8"LQG@^
M]7?>CJQA\]G"DO\$-Q*[H?<=6Y5WA@<Z\Y//BO<K\$#?_<D+G[!?\%SPKWZ_
MN _\[W8.X/*X5#S#"7,&\C,B>XZ@P)8T[)%9,':YGL__MH;!Q86^\ J UJNP
MQ3/.-S/WES1^)$5ZLYQ@ :'5@7WEG^:M*P*'.V9BTS?6P_KU82^EQ&K>:9RH
M\IYZ?51@W?B?:33XUZIP4B&R*3,U0@]C+20<U04>6.J)JRP?*I?H>*]SH8+U
MKL+21F>3_H@H-7JSJFR^]TT=?2JPWNX[!3.VL!E9M]AGOBK&3VO\&I:_7"S;
MEI\;W*O/?N6Q%0]DM?4K!7B@3B+IKTS&YE,YJ=Y AAM,Y+OL!ND8_GG@X'>C
M8Q75UJ7?LZJ>(8P>17FF=JU>"CB]1V(EW+@M..B%QL%[GZ?Z=ZJ=0<=RZT)^
MFX0<Y8%NR1OS0 .?N%7Q7&L>:&:;RG[#IO$G]>OA3\KB3VHPQZT>XA>T7A[H
MB<YP#AR(0-_N8>OS"\OL A:!F-%>YH'$W93#Y\I+H^KC>" D[-XFO(9ZE^0/
M3\AQ36O=-\\UD7T[T*J MF"P&R,[)Y^$!;G/66=JL+4"-I*3$S1S]A .M4XI
MW'7S/!,>&B(>O'?+:Y4K+,B8T!.T,Y[93$6&.3_ =GZ<ZRR0>]GD;PX:RC?T
M:;JC+)Q^*.;"Z1F)Z2.A<#S3:D@LWD#KI!M<E,EUSKQ>?2#_?,/,Z\LNWO'E
MSEZ/7DG+-]U=-;&4<$[:>-1*M!)6>_2HTC&E0L4!D]IN)@1D]-Q&KWI)S)Q?
MU7LO83U8GE/&< N*&LEU#O!^M57GET'3#E?M-7")V]^J>3&PW/YYN>.I<H@C
ME&&W)Q["^!5=*=O8#H_I]6ULNU0&M0YEXH2E40X6X'^EZ6<>:(I"Y6"_VZP=
M&L]A>W"*6S4PGS"[&1%\KKN3#?05LD\!I26H0CUX@IDH<[TNLP0H0@HE7ZC;
M=)%R+\N@>VI=&@CKVPA8_X0V.]8\$I1CX+(A59_SGK4^W7GY:&EM9(U%R&V%
MJL:I?J3,79GJ^S::Q^)V3WO'!=QKOO!$OD?&>5_;+3.",O-4O=C7Q^C%> "_
MH\#W4D&X%23+@?;"1>%]!M'=V0\6E_V*8.FU'"A!LVR1F9:H<'J6!\:144[Z
MM,O#8@^9FM9/OKAU@Q_2;WW^F*4NF%1N7]2B-EAJ1*;0*K6BXC13%FF5/=/%
M"94*KM^R_XO<O8C]/U(<7JXF\,Q[8 YHV0N9VBB_\4_D6,^69 I8OT#G!,YS
MK.+#X4"J(FSTYC_@0N&?</'_#$:G_Y$KD$6_ ]B!?SS4%H_=E@57>O,Y"Q8P
MJ^>!-*$G\=R]Y%E/D?WEC!6N$#_1=H$9*TE5T-ME<&!X5B46<Q*X9'_J+*)@
M%W.EHZE?Q>VE[TY;I$AW=L298]0+<9[5?%&W$QN Q4%$6D^C(C?.<]Z$\2]"
MP#7?#GA!Q9"AM; .#;/5#NI>'LC? R[RR0I;#9@[,.H(SP-SXCNPJ3F26=?&
MM=A*G$(L/_T.!ER 4U'V0-?5NG%H2:F<DG0/.B,OE$LVF4TS"E^&/^'OPJ5J
M__3DA@IPAWEK,J@^E70=*88VY)1P91$/55G!]V:U8C&&@^%8H_<^<;'KR/VM
M+;2F)SO4QJ(^T%$_KNX6_/%^];S5 1_&A&*(E4A*>0Y=Z5[[=;! MK>./ &2
MT')"\5B:ED:;;W69V.*I8IC"_2['K@N=M*,N(:GRSOLTK&?=TPOWCA4?'[YI
M?PM7F^]O_\ATOJV]Y*NT?<@WA[P3=$ID5/%:L_:7X.\W8? ;'.,(P_4N&YT[
M!6]DML=<'D:$FVK9C20]5S"W?]FB?=>F>SR+^5G<B^7:__:CO5E#E<5.5<&=
M=WH5=.#RCT:^RLRK*I<&E>JK)=G=MIHH'8RF*!&PMZ')F9//FUW7%S?3BI+4
M_OS[C GHV:CC/*\F^56"!5#JM,V[U:W:F"&(//I,] P/]"=)\(16\; 3?'2I
MRN);PRQ$=O&4.K;].*.2MISW,G#:F.EA83PQ:>==[M:A65AQ=@ 0B5]R8%U$
MN]7!1;DC<'ZP]$P)=&4O;.J@C3@I1 7!&4B[UIY>DSL?'Q8%;L?'HNV8MEV,
M2STBQ&:C\42V<X >S:.">JX>T7L QK#Y"$F$,"YJ3<+I9LU%/U@;48 K"\KM
MYP?OU?#=IH)_,+_%0WM@"?H;A6E*K4S[5]7 ]6XN:M9-MJ>][O1TZ!]D62[^
M^9S9&P5F6Z\"CD","=:1T)0ISOZZY2NK_2%$)AC^Y-M6F9+(O2ZZGX=N1W.?
M</;71<C]'H>V*S?=,"H"^\Q+SSJ'RONZ SEODFYV#+17GWM&SUNX^*A!R<6A
MU%XL'TIK<'STW,!^?V2>FIN^[_M:Y#14FP>B3<R/8'X5NBM@ QXHKHXT:S*+
MWRWV<#YCZ5S)?TTUDV)W%H!VIGN 0*>LCX8,-5O1L<N'&5(SQ-$L/-.//M?!
M_[/&K%)1LD\I4-DE&YQ9\7FRYEURJ"1>%W\#X8(JL6C\B?GH=FXU-&D&[8EW
MPNG6[#_78*F/4I1/NI7[-6D\7N]6E+JT#^*KC)<LZL.P3&S?RT=YSN==O)^8
M[XHK^]K_OAPNE=HQE)R1TN"4/YEL?3J_5>>_6BH.B+AOOO(/]GD3NK2,W.::
M"1'J3#Q8OZ/%&)"[NJ1$+VV@> 8.1@EXGN[XG8DIIL=H:@C"$>^NO2'BS$EN
M!:;N;C-Q >GJX%KKK^9*KY\Y)4_+ ..,W.YL1877C.Q.^$X@;;.+HM"39*+A
M4XPJMR*U,B%Q+WY<>]TR'F9LH.D^YS3\@J 4[3&Q1,]=BE2[TGB@-_9X2%8$
M5:W_R%?_IAC7.*T5>#9L/08:]>O -=RU@V4;[YN8)F18=Y%94QI+V*>U,29Z
M*=&A)^#.\Y>#_5E'PIB$\\J%-K;BGUT4QFXEX3OBN7OQ8 [D%R!AIR:G>2#X
M;HSX\*][1.QA;'W^QY.*Y1OUK=^CKO')E%0:8@'*EWM$K7:MB=4.KR,C)FZS
M.- D0+9G?"NM0B%HY 2S(X!56\$A9EHAPD]C.K/HDBW=&-!8F]!K2IBMJ1U9
MEW:RC[,>0R0Z3MF.SX'9XE)<80]^K'=!7W81EBT*%Z%"&"7T)>:';4BLV0'T
M@3= !XWE@15CG\-?8IS.G^V7W>S:WE7=)-&=S7"R87:5)W$/>\U+ZGCDFXV-
MV]MR3BZ.N9<V5^N0C[I^LM*U?QYO7,[!=_QPB*5\2T?K^2_D#Z<7]+>I2#)*
M<V\NWYBN-C<_U>;\4=6[-*DJVZ''_M+SL(K15-GFM=G4%[,NCQ:<PF^2,Z0L
M\VU026]L4%&UB^1I$A_"U_G!SOF%,SXCF+'QN2V4YJ]H\2M?9OT;'6LVWN";
M[6X>^RQ0S[K\ZR;BU[#$-?#$< ^6T<P#78%(<C]AE(!EEA[[ E,KM56TGP[?
MA[[^!KB$/LJHFX4SON6'TK4$;9&RGO4)1/5*!+!^)C) Y"&Q)NG;R@^MWWB@
M-G.H-S*1I! .G4BFK2P'L:  >>/NX(J>YRD6#1*/405<+S(K1L/V!*N,KR4K
MJ(UM6XX2\> .WVA-4DD ++K"_]4GJEDYXH:&)KH%+QDB1(4<8[^4-^+7LZ8;
M&UER^\<[5!H;.YVS*B8JG_?[KR'"UB("BCOX-MC[K^1S!+J55/RO)-73G =Z
M_'S;!CF)W?B]#G";!:=)06MQ;9/P^Q!PJ[(G&\+LZ400%/SKIL48V5W&D ,!
M7/$F((:NX7X[G6K-]"4E$(/TK;,MFK6]CO:O5_M,G-)>^XXQ1LOB9TWP-250
M,1,9_1X4!F+!])JE*9L=>IG;$T$5\1O#TA3O=6^:0>*L6NYU9"SZL$XIV)P;
MFT:\?F6Y=$GT+V&P^A_" .O"KS?*?-2,07(OHZ'\@DO^#[; %PN_Q(77')>_
M5V9NFT-= T.+*V3,"O3GZA'W;4B2(":>-##%F!91?B2U?;BS59@)OU<;Y+E4
M9NR3C@0#]6=)=]Q*4[\(.9 <?INYQ\&R9.VJ"IZFI)T4A!7-K9O:^6FJD[=F
MCU^==TZ:SD?CXYD7YUHS2MY$I:B=*1LI=GPA!K-6N9X]>G-EJ5\#PES4NIA3
M6;X>.@.;B-RH ![2"0FMQSE9I$#2;B":AE]VGH'M-Y\]AV^3BMS$[L$8H76;
M1JX-![4>1TN,A#>4C+=VE$^?D(6ELN4(*AN;]\(;TO4;1FI9CW\4LG[JM/5)
M'EK-NW9SO\'R? &F!?%SD2MTW =\KQG!$L ,R%K;:LFQC3AUK1+L4SCGN%WZ
MD3R0",F_9*15&GV.D;(J*3,<;AO=#W;7-C*P<^J(.L]\/"T9R3%/M*G8=^9H
MXNS3CZ9QAKWLT.Z;^U9%[N>?R#5^2VLMM3+J\,E2$;"YM5T@I=L7\JKM&WB'
M?<ESY_(_NU@W)'6$XP@N5>?%JI+:AZN<1&Q2<HI/Y[N+YN15&.B9O4[9>O&%
MXCXMEI9%TEAJ[+,0=[T?_)^['!XV^%+P9Q[F,A<R]MS+<W*"\MGK\N<V1! "
MJ=??U372BT0$[6I&GAB>LE^JV'F@.U5YJ$G-2M2X1JWB2%^>S_>.58FM07Z(
MNS-Q"280EA#Z1CWC8VEH<2#U0.Y;[.[=KWR/Q[%LAC!Z:',&J9T'.D"]9'/?
M1'\0B.Z2)7SZ9I5V+MC+L#C]^(%S+0U>0K?+ K*_/L@H/Q&A#[X??O'VJ&RX
MGZ!C<;SN[<^J/0<=3]K98'H>VFB&!*J1)QPK'*F_M39Y^%)OZY)F%*V+T)<X
ME="9ISFMA KN!_Y,3_E^]]%0=QME&Q9C!BIHICI=>$6L?_*4T/:<S2C;G '_
M@WE9:EH(P#+*1%S>+_2<8Y(3UV '%C$G+3QA9X>6;H@Z!W_"MNFI/-JK19IY
MR@<YC[YNF88F&"5+XVCP,7F3RK+O>' MYUBOYQUOI+=O$%+:V/&H@,2VV R?
M/T72RN^B#S,6VRB^9:DTK=]0?N8,;%QMKFKZ]+#=0+-A&25 UB[O@&634IJP
M[:5!AYL@<FC/E>?G>A48)['[+8=QV."H4*^68-7.P2HC&0DU&2_GLZ%Q^_-.
M&CI?#G*W9JF.?PAY$N?VY*HVZL,?_M%1P^$GU[S57I;'MPV66MC4A71T.]@W
MY<TIERH_'TDY,K66E#)35&_MMAPQ.<+N_F_ _%^.0<+!W*N5:[,X\RT<HYBO
MT=XVL._BR8L.?/4KR!$D\T![#/CQ75C4^J_JM^?_]KJ34<%"YW:FY;Z^M7_(
MP&E@QJ_LG$*7C?B!/=\MK4QQ[-VX_^G,Z]>KQ?KC+/RI&]N_\,7HW(NT5)8[
M_'6C@=K[MX#Z@[</K&XB(!U8A@U!&- W'T9K\]GK9"17"$K#BO@/R'DJ=6R#
ME^U"RN9E/2LB'DU><O, #GO7W^N_??3@D?NBYY9 )Q#KKO]V/A%(&M]_].+4
MT2<N&XYY@>_3VZXI?G3VWCL<:^UTV:2B\4&Y8XF2X5FG%!6#;H>4DISM:EGV
M]$=78L;&:'#FCU%.U3(F&ZH-_4^(0/KOK//A?9%ERO&KCZ?B97;.RG@VO;QU
M,B1MXF/ Y$CZ;QDI<P7YVMT?5C,F!00+GN#6FQ*T_' YV:>285JTKRL&QR?@
M<8Z81?MYXM"FW6':R\%Z714I]0D;HG\]XO10YC5*C9UN%1\Y,;[_IZK\KP^.
M@MY@P[A^/%#JX-^_C&*KT'SP.C/\'Q@!=^7G]HE?& 'G>F&NX8!C"4Z/."32
M3+G0C *!7P=]0U0M#RV'2I#O?(VSB\]/[] ]?_-HXG@2G>WIQ[J):9>]03I8
MNY*DJ,YIQEZ'[%-NS.Y<V<FV&$ ;(UF7V::,\#RP9M4L-(ZKS\#@:4@A]E4X
M>+*$4E U0Q!'^=@PCQ67>9S+V4V(K)!,@H]%J!@*A?R,VTI8."<CM\/4>I9:
MJB21=7J7N1+MYLPIH[J]^YKCSI;<W6]^"RPOL5_MPU<5^:$X,:.W-M973[&#
MX1EG7,H1(QL&S4VJ?2&?]IT_WM GG%R<<JLTX:*?D42AE+W?Z/SB4LGW_C+:
M4?<JVQ;16WS_/QT*-GE_O/+T6E2U,:V^$RG(]F" [W%5T:;,7?@DM,@LWPKS
MBAH,7(+N^*J&7I" UZLX'LB^*052H'+2OM*T]GWVZ4CUHZ6?0SZWZ2*FC[^O
M^(B2WV9Q];9^/=TV0$Q^N\P*YI(I]I^:91C"&S3@53%;?[@0M[2!D65(=2X+
MMF%EPZB[ U[NQJK;,LIJF,*=LEZ/!';9'3]QZ*)3L!L/Y'#QRH[OVI=EIN'[
M" 8]5_Q'*^#"EB5JWNIC*=[NU6)2<6VSC/2*/?J[' W.=X#M*U.+%@<[;U5;
MGVDL=!@MMB]VN37GY#YO%)JIC^!DO_O27%*M(>[@%?#,2>[9-F$U,$:[$?><
M!SK]K*!OG <*>EQ _KI5_),'VB#/;?"KP5W'>^]XH-A1EH5\-&%IF9Y?OG *
M:\0Y WM#^D'X*;$5P_+#]C*P;<>Q2[7<0?SVQ^GCA!%Q5C)W@0<Z#+?+XX'>
M9=PC+3GG8!<=GD@/<36UN"0G'F@DT/Q94=)6Q\TRLYO:*7$[P\B@+_O6E7U#
MOL/L:[>_L2UFP4+ V;9PF"0J^W=&W1-EIGM/!8"[-!QF+-B8I_\P.#NGM+^J
MZ;-=[58$':X7?UB[%\3UA,Z4X_>S(V?!DUQ;&5=7N!!0!+D_K?BJI:;>HW2H
M5CU?Z]QP..*[9!C"5S)R?'OTY]Z.20T*-%=NKS*YV0O3CG^-NT<4T=Q>,0=2
M*^N>G-!GEG);9NVB[9IB3ID;QES5@,"R8?XFG_[8/&U?]_#S9/&6RZO)W2(L
M'V;E6SRX507EU!41NJ H.MSLK)@A&5N&>K\0<Y@(%EJ@-%+@*+3&EZ$,WQ#4
MIJ1KEN1/:_EQE\U7ML'I&I\Q?E_C.TQ=G8$>IE@;%SR.44:K-S!0 V%:29+P
M SXLD?N-SR&R@8I[ZH;"^CRM+IRK8GM7GL8_VUF;WBU3I4$4O@VMZ9OR2(0J
M,S^:&3/[9N1S.PH,>QA(X2^W+1$/0RSECM"-V*:I/=ZA\C<"AWM<"VT%D])\
MN%VN$MFC994S%^?M]3)M#&(=6X(_[GW7;/R.V6R;%R)I'?>Q!CVNW7[]D\SU
MA@BIDZ6Q%6?O7_WNK6844G46/Q;@V!T:;>U\?[97AJ7^EA6_H<^,NS,;Q]P@
MT-3;*OPEC],X9I[VE+&%<;L8^S//+EO[7@VN6J:XG7C11:*XZUU+# ZB^WP[
M[LSJ/G+>(?WD>?]S'V_:W+6,YD2O$XP8+>0.R-Z^"A2D/=),:" 8;1I,&2/2
M["3YE;BV96!9<]0O".8Z="C'N%(X8%:U?7MC6M6=^MY;-<'*$Q;?[$S#2U[*
MA[47'!Y@P\I*/]0Y!BHJC+[0J]RSHM$NLZS<-!RL&33T382Y]5*W(,Q[I%'5
MD%#$H-XY118QT#\V\P(OANN^<BL*E7QU58W1>95ID!>A(_9X5FVDPN9D:;6Z
ME)NE[GRWFI!H>KB?5[A1S=*<6*=,J[I^]]E4(^#=0+.J94G V0+%1S?79NUU
M*O2E#<Z"L^QOI61X#3E8:VRK%K5^^?F/)Z2>P:<F+YT)B8D.$<G/S']1'YE=
M[V01%!" "*S2Z^KJ_] O'\'H$.H]46-]I$?<6CG=Q*%8!TXP H@EB.E#0 !3
MX'<&,3.MF X]@-+JC-J=Z%=!K7M2UO<,$>7Y\8D =;J4N)2U$;$2H=*0;NSV
M]:?#;*+,EQF!;X* %4L_L$!WE'L2[<.$\W5"XO2IUER'T^YXG(G54R^4<5N4
M8NK3\B0>Z*6) JW%<7G-5-UN "T7Z4.O\G!H3MMT:*AK1$H$1IZ<F+)D1ELF
MST(G%AV'RAH&T-8,S,H?KU^-:58'U_;;MCD&C%$BXU:6PG '+MMMW/;:HU%K
M:NXRM*1W.DO75CT5!JM[\[.$5)N&C&MV98EK=6+C,8;U#)5N.>A!N\@9* 1P
MM694 EBK6L;7\B[X 2[9*')IDMY7%>F90W486U[[?@-M6AYX$P5W&&[NAS@:
MI1CA-JI2OY96XQ>VLY>B8YZC%M_F;!#I!FA;#$8#GPR19/LJQ.7/?&);%*)"
MV[Q$&/7WN?LF &&KNI$3?HR(A@JV$>!!QTG:WGZ1X#?2*C=IDK591VEIS2AE
M<ST>,#;V9]HT7/?(5/TF$3B+F*V@W5Q'S%;2Y5NJU<I\THH3.WVT)0RO/8<=
M3*BT+SF2I>@0:^!4OOPMS[P3M5W[['I#:Y#!U]KYF9-OP-5TQJ?+-<*QL5"_
M.^V^![J\;T[<.&[I8),FM:=2$QFD]BG;XZ#'0<V:&?BG<?K:MA^N68(.$V";
M ?%E;,OQ9AF:5@(5K">BTH8YEDR/O[M>7(1P5ZWQ?[%LXA2RN[C>;E2WQ=:>
M5#]:R_HTHZ,KFYJRO&%U%^U4A*JQ>_-FL-F51I)LQ85-*S!W%]+L;(8=AH+0
M#J560HON"#G;II67TQ/D(\+YF@NTE=IO(<CHY-@CK:>8T*5HFK#I56H/5QG(
MEF(K<469N$X>2'(A J,Q6$.[R-#OA"?DP+JFD!U1[X;1SK3)B)8!ME]I7V09
MJN.BU+FPW,<G]+#[%R+=+?.?=:U'MA%V?B>!37:5 'X=FYM&90^0:"NZ1Y#E
M=KO(Z8UMF"Q0[,[,'.T:33D]AKGX;<XKZ]2FY"O/=T=$IYXUIE^I__/]K1,$
MN;3*K"LG#8.UM(MMJHT,@V0O^25=+%T*F%6;88Q46(:+#Q>>"#\OI5M4:NF\
M2-&Y]$UF[';>E=?;AGQ_];]T<W:O/=5LZ9=8F88R'..L7U84.TEP#/?=[^6.
MT[R44UOATA*%.J&6M^"\_OCM'I"A_&I/Q=KLS_+A(]*_:Z<U7P'33>,ALV-X
M+WI+YM14)C62^D=6T_?LHD\_7?HL:R>:B%^FOD9.K=IPIFD6XD[2KG-:;(D>
MK@.!Y<L#34B,D=;JNDF6E:O97"$^T5 =Y[SFL]:D1>RVFX\7#R2$[77HP&^8
MOL>NF]V)4^=,'N2!O-1XH'E1LTU&-CNI5<:L57&@EP=JBR&&A7]$V7(MX/OX
M[+>E$#O?2FDT8O!Q79$ S/% Y95R&MF -P]4\K0H2<WR;Q6)N<KMI?[$0AD7
MI[> 6);&^AJD!G[_I-D]%8$Z6!4FM]QI#?X5_@3R.I*-[V%+Z'#?2RTU\$ O
MQFE"''W[\N^D]ZVYR3S0%R2?<KX2Y+/DQ:/I>2@8C<1G^(E\D&^^8HO3/#\K
M!S$TD*:$9GR**AC=(DMUR$V%<H4T^!N60.%H; KI3P+4ER#L[Z)X=-SD& 5W
M_T?X&C.51?5_$!@5F]F=?^R9[K?^J?3S6B)YZ>K=/FJ]V_H6Z$RTB3I+,2RG
M-*'4LUSB*/3:EUG!&-%;Z4$3RPCC^2],*1&: 8XE:=#[<[@W]+-BM)!C!XUY
M,<3YY:7+XR+[3*,,GETLFK>^3E0+9:EEE#NF&@XGX5L@W_ =D#UF)B@I&GFI
M8C:7NA-]F<$#Q;6*H\]R7H2)N-H.8/9ZL!V9KAU,.@^48)2Y^2?:*8@1VG7P
MS"YJ+%+7P^KUJ_&EY3Y_=S3#K" IV__ZHHD2"XIJHF/_#$?>Q^]NW8=&##;#
MH-UR/% R1IY3Q35&FPSQ0-?_ .0J BEIJ96+6$8)6X.6?Y;5DU.6'ZV9';V7
MD9KUD$85ZCM6]LJS+>2*^R52T7OUOC2K,T=E1FZ5S9_-FWTW4O(T)UAGHZJM
M]Q;QJ)2JS<$0OR^/3';T^H\E9<7@JNYD2:;)$M4:@CU=3]K(N BH=IKL1L /
M>OHZ=GK?2JD8ZJ3=RFE(<_78);ME"15,R LQP+9K"-)P"28Z#%MZ^1(/-(N;
M4.\2PWPR.\80['(=(@54@H7-F:YM$#'ND3Z:YRW6&687KGLY7$]+%-!R':WV
MKN7V,>82:I>/AVFXVQJ+&']P><\NYVNH\X ;G41!<O?N8$QV8,%\SR=QCP(=
M,P2*P(;E$/O,#%]H^55Y<Y45K#I(![GRA"ZR]/RT[.M!K?4^\K[IB8G+=G2"
M%.5L8T1QZ:?/9@VW3KSX4:"U<"QIJ>-**\&5\OSU,T[\Z.0C5Q.:5/_>T1P,
MQS=29O1U^)&BG,OUV(!VKH(3#3TN_-A[-3ZI8^;G9<LS5H).2KTWPX_^F>4C
M3][K(?;XBI*M6'+_L[&L(VGZA@38XM9'Q5+HLHS1VH(S@;V$&2#5Z'=-(;C"
M3C1/IQE"!U4,;0H@M=@'$1M)@ Q?M*:TRC 4B27L(T 0,[H+*Q/\ WWX*432
M7_8/C-2 B=U59!#;P8?VZ4?5>N*+*[D77M;D.UKBF"2:X%MJ$E>?\Y@TDT%B
MV"-!V#9C; #V#K:.O!3""F:K 56LW[F#TYJ< JU6"%J2 ;W/%4>1NZ>/ "2F
MK0VG\G ]MQNX(]4=8WSAY1O&CUP:Q\HENV?<^A@^K$HS^ZEF*6=RT.O>SY^K
M\YR 89^UV+G@)N5,0EER57UT?<2Z'W,'WSW2?,KOSATAR?) P4B*RH8 X,3H
MZ]D&+^FQ(M"P>*Z0=14[FE&=2M<"?L?(L&\#6)8VVY>QF\@@=QIQLNY$TA"F
M/G3D\JX@1CU=HB>>*/QEE*B^:[ [XTMY;FC ]AV^*A(&K%DPU ?,(%]Y7H!-
M9M!44LWV<8=(BB?,=F ^&@EV4!,599E2L6@GVJ\7\+[&MT/WH=16.R\$**K6
M#!-C3I-G(5U-)%E@[-MQ6I8PLWS>/3/_ZQ2Q\P2VF/XVW&"%:G+P4^AG/[;Z
M$1[(\54MJKBYF5B#>-)*#JS7/_EV//1ENWE@QDE]L5=OSQ6"#[]K_Y)2VG_\
M5GN^=5_M896B4<I _K+$<6.+^;WZU_(>?2P)Z'H?>E^TKB8]J;E4V@*AJN%G
MT!7=6Z_:Y>7H$"TC6+@[J1)$F=RS]?"<BO*<L7&!O7;:;=!^4)=[17*0)V6S
MQB'[E-W1\ _I=F641I? ?J2O=5U&0.5$95FNW;'\?$ICX'S=<&,3D?P! J@=
M('>0)RY"ML_!E_S(H;BDF_MAF-W@.@M,@183VXQ8%>,*\4VBO+KAS /5QG*[
ML=NU,X1A(E=K$[=&*/M ^I)%@["$Z&2.VU<5!<CF!SC@ST45CCA8H"<H__D0
MT4H%V;/M^DV*+<$& U>Q!^H-(7)8W[;QEYRB5FE&#(85OK$FL1W]SU$0M@0/
MQ#V?W0G=\"#Y4CG^A-CU-1,%'NCH=7,>R.>&"O=)=QY WK3A@=:7L?-AY.%7
MF[F?5WF@&%6N\S?X06(5S#;9^I[]&P222%PD*]]PL:OK%5,]:_SG\@/MO)0U
MZ;7!S=Q%'J@FZ2<L,20Q.$R\&Y;YXH!A&Z?_I2DXN,6P5V+UX@96B_,^C)--
M:L]Y36KI<\HT>^]8Z^$:8M>K@H#J**HR3T._Z#R[N1N+QO9LC7I0I5!%>Q3_
M&"."G-U>!RL+_KGGK5/MFJDE5HT)H<AMQ %V+$U A'L([3[N-[Q4K>EQGO'M
M7JE;726=((V(O9@JUV%D8RU%*;]K*#KGT/JF8-QV2$/Q.%&89=5 %.5J ME<
M803=N,7^'%N#I8,*UA(6I#Q$X>E9Q="$E4/0".NR@>;#^W%E9.4_WEU-$G$W
MONUF12%D>BW,%>7+$CTKABJT5I0;D*->K.I&R%-&?.SEF)[':$O]6%2TV),K
M-^M3S[>7GC\MH)5'DPVN/0E\Z!"+*T_./$Y.O]GA5&E O%Z]1'H*B8?+K>N-
M$V.T.AU[*_TW3@\N2(W?,6$M2TXC'M5P!RA/32B7(QW;<_Z\^O-2Q]$6"N[$
MQZKUY1?,RVWB#%OQ 3M1VWT#C;WB@T8_K*\^-+-*'*A4TI(V[1;!ZF-K_-CB
M$&N@@KYL.4O[&"]XEWL"CHKZ.<2BD7!_8%1?C=7Z?PZ4S2??#Y\RLA,:[Q0N
MMT+*;XY%NF,>/I]T>Q]LGWD[N%[J J8&\Q$JV>R,C9&*;[8MNC3O'E%QHJA=
MX;1M[.MAK:EFLN9[X;D"U E-^*W2I"E;\5-&Q%=_7#<7M3_U-3W0,R=&?V3K
M\F;\:K7T!Z:,_H&O;UX4Z[:_Z:X#R]BU/P\*M6BK]G<N=H&T=M K;%"!(QE$
M"^=HG1^!QZ5V74R[OR]&NX>PJEN+DV?/<]Z@D<P[F$/<7C@(<X!MWP)H1+*L
MV*[,GKAF!Z;Q608WE0Z3 + =5#!7C.]& R)C%)>HL:(K%YV/O#"P7+LXR5I4
M+ZM_B;@3J/2DE]"OS@-15&@?LV-NETWS25@PU[CT6_[MR/)I2WQ-=ES9N1\O
MOIU>M7Q=WKX[Z4*ZY8)OZM<TEWT#[P:3.'(<PAM.#70F&U#F@;I6 -9;@13N
M!_@!,&ASCJ38("#0PSV&5N:4<F7/5*'N]9 8SAKJ[=LQ^67%=-L$)-2'?-<H
MJP)19!4IVA>Y(;PWF)C+BC8/#ZZ9UGCT4W3(TX;<>EMPX+K,5T697@-,O9GM
MGX4I[=>E\RS0$5+*P561>=<?1X6K7ZVY?((F8U-P<+C4?%%Q[&:A87=ZTC<S
MR E: Q,KQCQ]<)"\*N\B=KKOY25Y21B.[JZ7I]*QI7E,]R1@@M/NL*G75%%0
M&T6<.%%X_&IA?*:KTT0Y<YRM6___\77FX5"]X?^?5B'[ODXEA)!]&S-I(83L
MLDU(MAB2&ADS1?:M%(J89,LR)OL2)GLE9 ]AELJ>&<MTF,77Y_HMU^^OWQ_G
MKW.=<Y[SG'MYO9_K/O?3?62,S1U).X"&N48 L0]ZLZ/(U"9TL;%4QD+&98@?
M6^)C-_(HE1-&+4L$"7(J'DF_)K+GP3@+J)!U/ZH5T<1N'GPI8X8STVB\7FI.
MZ/I(_0$K;Y#@C]]^;[/1SM;3G9F8+"&5^T[VTK&!+R[.RTX$!WL_5W<U)YO[
M7-],82A@.DUBUO_;_.=82^?)!6HW_/A+PN<>E4-D07X-1/Z#FA-#'/HZPPGD
MGP\TX\X["59;)G:13TO6:PAKADCC+S48!-ME!4IX6#B>VM,?7/O[?,6;"1T(
M%:\ SJ/!R1?$?ZK>O-%[J^:G>=\KR!W9>M5!+N"N=:1I@]B&R7O',J[GBQ9A
MK?=ROCY"]&)29(^-8OP69N1(<*8P!YEC'4ZMZ\<TP+IATY1>- \01\5W%@A^
MQU=UG Y<?QND>5DU(0ZE1$[3\J12YGZLM/J.QAXE28J9?_]<B]Y2.GPQ^=Z7
M+._0:R9I'VN>O YK#KW6*4NA;=!KJ.#>C03XX7V0+X*7&01\\:(-](&I-.PT
MFLTG$4 X"3&@9H[.7OE(J[+T>JL>QU2/QI1>WT/1/'_J?K@=_V<'WU;^UB18
M.I/=*^O",@>G9C6&.;E4X>7['>,E]=]8#I=/E,=WD:B!03RIG6,EPS;<%FEB
M7ZR+2;*N%^IOC]V#L,'=_>K#^CE*W1-]-H=B,GB\/VS7-#-# @R1J=U'7COV
M6NML73?5$SIF^[W0_S)_D9B5A9+NR.YKQL&0OZ /B*,$,[WAAEF%H 3Q8RO,
M3M83S"\"IM..L/8/1]@I@'(Z+^\$]1(VH?A]T"T#=79=&S3ZCA!K'K;S[T 2
ME:W$"=O"]>\?^]\KF65C_VME,VFM'4.?3EICPW-AZON@NQN[4#Y 7IV5C9W1
MV@?=G.W5V8O!AF'FX+]4-AGTH7W0"^)_ZYT'QA; *H+MY+?9P]\K_1-C3; O
M=>09[(.>*QX_$%>5VON@R2)-C1*F.YR%/B#:]^,)ME9J1>5_Q0HAF1>E>5N.
M@JV!8LU3?6X2?9HG5A]S6!<_TYC*W>T.6WQL4U;FRHQEM3/ER3:2Z'%XG6E2
M(5)MEGQC''J</3ZIBQ:<T%FJ-SYL;+W93=J) 9+W5A8M)]<]ZGO:XA4:$JR#
M&(R@O+PHR_=GIX\MK/XX_5C9A*.0XQ2=. [V??Q3_DN,0H'^=8VASSCML)KC
MUT8^GT]2&]=4?B;=E]<=[/$6/-R81N4CXSM5$(?9WPH46[^C$)$',NP@%7K1
M>IN23]-2:<A9IU&T('#Y$Y2?U@(]A+W6,M$@PW<UI;/((:4'.R/@GQN22O_R
MWLJG?+K;3P_CQ>! ;MD#T61C/2<JX2EQ\L!QE9 I))LG(9CZ2;84/C%G003B
M1K82ZME07N*&I@24!TB6YH6][P,FMJ,2OW]N&G&;<>]F/)MT0MS/&0ZX._7\
MBE?R^MO4.3,AF6%!=Y$M.P5]5<EF)Z_LH^0JXB/>5TN&CZ*-R^=FIAZTLZ(]
MUS$13>"_,:/S5E\BZJ+:$82Y7Q@H1A#C93,CU6?(6T2:D^01LZ%=;?Q(:^IU
M/8BU!FWVT:)XFC4X.>U8]FLBC-_U:J'Q[ZQ2+)WFAY^;#Y2L?A%=@HPRC5;@
M%,D='=Z>HGL 1RI0_$ 9XT:@4G#934"*#$Y&BP1".>MKFI^7) )!I#L9I&$A
MX_68F[,S+E\46D+85R8WM. S5>$_6]M\@]:C*X>_MNT0PW>*CGQ'>_Y@NT<K
MW;=\YV3NG]TT';D/ZIZ]N/ZKJBUK ]'F:JI_=.\PYK3)J0CVE7V0\H$4HA>P
MWD'![*_80QWGT-_A0FKS?!Q,+6H[O3T*@6B&K[H^!M_^SM0J>6O.O3(O/UDZ
MMJVJ(8/*:(3WGF><,0N;>-+IO05YP'U^@+I3\SK>-Z7;%S@I*PL!4IWT)%RS
MI;CC"[FA@0V5SB4G%/^6J44VC\69FRGO+)'>3_:0E4VS3AHK9ZTZYEEH+XT\
MK7!\TU9TPGSVP:XW7NDJS&]B9T[]XH?FB8@Y>\L1[8^."^'EJV+TUI#\D 20
M3N_Z&G6V\^<?,ZZPWC!71!\LKG5P3?+!"YKZ)\DTUL]W1D8J-J+^6G-PH3<\
M4.'QE/D8TR,S2=_W04A9%8#%RL6$$%+@30][@J/(93V5:5H]& '454J^Y57
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M-^5"7K_J/N+MR8N#N&L$DU<&)$YZG#>U/:F&C8'Y@1/AG"@IVD?*PXSX&NH
MV6]MG0CF9_H"9L5N0#]IO;JF,FB!"ZJP7'",IC/90G1+V>TX!0>X%EU;QE%&
MP>1!KBYUGL 8'AOKYHGBQN::Y'W0'I5JW/$"YW\PMVW!Q3-YXA!'L2<0^^!
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M0;M>!V\1<#!9$K @S/1#>@XK!7H*Y=_ >L[4(\)^Y'2"&^^\1E 6GAABTQK
MJ;#ZTAJ&.[)THT=4\F&?E$<X:>%I%:Y^(Y8:Z.S4(=N!$ 2*Y\3E&#+Q>3)#
M S8K$<<%3#7B;#.N@S2^\T)CER^>?"9=#=M;B-3 3N%%F.L'#_[VL.!L"OT(
M52&K2+O;@J:X;D8=MJ"Y/XO,P]2I,A5I8BYCWA_/7<)5!NW=29_UE;5W+ZE=
MUZR/9"?)G_616.K/\&Z/KGG#0#O2-M;'&$I(#/T[ZQ5;'G5D,N3=*)YIYH/
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M@R2G6#5]H9LHL0FR@^*QD@.=9Y-\KO^L6.8=%UL3^;FN:DL0VNWI.KN>.O[
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M%ZTMA>^DHR&PI@!_-9*J//QCXJN^I8C9TTTF1*CPI(RTIR&^OO]/<VL]Q8J
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MBRUS]M='RPHD=@!'4)XDH3R"]KF:W6Z\)UL3HXV][6S;&;#326E4EJ:74>S
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ML9,2+0X]0W("',O%-L3<X_Y07L@N]'8(<W!09C)*,@*/[VD#%EFY]#&;](K
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M"9RHW%Z+U9N8GMQOP$PC.?B7$(4BKVK0)ZGB^I/RS$OSC8@00<H"M!?_N!:
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M_:*<XT.(PWUUF<=^BJT+O^UW<!FD3>K4OGB59ZZU]8B-S0&[56O^Z%:XNOI
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M]B+7;\U\]D6V'KQW*RPL(H(O=B..XVT&JS"\.Y25[?GE$/X,5"H^0&0V3ZH
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MUQ3:>AO*/U#7LZZ^QN]SH,/[5.QGFAI%H[0,[?9OX_]M"P;HR3I./1</K0D
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M#T=&OSYYH@4GYQ*@@\_VVOL]T""P2K\ JUFL/8347H8GVLEXNET5& GI22[
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M+/_'DIC1]7HWQA9[PVD6$\UEGT-OW_Q^47VJ_TTLH7AO%&[O_V^Z_\N$/^6
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MX"_(<=FTL&%;>/)=V=+ZXA]Z)V.[A.Q/=ZT-_F'"%/4:\ +>J2Y]" 9OT7>
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M ;=,5P$'E06*6P+PA[:(QQ-*[5*'>LAA ]&V5"@O_#=>&/.U64MXN..JCK@
M$%8RTR4U$H^P#*\H,$1/=.8UFO-_;<ZQ*G'@L=:HM FJU%@<]"L2^3AL^:B7
M)[EL4;KD G[ 7-(O#C>)GXR%@"W0IAC>UQX64S]A8L;2^QZF'-K60:\E+E0&
M:70L$(]RHI"X/6^\D?_.6Q?;"Q;L]ZJ%-^S\28M#<=,52M?$-0 ,S=CM3ND*
MA+M3&'@F0N*'8VU.+CA.FQ'0#83;\0?YBZ^M>X=^:9;W8@%Y[;XFW<*NPA^A
M\WT;N?-F7^;\1'I0S= 4S6U!A./X8T\O7]?KO^=17>^:W<ZVMK; I?T@>.AY
M$<?WA9$%E6CGH5;<LJY,UP_4O8 H* \J $;TUM@F9N\N3"C2]5@@WDZ)V=DD
M;DAWN%<\'>;^CHB08A0L3&P$3)$=ND<XO-O^"+P8,6EJZ:1U[&9"X_5L)/="
MWT_?C30^/"K_73<-0,B)%BL@ *<]Q>0 LI0>?LPEMZ1$V[=-S#PYD;ZT@ O/
M;\IX-"?3'*W>/NH]Y6'?DJJNN?762^A^H\WE@2=W6Q<'@E6%HDQKW-2"7OO@
MKVK'X/J[4YQ<B%?L,U[G6&B,.UDN!:GPT/7(PRI=3TZIZ_63>Z^D"A1<5>Y:
MRES[AGY[ISH>[R[;)U/N!M?#\MMC$.)R-[@<>!61RAKY" ,.\L;BSR.NK(;.
MO]]]YV-/PO1MF-3.53H8B$Z@/*'Q!P8Q"M6GM#;K5DG"VYJM\R'W:R\WA&5F
MNO+Y>PI-L4"8O<U/ASK/(P_O(WM5@74R/NOA)-( B1/_:[)3Q1LI3KB7&J:B
M.2*(8*,9O2VANQ$TDNXJ_<2.^[=+(I :AS+L?CVO!CXPT3Y.P_E%WWV$>S$5
MW@<6K]!$RPH?I[*24.Z8F)C,&B.SZNE/@Y42+XB3LW:E.4NAJ7PIH>K'P^BY
M .F(3;,8;SJ%W>962&?_D/@0CR<?YY!E.JCM6@?L41YM+??3KQ?(3$6KK?W3
M4")2RWYKXG&!(#?_*O'PMG_$BVXCS2#3*Z[R?K^,])+8M!:+=[E.C*.E0KZL
MV>1=P63;+J0@G.<-0%U]8GW[6(Z?<)/12D5]W5]A_E=Y3?,Z\DWFW[]U^ZO3
M(^6UY+B=Z=TSAOP&AO(IOPFPTL)32&VZ)*-([U@QW0:0H7%U_QM*$'B\*1&6
MB)"KNE&QNJUQ/DQ;2S"Q2+FIPZUW7K.YI'@M:S>\KC XS2_,^\1H6WU=T8!<
MKUI5X O5SPOLK_[HI>X _(?FS*\H0>0%N)HE(%M//\\"0=D[=8",;B?!7G J
MJM$@C=,'>@+K/<3) EV/@TTL3G6*W@QFB,.2G:0+0RI&T/!&G"H0T".N&(91
M<%1ACP]1B*AD$'8-CRII*T(/Z$(C($<\L2E%MF6\[91"/*8RLVOIER8QY@Z'
M ;LH8,\OTO<8E%K.5-6PS]%PDWNQM_E,N*\;)I9VEFY,G4/[*;\*+%O+OF.N
M^:P=2R0OI'ZV397ALA[\46>75#JK:4-"BWF:99 KXY)*-Q9EC1";D1@];L6^
M8S=TOJR-?U7;,)>=C)$S4E O$2)7> A.7K:E5-G!''ILJH4!'S6+),:FK%W,
MH[[=LXDU&8U7%63_/O'@0=#O%T^,-K8N]%X^=L%31L<9]/-A^V%M73UQC04J
M8#KLZ#41,#FA)BO;)2;5NZ.UPN;ZPN8:68FR99?_O]CU?\7*A/@M."1.G$U)
M?E70VJM*TF%_$80W:%^GH/#@.-0I.@\E+:&0'^%)'HEC@<!TD;*A:J $/R<_
MH?0GG]?X?7/\K>V0T."!V+"&ET1'YYJ]EKWS.&]/WZ 0C3L?'Q*3;=%RFGPE
M@EK3STR,M#,^$6YN1G3P"B<ORW;GN91?D352M7Z=5SJ6['&A7,[4VD<U<>*C
ME-CCM+_5BB[=$.O3<;DLPZ9SV/[DVI4^(?T4I!O=A_%1SX_&19&)1WFR0(!,
M2TR392I$+/@*]@-3#O%PTE\:VJB]4;=WHDM_I ?%OSHHB30 "LM/F=6JSZ.B
MMG[2N$=-I&EB1P5D4VDY=:$_UYE1AITO?S3)/-,.)!V*'G$=-$3*[B/M(/+3
MYT),WR:LV+3_$BQN]$O)'48^D\N7]EEID691'@#!@T4>:;];L>_D:^I,7X*.
M86-A',SSR*\0#B7$,6K 9[<+@/>1. \71Z/*X5XXW>!G6IR/-WYVC&LJ[+_D
MRH<Y3MQ6"JU9;ZO9R^FMA_]V7=,FS)I)#LU4VG2O.JG6)C]]$2N@EEQI_;IV
MB^)C2'S:Z%!N8645;IM/>+YFQFVLA&AM[>-_TUS\_G*ED-7G@=T U3S1$OM2
M9PNXBY+W]:3%5!5>CK;714#HX1DD?NX"C06B\WDM%&Y*T2"]!@J,8H3=X477
M51;H%&R!U&/8DKI'&=GTH("Y^^H0SC25N':EA^^!(/(R[J@=-1":TE")A9UA
MB@ ^ Z[L.&)S+07"([5;4M^=4\%,5OHF"Y4F]*KQB3Z#R/G_<U(RW>2.B>9^
MYE%S&3'V /*>O0L5+YSL,R<+,"H0QHQ2/4_$];<8* _"'\B@%(KG5B=<K_ZZ
M2]2J+O76VI8+.]]GWA3W5>Y\,3/?F$1E8APS?3(_A'CHIN<]^9 JP%%144%H
M0+Q,*;%0]BFQ794=,QTR_-3L=;>M-:^W]LK$[FNJ#UQ7SNAR]*7KI2ZS.M=D
MK5-\=N0G,^5--6R>W$E,OIB@&UR<J#"B]^[=2]VCQ&*!QA)O_'-E^:B9)FAH
M9=7[0072Z4[7&*A"\I.9]M_?'C#8]U<GVT-[YY2FIJP^4(W_V=Q400143R=]
M2F)<EY,917"0EUX5!PBN3Z[1.C:&-*RGX4&X!'WT2#Q&9\FN@'";L)-T:$#"
M,^4;J+#8'2ROCZJ9?D&"N]*"\[1LQ."/OUD@0T+-@IY99(5+NY;]J\ EEYGK
M_]![4AW(V=$8\-E'#6OBDG!_1"#E4]84W2^22^@O/[?5XS=*[GY44ME5B:G9
MA:-NQ!1"/!I]FT\M;2TY;.",\N7M5"<J>VO<;=8 'UX+T^:_9GY5VG,.EPER
M9NIB5BN-B0/!%?V_3-'TV[WHQ_;2!78QU;IGT4*40&# I0I^F\N'K\3()N76
M#:'4JEE.?C2''K\\/*\[3WZBY'KZIWD2:-6 ,W6+\MW59TYR\BB/\ ;*$T2%
M>AZ@8$,"5>KC\$)V;&Y X)GKU1N$X@_?_CRZ0/06CD2W;*U_1:HB3&G@* R7
MGP2.*0\XOYN9O>L\UXX]5XMP"-4ODY[@,O<M ^[?>C QMC6)'[WD.R2Y2NG>
M,BK87TZ5#8>D0,69XHCCW_XP OJRV][X^=-7V\[&%'EG"R_'[QRNU!(I%#&(
M&69:DC(P:CZQT]-PP]?K,7KQI7IO_6*!,$TE!N7KJF).&SDJ8XF=JE1D5'$*
MS'"RIOV*CY[*PNQ5_(NMH4V_]EN:@=7>M>77T$F8.+,.*O/=6'/)J?)27WL5
ML7%!T;>=C@64!H11X([B0-EYS*-O!TP104NYW<R21WW@V*]5=WK'<"8ZDS%"
M9DI9_(H:[U_G"S>B=9&%X"51_6PO^.VWE*=5_!5CE4YW1?W!/+E6Y::3E0F]
M]V2G/D_VF>43*A-ROZXME"L:3_D8\YP-M]./F!])Q-3SP8-LVFF"\1H!YWPY
MZEW[] I$"9HBW%QFL<Z^#DVC?TB;YNH6$W4"/]A<+ [:@]:RQF8UT;/CE-,/
M,WZW+$#I?"VVU)%-*!G[XW ^K:N0#^%*H&O2O(XF@IL%>I0F6!^#\ HH0>BD
M]4@/1%K:$!!F93]F5I3G1,=4W+%8W2]-+?D]'PR?2L1XY:X%)$*:5'"0'V:W
MO]$O5<& $8IQTE;3X3:_*]RMSS8*SP+Q;2&XT,/U"RH)V<WA*8NEV43C&$4G
M/]-=G%GJW!IE8&P)<G9ES,F;T.>UXB8"H*B6%'E'Q'T CM"N>%1X/J4E)40_
MH%O@P'A7IF>_;D.Q1K']&N7*.\*<JX=MG!FA5J,H\FI=<?.SA#*W3%_-1/";
MZAYX^RF[M^[P4,E^G?+DE7EJJXNR68^HB0-7]B(\&8&.J\];OM#^20E'"0I_
MJR]J*(I;N\!Y5SL>;Y-ZME.&>[/2J&4LD/UDX(F512&FRJ%S;*NZ]M= &QSM
M%#@6+1S6KG80V&,U^"M9RR^IWDRQ*&<0G%@96_^FQE;\>*ITF6O2URK/_4R7
M3[-_#M?]+(9'K!L]<R9_$14^F8SS+CE;5&M8'P]LVO2,C#X7'3-C:7F1!L'-
M.G<3,2Q0&O(<&I.*"7MZD);<?GPKBRD$I"WV%IMX_'9Q!IS[9/]) O-]-SXA
M7!.CP0().,.(N>;&1EVTD<TK5#.R93+B*A7K1!-K #[9?:).YOJ1_?ZZ\-./
MRX)VJE0C2<G9N3/'3(GWQFC3U(V0BAN!E7V5TZM8K[:6L3J/3QCU"(?8=B\R
M2LC[MT_!^:D_,)[5]VO"69F:S*@*I[5GW]9RS'>&LZN^FTM5M^%#R]<$'+2R
MGQCTNQ=P\+QR5(5Y_E-4Z D_<U8%$MN#:IFO5#1WG%=]K58S.1KM.UYB+&BJ
M"K]"676H?1Y2;M%Q8M4.=U^_+60-(:V&/;L,K[$'<[]U]_%0^WJ;D??^#5U]
M6"UQTB9;\3W&QP%WWTT@6$#YM80]__BR,20VV(M3%<8!-)K0LI)\ZU?&^I5J
M1PK/3/[NWB7&9E?=M9C,*4BI^F&2T,2 F73&1D*MW[?:%@SO$N$/3E0MU"1M
M%;1_T)$X\8 MC;977[!S"T8NQT=>=<.<@IQ$N';$X>84,#>82:5TD\0)%H@L
M2'.ZR)FUC">&Y )FKB]/"CK5%D:CGZ0/!BKU?7NR[#US^FJ:M:7[EQ$=?>,/
MPZ>>"*A%RP[G.PG"73RE8&!I0J"5?V8XO["5VS178HPIOQ+_$(>[KV1)_)[N
MTQH_Q.U G<?WDU7W0P(J%R3X!SE'K>S>.\:(?#3Y]O5RB-RDE5^;75$RKO^W
M>^V51\6)/_7OE>D,ZXS ID0A]?M#!HG0>:8NLMA;T^N@+&="8\IVQ_@D380\
M$FV@"(![L6>0?ST2$)>C@GL@W+YNYVAQL3LZT<VZ4['T&^X&;ZN]]RX$WY-I
M;'UUOT!=;*BF2UEI,378&#9" J3[DMM=R>;@!>,-?9J9<P=-I@?['=:;(X-+
M4<&WU:P'5<%9H-TP6F]&X +X1V.?;O0 .U%3BGHA][/39I>Z92 %''> P3-Z
MB-%[CZ&6DGX5FXSQA_3GFOL>%'@:#@LH@KN5G"U4B=^1X] /@OA"+GCZG(8D
M#!ZWZP7DST// :%6;?(KPA&17 L"']S/C-5L*17#+VFM2RXAVW4S;QNHG.GD
MCZN.+Q+QY@0>&3FX.N@+ZO1O;]4-S&6=W7D/;(CXU5>/0*XI\<L#8 _Y"7?^
MK7('#GNT?-U(OJSVMJ'ZSI6SB^Q3T();^G%"[**1.GB#G#><H!4.-JHDRC3D
MJ=O!G@EC57W(V<_OCZOF,[HBGY4A&Z=L\3__O9U[><K2XBKO^$++OI@E'T[^
MC.>'C.<OC2SUSNHGB+][$&AVB1@=HVATN41(YDF?S/,1R0+0,@9YGTF 8)9[
M"GGH=]H9R2CWVJLW:/6;)DHQ*=L](PF=EQHS' "%0PAPU<E;0EP#J WQ#&3S
M19W??DQI/9+878-RJ=5UI'UA; *O)17?-!)6*ZRI,)+%(5NZ>*6_HOL<C*]<
M!JW3Y1L&(VH5G5@:B[SP6.FQ*\S+5+4A>FVBVMHG4U1?^%F(@D.UDH2%7&FZ
M1>F:CDTY9T;%Z_ T(G9W>)+.MA"IL.O"R**KE-/]&4V=%U=7(XL! =_<>#J8
M"NV:^OJRG]:R&S^YX?&*+C$O)O9 4%@Y>LXRH?.O-3-?\O:9[MJ0H&IG9BCR
M,ZSA;/Z11E!BE"&O(HQI66@:B;*\,3T/.T&7HI%ZMWFZJ68+A434PME7,CV6
MB3E]T7KZ?NHK)' [-_43.;5Z?CL6<I8IMC+*B.H^.(6M<9TQJ8!'W1W7%&;X
M,S*P#Z!QJ 985$BD DZW,+[S(MV0QJR;4P)^T)8I^OBZ1EK$@E?JT@RDIT"/
MQJ?57*O4G"\:9THMC*DIQE"WHQ!7 WR+5^RU1HT#-:>^PJBW+RLKH^9+PE.^
MV%234%W6*)]6C/%]Y#>/444#80"%\];+M=LU)BNI7!?X\EG>2>\2E_0/R'B)
M4[ZHN,<9T;Q[%>XKXSU.$ZH\/92.?*_0L+%2LH7;<)YD>;_UA*?V5OW]6/E4
MB,K0JN>:#Q@<B[/K:4-A>P?Y$U/D,7PNKU?()19Y1:*:\B\S[*1V$B8J0R!C
M*GQ  *[@\J@F^ R ^WNLW9S,<#W97/YNG>A95EVZQG.*M]CM[ISD;@N7B%'Z
M,7FQ!J-T[EH^/]CP477',3FPGD?+E3.U"3V4,Y.)5D) (GRK@2CR3N<GJ9B^
M.'_\ET/M9*20SP%ZCUBSK1C@Q@$E\P@F4_MR"\&W7FA_6V*\8[2P0#X*I!_@
M><]E_+3*<3SM^#["BES(Y;22K7L ]^_E:#<.#/0)2=J\L:&;B7/TKCR[7ZM8
M*_7ID[>'83KQDF8/:H1RI"E:4'3^./Q!R!R:A]K75:MM_?MBFU9.2QR2$^[<
M[RWM.\BE\'%+I5,"WCTY1EXP&<545Z!?2[BMZ ;75>Y/G;?]/!&MMGK/UZ-1
M3MZF2U'1Q>=;5, /._@;M&[PNRF-XJ7Q,031!W66(:.>RC8L$4M=<^'-#=Q.
M$DIEXT@CZT'.+K;F.(Z<U07BSIR*>$/3.O]:P7/_INIW^#C^GJ<3AO-;<4DB
M<Z3$0B@%HC)FH(8D%E)MQ)S)X(T1BJ7@BH.@EI.H#;QF]048#'BX^!V_RP(U
M=TK3KV$P64?X(]#3)N7R*P<WV<PC[]]:(FA$:BW?R:]%11K\NR6FS (]J(^:
M$VH@'%7V.%V57A6^_D>O@+BCEH@W>!NXE6&;AT\@$^A*$5*DN& QA>%!9^_)
M+.F0A/R ^AV.8R^9:LP)%-4,G(1MT$Y%G#R\@QQ$Z@ I"Y>HTQ8-[9_&FXI\
M62 .%@BWZ3/9>S4RPOG]:-.@3M$4@H,R+@B=)MZT=ZIISK*9\0[?;"XI-@D,
M-^@'3K) )S]1-9=B?-'(,;=3DTW@\S\^OW*#X\CX%[X%%R;*F@S!H4'DI*25
MG<WC%&O)] @S$\W62Y$?IN-G.X?UOM:2G]S=MZ' S9>Y=<BTUL6=O#/49XG)
M<G96![5R/YX22UW]'V&1>]B?3*'[K1*X+8VABDB91Q0R94D^2Y#_'\JP?G%C
MP9G*=/<5ZZ*H;FJ=W\YMG&)1PN>GI@57!7>N&*G;O%N?7[/D423L^9J,:6RR
MWR8$^PD,$,S&-)*NFFN;C/U9A]=J;*I;$&K'QG#FA,W[7-SHS,P:5>?I:WR!
MN#.7:WQR^6V15Q#G@$O4^NN,4I1_&B"]C$?%,06!YX=Z=$L"'7KX!"$)A%!F
ME?L<O@77GZ4'TL#Q[3*T:IRN?LTZUJR1R@+UHKC=X-77,RRS2'>HL]NI2ZUC
M6QJ OP8^;E>PN^ B0<^=C 4#U8:9Y=_HYL7>R$NC95D<2J6YII,;%\>#]SV;
MWUI'A#UH_)CR\X6=X_U0V<^ZKV"Y!5 KSZ/YCV?D*#=],YBN8WZ&8J1?48)X
M[$*_!:>E8!OG:M]AOG$.4_%ULW-)5I=NFI2W/OK^Z5;MP3.VK)K P.C%"^W<
MC^VNV/B<MSQ=88MKLRD?E'_2_C.WC+(H)/M1YQ-DU<C$;@)'L1?&;OEX)D&N
MUXG7C'OJ\3UYTWY* JS3BK$XU],;['/-.B/Z7<?WE2=]\ZC-S,/C?=)%AY+K
MPE.;$8=*WG>R4-_7*4>2Z+YE"NJ,QE7+M[58+PB1JT>-M":N\KXET=O9 G"E
M%2S;*@1X>I? /7K;]++3_0X5=N\Q, 9LR$D!73P6!^.%></.T877_6@R\W$]
M^LH+GPM%.P5\;HU*#><O;,<Z3676>P?V[ITK%9YM6',3F7"SC91Q:#>OA3FJ
MG1*ZVGG'XM3IQYEL%Q=-3H@^>"">CT>X'UHPCP3*"93W8(=$[T&[FRS@2%ON
MMHJFLF^J4,WL8'%8<3V^^R\M_3S *4W?A6&\\)LSDD]) %?O,^8EZL,RB:')
MI.7,?*G)D@3[7N/T@,S(9RFRVB)2%^2!1[)M6P-RXVAY.\^:M;:,IQFCE H/
M%<:[?-W&P.6O%82DC-Q "_A7/0G!A#Q2AS5&T*)I.M\TO=9JP/KP]M YJ= 7
MGP6(QY2>)^>!+*Z(85^5;\-@W]*6%&A,"+%PMY01NVP.WMVG5B$> L=\UKU*
MD;.D8W2A*@TWX;&_7EX+B#ATH/,32B="ZH^[MA8,*Y#B(=P7I^@<>B.:0\Q,
M<H\C464\#43_FVK9PP*=7C'0!_PHV+/PWY^9<@U)MM2I)(14C??!$<=H#FG-
M^Z=NWY[X,YV4:U8ZO)@Q^"I9K4]137Y(Y*9:;6SU-:. K%HY.O\*1E?=U4%M
MDE\@[X^\$?_%K>PFDR]]O,_K8ZRJ9E0O.+4/Q*IP23ES.63*R%:M9V<U\64W
MX2PR=<>;\\0^+L]ZT5$CRX8:HGG/NJX<B*+D0X+6)^?<"I 1>9&%P87],7Q6
M?Y_\WS(;KN=39;>&C>\$DB#+;/4W!K'9.P%OPD(BE.L[LK9F'^L4S*IQR! @
MPT5>W>]/I!L=4TI697^T(,D[G5<PKC=0JG!/P.AB1@QG29" 3O<_[>FW0$'#
M(I#7J/,LD%] (JP)FJ9WXU#WB).U@DG<\ 6\N/!XV;]9#IMFZWVF+=RR,7AH
MX*+X@N#PK5T[K'SV&@O$15AH3I=JZ2 PQ8"GY':%XB'-UTP=V@F!P1!TW?B3
MG<#S/CEWH@4UG1KWY*Q3-LIUT_?<Q1/JO*33HV5D^ XN?W=J_6AN8Y4B;Z)G
M&)YR WQ-VU-^![UEDX1<<PC*W9,CY!$M5TC$QMT?@-^A<MI9N/Z?D?-T&*/(
M0,HX5+ K[4<N^8%<#=T1R$7Y-ID%GLSZ[4V&G/*N_>NH+L4CE5H)>@KOOD_/
MSNA/X'N@[MG+EK&0#]I'X4%D[^L4891"YTN)V#B#OX!!G'"-FPR@<B@)6%,B
M6* ?U;L^XQY/#OP;PP*T7Q:*(356J7J3>X7G]3R]#!**S8/"?.?-V2Q;$J>L
M,E:V?SCL7@)<#U7 /$##E"U-&S^21N)ISRU,AC5A\9^^(TQH2900^D7M'P&:
M'_S\_,BHD]ZI@[[DM+B"\TUC>C)DAO+<P-A<K_=FR@;I8:FS;3V[9-[OO*S9
M8?CZ%.C,[\19RJ58BP).^FX3K;%=OOG/Z\L?DNN-7M?M5YFZS=5F-4G(V40&
MX;]U7_LV&%F2D10KH5I5&U]5FN=C\YE@#Q?5S'V15Z[W4)IS1_Y.Z810V;%[
M/:+TF>2%J[?ZET\L/-]XHG.\?8_RA8WLU4/588&2(A;L%E*A9.'Q-/_]*P=3
MQ7X*J?D'J+:9< ]LO7_F<J$ ]F<6PI(%:D MP!A&&/G%TFQ]33_]&I4(G_VB
M>M>M/;T#:-^[.N(N8%^7WG+H>;+*R6VH>OLAX1EIP1*0[(=2-TC?_]YC@6)=
M@6M?%NJC'YNLKH49[!Q (#>8X>K@GR>1H4=!*(U:%"I\'\?(V>X&,VX^]OUS
MW:"PD!F[4Z;..!1HB_3@+4<_R)YI<LV:U&W4R/)Z,VVY2_<G[0K!Z-DSGQ1,
M#/GLV<_90,I=@OJP[&F#&@>);DE,@'&-7^U9"GUJZ5/")^E#F7WQ:S0.:#/=
MDCK2??ZAF9AQSQY2>M)=YF>N&=7H#1'S6DWN!!\+%%VU@!,\"^IYB5-4++U2
M#_MUGP4J\%TGK#-E?AM@%G)^FQRE0G:7Z34><!S30)7GI6'?[AZN2^;V/\CA
M)^6B] $+0M0F/REQ3];SCNO3[_>WFER &7LU.ZV6#B;>W*1YVJ5R)5W/I<ZG
M4SM>?D#KM?JC>1O?<)TSG^2#K=L _3(US%UT<6Y0"[0= 3U\@!QD2@! (5C/
M;%XIP&BT/8S:=V?"O^F1GFE.%#S(H7'JW0NN=>?^IJE#UY2)TF;[EN9LGFM/
M,OBR)K?4_13L8#^\YG61 W.G:<,=-,M>IJ#!7[3E!$6Z\0*WDTCSJ!ZDM-_K
MN'>.6Z%W:-VL<7869<E[2]E3H-OLTTJ-HE(Q!M.<VDG*.S?]'.3GBD^U^_OA
MQ9BMOI=P_4]LL)<0JA7V-,*:46)PB:[$>(D!_ZCO+3R'?4@27YWJU*%A>P..
M 7W,<XR(K@(U:K+P5M$[;_N#_(G86G*U@J-G\_OWXX_I-B5K,DXM-,C;(JE:
M9O9NZ=3E!='?W-WKL0OV^2Y5=V?T+G]_1,ZKMNVQQ1NASQA(B!@EKY-_'>C,
MV#V^D914)!ZJBW$_"7<#XZ;REG^41>#@HLU8 7*#(DD#9ST"I''CPI2EPQ[:
M"-U?[1-\V_(\U3UU</4&UW4-,HP_J=I(X_+W$#>KUU7([]#W@DF(,%K#]&XN
MH[!N<QEX15&2_]W%E!M%7*,PC*^/_?D1XG=J&><DB$>=7?<XO'Z+U&7E9AQ9
M!1>>Y'&GP-W_&O;U?5NWT'[(3JZ/[N1E=I..%R7UP7@\F@E;[?<.L,EZ*$JP
MN?A43^'Y3BD@EBA2J0'C\K[G+2[:.!DR>/A(HYX3"+*,LB!L:@TIBA#N8&M(
MW\&])"&]D$.]1X$(/T"H$CD2S@*]"#%+BW,3I5J45*RU[.VYG:0^>UNZZB8\
MY2\]N=0Z,=1#[0M$S\R2/D3:+YOE.F#N;@:0V7]-,3DUCQJ%E7\5C"^*>+@;
M/M7$ B43D26'EP'+.Y,[^F8X+]L)A+[[?+Y=CZKC&K'\Q:;0GWK>M>;F1ACJ
MP7KWY@Y$T_KKM;(>0QPR(/\)$]9EF0!DL&4Q?*&5IFXCRC@*.K6+TIB,N#R^
M9GSZ_;<[S;XI!Z\;;[N4"R-:/;W=5ZJHV7\D$3<7ZL]5PB/G26*!XK L:JRQ
MWBFP!L44HU;UH?^ILF@71?T,_YD^]2=1(Y=GKL;V/'QC .YRO_P^2T+$Z?6'
M0I<>PN"Z>S,+] @,2&CW8),+F[33F/)PF]W*H[SU);- >(@ "1@[-!D/!I^#
M1_7,B:'.N7#-6MX>]9_"VQ.-:M'7Z_ZBTCXY7]A0]&AH^-C<UMR(X3J\2F7;
M10$AASIT]3$#8;K!6/K<0#>XR9>X,QZ(34#X4>1,(BWQ<Y<GGN5V!/3HX@?-
M T,B(S2&D_YR<MY_]M(9)Q[WV?(TL/P9=1H)@0M29.*#MP4 7)>!  $A40FT
M6,1NG=:S$8R[YRIA0A/#8Q9,],LJ:U8%LK2)0_5$F50E)]_1$T,"W?I1 Y'1
MYV,2-V6\V;:]4I^>4NU[N%QN^5V]$TK94NQO2"XT^"JE>,HFIFL,MSA.;=63
M%)QX_T:7;W7!H-(HL=>NQ((SS4#Z;G2^H/7YY;PUR_TH:2KN.: 2#T1ID[^>
MU'TS,Z+V54J/<K<&J7K?^[[JFZH&O.?H5U^'RNQYVK>\0-'7 @)-WO;HV-<2
MILF/;'Y#D]P@N4<5]"S"';TZX\MFW#K>I"W#L(S7$#+Z^,Y%;JV,V]>\*>,I
M_;-<W^TI]WE&. EO('#4123XL2FUQ&NX*CC%B-0$KN5$8GX9;V*\V,0QY;H7
M$UV_@ZK9T@W6!8<C[FU+Z%\.TWOE!J,>&T0( 7Y?Y/4DBDN] J_$*!;?/?WE
M9]AQ]5>_?O^BM[+AW7:MY$Q^N#?J6L5IJ[31@#.&3A^2FJ<&YXD6,T/>H?5E
MI96!2CJE]2E?5/GE6V?=PI[YQ<9<^>4V]VNH&M]O['EBT?-$1VRB=V >Z(C"
MH<MH6<G4O .OU?V0>OVF=+_2 F)MA/-4T1_(5.%L:Y.5(4CS'_G/R2]*SX6?
MNW8"4HMT0H[Z',7928>C+/1X?"R4SGUTD72J3^2?,:QG[[$.(XJE?K^^[XYJ
M&Z2(:;?O>VB,&K!C@>;?%.[>P,X7DPZ\&5GKGX[135F@7;8WJ#5^F[&!L=T=
M>L/&D(K)/9]*%:-T\Y"&CHW:@S3!&<AR!?M^AK5M8&07@+ID[0#> 1J_PJKI
MWZT,^<[\]W])R[</Q?8N@:K^.::0[A@KR"[5V"1^-?G!JQLN\L=[N*OW<D,Y
M08J.J9>K0)*-YT"+[Q5H"Q1('RP)2K4"BP+5NW!&$CV@&G&9\58/4K6&/,LH
M1_E#SVR9PQPG'DOY1@;,9V]$U)B)$NT_+)SDTLQ.-="2ZD23ZX\[W[Y'_3BA
M9^$GF>:C$T81_?B@LCO'NM+-Y->=I&SY2LF,I_XNW\K/.FS*&]S,->^KYH@I
M4+8.?.T]6ORZFN(5:A2MXA_V]--X_K9P\+U9TPE;;T.9,,)JIPZ20!+$>M<G
MS,DS4J'WS,-)MR?HZH%GTP[O,'^\$'$-_<P"-8KE_S+4['O>*>1L*=IF_&^+
M9VDW]K/U\%32R?$V</=JLA,V:3%G]T+PW<YIQAOLD<*,AC9XX10"8K"G]:YJ
MY98-5;K"L_%S4I,8+NPY^ (%EJ;YBJ]3!DBCB>##\Z9TZQ,1OI2D<=]-+UOL
MF[^^6!/,,80_2;YB!J1*0(@*(4,WR-3![D)V)"<@84AEQ]6?=M;O3'GW:++W
MLK^TDD%1C4_+4_^.23W#FMGVEH,M;-6,FP]Q&!T8%%$Q,Q(H%[AQZ:[H3W!9
M>/A1^UE G\Q<Q^._X8QLW_=7?\3.45R@BYM(^_D9]-?5L<E\68SGYI6E'?S]
MU0$PQS\IIE?" S-"8(=&6J4JCRWD<)ENUDOYHBH=-XZ755HOYU3'YW+V1<4,
M<X@F>]3K_0;V9.J"8)G0QI@9U''4? FT>6KC=W7;ZH'EII+G/&PZC<R>)Y'*
M[<]<P!UH=T'2VD*B.IW6;;[MD([#P<X3BN>M KW+@:P1*ZU*OV?2 1.Q1E?V
MXRZF!GW[LP*G0X]?17 =PI%#6!ZF(A!!'NE-^S%Y>&,4ZIOV ]6SA^7I9".M
M$\S<R2,BAJAR,1D*Y/.(&.EO>XK*,80[]:,?FU6.0I+#6,AZP%G?]:#SWM8)
M N?-]MZ$I]^)E<YN>$U2BY8LJ[)Z:C6=]20YK&:!7UOF0:[$,5W$SI,)3^'@
MP":[L^$IO?F<H]7"?WQLT\-O3!.2PXB!<<U!V?+)I>6,.NBCM.>D,^UF\P&Q
M$%'FA2$:VW6:=C0]D&9F.HXQ5[@^T2Y4 F20@^TSX+XF4_<G\W">=7"LPP3E
M&X(7%1B@E=,ITTKXLUI 7#H8,*Z%T/F\=J^-*FDF*1GWI9'CVT]ZO.NB?-)!
MB%',\@6["&OON[P"2DTJ5G(TB \&RX'8;7.J).E(!KRGQ586 TBB9;-/EL]W
M$GM[Z*'<4<MKBA3TG9.@L>-V"O$"G7Q3G2?I<. 2[9+_'VP"]E3]#IAGI6T[
MD7D!<9W:HZW5XJ15))BDQU^\WBE$NWGG9DY'71H:*,$)9_]X>#8RS9J1@'VH
M%((P.55+;2/<&6UWK+Q1"Z1U9R,OTAX7<$WL'$9J-K6V&X?,]TY.X6#4E_M&
M5_LF[X]-V40^',;UG-KP?6:_1UN4YUNQS:DT[&VWCEYZ';9X$FFX>=[_2:._
M*,;38LA4V'1[J#:[CR.UQZ).(.9,MVFFJ*$)V=NF=[SDV@#\KEU=18VAT[G=
M"7FR+8W_\JI]R)-^^89*:+Z!XA'<VWI2\^YA@E'(TW1G6F=YB2],)'@(J11@
M.,X4N>L]23K6*:S2@Q+VN;PN7)90?2U8KSH)=K;+4U)+4$"XIJ&SE>CY'I.U
M-\!4(:&ZY)&*/N$M"4@E0.1ZFDMSVWCMCLIY1[@*Q2$*YM9*\*/?TXR85>EQ
M.X^ASI:GU=32C>=5+L %H.>^FU=="UE(42/APA\38&MM.AV'PP'?#W<1X](T
M46+:/R0;%#]^039D8@)AM2!V?6ZS\Q)<H(^,35.F-&&G9##OQQ&>\PRU 1Q>
MMR#_)'H+&WEZ$J.0L//4'^^(\H#]R"3!LM;)6DG/"B[1M&/:/5 G%W>Q$5Z^
M=8!*KPW=Z)OTM\?*.U<>ZZEZLJ<%:*I<@*T:B$>9C^W4GUMK:RZO(<)FU@2E
M;_M:=TV5K5(N_UDCS'9C=.WN8X!,W:8J*:EJ<V7?M?P1B:ODF>SX]Q\^>^TK
MFQ7<FS"VOW![7;%KB<^;(NK"[V3[X8WB [Y]YS0-?ODZ);S=K2WD<80Q8$63
M(4^DC'2EW/1!'J=FW(4+FK7=U=11NF_.A3M0_.8]&2I<8S5+4LXL]Q%&YH<^
MN5U&LFW&$ORE?0^Y>BQC.H^[&--(3$[4H3,B<LSD(U5[HX\:T 5]GQT7<A<=
MIJBIDM R)QN0!A%7JLUEN&07B&98 3;D6KO,/.>YU:6O^Z&J;CV21V)!:P7;
M@(U#0 YYF3@D-W6N\M"1[O&1YMK7#8G9+?M]A]K2M:G>:R UH6>^0"(J++@T
M_YZ#P9W)+;&:^A$P&G<&K,%RP9*GWY,,YIYV27BH!75C]D,;96)1#T:>BW,"
MZN1(I[V>EO";H0<L4"KSHF]B.KR$DH:'\)/ZZ^DW@;>4:LS@['JG!DUS=K?Z
MZ5B_@E.75$$^7ZV?>T#:=9Z[+IIACMWP"D5EX?R/KGI*%I9^CKVC&!E.C56;
MAJ;<;$D7CZ^1;L(O!G\M0KW.Z/:2%Z(&J7^F7Z"?6^3)4TJN6R6ODC\^&7_R
MVB4_-[J$TS]?4Y:A')75_^5S7QF'1Y],O47[_3R/ZR#YT^P7Q?O2J'Q_90Y;
M!#$54;L^D4^44R>?[5=O96S^S*_9U7&(S)V8_C0W9[FCX.*,UPC@>]FG85WZ
MRIRW6"_(4-%/!"^OVZ!G47[>:.#+_$E/SR_U@Q#QHTS3U[M!S>T59H%Z1P 9
ME9Y<E1\VE&<=E684, 0A/*$1AK \E$ \ZWP5,[OAI@E8BO7(40?QNO@>54,5
M/"2:%Q[:<]E8:G M!]FI[)G" MFM:5VWN-:G=YCLP1[U$H7+F4O]JQGRUCKW
M3GY'K9"A;9&K,3DF7&W/BW_,ZF<U%W.K5N,GFA#7Z]!M:I%A';UOYZ)_M[=,
MA.?"IPJ'$FMJGGU[[5.[&%)#M87E''T2.*+"D^#1';#XRE%A7]Y$4;>M&4=O
M]1$S2:F+FL>*K?/XD#B0:IB&+X0U4N-V+U"S@9"@'2>&)(^P0*<[IE<*KA*$
M@]]COWD6</@;K_*\[+WU4(C8=X8<UG=;G7?MVLS?(Z(>XE:TPGF5;@A1Y+-3
M(0Z<"CU+EZ(9?];]:!-"Q@JN"AR@2T-Y@KPJ5L<&"A^/[GSB,"FTF-+PS;]J
M_[Z59\@[C*^BP6%I&J'$.-(>][BS(2!,&A]REM3@5O"7-K9Q#P_F-0X\=$+\
M]>U>@D<.^#E48.=9PQA3%1YJ_/YY]FW BV;M'""H9S7M^ AI\"F?&[TT\P9A
M\5KT,H:(VMBI@E:/^VU>+\W-YZ][O6[^:RTSM&%M5T<OHE/8ZO/],L)=4XQP
MEUV&_SIW0MUTD5CV!"TH*!0C:J>1R0*Y7_O"/LZV/AZ>Z+3ON_N0\8%Y'#F)
MA$QHPJ(*%+*V7:AYZV6(FX '94AMKZOP@@'_^H#;E79]F@*Y ,M=F$"7J\3I
MV3@KMF1YF6*SYLA-^4;,.94KG44I>UL+(A:Z/R'?@E>,/;IPQ]DU38-*KMA4
M<]A4LGM?]\;C62#%C!^;#^:JAK3>=CFEN.B;6-5;!%=U$8.7!85Z7=&"VS(3
M;GM)UM;>93^+<UN]Q(%M)M]:%!2[E$/?^Q_WCO]3N_[WSY>G_N[7^9EW;.0I
M7+PLJSAWBVWD;%QJ^V6#N-0KJ[UA8H^8+6:T<!6'=RAG-- A.&(YI*<K?D-.
MO.CY=FK?^/,=2GO$@D,?-/HHM%IP'2C*5.]VO# [#A7G)G3FH"6>?N-*X@_T
M4Y(G06/ZUGD_,^<I3;ECS6/!^@*#5I,A$7G.WLW:O&T2B-E#:^:,&R>C4)/!
M-;_]#UVF'CD*Q<3U<(6A =]#=81:>N]RK^ SBN:/!6B"TZ?AX+1H**?&@NY@
M+>(:K;*Q*<*V->EZTU3(:>Z$7_4O2.^Q*7JA-,%KC$KH_#ND(G6Y#TIDOU'@
M=X.<W0T#X\.T-SX=JD26EA"[J-5=;1M*@112@@!'&\D&F%BXM:5G%KXL+OJ>
M.M%D):2[2BX1MNKQD"1?]_FS>DTJOK>ZXTG3&M%M0,OE>V*51FZ[]Z&C@MB?
M]ZHI\O :Q*RBQ@[:-/MC2B_Z4U<WNIS3RF="5=/66WO+Y@!G4B]O &&40^?+
M4W8+(3_HUQEIJ'L*)4O?Z>JIOH6<S/%"S%[LUF>M/2A/B+-0S<[(CW*R]#OW
MQ%L(WM(A[1Z2T(I#0R&/#Y,7T^IJ0-KQ):?A5.)([ @N<EHLA$N/GTR*(_W[
M@ZRSM]L%:ER,QK2?Q,W1&G>=7[5^2G9VZ,PYDVT5:6__[6WI@MW=B*3J!'1&
M1XSC4\?,!L&3UW:>!J6'9_197Q&2N%#06!^?_\CHM77)];-_5FS:7J"&G+V<
M6HR=8.TIKR5DQQ*?%T@(6;=[&/&D0KC,Y[*$\\=M)JY,/$MKKE=HT=WQD)]"
MO,R3DR7<XCL;)73 1,'"G61KSEZK)?QF@;XYM2]3INCI(PE'(LV2[LL"54RB
MW9)GH5#&R>IAI!*J7Q$H9($>')$K]B#%QPZM0K%A@>J;6* _K<)6+!"\B 6"
MO2<=O(TS4#]2A[=9H %UJ#OX4),4#3F(_SZU$AUYY(I[_3>6R7$T0/8K(QJZ
M,84\AUJ3\( 5#0Q49^FL/Y]ATEZ#KJ9_K0+]3 ?]G%B DFBH79Y$%HBPLOJ5
M!?KI]88%^H[49H%L5$^,OQ7]I;,^8D$_"!P*PV\GA8@Y':P;4<7R"ZI#O*Y.
MKR$EQIULJ5E)P0V4""&9)O@69O.^(E_&K3$QB::\C0F,N8'#S; 2(-(O_+RE
MP-I!?=+R_NVL@YBN#]2#EA.UV-BFD<95I"E/O%%Q6_[8.RZEC1K'$76_QW6I
M$N%[O>+\A+>3+%!/)Z11]I;GQ\E@0.P6Y+)G^CS_Q9TS?(?B35EN2M2ZND'Q
M7(KK<::]Q&.M\(Z8GM)MNPNWZH2^#![K%OT .F_!?=3H/=*2EVC\%NQL>X??
M?OIV0XSMV;^/Z]S)$P^[,COL@V:!HMH5JB2,*P 8;N\+G2>D9/5WT LUH<T?
M$\U9QS*[7 ISA4KW<P#[U:W#^GX7%8LADT$_NZS=Z>V6'8\7M#^#10"![)6P
M/. H%F%'M2^_*BK5+JY.L-:7]WX*[H<F:OBQF=^(\6P=+PK0O.]HQ[A_L"NB
M8);;+]:>>^MA:VY_RI;4K]J%L(<\USC;"0,?>A<OQEZ1SLP>3.%ZJ3",,*1B
M;T[0>>L!B=OJCR9S&AAEW9[MG1W"TAA?*<S<JTKO5W,S%EFO5L,S4V*+?#U\
ME#8]<F;;*PA#B&5 AN*62S$3^VO0V784X:4TQ$RI?91>VL]?F-0D>&LG4GIR
M[;K[PTP7WQR^\_W\6Y7DW$$E)ZXPI:5GED;%F8]/"5<Y%'!:=TV^\'UK56D?
M\M[.;C?J:<]H!G+#1_::B6D-+TUVX*[>LE!L>K)[KE$!] 2IK>K^^^].%Q!]
MX,C\6]]*8GN]PR+X[4N+*ZWRLON<+.E\.++XAW( ZB#.3EOLS*?L^]4MY/E"
MN#0=QO0N5;G"!7 W:$;E[B6(Z^,JTPZ='4 "N0D+.'L%!-("<,V;53 @J4O8
M+S_1// M"P0V .P$,LI\<M*Z4<EM-YT8?=%-# $E1X,+CG4EM7 6"(<]H^<W
M7RM)4NF))32-UL)E*".Q[>;*M95N3H\.I# %'\K60XG(%F_Q0NB*9O9S!"3@
MIPCJ--P"W."S%[Y9GTD>$F?SJO?A6%S3'6K)\(1D5Y&,?[GZ\+S9]C_W2K^G
MZOH4F.9%AD3IN5,7>G+.8,'M"O7]OKYE0-JU;_X:%?/O.VFP?X:SJP%AD2;"
MR93Q27MB8:R>MH?2ZU >?%#)][ZB@33TAV8]N5F9VFS#XD@1G^'5IID ;]G6
MWTXFZ$TG%7BE0EFG9.G'TL6OI7,8N=9KK16.1FJFFX7<0!23LYR:./B9MC['
M2]5.;+=<2-#S"IPO!.RFF'* ']GUX>2AX5B[>C50[](V%=#N'/E.^T7P5?UG
M2W-]?4Y^<T5D,*_;RA[O"G&<R#]1U[[S[S[,R9M4/N$Z= G<C)R=B#'16 ?S
M^DPA+TW23:A3EF,:FV"34:3NS,K!9F^<UX(9B6\DM 9(FI=);+*CBDVDQBU@
MFC\2,+)_PLR[ITT^/X(TM?2R0( Q72F40OH^U1T$%%M&%7(WC0BO3\).=\I\
M]RX N_K> )[-79X*^)-;>&Q-N':Y&WQV'7F%Q@+%W@>\R1T.+D",9PAUNR>[
M)<>2+A&:'=[[EH0X XS2G/&%_$W0,W0SQJL:NA@9E>1VN6U".42N4WCMG!M@
ML6 ):)(M!0P#*6:35'19?B0/#5E+68^PY(<GPD,JACL$8W:4M(TF@Z<;J[[:
MI-F.)4N(5'?P[J::-_]<,^_UV=WUEU-^\*?LW<3'\QUYM0]S_PMQ[Q75U!:]
MC\9C :2)]!H5! 0!E5YSD(,('$!Z$R(BT@1$B 0(1$5Z4Q!06D0(D1HI(5(C
M745J*!(42"(=))&V@9#<G-_XWX<[QN^^W3'N0\;.PUY[S3G77-_\OKWVVMM:
M*RN-JE.A6'%#I>+BX& @.K9EF'D:2NN;AS^]'"N&<)NHU5"&GH%GW2/>!1 L
MD!\ (RLR_%D@+IM,7\M,:?<!\L[H#'DI]7[V)R,%"9N>E?-X8K L+?-ES<IL
MB >M?_>0YMNGENIY'/":QYX*_. .?-WK&6*>H\LTD ON9W:3;N31Y8/ +O4C
M#$@E/-&Q:1P6XTQ.:/=_#[?OLX5#>HJE/^1V;3D0[1;7#HW 3;(T9,*YZ'U9
MVE3"NVR[C^WMXSZ))D2O;-OV\0V[;KN6]MXJR8*J(R/%=:RJJD1DB(JM2BWW
MWRDYI@:&\\,\TB;N<<:TR7AUR["J@*CVC&2TRVWSZ-!%P\G2T(B0(*$_/W^(
M_T9,+T2T? RLJ/_]Y\S7L.?G+PV%IITK*%RU^*HTTZRO(K*Q*W%[[-:S0K3*
MA0+[PMJ?V0%7K-;$:EUZ]95-/0?4V<)!.R$6#"?>KG\6.&AB19NMTLH+#,Z\
MC(]JF!XXE1DH%%J=UD>UCW;Y(Q3/YT&7*/2@R20&SJO]!=AT$6=GRF+%:8NI
M[RQAH9<?)E\<:QQP%_>Y^$/Q[)?@L5]:/^HZS]VOC&GH\3RW9*E"+CJ?Y#.N
M5O/NXQ0V6^%!KIM/YZ%JWH/YY',?QYFC45\=IZSB>>S:EQ$"Y/E_]B9#:F?_
M:NZ86HRYNWQ&UZ^7G$OZ<>_)V3$2YR>I<W+Y\\SO_7<_9'7ZO(D*=U)RR<G\
MM@#E3NBQ_'ZH9,/[/%X[L]?NN:\ML<<>G5AJ3X+X7NJ5WV)^[AH;A#2&?NRK
MZ@;]^7[GPPNT9Y-(8=W<[9[#!]"F#%Z'&KL,/N$K]"K/&N%X3V*6?:%W4%L@
M^>)Y_N1&D5@X<[+.<)C.]7$9+OU'?W(BHZ8\X%A^O^V'-D<0?EIUX_?CM'LB
M?]"/FC<^\NG?"^.)"BX*.>/2N":6=TZ,VH '/0E-.^%H$%4+$@/17?9F^6E#
M;RGNZ8)6_GF\TM]$!@*C!=9>8R_G<K]WT3Z?=<=8+DU*X-L"RE2^]-7=V]Y1
M'\,;E&1V"E_Y3^;HU;V=33:P4OK1^E5%(P+9Y?W(_/X9Y/W;K]TVL(NA\3=O
MS%I4QEI:[AX;24NX?4>FE&"]W2Q3NB6\Q/L.R+O>,PN>0+G492XB^8&L1?.%
M/U_DTM5[C%S;<*_><_-(O.^(BSCK,5.BVDI22+ZL61HJ9&E87(K9MZQ8T:8G
MP51T%[=X('[Q][*TGI&]?7%M35G1^CUVDUM?<,_6X@<=+0:XTKHF!^CU-M-V
MU>3+6DH64K_%>!Y$^E&6.,M7;1]V4BKZ5!]U#A55]CIT65S9_1[UBOY*N+VT
M9'"#]F/LEHUH FI3T73(]EEE>Y/P8&6@2"7.=$=EY(A_!SL )>DS[; LT(D>
M%JA>F@V5(FS&9+..A[Y_FGI*5TS6".  _VTV5?PV'#M ^'\[US2O:2EI&EEW
MGZNVTO*D\QNC/.L9K7R]:[@ (/-0=!%Z$.]NX[FT:@!]& O^[) C]7^._2P0
MQY9O+L%Y_[/BNY130K:F(*%[?!@A!YM"E/$P'G0/A6G7B#M 3E6</\>3!=J1
M\]ZJ/C*S;1C;4-.4OG$P944,7S/'8G<D#Y."- ZY)5V*HUL'!EH3,F9G221.
M=/XBA>)";HKGJ=<:'=:G8J7@VN3AYP@3ZC 80)G0H,\0DFA/(*[74YFN51I8
MNBP#'M7X+$%A@1PF8);3);AZ'#X>T5?LZL [&AG]"S[! IT+TN!/(M"<CJX3
M/>A#;RB9\6#:O^[<Y!@R(3$/XT9+[%6;Z0M2VK\_9N!,/SLKZU\!A^S:$_S>
M32)4YLMSIWH(0O-:+?W)=XG;7.L:5&)B=[2C$N[B^H?&?,= MS^/HOK2.;5R
M;IN:QEI$+#Q'1GLZ+&,49IYWMM"KDK"0ROF'&TI 11]C<$U"+"#"ND.IS*'Y
MTL_KA?98S_#WQE_+\C%I'1=9H$Z7'<O-4PCP%,*#ELGDJL-X>OI#!8P,_.Q^
M ,C^N2:@*=]*W1/PHME%RM;1^9_%@G0M6]5$&??K_'9"DNJ2&=KSWH%E+%#@
MVK789H0>$#V/C/?DI*&Z;1*8HJ,&@C06Z%.^2 $YDP-NUMT4ZN+7<NHIVOUB
M.0KSW>UO@\84,6_0YXV+/7]$FYMS+9/OO2RGM?<_>V P=QS0HG;E/@3.#OP[
MBJ9%Q,^9/8%#;+226F1RF=)CTAR)EV^@@I/+7;YX^W U)7'?G)P55B@K<""N
M_]8XU!]H#;1L=UN,ME*:I,!+/HX'!U7_UN1.C>:4@^7^]KM\^3<6G?%3+KP1
M7[SPRE0HHTH@>7<T7>+*KIA;T-<B'<:C()U#BPDI;Z6='^$YKC>NIB$CKA=)
M>%)=VJ"3LC;\-PH??I12;Y?2O 2)?1QZT*>$+KWLI-)O\3KY?:T[L=2,W_1&
M(98G34WGQ%9:Z+#T%=#RE2AOF>'JZ,PSRX\S*]&SV')21SS&M#HP-13IS^W7
MXK 2(R>16UW_;PWF^[_Y]]_1/3TX:\K<)?M<.9L*^TN%>^S-I.JN9%WR=O5Z
M*2XMGSZN9RZH?(;>4G^M)>OYE?V&%[I9]76]M?B(UHY)A?<*IC$%>?KFLC/E
MR,^_MG_[,P/B51(_\9AS6FLMG:/JZ)ZX\X>SL[,R]Z <%<'NWS\R$ 9#>YIA
M5G,GIZ[8A);/#G@%5IKZ(WD>:31%G%W!3VK3.Q_6#5S,V4&3SC=]3'%R7O&/
M&9HSA-G<;ZFJ+9TJQ5M.&\JDNY;CG-TP[>O#SU@@?_!W&V.@F7H()8G.$WJ0
M0K$#$%Q',GIF^2"DGY"H!TNHX4C=EKQ4$@WA0#P"PBJ^!)&AZ9ZGGUZX,NWO
M*0_73!?1Y=CE:T4G?9@U$=T09J/'54!0PH\%DB1X;?(QQ_--G]XTZX-\'Z!@
MXK<]+-WB;UWX$?#?O:N!.=XU-_E2Q13+U!+R7%*Q(I&'6"9"_]Y7R;^ZE'^U
M*/.S@F3D_#R].++_WZ<OS,5+?/B_5E'3I F73OPE[J[O^O 1IX)A_4/^VZ$A
M61I5(Z4I&,E'T2XV)&//WT)K]E7699>T<5J5-_3^D#:,#N 'Q4-%4E828B2-
M=Q5C&;(SE8W^\J12&V&+MJNGLUH7,':.$_I?['^E_H+F;K)].$]?[]S00 'R
M>(90V*W)\6,R!=&T1'+3TWM_"D^XMIE6,MQ2_TFY$!'2+&KUE^(0I=>XKXUN
MPQ"VV<TW&S50H_63AQF"B9^TXV!S/7-)L8HTU ;D\)_A.RL?S<B0^%C!0_XN
MM9.KV69*_^"95^CX]%]COU46<QCZX5V*Z",'YG<B'_HH<W?-9@/YH?9]>&D8
M:#SA]1YO0/[3NFO<)?>F;DYV+7W]$SMB\(QB=_;=!,+XG9]6T/O EJ:"=RYJ
M;UH.G0F-Q =/4V8#F\U(F_()<U=),[=_=,CM!VTL%3)7Q:6#[G[8GJ#M/Y8H
MG&V;"/"^:F5$1SNU^<U9]EW#*&+:W$;PZ5V=R(8%%XMKYB18(+6NL![I;R+@
M*52;;Q5V_9T-_(L') _I@_J^1.9?+T'#RZ$G^BE0$80%D/[>?0TJ;J3+L)HL
MIR?VV:3%RC6:>^,G#6"4@4:SW!DK\S+<2)MNJ;M_K.A(=5+BC3&5+/-RU!J\
M3X!#@;-4H>*3=,Q1S)I.H)L]U'TE];VK%B8"8U5%\A^(#)C:BW)L:\K=D\BI
MR?\6K*IQ&)UZ*!FY>3=]XV[QGTFM5YH]QMC+G77QL=:ZMQ^!Y*1>/N,B&>_'
MG?I\S"7#?+S"[5&1N758]-> #957=V='4IS2SEI<\K^7=5M8:0)K!PMTS''+
M 6LL:146N,E5EXI=O]KH95UXWOJJQ6A+LXKP=17K+LKJGS[NULC-\,T&-F%V
M,PD]@7<"!R8-!^[.P'_YUQB-<E[KW'V>-BQV[;I<NNOSL9^=)QY9/J3,ZKS\
ME64^?2'=.T,^W\Q?^GG RYZ,W]\Z'6V_%\H*R(GXU4*MZ82XG1C/I>[_MLKK
MOP>>#?41'5I'JC4'E0Y=FH@A-34AE[%+Q"#5I=:,H=6Q@Z^KLPN4,X-!D?ZA
MDHW:3L-J-R[:3Q]\.&P?SY$UI!D/J6=@CLL_D9FF2B<9$3!1\7F%+V+?OC!?
M*^0K4G^:)C.]6+9UPVQ 05?WS\S;WS>NJ1<?D\Q$/Y) ]80D'JB^+ ?B7.B$
MY^$UQUT_BD3=:'X/Y)DVC.Y8UC<0IALW+"@'^OHK/4YY81I.#19?A&N^90A[
M9?O?_U5@CJY?F##\7<0"<<?\:H4U! ;[P$1_*M?$(D/_0#<T#SD84D>EN TU
M"AK7G]S!%3O&/-L0'9)(P'%TQI@P!2"I'4(F3S1^6N\:K(#/M%T,/1-M:-(9
M:S3&,"//I(K7>C<U?6@.;TE<? ]Y$$(RV;W4CJ=A&$+0SLG9JP DZ+*3GAE#
M2'(>F1#\#H@P"+K8)A(6.P8YV=A0 T^<-WI+;\2[8=,UN#,%&$K:?SD* @%#
M9_XP6Y/#GBY\YA+OO'5%+VIG^ 3/RTX=N[(Q0A-N/$CUP6902?N'5ESNY)^O
M?Z955=1J5$NO_G#[Z?X->W(0]TW5*W_695HN>2'#N.ZUL\/5#(=)L+ YY0/]
M=B-5,Z!1-IH%:IB:#!AVO%&&20C>C5=0T%RQ[1^8-N--*Z_["*]UBQV=$4ST
M$!$]^V[56*&R>QSVL+X]1\]JJSJ$ S[0A3R#4"^!3WUBRH\@?,C@LRN3)'PB
MPIY<Y#3@-J+9KK5@THE$K[8\V'-RSB6>.G8OP1?:UAIWZ7@%#Z;T4O_M,Z$'
M4[^64EF@>113#^"FQ(1111F"-A3YIX<0  /MR':A8]<[Z:<-O9V/4IF7YX9E
M!V)@:L\TA"7V.L&BLY%9+< 467GZ^YL>FQJXOGN:9>L8\SB;AABW@:G\24Z0
MAN&-\_/\@LS/8)QCC\\#H[,,MS;B3!=*R%->P+(J=H@%$E7Q@7(@[HV49ZM(
MYV:'8H#)WMQ%:?<NK1MCD:FY@L77*I[E35[J?C.4GC=UA6ZN3U$T*;HN$K&[
M?813D<@J^SUZ^7@%U^0G!WC++6M'11SS9T+*Q-<."93FBJF1K^?SJK&4ULH/
M]#W4\M -]9>9M^F6CB^[><N$=8,YESL_/(JZD_7P45@&QPF'BA<W#1N.U#.W
ME@-SYQ)W?A;'=J1KP\*W/>S=(/*-,8=?3(7L_E]>>G#][[5EFWF]$?#4K,H_
M8EFGHI;2^$*'U+][$RK 23ZW^&>IH^Z%>R?XBLO"USP%#Z_'CLZ=9(%\YA)(
MJ%Z;C%B]L39^LB37W?J&0Z^L+0_ZC=9'U1J;7(!RMY9R:"U\H)?4S:2:TZ82
MUV&\UO2]EIG(,\.7@Y7L S0H2[J-[]X5HK!*UDX>^W9.$S5!MS!ZQ'B]6Q5V
MC_(N>UN^&1S4U_PBM"#7,9'74CMC:VTYHQHBVY 2G9K\-F%VEBM8H3C2^QDW
MW"N]+-=_Z66NCE>RP*]<,WT!443&RV?]?[S[P$W@OLP9M9Z.<_\M/)V8C;DP
MURDACX61;=A)0[ME([02N@;AC!5?G3QK*=),5GMB)-)Q>($Y A%>S_MB7./R
M ]L%/7W[1Z=\%877<TLB(&P$(76$1LZC&U0)A[;^,E>/\B!>,V^REKK!]4(2
M1<.)1D8()-'VBR4+Q*Y'H[5HF;]HUN]&.B,":?J=+3TMZ*.R/^Z,?R9S'?0L
M8W$ I--3%$"24?R \B>FU*C!^?G-T_Z/\Q42&"KDFFO]IB,:O!>ZCH7XE*](
M6*-XVW/2<ZJ5ZDQ"0H1L*Q<^N&.C,L"GV@_OUJ4S9#;':14J'C<*<M6$8RJ,
MNWD3LSS'X.C!DZONW+G=^;'#DF\\Z>5957EWRG#6>.5'_11[R[TK#S^-3#@5
MJ];_,@H_RD%ZH^((]0EQ6,S3H)UA8<8-^M%ZU&8?)(,@H.F/<*?G42$I3U[.
M]8#/&/A'\2XLW\A)>/GV.S>8%X@=S.K^9^Q!S<L<9MW-)Z8>0R 05:?_>$81
MQ]^&%9TWAZX]NOHL6N;C+RH+A+61YAAQ%G;#*5O#E,V''@5L-,TI.:79CRKV
M^I6>Y$3[B)5E&7R="* $6#==**MRJ @.R ZR_ GX]TDHA5=4*3U\]OR\4 EG
MG_(KT*?C<O/>V?ENBN\M2!?^2E%\>PIO,\P"&0=LH5*A?RR-%%B@:0@=RRQU
MRXE2#V>P0-LB6%T U]\UG,)!)+- Z<@=B?$J"V@/A@6"^K- *P\U2IET$R;!
MB["CSH?P8:=+@0X+],R'V:5 W+T-&!.QC!0M'2GZ/GT-ZK,V)=IQ<7R!=C\G
M5!/]ZDHG) U6Y<KC+/)8]&T[/E'C"_6""RS]\>R-7,J!@GFCE:3H58.H! SZ
M*XH7V:F&:PWA9:.,,O)NS.,-&1<-PC2$;#CZ3&T';Z\0MVXWV\=S2G[Q8('<
M@'=TNE\,GS"6.WYP<K[F=,QQDQ02\Y_F26QY@0M=F,*?N^4Y/K>AEU89]?K<
MBYJ<%/P5_Z9<)^JO^("Z*&H==(<%$HQ@*GW!MLM/O22^07X>N$HXXJ &L4#Q
M.0?[JL7W9_/0_@?6*'9^Y;[X[N)B+-Q>E%.95+-1DOSW3:KC>FC>_?O^8JWZ
M5[.N'S@X/)+RGC(XOO;">&/TV9(<;UE&F9." +>E8LZS]('/IT5SE([IANSB
M5=6?Z Z%>>JJ;0C0+/AE6*"NN@+*9G<9_6 @)$@A+KM7[Q\20SMB^*P+R</5
M-'S0.SJ<.*."+B*G4%9J+[B4R+M\V1>EO*'S;QS#  37[*[9\T \K03A3 8?
M9Q@"_NQ_D[%\*TQ]6AE3 3]B=)X1,,$NGD4F9I,&IEY>E2:A''$:PI.0^EH#
M_5),TACI%X"U_HAG,.G83S:\B!-TLR0#WG?PL)M$A'C%[8!K0)A+W=B&;&*/
MITA+\:Z*?H]$RDJ3")@DD<8;%/T.WG"H][-VQ[WFK(Y&5S!3W>_%=[]E<]N$
M"];9\<Y.4G4UXDYV:!VB!=QA?[DKH#*_1J[4T?X5!:6,5S%PU'O= FA*.01X
M58S6.-EWCB>(]PM;X"<JR'7U2,<^"S5^._BR+=*ETZ*)K\@/XRA[(&?\PEQ,
M0988]R,"C)+6Q1;%7@2.WSJ,F<HP4"CMKYWU<'/[#LQT0OU2K8STQ\(7APK>
M^QVD#IR04.L)X2ZU4HO7;"[#I>P((/0KH-]-5!)JROY ZA7Z+C'E$08AO/"4
M5?.V&-HX"8CHX0^#%"&K5_[2]:+MI:@62N=I.S?M.K<8M<8$WVMHIL?&86TP
MK?Y_OC>BG),*GYP.VA<%K9_3"AMUKZ1=TZ'*&MB7).7*H*G6PEYV9]&>.0Y'
M.0\,<C 6-?F(^E%38D#[I3]W%;^JEW[SS?Q$[!]+NVA7<[HQH%\POF<$U=!S
MAQZ^N7XU7.GCX*715_D5-]!Z'Q&.7)-=%!J0IA+PJI1*.!U[OI_B[CNZ.(X>
M#]YP6K12O]714& ]@=/GYDY:#UEGF)9[& <:I5,AO)X:42$IVV]JYE^6Y_:[
MX9XIJ]AZX7<?WY?ET#GG"Y*B$E]$99C)UGW^C#4$GI8-:?SWH/>T=3M9LHY2
MI'$]>0DJ:?DXT6WLQ[O+V>D1?^LEY'K?W\<$ZNYQX#-]H&> [IX#A_Q@-!LO
MC@5XZM'*2S"]4:3,!,UV[L-@A69NE2J3MVOX*!7<;Y1*5?^5UH:I]*&E<"O5
MNY\WKF VJH9RI15-+SD^ORJ6$AJ^XH$SGRAX'CB>V'X:R5/9IU';7H:.L!>\
M+,]7=#NPPJDR%.U9*WC2J2S J=6^QX0[?G='T3:GO9JL&N5PN[+O+!QNBR_G
M[!Q0_2W6Q-EY^<:8\9=SZ_O&=M6""R?N+51_U\_X8W(,[R_[C',^C2K[?D=!
M]U<D#U1\VZ\40I+A!O#E7SLC3+2[YL3F3C[B5,+KJ1943G\V^8O;+$(N**TT
M9[$$F>H<$3P"1)!]>]-C775O---ZL7'KI78/$P()4@$=TA<NW-SB$=D3O."3
M.STG@']0GS:D9 UWMLQ!;R@Y=%_/6DP?+T1G[ ;K63"(*4[MXS7B#U7EOOC\
M)GX[[W2[+N^BE)96[86M-,S)G9L^LS^;^P1_W<(H*'#4Y,S5M^(YXH]%%'U*
M ^E1I8_]2LM=Y]#<FDM'F%<'&EW.ZY*1P#5,(5SO[&Y@5M#,4?9H'.\VL.CN
M)YR13WQP??7,.N+B_*:N9LS=<,%NX9K2N<"HBP6I:BF>5]KQ8PPKBK0:.3?O
MO6G8M65/4 O*@UZS@:[_1$0/I\,,5;NZKYOLOK[;K*<5K[F[)]_?<V:@WG3'
MAALPZ6;RC!'-:),Y?&_NW,]=O9-E&1H6'?%PT3+=Q('0EAMC8C\>?$\<93NN
M&KQY7VX_J^F8%.S*]/WOI)%O5>2J+MN!ASBU)P=?G_N8WO^8\WEMS+SRP\ '
M?+I%96&=SG?R*R\[)BZ?*E3RO-OYZT-XBFK1OT11#C/U7!EG^UR;N#R#*Q,!
M"HJ6X-<DA_?-_5Q/X3F7NM1.P:VG.@_D]$S;>R>.B)9&)56KI.<)T4>![N,7
M125JL1'G[[LL$II_*C;BKTY_[_SUW<5]QM7-G<UUZ>Z4G*6G/K2I!,0ELC\B
MFJ[=C]?+P3XS$&DIBP43?ZMLBZW_1EA2D$+PW&B5&W/=1GRT7O11]IK>NY6#
M<DQHY'M_"=7XT@#29(VWKX(S'=*OY]P-/@;'4D[A Z.1&+B]6<M$&3%\/,/#
MTJDY^9_'$EIOA.I-A/*+<<B+M3EWLBV%^".C3P_+A8:$;CW.*6'\2_--DSM"
M0_P@R1#>-K6R%23?;X9F#<.(MOD<IMPNVQFEA:XRJ>;FA5!4?K?+XRDV K-K
M=7Y.HD1WN$777"\^5^]Q00G\/NF/NR:\0MLNK,)I".;S>!V?\[OH70[*=$"L
MUZ_9\>7JK1(;?HLB"=M0M'6A(C%3O>B5BO3='T5+Y?B@IIF(H'P2/@GY@/_$
M-%@X4(8?N$H/,6F\T3S5 49<"1$#+"F\\6DA'0L,T6J@WVZR39,NZMS0Y"HS
M=WVBD05*@,Z$*>3X5TY[6(;XJI4PSAV]8YYD1#4<.G?.I71P L^^E*ZT["P6
MD7\B;5JF-&K4G$'3/]:,P%NB3J-?7AFFC:YJO=#L*!'N39]O:FW*%2+#U#+5
M*#$*MXC$W7M'90A;,N_=ODWK]O:"3[-G:$=-%:6K9PQK*(0$AB]=LJM#SSUP
MP+PL>?XCK4VTWD3V/4XN1ZH)349RQ(Z(R)RB@S]MGG%CB -5AT9 >O6V/YL,
MQ <%4: @_P-\ C8\QIM,2&5*!HH:G9FX0'-.14#>N\W-N!J_=UG)R_9CRM!%
M$B,CM%[Z1P<7/MAWPRM/:V4]7GTW[IE9^1*=6W&42\S\A]BP%RM9CF_8\27)
MGP@'_>X\'?8GN^_FDC]'5K0W4;S6K*=#4C2+%-#R[PH&GF>=$EH>8%TC9R,I
M5ARD[A!_)42C:K#D8OJ>N;]"3N2]D9\SG1?V?3MMDIC:4[ Y:88JT%H.1-@
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M75PAM8?/H?C_^,(]>.9@D]7_W]8Q+TX*&?J#OM^Q<\&[^%_B_PU\VHDJ2W\
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MV#6F*UH[YVC"#W@M&\PO<Q$PG_)5SNC*V6>5YJ>F/I=>R+.WSU_@"WG>.'/
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M;D%D/I"QNPZ%A!N2YN#XYN# @7#J/T((@*KYDQN#M4 (,W;>%VF+^Q+()X&
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MU+21=KG+X71888U[Y!-5ZO16)<0[;;.W5#.$D.LOV(O2/H>2.2B6[;J4^ZA
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M-_YV]A[;*0,RW#]PJM'5>8;=B/Q6<NQ@HV&HCLD::[0MO3$XS2J[YM#8IO;
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MA'1_QFGQFR"H1VG7*C^.H<"6%3+[GBU2QI YC]TNN@":-$%^MLZ4#?!YI)O
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MXC)Z[8%XJZOTE0D13VY%"S"LG3EW[E/#.&TJ?%)_*C&]A0BQ_]SW6=IZPOL
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M7,S RPX5R?^HC&Q*0[;.($7[S$WFO?+,\4.R<K2+Y.@8 AV-)_U"XA/AE)>
ML^1<$G?;OR_=+@&Y[,3/4"RW"@-\$WT?TT7&XP7DR^UC>IJ(E:$W=+:4PGGQ
M">)OU]_1%0M%_(%SAN;MA?P(8$[AY&9O>_\3B#$%XH66NB\:I0^NA<\LU?:6
ME]@!4[WR%D(-,<-1)YXQ-25WX_2Q@OM)P4<LSL;T[X/$?HB(_=@3_*Z*$$SO
MV1VW7/0R'[JW7A)B59\U[%ABM"(O$<Z.,F\K_SJH?QS/K4DR!M>$<, QY(7
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MGI.63&4O+XK_:2L^ZD(+$J7>Q&/4BI'H..,;;WW\8\@7+#=7?D+'T2G]]VE
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MR0#5'S! -TW5,:O%4)X7@U3M6?HIH['R)Q /+ .$X<>,B09=P??0!>C?F5_
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MMH1C>.C\93(?[:5N*.4Q_1N$32&$PP0_O 'ETN4CZJPJ=VF2K%\)#\:UJY/
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MO@R +VM/UC5K0J/7G+?V\UM;"W=Q7:*;DZ%WIS*Q<LF(HZK'4?E%0W"@I.;
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M4ZX'%#+F8!-*U[-Y7W$Q!J)[F2V'_\@U<8OF^T$1E9=_G#US\HJ,A*@5 ^3
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M%DJR'$#50P9WT\#@?QR9Q+NHIRL-@]W,I(\!XH[F&2.-X2!)G<HRSZ/E$ I
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M5P X$\7\AV(JQ#]!!0$/YH_527W8P_]GO!?T]S?X8![?]G^,*WD=+J$VTX\
ME"7 _^]OGCA_B-1K[60E=L5O2^ ?@!WJ1,>2.FA' ')(SE5Z'%F=QD,H94C7
M#FXT^ET<M8N.TX^RY>\"I^8G_M;_'GLG@#4#\DP&(BOPL5@R/J=FQG.!-,\]
M)E.0=?WT ^/6SN"L[<[3(0&Y*T'51X .$M'0I HLPHKQQ;)W/9T1&FN4""C]
MX;F^]DS%3=BAXF4:\='NK'%86=-(4;@]=XSPS22Q)Z%RDM1MV+.2YZX?G^L6
M16:+6@&Y1,4,A5-')7B%MXNU[?E,.>S0(^65^=$+F ?N^46/XB/,ABW21QV
M$U=U#=/GE-YW*+AP/1,>-WH@!/-T=[3_=?6\A.]AK'O9E7"732N4J"[OBM !
M,)$!TI7?@97*_RKN).E)'3QX;'OI[NK+UZ9;GBKM(9//M&^^6[QS<)<A]/U
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MIP/YFO2"<8956#OWO3=I$]O.U_O+%K##P"@TRS8H<N;*2/4F)SVSTR*)NS%
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M9C\U2]'3*2BB:2?^W+5!QK,#9>9OX+EM%ZIKO)_]_:2+(;*TKBY%;OK'*;&
MV_V7H^Y'=E% 49^'X%?2*)#)S+C=9';X]::NG/\T.]4,%(\Z>>SJ6 ?-P_K&
M8]/-_LZEPMK1(B X5S0_OSB0=C9F1U%8(>S & '9#3[F.!++CM28KGRU-6LT
M5Z-=CJ217_>S07)YY?=(V)(?S#]N TB7%G6D/N3BHE.&VO&58U&\[6BN'3 [
M5'V_.3>?[DOOZ] 5'RF]-I+^"#?DFPG)]' T3=R?"88M*:H>Z-AU[FX9QE)D
MC7UDF9(PDAA^MN"&J:@P/I(I:TN"=!>"09\^(U;O_9U-<-DBOT:UZ7PAEM[)
M_9YBQNKA)=_49L/JJ79N\^O919_S^V5G&@M+"P2B8SUD<)-_X-W?)E=SK0;W
MEI"]K3D\3V_6RG[)&*-QA2L;6UN@)N@_NQ<N.@G=9#(_T'P?J_XIRWH64&#&
MM2;2H7$$8->]MB2 Y*9Q%N6ZU^N6EW LI(8632VE3*\EW_(@7MH3=J&S*^?F
MO2NW<FE3>1H[1@^D#K7@V1CR^0@0>3%*KE&)W"O>^Q)W #.L__[)([S2Y'1G
M 4IGIJ10XY,L<W]_%TKUW^0N[D1WU[8EQ>"I5H?('2?J9EAC<)F^)/8FCI9.
M@%]P#PKM_;I9%=EN6+0LS(E6S*C0^;496@HAYK=PP -]/%3?$PY-F+_J#3OD
M16:M"4V@.0N[+IJ)O,R^H\#D\M[SW<[?NW^?C& Q<O*20@GR:[XE)2+7/9P"
MOU88\7?*9M:MIU$<0FK2(!DO5'X7$#Z&*,#/ZX@*_U9"B$I6#+9:%$5_N*%*
M2\[5AN6:?+O69&/I5VANT6Z54.M#JSL(*Z;JBK"F/ZM;E::$U(HX5 >\[JX2
M_ITCP"UC\F'E.?5"QX-X,:,!0KT?M.@GU,%3.=[C7^X!SQ'@YU/\;*T>"UJ%
MR3KQ6N4WZ(5L(U)(>R[>56)LY CP]#[CP>&7_[;@HJI5[[_H1UY%#N0(T]EG
M9<NMC#RU!0XD&* JND>AHZW)8Z'2'6"L)K8]DX 39/;W"?IOL77\JR4K$G,(
M9*[U_PJA,0_+F$+G0OSXQCJ. !.\NX9T\0SDY _=*\BQF5-TUKP0M7JZTQ?C
M4\9G*E!D>(RX.G4ADQ(LJSR6QFWGGN..G<CJ.D ?\")_OV/^=*RL;06]!B,S
M.JN.(T5K?\><O+]&H&$T\PH]=G>O \_3:/+7A&5,D:(HOLJ4&,V@^/'V[*YO
M17@_"JT/BSS9! W&"E@(VGF-F/A"#=0J^/C1A :"I=WT;__JE-I6RZC*'B7!
M&*U#__I6\Z "BT1@6K,RS S:YMU&SBDZ>$'^.0QQM)0A5W4Y9(.G%PL*5M>S
MA*2_W&Y=C$?_>CI4$O,2BX<$NN%9F@.TCP"Z!XS4]-EWYOH7 ?^]+/_ODHJ6
MR_\[AZZ#IKL< ?)^@%V90JAE99 \:C8/N/48/YMV!-A]CS[&AY7W]$W'HNI_
M_]7K!OY_/*MJR,=<3#T"C)6BF 4M.TKH#2'P8? OT([N90?>.?@9A@K-,:'4
M#\6+>$ZRHJ'"UU^Z#*J9^Y78N <]SIR9>;+\ESBUO)\0?<)/M0DA:3_4>CWS
MX]PGXSWWOPD.G;OV#S:,UCT=U-_;VE]Y]T56Y)L/+JGN=\.;(X#51NZ\MVR?
M-J&/1$"S,B1F%?G=%,EF @025YGV1:)4'(8BH.[/,8N1(O1^-H.%RF/&FR%F
M6FV4A=]:#<$1C9&_5=\(&\=[<RE3"V)1SOA3#M/TN;:,)$(OYY:@;E= V00]
MEDR)Y7#87Y*3-$/)G8"K"2JVJ3Y\YQSQ^GI5F^,2R]!FXA%@6^NU_U,DN?M?
M-E_%Q[[3QBS>F'>"%P"%OS^%=&JH:YP>TGV4 )?ZQ$\]%9W5Z7!A_$3:-?V7
M'#^-5 $D3H8C-2E>^)^V;!DTB)'A=,6=/7\*TUJ9["334BO$BKO?_^NYR\\>
M4>3+^P.:6BZ('L(,@-87I: M.\?%3G2? 0ZKN<'_#+VH:\#QN%<\85\-+@F.
M$SF ]<#ROI]\!(-$CS>_RG^5ZW2@RQ!_6:82SS5E=$.E_X1@"V/_!#$5=S G
M>!Q.OQ\!;, 7C&X?3IPJ#639CQ=OR<H D)%R]+#9A?19CH<ASZ+N5=!#"U?2
M'JX4842&AS:JM:HN6G&75^1 6GV\GT]P)9^#/N7AX^QLG"23NL 3(+,4([H7
M=;'#@:<Z\^%8Z:01M2D.5B*9L3UPYYLMNWGQ77&B+?_@Z.^1\Q7$(AM,F\O$
M)$G!]]JP!T<^,S$CM:3O.T:-0U/VP+J-HW1W[*'9J=1;; [J@'11S^[>:NJ#
M5!<OOEYTF*^6;)TSQ^F1] A<B6SFBY=_6KT\OG5XG7*I?2%T(?*%'_&/FO?C
M1*71^/*AMKMOD?N8*(R<&<XJP3VUZ*%QR;0F)UA?0,"?D75?I?YC/<B\RWF8
MRGE1RB%2BR,)&^]1LUKO]^IC/<+^"@ZOF@DM-'WD76M%8FG4H5W9[*JM=XQ4
MQ<<8R$+A:I_*),-LMOSB7 <\7&%P7#>+1S&D<_2,7[7QBT?Q]L8?(DCES:.,
MLQ0\!VQ/X]TR$1_9>.=I/;+)CZ6JNGK](S=$6X!GXG=ZX;.#)V[WV>&:_V@U
M<^4?=S)ZS$_73#I<XN$W>W^_&%M7_K0XMKBCXO*K+W$1[RJ><EP:VCECK&$W
MG<RO=JHGBSO2_-TK&]'KI^NN&K#.6CNF92N,!<LN>^CPPC [.M]#'2<ZVK(?
M6\&,#TP'LGBK/KB5U$-[3?HQ(/?4+)Q7$Q<;])AM7XM2C R1)H_C[+D7<FQ]
MQ[\U?(_XEL,>?*M';2;7[SH/!*+'*V/RX[[#<W77]TDY#,AW.JNVKD@%O<F%
M//XU1K>'G+3^27'=Q6@N[99#9^<1P"1'NMU8(?5\J4O=5MZ!C-;ML\I!K\KQ
M8G(;B%LLA&L/N%A>?_QS8BCI3J+T(GA8][[M5-8ET=;+0O\J#9RTW_TJ?6"J
M>-YH]HRI$YLS/9C2=UHW12&I ";.2A-+3(GSD3N&<F+V6W:G?&/1GD#1#?12
M$"KE!N*::[0Q:%,R72B'CQY*;6@9<GQ"![>,VLD1L^/W/?8F7(<E$Q<Z*;#@
MAN@7;U<?I?$N/+%IO>FGGW$K+^?>!^TQ@TVLL!]-+U,K*_ =[8_1^&0#"Y?<
MW OOAMOC=RMG"R\G%)"XPUQ]6D#^0J ZPK<^)#H"\ JIV8]D1RRV!^DFS6'9
MW>S&8D4,OVNJY:_:=Q3WYMF<DF^)A$ :7-)F>M;E_,&O'$ XTWFGOH\Y<1!X
M5(;U6[50H,/ =J]6RYS1D&_H<^)R?MQ]8;6$IISW!1![;6M99>+D9 ?L1;AF
M?:NHN9E*./3!6H8?$U%5U]E_=L.YD^VZQ&7E.T1EY1-L#9%6$4-8ZA_;!\83
M[W<#V=YQ77ZC]\[@SME+88D?3OPY IS7-C_0<DL?/0ZF$,5PCTV_)H,#Z\HA
M7]F2GJ)-;*GO']SPYI>T!:A$LJG.59Y;[$;OY7'&\ NAT6 S,O!BB%@-+2E&
M6YYLW>]$0\7LA!JVS\@-O)Q9WL16>X >U@SY>3Q?]G1._JT5QV$0;%-&KG;Q
M#TQM5ZAX0-N->5846)&&JY>3M&R:?=\M=>F3T-R+=W.W%"!:4^*B;Y+()-8G
M;G:1!5X7F;)XYC3MY&JZTNI^9VX)<=G">%ZZ@KHM\+GCZY)7-*$C;^(EKC;=
MYRL\X 5@Q\QN1S5;X^'PXGGJ\JX ,;Q!+UFBLB9Y02_Z:X99[WSR^1M:;^^6
M>GL\0J4B!4,T!9 L],?!N8S'M&/!@%L%L2V](+3Z$Z.BUC">$4WS\[]*2I>3
MW=2MDQU(9KX>:I#+\ )[B#;[LP /CFUKP"$L4-3G+LU,U+M#U;M#TE)?M$+Y
M?HYE:47W06V<4T6.!HOVE=L3#Q\Q',FC=+6S$<?L/9[)53&,O,IUQJUB.2.G
M>M;(KQ=B>NJQ;+U] ,&.)4@\^LJHX(RIJ.,STT!G6#KG B3F="ZX"KP1< C8
M.P+P3-1DSWIP_C1S^/M$/6./$.Q42NH]OT<LBNIT$#UK7I]S.I&U3*'5]D6:
MX.@MT<;"DS\N!M4OBMXZ)964D@C&@DQHTS9+9E126T%;C=($PGD%?5Z$L'MC
MW*R@ YH'Y$<X+^_2;(PO6MI*6E'4( $)XI)LDC;=@'WB1]I!^_/VBIO1.<JO
M6%F'.9O_8?B:,5&)NW[5HT1M5;L&DXWEY0FME=)G_,P*ZVGW@;SL*<_,>&*]
MA8?C^\FFL4]."\Q_C-PC@+ N?!/]$T0K]#F[!V0RCLD#M\%3YMP1@'1,,BBR
M*M[PS(/%K22&VS]\,^KZ$:#SRR_@%.I@B\30%PH[.!8___W+&_V9M?E_+I/[
MOR\;=0/E=038[$'1+K[@V@ =_H,SK[P6;4DF*6D[?5Y-G!4K*.S3?AK0B_1U
MZYL-U-5&3B@]&:>S:44--I[,D<ZT/69O<9X>U><\Y7WC?)/:*>QC<8]KQLMO
M\]ZKKN7]L3N#^@1G60 /6#BUMCP]U])V88H)",N)&F/QB=WZP12,KMX4I<?V
M=2(5AC9#O/A3V:NS]G7[N% NAQFJ*81N]23%5#E:JZ1%]GWWF!K*O7M*-0/F
MYB8>APX;,C,SX;"?*Z2-,K-0J^8CP/J%O0^!<R^*5?"GXQY=7\"ER32Q.MVX
M2/V=+?3@0GOAW*NZ*#U>/A=-A8N!U0L.@UD*]=@(ADI^B$2UI@ZS!+0VXD4^
M G#"K(I*9]P<N9B*8.]T_T'6C=SR436N"R1#6*C8X:KZA_VXE;15L>'R/(71
M,L<E?!@5(4MHUAGU*UG%1FPANBC"IW+='3B/YR1ANX\/E@8.0/D@M9TT8OS,
M7-<U\U*6^Z>$\LP4YN,%Y.78/=]Y;B\Q>5:\S.!70ISH[<+< 0L2J\W\:>Q%
MGI>]1%,(4F$CAA,N 4VUILZQ4A]Q&DI]KN>M5D.90NZ6L );- 7?P1_>!]5R
MXW9'BE;WWQ_=A$KFW7$EQWD8>\#%!Y*#)8>3)_1'IG&O,(TS#U->[W1X$'1N
M=3U$I1D.#3_=*["46)H.] [LY/3Z.8O^L,,RFY/GD[P/D)$X7B]\S%3Y>__3
MTOU#L\ 6@\ 86T$>"W]A_+PXD 6UID9#'P&L ]IE#N]A>_#_KXV&2)^. #]Z
M;OQ7?=&:B?ZT[ K<4O^%6M/@/0(4V)CK\[4%?M&_^/!L!'(0Q8(#$PUW4?0Q
M*F][I7Q-#"V,C(UO!CY9$;F?#.5%9-YK&BI5&[]X\5G YQ4!_HR.E,X>R8"T
M&S_BQ1Y'_491'P"3B%V=?1-=>M3-=H]=($YJ;;7X"?,W"(>-4OATYDM^R'.Z
M.0Q&GG:"I$I$7B>9T!/R6_,8AM3ID8S>;]-N2*F: X[YX8>J<7O+$K!%P:M1
M.F?%P.6,PUO87W B?/<%?6@6&[]\X,%L-R5W,[5!4;[8<R&^=&[*NBU#@SJV
M6TGW("\K>JI"Q$SM:FI3M<5H0ZW& 7YP:@_%8\W;1B=O@&[9L3!'0.J-[SPT
M+WKPC<?/R91HM3LL95[8IK9XSM)W7B//R4[IT3"Z@2V1-^6A)0S/+O,8.MPR
M@GD0EVTT2GB,D6)[U7[3^^:C#+.[.5?D+1:]'A98CP^7W!Q\?!5(!I+;C\7$
M7DM2$HDW!/H%V8L2" &[E-"Q%,Z(4J@PN@T<:S5JUQP1,-?MEPG%-;F:4E?!
MWU;4B9'I!>Y$@ZH7GAC&I!O/2B?SMX'E=CZZ YU4JY[ <@2HJETGE>I)"# )
M-%0[*<&2_CB_K5B_V X!F2T(US;%++=<N=K[D::;)#]=0^>8NK[.S9PX KCB
MZ==KU^9HBU9'@(C@(D38(SK[P9WEQ)<,ZP-EY, -2(@<G43N-7[A]DM]1F04
M?CHI ==3>"P%F))4SB**&>_CP;*7V*^-T5,?GQUT/$FU-N"14)CW??ZC)Z$U
MS/EM7NA@WEN5MP\ S)[.T!M*U3*#)1\1QH3!SJY38:U]O J2?=)@;M-388F.
M!K4J/Y4^Y&L(6V2YSZZ8/\17%L2D2OG1ZF8XBPPL\B'<<6W&HT66:0@3Y-]"
MILQC"2F3)OE0XK"41>J]X5P51E^C_BR:*-M!Q,8U0LI"+M*[%;Y3,J=1[<*Y
MDPQQVDX6STI&>[IPPN+$RSGJ7TP3'JT:X_%2W)(#G\*=YGK&D+EO/5<;!G(!
MCTNTHD68<CH;2>3-"%!5.L$>;#MTM29'S/L(X!#7,B-</M H4 #M$VS([!"_
M2A,;S2:'RIIMG1]<U0Q73_X*5(&;'A@PIX!5&FM5KD+T[S3+>]4TA]Q*$!M#
MFAK7,Y<4WZR)?V=24^_XMID? 3G0ZT1>:FC(#HG.JQF<&YI[M["_3Y2K#XFB
M;LZ2NN"3Z#FNUR@W$O$(T&)-.GUL,'2XPZ5:VMA:ZX$(/3(8UB<*$]>NU) G
MDXBG=HMB!TVG)<"TI*C2C5]H3N3YY8S((NBLF87M#HEG16#F\AN/E_B;-'17
M?%=G?$G$JUM8UOD0J;17F! ";QCS]R^5\\X5M(ZGKQ""LX467>1E&=_R\1 \
MUP,UMV";NQI9\QN=7 V1-Q42]2%"GZP[K!#W[U_O]*R^.5 2BPBT*GJ0R(FF
M>?%@9"HCGMR#EJKS<#PJLOB:)-F$9[*.444Z\>Q' &</()@^5' 8-F?=%1I
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MG3X T^&33,;0?,E(>C5CGK4 :?1!')EE]EW58T#AY[G;$K+6?Y7?BW5(Z,1
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M*Q^R8<E_A;YM2P%H'K&0!'LA1R"_=>0Q6PX%@+[(0K6?\93TOY"6;ZE-Y']
M%ZF@I.7_1M?_COS_"A06PL_8/ K T\UV4.ZLR&V:3 &8!(Y=.IF33T_]$V?[
M=_=WTLK_#A3]O+S@O/64\;Q)XR\*X-/*YI%&$W0IE 6(#1?Y1\@ ?V.!U(CX
M_Y30E<RM107,]?^7T+_^EPBM^0]RW?T'N>P.!C0X/T?727?H%BYTOTT<"Z[>
M)N J3%L3]11Z!:)-#*[V 5[B@7FK_[F91B<J_4!4ESW=GJX=0.[)G:IU)%A$
M=^#4FTLN6JQ?\ZH8"_1<(*M_NTF*_<%\9WU$8@F6?2^H!T4U:(?[#6I6^YBW
M\.?9:X.C0;G)B+N0'@/-9P>1UA>'AB!PXUX9F)Q"AP83#AA'-R#-Y[BB*_IN
MF\![CNC$DMCQ/*2BXX!'YOM <<>!X#/=/ED2/OQ4B[R\"I],[X,VE'>'!Q,>
M$76K6 1-SFJ1'H;,@TL8IE#/;(,19!2R(2]XJ!_!M?-HV[<$%+5VL0BMR3QT
M6V.Z$-@A.\"Q1=<+74 2PHG<5WMP3JC47DBT&X^FRRJ*+Y;,B8-_C7(O>@N3
M]U*=VD8MQJF59T]BU_WT"+&(% L9Y&B#H""+I?<ENHKN"\SEGVQ2Q-2;F;,Z
M8_MF*DWMT[HT%Y3+PTY;W)DM2F$^?G"[]UYAPZ9>HC9)[4P_/K>HSNY4AZGI
M.'_=*S[YA6S\?+ S*QRF/'+-JL3H2H<S7R#)_U24/ 1E@#B/2??/.[) 6$D/
MB-5X=K*Z_9H+E@6O:>IS'>Q,[,3(/V*I(,+ZT[7XTDON6U  ST#2]V.?X%)C
ML#>\FO)YYQ[X*@S-*P4;.)TK]<B&TE]X!-[;[^<0_-%LWWK:\3)A.O(2=LVF
MV*3B#>WY.L!YB3"H^>KN$X_'O&@I1P4W4_UJGKQS.I?HDMZHKL'T-ZNM LO%
M,EQ$9S):RT05%_7N5+M=+\Z2$.3LO1MIDA1BIB)N71E7M6OUH<HB R;ZM;VT
M)B,MR2RAZ3GG(&LY+:=YN1%]I=FTYQ.:.I&^Y?$G:2J O=7T!D45L4(7?A[6
M^]V#XC9,3,Q1;Q]?I-=HV4120R[!;O1K\_)2^YFJ=-HD9>'_ %!+ P04
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M>G3@"U(WM/'9[DJ1$]X2@&:TPLO%?PY:?J-0*%8N7RC<J+A@XB[_'N+6K(K
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MP1%*?]U4=:B;"]PG,I<[/D6#3?)Y*:B(_TKD. F\-BB,Y5V/[$N"VJ<TW8-
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MH[*D'^@.I3.NC,'6PY$AU<1LM'HM C$CU39VH((F4)+8'-[3 E.Z^Z2&GK6
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M&QJP6;38L,P-,6E+%C]-SH"6J8D6,1P3D36[2T0%<RA/<DF5;7")$WF O"K
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ML6_ZR0?C/KEQI\-*SB59GIMQVJ7[F^*!K3-6%&FP6&U>,*3_#8V>U"*C^C]
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M%FIX,M4*Z A(>=2I5@QDDL@^ D!K*?4&"67ME)OQ<^2=&BKA8L1:M/^A9[5
MRU\);LA"*<)R%N?XRYG4;>,]!PU].$VB#GP5,CESJIQ5"8^FB\PQ1A]F46DP
MNJ4EYPS^*G\-V0ZI;YV(+@-N,%6B[#-8G #MW]]H*TJ64W/$]EBDAK.4ILZW
M:1&O@"Q1JFQD^5\O,6HDNAR_F!4B*UW4#]&:82;XBI#5Y%)^DI5AU WQ5>K2
MLTT6,,?Y'<>6O8HUJAG-@%+1O2ET2\R^3_1U3$B$K5*T##N/MDMEM:AKSH]%
M!3F/8@;%LKI^DH</G3MXBZ<6V(:I1F+"=>GB'XU1=#$@56/+NGQX.39@JXQN
M8C##%O5ZS=!M8I-'UM.60HN0/THMD:/3#D^0-^?XMO18+Z)LL+GSYC]^51^J
MAIL+_FC[-EZ51WU"DM"O%BGS?%1V<6RRL G-QS[=>M3@_.S>0-B>A'-(HXQH
M_B9L]7O,_\&^%;LEAO6]7G:GKY_WN2)L].A'GT=^9983;ACF6&)K2#+/ X;_
M46N=\^:^<?J6MQI;78>()_\KQWY&F5>:'-7^BC5C'"LA?BVU/86>UE"85:OC
M_M_KN*+]F3 Q7R]>51NVT8PK()N4@5SZI-^4R(T]$#+BA! FY:A)BW&<@N A
M7;[1<YL<-4PK;-6?>2TB#S <5<X:52OD_&SGM<C;W_%9(@\I4BD5?7U#)EK^
M,K(/.PHS<T+H%N0=&G,RHWHB8GU-5^U#+/#^?[Y3PCF[<3$!.U@&Q-)0KV?:
M<+Q,Y/,2BT1#6D,A,6[&,XZY"J(B&XRF1K&)$]F]Y,12N10*\$G0='HY)<MZ
M6'J5W&__0SA 673LGKIK-)0>&S+2?H_=7L_^&@0CT09[1<X9H\G^ !Q#0 IJ
MTZ9:*XZ.MV@Q+._#0M##+:5XE)/^A;AW[T/DTV@@2LKB2T7^:$1!8D""Y,E8
M1]3CB/:R5^]>_N_)WD4E,!Y\A4_#MB(=K>+5/HJ,!9QCHL)DW-D+'4UC;WX=
MEP"9=\VH!E+D5(NF(Y C:A8$6C7Q#&WY[S#'@9)9.<!07MC*[KA$F[*+U3(M
M8K:P)C3#[7E-CC"?VZ#+BQWAM.XF+V)JF+G.6_X"ON@C^G(626LJF",#]P,$
M5<T_7&U%FS%>VM<@@J,@V:@XWQ.)"[@ZS/IAK&'S2Z&C9<B1^?)$U67G-5W>
MKX9DEPS/RD%R9Z_V7W+P F[)G\ =?M._LADE:2/N/&"UM[*]$%^9P(H^@JWO
MQ?:A^!_04;G.&6*B25A#?P62_GY44UT)DQRP/<K',^\,YB2II4TX<KI$35\R
MX1"@XQI60UN%".>BE@3<ZJ6<[(BM*%_&68U]"PJKH-WHT=DLDK?*0<1%"#_T
M-:TGVV@KZ4Z LCK>FYE^P8$H^Q;I?,&/TH2OI.=?HLF&JMQ;+!ZPPFA_U65\
M?OXONTRD[IM+Q-:!,,3KTT?]GOFBIG,)D9'WQB.VH:+?U70N<>4"3F,"EL%T
M:Y9D8H_H+_!OE$:76[JV";5OK :/G(X%[Z*F%1()28W#FS:C*_<^ QP?0:Z7
M2 R>SX7L09(/(\0KD^QEV"]@"L6WB?$S"[@<K82X"/)5YT=H:0@UW8N\\926
MLVHXCFHM<L&V(Y.\>^,4'^3#.X-I-[;[,78(G0XII"./,8(VMLD7OG;W@[/G
M?$:3I];22_O=7V ([9'6C7R!G,U4TW(8Z@'#2K ?GUM$R!2^539M,ZSOJ>5D
MO!RCK!5W7;D>8Z_D6WHOX!8+55D;&KN3HGK7-Y;J@_@.QM@KL,="0!<R(1<1
MP3/43:WDDIT0%U@LR1-806Y*LE,%D'R@95]22@=6];]M;Z?BFSBW:9:W;FK6
MD&IY5@.Q1JHDDZH?O8XE/&=R'@R\OGPQ:A2S]=V/M!MED>\H9.)8/)C;BE^,
MG:CKGJ8Z8FL+-=77O:EION*:Z%85[Y;8%F-$HA7:0&E5H+S34R#SC$BAXZ'U
MW4TTU"6\Y\NN:14>VMB7%)2Z%Y[XVYBL![ET,.AEL!@VM"<G1RRKFZ]JESBJ
M<HB.WLR!:&VA9$ZQ'/-& D;E\W2M:P;28W#HT2CRIN<Z4EWV!NE6-$^),0^B
MZ<Z'[T3N]8 )BVW#XNB6D\W1, E;=4.?B,ZWG?D\72)<CUF:B 1YY04BJ4II
M\43X5HVB39%%K.&TZ@@@4NK+)H-X;4"D9,L <-2'@,@RP)2+UO9.+^"<8B[,
M&K9G#<D>DP-QW8;TVOD"MO,0J#R)6JIRFE(?Q_J)90,&CU"6\P+N "*+(!@;
M+M>'?L5,79];E5A<XBNYE)S[K_'%O"9O3EU2N/]QU+4JX13\NQ<3\N?<'=M:
MG6-N]D)D/E_/7H*Y@XNG;@.2/@)H$+%D]P](W1/$1".^0ED-;>I1@RFU(ENT
M+MA=8O@:[+@-'.&(LMLL^@\H*7N&$=;1Z:(-5K2JG&.W%=6*?-#"+&^>Q2"C
M='U/0WZT83GA5!FXJVJM,R9-YE2R@'7KHWRW)H)?\:[(K&5'/$D4P)$L34"/
M,2^CK(R#\W=J=9:DG'B*XYBS*[KW#KIK(K1^OBC1.!\,YZ7-8,I,-B'  \>3
M4QAISARB(/.SF<PD>@YU#?D7,=X#L[X#;7Z"GJY1KXM")EK%>.&S)/%*X/X-
M;05&1MXTW/KUND]U,<>(@DQKH#K0Y5U"VO\,/3S95#3;=T/_,[*851.$%@Y!
M1^<K[V,7>SDQC<<+JBJ*[='W#Y'V-N*RZC-1EV,D(8@$1+8U"/\)O?1Z ^C_
MZ4ECZL$I==&+=R:CO *.4,D[2XTR.@)U]0+N- W'*@Y#B5/6QK[@7TYTY-@
MAF9JY!E2I(!]<Z<\($:25L$=H8!Y9)7T($K//#,I5"T.-$;0E=@/?=6)])R0
M2_N?)-\%':V#*QNC+R8'?OYM7,PGWFON).HF5110B$BFCBLT=MIJD'\1F?WV
M+T0UQ6!H)N9)>QN+]><012:4HJ5G*^O9F_J$)5X?-5PN90,(T;QM1$,D?M?!
MG.9G9S_ +!\7^3Z9C:?J3R&FQ8A2DRQI3-'9<R0^2!Y,RA*Y@E X_'!PZD^C
M,F<[-%67G_C.IU'8)1>^O>95Q?$FW+I5=XQ JKC_R^Z4%>K7?"LB0B-E=<<@
MX.PL7-CNOX"S8-%VH7@NVY1UEF[#<GVAT,<][6_:'05;.DRHY8;?C0@?6M]/
M<78M+F=%:NJJM/.T]D*V+;*W)%;SG>6+$J/'#N$"+'Z8KYIFU=)L(Z#OP&[T
MAEJ<V^2D#N)DCWP%F-HNY 8=O9"OZ9AGTRQ?^8_SS2A>V%&0D,))378,WV,$
M@0^ZR4'61T'IBY\\AU[<-0YE!N93**7:02EN4D[>,16>X@ :OP6,VP!.6<"E
MG0_%C@$A3%P3"I&[V?:LW:W]G+5>%%>6B;P3G@H*$O:?I<;B%T/F2.&5Z: Q
M,D-+M'WGO+@[R0@AL8X1 ?-9B8J<W \LL3Y[_NY9H5.TY&M@ Z]\4D['UKQD
M&EQ9^Q7R8R-?]WCS;5SSD=,O.@+C20>%]ML^\2['0TX/PV.2+Q7<?#A"WWWA
M9YZO_//Z0GH6W<IX]S5 T$ZT8F\ /)EATTLC[TQME6V)I9IXYT>WWJ+BH8ME
MQG 4]"J"Q5'7W5S +>LUV"MKBU."EQ.O/D=]]W5C.\Y5 W;']^D];1&^S%4X
MED#& 9NHW#M@G=%K%G!+V>90+*J3B7&8%5"B=-@W7;D31 N&V/^<PS;VBC:Q
M'"QI^O1P1VU^%A]NMCD.BI$4V#Y'(\"S_RGU!$HM+<^!F$X.AFE7+G%RFCR=
M>#G5E$;0.K?_!$:\82QO[ET09;3Z:-D"SADPCZ&I]5)Z^M=00"']"4+-N/VR
M$,;+4G<?!&4H42-(-^KA$E;@0320FSAQ?<2G$?5Z\I!U8U=7D]L=P#LF*NAK
M*FPSEAS3C*60LEV1Z<^/(+>S?J+G$)=@@7-D*$H)F1%:C/_7.,=>M(KAO!ZD
MP1QC^ A]VD59OE.C,@W'?)^!>C0R""'DL&W?E9J@9 >:C&=[DE5Q' W)C41&
M<YH"IE3VXM/Y!+CTH5IG,S9"!7G(C79G<T2<:R".E?J!4]1T%]3.F+283F'O
MNH"X)?2^LS\26-#D-^@L?,BBMQK<PCK]=_5 >\I8A1*'I6]O5(4>ES\8&[QM
MQHNEU^ND1"N@DQC6(F(IOX"R#B'E)'$6@?,3VEJ*)3+"0XHE(QO '<T<S<8(
MG;IL+4K+AZCH(>T!Y>3[[HYC' O("]W&1[1AZ:DF<)DN+2DJ;%^"L4"'(@^"
M,$'<R%(CK-2T?3Y?<Z?:Z$Z?MR!(%<8_UNNZ,)\'D L(>&AX2;07$4!@(#*;
M?V84\(W7Y8:JLH6<Q=BW]:A]<3)2W\*W:O)7W^R=QEM!^QJ[$C<TI-./(;I)
M)L*7B)R?(B*N;][D=*I_F]@22XD^DS3DGO-3OX$04^=@GV8S_/I=]\G7@W'V
M>O=4>*/7&_XAHROG=?0\V+U!NHB/NNFW(DP9TPGDM67 ;G+>DE>LT3;.$L.7
MV/<(*6V&MB24=1@.+*#@6!6M;#=P40#2/\HB3%"W N_D7"JW= 6BS$[4+6&U
M2XJ,F77S[;!7(Z\L2G:'-_5=WDX=Z-"G@W4,WTR1%;9NGD].079K*K(-7T$A
M"$EB&8[AD=%6CB5[/6AOG5W V6(GT"%9J1TRFHDE/0#:X"<UZ (N _KEDRY?
MM Z8M.Z&1W.@P$C41#,\*^,O9949UM$*/Q^(Z0"27<5&X_T.*6SE\434;J,W
M+56&H'SN8X-E#,411"?-[<("4:)$<:6(DU]E6(^=08AY/@&[Y91-2.FSMX.0
M%R*6723O*!N4/F253?_<>^;0:'\2_=4"3E+#"M.XIFF(V2H[BF/<YP6XZ\!'
MV"T-2]8$J1;%.7L&J7+JB-;>"H=WEV3.O@@^#UOWB,4\7 ,*'_L(_QBQ)PQ&
M&:YI4O<K#@0UKRO2J3NI>E,@1.KUF> B3+K2??+D"<@=*6SA9W+,#)ZL-OKE
M$9^:EQ13;&MA>"_&N8?]6-RN,C?2S:#]J):0GR3.IMK+BD8GY[5T+ML!9-QA
M<5M"F?D^*O.X4MN^F?D?3<;I@SQ]7R\;3V>))<05[%5@%G;+Q6Q(DCRF([0S
M3SIH7X:D:*)T<KIC3"D1>7%-^W>U<1I\X;/U%V&GE1^/]?[82R&P?-N=G9$K
MM_KK.=9)S)5[ JINW<%GBM7WC51J#$L6T@CSC-T@KVS,F8K^X.QDE!?7>?;J
M$8!OUUM6B3/>8]&QA"R#&\- 04A7/-CK(@!)T_(7:%73LCZ--&M).2J\)WG=
M'58&3>GE$^[?37%GMT58@RHMT9Y5/0HGMQ%-QU16U>PU$=@>Q"W=AV\RP IL
M)RS@S)->"<6F$>-/)PPXE)CG_=!:'61Y7B41N;WT:-I]:JWU^*V/)\.DR<2-
M#.-\+>! 5 7 P]%22_=VXT31<6!N9Z\W9V5,J//O2-B^/I'E. E.T'*6 86&
MQYLTX.6H \T!(J&U?M%716LF^-90B%;_DDR[\^Y3,^;0V7=E"VZEL1(,R^G(
MRO:VD57(KPYNLL[([Y7D2(W E'4/=BTI!_:DI9CO#=BWG?AY!\(2:!\<D\3)
M#J47D,.,/5Y MVK:0FJR$V#V2(C\"%(A)=H"@I;>]D!DBQ'1+*XVY;V;>G2J
M0\-< 9&15-$3Q%_N=X%7_NXI4&C%!89E+)?60>+DW)S?'M0"3B[PJ V@MU^@
M? FNE;$&/WR4$R[M%VKICG*D4B*V2Z*:C"7GHP089CE*/J]IKJF:J^/-K3"6
M?7(!M%3+S H=S66O"533S2 "@L>^+#+-1XIE%")*S*0L?MQ/QT\F6:BR52N@
M<[!NY;@5B(LEXQ]/&!;]/_;>/![J+_X?G5*IQ-AEG4JBQ+20;<RD0O)!R!(Q
ME<20)&0P9HKL6Q+*-D5VFL28$B9FT";[OLQ6R3YO,;UCC#O][KV/Q_?^<>_C
M_G'_O'^<F<?C_9YSWF?..:_7\_F<>;W. 5 /0VLLV\3%F\+NC?$R64N2OF\E
M_\6@X15'W5)%K, ,(,<2C*KQ%1*+:3HC+CMW^($F-Z=#5;UU2@M )>J]180?
M>L'E+=$;'C/<L97K;9X:[[B:"4W*0>S '9=_N:F1=+[F2N00;FWY.B5LUPJO
MX#LT]HW"3G^(JK>+0RB^9WL0:22%V4(QKOD&M:.&P/R3"N?O A1H*(FFPRQJ
M8L02?>.D2P^YZ\1/?Z.6(Z (JS">7:#27H4UN QL3TG>5U<B;-<< 0UD)ZY
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M^X<+P0V,_Q>D$MC(_LTJBUZ%*X-S+%(B_TJ+6D\(0P6L8TU^K 6#JW%FY-Z
M]&1&:\-8X?M74S.Y&AUU.RK"BGUSRQ+TH] V?>+UQMDOPH-DAQVP/O.*Z_[\
MH__^A<-_@>U"^<,>&OLD\?69U!0WGR2RAV@;5?)Y3[W0T6.<6R2!34@27M7/
MQ[.O"?4*C/\O%NW)+7PY%":O1%ZM:7_2<'?CN97VN:2YQO7AOP]X^K+V_VU-
M.BP1";.;[OYIR'LNX>@RJ.\\Z&C>JV"K0+,+L&(X69>2C]6TC3^Q]]U3>'/:
M>=O"MAN'-0]4<-BHO4@QE9!O#1#>3_A_=^Y$ .T7H/PK*H2!EYV <;W77ZU7
MW^X;XG#G5[GHC=6:30A0>1Q0'VXE_!FB;$(ZJMX690TN#/<*[E'8HM#T1+46
ML4U("YDJT+= 'HP X8*UH4T(.'B/F?_(4C7][Y+U60P^PO\-E3#S@,9A6Y*B
M-R%+-8&;D%3[_UG7HUW6('"N"SX@ 8-)F^*$EA'E3^#[I?S/7BQJE?X_/G":
MORZR@?$5B>^DIZ.W;T(8;HQ-B%+Q_VSO?9+6_W_[_\WMY\2$RA,NK8^/30<6
MO&K;>T_-M^'I8<WT5=T[V&WL__5QP03@G/N>3-B9ER!WUBJ8%66N'YMX=TM8
M;0NE=Q7S="LTT\LKZOB6!.=]AZ=Z5S>T/1)_],.+WBV_]+U]5>R@P;VP7:F\
MX8;,A,7J19F7CZZT[OF(#;%@-PBET3+4?FX^RFS16*J5<^!=02!-/K>ZHGS<
M2C>+Y/X\K=N]ULG][8#A#4I3:JU$16F<[HW^I>SS;9_41YL+>M-^'I-X"BN=
MWVH1G#(]$M3:^N&;Z5NW[RNJ=W_Z)Z?*N,7JZ(_O[+-R.(#_5#Y6ZVUC;7-4
M1$\Z:ZNO^XFQKL;#%O>:"KPA0L+Z?RTJ3,XKP[7>\X3RA4(.?YKB.0#Q$=%,
M>[8)0?2KK,[E2QQOG?X5D2^R=-_D^\&4C8DTR+R1*KB0%M0JJB)!V"&4]94H
MKJ._T!50E*CSC'7DG%0GX,?^MA^0Z;S7I<)A91,KW&O:&V*+'ORTP(55C'2K
M<KJTO+F+!:;DCY;4]PW^@8%Q8* >^^LX---;-NK5(:K>K!-1[PZ(T%.):H K
M.!]_7'(FR6]A*O3(A0*EBQ7.12FX_S8A"2>FE+_XWWQ6X'E!-C?6^$Y]%3M(
MQF[TVNN5_*)9I\I^*X\SDHY5#G?*1#5YF@L90A=^8H.X";DAU\B=JBBW 138
MHP]R^UGQ,=.4O(NU8>E_I,$ZY[MCA+@ 5[[ 8R+^8H;H8O6G&U[\C_A^-/<2
M8VR)EUZX;I/7Z8+:B1,)/E@$%\%I-37UW,CN05Y/O@(4Z7D>'O1.CO;LF#M+
M"2PXU/#V= D5M2I6]7Y]KMG:X?W[@5 =V]G(R;.7!FZ7M@R0E4>?E10N"Y99
MW]\V-F9;3![\;737=H=L@**!2A;BL=N5Q[M0ND.*BIH/,F=/?I/P7U>(:3K$
MNBU7=H9\1?_H;T//;N+)K[_ZJVRS,'=I&S';[9W:F+\Z7A9K#518*R0]<0RN
MLBNH)'2%,Q*>_9&R?;G?L]0EQZI[E'G'J6S79V+SYUILN98+W>DQ?BWE5T]2
MLZ%]KGTYHP3TOP+H5H0&LKJ@CL.KX;TDN(LM.5>P=C/[S,'F@5>VT^&''MW&
M+)5A-$,S'J;ONQ6<.Y19^<N@;J;Q9UYDL9\D?.D6V02CHVOO?7-DZM);W;0M
MXP<"4S_NOY)U!^6P"?%^&I(NP9=.I]_=N:"K3Y3$IBVYMCC!?-\'&%R*4K"I
MDSBVW"Y>\\3:YQ8TBY><]^X829L<_J<S^0M*_LOSN;!<IXQW_;JWJ_5&?U#B
MW-_.^R3^/&SZZ>_/0^?W9TDNI8DZ7'?2;:=*,@DOE^2"J'V:*7S-5JS_0QHV
MM+7)+.^.$QY!]W&M#'_Y-D?CA;F&I5:VU ^YUR/53A<&Y$5$G;SN3NSQO6DX
M'SA4J[<\(K#K+-S'W83$C9JKW/1R:+B6=YW;+1?[Z9AN'GV(]GNYR2:B+S,.
MNF?:]PB8'N@HI>L=7^;1_R1G6M;-M@QK,#8S_/O%D;#.@/T.V".MHT[G9W<Y
M(P0^RI?ZR:K'4R)B"[J>ADX0,0^+7N]V/[Q?X_+]B?/.1\NMO"%*:ZM6D#U9
M3IV01V):BEM<(#Y&>_>V?CO9+N0:TN8ON/>J>&]*'E"4@A[A?Z^;^YQ5&K_]
M-R6.L8"\@\[Y.-7]06ZC>!O'\-!J\$,E/WORDJ+FUZ+^(!=[C'[(P/7Y;CIH
M/6.6Z]-T+>-&J*&)B/66_)]/$36=(KF<H-$65:\@R6*EQ>32<C:RJEMI)/=N
M2;Q#B6V1;32&FKNZH.#,75W&1 P^&0M=:8%Q"8E>Y*SB<-@9,(99(,:VC D]
M<#U<UNP5J-DN4 :V%V5+-$0T-P6_=!$[:/7M&_[ZB5W2AU6">RU,[V_[_KOG
M1A@*,X<20[$"<+<'5KR"V/<+]VZDH+P8L"_>3.(N*PY:WE\*ZR_8M;&^SV(,
M&</Z^&KE3W-38Y2]SV,[E'R#/,716,[!)7V0>@.5:,.18=GMG)V2 CX--)EQ
M"D[2%(Q5%ZO*YR(64[G#__6MHM7 (O1.T-H***SR*<.JB=_LM 6<2@M.42O2
M)=O+9Y#R]<#Y_D7=G.F[:5H?KK^9H$BETUE<;).%4\S7X[*E56=2G,+20>U+
MZ6\P?:V?*U,O<"L^5UJ5/K'?F-[32%9:];J0/^M0DE2H)DW5M_J<6;QCXGI6
M?]:Y8?4W*2^4YQD?'=.??5J@;CNN&@^1>F1<>))1X_6%<D<M!41,&WD^^]BI
M^0M:0:H,18_ZL -C^=;0..1^RR+0X,J[(;[]BQ'08=WA?7RGYWZD#+?C!=O#
MQX4[]2"TR%*Q5V_=W]J;FD.G%"H/GLNQZ!,_X/ZKE!)S4/"9*)=6JQ"+[+Q6
M#DZ[]"!5YO!*W*'4J!/)1- -)<77X'+:"&.YTPGU5"CHYZ%N/\!W]S$$?!ZN
M,F1 XYTZB[<7^=;B<7GEW0%S-,2GB?!-2#WWMD0F27'===VH)S5_[LS+OA*'
M?+F)V8[@,K7+YE_&+"ZQ9J^]?INE'6F<6,K1&KMPP>J3F[WMW-0]V\4%$]@1
MZ]0,BM'?^(-!#[WZ,QX\^@!$;_GT*Q \VU%X$O1FG\=Y<?L[U Z#8>QQ3!8;
M@#_@FU5BT9</&8E8Y+@TF@]6S<J/WP^K'<A>[F!NK1L__[#BSR2<YPZFL@WZ
M%D/LI'&'FKD=S7#:'&$7E@M.7Z1P[5+)\*1"#;"*B1+YU2+?U,A]J<1?^U;"
M(46C9/@:!/]76'^SY',#N&-C::1@?U:J!8VN@()[M",4%.0ISLMC$^.3$VX3
M8[:5F6.38S8:Y,&7+-5!;\K;)%=OIWNG@6.6(4>F>TI2O@0;.[T>\&<='\A9
M!/1D,=</ZQL_+OGDF>HF\YR=FV7\9+;O2?FWG@JEX*H=@DRQW8\J=NEK44(5
MM3OL)E.*V!O#2W=M+RP$-(^CGF]"1I8$$@<V7K1(36 \I3>J];2HOO"M!VO'
MK3E=TE,T&D.AWM^CW6V9-S1E0A '>YX'GKK8,':H^$C[C[/37[\3Y^)Y-S9J
MD%L$PYL0Z#4PARO"EL_DU$#V7AW2V4=X ^:U13SIS5%")>-,[C@Z]NCK'S;>
M2=KO'AG7\-9?.[F<'2[Z-^*_+5<M+#Q^?PL?8VS@[I\W8@Z3_N5/U%,[&*/*
M[*D<()VID$IJ4N2('W^>;-_@J-$=A\,4=W@]YM#4#'NL:\H2]+0_]F/26.:+
MQ$-?)G47ORW*/J8J<$@0,"RAW*63VVRL8E0X%>JD=)BFT6D3?.$2L-?\ZVN9
M@KXT[2U['5[^6)\0/W^X*^H>5-FY-_9RI.M[C4./\YT3(\<_=T?.+JZ.;$(N
M[8E),Q%96>%C_'_3!+N$W'V[*!CPOV0:5(&^M-L2&BLX@'58'FYC*.'ENG Y
M;F6T)46KF_!]N2,M7PJL6]6.UD&K0!B]2"J@\G)[.4:F"7F RTA8Z8*O&$I:
MF+&I2;^/OH<]_NDZ7ZQ/<VJ]:73[P"L9Q8?51947Z?99+_-L.H+RKQSIJ[!U
M+'%.O>"$L;V3F['@VX>9U ]I+TK2?K0U2>OYUF>'[IV::B(<)_:OE/58F*D5
MR^8V1I"+7=RK5MT%_T&_#PLD1+FB[= 4:OWTO+AH.V&TG_UG ;,)V=8$FK&7
M$CP--LI;=N"[[UW_S4:^ !K'VXQ_/N 6T_$ZY/HAO8*(/ZW.IPJ/DN,OI-.&
MLT]>P=@!_E;-;R/7-[;J\>_'\Q0V6G#",=E&&N)KO\ I@36E?*,-(1%BOA1(
M;E0)W_,9;]+;C?@FF@LPS/HQC,$4,J>C93=P<.A,W]@:4S-MY=^&7Q%#&T2W
M ?(<2LVTJ"LPO.1RY\:0H)=1[Q.W*22*W-3;>#G^!9#,@:819%?A#V%0A"(W
M_3^N*B,Y-%WNU[\HIV-\_*!:N& _=IHU]""@=(QO JIRGCU\@TTDW5Y]V*>7
M9R*6J"]S5"V("0.U1.<= >T/8W!Z@"A'\[ZCW1!2DF\*SD65S)YH*]3A$N\+
MM+&1;7@-,!B5NB)F&$CBGV3#53%3>CTRK6H* _?FIA#OLWGCK?*>ZE':CNN:
MY[QCT7(JYW+J[.O]^YW+BS*%J'98[\?2\A?+R"M$0G':4LA4KCNI@C^/_\+8
M16: ASOYLC#>U 9Y$W(+.L)@!WX@CCIR7.8SF:A1:!M!M,70RKL8.\T^1AY8
M(,-E_2CWC+UG)S"G&C5^5#2_&:I^9:\36-375?)U6.Q.+?\P$"/89<;N5N*;
M"AERGC_J#:%U*1DOTH?<C3,"7%I)(V=I!)DF-&D.IHCRI2:C_^W]OK8)X;5O
M5.C#9+%5#F^'0@G2. M0D56U-/J>9<X<.!H02HVC1 S'DNKGHIQ_+)8):,C]
M> ;U#?JA/C36S:F,;K<#=QHPZ$!+8V$TP>X>A$:E[UH#*32 TWQSW:QWU7]A
M^:CQ)77[OM \IWY]_V35FXMSYX:/5M?_75SQ<%"^H'9 V-=$08<:E!O5F8(+
M!N T-Y%?4Z+<3CI<&KS7-X52 Y/;U!0!0@)"GT7=W44JH_GR?4I&)^<:TU-P
M<&1RV=G*[LC*&>/VEO<EK6'%1RDS?EB-G9IQ] M65K9HM^CI@,@W/T)TU%QJ
MLA^/+H7DYJW;NT=E"]Q:J!$S%?SOA-;CU*N!#Z@J39KK=WS1JD+:3DU!U6U"
M^#)+G3#AS+3!4QFU!O//.%1Y\ ^K,QFO!K[_0-V*L.=VLY?H]R@]B&L!;$.$
M"<>=I.B.R1X*RUT83"L.+[[0UKV@IAKMBN<)O^&A34BK@4!&^ JG^BS%43Q/
M<<E9?Q8RX;1T)1P29 !B'_X=P.G!#MR*C3D_C#P^-X7JN16B"O48'*8Y/\:,
M;4/N>MTTJ(<6]ZVS"R_Q%+7(_BF() T%V/&F-QZ'[+3Y0P],G-H*!JM.I_"M
MF OR=JIS>.4W[X=T^/M+0 5' )YR>WX!3E;>A(B"RK3C."NN?DX*PA+8S6AS
M]MPZP/=@Z< [+6DN+3I<NA*E&'N2E[[Q#+F??Q%0:"6(\!W!:VQ2DJ=,#GVH
MY0#7-K$2$[8VE%6!U71--@-:DHU/QTW928+JSN_Z W 8UEQD(KE[URLR:YTD
M.;,64)808I)ZAN4.3[E>>1705_)<:6E\T:59=2].K7?%Q670_9KA0*2MML<[
M>%E5&/79+!(*=!1P-)ODCWF8\:2D'EVI/PK[-G$)_L0U]3W^%M?.-FO*R??H
M0L 7Y4C??9/#'^,,[Z+&EJ,7>9J&"RF#N=\K9S[7EUCD5]AC[O87H/VU1OWR
M\]6[PL(B=9/&KI C_?JC^BA,H2 ]_^THX=,9%$^+N&%2<B_^!0<1LLI[]3^O
M/=GR%<QK;Y'G/HPXUW(8,(AO.J[67#,"^I_-I!M//2NRK '3+TD7&-#&'&?#
M3E4(66 "Y:V_^*&N$FJ3_.\\[,'EEQT_@<<OLXP</T$J&R[=N7/:Q.[B"3/[
M?$G4%@*3Z5ROME.X.IR5ARE.**X;:>3&65Y.HE29.SRYN@J6>_K$$Q<M&=W3
MABK2IDN=2'5PB5LGV&VP;NWO*07J '4=N2Z=Z%%EWC4PB.O"WA'S'+,VW0K?
MC4-S4<E4?[&%VW8)$7$E[,ECH$-;'T$%9YSC.5"_"9&8?6-3,D'3Z,DVV7DU
M,((HT='@]. K*[W$MN%$-L'IVI'*.RZ?@O?D;65664NI!098GJQ(S<O2[BF.
M?C5#D^K25S&M;ZZY@$LM-[;.-9Z\5.)0%'#Y8-',<I7).QN/DAMXVE9#2$Q*
M=.0T;"#::OI0_GE5&X(.6J+)7@B:SX0Z9WYU$R)VP@IOB#L+OB_%DF@MH@"J
M%:J,,^YI4BT?F6,H"%3\"L4!1FI]NO070*0]@I#2I,IU9+=/I0(*YW/,!6W<
MA?CXE2^I)K2Q* $Q4K])%95Z4SB0-/#?S[,HUH))^R9D+]\.?A_E TO-);1:
MZ9'BW>!).#D@*4"9=X>2QW))#$&ID-)"HDZV$11O(Q'CG_1>SQ:*YET>*EQ>
M.OLN5V?7T:6%C5W<6QSGYKT 5,*F)PM[)..KYE[G;)A4#&V8YW?Q[O=2 '3K
MJ=+NKXG/G[6_>TG[R.5JMZ"4YCC-*7\[[\J?*2_SA@.#2M=,T.S434CI!%,F
M?]44RU'LO!)U6"QT;APYNLK\73BQLC;\NQ;P$0Y/="9?%P36#V&M6Y6("S .
M=1<63H>]B4\2&.%\@(/XW2U@) #[(/3?&(*D.WZ8-V72$[+@2%/;R]U#V-(B
M!V;:U/?I])L!2$H9]B8,ZJ\&K>^MQBFRTZ6[_G*XRKS:_Y7,$ R:LX6>()ZJ
MAM?CFX/%;'?TJ O;,I4/8VU(JZ+I/.*;X32$#X##F6V4"W;[CODDA"CKH"S!
MYB@O;@GB.+?8:E@/IL1'@&'/P8]@X/K=@-O?,:4*T8!K)7ZJ,#"S<O?>"X]?
MS;)5C2]V_'1->2]^]&QTSN"[C8= FF&\TB/:P NEUV5N]0?R:^\DUY4Y\[(>
M)S6]PYPI_C[,\-R$'/"W]=:YE8>JNSKQ("5DP]*VL$Q%H(KUC-J!I/;#AJC;
M_V6321%:SU[?>(,4G=F$*)-:3''_@4X5@NY3M3BSH5!X?(1!*S2N< M0$)=:
MU>7/ADO.2()+G9+8]2O U\>_AH:-S2DC""<F0WJT2W]RLB,V8NAU2(0EG3&V
MU-IB5 _DI.JECY'< -W8]1OCH_A>M=U]?%7_5_Q]_03O.<9.0>^:)JVJ^[Z2
M[;.3YFP"= +;$!@=YGEB, 1SNV7_R[LS$=24$/>]MU;?Z32I=!_-=G*+/7R=
MBQU.:.MO/_)4*:W$\$@FW9'G^!/76Z40]^1E_M7\(P[YUSD'IP9F(\TU/QDN
M?VJOZ.@:-?^M$VJ7.U5!?&MWJ(M>)?E<Y4&G2>)W8#GVD^D#Q4ZWN*EEL=J6
M,=?I%.N@VWUG#UQ(#/)!9 _?.;G?6\;=PURGA'XN/IJM^.+)P=I&Z ^& S=]
MH8MMM\L5^X6#+%N_^XL@K4]Z@.*:IR>U&/0V;2_W?X11BBJC0<>^F*?S_O;H
MI2I_L"MWNXQSYG;?+\GK1)[@QCU.9T/E9I12!QDQ'"!%I\HW6VT34HP-$^S>
M\GR2CP5"2ZN ^ ^-L+;T1((\4IVOQ=5-+L6B;;@&=.OTO816=T)@LS7=.#Y%
MY^>N2+:-]!+/*)Y)3+A=/UY5I7U(Z!U2] A*K=K8RKV:];^[H+]L7Q1B U[D
M_F2[/F^@)%E-%V*DM:[%'<1HY%Z^X9UF6&RNNWS^<T+2UZ^R-ZG$P!$QWD.A
MHM'Q0Y%U:X(!_TY/39#*[GZP"9$5:."_;$)V"_9U:3"B$036>U@*2IYOP*WC
M)8'A1QMXA3+<)1I*=:2=FV/6BSBLTUHXU;F@-/F#M@GQGSW33R.1J,QBI/I&
MX:JX AN5N GQ2Y?"1G84RH&L4FR9.>C#C=B$T(A*.,5U,P:^NU",S!6EK0L?
MJ0P.7\EL9XCB;(!B![#$M+""-1K0(H]QX0EDN=GDJIDIB';%N2T;"+=)]ZEQ
M6AA&S^44Y;BE:3-=NA,A0SNBW:DG<ZY;MN=CM9*1USU+!\6]%3NJ79;U P$.
M;YP,H.EP"%\)) *:IX&<!TA9G.M&'NH&8]O14XU4&B$938;1[$9.,CN3]+L?
M-,+C%D@'N5[\FQM/FZQ8L''M#H-&8CIY4K,-)H/7Q@:V%>X -!.;3%[^\H0U
M-F]8]SGR/@]0O5)/6G.'Z>E)A9J 2Q+A-NH!4K4'=UF4MB2',P:IS*61.3JC
MOK--!\;N>O6:H1!*D@;[G0<0ZMS&)79]#0"G9[C/+;'*JU\5]07"]7SU=2Z)
M\&Y(ALLYK GZ;<AO6ZCO*&]JZZ+]J\;'WQ4UU->1*2E?@D)#@TTZMY.;I'9D
M8TI#DPP'"T8O">?87YL!:KFT"6',3Y,^S2L!:XNPOUN)DGP-=EY'<_\P&K07
M6JV7-9?#"J2G2Y3%%-(Z%!3<PN:[ T53FAQ+L*8_@##Z4Y(R?=B@(6(DVQJ%
M'.[G+8-EZP;@] =JO6[\^B5HPM1QH:?$XQRYW:W=N['*-*&_>"!DIS%HT [(
M.PL@8/52_:$+EZL%^W5?;$)VAN E>Q#VU4*8V"-0&K@5FK<)D9E%:E 21-;^
M\Q_W?KPSI5=1-RNW[_C1R,4L.8^Q2;$=S[PL+FOXQB1PO#->IXB[D:8=V<18
MH5(J:H'TM" Q:+%A#BI=GQ&+5-@@+5"]&0DM!_L0A]E+BF-^>'5AYX($G_!'
M0.^@DEFE>NZX?P+J%EP*]R^?.DYOP:]W09UX)J_UQ$,N-7[EDP:A4]AR]%-0
MG6V9@I?'&8#) ,4&E&/9I5'WZFU"8F'*Y/3XQIR.)25]7O'Z*7PKTA244TA9
M$(XI= =8W$G=Q03[ 67>? _<&]@307J(=N6B'C1MY_CT-^D7^XZE)HBNG!I+
M36)8ENI/5L[*N'\*$T^^\@%^LS[N/#MW4?L,FVWM>S-W;\G;\V-:WS/D)B\_
M42:#[NM^6 */3P;+, "<17E8HSFT0HS%&W#-NY/P$B/^8^]_$457&6E"MK"D
M7]9?/VE'=SM%#@:R!&HSN0TU/CZLO'4,,VUJ@V\:$;I79Z'T-Q:_3TBQ+700
M'NN:6()-+<CAY*5#1WZ]$8JH*YX[AILTF(QDA@3"I0AWY=T0O,F+"94$W_5_
M4#L&!I1W<KMI2JG3:0>'\/NQR4[K\E36 M2N/Y#\I1TBB*LDDR<4$I;=/ZGT
MOJQSK\^P5BG7;'B;VS>[PW<TZR:Y\5_T<>+O?6^37#6<L@W,^'_ G#8"UZ'K
M)/,/_Z ;BDX<0[N )4PTJ+F,[UW#9^OPU6KYEAO-)4#!=,)U\"Q;7/P"AM,Z
ME'M**)MWWA+R=+W16PB%(!9#SG0B)]Z]+Z1JW9$V]2\8(<9WK;N3*CL^2U!L
M$F<Q'C+DFCP &1;T@9ZI05NCRP.\.B4=Q7Q-Y%ZL.=NYEIX2,+U,XML7V:W+
MC?)W#"_6KPL][7F< 2=5L_.4@QU[E9+[461M;[?=V138*P)M]3G!;)C$6<.3
M^>O"P411,>DI1$E]ZABA0TT;C 6\V)2456H,00IY5-!-$"&+GS<KY:/!P!=\
M#$@NPIIPA)4\+BP.P7:!9UN)LOQ32&F0\&%*\5WX[9#R3\.ZGHLV/@YQ_3^]
MP3_K(6Y^> @8#FB[;-0A]K-("<-$LD(20J0$9\ M:'@!K'O&MS&VM.S$OF]S
M/D9*7=VP:\_-B>%O!T@=GONY],;2ZA"3 $>'S/_Z0FW4+4#OR H_)5_157-S
M MR%JDI@EB(U!_'&FO<#D0AL,2\:] \&EEJ%VHL0AT Q\XBCO]L$*GTH9G8N
M@QZXPQ5$7OZ9U&D/?MJ$0/<,MNSQ79-)'L'=#)F,;%>2E;J".YCVQXFRULU6
M)2XPN#0.G$;<@;5K1]63VG>&=$/PGXV'VXA27T1CR=!XAK1 !SO.2P0I%0+&
M*73]ZKS4R(Q GDN)$^R>X!^!281@]O6O$.*1BMFS_4SS4C+'6GE!=T#DCZ6A
MHN$'1=0PM]+9+36M2->M8WF(>WFR^UHXS_VIKGG-1H58L/?=JX_M#BR/)M6T
M5[\_%)L@;?$R91-B)% &<X0,6P30+0%@KD#90^HM6#RJKCL)>8BO-8SP*05]
M+D1%<H;;"N".;\%&Y$&L"*NTKL)?H9&:H!<(]6\0HJ,>41G,9$W%>A5=QH;_
M&&B1Q:Q]=3'^,?'F"@XI7'FQ_ /QO!2 ,C^) ;(#(MDY'=WC9SUZ^.+LCWK:
M0C,U9^4-@V;EN&, +^?Y;&YV]I  -;22T*+NAU?.G7/MVX2P#@'!M!?^ 2]=
M7\H(,4_5P2=EPXXUOD*:_LWR2: &+"AT$MZ83B?B?-;/X0*X-VL 2[?>0,26
M "Z-+=IJO2#Z ;D/?%?M9@>(L3OI:"5L#CT('*(QNZ,W(<%LPC:^&Z5V$+D?
MJVG5J]_]D/*%4V!],=YYCG +ED"ES.$'"))ZC-$OK3#E$-0>T.X#3 $!\PDJ
M&T,E(=7 WY8Y/ GP"W"616QG["EPM._C2[&(4M!QM6D6L575A-8STZ(!IH:_
M D6=!\C-UJ=!'XZ)<N0'Z,1Z<KG.ONS96=>%!>8_CA(NK74U6@ZNUV^M?C3(
M7/;:RVPK10<]9Q]OIX/RE'O#K\^&_@/Y8<GVH(#@;8GZS>U-0/7K[D#$?X#-
MGMI&*]G:]Y8'3C2>U-Y**&",P6D$2EA<?7H"4=0'@"T$ =K,0A++_Z\70(W1
M8XC/H>5QYH!)YR:D3B'-&29J%WF=9R"/WI7'B4I[1#$.B&U2LHPC!^"_M*W%
M\@J8JL.Y80LY\Y3GV/@V0AUJ?H%EIX )_E6HS:5^(#[T5 ,L4N_UZD]EL'64
M_^7?KBP$6C?Z>A>J!Y7-GAJ6SWPZG7ORX'\.EQ4D3INRD[2>2P@M\@9%/LBO
M$;NKQC=E> Q7O+_TG,=P1&3&%[/(K2?T?.[^K9*]'VA^[5W)K.1L;E3I"Q$1
MN0&IK^]83QI_9'3>/)MU;4!NWTK5UUV0T+\/C!9/?N13C3D(Y61'THS(?KWF
MNPLZ@W49_J$-L[IV]HV7(2*QD#TKLEO&>LUE(?;_HSC"%E_SEA:QFY#5L%\2
MF)6A]3+^GQ(=8C%?AI![&O=[W0'G0]XH)/@PDJE*M_=%SQ+BIW8.A=; [ I^
MI*FZT(DW3WDJ]GY_O,]3?Y"\7G/2[L2A"U$O\AY$HQYXA%T>XEM5SR$U &1-
M$ E+I$<T\ZALF[L+?R;G//<-O?HQ$%I@&]Q4'MEUYB>FZ6VM[)&Y/>=K+9)0
MM6CPJ(!R*'E]*]\J557:-*R3L:W)R"CH2V<ESH,;?7:;K>)6Q)]:M[8.LP/U
M=^O==SV1X@=,1*O9[ORQ<Q9_2]<BW&BOT80KT).?*ZA=0WH_T>(N!N>]-6/7
M_GW_H7'8-G!7-NO.JIRJXY.K '8LZV5#A>/HMS\/PPE/$0&=U[V)W__B\K-E
MH%G="K:%/=C\FT=*E,AJ#4\&]^@KR:[@GOS0\IN]VY1(O0]\TDG9X_/%^]<Q
M".=Y)\&M^ZVH]GUHUW&1YW]Q+64I/J*:KS5)!TCG=^Y$C=W.)[ZU.)X&739-
MF#O#R;^:$1,4DW_/8:<I%'$U!7;V(^G77G[(BLV1)P6%W=DUAR^/%_^XX,$>
M&S1!?3WF!R2]O](;%.#+^?KW=E-_3N,?!VN6O]U; =3OZ+^8?-67ZC_%/%PZ
M#/J+B%F+BTU.%4>U=2%&T5W2YHX9C=Q'KN7E>/6SH5&BL2&IR)V+9((DEFK#
M78R__KOD#</?;;S Y+_ZR&<NG\E)[E\2'OX)WI\T)/W[_*FRKCSNI04PZ&7*
MQH(EW2;F073C*CLM_-NEQZ*B*ASU J@2>A2#/P:*5\Z&/9I9N_T,Z/Z0FU9<
M?N7$4:6HV,(7XNV3\XO?#]YQ/ZO\19OZ224HV_ *!Z0>^%)^9Q.2?+G^;J4L
MRPT7W#&Z\NX%E)<_?K+JZ<V1)IO0"WD5SJ[Y 4>-*R<\W)Y4.):$(ZW._D6?
M_%(1M)22^?'W[$ALSD^$W=E#]*.(0>,GR[B&D#M VS5-TB!UY-=@::66IO6<
M81(7!R1^P);Q;FR4L4 BE\'RS#2@V<GXP^3Y@6R[.,'.(:04WX7KDXX0@:<C
M]MY$&G##$A !SVV"47$X&V;YPD]B>RXZX=8\/*3\JL^IKQ8TH)N>JM"A)@/$
M)S5)<;K)YNSNK7-KPP^;S$HGIS8AOH2;_A%R$VNW*WQ4!%[M!SK#MF74T/=9
M&I\X?Z)$',\$\SB$#SE #24M9%Q5IM58E-8LPIL9O YJ<&GM!LE 9@=#17 8
M;$2)^#(4D"J3?.NW0':%*84.C_?<WPP8Q&LFVS9Q6Q*#2F?M2F:N?S-DQ2]O
M0GC? ?@#7/CZ!>P<VX66_*Z4N]0NKO !+0W7&U\X,WP1@,8AO-F;D"V_E*CI
M. WVS_JTG0L(-*M[[Y?JF<:-)]G9#JU1(A^'LG_:)&]HMZJX%TP;O9+9GLL\
MW%/LJ(6M8%^+P5K\-C;\G.6AZ^::;RM?8/P,J2YN(H2=5CN%7?VTFUFU4AU"
MVC1YJ0G!3)-NZRC;<R/\U&7'78FQ>TZV7>6^:CZJ\=]13,59Q80OV3[&)(4+
M)#W <.2F=-&D&Y"J5%^&2%?!"'D_F9 X=:P?N??7\-J/]LYY^/KA2>S:N$U#
M_^+M +S4+P+7=FE4@2ZD5,&\OR]\U7M7%N3''0L]%'\"8K0]O#6=@H$W7\3"
M4\L2D*?XQO_./Z7*G4K4(,6$+D#9J_%M\4,X;=8"X0P8R]+Q_&/=VW)B)L=-
M;D I1:#-_3J<<1EC_!D;8[-^Q'BB\^45ZFC@CY@Q?73R6GHK-"T8.VSQVG_A
M'H=W?B.^WE3DD+J/3S5JWG1=!ALW-N<<?5M?1]J5;W"*6#GCM[.ION7QX:SG
MX;*\"-&%6E;@GME3IUIDN:))"'$F0\(5.]V&WO.RCU3=9"]<A"@HB8R.,29%
MKZ0JJ;/1\3W^PWU=7(KK6[",* =&V@*'2( ,G9)Q-LHG%)D9&KZGSCSCAM[K
M"=.8K]S0$RIO7E;9]*=>>'/I)%__BJFGWW+^;%O3C"/M+NN(%E->-\6MNF(
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MGP@Y'-7*@T31)HTF:Q=*TZ4;R,ARUJ%=?A_W0T R_0=%J"F=P+,[&K\DB7V
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M1D_(L"3C[GU0O73L@6:'<[4'4Z&<J^YG)S1IQUA7/VLL@8 <QQF6FV>IC_-
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M1XE_0B17>0#/WZ$D* %-E:P P--[5P;;?1OJ#?TR0;9J2I]P8N0DH+W),\
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M&7&DQV$;<(E$OUH^EC_@]AHU-T#MS*)/]!(%#+A*,5^U"KF!-Z5?@8F!PM,
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MBOH;/KTG7&HW"KYM5!J3XJOL?^/&I->V>-IXM]G)2KV<OMLO_OX<5$O55J!
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M=42,?D*(*\%Y!BH=CS8F6T]I1EVBPR(U:N^@W90_5BQ:,9(=\<_'9DD!G6!
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M86"0ZYW_9Y:1@S[ YL'1]T$4OEXP%[9;XRR=ZS$ZB/JW77X?="1R+P6-I'Q
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M6^XH6.-1K;W3X$V.LOD3?W@./:?<73FK3-4OZK)%Y0A]$:MTI/QHH(6IZJX
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M BD)=,S%Q72RZ4HI8Y?X&!0'FO"CLU%P/B6=*?=4FBRCO'6-'XAT7B0'.$F
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M/626=?V*_::[R6=&\WP'X?KP?4J)5NN4CQB[71Y[MK]%L00?M_M!><BC9EQ
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MM_;;- S791I>5^^I@P++1%J2ON;"[)^$=#/2-N!+18XY4A>B\B\6\^TT!?[
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M8C6]'@IPDK)6TB-!#3/_C?#G3;-TM Y!KJ+#8I>5<F8H6WG.F*,DD2<=@&P
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MI1(NC_<]FU>"/-;*)-R06  ]7256;;IRD&<YL>SH!Q+VJ8B=A8J6UIRM$%[
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M*Y@2KOVG2T6Y$FU![/3'L%]QI$7*[E9C-LNT,)P:XJR'L^2,%6J2"CI6W/3
M$$5=C1YT793E.RY6MF^?+#- K;Q>MEZ^,OCU/$$*<*+*_-'T+SYC\3802:LR
M.D1=\H>_ #%9794:?Z-QZ.J@B5CW0=+:0:K[6\?R5#7CHXG\3Y9=0I<.),U'
MH^_%19Z+?=W5?9]>?%%8L2]"1*:V72HLV4DW9+J%9NF=[;A48W YIV3I-T>O
MV)=WL.38Z$.$Y(VAV$EW/8\8CE[HM:K"K[AR;ZJ%<?G.AJVJYRILRKOAL^U@
M!7_;.EW,[(]0MF:=[#OJ1[&[<-$>A38CS3<Y4@=X%%(O,4"N-TX.1V-B(UX9
M>]TLF_Y]^?2D<TO]B,DD4_I+TJ?=^'<!%=@)\[J&D8C*KZE_]5[Y_F[+RX;W
M?_4&8OIV?Y)<RE;HCLHHV( Y4 =CIF[H8^Z*) 5GH03.CGOP/4(;K>$/L8V:
MQ;Y.@K:@<X18NAR.X5K,<X5**O+R%PMBOSXMFW[/6F8<G2N6!R7X'NLYC&!?
MSTX""FH$-#FG&H'^CEL1-'_J_*_BW<.KO6R%T KM%5E<;>B:<4A!TG0^K5+'
M&A"\BS8.':\)]1PK+;4('.U9^FT[9$1[G8G6X/PS?BV-P#[4::$0>K*TW*5=
MKS$"[:[KVOT5J7;&!J6MI+!W@/EF],43JDS(UP#C?[AN=XN4H^T/1]0&^,CL
M&$ZR?S/7_0R[_,]VO9C02P:C^'-!DB[7,W(Q/S[7@=HOCQL[[J&>Z"^4S&X+
M0OWMWWWBW?[H!ST!%>JO8J-RLX\Y\6H?RCS>)]V6[6R[>7/9=MY!\J)F-QOX
MF_$QS NPZDGE00D\-JG8&.RN0S;<%NISX&JA8S?6K!=^[!5:E4W->=_UL[U6
M<.H?.CWL0?]!A%JSD@=9Y_$#*NY7*F9FFG&;"!1 <>VMNZ%?(,FYL6GP)WPW
M+B]DM7_'POW@6X:5CK3S%K_Y8S\,EQE<\X?!X*>(9)[C@-"!)+ I/4.8)F45
MP\]=CZ45SESPTW*8#'2KD+HX-URL71KJ?V3O/TY)YB,X JXZA+N?X^AHK_0[
MM%G'#U]#36*B8TD/%<SC]<IY>A^*U>7NE>QY,7(/_7*&VWAX*./%]0](.9'G
MEHZ+76^.^2>M[FX]^B96]1_@&DRJYZ_']6&'=P[)]N1\_WP7ML7H].9B6^75
M61C1B;!O Y9X4ZC =8SN463%+9W@?5R%2T)9,I(?YU]#4AW#Z(87K) \;W)J
M63U.1W"P@$!^'EK.N8%379*%R,=!J\S5$*W'H96#&[ 9-G&'+TMXXBZ19=TS
M!-':UC*_4%O3(V<H4EW;&BZOA5>_>LK^NU_3U\"BKO*7RJWWM_]>ZRZZN=,@
M(*EM)3_33\T[)"AVF+9H5>KA_LA\^/RC+M=9/V8N8MJ%WX?AWW0Z\KAR^%A@
MQ^^?2"52Q_/N"$9-_M@A1#  %E;L-3==$33JA=!40)JY;?Z#'\2CNX--70-I
M>9Q4\XZF;E4KB4\!PYNK3UDDM@TE,@L,(I(J[]T[S(KXG.<^^]CX=QHM0_[!
MXY?J/6O/!QDS)/CKO/022*G'8J5S)4.$ $XUW@P*YSJ.K\%)R[7N8P_"8Q8J
M'M6F*YD.A-R:K\^LWB+W3J%OY(RD=;A)R8+8UQ#;M3$75Y*+T4U 60O@*9(W
MQ'051$_C9"Z /:G(OIBJON*",=$AX%4NPH#C>V7Z6']:S"-?_,*D5,OIB;_E
MF?G7:4E9X&QB\-#CE_?[HX8S+7[P8ZY#G!4#P^"!+I?9+F[P]]$GI: Q;9%M
MJA#=Y5B?01PUTNETR,-]0JL<+5;?][W[@TM&U#FJIY1+@G<&_53MLY>#CPLR
MH@P[KI_UWH"I^"D,TNNJ3JKI=*BH\1N>?SIVEWT&&'N +HF+MCS8][E4Q;%V
MZ&U*GIWDZZ)7I=GPJ6X!T0&]54Q(>HRKE,R[HAO %JR4296:G*_]#VYF/U^Q
M5I$[$.IQLK<=T!I/H6-JEW8MF<YXV09&'0OV^VJ6=9$RVL!D)XID 48RF4F4
M@*S;&-($([Q.T\LQ_!&NC SDYC 0+O0,"N"_==S<[6I7-NGC&VH!SZCUJ6!+
MXC9@3EY?**=&D#*R(0,F9]&D\JE;]O--68PHI4[ZMCDS10(*^+1;S*>VS/2W
M*;S6D9AOE_.6?16^7+R/KJ!>0':7SQ!E#_EB/&L:&^N]-!-=FQR(_34,]9H+
M)\NM2=\S=F'WONLX]M]0<XURX[FH8DGZ:]K/JUMW:@?84!WV3-G:*B JQJ.B
M"GS/8W==<WVH__6C,,+XAKN>2X?M1X>\QX$.JO9(G240>>11A,:H'B?DN<6;
M\TTC):Y'TXGY\)I(H=PD_\HZI9*@)@P!<3G\I*+/=1NP>^1S8/6C<*4DE&K4
MC4%F #VD>$OFLL%G\2_1%[Q,IFXV.T17MKP)7M$87KQ2FQ>S'CAHQ(/BN.4H
M?=P@+1$5%&_XZS9B W8C3\6O$9?M.T_8;'P_?,F_\4AO%<Y*^4E#\5!\GUSW
M@?4<)=;-!?U_*QEU*-^9,'GN"@R7YO-'F\.HKXT8G/4KN.8J-Y?A5?WNC)ZH
M*/7/H/.]ZDXY7TZ=E<'[97 JT&L]L]DR@1I\@P(TM,I,;0K'D*JN('C]FP[K
MQT:64O.>(O.>QH67G3%<CBD,:S1A[(&B+GF%7WFC>.,20^G#T:OLE%<*43?'
M,*K_C.7DZJ("G;#^.T9BRSES0X74N[T_]DG;.16KH_ZY:AJ6F$W;YVYW[I[,
MFUX MZ\@U\+\BI+T/4_W'*;NN<R0CMTE'LVT77@/C&$/AZ?LF6L^WAUXOG;>
M0<K)Y I[Y('>7\<E)2N^''=7GKTQ(Z%\\*_2:TI/89*/CG?,&$5_^+3KE-6V
MXZA9QL&?R!_$)*$75TK*)[4964[.0"N^"DS&*=H,H_5PH1J7OU<AJ_3='#97
M?-"HWX"=$@TGGAJ+5;AI5)H=[&J6,]:LSXN4QM5%,%[%FN1]']@_$E/XSY7A
MGWVZB;57FY+)N/MLUM/8(UK,DV/YVXS':OJ5O63>C[>//?GZZ>;<\)![2'?8
M!"WB_!CMT*GZW2U*6L%NI5._]3S(!VD_CUWM2#[@ED[X4.6.<RVWB)P\5O9%
M3^&ICO7>?*/73_5RAVHJ[!^VE/I/[[RQ>?Q3$&6LR#W/YNKKE_MAF]0.2[C&
M1PW(RK@-E6Z1(SW?+VLWLVZUEE/\9LU#=R&BXGN\57XX?TH]:0-F2:@@5 LB
M/SO8:-]<&'^R%CLK# E-_G-*&!\I",%?A H!8CMQQSA''H>>[&8H$4,0=S9@
MF_>/X:-+YHL/#."/E@KM0=>YII44U1.#/QWE5KP8+X>6JGW.O$[ .M:%35S*
MFU^VQ'V>^NXI_M],&5IW6!C-9=]F[Q9M#E4W@MX!<>?62TJ@7BXET>\0\!*R
M+H,T^=<&B%<P2@N8W;6J_2FW^I.:[9[;54"1_%HHD#:%DW$<1B80K4$12:S5
M'O2_F,!=&O8:(;#7GS?+ -9<;%*S_ R&[*?P!@Q*1EF#T6TZ'2]989Y^:HT#
MK9H0P=>AJU@./&,Q7<2%2X>RHK_)0P3NZJ<0I7S/>:7@X>HEQP'R+&)[_P9L
MRUO(OPSWUVP[P6+]G]JIHZY$=<)[OQTCM>RT:3BH5OVJ7)@PLAJ9*M9 !+E/
M825=WOU\=GJK=BAZ\R#>I[*=SIZ"*!XJ^SROS%7]BG34:7+^0NS;]'4#MD<\
M%-64G02UN>@^JE 1*N&%XW$Z'#JY=D5Z8GX#M@N/-*HI$]I!.B^$L2\'8Y8"
MNEH-AV*\FGTC.4NZJ])F'1U Z+0A> Z<\U,@N>NB7JT('3=@=RDXY_967:#^
M$2<RZ1:[,US3 3(3. H]UY_)GP+C$E<IBH1^,T:-)W,E";,;*=:%8=-JXW6J
MV_&>7,NWV#3O*Z2;,LE(U8]78TFOLZ72)[?_]&DQ^\K.(KY$+&[B$B7;-F#;
M"!AQAV6>X9$@=?R>2"/4#",?LZ(R9Q'4F4* ]P%T3HS%=$.UT+%^%*4&6L\X
M)2$_8[>CK+0;_7<]NK84E/#4MWVOC:#7<PASB;X'%\;T)"H2C/':T*-R0H_W
MGNG=8&0G5EGH"V2+:=Y9!7>KMZW8\!4T?-.?:VFEXU0#%2ED4FDI0B0OI610
M>((8=NGU^0M^7I/&1J<72F-%B\3?\ \SUS9@N_]D)E31N2?2P1V=:;B#WB0\
M"]6 #EPYO#1:#AA+JL*; E54(7M?ZS;11PQ\]7DDWH9'5OIFH9V-1\[0/S*Y
M6O5OM=9'HMY50:1V_BW_YC2^:-;Y!QQ&;/<6BV7,22A>YR[QBDP&BYXE.@9%
MSI Z(R<6.)W%FI!UP OA!<@6_,4)ZJ9D$J2@)'A*=?--^#V4I*%(!0^#<JO#
M"++@=,-3J/4]O]=F4',H(E9&=J[<Z%=;Y!9B^V&Q"'-FLIP7%T( 7C=17J@+
M4MK0NW,\ 'JG SO%>YS)WC?'>$7KD9'''VH>0_H2NQM^9>,B,!.67,^N2"F<
MHN"D.'"0SKP9:HY\?KYK3X.%62H2LRM\6F@DMA+7>>)6H3*NU6B]8%$D!<4Q
MV=M;M^/1X%<2N/#WX*J:JNUZL5"?.R7%<;XM[LE1>_!G1?MS'*(=(X\*+,U$
M,SNE*^;1>\&\JD!ZINV9D0FU[]6]RWY^?MC1^^HT@8GH$TMGR8W7%\;$[D++
M"/^N!8*2\5MGR I0/I>8BD#!J1#1 =3)7/SIDTXD/0C>W'D4UW .W$5*>!K6
M9)N"-+2TH3#K+;(*>M4KHJ2[:H<26+N.HY_ /[0&0N:EA'>,G<(0\?1!6B_P
M^P?0^_UPEFTY80P9_ 'NNN1LUVR[NLR FPV@3HOG'(JM:+DB+==[LNE\96S^
M,(_DZE,3'W7S9G3,N%R"V4F[J]FKL&=ING?^U_[\T)M7&S"M[1NPC\^(J\NY
MK+,2_PC/0!B SI-F)"Z*]/#F@'-G/'$3;O8D1)F))ZKB(L^ !NJ[H4R.^UNL
M-&Z%6?["YT(UF<N0R;3_'9-PHV=Q+??N])1A5>?)D*._(\%T?B^T#@3Q!Z$Y
MSI9AE#YW96+A-$FT@S=S+!R)4)21P8VWM2+7*UL/X*,A_YM<F<USIH2MHP;"
MD^E5<Z)-XZC3Q4C0B1*I_J#4UYH3KU_T=W]0G$#O%*&U<8Z-^4?AW30DWUY
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M@3RA';L5=4)@/5]\$# 1:0 VM+O]2TI1O/[4Z6/ UR=K'F3 TWE<=-!YIB7
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M-KP<V%5'\PM&:XW4.48O7L>5K9D-K3J@_3'!],E(_F>0(51MF&F)X]>OEV[
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M:CT7I[@)VI.=M[*2HD E)GQ'G97%+)/E5Q(D^^:-6U%(O$74PS*>N;<IP^"
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M+J1\*DU2A,H%=Z=%G:PD<\M,J=PF15 !G7**W M3MBESBW,J\4P<\4L_?O\
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M @!. =-ZL'K@WKX1^,,6]O G@J%?5&P/]9OYM]0"K,/]RZ.:V-<O:28SU T
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MKGP&@FA<Z,J]2S6'D-*2/'1<.3DI'"1")%^@I0CH/08ER1CK($9W,3XI[]S
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MK-GE7PZ)% )0L^LNVQ;>%XT^193J'%)*2@HH..4!B@^T"5S.Y1BP<!*1'C$
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MMP*3V5)<P],EC0M,]42NPIZMUY0ZU('(SMTS*EMUC=)5P]C&#GDO3H@ZRN%
M)X"*KB U2)"$KA(2O5E@^?$DN:[SN_\CR*:+;=2/UI;X6Q),R8&XD'MAVCYM
MHT_MRQ<G9[O)M /Y\-\_\G>9AW^,C>V?&K'E'FN_/M<P;W0F?C6GO?6F^&6[
M@('>T>]K=8"O4]LT8U=WU=YASOYKG,VKL@'I:IOFHC)/Q[NG;[GD>,?D'I[]
MDO3ZL_>.?_66P;TJ 0T(PN78>"_FL'5CD(88!!P#E8!M!!,RL:>U[=/U4>=Q
M'&_"Y>5B-8L 5$A-N*E!-*&5-SA92#7UK('MW^UX] YM!T1(C?^@8!^?^K+
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MTH(VG) <4/_">Q^,ZW]0QT&1#N=I995B,(5<21,RS)C.@82*. #&2^ MDJZ
M!NO99;G/-Z,YL&L=V0R?P_PFZET.Y]>T/7#$+38[4N-?HS3?RHALUQP;WZJS
M+4.7#Q$SX[V8_VWS\+K#NB,3\9W?S$5@MTI:24PDYI][)R''R18TD<7B_B%V
MKR%!V6&2)&MKFU]:[9PB//8JP 2:3O5.Z5!@BNO D1-5&VM8QP<D96%9I\O;
MBKX,S1Z/R?*PC;?!U!$L1[CM\[=]<'O)+R?GU5R>YE]'S2E_[A YNH5>55[M
MSJG!7I.$'R A]05:B5M^4QYQCP1#7UW3 $\OL+MCO3PUP )UVXE\<N7PX'L7
M?_QU7B6YQ&'HUNH1#7"1S2M;Q1WF=F*AW1 ?HB'W-$#1>^[(@A<@,H>&R1:T
MX 1'G8;&/.4$H!E-7>(U*H<A2RX-W4?MH8+C36V0D$V,6M\&5!LU@-P([X;4
MI'9E?(O+(W+?P,96];=Q#9!&WOT4_.3S.R1?)_A>;Y;YS0'3U@!59&*,$K+9
MKU:+NZ#0MS&0T(C=S<0$,BZ!U7A,_0=!BQO4>2<),FPDKK#25X,(IU?XU509
M_S>S"US2L/0\=]=O306.L?1Y&N#ZJKT:(&FJ!NB;XD][(8!)^"?6/I QW/5B
MFAZC>[56K;9ROKH,UBG LD?)L$12RL54[-<2]+RDHD #>([&YHAM7KR/FMD_
M^C$S#/^NAAHY_SX8>M[?,W$M#?".1!2=3 #2R=]'U7D0H@M&4M301\EC H/Z
MWU6K^\ 0==ZQNB9LN>U0P1]G3A/,.$W]YK#[0UYI;9/7*Q=I'[G8_I\(#?YJ
M_?MN_/5-A+#D,%20ZP*]%)P8\L*<^P:)5DH1E#'P.<0.&J!930N-!"4@#WU-
MB'06+E!X=1RECAL?(*._\?##<?G8<PT :( O"0V$'I((2C,&(E4;D59\6::R
ME3#E-,[YD=OG>"P4*L'6T7JH1"S'^<U_A43>/Q,*A[^% HH$\83/X']<4GG^
MU4Q:@:J/$)@6E-(+4'/V,@T@BH.^G;=S^$A#=33 <8H#D7RU^H\$;UJW(_3N
MPE\ U5O_U_/]'7O$"4$NMG(T]OK?_/V_0AKT VANI ?LU[];Z?PE+^)6?+DJ
M.1IS'AOL(X(I*8O&YS@/%?XEF/2A?RJ8C7^&H3_%%?>?.^8,2 BQ7T'?AE1>
MD-R8W<U5D]K^XU*[DOTW,Y;4L:8!_!]CGUC15ZO6:("FRB$K0E/XJ,*A$7#;
MGZ[Z=:G^:NUO0!K]XR)^OBL!G[=$ _PQ)PQ:H0%J0=5U).'/(N;U?V083ZP1
M7VV:1<^-.9*KOJW 8TZ-#@UT_ .8IT(R@8 .?E>J\P2(KB"2^E>4_X]+*E?R
M2"L![X'78FQ$#8V/_,/<!/]+N7FC 6YQ>9V2-[A72RK]YM7ASDJ>_S\JH>5$
M">'J/XCM>I3IQ-4%ZG)PG'S[3U?O#JJ)@L1PQ]^;O)H(*NC,&UACJ]8M)6&;
M_#3 ZG5_YW\%&26(M F/%80.8^L8/3M^4 3G3];X37^EC9MU5C2B!PR&CK_:
MK '6'11J "-";KV:7B:X"DG)ZF94C%NJE 0Y<AG=KAI@>K:R30-\8N?]Z2JO
MM"270^1\M/^GC/8GXXCZ'YL5_DMFE1=?-VD 7@%[Y'>%*SK:1&YZ@__R7Y2U
M'Q7U_=\ZZS\,+.E?#.S_G(]3_P25?P94\)^CXV7_,I9^6/N;I/BO2M&_%RC_
M?QC_OQC&U:E1%V?1+Z:[QXSDS:*_4'2ZL4_^YYGHE1A:F4I?,[C&EK=V3?Y_
ML>,WZW -\-W==>R_@C&I7K:8.K0[AK&&$.4+_FLP>7'F*_+J@28J[Q\+A'^-
MSD3!:R[.&+B8&MV7N_HO IF@XSXK->?]OXK06\3=DR:H_]CGE3$D"-,OR7.-
M5"=J@,@PR_ )+\MMU-R9[^ZO7N][PFWQA;6\LHK_ ;=D(MCDOP9[PE^"?58#
MJ*Z;%K^(O@*_K9]G2)VV0_RQ8:G1]V,;'X@_>AS.H$[,WL6(9^9E+7CV4^+G
M9TNW3@:7TCN2OYJ."J+'3$RV+Y^JNP9; YXF2LXV6?@8L;X<,B==_K5WP:SI
M7Z^M>3KT>&1@BW[WDBL:X+S00P-<NUR@5A,GP8WU=?"SOMRQ4:CQ](\*/WL)
MHZ.9,$FY[SX:!V>*)' 2LY[1':V<A9Y<4*).DZE/0>?PY83Z /A&K(VO7W'E
MD4MVM]0BYD*))9.[UGE@?]6M"TX.0SX&JBT=!P>=+&EG,O&I"#+>*@Y:7-TA
M"*'%5="TAC1 & ==*!G,D-+,W^#-N?/;* N9Y^2T04.X4YF!/M))97G H[C.
M;C1:*"#A\U%(>0AQB)M?5HJ>X3&SA11;?D7[]A[_YN[>)9PWPXE5YO4.*;F6
MG#H-8.Q(U6?VU"/,BW7L91S/3EGZ&)5JPG)!XA,0[=INZ9G?M6XS:8W\F<UN
MWC>I?_2$5_GD/)DHTH+!1,D#\6"#@I%@O0)>E2 C34 M=R(&Y:IU*#'*\)>U
M'-<+R":RCH6J;U7K(0ZU-%-\15@'=+ D0#"3>?<GM%)1(M=]_[@R,MS!\+.R
M-3! 7?9RALY'7KT$72INC-T'G1_W:R1U0;+H<^42#G\B$6Y_%A/=K2.D=I-H
MZ/7\W2P]8NT"WF9!'FQL9JUK&^6<%1CL?XTOP>:UEX.H]^P6EFNPG#$!\VB]
M-[_5D3.S_RMZ:D>;_>@72%K +2>)N#W>4FCP&^PMLZU]3-*AL7NABN'!0B1@
M*T*0LV"F?K (GZJ^R-9#M<6*AB#C*GBX7GVT4\B>^YB QEA VSVW-:<F7V=$
MR4D30]EZ7%$W)5N>0Q?U6H\?DY(Q8TM<=PSV4OY:H_[]$&4B9H@4)%1#<*>T
M\PP4:A<^+/N8<N,I,N"'+KK1OXIOBB0D'^\YE;/.9^[P%L0W^QBB5Y\5=+'H
MI/4D))=W&[THC/;MG?NXNN-0C9^/^IP&D.;Z.\15ZTMK2,H0U/(Z,UA6T*!B
M<'JU6\K(>KL^9:#!"C<+W\P;5,1FR\.6K):OH$F$2U#*+7_T!NZ=!,KLS5(<
MDHUWY6[._TU;3NT!Y9*AO0S5=G9W-U1/1"9(?94]"Q<+X)_!,]SR F(,. D+
ME">0A#J>$9%B&GI&M;\R-5M1P4-L93\_1G:ZZ=Y%_:3DN+*(YU"\Q)PR@_8I
M*V; I?=JH;CP2\:C-&=<ST.1A,_&&R@S&6=RI[4[\KI7-"D7PV!CI.V6-D%H
M#VC);B);:X"#DG,5 E/,5<J=R8P?5AZH4F>7)6*+PGC,N1^':[LSA_1M&XO]
MZG#[A(9^6%G?*]GX /'[I $:&6]:E?KJ&_C"3Y %VQU_1=/FKV!1X8\)-Y@1
MFQ"ZB#?Y4^_RJLIF-Z?B<'P>K,QP2G^D_S$#VGM]8%Q94M2_-=PBMF57N'_:
MRW?WT\.<DZI]5&1V/;X2_<(M&T[6 '3)67RV^II-!Z8K3\27AN>:MMI7T\Q3
M^#/$P9%2DD4#^]-VAUG,'=ZMCA)2F+5CNBFRQ=KX?BE\IETB-&ON7ZB%]DN'
MT:650S09#;7E$&0!R3/KN5UYC> L?&&8!BAW;G2WE%$)8C5D=_A_Z$P$Z;2N
M"@W@RS!&XZUL9,Z#<<A9&A#T*>M%+QF-NL-LE9\HE G.5>GS2Z4"<S1%OC]K
M+'4_;'U1;<BR0M-"D 39C_?+4_P/Y1S+ZQ>8L*U0&[E]SLW>Y]/&JO8DI&'+
M\YFYK3]7Y[XI+QL[L2P\*>*(4ZE3]0/1U_4GEFG+W@7@NI4:8&)C9^1&;C'[
MB:"TXVX^3T1*A(P[O03P@9RH&PXIN%W )R7!)?E[S [$+F*Y*U[+WDWH:PB:
M8A9<9]&1=_W3>/%P0DC;R/,E#]ERN+SI-,M8QB,Q7>N/A([KQ%7;7N^WMH![
MXVX-5K:6[='V:"TNR['<W"K=OGZ5_Z%L>B0]8LH\KXD+3\LV #'NIB]X*<<7
MS-;?V-S'&7T&\LB7#P:$KXK^=89M^MJ-'AL-7 ]/[;/-^-X\Z?,B+9V,)XW'
M>K+\__I;NSO1T1T="_<_S+#Q2"U=-L/VFICVO/-ZWPS;1I?IJUWB[H\_$<C!
MWZX9W$G^ ,I6-$.?YD1J ,@<"R5J_?F/-A!7J<9HR#6#>_\'W$!Z04.7C(F'
MTZ#2X3I:5\\.U%A!3<:G(.8-I!ZZ\A2Z1-ZC <Y83T0]$+*"4@@/R"?F+DYI
M\-<1DJ:QCL,,#L721V'WD_NJEV41Q='"S#"&N^#9ELAYQFR7'RKB;!G[C?5,
MXFLTWL"?C3*0$RI_]6TP='@ZNT,#6+)6(A-:E4R8J$DNF<E5[E)?OL=?$$[3
M=[-"AJ5C@XAL>!9J*3-O;$KGKWBLSM( !S1 ^@74>U-),T6'V2JFF41>9TQC
M=M9^"W.)'M5%M(709/9BSB2>"-)':8TIQ'E)\90E3%.61Y@^"A>(.),W1SG$
MN87=2**.DQ,==1T.27P$G+&*ET<64:LCFBC6V 3U);8Q1D4XC=QXR52V%7.E
MG,?1 +*EUO9(1]S-NC#>@)Y"8N$LXEAM[)S3=5".5(H60+-0OA7%=5.UMWP,
M,AS8?.IN:=!TDHB72JLT'YJ)G"%$C*2;HZ2K2Z-X9[G:@@-4= %C,%C%9NFA
MP3QLB9I;O1L^);_<URB9BK<3<@G;(*.ECV<FXS,^TV;9M&![\S%#F'[&%XP3
MS.1;#^1.;XO:$SZ\A;.CO:6WKCI9C$_=H&*@G?C4Y5(-D#!.3N,[8NYP-$<0
M(7FS0Y9^$5XIYNJ"]"D:8#]'E[44)9ACHAK=K-J%M]!T^;-9)]I9)!FWFR)4
MEK0.EO.2*?/0^=?#V&Z/2A&'9$>: ;J=.NESEM7'\LAK^$NB<S^$I+^_E),G
M,F\IE&[J[%']8%EY/#<?U1]E)&09E!2@?C^_QK;)08M/5V(H"7>$)Z_W>%Q#
M2QMZYW5B%&[7"T<[JN^CART44;V#0R_F Y.5.Y'+8LZPVS:X5/:Q/!;QECL(
MJ2E\L,W!\;9!GIR1#$XN=INS%[XKG_3ENJ7XE'D*2RM$2M;Q9P8$/L@EP/13
M):S,,2U[EK'L,.D5A-H6G(>D-ZO,AS8@!\:4M]IP^\\T_2@&:4\@FD5+[%T*
M4Q[#SW$SDZ.?KO@>9DU^7>T:/?]+@DSU<EVKJ-<.SD9I/@0LXXK89BC7!^YK
MB-#CI&8=M #/L"-@\5"$*@2E!:4HDSL%$;'>C6R]3J+1/B0;$J]_3&<_M::@
M-%AO"PK=89ET" Y&1BNCX)PF0D>9,W5DC#.XFVT#]SQE2MDCM#"V$!7(HT4U
M>J+>F3 YU4\49%&99(L89*H)Q5P?? V Y'LCGSZE[.MS.]9IE6#E[N7_7;M6
M Y0D#))@B2*W1N7#)"LC4'/9<#=)E#L?X::64U-]^5->+T )V.DR1+MY=$*G
M))4U&09Y'(.N#?0Z17IOXS2X5,0MR(Z]UT/K]0_?\=;_[4N]TVP*2L7UQI#,
M!JA4 S2 W0F$(#_+1C^.21L*A* !M@LUE?ML'%!PA<,&S IQD+H0-\5?53G4
M\Q+)IK@M^Z6U,;J<@40TXA9H'AT)KM>61G,H+NB"CAXAWPGF)E9[[<=-*#8=
ML:\4^-2="$?)5-_!;5&&\BY\B',==:X?'\:,.V4:8$CG#NJGN)R9"M)Y7?'D
M[@Z)DO^:8 5;F5I"-#OP'-^MJMF)E$R9@-K W^3#B?@"9N[79Y\'Q%6,1&SY
M=53'"_;-#U: U4/@KQ+4-BZ]$/'V>Z"^2M'U?X>%Y7;WR0]N91[HMG-H6-G#
MU  ;T'O[,]=OWIARRW(XJ7=6,WOV@,WZ^ZU^0<B5C+URG\@H??]NU_)1,)%;
M2@ALY! I[83$F#*=M1QY02Z+CL-TI(+T$N9%CY*VBW)N'&X>.. G,'!DF"<)
MH3!_U%HE\G]'H*FKPB>/%FX<M.NY_I/T7P#L%&R+F6D Y1DT3>%PMM<*+L",
M"2[DSX5,,2?U)<IJEC_,.TL=TD(\Q?QI1+E&8KL0?@8<O?4UCV+.?L%>CFZX
M-J !# C-(=#O%UBSEPN1 3FOSMUH8"=DAMFB1^ZBV;M@WU+Y0N4/;5SG"871
MNBN5"O4YIQZ"(JDR<T(IM!#)N)C'-!;VFJ,UIQ0T*];N%@T0XC"3Z2DSB),[
M<*RUV]@F3-IF6"=Q*>9]C9G2F&O24JV#6,I-;R6%R+NPE0J]QSZG?CH;&3 *
MRNF#/)49:S]Z&>Y1F(N:S@BFN@4@7C+]BG,%F O2/I8P9$?0VTMR?>Z<A(9>
M$_BKI/\E?4&AC#,5K9B"[9!Q] :"MQ/%EU"]B1ST>J3'SG>S?2_G-$%=X)L(
M671C\2EE*AJMHK L8+J8:C3 7X;8ER#>0MRDU9$HL;<1T/1,?(E*%?NS*:D
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ML<,7H23%?K-N\OF1@9-ST3RX: 7+'CD:]/#*]T.XQ;JO_BSW!^9@%T6WY$(
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MDZ36#?I=8WJN2Y8M%\*/T3QQP;IT/-C$@R$PXBO^'K%SO\8SQ6KVOR1A0N9
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M%_?&!.E*F\ $=U*)MG5#I7,K1NWQ++Z&7O12#4M3?+!T*?;@I(-DH1AE)Y/
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MONC9WY0DR4=F20^(5Y7GVCL]/A<,&UC"^!Y_)SZFUK%^6?W:\^);Q_S2T^!
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M+49&6LQKC#P,=LT3&JA+D2SQ(9KV$"R]Y !H7L92 !M+ ZE_Z=7HFL+<9ZH
MA15]2=7*59DGA>SP+?$%ZA-IW=_I^OGM(KR/9$?49$A/!4@I/KJD]HZ6U[,5
MG0]6R9Z3RA[;;'DK"3.%J7GW64W"UR#CT19O*X=KNMEHQ7,#8@Z("XJN=W<
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M<?:M&.0 7W$5)LARE76354B[I4>A/6);A%AI=D%$4?VVA+N-QA"C"\[U$W<
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MG<@,],Y\]U?A\4[MJ[ ZI5N/7T.N@JU%OALLJ%N/B:J[)1QU[P"K&4XB6<#
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MR.'R^\KR7]",V#!5&BRRP=^*$%-O+ZW"4KY+HT6<5"N#(U![A=0)^EU!\.S
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M;1MG(DY(-@8^?&-\("M=B03;OB0KFR]6R%+2/[P]WG:?0A9H=8NH+QKU6 P
M:,G1A1YZ5K4OAQ:JE5V&KQ@+3.<==-\,F1CGOOATDKN3\^%D_HE_$O1.S06<
M%R!'Y]ME^@,+1ECM*0-%,'IE,AWE7L4+L!=D8D[7#9H[!_HUT_N(MD'!<5$U
M_-T^>W-,&@K?<ZU[OUOYI$]\FI+0MP/29FR2.?)QR&.XY2HLR0HHD*71;C.
MO'[&;]57C*U2&)!</[$=OYE ;D-OE76#IDE584^Q:T*ML\.6/*A5TTVZG7?U
M]]0N'PI'ZU/\@=\W[_^<F/ /4SE?;6K8/UL]N<BS7G@,[[69XQE*P@?4Q6=
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M_JLP4 :Q[>,.;+R8H^35 \RWZ^(RI?;@NPBE3@3\ATFKK] )KC,E3\9J*59
MTX2^*TPR1G=):N2@DP-U"93:\>K$\U"VR-]*M*=LMFQ9(02A(=43RUEG6?CU
M"1C3B:GKFG4 NB11;T [?P)5V'2'KDO<"S"8<31=PK(<O-+,D9J0C9!4*Z8H
M3I&VUD.>H'*GS !Z*("G&5,]91\1@!OE+D.NOL.HNC(.;H-,C>#+EJ#E&2BF
M:N&@/-&0P1^0MX"F0K0?1*\G'H/&!!3-<*H.@I6?^S *\/1!J]9"^"I"UKS\
M@A.)6D'BF16\'3E3$LM/('H^#IDP P,EX$H9T5.(W"+=#6F!"F?_F_SF+-^M
MVV"9A#C2JB#_O>2U@R*Y1+HT;HWG6<\)M;[G6W6%>\FVAN3O+5=B,M9VQX"&
MG??V<:48R52][?%%-OV/OEDDJ16<ZT*,)3"M';Z[A8HBU@X**1F[5DID,*+J
M2M7$H)"?+ T7X'CKL?J$-0Z45O_EPU#E::B.!F4+R>T1.ET]-)0UA8U+UE5B
M]?H8Z:_O-T'M*&TGQXFNPN$KCS&""KX&29W43:YE=.&4B @N,0[4D634O0%=
MR@6%6 $C$[6K+&QB.W"]61?B,O,/K\*2BJM[!<CMA#M=N P68K/)]<Q@23)Y
M*P%[' RF$.%/I<>A4&%F7%>L9Q&)MPIKFIP-6D;)1G#U<M"AI$BN06/MV&6;
MC^&K,&6B3BEDZ(_00!G20C$O*;.98!2;K$/2@FHP*?2]P/K73PAV(K@<JHJT
M0%FF>-RF"_ .QVBBX$$1I:$^=)J OU:*@\J.RJ/I!;G=/EO@V855]X9B1$HL
MCL8T1I>T;6*,,-..J\LM '5<("3P5,S2J8-:VNA_ $W,:KW3K8!5)QEAVY@&
MR,8D 5!#*30IZOI>7NH/%721MY)0TI,C* >@H,.G:88R2UF.)_51Z[KN,D)M
M\"D,!=0.,5(N'^LF._BC>JR\HKW<Z$(REHM$.2_[2DE<M)H_(5?"=\-O)"B?
M@GR7K2"K#M(^B WZNG+I.Z$K-M4[5:Q.<HE8(*^#Z0]1']\BR,V15%,LJ<T6
M,5BX1+0&I"!8<? :(.T@R ,\#9YJCKR+K"'J6Z_"9N\M&\MZT"H0=?DOO]
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M>DBKS,K?.%@;;O4Y.IBS\5"E7W#U-S2%;^FUFO&!HJ4;;[=9]FU%R*CM15G
ME%$U,&[8%016(JD_DB;%I+=?SJOQMR$05GMQAJK]XM&]491C_^R2J4WV1=(Q
M\23+5D+INGZ&QRDG =L*V:JQ%> R6Z9#.)<;J=BH69U3(9^[N;_Q%J@X7"A(
M\FF,2Y%QLJI.HL**R*H,%4^*ZS*K*,?>)S5=K?*GWMT];GXMV*GJM.+^6] [
M\^!.W=XNKKL0K+,G93Q CL I\=#2H3$%N?,] 1L7!XJ^@W\E;(+VTR\?9Q#A
MU/BX\O?BIV!8<QIMA#X3"5]G%ITIE&;FNX6^B3RPSU+4N-IPMX%!*3$3-\;[
M8<&BQ:IGI@Z<P\_OWFTJMW9V_3S:1"XY1LKT>>H7[S<3LTGU\*"81#NC<Z"(
MGSSHBJUU*'U\>T*TX>OZ_K^YL9G[G4I>GNX_H^RM"8*>.F?<.$*Y;K_R:>??
MEUV@M9TY/XE$[7- IY?<<B[?RZCRD(BSQ_G1C245]B>_:O]Y_]I=:RLI_,KR
M;^,<.UCN4.*D'9O_<U*"+B%G%P4^%HY28[9&A3@1]NDQ?TZ09*?H_CI Q0-_
MAVSU&.?J*EUWOQXS-HK73+.1 -PK,8!H4 ;,+$"%Z$VS4)U-\&7>F$Z#LENA
M.?"QA?6_M#@!/&C08S[/YNJT3GJ,I:_:'>4H1 B0W$%S093!#3TF_;H,_UF/
MX:(T.EY 0>IN(G[@U44I7$TIZ6W8_T8OL!O 04DGUBC6D21"\!6^MR8IUH2P
M:(4JJ^AZ9CJRSUJ4BYPZ(24;,K;50XZ-J^]3&R;.ZS!PO!18ZKMUR>("6?Z7
MIN4W1]]$P2S9<HQ=QDW,>Z/,UGU7+@.]'DZ</>3W3Y*$4W$D70J*)3P_/4;P
M4IM?J<<(6RFSXR2X"/,W2782M=HENTSJYT+$]U6$+O5-#P7X]<3CFX@OF"V=
ML+N"701TDN2;S5]':#QX!_WF@H/_I0G2O]CHJU65R&; ^"SZT=0W-56/04,@
MJX<<J"TI^.#W.KD(*V M*6 W3V 41HZ.T'+%KG%MD4_2Q]V3_:*[NJ?]O#$Q
MB3QS:*;[[,]+<-F.PY5 Q/CGGF'Y.'O&+_75245>:6G;78/KJ.%9,D>L.J/L
MYVULV+?U:_*8MGCRZ8OXU-_E/S-\P:QN-].]5]@0F9[[:>S@V]+*7<)=?VQH
M^:\LH9RWQ$>JW1L$![/N'(TB>O4IH*#\"OJ3=J9W__2;B,[1U2V-]=#\/6/[
M*)P%T1&^-KJCDH4_ F:R",XRH754(>9=_[&7-6=^L4G?1Y. #^=KI.\VW5L'
MO V';*L(@.!)ZHNMYSR3EM& ?_& ,HT]FD_8=)[J-2#[3^,!O;Z''$COPB'S
M\?Z5_?N-1)>P>Y;(6?!1G?EK>^6LYN(7.-B7L:]7C6:7Q+6OH-*D3V%DM4])
MSQR! >ZP,$M2?)B1OEUV->WW0-Z_34XSLIEC# BULSK+TC5ZS-\T'/BP%>TJ
M:58"'Z2CV'!]<$"/B8C68SZI;+5S9-T&UK_8K-?(18\Q<>ZD?-)C4E#Z.9;%
M^QSF^^^-THQ\^WN0)S[,GV^I6!_TF+E,IX6%_QAH'P"Y+G@&=/X)%B)ZC 20
M[9+C=<&'_M=VT4']2\!YNI=ZCOR'X68^T_^W _A3'QIZLSAT^ &>/J5+<)&L
MTE^SS5)::*HI(]<%?_WO]&//^[GD9;GTGJ%U.-;!R^<V ?]FU2JX0+9F*U75
MT\\?76/T2?="^#?\]J0-FA2Z099VD9MC20/6/%6T#JJD.56]2%ZXX(L9X-4<
M0%ZS18_Y^-1K%9 XE%HV/E;>ROR<;M0\>W:NU\@9[0:N\YA0?:6L=]E\_*W9
MN4+JL/-C<NF849T?218!^[+@7V-VK@+^X,D).F#X#?/Q&#MF0H_Y;U-6 <F\
M=4U\R=Y#8P4L+)RUD#Y!JO\I">-[4[S59+&1@+KD"JG!;14:O2C;R9I+CCRX
M$]GI^&M=_;],'O#/_G%Q9YQ_-Q<SU*#<ZSNTK*BIH/KHF_&BNNM5<& HK]_-
MVUUG[$)MT.[I5/D5#:F[/XJ/Q7VH/?/#-?NL]==67I6?W]N.; )54Q)P+3^0
MOD.:R:<N1%:!Z2^JW!_'RU %;QP! [*1_-/O7O0<9 <]>LEPDK4YD8L/%Y+[
MIMN\57>:8PM.5$2K?<CUQT+WV3[Y[YUW(W,=_>N?F1+F$B'9#,ZB[5*B,\*9
M;5F50YZ/KJ<DL1UKOK08(* CO/K[VW<J'#^/>4?^JQ'_)9]CSN5"N,XOS^%5
MG_+B91)SQYT*W/ K3,3%K9LD_V>A!?RSZWUWQLT+:SD9CGO25U%$;Y H=__4
M]TIR]+K'FO9]EWG-S9'+OB_8_)M)\]5/6Y+/ED5+6=/H'(D!R"W&WCEJV]]?
M5Z6Q?UGP6;KL"MEQ>D'D/0Q=2OMC>O)UO.B6XR"J,8QX,G]?.9GECH90XRL:
M8.$+Y;RC7@DZ!#<+2IT*^!);/,% ZER<OT;^C#)(\Z(8_3%J"!C$1,N 9?P[
M,',C;<D,/4$P0$OY9F+RM?W5*Q>^."NJO2"YS*#<B[43"NQ-@?8DT447PC:%
M32_!HQK.# 3OJ-F6TR=D/-,8I4*XK.M6;%+IK5.WZLJK*?0#8OB>:!^T9)#@
M=O>U^PW7W/P-.EW9\^CR%Z+-6WZYQH(\SM;_HA1[G9EJW'#PA<?Y@*=>G ^2
MY#N-_6%JO[8VNWD^_(<-,/>>K3G8HE(ZD'1 C1X#;L#JMK3&RXT$[,R?X=R#
M<"CI"L&)"CD+0M:+<EIW29U+4 4!4;-:=U6$U5ZIKH&!/45_XV>>.'SY?DFC
M7\*C,R]^/YG.L;$JVG!V#W6?\=,[;\J,GP['O"E;Z;6^^OS#D*8;MY[CWN4,
MNIR\P3E5'<+-Y>P=";ZEQUS08Z;=*P.#;ZE1+MZ;K7LT]OG[PN]^L3JT#_/O
MAW7GO^]R5/VO=5I^6?!_H1K+Q/O;.9C/@>H_M+?=*,,<Z=OP+T'JY3C=&D8H
MA'HD+A-GH#-D>'$'(WM=62N1TW"/7+FC@VC<"/EFN=30O%A8.I8?'Q-<2H +
MY?8!7H<&&O 9.@OH=%79>,C0@]@393&XI8P?M<4\:8TX,G5:8HN@>?C2Q5C
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M?.DJ;3-P!F!)L'K,25*^(V5**_N-ZZF3D!H2V['#**J9HLH]"FLV?FU"CUF
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M1=^K,U:A 0!HR]QXZ2UM77VPB9QR18\YC;O,KI>PN%:<_*F$\2E:[(BI4>#
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M5[PE@P)5I%=,)/U=R=?&RI,8;L6'AZ@$D\3:F%(WC1?S-0^51#^P+@'+>*<
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M+:J=.#X:^Y#O=ID3)?[[16V%5->' _=2Q8%R2@<)(WZJQQANT-XF_8C+(2Z
M4T&*O">;N$ G(:X#AQYK,+K>T@TPM79<K,?D$%9#7C)JIS#=O934J[.C%Q[-
MF/RN=W[W,7,DL+_5V["IL&Q2C,][ES'_? !('=T%?](L04G;8E($+I_2:"3
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M-#I.0IB7 *STT/CD>U'$[3/J@4FPW68ID7/J>G=$]G$!5NKP-&Z715M?<:[
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MT)@[TUR\$_!KJ B2/,74;FT6#PZ+S(5R[@/SI3$&#Z\-_S#D\$P<*LM^W7I
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MOG>F-QR>0O$%J&[ 6$89TAM,[/;6+2E#C5FR%S)&C<=M,P3S#>U@865PN]2
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M =E!3(9NH!C%1]6BX%(BF:<81\KI9WL(KD*_%RA((;WX*"O ^/,L2W1-8+Z
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MGQ0CBU$F2OZ4O1WZ^JS9[@\3A1M O_*T\W?ZWW ]X^)MOUH]BZO ;O 5DH(
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M\>(%J)NKA9'QJ+-*FGGKY+?PL(!; 2:/=I\UG71=P*I55)]_"_]#7'YZY^2
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M5*PU^:]%Q#/]T@5[2"@EC1B!_K>!&&F5TB>4H'A5WE/(0=2J-41$M]3[+Z-
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M.<E41UF,=8JB1PH/3[?S4C%V@!49^V@/EFIV;4E>H)<-DFL7HUMK][=MS?9
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MS>*[: M'VS&/FR/8H/Y%@:]RWX ^4H?HZAZ-.&3.;'I1##<QC$%9DNB\E#4
M:L7DR.2XN\QRS,HQV!'.G/R,_HAA$%_]4R-KY ,;-&:9S6'M"N%LT CQ1\XO
MQZUX-DCI(7C=EN-J,?,OS#58 NPPV@!0A +SU#9:*E#V<@8P'0 WX#9<J)&]
ML".=QL$+^R=4)C:WM_9Y <W>:9]&;2DU'0N99=ZC 26!TU*>;3_W1.'XUFH+
M><JV)[21U0UYL]BE#:C UE=(6[.1M(><;/2P)-)C=SB3"<CD5,&3W[UW@9)>
M*S=J^?LPLORUV_K(^\/*RDU>]/<>X\=NI KN\[ _\;R]SNK?DGMB)X=51!NS
M^A3$F/&=!I@NLV7*:"K#AV[ B**.)G<J(7_;4L-3MQ!F%PIUJ &)9N9+TCLU
M7+U[3H6I=TM'20A)I$L/^CCEG5SD7S5A\L>%-\Y-;51T-+<2-2#$1'"](*X>
M]@CG7Z> NLI\@]9#"I,J-G0I2[17E(!$"SWTEXCT7G!"!#C-0AQY<[';@H>"
MSB-KNO=4^I<Q5+YL.SZ(PW_P=$Z]YL_3-S4U7S/5T5-2@8=01B -HTPE]24L
M2R9]5I@-RI< _S/;;(OVGNJ]18;B"!OTY^N1<99]%(<6?4N%I2Z^5>E*)W#1
M,IC/<,%U8,/D@3Z7F8J+0&,50XK53>4/*I2!UZ5:2(ZCCBU94]$)>_YS<,Y'
M_0.S>>T.+ZR\F_$N?2<3D/3P*AI&1##$)HB\ZSO:&UCMGJ6E?!:'^4NRCC&"
M@)_ZB^*UKWA3.E56=O<02;S124$/4DD=2CV5\YUY?NK![RY_' MIS9"^'JO'
MJ<-_#4\5Q#BEQ!W-S-#&$5\\XS3RB66(N,MZF7Q6:M([8&&1)?E@&++T!-P@
MWU[1[_)2_V_)+R"TH"9C&]_+9<UKGR;N5"\((\!8?/LH ;1L( 6MC"4@:'^8
MV!V.V%20 @*68$+HSY!&;*K%8:0<V>4)0[',Y>6*0:$II: @KJH\&"I<]'6X
M=%7*,SA(-%@R[<=R5&_&5_OM>(9N^H8N&V3/#RQS6M&/9L4&+?/8_G,K[;8
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M^]]3EP?,M HO3>5_>'JUK=FOD^]B-']+5Q?!3ORU6[[B:.G*O':0T^\NPX:
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MO1P,Y$KSWW_[EZVOOJ(MWXOKBF9.:NT:ZFY#U-NI#DF<^XV4G8>L&<8PHHJ
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M)N5!GF$,6AIUAZ+2JWWD\@R0\X'PH(Q<H-)KN"!!V:R!D]J&Y>_37^T,WG*
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MIG?.N?S]\ET4X%.)E 5\BP%KI];19SXN$TCS"J,B]PN>W(!;1WWP[X:@,@<
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MB#TBVE!79IQ<W]PPX2WT30?/4YUBU!)Z=?7Z;R>+7\O! >G!WY_9?</<U<B
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M]-1HUYP8W<F7C"%9'8&ZP0(H,! +\6C&3,F2P>O3M"UR!F.@22.2<98Q#+Z
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M!N9#MTMKJ]#$.[04>Z L'G<9/?Q'H+K)#I^3 +H[#7ZZ(',^*IWB0WJY@TE
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MCCE.SYQKXTN H^N!$6-4"TKT$3)?("3 TGN.0!=^T*VI"BFTL#XBF*_6#)<
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M\7!1X?$LF-V:UYHU.L4ZPR\W*E=J0VI09FL0FT]CCE4EL$_%Q_?:]U[Z6Q$
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M?YHL1:H#+NR!/D\@.R)5:)S1#!'&\+Y=)#]Y?"I]%WF83ZC794;,V36.6/?
M.)K)/P)#N:U!AV@G6^VF"T%$F;#'#.FBOQ,^D@:VIZ_\+3!I:2 QS.0*GKK*
MB<)$(!=C* >WW_<JW60K>_)>Y9%TN-[S'*^'I]JU^,[(G#P"J8(%C\,FZPA4
MM_>ZQ?K &#4TQ]YB/8^]P!B%"#!DZ9ICQTBXX3-/Z.!D 2P@)^@.0VCWS<0<
M36IZCP]F%P:-QO,"%HK,0-"N'T!>@+^&"*IM<GL2^%"7U\0$4[JU^G$8_&5$
M,R4M<[Y5I7(<,A^3@7J[X!/?2_8:9$&LD15C\!R !MFH(Y&S&WN^Q9NZUL7X
M'_;>/*B)K>T7C:)$0(B @(Q1F40$5$!D,%%1$1'B" I"MJ)"0(P*2(205D89
MHSBP!2$B(")"!!D4(0$2P F164#)I#)+MT)HR72RW^_<6^>^^[OU[ENWZE;=
MJO-'4^E5R<IZGO4\OZ%331N N&L,%6D'<VD$/=[("4+'8;1(S_V@ 9:SMR0_
M3+II[!=<TBI'61>T9DUO+IOSO"3M6VZ;D3'T #EK62QGQZ$/Y7Q/%2\&8<Y&
M"1\\=+Y187PAHZ:Q9N9ZA!]J1?"%P0F'RW<7SE;;JUH>>I[O&.'<L6^9V>U/
M_AYJA:JM1=MTA''/EPTH[E'G+7IW\T*WB6I-[C?W(5UO\[ GT\N?*&U\]TV>
M.4!;GKD,6O4\FS8XPP:6)+?C!\O/0M]O%>W@ZQ=+\L4ZO Q4L]0:Y$P!/.;@
MNR:\.F4EH=Z\I<-C#^Q'%UM!>ZAT4IE[C;P(<5>C\LWBV=Z^F=E\:N(6)_].
M5D?,K+,P7-Y 9%_R8DGI#RRA8S. <*7#52*I,CH&"CP(CB86=Y,)D#LV%#<D
MXM9-:X%F6!TX<Y?()\5M:IY+3*9LA&,)BG61D6%% :1^J$%)FU8T$?U>9S7Z
M#[&!I!(X2QU2. [ADJ7+R:$@FNT9U02JNK8Z;8DOK9_(\<ZT;_1CX<&;*H9>
M'-R+7I<-9'>>)&H[3HMP<02.G"LWF]^O1QM^D+5D84W-L2S<F@]OV&&V.UL3
MWBU^;NEURF3C-7^3/??NG)++SJWK1$ N?AG0;(0EV"R#0]OJ-<B^L.[38Z1;
M>\&@J_:=BJ2%3KY#NPRQ3'P(OL+K',(=A>>BEK+Q->;)TJVPJQ O,O'I7Z#$
M<U&#D[R5(PI$=<FKUH&#G^!7^^! /CWI]GDF-Y6F6P3>H<;/=J8QD=7.K1(J
M-FAF<(:/9!]O,'Y,&FT%#%T\19AFD9/?N._9,C0;M20TP 36!</;G,R;O@3Q
M!MB<)607^!Z?DP2LE!K _2/$ZS+$\YD4\L7B2:/UT&KDK*< GRI%PA<#>5\.
MMTE7UX%"&K]3'S;FM2=7C-8RZOW]VF@:9/=BDFNSGH&"5VWCS=,0\OI<A[%G
M'>/%L8@R G':K-=F:OK1KY[N\N^_M-Q.7/L032Y^*6Q78"*WE?WN QW$ZJ-M
M^=IPGL@%[M:G#_[TQ/+<4IEG:;K%\RG3+J$0DH]O@AF*E&ZTKIP]W_'P4^V"
M-3P;1##&4*ZQ+P\(E,?FG>QI<=)5L%_37:EZ?$N. RNW4^$=5Q^?B.[22KVS
M:XEZG)NY>:+Q][8]5PQ_.T[';;=[8G'_H;:11!'G>A5I<.M:;WC;E0Z/ UZY
MMW]23M8I0*L7+I%&TXV"%;X-XX=UA,1>#": \JX?K17AUSFD@',W;83]C>[Q
M\?#>L/)3/<0:7%W'AAP]@E*Q9VAQ2%I0&:.HWE_R(Q=X=#P 5SKX^7C[["[?
MIX>>[4U]._4JKC7Y5#XA^3T[R$S3R4[%9I-NW\,-3\OK?OD)&R5)#7C17@ZE
MOVJ<@OE(=@P4[96R\K4D6;/O_+W: ^[B4*'U*#8MG6+?")TM"2_\,MQAG199
M)%?2W6'EU:6K^\/.5T^^S#J=R>_+YC$S..#N23GYB ,EQ0TXL*2-H00[<VW2
M\<OFF,D TJ<YQPE>*Q+&?JS!#K*::<\GQ4NJ051< S*HF#0I#.RO<#%]3';M
M%2,XFF(;;KDYVV@;M*>TA&S"A.,#2\1NMQ6$,P)4^XQ<SBTBZ^NPT6E2QRZQ
M"G=\KA-%.OO.KT]#^L/*@TVQ:4C#@;6)14/!PNC\DK*0(<E4"K'X^'BM3WC
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M@_FY]KH:B^?I<P=_R[^?0;L3C@9II" IA0B !Y_($#\-__T<$='R=N,EK>A
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MOA67\_1K@>,.!YV5N=\(K\P6AO&N'E(-8%4@S8B\SR02"U9)5P=6V-)@]UC
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M-':#;?EF<#@_#,DUGW* )@7?7X*=>_M<//E?C*>-E&!/NJJ*3^\9J.$S\3K
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M#T5WDHFJ0<73%!F;Q^2F3JHH/@>V9PJZK%P.BI! \V%LJ"24-\^>T9_$+BZ
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MC#U'3,(OD]J3S2&=#(8N>8LDF^QW$=1L&C*C/OQ$LFD9H*C!G9"\Y37):_@
MF@-3^=KW^*=AB&L5@^NU(\9O(CG(V1O5H/,41K,U@D>L(9^4J]@S3)[F7U'F
MHP7Q<AD;9AL_+D,85:.4X".S(">YLV=/#THZ-, %DIC$SI01*PC+VF;+XJ#G
M,M0&O"#4U##(\02I;$\=X84!<;CH($P7F(M76@J J2"1^V2.^77I*M(EK"*)
MLUV2*T:!''<X%ZQCTYX+[_$RUK99>7A!0=,HWO3A[8U,T#][LGWJ#(1O11L
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M0+GR*L38=#,T=G!M$N4GR%3I>I*;T*ZAUQ2^)L+MX.&3F<H-,2)??\K0%H<
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M:R[&W_D=+TXXMV3%X)+%**06["F@P6NSI\+*0P<6^J]QT=<QJI6]YTU?4'?
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M@G +K"KR&"8%#/,O7^.;R#?#=2<4E1"1)I>J,VW \AFW.!>@T!>.:1M1JF\
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M">3W42MQ!UJ9.#D\_$[['UONV,A.V,7^/-,+/[P(Z\SZSU?I0_^6FF4,%3Y
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M5; JD+0!?VS@^B)M/<83E5 C@6B<A\D&$J''V<LE3553Z,!>O-.&E/ B^[*
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M_W:L%BZ!/YA$M<.E<*N2N.1XI%0FT>>'Y5S '< XUS\M')X207KV17@!F.]
M)>DK)6,3K2DIA!TX^?D.I")\D:($6AT#(X<_Y1%?X#Q:X+QIYI:6V^&\^0T@
M4FKC!9#.K\1RSF4GA\.'>@?I^E:BBBIIEL[S:M=7?@DP4Q'>@NN#WMW$*_#-
M(-0=W WDMD@@=>@TW[= "1DY"^6A9?$^8 M XA%G[Q;A#?L:H44@FP%3:K3E
M1,TG5@MW0,1WA/_+,/U3Z(5.Y!J7V$K;0N0\K6?7V[=TH>AC!J";@,&W;U>
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M=CD9(,T4 HQE+3 G7QG<ABD2H@6&=AJ#EJ+0Y0HP"3#W%A0SV] I#?X)B"C
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M[\J(XA\2"@ODU'P;T[X[/;4U79*Q8P$W?CVY<WO>Q(S-]95_;?]T1#&13P[
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M%5&<-F V,.=O%F_TTG[V&PF;8':O&&VC&O)#N$,E;39ZZMLQGB%"U$%=0L(
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M%\T7J'M-XPJ;C/Z^0I814DA.K'?DNLPV>@K/!G:6 ;F2!L\Q>"NF>:A3BQ2
M%<->^0(Z5X7I4+X^<4$U(U5&$(@72=!^2_6TD(";H#8L>Z+R1/S@4'F>KF $
M3U[&,I8P=\#ABCS7-AY^@+29:=\$WUF"YFWRU."VHMLR<:>O:O=J<.RQ$3['
MQVG(%5U:) ^,I%#@J,1[M/E@CCPO&+^8Z0^GJ_20W7"TF;"HC^FMTF42X;!Y
MML W7OAT68.,FCI4V4[.EC1H<-G$P-I.($11ZJ \!7O(7@9X'N@,+)Y3> XS
MW52_H.^N( &ILHJIRIQFZ@7P&K5[EF[Y\:G39*8B9\I+SA%82884RH<-T.)R
M!<=\;*VX#5A,/"7#9(!]41LEC6^.6$N/;YB1F"!'81E4)%6R97GNOH0.72G%
M(!G8V:*%#<,#E'&W\%!OV:WH+PK[Y*T];@INL#M$3:,^I HIPT.BCF)\*S6?
MM;(/,ST4V4 *NA@A/4D*E')$W!RJ <D..=*'.*O(S -0D]#13TZJ #LH&0FN
MZ:R5M/-H'QGO3#9V[> 8C)$6=]?R+,*O,>Q;;-S@>/DPQX+!G=HM)PS;_Z"N
M!\)+O61763WHJNY?B#[0KS"YM<RL2=U0"2=5,1U341WCIYRT.Z^'=_9BP#EX
M3M+:S7HS81GPEKF5#P)3N^.AUS_U('8*MKTJM.WIG]HSUY*3 "Q>/R6BH0@-
M?$0?"D27F@$*)S/80^!NGQ6C#I@6&3%<CW4[TP<I<E*5C#/X1;"9]8Y3U]3"
M21O9!O*%D?LG**]1X@N(IO2"1MO%0TZB'J=LYKXSTG?^K9F'>RO@T'*8*@PV
M[OM#@KZF?EN7,J-L!72$1,J1.[&-VBTKV]G?P?X=) /U[PU.> ESPQ-XMRHR
MF"7FX-$U\,5MA(7(3T6'7Y,\F OS10JS;.XOI.7,G?F=!Y^EB@BZ)$(K^&@^
M::M 2GAV(]3"K2.AB2(FO$_(/HD'_M;@\@#W8DX' *^7"/&IP=_!<DPK>\=#
MM#:6A_KWVF97U98AYD:(W:;O=&2 Z8^1C00$.LAYZ&HXO8:1>J([5FP*1[=Q
MZEV%U!4(L8MERL@Y#OO++(CQTD1J&LD#SI/AS49V0KHR\:\:7 ,>,>8&P>E0
MX$[P6$GE('RX?UBV+ NLG>O@UU%%"D4DI15U@R^J;#&MK[Y]%L3\UD*>-:SS
M#\840CZ;MP'F@^*CZIN8 31F+$[2_0$4,%W@V#^8YG#[A?O)K*_2;Y$*OW\T
MZO&5LO>-9*(T=*7>+%&O&$G&DB.,/W1-FBG4X%+)VJ1EC*9 J"CW$W 6(""[
M>V94],'.$S#G@FH'$OWM(UJI:S)B*Z5<"A@53'Q/] "M6@@F?B+4@=T^XD(C
MZ(0%+WU:-MQQ;,0!U.#2$6TN Q"6+;K%ZN4W4=O)^5EG[#)%DA2@[E.IZA!3
MQUXXQ)Y\R8U@;>U&\-#6?>IFIAGFAU-MW!I[>3J#\%D*GD'ID"S3X$[O8^Z6
M<[Y[B_C5P4D7H,-X8_B:,ODYV'3IIQ[FD@6J^8KC9_;9CDL4^W?@KA[ O?CG
M*;Z#?X.21FAP0DR6]@C(C_B9L[Y; P8:S/DA0";)$:[^ _D9UH*N[83FVO%#
M=IB7:^Q17@87SE.3R6??>;>6V4"CK6PKAI5LI$2:2#""IZ6UF8J%?;/6Q\9'
MY1E7%--+QU&S^;HVP!#SB+>'[-DLLZ:<V1*Q)1Q"Z2'_K,.S#7<!ZG8/9-1+
M+"> !C.A4ZZE_91A8W'-W:I[XZRE7<!9@GXK.'"T*^:-TVQ0:)M[W!6B!F>)
M>"EVRN'9H.U:2E>'RUO.1U\L?"$*5C^;]WOP+YATACT49(S:&B0M&MR0C[*5
M9-1%#B-GC>A?D\\)IPW?(.L?J4M8J^ 2WRZ>7A@5I(@S;%:#W [R18EY;,X/
MH%..<Z;ZC^:M(>!=<@IJT^^\>^ ,Q!'J3GG(VD>SF Y<.'_B"A@_Q?[VHNTX
MD1 =#_8(O^W[Z1LE90]]Z&SEZ,=(+@)&S>M<A00KINMC]=UI%@Y6*0AYI)6(
M-NPMJW9*!0RW$18P+5YO:/:2EOI+7=GE<+H\R'0"->9D-6M#38(BB1Z.?/-+
M_4^&YQ/.B[X>_E>*TKX6PL]5WD#K7F*4:BNMS*(OEF!]/!@>P%!W:CD^A1B*
M.>;#ZGN(%V0FU\Z=J7%0,IJ^[>9@;9THQ4^JY<#%X'6)G!6LKKD$((](!B4[
MNCJN2/E:5!%DJ1*2EZ);/I(VJS0X9;;Z'C]L6AM]Z\)93#+NK*6-V(#3Z?R?
M\:8BD"O A,- -C,Q'#+:!7]1>3$!.%:U=SQX$_RN\J5V.LN(WP:DD'7E\"WP
MDT28,)URJA<Y*E-56U5S; 9IJ6UQR82:15<.Z!H<V+3E;>%V7/0+^P<?"O8_
M^.OJGKWC@BNMYMO=M%.GJ7^W#TQAX+'($BZ0 F;P[6DO]2W$02:&=Y/#8=0&
M)O4H?X4+;L'/Y*[9B(_*BA$J=VIEIY,-&H*,9&8"JB7#*@"D=U@!639+V.U4
MG5AK&]%>J#V%N;4!5BOH5L?A^/:GDAY=U0^8_?=QGLXA6#4;A=R$XUOF%[$[
MN(N0K6!%"6(!#RLHYC!>QJM1_8R8P'[86.=:ZJ-<,%Y UB92;S'JE$<AIW9*
MSHA'?ZCZ)L^1(B.L. 'O4J$&TTMA>BO9'"%4XEBCW]VYK/,7N"<POPR=,=W9
M>R4UM?/7)/2Y][T7%KB!]QK<Y"W(5<GO1\G(\6Z>6P1@X.P09*:,*Q3)."G.
MU)1NYC8X"L*+^#ID&F%H6/J!#VUQLNZ4E>0X+6-TRJD"^D+6*X[!+'FQ:Q[A
MAQ(OF%_)X+0&6W-:"]V39IO^#L:K;P.TWS?R<&B7S6J"-?.,.[+]08\&%P[@
M1UA_<2R86K+IU'E^'CF<\N;LL,(U>1LAM9%G'13=;D980ES$99[BM$H,#,E9
MI-58"$ENO8!L(Y3'3D'\[^W"$&9_%>[JEE^W!%:-O?IU:VKN;*O(:\^1O$&/
MI/-O4)::]O4-7*HZ#K1Z89E L'9*KY?DD9;W-9]2$5E=(_9PZ%V$I+[6''T&
MPLO*GDG95FB7I22%>0+R:9.8H(9OASJC%/AT&QQ,E_$SYBDI1/H?B'>)G)N[
M3:(-ERMC?X?+#\#IM^)R5+Y8,'\D[E2(<UB68&E&5CD<P]P-.T@)F:XVJ]4<
MD@N<VA% %Q!L6/V<1YRVEP[*W*8>6]@>G) M;KH+9RK#X#Q(I #:':UYGK0Y
M"9[I<Q<&O![#%\ AB714Y+D:AY=L.G+CNPOOS[_QG)\9>^6N*/MM\G_R(LLN
M7&)$ID\O8WI##64E9CDB 2>#;(KHV$UBB.,D%QN- RMF"):LX:>B5KY-Q"98
M$-R_I@=9)9/@T5>%AYG'30EZ]:5F;:A),P\<S:N?\,3+@J]7,3S:61<Q5GN@
MKB:YHKW[(.I)^)WBN=.AIW0=IB4D2D$)]@+/4%GS/)#)C+47/J-)LC6X997]
MS7:WQ)"6,ABNN\\X+ /.<@G[Y$Z6M.+IM&9"=1 L.M8$F;2W_Y',>OHO@ EK
MF4/$</?K'3H7I[]RH'(MR1>RPF<W;JTV_P/0D?L_.^EHC/O=1H.[CH'Q_U*F
M]0>_^^F_./V.0]DD*:WGWLUE]L(EA:Q58 6RQ/8IOW?C#*WJX*+PR9+]O<[F
MBANY%LR<$F/:^<%-6>>^,ZC;RQWV-Y/SORYEV*(=X9CIMAJ8J+_YW>-I*^!/
M5RRZ#XL$G/FXQMJ.?V^YN:PU 7\3/5*?\Z_/T+!3OO+?)V$9/NG73YZ9NC5P
MZM_F(W_4>G [^WO<O__*N0'?WUP62@75=^OH:\R69^Y;<-@%++_VYPJ#?1V;
M$F+LN>*$T<D)663P>&!UC0/E<;'WAB^^H?0-^6ZJ[DXK#YO?[?+?_O3KHJ2C
M^RY^)*\WHH72G<N;S@XXA'O4WWE7$M?PIIB2%-DP.:E\^C0NKEM=_X7DCLFW
M8/""]&/ .3QUQH.".ON2'PVDZHB5IJ4:7/(QH-^6&B)-P/]Y"+OBJ@.?T7!
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MVH?)ITMEW\,^$"!B?=?',XG8TO#AF<P/O-8N,6;2%7B=CRP'R#X#L:@:*S.
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MJ+$$$%OMKXL8:$9_/EZSOYL,)MX#+/M:H&OA,]ZD[.'#9'SZK'AIYNR1REO
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M"ET,=?Z,?O-_%A__E[V<9H;^%U!+ P04    " "Q@'16+[,2^"QK 0"<D@$
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M_'5(2L1E^9G4\Q6O5Z9M>W;LD$_6"=\3&)'\R>=K*!1)'.4B><$D,6H"M!I
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MP].GOX83?V0*CYI@1:I]5T*6U+0JS*CY4O;%>L4%GO%TMRUJS0IA2(2YTRP
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MS_\3F\1_2,W?2N#?85/4?V(3Y6^DYV]E\;\E4^U_(I/GWTC0'[/XWR)L\)]
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MJ8&C.HNJJZ1QWA3KP"C8J$UCA@3?#=\JZ7H"^^2K2V7O[7_K?T[R$!(EC5@
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M@:>UP"7;0&A#SH8[-6.E2Z!+)7'2P"H+T'1,Z?7U3,%LP\]5P_55TQ5C^E;
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MCL/C$D%S*G,[F(5WI*^AOXAP0AY]#R'%VQZ\HG 74WFRD7J*<WJ\:Z*#&__
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M-.,\?'1 =!,J$;OB+-IM<9/\[W?%YR,1K\FI\0B2J<Z01FVA */5)B"NE6!
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M@3XS1@I'BA]KGO?%4(O9F(;7T>,GVN\9'TM^;(81/3QS#Y-)C(*/-(D>0E?
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M#%_K&#,SF'T+?H7\'T.)CB:VG969X>'2IW)8[,+(-\QME-ZP?=WM$"W(NX3
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M^^AQQ!]  CMVY*?0(NW[KO@QDU7?"19X7>@]CYN)4&VHSBJ$+')7V %0J@(
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M$M'X.H[S*5>!RY( =+GH8,@)2KU&"R:C-@CDU &4,"3,E6C4Q0P(S1NT3BM
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MLP^O#+$?C _64,DMW8(94)CC-MXUSY<H%CK[5(V(V%P=^/CB9VKRU[VYIL)
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MC3 3CD B.WO]X:ED?CPT%NF..8D" :;VE%.U1?EAUI1CK11MS\"UY. *R<J
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M2C0;)5X"=5OI*F9-EB4$*M=B-6Z?\,JS6>MF:LP"#/5Z[@S%[=<82&:34\F
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M=-Q@ ;UE5C8E4+/$!:8T'&"UMV!]&.S:W^=D$@]GK'MG=):@Y')FJ*;"YMR
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MF*L\%5">'T+IQ"J;X^_KFX!+B;97KD[E-.J%1*MQHA,ZRI;DX5MPUF<J.-]
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M,.%)<&>O*=/E1HCIH%>!8"=*@Q 2)#N2/[:\)ZS(DA-^="75;OF[M8_'A<#
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MXI#6A5=5KJ<%9X-/#&.]<(]M$[,S)@I.[3==T.,^.K_H^5@^X(M);FHR'<B
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MJ14],4_2^XEY-U/!"X.Y.5R!4CHFMP'QE% N0F-^S3C>7'?/S?RF4:%#F6=
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MRO8, *TDY112VW*H 1 YNVK*P=$7/,@$<3Z01X;@\E-D7Q-YV7N?TNA7Y;3
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MX'H&#CR@?TB(?'2&5F!TH&E75D)$YOJ>J*Y1^CJHR= XB:N='+>-U'E&8;>
M0:G$W< AHCE4,/X>+% >?- 9/63?A5R]1ZM0&MWD;V">6&0+6&J*/;O03$*
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M#KQ\QTL?_Z[Q?3)J[>F>VKCFR\S3FI=43Y\$T]<0X*;/<UG]#"JX@?\I2W<
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M$SZI6T67XY8[@J14_OLKAT0Q7!;E.7>"K.$,:"?5U/%)R#>PK\2&/E^8HIS
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M@(&4ZT)OD-O>1 V"6\!*];?U!Y$=*X'+^@<77>E;@:,0.H>.0WQ[MK@%! :
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MPPBT!_5WB>NC%>9J*,"(NT0L7*\NR.93E\*,/4TP XH\VCWE[!"K+82YNJW
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M[ 1KQGJH73P28W7+O9/BN0Q;]7;IB<P65&@RV\FE8>$:LO*;/=16M@IRW4"
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MJRT'$>/C/W7IF:QQD*U%OX;V+Y']WP66^/\4V;\']A]Q#0(+M;7(Y&DO 4"
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M54C/GNIN5X-1R2*V._($F4ISW82:[_#>%K$2C4\IZ8Y='.@1:Q:&-YZ[R/<
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M'EAZ1'@Q5HL]DHU=;=I4C._HIFV(_7VHO4U-,G&B#Z<[Q$%=3E;>KUCRJ-B
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M6+PW+5Q>7XNU%;'R18TA/ 06$0:/>\DB:J4LQCK\NK]$;]G=';N%1%71W",
M>%I@R9H1,8Q=M:7<]!'M/KLF=RDWK7 I,I.%4^7Z&\RC0T4$K7MRNDKG4-UI
MRO"$V45%E73-C]1W1T<M'K,+5 MQ'1(F81+2[QQ3%S2YE[=48MG2CF9QBH2"
M[RX?VG/R01-)BVR[8Z'\^IM;A2ZLOCY%S.-FX^Z^YW$I<[EW3_WO&QI)2V8H
MI5A@G4H!67PK/I#+HZ?C!XHP*J&W]E@EUGGHI8.!KU\U4GC5=660*J@U(,?I
M3..Z#$E8T\E7S,'M#IGT@H=#A_!09*:CABS;I]1YG+4M4JZ)#_).0N@FH>".
M1RANMJC*.NEW5!=[4NRL-)"D$4)U4EA5=%A8#USK68K>_^G61MMQR>"8\K*Z
M!&>J@G%'<C$LHH-#0U)%M+3 &6%PJ/(&-J/R8'6*3'A+WF$@XB]NS^$9-*TM
MQ9VPA')&Q(@%2FN#TBR=$MY_Z4<SG5-<MQ2=&DRY/^M__VTHW:;7S9H8HB)T
MZE42]-14.((QZ-*O%*MSP$CQE49P<L"ZE6[$7HM016 658MP9DWY]$ZY&0X?
MA43W:KMQ"U1'%I!55V Y)IR]^8KM7(*5B2Z4*'F5;I5W(K3D /4/A_]MJ_+_
M,HQ-<S(FWZ?=&YWAUN0T6]"7SSS9OO7%-X'_ZZ[4?TDD.J:LPPZH=K+UU0UN
M5#(17O!)#9 TRU6L*FV85%42G8S:L6;:PHE9DR34UQ>+CAX5DT*$PK%AKW"S
MAGM<03G#!*.U>07TQ'+G3006_D)8(_75!58'@_U%VT?HHZ3PC:!AZS5 !W7
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M@#)#@B9*UDYUY.Y!DV6;N/YH<NNG ^'8<]@]7V,9>$C<C>^!?_9N7.[""V+
M_<S&H%7-K9</#&6"=W@?7TRS U6%ROD\#^YFK%W%SF39E'-/(L4P64[+<C6K
MZX&B04&8B92>Z,G2Y?ZTA=VJM54VA4W(@@*:"1G>6+MJ&]@2M=/8AB[Z]J@_
MG!-_;N2=SD*PXW^!1)IVZO]N(/D_#62=_<R5J69CRT;'+57*"U0'Z%0N10HN
M/6DHD&SP3WH0"Y%I8(SBVDSI!;&Y.B(07I7S<1I#6RB4V,BMS[J-#ISD5M=M
MB.YF)28!Y[>6<FZT*J.V)&<E:8,#"U,=7A/LK[H*_,2K/ZG?$R/Q0&@RJN,
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MO@F-S'_P=B]#41[3=ZNAL?#KB;LKS-ZX!.OF8O8B?)7A,<\<*YR \[*-5./
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MGYN'V*G'6N+##@/H.-S1@GT'#^;Z$55CYN!Z,.+?\V_FZ5)PAMYSLDK(N$N
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ME0(<G!C!-7!PB]OL]CTOZG\W^LCH"\#,]NI=L6[J/+#E45@,U0^V*\16L\W
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MA&K6><:?:;T:6O=1=+'L08S#<="S;OQ9_,^9E4L)"!^LY:'%2VBZLWQX-\_
MXHU4,^[T?.O"QWOO-.'R5B[VN@N;WSE-$%@:KKJ.AYXW75T^MC7?Y\;X-ZY?
M5.$Y+;_"?_6L[OU)%9-%\C&+FQYR>>ZK^#/;@B(H1%%U657CQI*I6A_G6-N\
MA^UE,EK?W>X[73\UZX+\W:'. 639QF':E^(M+NW?._R^[Q1CS.*#[,R%;R4F
M]\MNS1;3Q*IBQG^GE%:I8M4M&GQH":1YBWO^2'1XW/A_=])F=D*C2_%]9$,R
M8[3@>_(MSV!*)5!*. Z-]5W" !Q2S#XY9/ZS7/-6&B8?O[E6]_G]GV]R1D>9
M5:H2UD]_(O-_*?B?/POLX__Z_OEM%E_*65-S>0\LRTZ@6;[;^FOO949T:%V6
M(,I&L=5<VK_S3,7[(S\4F3'/,'U_>+WB<%36OMLKM_]L_M<:;\HD]U]\&]Y>
M^/S/H>'>\T[;SHCA(D ?48P.HBM)3GIR9OFS>L1+J1NXKF-:=$27?;DEC]+3
MK]P-.IG[ZC3IEF[,-.WMVO-!)!+"S1"&V[S'%B$!7#9];F93K>BZ5#%PK7+;
M\;/!K*<O+@<U/ ^,2^-ORCJQ<R/:?_H5(>' P;B'[8&.80^'^Q_&^;JN7M70
M*&PH<4T)"PR+5L3E77^8$[*L/FW>WH_%,>'.N5Y19P_N^R&4$<)0A#+>180.
MO%/V2\Y%IL2<MGE5]K&L.]"KLJ?L;W?X?=C[YJ%UULUCBSHWO'3<\-T*HU?8
M9NCE(B#%H;]>0\3N)#>R:*@U']L[II\W3>@KQOXF3]T5$B,0I!W;4=%&UJ\4
M+X0FK'N&)3/MQ*<)__&@=P'8WW(=[CUZ5JJ2"6":H(LSE @WS]0&2ER_<&:S
M! ?%;VH%V1&K#7?BG>6U?]YYUO F\96U[@G@:YAFPSOC7+<7P4/4%9VU+X8_
MK/^W/GS?7XXW-U>-;NN\25L,'2/GD)89TC$O-&2F?1CV3G<5LP3'D:B6*5^>
M4UAUD(LDPO?:23>_N4C>]MZ*L!V)O$RJ5]ZN-Z-U#RL#7W*E3V*N,JL*9M72
MG0X3/R5A\[-I6C,J:58A&]+O+-DIH<%=-/N.O7^^-/J?+>-5*9BI!Y[CDS!S
M5 XW]-/K^;M@7AMO;H"_3$K,EO>^#8J?'?X3^0#,S'=^DA5F") D?Y%XIO6M
M:H2Q:J?RYW=;3]<<Z)P0-#^32QO81YN?[SZ>+E%[+.@G2KTVG#Q+YP5]%(9(
M%U=9/"5O5K/;W,LVM=FCJURL%[A%=Y>%%BX_?<6G^T&G9*94\[=?70H6VYFQ
MTC6#&1R7[A9ILSM-BW9])[CY<\S7*)(#\CK\CSUL7PUUE_J'QEAQW^&_W6>?
M:PLW965K'ML''SQZ^KNLX^EMV%(6N9ED]<+P6("1/Q<W5G!1CZ.:\!/MF/6+
MKC-,]2O7 V]/N4\3ZH5AI]U4M2E,\U<V5Q]2LZ<NAVZ-.[>R\74=E5_>FG3Z
MZ$?E8B^Q/20Y0HN;F7.OX8WT1%(+]-[LN5U,U%_-6!+GD-HR7,JR^>*91W=$
MHY'((Y650XU(?H/%M:,JHO'[G14#GW]Q6A2A^.0=6I3[3R?MUYE5>6O9=AI*
MGZ5H%BM2L['Q.,+IESQ-=F1#O?%N_6%(Z[]\<_'-6^#?9L6:<CI7\;=/8A'W
M2\*KY:/"G14@=MZMYW)A@)<\%U*[3YW1V1KR..0936&<T)$U8+,P+L*UYVU7
M.+B/S*W,<.#QA%&ZTTODSU\62Z6AJXM3/228T]=0<Y>=KUK;(T#Z/OG$S6!8
M;$;-A3Z3CN:W1\UY<@/+"M]/??WQCPZ;8GK6$_96P276&6[1B[669=<.8F\U
M"Q3YB\ZP#]F9%Q3L$%+MYI)[GW&'XM4BQM5@Q#IK?4B%):M.NICC+.69_W9D
MDE))7_'2]5![M?VZ2=E/00[=I:837Q\]./#D[[RE+;TE%/>6X/M9?S\^L$;C
ML>1'+ ]XP/7-RCDB6Y0*MJE^%S),V5XPDRNTN4TM_>YY]RG/,8NAIU/QC0-E
M"=5;G=INL]P47Z8._Y)F\J+DC+G0\F2._P]_7+Q[[MVSU[.&WR20MV#4VBGL
M8^GVJZ2")?ZFOY9MSUR;L&9?A8U#PM#>"M,#0\VN.YH7#75E. O6+;/_\-_[
M:<*&ZC_^CHC,;SNQ"=UV)(+V7=LO"!@)/_=5WAIY^MV-[1Z+<RI] XJ?NMCD
MMFC6OMP^OT>P]]YVO^IMB_:&+I$PKD/PGHY^$UV:(9_JR"K2,BZ(9J/KP4V8
M+SDDGI=@2#F,U+>]@M3R[ FZ(_L8&%;STQ0,KA]%W4%D+P>7G@R56.6UA@;G
MH0<U;M#>-V\URCU=XW3SF(8/2MV'@?2IG0PK'&*V0L?Y]AP%[8DXGQ9%G\O2
M2QD+$NGV+*F:F',"X><*EST P[N[XD76[",PO6W>22W\^J*F8\Z'B(ZJ6)%1
M5\(:%Z9EGZSB76RP(JWUW.EX9M0FD\NL4LQT,SRF*F4IU=ZC>V>* #I44:-A
M:EQF"-H<[*1AS-R(#8CR_)B(7. H2YZ4\G(C7)#X^N971BV8*4Q]?E3EE$QV
M/!(W8%9W63+5>_G<G:%)ZBJ?C@N)1/L4ES3H%.U\*'8?OJPN+T-2U 5*&2VW
M9#Z(?Q0380^731/RF"@Q53.6(S83!B!A$LR^!GDU3<@8C4_P59* ;]. +U(O
MA1:P>I52I94? QYK;JC/'>^8<Z3_'2. ^9%O _TRELNPQ'QFNG/:5W)<6"9;
MGQCNB%7\8O(((UY]G6<$+A]L@)FY0G\-O:!D31?F\JI*JHU?15P(4L>H?JSB
MMLFFE[<_)9?ABEE(.Q.O3:6&->Y^SRZHP$?=!8INI^?RG]3SJL1QO*S0W@OZ
MM</D)R;9[,5J7*QTD#QZ/G8-&DIH411'SFN^%;I9]2$@T%#JMUX]39C_B;8X
M7GBZ$L5-< 9W/TS/IZZ*'E@K[/1;H^$M8>&>H4(JF,O:]\Y(.4X!JQDM8=,$
ML(*; ZGNRAGSV38N!6P;O3\[%.<: 7M)/3+P(D8=V$]/KV']A=L;ZJ).;"DM
MO<[IJ'NBOYFD_G1T\8>QM!^M8N4;.^[%'+*E?_=T:'2:P*0YL=>"KW"@JFCT
M ERC%C0[$7570 KBW$:;B^OS34 F8&\%OV#.8#W\WZ!FK!7B3A-L^V7D>=C"
M ?:J%YT<FZ$I)4_HJC5[(;!D!;8FDS/0<-O[*:H/43L?O_4216Z?:?_.WO9V
M9IZ(NA'_)ZX=X4JLP<,V\6S1!O;L9Z#33GJ30[$XS(*T;O+\1Q,TJWYT(Y1M
M'?MD.)28A<:<L^!7M",F(W:*+_RX>T?>;ZEX'WA7]@K]%3_94994)RM^Q\%M
MFU.M6_ /</!(C_Y'K$-I+%P&FZB?UL/M@;!+-BV6>6%@J>&F:!UZ"J%6:*&<
M:<*B+QQGH.A0,W(2.RS8&^#1@9MJY3R6@[*%X_*B=YTPL3+687>U6D6\0\&O
MO8SV)"-B+=BKNNG81EJ+!.=RW-CG:@TWQC\8;0%'D:7# Y8@[S[J**=2/\4@
M=M+BBLQ:I27P^!&A-]^TI2T&+H=[$EBC?J?5J9%!2%'&]</P-M%S33B)EP>I
M[C!JGE; '2T<+^"!=*BJ:LZIQVRQU\E;&>C.;N$Y-7W.YQ)'PQV1RY!H 4C1
MB,UCI^AI=95A;2('\/QN'QCH5Q%YJ.5=D*?FXLCO,+/ZCXX41V\DK>@=9]Y
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M%(J&B*#F$#B-F#0YK+H85Q'W/YQ_AW1?0P_W*=X/'(GUMM6]V7+ZW@=9E/G
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M?"3Y[ N5/74I, IYD1Z$%$AYQU!4;Z(N:H7FLADPF8LM![;Z@WQIR:K KO(
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M9Q_+2#4I[5!0Y:HD/$N-WG'^+B8WCW$A*]37^#;<5TM/FR:0_?Q51 6E!?-
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M2-VB/=6$PV9MA,>5Q/N'92\K1$XU1>N9GCN-G)WGWOOE\</W ;M>Z"I)5IM
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M@H):TAU_,'J77.N#):BDN!6USH9%RI\O(9G7=L#2;@)\U8Y4+80?>"+2_:0
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M($6!GO)G> ZBB9&C3+J.(QS)9]WTIV$8I#N;HZ?X1.(XB477!: Q2,X"$6/
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MNLM ;YR1M.?HG2CN?VUI:/WOP%]'FYDZSU9HU"\)V*:!OLRO)63=XU49T.@
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M%"W;FW)DZ=:KI*PJ*_L+I"]YNB"T2"W,FMB-F(906IR7H4Z(Z>ZN46':GB[
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M)_8Y!9]]W^OM9Y'_\AMIEJW#7# SD=RO5?.''9$'4,_@#D1<7Q?68B0Y^80
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M49 G.H'.X?0V%UBA,OU!O/?R<7$Y>]@$#FY9%]<$O#;592(G4_1A!#(GU@4
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M@E2^:0/)7LT >>"&"[:Y%GY#Z*,)@Q36O*[LB:IT@0GO7T28^I]C*^QP^&\
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M,X(AE<CI,M&V5'OK3[ 5]@!?$RY-BM,9YF>. M ZRC38YSH\-9[LLO8NT6Q
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M$68RW_19)ROPF>-X:P:C#-2J&O I1+OU]+@:FX4@O\[1HXYM1EQ!#<CF7_D
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MVP]HGU7%:=8PSD%9PVU]GEB>7*(@]5 4 6E,)\0;#H/<*%"&- 5QHH*J75!
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M;_5(AP#!MZU?/=!O_*,ZW#0J.A]NU@2^\X'$ZE18"*KJW*5UM(NQ*^!QB'8
MOI]%L6 8R?V.*L)$G)0^?.9VYZF;3@Z(0GAP]]3=['8<.<L@7$),D.MPYHS9
MD/?-:_D1!]K)A_$#1KBI#NM?69D%GVB>"K 7&C*@^$>:W3_A;38-OJ'Q8S:S
MRZ(+L3()MAO/G&JSOE9[WW,+4(QV82QVDK&I))* (QW6>& 2._(F96JV)SF0
M79^]R-)G>/!H863%9%)JX9"-T>_M57LCG@Q0'\!%>SL=QP88.PKH<0?;IKZ/
M^A4'^FF+=+@_L:0ON\E6GV<OX(_W4"J.QW=N)AC^MVG@*RP8W^K]=X\,\I'U
M82,W=+@=(=I"/H3%&QY-6D7Z"BH#>LWVZ-5)L4*_W(<$E>EPDKBI*2(+Y!J<
M6H=[<5@;:].0-96=7FTBR8JD7 A[$*.NN#&,P@YS-D'2^B8W 9O;CYCI"3!7
M\2-89H@U;"X#WE+5)G!9$7RUZGP>'"J0?<]< T^-I-0#^0UX4YBPE]=>XE\3
MQ,_TM 8+Y7TYC^%L2=]HP]-(\MV/3+..J*HM^(3@W6-2V+XPM:1JO\8Y0CQ!
M6 3(F4&UT'JE(S_)T^\18P>&E:FXI;O)R_KK,P *[ %F*2;J.<9#Q"7)0O8"
MWB)D<1>B_X#Q757G>&],?5=L1^%V2"\%"7@8T4;G!.,>_3^UJPX'-K'+ [3+
M8]2Y.EP]9CC2Y(*'7V?[LWLW$Y))X%Y"MT9=@L76";T.Q LSF*/V7E5T83"S
MC?3TNJ%\9&ITKE?^H%02Q!F1:EP&*NUXIQCK-1L'+7^MZ)O;5>: GS]XSH0"
M'/T86Y!\O!#.%!T M7V%#RCQ(K?A3LVQ96WW_YI-':%]9'NW>1C;K6GB$7<,
MC]]>&1LJ.R..[)]NA1K0=#B[5 R989O^T:9.G(:^=IF<>5J'(YAB?T4 8ZYW
M\9>!KQQ\'Z$; XLU, 66@7^ Y3S"/V$ZJ> -<H2D*U("5H3$J#]WG#5T(M#S
MO,GZS"[@J4^M-)DTZX>N4\.(/B;I#L'O09(B.5.'BV"GA2X']]YVYIM(PR>3
M$WGKX?OXU*",JLI" 0<^EDYUPD=.&B=@VL=M)W1![VV8&N,J'PJ\:F)D$YL,
MA^$QLJ)\<;7)'0,$KFCW1A&R"9/<;S9C6ALS?,/YA9C</*+,[$^#\0K52#R4
MOD7[&-FAQ">%VD+]#50C/74>/%W&3B"4LFI[(Z7U0?@1<XT9?135SU("DH0&
MGB=HD;BXR[\&)4)Z&3RW06#N&B(!B8L3:HAEH). ,L>9-#4SC0?UI2N:;PWK
M<*?8/;,^2!7)EURB_!N>AAY"WQ&XS"+(B0)C55V%>DN[,RN9,A.0L2FS21%%
ME+<5,E']>8:^0ALG.W%'Z63>J'C1:RB,R.]A[/\-7B+CV] ;^NMC+>K95B'P
MA"].>_L??!V+G[*!.Y-=RAK&,-TB0'0X@Z\B%2,O'&\CW4T1-L(!U:,UI#)*
MQD@!1!L>*AFB+-+ACA$R $O$K0A.J-7AYB)4N=-EP)2HS[ $DVOBJG>2Y\(D
M3!=/W:G*:U904DGAA/GA:J_Z@!8X?3LM;7(B<YQCUM-+UQM_=U:'(_5#*O$W
M%X@+":5A(]>WZZ$&6(S]\#,>.8JYHYVD/KD?RAJVQM1'YV1R+9Y O@O4[@+"
M.3.[@]$> -PW8J?T:2-^PZQWK\[_4#HE%+;I<)%W3.M#5V>KZJ6E!<4/18_I
MH_7S+0LS79K<)1\)^(')YA3:&%M_,):0^(0;94'6EOW/'1B_(?UK]'\/?(VO
M.94K[N(3FX>Q+)V)J1N5A [T/D=K-B!DK)+34T1@YN:?_#4,M<$TWU&T2:2>
M)MID#,AOG685*H.!BJQ,A(81F"PLJ0P_DQJ;=7D$X[G=S :I 6I'[_'N6-X:
MS9Z!&,/5FN\9RV$J5%@?1$D9R;62ZH60!"K3(2*!2&Q?PQTY*G_/XY,RSX:$
M;>YB;"H<DH2]),Z'JR%;1=;P6LB^IM)^A KFR"U$>G"_QIOA#J^%_)4LH7V+
MBVH^LPDUT):C+LA:6)_3!_-]H-U7H:6./LJ8&AWN<H#4N&J>QGM Q:%SZF,.
MN',:[A@#&.#>J!5CTS^2IA3M,AWN#<8FTL,8D6* .J;#?7BJ5@U>S>7RIP0_
MIGI^_4<VPTI<,9J1Q(N:FF*A -*(BX%:EY-5'AAV" R/#N)&H-85H+(7A3*6
MPLT0<4(Q\BM65EG9#Q]U$S0OPJHLE_&D' 5P)8:W@ ]G*$VIT"Q%EQ#QE14'
M1>T3"++-*J]WG:O@R[)XGMH'".4QL\4=WU  Y\3)^4E,*VT68]IC*LF4N1SV
M5:Z.98WD/4!(T#5FKP.8HTB^[.FOZ%U/@=?.KW:JI19;"23Q?0EW$7<X^1'B
M"SJR!*K$V$_I"EH2TQPW:?K5+$WX"M,7?4I;,7V4JJ@8EFH."_^:S4(!]^,E
ME'WE%7"4LN?1V!"G6ZR>G21!'<CZ'R?V'7RW(T*SSN>GGT,>.-+6]S3.&5IT
MY<C-C:XOV4>!6O>T"L1T2&U^;$^*]#?1</W^:4?FD6M),\SW'+RY9!MNM>_<
M=3M<?H< =(>%D*]93C'AC^N)BZ:C^LTZW(H)[65@N DX@=?N"]6[B\?@>VGK
M6DKW-W_*?@'"V9($VX+9<+_R]*LAQ,LS;.,"D<MD^N_\?O9' "_GO"0EL\'=
M9$F>[$/&(Y@L$R-FZ0V ,<,P3HFWI+\1U!V@E%+JG.8&1[BS,A'?1_2BP.UE
M%+-(2U[I6<ZCCUEK+!5C]Y.6SHY2'K6.X8,B=D6_=CE5Q(?3 !SVX\OJHGG9
MQW\_,7U:0/)Z][(?;T728V^L4'P.V/E3P<>^[[4%809I1CO7K#J]KU-Z=&*-
MV^L-3FFP*/5YUDQ%\RSYC^<_T5*;OGU^\IR/XKNUUU<H'LF"\E(S"0F0LWGL
M3_<V=*A=/K95[KZSHR& 1)YP0T8)&$$J5O3I<.^T9!W.E'*+\"\[(LE9)%KS
MY$XQ"X#,T&D 9"[5%M_2X5K7YV#:]("W#M=\]+T.UY%IIL/EU=8 \ D(4XYW
M$S!1A+'#F7$2XF<EU; Q;:&@CDY'%XRJ,?)]4$S'I/P\L@Q3^_-\D+7](U\P
M'1$$J="E[!HG="EKY*0(3?U5BM'T,R<T3F_R:AU[C+X!C\55GSTP-I?)5@&?
MF(4Z7&K>?RS"_ $0V#"E[+$;'!MLK97(-U-'P_C?4\LG#3J$8B1?[P_/Q'[N
M_3_W_X,.MV^#/\K2P\2'/*=>A5["MVN;M<T=.ASD3/OG0IP_\/#1YIY1])<R
MI13Q)EV@(-Y?L599*6'2[@R K'K)_S),^.AC +3*9"1D/?T.EG>V3 +5.MSO
MDVS4+N.?K^_RY2)VJ/,:)M!VH H[2THAB GBE+RO&DI=CM43W[W!!$EB(/;
MI@3M=CEYTG,1%G1)-%/^Y&S,J_P)DC]VR-;_6(C_[;]XT.QKED*[_@ &;F/Y
M#RQ:JL/U/P4>+5JIP_DD7)C2;0JL2M^B-XA.H/T? 3C;[9^+B#_H?<5W_VHF
M23=+:[J1CYH?HR!J_+AM(FD _)& +JS:C66.Q5K2N_\ X+8/0^]'AS#-71_P
M?^FE_Q/;V_ZY=Z3FJYCXJA,TP6MUN/MA;CI<W9-T'2ZW%GWP8Z'6QAC3$ *W
M5*EV!J%0\T]LA_^](#(#J"=(8[L^8$78_JO Z%O2_Q0_+K<S9_UQ1K2)3KR+
M9U9/X_SA]#4D A4J E3V#Y<RIJ&/1!WG7JHPR!S_3\C,QU:+GK*1.[VV)J82
M^&P'>>11QK\SYT==8_<$H_J[8\.4'-&I=7BDQ8^. OT%1GNT%V=;$D92K['@
M;L+("S'Z.N0>>JA3:LRLX7-G-HM(%]B6/ ^T-W0%/$'3;(*+ZGF.8&%"&>6"
MU(BA1W.]I^#H1?+F= B&<@TZ5G-L\<<?B3:XG<O^=;LZ\N>>NO9&EP!0.DS5
MT) 5D%M#!6RNH:"-H00X!CJCO@"70FBC@#0?..R4!IAYALGC Q2??I_/?T(_
MUR\*-<%H^R+#NI6QI7 P9N_LLSTO>3;A%H[3YT4O:INVW/-FKE-/_ZVJ P8E
M>D,PLCS2S*&SKK-X&/QRP$IO8Y/<X<@*47;9RL\BR<8-07X.W0$I&ZK2-?:"
M7Q.6*5;KF9*3-E VU'RXG11PZ0U(GZU<OV9#<^FD\XK5&L?7OY7]^NT"Q*-H
M[V%S\\ WO]H3?6Q'7G'O+%7Z/^LJ;!M[-'YGG<,MYZ8C\<374<&[+HWO#*TM
M_+AOJ[AK3^B2E>>-BNO7]CI$W3EF,//,U/LGUI=_60MJ:I9NW'<P_PI]O>";
ME4=^%:I3\E,BEAS+!.Q,/4\%AH4?B?"ZU4Y[ X!Y@ PCH[%8]M-D+$TJL2+>
MC\B"]_)!+!PG-Y'?8D62>2&DU.$*V*&#7VZ/>X4'F5(&)TO#*QTB)=YY;R,L
M'[5QE8\C7$T:P,:C!9%VTI'L^.M7?9?M"^QNGEEUU:,!NO6NF.A'V):M\>VT
M:W,.C-YDXG<DQ,(_:V?[GQW<",;6%XPM=E>9Z@\JW_AX9LAI[I?BS*>_6[(D
MTWZ0K@+J,C"OL#%V_<BL(\#%)!9!ZSQ)DF/"M!:+C8%QTF$\<H M8J'9\;AX
M_X?AV3:<P\0;10,2N^+\0WU;'AV*""JY5O Q**HA/PJP*8IZ^.Y@J*0YC'B/
M]E@P_Y'1V---?P3]NC=R[<N*J\MJH\9"3%JCO^.V<H,WC/?D%/7^Y.!G[U>>
M?JB*[V6M[:LP<WV97=:)',_C/>^862^^6NKST^=[BY$B+*NXH08 QFZ/-+,!
M!1?U!,;:L?HLT0HK,4E8&'9H+Y.@(,"&-!DQ-FWL.%_ 3SYW$^@NS\6!1B5W
MM$4/J=)N-6\.*"Q+5G\JN>I31$UZ(]V9]FXHZ+'7G-B")WL^6E[YL2XKRW3V
M=?-K\G[!J[-:K^U9-3:XK.V=6;O\@G=FU3(77-O5>;1US0_5K4<[N!-M37<F
MP\4WR\6Q6T.]W >S#K0<"ER]?ML5_L:_9U)BWWRP*#+Y$& (!XXW=,BZ<H)I
M^'#1P:@3'3O+)8+(I)?2.T&])VX[CMN>5K_=%V&;&>WSX[ACE9&,NL&Q^&35
M/%F.!W73.HPR2LNY(#LYJGAXS.\ =2@CP)N;9.VRM+QUW#>#O/=Y!_?A_M4N
MAAE;U=3&\_F5S\\SJ?^-_;Z^?]QDA6_;6+'AKM)6[J;UOJW.4>NDPY4G6/<C
MNH*V72V0%'E>ZB&W.P]$#9\L[MJQ#+"3S,[K4RWQMWTY @+#"TXK*/ *'EV'
MR\AA $,BI(W6W5<]!YDSM1+[2S7Y[>8X%FS'%EW8ME&&<77[9_R]!8L_SUYL
M":DNLW_30\S\94VJ!HS2#9GO@-\RQJ361'=8H+X$_32$I;O=^ RWJX/H6J@P
MF;%0?L?7%_SX%JC=/=90"@I+V+(H.U_#3=YE47O7?'+1/S6>\_S/LJ0_IH\!
MMAW,(U=8>[^D?=%#S6@(QN<HRU\]5X<31B#85@<+6[\.O.E#PU-7-56V.<?U
M^NSL<G*^LW0BH 7@&B<4A0Z66\267)*4509^++X?&3#_<]^@_??<#,=HI^$O
M(T)MY3*W2_2K\YC^?]/Z75U=;UXMRWPC:6O;6%*B*LALF^WX"W5DZP??WJWJ
M8Y<V_!+<J'E54,6KC*:FOWAT_/?GOP0^B'']:9//!X<_"5_G&Q]DA13&)(/6
MIG!XB0Z7U@Y#.EP[^2Z>\PR[;,7+<<(MSL_ 5W%+^"JO7=A(EO#9$C*J3[U$
M^G.4N#9F:D)H%+/W,KK9)/[BIFF<RK\V-%JDT!L.Q Z_$+ZJ9%W()8J!4TYO
MR\4'M7>8=O0L!>=2%)<-VZD:<N+=OH<LTHBSD4#8,#Y"<>L45G 69HD#)IUM
MYL(B1?S.-V+?JE::+;3\9F*<ZSWB'6I\?F0HYW]TV[K_OS8A\J8NRIO"&F_+
MWW3Z.54=TY3_O*-$A3C*H[:J B_UB0^^X(/JC+CH(DG@JPB7.P7%IZ./KY;<
M*7Y0R60[%I>-71-$N;*/.^LONMER:\RYV-ZGY<F1=N=-#CM:QAK/.&PI"*^,
MOGFMH&;T=?ONEH.#8(_DN_9=JM7%BU:TO6Y:EMB;'O":\G>2UF8"Y5@LZX^]
M5S^2UE(68[KK[Y!?_-15VWP>(D)&PM_C^''UU%4+;?)&S3_CO^ZSO*_'=(L>
M)@9GNMFB"TTT5W4X^[_>(U3I<(%FVNM%8P9_7CS]HSXN]?V,L)^_NS*;* .I
MHV>4A<,^V#7SM7=YUKY@8P-001@^7#"P#E;)Q/7K8^08<TTTI%N'1/,O\A>B
M!.0,>./Y\XXIJ,8VL=68G$MG+@H_9[/XXA.C)FER2;2OG_OHSHX3W,Z3U8GH
M;*!VS[*8GU$)^VE22/<;DBP;L/G6<.T1/23*ZX)^C36N9I$!;G)T"C^E#]JX
MM\L<XD_$K_=E'^2V.W&#_8Y$8:(E2.S=:5?^O-.9&K7[H,VDD:U_[INV>)]=
M:?+5G$(N-_N#_K+RC*+W3G\3\X]&N-:SWGQH4#=[M3Q1G:TV8JS-#Y5$N$>5
M?;@AOY$MD3/<"D*V4*T;V/+.W#=O#M\+?&5\TXY;=COJ0# ]Q,AK,Z@NIKK<
M++X7[EZ6\2;_^)/>@Q^SM^4\[.ZE6AZ[V1Y162TL'N&"?D41;=W=KPX_:K3J
MZWX5%JX>W=;5<OW+T;_'R1^M*'/HH:*#E9!15A)C_7$%5A!PL8IQ;N" NW=)
M-5-<:IC3'O^DIUOT*,2JY^<UM#D3Z^(+Y-^US_IQ=N^_$]?\?>LV6ON<'J(8
M ;6>MP'Y5F3GGV>PBJ3V0,J?9TG@]Z2>Z7I0R:\,XZF N(1'7#'KUNJA>S&K
M5VC?$ZL*9>+AX+](T%IN?:8VUT3[G']DQ,M7C#JA+11+SBE/#'0S^N#VN(<^
M"H[$1]E<SY(01*ZN[1%2T+_7KF_3=%^H4&@$[ *+']PLI;R%3[1O?]89[4?]
M_M+H03Y.:_KO$T_7YZ[F/=P73_EE7'[[N*'O'=*>=M7=2Y]%>YY67_(-[C$<
M\KCUH:SJ6759-C6XT>/6\?+*\NR#]AG*<_Z)#^ENM=EEV1$2?@*RI"BB-7"@
M\N0!R\*DL]9;7SNZ"0+\XN35K@X>3>YQX5P=SCCT11_,;-AP4_S=BZN?SKXM
M+CRZ\@O[;[H^I]KBNPX7CWCJWM:Q$*\@[B5%5_M!7AM7TQ34U@79IWWN$N_[
MO?SF9%_7)X><E$\C]YYG6MWZ9)?Y_;&K@N[V)\XCMN3?VL[F6!DY[&P;.?);
MNW/QFC;Q[G;GG@73Y@8.3L9?WQ/X5K)U8541]>#22XY_V'K/2/OB]N](AG\O
M]\3!53[(*J=T!NO+<HK)"QVN@\4Y@/_*).504P6I6X0:4!6 ,9TEL-#ARIN'
MUQLEIR*D$OHIE$J"[2I$&U1+?Q./%54O_1R\8VJ,2OXA+^N.<^)?JDN;:)X[
MUN7YSFA-RN#U:N_P3)QJ"-T:&:7FLKA'& 'ZR_H%A,NIBJ2VAI2^991D&_U6
MST65FO"BAY&-#UR?.A]^>,<QVF][Q(<_)49;06_U;1Q)U_V_ %!+ P04
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M&QX]6B>&F4H+SJ+B$4ON(:NB;6R*Z!:%:2NPR%SY)H858$&*2%8@+8;U1".
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MUP;W#E^[^_-]'G5,B"IT4D+]RKC!Z_E_LJN\S-V.K/.ZP$X14#.]>*@-ELJ
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M)%M@D\H3Q34XB="D'Y)4=10 RD+%QY?_UE(D,2Q/>@KW#S8DBFE;"=^6U(<
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MCGPE&%M@)V$^?V&V0*-,#+N"3[&':"6LL6E4W?8&Z@N\Q5EZ2KL3?Q/65V]
MI!&0?S#[-]!G=B9GE>D$%R!!B6IP&A5U*YP"X:_5MXV$E?&IDMG(O]@7?W55
MH%C-_2D(!NH8/:8KY\$7HSXB%E)7^* (<&Z G,- T\Y6V0'Z5-Z89$HJGC,_
M]T0,4P\BK)LB*>"C.H& [UW*O@8C0:$QP(\?W4X?CQBCU'RQ*J0$XAWHO@0-
M7DA2=Q#B<Q$=NB17*->_5("#VOCF!#_P'/D9/O/D2V Q^SFQUQR5:*E'4&8'
M'1?HA)B0)<W )<4V!X$Z[0B$D71S4P,X' >B.!LBB27L;MZ.S[XEQ3/TEW5W
M=%$!N>2Q [A$A+Q^V$$Z1I4R1F'D2V7A-ME,\60)YR3I^,/18>48&&JRJB3:
M06:.E<0U.P.<E>Z.:HQ*;Q)5;XFL/J,T,J9><IE=ELN2^7PG0KJK=WP6+U%H
MV6+83A2.=$?%:.Q Z5."+HA((>BS>:G(G=D76@!ZDD"'PR=OP%.LP:Y[ EE.
MV;V1,,1FB&P_LC3>#=^('W$9"./W&" 8ZAK#1N-SLB>_P=<3/WFRX@52H :'
MG&R)X=+'',X G;0IW.8QR(&!JB)WH$:5/8"5*DZ/RX\MEK:54/5*OL2ZY=;6
M#?U+;PH'F[VXLOYH8"2>H'&UL%NVL^PY/M,'^!Y/<_)O$MXE[O E,D7:PGAT
M!UW.E8U*+F_&^$5S-(<MK<0PF4V;F\- ?0^H](5Q<?FD,@[>I55+K_3QF/GF
MM,W^_G3?^/C[;.6S(]0)XA#K56\<*9"UA8 $5A,)KI60A1OD"N+:)8A!1$ )
M-GT$6<YX$*J+J-!OZ? $\P.?\)JNT*S+)25,&O>EDSG"6_-KN"1+@RB]&,Z^
M)]#/=M-6-7#U'D&;$ZTH];571M+S%UN5!?8 ^5Y8;RQJ/2H EZY^&%2^APIP
M0LS195H5Q@@[0;=4@O(4?32;BZSBHP2V(WIA?[4:6P.]71ESI)U&LGX,^I90
M]#UU))120?!R-#T_9+G;CU0T$TD;IGB]ELPR+E9^GI+29_;&FR?,]X"W/,'%
M^WQGJ'K*Z35E/63RG6U#36H]A-=I0ZQ'JA("071'"]%)C8 &/J0 WQCM.>'I
M\R2V!@U*>([7=JO-[$1L)VCXL^=Z$R.S$YL-G]H\E;BA&TJ1]D;/(> D+&NL
MX#71>+B2%%!A*(F_P,KT=1-:PC%LW@(*#$2367*"G58 =+!1*>TY%,7UI7'I
M:H3]4 P;O7U:W01"PSM0\GBO4T-:P! ]86E!M7:(-/5X$I' <4L6'258")\B
MS01'H:07 M]ZJ&NJ=T? 6Z")^4J &B(X ;9MJ'6BP_@SFE :,,?D<:E2 G=@
MA$&"024=M21Y;= M*;0WD2C?)W!F.RD&!&9'!GV4M@%T1%O5@+F5=*B:3;F'
MEFF5(X33A_1$BA@Q3 EY )_M#?!B+"W83G?^]"&<$SYME0Y$;!?I>,\BY.)K
M),W1; K25_R@ J#)%Z R6N!=*\YSYH'8QFM-+_!ZXVZ@WJ-5(0'+-Q(Q6%M(
M5RD[ T7'H*@*@?6P,4].L ]0;D?O1.-9WOW&#8*+J%BB ;&/@@CK35;Y,HQ4
M[_N2RR$Q]5,0-%,F29E@-SB?W]V^NCK2Z.TKT<]Q"T?4)[_/OX =?);\[X?.
MKP\2*$[<B )NZ M4N7]*J$4>!1VB.N>[K5R.R:9?O/QP*>1Q2+(H%?N#M[(J
M67M!H"ML%1T1?4#M$=CP3Q.'Z=4X)F74SQ&J*A8<!%?G\T#3=I2,P*W$!J0X
M?C1"J?2$4*%8-CU]V=V_$1#%:2=PS74GR8IC)@V5[K,&:&;XYEJ88$PB,%^R
M!Q"B+1CV=%B%ABNH3M9>2.&;'"AC"U4FHWK\? ?0;J **Z#1,:^BYR%SLJAT
M;/?U<MVGS;2<J-)GZ3I_:?WQ"&6.NB+)(U*8*\&BXDC;A1C^'DG%6=%Q/.B
MM$ A=@HWGP3V^@CI3@O.0"\7'K,D$>B-EY(XLJYM\G@X^T =AY4RJ0E^3[0T
M>,%D5UR^ AA^GN5M?_@\0GW/0*JRLOI1X0?03;"#SR9U\$99'8AJ_R[T.$FT
M59]_!N_@!;& 3"XS.YEH)8@&W#K("+Q#!TDZO7A-/[X943Y+WZPQ8(3>B(^/
MMJLD>!7I)2"+GD]XCGE_PGI>Z%,FC:V,W9"!6<^?L.JT.G/&=A?JW1W4.GH
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M>IA?$E'<1<5?$F ]%=_D7*H 8BQUB@)4I..:G3!^QN1VD@0$L#X'HOW.0Q&
MLCVYHY1+D87.D:2@^\'J[YSB\K5KLR\VQC)6<H*KV&_W#]7T;L&(]H':]Y;U
MZQB2V$.'Q3#;OOOGLI_U;G_JG%IRL%/NP=<#!;LZC^4^R'WEG!K\9;Q/J^+M
M8_8Y^5(7YWO[U#'G;J;NVU7Q]=#;YTP/T]L+):[S^NFDG:%463R"*0^5N0R$
M.J1I,&:>]TX)]Y73:VH0"J.?YEA;F]&%^%NG9#&E@4C%UD'+JU,(Q>DK,YKQ
MNBC?>C O[_/*MZ&GD"U'?T$*1'!;Z: 4@R2]I#,AQ>Y*_UHS7*./F*LUGXSE
MJ.VWT#WE THG+GT?"<UM\;+I_S)L3%&8$VT>K*BAU'D'JMBT/* $9+Q;_/GA
M:R@N5N)K<=4S2#)0U39$<,B[,2M9.88SIDE/6>[=[(7U#+XA(_):1<15OVVF
MN))3N@/=B@>NMK 4L^O<3/6CM;H^Y@3GE<PHF31>>^B'*9[)<CYBDF5R5(M6
MU/Q[U;BB'.Q.#5DSX_B$YJNS_0X:#1-HKZP;19$K97\UL$N-BE1V8#A::D8O
M1HS-[='O!K\JMDQ/VK,V/@8_*,-[3QU*#7DXQ &--:YKF;YHUM L\;0KZ>[N
MWD(#-2L%_@STAM!$F@-%F7""W@C%<(-NOG/F1%%WV*E7%+)F5U]IL *O6/"U
M)&CF<[DV9:$Q[_V 4953J$:RQU#F.#O^X.7XS?N2)\<V9ZE&!6BX5RRP3RB9
M/8V#I1\L.*]DQKUPVG?GB=<*SNB0N#;VC0M#EKJ[G),O!1O8N[90#WUX=_/F
MJR#[X!SL1(D:[E>^Q;&N:Q=]KM\^4+D_:+I$Q_6NV]<T\T.'SSL[%AULNX#A
M+Q^0@'OH8VL;19(G#+/A(<S@RHFMS1GN<3#8=CO-P^E;M*4RT8J"$.'3Q:!@
M*D$9^":PUJW)\,2*CM*N1NQO<'P;5@@%_W[[S/ "/\W6QVERRR5LT(&SFDE4
MR@ I@)?DIBX-W/,T2;NY(M("$QNJ:NOCWGW&Y!PY6%86>+ZQU,#[7']7T:?W
M)>^3[18K-7Y?B:!FB*0)^TA).8,CGH_R1]J(B*R=0]KW_M(>TO<Y_1)/<GIT
M]$J$'_-#P>U4W\X/[L.HPR)1W]P\%'6XW;5]L/?6A7RE%*S,&8<<X\/631=+
M'<LN7#R0=UB.I#CSP27DGM\AHF/7'ML<3K7]GIV,[0Y&G9TR1SL&<DLLC57^
M#/,[:<P9?+DTK.3*]"L[U!Z*L<\S,S;OZ8H#2 RZJN!D?3U)9CH\LOP*N_-I
MA<^[K+$_W/3Y;XD3%8'';!5'TGM;W?=F?3]_+6A!ZH^<!8(CWTK@"C!C9UT#
MLG*^%MK[SHGD4OK*)SSWIS&_#>3T]XO<[\;_5.D<!DZ?F7FT_WW!$MUQX'I-
MMZJCX=F!A26A_KF8H/*:.9FK\?V=&SH_/8W7&DL^YS%1?:2_)M-),_.M9EK
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MRG3:3.P^"L&[2+OI_KWW)$.G_CRWB' 62GL&D<^ J':*G."F\'&KLL"N#WF
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M+$A$EF ?]!#H6KGV4718("=\*M(@_ Z1BSYIIXFV"0R!.$I';WR^:LH*":*
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M:DZ,MZ^W-N_/<<5I8OB9\#O\B0&)Q*6M%/N'-[JP:99%3MQF\1=L%JQ>OZJ
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MJJ.JJ_;.[P 7%X)E&C.W= SVH?T.CF!G]B/H"9"[T [(L\C[+U0,242&,7Q
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M+ PS?K^=*.*VLDJ_*K+?=BC\E9D0@6^$VP^AA0-5X[.:1!GHN,#")>^Q,7E
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MKY(8*W&=4Y<'#"=\'7<R/!VK$"@0U[C:*JAN[S\PCHJQB#"K,J'R.C7X6W7
M7E2-.RM@:\TB@W\><7"G;1E\2VH34BJD=@2<6BMM3]5T]NKT5AZC]&U+J\->
M[9@I*FZI-#8A%<3D(G$;:XI:+BVU#<FS7#J2+P[8#_RJ!E3-^-XTJICW3FKO
M-7B1-L<MRJ+*W/#:DC:K/? BFX\R^.XUCQGL9E/$9);"04XPISM$@I6*+$+;
MDQ56@,)P MPM;T$D\T^)PF$$T[#MC/F5<?=+L-L3^G0^'*QN,^<E6W-T%"28
M<S$-<YW<3!/#PX&*R]N#+*W<25-4EC9A&&U= $N'ML'!5GW&(ZH*XK9,&V@U
M%D=:UKTPWJG0F*X;E<^4*@G !!2 &V.#36-@E)0BMV"BG1U&U9#!1Y-'!I-:
M+&K\M_M!&0&^"A:DIPH_I7L'6R9+TWV'>OY2[>FIJ>R\%1@Y9B5:\FE^ 0$4
M0*M7I[D1&6;_2)C*[0/N4O 4HP(57;=$85I="DI1*IUOUARC;>6A7"0%QSUU
M]C4,J>PI?PFYR)E6D%2BECR9_>/4GT3_ ;FM99+NI=>%%9.T.ULZXSBE$FO[
M*C\O7VE+K<F7^_4W"\G-+_O>@E[J7F2K5+%:UD@1CYJ'M6VU@T4<M[@5E[C3
M+Z;1.$O.J]ZBK#G%T'9(S9QH(&&DY@,F)U.ZK:ZWWA^5ZJ4B>,4S9-^+I7Y,
MZ:%OAJEOT<CB<_A]+0PO+(4(LIKL4 L+S(7"1D5.#Y)4@(HCJMF7/4#4.-^,
MDXHQK^HB(A5K A1%M!JU+*Y"LFE*G(O0,3=3QE3(TSW)!D*=RLB>:>+$HM\.
M0#Z5QV&R1L'?L[I3IS7UM/2DE_Q&M[)VDC$4Q*EE<LN%4%5574T@!CPC$HYG
M/)&8$C3E0V#\X/?2E__^+3G7!G:RJE*V#?X&+:J65/1)#RSM@8)U3F(QT?F"
M\0<UB][1N,B:I(,I6]OR%Q7:MAJ3BC[ILS@%:"W54"$0M96]BJ.',_Q#9ZI8
M<L4>Z0FAA_<6LQ2&GFNF8)4B\!E!TJ3L7W7BH1+XK_TC&R:CB.FJJKAK<H44
MD%I6=0\RN"YN)/OE@=-V!FO7:QHICM8A [G,N;'-<=I"A;\\_#4]&WU+0(M-
M0H.;S5S<TD[5-5D:VHY>Y; LX?[\856E"Y..3F.FON63ZMD7<3@J*/!QBG.U
MY^N.URD3^Y%/+Q=)KMM&GGZ[_PO<&B\36GD!^PT2;73AQ/R)-R<V:68/INW_
MUM#B*EN]DSQ?4&09RA=$GLLP\O-OJOOLJ_VPK9DV^\W!O4G;-*#3>#D8="<D
M039S L(F-!5N* D>#D#QV3%LHYD>D'A8ELC Q6;&KHJ3G"U!R,)=E_(&$I._
MY/]&+0=3(B\R0E3\Y+LL9WIF5CL3L ^WDA(=_^:\-/$[^Q+FI8*K14VZ$^#L
MHN42%,!^F.<Q%QC$#YI:VIO+9)Y79#^L4!K_4S'-'%Y=:U7P6QJY>DOZW8J2
M4JG5LM%A]]>L+O*$X;U%UNNSE[_W"<]\#ODQ(XRE?%O0#(9FFS/GZEQ:''T0
M?4Y"5IV+J]?/4=,Z89>E<]'11QS/X47=U@D; = D[E1K^X%B5!1"0'1R!"OM
M]WERY7-& PC?H&7.5%_-\/)GE%@V,N<B"B91@CNMH[<[_<^\#?1"2$>ILO"K
MYA;,N+BP? HT5G%-,2=\KE?+4,'-"P[WEOCJ<>A9T#";$*[K\3 /A33+GK%V
M. 98K1F3"CX'0\'JHAZ=SSMWW:T)^;ZB8%D9/,IJXWYEPU=&"E9\6^'SR$"?
MJ).1M_:E ZES'-[Q$T<<V:U[_FVBX5Z[@0< 8XJVW$<]1?>G+YJ;HPN3_(RW
MH\'E>/SXO6*O$8P6!:4)W_^DT8S_[_]@75O6.\]RJ0J[3S-'RMB=I>CK+!*=
M$WH9M R]HJK%8EO2ZS&\$R0OQ5J%@@KO*TVWTN$'5A)U[TSO+O<P_2JT0081
M-]U?]V'0@VM>SQ4RXZRGS:.W)A]VJ._UM2<(+26A_O291("S=I&*.*9";YH7
M;N+'L9S,)=1<8PIF/P=FB\)2D+]%7USZ2;PU,FCHOUE@6 [ 8;I'DE[MZ+QQ
M)4+8KMKSE]><#,/7'11>?>YT<K0KIK9)E:^5>)K;-T5HL[HC<9CM7S^,]ZQ;
M!N)3XH9 ,7[.16/^;[)5 6,XXZQUT4:3CBSEYF>,?*!@<I9[(F/\![;\P^D&
M]?4)L#;P"J'Z\32!D30^ 1L8UQ-( A_$GEMJBUAI8QSV+\0%%*'R+ __C7?_
M<R-P'^X4]'>WO_^;?]J0'I*#3\+AX^'K*B7=&%5L8L"SP/J,[MK@N,G85P%[
MF+A3[P"ZA5MKL8S ?1'*O8NF@JNI+N-VYIG&V/+RBAY5F,Y:/00GP<J.E)7#
M>-"?YJ=#>JP*)B>2/^9$Q.8WSI7)=#^;I,QIGR%OPUA.\-,?K9S@HQ5P],Z@
M,QC.DU\7:G:-L\"#$^$"@RMF7P[9,4(*X,D!U5$5Y=I_=+4QT\79 /1YQL:V
MC1#DRH!@GQ53J9WZ%RBHF+X]]P=N<MD'(P)77MR#?7O/B=#):CD3Z+?A?Z/E
MV8>1P1-7CS@HXMNN_QV?B<+-I+9"(Z$G,>Y;#!QIC0>NE@JYQ'@&%0V^@4*H
MZ,CVW1_8;*[NIKU@3,Z'OO147'NIA#__I2H]$%D#-7GU3!D\4<V.8D9LZQVO
M5L:V9_2DA@)E4-%*,5F7![8^->@7+-IC! Y%S=XOVVT+U;T4B<.WK;.\[93U
M78N@3J7^ZD #1:XLHS1>A\-JZ7_O.DLI*W88-)D 2NRP4<FJY]L;[]WJU-BP
MB8[^?&5&L$+R3V=)B?(Z1'7&4[ZG"B+Q;Y9^.SY%ES/NNU5K18G=]Z<T*YLO
M)>LN3+,2TE#<O2Z>9""L2-]8_(K],F %P?#_;G?$487Y+H.'GH>I4[*C@)RH
MBT<<X-J&^#EO/PHA&TD_A;(+Z/KU>,T?*5\-6W:3&'Q4<;,J*[@\Y(<8)^&S
MLQ/*D&316^?0SQX:\#DXXA@3>TP\_/EZ9#XHPRGL+?U]\)Y2XH,N!_$6<RX/
M#,.Q+S1+D-$14J,;80]*"$,+Y[@W"3*V4P&AP%.H-OD&7=JD)M5HH&:DH?_/
MW+!G(MFLBHC?MR&^IOXL3.SSEU@7%MV,V)9F)>Q#V(_(0$GB*H*QKAM!B0\I
M8AF3OU=B6LYZ3T=MU3LMFU\RH9MTW(5KEF5]34E5JWO$J?ING.2^(?#^W]'3
MKGVW.Q<&LFZ*%/_>^L@4\.AT6>HO GDV>@PV2U=]I"K5-)3]3"D_@.:1V,^A
M N9RG;+3*-()>T"J"Z-SSC%8E_.?A.U@QS"LYJL*^>?&-C.2(=L.J.)7KRUS
M3@MA5;?#"J+R?G$*5 [4!$J2KZ=0_Q:L0R37DA%S\B\BS-P1 Z5//U6K='H,
MG(]1-A9.BVKFAYUZ>NNF"6HX)O^5_A7+O*]!@S<>%<?<%)+O%1#^5"TH.5&3
M]V4/DVU\_F313L4=:QQ_(LY4$INLZ;&HLNIKJE*;)PQ#/*T3A]X;RMA9,O-4
M!-7VPLU\J,VR4058'81H46?C\$<C10/A<'[<64\A#H&K9\@)=4!(R$F/]SWY
M;Q-UY6<DQ.YU0/66WFR836A>#,Z>(;/WH]4!ZP!SZ)>UM0[G"[@\N!N;  J
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M=]7] \=RQ1KPW=\2%+5D&"S0RY5_Q^XE%RBE=$?-V^@PM6ZD72KL9G7@/YZ
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M;8Z(?%KQ%!V<,E!,Z]>MI?2\YNN1@)9! S(V@XL;LUYG$\)Q+MY,4 8G);>
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M]'NA2V'\$*1%UU\\.H#<V@A3:Z1J1O1](NZ^8]P:WS>@RU,(W1F0&UIWD&>
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M;6<!KQ/[Z[VF4ZK_EGVW)(:7RP.$M_]L'J:=%C/8&0,H5O\S0"R$9T?#K4,
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M>?QN,G/<*<0^JW>)HXF:7LY9#RM;1")"0&4CTZ,B*6< T;GK-@J;#*'(;V>
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MLBT^_)O;/]PHAW:3HS!)_[XM<P7HBWGKR)P*QZ.)-7OE)J=0U.!47NBZ+RC
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MXNQX="UT58UG<M?D:GA)Z,>GB96F:TKP6KGNU>A*_%@PT;7(8/$^M&3U^L"
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MT1Q=TL<J&ONXWB9F[E#?@GJZXJPW@G,8.^JX80$-%T)Z5'L5,)-L8G:54I9
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M.ZO/,G<G5H&-Y1 0?Z;?KS 3*\O>I\+T$H,P@%*-L8D6VBK(RS XY/C+5JM
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ME6V8)'%P5@U6?46<59RW'QR<$KC/\@!F$%*4V>7^V2LX9+TK95Z7GB:+\(U
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M';[[>:B@2?"F*%]G9U/)H-6G3_GZ>9NLGX(Z]8JJ'$.4V#*& ZC)#MJP#4(
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M^0SL^4TR_>^U1O%6R,3TJLM*01MY_4#K^)T>"*IN?\H4+<70E8S>&DG'_;1
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M? FIXA9?GJ?M\<811?CZ\^2J?SFE"N96V8I["SV;G=1XX*_@\>>W_.KX<$T
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M$?X!.63FSL9YZ+V7*ECU?^J@X+8IWIII$V8%2S[D!T2'NS/]>%242LD<% X
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M%=PD4M^BTB 5:6Q1L^/N\[QJ_0+_@"E:@AL5M%B:9*G/<W3FGX6E/C? 6ES
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MNM3RW54&+*W?2CG+[Z[O,_ [ZIKP/VBU3%X]LOLM^3O ;J?D=ZXO,Q2^;-M
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MF;_=25/)6S-Q#&9Q;4F)D#^UXY3X4G9CK-1#6<4<\US1-P/)\:MW5YFD,J"
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MTT%!;BKN>/BP@B7L))7KL7N<WUAMJSKKQDR=Y,HA3]E>$HF#_=R!AF%<6GA
M_8Q@CN.&HY'T'@?44G\H42'L WSLJOO<]91/EN*K(4D7WET^D+BOH?&/ &S7
MH8QL65F]S@L%9R41PY)+]79">=+Y?Z6'SA;3IO)?)@&3Y0;\3]D?V>N SN#^
MF?9C!QL=9:'-1[5' 9Z/?C3N)P-N=FB7_=Q$]K.Z&_D(*K?%Q]U3 Y54MMDE
ME"HKWS-\ZWV[+CKP+JZDP7KU[B6@!&O+J(OE5(<V#%[46F'O,1?S-!S.VSYM
M\S)JV2^RWB['W- SX.Z2<[,>T6VD+O>Y1RQ[IYH"Q&[6%&F$%"E4 ;':C[8*
MBY4)%>Y@7S>W>[H'6&*>^TEW@.YU1K@R5#:ZF3+A+&-:A194L:>PCM$E4^_V
MA*MT C_/Z;16 WZ:3NBX/_N?N_RO77NG6Q.*[ ,DMB%C%)ED^_QG;1TI3M8S
M2DY#G=[[#7:I8"^M.4N<D11'NNM1'_]8%?_JVRAZ&6G7I.>]8,GRG&OJGW4?
M7N<2+/I("L@J0HRK6I: ;QF;>SZ41PI+HB0K1GL&V#F:3<O$PQ[/'+1LY8-A
M,A)-S!UR7*&99:;Y8#A'QT<DMW%6&V2@P0PI625TW !1/'GNCV2\'QH]=GWK
MNA!C5.G].[<:WVX:.G%0I2@E@"CC9F_"HI5#-VEMN+SX61G NF7"UX7EZ.<S
M2^F*$=>(Y!M]$,8:7V?AUDSUP#2;\N0=:7D+7%"-YKC5Q'Y-D(:LR5L9+]F=
M,C8[A__6LH&^C7;^;4!_T";?Y^%T1G(?T+\/T$]\I?C9PM[M=-@([>9X*QMB
M?%(AJAY!EDUTQ"Y)#"&0KA^:>!5*D<9/RQQ$MIV%31_4@*:$_SFP>*M)1;8H
MO4R8N*)(@5>#V*<D@H8\KR.)EDYP4 H7M:LSG.=..XMI"+#[_C&FK;[EH5!C
M6[J0U,0[&YM/[X#@>UI#2[(488(1LW[MGRM9_?#_I+Z]NU?;[!Z]?I& ^<]N
M@MN[V_VS%);.8??NKXCA4CKQ;]\$BZ]E_-'PVU)?/9EYS7*__UG^D;]9.4U"
MD:\5\+HFB..D(6>I]@SVO4^\9]W$<8Z9W85D53[I42.5W3EOGH33;]J%EF>U
M'A=* $T5V 9(HVQ>F?0E4&3JV[L9A!Q+'>?T#]R7&-_TW9G>C_OC[6L)7V>Z
M,C?&*ZD:Q.]DDF?JP/)H(K#JV:A?Y79HP^^YGYNA0951+UK;/MQ^5FTH57KW
M]-3B1Z"&AP9\(+W<(^GV&]_JFCTA[3</LKZEJCUC5M+[2'?UP07T^'@:O#8U
MG&QH1;G[R5:[F + KZ>64]"8-NGJ3"$!.4H\BO*2A</:"!T'U_?]X\OXJ[E-
MN"NU9%3LBY%IN.593>IW)=:Y<*5+<KDNIN80YS7CP%>'<BI)=:MH4)I ,G+7
M Y2=HVQ:DF-M4JP]?!/E6.U@^P^'$0T4V+Q8FKY!KDCY/?9I2>Y'LCWXR4IG
M3X+<^S)+\TV#NB (KNQ&H,=,_[2YQV1)7)DR*-7+R/86LN;*.=W;('H>)F%@
M)+GYZ=NHSHVXUU"GK_>\WDS84KHQN7]/ENIO*/V0_>/$D"P>O=?<^LP$7EM5
M14$:):Y^/H/#A)PM%A#S@-NTNP[+7D/KGH5J@P;-TBE[<M;]]+Z9P$M.2E36
MLT]:$$!<9+WLCA49AUE2HAB1#9^<U76[G9G9Y?>A2"Z&E& 4E9LRJ+6C3A8\
MZB,-?/FXI<E#5CS,2^GBG&>)Z1(G:24I -@A)ML>09$,T+09S#3'B65SR;8"
MS.^<[HH2>:"1E+<BTKAR3A?KJ$&*3P$ZG;+]KP(A[8Y'-T_W2]E$)P;JE5KJ
M(PKX5+"/'-V[33KMUU1L_O''05?7-T'3=?<H]=/6"?(H+X;PGF'R<Y.1-I7>
M3XF#O<QHQ4\1@H( 0<JWC,9&%;6<WZ"B2AA0XJ "B^(@3E7_4]T_I)6"UX(,
M]!W+3 \[LCI>J?!)QJI*8LQ.IET?R0],^?F]RMY2,2BQ6DMQY4)#FBB;*PC&
M;:5@ *N6&PO7IB5'G6];_M?(FVR8DX"<\3SA\;@.IS)HZ);[G5>UTY\IA:-?
M3>LP#P!WNPXIP60G/&)@GVGK)+YWG\.:DF(#P=EMVUYNFN%13NZX[^,MTARE
M=1,*?IK&#S9JDNYBL*,XMTSLP>\U<<[<$O.CKL+LSAIH$IL EJ S%WW*6UD,
MDP>11O_W]''$9/ H.?A(D/+A5&(1RD+@[.UFH I-PCC/Z6XL#1)$XE<8G.8$
M>T[6V\DL]CBJ6S'TD0'9G,:#"SRGH]^>RTOZ8RA[T]H.FE-TC>S6'WD!VOR4
M@L(C$I=9]V"N*YVZ3[+ZK)8TS]X?1LZ6NW/39I7*D$.EGCR@#.5TH#R!%TK
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M^H\E*A6B^V%62HAZ2TOW3TDGEU;!_^_+KO__GZD2@([G="%#6MMCSN=T**Z
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M03JS0!YEP_PW61TE_O0?15[MT=$1(M-"\PUN%!$C,PRX<J'CZ4]&/CPQ93N
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M+UA\^SN$=5@1BF3A6*T[9#3)8.?"DL*KO/- ,8E[O$J<;-O)&H54( LGTVX
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M $:>NPN8+ZW39*EBTU1>XO'.[26#.-IUJF$M!97<YD'"TLW#"\^H)+URQ6B
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M62$C _'"/JOZDAO2W'H! C4WX:NZG=MI&IR/4_1ZBEXJ5:O\V!"^JA5<N.6
M+->RQFQFOO 2X'81GL)FGX+N3VZ3CN_*6LH-#?OY/D\S%8!R30P@2.I+:2_J
M;>* =TD1\KM,]OUCI2>Y876K09+ZG%*SAO;J$M:B.:8.:KYEW7XPDP'^:'_3
M8G7]!M[2(>7<#*-Z*:LUBW0'BY4"GB&_]&53 6KC\6[D+ZF;MT':G;PTZS_X
MZ%.0)Q.+K6/6 PI71![/1)[2@29YFM^J+L3Z^AVO4D?Q][Y^C_\8/?6L^B-6
M]%P?%Y(\VY[:@U,@=R3^MRA*8I%Q=F1XH+:!_L$@+_M8R9@#%@R=\_EHG\V
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M7::: ];'I@C/SR>Y5 62<-PIZ"I2EGJ50HBD2>MY4<K->+UPMP%(^+$:T.A
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M[QZ\QC75[+]M%:C%B7.6AE\L\ 6*QS'8RW_^_I$(I!Z0.\)E,);D4' G@Y\
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M!!;F69[3-2A#R)=%<&!]X:/LIY-TLY=D-HY3VG3!_:^S=J=(V#G8]C?$*7'
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MHM8X;\4ILN1.@-Z)I'Y.4TP=CH]<>UG5DWNPK%_]@N YMQ2B+X&6FJ_\Y_[
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M[F!?YCBPIW7J7J+XY%J]DO>7^EFE'R6RL6:&&XURR;Q]%?HT*=AW*;[;U'=
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M7+3)$ M4+D[H>;E4T;_9[Y(>T>817##L$4W0;_F)*FN->80)$ORK:S PO#&
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MS<L$BZ:ZM!!7S<<V4]J^/HUDLE%MZI*"_HZ:H$.;QM(%T9DLT O$=>(5>C6
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MHV&#X'JA3K:DL)LT?D<*CHP(![VLH+EVATE&V/Q40@4/' 7JZH&$%ZO^>-3
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M0A13VS2=0Z(\MIIN!133;N]!OZJC$O(,8]1-3;KW!"NV[&@C/V=<:40BBA+
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M/7D_SN89FD$%C<6TB2J5@ 131#0IX8AK(GPVN,:J0Q/&@.C5:=B#T;G\O4>
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M 8IG=NQ2)CG]7'U"L!%#$)'?5\0S_AOIM=:$ZE9 "E2N74;J3.&UD0Z3^+.
MHO51.<2$"B-SV2/.+RV35I./0;X!9^@/@$#*HN-0OP7@Q.!,Y_>!LR*Y:(<G
MGHC%,P->O3-<:WB.KS@?>4)2_L!,D3#5K)A<]UD1D SMOI$8XRI&XTN'6+US
M01SV16G-X%2K7;V?YWDEO*-5;"J3Z[]Q]4)Y)A6"_?G,I[#--PBQ4,'DWAIH
M=J7]QE-@P@)?)&^IR^_DO4<2?@RFVB[/?D#8'O;.I<?@-;W_+"#@I+9TY"FR
M.!450[=:&4V..@T<T9*[8:<8(D#-QR)V*E\ZTJG&<5"J%YT(9V]&<P)" V.
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MB%6Q[CU%<">_D+*B0++P6(WH8HI<KL/!.4WC;R+7AW*RP:Y)I)N/*P\]?H4
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M4AZ5Q,O@W3[8RG!>KNW+S'EFY3C\I)X6U61WG%4_UU\ZY,.4X]@18R,_:[P
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MYVU?4R#E[PP^,-6-Z7^W+.!0'KR%\S%:54*/9(5V!G<HU8WLB[:+%@:6\$7
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M)\!IR2JNR*?&@,,GK)>^Z] K?S?-2T_S3RD]*+3;A^H,=K3+#D.THEK%S H
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MXERIFR_X5%%\MB=4(J",TX[C@$D2$8NN-N24J):]'HO6RO#66Q"YX>N<,]S
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MO8_#S_([/$B:..X>/I:%YGX8*YD;JSG'?5SE?+D7[YRPPHG47 #TM\DFP;W
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MB1Y7.FV9I9OYH7["16%,#O(SXTOI)<>>3%RYMAW'_A -IJ^_(9S7F.\,BQG
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M0@:-C09*9V*NRM0K*=6Q^U$(=I81"H3WZ]R/K*WUGZ,0H!FH;ZD=D<>8L%\
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MM5X6:+GC9WD'2,CMP)?&:"[9&QA-3,8)=W%!50DM2>N'(Q SE%)-'8 SPJO
M/&I6YUA?RVS(;LS37@GML_*NU7SXDT$@^8<PE$H@;LN1)70IJSWOBJRW@ HJ
M\Y.U@);D2/R*D;H#^ QS*N__V1[+^E!RDH>6AVI0^EZ_J<5W\1_W?^#?CLI
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MY/W\Q:4_2D'RX:EBYMU.!4O8KKM2;<8?+'YBOM*@%2Y6Y>DIH[N@][B224"
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M;$2\%-+BVW9+7T_YBIWG[I2XG_WGNN]NS?I\C/5?UHZ<NNJ#-*?Z.8G=/%
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M4C>A,N/M:.7:8U8/3:LQH=O;&C3CA2S1Q9*VUJ'NH[7'?TKM&W]7396R9XA
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M=KA4/O0L:/,IXXG/GVQ/#8WPG]'=R6GH]TQ0S!/CO:^-ENZ/&49TN?>_Z&G
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M5!.<!X"Z-$9?;9@JG;DA4.?2]%<#MC$G\#U1%-6%YM&712V@Y&@M/:-12SS
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M=_9)GZI]] @WN6VWA4E,$""KM2E3BAI=4@.L*,0YR4FR5G\:!/4!<IK!Q_B
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MC@D*]HK%[_F8,D$G"Z*A7\.H7@Q^G"@KIA*T)A/TGP'_E]O0KRFJ'(*#H$
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ME97YRX4N=%P24O-0TX2,.D>W',->)CD.$<% 5;=(7+R*\OT0_S-+4!Y$Q'9
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M_N48+K!G@0Y"R^O^8T7(.A;]50<.P, ,)PA-1!6^ R/AJ5]8JF3%;1.Z::;
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M5\?/&H6[V7E2^KU;)3?T_KH<!]*D69:/-$GVP'$SW \HRU&$A63@E<J\@PB
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MF=]>5B0U#"P+&K>M!ROJK-@:(Y1NC"+92^"A?BW7QI7L7DA@K1J4'A)NLW;
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M<DM"G4K&GN@UU3:QKMJ)[Q3NIYB>7/ ^$X3Y+P;6_#^!4,_^#5!+ P04
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M4T-^GEPUYQO7T\Q-['T0C37W:LVPLQ0^)+'^QM2@%\*>CP<0UM: !6SA@6,
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M;O3VB#'*\>T0^CDZ/B434@==-4,5E=DYMSXI.JDH$HR*=[[(8-@CD <Q\1@
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MVD.!.OM8([^FX;!)A<]90V*8$WQX#OP_PY!'<)6Q)ETAR^*3^8 P@Q!8X!L
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MN.:)(^#8!^:[FYV[ZG.U[Y=\^^6=%>=G_U#+CC/=H6T-QFE],19>*A=LAR7
M&<QZ;?E>@(6-1+J<(\Q#A^'6?VR<I'?1Q[@_1%N@RX!/>OM!@SIP&?"= 8-/
M#SUMBK C5\S]A!DK6-\:=RAL;P=MVZ>K6=\65W,O2MFM^1%DE"4AL_7VVZWQ
M^[]L//A#@2@O&J< !RFW*!I-I'#!"5$7S9('-Y-,_LRG_&D?8*1+C+B5$DE1
MP)/]LQ6,T9MHZB$CUI=@LF]VVM#$(C9-9L#L6Y)7!+'Q<XCIXQL2/&8RB54F
M1@ >5% /F;)$260"?J1X9<A%F+=H<9M-ER(QCI,NV<JM=&K+!S/3=XOV09:?
MC,DI-GNCHTH=C4>RN@I#B(:OWU0/<@!ZHMW6,T6K=3E+9$"5GPP:"#P(^_N(
MIJ)>RJ8F11Z)34D-.S%_A$>Z;3'ACSV6?>WWRT4E)=.E.-_1;[8.CL,F"U%Q
MENR+=<W5\9P=@>[?REWAU'HE&D:_LBS%"8QA"S-0-?H/7D!;><\<690-),9!
MHC3>&W<74R/3_KQTC0Z65\A0FAGV$6ED_/P4A)U(PRGXX3-_=-2<)>QLZ)OZ
MWN$=H[X(*>D<&]!/X\/D)^$&Z0INK>@CT9 W[P=2SH#NI?@RVC9B&[U6I7&[
M:TA)J+I3EHT]37H0<7/HL+7=VR"I$7+I1,C4ILP?%D=NH5]\('O^[O\2LSR+
MZ48EHEE?C%!C26Y>+ RDLLAW (4"'=%(_I97CVOCY-FXVY5VNR!C8=&VAB9_
MZ^Y3H!I'0>?4[G0'GR:K2O,>!R\Z$%3K7=5(<*%X-%EOR"M7A52,1/(F@JAC
M#RF &PG4>U@ *+/M&M;8I0H\20Q'@@L.^#EYY=(##ZPW<YVY45JZ+\=0_Q?;
MDQTK1MP-;[IFWG]0#1V<(KD:]_KUYIE?1WD..*7DAR%%ISE'6O2^W-3*VO?)
M7N/QH^G*SSY?5KC^<"GKA.T=(.JL"9@AJ=*QF.35WG8-?+ ?.A$EH^H%3O(,
M/(>>)9TQB53M(ZJ-@G<'VF(JRXQ- B^*K 8AD\**A4SGF^6^3KZ>O]\'P]!K
M(JP7([ )F]_ DL_"DBL(6+ JZ*9Q=$S. D^@9TR1)LJ=KOU$*IH1(R86PTJQ
M=H;]I\8>ROZP46:GO3^_;L#PKRK<$'/,622K"(N;$=Y-3.^"^TI]R CH2EFP
MJ4_K:OQ!1F40B .'&=.-VF:\9'YG%2ZR(KUZK"?4(]Y+P\D>;4!B+]*!4_2)
M]$LPHX^'*0%#C[8-M&H96=GC=X8X@&Z@U15"ZD Q[;&.C7>^;C]1V_W%> "8
MKA.NF>4'.@> MR,TO=9FN_YLS]*C@!%H:!.9WS'Q9]N4(RRODG"8#F0\W_9Z
M2(RXU#N:T3G/1K9MWE.4.7DYMS3]:D%_5*_BK (VVO9EWR1X:;3W)\HRZ&RW
M$.VD<?D7XI\L'\W ^'U:MZ1N?SQBDS@C<W:'X=-ZC_N[Y*7/A6=WAO\=FXL0
M.8L182APF_L=]#E,(GH=_,P=U$''1YDAB,.45_SF2LAAF&!FE1I%50Q%U?FT
MQAT=[C=+)6UHPL:]F#RR6ODFY.EL= --;8#+3AI?[1>TYTJ&-%CGE[$GF@U6
M96$58D63F'5H%DR3JAO:W,?)K)Y5+53'<%@1?J)5U?@]QSV1M*G6T(3#8[8A
M54__D_EY#$M3'=(_N#Z+H57_ABWH4>YH-!^9TN*M37\^*5)"IC%5Z*QD&&G#
M2*VH6BLR%,'3$,EFPP8[#CZ)X[C?(:D0@JE8;5UTM3/7WZ;*M1)4;1_/+PVW
M>)C((J':7DPXA^%TJ[K*+C=ZDROP5PU]V%WM('6_^_A>QV&XPMYB AX.@@B"
M6743123K*H@!!QS[2%<HR=KJRE,AJ!H,5YKZ^5BN<Q=]_<Q]AO;C8M"H Q6:
MQ =&W74K]N(+#UZ,'X2L!S9*KK+?V6ZX_!*U'IMKE;JDI=-.TQA:L! C-N#3
M7 >BN))G^RLY] &+)ZJGJY/$B&-#M1,SVD?,S(5._^!-N:9/;R3ABY4.$^K/
M+GK\S];E/UAGO]]MTF/3-?'1[=H;>1G)1?C"U@"C3U&H#?B\-KNM Q51<?(8
M0%05;$DIGVGLS(G)/C.G?K4T,-RVF%L\N(<1CC/.=-4PNM!H;2C)CB6!^E:0
M<N.0YS9A*CKHR^D^IUL$%4 G[)ZTQ/75O=FW,G]>)WK-=[:C@>/NH^JCWY"C
MW?R+J;=_'X6/0K1,/U='&4A6.E<:<>4,);^<)ITS&XWY3*X1O:/41&Z-F@""
M6_9#Z_HZT3I+RX-I?"UANLE'F)<$H<>F=.;H,@0IZT M\VU]%XEG>0G+%ILD
M?EW!5'4M/$!L1XYEL];#370$&WFKI9?TU^7 C*9+M*-PB*42>T@U],0_M_+I
M#4D-[-Y;8L3:2!.,BS"-%(KML?+J)VX!][2*6G\R63X9XQKE1F_CU/=S+Z4.
M^>Z_$)4I%U^)M%@E8Y1(C&/HKYIHP,-,L,=]',[GD\[DRY+3.-#JY6,T*QW]
M2G^ZE:"3><I)Y1IM!\\HWEZS_NM[6Y=@ [T:3.T#$&;_:W^)$?^HD\[A!+HU
MI#EW3HRPZ'_NE7G4_;ILO4](K]:Z=^^V+DM=C VV+5ORD%&;)B?39,$<MBVN
MA:)(V,'NU0+WMM_8,SN^F&CC7W@:.Z4]M/#M79:"P]'!IV]J7I\HNA*R/3CQ
M05#*R[M%1']1%PIP1H_5\.6$9<3MHCY,=4ZZW6YH)QC%<V5$C\NDTB^FHSMU
M3@CS"GAA'VN"RQ@\U8/ Q]*0\)<SJYU/0L+"BV=C".IO0_B[,4R-D_&3TS68
MD>L24MH'M^@,JE]V]+IO&\Y]J]8E_&DH^?LY;.T^/WL8T$^:@5:Y.[C<RI.B
M(5*MX?GPL/5S<S9(X*/]O6S=N_]0ZP][2QG?K3;T\<"N>NV"! W96=<K'FXQ
MV*=Y+]!8XGO"O7-RHBNPQVI1/_^"#9PC^EC#A]-@4)G]A'3T)*+]WM:M2B[[
M=9=M K.96LUK94+C_GNLR\ ,I &S$ 9$\P7"QW:&HFZT9F1M,Q#<'H=\5SV\
MO39IT1M IUUI^@T93?=N>#DA%;.89!&!(UV^D/_Y<TN.;^2OCK#8K=E @DBV
MG!?M!5+8E'$-D<+,'RX0<@W?-CW"0"+F\N4 3)I%;VU;"7&$7FWQ10''PJ6(
M-@W6W;R*P]F$L^),C$^&*AXV?3:P))3[R>$(.D2:O)YVU.#LJ< LB:V*O05;
M,\$'7J <]&>'XZ<_'4A3G, -;]:"JD<M)(8;Q*-9A>@JK5_08>'?34'%C"M7
M:=LOJY_\.:^M"R(YM8:Z(]!^3DK1H!XP]2#"NB.8HS'?O4_=UJK#;FO=6P38
M())%\[HXR9#2(K]RB YW7/4&J::0.VO"+\ZABP0<HXQ[8<XL5(AV$=2&*_6'
M=4$CPHJ\KDX'&ADENYR^]_@ NC8@S,SCU3!!K\A>))O [IA<7'8JJB[;6K95
MJ?1%UIZ#*UH*)#-MW0&[S?#5OR<!,%M:!_F!(214B_O$"C^*I_>QANVRQ/7V
MU^BB5%.YZ<#/DZ)1P*XJRG@/=I74UINBFGNJLKC$];KW+P'2H\\BI#BA0UMM
M<.DML@G.)@QPHCF"SP/U.#B$J$_=F*2 QJ''7-NCZ=)BQ!7R'=5,W]D&OC8:
M>,(=OL7<N.2V?=0!BTR$(BPIIH7A&W+D0P*T>09\>G*M(&]2N]=IJ,X#.79W
M1\K<M%'6ON^:FJO:(E%R0H_=?WX#()@MDCLO1ABR88_=)HUE$8<HJ\]L8C%A
M(^T4P OYVQD);9(7?<CFOQ0CAA2GQQ'@A$CANQCQE[FHA<EWN01'+Z5]6>""
M22,!.#144,I?"X.>JY6H2&1 '3_Z[[9TB;"D?QW^IR 8B!B7T5\-F0#.3/@D
MF*L@1CPW:+,6_?7\?PQ<GG\5W/DNI:(SMZ[3]M<]B4'6==FU1]?)Q$MH)^<W
MH09@\2=(K *4/.U/ZP WD5<G4*#1R$(QBZ*$I_#/"0LM)B5A3:%-\_R;@':V
MZ?/@ID%<81VPPM5CB1$*H[YN)M04[V\+ ?@L-].IR<JF$[@HK:-G4!QD*F[[
M II%92+L=HK>8=1LML'8.R.,;]IM6L9#L<T2([M)$U1676VT;U .UT1@>/#\
MA?&1E#KAGLL7K4GW[#3 XY\"IML3CN=Y Z+T9Y=7EY?S"["LU,AYRIS$^#K@
MXNZ2!</)VV^WM'3%O=XBFEE2@> ^F.$KV@V=A#V32QSVE8$V-O"M>;0*-F[#
M6;\0.VOX]<>$:. >>2MX"G"Z5#>8S?H2<\^TOA]?VMD8-Y6?FY-\51\;YKGL
MIM.Z^AGYK)LSL0^!MB=HB1$R,B2&)L&+C5X/OB1.4M9!YC2#/O,G>'Q$Q\_Y
M7/<T<\D7HXQH_71.G&&(JO,QWMK'NNE!Y:-IY2G<1=:3[:_?I'6_SBX6(Y)_
MPQ>I29_=RD20 "R5]/-NLU\K!7!>!/5\$J#=[-YULW3 ;7$TP7. 8/1T1J0Q
ML(Q4@:N7%!3"R1.8((\W#)A0":[3*!6\V6D>.LU"\-PDD'*&9Y"R'.85,&)A
M\&;((MU)X-'XNC&')-+Z,\Z"^6]1"+$% R:1:JABQ($7"( *DBB08K<H2P&0
M@>&H<06.Y^?_\N)&_@,9:/8@"G#%K3KE+,")F!(L@(W[J_$I4NY?22'_B].5
M3Y+^M0CXPX9HUD,AG96+>:4JVD99F!<C/L[7(6(7%SX)SOSY<A_Z5J7=#F*W
M&+$%4N;5L)<?TI_CO07MHG6#VJO_=+7GGMW<8#5NNQ31%A8='*M0QRWN[XC
MH?*P4=+M^D>",IQ6=S;EL'I;Z/&4FI$[)#:&L :T *@LS"VGPIL59$F"-AC-
M1B79;52?*MKFYNRCK0YX9SZ[W.4UN'GX<T HZH*JCY&4D4WUNOO4BG_'LJ0O
M/N[]\+[.\J'QGH.GI!Y*1;U'/-^J5*28?\W%)O/>[\.5^[]L(%Y97W7R?8O:
M)<^L7<=/6OW\_8S$.$D*@KTNDH.!2_HT@.$6"SSQ>2WJ&^HB!#O<@<"6U:YD
MF@W!O6^I8A]!(PNC.H7W<0*0\5 TF[EV8G)NQ+(_]#YRP;79=_7(C_1BEHNI
MIQWBS]R<MH;8SP1.FXT;3?LL+ KL\0V<E85/0+!(5H:#T<)36ZM.$S  )B&2
MJH5'37>2*^=6LPBVX&,V4V8<??<KD#^!;_(LF5$]8?DD9O5B;N77U]7W)%>3
ME*K4UIT.7MRP=I?L3J19YXT[DUF[;N1F;JE?N+5KM#,"VGES1>J^\_.E+V*$
MN1A1A8.4%V$^$ ]7,-0&N,HL@H96[6+$N#('T[$X3CJ4S1$C;A&46=1Q&0ZU
MU3T)76-VR\;K9G@9P1K M&)D(3,>.K%V J=XV6Y+;J>;3^=J':VL(G3UY<BE
M;W/KI)N4XN ^2.H?D,PK9;MST?^V+6POS8IPBH?I,C(;VT5 @G4"*T(0F%Y&
M:^"Y=J!KNK@R!6#&M]X6,4)Q>:@A!9\0 *(YE'63^.M(E;GC%E3ED/&ZFK,O
M,V>??3N'G,@U F'F&+\(RVVE-" AI5\BN?T&+:AX7W>&&*%*V)[-<F_MU:(H
M0/; @Z&I8F0*Y/P<_]$DE(-4#+'N?%QF;'4_I/%ZQ<M9W1MB1+#"^M"@&]G3
M?P8=L5T=V(/!R$[<:'"++^AT^"T=#.=Y^0/M_3MN,'6][73Z""YKT ]]0NM&
MR3%99PZ^@]UZ^#]$H9Z<-B1HZRJ2Y7)<+B1PJ NS F]HU^/A[2LQ&RA +\<N
M<WW[UFN_##((!N7FAHP:W1CC:FO$88W19P(Q@NL %[JM?[)7C @ACZ;QZ\!3
M+,SX1W\=3G0';FPO/Q/ W"'(3"_&BQ%:-CNBHCED18(F+Y]<<-DGP. U&!$%
MK&H(_3S?-E0/%+AO<>5/O'UDS/TP$N$HB2#"GV$TB1$_DRBC&J+WQLS5;#"?
M'F+$\Q$I?&FLHXC6?1*LU8@M][L=!KR(Q1:&14BWU#6Z*^/ONX1=/Y]U$!>9
M= 2:"*EW5\N4RBR+ZN4>JJZ_%I%1>-\IYMJUFPNQOV;M-_RO=QON]2A]R4&L
M.2G8*,%88B7\0&Z2@$;_+X@I_W\B9OGO+-B28V!V6ZX!I*(L4N#E^/&T;S]S
M+"4.B!&H.JV#RT^PQ_I/=+DW K@V[(&P0\O+\N51M56OF],7SKW]NPMGP1)L
M/Q+<'K5*AS-8 NB%-CET4N0AM1?P*<WMS AK )EVY@:PJND@QP]))FH/18D1
MDI [<&O@RRZ\;U>[NDI20SC[_25:_HZ\D\EN3PR.C(]=78BW:+U%3/;$=!.8
MP%GTA!C!-\:&[17)_=DG>Q_\S2)M\-N5L<(G"S.NFKN38??UO-Q[=KSCY;QG
MB/HR/Y/M.&3W(6J+>5AL5R,FM:!:KPCXYXCZ%'IH<0PEDI>$A0P)&]2'!_A1
MPE<T);"P0]4T+(=-3XOR8R9B5/)_[%XSZ8@%VCA/DA.:L"\FQMUM;O3/-6XF
MOYBY_OF5J^U1MKK5->3 SIV[C8.\':,N?][ALBE!0V;K-A^U$ULR[RG?O[ZO
M6&G;UK52?V<FC"C43H^LMX>< ^V1)0<63DR<J1IS<A$C[""O^>^4\4+^4]!*
MH DAP#R!"Q3-.T6](]H"&0%?F2D6W$,>031Z[J[S_4W[GYXN"1XBN')L/2MJ
M_65<Z[US?YUX>QL=O3'K= OZ )U5#3/&R6#^!A#%QDE :X%?D+NP"1V:?A5S
M!Z992$:8>K]6;+MO;[J%8WW5&YZP-^GC]R:@ZS;E1/6;?,ZRSB?3J/(*HV.#
ME9O'_;Z2_TQK#L$.M%QB@@96"Z.Y,O>B9D5ZQ"&F9ET9;:]HE*E1%SNVW!S+
MP72A56T_ON&DD%-PSOQ\*ILN%SI>65P\XYO_-+"9MVGQ.;[+JZYNB. 2&Z;Z
M/1A2_,Z_"+X77(1(O%Y(U8K_ W@PG,YSF$[*I6D)$V@RV/<1MO2%"8&1HR:
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M5"U.,^VI(L*D:FZA^'%(\/.,L!]FO7I'_)XLI/S>Y%0OH"@HO_E1=1$Y3GE
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M:&KPVW^XY>]_8.!DH_\%4$L#!!0    ( +& =%;$RVG)%Z\! (;: 0 0
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M)T#WLOH\#!?!$RWK=9JAV?03[J.A%0IHB%J@:G"LP5*V "L=[*SD^G?Q O!
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M%'=NBH9JRT'V*D2LOF:R0#F;*?&C=J"[4TQ%!3*7FL3=3T"&S@<*QVJK[H(
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M3<2/3P]-&:OAXTXA;0.K2>'ARD13#*M-%<0*HIO5Y"5E.N(_@&#C%YS3K-P
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M+J!)E/0V).\Q(DED3>?8^M(L54=+??XL+U]_Y[7DYGLE+<,W?:]N8V;@FJ2
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M+&Q);[7GD]E/OU,>/U?F_2E$IGI Q>=EJ6_!DL-0K)ER5O7 LFWT'&*)J.]
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MO1F./+2EO#H\V35E,G& GO'Y)E,SY0%-)NP/T0IQ^T$)-&\;8MS'M4<#N-^
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MV#(ODZ#,"E&A1<Z2>W-XK;E957!$#L"D6!!.80$':3*R[D_#'=R"G6 X"1T
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MG<O';.12^4.PD?8JHYE>47ZQ1.^%F2)V@ER.%<N)F@W-\GX&*MMR1D:I,P[
M#-P1+;^)K7Z(/H[[W4B*9Y5$7U1IZI(7%]P?VKZ[_YANJYA)N<>>1PC+'R?.
M:=NP'9 ")=B8I-3F0&1H']^2TQQC@^S3YG/FH;]K-QLN$80^FQUWE>U34X&
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MFPU*E'R6^2C7@C5O(NY=?0<Y;=@R4>VK*R=9P'.[6$;P(:A6A4_Y%=X.<F[
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M<010WW"*9)J> 0T5ZI3H>'+ZK#J%5_,<?%5Q'UG93R 0]Y33K#Z69CQBB=D
MY675XU&_Z3_=#$X\HR\[-1;D 'T YS,$!(<L^%*,JE0(X+A*LO5+NJ(PT%?)
ME5C35XCI=UK,\V$'*W62IO6W4]"^ULZT:M0CCD"XHY&EC!*E.H,9J\ NWJ-Z
M)L2-"M<#A&N5:I@<#\[OU-QLZB=Z\2,L9A.$'"7!(CS(3?= X*/D+HKPHZ3
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M4J)*1E*8L[<:SS+^;XIX-H=_)"??4WX5P;-XI\ 77*_]X#FZNE5:_T_!@K/
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MS=@.UHX;N)N)SQ*SMREZ$<2JN88U@M]#$[)@R 8VX7F(T+2/OZ?H']'0&<S
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MP,W+!'\A"A$RB5+<8X[?4J)>(F N9?R@MU![?S<PQ4<)?4(IJ,@ SR**&>:
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M^DU&L6 3Z,;)Y9_5?T?)ZQ 3D"89B&2XX('+'*!*EP>)-.CEQAX!H@?GJB)
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M/")$NG%Q1Y1=T[^*M%EAY(CA8EI[FS;O*K>5938>[0YP6[4H^"(85O*8<C
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M2X*1>? YX.MQ0QDO^"Z4/X^P<M5O@W\)N?I.WV*"#&$]/^[I9R&*)\R2C^;
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M15?$ =;&Y9OG$39X_#C:@K]7:?E Q5E-30"1+81LQ>II"V"$<X%ZYC[5'U*
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M?ZMIJTYNNJL:X^\$+^FN@;))E<I_ZVN*OEUV]5V#.G&GA&-%#5!SK=\QR\8
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ML'>^M]F+NRW\>V&2'7J;#]J)4BJ6<]L[M!:Q(QL!0A9_VX@#Y IP#P!LEHW
MJH<>,X5I]<49'2"AFL-26')4C(QR P>WW40O#=?KNK*+W'-YPZYZ= @D NW5
M@@<JSYVD)D,$Y Y\(F<N3,^WA=U?@F%<S>\"1ZHO$'YM(U@N/%<ZUBC+&VHQ
M.DEQ_B:9MK*J J)U'.[91IXY4\$<J@K9^E;>-A)7Y$%IW;S1["5C;X^RL4G
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MPZW>:_@391?6B*^PT*@SU@*(CB709Z=(YZ(WBTCSS"EY&LJ^3*QM+D_I#]!
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M[Y+[ ^K0"1:VWKP42Q<Y$_8\(5*GTCGQV'IU"\WM"&]2IX?'J CU,JNZ7VB
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M/56N<X1V%!O<KS#.H\86PE48B8F*QO@^8%OD>58L5E0LC-Z/L?)-'\<"-C?
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M1;?P_:PW&-OUPES9"UD!<RG1/T5YOJ,82VS2S<39B*Y7V&K"RJ)F\7\EO('
M*,[55"(L[80RE"A$&R* ^"Z(,YPIQ-Q8LWF"=P9,@"^D&X1-=.VVO5BY@N;!
MTT6@_KA+I]'N"L->KYY#J&E:'YKU ;EF#0;N6+=>1 ';6D,%2GIOE%ZDH'J!
M^W*6G<0!=6*1#(>4DV(M.S1#P?9B#\KF2^AWAF3S&/"#9)\ "E%(#L[#YYZL
MS'191CH._1.^9Z<TF,?=C$Y1BD:K3;TJP_*+J$PI<SO.=%'.Q./1D%:9-M34
M2JYC+UH[19'K*'"RP]N#)C-DO1(,YR0X@N<5$,M:QO\$L#X#E9C:\/ZA&&>1
M$C)G85 U-1"S4\!]IPRW=:-6O;B(" +M3Q)4V"G"_KR1;0N2])I1D;$H6J]6
MF>:DB.I"!))H3&PP*74%";[6?TMLC*Q<9@#@ZG5S>(D'L/>W3Z58UO+BY%<'
M]X!?H%7%36P//.#>YAG6M?\Y5[!+N'=$4U?)#^-WZQ;#)UBV_.YBJ:OU-A2.
M3>_EF9,F]7(\.!0DM1W*Z)];9RTO1LI; V/TY4T<N$ 3G5Q\%?<! X; L&9W
MEC?3[^'-"B[JJSC'EJMG4?.9[@)S7O<&>C:\CG@K<Y;I'[(7ZT$,0G>#8/!$
M+Z*".J7(^<'TCL9YA'HM.<(FE5SVLDY0\QN9.(?A9!/P5X_J2/,?)@V.M]9M
M?5$#J(:TK:T=\ )\A8:_A,/W??:\B\&8877^SSFA&B6@?>3?O];CKR=C/@CT
M4Y2^,#-Z%&5=(59SI*%@@^$GG$HN6JMH/N$!?6&]16?X699!&X#]]%O,;]N9
MG^(QUH?\%?@W/83/4,)RE-F(-IC5(I+N,/]+XURMS8[BG>T2?VISGRG'K;[_
M.55YUM=:P _G]]-HDGCTE+Q_O?6.+!EVFJ*<X-UE9&"=B*P03F(+RES!&!J-
MC(E&VZ=K7B?, YF8J^2LQ1-W:,-=[%1T[7*Y\5O^8JQ2E,6(ODNR6[F UB2B
M$DN&6//3N0N&$VPHA/#-JJS#_[*=]?P3RIWO=OI?H/SG>I,IDOWFV-4J?H^L
MSERA9\V$3J"JL;4/^.IS*I* /?!H*<I6J+,2/'OH4/@]4$P:Y5IZ/O,3R!F\
MH2IHO_GKBUM,\Y/9MI+#:)\98GN!5%T+RRN8EBM;>#ILT;?6!XR33Q,&:6B1
MU>.LGJL-,8KP!0%?@NT&6B%<<Z62Q!Y=#6U4A>H,[@KZ K#MP'2ORTOUU;0Z
M35,FB\8)7<"+0]1RA\:,)O8\AH?UB;&7D7R36(:6W=5SXL^8C:KZ.GG?VN5E
M,ZPV[>PW=@4F^(3Z"FF[\BV1X ,2,1:/=O/]\!E@-SI@H#6I!25LI2-5(9T#
M/"Q,?I_NQ80 /DYWPC_MQ/T^\7Q_?_J'J:R'UGJ(C<(Q(/,D344MH,T89U\*
MH<WS9GRNG>4&G^!%&:BC0VB(^18I,M)0WR:6-^YJ63DLF^ZF9M6/\36D/ H9
MRPS)&9-N D*#&G<Y,=&<> 3U5K6,O#NU]76W)%!ORK]&^O*28D'P%&6>>GD1
MMMS;/R;T#I;U^0Q+SM5A5N@1X5[V/W4U-QLLW"/\MK)-G<RYT)= A1J1\IQ$
M4I6E)B<LZI38H2P$O@)M,!R>HJ2PM49#'8E$6IVROC@/.HL6JDI^??($\@1>
M'+TX[\S:9!_?#L8&]-X4)>HYIE8ZTI1,AYZJZDC13=,4)9D%5I0+:I1HU4L#
M33N;.Y\7%H^YY["2,@/HO7';->FB/E8KTYG\ZLO\+MDLQK:'_$[FZNF?R2)%
M3I /*J&]H,F%O4)#?+F":C?,>LG*G>XG$",DPL!W'Y1,>_2(UCUK,^ON[T(V
M+.\I(([@1S$.Z=N*#3<K,5'+&GZ[SP9@12WF$]97D+N19<LK-<=J<#_TOCGQ
M-288LUIF#3Y/%LW$.=/[XS0*E?%8)<<2",(,=DJV8.\CD26!5V%83'-8S5P&
MDIH2Z!V2D^YRMMN@RBCK*U/OPNQ4A;+\6&NQPF&*<E'D*%F9B!7O!"'8S?=]
MK7Q*A^RX2'LOC84\*!F?P%V&_X!<L33^XBC$*_R4X9UJU![65QY-2[\=MQT-
M$CXBZ;I8&-Q&'7I?@-\%?5C#7NO_ZDM+)L@LV.$I,XRE8MD2/_4O105%$GLQ
MSRNFC94LFXV?Q@2C-_3"HC,PM>:\ Z(65+_UW0\ZRWFP09?%5F@SFL-V1VYN
M)Y:FAA9G5=O6:*H=(^3:F+>T&G\YS0=NWL9*H<Z()]09/D&H>]82Z[_)6#\5
M9;W'7P;HYG) -[![!PS?PYY2U_A8? =8CSB8J%#@*\RNM=%W2UR?:4X?:(A#
M=;D;XC@;B0[8B[>*)+]M^RG6\7LR<EKT=[7O908CVM!$6T38@](FEGN-.$_J
M]PIP+-N@&1)K%2L9GD.\A6V@0-(U3RJG**J%74Q7R ;=E4"S5N*Q-YU!)L*6
M+T0U!:.,\+/6)Y6@T #G21<>YNGD)&-]0/SJQAH0M99F%O?PY^*K@?P)>:.W
MSUIV#M47".>!BJ:$E<#[(4]L'JM[5:B0N> G+;L2>!GF!&LEDPXX>K?&'T Q
M86]AR:>-B!/?#5^%?B^SAQ*Y6#ERI1'1%6K;[,;]=UX=#C]G'A>W<'-\_*WE
M3"K<O(:P/13+HYO_!:B5R;1J6Y(N"A.6:!CA*99(?B?;'C[V&DZ&%Q_607O:
M/]I?-Q:I%6G)X B(^4R&P7F2M=@"V)$7%J<AUJ=*W7J"J?,<?H+HQKJQJY;S
M0](-H+F<_TMHTM@!@\D)A)CCK'>>XDL?XWNMM[_MII."SZM9]NQ*!5:JCU$U
M>C41WM9<J?=@_?+G6(BQYHH ":>WG-.,V1OBA%Z@?T3%=B)5_U&US>\I/?7<
M+ KKP:AP[XZ((]@(^^8Z7H-9 Y+0:&(N^_Y@K$@H2V85TF8^';=&FAE8E(*5
MTT_M9&S!UL=TLX[2!"+GC^]FRW> %(2>DV +[I8/PE[CL"O(W/*B+;URN1F5
MT^25&0J-YZ_%)RO%/TG#K"1 I-Y>']WF"[RQ"G,3J+A;+N?F:J<HH\;'/)-Y
M=>?'-VJMQIS;(V7R+*3=E=KS.^K<1"]@^2+I3"@8<%'3#O!YB5W^G78X*>!M
MB)RV@.F'[^UB+L&W=Q+4D?O-7]':;#U\:O /P*1BH=$5451\!S:0*UU+M)L>
M:W'2R&1]CY] B^4-]-YL_=O^/-%\<C98VN(=*'>4BW[YJQ:^X)[P:1>Y)F30
MR@KHX]0%X)Q144QS(P(CD-WT5ID=X[0^?AU]P6\C/OZ8P)@QQK%L 51S&SA]
M!Y0;)UIOL_;0T -3E$ME82""8UD#?XVO 4?U45DL=PA&/YACNPE'Z"M4W'*;
MNA]<QR(4Q=+%)-K)+2*'."@2E,+&5^/<_(PI"EK(RV2#E8;("@IU>,%EX=XI
MRLC0WYH/X1C=R,479K8REUL?!XN=\<_ 6[2P6><D#?$J?&>CGVB)HH%L@RB+
M<)Q^,KH)#=N"^BO8V7_]9)FY17^>TQP[,?HYTQ=,&%J+_%4R[8B"Y?:>?J<+
MIR$L =\'Y2J%.6=0\,% 'QO'Q I:]81<EB=";PZ+G*I%;JG/>9F(GZC%E'\2
M5.Q#J=FLM*@+/:*744J=0/M(:'$'+DW/U$;AA8/GBA7JPC6P_!!^-BU1D;"V
M1]].>$&>[$O]3,!&/]I,)MV3K9%]1;\,5^M:82\HHY/_Z?"WR:(7X^^++'Z<
M4U.4ED!$1!6WTK1A2%T>@U.%[[/>#]:TC[Y+PYVQ$)+KIBC'WIYJZ?=H$W^T
MNC27!?<0=-[ZO>T[*I#"TYUPU+K0;Y,ZEUUPFVZ#_4I'A7]4&<NB/%MO72S;
MA/87E86>J?KYOPZ++?-2X,FBP8\S>O^KVL6,UA3X+P:O@FCJ=R<MG]9ZYO1_
M.Y(^ Z.1"]$,SR>-@Y+F [FC%;NZ3\-Y)40VTL>>TSM8'ZC)&Y]1H30*'=[)
MH3+:\Z[@TL;4OB^N].^.WMNA[ZZNDW8^G393U4_=MF50_ZQ3"&<3O[,=92E1
M!=*5F.:*-'!$Y !E&FF_C6P%"%9GWFPMA2+O :E:S\KE._/?340/3I>*\)(_
M)3K[P['9K^\3[?6BT7?W\0.8G3S02\%<WTDL!I/$Z3;)IKM#L;++'W5=<-\;
M8XA0EJ3KC3'$*'4YD^<X/F&D]D%[PFVV<^*7_Q5_+LH9CT%9.?2/#BMJQB)W
MM!F[-[P+B)=V!)>^33S86=T8%MU8W447IU56'KW!GP5(\VM+!J]>/#^.%RV7
MS5@2==G'HX?I!S$P53/+&:BV76^)%1;AFRQ?3O^"3\P?U)JSL0^?EZ7HVW2(
M;FS\'D^VLZ.*N6#GZ:K4XM#<JX:=N,MY_:%1QHD9?V44B.$3;)KPPDUV3:!L
M;&]:Y2#-5:8O9BW\&.4T*)HC66K7Y&#*@9UDR3H*OLMZCUC-[Y:&H:HL$\,%
M51LS+FI:=AM9^80'F\9SDS=_X&UK#D0SY2%E]CW,5545?PU,M[:GH7O46G\Y
M/(?4S .MQ'I0:3D . K:;":3EX@DM=*=@/JS#GPI*> 7\7]DH7ME%%Z%^36Z
M46QD][[4#[3LGJLV"S22+7? -KVH)<W],.A#79 0)=L)"N]@I&#J0R -VVB.
MA =-9@08,7\]=51@5!<2MAWIR4S_%!ODQ*VC]U.EB[J)@)2;GB(%/9^8B<Y^
MSN4@5.I(/Z6;OTR7<J8LH"M*\#$P3)'@4:J85-;>/A9TO./O-OXQXD=6K;M<
MW6O987T(!53P?Z$Y,!<##2*^Q$IC74X(N*YGC0X]('X,55]F.%KF\V@DJ!>5
MW< X^C.O#5.4Q2-2.U!L/.]K[N@8IPL<GT!;L1#!:5EN;0E-&1QETP=]68O2
M!!?6O(<V6;[CO53H//U(\TO3RO4:^=NH)E:-72O+9F0R@U2*N?RYH!P+,23E
MR!)-8+EM\>A;NU8/QEZ43UAB03:,+1@P7WG>79WY=F/G/BPI'Z(:Q(+8$1UP
M;[Y).->8WP5L!@,HV_R#]58:Y)B$?9@VKX.KB140'^Q$9#/Q;>A ML0>RS;Z
M%S"#>$9C5*O:&S_71;@!$\(25N<%;:#/Y<UF]XI4.C>F$T^-V%UD>@#W/6#I
M$YY\#[899!H\R:0+P5V+")>X$$7?%$50,D!.W@CB/A:%P%DT=V+)R+5!G]6D
MZ4VI@7N+E:S%)L@?[6P^%]Y5?"Y0$E*BEGLOP;=B_.=(8ZA:X:LX&%M45JHO
M)-4.+<ZL5>$+ XQ2(78-S@UEC_Y]'UR/K@,7C71'," /G:(HTNR:Z]CV?Z"L
M46?+IT1/B-2Y71)_5^@SQ'8+>H]'8*5[VT](DM/5-D,;;7:]ZOAH]3W4:>C
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M2N'L%)] C(J[>"G8[B8B'"3IWY>B(9L!5!:"1HW)-V:C?ZGT&3G\(-!G$!5
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MS<Y,T"C!6GX>Y$R?>(SP%T/>X 99:=&3061'+)MTIVDX2^* G3J#Z\ARPT/
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MZP8>P+^HM"%6)TE<Y2Z6O3@#]!FODD[%8JR[;^I:"/AM,73Q!-/.E&6'V-9
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M^H9-5VJZ;Y-+J/9CVZ/'\G;N_9)"\0C^'[;J_Q\;/#?TOP!02P,$%     @
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MA=9\E=^+(<M+JF-5[41D9 (9,_XYE28OBR%[4(J:+(CW$;(288M.<LD,?_X
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M6U/8_M$-%'L'\2GXK3""H-2R^3M&YUQLC]MLI:SH&GA9A:(S8(7,\/2S6?W
MKMKX>-,D>"/A>^UWS@A>8T>S07Q87DH[80T+\0)H8\Q7$%@(V;"B,;<W'?_,
MYZ&P1^3^T=Z007:3O""'\CQU]K#*R5;"'[2',RVHX0K((BJ4RK,(Z/:]$ETN
M=^7S1<CHCMF\3J755LIPI&D:\S9Z;C9(:'2=%X@Y*D2G+5::MU]9?3=RRX^R
M*@0.<C*+I^O/EUV.9BRZ'TZ(-+ CW=;+B<Q(G<QTW-&32&OGC";":G9(X/\.
M?_ O!XW;6>L9K A6AO?)]Z73>"7J&;3:9_+%8:O,XWLZ\N(8&;&'*EO6*I>^
MR+8H9,-:]ZT.9(>>J)O^VG#'ZA?!$0'^:"KOH96#=1<5\,&"9G3!=<1C\D(Y
M!*YKR5@CJP&<*O(^<3]WN5D5W@66#K"&K.S,PT+>.E[FO@_F#?@J;K[[YE&[
M\?8+\%?*._HSZSD_\;KI\]/4&LY<.T#@WNV.V%X5A\ XJ.54)VRICBXZ[L7W
M3+7V::#8" ^DWW73[.5CU6?N5NRR-#?+6(/"*_0*QA%.ID"9<!W"5)M"6BFM
M2"S1DI;O;K]$P+"('.W DZ!8C"._B:J<IJ_V=60SQS67W7S2^79V\RD$3<N=
MV\,RJ^QCKN7YX('HJ4[:*/W8,V$HI#,/*\6(W>&Q.Y(B58]9+J$]_PDKM'=D
MZ(/0T#]2ED=4[MT>+[JSW>O) +3U 0)3QX/.9SMO#4B''Z9OW<#]LGYJ<Z'D
M@^OLAYW=AEL'9(#A.3IBU:#D)O54SUH+:@AQ))BGUV;^?4/ 6>&E7!X2-ZXX
MXXFQU!Q9HS*A4^?/68[ZX@%2WY&R)V">P/!=5NNC[$+6;FHD/05?HP>M=Q<K
M1P992#+AW0%NPG91%/B0CU:GO).B],]5-#MQB0:0NJ24HO]>]1L=Z5MK>G0\
MF884+!4PN)MUZF/G8F?7WZ\;0WJ36S9\'[J2W,"S,%I#?>B[V5QC0,WNYU@U
M_K8I.P]V16HS=A78!*\)$).=$3^'2^B0W9- RBL\DY;>O!/X"2L1 :<V4<RA
M4\!2YQ41T[ TA14^KP &N[M&>7OE__ZRJ:4E]PW'.C..ID&ZR@C&K!7\L,?)
M+*]HR.-(3.8B6-= :,7K0ELEQ;%4T!</',5\6@K$KV:=0R?I/_HM/&^25+LO
M9VI_'5A9\ETD#!@MN2Y<?=5(-'DTT35U6A^3+H@KV.UI\> -KUS@+6*NW_OZ
MP^ZL@[L_?DE0)RTROGK#2CV ;Q=!CAP/1,)JFY#W/%UU=W)>#\*#5Q_,<)B$
M:\U;XBY(46NH@@SQ6E*^"QL)\-W/&_KXMR*O#-]L-HP++3]4R7&B6M&3%VB*
MX >#F*M OAM[T?-[HNBPI RG1ADEU++:YD>)7&R:L1#?CL[ &30(=9,NMFX<
M6,BOG ^O @,Z+IEO9HU0M@*%3<0GI/B.O%-W'$,KPH?#M8?5UT9O02WO^9>;
MP/^YH;_A]TM1]^KLB5)46%H_=3'N^Z)DK^]/S$/JVU$C:RFJ[L T?KEQX0K\
M]W]>J2MY9KIW[R2-475%'+_L_>0!VAH,!N)Y+JV!QGZ %-6&3J;(@ $/P)1.
M_=[,N/=Z/,[-6,SJ<-ON#&@_T-+$S_3T "2928^_L2JL7CX?8/KQ[_PCB*H<
M\O,[E>G[BR])87T-X8#;NR7YH7,('#RQOA:Y',+X%BDR0H:;2^768D11]!H%
M^,&$#$)F<_YODYYCT_$J9 5A.:\[JT6#[ VTY$X2DUE:]EL8H%XW16.H^$X@
MMH.B(\3EX[(KIZTSM+,]LB=.!'JN>5Z?I]SD&_>\[OF-;V8E'J)T%'R8Q?V;
MH $AGI0+DSQG8L!--($?W\&M@U!#[![W[C3"_=MBZB5AXH'1=?U6&;,"ETY,
M+3K#JF>A@4WOV#.:-%U=S2Z<?(^S'MC.K66S/<!6;N">;AKPJQ%!O0M4;K$Y
MSVWRPB.D*J^E<A]A-'[R#*:VD,W%FO!0([]3:=H_IS1A:\-'G $IY1 [T,AM
MK&DOBX>JR?"^S8*V4M7IZO WA(E0N?D4.60HA90W\!9P8\6,.DF//YR,%< ;
MX/<<?<&#^_:.0,(D-F4DNMF!\6G&Q\ J(THV@.3=#N]FLL\&W%]P&QZ(_9K2
MH8]-6;3#]/1^(DRZW$1H0AV^&KNBC^0JD=[S01NR@Y@(?]@33UU-C4"OB:B>
M#NVLC;BBMK+*@V'FMMO<])Y.]$WTA=\/5%D5:,S'Q@KC&F?.CC<K"F7;Z_V?
M*"S,RG?$[^RV5+G3OFUSMKO!HVSW]1DM-J>RU]TY\>C6H[1-.WT.:2<6O/(D
MO.N&-/"B%O -@.9/=>#!C<.0MFR'9X+X..6M;4 0_ ZC$V?S(Y,A\!5O;9?O
MG+K)+%#Z1_ C2<3BXI7'1LV>W3U&1QCJS8.CD\X#48^%>FWS& Y]^B_U]FV.
MZXPW? DY= SWX ;ZH=S157W_JWVA_]9DH.[OA'_J4S*E*(&&K2=<]=*(5:H$
M!R]@?P4X(>Q!E%I@*D7Y!M$(["24MI?S?VHZT'M*.^>?FGE(-QA^7RO:)T4-
M&+RRDNP:_FDE1E/?]K  /YIX3^^(K!1UE(CZJ+#0\Q]V!60#G<J\/P*4@N[)
MC\,_6Q&P1+C C<N4OGGQP97-,^ X'33Q2"OA4";P,E91LJUX'9SV!"GQ,!"?
M3(VDCO1XO10;-7&Q:R/\'RU3LO>\*/)_O;URT2+ B_W#H+6_]T+H4XP6J,P;
M?,E:<'+?$G-#QC[X:Z]W=_!GK3D9TVNN*/@RB\MB50OHG:P1\X.2EY"!4&^?
M)!=_;D5GN-^DUUFW>F;ZTU.C+"OM/&R=IO-Z,V E,+_#(NP<Y/P(_,!_RW$&
MG),$F9TEY9,O+,<5H_3:)_8*@PK*R0S %%:[.DQ.  B\T$Q[+R3(;JV$,,CH
MF# %3),7:1H@G4N<FXZ;Q"0&;1R.KOND5EE)WB%T$+&B$BI  V^6W[R]7=QE
MK4 3NN4>]N<@-]F@SQ<Q3%T6@]K:BJBW=7@NG:5L5>F/ ;?DSJ$G"["=U ;?
M3HSR#-M_FE#'Z)+L$GX%>N<D#R)T!:$.\'6>(/C 4&Q&@=OA%SEOMU:2"9/7
M+VP1T8"[1P>IE315,,$)R$U9P"N1@IW[FVUX=)5I?6(*<D>@UC;LUF=I*.M<
MD^C>MQ"%.5*=;F!A[=:_((Y,L,![UB7;19J[;JR_KFMV^ZC"SP"$\YE1APSP
MW!H,F(Z!M;S^GT_X+HPXHZB[J$+-%,FI6E@9T<>I#Q&M;H7YGYZANO^)=&FZ
MTL,5!$4,J"M]I$E1L-;P]]*5U4JE.U3N@T)S\"Z/ )YBC!6+CF+4FO'%2(T$
M[E &J?*T=J(B6,:\>FS^2)1RNW^OJ!-\*=3)'4E:& T=:8VR#_R\KEAL\H;E
M\]\ 5L5MG'J87557KNITO+\B3O4B/\%=OTL$#_7/^S;5)_V(MHAMBDR;?#Y@
MTL#,"K@_69M^^71#VE08Q#3)#"#TQRI["E03?/ICW>W'_3Y5BAC4\!(_JV_%
M<3I9!6$[YJ,W)@I\EVK'1D;\<[7& T\Z$U?9OWLB1?5V0[JY_*DDRBK*)PYP
M@',+9]4'76:00E])44Q?@7)"V31>I04#,OBE-*(FDI-APK/WHM I9%GN5>L3
M0D+J#WF)X%'#^;#1D"^B'(W B&.=H@";<<HA).*0+EH]I:C0WM$$T4&@MPVS
M"K*4/(.L^)[JE"%.]?&OR97"!-$N23$.35+:6X<?3>11:A.,RB81%[#0"VC%
M<,W>X- +1@7RHI)<VY*'6^H+0N0[EK8]D%UN'&X^5$3R/3A =N%?#74!."EU
M&?&-@\QY]0@?_QT9)0'&YQ(*G'X?B+:8JZC,.9B^VVJ@;\.EC6\UY4^!ROSX
M=D9ZGHU0KQV- 8WY^!2?KP*#($ O?0&S]GM/W-K5;I<&[>V>1.PQMRW?^MO]
MFT_5 K5]N:$9. W0&%:B(6!Q55+6HD096/:&#DGN(&A^GZ/""MU+EA=;10XW
MT(!</EZP4>P$4OW![ HH''S,"X@L-\ ;G03U6O?D!*T"<I.@4T0^9LVHT]-(
MVV;;N)>+B\N$BPB;HHT0N;F0)KL+4XN'M'U%VF 4#SM".]ZW<H+O.@8E145X
M)E%7QV909<AFDF)6J&<6;,F&UT78XC,H^J3+YYK5R3%<56J'+3$=DN?/HM%C
MLSX(UQAUI\90U.[O^%M&LKWZU&O4]>$; 1Q9XX8C9Z8R7[9E[3-]K@,-(NX*
MM_?D!R)&ADI1J\%I?7QJW+BQ^R K"IT:ZL->>!]ZE%T1=\#=X)6^5^#!_K?\
MO=CV<-L61LFN\>YM!78^ Q4&NHWWYBZ2#^.)GJ-($@TE(F3?%]K_$>< \G]V
MX&M\.^;EG<2[:3KC_F#O?G 3T7(>0XI 7#"A*W2N*N.]U.^=L]V383NMX$8_
M2/?IYPY9J=I*4<<:!Z/C4.BYEG3X7(LAM=6;&CX(KNP3KUXBKQHV!JG\*%-8
M"2_6FV&MQ8=3U\Y0] M[NO13:+'$D0PGL$"-P>4]G+'U38;,5><S@@>(<1:V
M#JN6N_@<[P1EL]BF!+M@_T932&_,HY]UA@YN,Q5$"LU%,2T9[1S @S7FU$FH
MJ<_ESJ\B_:,L">87YI: /UMAF8_V7M0GLZ,Z2:7)5HKSD)OD<<58>U3YZ)C?
M@=,UXB/"US]1YY?UH,J'DU3Q 8^[4E0YPX4QW<:ZC4ZA,^ESXBIJZX &6.L-
MEG&)JTMI>.X]EEJ+T72>9T:S;U'8<A*CD[X.I+=1M6-I-_7N!G)V%'(T UKS
M7A8BG&%-)_/+\-(:V+TB9OR;$LQRNG&8>V.UJW&IYWX7<''=VLTR _^I8+IZ
MK/:,0/G#9UFGYG_YQ</*.Z6HLR/B#=095:X^G/NUT"SX<DA<UM[L+SF'UGEM
M2O_-[VOV^#U-R^/;^W?+*?\,76<%Q5+>8!H:YMRY#' O H-*3#Y=CS+(DK&W
MYDI1Z2P%UEE$H:E!Q$JR&_"A@.NYEC3UJE 3",J?Q"J%M>QM8B6V^=IR4IAV
MYN,F<(\X?+/MX\<3]"A1?GY :C$*[@YC=&+')D4;)"W4L-YTBKJDC,HMX #'
MT6OAGKP?&<"P&U!? !#] %H*O(/2@]?(;*FMB!22:GX>R7-W<V$SHZXX^/1Z
M#D#>%[B,5-^+TWG.F55_YOQ&3N0AH"Z_&4&D'Y2V;(M<A._ BJ$EE$\$U076
M#@,D.UQ@Q2E^]U <=:[G6,G/DP.PDELH'Z,1.+ZF4.]O3CA^3=V6VR??1^UD
M9A9=DUW.*V)IX$.(*\>-%!W%WA-CH$^/Z"Z;LHKL:;VZ_2CH)3X6GDN0M?=]
M-//4"^.2&R ,-FVO=/L](#G!JS2L<.]@W.I"TX/UQ[RI@K/TI^&CS,R2LD<<
M_XB\0$ESO(]M3GZ,_&*2H.ZMD4&&6X_?EH;G-X[;9(6=(7TFO^UTW;Q*HBV;
M3?<WDZEP/79P=W?0W[=M6A7^@6A.T!R2P.?Q1,*M*P[S;1QPB^><_/E&A-UA
M1=\/ FT15V*'(S%S@V*'6?691F(6O!?,]^W7GSP*)(']E7%4T"4NM>+'C@4'
M!5=A2N;V2[/^"DD53$X_$=R*S-ANGAZD92TZ(EP2[!9ZGFV@/JX(,@!]@?ZA
M93N\.ODD6%FI> J@7UM CW_^(#_X[F($9=- Y=Q\0#NLPXZKO##WXWVZWV?X
M"K55'<\M).BUZ"" IH5 YR-,PU^X%=_<@<=#[ .$)K/>-6)M*6I5B_H,\=$,
M#@TJ/@@_RR>1[:/.+10HB3OSCM>,%6#$YFT3J_+6Y;^BE<V\PCQB 1Z$3UCN
M%*05*?($(\7;H+7,GPN]:T9:*B>IZ\;''-580CS_$G.])HG--TV=V/1A>/3K
M@L;8= [1JBW,:"U[ :OL=R16H/01.Z[]EU$B[OFZQ_^SHGLC18V5B^+!/F&\
M: @9LBOD"Q*Y99 ;%S/2(+H%<B8)F91--#_@1T[A&H"1@=0^FAZ(V3\8REZ\
M&NP^&-<Q0'9_ZA^^G]V^QW9<T.11RPEP/E,;:,$ M_O.+0GS10623(L674@)
MB.JFD2^QZAASM,D& -(?3H%P'" 5LD:*Y7IPJBNO(B\E/:X2[4:*Q:J$V>94
M6CQH21"SJG_9QCW^^G.LW72&J2T#TL0'R?*2<E8(?JRIDP5X$3XQN *:P(E'
M&#7F$:_A-. 15@VSE$:V!GKY/@U4H##J&#X)4X=N)6J1)@+M7N5UI]N;\Z(.
M(X%5: 9@TQ8%.O:.11GH.;?.@6^%2R[_L#"@K&@,F8HJ*$22'XO))-2DK!QF
MIWTR%<6!(]S>43>^48JPMEN*4K/W%#M1!EA:%-WW>VJ!?%X7@A$W"S<).<D4
M(V@CT'OK ,X8O$Z=1&N-1^)V!T3ILMOS*'FQXJ87^ =OS617]D2HXG5P'Z:.
M*IA>$8[@&)#1FE-H H:+MU+80?9"3G=!-#+R^ /T5B.=04N"8E#XE8_]<?EB
M1%C^-OZ>E^ETV(V@.C8S^J=_P8<"P\X_]\0?F]%E[5U9<-?#V8'%*P>)8=+N
M3HXF;$ *.(@\>@(= .93<:M)=%>".BEGMLWV8'8HO_+H9[+SQRWLA=TAIB)6
M6E3=H2C+0+?CEY+;CP[PGM^Q.;>!OAQ8= V_#E)%!GH3N)0F1"#&5,CJD*+6
MDKT2)I'L),ZQX\3X[XT>20_"<X+4P!<7RB#U?EB- ^8?TQ-<KB1%&,00G\SF
M-$95CHL_5XCV'#OYZMR/T)=0%3*LMR1K6+$/Z1L1\#?"*)]AU2&R024Y6$B
MM)=$UX525"==A:P'YD^:"_:/!4H>-+O'/ "?SG<NGX'5$/&VN^.*7AOVAG_7
MO0?@#,G;]_G C\7+==C5$^!#6D:=B F7XG9!I\$H,0[:#EX7UDZB,RSIJR L
M&,AS('2U[!5>:KCP)7QYS_4B_S=QEW<>K;0:_]*JR3["WCZ9[S6X:)[ACCU2
MWS2P0U#Y6(I"LGO4?)(C0)28PD9JZZD60U+P0=I)H#>)8@[MZZ-HDC6! [<:
M*QFO\"/#CDWY/D)\^J)YY-&HZ+@FC/(HJ9C?W1'P)>_K(D;=[7)1>&Z*$[O9
MZO&):Y1YQ&_-"-UVI%XG-##F;(23HJ?(?"2#NSM@W! U$K_6_1&D)CP);QJL
M(Z9.J $-UZS<]Z,UR,$ +2W]C;V1L;"A8ZN5PWI<0U15V').&M=,=_8(ZR/D
M'$^,7[Z][ OI-L!KHM^;)E<UNR,E9$5&G2-=<;)?QC$OD#D-V+F5G0HS_83K
MI1.UA,\D*:I]PH"]X0PS>0*S+CPFX(0+,;*8O/'CX&//&0RWM TO \F >(#%
M);8)#.WQP"12.*^1MP##KT9WV;V-E:*42=C]U0"<)C>L6=M[.7;[]HT)/;.Y
M=WXL"TJ:FW("[G_-?KES,-_@Q"H'1YLOF)-QZS75U-#F+];+_BR&%<7("'TD
MZ7CN8UB%J@GW2%&Z%8M$G? ]YP-)\US&K8V);52#%GTW\[^V- AIUW94337N
M\5G*$&GQ::J!I+NMN?$W J[B.W*)*D78O@J:/V2/F(O$5ZL"-00SYM85B:#)
MKB%[/[$NY7.>SJ=A>XPX$/Y@;1VD)8P [UCNK'HLE&U;WE/&DV"[H^QW??;G
M1*ISP,CN>)]C%HFD@?!RBZ3N5[:FD(X3K+2R]7=GN(Z33 4"T->76(:LL]-6
MKG6>2M16#RDJA*8L19T#*<H!&=?#BQG=M.1EW>Q'W0\CCAVX>Y+0&_*8Y-*!
M7;^KE<=0)KLU!62>WH>>79TN1(\@^N0.J"S^G;S[8\MO\ >";K.JD,[+3?76
M)]ZREV6,1#:>/GGP:73L^^,67\1G$QGA/R8.EO/&+PY[#,?FOQ)=*:1'QM*4
MQ!'U7(\UK=WX*8=?<JO4$OZXK>#E?E9IU\6+YU&S='9_2X"D0HJ*(HP01?H@
M@2I,%%6 ;"XC$:=0[S?)_F'O^63W++QMX(^4#U?1KUK4V,'-0F(6\Z>&9J96
M6QZNO*RRL2?>HF[/><^8M0H#@[]L5DX (5/]GM+! =Q)4<U887Q7'JW#<U2A
MXU"(WC5J"/7&T&_@["3C%I9Y)SMLZP5>4\"3*'O#Q[-:[EHG(N"=K#[O$ZGN
M>LD6S<YE77F!W5]NL>I[(9TQ6-GO(KP.Z3H2LAYF<?.IS\Y6VH]&,\57*1\G
M,$FP+=D+8+XN;#_Z4D*'#?EA%:H=JT0<CZ'FW64<-_G%@I<=U'6P4:30K;A]
M&>&<<@CJWMA*Z40X\>4I,(U+4YO%KUM1))K=<?%"+5$#.$7%9N$L2;6!0_;3
M9#?J(\),95P(U]SAXH^9Q?D'0)U/XP0C_((A*P-RX3?EA[!NR_Y3B!]Q@I41
M$B;_(FZ(2J3IK^AG-P)H.E3'=HL4ZT+*0V<310_ 3M[E48<\:C=1/V)/5>.6
MPN*P?SKCB\'<PW6UO@TW+%RX[IG0I0E3ZM!5++QF);QH; HJC%5[B_6,]BJ*
MP(,SSOD81OH!=?%4W>@X@]2H!P/VSE>%C3:G0*9I:MR6^@;QI5*%6U'CO(9Z
MMJ"?XU976]T@"7<V?_[W19<C/[-V):C<.J^P=H;4_EWV5]P@GON9M19^-SQ,
MV;Y"!*BM2(V,I'Z*/"X^.5J'6=T<S']!L8;?YPX[0Z_KQ#29&4;)D:A'<:Y?
M!J#3+"ULY="AD'1%-X?F>YZ":@06M>#6?@E=U+WR01;R"AM*)V_JWQ37#'+$
M\J24HWTX,X='ZW(F?89:=&9\O"-&OW*3';?6_-MJL%S8QZMY,S96*=Z&(_#C
MK6LU?U.SF>V-=MF//GDF5.[,^AN.*-@=04HN@L1 -))^9^%Y'DO  'IYO6WH
M+*6^[[:L9'PT)A& %,!V7N"!)+=,$_:DZ"YVQ-YJNU[61^4U\/8P_\R.&XJF
M_=HZMV+SB)#!/!]_W3^*T<%9V475\13E2?Z,O>I'[\ 9@L%\M*$?W,>JB4_M
M>=TU:HY%;\ZI/S;M>[%B=@>3O[=E*\?%:O#=4&>U:+?XI]B#TDZOP0CR>2*@
M5^ FMB6;@+S2#*?@T(1)QIKPAA;3OLHW!>E@3->E;#^0U:ZI:'KG +V]\=M]
M^XMV;]9G&!,9[7@M:BL3U@-5&1/D_<C4':6,KZQ=0%HI7>CSR^DDK4/"Y 9A
M+=>H/![U,RK*JE>&U-NA>V6B+')[VI?/)TFUG3CKAG3%D@^95VZ.OI7)Q@C:
M$8^HP^W6M\-9]=:0%H.7LD* C]],"S;MDJ(^R7;8YA0(M_%UXC+$P?Z@VU/_
M"/T/C"='#'=,U??!.F0\('EZN0]7KMG!'EXHK2 [ DM).,,9EG9S IF%)F-X
M=+D):)\0R:A;A3V'::\F]/L6MMJ[\.UZ=4]N&1S,^KMP;?^#9GI@GMULAMO.
MX/.S,1=4#OI1\W:*W1 T1DCH,X_O4E18[X@6-Q[2H?+VY,V$@(_%6R++ ,9D
M\U"$DO*X+Z^ D50Q.<@,3=/E7U5HQ<A/50>DB#=3-JC7O,=TX^L4!#U"&JRV
M&2P#:F'%"V(KR$A20@VF7Q_J'R&O[/44D?(G:3># 84.C JT&^A.BSK%QBE\
M'WH6%/'D+HGC59_^TT,<$SY*2V-Z/7YS^4'I30@C7-T/RB*3?[IW#4B'E3E(
M4BO@@=_1F:,FQ0HKU!PKI*5""+;+?0-W\BL=[KJ"O4+L@8$MM4*\8 L?X8@1
MX9:[$?R/]*<4/#V!V80V[EC&)I)-0G,(R4&_I700AG\[^J+K\N8['H=,(:[:
M-=1JU*KF8>Y2&R:%*H/3(SN 6(#6UAAZ'=:#M@-9:5SJ*I*+:V9_SWY@*F5N
M([MNS/F.WY8732_4V[]Q(JS9XQ'ZCQ<:]+.*8V*>G/P\[CX=^U^M5Z.\,9?8
M#?,7:.]"I[-OH_?.)G<IS_Y"(B*1AJ17]1X6<(0X8DM(H2K:.^FP!#2QV_?E
MI>06M2IZ3#BN%"AOVWG9/SX#WCM3[]&[Y<\\^_B+82Q5]R^K58.[[V3NGS#T
M/0+XIE<4H> P%G>. V[/A^+ _,O(;+V3%-K[GP7M -^.ZI.4 2/COJJJ/S+X
M>MUH54Z@BT);Z1T%USBL H1I2;:CJ_M_,&$.M&P[J!GI&MVR/OQ*TM(H!SCK
M FE5D_%<&B)*@&.LU$:Y8&_P6AS^.J'VYK#H6?-MDMV^02]X)VG>+=SG[,%A
M>[_2<"K:4G!P4("UT&J%[=@FD1D.X:TP(LU"."/#?)J@6'P$"9K\EK7M.*;0
M>K*[(PK3FA?X=6H,.]0_&= 225,GM7=H)EJ,]#7O+#:IY,_K1*BXC84U!I4^
M.7Q!FT80S(MW4WJI:M00]#7\&OS9^9M7XD6^[?0;$S((L*U\@FK,57TBT.^[
MCU=K3$7$Q0>_OQAB2@Y,1#8*OCM'2D*/M321+3\]0,>B9*[]9C,Y$^.&N.CF
MJC7&&P#'"J(ZB=C>8O$QCJI,*G?L([OS:.KAPU=P+%ZO>O@EVP^)5>'6@!53
ME%L1MORGGBVEM#0HP&YLW"]HK#?J@FSSL0YA[=91A,'?1ZHPO&8C?_X:1LL*
MX;'#\)HDL>,,_9EI=\_L$R95#_XP;.WK3YL[)>P6V[CY@_$=>+1\56D(][EI
M9*:K?Y<E08?D[5JXO).'5P'5I@E!::S:4&B]>3#0SI?0YGR1'"D$]R!.\6",
M+H]Y/"ML[[(>5O"5Y, [IAOBXQMQ]$FL(OC/V%&A$DG/<7@QROADHF?ST")+
MDZ2TSC*CZ1!LVEWILB.1*+&J^;'V@XV"PY7URUG%M&@F1(.B)/=;9"C#!"!F
MJA-_'9&3;71%<C#HRZ>!QI3[.\IYF+4CA^*B#!=+!?(\8G6D[9Z'X5:%U3R6
M^O3L]MD2D-;>F'6O:KJ(/S6GG_3B^9_/%(JAH)5#I5"0I YG3BH7.2*/5,EK
M$D4U(.-!>Q2Z S\ZSX_PY&%&(KE9!4][$DI+TQZX1P?J_2ZL&&+[1Q"+@F8(
M(U=\F)>+WY@F-ML(H]\\>I8_0CTC18'6DZ]FA7MZ1/5(G^50,,)82C'USOT&
M3#I_QJT,?D]5VOS\.=R'"& _(-XOK2Y2H.?R\OE+]\U@HAL;,E6S8%HH\%(2
MF9:[Z(54;JX4I4A9"RD@Z7EK)3T)"C@5$KJ-HX+@!$Z"O'K:0K:U10[PH84^
M "/W]4^"QL#^:5XM^]SI=&.'0<'XQ,,GA ]G60.+YCWC;EXOFE@O7[RXN]S\
M0$DDJA^J!_S]Q]JC(J-4+HF&GAU\-C8VUG;#[(\;:]HZM34.EJ\_WY6AO^GI
MMJ3CJUZA5-1N_(?MW4<;C!ZL7W_KVGD7I]X+;LXHD\$OW#-_W\V"68]]W SV
M3CUOS!H:WU'5O^;'CV.; S+JZOUT1W:4'M?\;-'XWNSZV7CU7[2O29]'F,XK
MWV]@B'JUK&16=.V_:K@(R3-\!/TFO1H[-R8DBAZ#DQ5NQ60KT('GQM"8->FW
M,1V,*_]5DG@8&+ZY8!#6O>R9VDS@!SH= H:2M"MU'@PLNH43?YRK6VA\V8"(
MBGG0#"UH%6; 2CO%ON3?)14XJ_%S0GR'@X]9,YX7Z=93SD"3;0!=FCH;,@#F
MV\IBJBT6"*K3J]9^R]MK$3+,G"T@=EYYY%Y%2OR]<%+2SI2BT-^#MO4Q/=5(
M](/]S<Z\\1C/IOZX7O3L:%QA=5&D?R!D04PHF1GU*5;M3"XNG0AH:HT+C9>K
M7U)OZMQF?^XM-0L#;B-"^L9B._AC#4(@=:G<@N4?U\7;R4$MV0QBBRJ8O1@J
MR2=[V7S:H7? UB.WBE3,TUGH#'GQCZ4;6A.T&GM3QX:V\,9B+CPY* ,,0^L0
M1)<3Z(TV=&'!K2D=#NI6+<EQ])&?HAAK4?O%6=\<_^B'0AI?[=ZW>]GNA;3X
M1V2;OL6$,W<FB )Z:J.33>$'WB8IRK%"94K687?6A;\G\4$4YC_#<][B[20%
MT5;)GRURE+<LU4UI9 O B3>,\(O&/\]OJ9LP%<HSBX)([5VCMUQ3BT\(61G1
MBPS=B&]6KM0Z9D(B4?NWU"+:3,2_'^LU_W4;P4JHLFP2(W:*H\-U>C=GEXF,
M;TX(?/Y37WJ+*E =HBY_#-)ZH$1_U@M52!"X011S;;PD38I:="8K,*9G6'\1
M/H7"/A0DZR:H(TTK1RF7BUIDAQ<6_]>?V?^OFHG" XB%F7IO\9^+I^_/C3PI
MZE> =Q=>E#R+EX1A%8<7.(1WU)37>.!2Z:UK&[*1.2?6RJU25(#U%=K<$[]?
MNOW)GIOX,1U5+E:1HM[V<H" 7K$U]1-=BOK=]]45N+#\UTU)\CI/:/W*7H!\
M\]%7SR0%2&+?0FYD15#%P\7KVEO/VJT_=DL<_C>^.N+_O<EN%J< TW\O&OT-
M[]T[X[C>EQ??Y3E*[2RTE+!P6T%96+%5K 3I2AXB8H!U@ZI,M@+HHAQ)/<Z*
MU(5)9"GA%,."3 8P?'02]>PL)W5"'T!G4<P@;^$!VA969MQ\2J%2=:(K0!15
M9<=5170?M\Z++A 7?9&?RK[W>OF9H13EQ7E,032RWGR4O8(P!5;6$N\%E[QN
ML$4W^ZC<IX0Z/8$B PSU*M@H-&H"W$2)P%3[U1@NL:/'S2;P_]HZ/1OE]17%
M7K-=+B_?9BZV*_5:VS?AV9&J;>H,[_:GZ-]JLC7^]N'C^P/QMY6_*?Q(_RU7
M?]!AGV6-WF6;Z(?[>^=S__%>6A/T(_-WWA^]'\:9?+-7N#^8WZ/_X#S+CP<_
M^A_\7;8R;];\0_T=429U:A?WZ&V;]7?+]5DL94:'?Z>LW9$N\:1'/J"@7HGC
MCY'%^@.@'9ZE_V9^%/[']1P8Z?[ ILV_[-CHQ^:']G?$;_G/\%;Y(TOFI*-V
M:S^<_U;2_F#J]X:M9Y./QOGLS[[PQ_:C\S&I9;T/SO*^\RG;IW3=Y&;.-,NS
MDU?5?3_^W?'KD^+))]CGL5N>JWA]OHJAEISTBX8Y#A<<O_Q%X<OC=58EM@=E
MP@_$;YW^1]CXF^_?37]2'\IW[1>M,7R<S_VGZ -;IWV;C?!OAQJ^'TL_<C\(
M/W:?[T?4HW>O_OES'?W(_+"_H\9VU6LY<>_?KV^_SN?[,?MWL?O&?7OW[MVX
M>=NN/;MGU>]?L8"_PSY%_X=Z_IOEO_GO5'R/_2'\(#?53KDF8KKO_$?'C\WO
MK+/^>/SH?X;>_<(J%Q=],NGXD_C1^U%XAXWWH]5G[;W;<\JD9*=^F[\@:DMF
M(=NTZ7$IGVIW=6\MG/.I\D <YPD)F00^]@V2)Y_L&N@S8:B#_]\$ %!+ P04
M    " "Q@'164^KN%Z?C  #:\0  $    &9O<FTQ,"UK7S Q."YJ<&?LNVE8
M$VNT-1A$91+"/$-4%%"$.# HQD1$042,BHJ@$!5E/!A1D"@Q)?-,CJ)RA ,1
M4%$1H@RB$!(@@8@3DX" $I*HH(!4J6 )E>0K[_WZ?MW]](^^_?WM\-2/D*I=
M[]I[O6NO77FB>*<8Q6CO\O#RP"@I*6&.H7\8Q3#&_<^[_ZW7GR#_NS&4%,T8
M'54ERH(SRDK+,0MTE)1UE!0"# Z#45KTGR=@_N=+:8'RPD6+5535U#70$^JT
M,0N4E)47+%1>M&CA0O332^CGF(4ZBW27K7-;K+?ON,KR:/WU"5=*5*VV/6XQ
MV-\-KMAPXFRBFKJAD;&)Z4IK&]M5JQV=G%TV;G)UW[[#PW.GUR[? P</^1WV
M#P@^>2HD-"P\XEQ,[/DXVH6+2<DIJ6GI&9E7\ZY=OY'_S\V"TK+;=^Z6W[O_
MH+JFMNY)_=-G#:U\05N[\'G'BY[>MWW] ^\&A\02Z<=/G\?&OWR%OO_X.3/[
M"_X]]P>7$D;YOZ#_/^+207$M6+A0>:'*'UQ*"^+^G*"S<-&R=8MUW?:I'(_6
M6[X^055_VY62QRUJ5AOV@P8GSG:K&ZYP%*^$_D#[#V3_[X E_G]"]E_ _A>N
M(<P2926T>,HZ&!)&+K<MS<2LYK&FYH"9KV8= FW'ZA?VH^H^;2VG%)@=2IZO
M6=N$"T=3WDA;#)"K0 L!&*UAK(<5& 5F$7F 8R_%#I'%:;G *=8P18"K]4P@
MG:0D%EM -LE5A'.@C9_L^DR1QM:NF4[S\8 U:^$:_F/Y6[E)#ST<PK7<EW04
M%>]\7E-P^&0&1F6F=X<!_ $-:Z; )++#1""9G3&B!(??IZ\%T[(=D&C05\)J
M#W/JM)!W$;&PQIU7+(U8,G:\3,Q+E$#85,+N$0*<(_G-V8YK)>JGE%XXE9R:
M3SJC/.N1B5QYA,9\0-_<)'L(A+ &O??#IZ14S0A6K5$+=3%-@3D,A6;66>#=
M%9@4>\A.(DIQ4F#2<>H*3.ATIJ7FL?IU=$\H+96C(@T]?.*:9]C<DC.>8YZ2
MC:9<3Y9<@_T #AV-%0H5F S6X_IT1$^,-40P<,?\-GDG.PIZV6JY#,AZ@EO
M74&+; [:"#(X7\3O3L#[)/K,]CFC3(]Q)$H7]G+Z91;R2&,KKMO) .X&5>3J
M.1)@R$X\)F":T31F+W3/O&2F K645NS@]_FC(%Z88R:Q:<%:L+(".E,Y+C;9
M<@.$!H[QZ[H(YQ48]3J1V7:6"6<=-OD0>:%&R%7_$9_D.>%D-)I>;=9L':C
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M7)6^G]0SBS=:2ZE^DC:*,XV06W*?0:QV'(:^$13E./$2G^2]+M_PM4&$K#X
M\9)B\!GE_.\P6>"JP+260=26'O@U?9-3:W/#)]ZW)3SH2QJ:193_B<WCO$>
ML-)NE%$&[A^0[&@;:&9K(C'/.-2<("WX@C0G?O< 8P,VF0(F(\:PO\1""=D'
ML23K.3X2 -Z!V*P@?U+2.OCV>3/N28S?I[MU:-@H6>+/+>Z2H.N7H((+,]@4
M[LI>@HO$WFPG3(5P!][6%84&P<4\5:W\T2B\!]C4)A285,K7>^'Y.'WL8J'D
M7F_[TN&7U<[,T+_I)'2%_8PWIHC(E"I?1?.5,%NF-9!U<)]4@4DF6E)UZ6M@
MX0-XHFW.LWE*CS_T2TC);IANG<**;W-MX1V@5+P5JDKF;H)<LC+(BU+Q4A'L
M?E-[K\K408/?@5(L;%<_N7DTRKUMUC5-P#*/V$=S$8ZLA ,?1,@-X7505GNQ
M60/$3D#T*I&#T+><4CAK&WA'E$8@XY.(YF%YM)?M66+A,XHZ[>2W IKTBD\C
M%1BMXCVJ9+9^\)7(RR"_=D.>UD^L95BQ)N29[L#5HI\XU<6KIVN6( >ZD,#*
M=R[)C,%2Q!7"\IOBW:'KO.Q3F7AU4HK3TQ7A>3&9EW$/8OP^,\K0G ;(TF+(
M>H@GR&V"<L>\6.*<_+8C;/V(AGH^D.%*39G1)(^>@\,9MN%$-:@,#I7KL-*)
MR\&8("=P7V$K0^,I1,HRAIE;CX<[YMGD;U!@6GP5F& SDBY]&>B7(;>"\YI'
M\+ PSB(_C6 O%:4H,+IT$PE5731!W/P4)HN?HI$MEX'O]>@$0)_N(>0#*CC#
MMB66=M"UCJ@3I^Q6W%.:.[A#?Z_2_SP6GMUI94(:>_^KS7-LGL&27;P^AV7_
M=$+<&$.D^GQ$7Z-95(M##)C^<"A4,ZO Y/)G"? =L3>0%(!O(0]VCN+;*.]Z
MF^>VDU0(BZ1-T;SP:3-:EKAI0%"IS+_R/F)N.H,3KL"H"O_IHA&]3JU_U:%[
M&?MM028D2N)NS)*HM%)2N(0G QP722/5''$&L=G!$#5I SZ!LY/@=BLLH&<B
M2+,XG#-(WR+95V'&4JMY?*6R=5WHW^M()O)A'+B/HB3GLPQY)]D8^D[P;DF<
M&#=TKKW8%1QIA [0TG;W<)S 8!_P4(YX< 4$Y$BN;&^XF^5<+PG4X[^*<UNQ
M9K[ ZZCJ9XS,H91G2 JAP/8JDS^@@=%?S:(,D0%AE90YV+M/5L)U@-FCO 3Z
M2DF.70"4<CT_XR<IHP,L=&.V,S:!8VE3"%[<R#2 L_R[^C55VC8<\=:8.#]Y
M\E+JKLD_X!==DA5P2'?I3I#19<?.#)X^8B-EYQ:;P+9T]Q+Z:KCDE'79'3BM
M163H],%(0FG-L>!:4N%Y<>J 7"]RQ.0X^+C*O',U$;)XE'L,.Q!@]ST #]L)
M)V]&$>_?.PJS#KZE&U0$(&L;X8-5L%$KH"U?3BN3]"!D>)V$DCL^A./C-&C[
M 8.P:!@0_TITFLB?=_=>:WJT>KV[\\3Q29P6,'H;[27MN&RY,:P""J6'\B73
M&8P-8-5U2:?:D:%PRZ54C8GN"99F+3[KHDT:3[PARH"^EJ=M)LYM+*-[D]7-
MDB3_<&Q;)X?T_79A9&JE/")GY3R=OJ81CIP_@AR#;X:[M"@P:;AJ_)0RY#L:
MEX-X2\R>T[<ZY<-'N:8_"(&E3"V/[RL8>, DK,$HF8-?$=QV=O>$F?TKMK[=
MBV%T$QQ48$XT3I"2C!08L-II(AZ76[SY+=<(=OW^0\P2-!'YV^&B$KB%KD1*
M9%CO&C'S@^,D'G!RI_@D.):ULNY*U=\FSJUT(4:&+^79+D?%JDW>VONE0*LQ
M&K(1GF>80SY5=55?+%<5CI+;S?!:+I=_DBQIY\3$>FAE; ?'^@J>#V 1-^AN
MAKBB,V-2)>F0)$3G3=N.CN(!N;IPWBZ\H$V8RE@)%P +:!5RP[A<.4Z6MQ,<
MRT8NB8N4/4&7*9T*^>L"FQQZG)2]! XB:\)8OMP&SK',$<>0]>L::'YM0Y.&
M^5-K?<]B2(=LV:F,10P1I88\A8-"!:3%1#UX^&@_(;8$CA.,;$S $W&T7GZQ
M.12:2,!"2Y$5D$H6HB/=$L__(B:E6QJ3TU^,F*+"F]7JYZ*SX73L*9WV/A#/
MQ\+VS)0J1YP&XBTKYRZ*9%4K,,WX#$"+NQGQAP.AJ]3T G)[A3V5SZI)RZXE
M+:+->T/,)$1-?!ZR28C]G2\HT$([6PJ=8I1U\/-.AV575>IO84?4[;[G;T-3
M6L5X!0SC#/4DSDWWZ=:/X>,J&76%3A W0>IC)2@82R.H@&0Q3DBRN-LT>BFX
M]3$MO\62! I3B6O"/C&,WI?!+]O6EWI3_XK['3T5"+0$\(Y';O&5Y&8J,,:G
M]0[ Y'OAAD3;1)%8),@:>SNS)5B2GT;$>MV%EY6"?7SZUCP^SI@>+IY.Y:XE
M:]ST3$8"'_+#+\SNSC-6^;K(X/>^>0^@91_# +&59==V#I/%K#0V=PW-[##<
M(B8GE'E"AF45B$%#%Q)518](&[7)6 [UHLZSE4\!31$'.+'AK:5+[EC+5*SN
M^ :"S0O5EQ^!A0K,: UK,1T8I6"1[7#YK7=T(["O+W]J2YS$)QRYR-)Q_ Z$
M8C-):@S=#I?6M^! 2FHCA'6#*R6XS#D]6,>G/(ES\K6Q/T'[Q?#?RK-O,I';
M \#H(]:C_-2I6N]I?<07.IVV4L;+/%U'PHKH>K" X M^PR] /,#.5JHY*Y.K
MD26>@//%UC5B((/H"L:E.-AS(L,U+HPL WM;&PG>4='G!OW_-!%>\.9_B$M\
MXB ]P<7 >B%@$B'2)& OL.GV<)ZXR16+"P-T[\!>E32[]LHJ.,0:OB"QE5N-
MS_%2!O@CJ^./L)Q%]](K'JE\\3& IT85&'@->Y(EG<[%J1)U:2=^M=4'& EY
M:E5LU#<;5H[R3.% AAW<)[>UN7P2!!((!E7P 9AUM"NJ!*5E4EN0 URH;]7"
MT 59J3/]Q;3<WY)OM6S83C1I)C$^326L@EB'H,!!.$=,30X@I7'LP'J)9P9G
MGY2M1_O$H<D7]A'4;HT'&152H+%4^G'4@]8+.\1X WB7"6'5F0:5=(WW>51,
MMO(,,?.W\FR(K X(Y0V-PQ+JX(^V!F9.#"I&0\^[">X//\"D=DOSGM/^L51M
M&N#J4"FQT'H?^;QA+*WN&KGF"53W$O,L9$Y^6=VV]#\/]G]V2>0U2OA&1C].
MFW>"^0XK31/RDL^[KN#IU58P4XL7@8;W)8W!<6*R!JU<(FS#+Z#;=2/'V0\>
MX4O@7603E%8^Z]<.KRAPR]U!=;KQC#UX;A0_%3>_!6&0M1 *&CKW/:.?HD4(
M!+._YK,TB,XT/3$O5>X2!NC]C(KS\HD7 AJQ*(B++DG.=-Q5PB [&?$2XPVW
M<%Z?[I0:GNC=I33'VV'P.Q]M/AIHN&1:W.R2Q[">[(X8_0_,%)!P1*L) $MP
M95@A46!Y,UDIS#4NF6$*%TJPZ83C4FH&=QGJVS/M:W'8YB%]2^/,"U$?K]$J
M!$%F*2;!#5>>JWRY8P#[W ):* QK6L4^V3_?:D7O2N?YQ8ME):13;'UYOWP9
MY"? ,N?PB;'D1-9BAB$[3:7M0Z@P2#5/+!BQ)H%9+-,P'IAZX80!].AZ!EGE
MA6D OP\8K07 3,0)KH&8$MSD("D)P8XR!PL4F-F[(!'%HVD"4@6 26SG@LB
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MK>FXIBJUV(GZ[JNM\J?I9* &O32!NWH \05GQ]J'B%>JD"WP9K#"#3XQLGD
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MW2S7T%1@O,+AQV@U?4?'%)@-,8#@)"B5IZ%J#9HH,*R?7)0/&89S9*#;C*S
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MIJ:P5!S9CS1-NN.^61H^#;X1J_*IXXU_M=W<@ *3= KXBS)$GAU&<\1 JZ;
M3+E!9'^X"=+B2Z>9!+LH2<Y9X;9>JB^_P2-+'%_DXDW[J:G5_O[VAH@!K3M)
MK^X-W]BVO11HZ#B7;0U<>SAF3>^^_INRIO2CU,'?SFM5V,]?5\._O)>?EXXH
M24B:&_.=1T?6O;BQH^BC>7WF-4JC[7V/?==._WOTE,F.\I6V/ _& _DKT2-L
M,WEPLP1H9V8I,!H\\<9\(<N25(T3%K"S.<==TE^$%^/Z8YOBMW=W9T?7#?&C
MV9'+.&0)#]Z%A!+V='M+C7"-A=/JMNS#OY?^Q]/1IUA+"NW&RQ:B]5N"QN*,
M>[2&7OY0Y71*)<<M^CX[E>UTO7=%U*K8LM+%_X3Y-A@477=;[2+HP$_[@=Y_
MOAB[(Q\(V!VDV=G*PQ2Y!\I8]$405G # !.073@P$X@:?S6R"7[UD<;\#)\3
MXW7K$2OW5K0KM88=7C#8\5SEFU\[.U&D"82Q4HI=8"LHJ;4A-)=AB'B!,I2=
M]$CQI9UKJ_M^-OF&G]*U6G-_Q=E55UUR^J[N9]Y0CF3$T"W0%1 8+TB+/L)W
MV.'<U;)[]'C(2!+:NL5[-I8I&6MC#E$DE!PY'ED%&]U/<D4VP!;21K:V4()-
M)EKHK=$]XBUV5\DRC,GA]I/5OAM-52@PBX[)RGBAO'>\V0-P-U@C[FP%#)'S
ML%!JOQQK3M-H>UWYI<$3L3.Q'OAYDQ L'AVQ \O@6,0OVC A>E0J81NX*Z/X
M/-65-^RP9;YE:#-&*'6> B"'HCR)7+B+V,%'P"R)48L01D=BE8-OG7+<A1<C
MP\@EXPW-7< C#G[- I+>$RYACRY%GVR45.)F(,P^?<)>#WZ7/6&S1S3TQ6Z2
M):W^/6?9;I8*9QDES7U_@5O=].N#RR7[\[T-AT3><:0(@IDXGJH*^_(9!M7/
MWLYHX#1A8"<HJ_S6=+^S$KXQ)]S>8__S>A3U\-7CUI55SX^_'GDRN>+IE??/
M2SX,D>WAI'EG^FKX.I0OQ@M))N.A09"P6:8L.90"OH_0RZ!O*K%I.P2*H2?W
M8@P\F'X#UI:JW2=^K+2U8D9GG<Q=D?49KRP?'%D'I\R?H?%GCX'M"2#+%SXU
M.IT2I ?7W*/OJH$&LLP$#;GYTDHJ!9S-*@N;PR/+I:V=59K CMA\2P>5Y_A/
MVZNO!\BL=!.P1;;-RK>^R,WE6TAX=\V,5DG^O!7Y;A9[9+JWJLF1\-X#9Y"B
MP-"[!W=UQA0/^%@W? B8J+SY@YS!.T5*"EH/-TF8N<3UX.3("HB9K<"$?O";
M#80,N)45$59\/Y$*P;VJ*%Y U'9==D7O)63Y!'YZS>7FBC7G-UV_3I&PE@ M
MYJ2334O"9R_*!MI9F:1WKIXMK$4P\9>$V98#M.?+%\,4<+.$FLC TVQ&9U-_
MZ6YC@>QRB,2?7LR71N*TB[:-M15K=4<1K!RO'CE*I?0P5>C^, 52'_/_,X1;
M-0=MY(+P\,-AF-SN:I3.KCW&-^Z7=E591^ED'8\^H__+9*-*;^1M 6S/.\8:
MG)ZW$A2KFU*RHNB:$O90)U_TY-18PB1">>@MKB1)26G(<51DT]UJMUBN_W(+
M5FYC:3LNA-*R"88F=+M822-+[_7'I9#YQSA<W<!D%&@U*X;]55J (9O6&EI]
M<__()M!/8._:+SK45VN_YZ6@>,& $:7G]+*^J;U'US\'ZNB;SVF_JZ:1!99+
M$YR]UOYSZ1SG(JX7B3#A];%&I+G<9S-"RE]=*I^,<H%1)NLQ3\#,(!G)[6C5
M0DE@>Q-4/=P^2]Q0ER4)>3)B_IAL&8@0^PEG8E3S;+;-'WH&5K2D=K\2P*Z!
MBPW )0R=]\T^DFG8:GHR7FI_8OK LUJXIK2J3I+C*0C:W(,L@SP#P=D\R%XT
MFP$93?F7?,'IQUP_Q!0$68+,]B+@*(1/&B4>?5(=Z5O!>;S^%<DW)'76C^@S
M_?=BTJ?>33.?TCO'/(8[74WD@^FJGX<G_RTF<;3DLF;AZ6M*OUW$;-@J=#)>
M;!]Z!,*F3#.<PHNM^HA6]+4PJQQ.I68US,Q6EM *Q2X"!<:<?A0\6J!US[-P
M_1$X3:*2L_PZ_2#JKL^A,F!?55?S>V7]W7Y4K1=FRW)K->.;!QI.YT&N(GZQ
M9BU\\;3<H@W""\B@5'+^#NC=SE@%C34W!4NJ4HD4,SA);)3!0<T0L^7<APL1
MU2VW+MW%Z[%3[6\"^SF%G;]1C<QG_IZA-,I$3;TR=N/TO@M&(U0$8)!0DT8*
M:@)<,?"TV&C2;)Y(QSXJ](&!V_#5H1?3LR$P,+\B,.=(6P'W]A08)XZD2>4Z
MK^UBKK;K!67#$X+E5)U)%^RU536G![GQJ-U)])2_[D;4@<&D-ODF63G7EO%Z
M52E"!!\"2G(;1A=C/<KW.M"O=1 GU^Y4=C1.$UBU/EX3H$35:J-W/Y>;=UD-
MI;Z]P'JHOU=%4IR$IN(4; = +&&0*\R7LC,!$SDNLA*,BL$G$_%0?59G2JPM
M0T7>64U7ZG)28+)[A.=6(T?A#.>4AQ-Q.K1B-_$%0_OP8YRDMO6TTR.G9LE)
M +A+-.@[>MMR 5&_&LX"XL A:L9LL58?XBG=-+/%<T\/=Q6RMINQ*+) ;U?,
MYE-16@/B7VF.."SLO^#!=JL\ 7QC;#WS;::M\@]L*P7<11HT:W$E)I30XMVA
MV\Z6AGD[ U>>ID=7BERMT^:730"/4K-8SI3"E[(BCELE[<+MY6NY#E?H)Y='
M)F]&/@"C6:1'UQ.1K3U_T>VDA61-9"]\L)QN!:6E+H.3*JUO]*^E6;7@U*8)
M0;BP@7P)/IUA0=/CCY@ ^K+['WJV;%]S;*+'2)9<>IFHTPT<(R<$F<*RT/D]
MM!,4RW% ?PUQ)3T8SH]SSI<6_053 _L8+O"&9N)"Z'.&1%/SL'6=N,-/[)?
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MOQX!!%2M\0!<%E'3YT[XC8;8-V70Y4"*F;=;(3HYJY*8QM-+C[F\4FLV[ES
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M'>C\&/U5M5+=5OEW$;J2,<2BCQ/.9KR9NR-LI6#H^^%H*5/O2[$^?/\N+2N
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MECP%5[%'P,!V#QW\OA&^QBXZJX@UKY,3Q'=@O^8?L#QH=_'XSWK3Y>-NB;5
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M*#Q;EG=72XBLFPXOY.?\87#R'P[CL)WROMO*N[O6\ATCAS'UZ_R8@IO$41'
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M8N<!U<#.0E#Z!=7#A,WWW_I@1_:#*Y<*;(<>;,BGW>H_]%:@S)QW5C!6S1[
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M-315#?#7<T)[FFS#M#'*5IQ,?2X2,K#1_B8E=A.9/ZV-O$1NCS&'^0FU0I3
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M T7M;B?IJ1L))"3=#KN_J%W@H;*ZTW*;K$O -#%LP:87IT'59O^-#\Q]J;[
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MF.M4PQ;]@J1;Q^+0_G+#[ UUB6CR5P FG(18('[V&T0+QPOAZL&#JZNDU>0
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M#/>E<@XMP$3QN5V_;W?^<CC7Z5%SJY5R(XC"VK3MX,6-'P=^/6641E5(;BS
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M,QFG2,24?8?N5E(IO.4"X-Q#?ND6<O5W?K )#+1,KT,^#<TX;3J>#QZ9*OY
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M;D$V"FM?HW<'+=L\J/=TZ4WH?[QD^[O%]_=:E$Q'^.@J+.GG%D31B&"]B<^
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MQN$T\&,3?6'3[:JR3MA?MM>A>;:MMRY!^ZAU2)[<,"ND^P'[P4R_^"*Q[M!
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M^(&CD%X?>ZZUIP+O,X;!>P29VNHM9E7SG:\,NHO*H!&_]GFF6WX\CEN8!&V
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M!G+R7W;L%VNBB<.\?^K_?[)!7!@S=YH7R&UJ;'OZ'W]H_HU9_/]CV;8U_K\
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M4,LLSQH!$/TQ [7%E44C2QZ79!H;&B Y#H**S*0?G1!I0XL]*%5'9QO%$N.
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MVN8+P7I_7]PDCSNZ@-X'(,[?O9T3A!#4WSU.!QPQ?"N!^ZA$H,S80X/5@K-
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MOGXVPTE%?XT!'3QK[.OP\UZK-)"\<\ 5P-DR39^M-KOM"/E&Z##[XXBP$TY
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MS!=AIN^SB0$%NPM^M9$L?.!/"%L!083L\E<_QP.ITW)[H 7,?FF2J$G87F[
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M^<;.IXSB?QW3&Y0Y=,7]VCXI@HV2=YWQ7=G Q \5/S-X'BF"3#K("ZC ;6-
MDC:X'PVF8EMF$_UVV_,.!3N,-8/=,$^89_Z=-N?\]L/8@\2?KBJUS,3Z^*V+
MV*XJUV\]RFMU3W@?#D)O?(Q[$:Q"YH*^[<YZ=@S*.+(N[Y5H+*N[M 0A@PI9
MW\GU>*0D!HZ2:_EIZ:]OE$!KE5MI5*,K@:X='5FRM7SPN._HA_3>\K%YYY?*
M%[K%\ZVULV[&.UCUO?YM<BZCAEC_^/&"MQ*A3(U46V$OOEQ>I5NVJRSE_:[F
MQ9W*2>) O[^[>]?Z G84!BK\9, YQD)?O(V"D0 +K8;[!Q#2-E(,4YW->4P[
MK4YU%XX=[".\14;/R(TJAO\4TNNPN^5G;5%*/O8FUV1?VP[V@T,-B1V.FUW?
MN)!&*CWU+OX.NKYG)BHKIELSQB%7> B#JV1I3,S8#F_Y@]%_+GUEG::A;,DR
M"^D&MY=VNG*?S25"7!FD@B<E5ISLXD1;B^:D'OOZ]V.*<<7O7\CK;=]GOR+)
M<[[D"H\VBS#FZXY3F_I:=*F*8]5\!96N/C+8N)*E4'Q\LQU-VN/C&-1W;D9F
M>;R>H\[$)T&-0T*J@0B7<0V/YI=JY]ZQM3]+W8TV+0+M>P,Z/WCL,<]?T"F>
M]%&,&!7EMD[?(3Y[MQS2YVOX,J1^QSH[.$0\IW,E4+W0P=;9L//QL'6<]ONX
M>*LS<<H.CSK)5!P(,&W7MR-&S,Z E^2/?JUDS=1X3<N//-#.T1VA2XJY#*!0
M#^AWS61\$^+NI11,-GPB@^XXI*(KMB,!W"P7E"!CVJ$ILI+9B(O;HI]Q\1MR
M&UF[-X)2\U-C>9=Z>=J.?C67>[/3%4-&QM;K8T1,'TX<I,I=7DO]6O0B9!?"
M@]5%&\R%1%=#G68G=U>J3@PP@U;*= PN;OX=7EXQ^0J%%W]FPK5_*8QAU&FX
MP^ADJPQIBE"B"G+D9Z<#SK>6 .J(==^N9)[Q_Z<".^C*QRNI5I1'\T^B@3_$
M6;7)/[OR)N?S=Y#?"H00TK9^R%<R5XZIV8V,),E/:%?,E?@X:]3.S0@O.6?D
MZ/]]\,^,LZO/6;A'@)*68I=_B/"'?]Y<6] X.+<)%T-[.K.K.0I+SJ:Q0>H.
M]HR>-O^8#*,3(]ITYX[=FXPM^GHG'#+E1/%];#_2%UCDXG)%E$:9YIQ2SE6S
ME#EJD/Q^&F,(^)9.32&7Y7D9&OGA(08_7%VG >2EQJ;&QN,V3FM^GB,_LYX,
MC#F=S#7Y)^I&_],S'F?.U1-WQG+^8LMGBX+J%@-?9*K7F3O-N$3.BS>_PT\5
M_26TBN7M<;D>? 1):[R293";EX 3PB!HLO,-J9.7&7^2FO6J?"8"G+N5<NBK
MFU/V8549OZ:#AM4)GT4L<HK(^)>NV&\SA[1W_:,EG0LI PG^S(C.:65&YO/J
M8/7]]Z/J8$) /Y2_]/:**JH4VNB7&[R2?5&X^_O;VJ%I%W^;QMIAU/IZI2%E
MI W+.[2NOKX)X4,;FXX=UR!2HE.H+;)P$O%\_K/"I-\#X\/H=M-[7L-!Y_U%
M?IN)_R2) Q &/WEGK(H+BMZ4.U 7?MZ<&47,%F'RE= D/PQA[$HA@+5"_7"P
MNN^MFOJ:L6#4I?Y*(=\+JY1=VQR_F)Q@!;?#V0Y%]"?RTU-=8QL+ >9.L"C$
MM8:36<W.J4T.5CK!C8THE^!1*LMV%XTYR#"IIX&%@5:7T2"Y0/(.@_%S.Q =
MNLWTP^,]&'6MT>M!']7\/,--39FDHKF\@[_D#XP>L@\ LAW'5L>,VGW1:9?I
M#!:*@<#HP20T@ND:Y+9M#GB4]:1TF9)@>5<CAQK.;]TRKK.R0M>E1A=XZV86
M+SE73A"+IP-1RB][%P8^?&8&9"VNSNU"T3$VT4A1C";#I*)\&5^:;5L^V1-<
M^D-YC/AFQ/F;SEA'2U=TNB^5K;5RM;;NY""9WX30Q-BT]W?#0PHH>X@8YD_=
M9#QC(*,1Y,?3LHV,!_K!TRF> ?XJ4>N5B^])7SWC%Z1/AFO>J!E=J\+3<JTF
M.GY3UX8*FNZG1C]I8Y=C)1W;Q2<26,8E&%WSS6QUO^D)VK7Q/*K0WZ!$2[.6
M\4VVMUJ=\/5I.8D=LL68Z\@-WUM1Q2-UB4;TRN!$02[H>J5!\J3_]L/:^HGJ
M+7 \5F($M2EW?\+XY,ZO_/$U?P^&7:6D,_]WRA*>\*L.%NMZ=$A'B'S,N\B'
M\B*#TC8\/D"[]IG)!:VF[^IAK@_I: HL<V1KG318(OSD!#E?J['Y9J9>=)#<
M11TO@BI*,-QDSB&Z8Y$L3!-V1AW[X62M[71,]FI]U$-U\+>5;?N&L6 8 :/,
M"-ZN&?\ KZRLUZOQ:=)!K+A<]0D9JBXY]OZV3V-]].RX\EB!X\_1.DO9E?H,
M1*S?O4L'H8A=7Y80(R82GGB?F9%-"Y?6V<4=FH: ^CSG#!(E;S6JRR3Z&1K8
MQALXSC:>7:KG.^AW8WFXI^2R]LBGMSX_L-^0/"/F0\'9$#D YUPW$9PC=#E^
MT*0I:0.QY[%A]D-!EFB,Z;L^]:(_,>.?=UV(X1YU037ZUXI:1O\<S]#JJ,[<
M/<?YXBKR02]+CXP7\&H,82G+2TQ,>^N$+;S/[H*!,:8:950GUT6;L4)BTIP9
M\UQ#JJK"\-6=C'M-=;D+PV(''K-?PCQ6S*'&-%M&7_NV*@V1@,)UR7QQH%2E
M$S^JYQ*@3G<K?"?^62%N3_27^)YF?_ (#L(T20N//GZ^+RP:-/&5"_)=?^JJ
MH*^_U"I%DKW.41A-2BE$]%:3O<.>E')!'99EP#7UNX2F7&D-^Y5.BE$1=>K\
M#<+Y)>?N B_E83S^>%.]Q3I'&A,(A#%#G)FNR;.:1QR!'"@$E>_B$]H=ITXJ
MH$Y&3:QC;A:U\[VN=OKQP]E'\K%,240=&^9(O'RHT6/^7><*U'9RRNJG/>Q#
MZRK97SU]*Z9]YB#9Z/5=5+ZW@ZZ>/C55^,Q(YVG:Y@C]I\PWP6VC,T0CI:BA
M^O8J!,Z[S7[S8$P92P,P913,TKNFTQES9&=(I!]>&P+V3EMJQ/PYUQ= '3PH
M9Z^^7Z 2[[^VF&SV%=DIDTA\HVYCH'H!/]Y^:5?_!"@L^.BG3_=XM4B6'B_G
MS7\8@QZ%ZII2X6_W9WV6=H*;\(9N297<O"0]![\Q_R*I+;GQ\0'^BS_VO[U(
M[X7*F^./ 1\9F99 F41$D0_I+)!&==1V,5%W/4@Z!G1S0>WU$\/O/D7WW6H9
MIFVL$WH^0S.TSL9-GTN+24'\6)%8N&BUZ2_*JA!]/FD)FOPQ^]Z&OV]0Y07C
M?#PEP=K*_.3'DZNC-HWQ-W=/^]?_C:.=D_+YIY-:;E<0%W$CRD?*^4)62D24
M\R/7SY7YUF>W@WVZ[9YXG+' ?-;R8_X-[")RCC RZ1"&_XU1G;P$/ TN-XG.
M:\^5_AJT?M0'S/AH&DTX6$<WO<ETB(8"F]]UG-3(=4EX[9 0&]>75]S2YF$N
MJTCX*!>4B&Y]H6%TRGB."XJZ 9B2=TX6S3;-B*V4,0UNC<E Z'(\9 9@S4')
M[U[>\(@:7]OM7"I>^B-B++>BDWW; A/%F^Q3J6*=G=9LNS%1L\$^_./ZWU\>
MGS<11<^B98P^UY2=&B:/5<@<+1])%#P3461=6""(^19SRC)G(B,E'L2_GV3'
M_H<+^IG"!4W=9;_C@K:>L*[ARU?FX=_!'',(>QQ"T>2"'/(ZG47-E=)3AQ1?
M[%3_Y^O4?^4V[@54M@!8O#P!5:6Y& W:,1;CU%1&=!)UF=!O&JO5=Z^FRY]H
MV(A,Z5%OZ="W]%8[9W5P0\OA_;NG4#TRLK:G(T\0G4"6/SV$D2WZ[NLJ- (Q
M8[0 J0LT%_E>0F_0C8S>\Z^:/Q$F^_U4G5[+6-HSX?%9_.8Z;&O+7/@V882P
MF_PT3TR",SZ\9H \7$4OH:P.LQQ=)GT>H_CR'Z2U!Q[3(](5#9M71#]+K<;;
MN:DN+5-)BABCKQP5X'PGB8]YE))#3*,ERB^:D!J'_/GRRBGDAT.?,IV#EZ)G
M$4AG^-$0B9KF\U=K38H=3U[//YA.\4:ZR.6IFO^B8,WI$W9C;^!=D - 6H^S
MF!=)&BBBX:,R\3C4P^GC#!=\U)I.5%W"HRGO4NA=*EYBR?O  +5E(&.DP_WF
MT11/GP4DYAS3:N(%5(5FX/]"_L+()A+L389/0(5])2.X(*HL<W32W]AG6N5U
MLUKPK^"#RLUB_9 8G1PP/,/2"U2;!"UG#NYJNUP5E]U^Q2X7[%:,*_2/(T$<
M[LNZ3W]CZ.=[*DDHY6OI2IP5C"?@/%:(@ZQ[@W0;PTS:_>AS?]$JT+G\P8#A
MG$W+.BY(C"CUQ>K,K=+N8M$B?9]*[Y[E(R7Z#RMZ!V72Y:8\-1P;/G/FL^(M
M[*%AVT7LA.I6;YR(,0T,P!^P%#4R&7A;QOV88Z%&^:%WF>'K\6IUOG!17QM'
MWU"=<3R5;F#J8C.L*4@.*U$?^/#$N\Q'\L_7)09E CI3@Z,[E"W]7G(]R29L
MN3AW;""RYFP0_KS]=]5G(NN$ [LR*27/BP?C_% EM;M\5=3(#^/WB%9NIZ'G
MC=("#7NBZ_KHI\+WM];0:5Q0_Q?.F"E[/:Y1FH,]R 7!XDH@WT,9>Y@H?&[W
M%A8BIGUN)YEW(:4[/;U*O.)QY"W%BD=_W CQ$QX[;S17-_9@TQ4XY__VU[0R
MNR 8)P\@R3CA32YH/Q!V)9,\A$@4==$=-!YY@%=?"[8R==1_*1-,2@QX4M)?
M81I<73BM,+J937?C@BZ/;,JJPRQI):LS>RK)HYL<F=ALIJJU3/IZ>SK@3UV"
M(JAE=;:,/]T[?A]H4V'F0.WL"DK,\=\Y0TC'O,XLO\2Y%N55*A<4F7:)D1R]
MFC]&V U#71FT78I9;7I\<:^JV[-T*R2N\3@;_/R#G1_L?EC#;7YV,<SG3M1E
M=2Y(R/BJ3;G>DZ0^+DC@G&!*J;V6A$AI;_H[V>M/!]-U-+^K;E<Q87%X EZ4
M,VPS ZAV[*R3<>( O_WH)J(/" 8?^;7#!<77Y;A.+Y*)) 4"\G!K=#H+FB5?
MZ_GP9.-'8ASOV:7+#QQ,K=C),%^VZ!]KT@@7Y"=W99NMH8V".X_6X?E7ZE-7
M9(@Y'OG?I@B-80 -(;"9<TW[0M''(05$N&[8Z^G?"]-ABTV-+3O/(=^Q?X=/
M@^EZNW8B=6]46&J#X)K[-]->\S\3-1=_!'VW* @Z4Y'!YP]XK SN7$RF%'!!
MAUVCN* O5B!,7? N/\9Y"&/.E.W&'6SU[FN-PJH"44Q^5Z;<UG8VU:#%U\Q?
MT-5+)KPZD3KY;ZL5D $#+SN_=#UEI,34;:UT_?ZC:F>%"_I.4<;'D'K5IU9#
M9C[PTWFXH(/\"1AC*IY2@^1S!1+LFYDZ!5Y9_ F05=*I<:R,"\9P;,O0I;KY
M\1^L4NKWPKJ)(+W1]:SIZ9V!#E^Z_F].^Y8L%U2.HV;B8;\68#[)K(NADES0
M.>V8;61+>P]=<_>6V#=<QY>OT3@(<.4P[ SH[PJ"G0+S6A?WVL''8&QW'<RK
MT&'VC1/^:P3?&<'E"?L_#HU%>1'N-4G;3JP;PWWYORCXF&"VI]D0G=0;4M)/
M&_%I_,'TDK!QP29-FKF9BIZ:41JVF%32>/K)^$CQ];.@GZC=9K\;Y1W:?Q_Y
M?R]>5A1-IB"WB\&J+Z_BXF4$SS<6F,^;-K4++Y@-%:8^6"'J04\I6?KO:KG"
MI=(X,HCMDAOFW48G?SV0?BAHA*/R2TT77@#=V7_6.O 2Q#:\"->(6R_B@F2,
MAENG8'^&]W -T\X%'6IYP@69[H4>CMKWM?5O7 %'.G2#D^2^O5<#D3/S<1MB
MER!P]O_EXLIH=HZ&6![@C:2\I%[/1M*B$XXE"A8^(E0<S>5U:5=\O($IOO?\
MVJW70TXY("/BK@47%,0%S5ARM/\_]?[>AWS/6 CO@GGO^=$\16 /=+/?$@_*
M/E5"*T>O'K$>]_AY-XY?;$\[35?<T!?L& 1XM*G)<?/B6>*""/@_</9FZYPI
MQ6&WA+.#9.)?P?Z;?7'_N7+_^HLWYKLW,7SI F>,("QT%.F>PG4$%9H@?:8S
MYES^(X&_M^0ZS]W 9N/?8"1W=;U(8LR!UTPA6R"'F4G3C-4VE$1^)2@#R7,&
MZCBKH0?-<(T(C8:=\*CB9X5=<OU<$$LQZX'-X/&7L9&?RJ%=IS>#_]=<OB?@
M.(X0FK];7GV8%4!#'ORE/Q&OC1 V-1T.[FNH+AA]0,@Q^^0Z0Y?8.)ZW^F%J
M>9QX-])D?.+V^-UZM/N8SM51;0Z$I<Z(Z9A2 @+;Y&6&H*K4\8:&5I2!>;Q7
M>MW!1(*)]Z$J56OGCN$>J\3"3%1Z].N['KY':NL)];6;C:=XYMGZ WUP=D4S
M2KTN/3UG:X^:[,[Z3IFL#8_ HQ<X]X&4N6\*N=NT4^IK?H7U5]%N87&R(HMW
MO<\G/<4H70/2PIC*V!,8VX"P$KFS+",C#7L X4.Z?8,+\G%$7_W^(,8QX$A#
M*C"=.J&I5"2D>QJKQ!G,<NA$RC@!.^ XF"1)#ITTV4%NGQ!CG6<FUL>@ZEPD
MU.T7G6JM;(8WKHV?R%WHWOG-I/N=^"UMLWPOW<,F^X('^XWQC&4QGFZ\>T,W
M_Z@O=-R2:4N._JWJ+5T0_1NAS?#,$R<,5Y@>*Q9_]MKZ\+Y]19),U6H*)^.T
M0^?0 CHTM7CAHV??(75KK^EM7_$KS38M.;,%&HD-OT+A9%@4G4&;="(DT/@[
MU^6)^$KS2C:>%I,@N0=PEW)0)_3OQSQZL$IJ+Z!4X?.\[[BEN.<Z[4M;_-$J
MULL%\<XG6XP&(459AL#47G6!O1"O>;3D1;/'; )_[3CK?O!ZO)$DD%@TJ9U)
MZ6(38XK0H2,=7]$WM1-4G3:G$):CFIXM1$2KAO-.$*<O,X;CY[E=SC(ZZ>7^
M%ZUP<R_4/H;LA=KY73L<=6 (]C<^?[)XJFZD[Z9^>CDI="/XC(&*BN#9QQ:]
MCZA+PT7O5J1._DF?+AG(A+W7C LV-(6/Z\ H[K0KRSMRVW&E:/C-8<\)=43;
MQ+@S?\*FBZ\#PR.C@$9W[;$8W\I.EICQ0>%")(HQ%5-(\DZ\#PGRL:;F_4X]
M=;%#4P2MTC%]C,'F@KIP,NCGBU='@PVO<'9HBZ9HS-6L(FHSIV]TPO%K78N'
M-NJB<B[9JH8P06UX_B66,T-HERLQ^(^#X/[&EV]@O^A](/BT$EKIMZY'/>WI
M9(,O\O \QHA:]&3(WWM[[KJ"0$AJJ6G*M5V198II%%2$FB> ><B$1?YD:,30
M# ^K^U^KT0W]\R+M%K,^"NI1Y.,*&\N\D<XRK?9>H?9-"2XZ-Q)2U];Z.D/[
M*;%^?L5.F%KR# ,.CWOTJU$,(&^7,D==E4<Y$ !&1HJUOM=HOEQ^F2;L<(6Q
MF*R=8S(.%EMQ5:AE\M51TTHQET:#K;34L6,:[J-J#C>3A UVKR"$D,62LP=J
M?Y!](73XKI5YP$,_]VA>H(7:G?5D]?[9Y2.(#I*@UI?MPY7UY?'RX]?0BV99
M%W6#>+9=FA0@P%Z6JTC)^WN:HKG%N/$6_,9T]2 M848 <YEA&H_S1LJB>\BY
M!HR2N&8C[:H0Z\;&FJ%@=>>%TT'JV [505&D@!_T-&I[)5QK^KO"5'"IG+73
MEVW=H6Q*R2K_PZ_HIHX]%D:GL66IX-A-0TLR!=[>-^EBZ\APB*C$8]1/1AV8
MB:'B)"@_S,LFES5/5CT,]B0-U9U:WTKP91\.JV@R-+7:X>%(/UKG).UYXU[*
MS=GC'QOBIBRM^1GVL4&Z'1<48W"-"UHX\]3H8=ZV ',T==JPA.[+=#>S<G!B
M\K56R&F@K,>7-VS',"K4=:$E478U1,SX5 19TDAFI-FT^!OQP9K.^2?B++T;
MTTTJ1,PQ]JLM?'2>J XL+O<D\*$*8SX1K'D874'FWWT\L(C*?4T#BZ!Q+A^(
MP\+;]>6DJ!+OFT"HT$'M<+DJ[19+NM:RI$1OZ4'/C]/9VW>:XK7FMC/9Y;V@
M67 <1=-#Y0WZ>-)9\#4W:[[#OB",P/M=8V<5NMWN=1T*LCA=YP/01"7FJEO1
ML=^"YO8#YQ8DEQ[TPKXKQ9WT<BJ\=J?\&,^J5,EWF8I#[S\I2;5!<Q_F@U3*
M]ID<5%1/[(;_3]Q!:ACOGG,UEX&QM%OI-_0.<4&]U[\FRR7MH;%K05ZCP(
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M1_R[S&XQ ' M'851-=D%:B-VG,[ZW/YFV6)+X:JY!W69Z4W 7J%SX(PY1MT
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MNW0'F^,)[N2")-#Z&XY.=Q@_-RPKO+)0VR^IG8]W$GH73LTW7][U6G'F3\3
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MKRU"398;!WD _]L16T=:106?E< 3ST4)\BS/2],-7E!\;VPYTH\WE'B%*R;
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MN%>CEC.<-VVZ-C,L<L'V:WE1^2+"[.1FAK7<B0NA&\7BIFH5\V.%E:&^;7E
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MF]*2?7$H31K^?5@ KBOX'=,7$(MX*/F2*H$P;,RRI+_LLJF4K',O7E&WN<'
M7E;ZL#P]AR\L?7-R@.&O=B9^XB0(=.HH\YWXMHO6G_!@G?#)K^"F&!,(T53W
MR V'?@U2^M/AXE$Q\+6!F46E:$&M?O,RO0@O)463W%SW@-+9SM$[R9?]_ZQ/
M@-E9L@\PO;;, /*1 ]#YR;6U<.Y@_V<I/>&"GFZ:GNY9Y\#ZYC M3'<V\.8
M9 BC]QV .&NF1@] ;ZW!M&*6+&9XDAEPF%80C* #T&^!F^ [H_8"]+86XW^+
MK+.$GL'=&P>@- A@BOZ&95(/E6"L$EV%E4983&?QPQI*#T#7*T"[W#WOE,6#
MM3UK7/J^1[RU5:Q!(@PGMQ4M;XUO_\6/JG6H[QB,K?V&3UWQ41.S]_%;+WK
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M1%'88>:H]T/E]-8<4L^7'@$8_=<0Y +&RFNC2\=AZ-X@R=S3;$0]$Z5E^FE
MQ4>9'(J$U:?UW$+NF!LTHPZLRB8Z.U6-(4J"+HBL_.4D[8OX0W^8LQ4115XN
M*D @H@CPNPW$%2#,_&:D11>UGE;C3_Z7,>V738)"BWNT!:R&NZ7/T<\[-JAF
M,.?7%CYYV_WMZ8"SM?>G]/[H@@QUF+8'>I;+G*_;"=SDESX..6.81QC3SX>/
M[Q.-I_(G%&WM#H6Y&I58@HGC\PZ$*R5,K N;'S("058'&B%8D:%[0F-8%\![
M13EM>[QX4KOWS+N%Q_/#VT-=*Q/E(VEK5 0XBJRGY9AM]EG)I?_[=O?F)NW[
MY.)@QPC[(O"6#H[-EA[2Z#GL7>30[P\3 3*_!FIU>F\.)WMSA ;S^S6@RZ,2
MJM[BCD[7/08VS$SEJ@:5'B0RAA'G/+S9<SE?H,S;)4H;"@$LT>=OD'9:@<%5
ME!9B=&5'@,96>+FN0'"'-C(AP(?2*-7OGVD6O5)Q1@XE;]HH%%ID5G5Q/8?J
MFHBO;&\F'-T#42?Y@1SFCL& ALIQ9/:%NJKJ$;+CMP?#NOJ!FUT6*ZY66E>:
ME3VINVG<L=WC!R1)Q]]? ^W<BOU7QQ'? VT^W -]&)A&L\4Z]D#?UO%45\Z/
MJ74X5F!?NUZ#_I-Z!GGUH=%G#Q39M/NV:9X$2.R+]2?XOWK2S)$]4)76KD@.
M%WZZ&\8Q>0_.&ST9>30,$MZ;],O<+WCV149D9LG"\):?O=X$N;74^<OO:RBC
M5E(:XV;LO3+CGM_/H#%WW348.?_/"Q5+;];NOIT*9+OD'! *YBKY%OKQBZ,G
ML1%&$#%7'S.=7VFHJ.Z?"O[XKHC7P'\P-%\B5>OJFK45.9T4!^1.*IE"?JS#
M7DP>R:3W4%>C&@_6L 1+&#5L,;HD7W,_D.+0,:2K+Q=>8%344[YXIOZY#_GB
M.5&UE\O]MUK?I*2XE+A>D5_QVU$KCM=JRSDH\/:;^+NBY"/?Y'Y*L5.^S+#(
M^XB.WU'#]R&86AS^7WN@7\%"EOU*I&IT"#8\P^_UG.UD_Y,GF;&SA;\VTC_%
M6EH69GI?M@Q+:#RA\W\6>S3]CUH//V84 QJ&.\?IRY%D6TZ['ON)*:.6,?,V
M'_7FP/LS[ ;L'$DLUQ6Q(+\"I:&6IRQ8R.&*D@(G<X&2SY?;2QS>UE<I\_P<
MY/^O9U(!SL/1\W*D//BS\0.AX[,W+=U5#RYVJ:1%/#>/_D$/O\"SYMK>](G8
M+BW-Z:O&BP;D1(MC<=Q,T6A4O2&SB%IKT303JM.2#*38#JDCS9&.0%RQ*<H7
MS#Z'!_]WC]46+XCCPUCN3^DI3'IK<%,"1R:(EIV39^J^C30"84S:DT3V]8E*
M\ZY?BRN_[C7Y6*P=LABX=<1_?0!-+E'/XK)BV47YYX@ B6"PO:E(+L,LB1<#
MWW%DJ4N='IB-W7%,-W/6'AI&')#B9>;-:*UH,7IB7 XPMQ(Y8!<,M)E&;":H
MM$"T:E,LAC*@@IBA>IF"1?CL:ZES+[\6.27(M">58J2FJ :T5<LA4H<2V^XP
M.TTSL3]T=E^ )>PX>./.?V*"PPFD'@'3"GMOJ 3GL ,0985"W^Y/I\+]\:+U
M0EWE2FE%AY*1ET8N5>^!W#[^^.NS-O)+)VE0[GKLLIR-Q'C-6O/S,ZA/X=]1
MCZ<C^<O(X0?CWH&S\$@"TKR7 ^XJ\QX(C3/MA9S#GAP)()C.))NAU$P&&I4Q
M!IL<SKQC_L!YD:=IUCTZ1V[EF]5GY58#FP4LDTWEH<8+B*E3%8TJ6"V\-$+;
MYG=,P1*U7>I\#,H_DSP(HJ136=Y]P$/@PT3YHY%:W:K&K==.;9M,F1OC'QI^
MUFAN4(PF)W"./DYG;STAP\D(([F!@E.=&8[P6XX* 795\SVU5C=2(^>$2)A4
M_;<.N1.-7%?/T_5MTW1?ZA\>>?<.NT%7D>+\$&]J$3"D<HX,XXXO2@N1&NQ:
M:Q,VW]+?L/6TXLHU$C1#$M3:TK=,$6C!(O>2AM\%@86+:U7MLA/CVPGY?\U4
M:^/_B5*)L=*5TLT$DS;MHN<<1:QN'Q$;6*;<P'#(9_UN*M\#>2VRQB=A HSV
MBD7QU,:L7[N?Z!&-F6B4=Q>$>B3QR!9[@K$:V<2$Y8C&5=?MYI8_4@F 2F"6
MVN&_*1^ ):,^MCY#TJ2]\3R9I?<GB^#-!&Q#2M:=CW(FQJAIMD2OS8.,A\@8
M'WZMRY^K&>_2%1:;5)H^+K:]?C@DGE)FT4=:-#) C4U:7%IPF,\()C@3/;;=
M&-R ^?O%1HGP5EL<;]50O>?,-1):$%)4N& \Y\PJZ(XI-_?U]%"L3B%WDR%1
M'H3S\?ND4I/6S-?IKF!,D @6S"R8ARL5%.;D+FP_?.O^,,D=X5DP1AMU&,U7
MDE$_#J>5W[GQL=XJ+>;8B8#7J>-239)$R'__I^@$'$K4@VVF-HZ(3)E5#;AE
MV@(I'^+:=D[@SGS:0;HN<(2J&L/MZ_NPID'YKLAJRN5%N^111..EP0>#NK[\
MC?+I\RI14HJ[L3A1+VU<!'TUB2;P"XZ.^<5Z)*H]TI+U<#%H W&F5S'-_ :\
MQX.[L!+!$>N;=@OB#]O^HV3H,)BV"A\A-QALQ_=\\%'/&:UC')(Z!P2Z%V*O
MC1#R^\E3/-[;L,AR@JTS%#9TOH$TLHPB2PL8\6\K[UIT_^GFH*!W!AJIA)\%
MQ?6484+\<2\X!KT9TH_5YPF;HNZ!^.^Q5*+88#2Q,+W8:_)TNO4 F_>^+/.'
M=NMP'MY-HV?S2FC8XE>B\H9"C*7M;[&W-K*6+#E"'J=Y>RIJ?8I[$M>OF88[
MQER-J0]A)/$M:&LED2:T45+XF.#LHG(@[W:2M:M@8S$M>$G[7>UP@LYD1^E"
M\ L1,Q0NK;KP(EO%;#<;?R^3>!3PO,'J6;$1K"M=$+>)S"GWEI)F)4;046K.
M*>:#!+*$P^\^&69WWNE+=K#*@3^6ROKU52DVR?_^K&Y<^S//M6%XMV\_UN C
M@+4]*[&(/A4A=9KID9J6%4!$?@(\J;6VR1D^"<7VWMH:75V#P:'UZ1FXK%+:
M0FUDRF-&R(WZZJK:JN1K;A'-!DU5C77T!D-&BWA@LWE(\WRV_%  \;1)'@:^
MW2X>R@YOW<K(+LSP3PFM&+!FLGN7GJY5.5%+YZT3;O,U:,+DUYJ, 8>=@T"@
M+4NS,A\W*"3;'D<"1[M(#JW\8C5%3@_,5 .O0.:VF]^;J<V:'T,IAK4J)1A3
MM/EL8U3PRX^)\^=>IUL!CONJ:[..=7(J1GV*=JZ3:K4H+I5#'YO@NLZJ#D?1
M10<>L=48*H).M[)/US,)N['>V_&3%X?KS0(91]*DCTD+N<**#4N_G/_[C&=^
M*Q)[D2G3\M1R<D'J!.!:\C/N5'4.8*Q[I=\DS[NZ^U'\RYY"?;W&U#+:O_2T
M.,5S(Y:4>C7J[U:YM0$'$V95,^?B %LI=V&2KY=M73$?W+H;F9J'J'V86>H-
METHH'7-"HH_^'#W7462_;S#(-8-<9N)&Q<CCMV=Z&L'RL[R ]/XO6?:Z1TG9
M3*W%6&VYUM??Y)SSLBTI2SHF5^D1A"PU0=$O_'B)=U]*#T:5C7:X!^6;'$YM
MBPDH\A:IKHT@$K'2^)]-T^T)8^TTZ95K19@XEW0+%G>F>J,"*S+B:;(C\ YS
MW?MRY8"N6D&G$OE=ML"G3)/(1<?" 2O.F@4I><J,4DEZP;6A>>P0\CGI]+N#
MCH=CW#OD=9/]4C8T9+%]X)7G.RHF0L:X:VQ=G1/*>(K;_%7)XR:W_;FV!W.8
M/W,^K>Z*0J-R +VH/5#,>W#^/#$32J^$>DQM*^/!4&;(OE<0-F%KRB_7[8&,
M>NAS'+#;'HCAQ;6@C3"ZSWOGYK04H%?EJH6GWL=U-JT[<:3PTYO2'+DDX!%L
M-) 3ET/M84OM+\*67IX2K!V)5;!*A4:+Y @02;LJ#,F>,+8Y>MK<S"9!=D!]
M#R3:E3<I'X4../(KDJ%521G*&'8D8V2-GSNI^^03')FSY.D^THT1$3'R3W6D
MR)#\S==&<A5IO16Y?EQ'4@VZ_!]X-?^S3P+=R/,EGL&/\6PZ^S^ GFZ4?/G=
M1'OYZB]\W5WK?17W9@2WFI@C:&$\U%;[YG0B^$_EN\".,T]EU(>S_SY-[E->
M6)W=>E'Z737WEGK%L)Q-EE=^D058<+Y;^0/9R *A[-7ZMW-%+JE(J?F%SN,G
M+<G7.LX^@=7HOML>^6$'_1L4++V;J1+3M.&#@1 <.?^IR$/>WZ=.<R23'SR5
M"/A9JSK])/S]EX6NH/;GG(M8'8"PXPS?M_:"NFX?@ &SOB9/24>+H0!);CI1
M45&%#(L-/CP4D=5%>Q^FT_G&/W,X<>"'ENRY-7ZSX^!;*XM;(7N@FZ;5*<FS
M:/_UZHJI,/,@]5"JT8D[E_]W7</WQ\'X8=5KR<YQYPEK!R[8VCXXU"J19BMW
MX9?2N;/?V_XL/Q-V"65N,0*?<RZTETY@9%K@*C&/_%&W0F4L:_K#;RIM7'"/
MG1_K^GWCI.5RQ7)%^9^[I. 7HMPA6..WD(S9L$K7^I.QK+K?7]L[:]2ZKTZ^
M7:@)3N('E)C0K_A#2@&A*E^VS2?3W8FNU!+7]J 02-XO"27E3I-]*\%;<!1%
M"N4RK23W^RL8?-)KB!?.C'L[6Q/_#/SX[WT. S]U? _$4@]2Q?M"5Z/W0$!&
M6BPHKB-N)V8/A#793ZX154;3\?E)_MZ-GA- Y)].4^9(I#]R#W0,22,,/G(;
M6$^0&YZY,Z3RX+CQ'_=/'TF?LXWN*G[7XC^D4_N=CCL+:)D!X73IDQ@)1[.F
M9;0XQM6964A0"C]5,3.@,:&\=6L06\)O;?RIPR-4_7*ZP=.N*_1D$ZL#^Z?$
M3AYF]41O]/ !KBW9TL/D)#[:?&"VS,"C\T)3B*><<]7)2S<_IYXZU] P[KLL
M=$,R-RM[<O9LAM*GX)P4T2UA#I"TO^J(Z>S#3+_I?2\K!.2TUZ+&<=)#6'-$
MWKSV,)%A_I#&=^%>?T$:QTO1H\%1PO&:1A;\M[FKD[]0%S[X.%7?TUV(NOZS
ML>I"!<5V.:D*J=CW$:UJDS=&3EQ9G.^@Z*0.I5_ZTGNH\;;K.&R' =U?FG(J
M?^1W6?O )7Q7D))'&'RJ5/*S8+F:,M(WVC#(Z[\)?U#]<M$.R?7YY9B]6:B'
MY/@.MBRPCN+@?+OO3^Q.2S!WNMQ;D2+"@O:CVN$\[J0\DV)OS:=6WMOD02T[
M$9I+6KK:C9'MU-:&A'6F/9S79S:R>_'&BWRA5)!/50@ZGY99@NLY<5,VS>%A
M7'#[X7*AB8G+B;)J-QG#D^[BUU-,F\"SNKX=+BK,N<T8P)3E:&DN^@5RC=D4
M0_[=5SB2&.65_I3V0SPT=5#;I[ V,16/1H7D+VK;EH06.2+%S=<MO>%7:^*G
M'(U^%P1O1>>&WQGX31'U^UE?Z72]-C7^97OQ LJ/;TR)DZ7.'!^CAB#/]SDY
MFOH>ZBWO:[FM=E/&<DV+BA[UHQ.;5\4=L(;]Y?6&I9CO4/!BK<!<7+U1:6M0
M2(GDDS'JTV!.E5YAIGOA0B<12)3F N"==VN<(>/.C@C-3R9B@\2*_)=<2\_Y
M;W!57@/M@<KT!X-/?MNV^O=_I_"/ 8T58=N=!\&VE86+Q()%K6"Y0D65%95,
MV+#_;/2BN,T>:%3V-7SQJ8%7QN9WM#)CK"NI*T:K6-NWYT33XB^3?X8'X\N/
M)E^_=_?EW9?&^FWZD@D@J?\KR)_(G3OFX)N#&G%OQL<0U9\FG?Z)P$*N4I[S
MIZC;/OWFXY-O/_06M6*%?!O-BSZT=B)FLTS&=8";G.<--W2:="@L\-3(G$#\
M'G>YGG[$/4B),R+05?+*)JE35_C&="IFPO005WNC%#L$<&;![J2;,.7CL=<8
M O>EP5XNJND6)&&C ' $5A_MOB](GM F6OG[ZAP6,^X[C?XX.ZB^H&&N:7[K
M^Q!:*>_S)O#!-H'_5=OIXLE#OM.:W-?IE3V/WOEWM,%^0'GV0![2+Z2YV"8A
MC)PHB$@]<[- /LHD0G$YLL07DI*_H&9*'PTXI:XCIR3P&CZ8#6;F#@5JM_1A
M\# 2N:JJ*NQ"SL+.72_ZC?OVA;.*3\2^N$?=^W+L+[].XH^6!QOO>77?M-_0
MWP.!8!RYE/\%2P9)=PZ;*C)>SBEG"<J<O7:**E!Z]/.E@@=.VM/%]RKHA+[_
M>;O_;G:W0M3$V?N:Q7^_M_55VIY7RW_UV:_[\J@E]; @%_@HD,!:W<^F'%&
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MU1F/J!9IL!-R\C)0<'(K0E?8?]/E,FO_E+J!/ZLK&V.FG//F#$<T^*<WS6W
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MP4.Z@=/28L"3.4N68$1@ <;$X?]H[CN_FMC"=Z,(Z$% D28(*,5&DWZD14%
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MJ[F#P9<F;08L/PFOJ\.N'X.]5=>Y,^\@;?S_GNO^__'8LCGROP!02P,$%
M  @ L8!T5N<HJ+JP;   (7P   T   !I;6%G95\P,#,N:G!G[+ME<*3-CBY8
M9H9VFQG;S-!F9F:&-F.9F>UN,]MMMYF9F9F9F9F9V>OOW)D[YYN=/1=B=R,V
M8K-"/RKRK5)*>O5(F5)^+'YL I E125$ 2 @(( ?GQ_ QPI "  -"0D%"0$-
M!04% P,-"X^*  \'!X^%\A4)%0^; !\/&Q>7D)2.G)"8A@07E^([)0T#(PL+
M"P$Y!P\[$S<=,PO37W\" @T# P\'CXF @,E$A$O$]+\\/CH!7Z!!J$$EP$"(
M :!?0,"^@'ST @@  ! (D'\,P+\-$% P< A(*&@86+C/!^J0 : @8&"@X& 0
M$.#@G[->G_, \"\0*$2, I!?%?2AB.U0F?QBLJ!)!*NZT!2G+DF9#>S]86#1
M,3"QL,F^D5-04K&PLGUGY^ 4$A81%1.7D%125E%54]?0-#0R-C$U,[=P<'1R
M=G%U<__Y*R P*#@D-#;N=WS"G\2DY.R<W+S\@L*BXNJ:VKKZAL:FYNZ>WK[^
M@<&AX>F9V;GYA<6EY:WMG=V]_8/#H^.KZYO;N_N'QZ?GO^0" 8"!_/OX+^7Z
M\BD7*#@X&#C47W*!@+K\]< 7< @B1D@4 04H?;NOQ$Q^T*B",5E573 DS(J7
M: ;V4[#HI"Q;9%=_B?8/R?[G!//_WY+LOPOV'W(M ^#!0#Z-!_8%P ?0XN**
M$#RC!1K>?/,\T^DT!2./&Q#0W+@,LMRXV?H Q.1\ +8++UU>(YSU+OG>0$KF
M2E8K=)7WC#R]P4#DOLB, \_=Y%Z)EA]>'WUVS3X C\5\6X@+'0<]'P 2L0]
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MM-M8H &GIG]FW&%F/0.CQTM,IB:2EERC7L)T9D.NW2-%<6LJ+;7VQY?:O46
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M,W3]=*5W]2?A8EDJ+N[K0)3%_'_E!)%NVW5^!^DBD:18)H:^% @A%*04-+(
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MR HBJ(!_(Y#//?[?RMYJ?R^*>RCS!7W=OMJX8+[[ )#\RZZ<(*RK"J'5H0^
M[YN/\&="8I?>J:H73.[/0[:93IG_W8IV)Q 4;/!L$M05#X;T%C"?9VJ)_ATC
M9GG,9"JLA2N@,<1X?*"32CEF<-!PPC!4^@MZB /.D(\9<*^^)=2!YG)XZP,P
M[]D5'P0AB\C#(&*IJIMDZ(2?Y56DYR9EYT@281 21F.7R8X3C$5:\W4@ST(^
ML#OTWQH,,A74M]]OA1R*N+JMMETB@+%\J=$KHMKU(.3U[)"^',#O@G,&TPC)
M6NN:VLR9;OJ!F)CDR7# >!R[)X>%I]F%9>?&:CFCL#+6BI41(2<;9TWQL_HL
M*F9"TH15$*LSK/OR@+N2.0=KENB%8*W1L#,A@P 5JZ"5<2%$!H[7(^M6$;2Z
M@K1[%],=QH/X(?FF3O*TGDR>Y^T\TE!@34)=F/H":PP0/\M]63;)8X_E?L%#
M9IB=3J@Z-8,&*/0S=7K%/)UBIG;P*W;\:1Q_F-.!'G.MS7ZLANWF@0DDVA^2
M#K1IH7+)^0BR\N@7DE^2AYA9\!*8< UVA[)V,U5'<C+6;J%B0'.\WNL 2NR)
M.JB1IG9[)I^+F$=Y# X")+-WX@AZ',6:CN\SB<L<UG3",0%J[/!Y$T3.]]PN
M8^9L*45KKG37T_LS"EXJTWQ<9U]IAJB#(,)_U*_:NG9?^6G-/^\V* D;S*R<
MED[E2,_ EW#Z\VK;0]K*>B<56==I "_P6:IO?H3D2.0Q0U!-//!KVW-@<>"Y
MCJ'#G3A$_A1:V I2CNV>.MM+4")KJ18!^P 4P]H&2V:=XA1Q)X>^B"^0S<JL
ME>6WUX^ #5C%6@#&4/,9;SX I2\MOL=RA*D&+7AT)_(>U)3T#";-:0T41/YT
MF+ZY((><_E['&'/G2KK)BY(1\(H0KA Y"<J+F!V)B.SDY]MAA"T<$8:R5SJM
MERN'5Q;256Z$VG4WXD;@! SM1P#<JXB"V2]R'5.M8I9V)O4NG+/SVV/8^O<Y
M]$FV3+!--VB_D<4H[*+96>>'BJ3)W++-L*=*EUU=2*C1"=8G!,["Y_5>R?B,
M*A5\'&P@MN+RAMW "9=EY:NZGBHY.$[XM0]JWZ"TJMP.&FOFN5.2"F*E/&C%
MD[['R]&&,8='M3*?A/M3"P[T/+\. ;\5^12_957P38.KG182??D!0/6+6!R'
ME+@O;W\^US+VU=(*2S*-&XF0SH(2M->""D?LG ,I'QX<378C0@,S<2)H-5E&
MMAN<4+T]=5<PPC!EM,E_S)&=/MOISW._T>JF&UTHO<#U6VRAPY/8,>NNA+HL
MY.;(<8VD]H@KTMSP,9.]$J_1UH8Q!)$3Q9D8!>!%X9V4-"[0B]1U"Q30+Y]-
MBZ;)=)^%F1TC\EIG[H"MER];,&EK!Z>O&+!$H-J[^?ZA@C%LP$7D,5NE.S.,
M"I*\PAMM]J1Q:C'[ #BS<I!U$+3]>/I&C!F/YQ#1BLR8?-S*9^-C"72#N)'>
MLC%^898A3^R'WV-:(GTX&1-!"I89S[.TA,C^C,6C_9M0(E1:MM*>(_W,,4-]
M''4>MTR$,U]V4225X:)!0IE #"3?SL4("@LJTY9J1,3 1^QL4(_28@F=)K2_
M),<F^G^B/H1>*U5@[-4'P)1"(]NKFMT@EAH@%0LI<.)/U1!JF*X'OY[7/'BJ
MXI*KL3YUCM,YP$'=W$1KSZ6U\FA\.2V:4 Q4=*/=?%O_ -0215$QQA;C9O"[
MY2Y.\WPE81\</.:A*.5!QRET6O,Y<X!)RO4M#<-(*.5N[R$OF&^@S/J_;&7Y
M+PC+_?5R(!_'33_9N=6I(113'(DDW19F$QY4@@>0?^C"V-A6^\)=O\#V '_3
M0PU)..@2J(J+QL'^;) [3V--%Y#6ER),5UH.?E6:^\NNMH22)%\(%W\ =8VN
M?Q]GY4WP85@KI3_<38'1.)(%4R$64HXT+O*V.2JK2.3OX>'_^1#QGY@!5#T3
ML,5GX6-[+.CIE+-6^<U%.9X<;NS.--'"B@X?- /+S&T;)/!:R=0KN*H19=D/
MN)VX%0V_-0 1>]#K)XQQZ%Y%< *M5_J9)'B8.*]4Z8AF1%KS=[5HF(A+PT_1
M)",A9=WAK^Y*YZ;H(IH%E604@R]#2$)^HOX V#Q4<YP-Y<YZ<I&MTE6M4L7_
MYH:5D"\9HA*':OG:>4IQ"%$FXIC&):[O (JC"H,<H97$\:2,(NK^/-V6$&)G
M<3\M9*(?9).$9?>2#853Z:T4?E<$F1@D75/S(YQVU/3@:6#DW"?-5&1KZ#M$
MRJDHYF5)-4FSR@W:1%(ZS)/7$T=.(;8_D(Z&>,(H-0<"A>+L%_M$)D#9)>:(
MNFAEP@.O>2W@&Y8QD9T_)),L<UR?6N/E7>T%27#9S\:4?490 5O :Y7<G&/3
MA5&@N$A<M?!E97-X)4C5#;P+YJN9?I;U@5QE6YV45IAKGB]NKM$E].U OGG,
MZM&R)P8E3BZCYMF-[\2P+>,=>^>%O+EJ!5KO1;5(*,D>_S>9W-OU3G<4=E9U
M5W>SH01:4=5&G[37:UV>K0?_DG[(TZM#,]#1Y/HD;CF:$):(#*)LME@L;_U4
MS/OS+D!ZXG:&*7X<8AJ\<W1_?0/"-:'0S?=&[EW#U-L^U3B1#(6XL3FR,#?C
M84WN8#1E-H8EA-1V'WCE'KG&^KKJ4-" 3+4P6SPP2I!+]YA^+WLSP&SDG\(^
MZS^(?QC< CK#@U2IV*+%N0UM2_!%$XC9N("@$O@3A$ROPZV&>)T'1QKHWMC-
MH?/B!VWX1N&]M<)[]JBVXKBON;<[+/.7K?GO'!'=F/,\OR"-^L$@V,' TU:O
M.<8 NI8$B&VQ)6(%=64UT3 QSOT#A>0\<EE%YT33%8:66HDDKKV/BR-=T>6G
MX1[X=:(//;&LP?Y=96?7,?V/,G[WD >$!'HS:,2'B$#\=:EX8X8G"T$?]#[!
M7B_4#\"&J"]U!+5DE$*06I12?>0\<0E*":'(,@,RK_?%"VL.;TJ.SOCEF(TE
MZ?3W]*F$I\0=G*O4G8:LXOIEF._$V_?4H"Z,#%T8Y_WR%(3XKPY]3!,]%>9E
M QX'D"'(@)9%M!]^#!B8U'ZK#YD(EW_=/\,%<"G\H]=8!(!J]#PE D ;.VX>
M+[/D+;^W6V1M3X*5/N*],Q=0' 7[&;!I%VV96SHR@7C$&3"SNK9$,\V[]I)V
MW[[1TN105W5.R76+S5%PM7LU0F.OWD>0Y(;*1C=JQ\1,W,@;2^&YDX5[SUJ0
MX]J,H-6'L2Q^+2S1<AI+LI>_Z#P4,_GC=L"BI5#=C.GH>L@+"+8\X' ?1*9^
MEHIKC7G@[+J=9H,?Z'C"58@.7CO3@..R!]$..7_BS[[Y4Q#2>&";5I:TMKTY
MM/?H >/,1.4[:=7K:/$2:8G7NBC4D?3/@80'I;:Z\C36OHDD%&(A;JMRTK7
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M78QM,%,I6M(9]XKC:5 #HL.O(M4)K*Z4-/0LXE:6>VRXJ4GZL?+2V:+ML!O
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MX#F!@2^#P+YP M9&&X:TU&S## P>AK^<,,60F\7(Z>T"Y,L^7PMC_FP3RS.
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MRQ@BWDD%$FVE=E@?J4X">D.DK'5=D%C+>G6S\3,@Q'WNHP1+("HX9"X_O >
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M@TDY6(1U[K!BE[]C(_K7H!@I<MJWFM51G*9U7G23V\T1J_,K8XPP.BXU_O&
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M,C,Q+GAS9.T=V7(;N?$YJ<H_($Q5XE0MK6M]::W=HBC)4862&%&V=_.R!<V
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MQX=UB]/UFCJJA\NK01]FL<68"S4FRYI]##O(;[=T?;]C<KG Q_\"4$L#!!0
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M^3U.Z7^DF5UQFD9T@9/C**>/-*<D.T[C3SBCP,05)QFP(PN:F-^*Z(#"75"
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M$)^2SEA#%.XI:X?!]P%BH!$JP.6U_EQ&G4?[1&901IL-<")BA^R[ )'=1-H
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M/+*AM%X\[F;OJ&442L4__?&'PX-W]9&IL5G69G ;3+]99WI5%75EO,?A=_E
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MQ10W1O&CF.?2>&^"T'R?;X7V<9#$Q6_$YDC,G/DOA@LVF3+Q)?OG L( />)
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M[ML*9HT4$'Z?',,OL\/V *[TWU8$Z\2 (/QL%<([/$\C?XKB&A-4H"?KNAW
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M5S<*;M/'@/@WXS'FTY%XGP!8AIL1>8LHM]0"!+*U"[_:,L ?O#:)MV@'K70
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M1^P*%&:%&W"H*4& Q*B>\*)TCD_#'@?B+(CQ^(7-NB@JG$\"CX3%$X24RBN
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M<WA=7JRV!%+G.*I"VJ];F)%_G\<%N]M%[Z+3W<&X**3#V&Q)L%K[4#.4:Y&
M"B13T%HBJGHB4=3(9 N4L)/J9Q)#]X\:8#=']N+X)Z."U9@Z%<<-Q3?-V@5
M$V?@I0'.@N(IP451KW=5PYJ<#%83:'443A]J8M10>QWCM*<M33#>9MOHVNQ*
M3#N.4LN!U8Z'&2&DGFK:ERV]ZQ!%CP=*OV3/.*_OIN T?.D>FE)T/1,#K,:S
MU%:8O+1LB/.ACM%SJ$^^I^$M^'V61DKO*"&"U2P:#<5SV9H4,5JOM?\AR#_A
MDIX3=7 XQP^J4"L].:P6L=)UW#8=4[]_4#:_S531I#^79)Y9L*<#>#( 52-I
MB($UD5E3H8$8"V(\B#^CP+F@M,\JH='*Q.1GO$Z?<7WB9VXJ'1_85K-06MN
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MO%X[=V0>\OGRJ6S"N=3[@J0+$/@/F#N%DEHD#HSBF-E3=V254 WP]99 O'_
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M"(\!"C(=@?W4#/93..PH=JB63$=@_V &^P<X["BVJ)9,3-C/V3_']"%YEMQ
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M;T&%L.,/+[XE*CQLU_;6V?(I[+N]O8BD%.*C\&V1P=D[P1/ O@#=MZ >]TX
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M)P( "@              @ $     97@Q,"TQ+FAT;5!+ 0(4 Q0    ( +&
M=%;&'RAQLP(  *84   *              "  8Q.  !E>#(Q+3$N:'1M4$L!
M A0#%     @ L8!T5MX%4O,N P  :P\   H              ( !9U$  &5X
M,C,M,2YH=&U02P$"% ,4    " "Q@'16@0YL]ED(   320  "@
M    @ &]5   97@S,2TQ+FAT;5!+ 0(4 Q0    ( +& =%;>UA6L6@<  !PM
M   *              "  3Y=  !E>#,Q+3(N:'1M4$L! A0#%     @ L8!T
M5E7[L(^9!0  '2\   H              ( !P&0  &5X,S(M,2YH=&U02P$"
M% ,4    " "Q@'169SBM6^'H P#=]B  #               @ &!:@  9F]R
M;3$P+6LN:'1M4$L! A0#%     @ L8!T5N#+3O]D_@( .W\# !
M     ( !C%,$ &9O<FTQ,"UK7S P,2YJ<&=02P$"% ,4    " "Q@'16J#>M
MX5M4 0!C8P$ $               @ $>4@< 9F]R;3$P+6M?,# R+FIP9U!+
M 0(4 Q0    ( +& =%;T^L_^P.T! (/\ 0 0              "  :>F" !F
M;W)M,3 M:U\P,#,N:G!G4$L! A0#%     @ L8!T5@J2Y%HQT@$ (.L! !
M             ( !E90* &9O<FTQ,"UK7S P-"YJ<&=02P$"% ,4    " "Q
M@'16+DFI2YN  0 UI $ $               @ 'T9@P 9F]R;3$P+6M?,# U
M+FIP9U!+ 0(4 Q0    ( +& =%:-RD4_.VX! /^8 0 0              "
M ;WG#0!F;W)M,3 M:U\P,#8N:G!G4$L! A0#%     @ L8!T5B^S$O@L:P$
MG)(! !               ( !)E8/ &9O<FTQ,"UK7S P-RYJ<&=02P$"% ,4
M    " "Q@'16=2=HK40M   +,@  $               @ & P1  9F]R;3$P
M+6M?,# X+FIP9U!+ 0(4 Q0    ( +& =%94PBW95C4! #1< 0 0
M      "  ?+N$ !F;W)M,3 M:U\P,#DN:G!G4$L! A0#%     @ L8!T5H?1
M8X8S!0, LQH# !               ( !=B02 &9O<FTQ,"UK7S Q,2YJ<&=0
M2P$"% ,4    " "Q@'16B1J'?$U(   [3@  $               @ '7*14
M9F]R;3$P+6M?,#$R+FIP9U!+ 0(4 Q0    ( +& =%8-2@+EPE,  %)<   0
M              "  5)R%0!F;W)M,3 M:U\P,34N:G!G4$L! A0#%     @
ML8!T5L3+:<D7KP$ AMH! !               ( !0L85 &9O<FTQ,"UK7S Q
M-BYJ<&=02P$"% ,4    " "Q@'16*&[,)U=#  !_20  $
M@ &'=1< 9F]R;3$P+6M?,#$W+FIP9U!+ 0(4 Q0    ( +& =%93ZNX7I^,
M -KQ   0              "  0RY%P!F;W)M,3 M:U\P,3@N:G!G4$L! A0#
M%     @ L8!T5E-T2#907@$ HF@!  T              ( !X9P8 &EM86=E
M7S P,BYJ<&=02P$"% ,4    " "Q@'16YRBHNK!L   A?   #0
M    @ %<^QD :6UA9V5?,# S+FIP9U!+ 0(4 Q0    ( +& =%9I"^:I>1
M ,ND   1              "  3=H&@!L=')N+3(P,C(Q,C,Q+GAS9%!+ 0(4
M Q0    ( +& =%8$,>:%[Q$   C2   5              "  =]X&@!L=')N
M+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "Q@'167ND>OA B   1^@$
M%0              @ $!BQH ;'1R;BTR,#(R,3(S,5]D968N>&UL4$L! A0#
M%     @ L8!T5NIZWNPK8   <$\% !4              ( !1*T: &QT<FXM
M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( +& =%;4Y[-"!CT  "CH P 5
M              "  :(-&P!L=')N+3(P,C(Q,C,Q7W!R92YX;6Q02P4&
/ !T '0#M!@  VTH;

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
